<!DOCTYPE html><html lang='en'><head><meta charset='UTF-8'><meta name='viewport' content='width=device-width, initial-scale=1.0'><title>Causal Knowledge Trace - Evidence Report</title>
    <style>
    body {
        font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, sans-serif;
        line-height: 1.6;
        color: #333;
        max-width: 1200px;
        margin: 0 auto;
        padding: 20px;
        background-color: #f5f5f5;
    }
    .header {
        background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
        color: white;
        padding: 30px;
        border-radius: 10px;
        margin-bottom: 30px;
        box-shadow: 0 4px 6px rgba(0,0,0,0.1);
    }
    .header h1 {
        margin: 0 0 10px 0;
        font-size: 2em;
    }
    .header p {
        margin: 5px 0;
        opacity: 0.9;
    }
    .section {
        background: white;
        padding: 25px;
        margin-bottom: 20px;
        border-radius: 8px;
        box-shadow: 0 2px 4px rgba(0,0,0,0.1);
    }
    .section h2 {
        color: #667eea;
        border-bottom: 2px solid #667eea;
        padding-bottom: 10px;
        margin-top: 0;
    }
    .pmid-entry {
        margin-bottom: 20px;
        padding: 15px;
        background-color: #f8f9fa;
        border-left: 4px solid #667eea;
        border-radius: 4px;
    }
    .pmid-entry h3 {
        margin: 0 0 10px 0;
        color: #764ba2;
    }
    .pmid-entry a {
        color: #667eea;
        text-decoration: none;
        font-weight: 500;
    }
    .pmid-entry a:hover {
        text-decoration: underline;
    }
    .sentence {
        margin: 8px 0;
        padding: 8px;
        background-color: white;
        border-radius: 4px;
    }
    .assertion {
        margin-bottom: 15px;
        padding: 15px;
        background-color: #f8f9fa;
        border-left: 4px solid #28a745;
        border-radius: 4px;
    }
    .assertion-header {
        font-weight: bold;
        color: #28a745;
        margin-bottom: 8px;
    }
    .assertion-details {
        font-size: 0.9em;
        color: #666;
    }
    .streamlined-header {
        background-color: #f8f9fa;
        padding: 12px;
        margin-bottom: 15px;
        border-radius: 5px;
        border: 1px solid #dee2e6;
    }
    .sticky-relation-header {
        position: sticky;
        top: 0;
        background-color: #e3f2fd;
        border: 2px solid #1976d2;
        border-radius: 5px;
        padding: 12px;
        margin-bottom: 15px;
        z-index: 100;
        box-shadow: 0 2px 4px rgba(0,0,0,0.1);
    }
    .label-text {
        color: #6c757d;
        font-weight: normal;
        font-size: 0.9em;
    }
    .predicate-text {
        color: #495057;
        font-weight: bold;
        font-size: 1.0em;
        background-color: #f8f9fa;
        padding: 2px 6px;
        border-radius: 3px;
        border: 1px solid #dee2e6;
    }
    .pmid-sentence-line {
        margin: 8px 0;
        padding: 10px;
        background-color: white;
        border-radius: 3px;
        border-left: 3px solid #28a745;
        line-height: 1.5;
        word-wrap: break-word;
        overflow-wrap: break-word;
    }
    .pmid-part {
        font-weight: bold;
    }
    .sentence-part {
        color: #495057;
    }
    .pmid-link {
        color: #007bff;
        text-decoration: none;
        padding: 2px 4px;
        margin: 1px;
        border-radius: 3px;
        background-color: #f8f9fa;
        border: 1px solid #dee2e6;
        display: inline-block;
    }
    .pmid-link:hover {
        text-decoration: none;
        background-color: #007bff;
        color: white;
    }
    .footer {
        text-align: center;
        padding: 20px;
        color: #666;
        font-size: 0.9em;
        margin-top: 30px;
    }
    </style>
    </head><body><div class='container'><div class='header'><h1>Causal Knowledge Trace - Evidence Report</h1></div>
<div class='section'><h2>ðŸ”— Causal Assertions</h2>
<div class='streamlined-assertion'><div class='streamlined-header sticky-relation-header'><span class='label-text'>Subject:</span> <strong>APP_gene</strong> <span class='label-text'>Subject CUI:</span> <strong>C1364818</strong> â†’ <span class='label-text predicate-text'>CAUSES</span> â†’ <span class='label-text'>Object:</span> <strong>Alzheimers</strong> <span class='label-text'>Object CUI:</span> <strong>C0750901</strong></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/16369530' target='_blank' class='pmid-link'>16369530</a>:</span> <span class='sentence-part'>APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20955934' target='_blank' class='pmid-link'>20955934</a>:</span> <span class='sentence-part'>Positional cloning led to the identification of rare, disease-causing mutations in APP, PSEN1, and PSEN2 causing early-onset familial AD, followed by the discovery of APOE as the single most important risk factor for late-onset AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25018108' target='_blank' class='pmid-link'>25018108</a>:</span> <span class='sentence-part'>Together, our data suggest that APP K724M gene mutation may contribute to the cause of this Chinese early-onset familial AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25220527' target='_blank' class='pmid-link'>25220527</a>:</span> <span class='sentence-part'>In addition to mutations in APP, PSEN1 and PSEN2 genes, that cause early onset autosomal dominant AD, several genetic risk factors for late onset AD are now known. Alzheimer's disease (AD) is the most common form of dementia characterized by deterioration of memory and other cognitive domains which leads to death in 3-9years after diagnosis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26225732' target='_blank' class='pmid-link'>26225732</a>:</span> <span class='sentence-part'>Although genetic Abeta variants cause early-onset Alzheimer's disease, literature reports on Abeta properties are heterogeneous, obscuring molecular mechanisms, as illustrated by recent failures of Abeta-level targeting trials.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27274215' target='_blank' class='pmid-link'>27274215</a>:</span> <span class='sentence-part'>Linkage analysis was the first milestone in unraveling the mutations in APP, PSEN1, and PSEN2 that cause early-onset AD, followed by the discovery of apolipoprotein E-epsilon4 allele as the only one genetic risk factor for late-onset AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29478590' target='_blank' class='pmid-link'>29478590</a>:</span> <span class='sentence-part'>Genetically, the first clues were provided by genetic linkage studies that led to the identification of APP, PSEN1, and PSEN2 mutations as the main causes of autosomal-dominant early-onset AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30168435' target='_blank' class='pmid-link'>30168435</a>:</span> <span class='sentence-part'>PSEN1, APP and PSEN2 are the major causes of monogenic EOAD while GRN, MAPT and C9ORF72 are the most frequently mutated genes in familial FTLD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30851551' target='_blank' class='pmid-link'>30851551</a>:</span> <span class='sentence-part'>Generation of two iPSC lines (ICGi008-A and ICGi008-B) from skin fibroblasts of a patient with early-onset Alzheimer's disease caused by London familial APP mutation (V717I).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30909216' target='_blank' class='pmid-link'>30909216</a>:</span> <span class='sentence-part'>With the exception of rare mutations in APP, PSEN1, and PSEN2 genes causing autosomal dominant EOAD, little is known about the genetic factors underlying most of the EOAD cases.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31446431' target='_blank' class='pmid-link'>31446431</a>:</span> <span class='sentence-part'>Abeta bearing the familial English H6R mutation, known to cause early-onset AD, had an even greater inhibitory effect on protein degradation through the Arg/N-end rule pathway than intact Abeta.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33519353' target='_blank' class='pmid-link'>33519353</a>:</span> <span class='sentence-part'>With the exception or rare mutations in PSEN and APP genes causing early-onset autosomal dominant AD (EOADAD), little is known about the genetic factors that underlie the vast majority (&gt;95%) of early onset AD (EOAD) cases.</span></div></div>
<div class='streamlined-assertion'><div class='streamlined-header sticky-relation-header'><span class='label-text'>Subject:</span> <strong>APP_protein_human</strong> <span class='label-text'>Subject CUI:</span> <strong>C0611285</strong> â†’ <span class='label-text predicate-text'>CAUSES</span> â†’ <span class='label-text'>Object:</span> <strong>Alzheimers</strong> <span class='label-text'>Object CUI:</span> <strong>C0002395</strong></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/10212241' target='_blank' class='pmid-link'>10212241</a>:</span> <span class='sentence-part'>Polymerization of the amyloid beta (Abeta) peptide into protease-resistant fibrils is a significant step in the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/10729621' target='_blank' class='pmid-link'>10729621</a>:</span> <span class='sentence-part'>A small fraction of AD and CAA cases are caused by gene mutations leading to increased production and deposition of Abeta, but for the majority, there is no known direct genetic cause. Brain deposition of the amyloid beta-peptide (Abeta) is a critical step in the pathogenesis of Alzheimer's disease (AD) and human cerebral amyloid angiopathy (CAA).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/10880853' target='_blank' class='pmid-link'>10880853</a>:</span> <span class='sentence-part'>The amyloid beta-peptide (A beta), a hallmark in the pathogenesis of AD and the main component of senile plaques, generates free radicals in a metal-catalyzed reaction inducing neuronal cell death by a reactive oxygen species mediated process which damage neuronal membrane lipids, proteins and nucleic acids.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/10899433' target='_blank' class='pmid-link'>10899433</a>:</span> <span class='sentence-part'>Polymerization of the amyloid beta-peptide (Abeta) has been identified as a major feature of the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/10949910' target='_blank' class='pmid-link'>10949910</a>:</span> <span class='sentence-part'>BACKGROUND: The amyloid beta (Abeta) peptide is a key molecule in the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/11483961' target='_blank' class='pmid-link'>11483961</a>:</span> <span class='sentence-part'>The former process (termed gamma-secretase cleavage) generates amyloid beta-peptide (Abeta), which is involved in the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/11588612' target='_blank' class='pmid-link'>11588612</a>:</span> <span class='sentence-part'>The formation, aggregation and deposition of amyloid beta peptide (Abeta) is implicated in the aetiology of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/11786314' target='_blank' class='pmid-link'>11786314</a>:</span> <span class='sentence-part'>The amyloid beta peptide as the major culprit of Alzheimer's disease pathogenesis entered the research arena about a decade ago.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/11815632' target='_blank' class='pmid-link'>11815632</a>:</span> <span class='sentence-part'>Extracellular amyloid beta peptides (Abetas) have long been thought to be a primary cause of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/11912198' target='_blank' class='pmid-link'>11912198</a>:</span> <span class='sentence-part'>Amyloid plaques formed by aggregation of the amyloid beta-peptide (Abeta) are an intrinsic component of Alzheimer disease pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/12025816' target='_blank' class='pmid-link'>12025816</a>:</span> <span class='sentence-part'>Increased production of neurotoxic forms of amyloid beta-peptide (Abeta) and abnormalities in neuronal calcium homeostasis play central roles in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/12025858' target='_blank' class='pmid-link'>12025858</a>:</span> <span class='sentence-part'>Our data show that Abeta can impair cortical neurogenesis, and suggest that this adverse effect of Abeta contributes to the depletion of neurons and the resulting olfactory and cognitive deficits in AD. We now report that amyloid beta-peptide (Abeta), a self-aggregating neurotoxic protein thought to cause AD, can impair neurogenesis in the SVZ/cerebral cortex of adult mice and in human cortical NPC in culture.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/12063304' target='_blank' class='pmid-link'>12063304</a>:</span> <span class='sentence-part'>The amyloid-beta (A beta) peptide, which is derived from the amyloid precursor protein (APP), is involved in the pathogenesis of Alzheimer's dementia and impairs endothelium-dependent vasodilation in cerebral vessels.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/12074840' target='_blank' class='pmid-link'>12074840</a>:</span> <span class='sentence-part'>Metabolism of amyloid-beta peptide (Abeta) is closely associated with the pathology and etiology of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/12176077' target='_blank' class='pmid-link'>12176077</a>:</span> <span class='sentence-part'>Over the past several years, experiments with synthetic amyloid-beta peptide (Abeta) and animal models have strongly suggested that pathogenesis of Alzheimer's disease (AD) involves soluble assemblies of Abeta peptides (Trends Neurosci. 24 (2001) 219).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/12359256' target='_blank' class='pmid-link'>12359256</a>:</span> <span class='sentence-part'>Polymerization of the amyloid beta-peptide (Abeta) has been identified as a major feature of the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/12391610' target='_blank' class='pmid-link'>12391610</a>:</span> <span class='sentence-part'>Metabolism of amyloid-beta peptide (A beta) is closely associated with the pathology and etiology of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/12392766' target='_blank' class='pmid-link'>12392766</a>:</span> <span class='sentence-part'>Amyloid beta-peptide [Abeta(1-42)] is central to the pathogenesis of Alzheimer's disease (AD), and the AD brain is under intense oxidative stress, including membrane lipid peroxidation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/12446966' target='_blank' class='pmid-link'>12446966</a>:</span> <span class='sentence-part'>It is generally accepted that amyloid beta peptides (Abeta) play a significant role in the etiology of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/12446972' target='_blank' class='pmid-link'>12446972</a>:</span> <span class='sentence-part'>Over-production and/or altered metabolism of AbetaPP, resulting in increased amyloid beta-peptide (Abeta), appear pivotal in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/12493601' target='_blank' class='pmid-link'>12493601</a>:</span> <span class='sentence-part'>The amyloid precursor protein (APP) and its proteolytic cleavage products, the amyloid beta peptides, have been implicated as a cause of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/12607822' target='_blank' class='pmid-link'>12607822</a>:</span> <span class='sentence-part'>Amyloid beta-peptide (1-42) [Abeta(1-42)] may be central to the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/12846562' target='_blank' class='pmid-link'>12846562</a>:</span> <span class='sentence-part'>Cellular release and subsequent aggregation of the amyloid-beta peptide is thought to be causative for the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/14646594' target='_blank' class='pmid-link'>14646594</a>:</span> <span class='sentence-part'>Amyloid beta-peptide (Abeta), a causative molecule in the pathogenesis of Alzheimer's disease and the main component of senile plaques, is known to be neurotoxic in vitro and in vivo.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/14698294' target='_blank' class='pmid-link'>14698294</a>:</span> <span class='sentence-part'>Extensive data suggest that the conversion of the amyloid-beta (Abeta) peptide from soluble to insoluble forms is a key factor in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/14732699' target='_blank' class='pmid-link'>14732699</a>:</span> <span class='sentence-part'>Amyloid-beta peptide (Abeta) is central to the pathogenesis of Alzheimer's disease, and the low-density lipoprotein receptor-related protein (LRP) has been shown to alter Abeta metabolism in vitro.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/15065253' target='_blank' class='pmid-link'>15065253</a>:</span> <span class='sentence-part'>The cerebral deposition of amyloid beta-peptide, a central event in Alzheimer's disease (AD) pathogenesis, begins several years before the onset of clinical symptoms.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/15267231' target='_blank' class='pmid-link'>15267231</a>:</span> <span class='sentence-part'>Gamma-secretase is the second of two proteolytic enzymes responsible for the release of the amyloid beta-peptide implicated in the etiology of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/15304503' target='_blank' class='pmid-link'>15304503</a>:</span> <span class='sentence-part'>Because Abeta peptides are thought to be causative for Alzheimer's disease, inhibiting gamma-secretase represents a potential treatment for this neurodegenerative condition.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/15341515' target='_blank' class='pmid-link'>15341515</a>:</span> <span class='sentence-part'>Gamma-secretase performs the final processing step in the generation of amyloid-beta (Abeta) peptides, which are believed to be causative for Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/15347683' target='_blank' class='pmid-link'>15347683</a>:</span> <span class='sentence-part'>The deposition of the amyloid beta (Abeta) peptide in neuritic plaques plays a critical role in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/15502844' target='_blank' class='pmid-link'>15502844</a>:</span> <span class='sentence-part'>The Arctic mutation within the amyloid-beta (Abeta) peptide causes Alzheimer disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/15633014' target='_blank' class='pmid-link'>15633014</a>:</span> <span class='sentence-part'>A second example is the cleavage of amyloid beta-peptide by IgM and IgG from aged humans, a phenomenon that may represent a specific proteolytic response to a neurotoxic endogenous peptide implicated in the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/15880461' target='_blank' class='pmid-link'>15880461</a>:</span> <span class='sentence-part'>The potential neurotoxicity of soluble forms of amyloid beta peptide (Abeta) as a key factor in early pathogenesis of Alzheimer's disease is being recognized.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/15882358' target='_blank' class='pmid-link'>15882358</a>:</span> <span class='sentence-part'>In this review, the case is made that amyloid-beta peptide in the brain of patients with Alzheimer's disease is a primary cause of the disease and that immunotherapy directed against this peptide has the potential to halt and/or reverse disease progression.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/15955457' target='_blank' class='pmid-link'>15955457</a>:</span> <span class='sentence-part'>Protection against amyloid beta-peptide (1-42)-induced loss of phospholipid asymmetry in synaptosomal membranes by tricyclodecan-9-xanthogenate (D609) and ferulic acid ethyl ester: implications for Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/15959937' target='_blank' class='pmid-link'>15959937</a>:</span> <span class='sentence-part'>LRP also binds the amyloid precursor protein (APP) and its proteolytic fragment, the amyloid-beta peptide (Abeta), which are major players in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/15975052' target='_blank' class='pmid-link'>15975052</a>:</span> <span class='sentence-part'>The amyloid beta-peptide (Abeta) plays an early and critical role in the pathogenic cascade leading to Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/16255678' target='_blank' class='pmid-link'>16255678</a>:</span> <span class='sentence-part'>Aberrant production or decreased clearance of amyloid-beta peptides is widely accepted to be causative for AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/16364896' target='_blank' class='pmid-link'>16364896</a>:</span> <span class='sentence-part'>Aggregation of the amyloid-beta (Abeta) peptide in the extracellular space of the brain is central to Alzheimer's disease pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/16446073' target='_blank' class='pmid-link'>16446073</a>:</span> <span class='sentence-part'>Ectodomain shedding of the amyloid precursor protein (APP) is a key regulatory step in the generation of the amyloid beta peptide (Abeta), which is thought to provoke the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/16595673' target='_blank' class='pmid-link'>16595673</a>:</span> <span class='sentence-part'>Amyloid-beta peptide (Abeta) is pivotal to the pathogenesis of Alzheimer disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/16696577' target='_blank' class='pmid-link'>16696577</a>:</span> <span class='sentence-part'>Genetic and experimental evidence points to amyloid-beta (Abeta) peptide as the culprit in Alzheimer's disease pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/16781151' target='_blank' class='pmid-link'>16781151</a>:</span> <span class='sentence-part'>The interaction of amyloid beta peptide (Abeta) and Abeta-binding alcohol dehydrogenase (ABAD) was recently implicated in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/16817891' target='_blank' class='pmid-link'>16817891</a>:</span> <span class='sentence-part'>The amyloid beta peptide (A beta) is crucial for the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/16893185' target='_blank' class='pmid-link'>16893185</a>:</span> <span class='sentence-part'>Aggregation of the 40-42 residue amyloid beta-peptide (Abeta) into amyloid plaques is a central event in Alzheimer's disease (AD) pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/16897184' target='_blank' class='pmid-link'>16897184</a>:</span> <span class='sentence-part'>Deposition of amyloid beta-peptide (Abeta) and neurofibrillary tangles in the brain are hallmarks of Alzheimer's disease (AD) pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/16946102' target='_blank' class='pmid-link'>16946102</a>:</span> <span class='sentence-part'>Accumulation of amyloid beta-peptide (Abeta) is considered a key step in the etiology of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17035538' target='_blank' class='pmid-link'>17035538</a>:</span> <span class='sentence-part'>Aberrant processing of the amyloid precursor protein (APP) and the subsequent accumulation of amyloid beta (Abeta) peptide has been widely established as a central event in Alzheimer's disease (AD) pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17054909' target='_blank' class='pmid-link'>17054909</a>:</span> <span class='sentence-part'>Amyloid beta-peptide (Abeta) and glutamate are generally believed to be closely related to the pathogenesis of Alzheimer's disease and cerebrovascular disease, respectively.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17169612' target='_blank' class='pmid-link'>17169612</a>:</span> <span class='sentence-part'>Data accumulated during the past two decades place amyloid beta-peptide (Abeta) at center stage as the main perpetrator in initiating the pathological cascade that eventually leads to Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17177887' target='_blank' class='pmid-link'>17177887</a>:</span> <span class='sentence-part'>We have found that a quartz-crystal microbalance is a facile and useful tool for detecting the specific aggregation of the amyloid-beta peptides responsible for Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17382287' target='_blank' class='pmid-link'>17382287</a>:</span> <span class='sentence-part'>The aggregation and deposition onto neuronal cells of amyloid beta-peptide (Abeta) is central to the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17404210' target='_blank' class='pmid-link'>17404210</a>:</span> <span class='sentence-part'>The conformational change in amyloid beta (Abeta) peptide from its monomeric form to aggregates is crucial in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17428603' target='_blank' class='pmid-link'>17428603</a>:</span> <span class='sentence-part'>Alternative proteolytic processing of APP releases potentially neurotoxic species, including the amyloid-beta (Abeta) peptide that is centrally implicated in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17471072' target='_blank' class='pmid-link'>17471072</a>:</span> <span class='sentence-part'>Accumulating evidence suggests that amyloid beta-peptide (1-42) plays an important role in the etiology of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17495608' target='_blank' class='pmid-link'>17495608</a>:</span> <span class='sentence-part'>Intracellular cholesterol levels influence the generation of amyloid-beta peptides, the toxic species thought to be a primary cause of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17511455' target='_blank' class='pmid-link'>17511455</a>:</span> <span class='sentence-part'>Dysfunctional interactions of metal ions, especially Cu, Zn, and Fe, with the amyloid-beta (A beta) peptide are hypothesized to play an important role in the etiology of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17551018' target='_blank' class='pmid-link'>17551018</a>:</span> <span class='sentence-part'>Aggregation of the amyloid-beta (Abeta) peptide in the extracellular space of the brain is critical in the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17606418' target='_blank' class='pmid-link'>17606418</a>:</span> <span class='sentence-part'>The amyloid cascade hypothesis assigns the amyloid-beta peptide (Abeta) a central role in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17876751' target='_blank' class='pmid-link'>17876751</a>:</span> <span class='sentence-part'>Amyloid beta peptide (Abeta) fibril formation is widely believed to be the causative event of Alzheimer's disease pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17897958' target='_blank' class='pmid-link'>17897958</a>:</span> <span class='sentence-part'>BACE1 (beta-site amyloid precursor protein-cleaving enzyme-1) is a membrane-bound aspartic protease that cleaves amyloid precursor protein to produce a neurotoxic peptide, amyloid beta-peptide, and has been implicated in triggering the pathogenesis of Alzheimer disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17997700' target='_blank' class='pmid-link'>17997700</a>:</span> <span class='sentence-part'>Amyloid-beta peptide (Abeta), a major peptide deposited in neuritic plaques, has been considered as an important initiating molecule in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/18063474' target='_blank' class='pmid-link'>18063474</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) is a neurodegenerative disorder, due to excess amyloid-beta peptide (Abeta).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/18252750' target='_blank' class='pmid-link'>18252750</a>:</span> <span class='sentence-part'>The 'amyloid cascade hypothesis' assigns the amyloid-beta-peptide (Abeta) a central role in the pathogenesis of AD. Although it is not yet established, whether the resulting Abeta aggregates are the causative agent or just a result of the disease progression, polymerization of Abeta has been identified as a major feature during AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/18258258' target='_blank' class='pmid-link'>18258258</a>:</span> <span class='sentence-part'>Aggregation of the amyloid beta (A beta) peptide plays a key role in the molecular etiology of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/18385378' target='_blank' class='pmid-link'>18385378</a>:</span> <span class='sentence-part'>beta-Site APP-cleaving enzyme 1 (BACE1) is required for the penultimate cleavage of the amyloid-beta precursor protein (APP) leading to the generation of amyloid-beta peptides that is central to the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/18387708' target='_blank' class='pmid-link'>18387708</a>:</span> <span class='sentence-part'>Amyloid-beta peptide (Abeta) has been proposed to be the primary cause of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/18400162' target='_blank' class='pmid-link'>18400162</a>:</span> <span class='sentence-part'>Aggregation of amyloid-beta (Abeta) peptide into soluble and insoluble forms within the brain extracellular space is central to the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/18411275' target='_blank' class='pmid-link'>18411275</a>:</span> <span class='sentence-part'>The catalytic domain of insulin-degrading enzyme forms a denaturant-resistant complex with amyloid beta peptide: implications for Alzheimer disease pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/18471993' target='_blank' class='pmid-link'>18471993</a>:</span> <span class='sentence-part'>The aggregation of amyloid beta-peptide (Abeta) into beta-sheet-rich aggregates is a crucial step in the etiology of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/18625450' target='_blank' class='pmid-link'>18625450</a>:</span> <span class='sentence-part'>The 4-kDa amyloid beta-peptide (Abeta) is strongly implicated the pathogenesis of Alzheimer's disease (AD), and this peptide is cut out of the amyloid beta-protein precursor (APP) by the sequential action of beta- and gamma-secretases. gamma-Secretase is a membrane-embedded protease complex that cleaves the transmembrane region of APP to produce Abeta, and this protease is a top target for developing AD therapeutics.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/18930548' target='_blank' class='pmid-link'>18930548</a>:</span> <span class='sentence-part'>Neurotoxic oligomers of amyloid beta (Abeta) peptide have been incriminated in the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/18957217' target='_blank' class='pmid-link'>18957217</a>:</span> <span class='sentence-part'>Impaired degradation of amyloid beta (Abeta) peptides could lead to Abeta accumulation, an early trigger of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/19057576' target='_blank' class='pmid-link'>19057576</a>:</span> <span class='sentence-part'>Amyloid beta-peptide (Abeta) accumulation leads to neurodegeneration and Alzheimer disease; however, amyloid metabolism is a dynamic process and enzymic mechanisms exist for Abeta removal.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/19075706' target='_blank' class='pmid-link'>19075706</a>:</span> <span class='sentence-part'>Extracellular deposition of amyloid beta-peptide (Abeta) has been implicated as a critical step in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/19122666' target='_blank' class='pmid-link'>19122666</a>:</span> <span class='sentence-part'>Amyloid-beta (Abeta) peptides, widely presumed to cause Alzheimer's disease, increased mouse neuronal expression of collagen VI through a mechanism involving transforming growth factor signaling.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/19198114' target='_blank' class='pmid-link'>19198114</a>:</span> <span class='sentence-part'>Genetic and biological studies provide evidence that the production and deposition of amyloid-beta peptides (Abeta) contribute to the etiology of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/19277012' target='_blank' class='pmid-link'>19277012</a>:</span> <span class='sentence-part'>Accumulation of aggregated amyloid-beta (Abeta) peptide was studied as an initial step for Alzheimer's disease (AD) pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/19352532' target='_blank' class='pmid-link'>19352532</a>:</span> <span class='sentence-part'>Dysfunctional interactions of metal ions, especially those of Cu, Zn, and Fe, with the amyloid-beta (Abeta) peptide are hypothesised to play an important role in the aetiology of AD, and disruption of these aberrant metal-peptide interactions via chelation therapy holds considerable promise as a therapeutic strategy.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/19402777' target='_blank' class='pmid-link'>19402777</a>:</span> <span class='sentence-part'>Genetic and biological studies provide strong evidence that the deposition of amyloid-beta peptide (Abeta) contributes to the etiology of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/19450545' target='_blank' class='pmid-link'>19450545</a>:</span> <span class='sentence-part'>The overproduction and extracellular buildup of amyloid-beta peptide (Abeta) is a critical step in the etiology of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/19469700' target='_blank' class='pmid-link'>19469700</a>:</span> <span class='sentence-part'>Most disease-modifying therapeutic approaches in Alzheimer's disease (AD) aim to reduce the accumulation of neurotoxic amyloid-beta (Abeta) peptides as a hallmark of AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/19558683' target='_blank' class='pmid-link'>19558683</a>:</span> <span class='sentence-part'>Extensive genetic, biochemical, and histological evidence has implicated the amyloid-beta peptide (Abeta) in Alzheimer's disease pathogenesis, and several mechanisms have been suggested, such as metal binding, reactive oxygen species production, and membrane pore formation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/19646546' target='_blank' class='pmid-link'>19646546</a>:</span> <span class='sentence-part'>The neurotoxic amyloid-beta-peptide (Abeta) is important in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/19751725' target='_blank' class='pmid-link'>19751725</a>:</span> <span class='sentence-part'>Subcellular and metabolic examination of amyloid-beta peptides in Alzheimer disease pathogenesis: evidence for Abeta(25-35).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/19782682' target='_blank' class='pmid-link'>19782682</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) is the principal cause of dementia in older people, and accumulation of amyloid-beta (Abeta) peptide is a crucial event in AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/19837693' target='_blank' class='pmid-link'>19837693</a>:</span> <span class='sentence-part'>The hypothesis that amyloid-beta (Abeta) peptides are the primary cause of Alzheimer's disease (AD) remains the best supported theory of AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/19841277' target='_blank' class='pmid-link'>19841277</a>:</span> <span class='sentence-part'>Accumulation of amyloid beta-peptide (Abeta) and tau aggregates, possibly linked to age-associated deficiencies in protein homeostasis, appear to cause Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/19862643' target='_blank' class='pmid-link'>19862643</a>:</span> <span class='sentence-part'>Recent evidence has been provided that neuronal IGF1-R increases during aging leading to activation of a signaling pathway that causes an increased production of amyloid beta-peptide, the principal event in the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/19906677' target='_blank' class='pmid-link'>19906677</a>:</span> <span class='sentence-part'>Microglia are critical for amyloid-beta peptide (Abeta)-mediated neuronal perturbation relevant to Alzheimer's disease (AD) pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/19926793' target='_blank' class='pmid-link'>19926793</a>:</span> <span class='sentence-part'>The amyloid-beta (Abeta) peptide, widely known as the causative molecule of Alzheimer disease (AD), is generated by the sequential cleavage of amyloid precursor protein (APP) by the aspartyl proteases BACE1/beta-secretase and presenilin/gamma-secretase.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/19928820' target='_blank' class='pmid-link'>19928820</a>:</span> <span class='sentence-part'>The adsorption and aggregation of the amyloid-beta (Abeta) peptides on the cell membrane plays a causal role in the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20008660' target='_blank' class='pmid-link'>20008660</a>:</span> <span class='sentence-part'>BACKGROUND: Supported by compelling genetic data regarding early-onset familial Alzheimer disease (AD), the amyloid beta-peptide (Abeta)-centric theory holds that Abeta is involved in the pathogenesis of sporadic AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20014755' target='_blank' class='pmid-link'>20014755</a>:</span> <span class='sentence-part'>Amyloid-beta (Abeta) peptides exhibit many distinct structural morphology at the early aggregate stage, some of which are biological relevant to the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20021564' target='_blank' class='pmid-link'>20021564</a>:</span> <span class='sentence-part'>The protease not only releases small peptides, such as the amyloid-beta peptide, which drives Alzheimer's disease pathogenesis, but also intracellular domains, which can have critical functions in nuclear signaling.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20026079' target='_blank' class='pmid-link'>20026079</a>:</span> <span class='sentence-part'>Aggregation of the amyloid-beta (Abeta) peptide is considered a central event in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20030227' target='_blank' class='pmid-link'>20030227</a>:</span> <span class='sentence-part'>Several lines of evidence indicate that the production and deposition of amyloid-beta peptides (Abeta) contribute to the etiology of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20088802' target='_blank' class='pmid-link'>20088802</a>:</span> <span class='sentence-part'>Overwhelming evidence supports a central role for the amyloid beta-peptide (Abeta) in the pathogenesis of Alzheimer's disease (AD), and the proteases that produce Abeta from its precursor protein APP are top targets for therapeutic intervention.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20157254' target='_blank' class='pmid-link'>20157254</a>:</span> <span class='sentence-part'>Misfolding, oligomerization, and aggregation of the amyloid-beta (Abeta) peptide is widely recognized as a central event in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20447471' target='_blank' class='pmid-link'>20447471</a>:</span> <span class='sentence-part'>We recently reported that amyloid-beta peptide, thought to be a key mediator of AD pathogenesis, engenders S-nitrosylation and thus hyperactivation of the mitochondrial fission protein Drp1.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20456731' target='_blank' class='pmid-link'>20456731</a>:</span> <span class='sentence-part'>The abnormal processing of amyloid-beta peptide (A beta) and resultant formation of fibrillar A beta (fA beta) are major events in the pathogenesis of Alzheimer disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20483339' target='_blank' class='pmid-link'>20483339</a>:</span> <span class='sentence-part'>The amphipathicity of the natively unstructured amyloid-beta (Abeta40) peptide may play an important role in its aggregation into beta-sheet rich fibrils, which is linked to the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20514639' target='_blank' class='pmid-link'>20514639</a>:</span> <span class='sentence-part'>At present, it is rather accepted that amyloid-beta peptide acts in parallel with other factors causing Alzheimer's disease that should be also considered at the time of designing useful therapeutic strategies.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20590832' target='_blank' class='pmid-link'>20590832</a>:</span> <span class='sentence-part'>The turn formation at positions 22 and 23 in the 42-mer amyloid beta peptide: the emerging role in the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20596738' target='_blank' class='pmid-link'>20596738</a>:</span> <span class='sentence-part'>At relatively early ages, Down syndrome patients develop progressive formation and extracellular aggregation of amyloid-beta peptide, considered as one of the causal factors for the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20643087' target='_blank' class='pmid-link'>20643087</a>:</span> <span class='sentence-part'>Amyloid-beta (Abeta) peptides and other amyloidogenic proteins can form a wide range of soluble oligomers of varied morphologies at the early aggregation stage, and some of these oligomers are biologically relevant to the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20674685' target='_blank' class='pmid-link'>20674685</a>:</span> <span class='sentence-part'>The amyloid beta-peptide (Abeta), which is thought to be the major cause of Alzheimer's disease (AD), is known to be capable of aggregating in different states: soluble monomers and oligomers, and insoluble aggregates.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20691893' target='_blank' class='pmid-link'>20691893</a>:</span> <span class='sentence-part'>The axonal protein tau and amyloid beta-peptide (Abeta) are key players in the pathogenesis of Alzheimer's disease, and tau mediates Abeta toxicity, but it is not clear how.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20721410' target='_blank' class='pmid-link'>20721410</a>:</span> <span class='sentence-part'>It is well known that oligomeric/aggregated amyloid beta peptides are a key player in the pathogenesis of Alzheimer's disease and that different nanoparticles influence oligomerization/aggregation processes in experiments in vitro.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20858952' target='_blank' class='pmid-link'>20858952</a>:</span> <span class='sentence-part'>Laboratory research on anesthetic-induced structural changes of amyloid beta (Abeta) peptide, from normal monomeric alpha-helix to the micro-aggregated form, has generated much interest in the scientific community as Abeta oligomerization is considered a key step in Alzheimer disease pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20974113' target='_blank' class='pmid-link'>20974113</a>:</span> <span class='sentence-part'>Amyloid-beta peptide (Abeta) is shown to be toxic to the mitochondria and implicates this organelle in the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21068297' target='_blank' class='pmid-link'>21068297</a>:</span> <span class='sentence-part'>Nonetheless, a growing body of evidence shows that Abeta peptides are unlikely to be the sole factor in AD etiology.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21091946' target='_blank' class='pmid-link'>21091946</a>:</span> <span class='sentence-part'>The identification of disease-causing mutations in Alzheimer's disease has contributed greatly to the understanding of the pathogenesis of this disease. The amyloid-beta (Abeta) peptide has come into focus and is believed to be central to the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21223993' target='_blank' class='pmid-link'>21223993</a>:</span> <span class='sentence-part'>Among the pathological factors known to be associated with Alzheimer disease (AD), oxidative stress induced by the amyloid-beta peptide (Abeta) has been demonstrated to play a key role in human brain and animal models of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21297277' target='_blank' class='pmid-link'>21297277</a>:</span> <span class='sentence-part'>Amyloid-beta peptide (Abeta) is recognized by many as the leading cause of Alzheimer's disease (AD), and Abeta oligomers play a major role in the early-onset form of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21491887' target='_blank' class='pmid-link'>21491887</a>:</span> <span class='sentence-part'>The interaction of amyloid-beta (Abeta) peptide with Cu(II) appears to play an important role in the etiology of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21513747' target='_blank' class='pmid-link'>21513747</a>:</span> <span class='sentence-part'>Amyloid-beta peptide (Abeta) is believed to be central in the pathogenesis of Alzheimer's disease (AD) characterized by cognitive deficits.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21527912' target='_blank' class='pmid-link'>21527912</a>:</span> <span class='sentence-part'>Extracellular phosphorylation of the amyloid beta-peptide promotes formation of toxic aggregates during the pathogenesis of Alzheimer's disease. However, mechanisms that increase the aggregation of wild-type Abeta and cause the much more common sporadic forms of AD are largely unknown.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21559427' target='_blank' class='pmid-link'>21559427</a>:</span> <span class='sentence-part'>Amyloid beta-peptide (Abeta) accumulation leads to neurodegeneration and Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21629967' target='_blank' class='pmid-link'>21629967</a>:</span> <span class='sentence-part'>The calcium homeostasis modulator 1 (CALHM1) gene codes for a novel cerebral calcium channel controlling intracellular calcium homeostasis and amyloid-beta (Abeta) peptide metabolism, a key event in the etiology of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21712440' target='_blank' class='pmid-link'>21712440</a>:</span> <span class='sentence-part'>The proteolytic processing of human amyloid precursor protein (APP) into shorter aggregating amyloid beta (Abeta)-peptides, e.g., Abeta1-42, is considered a critical step in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21858698' target='_blank' class='pmid-link'>21858698</a>:</span> <span class='sentence-part'>Substantial evidence suggests that the aggregation of amyloid-beta (Abeta) peptide into fibrillar structures that is rich in beta-sheets is implicated as the cause of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21958962' target='_blank' class='pmid-link'>21958962</a>:</span> <span class='sentence-part'>Extracellular deposition of amyloid beta peptide (Abeta) has been implicated as a critical step in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22044482' target='_blank' class='pmid-link'>22044482</a>:</span> <span class='sentence-part'>Amyloid-beta peptide (Abeta), which is generated by the beta- and gamma-secretase-mediated proteolysis of beta-amyloid precursor protein (APP), plays an important role in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22090477' target='_blank' class='pmid-link'>22090477</a>:</span> <span class='sentence-part'>According to the amyloid cascade hypothesis, cerebral deposition of amyloid-beta peptide (Abeta) is critical for Alzheimer's disease (AD) pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22102917' target='_blank' class='pmid-link'>22102917</a>:</span> <span class='sentence-part'>The accumulation of the amyloid-beta peptide (Abeta) into amyloid plaques, an essential event in Alzheimer's disease (AD) pathogenesis, has caused researchers to seek compounds that physiologically bind Abeta and modulate its aggregation and neurotoxicity.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22202057' target='_blank' class='pmid-link'>22202057</a>:</span> <span class='sentence-part'>RAGE is an important cellular cofactor for amyloid beta-peptide (Abeta)-mediated cellular perturbation relevant to the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22267726' target='_blank' class='pmid-link'>22267726</a>:</span> <span class='sentence-part'>Pyroglutamate-modified Abeta peptides at amino acid position three (Abeta(pE3-42)) are gaining considerable attention as potential key players in the pathogenesis of Alzheimer disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22279212' target='_blank' class='pmid-link'>22279212</a>:</span> <span class='sentence-part'>An early role of amyloid-beta peptide (Abeta) aggregation in Alzheimer's disease pathogenesis is well established.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22332002' target='_blank' class='pmid-link'>22332002</a>:</span> <span class='sentence-part'>The 42-mer amyloid beta (Abeta42) peptide is thought to be a culprit in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22384101' target='_blank' class='pmid-link'>22384101</a>:</span> <span class='sentence-part'>Here we report for the first time that tacrine-6-ferulic acid (T6FA), one of these compounds, can prevent amyloid-beta peptide (Abeta)-induced AD-associated pathological changes in vitro and in vivo.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22514691' target='_blank' class='pmid-link'>22514691</a>:</span> <span class='sentence-part'>Amyloid beta (Abeta) peptide is the key molecule in AD pathogenesis, and has been highlighted in the implication of mitochondrial abnormality during the disease progress.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22528098' target='_blank' class='pmid-link'>22528098</a>:</span> <span class='sentence-part'>Neurotoxicity in Alzheimer's disease (AD) is associated to dishomeostasis of intracellular Ca(2+) induced by amyloid beta peptide (Abeta) species.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22544746' target='_blank' class='pmid-link'>22544746</a>:</span> <span class='sentence-part'>Aggregates of amyloid-beta (Abeta) peptides have been implicated in the etiology of Alzheimer disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22551668' target='_blank' class='pmid-link'>22551668</a>:</span> <span class='sentence-part'>Cholesterol accumulation in Niemann-Pick type C disease (NPC) causes increased levels of the amyloid-precursor-protein C-terminal fragments (APP-CTFs) and intracellular amyloid-beta peptide (Abeta), the two central molecules in Alzheimer's disease (AD) pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22570624' target='_blank' class='pmid-link'>22570624</a>:</span> <span class='sentence-part'>The aggregation or oligomerization of amyloid-beta (Abeta) peptide is thought to be the primary causative event in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22621900' target='_blank' class='pmid-link'>22621900</a>:</span> <span class='sentence-part'>Proteolytic processing of the amyloid-beta precursor protein (APP) and generation of amyloid-beta peptide (Abeta) are key events in Alzheimer's disease (AD) pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22735675' target='_blank' class='pmid-link'>22735675</a>:</span> <span class='sentence-part'>Amyloid-beta peptide (Abeta) is considered a key protein in the pathogenesis of Alzheimer's disease (AD) because of its neurotoxicity and capacity to form characteristic insoluble deposits known as senile plaques.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22834820' target='_blank' class='pmid-link'>22834820</a>:</span> <span class='sentence-part'>Amyloid beta peptides, causative factors for AD, potentiate the influx of Ca(2+) into neurons via L-VDCCs.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22879596' target='_blank' class='pmid-link'>22879596</a>:</span> <span class='sentence-part'>The amyloid beta (Abeta) peptide, which is abundantly found in the brains of patients suffering from Alzheimer disease, is central in the pathogenesis of this disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22886024' target='_blank' class='pmid-link'>22886024</a>:</span> <span class='sentence-part'>The Chinese hamster ovary cell line 7PA2, stably transfected with the 751 amino acid isoform of amyloid-beta protein precursor (AbetaPP) containing the Val -&gt; Phe mutation at residue 717, is one of the most used models to study the biochemistry and toxicity of secreted amyloid-beta (Abeta) peptides, particularly Abeta oligomers, which are considered to be of relevance to the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22988239' target='_blank' class='pmid-link'>22988239</a>:</span> <span class='sentence-part'>In this study, we investigated the effects of two different crowding polymers (dextran and Ficoll) and two different experimental conditions (with and without shaking) on the fibrilization of amyloid-beta peptide, a major player in AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23023105' target='_blank' class='pmid-link'>23023105</a>:</span> <span class='sentence-part'>beta-Site amyloid precursor protein cleaving enzyme-1 (BACE-1) is a transmembrane aspartic protease that mediates the initial cleavage of the amyloid precursor protein (APP), leading to the generation of amyloid-beta (Abeta) peptides that are thought to be causative of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23092134' target='_blank' class='pmid-link'>23092134</a>:</span> <span class='sentence-part'>The biogenesis and clearance of the amyloid beta peptide (A beta ), the main component of the lesions, lie at the center of the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23196551' target='_blank' class='pmid-link'>23196551</a>:</span> <span class='sentence-part'>Genetic and biological studies provide strong evidence that the deposition of amyloid-beta peptide (Abeta) contributes to the etiology of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23232068' target='_blank' class='pmid-link'>23232068</a>:</span> <span class='sentence-part'>In Alzheimer's disease, amyloid beta (Abeta) peptides and their aggregation are believed to be at least partially responsible for the etiology of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23237322' target='_blank' class='pmid-link'>23237322</a>:</span> <span class='sentence-part'>gamma-Secretase plays a central role in the generation of the Alzheimer disease-causing amyloid beta-peptide (Abeta) from the beta-amyloid precursor protein (APP) and is thus a major Alzheimer's disease drug target.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23249207' target='_blank' class='pmid-link'>23249207</a>:</span> <span class='sentence-part'>Copper(II) binding to the amyloid-beta peptide has been proposed to be a key event in the cascade leading to Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23270374' target='_blank' class='pmid-link'>23270374</a>:</span> <span class='sentence-part'>Deposition of amyloid-beta (Abeta) peptides in the brain is a central event in the pathogenesis of Alzheimer's disease (AD), which makes Abeta peptides a crucial target for therapeutic intervention.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23387074' target='_blank' class='pmid-link'>23387074</a>:</span> <span class='sentence-part'>Tyrosinase is a key enzyme related to skin pigmentation disorders of elderly people, while self-aggregation of the amyloid-beta peptide, Abeta42, has been considered as a key event in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23420419' target='_blank' class='pmid-link'>23420419</a>:</span> <span class='sentence-part'>The accumulation of extracellular amyloid-beta peptide (Abeta) has been considered as one of the important causes of Alzheimer's disease (AD), the most prevalent form of dementia.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23456036' target='_blank' class='pmid-link'>23456036</a>:</span> <span class='sentence-part'>The selenium-deficiency could possibly promote the onset and/or progression of Alzheimer's disease (AD) dementia, if the Abeta peptides initiate a sequence of events that lead to AD dementia.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23461850' target='_blank' class='pmid-link'>23461850</a>:</span> <span class='sentence-part'>In the present study, we investigated whether SalB has neuroprotective effects in an amyloid beta (Abeta) peptide-induced Alzheimer's disease mouse model.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23509904' target='_blank' class='pmid-link'>23509904</a>:</span> <span class='sentence-part'>The amyloid hypothesis asserts that excess production or reduced clearance of the amyloid-beta (Abeta) peptides in the brain initiates a sequence of events that ultimately lead to Alzheimer's disease and dementia.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23525279' target='_blank' class='pmid-link'>23525279</a>:</span> <span class='sentence-part'>The accumulation of amyloid-beta (Abeta) peptide is thought to be a major causative mechanism of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23565721' target='_blank' class='pmid-link'>23565721</a>:</span> <span class='sentence-part'>INTRODUCTION: Alzheimer's disease (AD), which is characterized by progressive intellectual deterioration, is the most common cause of dementia. beta-Secretase (or BACE1) expression is a trigger for amyloid beta peptide formation, a cause of AD, and thus is a molecular target for the development of drugs against AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23585568' target='_blank' class='pmid-link'>23585568</a>:</span> <span class='sentence-part'>Presenilin comprises the catalytic subunit of gamma-secretase, a protease responsible for the generation of amyloid-beta peptides causative of Alzheimer disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23659495' target='_blank' class='pmid-link'>23659495</a>:</span> <span class='sentence-part'>In addition to amyloid-beta (Abeta) peptide and phosphorylated tau, lipid dysregulation is suggested to participate in AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23708585' target='_blank' class='pmid-link'>23708585</a>:</span> <span class='sentence-part'>Aggregation of amyloid beta (Abeta) peptides into fibrils has been implicated in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23714261' target='_blank' class='pmid-link'>23714261</a>:</span> <span class='sentence-part'>Abundant evidence suggests a central role for the amyloid-beta (Abeta) peptide in Alzheimer's disease (AD) pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23948943' target='_blank' class='pmid-link'>23948943</a>:</span> <span class='sentence-part'>Soluble oligomeric species of amyloid-beta (Abeta) peptide are presumed to be drivers of synaptic impairment, and the resulting cognitive dysfunction in Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24008925' target='_blank' class='pmid-link'>24008925</a>:</span> <span class='sentence-part'>BACKGROUND: Generation of amyloid-beta peptide is at the beginning of a cascade that leads to Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24081144' target='_blank' class='pmid-link'>24081144</a>:</span> <span class='sentence-part'>A common hypothesis suggests that AD is caused by aggregated Abeta peptides, but treatments with either inhibitors of Abeta production or anti-Abeta antibodies showed no therapeutic value.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24251391' target='_blank' class='pmid-link'>24251391</a>:</span> <span class='sentence-part'>Accumulation, aggregation and deposition of the amyloid-beta (Abeta) peptides in the brain are widely accepted as the central events in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24295810' target='_blank' class='pmid-link'>24295810</a>:</span> <span class='sentence-part'>Amyloid beta (Abeta) peptides are key molecules in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24361736' target='_blank' class='pmid-link'>24361736</a>:</span> <span class='sentence-part'>The amyloid precursor protein (APP) and amyloid-beta (Abeta) peptide play central roles in the pathology and etiology of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24366271' target='_blank' class='pmid-link'>24366271</a>:</span> <span class='sentence-part'>Accumulation of the amyloid-beta (Abeta) peptide in the brain seems to initiate a cascade of key events in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24446231' target='_blank' class='pmid-link'>24446231</a>:</span> <span class='sentence-part'>Defective clearance of the amyloid-beta peptide (Abeta) from the brain is considered a strong promoter in Alzheimer's disease (AD) pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24494584' target='_blank' class='pmid-link'>24494584</a>:</span> <span class='sentence-part'>The amyloid-beta (Abeta) peptide is one key molecule in the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24503618' target='_blank' class='pmid-link'>24503618</a>:</span> <span class='sentence-part'>Amyloid-beta peptide (Abeta), the cerebral accumulation of which is thought to cause Alzheimer's disease (AD), is produced throughout life.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24503620' target='_blank' class='pmid-link'>24503620</a>:</span> <span class='sentence-part'>Since both modifications are increased in Alzheimer's disease (AD) due to amyloid-beta peptide (Abeta) accumulation, we have studied their effect on albumin, the most abundant protein in cerebrospinal fluid and blood.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24512022' target='_blank' class='pmid-link'>24512022</a>:</span> <span class='sentence-part'>Amyloid-beta (Abeta) peptide is the original causative factor of Alzheimer's disease (AD) according to the amyloid cascade hypothesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24566006' target='_blank' class='pmid-link'>24566006</a>:</span> <span class='sentence-part'>Amyloid beta (Abeta) peptides, which are generated from amyloid precursor protein (APP), are thought to play a major role in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24649396' target='_blank' class='pmid-link'>24649396</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) is widely considered to be caused by amyloid-beta peptide (Abeta) accumulation in the brain.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24815946' target='_blank' class='pmid-link'>24815946</a>:</span> <span class='sentence-part'>Neuroinflammatory responses induced by amyloid-beta peptide (Abeta) are important causes in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24832605' target='_blank' class='pmid-link'>24832605</a>:</span> <span class='sentence-part'>Although Abeta peptides have been proposed to be the main cause of AD pathogenesis, the role of AICD has been underappreciated.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25221640' target='_blank' class='pmid-link'>25221640</a>:</span> <span class='sentence-part'>Mitochondrial functions can be negatively affected by amyloid beta peptide (Abeta), an important component in Alzheimer's disease (AD) pathogenesis, and Abeta can interact with mitochondria and cause mitochondrial dysfunction.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25456402' target='_blank' class='pmid-link'>25456402</a>:</span> <span class='sentence-part'>The cellular prion protein (PrP(C)), a cell surface glycoprotein involved in prion disorders, has been shown to mediate the toxicity of several pathological aggregates, including its own misfolded state and some oligomeric assemblies of the amyloid beta peptide, which are thought to be primarily responsible for the synaptic dysfunction characterizing Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25505877' target='_blank' class='pmid-link'>25505877</a>:</span> <span class='sentence-part'>As amyloid-beta peptide (Abeta) is a causative factor for the cognitive impairments of AD, developing a mechanistic understanding of the contribution of Abeta to cognitive impairments may yield important insights into the pathophysiology of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25533654' target='_blank' class='pmid-link'>25533654</a>:</span> <span class='sentence-part'>Amyloid-beta peptides generated by proteolysis of the beta-amyloid precursor protein (APP) play an important role in the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25553446' target='_blank' class='pmid-link'>25553446</a>:</span> <span class='sentence-part'>Amyloid-beta peptide (Abeta) is believed to be a central player in the Alzheimer disease (AD) pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25650940' target='_blank' class='pmid-link'>25650940</a>:</span> <span class='sentence-part'>The aggregation of amyloid-beta (Abeta) peptides plays a crucial role in the etiology of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25747232' target='_blank' class='pmid-link'>25747232</a>:</span> <span class='sentence-part'>The amyloid beta-peptide (Abeta) is suspected to play a central role in the cascade leading to Alzheimer's disease, but the precise mechanisms are still incompletely known.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25818846' target='_blank' class='pmid-link'>25818846</a>:</span> <span class='sentence-part'>Abeta is aggregated with Zn(2+) and the aggregation of Abeta-peptides is widely considered to be the critical step in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25825723' target='_blank' class='pmid-link'>25825723</a>:</span> <span class='sentence-part'>Metal ions have emerged to play a key role in the aggregation process of amyloid beta (Abeta) peptide that is closely related to the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25997382' target='_blank' class='pmid-link'>25997382</a>:</span> <span class='sentence-part'>In addition, phenolic compounds and hormones (cytokinins) found in coconut may assist in preventing the aggregation of amyloid-beta peptide, potentially inhibiting a key step in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26023729' target='_blank' class='pmid-link'>26023729</a>:</span> <span class='sentence-part'>The aggregation of the amyloid-beta peptide, Abeta(1-42), is believed to play an important role in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26024352' target='_blank' class='pmid-link'>26024352</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD)-associated amyloid beta peptide (Abeta) is one of the main actors in AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26092626' target='_blank' class='pmid-link'>26092626</a>:</span> <span class='sentence-part'>Flavonoids have been found to play a neuroprotective role by inhibiting and/or modifying the self-assembly of the amyloid-beta (Abeta) peptide into oligomers and fibrils, which are linked to the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26271894' target='_blank' class='pmid-link'>26271894</a>:</span> <span class='sentence-part'>Amyloid beta (Abeta) peptides are identified in cause of neurodegenerative diseases such as Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26359500' target='_blank' class='pmid-link'>26359500</a>:</span> <span class='sentence-part'>Alzheimer disease (AD) is a progressive neurodegenerative disorder characterized by loss of neurons and formation of pathological extracellular deposits induced by amyloid-beta peptide (Abeta). Thus, this study suggests that GAPDH aggregates accelerate Abeta amyloidogenesis, subsequently leading to mitochondrial dysfunction and neuronal cell death in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26491725' target='_blank' class='pmid-link'>26491725</a>:</span> <span class='sentence-part'>Decreased brain clearance of the neurotoxic amyloid-beta (Abeta) peptide is a central event in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26593432' target='_blank' class='pmid-link'>26593432</a>:</span> <span class='sentence-part'>In the present study, we investigated whether these compounds have neuroprotective effects in an amyloid-beta peptide-induced Alzheimer's disease mouse model.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26652010' target='_blank' class='pmid-link'>26652010</a>:</span> <span class='sentence-part'>Understanding of the mechanistic progess of amyloid-beta peptide (Abeta) aggregation is critical for elucidating the underlying pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26794527' target='_blank' class='pmid-link'>26794527</a>:</span> <span class='sentence-part'>We describe a strategy for fluorescent imaging of organelle transport in primary hippocampal neurons treated with amyloid-beta (Abeta) peptides that cause Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26868929' target='_blank' class='pmid-link'>26868929</a>:</span> <span class='sentence-part'>The oligomerization of amyloid beta (Abeta) peptides into soluble non-fibrillar species plays a critical role in the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26890786' target='_blank' class='pmid-link'>26890786</a>:</span> <span class='sentence-part'>Neurotoxic amyloid-beta (Abeta) peptide causing cognitive function disabilities is one of the most characteristic pathological features in Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26963025' target='_blank' class='pmid-link'>26963025</a>:</span> <span class='sentence-part'>IDE (insulin-degrading enzyme) is one of the major proteases of amyloid beta peptide (Abeta), a presumed causative molecule in Alzheimer disease (AD) pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26981406' target='_blank' class='pmid-link'>26981406</a>:</span> <span class='sentence-part'>Alzheimer's disease is the prevalent cause of premature senility, a progressive mental disorder due to degeneration in brain and deposition of amyloid beta peptide (1-42, a misfolded protein) in the form of aggregation that prevails for a prolonged time and obstructs every aspect of life. One of the primary hallmarks of the neuropathological disease is the accretion of amyloid beta peptide in the brain that leads to Alzheimer's disease, but the mechanism is still a mystery.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27030596' target='_blank' class='pmid-link'>27030596</a>:</span> <span class='sentence-part'>Accumulation of amyloid-beta (Abeta) peptide in the brain is the first critical step in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27093940' target='_blank' class='pmid-link'>27093940</a>:</span> <span class='sentence-part'>Accumulating evidence points to the amyloid-beta (Abeta) peptide as the culprit in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27137996' target='_blank' class='pmid-link'>27137996</a>:</span> <span class='sentence-part'>Amyloid-beta peptides form polymorphous amyloid fibrils are correlated with the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27151330' target='_blank' class='pmid-link'>27151330</a>:</span> <span class='sentence-part'>BACKGROUND: The accumulation, aggregation and deposition of amyloid-beta (Abeta) peptides in the brain are central to the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27163800' target='_blank' class='pmid-link'>27163800</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) is thought to be caused by amyloid-beta peptide that triggers tau hyperphosphorylation, which is neurotoxic.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27392871' target='_blank' class='pmid-link'>27392871</a>:</span> <span class='sentence-part'>The involvement of Abeta peptides in the etiology of AD remains a subject of debate.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27441457' target='_blank' class='pmid-link'>27441457</a>:</span> <span class='sentence-part'>The aggregation of amyloid-beta peptides (Abeta) is considered as the main possible cause of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27562438' target='_blank' class='pmid-link'>27562438</a>:</span> <span class='sentence-part'>Polyproline-II helices form two interaction sites in the amyloid-beta peptides, which are pivotal for pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27580372' target='_blank' class='pmid-link'>27580372</a>:</span> <span class='sentence-part'>gamma-secretase is responsible for the proteolysis of amyloid precursor protein (APP) into short, aggregation-prone amyloid-beta (Abeta) peptides, which are centrally implicated in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27660034' target='_blank' class='pmid-link'>27660034</a>:</span> <span class='sentence-part'>Accumulation of amyloid beta (Abeta) peptide and hyperphosphorylated tau protein has been proposed to play roles in neural destruction which induce Alzheimer's disease (AD) progresses, glutamate transporter type 1 (GLT-1) and Glycogen synthase kinase3beta (GSK3beta) may be the pathological links between Abeta and tau pathology.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27663971' target='_blank' class='pmid-link'>27663971</a>:</span> <span class='sentence-part'>Amyloid-beta peptide (Abeta) is considered a key protein in the pathogenesis of Alzheimer's disease because of its neurotoxicity, resulting in impaired synaptic function and memory.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27750416' target='_blank' class='pmid-link'>27750416</a>:</span> <span class='sentence-part'>Histidine state (deprotonated, neutral, and protonated) is considered an important factor influencing the structural properties and aggregation mechanisms in amyloid beta-peptides (Abeta), which are associated with the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27769888' target='_blank' class='pmid-link'>27769888</a>:</span> <span class='sentence-part'>Aggregation of amyloid-beta peptide (Abeta) is a key event in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27777990' target='_blank' class='pmid-link'>27777990</a>:</span> <span class='sentence-part'>Accumulation of the amyloid beta (Abeta) peptide in the brain is responsible for debilitating neurodegenerative diseases, such as Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27796749' target='_blank' class='pmid-link'>27796749</a>:</span> <span class='sentence-part'>Oxidative stress is considered a major contributor to the pathogenesis of AD, and accumulating evidence indicates that high levels of reactive oxygen species (ROS) are involved in Abeta-induced neurodegeneration. Amyloid-beta peptide (Abeta) is one of the major players in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27884599' target='_blank' class='pmid-link'>27884599</a>:</span> <span class='sentence-part'>The hallmark characteristics of plaque formation and neuronal cell death in Alzheimer's disease (AD) are caused principally by the amyloid beta-peptide (Abeta).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28017718' target='_blank' class='pmid-link'>28017718</a>:</span> <span class='sentence-part'>The toxic amyloid beta-peptide (Abeta) is a key player in Alzheimer Disease (AD) pathogenesis and selective inhibition of the production of this peptide is sought for.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28052060' target='_blank' class='pmid-link'>28052060</a>:</span> <span class='sentence-part'>Aggregation of amyloid-beta peptides into fibrils or other self-assembled states is central to the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28096459' target='_blank' class='pmid-link'>28096459</a>:</span> <span class='sentence-part'>For example, increased intracellular copper or zinc has been linked to a reduction in secreted levels of the AD-causing amyloid-beta peptide (Abeta).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28260388' target='_blank' class='pmid-link'>28260388</a>:</span> <span class='sentence-part'>Oligomer species of amyloid beta (Abeta) peptides are intensively investigated because of their relevance to Alzheimer's disease (AD), and a stable oligomer will be a cause of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28288354' target='_blank' class='pmid-link'>28288354</a>:</span> <span class='sentence-part'>The enzyme beta-secretase-1 is responsible for the cleavage of the amyloid precursor protein, a vital step in the process of the formation of amyloid-beta peptides which are known to lead to neurodegeneration causing Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28360830' target='_blank' class='pmid-link'>28360830</a>:</span> <span class='sentence-part'>Amyloid fibril formation by the amyloid beta-peptide (Abeta) is considered to be an underlying cause of AD, and strategies designed to reduce Abeta production and/or its toxic effects are being extensively investigated in both laboratory and clinical settings.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28400058' target='_blank' class='pmid-link'>28400058</a>:</span> <span class='sentence-part'>Amyloid-beta peptide (Abeta) is believed to be a primary cause of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28562008' target='_blank' class='pmid-link'>28562008</a>:</span> <span class='sentence-part'>The self-assembling of the amyloid beta (Abeta) peptide into neurotoxic aggregates is considered a central event in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28569090' target='_blank' class='pmid-link'>28569090</a>:</span> <span class='sentence-part'>Impaired brain clearance of amyloid-beta peptides (Abeta) 40 and 42 across the blood-brain barrier (BBB) is believed to be one of the pathways responsible for Alzheimer's disease (AD) pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28570778' target='_blank' class='pmid-link'>28570778</a>:</span> <span class='sentence-part'>Zinc-induced oligomerization of amyloid-beta peptide (Abeta) produces potentially pathogenic agents of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28650319' target='_blank' class='pmid-link'>28650319</a>:</span> <span class='sentence-part'>The amyloid beta peptide (Abeta) is a key player in the etiology of Alzheimer disease (AD), yet a systematic investigation of its molecular interactions has not been reported.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28670737' target='_blank' class='pmid-link'>28670737</a>:</span> <span class='sentence-part'>Brain accumulation of soluble oligomers of the amyloid-beta peptide (AbetaOs) is increasingly considered a key early event in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28674340' target='_blank' class='pmid-link'>28674340</a>:</span> <span class='sentence-part'>The abnormal aggregation of amyloid beta-peptide (Abeta) is central to the pathogenesis of Alzheimer's disease, the major form of dementia.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28687859' target='_blank' class='pmid-link'>28687859</a>:</span> <span class='sentence-part'>According to amyloid cascade hypothesis, the deposit of amyloid-beta (Abeta) peptide is the main cause of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28861757' target='_blank' class='pmid-link'>28861757</a>:</span> <span class='sentence-part'>AD-like pathology was produced by administering AbetaP (1-40) intracerebroventricular (i.c.v.) in the left lateral ventricle (250 ng/10 MUl, once daily) for 4 weeks. Alzheimer's disease (AD) is one of the leading causes for disability and death affecting millions of people worldwide.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28870815' target='_blank' class='pmid-link'>28870815</a>:</span> <span class='sentence-part'>Cerebral accumulation of amyloid beta-peptide (Abeta), which is produced from amyloid precursor protein (APP), is the primary cause of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28889204' target='_blank' class='pmid-link'>28889204</a>:</span> <span class='sentence-part'>The beta-secretase (BACE1) initiates the generation of toxic amyloid-beta peptide (Abeta) from amyloid-beta precursor protein (APP), which was widely considered to play a key role in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28941799' target='_blank' class='pmid-link'>28941799</a>:</span> <span class='sentence-part'>Amyloid-beta peptides (Abeta) accumulate in cerebral capillaries indicating a central role of the blood-brain barrier (BBB) in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28985224' target='_blank' class='pmid-link'>28985224</a>:</span> <span class='sentence-part'>The accumulation of amyloid beta (Abeta) peptide (Amyloid cascade hypothesis), an APP protein cleavage product, is a leading hypothesis in the etiology of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28987946' target='_blank' class='pmid-link'>28987946</a>:</span> <span class='sentence-part'>Amyloid-beta peptide (Abeta) ranks as a pivotal cause of Alzheimer's disease (AD), a common devastating dementia form in elderly.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29118109' target='_blank' class='pmid-link'>29118109</a>:</span> <span class='sentence-part'>gamma-Secretase is an intramembrane cleaving protease that is responsible for the generation of amyloid-beta peptides, which are linked to the pathogenesis of Alzheimer disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29132916' target='_blank' class='pmid-link'>29132916</a>:</span> <span class='sentence-part'>While impaired clearance of amyloid beta (Abeta) peptides is considered as one of the major causes of AD, it was recently complemented by a potential role of other toxic amyloidogenic species.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29138762' target='_blank' class='pmid-link'>29138762</a>:</span> <span class='sentence-part'>The aggregation of amyloid beta (Abeta) peptides plays a crucial role in the pathology and etiology of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29161341' target='_blank' class='pmid-link'>29161341</a>:</span> <span class='sentence-part'>Accumulation of amyloid-beta peptides is a dominant feature in the pathogenesis of Alzheimer's disease; however, it is not clear how individual amyloid-beta species accumulate and affect other neuropathological and clinical features in the disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29192843' target='_blank' class='pmid-link'>29192843</a>:</span> <span class='sentence-part'>The amyloid beta (Abeta) peptide is central to the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29199321' target='_blank' class='pmid-link'>29199321</a>:</span> <span class='sentence-part'>BACKGROUND: Vanutide Cridificar (ACC-001), a novel investigational immunotherapeutic vaccine designed to elicit antibodies against the N-terminal peptide 1-7 of the amyloid-beta peptide, believed to be important in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29210443' target='_blank' class='pmid-link'>29210443</a>:</span> <span class='sentence-part'>BACKGROUND: ACC-001 is an investigational therapeutic vaccine designed to elicit antibodies against the N-terminal peptide 1-7 of the amyloid-beta peptide, believed to be important in the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29224965' target='_blank' class='pmid-link'>29224965</a>:</span> <span class='sentence-part'>Compelling evidence suggests a crucial role of amyloid beta peptides (Abeta(1-40/42)) in the etiology of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29310862' target='_blank' class='pmid-link'>29310862</a>:</span> <span class='sentence-part'>AD is featured with the loss of cholinergic neurons, the amyloid-beta peptide (Abeta) plaques and the neurofibrillary tangles and several hypotheses were established to explain the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29315574' target='_blank' class='pmid-link'>29315574</a>:</span> <span class='sentence-part'>The production and accumulation of amyloid beta peptide (Abeta) is considered the core pathological molecular event in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29440986' target='_blank' class='pmid-link'>29440986</a>:</span> <span class='sentence-part'>The so-called amyloid hypothesis, that the accumulation and deposition of oligomeric or fibrillar amyloid beta (Abeta) peptide is the primary cause of Alzheimer's disease (AD), has been the mainstream concept underlying AD research for over 20 years.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29448601' target='_blank' class='pmid-link'>29448601</a>:</span> <span class='sentence-part'>Amyloid beta (Abeta) peptide is considered to be the critical causative factor in the pathogenesis of Alzheimer's disease (AD) because the hydrophilic molecules accumulated outside of the neural cells and results in the formation of highly toxicity amyloid plaque.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29491833' target='_blank' class='pmid-link'>29491833</a>:</span> <span class='sentence-part'>Accumulation of amyloid-beta (Abeta) peptides in the brain is a critical early event in the pathogenesis of Alzheimer's disease (AD), the most common age-related neurodegenerative disorder.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29619615' target='_blank' class='pmid-link'>29619615</a>:</span> <span class='sentence-part'>Genetics strongly implicate the amyloid beta-peptide (Abeta) in the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29648443' target='_blank' class='pmid-link'>29648443</a>:</span> <span class='sentence-part'>Senile plaques formed by aggregated amyloid beta peptides are one of the major pathological hallmarks of Alzheimer's disease (AD) which have been suggested to be the primary influence triggering the AD pathogenesis and the rest of the disease process.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29658548' target='_blank' class='pmid-link'>29658548</a>:</span> <span class='sentence-part'>The self-association of the amyloid beta (Abeta) peptide into toxic oligomers is implicated in the early events leading to Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29743204' target='_blank' class='pmid-link'>29743204</a>:</span> <span class='sentence-part'>The beta-site amyloid precursor protein-cleaving enzyme 1 (BACE1) initiates the production of amyloid-beta peptide (Abeta), which is central to the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29764453' target='_blank' class='pmid-link'>29764453</a>:</span> <span class='sentence-part'>BACKGROUND: Extracellular aggregation of the amyloid-beta (Abeta) peptide into toxic multimers is a key event in Alzheimer's disease (AD) pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29781021' target='_blank' class='pmid-link'>29781021</a>:</span> <span class='sentence-part'>It is believed that the self-assembly of amyloid beta (Abeta) peptides in the brain is the cause of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29899186' target='_blank' class='pmid-link'>29899186</a>:</span> <span class='sentence-part'>Accumulation and oligomerization of amyloid-beta (Abeta) peptides have been known to be a potent cause of neurodegenerative diseases such as Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29905953' target='_blank' class='pmid-link'>29905953</a>:</span> <span class='sentence-part'>In recent years, actors such as metal ions, oxidative stress, and other cofactors have been proposed as possible co-agents or, in some cases, main causative factors of AD. Amyloid-beta peptide (Abeta) accumulation and aggregation have been considered for many years the main cause of Alzheimer's disease (AD), and therefore have been the principal target of investigation as well as of the proposed therapeutic approaches (Grasso [2011] Mass Spectrom Rev.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29906302' target='_blank' class='pmid-link'>29906302</a>:</span> <span class='sentence-part'>Probes for monitoring aggregation of amyloid beta (Abeta) peptides are crucial to advance understanding of the molecular pathogenesis of Alzheimer's Disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29927573' target='_blank' class='pmid-link'>29927573</a>:</span> <span class='sentence-part'>Accumulating evidence supports the abnormal deposition of amyloid beta-peptide (Abeta) as the main cause of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29945719' target='_blank' class='pmid-link'>29945719</a>:</span> <span class='sentence-part'>Overt accumulation and aggregation of the amyloid-beta peptide (Abeta) is thought to be the initial causative factor for Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30043821' target='_blank' class='pmid-link'>30043821</a>:</span> <span class='sentence-part'>The amyloid plaques are mainly aggregates of amyloid beta-peptide (Abeta), a primary factor contributing to the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30086173' target='_blank' class='pmid-link'>30086173</a>:</span> <span class='sentence-part'>Although the aggregation of amyloid-beta peptide (Abeta) clearly plays a central role in the pathogenesis of Alzheimer's disease (AD), endosomal traffic dysfunction is considered to precede Abeta aggregation and trigger AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30214656' target='_blank' class='pmid-link'>30214656</a>:</span> <span class='sentence-part'>The soluble oligomeric form of the amyloid beta (Abeta) peptide is the major causative agent in the molecular pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30260016' target='_blank' class='pmid-link'>30260016</a>:</span> <span class='sentence-part'>INTRODUCTION: Aggregation of amyloid-beta (Abeta) peptides represents a crucial step in the pathogenesis of Alzheimer disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30264333' target='_blank' class='pmid-link'>30264333</a>:</span> <span class='sentence-part'>Accumulation of amyloid-beta peptide (Abeta) and massive neuronal death due to apoptosis were the essential steps in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30268822' target='_blank' class='pmid-link'>30268822</a>:</span> <span class='sentence-part'>Dysregulation of the Amyloid Precursor Protein (APP) processing leading to toxic species of amyloid beta peptides (Abeta) is central to Alzheimer's disease (AD) etiology.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30345755' target='_blank' class='pmid-link'>30345755</a>:</span> <span class='sentence-part'>Aggregation of amyloid beta-peptide (Abeta) plays a key role in the etiology of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30362029' target='_blank' class='pmid-link'>30362029</a>:</span> <span class='sentence-part'>Growing evidence gathered from transgenic animal models of Alzheimer's disease (AD) indicates that the intraneuronal accumulation of amyloid-beta (Abeta) peptides is an early event in the AD pathogenesis, producing cognitive deficits before the deposition of insoluble plaques.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30402707' target='_blank' class='pmid-link'>30402707</a>:</span> <span class='sentence-part'>Amyloid beta (Abeta) peptide is a critical causative factor in Alzheimer's disease (AD) and of a variety of fragmented Abeta peptides Abeta1-42 thought to exhibit the most neurotoxic effect.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30426203' target='_blank' class='pmid-link'>30426203</a>:</span> <span class='sentence-part'>Brain accumulation and aggregation of amyloid-beta (Abeta) peptides is a critical step in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30480246' target='_blank' class='pmid-link'>30480246</a>:</span> <span class='sentence-part'>Evidence suggests that fibril formation of the amyloid beta-peptide (Abeta) is a major underlying cause of AD, and treatment strategies that reduce the toxic effects of Abeta amyloid are sought for.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30486385' target='_blank' class='pmid-link'>30486385</a>:</span> <span class='sentence-part'>The amyloid beta (Abeta) peptide has been implicated in the cause of AD, where the peptides undergo a conformational change and form neurotoxic amyloid oligomers which cause neuronal cell death.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30551397' target='_blank' class='pmid-link'>30551397</a>:</span> <span class='sentence-part'>The progressive accumulation of amyloid beta (Abeta) peptide is neurotoxic and leads to Alzheimer's type dementia.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30675620' target='_blank' class='pmid-link'>30675620</a>:</span> <span class='sentence-part'>The potential therapeutic effect of puerarin against Alzheimer's disease was screened by in silico methods and confirmed by the amyloid beta-peptide-induced Alzheimer's disease (AD) rat model.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30704515' target='_blank' class='pmid-link'>30704515</a>:</span> <span class='sentence-part'>The adipocyte plasma membrane-associated protein APMAP is expressed in the brain where it associates with gamma-secretase, a protease responsible for the generation of the amyloid-beta peptides (Abeta) implicated in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30794963' target='_blank' class='pmid-link'>30794963</a>:</span> <span class='sentence-part'>The aggregation and accumulation of amyloid beta (Abeta) peptide is believed to be the primary cause of Alzheimer's disease (AD) pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30830576' target='_blank' class='pmid-link'>30830576</a>:</span> <span class='sentence-part'>Human genetic and clinical studies over the past three decades have indicated that abnormal generation or accumulation of amyloid-beta (Abeta) peptides is a likely culprit in AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30900203' target='_blank' class='pmid-link'>30900203</a>:</span> <span class='sentence-part'>These pathological protein deposits, including Abeta peptides (which form senile plaques) and hyperphosphorylated tau (which aggregates into NFTs), have been assumed to be 'the cause of AD'.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30911827' target='_blank' class='pmid-link'>30911827</a>:</span> <span class='sentence-part'>SORL1 encodes SorLA, a key protein involved in the processing of the amyloid-beta (Abeta) precursor protein (APP) and the secretion of the Abeta peptide, the aggregation of which triggers AD pathophysiology.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30913789' target='_blank' class='pmid-link'>30913789</a>:</span> <span class='sentence-part'>Amyloid beta (Abeta) peptide is secreted from the outside of neural cell by a neural signal pathway and it accumulated each other results in the highly toxicity amyloid plaque which is a critical causative factor in the pathogenesis of Alzheimer's Disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30949973' target='_blank' class='pmid-link'>30949973</a>:</span> <span class='sentence-part'>The pathological form of amyloid beta (Abeta) peptide is shown to be toxic to the mitochondria and implicates this organelle in the progression and pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30964132' target='_blank' class='pmid-link'>30964132</a>:</span> <span class='sentence-part'>Aggregation of misfolded oligomeric amyloid-beta (Abeta) peptides on lipid membranes has been identified as a primary event in Alzheimer's pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31048748' target='_blank' class='pmid-link'>31048748</a>:</span> <span class='sentence-part'>Aggregates of amyloid-beta (Abeta) peptide are well known to be the causative substance of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31164420' target='_blank' class='pmid-link'>31164420</a>:</span> <span class='sentence-part'>BACE1 is the rate-limiting enzyme for amyloid-beta peptides (Abeta) generation, a key event in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31234321' target='_blank' class='pmid-link'>31234321</a>:</span> <span class='sentence-part'>Amyloid beta (Abeta) peptide is known to be a major cause of AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31247730' target='_blank' class='pmid-link'>31247730</a>:</span> <span class='sentence-part'>The variation of amyloid beta peptide (Abeta) concentration and Abeta aggregation are closely associated with the etiology of Alzheimer's diseases (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31365254' target='_blank' class='pmid-link'>31365254</a>:</span> <span class='sentence-part'>Excess of amyloid beta (Abeta) peptides and their aggregation are the basis of the amyloid cascade hypothesis, which attempts to explain the causes of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31367507' target='_blank' class='pmid-link'>31367507</a>:</span> <span class='sentence-part'>Amyloid beta-peptides (Abeta) play a major role in the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31368868' target='_blank' class='pmid-link'>31368868</a>:</span> <span class='sentence-part'>BACKGROUND: Aggregation of Amyloid beta (Abeta) peptide is a crucial feature of Alzheimer disease (AD) pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31369984' target='_blank' class='pmid-link'>31369984</a>:</span> <span class='sentence-part'>Thus, the sialic acid-binding site on CD33 is a promising pharmacophore for developing therapeutics that promote clearance of the Abeta peptide that is thought to cause AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31595293' target='_blank' class='pmid-link'>31595293</a>:</span> <span class='sentence-part'>Amyloid-beta peptides (Abeta) are the major drivers of Alzheimer's disease (AD) pathogenesis, and are formed by successive cleavage of the amyloid precursor protein (APP) by the beta and gamma secretases.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31607898' target='_blank' class='pmid-link'>31607898</a>:</span> <span class='sentence-part'>Processing of amyloid beta precursor protein (APP) into amyloid-beta peptide (Abeta) by beta-secretase and gamma-secretase complex is at the heart of the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31796114' target='_blank' class='pmid-link'>31796114</a>:</span> <span class='sentence-part'>An impairment of amyloid beta-peptide (Abeta) clearance is suggested to play a key role in the pathogenesis of sporadic Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31809572' target='_blank' class='pmid-link'>31809572</a>:</span> <span class='sentence-part'>The aggregation of amyloid-beta (Abeta) peptides into senile plaques is a hallmark of Alzheimer's disease (AD) and is hypothesized to be the primary cause of AD related neurodegeneration.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31814468' target='_blank' class='pmid-link'>31814468</a>:</span> <span class='sentence-part'>Truncated or post-translationally modified Abeta peptides are becoming increasingly recognized as important players in the etiology of AD and a more thorough comprehension of their cellular origin and biochemical peculiarities might break new ground for therapeutic strategies.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/7556364' target='_blank' class='pmid-link'>7556364</a>:</span> <span class='sentence-part'>There is growing evidence that the amyloid beta-peptide (beta 1-40) is involved in the aetiology of Alzheimer's disease also implicating an altered calcium homeostasis of affected cells.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/7777177' target='_blank' class='pmid-link'>7777177</a>:</span> <span class='sentence-part'>Two conformational states of amyloid beta-peptide: implications for the pathogenesis of Alzheimer's disease.</span></div></div>
<div class='streamlined-assertion'><div class='streamlined-header sticky-relation-header'><span class='label-text'>Subject:</span> <strong>Ablation</strong> <span class='label-text'>Subject CUI:</span> <strong>C0547070</strong> â†’ <span class='label-text predicate-text'>CAUSES</span> â†’ <span class='label-text'>Object:</span> <strong>Atrial_Fibrillation</strong> <span class='label-text'>Object CUI:</span> <strong>C0004238</strong></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/10354972' target='_blank' class='pmid-link'>10354972</a>:</span> <span class='sentence-part'>Since suppression of inducible AF or atrial flutter is used as one of the endpoints of success of pharmacologic and ablation therapies, there is an obvious need to define a minimally appropriate electrical stimulation protocol for induction of AF or atrial flutter.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/10987620' target='_blank' class='pmid-link'>10987620</a>:</span> <span class='sentence-part'>OBJECTIVES: To test the hypothesis that when activation of Bachmann's bundle (BB) is critical to the unstable reentrant circuits that maintain atrial fibrillation (AF) in the sterile pericarditis canine model, a lesion in BB would prevent induction of stable AF. CONCLUSIONS: In this AF model, catheter ablation of BB terminates and prevents the induction of AF by preventing 1) formation of unstable reentrant circuits that involve BB, and 2) activation of the atrial-free walls after a nonactivation period. METHODS: Simultaneous multisite mapping studies during AF and after ablation of BB were performed by recording (384 to 396 electrodes) from both atria and the atrial septum during six induced AF episodes in six dogs with sterile pericarditis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/11513440' target='_blank' class='pmid-link'>11513440</a>:</span> <span class='sentence-part'>Patients with recurrent AF after ablation of focal AF triggers have significant improvement in QOL and symptoms compared with before ablation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/12212693' target='_blank' class='pmid-link'>12212693</a>:</span> <span class='sentence-part'>Stroke as a complication after ablation of triggers of AF has not been previously reported.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/12417842' target='_blank' class='pmid-link'>12417842</a>:</span> <span class='sentence-part'>In persistent atrial fibrillation, ablation and pacing will inevitably result in permanent atrial fibrillation; this may influence the decision for pacemaker type and the timing of the procedure.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/12494165' target='_blank' class='pmid-link'>12494165</a>:</span> <span class='sentence-part'>RESULTS: Efficacy of both methods was similar but the use of the 'novel' technique was associated with shorter overall duration of a procedure and fluoroscopy time, lesser number of applications required for successful ablation, and lower rates of induction of atrial fibrillation and of atrial flutter recurrences.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/12652179' target='_blank' class='pmid-link'>12652179</a>:</span> <span class='sentence-part'>Ablation of focal triggers of atrial fibrillation is associated with a sustained improvement in quality of life.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/14574038' target='_blank' class='pmid-link'>14574038</a>:</span> <span class='sentence-part'>Subsequent experience has narrowed the electrophysiologist's attention to ablation of triggers of AF, most often residing in the pulmonary veins, rather than requiring more extensive ablation lines to control the arrhythmia.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/15028051' target='_blank' class='pmid-link'>15028051</a>:</span> <span class='sentence-part'>We retrospectively evaluated the outcome and risks of ablation for focally induced AF in a single-center patient population. CONCLUSION: Trigger-directed ablation for focally induced AF is associated with a relatively high recurrence rate during follow-up. Ablation of focally induced atrial fibrillation: selective or extensive?</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/16426357' target='_blank' class='pmid-link'>16426357</a>:</span> <span class='sentence-part'>BACKGROUND: Ablation of the left atrium to isolate the pulmonary veins has been shown to interrupt electrical foci that may induce atrial fibrillation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/16843185' target='_blank' class='pmid-link'>16843185</a>:</span> <span class='sentence-part'>This suggests that CPVA and EGA eliminate different mechanisms in the genesis of persistent AF.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17017100' target='_blank' class='pmid-link'>17017100</a>:</span> <span class='sentence-part'>Since the first report of radiofrequency catheter ablation curing atrial fibrillation (AF) nearly a decade ago, numerous techniques have evolved, from linear ablation to modify the reentrant sustrate for AF, to electrical isolation of pulmonary vein to eliminate triggers of AF, to hibrid approaches of circunferential ablation around and between the pulmonary veins and mitral valve annulus to modify both the triggers and sustrate for AF.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17038349' target='_blank' class='pmid-link'>17038349</a>:</span> <span class='sentence-part'>After ablation, two attempts to induce AF (&gt;1 min) by decremental coronary sinus stimulation were performed.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/18462320' target='_blank' class='pmid-link'>18462320</a>:</span> <span class='sentence-part'>METHODS AND RESULTS: In 67 patients presenting for initial AF ablation (42 paroxysmal, 25 persistent), LA and CS mapping were performed during induced or spontaneous AF.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/18462325' target='_blank' class='pmid-link'>18462325</a>:</span> <span class='sentence-part'>METHODS: Over a 7-year period we studied 1,165 consecutive patients undergoing 1,506 AF ablation procedures using a consistent ablation protocol that included proximal ostial pulmonary vein (PV) isolation and focal ablation of non-PV AF triggers.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/18721515' target='_blank' class='pmid-link'>18721515</a>:</span> <span class='sentence-part'>After ablation of all identifiable autonomic ganglia, high-frequency pacing was repeated to induce AF.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20458822' target='_blank' class='pmid-link'>20458822</a>:</span> <span class='sentence-part'>OBJECTIVE: Additional septal linear ablation in patients undergoing ablation of long-standing persistent atrial fibrillation (AF) could be beneficial due to additional extensive atrial tissue ablation and incidental ablation of sites with complex fractionated electrograms.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21070924' target='_blank' class='pmid-link'>21070924</a>:</span> <span class='sentence-part'>RESULTS: PVEA failed to terminate AF or affect AF duration (742 +/- 242 s before vs. 627 +/- 227 s after PVEA) but decreased AF vulnerability to single extrastimuli from 91 +/- 4% to 59 +/- 5% (p &lt; 0.001) by increasing effective refractory periods at sites with suppressed AF induction (from 78 +/- 4 ms to 102 +/- 8 ms, p &lt; 0.01).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21692897' target='_blank' class='pmid-link'>21692897</a>:</span> <span class='sentence-part'>This suggests that at least part of the beneficial effect achieved by CFAE ablation reflects elimination of non-PV AF triggers. OBJECTIVE: We compared the impact of CFAE ablation on the prevalence of non-PV atrial triggers inducing AF in 2 groups of patients with LS persistent AF. After ablation, infusion of isoproterenol up to 30 mcg/min was given to reveal non PV foci inducing AF.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22183745' target='_blank' class='pmid-link'>22183745</a>:</span> <span class='sentence-part'>Ablation-induced AF-to-AFL and AFL-to-AFL transitions were defined as a sudden drop in the dominant frequency (DF) of at least 10 bpm, followed by a regular rhythm.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22371231' target='_blank' class='pmid-link'>22371231</a>:</span> <span class='sentence-part'>The AF inducibility after ablation was significantly lower than that before ablation in the two groups (98% vs. 28%, p &lt; 0.01, in the CPVa group; 97% vs.14%, p &lt; 0.01, in the BOXa group), and the induced AF lasting time after ablation was significantly shorter than that before ablation in both groups (233 +/- 40 vs. 70 +/- 29 s, p &lt; 0.01, in the CPVa group; 240 +/- 41 vs. 34 +/- 22 s, p &lt; 0.01, in the BOXa group). Before-and-after ablation left atrial effective refractory period (LAERP), AF inducibility, and induced AF lasting time were measured in both groups.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23373588' target='_blank' class='pmid-link'>23373588</a>:</span> <span class='sentence-part'>CONCLUSIONS: This report demonstrates the feasibility of noninvasive panoramic mapping of AF in identifying active sources, which include unstable rotors and PV foci, and its validation by ablation results.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23979215' target='_blank' class='pmid-link'>23979215</a>:</span> <span class='sentence-part'>These developments include novel ablation catheters designed to increase safety, efficacy, and precision of the procedure, ablation strategies to target both pulmonary vein and nonpulmonary vein AF triggers, and improved imaging and electrical mapping to guide ablation procedures.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24981869' target='_blank' class='pmid-link'>24981869</a>:</span> <span class='sentence-part'>METHODS: Attempt at induction of AF by burst pacing was performed in consecutive patients who underwent AFL ablation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25110156' target='_blank' class='pmid-link'>25110156</a>:</span> <span class='sentence-part'>The strategy of anesthesia used during AF ablation may impact the provocation of AF triggers.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25713734' target='_blank' class='pmid-link'>25713734</a>:</span> <span class='sentence-part'>This review will summarize the state-of-the-art of AF ablation techniques in patients with persistent AF, discussing the evidence underlying different approaches with a particular focus on adjunctive ablation strategies beyond PVI including linear ablation, ablation of complex fractionated atrial electrograms (CFAE), ablation of ganglionated plexi, dominant frequency, rotors and other anatomical sites frequently involved in AF triggers.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25753968' target='_blank' class='pmid-link'>25753968</a>:</span> <span class='sentence-part'>METHODS: Sixty-five patients with CHADS2 scores 1-3 free from AF 3 months after ablation (AF ablation [n = 49] or ablation of possible AF triggers [n = 16]) were included. CONCLUSIONS: Rhythm monitoring by ICM in patients who have stopped OAC after catheter ablation of AF or ablation of possible AF triggers seems to be a safe and promising method to monitor for AF recurrence.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25991408' target='_blank' class='pmid-link'>25991408</a>:</span> <span class='sentence-part'>Electrophysiologic and Clinical Consequences of Left Atrial Anterior Wall Linear Ablation in Patients With Persistent Atrial Fibrillation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26318871' target='_blank' class='pmid-link'>26318871</a>:</span> <span class='sentence-part'>In pericarditis or post-cardiotomy, colchicine decreased recurrent pericarditis or post-pericardiotomy syndrome (RR 0.50, 95 % CI 0.41-0.60, p &lt; 0.0001; I(2) = 0 %; 8 RCTs, n = 1635), and post-pericardiotomy or ablation induced atrial fibrillation (RR 0.65, 95 % CI 0.51-0.82, p = 0.0003; I(2) = 31 %; 4 RCTs, n = 1118).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27566694' target='_blank' class='pmid-link'>27566694</a>:</span> <span class='sentence-part'>Pulmonary vein isolation has been accepted as potential target for ablation of paroxysmal atrial fibrillation (AF) given that the pulmonary veins are the main source of AF triggers.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27637120' target='_blank' class='pmid-link'>27637120</a>:</span> <span class='sentence-part'>Ablation therapy is used to destroy abnormal foci responsible for atrial fibrillation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27838125' target='_blank' class='pmid-link'>27838125</a>:</span> <span class='sentence-part'>BACKGROUND: Aortic dilatation was frequently observed in patients with atrial fibrillation (AF) and non-pulmonary vein (PV) triggers are important for mapping and ablation of AF.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28279291' target='_blank' class='pmid-link'>28279291</a>:</span> <span class='sentence-part'>FIRM ablation terminated AF to sinus rhythm or atrial flutter or tachycardia in 59% (PAF), 37% (PeAF), and 19% (LPeAF) of patients, with 15 of 67 terminations due to right atrial ablation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28496631' target='_blank' class='pmid-link'>28496631</a>:</span> <span class='sentence-part'>Ablation addresses the root causes of AF and thus may be curative.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28626989' target='_blank' class='pmid-link'>28626989</a>:</span> <span class='sentence-part'>We describe an ablation approach (\Maze-like\-LAAI) that (1) modifies the underlying LA substrate by linear ablation (2) eliminates the LAA as a putative AF trigger site and (3) incorporates an unambiguous procedural endpoint.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28765764' target='_blank' class='pmid-link'>28765764</a>:</span> <span class='sentence-part'>Focal ablation for atrial tachycardia from the double-exit of the Marshall bundle inducing atrial fibrillation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28862969' target='_blank' class='pmid-link'>28862969</a>:</span> <span class='sentence-part'>Finally, a 3D human heart-specific atrial computer model was developed by integrating 3D structural and functional mapping data to test AF induction, maintenance, and ablation strategies.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29424013' target='_blank' class='pmid-link'>29424013</a>:</span> <span class='sentence-part'>The impact of smoking on ablation results in persistent atrial fibrillation (AF) is unknown.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31116439' target='_blank' class='pmid-link'>31116439</a>:</span> <span class='sentence-part'>The mechanisms of atrial fibrillation (AF) induction and maintenance, including those involved in paroxysmal atrial fibrillation, are not completely known; this limits our ablation strategies and prevents us from understanding what we are actually doing when performing pulmonary vein isolation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31171960' target='_blank' class='pmid-link'>31171960</a>:</span> <span class='sentence-part'>A second patient had ablation of an extra-pulmonary vein trigger for AF.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31929239' target='_blank' class='pmid-link'>31929239</a>:</span> <span class='sentence-part'>The use of antazoline, a first-generation antihistamine agent used for rapid conversion of recent-onset atrial fibrillation in patients with preserved left ventricular function and for rapid atrial fibrillation termination during accessory pathway ablation denotes that anaphylaxis-induced histamine production could be the cause of atrial fibrillation at least in some instances.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32078054' target='_blank' class='pmid-link'>32078054</a>:</span> <span class='sentence-part'>Importantly, in vivo experiments in SCN10A     -/-       mice showed that genetic ablation of Na     V      1.8 protects against atrial fibrillation induction.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32461886' target='_blank' class='pmid-link'>32461886</a>:</span> <span class='sentence-part'>Provocation and ablation of non-pulmonary vein triggers in nonparoxysmal atrial fibrillation: Role of the coronary sinus.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32477760' target='_blank' class='pmid-link'>32477760</a>:</span> <span class='sentence-part'>These developments can be divided into new techniques for myocardial ablation, improvements in the understanding of AF trigger mechanisms, and advancements in atrial mapping.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36233544' target='_blank' class='pmid-link'>36233544</a>:</span> <span class='sentence-part'>However, the clinical outcomes and effects of additional ablation for the trigger sites of adenosine-induced AF (AIAF) are unknown.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/8930738' target='_blank' class='pmid-link'>8930738</a>:</span> <span class='sentence-part'>The aim of this study was to evaluate changes of AV nodal properties and RR intervals during AF caused by ablation of two specific areas in dogs.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/9511888' target='_blank' class='pmid-link'>9511888</a>:</span> <span class='sentence-part'>After total ablation, the incidence of induced AF was similar between the two groups (MP vs SP: 1/29 vs 11/221).</span></div></div>
<div class='streamlined-assertion'><div class='streamlined-header sticky-relation-header'><span class='label-text'>Subject:</span> <strong>Acetylcholine</strong> <span class='label-text'>Subject CUI:</span> <strong>C0001041</strong> â†’ <span class='label-text predicate-text'>CAUSES</span> â†’ <span class='label-text'>Object:</span> <strong>Atrial_Fibrillation</strong> <span class='label-text'>Object CUI:</span> <strong>C0004238</strong></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/10545775' target='_blank' class='pmid-link'>10545775</a>:</span> <span class='sentence-part'>We studied the role of acetylcholine (ACh) and calcium overload in the induction of atrial flutter or atrial fibrillation (AF) in right atria from 34 normal male Syrian hamsters (F1B) and 33 cardiomyopathic Syrian hamsters (BIO 14.6) associated with focal myocardial necrosis. In contrast, ACh induced AF only in 1 of 12 myopathic atria. ACh (0.1, 1 and 10 microM) induced high-frequency AF (around 33 Hz) along with tension oscillations and contracture in 7 of 12 normal hamster atria.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/11021474' target='_blank' class='pmid-link'>11021474</a>:</span> <span class='sentence-part'>INTRODUCTION: Prior studies in isolated canine atria demonstrated that acetylcholine-induced reentrant atrial fibrillation (AF) was triggered by multifocal activity in the area of normal impulse origin (sinus node-crista terminalis).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/11767444' target='_blank' class='pmid-link'>11767444</a>:</span> <span class='sentence-part'>Meanwhile the perfusion of acetylcholine, alone, did induce atrial fibrillation in all animals. [Isoproterenol potentiates atrial fibrillation induced by acetylcholine]. The mixed perfusion of isoproterenol and acetylcholine led to decreasing the threshold (minimum) concentration of acetylcholine to induce atrial fibrillation. A perfusion with normal Tirode solution containing isoproterenol, acetylcholine and their combination into the sinus node artery of the anesthetized open-chest dogs was used to induce atrial fibrillation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/12695296' target='_blank' class='pmid-link'>12695296</a>:</span> <span class='sentence-part'>METHODS AND RESULTS: Acetylcholine (ACh, 1 micromol/L) was used to abbreviate atrial APD and permit rapid-pacing induction of AF in isolated coronary-perfused canine right atria.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/13317020' target='_blank' class='pmid-link'>13317020</a>:</span> <span class='sentence-part'>The effect of KCl on atrial fibrillation caused by acetylcholine.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/14141258' target='_blank' class='pmid-link'>14141258</a>:</span> <span class='sentence-part'>EFFECTS OF ADRENALINE AND NORADRENALINE ON ATRIAL FIBRILLATION PRODUCED BY ACETYLCHOLINE: WITH OBSERVATIONS ON THE MECHANISM OF FIBRILLATION.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/15013134' target='_blank' class='pmid-link'>15013134</a>:</span> <span class='sentence-part'>Beta-blockade by propranolol (1 mg/kg) did not prevent ACh-induced AF, but increased the threshold ACh concentration for AF induction to 23.5 +/- 3.4 micromol/l (p &lt; 0.05). METHODS: Perfusion of catecholamines and acetylcholine (ACh), as well as their combination, through the sinus node artery was used to induce AF in 20 anesthetized open-chest dogs without electrical stimulation of atria. Acetylcholine-mediated AF was facilitated by isoproterenol (1 to 2 and 10 micromol/l), which decreased the threshold ACh concentration for AF induction to 0.5 +/- 0.1 and 0.4 +/- 0.1 micromol/l, respectively (p &lt; 0.05) and increased the AF duration (from 25 +/- 7 to 141 +/- 54 and 233 +/- 60 s, respectively; p &lt; 0.05). RESULTS: Isoproterenol and adrenaline (10 to 100 micromol/l) induced AF in 21% (3 of 14) and 17% (1 of 6) of dogs, respectively. Acetylcholine (2.8 +/- 0.3 micromol/l) induced AF in all dogs.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17707096' target='_blank' class='pmid-link'>17707096</a>:</span> <span class='sentence-part'>It is concluded that there is a marked spatial heterogeneity in the expression of the M(2)Rs in the atrium, which might create a substrate that would favor the initiation and maintenance of acetylcholine-induced AF.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/19342855' target='_blank' class='pmid-link'>19342855</a>:</span> <span class='sentence-part'>METHODS: Twelve pigs were subjected to acetylcholine infusion and right atrial pacing to induce sustained atrial fibrillation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/19808494' target='_blank' class='pmid-link'>19808494</a>:</span> <span class='sentence-part'>Acetylcholine caused abrupt onset of AF (n=22) or induced AF by burst pacing (n=9) that lasted &gt; or = 10 minutes. CONCLUSIONS: Before GP ablation, acetylcholine (100 mmol/L) induced sustained AF characterized by rapid, focal firing. In 12 separate studies, a propafenone bolus, 2 mg/kg, was given before and after GP ablations at the start of acetylcholine-induced AF.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/19952329' target='_blank' class='pmid-link'>19952329</a>:</span> <span class='sentence-part'>Acetylcholine (0.5 micromol/L) and burst pacing induced atrial fibrillation in 100% of control atria, 75% of ranolazine-treated (5 micromol/L) atria, 16% of atria from amiodarone-treated dogs, and in 0% of atria from amiodarone-treated dogs exposed to 5 micromol/L ranolazine.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20478403' target='_blank' class='pmid-link'>20478403</a>:</span> <span class='sentence-part'>Acetylcholine (ACh, 1.0 muM) was used to induce persistent AF.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20562443' target='_blank' class='pmid-link'>20562443</a>:</span> <span class='sentence-part'>Pretreatment with 3 micromol/L NS8593, which had no effect on QT interval, prolonged the atrial effective refractory period by 37.1+/-7.7% (P&lt;0.001) and prevented acetylcholine-induced AF (P&lt;0.001, n=7).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/2067190' target='_blank' class='pmid-link'>2067190</a>:</span> <span class='sentence-part'>[Study of acetylcholine-induced atrial fibrillation attacks in dogs in situ using a new 256-channel device for electrophysiological mapping].</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21319018' target='_blank' class='pmid-link'>21319018</a>:</span> <span class='sentence-part'>Atrial fibrillation induced by applying acetylcholine to subadventitial layer of pulmonary vein in normal canine heart.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21718913' target='_blank' class='pmid-link'>21718913</a>:</span> <span class='sentence-part'>Epicardial ablation of rotors suppresses inducibility of acetylcholine-induced atrial fibrillation in left pulmonary vein-left atrium preparations in a beagle heart failure model.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21884675' target='_blank' class='pmid-link'>21884675</a>:</span> <span class='sentence-part'>Acetylcholine (1 MUM) was used to induce atrial fibrillation (AF) and to test the anti-AF potential of Wenxin Keli (5 g/L).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22306784' target='_blank' class='pmid-link'>22306784</a>:</span> <span class='sentence-part'>METHODS: Fifteen dogs were divided into three groups (five dogs/group): group 1 (pacing-induced atrial fibrillation group), group 2 (100 mM Ach-induced atrial fibrillation group), group 3 (500 mM Ach-induced atrial fibrillation group).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22455093' target='_blank' class='pmid-link'>22455093</a>:</span> <span class='sentence-part'>Effect of fat pad ablation on the spatial and temporal stability of complex fractionated atrial electrogram in acetylcholine-induced atrial fibrillation. CONCLUSION: Selective fat pad ablation can affect the spatial and temporal stability of CFAEs in ACh-induced atrial fibrillation in dogs. OBJECTIVE: The objective of this study was to investigate the effect of selective fat pad ablation on the spatial and temporal stability of the complex fractionated atrial electrogram (CFAE) in acetylcholine (ACh)-induced atrial fibrillation (AF).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22487376' target='_blank' class='pmid-link'>22487376</a>:</span> <span class='sentence-part'>Vasostatin-1 significantly decreased the duration of acetylcholine-induced AF (11.0 +/- 4.1 vs 5.5 +/- 2.6 min, P = 0.02).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22907956' target='_blank' class='pmid-link'>22907956</a>:</span> <span class='sentence-part'>Using acetylcholine (ACh)-induced acute canine AF models (n= 4), a total of 128 electrical leads were attached to the surface of the anterior and posterior atria, and the pulmonary veins to form an electrocardiological mapping system.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23179922' target='_blank' class='pmid-link'>23179922</a>:</span> <span class='sentence-part'>The duration of acetylcholine-induced AF was determined at baseline and at 6 h. RESULTS: LLVNS significantly decreased the acetylcholine-induced AF duration by 8.2 +/- 0.9 min (p &lt; 0.0001).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23933296' target='_blank' class='pmid-link'>23933296</a>:</span> <span class='sentence-part'>Ventricular rate, mean arterial pressure, dominant frequency of AF, PR and QT intervals, and atrial (AERP) and ventricular effective refractory periods (VERP) were measured during atrial pacing at 150 bpm in an anesthetized pig model of AF induced by intrapericardial acetylcholine and burst pacing.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24046327' target='_blank' class='pmid-link'>24046327</a>:</span> <span class='sentence-part'>VIP is also shown to prolong the duration of acetylcholine-induced atrial fibrillation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24152033' target='_blank' class='pmid-link'>24152033</a>:</span> <span class='sentence-part'>Surface ECG and intracardiac electrograms were recorded before and after the intravenous administration of 4 units/kg of 1,25[OH]2 D in heart failure (HF) rabbits (4 weeks after coronary artery ligation) with RAP and acetylcholine-induced AF.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25037694' target='_blank' class='pmid-link'>25037694</a>:</span> <span class='sentence-part'>However, acetylcholine infusion and rapid atrial pacing (10-20 Hz) induced AF in control LAs but not in testosterone-treated LAs.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25381330' target='_blank' class='pmid-link'>25381330</a>:</span> <span class='sentence-part'>Rapid pacing from each site before and after addition of acetylcholine (0.5 MUmol/L) was applied to induce AF.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25546810' target='_blank' class='pmid-link'>25546810</a>:</span> <span class='sentence-part'>Acetylcholine (1 uM) was used to induce persistent AF.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26331943' target='_blank' class='pmid-link'>26331943</a>:</span> <span class='sentence-part'>METHODS AND RESULTS: In 6 closed-chest anesthetized pigs, AF was induced by intrapericardial acetylcholine (1 mL of 100 mM solution) followed within 1 minute by epinephrine (20 MUg/kg, i.v., bolus over 1 min). INTRODUCTION: The anti-atrial fibrillation (AF) effects of GS-458967 (GS-967), a selective, potent inhibitor of cardiac late Na(+) current (I(Na)), were evaluated in a novel model of AF induction that does not require electrical stimuli.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26396675' target='_blank' class='pmid-link'>26396675</a>:</span> <span class='sentence-part'>The purpose of this study was to test the efficacy of Berberine (Ber) on atrial fibrillation (AF) induced by acetylcholine (ACh) and explore its underlying mechanisms of action. The termination rate of ACh-induced AF was higher with IV Ber (1 mg/kg) than with IV saline (sustained 1 min AF: 6/8 vs.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27108587' target='_blank' class='pmid-link'>27108587</a>:</span> <span class='sentence-part'>METHODS: In closed-chest anesthetized Yorkshire pigs, epinephrine (2.0 ug/kg, intravenous, bolus over 1 minute) was administered alone to induce APBs (n = 6) or in combination with intrapericardial acetylcholine (0.5-4 mL of 12.5 mM solution) to induce spontaneous AF (n = 11). The combined administration of epinephrine and acetylcholine resulted in AF in all animals tested, which was invariably preceded by APBs.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27520541' target='_blank' class='pmid-link'>27520541</a>:</span> <span class='sentence-part'>Group 2 (LL-CBS on electrically or mechanically induced AF with acetylcholine): In subgroup 1, sustained AF was induced by injecting acetylcholine (Ach; 10 mM) into the anterior right ganglionated plexus at baseline and after 3-hour LL-CBS (n = 7) or sham operation (n = 6).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30939909' target='_blank' class='pmid-link'>30939909</a>:</span> <span class='sentence-part'>Acetylcholine and electrical stimulation were used to induce AF, and ECG recording was adopted to assess the influence of SNX17 deficiency on AF susceptibility.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31629862' target='_blank' class='pmid-link'>31629862</a>:</span> <span class='sentence-part'>AIM OF THE STUDY: The combination of acetylcholine (Ach) and CaCl2 has been widely used to induce atrial fibrillation (AF) in animals.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31749267' target='_blank' class='pmid-link'>31749267</a>:</span> <span class='sentence-part'>Intrapericardial acetylcholine and burst pacing were used to induce AF.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31789885' target='_blank' class='pmid-link'>31789885</a>:</span> <span class='sentence-part'>CONCLUSIONS: Intratracheal delivery of metoprolol effectively reduces ventricular rate during AF and accelerates conversion to normal sinus rhythm in a pig model of acetylcholine-induced AF.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/3632145' target='_blank' class='pmid-link'>3632145</a>:</span> <span class='sentence-part'>In dogs, the drug is effective against post-infarction and ouabain-induced ventricular arrhythmias, and abolishes acetylcholine and aconitine-induced atrial fibrillation; it elevates the threshold of electrically induced ventricular fibrillation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/4546113' target='_blank' class='pmid-link'>4546113</a>:</span> <span class='sentence-part'>Prevention of acetylcholine-induced atrial fibrillation by electric pacing.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/4724579' target='_blank' class='pmid-link'>4724579</a>:</span> <span class='sentence-part'>AV block and atrial fibrillation induced by acetylcholine into the AV node artery of the dog.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/9057071' target='_blank' class='pmid-link'>9057071</a>:</span> <span class='sentence-part'>These results suggest that (a) PACAP-38 induces negative chronotropic responses and liberates ACh from intracardiac postganglionic parasympathetic nerves, and that (b) PACAP-38 reduces ACh-induced atrial fibrillation threshold in the dog heart in situ. After treatment with PACAP-38 (0.1-1 nmol), ACh induced atrial fibrillation significantly (p &lt; 0.01).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/9242949' target='_blank' class='pmid-link'>9242949</a>:</span> <span class='sentence-part'>Atrial fibrillation was provoked by acetylcholine injection plus rapid atrial pacing.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/977087' target='_blank' class='pmid-link'>977087</a>:</span> <span class='sentence-part'>The effects of a new series of glutarimide compounds have been studied in acetylcholine induced auricular fibrillation in anaesthetized cats and epinephrine induced ventricular arrhythmmias in conscious pigeons.</span></div></div>
<div class='streamlined-assertion'><div class='streamlined-header sticky-relation-header'><span class='label-text'>Subject:</span> <strong>Acetylcholinesterase</strong> <span class='label-text'>Subject CUI:</span> <strong>C0001044</strong> â†’ <span class='label-text predicate-text'>CAUSES</span> â†’ <span class='label-text'>Object:</span> <strong>Alzheimers</strong> <span class='label-text'>Object CUI:</span> <strong>C0002395</strong></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/14685807' target='_blank' class='pmid-link'>14685807</a>:</span> <span class='sentence-part'>In conclusion, the bioactivity associated with the AChE-peptide sequence may account for the non-cholinergic actions of AChE, whilst its neurotrophic-apoptotic-necrotic spectrum of action may be involved in the aetiology of neurodegenerative disorders such as Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/16772751' target='_blank' class='pmid-link'>16772751</a>:</span> <span class='sentence-part'>The accumulation of evidence implicating AChE in the pathogenesis of AD raises the question of whether, in addition to their palliative actions, inhibitors of this enzyme are able to act as disease-modifying agents.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/18669022' target='_blank' class='pmid-link'>18669022</a>:</span> <span class='sentence-part'>Acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) are the key enzymes in pathogenesis of Alzheimer's disease (AD), which is characterized by a deficit in central cholinergic transmission.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20026160' target='_blank' class='pmid-link'>20026160</a>:</span> <span class='sentence-part'>Therefore, we initiated a study to screen the methanol extracts prepared from the aerial parts of 33 Turkish Scutellaria species for their acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) inhibitory activities, which are the key enzymes taking place in pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20689242' target='_blank' class='pmid-link'>20689242</a>:</span> <span class='sentence-part'>BACKGROUND: Several studies implicate acetylcholinesterase (AChE) in the pathogenesis of Alzheimer's disease (AD), raising the question of whether inhibitors of AChE also might act in a disease-modifying manner.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20732375' target='_blank' class='pmid-link'>20732375</a>:</span> <span class='sentence-part'>Since, acetylcholinesterase and butyrylcholinesterase enzymes are taking place in pathogenesis of Alzheimer's disease, in vitro anticholinesterase activity of the essential oil and the extract was also studied spectrophotometrically.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21384354' target='_blank' class='pmid-link'>21384354</a>:</span> <span class='sentence-part'>Therefore, the extracts were also evaluated against acetylcholinesterase (AChE) and butyrylcholinesterase (BChE), which are chief enzymes in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21762104' target='_blank' class='pmid-link'>21762104</a>:</span> <span class='sentence-part'>Cholinesterase enzyme family consisting of acetylcholinesterase (AChE) and butrylcholinesterase (BChE) is important in pathogenesis of Alzheimer's disease (AD), explained by \cholinergic hypothesis\.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25951978' target='_blank' class='pmid-link'>25951978</a>:</span> <span class='sentence-part'>Cholinesterases, acetylcholinesterase (AChE) and butyrylcholinesterase (BChE), have a role in cholinergic deficit which evidently leads to Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26527154' target='_blank' class='pmid-link'>26527154</a>:</span> <span class='sentence-part'>Acetyl cholinesterase (AChE) and butyrylcholinesterase (BChE) are two types of cholinesterase enzymes that have been identified in vertebrates that are responsible for Alzheimer's disease and related dementia.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26832327' target='_blank' class='pmid-link'>26832327</a>:</span> <span class='sentence-part'>Acetylcholinesterase (AChE) is an important enzyme in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27801451' target='_blank' class='pmid-link'>27801451</a>:</span> <span class='sentence-part'>Hyperactivity of acetylcholinesterase (AChE) in the brain is the immediate cause of Alzheimer's disease (AD), which is one of the most prevalent fatal diseases afflicting numerous older people.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29303784' target='_blank' class='pmid-link'>29303784</a>:</span> <span class='sentence-part'>Acetylcholinesterase (AChE) is an enzyme that metabolises the ACh at synaptic cleft resulting in Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30316049' target='_blank' class='pmid-link'>30316049</a>:</span> <span class='sentence-part'>Acetylcholinesterase (AChE) is one of the major cholinergic enzymes, and there is no report to show the relationship between cAbeta accumulation and peripheral AChE alteration in early stage of AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30530106' target='_blank' class='pmid-link'>30530106</a>:</span> <span class='sentence-part'>In the present study, 26 novel O-alkylcoumarin derivatives were synthesized and have been tested at 100 uM for their in vitro inhibitory potential against acetylcholinesterase (AChE) and butyrlcholinesterase (BChE) targets which are the key enzymes playing role in the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31002611' target='_blank' class='pmid-link'>31002611</a>:</span> <span class='sentence-part'>Previous studies showed that some mushrooms are highly efficient in inhibiting acetylcholinesterase and tyrosinase, the increased activity of which can trigger the development of Alzheimer and Parkinson diseases.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31639294' target='_blank' class='pmid-link'>31639294</a>:</span> <span class='sentence-part'>Previous studies have shown that fascaplysin might act on acetylcholinesterase and beta-amyloid (Abeta) to produce anti-AD properties.</span></div></div>
<div class='streamlined-assertion'><div class='streamlined-header sticky-relation-header'><span class='label-text'>Subject:</span> <strong>Aconitine</strong> <span class='label-text'>Subject CUI:</span> <strong>C0001159</strong> â†’ <span class='label-text predicate-text'>CAUSES</span> â†’ <span class='label-text'>Object:</span> <strong>Atrial_Fibrillation</strong> <span class='label-text'>Object CUI:</span> <strong>C0004238</strong></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/1023843' target='_blank' class='pmid-link'>1023843</a>:</span> <span class='sentence-part'>Its effect on aconitine-induced atrial fibrillation in the dog was examined.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/13320337' target='_blank' class='pmid-link'>13320337</a>:</span> <span class='sentence-part'>The formation of acetylcholine in the heart; its effect on the systemic output and its importance for auricular fibrillation caused by aconitine.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/13533254' target='_blank' class='pmid-link'>13533254</a>:</span> <span class='sentence-part'>Effect of hypercapnia on aconitine-induced atrial fibrillation and on ventricular fibrillation caused by focal cooling of the rapidly beating ventricles of the dog.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/13949441' target='_blank' class='pmid-link'>13949441</a>:</span> <span class='sentence-part'>Studies on the appearance and termination of aconitine-induced atrial fibrillation with microelectrodes.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/14002427' target='_blank' class='pmid-link'>14002427</a>:</span> <span class='sentence-part'>[Studies on aconitine-induced auricular fibrillation of the young rabbit by the microelectrode technic].</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/14008934' target='_blank' class='pmid-link'>14008934</a>:</span> <span class='sentence-part'>[Studies on aconitine-induced atrial fibrillation of the young rabbit by the microelectode technic].</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/14704594' target='_blank' class='pmid-link'>14704594</a>:</span> <span class='sentence-part'>Application of aconitine caused atrial fibrillation with an increase in ventricular rate, but did not affect arterial blood pressure.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/16725344' target='_blank' class='pmid-link'>16725344</a>:</span> <span class='sentence-part'>Tertiapin (4-41 nmol kg(-1), i.v.) terminated AF in the canine VNS-induced and aconitine-induced AF models.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17350982' target='_blank' class='pmid-link'>17350982</a>:</span> <span class='sentence-part'>CONCLUSION: NIP-141 terminated AF in aconitine-induced AF and prevented the atrial remodelling by short-term rapid pacing in dogs, possibly via the blocking of Na(+) and Ca(2+) channels. NIP-141, a multiple ion channel blocker, terminates aconitine-induced atrial fibrillation and prevents the rapid pacing-induced atrial effective refractory period shortening in dogs.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25030741' target='_blank' class='pmid-link'>25030741</a>:</span> <span class='sentence-part'>Since it has been reported that constitutively active KACh channels can be observed in atrial cells of patients with chronic AF, aconitine-induced AF may be used as an experimental model for evaluation of drug effect on chronic AF. Termination of aconitine-induced atrial fibrillation by the KACh-channel blocker tertiapin: underlying electrophysiological mechanism. This study was undertaken to determine the role of KACh channel in aconitine-induced AF in guinea pigs. Recently it has been demonstrated that tertiapin, a selective blocker of KACh channel, suppressed aconitine-induced atrial fibrillation (AF) in dogs. However, the precise mechanism by which the KACh-channel blocker inhibits the aconitine-induced AF remains unknown. Tertiapin terminated the aconitine-induced AF in anesthetized guinea pigs.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26756601' target='_blank' class='pmid-link'>26756601</a>:</span> <span class='sentence-part'>An aconitine-induced rat AF model was established without intubation anesthesia.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/3632145' target='_blank' class='pmid-link'>3632145</a>:</span> <span class='sentence-part'>In dogs, the drug is effective against post-infarction and ouabain-induced ventricular arrhythmias, and abolishes acetylcholine and aconitine-induced atrial fibrillation; it elevates the threshold of electrically induced ventricular fibrillation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/4391942' target='_blank' class='pmid-link'>4391942</a>:</span> <span class='sentence-part'>The efficacy of antiarrhythmic drugs in the prevention of recurrence of aconitine-induced atrial fibrillation after electrical conversion.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/5820461' target='_blank' class='pmid-link'>5820461</a>:</span> <span class='sentence-part'>Experimental studies on aconitine-induced atrial fibrillation with microelectrodes.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/6173520' target='_blank' class='pmid-link'>6173520</a>:</span> <span class='sentence-part'>Increased concentration of plasma cyclic GMP during aconitine-induced atrial fibrillation in dogs and paroxysmal atrial fibrillation in patients. The concentrations of cyclic nucleotides were measured by radioimmunoassay in the plasma of dogs with aconitine-induced atrial fibrillation and of patients with paroxysmal atrial fibrillation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/6302761' target='_blank' class='pmid-link'>6302761</a>:</span> <span class='sentence-part'>The concentrations of plasma cyclic nucleotides in patients with atrial fibrillation and in dogs with aconitine-induced atrial fibrillation were measured. The concentration of plasma cGMP in dogs with aconitine-induced atrial fibrillation was significantly elevated at 30 and 60 min after the onset of atrial fibrillation, whereas that of plasma cAMP showed no significant changes. Increased concentration of plasma cyclic GMP from aconitine-induced atrial fibrillation in dogs and patients with paroxysmal atrial fibrillation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/901074' target='_blank' class='pmid-link'>901074</a>:</span> <span class='sentence-part'>Both drugs raised ventricular fibrillation thresholds, reversed aconitine-induced atrial fibrillation, decreased ouabain-induced abnormal ventricular beats, and increased atrial refractory periods and His-Purkinje conduction time.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/9772688' target='_blank' class='pmid-link'>9772688</a>:</span> <span class='sentence-part'>On atrial fibrillation induced by aconitine, ouabain or adrenaline in isolated guinea pig atria, the effects of CVB-D were similar to those of amiodarone.</span></div></div>
<div class='streamlined-assertion'><div class='streamlined-header sticky-relation-header'><span class='label-text'>Subject:</span> <strong>Adenosine</strong> <span class='label-text'>Subject CUI:</span> <strong>C0001443</strong> â†’ <span class='label-text predicate-text'>CAUSES</span> â†’ <span class='label-text'>Object:</span> <strong>Atrial_Fibrillation</strong> <span class='label-text'>Object CUI:</span> <strong>C0004238</strong></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/10079775' target='_blank' class='pmid-link'>10079775</a>:</span> <span class='sentence-part'>Three instances of adenosine-induced atrial proarrhythmia (two atrial fibrillation and one atrial flutter) have been observed in children with manifest or concealed Wolff-Parkinson-White syndrome at the Hospital for Sick Children, Toronto, Ontario since 1990, which indicates a previously unreported risk of atrial arrhythmia for children as well.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/10666766' target='_blank' class='pmid-link'>10666766</a>:</span> <span class='sentence-part'>Adenosine induced atrial fibrillation precipitating polymorphic ventricular tachycardia.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/10875733' target='_blank' class='pmid-link'>10875733</a>:</span> <span class='sentence-part'>Because local f-f intervals during atrial fibrillation correlate with the atrial refractory period, changes in mean f-f intervals in the right atrial appendage, His bundle region, coronary sinus ostium and distal coronary sinus were compared before and after injection of adenosine during induced Afib. However, bolus injection of these drugs has been reported to provoke atrial fibrillation (Afib).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/10921803' target='_blank' class='pmid-link'>10921803</a>:</span> <span class='sentence-part'>Adenosine-induced atrial fibrillation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/12152390' target='_blank' class='pmid-link'>12152390</a>:</span> <span class='sentence-part'>The recognition of this uncommon effect is important, since the repeated administration of increasing doses of adenosine may induce sustained AF. We present a patient with atrial tachycardia in which the administration of adenosine induced a transient atrial fibrillation (AF). [Transient atrial fibrillation induced by adenosine in a patient with atrial tachycardia].</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/12741705' target='_blank' class='pmid-link'>12741705</a>:</span> <span class='sentence-part'>PV triggers were provoked by isoproterenol, adenosine, and AF induction followed by cardioversion.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/12890705' target='_blank' class='pmid-link'>12890705</a>:</span> <span class='sentence-part'>(4) Extrastimuli delivered to hearts perfused with Ap(5)A- or adenosine (&gt;/= micro M)-induced atrial fibrillation, the incidence of which correlated to the concentration added to the perfusate.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17689721' target='_blank' class='pmid-link'>17689721</a>:</span> <span class='sentence-part'>Adenosine-induced atrial fibrillation during pharmacologic stress testing: report of eight cases and review of the literature. Adenosine-induced atrial fibrillation has been described in the setting of treatment of supraventricular tachycardia, but has been rarely reported during adenosine infusion for pharmacologic stress testing.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/18081760' target='_blank' class='pmid-link'>18081760</a>:</span> <span class='sentence-part'>Ultra rapid local activity in adenosine-induced atrial fibrillation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/18156545' target='_blank' class='pmid-link'>18156545</a>:</span> <span class='sentence-part'>Pre-excited atrial fibrillation triggered by intravenous adenosine: a commonly used drug with potentially life-threatening adverse effects.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22676712' target='_blank' class='pmid-link'>22676712</a>:</span> <span class='sentence-part'>During atrial burst pacing, adenosine was then administered, which successfully induced AFib. Induction of atrial fibrillation with adenosine during a transesophageal electrophysiology study to risk stratify a patient with asymptomatic ventricular preexcitation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23224932' target='_blank' class='pmid-link'>23224932</a>:</span> <span class='sentence-part'>Adenosine-induced atrial fibrillation during fractional flow reserve measurement.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23778252' target='_blank' class='pmid-link'>23778252</a>:</span> <span class='sentence-part'>Adenosine-induced atrial fibrillation: insights into mechanism.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24838362' target='_blank' class='pmid-link'>24838362</a>:</span> <span class='sentence-part'>Furthermore, 10 MUmol/L adenosine shortened atrial repolarization and led to pacing-induced atrial fibrillation in 6 of 7 HF versus 0 of 7 control dogs (P=0.002). Adenosine-induced SAN dysfunction and atrial fibrillation were abolished or prevented by adenosine A1 receptor antagonists (50 MUmol/L theophylline/1 MUmol/L 8-cyclopentyl-1,3-dipropylxanthine).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27462069' target='_blank' class='pmid-link'>27462069</a>:</span> <span class='sentence-part'>In 10 hearts, adenosine induced AF (317+/-116 s) that, when sustained (&gt;=2 minutes), was primarily maintained by 1 to 2 localized reentrant drivers in lateral RA. Sustained adenosine-induced AF is maintained by reentrant drivers localized in lateral RA regions with the highest adenosine A1 receptor/GIRK4 expression. BACKGROUND: Adenosine provokes atrial fibrillation (AF) with a higher activation frequency in right atria (RA) versus left atria (LA) in patients, but the underlying molecular and functional substrates are unclear. Adenosine-Induced Atrial Fibrillation: Localized Reentrant Drivers in Lateral Right Atria due to Heterogeneous Expression of Adenosine A1 Receptors and GIRK4 Subunits in the Human Heart. METHODS: We applied biatrial optical mapping and immunoblot mapping of various atrial regions to reveal the mechanism of adenosine-induced AF in explanted failing and nonfailing human hearts (n=37). We tested the hypothesis that adenosine-induced AF is driven by localized reentry in RA areas with highest expression of adenosine A1 receptor and its downstream GIRK (G protein-coupled inwardly rectifying potassium channels) channels (IK,Ado).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27753716' target='_blank' class='pmid-link'>27753716</a>:</span> <span class='sentence-part'>CONCLUSIONS: Atrial fibrillation, as well as its conduction to the ventricles, can be caused by adenosine.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27920077' target='_blank' class='pmid-link'>27920077</a>:</span> <span class='sentence-part'>Letter by He Regarding Article, \Adenosine-Induced Atrial Fibrillation: Localized Reentrant Drivers in Lateral Right Atria Due to Heterogeneous Expression of Adenosine A1 Receptors and GIRK4 Subunits in the Human Heart\.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29255508' target='_blank' class='pmid-link'>29255508</a>:</span> <span class='sentence-part'>Value of adenosine test to reveal dormant conduction or adenosine-induced atrial fibrillation after pulmonary vein isolation. After additional ablation in positive dormant conduction group and adenosine-induced AF group, AF recurrence was noted in 4/21 (19%) patients in positive dormant conduction group and 2/11 (18%) patients in adenosine-induced AF group, which was not different from that of patients in negative dormant conduction/ no AF-induced group (14/112, 12%, log-rank P=0.67). Background: Recent studies investigating the implications of additional ablation guided by dormant pulmonary vein (PV) conduction testing using adenosine showed conflicting results, and the data about atrial fibrillation (AF) recurrence after trigger site elimination in adenosine-induced AF are still lacking. Among 148 patients with adenosine test, 114 (77%) patients showed neither dormant conductions nor AF-induced, 22 (15%) showed positive dormant conductions only, and 12 (8%) revealed adenosine-induced AF (6 of them also showed dormant conduction).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30375070' target='_blank' class='pmid-link'>30375070</a>:</span> <span class='sentence-part'>Ado-induced AF episodes originated from the left PVs in 6 of 12 (50%), from the right atrium (RA) in 4 of 12 (33%), and from the CS in 2 of 12 (17%) cases. Is adenosine useful for the identification of atrial fibrillation triggers? Altogether, Iso-induced AF was more likely initiated from the PVs (93%) compared with Ado (50%) ( P?=?0.02). INTRODUCTION: Both isoproterenol (Iso) and adenosine (Ado) are used to induce atrial fibrillation (AF) in the electrophysiology lab.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30535950' target='_blank' class='pmid-link'>30535950</a>:</span> <span class='sentence-part'>While exogenous adenosine can trigger AF, nothing is known about the behavior of endogenous adenosine plasma level (APL) at the onset of AF and during ablation procedure.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31471041' target='_blank' class='pmid-link'>31471041</a>:</span> <span class='sentence-part'>[Intracoronary adenosine induced-atrial fibrillation during fractional flow reserve evaluation].</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31549494' target='_blank' class='pmid-link'>31549494</a>:</span> <span class='sentence-part'>Background/aim: Ticagrelor  is  a  drug  widely  used  in  patients  with  acute  coronary  syndromes  (ACS)  that  specifically  increases  the  plasma  level  of  adenosine,  which  is  likely  to  cause  atrial  fibrillation  (AF).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31808225' target='_blank' class='pmid-link'>31808225</a>:</span> <span class='sentence-part'>Adenosine-induced atrial fibrillation arising from arrhythmogenic right atrial appendage.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/8639208' target='_blank' class='pmid-link'>8639208</a>:</span> <span class='sentence-part'>Adenosine-induced atrial fibrillation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/9290409' target='_blank' class='pmid-link'>9290409</a>:</span> <span class='sentence-part'>However, the hypothesis that excessive accumulation of endogenous adenosine in atrial tissue may induce atrial fibrillation is well substantiated by other investigators. Exogenous administration of adenosine induces atrial fibrillation in up to 7.0% of patients.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/9312997' target='_blank' class='pmid-link'>9312997</a>:</span> <span class='sentence-part'>MEASUREMENTS: Frequency of adenosine-induced atrial fibrillation. Adenosine led to atrial fibrillation (n = 22) or atrial fibrillation and atrial flutter (n = 2) in 24 patients (12% [CI, 7.5% to 16.5%]).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/9610516' target='_blank' class='pmid-link'>9610516</a>:</span> <span class='sentence-part'>Adenosine induced atrial fibrillation is due to shortening of the atrial action potential duration and atrial refractoriness, whereas shortening of the antegrade refractory period in the accessory pathway leads to rapid conduction to the ventricles.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/9869948' target='_blank' class='pmid-link'>9869948</a>:</span> <span class='sentence-part'>Adenosine provokes atrial fibrillation (AF) in some patients with paroxysmal supraventricular tachycardia (PSVT).</span></div></div>
<div class='streamlined-assertion'><div class='streamlined-header sticky-relation-header'><span class='label-text'>Subject:</span> <strong>Adverse_effects</strong> <span class='label-text'>Subject CUI:</span> <strong>C0879626</strong> â†’ <span class='label-text predicate-text'>CAUSES</span> â†’ <span class='label-text'>Object:</span> <strong>Alzheimers</strong> <span class='label-text'>Object CUI:</span> <strong>C0002395</strong></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20066010' target='_blank' class='pmid-link'>20066010</a>:</span> <span class='sentence-part'>Dysregulation of beta-site APP-cleaving enzyme (BACE) and/or gamma-secretase leads to anomalous production of amyloid-beta peptide (Abeta) and contributes to the etiology of Alzheimer's disease (AD). Since these secretases mediate proteolytic processing of numerous proteins, little success has been achieved to treat AD by secretase inhibitors because of inevitable undesired side effects.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20190429' target='_blank' class='pmid-link'>20190429</a>:</span> <span class='sentence-part'>To date, acetylcholinesterase (AChE) inhibitors have been clinically effective drugs for the palliative treatment of Alzheimer's disease, but their clinical efficacy is limited, mainly due to their adverse effects on peripheral organs.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24053611' target='_blank' class='pmid-link'>24053611</a>:</span> <span class='sentence-part'>EXPERT OPINION: Amyloid-based immunotherapy for AD is a novel method with potential; however, some clinical trials were terminated because of the adverse effects.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28065587' target='_blank' class='pmid-link'>28065587</a>:</span> <span class='sentence-part'>Thus far, phosphodiesterase-4 (PDE4) inhibitors have not been approved for application in Alzheimer's disease (AD) in a clinical setting due to severe side effects, such as nausea and vomiting.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28788095' target='_blank' class='pmid-link'>28788095</a>:</span> <span class='sentence-part'>Tacrine (THA), the first clinically effective acetylcholinesterase (AChE) inhibitor and the first approved drug for the treatment of Alzheimer's disease (AD), was withdrawn from the market due to its side effects, particularly its hepatotoxicity.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32709074' target='_blank' class='pmid-link'>32709074</a>:</span> <span class='sentence-part'>Recent clinical trials of synthetic compounds for the treatment of AD have failed because of their adverse effects or lack of efficacy.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33534126' target='_blank' class='pmid-link'>33534126</a>:</span> <span class='sentence-part'>Though several drug candidates have been developed in the management of AD, an alternative option is still required due to serious adverse effects of the former.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33596779' target='_blank' class='pmid-link'>33596779</a>:</span> <span class='sentence-part'>Development of ABT-736 for Alzheimer's disease was discontinued due to severe adverse effects (AEs) observed in cynomolgus monkey toxicity studies.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/3387586' target='_blank' class='pmid-link'>3387586</a>:</span> <span class='sentence-part'>Changes in hepatic metabolism in AD may be relevant not only for drug metabolism and the development of side effects, but also for the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37156292' target='_blank' class='pmid-link'>37156292</a>:</span> <span class='sentence-part'>Exposure to exogenous chemicals may exert adverse effects on cognitive function, and we discovered 15 chemicals in human hair that may contribute to the pathogenesis of Alzheimer's disease.</span></div></div>
<div class='streamlined-assertion'><div class='streamlined-header sticky-relation-header'><span class='label-text'>Subject:</span> <strong>Agent</strong> <span class='label-text'>Subject CUI:</span> <strong>C0450442</strong> â†’ <span class='label-text predicate-text'>CAUSES</span> â†’ <span class='label-text'>Object:</span> <strong>Alzheimers</strong> <span class='label-text'>Object CUI:</span> <strong>C0002395</strong></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/12446934' target='_blank' class='pmid-link'>12446934</a>:</span> <span class='sentence-part'>Other studies show complex interactions between nAChR, nicotinic agonists, and agents implicated in AD etiology.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/14657205' target='_blank' class='pmid-link'>14657205</a>:</span> <span class='sentence-part'>In addition, because many neurodegenerative diseases are associated with increased oxidative and inflammatory responses, an attempt was made to include studies on PLA2 in cerebral ischemia, Alzheimer's disease, and neuronal injury due to excitotoxic agents.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17047367' target='_blank' class='pmid-link'>17047367</a>:</span> <span class='sentence-part'>Processing of the amyloid precursor protein (APP) by beta- and gamma-secretases leads to the generation of amyloid-beta (Abeta) peptides, which are the toxic agents in the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17920304' target='_blank' class='pmid-link'>17920304</a>:</span> <span class='sentence-part'>Amyloid beta peptide (Abeta) is considered one of the main agents of Alzheimer's disease pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/18093473' target='_blank' class='pmid-link'>18093473</a>:</span> <span class='sentence-part'>A-beta is indicated to be the primary agent in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/18631951' target='_blank' class='pmid-link'>18631951</a>:</span> <span class='sentence-part'>During the past dozen years, several agents have been approved that enhance cognition and global function of AD patients, and recent advances in understanding AD pathogenesis has led to the development of numerous compounds that might modify the disease process.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/19233290' target='_blank' class='pmid-link'>19233290</a>:</span> <span class='sentence-part'>Soluble oligomers and fibrillar deposits of amyloid beta (Abeta) are key agents of Alzheimer's disease pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/2197055' target='_blank' class='pmid-link'>2197055</a>:</span> <span class='sentence-part'>Aluminum has also been implicated as a toxic agent in the etiology of Alzheimer's disease, Guamiam amyotrophic lateral sclerosis, and parkinsonism-dementia.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22124704' target='_blank' class='pmid-link'>22124704</a>:</span> <span class='sentence-part'>These findings suggest that Wnt signaling can protect neural cells against apoptosis induced by toxic agents, which are relevant to the pathogenesis of Alzheimer's and Huntington's diseases.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23161037' target='_blank' class='pmid-link'>23161037</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) is the sixth leading cause of all deaths in the United States, and the fifth leading cause of death in Americans aged 65 and older. During the past years, several agents have been approved that enhance cognition and global function of AD patients, and recent advances in understanding AD pathogenesis has led to the development of numerous compounds that might modify the disease process.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23526599' target='_blank' class='pmid-link'>23526599</a>:</span> <span class='sentence-part'>The amyloid-beta peptide (Abeta) is widely considered to be the major toxic agent in the pathogenesis of Alzheimer's disease, a condition which afflicts approximately 36 million people worldwide.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24448248' target='_blank' class='pmid-link'>24448248</a>:</span> <span class='sentence-part'>The amyloid-beta peptide (Abeta) is widely considered to be the major toxic agent in the pathogenesis of Alzheimer's disease, a condition which afflicts approximately 36 million people worldwide.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26248483' target='_blank' class='pmid-link'>26248483</a>:</span> <span class='sentence-part'>Herein, we reviewed the evidence stemming from the development of diabetes agent-induced AD animal model.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28098204' target='_blank' class='pmid-link'>28098204</a>:</span> <span class='sentence-part'>Low molecular weight oligomers of amyloid-beta (Abeta) have emerged as the primary toxic agents in the etiology of Alzheimer disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/2884783' target='_blank' class='pmid-link'>2884783</a>:</span> <span class='sentence-part'>So far, however, there is no proof that Alzheimer's disease is caused by an unconventional agent.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29905953' target='_blank' class='pmid-link'>29905953</a>:</span> <span class='sentence-part'>In recent years, actors such as metal ions, oxidative stress, and other cofactors have been proposed as possible co-agents or, in some cases, main causative factors of AD. Amyloid-beta peptide (Abeta) accumulation and aggregation have been considered for many years the main cause of Alzheimer's disease (AD), and therefore have been the principal target of investigation as well as of the proposed therapeutic approaches (Grasso [2011] Mass Spectrom Rev.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30550626' target='_blank' class='pmid-link'>30550626</a>:</span> <span class='sentence-part'>Amyloid beta is an inherently disordered peptide that can form diverse neurotoxic aggregates, and its 42-amino-acid isoform is believed to be the agent responsible for Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31876280' target='_blank' class='pmid-link'>31876280</a>:</span> <span class='sentence-part'>Advances in the research of molecular factors involved in the onset and progression of Alzheimer's disease, have led to the creation of several pathogenesis concepts of the most common neurodegenerative disease in the world, and amyloid, cholinergic, and neuroinflammatory hypotheses became leading. In this review, based on the latest experimental data on structure-function properties of chemically modified amyloid-beta isoforms, the concept of the origin and the mechanism of action of amyloid-beta with isomerized Asp7 residue, as a molecular agent of Alzheimer's disease pathogenesis, is presented.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32431878' target='_blank' class='pmid-link'>32431878</a>:</span> <span class='sentence-part'>A   beta     aggregates, especially the low-molecular weight oligomers, are the primary toxic agents in AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32991975' target='_blank' class='pmid-link'>32991975</a>:</span> <span class='sentence-part'>Biological evaluation of naturally occurring Bulbocodin D as a potential multi-target agent for Alzheimer's disease.In recent years, with the in-depth understanding of the pathogenesis of Alzheimer's disease (AD) and the development of advanced pharmacological technology, \multi-target\ strategy has recently attracted the wide interest of scientists.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34502472' target='_blank' class='pmid-link'>34502472</a>:</span> <span class='sentence-part'>Abeta(1-42) peptide is a neurotoxic agent strongly associated with the etiology of Alzheimer's disease (AD).</span></div></div>
<div class='streamlined-assertion'><div class='streamlined-header sticky-relation-header'><span class='label-text'>Subject:</span> <strong>Alzheimers</strong> <span class='label-text'>Subject CUI:</span> <strong>C0002395</strong> â†’ <span class='label-text predicate-text'>CAUSES</span> â†’ <span class='label-text'>Object:</span> <strong>Aging</strong> <span class='label-text'>Object CUI:</span> <strong>C0001811</strong></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/16128149' target='_blank' class='pmid-link'>16128149</a>:</span> <span class='sentence-part'>In this study, we hypothesized that a quantitative EEG (qEEG) method for measuring EEG variability combined with specific psychophysical tasks could improve the classification accuracy of subjects with normal aging vs. mild cognitive impairment (MCI) or mild dementia due to Alzheimer's Disease and Related Disorders (ADRD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17006763' target='_blank' class='pmid-link'>17006763</a>:</span> <span class='sentence-part'>Mild cognitive impairment (MCI) is regarded as a transition stage between the cognitive changes of normal aging and the more serious problems caused by Alzheimer's disease (AD). Since these proteins are involved directly or indirectly in microtubule destabilization and hyperphosphorylation of tau, and also in APP processing we hypothesize that cell cycle disturbance may be important contributor in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/19647374' target='_blank' class='pmid-link'>19647374</a>:</span> <span class='sentence-part'>Taken together with other phenomena such as cell cycle re-activation and ectopic re-expression of cyclins and cyclin dependent proteins, we propose that AD is an oncogenic phenotype leading to accelerated aging of the affected brain.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20413856' target='_blank' class='pmid-link'>20413856</a>:</span> <span class='sentence-part'>Additional work is required, but such associations suggest that reduced cardiac output may be a risk factor for Alzheimer's disease (AD) and abnormal brain aging through the propagation or exacerbation of neurovascular processes, microembolism due to thrombosis, and AD neuropathological processes.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21514249' target='_blank' class='pmid-link'>21514249</a>:</span> <span class='sentence-part'>The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. The National Institute on Aging and the Alzheimer's Association charged a workgroup with the task of developing criteria for the symptomatic predementia phase of Alzheimer's disease (AD), referred to in this article as mild cognitive impairment due to AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22343502' target='_blank' class='pmid-link'>22343502</a>:</span> <span class='sentence-part'>UNLABELLED: In the recently revised diagnostic criteria for Alzheimer disease (AD), the National Institute on Aging and Alzheimer Association suggested that confidence in diagnosing dementia due to AD and mild cognitive impairment (MCI) due to AD could be improved by the use of certain biomarkers, such as (18)F-FDG PET evidence of hypometabolism in AD-affected brain regions.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22594104' target='_blank' class='pmid-link'>22594104</a>:</span> <span class='sentence-part'>METHODS: The rat model of Alzheimer's disease (AD) was established using D-galactose to cause subacute aging combined with Meynert nucleus damage.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22773365' target='_blank' class='pmid-link'>22773365</a>:</span> <span class='sentence-part'>To this effect, the Alzheimer's Association and the National Institute on Aging have developed a new classification scheme that has categorized AD into a preclinical phase (research category), MCI due to AD, and dementia of Alzheimer's type.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23026363' target='_blank' class='pmid-link'>23026363</a>:</span> <span class='sentence-part'>Recently, the National Institute on Aging and the Alzheimer's Association identified specific structural and functional neuroimaging findings as valuable markers of biological processes occurring in the human brain, especially processes that herald impending dementia caused by Alzheimer's disease (AD) in its prodromal form.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23138093' target='_blank' class='pmid-link'>23138093</a>:</span> <span class='sentence-part'>Currently, healthcare costs associated with aging at home can be prohibitive if individuals require continual/periodical supervision and assistance because of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23760360' target='_blank' class='pmid-link'>23760360</a>:</span> <span class='sentence-part'>Early identification of persons at risk for cognitive decline in aging is critical to optimizing treatment to delay or avoid a clinical diagnosis of mild cognitive impairment (MCI) or dementia due to Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27025083' target='_blank' class='pmid-link'>27025083</a>:</span> <span class='sentence-part'>The Natinal Institute on Aging and the Alzheimer's Association proposed AD dementia, mild cognitive impairment due to AD, the preclinical stage of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27071083' target='_blank' class='pmid-link'>27071083</a>:</span> <span class='sentence-part'>To address this problem in a systematic manner, we performed a meta-analysis of about 1,600 microarrays from human central nervous system tissues to identify transcriptional changes upon aging and as a result of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27567815' target='_blank' class='pmid-link'>27567815</a>:</span> <span class='sentence-part'>Both healthy and pathological aging due to Alzheimer's disease (AD) are associated with decreased brain grey matter volume (GMV) and disrupted white matter (WM) microstructure.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29316249' target='_blank' class='pmid-link'>29316249</a>:</span> <span class='sentence-part'>Aging is a major driving force underlying dementia, such as that caused by Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30777767' target='_blank' class='pmid-link'>30777767</a>:</span> <span class='sentence-part'>Beyond episodic memory: Semantic processing as independent predictor of hippocampal/perirhinal volume in aging and mild cognitive impairment due to Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33164934' target='_blank' class='pmid-link'>33164934</a>:</span> <span class='sentence-part'>CONCLUSION: These findings extend previous observations in cognitively normal aging, demonstrating that entorhinal tau continues to be closely associated with hippocampal hyperactivity and memory performance in MCI and mild dementia due to AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33816761' target='_blank' class='pmid-link'>33816761</a>:</span> <span class='sentence-part'>Association between regional tau pathology and neuropsychiatric symptoms in aging and dementia due to Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34655980' target='_blank' class='pmid-link'>34655980</a>:</span> <span class='sentence-part'>Brain atrophy occurs in aging even in the absence of dementia, but it is unclear to what extent this is due to undetected preclinical Alzheimer disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35908596' target='_blank' class='pmid-link'>35908596</a>:</span> <span class='sentence-part'>In a society where the global population is gradually ageing, the health threats and financial burdens caused by AD are becoming increasingly severe since AD often occurs in old age.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36223647' target='_blank' class='pmid-link'>36223647</a>:</span> <span class='sentence-part'>AD overture proposes that sAD is: (i) a multifactorial and progressive neurodegenerative biological process, (ii) characterized by the early appearance of 3R + 4Rtau NFTs, (iii) later deposition of beta-amyloid and SPs, (iv) with particular non-overlapped regional distribution of NFTs and SPs, (v) preceded by or occurring in parallel with molecular changes affecting cell membranes, cytoskeleton, synapses, lipid and protein metabolism, energy metabolism, neuroinflammation, cell cycle, astrocytes, microglia, and blood vessels; (vi) accompanied by progressive neuron loss and brain atrophy, (vii) prevalent in human brain aging, and (viii) manifested as pre-clinical AD, and progressing not universally to mild cognitive impairment due to AD, and mild, moderate, and severe AD dementia.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36876565' target='_blank' class='pmid-link'>36876565</a>:</span> <span class='sentence-part'>One theory claims that AD is due to brain aging affecting mainly the functions of mitochondria, therefore, the factors leading to mitochondrial ageing should lead to the development of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37422287' target='_blank' class='pmid-link'>37422287</a>:</span> <span class='sentence-part'>DISCUSSION: Amyloid beta deposition and striatal dopaminergic depletion contribute to regional perfusion changes, clinical symptoms, and cognition in the spectrum of normal aging and cognitive impairment due to AD and/or LBD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/38645748' target='_blank' class='pmid-link'>38645748</a>:</span> <span class='sentence-part'>As such, CR may slow aging and reduce the risk of all diseases of aging, including dementia due to AD.</span></div></div>
<div class='streamlined-assertion'><div class='streamlined-header sticky-relation-header'><span class='label-text'>Subject:</span> <strong>Alzheimers</strong> <span class='label-text'>Subject CUI:</span> <strong>C0002395</strong> â†’ <span class='label-text predicate-text'>CAUSES</span> â†’ <span class='label-text'>Object:</span> <strong>Amyloid_deposition</strong> <span class='label-text'>Object CUI:</span> <strong>C0011560</strong></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/15141356' target='_blank' class='pmid-link'>15141356</a>:</span> <span class='sentence-part'>Especially cerebral microangiopathy is strongly associated with Alzheimer's dementia, it triggers the vicious circle which leads to amyloid deposition.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23945233' target='_blank' class='pmid-link'>23945233</a>:</span> <span class='sentence-part'>For example, FDG-PET demonstrates hypometabolic regions in the posterior cingulate gyri, precuneus, and parietotemporal association cortices, while amyloid PET indicates amyloid deposition in Alzheimer disease and mild cognitive impairment due to Alzheimer disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/2566117' target='_blank' class='pmid-link'>2566117</a>:</span> <span class='sentence-part'>However, since increased levels of PreA4 are not present in Alzheimer's disease, additional factors must account for the amyloid deposition in that disorder.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/2682324' target='_blank' class='pmid-link'>2682324</a>:</span> <span class='sentence-part'>Advances in our knowledge of the normal posttranslational processing of the amyloid precursor protein may help to elucidate the defect in Alzheimer's disease that leads to amyloid deposition.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28124588' target='_blank' class='pmid-link'>28124588</a>:</span> <span class='sentence-part'>Cellular Model of Alzheimer's Disease: Abeta1-42 Peptide Induces Amyloid Deposition and a Decrease in Topo Isomerase IIbeta and Nurr1 Expression.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28304292' target='_blank' class='pmid-link'>28304292</a>:</span> <span class='sentence-part'>The aim was to evaluate brain amyloid-beta (Abeta) deposition in patients with mild cognitive impairment (MCI) due to Alzheimer's disease (AD) using amyloid PET imaging and clarify the relationship between the annual change in Abeta deposition and disease progression.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31068220' target='_blank' class='pmid-link'>31068220</a>:</span> <span class='sentence-part'>AQP4 redistribution has been proposed to impair bulk Abeta clearance in AD, resulting in increased amyloid deposition in the brain; however, this finding is controversial.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33883492' target='_blank' class='pmid-link'>33883492</a>:</span> <span class='sentence-part'>Asymmetric Amyloid Deposition as an Early Sign of Progression in Mild Cognitive Impairment Due to Alzheimer Disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35328176' target='_blank' class='pmid-link'>35328176</a>:</span> <span class='sentence-part'>Amyloid positron emission tomography (PET) scan is clinically essential for the non-invasive assessment of the presence and spatial distribution of amyloid-beta deposition in subjects with cognitive impairment suspected to have been a result of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/7724603' target='_blank' class='pmid-link'>7724603</a>:</span> <span class='sentence-part'>The data demonstrate that both apoE epsilon 4/AD and trisomy 21/AD lead to increased amyloid deposition, but by apparently different mechanisms.</span></div></div>
<div class='streamlined-assertion'><div class='streamlined-header sticky-relation-header'><span class='label-text'>Subject:</span> <strong>Alzheimers</strong> <span class='label-text'>Subject CUI:</span> <strong>C0002395</strong> â†’ <span class='label-text predicate-text'>CAUSES</span> â†’ <span class='label-text'>Object:</span> <strong>Atrophic</strong> <span class='label-text'>Object CUI:</span> <strong>C0333641</strong></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/12899186' target='_blank' class='pmid-link'>12899186</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) results in atrophy of limbic structures, whereas normal aging relatively spares limbic regions but affects prefrontal areas.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/19955375' target='_blank' class='pmid-link'>19955375</a>:</span> <span class='sentence-part'>Thus, it is possible that the accelerating atrophy with increasing age is due to preclinical AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21674695' target='_blank' class='pmid-link'>21674695</a>:</span> <span class='sentence-part'>BACKGROUND: Alzheimer's disease (AD) and mild cognitive impairment (MCI) affect the limbic system, causing medial temporal lobe (MTL) atrophy and posterior cingulate cortex (PCC) hypometabolism.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22383167' target='_blank' class='pmid-link'>22383167</a>:</span> <span class='sentence-part'>CONCLUSION: Our results suggest that (i) hippocampal and amygdala but not entorhinal cortex, volumes differ between AD and LBD and (ii) factors other than current markers of neurodegenerative pathological change are responsible for atrophy of medial temporal lobe structures in AD and LBD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23024883' target='_blank' class='pmid-link'>23024883</a>:</span> <span class='sentence-part'>Clinicians and researchers alike are in need of quantitative and robust measurement tools to assess medial temporal lobe atrophy (MTA) due to Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24167442' target='_blank' class='pmid-link'>24167442</a>:</span> <span class='sentence-part'>Conversely, patients with hippocampus atrophy due to Alzheimer's disease, but not patients with Fronto-Temporal Dementia, were less inclined to favor options that required mental simulation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24787913' target='_blank' class='pmid-link'>24787913</a>:</span> <span class='sentence-part'>Our results demonstrated that subjects with increased medial temporal atrophy (MTA) severity on VSRAD, increased Cho/Cr, MI/Cr ratio, and decreased NAA/Cr and NAA/MI ratio on 1H MRS at baseline were at risk of dementia due to AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25082631' target='_blank' class='pmid-link'>25082631</a>:</span> <span class='sentence-part'>In conclusion, automated MRI brain tissue segmentation differentiates shunt-responsive NPH with high accuracy from atrophy due to AD and normal aging. To better characterize NPH, we test the hypothesis that a prediction model based on automated MRI brain tissue segmentation can help differentiate shunt-responsive NPH patients from cerebral atrophy due to Alzheimer disease (AD) and normal aging.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25120483' target='_blank' class='pmid-link'>25120483</a>:</span> <span class='sentence-part'>Medial temporal lobe (MTL) atrophy resulting from AD lesions and cerebrovascular lesions [i.e., white matter lesions (WML), lacunar strokes, and strokes] are often revealed concurrently on magnetic resonance imaging (MRI) in MCI subjects.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25260848' target='_blank' class='pmid-link'>25260848</a>:</span> <span class='sentence-part'>In a previous report, we proposed a method for combining multiple markers of atrophy caused by Alzheimer's disease into a single atrophy score that is more powerful than any one feature.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25324775' target='_blank' class='pmid-link'>25324775</a>:</span> <span class='sentence-part'>Glucose hypometabolism and gray matter atrophy are well known consequences of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25750526' target='_blank' class='pmid-link'>25750526</a>:</span> <span class='sentence-part'>BACKGROUND: An increased electroencephalographic (EEG) upper/lower alpha power ratio has been associated with less regional blood perfusion, atrophy of the temporoparietal region of the brain, and reduction of hippocampal volume in subjects affected by mild cognitive impairment due to Alzheimer's disease as compared with subjects who do not develop the disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29420642' target='_blank' class='pmid-link'>29420642</a>:</span> <span class='sentence-part'>Inner retina in Alzheimer's Disease (AD) may experience neuroinflammation resulting in atrophy.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29844294' target='_blank' class='pmid-link'>29844294</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) represents the prevalent type of dementia in the elderly, and is characterized by the presence of neurofibrillary tangles and amyloid plaques that eventually leads to the loss of neurons, resulting in atrophy in specific brain areas.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31054405' target='_blank' class='pmid-link'>31054405</a>:</span> <span class='sentence-part'>In this study, we assessed whether patients with hippocampal atrophy due to Alzheimer's disease (AD) are still able to retrieve overlearned arithmetic facts from memory.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33407913' target='_blank' class='pmid-link'>33407913</a>:</span> <span class='sentence-part'>BACKGROUND: Alzheimer's disease (AD) and behavioral variant frontotemporal dementia (bvFTD) cause distinct atrophy and functional disruptions within two major intrinsic brain networks, namely the default network and the salience network, respectively.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35068451' target='_blank' class='pmid-link'>35068451</a>:</span> <span class='sentence-part'>CONCLUSION: Data suggest that less atrophy of the Ch1/2 area and younger age are associated with a more significant cholinergic deficit in MCI due to AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35109316' target='_blank' class='pmid-link'>35109316</a>:</span> <span class='sentence-part'>BACKGROUND: Alzheimer's disease (AD) is a progressive neurological disease that leads to atrophy of the brain and cognitive decline.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35770026' target='_blank' class='pmid-link'>35770026</a>:</span> <span class='sentence-part'>Multiple experiments were performed to get the data from three lamb brain phantoms that realistically mimic the whole-brain atrophy due to Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36038918' target='_blank' class='pmid-link'>36038918</a>:</span> <span class='sentence-part'>This alteration persists throughout AD progression and leads to generalized dendritic atrophy at late stages of the disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36410182' target='_blank' class='pmid-link'>36410182</a>:</span> <span class='sentence-part'>AD is characterized by two cardinal pathological mechanisms: amyloid beta (Abeta) plaques and neurofibrillary tangles (NFTs), leading to atrophy of the brain.</span></div></div>
<div class='streamlined-assertion'><div class='streamlined-header sticky-relation-header'><span class='label-text'>Subject:</span> <strong>Alzheimers</strong> <span class='label-text'>Subject CUI:</span> <strong>C0002395</strong> â†’ <span class='label-text predicate-text'>CAUSES</span> â†’ <span class='label-text'>Object:</span> <strong>Cerebral_atrophy</strong> <span class='label-text'>Object CUI:</span> <strong>C0235946</strong></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/18280925' target='_blank' class='pmid-link'>18280925</a>:</span> <span class='sentence-part'>RATIONALE AND OBJECTIVES: An automated method for identification of patients with cerebral atrophy due to Alzheimer's disease (AD) was developed based on three-dimensional (3D) T1-weighted magnetic resonance (MR) images.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20157252' target='_blank' class='pmid-link'>20157252</a>:</span> <span class='sentence-part'>Although it is established that Alzheimer's disease (AD) leads to cerebral macrostructural atrophy, microstructural diffusion changes have also been observed, but it is not yet known whether these changes offer unique information about the disease pathology.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22011258' target='_blank' class='pmid-link'>22011258</a>:</span> <span class='sentence-part'>Abstract   Posterior cortical atrophy (PCA) is a visual-cognitive syndrome caused by Creutzfeldt-Jakob disease (CJD), Alzheimer's disease (AD), or subcortical gliosis. Clinical manifestations of PCA caused by AD included visual agnosia, cortical blindness, optic apraxla, delusions, hallucinations, agitation, depression, amnestic deficit, Wernicke's aphasia, acalculia, and left/right disorientation. Posterior cortical atrophy produced by AD can be demonstrated on magnetic resonance imaging, positron emission tomography, and electroencephalography; determination of the etiology requires tissue examination.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22265212' target='_blank' class='pmid-link'>22265212</a>:</span> <span class='sentence-part'>The progressive neurodegeneration affecting parietal, occipital, and occipitotemporal cortices that underlies PCA is attributable to Alzheimer's disease in most patients.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23138762' target='_blank' class='pmid-link'>23138762</a>:</span> <span class='sentence-part'>Overlap in the linguistic profiles of PCA and LPA, which are both most commonly caused by Alzheimer's disease, further emphasises the notion of a phenotypic continuum between typical and atypical manifestations of the disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/2428577' target='_blank' class='pmid-link'>2428577</a>:</span> <span class='sentence-part'>Comparison with records of 22 patients, with cortical atrophy due to Alzheimer's disease but with only mild to moderate dementia, showed a similar low frequency of non-specific abnormalities.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25082631' target='_blank' class='pmid-link'>25082631</a>:</span> <span class='sentence-part'>In conclusion, automated MRI brain tissue segmentation differentiates shunt-responsive NPH with high accuracy from atrophy due to AD and normal aging. To better characterize NPH, we test the hypothesis that a prediction model based on automated MRI brain tissue segmentation can help differentiate shunt-responsive NPH patients from cerebral atrophy due to Alzheimer disease (AD) and normal aging.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25589715' target='_blank' class='pmid-link'>25589715</a>:</span> <span class='sentence-part'>Left temporal lobe epilepsy revealing left posterior cortical atrophy due to Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25869784' target='_blank' class='pmid-link'>25869784</a>:</span> <span class='sentence-part'>AD and LLD led to brain atrophy in networks only partially overlapping.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27180794' target='_blank' class='pmid-link'>27180794</a>:</span> <span class='sentence-part'>Therefore, the PCA was considered to be a result of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28116234' target='_blank' class='pmid-link'>28116234</a>:</span> <span class='sentence-part'>We investigated the association between RAVLT scores (RAVLT Immediate and RAVLT Percent Forgetting) and the structural brain atrophy caused by AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28394771' target='_blank' class='pmid-link'>28394771</a>:</span> <span class='sentence-part'>BACKGROUND: Flortaucipir (tau) positron emission tomography (PET) binding distinguishes individuals with clinically well-established posterior cortical atrophy (PCA) due to Alzheimer disease (AD) from cognitively normal (CN) controls.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/2872473' target='_blank' class='pmid-link'>2872473</a>:</span> <span class='sentence-part'>These volumes were measured in 4 patients and the results were: 11.0 ml ventricular volume, 68.7 ml total cranial CSF in the patient with benign intracranial hypertension; 606.6 ml ventricular, 174.1 ml total in the patient with hydrocephalus due to a blocked ventriculo-peritoneal (V-P) shunt; 83.4 ml ventricular, 108.5 ml total in the patient with normal pressure hydrocephalus; and 52.7 ml ventricular, 181.0 ml total in the patient with cerebral atrophy due to Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30425798' target='_blank' class='pmid-link'>30425798</a>:</span> <span class='sentence-part'>A patient with posterior cortical atrophy due to Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30568088' target='_blank' class='pmid-link'>30568088</a>:</span> <span class='sentence-part'>Our proposed method would be useful for the accurate evaluation of cerebral atrophy caused by Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32603972' target='_blank' class='pmid-link'>32603972</a>:</span> <span class='sentence-part'>Influence of plasma matrix metalloproteinase levels on longitudinal changes in Alzheimer's disease (AD) biomarkers and cognitive function in patients with mild cognitive impairment due to AD registered in the Alzheimer's Disease Neuroimaging Initiative database.OBJECTIVE: The present study investigated the effects of plasma matrix metalloproteinases (MMPs) on longitudinal changes in Alzheimer's disease (AD)-related biomarkers in cerebrospinal fluid (CSF), brain atrophy, and cognitive function in patients with mild cognitive impairment due to AD (MCI-AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36419215' target='_blank' class='pmid-link'>36419215</a>:</span> <span class='sentence-part'>INTRODUCTION: Carrying out a randomized controlled trial to estimate the causal effects of regional brain atrophy due to Alzheimer's disease (AD) is impossible.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37370645' target='_blank' class='pmid-link'>37370645</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) is a progressive neurological problem that causes brain atrophy and affects the memory and thinking skills of an individual.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37930972' target='_blank' class='pmid-link'>37930972</a>:</span> <span class='sentence-part'>N = 43 patients were studied of whom n = 13 had DLB or PD with Dementia (PDD); n = 13 had PD; n = 12 had typical, memory-onset Alzheimer's Disease (tAD); and n = 5 had Posterior Cortical Atrophy (PCA) due to Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/9613493' target='_blank' class='pmid-link'>9613493</a>:</span> <span class='sentence-part'>PURPOSE: In the older patient with dilated ventricles, it is often difficult to differentiate normal pressure hydrocephalus (NPH) from cerebral atrophy caused by Alzheimer disease (AD).</span></div></div>
<div class='streamlined-assertion'><div class='streamlined-header sticky-relation-header'><span class='label-text'>Subject:</span> <strong>Alzheimers</strong> <span class='label-text'>Subject CUI:</span> <strong>C0002395</strong> â†’ <span class='label-text predicate-text'>CAUSES</span> â†’ <span class='label-text'>Object:</span> <strong>Cessation_of_life</strong> <span class='label-text'>Object CUI:</span> <strong>C0011065</strong></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/10404929' target='_blank' class='pmid-link'>10404929</a>:</span> <span class='sentence-part'>CONCLUSIONS: Although Alzheimer's disease is widely regarded as a leading cause of death, dementias are reported on the death certificates of only a quarter of demented individuals in the population at large.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/10459279' target='_blank' class='pmid-link'>10459279</a>:</span> <span class='sentence-part'>The trend likely reflects changes in attitudes of physicians and the public about attributing Alzheimer's disease as a cause of death as well as the availability of improved diagnostic procedures; the recent leveling in mortality trends from this condition may signal that death certificate diagnoses for Alzheimer's disease are more reliable now. Alzheimer's disease is a major cause of death, which exhibits variations by age, sex, race, and geographic area. Physicians report that Alzheimer's disease caused the death of 21,397 persons in 1996 and contributed to the death of 21,703 additional persons.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/10681274' target='_blank' class='pmid-link'>10681274</a>:</span> <span class='sentence-part'>Alzheimer disease is one of the leading causes of death among older individuals.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/10822478' target='_blank' class='pmid-link'>10822478</a>:</span> <span class='sentence-part'>OBJECTIVE: To describe the scope of mortality from and trends in Alzheimer's disease, to show how Alzheimer's disease ranks as a leading cause of death, to describe a methodological change regarding ranking, and to discuss issues related to the reporting of Alzheimer's disease on death certificates. RESULTS: Alzheimer's disease has increasingly been reported as a cause of death on death certificates in the United States; however, this increase may represent a variety of factors including improved diagnosis and awareness of the disease or changes in the perception of Alzheimer's disease as a cause of death. CONCLUSIONS: In recognition of the importance of the condition as a major public health problem, Alzheimer's disease was added to the list of causes eligible to be ranked as leading causes of death in the United States beginning with mortality data for 1994. Alzheimer's disease as a cause of death in the United States. Overall, Alzheimer's disease was the 14th leading cause of death in 1995; for people 65 years of age or older, it was the 8th leading cause of death.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/10934557' target='_blank' class='pmid-link'>10934557</a>:</span> <span class='sentence-part'>So far, three genes have been identified in which mutations cause autosomal-dominant AD: the amyloid precursor protein (APP) gene on chromosome 21, the presenilin 1 (PSEN1) gene on chromosome 14, and the homologous presenilin 2 (PSEN2) gene on chromosome 1. Alzheimer's disease (AD), by far the most common form of dementia in the elderly, is clinically characterized by gradual, progressive loss in cognitive functioning and changes in personality, ultimately leading to death.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/10993580' target='_blank' class='pmid-link'>10993580</a>:</span> <span class='sentence-part'>Alzheimer's disease type dementia is a growing health problem and is one of the leading causes of death among elderly people.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/11182240' target='_blank' class='pmid-link'>11182240</a>:</span> <span class='sentence-part'>(6) AD is associated with a reactivation of developmental programmes that are incompatible with a differentiated cellular background and, therefore, lead to neuronal death.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/11279271' target='_blank' class='pmid-link'>11279271</a>:</span> <span class='sentence-part'>beta-Amyloid (A beta) has been strongly implicated in the pathophysiology of Alzheimer's disease (AD), but the means by which the aggregated form of this molecule induces neuronal death have not been fully defined.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/11400868' target='_blank' class='pmid-link'>11400868</a>:</span> <span class='sentence-part'>Alzheimer's disease is a neurodegenerative condition that affects approximately 5 million people and is the fourth leading cause of death in America.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/11433428' target='_blank' class='pmid-link'>11433428</a>:</span> <span class='sentence-part'>beta-amyloid peptide (Abeta) has been implicated in the pathogenesis of Alzheimer disease and has been reported to induce apoptotic death in cell culture.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/11726544' target='_blank' class='pmid-link'>11726544</a>:</span> <span class='sentence-part'>Mutant ubiquitin expressed in Alzheimer's disease causes neuronal death.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/11803006' target='_blank' class='pmid-link'>11803006</a>:</span> <span class='sentence-part'>Alzheimer's disease was the 11th leading cause of death.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/12410910' target='_blank' class='pmid-link'>12410910</a>:</span> <span class='sentence-part'>Only 13% of a group of patients receiving the AD therapy donepezil had AD as the primary diagnosis, and AD is rarely included as a primary or secondary DRG diagnosis when the condition precipitating admission to the hospital is caused by AD. In addition, AD is often not mentioned on death certificates, although it may be the proximate cause of death.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/12861345' target='_blank' class='pmid-link'>12861345</a>:</span> <span class='sentence-part'>Potential therapeutic strategies for AD treatment include palliative treatment with nonspecific neuroprotecting agents, symptomatic treatment with psychotropic drugs for noncognitive symptoms, cognitive treatment with cognition enhancers, substitutive treatment with cholinergic enhancers to improve memory deficits, multifactorial treatment using several drugs in combination and etiopathogenic treatment designed to regulate molecular factors potentially associated with AD pathogenesis. In our opinion, the pharmacological treatment of AD should rely on a better understanding of AD etiopathogenesis in order to use current drugs that protect the AD brain against deleterious events and/or to develop new drugs specifically designed to inhibit and/or regulate those factors responsible for premature neuronal death in AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/12907842' target='_blank' class='pmid-link'>12907842</a>:</span> <span class='sentence-part'>Among neurodegenerative diseases, Alzheimer's disease (AD) is a leading cause of death in elderly individuals.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/14769384' target='_blank' class='pmid-link'>14769384</a>:</span> <span class='sentence-part'>Amyloid beta-peptide (Abeta) contributes to the pathogenesis of Alzheimer's disease (AD), causing neuronal death through apoptosis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/15519530' target='_blank' class='pmid-link'>15519530</a>:</span> <span class='sentence-part'>Alzheimer's disease is the fourth largest cause of death for people over 65 years of age.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/15526713' target='_blank' class='pmid-link'>15526713</a>:</span> <span class='sentence-part'>Humanin and its analogues have been shown to protect cells against death induced by various Alzheimer's disease genes and amyloid-beta-peptides in vitro: the analogue [Gly14]-humanin has also been shown to be potent in reversing learning and memory impairment induced by scopolamine in mice in vivo.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/15639804' target='_blank' class='pmid-link'>15639804</a>:</span> <span class='sentence-part'>Neurodegenerative diseases such as Huntington's disease, ischemia, and Alzheimer's disease (AD) are major causes of death.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/15825927' target='_blank' class='pmid-link'>15825927</a>:</span> <span class='sentence-part'>Alzheimer's disease is the fourth leading cause of death among seniors but its insidious onset makes it difficult to distinguish from age-related decline and little is known about how much knowledge and fear people entertain about this disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/15883266' target='_blank' class='pmid-link'>15883266</a>:</span> <span class='sentence-part'>BACKGROUND: Alzheimer disease (AD) is considered a leading cause of death, but few studies have examined the contribution of AD to mortality based on follow-up of representative US cohorts.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/16189900' target='_blank' class='pmid-link'>16189900</a>:</span> <span class='sentence-part'>Alzheimer's disease was the eighth-leading cause of death in 2001.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/16199521' target='_blank' class='pmid-link'>16199521</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) is a neurodegenerative disease with an insidious onset and progressive course that inevitably leads to death.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/16712493' target='_blank' class='pmid-link'>16712493</a>:</span> <span class='sentence-part'>In addition to Abeta pathology, an invariant trait of Alzheimer's disease, disruption of tau processing is a necessary event in the neurotoxic cascade which eventually leads to neuronal death and subsequent dementia.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/16787840' target='_blank' class='pmid-link'>16787840</a>:</span> <span class='sentence-part'>In the slowly progressive neurodegenerative disorders like Parkinson's disease and Alzheimer's disease very different neuronal populations undergo degenerative processes, although the cascades of cellular events leading to death are supposed to be similar.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17017864' target='_blank' class='pmid-link'>17017864</a>:</span> <span class='sentence-part'>Although oxidative stress and mitochondrial dysfunction have been linked to neurodegenerative diseases such as Alzheimer's disease (AD), it remains unclear how mitochondrial oxidative stress may induce neuronal death.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17115369' target='_blank' class='pmid-link'>17115369</a>:</span> <span class='sentence-part'>Alzheimer's Disease (AD) is the most common neurodegenerative disorder in western societies affecting up to 15 million individuals worldwide.It leads to death after a progressive memory deficit and cognitive impairment accompanied by the appearance of two pathological hallmarks in specific brain areas: neurofibrillary tangles and amyloid plaques.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17192682' target='_blank' class='pmid-link'>17192682</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by cognitive impairments that become severe enough to interfere with the daily activities of patients and eventually lead to death (Chung and Cummings, 2000).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17401657' target='_blank' class='pmid-link'>17401657</a>:</span> <span class='sentence-part'>Alzheimer's disease is an irreversible, progressive neurodegenerative disorder leading invariably to death, usually within 7-10 years after diagnosis and is the leading cause of dementia in the elderly.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/18042001' target='_blank' class='pmid-link'>18042001</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterised by severe cognitive impairment that ultimately leads to death.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/1830977' target='_blank' class='pmid-link'>1830977</a>:</span> <span class='sentence-part'>Alzheimer's disease, a devastating, irreversible and progressive degenerative disease of unknown cause or cure, is the fourth leading cause of adult death.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/18322383' target='_blank' class='pmid-link'>18322383</a>:</span> <span class='sentence-part'>Structural and functional genomics studies demonstrate that genomic factors, probably induced by environmental factors, cerebrovascular dysfunction, and epigenetic phenomena, might be responsible for AD pathogenesis leading to premature neuronal death.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/18406539' target='_blank' class='pmid-link'>18406539</a>:</span> <span class='sentence-part'>Recent studies have indicated that amyloid beta peptide, which is implicated in the progression of Alzheimer's disease, may be also responsible for retinal ganglion cells death in glaucoma.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/18488798' target='_blank' class='pmid-link'>18488798</a>:</span> <span class='sentence-part'>Every 72 seconds, someone in the United States develops Alzheimer's disease, an incurable affliction that kills at least 66,000 people annually, making it the nation's seventh leading cause of death.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/18631956' target='_blank' class='pmid-link'>18631956</a>:</span> <span class='sentence-part'>Alzheimer's disease is the seventh leading cause of all deaths in the United States and the fifth leading cause of death in Americans older than the age of 65 years.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/18647630' target='_blank' class='pmid-link'>18647630</a>:</span> <span class='sentence-part'>Humanin (HN) and its analogues have been shown to protect cells against death induced by various Alzheimer's disease (AD) genes and amyloid-beta-peptides in vitro; the analogues [Gly(14)]-HN and colivelin have also been shown to be potent in reversing learning and memory impairment induced by scopolamine or quinuclidinyl benzilate (QNB) in mice or rats in vivo using the Y-maze or multiple T-maze tests.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/18800967' target='_blank' class='pmid-link'>18800967</a>:</span> <span class='sentence-part'>Alzheimer's disease, the most common neurodegenerative disorder, and cerebral ischaemia, the most common cause of neurological death, are used to illustrate our current understanding of death signalling in neurodegenerative diseases.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/19036982' target='_blank' class='pmid-link'>19036982</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) is the most prevalent form of dementia, resulting in progressive neuronal death and debilitating damage to brain loci that mediate memory and higher cognitive function.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/19177976' target='_blank' class='pmid-link'>19177976</a>:</span> <span class='sentence-part'>AD is the seventh-leading cause of death in the United States (Centers for Disease Control 2006).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/19426951' target='_blank' class='pmid-link'>19426951</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) is the sixth leading cause of all deaths in the United States, and the fifth leading cause of death in Americans aged 65 and older. Whereas other major causes of death have been on the decrease, deaths attributable to AD have been rising dramatically.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/19864195' target='_blank' class='pmid-link'>19864195</a>:</span> <span class='sentence-part'>In the United States, Alzheimer's disease (AD) is the leading type of dementia and was the fifth and eighth leading cause of death in women and men aged &gt; or = 65 years, respectively, in 2003.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/19897016' target='_blank' class='pmid-link'>19897016</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) is the most common form of dementia, which is one of the four leading causes of death in developed nations.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/19903243' target='_blank' class='pmid-link'>19903243</a>:</span> <span class='sentence-part'>The cellular pathology of Alzheimer's disease is progressive and protracted leading eventually to considerable neuronal death.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/19912228' target='_blank' class='pmid-link'>19912228</a>:</span> <span class='sentence-part'>Chronic degenerative inflammatory diseases, such as chronic obstructive pulmonary disease and Alzheimer's dementia, afflict millions of people around the world, causing death and debilitation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20064601' target='_blank' class='pmid-link'>20064601</a>:</span> <span class='sentence-part'>The neurodegenerative disorder Alzheimer's disease (AD) is the 6th leading cause of death in the USA.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20298981' target='_blank' class='pmid-link'>20298981</a>:</span> <span class='sentence-part'>Although other major causes of death have been on the decrease, deaths because of AD have been rising dramatically. AD is the fifth leading cause of death in Americans aged 65 and older.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20345790' target='_blank' class='pmid-link'>20345790</a>:</span> <span class='sentence-part'>Our study suggests that decedents &gt;65 years of age in an ME practice are afflicted by common causes of dementia such as AD and FTLD which could contribute wholly or in part to their causes of death.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20383807' target='_blank' class='pmid-link'>20383807</a>:</span> <span class='sentence-part'>Currently AD is the major form of dementia and the fourth leading cause of death in aged population.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20615444' target='_blank' class='pmid-link'>20615444</a>:</span> <span class='sentence-part'>Beta-amyloid (Abeta) peptide, the hallmark of Alzheimer's disease (AD), invokes a cascade of oxidative damages to neurons and eventually leads to neuronal death.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20664211' target='_blank' class='pmid-link'>20664211</a>:</span> <span class='sentence-part'>Whereas other major causes of death have been decreasing, the number of deaths due to Alzheimer's disease is rising.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20667675' target='_blank' class='pmid-link'>20667675</a>:</span> <span class='sentence-part'>RESULTS: In France, in 2006, AD or dementia was reported as the underlying cause or a multiple cause of death on 45,597 death certificates.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20739349' target='_blank' class='pmid-link'>20739349</a>:</span> <span class='sentence-part'>beta-Amyloid deposition is one of the main hallmarks of Alzheimer's disease thought to eventually cause neuronal death.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20926742' target='_blank' class='pmid-link'>20926742</a>:</span> <span class='sentence-part'>More than 5 million people in the United States are afflicted with Alzheimer disease, a condition that is the seventh leading cause of death in the nation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21155625' target='_blank' class='pmid-link'>21155625</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) is characterized by dysfunctional intracellular and extracellular biochemical processes that result in neuron death.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21238939' target='_blank' class='pmid-link'>21238939</a>:</span> <span class='sentence-part'>We will examine the current understanding of caspase function in developmental neuronal death and then illustrate the role of caspases in neuronal death in disease employing two diseases of neuronal loss, Alzheimer's Disease (AD), which is the most common chronic neurodegenerative disorder, and cerebral ischemia/stroke, the third most common cause of death in Western society, which is an acute neuronal disorder with chronic sequelae. Alzheimer's Disease, the most common neurodegenerative disorder, and cerebral ischemia, the most common cause of neurologic death, are used to illustrate our current understanding of death signaling in neurodegenerative diseases.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21374507' target='_blank' class='pmid-link'>21374507</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) is the fourth commonest cause of death in the United States; the recent outbreak of new variant Creutzfeldt-Jakob disease (nvCJD) has raised the specter of a large population being at risk to develop this prionosis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21414557' target='_blank' class='pmid-link'>21414557</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) is the sixth leading cause of all deaths in the United States and is the fifth leading cause of death in Americans aged &gt;=65 years. Although other major causes of death have been on the decrease, deaths because of AD have been rising dramatically.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21694457' target='_blank' class='pmid-link'>21694457</a>:</span> <span class='sentence-part'>Synapse loss is considered to be the best correlate of cognitive impairments in Alzheimer's disease (AD), and growing evidence supports the notion that certain events that trigger neuronal death in AD can be initiated by the local activation of caspases within the synaptic compartment.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21695038' target='_blank' class='pmid-link'>21695038</a>:</span> <span class='sentence-part'>We analyzed the US multiple cause of death files for 2005-2006 and 1999-2000 US deaths with Alzheimer's Disease (International Classification of Disease 10th revision code G30) and other dementias (codes F01, F02, R54) coded as underlying or contributing cause of death based on the death certificate.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21766442' target='_blank' class='pmid-link'>21766442</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) is the fourth leading cause of death in adults, characterized by hallmark neuritic plaques and neurofibrillary tangles.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21793014' target='_blank' class='pmid-link'>21793014</a>:</span> <span class='sentence-part'>In view of this complex pathogenic mechanisms, and the successful treatment of chronic diseases such as HIV or cancer, with multiple drugs having complementary mechanisms of action, the concern is growing that AD could better be treated with a single compound targeting two or more of the pathogenic mechanisms leading to neuronal death.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21840361' target='_blank' class='pmid-link'>21840361</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) is the 6th leading cause of death in United States afflicting &gt;5 million Americans.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21920373' target='_blank' class='pmid-link'>21920373</a>:</span> <span class='sentence-part'>Alzheimer Disease (AD) is the most prevalent form of dementia and the sixth leading cause of death in developed world.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22133718' target='_blank' class='pmid-link'>22133718</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) is the only leading cause of death for which no disease-modifying therapy is currently available.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22212311' target='_blank' class='pmid-link'>22212311</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) is the most common form of dementia, and one of the principal causes leading to death around the world.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22254735' target='_blank' class='pmid-link'>22254735</a>:</span> <span class='sentence-part'>AD is a neurodegenerative disorder characterized by neurofibrillary plaques and tangles in the brain that leads to neuronal death and dementia.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22265578' target='_blank' class='pmid-link'>22265578</a>:</span> <span class='sentence-part'>The characterization of AD as a leading cause of death among the elderly was crucial to sustaining the movement, but also operated as a \double edged sword\.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/2231117' target='_blank' class='pmid-link'>2231117</a>:</span> <span class='sentence-part'>Senile dementia and Alzheimer's disease (often considered a single process) rank as the fourth most common cause of death in the United States and outrank in cost to the nation the three leading causes of death combined.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22404854' target='_blank' class='pmid-link'>22404854</a>:</span> <span class='sentence-part'>Although the proportions of deaths due to other major causes of death have decreased in the last several years, the proportion due to AD has risen significantly. AD is the sixth leading cause of death in the United States and the fifth leading cause of death in Americans age &gt;=65 years.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22543304' target='_blank' class='pmid-link'>22543304</a>:</span> <span class='sentence-part'>AD is a complex multifactorial disorder with a number of genetic, epigenetic and environmental factors which ultimately lead to premature neuronal death.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22681044' target='_blank' class='pmid-link'>22681044</a>:</span> <span class='sentence-part'>Alzheimer's disease is a fatal neurological disorder that is a leading cause of death, with its prevalence increasing as the average life expectancy increases worldwide.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22696871' target='_blank' class='pmid-link'>22696871</a>:</span> <span class='sentence-part'>In AD, neurons have been shown to enter the cell cycle inappropriately without the ability to complete it fully and the aberrant re-entry leads to its death.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22778828' target='_blank' class='pmid-link'>22778828</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD), an age-related neurodegenerative disorder, is the most common form of dementia, and the seventh-leading cause of death in the United States.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22888398' target='_blank' class='pmid-link'>22888398</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) is the most common neurodegenerative disease featuring progressive impairments in memory, cognition, and behavior and ultimately leads to death.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23106978' target='_blank' class='pmid-link'>23106978</a>:</span> <span class='sentence-part'>Tacrine-6-ferulic acid, a novel multifunctional dimer against Alzheimer's disease, prevents oxidative stress-induced neuronal death through activating Nrf2/ARE/HO-1 pathway in HT22 cells.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23113839' target='_blank' class='pmid-link'>23113839</a>:</span> <span class='sentence-part'>Because of the toxicity caused by the heme redox-active iron proteins, their elevated levels, localization, and accumulation in the brain, many forms of neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease, and Huntington's disease, occur as a result of which the brain becomes vulnerable to oxidative stress, ultimately resulting in neuronal death.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23161037' target='_blank' class='pmid-link'>23161037</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) is the sixth leading cause of all deaths in the United States, and the fifth leading cause of death in Americans aged 65 and older. During the past years, several agents have been approved that enhance cognition and global function of AD patients, and recent advances in understanding AD pathogenesis has led to the development of numerous compounds that might modify the disease process.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23170058' target='_blank' class='pmid-link'>23170058</a>:</span> <span class='sentence-part'>PURPOSE: Recent studies have indicated that accumulation of amyloid beta(1-42) (Abeta(1-42)), which is associated with the progression of Alzheimer disease, may also be responsible for retinal ganglion cell death in glaucoma.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23376032' target='_blank' class='pmid-link'>23376032</a>:</span> <span class='sentence-part'>Neurologic conditions including stroke, Alzheimer disease, Parkinson disease, and Huntington disease are leading causes of death and long-term disability in the United States, and efforts to develop novel therapeutics for these conditions have historically had poor success in translating from bench to bedside.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23397250' target='_blank' class='pmid-link'>23397250</a>:</span> <span class='sentence-part'>Neurodegenerative diseases such as Alzheimer's disease (AD), Parkinson's disease (PD) and Multiple sclerosis (MS) involve activation of glial cells and release of inflammatory mediators leading to death of neurons.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23399672' target='_blank' class='pmid-link'>23399672</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) is the most common cause of dementia, and its pathological hallmarks are senile plaques and neurofibrillary tangles in the brain, which eventually induce neuronal death.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23424127' target='_blank' class='pmid-link'>23424127</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) is one of the leading causes of death for older people in US with rapidly increasing incidence.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23507120' target='_blank' class='pmid-link'>23507120</a>:</span> <span class='sentence-part'>AD is the sixth leading cause of death in the United States and the fifth leading cause of death in Americans age 65 years or older.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23507421' target='_blank' class='pmid-link'>23507421</a>:</span> <span class='sentence-part'>Potential gains in life expectancy from reducing heart disease, cancer, Alzheimer's disease, kidney disease or HIV/AIDS as major causes of death in the USA.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23624206' target='_blank' class='pmid-link'>23624206</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) is a neurodegenerative disorder that leads to neuron death and synapse loss in the hippocampus and cortex, with consequent cognitive disability and dementia.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23650720' target='_blank' class='pmid-link'>23650720</a>:</span> <span class='sentence-part'>The basis of AD is neurodegenerative process that leads to death of neurons in the cerebral cortex.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23653484' target='_blank' class='pmid-link'>23653484</a>:</span> <span class='sentence-part'>RESULTS: AD and pneumonia were causes of significant excess mortality and the most common underlying causes of death in the AD patient group (23.53 and 17.65%, respectively).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23742787' target='_blank' class='pmid-link'>23742787</a>:</span> <span class='sentence-part'>Alzheimer's disease is the sixth leading cause of death in the United States and the fifth leading cause for people aged 65 years and over (1).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23984328' target='_blank' class='pmid-link'>23984328</a>:</span> <span class='sentence-part'>Alzheimer's disease is the most common form of dementia and is the only top 10 cause of death in the United States that lacks disease-altering treatments.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24201446' target='_blank' class='pmid-link'>24201446</a>:</span> <span class='sentence-part'>We have also focused on their involvement in neurodegenerative diseases including Parkinson's and Alzheimer's diseases, discussing the contribution of this type of glial cell toward mechanisms that can lead to neuronal death, which was previously attributed exclusively to neurons.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24471710' target='_blank' class='pmid-link'>24471710</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by the accumulation of beta-amyloid peptides and neurofibrilllary tangles in brain, resulting in neuronal death and loss of cognitive abilities.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24689364' target='_blank' class='pmid-link'>24689364</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) is the most common form of dementia and the sixth leading cause of death in the United States.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24818261' target='_blank' class='pmid-link'>24818261</a>:</span> <span class='sentence-part'>In 2010, official death certificates recorded 83,494 deaths from AD, making AD the sixth leading cause of death in the United States and the fifth leading cause of death in Americans aged 65 years or older.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24838579' target='_blank' class='pmid-link'>24838579</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) is a neurodegenerative condition that leads to neuronal death and memory dysfunction.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24846640' target='_blank' class='pmid-link'>24846640</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) is the most common type of dementia (accounting for 60% to 80%) and is the fifth leading cause of death for those people who are 65 or older.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24850589' target='_blank' class='pmid-link'>24850589</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) is one of the most frequent causes of death and disability worldwide and has a significant clinical and socioeconomic impact.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24878198' target='_blank' class='pmid-link'>24878198</a>:</span> <span class='sentence-part'>Alzheimer's disease is the most common neurodegenerative disease and is one of the main causes of death in developed countries.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24922524' target='_blank' class='pmid-link'>24922524</a>:</span> <span class='sentence-part'>This study was designed to uncover the cellular and biochemical mechanisms underlying the neuroprotective effects of tacrine-3-caffeic acid (T3CA), a novel promising multifunctional anti-Alzheimer's dimer, against OS-induced neuronal death.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25075874' target='_blank' class='pmid-link'>25075874</a>:</span> <span class='sentence-part'>Alzheimer's disease, the seventh leading cause of death in 2006, became the sixth leading cause in 2007, and Diabetes mellitus, the sixth leading cause in 2006, dropped to the seventh leading cause in 2007.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25220527' target='_blank' class='pmid-link'>25220527</a>:</span> <span class='sentence-part'>In addition to mutations in APP, PSEN1 and PSEN2 genes, that cause early onset autosomal dominant AD, several genetic risk factors for late onset AD are now known. Alzheimer's disease (AD) is the most common form of dementia characterized by deterioration of memory and other cognitive domains which leads to death in 3-9years after diagnosis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25250042' target='_blank' class='pmid-link'>25250042</a>:</span> <span class='sentence-part'>AD is the sixth leading cause of death, and one of the leading causes of dementia amongst the aged population in the USA.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25405415' target='_blank' class='pmid-link'>25405415</a>:</span> <span class='sentence-part'>Alzheimer?s disease (AD) is the only cause of death among the top 10 diseases that cannot be prevented, cured, or slowed with the current treatments available.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25408208' target='_blank' class='pmid-link'>25408208</a>:</span> <span class='sentence-part'>RESULTS: The National Death Index identified 175 subjects who died with AD listed as an underlying (n = 116) or contributing (n = 59) cause of death during 11.6-year average mortality surveillance.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25472798' target='_blank' class='pmid-link'>25472798</a>:</span> <span class='sentence-part'>Alzheimer's disease is one of the most common causes of death worldwide, with poor treatment options.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25609918' target='_blank' class='pmid-link'>25609918</a>:</span> <span class='sentence-part'>Alzheimer's disease, the most common type of dementia, is a progressive brain disease that destroys cognitive function and eventually leads to death.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25833944' target='_blank' class='pmid-link'>25833944</a>:</span> <span class='sentence-part'>The expression and subcellular localization of Set-beta are altered in Alzheimer disease, cleavage of Set-beta leads to neuronal death after stroke, and the full-length Set-beta regulates retinal ganglion cell (RGC) and hippocampal neuron axon growth and regeneration in a subcellular localization-dependent manner.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25857971' target='_blank' class='pmid-link'>25857971</a>:</span> <span class='sentence-part'>Beta-amyloid (Abeta) peptide, the hallmark of Alzheimer's disease, invokes oxidative damage to neurons and eventually leads to neuronal death.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25954942' target='_blank' class='pmid-link'>25954942</a>:</span> <span class='sentence-part'>Vitamin D and neurocognitive disorder due to Alzheimer's disease: A review of the literature. AD is the sixth leading cause of death in the United States and the only 1 among the top 10 that cannot be prevented, cured, or even slowed.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/2597884' target='_blank' class='pmid-link'>2597884</a>:</span> <span class='sentence-part'>The distinction between Alzheimer's dementia and depressive illness, based on their natural history and causes of death, was reinforced.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25984581' target='_blank' class='pmid-link'>25984581</a>:</span> <span class='sentence-part'>In 2013, official death certificates recorded 84,767 deaths from AD, making AD the sixth leading cause of death in the United States and the fifth leading cause of death in Americans age 65 years.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25989911' target='_blank' class='pmid-link'>25989911</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) is the most common type of dementia that leads to increasing death and mental disability among humans.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26022359' target='_blank' class='pmid-link'>26022359</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by severe cognitive impairment that ultimately leads to death.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26265552' target='_blank' class='pmid-link'>26265552</a>:</span> <span class='sentence-part'>The number of patients with AD will grow rapidly each year and AD is the fifth leading cause of death for those aged 65 and older.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26435705' target='_blank' class='pmid-link'>26435705</a>:</span> <span class='sentence-part'>BACKGROUND: Alzheimer's disease (AD) is the sixth leading cause of death and the most costly disease in the US.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26470401' target='_blank' class='pmid-link'>26470401</a>:</span> <span class='sentence-part'>Vitamin D and neurocognitive disorder due to   Alzheimer's disease: A review of the literature. AD is the sixth leading cause of death in the United States and the only 1 among the top 10 that cannot be prevented, cured, or even slowed.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26510980' target='_blank' class='pmid-link'>26510980</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) is a progressive neurodegenerative disorder and the fourth leading cause of death in the United States and most common cause of adult-onset dementia.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26517378' target='_blank' class='pmid-link'>26517378</a>:</span> <span class='sentence-part'>A variety of stressors, including beta-amyloid (Abeta) in the case of AD, can force neurons to leave quiescence and to initiate an ectopic DNA replication process, leading to neuronal death rather than division.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26690394' target='_blank' class='pmid-link'>26690394</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) is a debilitating progressive neurodegenerative disorder that ultimately leads to the patient's death.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/2680026' target='_blank' class='pmid-link'>2680026</a>:</span> <span class='sentence-part'>Alzheimer's disease is the fourth most common cause of death in the United States, and is the leading cause of functional disability in the elderly.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/2682166' target='_blank' class='pmid-link'>2682166</a>:</span> <span class='sentence-part'>Alzheimer's disease, once a rarely applied medical diagnosis, is now considered to be the fourth or fifth leading cause of death in the United States.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26983930' target='_blank' class='pmid-link'>26983930</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) is the fourth leading cause of death in Puerto Rico.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27127760' target='_blank' class='pmid-link'>27127760</a>:</span> <span class='sentence-part'>In Western societies, Alzheimer's disease (AD) is the most common form of dementia and the sixth leading cause of death.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27182464' target='_blank' class='pmid-link'>27182464</a>:</span> <span class='sentence-part'>As a result, Alzheimer's disease (AD), the 5th leading cause of death for people aged 65 and older, is likely to increase in these groups.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27190276' target='_blank' class='pmid-link'>27190276</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) is a leading cause of death and disability among older adults.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27235708' target='_blank' class='pmid-link'>27235708</a>:</span> <span class='sentence-part'>AD is now considered to be the third major cause of death in developed countries, after cardiovascular disease and cancer.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27570871' target='_blank' class='pmid-link'>27570871</a>:</span> <span class='sentence-part'>In 2013, official death certificates recorded 84,767 deaths from Alzheimer's disease, making it the sixth leading cause of death in the United States and the fifth leading cause of death in Americans age &gt;= 65 years.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27758699' target='_blank' class='pmid-link'>27758699</a>:</span> <span class='sentence-part'>BACKGROUND: In 2016, the statistical reports stated that Alzheimer is not just memory loss but it kills and has become the 6th leading cause of death.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27776890' target='_blank' class='pmid-link'>27776890</a>:</span> <span class='sentence-part'>AD is the sixth leading cause of death in the United States and is the only cause of death among the top ten that cannot currently be treated or cured (Alzheimer's Association, 2011; Selkoe, 1996).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27942104' target='_blank' class='pmid-link'>27942104</a>:</span> <span class='sentence-part'>BACKGROUND: Cognitive disorders and dementia are common problems, and Alzheimer's disease is one of the major leading causes of death worldwide.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28043897' target='_blank' class='pmid-link'>28043897</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) is a severe, chronic and progressive neurodegenerative disease associated with memory and cognition impairment ultimately leading to death.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28246336' target='_blank' class='pmid-link'>28246336</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) is one of the fastest-growing causes of death and disability in persons 65 years of age or older, affecting more than 5 million Americans alone.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28396328' target='_blank' class='pmid-link'>28396328</a>:</span> <span class='sentence-part'>METHODS: We obtained data on all community-dwelling adults with a recent diagnosis of Alzheimer disease in Finland (2005-2011) from the Medication use and Alzheimer disease (MEDALZ) cohort, which incorporates national registry data on prescriptions, reimbursement, hospital discharges and causes of death.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28417590' target='_blank' class='pmid-link'>28417590</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) is leading cause of death among older characterized by neurofibrillary tangles, oxidative stress, progressive neuronal deficits, and increased levels of amyloid-beta (Abeta) peptides.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28426958' target='_blank' class='pmid-link'>28426958</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) is the sixth leading cause of death in the United States and the most common cause of dementia in the elderly.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28442216' target='_blank' class='pmid-link'>28442216</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) is the most common form of dementia and the 6th leading cause of death in the US.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28490901' target='_blank' class='pmid-link'>28490901</a>:</span> <span class='sentence-part'>Amyloidosis, the aggregation of amyloid proteins to form amyloid bodies, plays a central role in the pathogenesis of AD and other human neuropathies by forming intracellular fibrillary proteins. Breast cancer and Alzheimer's disease (AD) are major causes of death in older women.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28542120' target='_blank' class='pmid-link'>28542120</a>:</span> <span class='sentence-part'>Alzheimer's disease (Alzheimer's), an ultimately fatal form of dementia, is the sixth leading cause of death in the United States, accounting for 3.6% of all deaths in 2014 (1,2).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28624131' target='_blank' class='pmid-link'>28624131</a>:</span> <span class='sentence-part'>Alzheimer disease (AD) is an irreversible, progressive brain disorder that causes slow loss of memory and thinking skills, normally leading to death in 3-9 y.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28634681' target='_blank' class='pmid-link'>28634681</a>:</span> <span class='sentence-part'>Currently, AD is one of the leading causes of death in developed countries and the only one of the top ten diseases without a means to prevent, cure, or significantly slow down its progression.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28825647' target='_blank' class='pmid-link'>28825647</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) is currently ranked as the sixth leading cause of death in the United States and recent estimates indicate that the disorder may rank third, just behind heart disease and cancer, as a cause of death for older people.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28889269' target='_blank' class='pmid-link'>28889269</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) is the most common form of adult neurode-generation and is characterised by progressive loss of cognitive function leading to death.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29024348' target='_blank' class='pmid-link'>29024348</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) is the sixth leading cause of death in the USA today; therefore, it is imperative that public health initiatives and clinical strategies are developed to prevent and effectively treat AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29060753' target='_blank' class='pmid-link'>29060753</a>:</span> <span class='sentence-part'>Alzheimer's Disease (AD) is one of the leading causes of death and dementia worldwide.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29061973' target='_blank' class='pmid-link'>29061973</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) is one of the leading causes of death for people over 65 years.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29164499' target='_blank' class='pmid-link'>29164499</a>:</span> <span class='sentence-part'>Alzheimer's disease, thought to be the most common underlying pathology for elders' cognitive dysfunction (Willis and Hakim 2013), is already the sixth leading cause of death in the United States (Alzheimer's Association 2016).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29270150' target='_blank' class='pmid-link'>29270150</a>:</span> <span class='sentence-part'>Alzheimer's disease is the most common neurodegenerative form of dementia that steadily worsens and eventually leads to death.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29336270' target='_blank' class='pmid-link'>29336270</a>:</span> <span class='sentence-part'>Characterized by the formation of beta-amyloid plaques, Alzheimer's disease (AD) is currently one of the leading causes of death across the world.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29372919' target='_blank' class='pmid-link'>29372919</a>:</span> <span class='sentence-part'>In Alzheimer's disease, it is believed that amyloid-beta proteins may be responsible for pore and defect formation within cellular membranes, leading to a breakdown of cellular homeostasis causing eventual neuronal death.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29446066' target='_blank' class='pmid-link'>29446066</a>:</span> <span class='sentence-part'>Those who died of AD were selected based on underlying cause of death.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29538632' target='_blank' class='pmid-link'>29538632</a>:</span> <span class='sentence-part'>Background: Alzheimer's disease is a progressive disease that degrades cognitive functioning and ultimately results in death.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29549645' target='_blank' class='pmid-link'>29549645</a>:</span> <span class='sentence-part'>Among different neurological disorders, Alzheimer's disease (AD) is recognized as the sixth leading cause of death globally.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29677545' target='_blank' class='pmid-link'>29677545</a>:</span> <span class='sentence-part'>Beta-amyloid (Abeta) peptide, the hallmark of Alzheimer's disease (AD), invokes a cascade of oxidative damage to neurons and eventually leads to neuronal death.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29714994' target='_blank' class='pmid-link'>29714994</a>:</span> <span class='sentence-part'>Alzheimer disease (AD) occurs in 8.8% of older US adults and is the sixth leading cause of death among older adults.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29749899' target='_blank' class='pmid-link'>29749899</a>:</span> <span class='sentence-part'>Alzheimer's disease is one of the leading causes of death worldwide and currently does not have any cure.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29772289' target='_blank' class='pmid-link'>29772289</a>:</span> <span class='sentence-part'>According to the Alzheimer Association Report (2017), Alzheimer's disease (AD) is the 6th primary cause of death in the USA, which affects nearly 5.5 million people.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29862455' target='_blank' class='pmid-link'>29862455</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) is the sixth leading cause of death in the United States where it is estimated that one in three seniors dies with AD or another dementia.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29932100' target='_blank' class='pmid-link'>29932100</a>:</span> <span class='sentence-part'>Alzheimer&amp;rsquo;s disease (AD) is the most prevalent neurodegenerative disease, distinctively characterized by senile plaques, neurofibrillary tangles, and synaptic loss, finally resulting in neuronal death.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30039745' target='_blank' class='pmid-link'>30039745</a>:</span> <span class='sentence-part'>With rapid aging of world population, Alzheimer's disease is becoming a leading cause of death after cardiovascular disease and cancer.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30106219' target='_blank' class='pmid-link'>30106219</a>:</span> <span class='sentence-part'>AIMS: Alzheimer's disease (AD) is one of the leading causes of death in elderly people.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30108425' target='_blank' class='pmid-link'>30108425</a>:</span> <span class='sentence-part'>Prolonged AD leads to moderate-to-severe AD, which is one of the leading causes of death.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30110946' target='_blank' class='pmid-link'>30110946</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) is a neurodegenerative disorder mostly influencing the elderly, and causes death due to dementia.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30171866' target='_blank' class='pmid-link'>30171866</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) is a progressive neurodegenerative disorder that is the most common cause of dementia and the 6th leading cause of death.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30236015' target='_blank' class='pmid-link'>30236015</a>:</span> <span class='sentence-part'>Alzheimer disease (AD) is a progressive neurodegenerative disorder that affects approximately 5 million people in the United States and is the sixth leading cause of death in the country.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30243157' target='_blank' class='pmid-link'>30243157</a>:</span> <span class='sentence-part'>Alzheimer, the fourth leading cause of death embodies a key responsible event including formation of beta-amyloid protein clustering to amyloid plaque on blood vessels.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30328325' target='_blank' class='pmid-link'>30328325</a>:</span> <span class='sentence-part'>PURPOSE: Alzheimer's disease (AD) is the sixth most common cause of death in the United States.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30371351' target='_blank' class='pmid-link'>30371351</a>:</span> <span class='sentence-part'>SIGNIFICANCE: AD is one of the leading causes of death in America and continues to affect a growing population.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30486438' target='_blank' class='pmid-link'>30486438</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) is a progressive neurodegenerative disease that represents a major cause of death in many countries.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30532546' target='_blank' class='pmid-link'>30532546</a>:</span> <span class='sentence-part'>Nowadays, due to the increase in the number of aging population groups, there is also a growth of aging diseases such as Alzheimer's disease (AD), which is a progressive brain disorder that eventually results in death.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30545070' target='_blank' class='pmid-link'>30545070</a>:</span> <span class='sentence-part'>Brain ischemia is the second naturally occurring neuropathology, such as Alzheimer's disease, which causes the death of neurons in the CA1 region of the hippocampus.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30560544' target='_blank' class='pmid-link'>30560544</a>:</span> <span class='sentence-part'>Despite major academic and industry efforts, Alzheimer's disease (AD) remains the only leading cause of death for which no disease-modifying treatment is available.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30565076' target='_blank' class='pmid-link'>30565076</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) is the sixth leading cause of death globally and the main reason for dementia in elderly people.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30707915' target='_blank' class='pmid-link'>30707915</a>:</span> <span class='sentence-part'>The pathogenesis of Alzheimer's disease (AD) is involved in the aggregation of misfolded amyloid beta (Abeta), which upregulates the activity of acetylcholinesterase (AChE), increases the production of reactive oxygen species (ROS), enhances neuroinflammation, and eventually leads to neuronal death.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30740125' target='_blank' class='pmid-link'>30740125</a>:</span> <span class='sentence-part'>In this study, we combined expression quantitative trait locus (eQTL) studies with the GWAS, to comprehensively define the genes that cause Alzheimer disease. Alzheimer disease (AD) is the fourth major cause of death in the elderly following cancer, heart disease and cerebrovascular disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30747418' target='_blank' class='pmid-link'>30747418</a>:</span> <span class='sentence-part'>In the aging world population, Alzheimer's disease accounts for more than 70% of all cases of dementia and is the sixth leading cause of death.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30881282' target='_blank' class='pmid-link'>30881282</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) and cancer are among the leading causes of human death around the world.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30922415' target='_blank' class='pmid-link'>30922415</a>:</span> <span class='sentence-part'>OBJECTIVE: Alzheimer's disease (AD) is the sixth leading cause of death, with an average survival estimated between 5 and 10 years after diagnosis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31068785' target='_blank' class='pmid-link'>31068785</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) has been categorized by the Centers for Disease Control and Prevention (CDC) as the 6th leading cause of death in the United States.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31201463' target='_blank' class='pmid-link'>31201463</a>:</span> <span class='sentence-part'>Alzheimer's Disease (AD) is the sixth-leading cause of death in industrialized countries.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31211444' target='_blank' class='pmid-link'>31211444</a>:</span> <span class='sentence-part'>AD is one of the leading causes of death in the United States.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31262433' target='_blank' class='pmid-link'>31262433</a>:</span> <span class='sentence-part'>In recent years, autophagy dysfunction has gained considerable attention in AD and other neurodegenerative diseases because it has been linked to the accumulation of misfolded proteins that ultimately causes neuronal death in many of these disorders.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31354494' target='_blank' class='pmid-link'>31354494</a>:</span> <span class='sentence-part'>AD is a leading cause of death worldwide and is progressive in nature with symptoms worsening over time.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31379558' target='_blank' class='pmid-link'>31379558</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) afflicts an estimated 20 million people worldwide and is the fourth-leading cause of death in the developed world.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31422384' target='_blank' class='pmid-link'>31422384</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) is a progressive neurodegenerative disease that ranks as the fourth most common cause of death in developed countries.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31430752' target='_blank' class='pmid-link'>31430752</a>:</span> <span class='sentence-part'>AD is the sixth leading cause of death in the USA, affecting an estimated 5 million Americans.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31524171' target='_blank' class='pmid-link'>31524171</a>:</span> <span class='sentence-part'>Most ADRDs are characterized by progressive neurodegeneration, and Alzheimer's disease (AD) is the sixth leading cause of death in the United States.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31540705' target='_blank' class='pmid-link'>31540705</a>:</span> <span class='sentence-part'>Alzheimer's and Parkinson's diseases are one of the world's leading causes of death.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31592230' target='_blank' class='pmid-link'>31592230</a>:</span> <span class='sentence-part'>In 2018, AD was the fifth leading cause of death in Americans with 65 years of age or older, but the progress of AD drug research is very limited.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31689949' target='_blank' class='pmid-link'>31689949</a>:</span> <span class='sentence-part'>Increasing evidence has demonstrated that amyloid-beta peptide (Abeta), the hallmark of Alzheimer's disease (AD), evokes oxidative and inflammatory cascades, which ultimately lead to the death of neurons.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31704512' target='_blank' class='pmid-link'>31704512</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) is a progressive, chronic and severe neurodegenerative disorder linked with cognitive and memory impairment that eventually lead to death. There are several processes which can cause AD, including mitochondrial dysfunction-mediated oxidative stress (OS), intracellular buildup of hyper-phosphorylated tau as neurofibrillary tangles (NFTs) and excessive buildup of extracellular amyloid beta (Abeta) plaques, and/or genetic as well as the environmental factors.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31837630' target='_blank' class='pmid-link'>31837630</a>:</span> <span class='sentence-part'>Alzheimer's Disease (AD) is one of the leading causes of death in developed countries.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31848379' target='_blank' class='pmid-link'>31848379</a>:</span> <span class='sentence-part'>Assessing the therapeutic potential of Graptopetalum paraguayense on Alzheimer's disease using patient iPSC-derived neurons.Alzheimer's disease (AD) is the most common type of dementia and also one of the leading causes of death worldwide.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31862920' target='_blank' class='pmid-link'>31862920</a>:</span> <span class='sentence-part'>Alzheimer disease and other dementias have become the 7th cause of death worldwide.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31866858' target='_blank' class='pmid-link'>31866858</a>:</span> <span class='sentence-part'>In developed countries, AD is now acknowledged as the third leading cause of death, following cardiovascular disease and cancer.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31871211' target='_blank' class='pmid-link'>31871211</a>:</span> <span class='sentence-part'>Alzheimer's disease: A clinical perspective and future nonhuman primate research opportunities.Alzheimer's disease (AD) is a progressive neurodegenerative disorder that is the sixth leading cause of death and the most common cause of dementia worldwide.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31989900' target='_blank' class='pmid-link'>31989900</a>:</span> <span class='sentence-part'>Recent trends in management of Alzheimer's disease: Current therapeutic options and drug repurposing approaches.Alzheimer's disease is one of the most progressive forms of dementia ultimately leading to death in aged populations.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32097673' target='_blank' class='pmid-link'>32097673</a>:</span> <span class='sentence-part'>Magnetic targeted delivery of the SPIONs-labeled mesenchymal stem cells derived from human Wharton's jelly in Alzheimer's rat models.Alzheimer's disease (AD) as a progressive neurodegenerative disorder is one of the leading causes of death globally.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32157811' target='_blank' class='pmid-link'>32157811</a>:</span> <span class='sentence-part'>Official death certificates recorded 122,019 deaths from AD in 2018, the latest year for which data are available, making Alzheimer's the sixth leading cause of death in the United States and the fifth leading cause of death among Americans age 65 and older.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32241275' target='_blank' class='pmid-link'>32241275</a>:</span> <span class='sentence-part'>Differential co-expression analysis reveals early stage transcriptomic decoupling in alzheimer's disease.BACKGROUND: Alzheimer's disease (AD) is one of the leading causes of death in the US and there is no validated drugs to stop, slow or prevent AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32265696' target='_blank' class='pmid-link'>32265696</a>:</span> <span class='sentence-part'>AD was ranked as the 5     th       leading cause of global deaths in 2016 by the World Health Organization (WHO).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32327491' target='_blank' class='pmid-link'>32327491</a>:</span> <span class='sentence-part'>Antiepileptic drug use and mortality among community-dwelling persons with Alzheimer disease.OBJECTIVE: To evaluate the risk of death in relation to incident antiepileptic drug (AED) use compared with nonuse in people with Alzheimer disease (AD) through the assessment in terms of duration of use, specific drugs, and main causes of death.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32337953' target='_blank' class='pmid-link'>32337953</a>:</span> <span class='sentence-part'>miR-143-3p inhibition promotes neuronal survival in an Alzheimer's disease cell model by targeting neuregulin-1.INTRODUCTION: Alzheimer's disease (AD) is still the fifth leading cause of death and most common dementia worldwide.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32341952' target='_blank' class='pmid-link'>32341952</a>:</span> <span class='sentence-part'>More than 45 million people worldwide have Alzheimer's disease (AD), a deterioration of memory and other cognitive domains that leads to death within 3 to 9 years after diagnosis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32481301' target='_blank' class='pmid-link'>32481301</a>:</span> <span class='sentence-part'>Acupuncture therapy for Alzheimer's disease: A protocol for an overview of systematic reviews.BACKGROUND: Alzheimer's disease (AD) is the fifth-leading cause of death in people more than 65 years old.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32486897' target='_blank' class='pmid-link'>32486897</a>:</span> <span class='sentence-part'>AD is currently ranked as the sixth leading cause of death, but some sources put it as third, following heart disease and cancer.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32515311' target='_blank' class='pmid-link'>32515311</a>:</span> <span class='sentence-part'>PTML Modeling for Alzheimer's Disease: Design and Prediction of Virtual Multi-Target Inhibitors of GSK3B, HDAC1, and HDAC6.BACKGROUND: Alzheimer's disease is characterized by a progressive pattern of cognitive and functional impairment, which ultimately leads to death.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32531244' target='_blank' class='pmid-link'>32531244</a>:</span> <span class='sentence-part'>The Physiology, Pathology, and Potential Therapeutic Applications of the TREM2 Signaling Pathway.Alzheimer's disease, obesity-related metabolic syndrome, and cancer are the leading causes of death and among the most costly medical conditions in the Western world.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32593336' target='_blank' class='pmid-link'>32593336</a>:</span> <span class='sentence-part'>Clinical and biomarker changes of Alzheimer's disease in adults with Down syndrome: a cross-sectional study.BACKGROUND: Alzheimer's disease and its complications are the leading cause of death in adults with Down syndrome.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32600151' target='_blank' class='pmid-link'>32600151</a>:</span> <span class='sentence-part'>Rapid improvement in Alzheimer's disease symptoms following fecal microbiota transplantation: a case report.Alzheimer's disease (AD), the most common form of dementia, is a leading cause of death and a major cause of morbidity in older people.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32628119' target='_blank' class='pmid-link'>32628119</a>:</span> <span class='sentence-part'>Diabetes-Related Topics in an Online Forum for Caregivers of Individuals Living With Alzheimer Disease and Related Dementias: Qualitative Inquiry.BACKGROUND: Diabetes and Alzheimer disease and related dementias (ADRD) are the seventh and sixth leading causes of death in the United States, respectively, and they coexist in many older adults.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32709243' target='_blank' class='pmid-link'>32709243</a>:</span> <span class='sentence-part'>Alzheimer disease (AD) is the most prominent form of dementia and the 5th leading cause of death in individuals over 65.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32807227' target='_blank' class='pmid-link'>32807227</a>:</span> <span class='sentence-part'>Cerebrospinal fluid profile of NPTX2 supports role of Alzheimer's disease-related inhibitory circuit dysfunction in adults with Down syndrome.BACKGROUND: Alzheimer's disease (AD) is the major cause of death in adults with Down syndrome (DS).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/3285438' target='_blank' class='pmid-link'>3285438</a>:</span> <span class='sentence-part'>This could be responsible for the occurrence of senile changes (senile plaques and neurofibrillary tangles) which are both characteristic of so-called normal aging of the brain and of Alzheimer's disease and lead to neuronal death.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32894711' target='_blank' class='pmid-link'>32894711</a>:</span> <span class='sentence-part'>Multi-view Separable Pyramid Network for AD Prediction at MCI Stage by 18F-FDG Brain PET Imaging.Alzheimer's Disease (AD), one of the main causes of death in elderly people, is characterized by Mild Cognitive Impairment (MCI) at prodromal stage.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33011665' target='_blank' class='pmid-link'>33011665</a>:</span> <span class='sentence-part'>Estimates indicate that AD may rank third as a cause of death for older people, after heart disease and cancer.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33047398' target='_blank' class='pmid-link'>33047398</a>:</span> <span class='sentence-part'>RATIONALE: Alzheimer's disease (AD) is a chronic, severe, progressive neurodegenerative disorder associated with cognitive and memory impairment that ultimately causes death.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33126501' target='_blank' class='pmid-link'>33126501</a>:</span> <span class='sentence-part'>Alzheimer's Disease (AD) is a progressive multifactorial age-related neurodegenerative disorder that causes the majority of deaths due to dementia in the elderly.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33138782' target='_blank' class='pmid-link'>33138782</a>:</span> <span class='sentence-part'>BACKGROUND: Alzheimer's disease (AD) is related to higher mortality but it is not entirely evident which causes of death explain this.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33282526' target='_blank' class='pmid-link'>33282526</a>:</span> <span class='sentence-part'>AD is considered the fifth leading cause of death in Americans who are older than 65 years which prioritizes the importance of understanding the etiology of AD in its early stages before the onset of symptoms.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33316174' target='_blank' class='pmid-link'>33316174</a>:</span> <span class='sentence-part'>Diabetes, Alzheimer disease, and heart disease caused the most non-COVID-19 excess deaths.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33434704' target='_blank' class='pmid-link'>33434704</a>:</span> <span class='sentence-part'>Alzheimer's dementia (AD) is the sixth leading cause of death in the U.S., with an estimated $305 billion cost of care in 2020.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33438444' target='_blank' class='pmid-link'>33438444</a>:</span> <span class='sentence-part'>OBJECTIVES: Neurodegenerative diseases (NDs), such as Parkinson's disease and Alzheimer's disease and related dementias, are a leading cause of death and disability in China.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33500732' target='_blank' class='pmid-link'>33500732</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) is currently ranked as the third leading cause of death for eldly people, just behind heart disease and cancer.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33529936' target='_blank' class='pmid-link'>33529936</a>:</span> <span class='sentence-part'>Alzheimer's Disease (AD) is the most frequent illness and cause of death amongst the age related-neurodegenerative disorders.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33532133' target='_blank' class='pmid-link'>33532133</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) is one of the most common neurodegenerative diseases and a major cause of death among elderly individuals.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33532699' target='_blank' class='pmid-link'>33532699</a>:</span> <span class='sentence-part'>Background: Alzheimer's disease (AD) is the 6th leading cause of death in the United States and has no cure or progression prevention.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33750334' target='_blank' class='pmid-link'>33750334</a>:</span> <span class='sentence-part'>BACKGROUND: Alzheimer's disease (AD) is one of the leading causes of death world-wide, but little is known on the role of comorbidities on mortality among people with AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33756057' target='_blank' class='pmid-link'>33756057</a>:</span> <span class='sentence-part'>Official death certificates recorded 121,499 deaths from AD in 2019, the latest year for which data are available, making Alzheimer's the sixth-leading cause of death in the United States and the fifth-leading cause of death among Americans age 65 and older.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33802718' target='_blank' class='pmid-link'>33802718</a>:</span> <span class='sentence-part'>Specifically, 3.2 million deaths are reported yearly due to heart disease, cancer, Alzheimer's disease, diabetes, and COVID-19.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33839469' target='_blank' class='pmid-link'>33839469</a>:</span> <span class='sentence-part'>The paper recognizes the value and need to fight the image of AD as social death in research, the medical system, and popular understanding, but proposes a family Memory-Relationship self to conceptually capture the trauma many families feel as AD increasingly impairs the loved one with AD and leads to their death (unless they die of something else first).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33916001' target='_blank' class='pmid-link'>33916001</a>:</span> <span class='sentence-part'>Recent studies suggested that gut microbiota can influence AD progression; however, potential mechanisms linking the gut microbiota with AD pathogenesis remain obscure. Alzheimer's disease (AD), a progressive neurodegenerative disorder characterized by memory loss and cognitive decline, is a major cause of death and disability among the older population.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34021875' target='_blank' class='pmid-link'>34021875</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) is the fourth leading cause of death in the United States and the most common cause of adult-onset dementia.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34030620' target='_blank' class='pmid-link'>34030620</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) is the only leading cause of death for which no disease-modifying therapy is currently available.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34098466' target='_blank' class='pmid-link'>34098466</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) is a chronic and progressive neurodegenerative disease, characterized by irreversible cognitive impairment, memory loss and behavioral disturbances, ultimately leading to death.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34208980' target='_blank' class='pmid-link'>34208980</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) and other dementias are now the seventh leading cause of death in the world and are projected to affect 115.4 million people by 2050.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34219726' target='_blank' class='pmid-link'>34219726</a>:</span> <span class='sentence-part'>BACKGROUND: Hispanic older adults are a high-risk population for Alzheimer's disease and related dementias (ADRD) but are less likely than non-Hispanic White older adults to have ADRD documented as a cause of death on a death certificate.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34228042' target='_blank' class='pmid-link'>34228042</a>:</span> <span class='sentence-part'>Importance: Alzheimer disease (AD) is the leading cause of death in individuals with Down syndrome (DS).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34229061' target='_blank' class='pmid-link'>34229061</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) is a severe irreversible neurodegenerative disease that has great sufferings on patients and eventually leads to death.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34273065' target='_blank' class='pmid-link'>34273065</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) is now ranked as the third leading cause of death after heart disease and cancer.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34350508' target='_blank' class='pmid-link'>34350508</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) is a neurodegenerative disease characterized by amyloid plaques and tangles that have become the fifth leading cause of death worldwide.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34353220' target='_blank' class='pmid-link'>34353220</a>:</span> <span class='sentence-part'>BACKGROUND AND PURPOSE: Alzheimer disease (AD) is the most common form of dementia and the sixth leading cause of death in the United States.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34424488' target='_blank' class='pmid-link'>34424488</a>:</span> <span class='sentence-part'>AD is recognized as the sixth leading cause of death in the USA, and its prevalence is predicted to increase exponentially in the coming years.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34522196' target='_blank' class='pmid-link'>34522196</a>:</span> <span class='sentence-part'>Background and purpose: Alzheimer's disease is considered one of the lead causes of elderly death around the world.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34535721' target='_blank' class='pmid-link'>34535721</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) and other dementias have become the fifth leading cause of death worldwide.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34572985' target='_blank' class='pmid-link'>34572985</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) is a neurodegenerative disorder accounting for over 50% of all dementia patients and representing a leading cause of death worldwide for the global ageing population.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34577590' target='_blank' class='pmid-link'>34577590</a>:</span> <span class='sentence-part'>Several risk factors are involved in the progression of AD, modifying neuronal circuits and brain cognition, and eventually leading to neuronal death.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34606321' target='_blank' class='pmid-link'>34606321</a>:</span> <span class='sentence-part'>Compared with White males and females, non-COVID-19 excess deaths per 100 000 persons were 2 to 4 times higher in Black, AI/AN, and Latino males and females, including deaths due to diabetes, heart disease, cerebrovascular disease, and Alzheimer disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34646644' target='_blank' class='pmid-link'>34646644</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) is the most common type of dementia and is among the leading cause of death in the United States.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34687637' target='_blank' class='pmid-link'>34687637</a>:</span> <span class='sentence-part'>Adults with Down syndrome develop the neuropathological hallmarks of Alzheimer's disease and are at very high risk of developing early-onset dementia, which is now the leading cause of death in this population.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34707479' target='_blank' class='pmid-link'>34707479</a>:</span> <span class='sentence-part'>Given that Alzheimer's Disease is the sixth leading cause of adult death in the U.S., elucidating the molecular interactions that characterize Alzheimer's Disease pathogenesis will allow for better treatment options.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34712129' target='_blank' class='pmid-link'>34712129</a>:</span> <span class='sentence-part'>Around 58% of the affected patients live in low and middle-income countries, with estimates of increasing deaths caused by AD in the coming decade.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34751889' target='_blank' class='pmid-link'>34751889</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) is considered the sixth leading cause of death in elderly patients and is characterized by progressive neuronal degeneration and impairment in memory, language, etc.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34867153' target='_blank' class='pmid-link'>34867153</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) is a neurodegenerative disease that impacts 45 million people worldwide and is ranked as the 6th top cause of death among all adults by the Centers for Disease Control and Prevention.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34891761' target='_blank' class='pmid-link'>34891761</a>:</span> <span class='sentence-part'>Alzheimer's Disease (AD) is the sixth leading cause of death in the US.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34971144' target='_blank' class='pmid-link'>34971144</a>:</span> <span class='sentence-part'>BACKGROUND: Alzheimer's Disease (AD), a progressive neurodegenerative disease and the second most common cause of death in Australia (ABS 2019), is an increasingly prominent societal issue, exacerbated by an ageing population and the absence of effective disease modifying treatments.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35023084' target='_blank' class='pmid-link'>35023084</a>:</span> <span class='sentence-part'>INTRODUCTION: Alzheimer's disease is one of the irreversible dementias and leads to death.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35109084' target='_blank' class='pmid-link'>35109084</a>:</span> <span class='sentence-part'>BACKGROUND: Alzheimer's disease (AD) is the leading cause of disability and 5th cause of death in people over 65 years of age.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35109462' target='_blank' class='pmid-link'>35109462</a>:</span> <span class='sentence-part'>Alzheimer's disease is the 6th leading cause of death in the United States.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35186657' target='_blank' class='pmid-link'>35186657</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) is a neurodegenerative disease and the fourth leading cause of death after cardiovascular disease, tumors, and stroke.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35218718' target='_blank' class='pmid-link'>35218718</a>:</span> <span class='sentence-part'>Apart from deaths due to AD, expenditure of treatment and care of AD patients is higher than that of treatment of HIV and cancer diseases combined.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35280344' target='_blank' class='pmid-link'>35280344</a>:</span> <span class='sentence-part'>AD is a progressive neurodegenerative disorder characterized by decline of memory, behavioral impairments that affects a person's ability to function independently ultimately leading to death.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35289055' target='_blank' class='pmid-link'>35289055</a>:</span> <span class='sentence-part'>Alzheimer's disease was officially listed as the sixth-leading cause of death in the United States in 2019 and the seventh-leading cause of death in 2020 and 2021, when COVID-19 entered the ranks of the top ten causes of death.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35431257' target='_blank' class='pmid-link'>35431257</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) is the only cause of death ranked in the top ten globally without precise early diagnosis or effective means of prevention or treatment.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35458896' target='_blank' class='pmid-link'>35458896</a>:</span> <span class='sentence-part'>Alzheimer's disease is the most common form of dementia and the fifth-leading cause of death among people over the age of 65.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35486224' target='_blank' class='pmid-link'>35486224</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD), currently the single leading cause of death still on the rise, almost always coexists alongside vascular cognitive impairment (VCI).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35556967' target='_blank' class='pmid-link'>35556967</a>:</span> <span class='sentence-part'>Currently, an estimated 6.2 million Americans are living with AD, and it is ranked as the 6     th       leading cause of death in the United States.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35599847' target='_blank' class='pmid-link'>35599847</a>:</span> <span class='sentence-part'>It ranks as the sixth leading cause of death in the United States, and the proportion of deaths due to AD has been increasing since 2000, while the proportion of many other leading causes of deaths have decreased or remained constant.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35624938' target='_blank' class='pmid-link'>35624938</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) is an incurable neurodegenerative disorder and the leading cause of death among older individuals.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35665670' target='_blank' class='pmid-link'>35665670</a>:</span> <span class='sentence-part'>Alzheimer's disease is the sixth leading cause of death in the United States, and the number of patients with the disease is set to hit 20 million by 2050.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35748395' target='_blank' class='pmid-link'>35748395</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) is a cumulative form of dementia associated with memory loss, cognition impairment, and finally leading to death.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35784755' target='_blank' class='pmid-link'>35784755</a>:</span> <span class='sentence-part'>In recent years, neurological diseases including Alzheimer's disease, Parkinson's disease and stroke are one of the main causes of death in the world.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35836098' target='_blank' class='pmid-link'>35836098</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) is a chronic and progressive neurodegenerative disease, characterized by irreversible cognitive impairment, memory loss, and behavioral disturbances, ultimately resulting in death.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35858523' target='_blank' class='pmid-link'>35858523</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD), as the fourth leading cause of death among the elderly worldwide, has brought enormous challenge to the society.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35887134' target='_blank' class='pmid-link'>35887134</a>:</span> <span class='sentence-part'>As a neurodegenerative disease, Alzheimer's disease (AD) shows a higher incidence during the aging process, mainly revealing the characteristics of a significant decrease in cognition, uncontrolled emotion, and reduced learning and memory capacity, even leading to death.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35961638' target='_blank' class='pmid-link'>35961638</a>:</span> <span class='sentence-part'>Introduction    : Alzheimer's disease (AD) dementia is the sixth leading cause of death in the United States.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35968378' target='_blank' class='pmid-link'>35968378</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) is the sixth leading cause of death worldwide and cannot be effectively cured or prevented; thus, early diagnosis, and intervention are important.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36165518' target='_blank' class='pmid-link'>36165518</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) has become the fourth leading cause of death in the world.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36197131' target='_blank' class='pmid-link'>36197131</a>:</span> <span class='sentence-part'>AD is the leading type of dementia, accounting for 60% to 80% of cases, and the sixth leading cause of death in the United States.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36268188' target='_blank' class='pmid-link'>36268188</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) is the most common form of dementia and is ranked as the 6th leading cause of death in the US.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36408377' target='_blank' class='pmid-link'>36408377</a>:</span> <span class='sentence-part'>Background: Alzheimer's disease (AD) is the most common form of dementia, which is among the top five causes of death in the United States.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36475205' target='_blank' class='pmid-link'>36475205</a>:</span> <span class='sentence-part'>Alzheimer's dementia (AD) is the most common major neurocognitive impairment and the fifth leading cause of death in older adults in the United States.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36502321' target='_blank' class='pmid-link'>36502321</a>:</span> <span class='sentence-part'>Later in life, AD leads to death as a result of the degeneration of specific brain areas.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36537919' target='_blank' class='pmid-link'>36537919</a>:</span> <span class='sentence-part'>Alzheimer's disease is the sixth-leading cause of death in the United States, and the number of deaths from all related dementias may be twice as high.[i] Years of investment and research in Alzheimer's disease and related dementias (ADRD) are sowing seeds of hope.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36583187' target='_blank' class='pmid-link'>36583187</a>:</span> <span class='sentence-part'>AD is the fifth leading cause of death among Americans age 65 and older.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36589440' target='_blank' class='pmid-link'>36589440</a>:</span> <span class='sentence-part'>Non-communicable diseases, like diabetes, cardiovascular diseases, cancer, stroke, chronic obstructive pulmonary disease, osteoporosis, arthritis, Alzheimer's disease and other more are a leading cause of death in almost all countries.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36593834' target='_blank' class='pmid-link'>36593834</a>:</span> <span class='sentence-part'>Alzheimer's disease is ranked among the top five causes of death for old people.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36674771' target='_blank' class='pmid-link'>36674771</a>:</span> <span class='sentence-part'>Nowadays, cancers and dementia, such as Alzheimer's disease, are the most fatal causes of death.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36708701' target='_blank' class='pmid-link'>36708701</a>:</span> <span class='sentence-part'>The pivotal characteristics of Alzheimer's disease (AD) are irreversible memory loss and progressive cognitive decline, eventually causing death from brain failure.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36780546' target='_blank' class='pmid-link'>36780546</a>:</span> <span class='sentence-part'>After amending death certificates that reported Down syndrome as the underlying cause of death, Alzheimer disease and dementia were the leading cause of death among those with Down syndrome, occurring 2.7 times more in adults with compared to without Down syndrome. RESULTS: When analyzing death certificates without addressing the reporting of Down syndrome as the underlying cause of death, rates of death due to Alzheimer disease and dementia ranked as the third leading cause of death for both adults with and without Down syndrome.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36841050' target='_blank' class='pmid-link'>36841050</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) implicates neuronal loss, plaque and neurofibrillary tangle formation, and disturbed neuronal Ca     2+       homeostasis, which leads to severe dementia, memory loss, as well as thinking and behavioral perturbations that could ultimately lead to death.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36842068' target='_blank' class='pmid-link'>36842068</a>:</span> <span class='sentence-part'>BACKGROUND AND OBJECTIVES: Alzheimer's disease or related dementia are a major cause of death in the United States.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36918389' target='_blank' class='pmid-link'>36918389</a>:</span> <span class='sentence-part'>Official death certificates recorded 121,499 deaths from AD in 2019, and Alzheimer's disease was officially listed as the sixth-leading cause of death in the United States.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36940723' target='_blank' class='pmid-link'>36940723</a>:</span> <span class='sentence-part'>Wealth of data has shown that oxidative stress and AD are closely connected that causes the death of neuronal cells by producing reactive oxygen species (ROS).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36961417' target='_blank' class='pmid-link'>36961417</a>:</span> <span class='sentence-part'>The notion that AD causes the death of neurons point towards protection of neuronal morphology and function as important therapeutic strategies.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36993752' target='_blank' class='pmid-link'>36993752</a>:</span> <span class='sentence-part'>Alzheimer's Disease (AD) continues to be a leading cause of death in the US.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36995136' target='_blank' class='pmid-link'>36995136</a>:</span> <span class='sentence-part'>METHODS: publicly accessible data on the prevalence, death and disability-adjusted life years (DALYs) because of AD, and other types of dementia, were retrieved from the global burden of disease 2019 project for all MENA countries from 1990 to 2019.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37038213' target='_blank' class='pmid-link'>37038213</a>:</span> <span class='sentence-part'>BACKGROUND: Alzheimer's disease (AD) is the 5th leading cause of death in people 65 years and older.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37109528' target='_blank' class='pmid-link'>37109528</a>:</span> <span class='sentence-part'>Presently more than 55 million individuals are affected by AD all over the world, and it is a leading cause of death in old age.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37208979' target='_blank' class='pmid-link'>37208979</a>:</span> <span class='sentence-part'>Compared with AD, hazard ratios for \nervous system\ causes of death were significantly elevated in all LBD groups.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37256433' target='_blank' class='pmid-link'>37256433</a>:</span> <span class='sentence-part'>INTRODUCTION: Clinical Alzheimer's disease (AD) begins with mild cognitive impairment (MCI) and progresses to mild, moderate, or severe dementia, constituting a disease continuum that eventually leads to death.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37304012' target='_blank' class='pmid-link'>37304012</a>:</span> <span class='sentence-part'>Alzheimer's Disease (AD) and related dementias are a leading cause of death globally and are predicted to increase in prevalence.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37375767' target='_blank' class='pmid-link'>37375767</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) is the most common type of dementia and is listed as the sixth-leading cause of death in the United States.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37486697' target='_blank' class='pmid-link'>37486697</a>:</span> <span class='sentence-part'>Alzheimer's disease is the only major cause of death that is still growing.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37507902' target='_blank' class='pmid-link'>37507902</a>:</span> <span class='sentence-part'>Currently, no drug is effective in delaying the cognitive impairment of Alzheimer's disease, which ranks as one of the top 10 causes of death worldwide.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37612307' target='_blank' class='pmid-link'>37612307</a>:</span> <span class='sentence-part'>In 2015, AD is reported the US's sixth cause of death.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37672968' target='_blank' class='pmid-link'>37672968</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) is the most common dementia type and a leading cause of death and disability in the elderly.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37679478' target='_blank' class='pmid-link'>37679478</a>:</span> <span class='sentence-part'>Alzheimer's Disease (AD) continues to be a leading cause of death in the US.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37693600' target='_blank' class='pmid-link'>37693600</a>:</span> <span class='sentence-part'>Alzheimer's Disease (AD) is the 6th leading cause of death in the US.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37955252' target='_blank' class='pmid-link'>37955252</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) is a progressive brain disease characterised by progressive memory loss and cognition impairment, ultimately leading to death.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37997077' target='_blank' class='pmid-link'>37997077</a>:</span> <span class='sentence-part'>BACKGROUND: Dementia and Alzheimer's disease are the leading cause of death in England, with prevalence estimated to rise with an ageing population.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/38131985' target='_blank' class='pmid-link'>38131985</a>:</span> <span class='sentence-part'>Alzheimer's disease is the sixth most common cause of death in the United States (U.S.), with one in three adults 65 years of age and older dying of the disease each year. In 2021, Alzheimer's disease resulted in 36 deaths per 100,000 in the U.S.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/38137554' target='_blank' class='pmid-link'>38137554</a>:</span> <span class='sentence-part'>Conditions such as Alzheimer's disease (AD), Parkinson's disease (PD), and dementia are becoming more prevalent and are now the fourth leading cause of death, following heart disease, cancer, and stroke.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/38213663' target='_blank' class='pmid-link'>38213663</a>:</span> <span class='sentence-part'>AD (for which there is no exact cause and cure known so far) is the sixth leading cause of deaths in the United States.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/38326859' target='_blank' class='pmid-link'>38326859</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) is the sixth leading cause of death in the USA.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/38371416' target='_blank' class='pmid-link'>38371416</a>:</span> <span class='sentence-part'>A recent report from the Office of National Statistics showed that AD is the leading cause of death in 2022.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/38381402' target='_blank' class='pmid-link'>38381402</a>:</span> <span class='sentence-part'>We know that many neurological age-related diseases, such as Alzheimer's disease, stroke, dementia, and Parkinson's disease, are the main cause of death in the last decades of life.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/38414336' target='_blank' class='pmid-link'>38414336</a>:</span> <span class='sentence-part'>INTRODUCTION: There is no cure for Alzheimer's disease, which is the sixth leading cause of death in the U.S.A..</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/38429957' target='_blank' class='pmid-link'>38429957</a>:</span> <span class='sentence-part'>RESULTS: During the study period, 751,493 deaths (1.7%, 233,271 males and 518,222 females) occurred in the EU-27 because of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/38612514' target='_blank' class='pmid-link'>38612514</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) is the fifth leading cause of death among adults aged 65 and older, yet the onset and progression of the disease is poorly understood. Interestingly, as AD progresses, less Abeta42 is detectable in the plasma, a phenomenon thought to result from Abeta becoming more aggregated in the brain and less Abeta42 and Abeta40 being transported from the brain to the plasma via the CSF.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/38640743' target='_blank' class='pmid-link'>38640743</a>:</span> <span class='sentence-part'>Although Alzheimer's Disease is a leading cause of death in Vietnam and other post-conflict, low- and middle-income countries, aside from studies of veterans in western populations, research on war-related violence and deprivation as risk factors for cognitive disorders remains sparse.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/3876409' target='_blank' class='pmid-link'>3876409</a>:</span> <span class='sentence-part'>Such a DNA repair defect could cause an abnormal accumulation of spontaneously occurring DNA damage in Parkinson's disease and Alzheimer's disease neurons in vivo, resulting in their premature death.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/7485229' target='_blank' class='pmid-link'>7485229</a>:</span> <span class='sentence-part'>AD is the fourth leading cause of death in elderly persons 65 years or older in Western industrialized societies.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/7921490' target='_blank' class='pmid-link'>7921490</a>:</span> <span class='sentence-part'>Alzheimer's disease is the fourth major cause of death in the developed world and is a major social and health care issue.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/7997077' target='_blank' class='pmid-link'>7997077</a>:</span> <span class='sentence-part'>After heart disease, cancer and stroke, Alzheimer's disease (AD) is the fourth major cause of death in the developed countries.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/8195568' target='_blank' class='pmid-link'>8195568</a>:</span> <span class='sentence-part'>AD is the fourth leading cause of death for adults, taking more than 100,000 lives annually.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/8195569' target='_blank' class='pmid-link'>8195569</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) is the fourth leading cause of death of older persons.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/8610107' target='_blank' class='pmid-link'>8610107</a>:</span> <span class='sentence-part'>In rat hippocampal culture, betaA exposure activates tau protein kinase I/glycogen synthase kinase 3beta (TPKI/GSK-3beta), which phosphorylates tau protein into Alzheimer disease-like forms, resulting in neuronal death.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/8752460' target='_blank' class='pmid-link'>8752460</a>:</span> <span class='sentence-part'>Other forms of dementias like Alzheimer disease (AD) and vascular dementias are on the rise and the leading cause of death is cerebro- and cardiovascular diseases.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/9154214' target='_blank' class='pmid-link'>9154214</a>:</span> <span class='sentence-part'>Since its first description by Aloys Alzheimer about 90 years ago, this neurodegenerative condition has advanced to become the fourth most common cause of death in the elderly, and is found in more than half of the very elderly demented.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/9165306' target='_blank' class='pmid-link'>9165306</a>:</span> <span class='sentence-part'>The major hurdle in understanding Alzheimer's disease (AD) is a lack of knowledge about the etiology and pathogenesis of selective neuron death.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/9333421' target='_blank' class='pmid-link'>9333421</a>:</span> <span class='sentence-part'>AD is the fourth commonest cause of death in humans, after heart attack, cancer and stroke.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/9413702' target='_blank' class='pmid-link'>9413702</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) is a common neurodegenerative disorder and a leading cause of death among the elderly.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/9460797' target='_blank' class='pmid-link'>9460797</a>:</span> <span class='sentence-part'>There was no significant association detected between a diagnosis of presenile Alzheimer's disease and dementia as a parental cause of death (p = 0.25), nor for vascular dementia (p = 0.67).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/9520072' target='_blank' class='pmid-link'>9520072</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) is the most common neurodegenerative disorder characterized by progressive dementia that ultimately leads to death.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/9647903' target='_blank' class='pmid-link'>9647903</a>:</span> <span class='sentence-part'>We examined exposure to magnetic fields, assessed as duration of work in exposed jobs and through an index of cumulative exposure based on magnetic field measurements, in relation to mortality from Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis, considering both underlying and all mentioned causes of death.</span></div></div>
<div class='streamlined-assertion'><div class='streamlined-header sticky-relation-header'><span class='label-text'>Subject:</span> <strong>Alzheimers</strong> <span class='label-text'>Subject CUI:</span> <strong>C0002395</strong> â†’ <span class='label-text predicate-text'>CAUSES</span> â†’ <span class='label-text'>Object:</span> <strong>Degenerative_abnormality</strong> <span class='label-text'>Object CUI:</span> <strong>C0011164</strong></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/12955221' target='_blank' class='pmid-link'>12955221</a>:</span> <span class='sentence-part'>PURPOSE: Alzheimer disease (AD) causes cortical degeneration with subsequent degenerative changes of the white matter.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/14675724' target='_blank' class='pmid-link'>14675724</a>:</span> <span class='sentence-part'>The ensuing homeostatic responses to myelin breakdown further increase intracortical toxicity and results in the relentless progression and non-random anatomical distribution of AD lesions that eventually cause neuronal dysfunction and degeneration.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/15140940' target='_blank' class='pmid-link'>15140940</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD), the most common neurodegenerative disorder, results in progressive degeneration of synapses and aberrant sprouting of axon terminals.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/15234342' target='_blank' class='pmid-link'>15234342</a>:</span> <span class='sentence-part'>Alzheimer's disease is a neurological disorder resulting in the degeneration and death of brain neurons controlling memory, cognition and behavior.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/15285803' target='_blank' class='pmid-link'>15285803</a>:</span> <span class='sentence-part'>BACKGROUND: Neuroinflammation plays a prominent role in the progression of Alzheimer's disease and may be responsible for degeneration in vulnerable regions such as the hippocampus.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/15817373' target='_blank' class='pmid-link'>15817373</a>:</span> <span class='sentence-part'>Recent studies shed new light on a potential cascade of events by which neurological diseases such as Alzheimer's lead to axonal degeneration.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/16096820' target='_blank' class='pmid-link'>16096820</a>:</span> <span class='sentence-part'>BACKGROUND: Alzheimer's disease (AD) leads to a degeneration of the nucleus basalis of Meynert and thus to decreased cholinergic tonus in the brain.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/1614354' target='_blank' class='pmid-link'>1614354</a>:</span> <span class='sentence-part'>Considerable evidence suggests that in Alzheimer's disease, olfactory bulb damage may be a primary factor, causing degeneration and neurofibrillary tangles primarily in neurons connected with this brain area.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/16389306' target='_blank' class='pmid-link'>16389306</a>:</span> <span class='sentence-part'>Rare inherited forms of AD provide insight into the molecular pathways leading to degeneration and have made possible the development of transgenic animal models.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/16533591' target='_blank' class='pmid-link'>16533591</a>:</span> <span class='sentence-part'>Progenitor cells in the adult human brain subependymal layer are capable of producing new neurons and glial cells that may be useful as a source of cells for endogenous cell replacement for regions of the brain that undergo degeneration due to a neurodegenerative disease such as Huntington's disease, Parkinson's disease or Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17393059' target='_blank' class='pmid-link'>17393059</a>:</span> <span class='sentence-part'>CAA is present in most cases of AD, and it is characterized by the deposition of beta-amyloid (Abeta) in brain vessels, inducing the degeneration of vascular smooth muscle cells and endothelial cells.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20634578' target='_blank' class='pmid-link'>20634578</a>:</span> <span class='sentence-part'>The addition of Abeta(1-42) reduced the amount of synaptophysin in cultured cortical neurons in a model of AD-induced synapse degeneration.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20817045' target='_blank' class='pmid-link'>20817045</a>:</span> <span class='sentence-part'>beta-amyloid has been implicated in the pathogenesis of AD, and its accumulation may lead to degeneration of neuronal or non-neuronal cells.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20965261' target='_blank' class='pmid-link'>20965261</a>:</span> <span class='sentence-part'>Such changes are associated with traditional imaging metrics of degeneration and may provide a unique biomarker of the tissue loss that occurs as a result of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21214538' target='_blank' class='pmid-link'>21214538</a>:</span> <span class='sentence-part'>Similarly, the toxic accumulation of Abeta peptides underlying Alzheimer's disease (AD) triggers synaptic degeneration, circuit remodeling, and abnormal synchronization within the same networks.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21241801' target='_blank' class='pmid-link'>21241801</a>:</span> <span class='sentence-part'>These findings suggest that, in neurons affected by AD, Abeta is toxic, impairs mitochondrial movements, reduces mitochondrial length, and causes synaptic degeneration.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22329649' target='_blank' class='pmid-link'>22329649</a>:</span> <span class='sentence-part'>In this review, we provide an overview of some of the most recent evidence for metabolic dysregulation in Alzheimer's disease, Huntington's disease, and Parkinson's disease, and discuss several potential mechanisms that may underlie the potential relationships between metabolic dysfunction and etiology of nervous system degeneration.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24635394' target='_blank' class='pmid-link'>24635394</a>:</span> <span class='sentence-part'>However, a multi-target approach using combinations of (micro)nutrients might have beneficial effects on cognitive function in neurodegenerative brain disorders like AD leading to synaptic degeneration.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25129614' target='_blank' class='pmid-link'>25129614</a>:</span> <span class='sentence-part'>Despite growing recognition of the importance of white matter abnormalities in the pathogenesis of AD, the causes of white matter degeneration are still unknown.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25477959' target='_blank' class='pmid-link'>25477959</a>:</span> <span class='sentence-part'>Alzheimer's disease is a neurodegenerative disorder characterized by the accumulation of beta amyloid plaques (Abeta) which can induce neurite degeneration and progressive dementia.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26973531' target='_blank' class='pmid-link'>26973531</a>:</span> <span class='sentence-part'>In Alzheimer's disease (AD), which is generally characterized by memory dysfunction, connections amongst the cells in the brain are attenuated or lost leading to degeneration of neural networks.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27466341' target='_blank' class='pmid-link'>27466341</a>:</span> <span class='sentence-part'>UNLABELLED: Alzheimer's disease (AD) is characterized by the progressive accumulation of amyloid beta (Abeta) and microtubule associate protein tau, leading to the selective degeneration of neurons in the neocortex, limbic system, and nucleus basalis, among others.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29155703' target='_blank' class='pmid-link'>29155703</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) is a debilitating neurodegenerative disease in which accumulation of toxic amyloid-beta42 (Abeta42) peptides leads to synaptic degeneration, inflammation, neuronal death, and learning deficits.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29587294' target='_blank' class='pmid-link'>29587294</a>:</span> <span class='sentence-part'>Topographic differences between subicular degeneration caused by ALS and Alzheimer disease (AD) had also not been characterized.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29782616' target='_blank' class='pmid-link'>29782616</a>:</span> <span class='sentence-part'>Results: A step-by-step workflow was developed and used to take patients' Digital Imaging and Computing in Medicine magnetic resonance brain images through a process resulting in illustrative 3D-printed brain and hippocampus models that clearly demonstrate the progressive degenerative changes caused by Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30930730' target='_blank' class='pmid-link'>30930730</a>:</span> <span class='sentence-part'>Administration of the immunotoxin 192IgG-saporin to rats, an animal model of AD, leads to degeneration of cholinergic neurons in the medial septal area.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31356828' target='_blank' class='pmid-link'>31356828</a>:</span> <span class='sentence-part'>Even though traditionally Alzheimer's disease has been associated to Abeta deposits and hyperphosphorylated Tau intracellular tangles, several studies show that neuroinflammation may be the initial cause that triggers degeneration.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31415594' target='_blank' class='pmid-link'>31415594</a>:</span> <span class='sentence-part'>BACKGROUND: Alzheimer's Disease (AD) can cause degeneration in the retina and optic nerve either directly, as a result of amyloid beta deposits, or secondarily, as a result of the degradation of the visual cortex.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/3732820' target='_blank' class='pmid-link'>3732820</a>:</span> <span class='sentence-part'>Alzheimer's disease presently is the commonest cause in the developed world, causing a cortical-subcortical degeneration of ascending cholinergic neurons and large pyramidal cells in the cerebral cortex.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/7016437' target='_blank' class='pmid-link'>7016437</a>:</span> <span class='sentence-part'>Even though the laboratory animals develop tangles resembling those seen in patients with Alzheimer's Disease, no evidence has been published to show that the tangles seen in Alzheimer's Disease are induced by the elevated brain aluminum content. The patients with Alzheimer's Disease develop characteristic neurofibrillary tangles which lead to the degeneration of the affected neurons.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/8318230' target='_blank' class='pmid-link'>8318230</a>:</span> <span class='sentence-part'>Thus, phosphorylation of Ser396 may destabilize MTs in AD, resulting in the degeneration of affected cells.</span></div></div>
<div class='streamlined-assertion'><div class='streamlined-header sticky-relation-header'><span class='label-text'>Subject:</span> <strong>Alzheimers</strong> <span class='label-text'>Subject CUI:</span> <strong>C0002395</strong> â†’ <span class='label-text predicate-text'>CAUSES</span> â†’ <span class='label-text'>Object:</span> <strong>Dementia_Vascular</strong> <span class='label-text'>Object CUI:</span> <strong>C0011269</strong></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/15375590' target='_blank' class='pmid-link'>15375590</a>:</span> <span class='sentence-part'>Since ApoE4 imparts risk for both hyperlipidemia and AD, it seemed worthwhile to investigate the possible role of ApoE in the pathogenesis of AD and VaD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/15883314' target='_blank' class='pmid-link'>15883314</a>:</span> <span class='sentence-part'>The dementia was attributable to only vascular factors in 56 cases (probable VaD); VaD coexisted with AD in 61 cases, although the VaD component was the leading cause of dementia (probable VaD with AD); AD was the leading cause of dementia in 61 cases (possible VaD and probable AD); and in 29 cases, it was not clear that either AD or VaD was the primary diagnosis (possible AD and possible VaD). The diagnosis of vascular dementia is difficult in epidemiologic studies because poststroke dementia can be due to Alzheimer disease (AD) and evidence of vascular disease can be found in the MRI of dementia cases without clinical strokes.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/19896503' target='_blank' class='pmid-link'>19896503</a>:</span> <span class='sentence-part'>The latter findings are consistent with the concept that AD is a dietary-fat induced phenotype of vascular dementia, reflecting the extraordinary entrapment of peripherally derived lipoproteins endogenously enriched in Abeta.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22739039' target='_blank' class='pmid-link'>22739039</a>:</span> <span class='sentence-part'>DEVELOPMENT: The criteria for the diagnosis of vascular cognitive impairment have evolved, but available criteria were designed basically for differentiating between vascular dementia and dementia due to Alzheimer disease, and for research purposes.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23862185' target='_blank' class='pmid-link'>23862185</a>:</span> <span class='sentence-part'>BACKGROUND: Vascular dementia represents the second most common type of dementia after that caused by Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26157520' target='_blank' class='pmid-link'>26157520</a>:</span> <span class='sentence-part'>Epidemiological studies have found associations between HHcy and Alzheimer's disease (AD) progression that eventually leads to vascular dementia (VaD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28839167' target='_blank' class='pmid-link'>28839167</a>:</span> <span class='sentence-part'>The ultra-sensitive IMR assay was applied to detect the plasma tau protein levels of subjects with prevalent neurodegenerative diseases, such as Alzheimer's disease (AD), mild cognitive impairment (MCI) due to AD, Parkinson's disease (PD), frontotemporal dementia (FTD) and vascular dementia (VD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30696930' target='_blank' class='pmid-link'>30696930</a>:</span> <span class='sentence-part'>Dementia was further categorised into Alzheimer's disease (AD), vascular dementia (VaD), and dementia caused by other diseases (ODs).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35986673' target='_blank' class='pmid-link'>35986673</a>:</span> <span class='sentence-part'>BACKGROUND: Vascular dementia (VaD) is the most common type of dementia secondary to Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/38226362' target='_blank' class='pmid-link'>38226362</a>:</span> <span class='sentence-part'>Despite its importance, research into VCID has lagged as compared to cognitive impairment due to Alzheimer's disease.</span></div></div>
<div class='streamlined-assertion'><div class='streamlined-header sticky-relation-header'><span class='label-text'>Subject:</span> <strong>Alzheimers</strong> <span class='label-text'>Subject CUI:</span> <strong>C0002395</strong> â†’ <span class='label-text predicate-text'>CAUSES</span> â†’ <span class='label-text'>Object:</span> <strong>Diagnosis</strong> <span class='label-text'>Object CUI:</span> <strong>C0011900</strong></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/12410910' target='_blank' class='pmid-link'>12410910</a>:</span> <span class='sentence-part'>Only 13% of a group of patients receiving the AD therapy donepezil had AD as the primary diagnosis, and AD is rarely included as a primary or secondary DRG diagnosis when the condition precipitating admission to the hospital is caused by AD. In addition, AD is often not mentioned on death certificates, although it may be the proximate cause of death.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/12707840' target='_blank' class='pmid-link'>12707840</a>:</span> <span class='sentence-part'>DLB is clinically under-diagnosed and frequently misclassified as systemic delirium or dementia due to Alzheimer's disease or cerebrovascular disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/15683939' target='_blank' class='pmid-link'>15683939</a>:</span> <span class='sentence-part'>This definition is well adapted to Alzheimer's disease but results in delayed diagnosis or misclassification of dementias such as frontotemporal dementia or dementia with Lewy bodies in which memory deficits are minor or late.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17048151' target='_blank' class='pmid-link'>17048151</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) is the most commonly diagnosed etiology of dementia and may be caused by the progressive accumulation and deposition of neurotoxic Abeta/amyloid plaques and aggregates in brain with aging-the amyloid hypothesis of AD. However, Abeta/amyloid deposition is likely necessary but not sufficient to cause AD, and other putative downstream pathologies, including the aggregation of phospho-tau in neurofibrillary tangles, synaptic and neuronal loss, and glial and inflammatory responses, are likely equally important to AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20511105' target='_blank' class='pmid-link'>20511105</a>:</span> <span class='sentence-part'>RESULTS: Overall, 24.1% (425/1764) patients had a diagnosis of dementia, most frequently secondary to Alzheimer's disease (260/425, 61.2%).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21514249' target='_blank' class='pmid-link'>21514249</a>:</span> <span class='sentence-part'>The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. The National Institute on Aging and the Alzheimer's Association charged a workgroup with the task of developing criteria for the symptomatic predementia phase of Alzheimer's disease (AD), referred to in this article as mild cognitive impairment due to AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21514250' target='_blank' class='pmid-link'>21514250</a>:</span> <span class='sentence-part'>The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21747305' target='_blank' class='pmid-link'>21747305</a>:</span> <span class='sentence-part'>Alzheimer disease (AD) accounts for most dementia diagnoses.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22573143' target='_blank' class='pmid-link'>22573143</a>:</span> <span class='sentence-part'>MCI patients were re-classified according to the conversion status upon follow-up: 25 individuals retained the diagnostic status of MCI and were considered as stable cases (MCI-MCI); conversely, in nine cases the diagnosis of dementia due to AD was ascertained.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23011220' target='_blank' class='pmid-link'>23011220</a>:</span> <span class='sentence-part'>The identification of memory measures that are associated with Abeta is of clinical relevance as this may enhance the confidence in making a diagnosis of MCI due to AD in clinical settings. In conclusion, a measure of story recall may increase the confidence in making a diagnosis of MCI due to AD in clinical settings.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23070466' target='_blank' class='pmid-link'>23070466</a>:</span> <span class='sentence-part'>The results of this study provide evidence in favour of the use of biomarkers for the diagnosis of MCI due to AD, in line with recently published research criteria. Supporting evidence for using biomarkers in the diagnosis of MCI due to AD. The aim of this study is to support the use of biomarkers in the diagnosis of mild cognitive impairment (MCI) due to Alzheimer's disease (AD) according to the revised NIA-AA diagnostic criteria.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23114667' target='_blank' class='pmid-link'>23114667</a>:</span> <span class='sentence-part'>CONCLUSIONS: These new criteria are immediately helpful to the practicing clinician, providing more accurate and specific guidelines for the diagnosis of AD dementia and MCI due to AD. REVIEW SUMMARY: Four articles in the journal Alzheimer's &amp; Dementia in 2011 describe new criteria for AD dementia and mild cognitive impairment (MCI) due to the AD pathophysiological process (MCI due to AD) and the underlying rationale for them.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23531500' target='_blank' class='pmid-link'>23531500</a>:</span> <span class='sentence-part'>In Alzheimer's disease (AD), fatal neuronal cell loss occurs long before relevant evidence can lead to a reliable diagnosis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24392252' target='_blank' class='pmid-link'>24392252</a>:</span> <span class='sentence-part'>Practical diagnosis and management of dementia due to Alzheimer's disease in the primary care setting: an evidence-based approach.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24678299' target='_blank' class='pmid-link'>24678299</a>:</span> <span class='sentence-part'>This piece aims to stimulate discussion by identifying the ethical challenges involved in the use of biomarkers to make a diagnosis of mild cognitive impairment due to AD and disclose it to patients.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25150733' target='_blank' class='pmid-link'>25150733</a>:</span> <span class='sentence-part'>Seventy-nine percent of responders felt \very/extremely\ comfortable delivering a diagnosis of MCI due to AD when both amyloid and neuronal injury biomarkers were abnormal (P &lt; .02 versus any individual biomarker).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25201782' target='_blank' class='pmid-link'>25201782</a>:</span> <span class='sentence-part'>Hippocampal volume is a promising biomarker to enhance the accuracy of the diagnosis of dementia due to Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25605659' target='_blank' class='pmid-link'>25605659</a>:</span> <span class='sentence-part'>The observation that similar diagnostic sensitivity was obtained in two separate study populations, allied to the scalability and usability of the test in community memory clinics, supports future application of the 4MT in the diagnosis of pre-dementia due to AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26424328' target='_blank' class='pmid-link'>26424328</a>:</span> <span class='sentence-part'>BACKGROUND: It may be assumed that increased public awareness of dementia due to Alzheimer's disease (AD) together with the availability of efficacious treatment will result in diagnostic evaluation at earlier stages of cognitive decline and diagnosis of dementia due to AD at earlier stages.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26478889' target='_blank' class='pmid-link'>26478889</a>:</span> <span class='sentence-part'>Use of these biomarkers for the detection of early and preclinical AD has become of central importance following publication of two international expert working group's revised criteria for the diagnosis of AD dementia, mild cognitive impairment (MCI) due to AD, prodromal AD and preclinical AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26502818' target='_blank' class='pmid-link'>26502818</a>:</span> <span class='sentence-part'>We suggest that amygdala function should be incorporated into the cognitive screening tool for the diagnosis of mild cognitive impairment due to AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26567733' target='_blank' class='pmid-link'>26567733</a>:</span> <span class='sentence-part'>Recommended guidelines for the diagnosis of dementia due to Alzheimer's Disease (AD) were revised in recent years, including Positron Emission Tomography (PET) as an in-vivo diagnostic imaging technique for the diagnosis of neurodegeneration.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27372368' target='_blank' class='pmid-link'>27372368</a>:</span> <span class='sentence-part'>METHOD: We mailed questions to all active patients with diagnoses of MCI or dementia due to AD of a rural memory clinic and compare features of the responders versus the non-responders.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28522977' target='_blank' class='pmid-link'>28522977</a>:</span> <span class='sentence-part'>The diagnosis of MNCD-AD was made according to DSM-5 criteria for possible MNCD-AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28733959' target='_blank' class='pmid-link'>28733959</a>:</span> <span class='sentence-part'>Here we present a streamlined questionnaire-enriched, biomarker-enriched approach that is more cost-effective than the current diagnosis of exclusion and is designed to increase clinical confidence for a diagnosis of dementia due to AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28787712' target='_blank' class='pmid-link'>28787712</a>:</span> <span class='sentence-part'>METHODS: Physicians identified patients seeking a diagnosis for mild cognitive impairment or dementia, possibly due to Alzheimer disease (AD), and recorded a working diagnosis and a management plan.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28891447' target='_blank' class='pmid-link'>28891447</a>:</span> <span class='sentence-part'>RESULTS: Molecular imaging marker of amyloid pathology, and volumetric markers of regional and whole brain atrophy support the diagnosis of AD dementia and MCI due to AD, and contribute to confidence in the differential diagnosis of AD and non-AD related dementias in specialized care.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29051531' target='_blank' class='pmid-link'>29051531</a>:</span> <span class='sentence-part'>Towards this end, we characterized the bacterial taxonomic composition of fecal samples from participants with and without a diagnosis of dementia due to AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29164600' target='_blank' class='pmid-link'>29164600</a>:</span> <span class='sentence-part'>However, the National Institute on Aging and Alzheimer's Association (NIA-AA) revised the diagnostic criteria for Alzheimer's disease and confidence in the diagnosis of mild cognitive impairment (MCI) due to Alzheimer's disease may be increased when using some amyloid biomarkers tests like 18F-florbetaben.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29164602' target='_blank' class='pmid-link'>29164602</a>:</span> <span class='sentence-part'>However, the National Institute on Aging and Alzheimer's Association (NIA-AA) revised the diagnostic criteria for Alzheimer's disease and the confidence in the diagnosis of mild cognitive impairment (MCI) due to Alzheimer's disease may be increased when using some amyloid biomarkers tests like 18F-flutemetamol.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29164603' target='_blank' class='pmid-link'>29164603</a>:</span> <span class='sentence-part'>However, the National Institute on Aging and Alzheimer's Association (NIA-AA) revised the diagnostic criteria for Alzheimer's disease and confidence in the diagnosis of mild cognitive impairment (MCI) due to Alzheimer's disease may be increased when using amyloid biomarkers tests like 18F-florbetapir.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29213740' target='_blank' class='pmid-link'>29213740</a>:</span> <span class='sentence-part'>A review of the evidence on cognitive, functional and behavioral assessment for the diagnosis of dementia due to Alzheimer's disease (AD) is presented with revision and broadening of the recommendations on the use of tests and batteries in Brazil for the diagnosis of dementia due to AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29318973' target='_blank' class='pmid-link'>29318973</a>:</span> <span class='sentence-part'>After a median follow-up of 36 months (range 7-74), the final diagnosis was AD MCI or dementia for 9 (24%) patients, and unlikely due to AD for 28 (76%) patients.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29365053' target='_blank' class='pmid-link'>29365053</a>:</span> <span class='sentence-part'>The goal of this study was to determine which measures, obtained when individuals were cognitively normal, predict on an individual basis, the onset of clinical symptoms associated with a diagnosis of mild cognitive impairment due to Alzheimer's disease. The primary outcome was progression from normal cognition to the onset of clinical symptoms of mild cognitive impairment due to Alzheimer's disease at 5 years post-baseline.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29512075' target='_blank' class='pmid-link'>29512075</a>:</span> <span class='sentence-part'>The diagnosis of dementia probably due to Alzheimer's disease is still primarily a clinical one.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29582053' target='_blank' class='pmid-link'>29582053</a>:</span> <span class='sentence-part'>Eligibility required a diagnosis of mild to moderate dementia due to AD and individuals aged 55 to 80 years.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29704037' target='_blank' class='pmid-link'>29704037</a>:</span> <span class='sentence-part'>While clinical outcome studies supporting the diagnosis of MCI due to AD showed varying accuracies (ranging from 58 to 100%) and varying areas under the receiver-operator characteristic curves (0.66 to 0.97), no respective data were identified for MCI due to FTLD or for MCI due to DLB.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29729732' target='_blank' class='pmid-link'>29729732</a>:</span> <span class='sentence-part'>However, the modern diagnostic strategies of AD present several disadvantages: the low accuracy and specificity resulting in some false-negative diagnoses, and the poor sensitivity leading to a delayed treatment.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30010131' target='_blank' class='pmid-link'>30010131</a>:</span> <span class='sentence-part'>Diagnosis of Mild Cognitive Impairment Due to Alzheimer's Disease with Transcranial Magnetic Stimulation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30399602' target='_blank' class='pmid-link'>30399602</a>:</span> <span class='sentence-part'>Final diagnosis in most patients was Dementia due to probable Alzheimers disease, followed by Frontotemporal dementia.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30560245' target='_blank' class='pmid-link'>30560245</a>:</span> <span class='sentence-part'>We set out to investigate the insights general practitioners (GPs) have into the early signs and symptoms of Alzheimer's disease (AD), factors that may be responsible for the late diagnosis, as well as their recommendations for early diagnosis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30756114' target='_blank' class='pmid-link'>30756114</a>:</span> <span class='sentence-part'>The primary objective is to assess the ability of the Alzheimer's Prevention Initiative Cognitive Composite Test Score and Repeatable Battery for the Assessment of Neuropsychological Status to predict clinically meaningful outcomes such as diagnosis of mild cognitive impairment or dementia due to Alzheimer's disease, and change in Clinical Dementia Rating - Global Score.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30814473' target='_blank' class='pmid-link'>30814473</a>:</span> <span class='sentence-part'>METHODS: We recruited 32 subjects with a diagnosis of probable AD dementia (ADD, n = 20) and mild cognitive impairment due to AD (MCI-AD, n = 12) according to the NIA-AA 2011 criteria.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30829855' target='_blank' class='pmid-link'>30829855</a>:</span> <span class='sentence-part'>As a consequence, the diagnosis of AD can be delayed, often occurring too late for meaningful intervention.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30900850' target='_blank' class='pmid-link'>30900850</a>:</span> <span class='sentence-part'>Disclosing the diagnosis of cognitive impairment or dementia due to Alzheimer's disease (AD) and Related Dementias (ADRD) can be one of the most challenging aspects of dementia care for clinicians.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31211217' target='_blank' class='pmid-link'>31211217</a>:</span> <span class='sentence-part'>Primary outcomes include time to event, with event defined as diagnosis of mild cognitive impairment due to AD and/or dementia due to AD, and the Alzheimer's Prevention Initiative preclinical composite cognitive test battery.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31439020' target='_blank' class='pmid-link'>31439020</a>:</span> <span class='sentence-part'>Over 70% of the physicians considered that a diagnosis of prodromal AD/MCI due to AD had an added value over the MCI diagnosis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31488095' target='_blank' class='pmid-link'>31488095</a>:</span> <span class='sentence-part'>A diagnosis of MCI due to Alzheimer's disease was given and a co-morbidity with a silent arachnoid cyst was assumed.</span></div></div>
<div class='streamlined-assertion'><div class='streamlined-header sticky-relation-header'><span class='label-text'>Subject:</span> <strong>Alzheimers</strong> <span class='label-text'>Subject CUI:</span> <strong>C0002395</strong> â†’ <span class='label-text predicate-text'>CAUSES</span> â†’ <span class='label-text'>Object:</span> <strong>Disability_NOS</strong> <span class='label-text'>Object CUI:</span> <strong>C0231170</strong></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/11142178' target='_blank' class='pmid-link'>11142178</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD), the leading cause of disability in people older than 75 years of age, has direct and indirect medical costs estimated at $100 billion per year.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/11345519' target='_blank' class='pmid-link'>11345519</a>:</span> <span class='sentence-part'>These results agree with the suggestion that the well-documented impairment in brain-energy metabolism in AD may be a direct cause of the clinical disability.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/12226541' target='_blank' class='pmid-link'>12226541</a>:</span> <span class='sentence-part'>This paper discusses the hypothesis that the cerebrometabolic deficiency in Alzheimer's disease(AD) is the proximate cause of the clinical disability.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/14611864' target='_blank' class='pmid-link'>14611864</a>:</span> <span class='sentence-part'>Without medical progress, dementing diseases such as Alzheimer's disease will become one of the main causes of disability.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/14738700' target='_blank' class='pmid-link'>14738700</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) is associated with neuropsychologic and neuropsychiatric dysfunction and is a leading cause of disability among the elderly.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/15554415' target='_blank' class='pmid-link'>15554415</a>:</span> <span class='sentence-part'>Stroke and a wide spectrum of neuropsychiatric illnesses such as Alzheimer's disease, Parkinson's disease, multiple sclerosis, traumatic head injury, and schizophrenia all lead to severe disability.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/16997144' target='_blank' class='pmid-link'>16997144</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) is the most common form of senile dementia and the fourth highest cause of disability and death in the elderly.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17132969' target='_blank' class='pmid-link'>17132969</a>:</span> <span class='sentence-part'>Alzheimer disease is the most common form of dementia in Western countries and the leading cause of disability in the over-65 population.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17226739' target='_blank' class='pmid-link'>17226739</a>:</span> <span class='sentence-part'>AD is a major cause of disability and mortality, and its impact on health care costs, including direct and indirect medical and social service costs, is estimated to be greater than $100 billion per year.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17334267' target='_blank' class='pmid-link'>17334267</a>:</span> <span class='sentence-part'>Most studies have primarily focused on disability due to Alzheimer disease (AD), and less is known about profiles of functional impairment in other dementia syndromes.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/1781964' target='_blank' class='pmid-link'>1781964</a>:</span> <span class='sentence-part'>Alzheimer disease is a common neurodegenerative disorder consisting of memory impairment and intellectual function that produces not only profound disabilities in the patient, but a significant cost to society as well.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/18368375' target='_blank' class='pmid-link'>18368375</a>:</span> <span class='sentence-part'>AD is among the leading causes of disability and death in older people.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/19586077' target='_blank' class='pmid-link'>19586077</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) is a leading cause of disability in the elderly, leading to a high burden on caregivers and costs to society.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20976693' target='_blank' class='pmid-link'>20976693</a>:</span> <span class='sentence-part'>Dementia, Alzheimer's disease in particular, is one of the major causes of disability and decreased quality of life among the elderly and a leading obstacle to successful aging.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21197431' target='_blank' class='pmid-link'>21197431</a>:</span> <span class='sentence-part'>Alzheimer's Disease (AD) is the most frequent form of dementia and represents one of the main causes of disability among older subjects.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21843595' target='_blank' class='pmid-link'>21843595</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) is a major cause of disability in the elderly.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22178471' target='_blank' class='pmid-link'>22178471</a>:</span> <span class='sentence-part'>Most chronic diseases--such as cancer, cardiovascular disease (CVD), Alzheimer disease, Parkinson disease, arthritis, diabetes and obesity--are becoming leading causes of disability and death all over the world.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22201914' target='_blank' class='pmid-link'>22201914</a>:</span> <span class='sentence-part'>As the aging population increases, the prevalence of AD has increased remarkably worldwide and AD has become one of the leading causes of disability and death among the elderly.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22447723' target='_blank' class='pmid-link'>22447723</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD), one of the major causes of disability and mortality in Western societies, is a progressive age-related neurodegenerative disorder.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22541861' target='_blank' class='pmid-link'>22541861</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD), which is the most common form of dementia, constitutes one of the leading causes of disability and mortality in aging societies.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23538412' target='_blank' class='pmid-link'>23538412</a>:</span> <span class='sentence-part'>Alzheimer disease prevails as a major cause of disability in the elderly population and ranks as the most common form of dementia that affects 1 of 8 individuals older than 65 years of age.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23762322' target='_blank' class='pmid-link'>23762322</a>:</span> <span class='sentence-part'>Among these medications, some might benefit, while others might exacerbate, the pathogenesis of AD. Alzheimer's disease (AD) is rapidly becoming one of the leading causes of disability and mortality in the elderly.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24323427' target='_blank' class='pmid-link'>24323427</a>:</span> <span class='sentence-part'>Neurodegenerative disorders, including Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), amyotrophic lateral sclerosis (ALS), prion disease, and other diseases that affect the neuromuscular system, are a leading cause of disability in the aging population.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26188654' target='_blank' class='pmid-link'>26188654</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) is the most common form of dementia and is a major cause of disability and dependency amongst older people.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26991979' target='_blank' class='pmid-link'>26991979</a>:</span> <span class='sentence-part'>The only disease-specific variable that improved the logistic model was 'disability due to AD'. 'Disability due to AD' was the only disease-related marker for depression in AD, although this marker cannot be considered specific for AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27074540' target='_blank' class='pmid-link'>27074540</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) and Parkinson's disease (PD) are the leading causes of disability associated with neurodegeneration worldwide.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27123241' target='_blank' class='pmid-link'>27123241</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) is the most common cause of disability in individuals aged &gt;65 years worldwide.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27567824' target='_blank' class='pmid-link'>27567824</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) is a major cause of disability in the elderly, leading to a considerable burden on caregivers and high costs to society.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27697061' target='_blank' class='pmid-link'>27697061</a>:</span> <span class='sentence-part'>Our review concludes with some suggestions for future studies aimed to advance research into NBS as a potential treatment for the symptoms and disabilities caused by AD and to enable comparison of results across trials.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28861757' target='_blank' class='pmid-link'>28861757</a>:</span> <span class='sentence-part'>AD-like pathology was produced by administering AbetaP (1-40) intracerebroventricular (i.c.v.) in the left lateral ventricle (250 ng/10 MUl, once daily) for 4 weeks. Alzheimer's disease (AD) is one of the leading causes for disability and death affecting millions of people worldwide.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29256351' target='_blank' class='pmid-link'>29256351</a>:</span> <span class='sentence-part'>Likewise, neurodegenerative diseases such as Alzheimer's disease, Parkinson's diseases, multiple sclerosis or glaucoma defined as ocular Alzheimer's disease, are associated with a large public health burden and are among the leading causes of disability.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29260173' target='_blank' class='pmid-link'>29260173</a>:</span> <span class='sentence-part'>As the aging population is increasing, AD is becoming one of the leading causes of disability and death among the elderly. These results suggested that fucoidan might exert its protective effects against Abeta-induced toxicity in transgenic AD C. elegans by reducing the accumulation of toxic Abeta and decreasing Abeta-induced production of ROS, thus ameliorating the progression of the AD phenotype.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29460787' target='_blank' class='pmid-link'>29460787</a>:</span> <span class='sentence-part'>The present study aimed to evaluate the validity and reliability of the visual estimation method, in long-term inpatients with different levels of eating disability caused by Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29466244' target='_blank' class='pmid-link'>29466244</a>:</span> <span class='sentence-part'>Neurological disorders have aroused a significant concern among the health scientists globally, as diseases such as Parkinson's, Alzheimer's and dementia lead to disability and people have to live with them throughout the life.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29575030' target='_blank' class='pmid-link'>29575030</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) is the most common form of dementia and one of the major causes of disability and dependency in older people.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30336640' target='_blank' class='pmid-link'>30336640</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) is one of the main causes of disability and dependency among elderly people.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30428832' target='_blank' class='pmid-link'>30428832</a>:</span> <span class='sentence-part'>BACKGROUND: One of the crucial challenges for the future of therapeutic approaches to Alzheimer's disease (AD) is to target the main pathological processes responsible for disability and dependency.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30775973' target='_blank' class='pmid-link'>30775973</a>:</span> <span class='sentence-part'>Among the elderly, AD shortens life expectancy, results in disability, decreases quality of life, and ultimately, leads to institutionalization.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31226738' target='_blank' class='pmid-link'>31226738</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) is the most common type of dementia and is the leading cause of disability in elderly people worldwide.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31367416' target='_blank' class='pmid-link'>31367416</a>:</span> <span class='sentence-part'>Aim: To clarify the characteristics of appropriate care methods for people with daily life disabilities due to Alzheimer's type dementia.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31413325' target='_blank' class='pmid-link'>31413325</a>:</span> <span class='sentence-part'>Alzheimer's disease and other types of dementia are the top cause for disabilities in later life and various types of experiments have been performed to understand the underlying mechanisms of the disease with the aim of coming up with potential drug targets.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31456679' target='_blank' class='pmid-link'>31456679</a>:</span> <span class='sentence-part'>Alzheimer's disease, and dementia, represent a common cause of disability and one of the most relevant challenges in the health world.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31788340' target='_blank' class='pmid-link'>31788340</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) is a neurodegenerative disorder and one of the leading causes of disability and mortality in the late life with no curative treatment currently.</span></div></div>
<div class='streamlined-assertion'><div class='streamlined-header sticky-relation-header'><span class='label-text'>Subject:</span> <strong>Alzheimers</strong> <span class='label-text'>Subject CUI:</span> <strong>C0002395</strong> â†’ <span class='label-text predicate-text'>CAUSES</span> â†’ <span class='label-text'>Object:</span> <strong>Disease</strong> <span class='label-text'>Object CUI:</span> <strong>C0012634</strong></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/10559765' target='_blank' class='pmid-link'>10559765</a>:</span> <span class='sentence-part'>In conclusion, the quality of life for adults with DS can be improved by routine, systematic health care screening to identify treatable diseases that may be missed because of poor communication or confusion due to Alzheimer disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/10993489' target='_blank' class='pmid-link'>10993489</a>:</span> <span class='sentence-part'>Cerebrovascular pathology, Lewy bodies, or hippocampal sclerosis in combination with neuropathological signs of AD of only limited severity results in a disease that is essentially different from severe, purely degenerative AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/11450439' target='_blank' class='pmid-link'>11450439</a>:</span> <span class='sentence-part'>The systematization of modern biochemical and structural date related to the action of physiologically active compounds on the nervous system apparatus engaged in the AD-like disorders pathogenesis was performed.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/11513911' target='_blank' class='pmid-link'>11513911</a>:</span> <span class='sentence-part'>INTERPRETATION: In-vivo detection of increased [11C](R)-PK11195 binding in Alzheimer-type dementia, including mild and early forms, suggests that microglial activation is an early event in the pathogenesis of the disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/11532247' target='_blank' class='pmid-link'>11532247</a>:</span> <span class='sentence-part'>All three isoforms are aberrantly expressed in Alzheimer's disease giving rise to elevated levels of nitric oxide apparently involved in the pathogenesis of this disease by various different mechanisms including oxidative stress and activation of intracellular signalling mechanisms.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/11585670' target='_blank' class='pmid-link'>11585670</a>:</span> <span class='sentence-part'>Utilizing both cDNA- and genomic-based approaches, these mouse models for Alzheimer's disease have already provided valuable insights into the pathogenesis of the disease and potential therapeutic interventions.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/11813874' target='_blank' class='pmid-link'>11813874</a>:</span> <span class='sentence-part'>A central question involving the role of A beta in AD concerns how A beta causes disease and whether it is extracellular A beta deposition and/or intracellular A beta accumulation that initiates the disease process. The discovery of familial AD (FAD) mutations in the genes for the amyloid precursor protein (APP) and presenilins (PSs), all of which increase A beta42 production, support the view that A beta is centrally involved in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/11816795' target='_blank' class='pmid-link'>11816795</a>:</span> <span class='sentence-part'>Further investigation of alpha-synuclein and its relationship to pathological conditions promoting Lewy body formation in AD, PD, and DLB may yield further insight into pathogenesis of these diseases.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/11935076' target='_blank' class='pmid-link'>11935076</a>:</span> <span class='sentence-part'>BACKGROUND: The main stumbling block in the clinical management and in the search for a cure of Alzheimer disease (AD) is that the cause of this disorder has remained uncertain until now.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/12459889' target='_blank' class='pmid-link'>12459889</a>:</span> <span class='sentence-part'>In addition to the association between apoE4 and an increased risk of AD, oxidative stress is believed to play a role in the pathogenesis of this disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/12464614' target='_blank' class='pmid-link'>12464614</a>:</span> <span class='sentence-part'>The abnormal accumulation of beta-amyloid (Abeta) in the brain is an early and invariant feature in Alzheimer's disease (AD) and is believed to play a pivotal role in the etiology and pathogenesis of the disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/12473185' target='_blank' class='pmid-link'>12473185</a>:</span> <span class='sentence-part'>The controlled activation of PKC-epsilon plays a protective role in the development of cardiac ischemia and Alzheimer's disease, whereas its uncontrolled chronic activation results in severe diseases such as malignant tumors and diabetes.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/12587940' target='_blank' class='pmid-link'>12587940</a>:</span> <span class='sentence-part'>Recent research, however, has shown that inflammatory mechanisms are also associated with AD and that they could have a role in contributing to the pathogenesis of this disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/12629906' target='_blank' class='pmid-link'>12629906</a>:</span> <span class='sentence-part'>Mutations in the amyloid precursor protein gene (APP) and the presenilin genes (PSEN1 en PSEN2) cause early onset Alzheimer's disease. Research in the field of Alzheimer's disease has shown that genetic factors play an important role in the aetiology of the disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/12845151' target='_blank' class='pmid-link'>12845151</a>:</span> <span class='sentence-part'>The prolongation of life and the rapidly increasing incidence of Alzheimer's disease have brought to the foreground the need for greater understanding of the etiology of the disease and the means to prevent or at least slow down the process.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/12884970' target='_blank' class='pmid-link'>12884970</a>:</span> <span class='sentence-part'>Small animal models that manifest many of the characteristic neuropathological and behavioral features of Alzheimer's disease (AD) have been developed and have proven of great value for studying the pathogenesis of this disorder at the molecular, cellular and behavioral levels.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/12900170' target='_blank' class='pmid-link'>12900170</a>:</span> <span class='sentence-part'>Although it remains uncertain whether the UPR plays a mechanistic role in prototypical neurodegenerative disorders such as Alzheimer's disease, this is plausible because misfolded proteins are directly implicated in the pathogenesis of these disorders.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/14599482' target='_blank' class='pmid-link'>14599482</a>:</span> <span class='sentence-part'>Cholinergic deficits in Alzheimer's disease are accompanied by a number of alterations in other transmitter systems including glutamate, noradrenaline and serotonin, suggesting the involvement also of other neurotransmitter systems in the pathogenesis of the disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/14720176' target='_blank' class='pmid-link'>14720176</a>:</span> <span class='sentence-part'>Pathological relationships between damage to the deep white matter of the cerebral cortex [as evidenced by myelin loss (ML)], cerebral amyloid angiopathy (CAA) and arteriosclerosis (ART) were investigated in the brains of 137 patients with autopsy-confirmed Alzheimer's disease (AD), in order to better understand the causes of white matter damage in AD, and the contribution of this to the pathogenesis of the disorder.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/14758647' target='_blank' class='pmid-link'>14758647</a>:</span> <span class='sentence-part'>The specifics of disorders in the operative memory due to Alzheimer's disease suggest that cholinergic mechanisms determining the sensory processing differ from those involved in decision-making.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/15172740' target='_blank' class='pmid-link'>15172740</a>:</span> <span class='sentence-part'>Despite very numerous studies on Alzheimer's disease (AD), especially on amyloid plaques and neurofibrillary tangles, little information has been obtained thus on the causes of the disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/15219712' target='_blank' class='pmid-link'>15219712</a>:</span> <span class='sentence-part'>Behavioral assessment of genetically-manipulated mouse lines for Alzheimer's disease has become an important index for determining the efficacy of therapeutic interventions and examining disease pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/15708428' target='_blank' class='pmid-link'>15708428</a>:</span> <span class='sentence-part'>It is well established that oxidative stress plays a key role in the degenerative neuronal death and progression of Alzheimer's disease (AD), although it is not clear if it is the primary triggering event in the pathogenesis of this disorder.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/15723159' target='_blank' class='pmid-link'>15723159</a>:</span> <span class='sentence-part'>The recent elucidation of the inflammatory pathways involved in Alzheimer's disease however, has opened doors for better treatment and prevention by identification of areas of therapeutic intervention that target the cause of the disease rather than the symptoms.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/15964666' target='_blank' class='pmid-link'>15964666</a>:</span> <span class='sentence-part'>Aging represents the main risk factor to develop Alzheimer disease (AD) and protein aggregation constitutes a pathological hallmark thought to be involved in the etiology of this disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/16139258' target='_blank' class='pmid-link'>16139258</a>:</span> <span class='sentence-part'>BACKGROUND: Identification of all susceptibility loci for Alzheimer's disease has been a major goal in resolving the pathogenesis of this disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/16250840' target='_blank' class='pmid-link'>16250840</a>:</span> <span class='sentence-part'>There is extensive evidence that changes in immune system activation accompany the pathological changes of Alzheimer's disease (AD), but a mechanistic understanding of how the immune system actually participates in disease pathogenesis is still largely lacking. Genetic and pharmacological manipulation of these Abeta-depositing transgenic mice is providing some intriguing and unexpected insights into the role of innate and adaptive immune mechanisms in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/16396232' target='_blank' class='pmid-link'>16396232</a>:</span> <span class='sentence-part'>During the past 20 years, research on AD has increased the knowledge of the physiopathological mechanisms leading to the disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/16471078' target='_blank' class='pmid-link'>16471078</a>:</span> <span class='sentence-part'>The overlap between cerebrovascular disease and Alzheimer disease produces a disorder that might be amenable to therapeutic approaches based on either mechanism.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/16472207' target='_blank' class='pmid-link'>16472207</a>:</span> <span class='sentence-part'>Most investigators studying the underlying cause of AD have focused on amyloid-beta (Abeta) such that the Amyloid Cascade Hypothesis is the predominant mechanism thought to be responsible for the disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/16624449' target='_blank' class='pmid-link'>16624449</a>:</span> <span class='sentence-part'>Besides the genetic, biochemical and neuropathological analogies between Down's syndrome (DS) and Alzheimer's disease (AD), there is ample evidence of the involvement of oxidative stress (OS) in the pathogenesis of both disorders.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/16752360' target='_blank' class='pmid-link'>16752360</a>:</span> <span class='sentence-part'>These data suggest that ABCA2 may exert population-dependent effects on the genetic risk for sporadic AD and support a role of ABC lipid transporters in the pathogenesis of this disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/16782202' target='_blank' class='pmid-link'>16782202</a>:</span> <span class='sentence-part'>Lack of an adequate animal model for Alzheimer's disease (AD) has limited an understanding of the pathogenesis of the disease and the development of therapeutic agents targeting key pathophysiological processes.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/16914877' target='_blank' class='pmid-link'>16914877</a>:</span> <span class='sentence-part'>For Alzheimer's disease (AD), the classical pathology is now known for quite some time; however, the disease pathogenesis has eluded our understanding for a complete century.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/16999991' target='_blank' class='pmid-link'>16999991</a>:</span> <span class='sentence-part'>Autophagic vacuoles also accumulate abnormally in affected neurons of several major neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease, where they have been linked to various aspects of disease pathogenesis including neuronal cell death.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17119296' target='_blank' class='pmid-link'>17119296</a>:</span> <span class='sentence-part'>Although the causes of AD remain still unknown, it seems that certain environmental factors may be involved in the etiology and pathogenesis of the disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17229880' target='_blank' class='pmid-link'>17229880</a>:</span> <span class='sentence-part'>To determine which hypothesis relates best to Alzheimer disease requires a broader view of disease pathogenesis and is discussed herein.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17245412' target='_blank' class='pmid-link'>17245412</a>:</span> <span class='sentence-part'>The distinct protein aggregates that are found in Alzheimer's, Parkinson's, Huntington's and prion diseases seem to cause these disorders.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17305591' target='_blank' class='pmid-link'>17305591</a>:</span> <span class='sentence-part'>There is considerable evidence showing that oxidative damage is one of the earliest neuronal and pathological changes of Alzheimer disease and many, if not all, of the etiological and pathological causes of the disease are related, directly or indirectly, to free radical production and oxidative damage.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17556794' target='_blank' class='pmid-link'>17556794</a>:</span> <span class='sentence-part'>It is accepted that amyloid beta (A beta) peptides are responsible for the etiopathology of AD, but the precise signaling pathways leading to the disease have not been elucidated.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17557921' target='_blank' class='pmid-link'>17557921</a>:</span> <span class='sentence-part'>Statins are reported to be beneficial in treating a multitude of disorders including dementia due to Alzheimer disease (AD) and vascular dementia (VaD) with varying, yet-to-be determined mechanisms of actions.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17605000' target='_blank' class='pmid-link'>17605000</a>:</span> <span class='sentence-part'>Oxidative stress is one of the earliest events of Alzheimer disease (AD), with implications as an important mediator in the onset, progression and pathogenesis of the disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17940659' target='_blank' class='pmid-link'>17940659</a>:</span> <span class='sentence-part'>With respect to Alzheimer's disease, several proteins involved in the etiology of the disease, including tau, neurofilaments, beta-amyloid precursor protein, and synaptosomal proteins are GlcNAcylated in normal brain.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17981707' target='_blank' class='pmid-link'>17981707</a>:</span> <span class='sentence-part'>The neurobiological links between the renin-angiotensin system and Alzheimer's disease have been investigated and become a source of interest in the pathogenesis of the disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17986152' target='_blank' class='pmid-link'>17986152</a>:</span> <span class='sentence-part'>Alterations in lipid molecular species in the brain induced by neurodegenerative diseases, such as Alzheimer's disease (AD) could provide fundamental clues to disease pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/1814411' target='_blank' class='pmid-link'>1814411</a>:</span> <span class='sentence-part'>In Alzheimer's disease, we found all ganglio-series gangliosides (GM1, GD1a, GD1b, GT1b) to be decreased in regions (temporal and frontal cortex and nucleus basalis of Meynert) involved in pathogenesis of disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/18245893' target='_blank' class='pmid-link'>18245893</a>:</span> <span class='sentence-part'>The impact of genotype of apoE, a major vitamin K transporter, on ostepporosis as well as Alzheimer disease and atherosclerosis, raises a question whether vitamin K is involved in the pathogenesis of these diseases.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/18289026' target='_blank' class='pmid-link'>18289026</a>:</span> <span class='sentence-part'>Alzheimer disease and the role of free radicals in the pathogenesis of the disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/18302763' target='_blank' class='pmid-link'>18302763</a>:</span> <span class='sentence-part'>Explorations of IL-1's role in chronic neurodegenerative disease have mainly focused on Alzheimer disease (AD), where indirect evidence has implicated it in disease pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/18378224' target='_blank' class='pmid-link'>18378224</a>:</span> <span class='sentence-part'>We postulate that a combination of diet, lifestyle, vascular, genetic, and amyloid related factors, which enhance each other's contribution in the onset and course of Alzheimer's disease, will be more likely the cause of the disease instead of one sole mechanism.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/18629638' target='_blank' class='pmid-link'>18629638</a>:</span> <span class='sentence-part'>Alzheimer's and Parkinson's diseases or Friedreich ataxia are neurological diseases sharing, as a common denominator, production of abnormal proteins, mitochondrial dysfunction and oxidative stress, which contribute to the pathogenesis of these so called \protein conformational diseases\.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/1877089' target='_blank' class='pmid-link'>1877089</a>:</span> <span class='sentence-part'>Molecular dissection of the neuropathology of AD has provided insight into the pathogenesis of this disease and has defined areas where investigation may prove useful in elucidating the cause of this disorder and suggest new treatments.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/18855662' target='_blank' class='pmid-link'>18855662</a>:</span> <span class='sentence-part'>Recent studies have suggested that abnormal hyperphosphorylation of tau in the brain plays a vital role in the molecular pathogenesis of AD and in neurodegeneration. Furthermore, several therapeutic strategies for treating AD on the basis of the important role of tau hyperphosphorylation in the pathogenesis of the disease are described.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/1927686' target='_blank' class='pmid-link'>1927686</a>:</span> <span class='sentence-part'>Metabolic abnormalities of the neocortices in late-stage AD correlate with regional densities of neurofibrillary tangles but not of senile plaques post mortem, suggesting that tangle formation is important in disease pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/19288120' target='_blank' class='pmid-link'>19288120</a>:</span> <span class='sentence-part'>Studies conducted on arguably the earliest stage of AD, MCI, may elucidate the mechanism(s) leading to AD pathogenesis by identifying early markers of the disease, and to develop therapeutic strategies to slow or prevent the progression of AD. Further, Abeta models of AD strongly support the notion that oxidative stress induced by Abeta may be a driving force in AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/19424834' target='_blank' class='pmid-link'>19424834</a>:</span> <span class='sentence-part'>Murine models that mimic the neuropathology of Alzheimer's disease (AD) have the potential to provide insight into the pathogenesis of the disease and lead to new strategies for the therapeutic management of afflicted patients.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/19746990' target='_blank' class='pmid-link'>19746990</a>:</span> <span class='sentence-part'>Our results provide further evidence for the capacity of proteomics applications to identify conserved sets of disease-specific proteins in AD, to enhance our understanding of disease pathogenesis, and to deliver new candidates for the development of effective therapies for this, and other, devastating neurodegenerative disorders.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20021415' target='_blank' class='pmid-link'>20021415</a>:</span> <span class='sentence-part'>Here we provide further characterization of a genomic-based, amyloid precursor protein yeast artificial chromosome transgenic mouse model of AD, R1.40, that makes few assumptions regarding disease pathogenesis to study the relationship between brain pathology and altered behavior.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20049724' target='_blank' class='pmid-link'>20049724</a>:</span> <span class='sentence-part'>Surrogate markers for the Alzheimer disease (AD)-associated 42-amino acid form of amyloid-beta (Abeta42) have been sought because they may aid in the diagnosis of AD and for clarification of disease pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20054780' target='_blank' class='pmid-link'>20054780</a>:</span> <span class='sentence-part'>Such a conclusion has implications both for the diagnosis of AD and in studies of disease pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20064547' target='_blank' class='pmid-link'>20064547</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) and age-related cataract, disorders characterized by protein aggregation causing late-onset disease, both involve oxidative stress.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20157260' target='_blank' class='pmid-link'>20157260</a>:</span> <span class='sentence-part'>The present study was aimed to investigate neuropathological changes in AbetaPP/PS1 transgenic mice (Tg), as a model of Alzheimer's disease, subjected to supplementary iron administration in a critical postnatal period, in order to reveal the interaction of genetic and environmental risk factors in the pathogenesis of the disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20308790' target='_blank' class='pmid-link'>20308790</a>:</span> <span class='sentence-part'>Circulating angiogenic cells and Alzheimer's disease: contribution of the bone marrow to the pathogenesis of the disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20431570' target='_blank' class='pmid-link'>20431570</a>:</span> <span class='sentence-part'>Among these, strategies targeting the production and clearance of the amyloid-beta peptide - a cardinal feature of Alzheimer's disease that is thought to be important in disease pathogenesis - are the most advanced.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20471965' target='_blank' class='pmid-link'>20471965</a>:</span> <span class='sentence-part'>Transgenic models of AD are a promising tool in understanding the underlying mechanisms and cause of disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20497615' target='_blank' class='pmid-link'>20497615</a>:</span> <span class='sentence-part'>Neuropathological assessment using molecular biology and immunohistochemistry, homogeneous definitions, harmonized interlaboratory methods, and assessment standards can identify 54 to 97% of AD cases and can eliminate 62 to 100% of nondemented subjects, but only between 8 and 42% of non-AD dementias, without, however, being able to clarify the etiology of most of these disorders.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20558146' target='_blank' class='pmid-link'>20558146</a>:</span> <span class='sentence-part'>Transgenic models of AD are a promising tool in understanding the underlying mechanisms and cause of disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20608291' target='_blank' class='pmid-link'>20608291</a>:</span> <span class='sentence-part'>Based on this viewpoint, this review article emphasizes that the morphological changes to small blood vessels in the brain with Alzheimer's disease convey crucial information and clues for solving the underlying mechanism that causes the disease. The atrophy of the brain with Alzheimer's disease is considered to be caused by the amyloid angiopathy of small blood vessels and the degeneration of capillaries and vascular feet.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20676620' target='_blank' class='pmid-link'>20676620</a>:</span> <span class='sentence-part'>Models of disease or the response of cellular networks to pharmacological compounds can be studied in vitro, allowing one to investigate pathologies, such as cardiac arrhythmias, memory impairment due to Alzheimer's disease, or vision impairment caused by ganglion cell degeneration in the retina.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20840725' target='_blank' class='pmid-link'>20840725</a>:</span> <span class='sentence-part'>The global pathway crosstalk network and the clusters of relevant pathways of AD provide evidence of cooperativity among pathways for potential pathogenesis of the neuron complex disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20936705' target='_blank' class='pmid-link'>20936705</a>:</span> <span class='sentence-part'>The wheat germ agglutinin-fractionated proteome of subjects with Alzheimer's disease and mild cognitive impairment hippocampus and inferior parietal lobule: Implications for disease pathogenesis and progression.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21091946' target='_blank' class='pmid-link'>21091946</a>:</span> <span class='sentence-part'>The identification of disease-causing mutations in Alzheimer's disease has contributed greatly to the understanding of the pathogenesis of this disease. The amyloid-beta (Abeta) peptide has come into focus and is believed to be central to the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21150306' target='_blank' class='pmid-link'>21150306</a>:</span> <span class='sentence-part'>These diseases, including Morbus Alzheimer, Parkinson disease and Transmissible Spongiform Encephalopathies (TSEs)--also termed prion disorders--afflict a substantial proportion of the human population and as such the etiology and pathogenesis of these diseases has been the focus of mounting research.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21439035' target='_blank' class='pmid-link'>21439035</a>:</span> <span class='sentence-part'>Although the idea that vascular defects are present in AD and may be important in disease pathogenesis was suggested over 25 years ago, little work has focused on an active role for cerebrovascular mechanisms in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/2149746' target='_blank' class='pmid-link'>2149746</a>:</span> <span class='sentence-part'>These results suggest that Alzheimer's disease may be an heterogeneous disorder and that a modification on the catalytic activity of hexokinase may play a role in the pathogenesis of the disease in at least a subgroup of patients.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/2184091' target='_blank' class='pmid-link'>2184091</a>:</span> <span class='sentence-part'>Recent linkage findings for psychiatric disorders, in particular schizophrenia, manic-depression, and Alzheimer disease, have raised a number of important conceptual issues regarding the genetic etiology of these diseases, as well as the appropriate interpretation of linkage results in studying complex diseases.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21902668' target='_blank' class='pmid-link'>21902668</a>:</span> <span class='sentence-part'>The origins of the sporadic cases of AD are still not known but there is evidence for a role of epigenetics in the etiology of the disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22079091' target='_blank' class='pmid-link'>22079091</a>:</span> <span class='sentence-part'>Furthermore, endocytic abnormalities have been identified in cases of Alzheimer's disease (AD), however, the relevance of these changes to the aetiology of the disease remains unclear.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22178988' target='_blank' class='pmid-link'>22178988</a>:</span> <span class='sentence-part'>Our data point to common deficits in the insulin-signaling pathway in both neurodegenerative diseases and support the idea that AD may cause disorders outside the higher CNS.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22251135' target='_blank' class='pmid-link'>22251135</a>:</span> <span class='sentence-part'>In Alzheimer's disease, for example, astrocytes may contribute to the etiology of this disorder.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22374313' target='_blank' class='pmid-link'>22374313</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) is the most common form of dementia among older people and the pathogenesis of this disease is associated with oxidative stress.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22458501' target='_blank' class='pmid-link'>22458501</a>:</span> <span class='sentence-part'>EXPERT OPINION: The use of transgenic mouse models that recapitulate various aspects of AD has expanded our knowledge and understanding of disease pathogenesis immensely.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22784036' target='_blank' class='pmid-link'>22784036</a>:</span> <span class='sentence-part'>Autosomal dominant Alzheimer's disease has a predictable age at onset and provides an opportunity to determine the sequence and magnitude of pathologic changes that culminate in symptomatic disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22795785' target='_blank' class='pmid-link'>22795785</a>:</span> <span class='sentence-part'>These data suggest that although the characteristic features of AD appear later in life, hypoxemia in the prenatal stage may contribute to the pathogenesis of the disease, supporting the notion that environmental factors can trigger or aggravate AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22805236' target='_blank' class='pmid-link'>22805236</a>:</span> <span class='sentence-part'>These findings suggest that bepridil is a plausible therapeutic candidate in AD or stroke owing to its multifunctional role in key cellular events that are relevant for the pathogenesis of these diseases.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22815194' target='_blank' class='pmid-link'>22815194</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) poses a huge challenge for society and health care worldwide as molecular pathogenesis of the disease is poorly understood and curative treatment does not exist.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22922141' target='_blank' class='pmid-link'>22922141</a>:</span> <span class='sentence-part'>The research conducted on animal models of Alzheimer's disease (AD) has provided valuable information about the pathogenesis of this disease and associated behavioral and cognitive deficits as well as the disease-associated anatomical and histopathological lesions of the brain. [Selected mice models based on APP, MAPT and presenilin gene mutations in research on the pathogenesis of Alzheimer's disease].</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23036020' target='_blank' class='pmid-link'>23036020</a>:</span> <span class='sentence-part'>However, therapeutic approaches in neurological diseases such as AD, including those for BM-MSCs, are increasingly centered on the potential for prophylactic therapy in pro-dromal states where the underlying cause of the disease is apparent but functional deficits are not.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23104637' target='_blank' class='pmid-link'>23104637</a>:</span> <span class='sentence-part'>The molecular basis of Alzheimer's disease has not been clearly established, but disruption of brain metal ion homeostasis, particularly copper and zinc, might be closely involved in the pathogenesis of this disease and its characteristic beta-amyloid neuropathological features.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23395747' target='_blank' class='pmid-link'>23395747</a>:</span> <span class='sentence-part'>This review focuses on the role of Zn(II) and Cu(II) in AD, and revisits the amyloid cascade hypothesis demonstrating the possible roles of Zn(II) and Cu(II) in the disease pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23546882' target='_blank' class='pmid-link'>23546882</a>:</span> <span class='sentence-part'>Amyloid beta-peptide (Abeta) accumulating in the brain of Alzheimer disease (AD) patients is believed to be the main pathophysiologcal cause of the disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23604855' target='_blank' class='pmid-link'>23604855</a>:</span> <span class='sentence-part'>Extensive studies of AD have yet to result in a generally accepted hypothesis on the pathogenesis of the disorder.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23695007' target='_blank' class='pmid-link'>23695007</a>:</span> <span class='sentence-part'>According to the amyloid hypothesis of Alzheimer's disease (AD), the amyloid beta (Abeta) peptide, as the primary neurotoxic species, plays a key role in the pathogenesis of the disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23834172' target='_blank' class='pmid-link'>23834172</a>:</span> <span class='sentence-part'>The elucidation of the intriguing relationship between oxidative stress and Alzheimer's disease is crucial to understand the pathogenesis of the disease as also to design a suitable drug trial with antioxidants against this condition.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23847532' target='_blank' class='pmid-link'>23847532</a>:</span> <span class='sentence-part'>We suggest that Abeta*56 has a critical role during the earliest phase of AD and might serve as a molecular trigger of the disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23850509' target='_blank' class='pmid-link'>23850509</a>:</span> <span class='sentence-part'>Perturbed cerebral glucose metabolism, an invariant pathophysiological feature of AD, may be a critical contributor to the pathogenesis of this disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24032632' target='_blank' class='pmid-link'>24032632</a>:</span> <span class='sentence-part'>Studies of oxidative damage during the progression of Alzheimer's disease (AD) suggest its central role in disease pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24059309' target='_blank' class='pmid-link'>24059309</a>:</span> <span class='sentence-part'>According to recent studies, there are molecular similarities in the inflammatory pathways involved in both AD and T2DM, which opens a new avenue for researchers with different perspectives to target the cause of these diseases rather than their obvious symptoms.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24059311' target='_blank' class='pmid-link'>24059311</a>:</span> <span class='sentence-part'>Although a number of risk factors have been postulated that may trigger the development of AD, the root cause of this disease is still a matter of debate.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24059319' target='_blank' class='pmid-link'>24059319</a>:</span> <span class='sentence-part'>In this review, we provide evidence for the link between T2D and AD, highlighting the critical role of insulin in the pathogenesis of these diseases, and we provide information on the genes that might be involved in the interplay between these two disorders.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24124693' target='_blank' class='pmid-link'>24124693</a>:</span> <span class='sentence-part'>Extensive research into the genetic etiology of AD has yielded knowledge of some genetic factors that are causative and other genetic factors that increase risk for disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24190781' target='_blank' class='pmid-link'>24190781</a>:</span> <span class='sentence-part'>Over the past 3 decades, advances in the understanding of the biology of AD have led to a somewhat unified hypothesis of disease pathogenesis that emphasizes the precipitating role of beta amyloid protein.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24198785' target='_blank' class='pmid-link'>24198785</a>:</span> <span class='sentence-part'>A change in the normal tau protein phosphorylation is also characteristic of AD, which contributes to the pathogenesis of the disease and is useful in early diagnosis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24204258' target='_blank' class='pmid-link'>24204258</a>:</span> <span class='sentence-part'>Once thought to be unique to these diseases, this mechanism is now recognized as a ubiquitous means of information transfer in biological systems, including other protein misfolding disorders such as those causing Alzheimer's and Parkinson's diseases.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24486820' target='_blank' class='pmid-link'>24486820</a>:</span> <span class='sentence-part'>Three points of interest lie in considering how Alzheimer, and more significantly Perusini, struggled to throw light on the cause of this devastating disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24737939' target='_blank' class='pmid-link'>24737939</a>:</span> <span class='sentence-part'>Because there are only a few therapeutic strategies against Alzheimer's disease, we need to understand the pathogenesis of this disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24778618' target='_blank' class='pmid-link'>24778618</a>:</span> <span class='sentence-part'>The fact that alterations in SUMO/deSUMOylation equilibrium occur from the early phases of AD suggests that global posttranslational modifications may play an important role in the mechanisms underlying disease pathogenesis, thus providing potential targets for pharmacological interventions.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24852227' target='_blank' class='pmid-link'>24852227</a>:</span> <span class='sentence-part'>We review the genetics, epidemiology and pathology of sporadic AD and give an updated account of what is currently known about the molecular pathogenesis of the disease. The amyloid beta (Abeta) hypothesis posits that cerebral beta-amyloidosis is a critical early event in AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24951455' target='_blank' class='pmid-link'>24951455</a>:</span> <span class='sentence-part'>Alzheimer's disease risk genes and mechanisms of disease pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25080056' target='_blank' class='pmid-link'>25080056</a>:</span> <span class='sentence-part'>The development of a cure for Alzheimer's disease (AD) has been impeded by an inability to pinpoint the root cause of this disorder.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25120477' target='_blank' class='pmid-link'>25120477</a>:</span> <span class='sentence-part'>Several lines of research are focused on understanding AD pathophysiology, and although the etiology of the disease remains a matter of intense debate, increased brain levels of amyloid-beta (Abeta) appear to be a critical event in triggering a wide range of molecular alterations leading to AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25225492' target='_blank' class='pmid-link'>25225492</a>:</span> <span class='sentence-part'>Diseases once considered constrained to a limited range of organ systems, e.g., central neurodegenerative disorders such as Alzheimer's disease (AD), Parkinson's disease (PD), and Huntington' disease (HD), the role of multiple central and peripheral organ systems in the etiology of such diseases is now widely accepted.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25516763' target='_blank' class='pmid-link'>25516763</a>:</span> <span class='sentence-part'>Investigations on environmental factors implicated in AD are scarce and the etiology of the disease remains up to now obscure.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/2554169' target='_blank' class='pmid-link'>2554169</a>:</span> <span class='sentence-part'>Young provides an excellent discussion of the alterations in excitatory amino acid transmitter systems that accompany Alzheimer's disease, and the interesting possibility that excitotoxicity may participate in disease pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25597552' target='_blank' class='pmid-link'>25597552</a>:</span> <span class='sentence-part'>CONCLUSIONS: The mini-KSCAr is an efficient instrument for the diagnosis of DSM-5 major and mild NCD due to possible AD in a specialized psychogeriatric setting, and its utility is greater than that of the MMSE and the CDT. An investigation of the efficiency of the mini-Kingston standardized cognitive assessment-revised in classifying patients according to DSM-5 major and mild neurocognitive disorders due to possible Alzheimer's disease. Medical history, psychiatric and physical status, basic and instrumental activities of daily living, as well as scores on the Cambridge cognitive examination-revised (CAMCOG-R), and the clinical dementia rating (CDR) scale were used to establish DSM-5 diagnoses of major or mild neurocognitive disorders (NCD) due to possible AD or no cognitive decline. BACKGROUND: The aim of this study was to examine the efficiency of the mini-Kingston standardized cognitive assessment-revised (mini-KSCAr) in classifying patients according to DSM-5 major and mild neurocognitive disorders (NCD) due to possible Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25680928' target='_blank' class='pmid-link'>25680928</a>:</span> <span class='sentence-part'>Neurodegenerative disorders such as Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS) are characterized by neuronal impairment that leads to disease-specific changes in the neuronal proteins.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25792373' target='_blank' class='pmid-link'>25792373</a>:</span> <span class='sentence-part'>Despite a causative link between diabetes and AD, general molecular mechanisms underlying pathogenesis of these disorders are still far from being understood.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25847999' target='_blank' class='pmid-link'>25847999</a>:</span> <span class='sentence-part'>These findings suggest that Edaravone holds a promise as a therapeutic agent for AD by targeting multiple key pathways of the disease pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25954942' target='_blank' class='pmid-link'>25954942</a>:</span> <span class='sentence-part'>Vitamin D and neurocognitive disorder due to Alzheimer's disease: A review of the literature. AD is the sixth leading cause of death in the United States and the only 1 among the top 10 that cannot be prevented, cured, or even slowed.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26236550' target='_blank' class='pmid-link'>26236550</a>:</span> <span class='sentence-part'>The review, therefore, emphasizes the importance of AD related risk factors, especially those with metabolic implications, identified from various epidemiological studies, in providing clues to the pathogenesis of this complex disorder.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26396519' target='_blank' class='pmid-link'>26396519</a>:</span> <span class='sentence-part'>In our review, the specific disease is dementia caused by Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26398935' target='_blank' class='pmid-link'>26398935</a>:</span> <span class='sentence-part'>Animal models of familial juvenile onset of Alzheimer's disease (AD) often fail to produce diverse pathological features of the disease by modification of single gene mutations that are responsible for the disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26401704' target='_blank' class='pmid-link'>26401704</a>:</span> <span class='sentence-part'>New therapeutic strategies in Alzheimer's disease (AD) are focused on targeting amyloid-beta (Abeta) to modify the underlying cause of the disease rather than just the symptoms.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26470401' target='_blank' class='pmid-link'>26470401</a>:</span> <span class='sentence-part'>Vitamin D and neurocognitive disorder due to   Alzheimer's disease: A review of the literature. AD is the sixth leading cause of death in the United States and the only 1 among the top 10 that cannot be prevented, cured, or even slowed.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26499250' target='_blank' class='pmid-link'>26499250</a>:</span> <span class='sentence-part'>Chinese older adults (aged 60 to 90 years) with mild neurocognitive disorder due to Alzheimer's disease (DSM-5 criteria) would be randomized into a 4-week intervention of either tDCS-working memory (DCS-WM), tDCS-control cognitive training (DCS-CC), and sham tDCS-working memory (WM-CD) groups. Would transcranial direct current stimulation (tDCS) enhance the effects of working memory training in older adults with mild neurocognitive disorder due to Alzheimer's disease: study protocol for a randomized controlled trial.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26567746' target='_blank' class='pmid-link'>26567746</a>:</span> <span class='sentence-part'>Neuroinflammation in Alzheimer's disease has been identified as major contributor to disease pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26639971' target='_blank' class='pmid-link'>26639971</a>:</span> <span class='sentence-part'>Although the neuropathological characteristics of AD have been known for decades, the molecular mechanisms causing the disease are still under investigation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26733416' target='_blank' class='pmid-link'>26733416</a>:</span> <span class='sentence-part'>The level of RPS23RG1 mRNA is significantly lower in the brains of AD compared to non-AD patients, suggesting its potential role in the pathogenesis of the disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26741695' target='_blank' class='pmid-link'>26741695</a>:</span> <span class='sentence-part'>METHODS: 36 adults with NCD due to Alzheimer's disease (NCD-AD), 31 adults with NCD due to vascular disease (NCD-vascular) and 137 healthy controls were recruited.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26756385' target='_blank' class='pmid-link'>26756385</a>:</span> <span class='sentence-part'>Alzheimer disease (AD) is the most frequent cause of major neurocognitive disorders with a huge economical and medical burden.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26801191' target='_blank' class='pmid-link'>26801191</a>:</span> <span class='sentence-part'>A reduction in glucose transporters at the blood-brain barrier that occurs before the onset of the main pathophysiological changes and symptoms of Alzheimer's disease is a potential causative effect in the vascular hypothesis of the disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/2690095' target='_blank' class='pmid-link'>2690095</a>:</span> <span class='sentence-part'>Clinical research in Alzheimer's disease (AD) is complicated by inadequate understanding of the etiology and pathogenesis of the disorder, lack of good animal models to predict potentially useful compounds, and methodological issues such as the need for new diagnostic tools and validated assessment criteria.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26907663' target='_blank' class='pmid-link'>26907663</a>:</span> <span class='sentence-part'>Response to the Letter from Lu et al, \Utility of Montreal Cognitive Assessment (Hong Kong Version) in the Diagnosis of Mild Neurocognitive Disorders (NCD): NCD Due to Alzheimer Disease (NCD-AD) and NCD Due to Vascular Disease (NCD-Vascular)\.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27058526' target='_blank' class='pmid-link'>27058526</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) is the major causative disease of dementia and is characterized pathologically by the accumulation of senile plaques (SPs) and neurofibrillary tangles (NFTs) in the brain. Although genetic studies show that beta-amyloid protein (Abeta), the major component of SPs, is the key factor underlying AD pathogenesis, it remains unclear why advanced age often leads to AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27100611' target='_blank' class='pmid-link'>27100611</a>:</span> <span class='sentence-part'>While histological changes in microglia have long been recognized as a pathological feature of Alzheimer's disease (AD), recent genetic association studies have also strongly implicated microglia in the etiology of the disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27414695' target='_blank' class='pmid-link'>27414695</a>:</span> <span class='sentence-part'>Dementias are disorders that affect memory and intellectual functioning, and are caused primarily by Alzheimer's disease and vascular disorders (multi-infarct dementia).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27498879' target='_blank' class='pmid-link'>27498879</a>:</span> <span class='sentence-part'>Dementia with Lewy bodies shares clinical and pathological features with both Parkinson's disease and Alzheimer's disease so it is therefore likely that it also has similar pathogenic mechanisms leading to disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27514990' target='_blank' class='pmid-link'>27514990</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) is one of the most prevalent neurodegenerative diseases, yet current therapeutic treatments are inadequate due to a complex disease pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27628303' target='_blank' class='pmid-link'>27628303</a>:</span> <span class='sentence-part'>Understanding how epigenetic dysregulation in the brainstem contributes to AD susceptibility could be of pivotal importance for understanding the etiology of the disease and for the development of novel diagnostic and therapeutic strategies.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27943641' target='_blank' class='pmid-link'>27943641</a>:</span> <span class='sentence-part'>With the gradual aging of the world's population, leading to increased prevalence of AD, and the substantial cost of care for those afflicted, identifying the genetic causes of disease represents a critical effort in identifying therapeutic targets.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28228716' target='_blank' class='pmid-link'>28228716</a>:</span> <span class='sentence-part'>Our results suggest that BMP9 may be a promising candidate for treating AD by targeting multiple key pathways in the disease pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28294067' target='_blank' class='pmid-link'>28294067</a>:</span> <span class='sentence-part'>Preventive and therapeutic approaches to AD in the context of an infectious etiology of the disease are also discussed.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/2836376' target='_blank' class='pmid-link'>2836376</a>:</span> <span class='sentence-part'>The voluminous data on Alzheimer's disease raise intriguing possibilities about the key event in the pathogenesis of the disease, but further investigation is necessary to identify the event conclusively.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28364127' target='_blank' class='pmid-link'>28364127</a>:</span> <span class='sentence-part'>A flanker test was conducted in 31 adults with NCD due to vascular disease (NCD-vascular), 36 patients with NCD due to Alzheimer's disease (NCD-AD), and 137 healthy controls.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28516241' target='_blank' class='pmid-link'>28516241</a>:</span> <span class='sentence-part'>It is now widely known that inflammation plays an important role in the development of AD, a role that is not only a response to the surrounding pathological environment, but rather seems to be strongly implicated in the aetiology of the disease as indicated by the genetic studies.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28527207' target='_blank' class='pmid-link'>28527207</a>:</span> <span class='sentence-part'>OBJECTIVE: We aimed to investigate the IPS with two types of measurements in the patients with NCD due to vascular disease (NCD-vascular) and NCD due to Alzheimer's disease (NCD-AD), and examine the associations between IPS measures and morphometric features.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28680398' target='_blank' class='pmid-link'>28680398</a>:</span> <span class='sentence-part'>Notably, loss-of-function mutations of either DAP12 or TREM2 result in a disorder known as Nasu-Hakola disease (NHD); and mutations of these genes have been associated with the risk for Alzheimer's disease (AD), suggesting that TREM2 and DAP12 may regulate common signaling pathways in the disease pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28739984' target='_blank' class='pmid-link'>28739984</a>:</span> <span class='sentence-part'>Clinical trials for AD are now moving toward these earlier stages of the disease, targeting MCI due to AD and preclinical AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28829364' target='_blank' class='pmid-link'>28829364</a>:</span> <span class='sentence-part'>While there is no cure for AD, pharmacological approaches to alleviate symptoms and target underlying causes of the disease have been developed, albeit with limited success.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28947385' target='_blank' class='pmid-link'>28947385</a>:</span> <span class='sentence-part'>Although the continuous investigations about AD have been made in recent decades, the pathogenesis of this disease is still not definitely confirmed.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29109429' target='_blank' class='pmid-link'>29109429</a>:</span> <span class='sentence-part'>Disturbances in calcium homeostasis have been observed in various cellular and animal models of AD and are proposed to underlie the pathogenesis of the disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29151989' target='_blank' class='pmid-link'>29151989</a>:</span> <span class='sentence-part'>Key messages: Human/mouse chimeric models using iPSCs to study AD offer much promise in better replicating AD pathology and can be further exploited to elucidate disease pathogenesis with regards to the neuroinflammation hypothesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29206067' target='_blank' class='pmid-link'>29206067</a>:</span> <span class='sentence-part'>In AD, oligomeric Abeta42 species is widely thought to be a major contributor to the disease pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29228201' target='_blank' class='pmid-link'>29228201</a>:</span> <span class='sentence-part'>The evolution of Alzheimer's disease tauopathy in cognitively unimpaired individuals needs to be examined to better understand disease pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29492246' target='_blank' class='pmid-link'>29492246</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) is the most common cause of major neurocognitive disorders worldwide.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29551631' target='_blank' class='pmid-link'>29551631</a>:</span> <span class='sentence-part'>Mitochondrial dysfunction has been identified as an early event in AD pathogenesis and is reflected by reduced metabolism, disruption of Ca2+ homeostasis, and increased levels of reactive oxygen species, lipid peroxidation, and apoptosis. Although an accumulation of brain amyloid-beta (Abeta) peptide and hyperphosphorylated tau protein have been implicated in the pathogenesis of AD, the etiology of the disease remains unclear.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29552692' target='_blank' class='pmid-link'>29552692</a>:</span> <span class='sentence-part'>Hyperhomocysteinemia is a trigger for many diseases, such as atherosclerosis, congestive heart failure, age-related macular degeneration, Alzheimer's disease and hearing loss.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29630139' target='_blank' class='pmid-link'>29630139</a>:</span> <span class='sentence-part'>The dominant theory of the?AD development is amyloid cascade?hypothesis, but at the same time, important?in the etiology of this disease is?the overphosphorylation of tau protein.?</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29660940' target='_blank' class='pmid-link'>29660940</a>:</span> <span class='sentence-part'>The research community is yet to decipher why the ApoE4 variant pre-disposes to AD, and how aging causes the disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29689726' target='_blank' class='pmid-link'>29689726</a>:</span> <span class='sentence-part'>METHODS: We included 62 patients with mild or major NCDs due to pure AD (with positive CSF biomarker assays), and 174 patients (from the GRECogVASC cohort) with pure VCI.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29745345' target='_blank' class='pmid-link'>29745345</a>:</span> <span class='sentence-part'>Till date, there is no cure for AD, but the pathogenesis of the disease could be delayed by the use of natural antioxidants.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29856605' target='_blank' class='pmid-link'>29856605</a>:</span> <span class='sentence-part'>Amyloid plaque formation constitutes one of the main pathological hallmarks of Alzheimer's disease (AD) and is suggested to be a critical factor driving disease pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30033062' target='_blank' class='pmid-link'>30033062</a>:</span> <span class='sentence-part'>TREM2 is a transmembrane receptor expressed in cells of the myeloid lineage, and its association with Alzheimer's disease supports the involvement of immune and inflammatory pathways in the cause of the disease, rather than as a consequence of the disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30040725' target='_blank' class='pmid-link'>30040725</a>:</span> <span class='sentence-part'>Although considerable progress has been made to elucidate the pathogenesis of AD, the specific causes of the disease remain highly unknown.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30136680' target='_blank' class='pmid-link'>30136680</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) is the most common form of dementia in the older population, however, the precise cause of the disease is unknown.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30315452' target='_blank' class='pmid-link'>30315452</a>:</span> <span class='sentence-part'>Lack of a satisfactory animal model for Alzheimer's disease (AD) has limited the reach progress of the pathogenesis of the disease and of therapeutic agents aiming to important pathophysiological points. Animal Model of Aluminum-Induced Alzheimer's Disease. In this chapter, we analyzed the research status of animal model of aluminum-induced Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30340518' target='_blank' class='pmid-link'>30340518</a>:</span> <span class='sentence-part'>Despite considerable progress in the understanding of the pathophysiology of AD, the precise molecular mechanisms that cause the disease remain elusive.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30415068' target='_blank' class='pmid-link'>30415068</a>:</span> <span class='sentence-part'>Being the most common type of dementia, AD is studied extensively; however, the data concerning changes in neurogenesis in the pathogenesis of this disease are inconsistent.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30445661' target='_blank' class='pmid-link'>30445661</a>:</span> <span class='sentence-part'>Despite its prevalence, only five therapies are currently approved for AD, all dealing with the symptoms rather than the underlying causes of the disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30465785' target='_blank' class='pmid-link'>30465785</a>:</span> <span class='sentence-part'>As a new starting point for studying AD, genetic and genomic investigations consistently strive to discover causative variants that are related to disease pathophysiology.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30521994' target='_blank' class='pmid-link'>30521994</a>:</span> <span class='sentence-part'>The aim of the present study was to investigate whether ebselen (1-10 mg/kg), a multifunctional selenoorganic compound, ameliorates memory impairment, hippocampal oxidative stress, apoptosis and cell proliferation in a mouse model of sporadic AD induced by icv STZ (3 mg/kg, 1 MUl/min). The drug discovery to treat AD consists to develop compounds able to act in multiple molecular targets involved in the pathogenesis of the disease and the repositioning of old drugs for new application. In conclusion, the multifunctional selenoorganic compound ebselen was effective to reverse memory impairment, hippocampal oxidative stress and apoptosis in a mouse model of sporadic AD induced by icv STZ.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30609547' target='_blank' class='pmid-link'>30609547</a>:</span> <span class='sentence-part'>Aluminum ions, as a kind of non-essential element, show a negative impact on plants growth and contribute to diseases caused by nervous breakdown like Alzheimer's disease and Parkinson's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30632506' target='_blank' class='pmid-link'>30632506</a>:</span> <span class='sentence-part'>Mutations of beta-amyloid precursor protein alter the consequence of Alzheimer's disease pathogenesis. Approximately 25 mutations in beta-amyloid precursor protein (APP) are pathogenic and cause autosomal dominant Alzheimer's disease. Therefore, investigating the mechanism of APP mutation on Alzheimer's disease may help understanding of disease pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30741678' target='_blank' class='pmid-link'>30741678</a>:</span> <span class='sentence-part'>Air pollution is a risk factor for the development of AD and as the number of Americans with AD continues to grow without a cure, we need to focus on preventable, early causes of this fatal disease and intervene appropriately.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30760863' target='_blank' class='pmid-link'>30760863</a>:</span> <span class='sentence-part'>It seems reasonable to hypothesize that the amyloid cascade is intimately involved in AD, in parallel with disease pathogenesis, but that removal of toxic Abeta is insufficient for an effective disease modification.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30819626' target='_blank' class='pmid-link'>30819626</a>:</span> <span class='sentence-part'>LINKAGE TO OTHER MAJOR THEORIES: Our hypothesis may link previous theories to establish a bidirectional relationship between sleep disorders and AD, which may finally form a new schematic mechanism to understand the disease pathogenesis and disease progression.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30877738' target='_blank' class='pmid-link'>30877738</a>:</span> <span class='sentence-part'>Because of its severity, AD has been the subject of extensive studies that address the pathogenesis of the disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30932886' target='_blank' class='pmid-link'>30932886</a>:</span> <span class='sentence-part'>Furthermore, the fact that osteoporosis and Alzheimer's disease are two common age-related disorders raises the possibility that these two organ systems are interconnected in terms of disease pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31030513' target='_blank' class='pmid-link'>31030513</a>:</span> <span class='sentence-part'>The enzyme is overexpressed in several types of cancer and Alzheimer's disease, and its genetic defect causes different incurable disorders.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31122236' target='_blank' class='pmid-link'>31122236</a>:</span> <span class='sentence-part'>This suggest that the threapy should not base on a single cause of Alzheimer's disease but rather a number of different pathways that lead to the disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31332445' target='_blank' class='pmid-link'>31332445</a>:</span> <span class='sentence-part'>The failure of recent clinical trials in Alzheimer's disease has highlighted the need for the development of a more complete understanding of the pathogenesis of the disorder and also a belief that therapies may only work if given very early in the disease process before overt symptoms occur.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31403949' target='_blank' class='pmid-link'>31403949</a>:</span> <span class='sentence-part'>These findings suggest that EDA possesses clinical and pathological benefits for AD with CCH in the present mouse model and has a potential as a therapeutic agent for AD with CCH via targeting multiple key pathways of the disease pathogenesis. The hallmarks of AD including amyloid-beta (Abeta)/phosphorylated tau (pTau) and pathology-related events such as neural oxidative stress and neuroinflammation play critical roles in pathogenesis of AD with CCH.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31577960' target='_blank' class='pmid-link'>31577960</a>:</span> <span class='sentence-part'>In the last few years the views about the drivers of AD have been changing and nowadays it is believed that neuroinflammation takes center stage in disease pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31771153' target='_blank' class='pmid-link'>31771153</a>:</span> <span class='sentence-part'>Hypoxia is a common feature of neurodegenerative diseases, including Alzheimer's disease that may be responsible for disease pathogenesis and progression.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32065096' target='_blank' class='pmid-link'>32065096</a>:</span> <span class='sentence-part'>OBJECTIVE: Thus, revealing the interplay between AD and major depression may provide novel insights into the pathogenesis of these diseases.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32292421' target='_blank' class='pmid-link'>32292421</a>:</span> <span class='sentence-part'>This process is well documented in Alzheimer's disease (AD), where it may participate in the etiology of the disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32390857' target='_blank' class='pmid-link'>32390857</a>:</span> <span class='sentence-part'>The data suggest that a 40-Hz light flicker can ameliorate AD-associated circadian rhythm disorders, presenting a new type of therapeutic treatment for rhythm disorders caused by AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32592177' target='_blank' class='pmid-link'>32592177</a>:</span> <span class='sentence-part'>The discovery that neuron-specific sodium pump activity is impaired in AD and other neurodegenerative diseases such as Parkinson's disease has suggested a role for the sodium pump in the pathogenesis of these diseases.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32625049' target='_blank' class='pmid-link'>32625049</a>:</span> <span class='sentence-part'>The expression of miR-29 family is significantly reduced in AD, suggesting a part for the family members in pathogenesis of the disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32719612' target='_blank' class='pmid-link'>32719612</a>:</span> <span class='sentence-part'>Despite a large improvement in understanding the pathogenesis of AD, the etiology of this disorder remains still unclear, and no current treatment is able to prevent, slow, or stop its progression.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32727580' target='_blank' class='pmid-link'>32727580</a>:</span> <span class='sentence-part'>Phosphorylated Abeta peptides in human Down syndrome brain and different Alzheimer's-like mouse models.The deposition of neurotoxic amyloid-beta (Abeta) peptides in extracellular plaques in the brain parenchyma is one of the most prominent neuropathological features of Alzheimer's disease (AD), and considered to be closely related to the pathogenesis of this disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32955528' target='_blank' class='pmid-link'>32955528</a>:</span> <span class='sentence-part'>Unfortunately, both effective diagnosis and treatment for AD remain elusive, probably owing to the complicated and uncertain etiology of the disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32958234' target='_blank' class='pmid-link'>32958234</a>:</span> <span class='sentence-part'>Following this view, part of the recent scientific literature has generated a new reading frame for AD pathophysiology, based on the application of the prion paradigm to the amyloid cascade hypothesis in an attempt to definitely explain the key events causing the disease and inducing its occurrence under different clinical phenotypes.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33035604' target='_blank' class='pmid-link'>33035604</a>:</span> <span class='sentence-part'>While senile plaques and neurofibrillary tangles have been proposed as the principal histopathologic hallmarks of AD, the exact etiology of this disease is still far from being clearly understood.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33078674' target='_blank' class='pmid-link'>33078674</a>:</span> <span class='sentence-part'>Results demonstrated that both AD and control participants generated more self-statements in the odour condition than in the odor-free condition, especially psychological self-statements.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33178313' target='_blank' class='pmid-link'>33178313</a>:</span> <span class='sentence-part'>Acorus tatarinowii     (AT) is widely used in the treatment of Alzheimer disease, epilepsy, depression, and stroke, which leads to disorders of consciousness disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33228179' target='_blank' class='pmid-link'>33228179</a>:</span> <span class='sentence-part'>Aging is the major factor contributing to AD; however, the initial cause that triggers the disease is yet unknown.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33384577' target='_blank' class='pmid-link'>33384577</a>:</span> <span class='sentence-part'>Using the APPswe/PS1dE9 (APP/PS1) mouse model of Alzheimer's disease, we utilized the Morris water maze spatial learning paradigm to systematically evaluate mild behavioral deficits that occur during the early stages of disease pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33642365' target='_blank' class='pmid-link'>33642365</a>:</span> <span class='sentence-part'>In this review, we briefly examine fragile X syndrome, amyotrophic lateral sclerosis, Alzheimer's disease, and spinal muscular atrophy, with a focus on disease pathogenesis with regard to local mRNA translation and axon transport, suggesting possible treatment directions.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33673244' target='_blank' class='pmid-link'>33673244</a>:</span> <span class='sentence-part'>Thus, Al     3+       should be considered as an important factor, alongside the known characteristic hallmarks of AD, in the development and aetiology of the disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34161823' target='_blank' class='pmid-link'>34161823</a>:</span> <span class='sentence-part'>While the detailed mechanism of the pathogenesis of AD is still unknown, evidence suggests that mitochondrial dysfunction likely plays a fundamental role in the pathogenesis of this disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34200581' target='_blank' class='pmid-link'>34200581</a>:</span> <span class='sentence-part'>Although the sporadic form of Alzheimer's disease (AD) is the prevalent form, the cellular events underlying the disease pathogenesis have not been fully characterized.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34481234' target='_blank' class='pmid-link'>34481234</a>:</span> <span class='sentence-part'>In the classical model for the etiology of AD, amyloid-beta (Abeta)-an APP derivative and hyperphosphorylated tau form aggregates in the brain that underlie the pathogenesis of the disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34589757' target='_blank' class='pmid-link'>34589757</a>:</span> <span class='sentence-part'>Although tauopathies, such as Alzheimer's disease and Frontotemporal dementia, are common amongst the ageing population, current effective treatment options are scarce, primarily due to the incomplete understanding of disease pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34657885' target='_blank' class='pmid-link'>34657885</a>:</span> <span class='sentence-part'>BACKGROUND: Mild cognitive impairment (MCI) is a heterogeneous condition and MCI patients are at increased risk of progression to dementia due to Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34765631' target='_blank' class='pmid-link'>34765631</a>:</span> <span class='sentence-part'>Neurodegenerative disorders, such as Parkinson's and Alzheimer's disease, are claimed to be of major concern causing a significant disease burden worldwide.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34842276' target='_blank' class='pmid-link'>34842276</a>:</span> <span class='sentence-part'>Our results support a common molecular basis for initiation of the pathological processes leading to both early and late onset forms of Alzheimer's disease and illustrate the utility of zebrafish and of knock-in, single EOfAD mutation models for understanding the causes of this disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35346005' target='_blank' class='pmid-link'>35346005</a>:</span> <span class='sentence-part'>The two important hallmarks of AD are the appearance of plaques and tangles of amyloid beta (Abeta) and tau proteins, respectively, in the brain based on the etiology of the disease including cholinergic impairment, metal dyshomeostasis, oxidative stress, and degradation of neurotransmitters.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35555555' target='_blank' class='pmid-link'>35555555</a>:</span> <span class='sentence-part'>Although it remains unclear what primarily triggers and drives the progression of AD, different lines of investigation point out to a central role of oligomeric Abeta conformations for the disease pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35710783' target='_blank' class='pmid-link'>35710783</a>:</span> <span class='sentence-part'>This accumulation may occur years before the clinical symptoms but it has not been elucidated if this accumulation is the cause or the consequence of AD. The most accepted hypothesis in Alzheimer's disease (AD) is the amyloid cascade which establishes that Abeta accumulation may induce the disease development.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35805958' target='_blank' class='pmid-link'>35805958</a>:</span> <span class='sentence-part'>Role of Impaired Mitochondrial Dynamics Processes in the Pathogenesis of Alzheimer's Disease. This review highlights aspects of altered mitochondrial dynamics in AD that may contribute to the etiology of this debilitating condition.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35832342' target='_blank' class='pmid-link'>35832342</a>:</span> <span class='sentence-part'>Several reports have shown that it has promising potential in the prevention and treatment of AD due to its significant antioxidative, anti-inflammatory, and antiapoptotic properties along with several other mechanisms that target the altered signaling pathways due to the disease pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35965800' target='_blank' class='pmid-link'>35965800</a>:</span> <span class='sentence-part'>Conclusions: Using a deep CNN and iterated RF architecture, we showed that brain image stratification is a promising means for evaluating AD, and examining the underlying etiology of the disease, by applying computer and medical images to achieve the early auxiliary diagnosis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35986296' target='_blank' class='pmid-link'>35986296</a>:</span> <span class='sentence-part'>CONCLUSIONS: The reciprocal effects of amyloid deposition and systemic infectious burden may lead to a vicious cycle fueling Alzheimer's disease pathogenesis. The infectious theory linked various infectious agents with the development of AD, raising the possibility that they serve as etiological causes of the disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36073854' target='_blank' class='pmid-link'>36073854</a>:</span> <span class='sentence-part'>Innumerable changes have been linked to the pathology of AD; however, there remains much discord regarding which might be the initial cause of the disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36324230' target='_blank' class='pmid-link'>36324230</a>:</span> <span class='sentence-part'>Alzheimer's disease and related dementias: From risk factors to disease pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36399267' target='_blank' class='pmid-link'>36399267</a>:</span> <span class='sentence-part'>For the last decade, human models of AD using induced pluripotent stem cells (iPSCs) have emerged as a powerful way to understand disease pathogenesis in relevant human cell types.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36469008' target='_blank' class='pmid-link'>36469008</a>:</span> <span class='sentence-part'>Our hypothesis may establish a linkage between the cerebellum and AD, thereby potentially providing new perspectives on the pathogenesis of the disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36552984' target='_blank' class='pmid-link'>36552984</a>:</span> <span class='sentence-part'>Herein, we provide a comprehensive review on Alzheimer's disease pathophysiology to provide a better understanding of disease pathogenesis hypotheses and decipher the role of genetic and epigenetic factors in disease development and progression.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36671568' target='_blank' class='pmid-link'>36671568</a>:</span> <span class='sentence-part'>Although growing evidence demonstrates that AD is a significant comorbidity of T2D, and there is a ~1.4-2-fold increase in the risk of developing AD among T2D patients, the involvement of possible common triggers in the pathogenesis of these two diseases remains largely unknown.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37158125' target='_blank' class='pmid-link'>37158125</a>:</span> <span class='sentence-part'>Emerging evidence suggests that abnormalities in ER/mitochondrial brain functions and dysregulation of Ca     2+       homeostasis are neuropathological hallmarks of neurological disorders like Alzheimer's disease, but little evidence is available to demonstrate their relationship to disease pathogenesis and therapeutic approaches.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37163849' target='_blank' class='pmid-link'>37163849</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) is emerging as a serious problem with the rapid aging of the population, but due to the unclear cause of the disease and the absence of therapy, appropriate preventive measures are the next best thing.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37366656' target='_blank' class='pmid-link'>37366656</a>:</span> <span class='sentence-part'>In the elderly, a debilitating condition known as dementia, which is a major health concern, is caused by Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37395272' target='_blank' class='pmid-link'>37395272</a>:</span> <span class='sentence-part'>Clinically diverse neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, frontotemporal lobar degeneration, and amyotrophic lateral sclerosis, exhibit unique and disease-specific biochemical protein signatures and abnormal protein depositions that often correlate with disease pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37452088' target='_blank' class='pmid-link'>37452088</a>:</span> <span class='sentence-part'>While our understanding of the molecular biology of Alzheimer's disease (AD) has grown, the etiology of the disease, especially the involvement of peripheral infection, remains a challenge.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37476485' target='_blank' class='pmid-link'>37476485</a>:</span> <span class='sentence-part'>The output showed no difference between the patterns of AD-like disorder induction.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37580797' target='_blank' class='pmid-link'>37580797</a>:</span> <span class='sentence-part'>Understanding this biology will ensure that people who have Down syndrome access the most appropriate Alzheimer's disease therapeutics and moreover will provide unique insight into disease pathogenesis more broadly.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37631373' target='_blank' class='pmid-link'>37631373</a>:</span> <span class='sentence-part'>The etiology and pathogenesis of Alzheimer's disease are multifactorial, so one of the treatment strategies is the development of the drugs that affect several targets associated with the pathogenesis of the disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37654709' target='_blank' class='pmid-link'>37654709</a>:</span> <span class='sentence-part'>Conclusion: Patients with MCI due to AD may have SEP disorders, and this new method based on dynamic evaluation of SEP will provide a novel human-computer interaction and intelligent early warning method for home and community screening of MCI due to AD. Extracted fingertip interaction digital biomarkers were used to assess participants' SEP disorders, ultimately enabling intelligent diagnosis of MCI due to AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37848007' target='_blank' class='pmid-link'>37848007</a>:</span> <span class='sentence-part'>The purpose of our study is to explore the genetic linkage between AD and MS through bioinformatic analysis, providing new insights into the shared signatures and possible pathogenesis of two diseases.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37855293' target='_blank' class='pmid-link'>37855293</a>:</span> <span class='sentence-part'>Although studies on the discovery of amyloid beta (Abeta) and tau (the essential elements of plaques and tangles in AD) have shed light on the molecular pathological processes of AD, the exact cause of the condition is still largely unknown.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37875373' target='_blank' class='pmid-link'>37875373</a>:</span> <span class='sentence-part'>CONCLUSIONS: These findings suggest that sodium benzoate may exert its influence on important pathways associated with AD, thus contributing to the improvement in the pathogenesis of the disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/38064104' target='_blank' class='pmid-link'>38064104</a>:</span> <span class='sentence-part'>Even though a century has passed since the discovery of AD, the exact cause of the disease still remains unknown. Since dysregulation of this kinase affects all the major characteristic features of the disease, such as tau phosphorylation, amyloid formation, memory, and synaptic function, it is thought to be a major player in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/38300883' target='_blank' class='pmid-link'>38300883</a>:</span> <span class='sentence-part'>BACKGROUND: Despite the number of people living with Alzheimer disease (AD), awareness of the early stages of this condition, including mild cognitive impairment due to AD-which poses management challenges-continues to be low.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/38357597' target='_blank' class='pmid-link'>38357597</a>:</span> <span class='sentence-part'>Additionally, the concept of entropy was used to detect the disorder of proteasome system, it was discovered that entropy is down-regulated continually with AD progression against system chaos caused by AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/38473858' target='_blank' class='pmid-link'>38473858</a>:</span> <span class='sentence-part'>Alzheimer's disease is a neurodegenerative condition characterized by a gradual onset and progressive deterioration, making it the primary cause of dementia, although the exact cause of the disease remains elusive.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/38623383' target='_blank' class='pmid-link'>38623383</a>:</span> <span class='sentence-part'>The molecular links between DS and AD shed insights into the underlying causes of both diseases and highlight potential therapeutic targets.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/7582040' target='_blank' class='pmid-link'>7582040</a>:</span> <span class='sentence-part'>The genes identified by studying inherited forms of Alzheimer's disease are now being used to understand the initiating steps in the pathogenesis of the disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/7583683' target='_blank' class='pmid-link'>7583683</a>:</span> <span class='sentence-part'>Cerebrospinal fluid (CSF) biochemical markers for Alzheimer's disease (AD) would be of great value, both to improve clinical diagnostic accuracy and to increase our knowledge of the pathogenesis of the disorder.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/7653697' target='_blank' class='pmid-link'>7653697</a>:</span> <span class='sentence-part'>CONCLUSIONS: Paraventricular CRH neurons in Alzheimer's disease and depression are hyperactivated, and this hyperactivation may contribute to the etiology of these disorders.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/7877576' target='_blank' class='pmid-link'>7877576</a>:</span> <span class='sentence-part'>There's no cure yet for Alzheimer's, but researchers are narrowing in on possible causes of the disease and identifying patients who may be predisposed to developing it.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/7967720' target='_blank' class='pmid-link'>7967720</a>:</span> <span class='sentence-part'>Senile plaques (SP) are the most characteristic neuropathologic lesions of Alzheimer's disease (AD) and studies of plaque cortical distribution, density, and morphology may lead to new information about the origin and pathogenesis of this disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/8090716' target='_blank' class='pmid-link'>8090716</a>:</span> <span class='sentence-part'>As an example, a homoplasmic, Caucasian, tRNA(Gln) mutation at nucleotide pair (np) 4336 has been observed in 5% of Alzheimer disease and Parkinson disease patients and may contribute to the multifactorial etiology of these diseases.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/8239278' target='_blank' class='pmid-link'>8239278</a>:</span> <span class='sentence-part'>Studies of autosomal-dominant forms of AD have established the central role of APP in the pathogenesis of the disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/8446172' target='_blank' class='pmid-link'>8446172</a>:</span> <span class='sentence-part'>Structural alterations of APP are implicated in the pathogenesis of Alzheimer's disease, but it is not known how they cause the disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/8528377' target='_blank' class='pmid-link'>8528377</a>:</span> <span class='sentence-part'>This case confirms that AD may result in prominent white matter disease caused by incomplete infarction or demyelination.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/8861021' target='_blank' class='pmid-link'>8861021</a>:</span> <span class='sentence-part'>Abnormalities of the endosomal-lysosomal system in Alzheimer's disease: relationship to disease pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/8881379' target='_blank' class='pmid-link'>8881379</a>:</span> <span class='sentence-part'>This review reports the different genetic factors that have been identified either as risk factor for Alzheimer's disease (AD) or directly causing the disease. The second part describes the mutations responsible for early-onset autosomal dominant AD found in three different genes.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/9520006' target='_blank' class='pmid-link'>9520006</a>:</span> <span class='sentence-part'>Among subjects diagnosed during life as having DAT or incipient DAT, only 7% were found to have a neuropathologic disorder other than AD causing their dementia.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/9546791' target='_blank' class='pmid-link'>9546791</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) is characterized by the accumulation of cerebral plaques composed of 40- and 42-amino acid beta-amyloid (Abeta) peptides, and autosomal dominant forms of AD appear to cause disease by promoting brain Abeta accumulation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/9749615' target='_blank' class='pmid-link'>9749615</a>:</span> <span class='sentence-part'>Recently, alpha-synuclein was shown to be a structural component of the filaments in Lewy bodies (LBs) of Parkinson's disease (PD), dementia with LBs (DLB) as well as the LB variant of Alzheimer's disease, and this suggests that alpha-synuclein could play a mechanistic role in the pathogenesis of these disorders.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/9990552' target='_blank' class='pmid-link'>9990552</a>:</span> <span class='sentence-part'>Four different genes have now been associated with AD and are providing insights into the pathogenesis of the disease.</span></div></div>
<div class='streamlined-assertion'><div class='streamlined-header sticky-relation-header'><span class='label-text'>Subject:</span> <strong>Alzheimers</strong> <span class='label-text'>Subject CUI:</span> <strong>C0002395</strong> â†’ <span class='label-text predicate-text'>CAUSES</span> â†’ <span class='label-text'>Object:</span> <strong>Evaluation</strong> <span class='label-text'>Object CUI:</span> <strong>C0220825</strong></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32134942' target='_blank' class='pmid-link'>32134942</a>:</span> <span class='sentence-part'>There is a limited evaluation of an independent linguistic battery for early diagnosis of Mild Cognitive Impairment due to Alzheimer's disease (MCI-AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32956392' target='_blank' class='pmid-link'>32956392</a>:</span> <span class='sentence-part'>Evaluation of choroidal thickness in prodromal Alzheimer's disease defined by amyloid PET.OBJECTIVE: To assess and compare the involvement of choroidal thickness (CT) in patients with mild cognitive impairment (MCI) and dementia due to Alzheimer's disease (AD) defined by amyloid PET and healthy controls (HC).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34029274' target='_blank' class='pmid-link'>34029274</a>:</span> <span class='sentence-part'>The purpose of this investigation was to determine the capacity for new rapid image and number naming tests and other measures of visual pathway structure and function to distinguish individuals with MCI due to AD from those with normal aging and cognition.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35523023' target='_blank' class='pmid-link'>35523023</a>:</span> <span class='sentence-part'>In this work, we report the preliminary evaluation of a self-driven AD multi-class discrimination approach based on a commercial EEG acquisition system using sixteen channels.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36318372' target='_blank' class='pmid-link'>36318372</a>:</span> <span class='sentence-part'>Reports on a significant positive correlation between consumption of carotenoid-rich food and prevention of Alzheimer's disease (AD) led to the investigation of carotenoids for the treatment and prevention of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36372804' target='_blank' class='pmid-link'>36372804</a>:</span> <span class='sentence-part'>Positron emission tomography (PET) offers a great opportunity to visualize AD from diverse perspectives by using radiolabeled agents involved in various pathophysiological processes; PET imaging technique helps to explore the pathomechanisms of AD comprehensively and find out the most appropriate biomarker in each AD phase, leading to a better evaluation of the disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37603693' target='_blank' class='pmid-link'>37603693</a>:</span> <span class='sentence-part'>Evaluation of the NIH Toolbox Odor Identification Test across normal cognition, amnestic mild cognitive impairment, and dementia due to Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37654709' target='_blank' class='pmid-link'>37654709</a>:</span> <span class='sentence-part'>Conclusion: Patients with MCI due to AD may have SEP disorders, and this new method based on dynamic evaluation of SEP will provide a novel human-computer interaction and intelligent early warning method for home and community screening of MCI due to AD. Extracted fingertip interaction digital biomarkers were used to assess participants' SEP disorders, ultimately enabling intelligent diagnosis of MCI due to AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37900942' target='_blank' class='pmid-link'>37900942</a>:</span> <span class='sentence-part'>Although we did not perform extensive histopathological evaluations or measured microtubule stability, our findings show that MSAs can rescue the consequences of AD-like conditions but otherwise be harmful if administered at a prodromal stage of the disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/38251056' target='_blank' class='pmid-link'>38251056</a>:</span> <span class='sentence-part'>Contingent Negative Variation in the Evaluation of Neurocognitive Disorders Due to Possible Alzheimer's Disease.</span></div></div>
<div class='streamlined-assertion'><div class='streamlined-header sticky-relation-header'><span class='label-text'>Subject:</span> <strong>Alzheimers</strong> <span class='label-text'>Subject CUI:</span> <strong>C0002395</strong> â†’ <span class='label-text predicate-text'>CAUSES</span> â†’ <span class='label-text'>Object:</span> <strong>Evaluation_procedure</strong> <span class='label-text'>Object CUI:</span> <strong>C1261322</strong></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32123490' target='_blank' class='pmid-link'>32123490</a>:</span> <span class='sentence-part'>MCLENA-1: A Phase II Clinical Trial for the Assessment of Safety, Tolerability, and Efficacy of Lenalidomide in Patients with Mild Cognitive Impairment Due to Alzheimer's Disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33355065' target='_blank' class='pmid-link'>33355065</a>:</span> <span class='sentence-part'>RESULTS: At latest assessment (mean 2 years) 61 patients had probable MCI with Lewy bodies, 26 possible MCI with Lewy bodies and 57 MCI due to Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33731557' target='_blank' class='pmid-link'>33731557</a>:</span> <span class='sentence-part'>Experimental pain studies using psychophysics can further our understanding of the pain experience in AD, which may lead to improved assessment and management of pain in people living with AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35813951' target='_blank' class='pmid-link'>35813951</a>:</span> <span class='sentence-part'>To comprehensively understand the context and distribution of pathways that contribute to AD, we performed text-mining to generate an exhaustive, systematic assessment of the breadth and diversity of biological pathways within a corpus of 206,324 dementia publication abstracts.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37213535' target='_blank' class='pmid-link'>37213535</a>:</span> <span class='sentence-part'>Validation of the European Cross-Cultural Neuropsychological Test Battery (CNTB) for the assessment of mild cognitive impairment due to Alzheimer's disease and Parkinson's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37355905' target='_blank' class='pmid-link'>37355905</a>:</span> <span class='sentence-part'>Diagnostic Performance of an Eye-Tracking Assisted Visual Inference Language Test in the Assessment of Cognitive Decline due to Alzheimer's Disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37502020' target='_blank' class='pmid-link'>37502020</a>:</span> <span class='sentence-part'>INTRODUCTION: Although many cognitive measures have been developed to assess cognitive decline due to Alzheimer's disease (AD), there is little consensus on optimal measures, leading to varied assessments across research cohorts and clinical trials making it difficult to pool cognitive measures across studies.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37838690' target='_blank' class='pmid-link'>37838690</a>:</span> <span class='sentence-part'>Clinical assessment and biomarkers, together with ML techniques, could prove pivotal in improving diagnostic tools for MCI due to AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/38230722' target='_blank' class='pmid-link'>38230722</a>:</span> <span class='sentence-part'>Future longitudinal studies of population aging, incorporating biomarker assessment to confirm AD diagnoses, are needed to better characterize the course of MCI due to AD and AD dementia.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/38356475' target='_blank' class='pmid-link'>38356475</a>:</span> <span class='sentence-part'>INTRODUCTION: In addition to the accumulation of amyloid plaques and neurofibrillary tangles, the presence of excess neural activity is a pathological hallmark of Alzheimer's disease (AD) and a prognostic indicator for progression of AD pathology and clinical/cognitive worsening in mild cognitive impairment due to Alzheimer's disease (MCI due to AD). The HOPE4MCI study: A randomized double-blind assessment of AGB101 for the treatment of MCI due to AD.</span></div></div>
<div class='streamlined-assertion'><div class='streamlined-header sticky-relation-header'><span class='label-text'>Subject:</span> <strong>Alzheimers</strong> <span class='label-text'>Subject CUI:</span> <strong>C0002395</strong> â†’ <span class='label-text predicate-text'>CAUSES</span> â†’ <span class='label-text'>Object:</span> <strong>Functional_disorder</strong> <span class='label-text'>Object CUI:</span> <strong>C0277785</strong></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/11640946' target='_blank' class='pmid-link'>11640946</a>:</span> <span class='sentence-part'>The novel localization of such a transcriptional activating protein to selectively vulnerable neurons in Alzheimer disease provides compelling evidence for mitotic re-entry as part of the pathogenesis of neuronal dysfunction and death in Alzheimer disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/12451676' target='_blank' class='pmid-link'>12451676</a>:</span> <span class='sentence-part'>Alzheimer's disease(AD) is the most common form of neurodegenerative diseases that causes intellectual dysfunction.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/14675724' target='_blank' class='pmid-link'>14675724</a>:</span> <span class='sentence-part'>The ensuing homeostatic responses to myelin breakdown further increase intracortical toxicity and results in the relentless progression and non-random anatomical distribution of AD lesions that eventually cause neuronal dysfunction and degeneration.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/14970312' target='_blank' class='pmid-link'>14970312</a>:</span> <span class='sentence-part'>The pathogenesis of AD is tightly linked to Abeta deposition and oxidative stress, but it remains unclear as to how these factors result in neuronal dysfunction and death.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/15249195' target='_blank' class='pmid-link'>15249195</a>:</span> <span class='sentence-part'>The calcium hypothesis of Alzheimer's disease (AD) invokes the disruption of calcium signaling as the underlying cause of neuronal dysfunction and ultimately apoptosis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/15950763' target='_blank' class='pmid-link'>15950763</a>:</span> <span class='sentence-part'>The pathogenesis of Alzheimer's disease (AD) is now thought to be tightly linked to Abeta deposition and oxidative stress, but it is still unknown how these factors result in neuronal dysfunction and cell death. Mutations of presenilin 1 (PS1) gene are the causative gene for early onset familial AD (FAD) due to the overproduction and deposition of pathogenic Abeta1-42 peptides.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/16998901' target='_blank' class='pmid-link'>16998901</a>:</span> <span class='sentence-part'>Accumulation of the beta-amyloid peptide (Abeta) in the brain is a major pathological hallmark of Alzheimer's disease (AD), leading to synaptic dysfunction, neuronal death, and memory impairment.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17413025' target='_blank' class='pmid-link'>17413025</a>:</span> <span class='sentence-part'>Then, we will review preliminary findings applying imaging-guided microarray to AD and normal aging, in an attempt to isolate molecular profiles that dissociate the two main causes of age-related hippocampal dysfunction.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17416103' target='_blank' class='pmid-link'>17416103</a>:</span> <span class='sentence-part'>Early caution about the role of tau as a significant factor in neurodegenerative disease, especially Alzheimer's disease, has been superseded by acceptance of its key involvement in pathways which led to cell dysfunction and death.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17908035' target='_blank' class='pmid-link'>17908035</a>:</span> <span class='sentence-part'>These data suggest there is a shift in cholinotrophic molecular events in MCI and early AD which may lead to cell dysfunction and eventual cell death over the course of the disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/18201950' target='_blank' class='pmid-link'>18201950</a>:</span> <span class='sentence-part'>I propose that inflammation and cellular stress associated with aging are key events in the development of AD through the induction of glial dysfunction.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/18480253' target='_blank' class='pmid-link'>18480253</a>:</span> <span class='sentence-part'>Retromer deficiency observed in Alzheimer's disease causes hippocampal dysfunction, neurodegeneration, and Abeta accumulation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/19332976' target='_blank' class='pmid-link'>19332976</a>:</span> <span class='sentence-part'>The causes of cognitive dysfunction range from the devastating effects of Alzheimer's disease (AD) to treatable causes of dysfunction and the normal mild forgetfulness described by many older individuals.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/19350381' target='_blank' class='pmid-link'>19350381</a>:</span> <span class='sentence-part'>Evidence suggests that amyloid-beta (Abeta) protein is a key factor in the pathogenesis of Alzheimer's disease (AD) and it has been recently proposed that mitochondria are involved in the biochemical pathway by which Abeta can lead to neuronal dysfunction.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/19551456' target='_blank' class='pmid-link'>19551456</a>:</span> <span class='sentence-part'>While progressive accumulation of oligomeric amyloid-beta protein (Abeta) has been identified as one of the central toxic events in AD leading to synaptic dysfunction, accumulation of alpha-synuclein (alpha-syn) resulting in the formation of oligomers has been linked to PD. Most of the studies in AD have been focused on investigating the role of Abeta and Tau; however, recent studies suggest that alpha-syn might also play a role in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/19614678' target='_blank' class='pmid-link'>19614678</a>:</span> <span class='sentence-part'>OBJECTIVE: In Alzheimer's disease, toxic soluble and insoluble forms of amyloid beta (Abeta) cause synaptic dysfunction and neuronal loss.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/19774105' target='_blank' class='pmid-link'>19774105</a>:</span> <span class='sentence-part'>Functional impairments in ETS components have been reported in several central nervous system (CNS) diseases, including Alzheimer's disease (AD) and Parkinson's disease (PD); however, it remains largely unknown how the suppression of individual ETS complex function could lead to specific dysfunction in different cell types, resulting in distinct disease phenotypes.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/19839939' target='_blank' class='pmid-link'>19839939</a>:</span> <span class='sentence-part'>These will reveal how key players in the pathogenesis of Alzheimer's disease and frontotemporal dementia, such as the peptide Abeta (amyloid beta) and the protein tau, cause neuronal dysfunction and eventually, neuronal demise.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/19860724' target='_blank' class='pmid-link'>19860724</a>:</span> <span class='sentence-part'>This datum may be of high relevance for a better understanding of Alzheimer's Disease (AD) since molecular, cellular, and animal model studies have revealed that the formation of amyloid beta (Abeta) and other derivatives of the APP are key pathogenic factors in AD, causing mitochondrial dysfunction, free radical generation, oxidative damage, and inflammation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20445057' target='_blank' class='pmid-link'>20445057</a>:</span> <span class='sentence-part'>While Abeta deposition is the most prominent feature of AD, oligomeric forms of Abeta have been implicated as the toxic species inducing the neuronal dysfunction.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20816785' target='_blank' class='pmid-link'>20816785</a>:</span> <span class='sentence-part'>There is strong evidence that intracellular calcium dysregulation plays an important pathological role in Alzheimer's disease, and specifically that beta amyloid may induce increases in intracellular calcium and lead to neuronal cell dysfunction and death.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21219931' target='_blank' class='pmid-link'>21219931</a>:</span> <span class='sentence-part'>Amyloid plaques composed of the 42 amino acid form of amyloid-beta peptide (Abeta42) are a pathological hallmark of Alzheimer's disease (AD), but soluble and intraneuronal Abeta42 are the more proximal causes of synaptic dysfunction and neurotoxicity.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21237171' target='_blank' class='pmid-link'>21237171</a>:</span> <span class='sentence-part'>Mounting evidence points to the soluble oligomers of amyloid beta (Abeta) peptide as important neurotoxic species in Alzheimer's disease, causing synaptic dysfunction and neuronal injury, and finally leading to neuronal death.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21429865' target='_blank' class='pmid-link'>21429865</a>:</span> <span class='sentence-part'>Amyloid-beta accumulation in the brain is thought to be one of the earliest events in Alzheimer's disease, possibly leading to synaptic dysfunction, neurodegeneration and cognitive/functional decline.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21799246' target='_blank' class='pmid-link'>21799246</a>:</span> <span class='sentence-part'>In this article, we evaluate the hypothesis according to which tau deposition in the anterior subhippocampal region during the earliest stages of the most common form of AD, with predominant MTL dysfunction, will lead to dysfunction of neural networks implicated in context-free memory.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22101739' target='_blank' class='pmid-link'>22101739</a>:</span> <span class='sentence-part'>Alzheimer disease (AD) is characterized by chronic neuroinflammation, which may lead to dysfunction in neuronal circuits.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22726800' target='_blank' class='pmid-link'>22726800</a>:</span> <span class='sentence-part'>Amyloid-beta 1-42 accumulation is the major pathogenetic event in Alzheimer's disease (AD), believed to be responsible for synaptic dysfunction and neuronal cell death.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22753410' target='_blank' class='pmid-link'>22753410</a>:</span> <span class='sentence-part'>Swedish Alzheimer mutation induces mitochondrial dysfunction mediated by HSP60 mislocalization of amyloid precursor protein (APP) and beta-amyloid.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22879025' target='_blank' class='pmid-link'>22879025</a>:</span> <span class='sentence-part'>The vascular hypothesis of Alzheimer's disease (AD) considers cerebral hypoperfusion as a primary trigger for neuronal dysfunction.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23011810' target='_blank' class='pmid-link'>23011810</a>:</span> <span class='sentence-part'>The pathology of AD is strongly associated with accumulated misfolding proteins that results in neuronal dysfunction within the brain.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23799536' target='_blank' class='pmid-link'>23799536</a>:</span> <span class='sentence-part'>In Alzheimer's disease, soluble amyloid-beta causes synaptic dysfunction and neuronal loss.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23979025' target='_blank' class='pmid-link'>23979025</a>:</span> <span class='sentence-part'>In Alzheimer's disease (AD), amyloid-beta (Abeta) deposits in the cerebrovasculature can result in neurovascular dysfunction and/or cerebral amyloid angiopathy.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24024140' target='_blank' class='pmid-link'>24024140</a>:</span> <span class='sentence-part'>These data are consistent with a two-hit hypothesis of AD: oxidative stress leads to lipid peroxidation that, in turn, causes oxidative dysfunction of key energy-related complexes in mitochondria, triggering neurodegeneration.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24251395' target='_blank' class='pmid-link'>24251395</a>:</span> <span class='sentence-part'>OBJECTIVE: Preclinical and post-mortem studies suggest that Alzheimer disease (AD) causes cerebrovascular dysfunction, and therefore may enhance susceptibility to cerebrovascular disease (CVD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24251604' target='_blank' class='pmid-link'>24251604</a>:</span> <span class='sentence-part'>With AD, the loss of connectivity should first induce dysfunction in those representational networks with the weakest connectivity.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24715417' target='_blank' class='pmid-link'>24715417</a>:</span> <span class='sentence-part'>Based on lots of medical reports, ER stress in postmortem brains from Alzheimer's disease (AD) patients, animals, and vitro models have indicated that ER dysfunction might work as an important part in causing AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24918635' target='_blank' class='pmid-link'>24918635</a>:</span> <span class='sentence-part'>Deposition of amyloid-beta (Abeta) 1-42, the major component of senile plaques characteristic of Alzheimer disease, affects brain microvascular integrity and causes blood-brain barrier dysfunction, increased angiogenesis, and pericyte degeneration.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24954589' target='_blank' class='pmid-link'>24954589</a>:</span> <span class='sentence-part'>Disbalance of zinc (Zn2+) and copper (Cu2+) ions in the central nervous system is involved in the pathogenesis of numerous neurodegenerative disorders such as multisystem atrophy, amyotrophic lateral sclerosis, Creutzfeldt-Jakob disease, Wilson-Konovalov disease, Alzheimer's disease, and Parkinson's disease. Analysis of the literature suggests that the main factors of AD and PD pathogenesis (oxidative stress, structural disorders and aggregation of proteins, mitochondrial dysfunction, energy deficiency) that initiate a cascade of events resulting finally in the dysfunction of neuronal networks are mediated by the disbalance of Zn2+ and Cu2+.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25230232' target='_blank' class='pmid-link'>25230232</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) is a progressive neurodegenerative disorder, characterized by deposition of amyloid beta, neurofibrillary tangles, astrogliosis and microgliosis, leading to neuronal dysfunction and loss in the brain.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25359615' target='_blank' class='pmid-link'>25359615</a>:</span> <span class='sentence-part'>Abeta oligomers (AbetaOs), the typical cause of AD, lead to mitochondrial dysfunction and neuronal loss.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25552414' target='_blank' class='pmid-link'>25552414</a>:</span> <span class='sentence-part'>A reduction of this enzyme causes neurodegeneration and aggravates the AD features of the 3xTgAD mouse, inducing neuronal dysfunction, cell death and impairing memory and synaptic plasticity.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25710536' target='_blank' class='pmid-link'>25710536</a>:</span> <span class='sentence-part'>Subtle disruptions of APP signaling functions may be major contributors to AD-causing neuronal dysfunction.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25753421' target='_blank' class='pmid-link'>25753421</a>:</span> <span class='sentence-part'>The fact that AD-induced cellular dysfunctions can be avoided by UPS activity at mitochondria has potentially far-reaching pathophysiological implications.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25821477' target='_blank' class='pmid-link'>25821477</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) causes progressive hippocampus dysfunctions leading to the impairment of learning and memory ability and low level of uptake rate of glucose in hippocampus.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26118731' target='_blank' class='pmid-link'>26118731</a>:</span> <span class='sentence-part'>Amongst these, degenerative diseases involving hippocampus like Alzheimer's disease (AD) and temporal lobe epilepsy (TLE) are ranked higher as it is vulnerable to excitotoxicity induced neuronal dysfunction and death resulting in cognitive impairment.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26275910' target='_blank' class='pmid-link'>26275910</a>:</span> <span class='sentence-part'>In a mouse model of AD, C5a-peptide vaccines reduce microglia activation and thus neuroinflammation, which is supposed to lead to reduced neuronal dysfunction and AD symptomatic decline.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26484912' target='_blank' class='pmid-link'>26484912</a>:</span> <span class='sentence-part'>The major symptom of AD is progressive dementia that eventually results in dysfunction of daily life.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26487830' target='_blank' class='pmid-link'>26487830</a>:</span> <span class='sentence-part'>Alzheimer's disease is a progressive neurodegenerative disorder, characterized by deposition of amyloid beta, neurofibrillary tangles, astrogliosis and microgliosis, leading to neuronal dysfunction and loss in the brain.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26529297' target='_blank' class='pmid-link'>26529297</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) is a progressive neurodegenerative disorder, characterized by deposition of amyloid plaques and neurofibrillary tangles, as well as microglial and astroglial activation, and, finally, leading to neuronal dysfunction and death.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27199641' target='_blank' class='pmid-link'>27199641</a>:</span> <span class='sentence-part'>We review current work suggesting that neuronal differentiation is defective in Alzheimer's disease, leading to dysfunction of the dentate gyrus.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27430312' target='_blank' class='pmid-link'>27430312</a>:</span> <span class='sentence-part'>BACKGROUND: Amyloid-beta (Abeta) accumulation is a hallmark of Alzheimer's disease (AD) that can lead to neuronal dysfunction and apoptosis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27748454' target='_blank' class='pmid-link'>27748454</a>:</span> <span class='sentence-part'>This study confirms earlier reports on an association between increased brain iron-burden and risk for neurocognitive dysfunction due to AD, and indicates that disease-progression is conferred by spatial colocalization of brain iron deposits with Abeta-plaques.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27897204' target='_blank' class='pmid-link'>27897204</a>:</span> <span class='sentence-part'>In the mitochondria-mediated vicious cycle of Alzheimer's disease (AD), intracellular amyloid beta (Abeta) induces mitochondrial dysfunction and reactive oxygen species, which further accelerate Abeta accumulation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27910888' target='_blank' class='pmid-link'>27910888</a>:</span> <span class='sentence-part'>In Alzheimer's disease, the microtubule cytoskeleton is compromised, leading to neuronal dysfunction and eventually cell death.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28003750' target='_blank' class='pmid-link'>28003750</a>:</span> <span class='sentence-part'>Group I: normal control group treated with water; Group II: disease control treated with AlCl3 to induce the mimicking AD for 4 successive weeks (SW); Group III: normal control group treated with baicalein (5 mg/kg) for 2 SW followed by combination of baicalein and AlCl3 for 4 SW; Group IV: normal control group treated with baicalein (10 mg/kg) for 2 SW followed by combination of baicalein and AlCl3 for 4 SW; Group V: normal control group treated with rivastigmine (0.3 mg/kg) for 2 SW followed by combination of rivastigmine and AlCl3 for 4 SW. Baicalein improves behavioral dysfunction induced by Alzheimer's disease in rats.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28081713' target='_blank' class='pmid-link'>28081713</a>:</span> <span class='sentence-part'>BACKGROUND: Deposition of aggregated amyloid beta (A?) protein is hallmark of Alzheimer's disease, leading to dysfunction and apoptosis of neurons.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28208063' target='_blank' class='pmid-link'>28208063</a>:</span> <span class='sentence-part'>Data suggest that the contribution of WML to the dysfunction of the cholinergic system in MCI due to AD depends on WML distribution.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28869759' target='_blank' class='pmid-link'>28869759</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) is a neurodegenerative disorder characterized by a progressive deposition of amyloid beta (Abeta) and dysregulation of neurotrophic signaling, causing synaptic dysfunction, loss of memory, and cell death.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28988799' target='_blank' class='pmid-link'>28988799</a>:</span> <span class='sentence-part'>Dysfunction of autophagy and endosomal-lysosomal pathways: Roles in pathogenesis of Down syndrome and Alzheimer's Disease. The same genetic factors that cause or increase AD risk are also direct causes of endosomal-lysosomal dysfunction, underscoring the essential partnership between this dysfunction and APP metabolites in AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29116174' target='_blank' class='pmid-link'>29116174</a>:</span> <span class='sentence-part'>In early stages of Alzheimer's disease (AD), neuronal hyperexcitability leads to network dysfunction observed in cortical regions such as the hippocampus.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29156571' target='_blank' class='pmid-link'>29156571</a>:</span> <span class='sentence-part'>Studies for Improving a Rat Model of Alzheimer's Disease: Icv Administration of Well-Characterized beta-Amyloid 1-42 Oligomers Induce Dysfunction in Spatial Memory.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29274876' target='_blank' class='pmid-link'>29274876</a>:</span> <span class='sentence-part'>Moreover, LC neurodegeneration is not only a consequence of AD, but also drives clinical and pathological manifestations of AD, such as microglial dysregulation, sleep disturbance, cognitive decline, and neurovascular dysfunction.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29388925' target='_blank' class='pmid-link'>29388925</a>:</span> <span class='sentence-part'>The amyloid-beta peptide (Abeta), derived from amyloid precursor protein, is one driver of AD, but how it leads to neuronal dysfunction is not established.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29776894' target='_blank' class='pmid-link'>29776894</a>:</span> <span class='sentence-part'>Amyloid plaques with neurofibrillary tangles are a neuropathological hallmark of AD that produces synaptic dysfunction and culminates later in neuronal loss.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30031108' target='_blank' class='pmid-link'>30031108</a>:</span> <span class='sentence-part'>In Alzheimer's disease (AD), beta-amyloid (Abeta) protein toxicity increases the formation of reactive oxygen species (ROS) and intracellular calcium levels, resulting in neuronal dysfunction, neurodegenerative disorders, and cell death.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30108498' target='_blank' class='pmid-link'>30108498</a>:</span> <span class='sentence-part'>Background: The deposition of beta-sheet rich amyloid in senile plaques is a pathological hallmark of Alzheimer's disease (AD), which is thought to cause neuronal dysfunction.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30166454' target='_blank' class='pmid-link'>30166454</a>:</span> <span class='sentence-part'>Emerging studies implicate Tau as an essential mediator of neuronal atrophy and cognitive impairment in Alzheimer's disease (AD), yet the factors that precipitate Tau dysfunction in AD are poorly understood.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30244163' target='_blank' class='pmid-link'>30244163</a>:</span> <span class='sentence-part'>Consistently, social deficits sometimes represent the first signs of a number of neuropsychiatric disorders including schizophrenia (SCZ), Alzheimer's disease (AD) and major depressive disorder (MDD) which leads to a progressive social dysfunction.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30474638' target='_blank' class='pmid-link'>30474638</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) is a progressive neurodegenerative condition in which aggregated tau and amyloid proteins accumulate in the brain causing neuronal dysfunction which eventually leads to cognitive decline.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/7699466' target='_blank' class='pmid-link'>7699466</a>:</span> <span class='sentence-part'>METHODS: Twelve patients with higher cortical dysfunction due to Alzheimer's disease and 18 age-matched controls were examined.</span></div></div>
<div class='streamlined-assertion'><div class='streamlined-header sticky-relation-header'><span class='label-text'>Subject:</span> <strong>Alzheimers</strong> <span class='label-text'>Subject CUI:</span> <strong>C0002395</strong> â†’ <span class='label-text predicate-text'>CAUSES</span> â†’ <span class='label-text'>Object:</span> <strong>Inflammation</strong> <span class='label-text'>Object CUI:</span> <strong>C0021368</strong></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/12009502' target='_blank' class='pmid-link'>12009502</a>:</span> <span class='sentence-part'>Amyloid-beta protein (Abeta) is implicated in the pathogenesis of Alzheimer's disease because of its neurotoxicity and the ability to trigger local inflammation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/12646202' target='_blank' class='pmid-link'>12646202</a>:</span> <span class='sentence-part'>beta-Amyloid peptide (A beta), a major component of senile plaques, the formation of which is characteristic of Alzheimer's disease (AD), is believed to induce inflammation of the brain mediated by microglia, leading to neuronal cell loss.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/15811602' target='_blank' class='pmid-link'>15811602</a>:</span> <span class='sentence-part'>The major pathological consequence of Alzheimer disease (AD) is accumulation of beta-amyloid (Abeta) peptide fibrillar plaque in the brain and subsequent inflammatory reaction associated with the surrounding cells due to the presence of these aggregates.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17027528' target='_blank' class='pmid-link'>17027528</a>:</span> <span class='sentence-part'>Although the precise molecular and cellular relationship between AD and inflammation remains unclear, interleukins and cytokines might induce activation of signaling pathways leading to futher inflammation and neuronal injury. Epidemiologic data as well as clinical trial evidence suggest that nonsteroidal anti-inflammatory drug (NSAID) use may decrease the incidence of AD, further supporting a role for inflammation in AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20205641' target='_blank' class='pmid-link'>20205641</a>:</span> <span class='sentence-part'>Morbidities of aging and Alzheimer's disease (AD) have been related to defective functions of both T cells and macrophages leading to brain amyloidosis and inflammation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21278785' target='_blank' class='pmid-link'>21278785</a>:</span> <span class='sentence-part'>Furthermore, the dose of evodiamine significantly decreased the expression of IL-1beta, IL-6, TNF-alpha, and COX-2 that were involved in the inflammation due to Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24424131' target='_blank' class='pmid-link'>24424131</a>:</span> <span class='sentence-part'>It plays an important role in rheumatoid arthritis, organ transplant rejection, Alzheimer's disease and also causes inflammation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26827642' target='_blank' class='pmid-link'>26827642</a>:</span> <span class='sentence-part'>CSF YKL-40, a biomarker of glial inflammation, is associated with a cerebral structural signature distinct from that related to p-tau neurodegeneration at the earliest stages of cognitive decline due to AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29883947' target='_blank' class='pmid-link'>29883947</a>:</span> <span class='sentence-part'>In diseases of the central nervous system such as stroke, Alzheimer's disease, and Parkinson's disease, they often cause inflammation or phagocytosis; however, some studies have found that despite the current controversy over M1, M2 polarization could be beneficial.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30282364' target='_blank' class='pmid-link'>30282364</a>:</span> <span class='sentence-part'>The dominant model for Alzheimer's disease (AD) is the amyloid cascade hypothesis, in which the accumulation of excess amyloid-beta (Abeta) leads to inflammation, excess glutamate and intracellular calcium, oxidative stress, tau hyperphosphorylation and tangle formation, neuronal loss, and ultimately dementia.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30314800' target='_blank' class='pmid-link'>30314800</a>:</span> <span class='sentence-part'>In AD, chronic activation of this pathway leads to sustained inflammation and neurodegeneration.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31374883' target='_blank' class='pmid-link'>31374883</a>:</span> <span class='sentence-part'>Biomarkers of inflammation tended to be higher in the MX than in either the AD or VCID, suggesting dual pathology leads to increased inflammation, which could explain accelerated cognitive decline in that group.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32215721' target='_blank' class='pmid-link'>32215721</a>:</span> <span class='sentence-part'>Knock-on effect of periodontitis to the pathogenesis of Alzheimer's disease?BACKGROUND: Alzheimer's disease has chronic inflammatory components, which can be enhanced by systemic immune activation resulting in inflammation or vice versa.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33313759' target='_blank' class='pmid-link'>33313759</a>:</span> <span class='sentence-part'>Conversely, specific systemic inflammatory regulators may be downstream effects of Alzheimer's disease or consequences of common factors causing both inflammation and Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33963669' target='_blank' class='pmid-link'>33963669</a>:</span> <span class='sentence-part'>While screening for natural product scaffolds as potential anti Alzheimer's disease (AD), oxymatrine (OMT) was found to relieve symptoms of AD through diminishing death of neuronal cells caused by microglia induced inflammation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34503373' target='_blank' class='pmid-link'>34503373</a>:</span> <span class='sentence-part'>Blocking the Wnt/beta-catenin pathway increased inflammatory cytokine production in AD-PBMCs and annulled the effects of the FGF23/alpha-Klotho axis on AD-induced cell inflammation. We concluded that the FGF23/alpha-Klotho axis can regulate the AD-induced cell inflammation through the Wnt/beta-catenin pathway.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34620254' target='_blank' class='pmid-link'>34620254</a>:</span> <span class='sentence-part'>However, it is still ambiguous whether this observed inflammation is cause or consequence of AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35166975' target='_blank' class='pmid-link'>35166975</a>:</span> <span class='sentence-part'>This paper aims to highlight the down-stream pathophysiology of noise-induced mental disorders, including hearing loss, annoyance, anxiety, depression, memory loss, and Alzheimer's disease, describing the underlying mechanisms of induction of inflammation and oxidative stress.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36048350' target='_blank' class='pmid-link'>36048350</a>:</span> <span class='sentence-part'>Disturbance of these microRNAs is associated with mitochondrial dysfunction, oxidative damage, inflammation, apolipoprotein E4 (APOE4) pathogenic process, synaptic loss, and cognitive deficits induced by AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37571319' target='_blank' class='pmid-link'>37571319</a>:</span> <span class='sentence-part'>Neuropsychiatric disorders including Alzheimer's disease (AD) may cause gut inflammation and dysbiosis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/38382009' target='_blank' class='pmid-link'>38382009</a>:</span> <span class='sentence-part'>BACKGROUND AND OBJECTIVES: Fine particulate matter (PM     2.5      ) exposure has been found to be associated with Alzheimer disease (AD) and is hypothesized to cause inflammation and oxidative stress in the brain, contributing to neuropathology.</span></div></div>
<div class='streamlined-assertion'><div class='streamlined-header sticky-relation-header'><span class='label-text'>Subject:</span> <strong>Alzheimers</strong> <span class='label-text'>Subject CUI:</span> <strong>C0002395</strong> â†’ <span class='label-text predicate-text'>CAUSES</span> â†’ <span class='label-text'>Object:</span> <strong>Lewy_Body_Disease</strong> <span class='label-text'>Object CUI:</span> <strong>C0752347</strong></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17362834' target='_blank' class='pmid-link'>17362834</a>:</span> <span class='sentence-part'>FINDINGS: Abnormal scans had a mean sensitivity of 77.7% for detecting clinical probable DLB, with specificity of 90.4% for excluding non-DLB dementia, which was predominantly due to Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22118943' target='_blank' class='pmid-link'>22118943</a>:</span> <span class='sentence-part'>Our results suggest a contribution of established AD and PD genes to the genetic etiology of DLB and PDD though to a limited extent. The contribution of both sequence and copy number variants (CNVs) in known AD and PD genes to the genetic etiology of DLB and PDD however is currently unclear.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26405688' target='_blank' class='pmid-link'>26405688</a>:</span> <span class='sentence-part'>Receiver operator characteristic (ROC) curves assessed the ability of LBCRS to differentiate: (a) DLB from Alzheimer's disease (AD); (b) DLB from all dementia, and (c) Mild cognitive impairment (MCI) due to DLB from MCI due to AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30083812' target='_blank' class='pmid-link'>30083812</a>:</span> <span class='sentence-part'>PCA is a clinico-radiological syndrome that is often caused by Alzheimer's disease and other neurodegenerative diseases as Lewy body dementia and corticobasal degeneration.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32236399' target='_blank' class='pmid-link'>32236399</a>:</span> <span class='sentence-part'>Of the remaining subjects, 24 were classified as normal cognition and were asymptomatic, 6 were classified as subjective cognitive decline, and 3 were amyloid-positive (one with pre-clinical AD, one with pre-clinical Lewy-Body Dementia, and one with mild cognitive impairment due to AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32480310' target='_blank' class='pmid-link'>32480310</a>:</span> <span class='sentence-part'>We aimed to investigate the ratio between alpha and theta band power (alpha/theta ratio), as a synoptic index of quantitative EEG (qEEG) slowing-down, in a peculiar group of patients with mild cognitive impairment (MCI) due to an early-stage Lewy body disease (MCI-LBD), as compared to de novo PD patients without cognitive impairment (PD-MOT), to patients with MCI due to Alzheimer's disease (MCI-AD), and to healthy controls (HC).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32636325' target='_blank' class='pmid-link'>32636325</a>:</span> <span class='sentence-part'>To determine whether electroencephalography (EEG) differentiates the prodromal phase of DLB from other causes of mild cognitive impairment (MCI) and whether EEG is predictive for time to conversion from MCI to DLB, we compared EEGs and clinical follow-up of patients with MCI due to DLB with MCI due to Alzheimer's disease (MCI-AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33793069' target='_blank' class='pmid-link'>33793069</a>:</span> <span class='sentence-part'>METHODS: The LBD-MOD was completed in a single-site study in 342 participants: 53 controls, 78 AD, and 110 DLB; 79 mild cognitive impairment due to AD (MCI-AD); and 22 MCI-DLB.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34328531' target='_blank' class='pmid-link'>34328531</a>:</span> <span class='sentence-part'>PURPOSE: The purpose of this study is to develop and validate a 3D deep learning model that predicts the final clinical diagnosis of Alzheimer's disease (AD), dementia with Lewy bodies (DLB), mild cognitive impairment due to Alzheimer's disease (MCI-AD), and cognitively normal (CN) using fluorine 18 fluorodeoxyglucose PET (18F-FDG PET) and compare model's performance to that of multiple expert nuclear medicine physicians' readers.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/8676755' target='_blank' class='pmid-link'>8676755</a>:</span> <span class='sentence-part'>Immunologic features of Alzheimer disease and Parkinson disease suggest the involvement of similar phenomena in Lewy body diseases pathogenesis.</span></div></div>
<div class='streamlined-assertion'><div class='streamlined-header sticky-relation-header'><span class='label-text'>Subject:</span> <strong>Alzheimers</strong> <span class='label-text'>Subject CUI:</span> <strong>C0002395</strong> â†’ <span class='label-text predicate-text'>CAUSES</span> â†’ <span class='label-text'>Object:</span> <strong>Memory_Loss</strong> <span class='label-text'>Object CUI:</span> <strong>C0751295</strong></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/10410180' target='_blank' class='pmid-link'>10410180</a>:</span> <span class='sentence-part'>With the onset of memory loss secondary to Alzheimer disease, she became increasingly anxious and compulsive as a result of a failure to remember.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/11795357' target='_blank' class='pmid-link'>11795357</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) is an irreversible, progressive brain disorder that occurs gradually and results in memory loss, behavior and personality changes, and a decline in cognitive abilities.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/18288928' target='_blank' class='pmid-link'>18288928</a>:</span> <span class='sentence-part'>Alzheimer's Disease (AD) is caused by the deposition of insoluble and toxic amyloid peptides (Abeta) in the brain leading to memory loss and other associated neurodegenerative symptoms.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/19104051' target='_blank' class='pmid-link'>19104051</a>:</span> <span class='sentence-part'>Although defects in Notch have been implicated in memory loss because of Alzheimer's disease, downstream signaling linking Notch to memory have not been determined.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21154880' target='_blank' class='pmid-link'>21154880</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) is an age-related neurodegenerative disorder of the central nervous system resulting in memory loss and dementia.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22044024' target='_blank' class='pmid-link'>22044024</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) is a devastating disorder that leads to memory loss and dementia.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22266017' target='_blank' class='pmid-link'>22266017</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) is a progressive neurodegenerative disease that affects a staggering percentage of the aging population and causes memory loss and cognitive decline.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24304575' target='_blank' class='pmid-link'>24304575</a>:</span> <span class='sentence-part'>Memory loss could be caused by Alzheimer's disease (AD) and vascular dementia (VaD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24365147' target='_blank' class='pmid-link'>24365147</a>:</span> <span class='sentence-part'>Alzheimer's is a neurodegenerative disorder resulting in memory loss and decline in cognitive abilities.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24667360' target='_blank' class='pmid-link'>24667360</a>:</span> <span class='sentence-part'>Therefore, in the present study, the neuroprotective roles of PM and EJ for ameliorating the streptozotocin (STZ) induced AD have been tested in rat model. Therefore, PM and EJ extracts contain cognitive enhancers as well as neuroprotective agents against STZ induced AD. Alzheimer's disease (AD), the most common form of dementia, is characterized by the loss of normal functions of brain cells and neuronal death, ultimately leading to memory loss. Dipeptidyl peptidase-4 inhibition by Pterocarpus marsupium and Eugenia jambolana ameliorates streptozotocin induced Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25281744' target='_blank' class='pmid-link'>25281744</a>:</span> <span class='sentence-part'>Abeta is generated by the proteolytic processing of the amyloid precursor protein (APP), and alterations to this processing can result in Alzheimer disease. Alzheimer disease (AD) is a progressive neurodegenerative disease leading to memory loss.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25752209' target='_blank' class='pmid-link'>25752209</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) is a progressive neurodegenerative disorder leading to memory loss and other functional impairments.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25919992' target='_blank' class='pmid-link'>25919992</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) is a progressive disorder of the brain that leads to memory loss, dementia, and death.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26200391' target='_blank' class='pmid-link'>26200391</a>:</span> <span class='sentence-part'>In Alzheimer's disease (AD), activated microglia invade and surround beta-amyloid plaques, possibly contributing to the aggregation of amyloid beta (Abeta), which affect the survival of neurons and lead to memory loss.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26220908' target='_blank' class='pmid-link'>26220908</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) is a neurodegenerative disorder in which the death of brain cells causes memory loss and cognitive decline, i.e., dementia.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26292618' target='_blank' class='pmid-link'>26292618</a>:</span> <span class='sentence-part'>BACKGROUND: Mild cognitive impairment (MCI) is a clinical transitional stage between normal aging and Alzheimer disease, which leads to memory loss and a reduction in cognitive function.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26325402' target='_blank' class='pmid-link'>26325402</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD), a big cause of memory loss, is a progressive neurodegenerative disorder.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26358038' target='_blank' class='pmid-link'>26358038</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) is a complicated neurodegenerative disease which causes memory loss and dementia.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27414248' target='_blank' class='pmid-link'>27414248</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) is a neurodegenerative disorder in which the death of brain cells leads to memory loss and cognitive decline.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28098452' target='_blank' class='pmid-link'>28098452</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) is the most common form of dementia, in which the death of brain cells causes memory loss and cognitive decline.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28111296' target='_blank' class='pmid-link'>28111296</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) is a well-known cause of memory loss and dementia in elderly people all across the world.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28522119' target='_blank' class='pmid-link'>28522119</a>:</span> <span class='sentence-part'>Furthermore, using optogenetics to stimulate neurons can rescue learning and memory loss caused by AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28677497' target='_blank' class='pmid-link'>28677497</a>:</span> <span class='sentence-part'>BACKGROUND: Alzheimer's disease is a severe neurodegenerative brain disorder, showing severe beta-amyloid depositions in the brain (plaques) and in vessels (cerebral amyloid angiopathy, CAA), tau pathology, neurodegeneration (and loss of acetylcholine), inflammation with reactive astrocytes and microglia and cerebrovascular damage, all resulting in memory loss.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29445429' target='_blank' class='pmid-link'>29445429</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) is a progressive, and often fatal, brain disease that causes neurodegeneration, resulting in memory loss as well as other cognitive and behavioral problems.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29530541' target='_blank' class='pmid-link'>29530541</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) is a progressive neurological disorder in which the death of brain cells causes memory loss and cognitive decline.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29622019' target='_blank' class='pmid-link'>29622019</a>:</span> <span class='sentence-part'>BACKGROUND: Alzheimer's disease (AD), one of the major causes of dementia, is an overwhelming neurodegenerative disease that particularly affects the brain, leading to memory loss and impairment of language and judgment capacity.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29707568' target='_blank' class='pmid-link'>29707568</a>:</span> <span class='sentence-part'>Alzheimer's disease is characterized by the abnormal accumulation of extracellular amyloid-beta plaques and intraneuronal neurofibrillary tangles in brain regions and manifests as a type of dementia in aged individuals that results in memory loss, multiple cognitive abnormalities, and intellectual disabilities that interfere with quality of life.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/8146663' target='_blank' class='pmid-link'>8146663</a>:</span> <span class='sentence-part'>Soluble beta-amyloid induction of Alzheimer's phenotype for human fibroblast K+ channels. In Alzheimer's disease, then, beta-amyloid might alter potassium channels and thus impair neuronal function to produce symptoms such as memory loss by a means other than plaque formation.</span></div></div>
<div class='streamlined-assertion'><div class='streamlined-header sticky-relation-header'><span class='label-text'>Subject:</span> <strong>Alzheimers</strong> <span class='label-text'>Subject CUI:</span> <strong>C0002395</strong> â†’ <span class='label-text predicate-text'>CAUSES</span> â†’ <span class='label-text'>Object:</span> <strong>Neurodegenerative_Disorders</strong> <span class='label-text'>Object CUI:</span> <strong>C0524851</strong></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/10809400' target='_blank' class='pmid-link'>10809400</a>:</span> <span class='sentence-part'>CONCLUSIONS: These findings which are in line with previous results in Alzheimer's disease (Stadelmann et al., 1998) and Parkinson's disease (Banati et al., 1999) suggest that mechanisms distinct from classical apoptosis play a central role in the pathogenesis of PD and related neurodegenerative diseases.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/15262733' target='_blank' class='pmid-link'>15262733</a>:</span> <span class='sentence-part'>CONCLUSION: The lack of familial aggregation of PD and AD does not support the hypothesis of major shared genetic contributions to the etiology of the 2 most common neurodegenerative disorders.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/15533611' target='_blank' class='pmid-link'>15533611</a>:</span> <span class='sentence-part'>Many possible risk factors for Alzheimer's disease (AD) have been investigated, with only a very few showing positive associations and none defining the etiology of the neurodegenerative disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/15935398' target='_blank' class='pmid-link'>15935398</a>:</span> <span class='sentence-part'>We determined the concentrations of free homocysteine (HC) and total HC in the cerebrospinal fluid (CSF) of patients with Alzheimer's disease (AD) or Parkinson's disease (PD) in order to elucidate whether HC is related to the pathogenesis of these neurodegenerative diseases.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/19997871' target='_blank' class='pmid-link'>19997871</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) is a prevalent dementia-causing neurodegenerative disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21045163' target='_blank' class='pmid-link'>21045163</a>:</span> <span class='sentence-part'>Alzheimer disease (AD) is the most common causes of neurodegenerative disorder in the elderly individuals.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21172065' target='_blank' class='pmid-link'>21172065</a>:</span> <span class='sentence-part'>BACKGROUND: Alzheimer's disease (AD) is one of the most frequent cause of neurodegenerative disorder in the elderly.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21834057' target='_blank' class='pmid-link'>21834057</a>:</span> <span class='sentence-part'>The main component of the amyloid plaques found in the brains of those with Alzheimer's disease (AD) is a polymerized form of the beta-amyloid peptide (Abeta) and is considered to play a central role in the pathogenesis of this neurodegenerative disorder.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24687814' target='_blank' class='pmid-link'>24687814</a>:</span> <span class='sentence-part'>Frontotemporal dementia (FTD) is a clinically and pathologically heterogeneous neurodegenerative disease that can result from either frontotemporal lobar degeneration (FTLD) or Alzheimer's disease (AD) pathology.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25079797' target='_blank' class='pmid-link'>25079797</a>:</span> <span class='sentence-part'>More importantly, 205 dysregulated genes in AD blood have been linked to neurological disease, including AD/dementia and Parkinson's disease, and 43 are known to be the causative genes of 42 inherited mental retardation and neurodegenerative diseases.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26402766' target='_blank' class='pmid-link'>26402766</a>:</span> <span class='sentence-part'>Although monocytes and macrophages could serve as new therapeutic targets for treatment of Alzheimer's disease (AD) and aging of the human innate immune system, its role in the pathogenesis of neurodegenerative disorders such as AD are only poorly understood.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26528186' target='_blank' class='pmid-link'>26528186</a>:</span> <span class='sentence-part'>Neurodegenerative diseases such as Alzheimer's disease, Creutzfeldt-Jakob disease (CJD), Parkinson's disease, Huntington's disease, frontotemporal dementia (FTD), and amyotrophic lateral sclerosis (ALS) result from the loss of a specific subsets of neurons, which is closely associated with accumulation and deposition of specific protein aggregates.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27280392' target='_blank' class='pmid-link'>27280392</a>:</span> <span class='sentence-part'>BACKGROUND: Parkinson's disease (PD) is depicted as the most prevailed neurodegenerative disease being secondary to the alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27586004' target='_blank' class='pmid-link'>27586004</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) is a chronic neurodegenerative disease while the ectopic P-granules autophagy protein 5 homolog (EPG5 gene) is highly expressed in human brain and may implicate in the pathogenesis of neurodegenerative disorders.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28251365' target='_blank' class='pmid-link'>28251365</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) is a difficult puzzle to solve, in part because the etiology of this devastating neurodegenerative disorder remains murky.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28839167' target='_blank' class='pmid-link'>28839167</a>:</span> <span class='sentence-part'>The ultra-sensitive IMR assay was applied to detect the plasma tau protein levels of subjects with prevalent neurodegenerative diseases, such as Alzheimer's disease (AD), mild cognitive impairment (MCI) due to AD, Parkinson's disease (PD), frontotemporal dementia (FTD) and vascular dementia (VD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29632940' target='_blank' class='pmid-link'>29632940</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) is the most common cause of neurodegenerative disorder in elderly people, and has become a social problem in aging societies globally.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29687731' target='_blank' class='pmid-link'>29687731</a>:</span> <span class='sentence-part'>Age-related dementias are now a major mortality factor among most human populations in the world, with Alzheimer's disease (AD) being the leading dementia-causing neurodegenerative disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30845903' target='_blank' class='pmid-link'>30845903</a>:</span> <span class='sentence-part'>BACKGROUND: Prodromal Neurodegenerative Disease (ND) due to tauopathies such as Alzheimer's Disease (AD) and Synucleinopathies (SN) such as Parkinson's Disease (PD) and Dementia with Lewy Bodies (DLB) present subtly.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31876280' target='_blank' class='pmid-link'>31876280</a>:</span> <span class='sentence-part'>Advances in the research of molecular factors involved in the onset and progression of Alzheimer's disease, have led to the creation of several pathogenesis concepts of the most common neurodegenerative disease in the world, and amyloid, cholinergic, and neuroinflammatory hypotheses became leading. In this review, based on the latest experimental data on structure-function properties of chemically modified amyloid-beta isoforms, the concept of the origin and the mechanism of action of amyloid-beta with isomerized Asp7 residue, as a molecular agent of Alzheimer's disease pathogenesis, is presented.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32507685' target='_blank' class='pmid-link'>32507685</a>:</span> <span class='sentence-part'>Inhibition of STAT3 phosphorylation attenuates impairments in learning and memory in 5XFAD mice, an animal model of Alzheimer's disease.The pathophysiological roles of astrocytes in the reactive state are thought to have important significance in the pathogenesis of neurodegenerative diseases, including Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32908122' target='_blank' class='pmid-link'>32908122</a>:</span> <span class='sentence-part'>The objective of this review is to discuss the possible molecular mechanisms that contribute to the pathogenesis of neurological diseases in which CHIP has a pivotal role, such as stroke, intracerebral hemorrhage, Alzheimer's disease, Parkinson's disease, and polyglutamine diseases; furthermore, CHIP mutations could also cause neurodegenerative diseases.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33114455' target='_blank' class='pmid-link'>33114455</a>:</span> <span class='sentence-part'>Potential Drug Candidates to Treat TRPC6 Channel Deficiencies in the Pathophysiology of Alzheimer's Disease and Brain Ischemia.Alzheimer's disease and cerebral ischemia are among the many causative neurodegenerative diseases that lead to disabilities in the middle-aged and elderly population.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34072862' target='_blank' class='pmid-link'>34072862</a>:</span> <span class='sentence-part'>After a brief summary of the molecular and cell biology of AD and HD this review covers what is known about the role of these three groups of kinases in the brain and in the pathogenesis of the two neurodegenerative disorders. Alzheimer's disease (AD) is a mostly sporadic brain disorder characterized by cognitive decline resulting from selective neurodegeneration in the hippocampus and cerebral cortex whereas Huntington's disease (HD) is a monogenic inherited disorder characterized by motor abnormalities and psychiatric disturbances resulting from selective neurodegeneration in the striatum.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35434157' target='_blank' class='pmid-link'>35434157</a>:</span> <span class='sentence-part'>Background: Alzheimer's disease (AD) is the main cause of the neurodegenerative disorder, which is not detected unless the cognitive deficits are manifested.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35719134' target='_blank' class='pmid-link'>35719134</a>:</span> <span class='sentence-part'>In the field of neurodegenerative diseases, an example of a digital biomarker-based technology is instrumental activities of daily living (iADL) digital medical application, a predictive biomarker of conversion from mild cognitive impairment (MCI) due to Alzheimer's disease (AD) to dementia due to AD in individuals aged 55 + .</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36579548' target='_blank' class='pmid-link'>36579548</a>:</span> <span class='sentence-part'>Immunosenescence and Aging: Neuroinflammation Is a Prominent Feature of Alzheimer's Disease and Is a Likely Contributor to Neurodegenerative Disease Pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37927338' target='_blank' class='pmid-link'>37927338</a>:</span> <span class='sentence-part'>Controversies surrounding the validity of the toxic proteinopathy theory of Alzheimer's disease have led the scientific community to seek alternative theories in the pathogenesis of neurodegenerative disorders (ND).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/38243562' target='_blank' class='pmid-link'>38243562</a>:</span> <span class='sentence-part'>AD is the most common cause of neurodegenerative disorder in the elderly.</span></div></div>
<div class='streamlined-assertion'><div class='streamlined-header sticky-relation-header'><span class='label-text'>Subject:</span> <strong>Alzheimers</strong> <span class='label-text'>Subject CUI:</span> <strong>C0002395</strong> â†’ <span class='label-text predicate-text'>CAUSES</span> â†’ <span class='label-text'>Object:</span> <strong>Neurofibrillary_Tangles</strong> <span class='label-text'>Object CUI:</span> <strong>C0085400</strong></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/12707087' target='_blank' class='pmid-link'>12707087</a>:</span> <span class='sentence-part'>Unexplained sudden amnesia, postencephalitic Parkinson disease, subacute sclerosing panencephalitis, and Alzheimer disease: does viral synergy produce neurofibrillary tangles?</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/1307688' target='_blank' class='pmid-link'>1307688</a>:</span> <span class='sentence-part'>These patterns closely match the hierarchical topographic distribution of NFT and SP observed in AD, suggesting a commonality in the pathologic processes that lead to NFT and SP in both aging and AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/15265277' target='_blank' class='pmid-link'>15265277</a>:</span> <span class='sentence-part'>The microvasculature plays a crucial role in maintaining brain homeostasis and deterioration of its integrity may have deleterious effects on brain function in AD, possibly leading to neurofibrillary degeneration, plaque formation, and cell loss.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/1614354' target='_blank' class='pmid-link'>1614354</a>:</span> <span class='sentence-part'>Considerable evidence suggests that in Alzheimer's disease, olfactory bulb damage may be a primary factor, causing degeneration and neurofibrillary tangles primarily in neurons connected with this brain area.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17055667' target='_blank' class='pmid-link'>17055667</a>:</span> <span class='sentence-part'>Here I hypothesize that it is chronic infection of human neurons in Alzheimer's disease that produces neurofibrillary tangles by a pathway similar to the chronic SSPE infection tangle pathway.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20188796' target='_blank' class='pmid-link'>20188796</a>:</span> <span class='sentence-part'>GRB-associated binding protein 2 (GAB2) may function as a risk factor of Alzheimer disease (AD) by affecting hyperphosphorylation of tau, causing neurofibrillary tangles.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20679486' target='_blank' class='pmid-link'>20679486</a>:</span> <span class='sentence-part'>Accumulation of tau into neurofibrillary tangles is a pathological consequence of Alzheimer's disease and other tauopathies.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21507528' target='_blank' class='pmid-link'>21507528</a>:</span> <span class='sentence-part'>As with prior studies, our data indicate that the development of neocortical neurofibrillary tangles is the key pathological event that is not observed in pAD cases: Braak stages III or IV pathology are hence not truly a substrate for \intermediate likelihood\ that cognitive impairment is due to Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21630160' target='_blank' class='pmid-link'>21630160</a>:</span> <span class='sentence-part'>Once both of these hits are activated, AD can develop and produce senile plaques and neurofibrillary tangles throughout brain tissue.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21813771' target='_blank' class='pmid-link'>21813771</a>:</span> <span class='sentence-part'>We have previously shown that expression of nonmutated human truncated tau (151-391, 4R), derived from sporadic Alzheimer's disease, induced neurofibrillary degeneration accompanied by microglial and astroglial activation in the brain of transgenic rats.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25963683' target='_blank' class='pmid-link'>25963683</a>:</span> <span class='sentence-part'>Herpes simplex virus-1 has been proposed as potential cause of AD because of its ability to form beta amyloid(Abeta) and neurofibrillary tangles due to tau hyperphosphorylation and action of beta &amp; gamma secretase on amyloid precursor protein(APP) together with genetic association with apolipoprotein-E4(ApoE-E4), which points out to latent Herpes Simplex virus-1 as an agent causing AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26289409' target='_blank' class='pmid-link'>26289409</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) is a polygenic and multifactorial disease with a complex inheritance caused by the formation of amyloid plaques and neurofibrillary tangles in the brain. Increasing evidence indicates that many genes including interleukin-6 (IL-6) and alpha 2-macroglobulin (A2M) may contribute to the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27814651' target='_blank' class='pmid-link'>27814651</a>:</span> <span class='sentence-part'>Alzheimer disease (AD) and Parkinson disease (PD) brains have reduced respiratory capacity and impaired mitobiogenesis, which could result in beta-amyloid plaques and neurofibrillary tangles.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30412490' target='_blank' class='pmid-link'>30412490</a>:</span> <span class='sentence-part'>In AD, neurofibrillary tangles (NFTs) appear first in entorhinal cortex, implying that aging processes in entorhinal neurons promote NFT pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/8988457' target='_blank' class='pmid-link'>8988457</a>:</span> <span class='sentence-part'>In Alzheimer's disease, susceptible neurons produce neurofibrillary tangles and neuropil threads, while in Parkinson's disease, they develop Lewy bodies and Lewy neurites.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/9617789' target='_blank' class='pmid-link'>9617789</a>:</span> <span class='sentence-part'>In AD, susceptible neurons produce neurofibrillary tangles (NFTs) and neuropil threads (NTs), while in PD, they develop Lewy bodies (LBs) and Lewy neurites (LNs).</span></div></div>
<div class='streamlined-assertion'><div class='streamlined-header sticky-relation-header'><span class='label-text'>Subject:</span> <strong>Alzheimers</strong> <span class='label-text'>Subject CUI:</span> <strong>C0002395</strong> â†’ <span class='label-text predicate-text'>CAUSES</span> â†’ <span class='label-text'>Object:</span> <strong>Parkinson_Disease</strong> <span class='label-text'>Object CUI:</span> <strong>C0030567</strong></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/10809400' target='_blank' class='pmid-link'>10809400</a>:</span> <span class='sentence-part'>CONCLUSIONS: These findings which are in line with previous results in Alzheimer's disease (Stadelmann et al., 1998) and Parkinson's disease (Banati et al., 1999) suggest that mechanisms distinct from classical apoptosis play a central role in the pathogenesis of PD and related neurodegenerative diseases.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/14722078' target='_blank' class='pmid-link'>14722078</a>:</span> <span class='sentence-part'>The genetic defects underlying several monogenic familial forms of AD and PD have recently been identified, however, the causes of other AD and PD cases, particularly sporadic cases, remain unclear.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20634620' target='_blank' class='pmid-link'>20634620</a>:</span> <span class='sentence-part'>Camptocormia can be due to central nervous system diseases, such as Parkinson's disease, dystonia, multisystem atrophy, or Alzheimer's disease, due to peripheral nervous system diseases, such as primary myopathy, secondary myopathy, motor neuron disease, myasthenia, or chronic inflammatory demyelinating polyneuropathy, due to side effects of drug treatment, due to disc herniation, arthritis or spinal trauma, or due to paraneoplasia.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23303475' target='_blank' class='pmid-link'>23303475</a>:</span> <span class='sentence-part'>The activity of metabotropic glutamate receptors (mGluRs) is known to be altered as the consequence of neurodegenerative diseases such as Alzheimer, Parkinson, and Huntington disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26209472' target='_blank' class='pmid-link'>26209472</a>:</span> <span class='sentence-part'>In Alzheimer's disease, beta-amyloid peptide-containing plaques and intraneuronal neurofibrillary tangles composed of hyperphosphorylated microtubule-associated protein tau are the two main neuropathological lesions, while Parkinson's disease is defined by the presence of Lewy Bodies that are intraneuronal proteinaceous cytoplasmic inclusions. alpha-Synuclein has been identified as a major protein component of Lewy Bodies and heavily implicated in the pathogenesis of Parkinson's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26528186' target='_blank' class='pmid-link'>26528186</a>:</span> <span class='sentence-part'>Neurodegenerative diseases such as Alzheimer's disease, Creutzfeldt-Jakob disease (CJD), Parkinson's disease, Huntington's disease, frontotemporal dementia (FTD), and amyotrophic lateral sclerosis (ALS) result from the loss of a specific subsets of neurons, which is closely associated with accumulation and deposition of specific protein aggregates.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27166223' target='_blank' class='pmid-link'>27166223</a>:</span> <span class='sentence-part'>Impaired protein degradation has been discussed as a cause or consequence of various neurodegenerative diseases, such as Alzheimer's, Parkinson's and Huntington's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27280392' target='_blank' class='pmid-link'>27280392</a>:</span> <span class='sentence-part'>BACKGROUND: Parkinson's disease (PD) is depicted as the most prevailed neurodegenerative disease being secondary to the alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27699087' target='_blank' class='pmid-link'>27699087</a>:</span> <span class='sentence-part'>Evidence from rodent and cell models show a number of neurotrophic and neuroprotective effects of guanosine preventing deleterious consequences of seizures, spinal cord injury, pain, mood disorders and aging-related diseases, such as ischemia, Parkinson's and Alzheimer's diseases.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28839167' target='_blank' class='pmid-link'>28839167</a>:</span> <span class='sentence-part'>The ultra-sensitive IMR assay was applied to detect the plasma tau protein levels of subjects with prevalent neurodegenerative diseases, such as Alzheimer's disease (AD), mild cognitive impairment (MCI) due to AD, Parkinson's disease (PD), frontotemporal dementia (FTD) and vascular dementia (VD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28974380' target='_blank' class='pmid-link'>28974380</a>:</span> <span class='sentence-part'>INTRODUCTION: We used a functional MRI paradigm involving conventional vs. unconventional views of objects to assess bottom-up vs. top-down visual processing in Parkinson's disease (PD) with normal cognition, PD with mild cognitive impairment (MCI), and MCI due to Alzheimer's disease (AD) as compared to healthy controls.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32634809' target='_blank' class='pmid-link'>32634809</a>:</span> <span class='sentence-part'>We compared the serial position effects (SPE) between patients with mild cognitive impairment (MCI) due to Parkinson's disease (PD), i.e., PD-MCI, and patients with MCI due to Alzheimer's disease (AD-MCI), and evaluated the influence of SPE and frontostriatal deficits on verbal memory recall.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36717892' target='_blank' class='pmid-link'>36717892</a>:</span> <span class='sentence-part'>We summarize the impact of COVID-19 infection on symptom severity, disease progression, and mortality rate of PD and AD, and discuss whether COVID-19 infection could trigger PD and AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/8033937' target='_blank' class='pmid-link'>8033937</a>:</span> <span class='sentence-part'>Lastly, degenerative cerebral diseases, such as Alzheimer's disease, Parkinson's disease, Huntington's disease, progressive supranuclear palsy and corticobasal degeneration result in more or less severe eye movement disturbances.</span></div></div>
<div class='streamlined-assertion'><div class='streamlined-header sticky-relation-header'><span class='label-text'>Subject:</span> <strong>Alzheimers</strong> <span class='label-text'>Subject CUI:</span> <strong>C0002395</strong> â†’ <span class='label-text predicate-text'>CAUSES</span> â†’ <span class='label-text'>Object:</span> <strong>Senile_Plaques</strong> <span class='label-text'>Object CUI:</span> <strong>C0333463</strong></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/1307688' target='_blank' class='pmid-link'>1307688</a>:</span> <span class='sentence-part'>These patterns closely match the hierarchical topographic distribution of NFT and SP observed in AD, suggesting a commonality in the pathologic processes that lead to NFT and SP in both aging and AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/14645482' target='_blank' class='pmid-link'>14645482</a>:</span> <span class='sentence-part'>These results demonstrate that, once plaques are cleared, neuronal morphology is self-correcting and that passive antibody treatment has the potential to reverse neuronal damage caused by Alzheimer's disease and, hence, directly impact cognitive decline.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/16437529' target='_blank' class='pmid-link'>16437529</a>:</span> <span class='sentence-part'>BACKGROUND: Alzheimer's disease (AD) may result in senile plaques being formed outside the brain as accumulation of beta-amyloid (Ass).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/16863248' target='_blank' class='pmid-link'>16863248</a>:</span> <span class='sentence-part'>The identification and characterization of possible environmental factors that may influence amyloid deposition in vivo are important to unveil the underlying etiology of AD. According to the amyloid cascade hypothesis, diffuse plaques are initial and visual deposits in the early event of AD, leading to amyloid plaques.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/18254079' target='_blank' class='pmid-link'>18254079</a>:</span> <span class='sentence-part'>BACKGROUND: Alzheimer's disease (AD) may be caused by the formation of extracellular senile plaques comprised of beta-amyloid (Ass).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20384814' target='_blank' class='pmid-link'>20384814</a>:</span> <span class='sentence-part'>Using the Tg2576 transgenic mouse model of AD, this study characterized a promotive effect of neuronal hypoactivity associated with functional deprivation on amyloid plaque pathogenesis in the olfactory pathway.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21630160' target='_blank' class='pmid-link'>21630160</a>:</span> <span class='sentence-part'>Once both of these hits are activated, AD can develop and produce senile plaques and neurofibrillary tangles throughout brain tissue.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22592705' target='_blank' class='pmid-link'>22592705</a>:</span> <span class='sentence-part'>BACKGROUND: Alzheimer's dementia (AD) may be caused by the formation of extracellular senile plaques comprised of beta-amyloid (Abeta).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22924088' target='_blank' class='pmid-link'>22924088</a>:</span> <span class='sentence-part'>The spread of amyloid plaques to the striatum has been reported to be a sensitive and specific indicator of dementia due to Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23478304' target='_blank' class='pmid-link'>23478304</a>:</span> <span class='sentence-part'>The transgenic TgCRND8 mouse is widely used as an animal model of Alzheimer's disease (AD) and exhibits an early onset of senile plaque pathogenesis in the brain.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24563468' target='_blank' class='pmid-link'>24563468</a>:</span> <span class='sentence-part'>BACKGROUND: Alzheimer's dementia (AD) may be caused by the formation of extracellular senile plaques comprised of beta-amyloid (Abeta).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25031402' target='_blank' class='pmid-link'>25031402</a>:</span> <span class='sentence-part'>In sporadic Alzheimer's disease (AD), impaired Abeta removal contributes to elevated extracellular Abeta levels that drive amyloid plaque pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26289409' target='_blank' class='pmid-link'>26289409</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) is a polygenic and multifactorial disease with a complex inheritance caused by the formation of amyloid plaques and neurofibrillary tangles in the brain. Increasing evidence indicates that many genes including interleukin-6 (IL-6) and alpha 2-macroglobulin (A2M) may contribute to the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27814651' target='_blank' class='pmid-link'>27814651</a>:</span> <span class='sentence-part'>Alzheimer disease (AD) and Parkinson disease (PD) brains have reduced respiratory capacity and impaired mitobiogenesis, which could result in beta-amyloid plaques and neurofibrillary tangles.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29134465' target='_blank' class='pmid-link'>29134465</a>:</span> <span class='sentence-part'>Recent findings With the advent of 18F-labeled tracers that bind amyloid plaques, amyloid PET is now clinically available for the detection of amyloid pathology and to aid in a biomarker-supported diagnosis of AD or mild cognitive impairment (MCI) due to AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29266373' target='_blank' class='pmid-link'>29266373</a>:</span> <span class='sentence-part'>BACE1, a key protein involved in Alzheimer's progression, initiates Abeta42 generation that induce senile plaques in brain.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29611473' target='_blank' class='pmid-link'>29611473</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) is a complex, neurodegenerative pathology showing, among others, high cholinergic and neurotransmitter deficits, oxidative stress, inflammation, A?-aggregation resulting in senile plaques formation, and hyperphosphorylation of tau-protein leading to neurofibrillary tangles.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32996088' target='_blank' class='pmid-link'>32996088</a>:</span> <span class='sentence-part'>Some of the neurotoxic metals such as lead, aluminum, mercury, manganese, cadmium, and arsenic as well as some pesticides and metal-based nanoparticles have been involved in AD and PD due to their ability to produce senile/amyloid plaques and NFTs which are the main feature of these neuronal dysfunctions.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34906975' target='_blank' class='pmid-link'>34906975</a>:</span> <span class='sentence-part'>DISCUSSION: Plasma Abeta42/Abeta40 is a robust measure for detecting amyloid plaques and can be utilized to aid in the diagnosis of AD, identify those at risk for future dementia due to AD, and improve the diversity of populations enrolled in AD research and clinical trials.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35887070' target='_blank' class='pmid-link'>35887070</a>:</span> <span class='sentence-part'>Furthermore, the crucial role of ANT-1 and VDAC impairment in the onset/progression of AD opens a window for new therapeutic strategies aimed at preserving/improving mitochondrial function, which is suspected to be the driving force leading to plaque and tangle deposition in AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36138973' target='_blank' class='pmid-link'>36138973</a>:</span> <span class='sentence-part'>One of the factors, which might play a key role in senile plaques and tau fibrils generation due to Alzheimer's disease, is inflammaging, i.e., systemic chronic low-grade age-related inflammation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/38356475' target='_blank' class='pmid-link'>38356475</a>:</span> <span class='sentence-part'>INTRODUCTION: In addition to the accumulation of amyloid plaques and neurofibrillary tangles, the presence of excess neural activity is a pathological hallmark of Alzheimer's disease (AD) and a prognostic indicator for progression of AD pathology and clinical/cognitive worsening in mild cognitive impairment due to Alzheimer's disease (MCI due to AD). The HOPE4MCI study: A randomized double-blind assessment of AGB101 for the treatment of MCI due to AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/6803359' target='_blank' class='pmid-link'>6803359</a>:</span> <span class='sentence-part'>Although several studies of Alzheimer's disease suggest that the frequency of neuritic plaques in the cerebral cortex is correlated with the severity of dementia and with reduction in presynaptic cholinergic markers in the cortex, the relationship between cholinergic cortical innervation and the pathogenesis of plaques is unknown.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/7884819' target='_blank' class='pmid-link'>7884819</a>:</span> <span class='sentence-part'>S100 beta protein expression in Alzheimer disease: potential role in the pathogenesis of neuritic plaques.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/8892356' target='_blank' class='pmid-link'>8892356</a>:</span> <span class='sentence-part'>We propose that the amyloid deposits in senile plaques of Alzheimer's Disease (AD) result from ancient mechanisms in wound-healing and inflammatory processes that preceded the evolution of the inducible combinatorial immune responses characteristic of jawed vertebrates.</span></div></div>
<div class='streamlined-assertion'><div class='streamlined-header sticky-relation-header'><span class='label-text'>Subject:</span> <strong>Alzheimers</strong> <span class='label-text'>Subject CUI:</span> <strong>C0002395</strong> â†’ <span class='label-text predicate-text'>CAUSES</span> â†’ <span class='label-text'>Object:</span> <strong>Senile_dementia</strong> <span class='label-text'>Object CUI:</span> <strong>C0011268</strong></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/10096843' target='_blank' class='pmid-link'>10096843</a>:</span> <span class='sentence-part'>AD is the leading cause of senile dementia and although the pathogenesis of this disorder is not known, various hypotheses have been developed based on experimental data accumulated since the initial description of this disease by Alois Alzheimer about 90 years ago.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/10740829' target='_blank' class='pmid-link'>10740829</a>:</span> <span class='sentence-part'>Alzheimer disease, the leading cause of senile dementia, is characterised by the degeneration of select neuronal populations.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/10867221' target='_blank' class='pmid-link'>10867221</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) and cerebrovascular dementia (CVD) are two major causes of senile dementia in elderly individuals.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/12134567' target='_blank' class='pmid-link'>12134567</a>:</span> <span class='sentence-part'>Homocysteine has emerged as an independent risk factor for stroke, and recent studies suggest that vascular disease affecting the brain and Alzheimer's disease may result together in senile dementia.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/12625839' target='_blank' class='pmid-link'>12625839</a>:</span> <span class='sentence-part'>BACKGROUND: Lewy body disease is, after Alzheimer's disease, the second most common cause of senile degenerative dementia with progressive cognitive deterioration, fluctuation of cognitive and motoric functions and psychotic symptoms.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/14501255' target='_blank' class='pmid-link'>14501255</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) is the most common cause of senile dementia, for which there is presently no disease-based treatment.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/15371644' target='_blank' class='pmid-link'>15371644</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) is the leading cause of senile dementia, and is a complex disorder.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/16788045' target='_blank' class='pmid-link'>16788045</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) is a common neurodegenerative disorder that causes senile dementia.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/18855671' target='_blank' class='pmid-link'>18855671</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD), the leading cause of senile dementia, has become a considerable social and economical problem.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/1889888' target='_blank' class='pmid-link'>1889888</a>:</span> <span class='sentence-part'>Since 73% of dementias are at least partly caused by Alzheimer's disease in the area examined and because the short test used discriminates demented from healthy octagenarians as well as tests involving extensive examinations, the findings of this study suggest with a high probability that the [Al] of drinking water is not an essential factor in the pathogenesis of senile dementia.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/1895528' target='_blank' class='pmid-link'>1895528</a>:</span> <span class='sentence-part'>Alzheimer's disease is one of the main causes of senile dementia.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/19195795' target='_blank' class='pmid-link'>19195795</a>:</span> <span class='sentence-part'>Body iron stores that increase with age could be pivotal to AD pathogenesis and progression. This communication explores the temporal link between the age-associated increase in body iron stores and the age-related incidence of Alzheimer's disease (AD), the most prevalent cause of senile dementia.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/19619524' target='_blank' class='pmid-link'>19619524</a>:</span> <span class='sentence-part'>Alzheimer's disease is the major cause of senile dementia with the hallmark of beta-amyloid deposition in neurons.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/19737808' target='_blank' class='pmid-link'>19737808</a>:</span> <span class='sentence-part'>AD, characterized microscopically by deposition of amyloid plaques and formation of neurofibrillary tangles in the brain, has become the most common cause of senile dementia.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20101721' target='_blank' class='pmid-link'>20101721</a>:</span> <span class='sentence-part'>Alzheimer's disease is the most common cause of senile dementia in the United States and Europe.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20369844' target='_blank' class='pmid-link'>20369844</a>:</span> <span class='sentence-part'>Alzheimer's disease is a progressive, neurodegenerative disorder that is the leading cause of senile dementia, afflicting millions of individuals worldwide.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20462385' target='_blank' class='pmid-link'>20462385</a>:</span> <span class='sentence-part'>Alzheimer disease (AD) is a heterogeneous and progressive neurodegenerative disease, which in Western society mainly accounts for senile dementia.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20552234' target='_blank' class='pmid-link'>20552234</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD), the most prominent cause of senile dementia, is clinically characterized by the extracellular deposition of beta-amyloid (Abeta) and the intracellular neurofibrillary tangles.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21349442' target='_blank' class='pmid-link'>21349442</a>:</span> <span class='sentence-part'>Alzheimer's disease is a neurodegenerative disease that is imposing an increasing burden on society, and is the leading cause of senile dementia worldwide.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23062696' target='_blank' class='pmid-link'>23062696</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) is the leading cause of senile dementia.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23173066' target='_blank' class='pmid-link'>23173066</a>:</span> <span class='sentence-part'>The pathogenic aggregation of the amyloid beta-peptide (Abeta) is considered a hallmark of the progression of Alzheimer's disease, the leading cause of senile dementia in the elderly and one of the principal causes of death in the United States.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23566654' target='_blank' class='pmid-link'>23566654</a>:</span> <span class='sentence-part'>The pathological hallmark of Alzheimer's disease (AD), the leading cause of senile dementia, involves region-specific neuronal death and an accumulation of neuronal and extracellular lesions termed neurofibrillary tangles and senile plaques, respectively.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24006337' target='_blank' class='pmid-link'>24006337</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) is a progressive neurodegenerative disease and the leading cause of senile dementia in the United States.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24523906' target='_blank' class='pmid-link'>24523906</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) is the leading cause of senile dementia in today's society.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24975171' target='_blank' class='pmid-link'>24975171</a>:</span> <span class='sentence-part'>Cu dyshomeostasis has also been concerned in neurodegenerative disorders such as Alzheimer, Amyotrophic lateral sclerosis (ALS) or Menkes disease and is directly related to neurodegenerative syndrome that usually produces senile dementia.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25446741' target='_blank' class='pmid-link'>25446741</a>:</span> <span class='sentence-part'>Alzheimer disease is the most common neurodegenerative disorder and cause of senile dementia.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25476252' target='_blank' class='pmid-link'>25476252</a>:</span> <span class='sentence-part'>Alzheimer's disease is the major cause of senile dementia, flewing out 10% of 65 years old and 50% of 85 years old global population.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26131055' target='_blank' class='pmid-link'>26131055</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) is a progressive neurodegenerative disorder and the leading cause of senile dementia all over the world.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26351775' target='_blank' class='pmid-link'>26351775</a>:</span> <span class='sentence-part'>BACKGROUND: Alzheimer's disease (AD) is the most common cause of senile dementia.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26606591' target='_blank' class='pmid-link'>26606591</a>:</span> <span class='sentence-part'>BACKGROUND: Amyloid-beta (Abeta) peptides are a family of proteins that are considered to be a principal aspect of Alzheimer's disease (AD), the most common cause of senile dementia affecting elderly individuals.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26849355' target='_blank' class='pmid-link'>26849355</a>:</span> <span class='sentence-part'>Sphingolipids are widely known to have roles in the pathogenesis of inflammatory diseases, where the precise roles for sphingolipids in inflammation-associated pathogenesis of AD are not well understood. Alzheimer's disease (AD) is the most common cause of senile dementia.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27865835' target='_blank' class='pmid-link'>27865835</a>:</span> <span class='sentence-part'>Super-activation of cholinesterases (acetylcholinesterase and butyrylcholinesterase) are linked to various neurological problems most precisely Alzheimer's disease (AD), which leads to senile dementia.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29220126' target='_blank' class='pmid-link'>29220126</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) is a neurodegenerative disease and the most common cause of senile dementia.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29260452' target='_blank' class='pmid-link'>29260452</a>:</span> <span class='sentence-part'>Currently, AD is the leading cause of senile dementia worldwide.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29411261' target='_blank' class='pmid-link'>29411261</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD), a progressive neurodegenerative disease of the central nervous system, is the most common cause of senile dementia.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/7175555' target='_blank' class='pmid-link'>7175555</a>:</span> <span class='sentence-part'>The temporal lobe cortex and hippocampus were the areas most severely affected by the increased neurofibrillary tangle formation in senile dementia due to Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/7778188' target='_blank' class='pmid-link'>7778188</a>:</span> <span class='sentence-part'>The pathological presentation of Alzheimer's disease, the leading cause of senile dementia, involves regionalized neuronal death and an accumulation of intracellular and extracellular filamentous protein aggregates that form lesions termed neurofibrillary tangles and senile plaques, respectively.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/9568532' target='_blank' class='pmid-link'>9568532</a>:</span> <span class='sentence-part'>Alzheimer's disease, the most common cause of senile dementia, is characterized by intracellular formation of neurofibrillary tangles, extracellular deposits of beta amyloid as well as cerebrovascular amyloid accumulation and a profound loss of cholinergic neurons within the nucleus basalis Meynert with alterations in cortical neurotransmitter receptor densities.</span></div></div>
<div class='streamlined-assertion'><div class='streamlined-header sticky-relation-header'><span class='label-text'>Subject:</span> <strong>Alzheimers</strong> <span class='label-text'>Subject CUI:</span> <strong>C0002395</strong> â†’ <span class='label-text predicate-text'>CAUSES</span> â†’ <span class='label-text'>Object:</span> <strong>Symptoms</strong> <span class='label-text'>Object CUI:</span> <strong>C1457887</strong></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/11084917' target='_blank' class='pmid-link'>11084917</a>:</span> <span class='sentence-part'>Myoclonus is defined as shock-like, brief involuntary abnormal movements in muscle jerking caused by external stimuli; and it arises from progressive myoclonus epilepsy, post-anoxic encephalopathy and Alzheimer's disease, causing disabling symptoms.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/11447834' target='_blank' class='pmid-link'>11447834</a>:</span> <span class='sentence-part'>The clinical symptoms of all forms of Alzheimer's disease (AD) result from a slowly progressive neurodegeneration that is associated with the excessive deposition of beta-amyloid (A beta) in plaques and in the cerebrovasculature, and the formation of intraneuronal neurofibrillary tangles, which are composed primarily of abnormally hyperphosphorylated tau protein.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17645242' target='_blank' class='pmid-link'>17645242</a>:</span> <span class='sentence-part'>As the average disease duration in sporadic methionine/valine type 1 CJD is less than 6 months, it seems legitimate to speculate that the initial symptoms resulted from Alzheimer and alpha-synuclein related pathologies.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17719211' target='_blank' class='pmid-link'>17719211</a>:</span> <span class='sentence-part'>Given that neurodegenerative burden and compensatory mechanisms might exist before accepted clinical symptoms of AD are noticeable, the current prospective study aimed to investigate the functioning of brain regions in the visuospatial networks responsible for preclinical symptoms in AD using event-related functional magnetic resonance imaging (fMRI).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21318511' target='_blank' class='pmid-link'>21318511</a>:</span> <span class='sentence-part'>Aberrant processing of APP was incorporated into the Amyloid Hypothesis, which supposes that the clinical symptoms, neuropathology, and ultimate fatality of Alzheimer's result from the actions of Abeta.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22619696' target='_blank' class='pmid-link'>22619696</a>:</span> <span class='sentence-part'>Except for some kind of cancers, no effective and/or definitive therapeutic treatment aimed to reduce or to retard the clinic and pathologic symptoms induced by AD and PD is presently available.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23665480' target='_blank' class='pmid-link'>23665480</a>:</span> <span class='sentence-part'>Memantine and ketamine block N-methyl-D-aspartate (NMDA) receptors with similar affinity and kinetics, yet their behavioral consequences differ: e.g., memantine is used to alleviate symptoms of Alzheimer's disease, whereas ketamine reproduces symptoms of schizophrenia.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25501055' target='_blank' class='pmid-link'>25501055</a>:</span> <span class='sentence-part'>In the past decade, amyloid deposition has been shown to begin many years before the clinical symptoms of dementia in mild cognitive impairment (MCI) due to Alzheimer disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26332220' target='_blank' class='pmid-link'>26332220</a>:</span> <span class='sentence-part'>Interventions for Neuropsychiatric Symptoms in Neurocognitive Impairment Due to Alzheimer's Disease: A Review of the Literature.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27697061' target='_blank' class='pmid-link'>27697061</a>:</span> <span class='sentence-part'>Our review concludes with some suggestions for future studies aimed to advance research into NBS as a potential treatment for the symptoms and disabilities caused by AD and to enable comparison of results across trials.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27870597' target='_blank' class='pmid-link'>27870597</a>:</span> <span class='sentence-part'>However, there was insufficient evidence to support a benefit of dyadic exercise intervention on cognitive performance and on behavioral and neuropsychiatric symptoms in participants with dementia due to AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28138509' target='_blank' class='pmid-link'>28138509</a>:</span> <span class='sentence-part'>METHODS: Associations among clinical symptoms, gray-matter volume, regional tau, and A? deposition assessed by positron emission tomography with [11C]pyridinyl-butadienyl-benzothiazole 3 (PBB3) and [11C]Pittsburgh compound-B (PiB), were evaluated in 17 AD, 9 mild cognitive impairment due to AD, and 28 PiB(-)-cognitive healthy controls (HCs).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29286086' target='_blank' class='pmid-link'>29286086</a>:</span> <span class='sentence-part'>The pathogenesis of Alzheimer's disease (AD) has still not been fully elucidated, however it is thought that the build up of amyloid plaque at least partially causes the symptoms of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29365053' target='_blank' class='pmid-link'>29365053</a>:</span> <span class='sentence-part'>The goal of this study was to determine which measures, obtained when individuals were cognitively normal, predict on an individual basis, the onset of clinical symptoms associated with a diagnosis of mild cognitive impairment due to Alzheimer's disease. The primary outcome was progression from normal cognition to the onset of clinical symptoms of mild cognitive impairment due to Alzheimer's disease at 5 years post-baseline.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29955659' target='_blank' class='pmid-link'>29955659</a>:</span> <span class='sentence-part'>Introduction: Autosomal-dominant Alzheimer's disease (ADAD) represents a crucial population for identifying prevention strategies that might modify disease course for cognitively unimpaired individuals at high imminent risk for developing symptoms due to Alzheimer's disease (AD), that is, who have \preclinical\ AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30282371' target='_blank' class='pmid-link'>30282371</a>:</span> <span class='sentence-part'>The French Minister of Health published a decree on May 29th of 2018 removing the drugs used to fight against symptoms due to Alzheimer's disease (donepezil, rivastigmine, galantamine, memantine) from the list of available reimbursed drugs.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30788058' target='_blank' class='pmid-link'>30788058</a>:</span> <span class='sentence-part'>BACKGROUND/OBJECTIVES: Alzheimer's disease is a neurodegenerative disease that induces symptoms such as a decrease in motor function and cognitive impairment.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32461027' target='_blank' class='pmid-link'>32461027</a>:</span> <span class='sentence-part'>We propose that the degeneration of the prefrontal cortex in AD produces symptoms of apathy.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32840196' target='_blank' class='pmid-link'>32840196</a>:</span> <span class='sentence-part'>We have previously demonstrated that the presence of two or more of these symptoms differentiates MCI-LB from MCI due to Alzheimer's disease (MCI-AD) with a likelihood ratio &gt;4.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32849173' target='_blank' class='pmid-link'>32849173</a>:</span> <span class='sentence-part'>Subsequent analyses involved splitting the course of the disease into diagnostic categories: cognitively unimpaired subjects (CU), mild cognitively impaired subjects (MCI), and subjects with dementia (AD-dementia), where all symptoms were due to AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33188391' target='_blank' class='pmid-link'>33188391</a>:</span> <span class='sentence-part'>Future longitudinal studies are needed to further investigate whether mixed ADNC/LATE-NC may be protective against agitation and frontal symptoms in dementia caused by Alzheimer's disease or LATE pathology.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33461093' target='_blank' class='pmid-link'>33461093</a>:</span> <span class='sentence-part'>Brain autopsy confirmed changes typical of Alzheimer's disease without evidence of active inflammation or sequelae of AE, establishing Alzheimer's disease as the likely cause of resurgent symptoms in this patient.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33792886' target='_blank' class='pmid-link'>33792886</a>:</span> <span class='sentence-part'>BACKGROUND: Alzheimer's disease (AD) causes symptoms such as dementia, memory loss, disorientation, and even aggressiveness, and is more common in women than in men.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34249072' target='_blank' class='pmid-link'>34249072</a>:</span> <span class='sentence-part'>NCS was determined by the presence of AD symptoms and neuropsychiatric (NP) symptoms caused by anti-AD (AAD) drugs (D) as a biomarker.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35710783' target='_blank' class='pmid-link'>35710783</a>:</span> <span class='sentence-part'>This accumulation may occur years before the clinical symptoms but it has not been elucidated if this accumulation is the cause or the consequence of AD. The most accepted hypothesis in Alzheimer's disease (AD) is the amyloid cascade which establishes that Abeta accumulation may induce the disease development.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36396271' target='_blank' class='pmid-link'>36396271</a>:</span> <span class='sentence-part'>Recent biomarker and neuroimaging research has revealed how the pathophysiology of AD may lead to symptoms, and as the pathophysiology of AD gains clarity, more potential treatments are emerging that aim to modify the disease and relieve its burden.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36894582' target='_blank' class='pmid-link'>36894582</a>:</span> <span class='sentence-part'>Our results indicate that AD affects specific EEG-RSNs and deteriorated network activity causes symptoms.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36912421' target='_blank' class='pmid-link'>36912421</a>:</span> <span class='sentence-part'>We investigated the cumulative frequency of symptoms in a longitudinal cohort of MCI-LB compared with MCI due to Alzheimer disease (MCI-AD) and analysed the ability of a previously described 10-point symptom scale to differentiate MCI-LB and MCI-AD, in an independent cohort.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/38086100' target='_blank' class='pmid-link'>38086100</a>:</span> <span class='sentence-part'>In vivo studies using transgenic mouse models and AD-induced symptoms have shown promising results, with SeNPs treatment leading to cognitive improvements and reduced amyloid plaque burden in the hippocampus.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/38363815' target='_blank' class='pmid-link'>38363815</a>:</span> <span class='sentence-part'>Despite negligible or tiny Abeta pathology, patients 1 and 2 were diagnosed with AD as the cause of symptoms. Despite widespread Abeta pathology, patient 3 was not diagnosed with AD as the cause of symptoms.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/8146663' target='_blank' class='pmid-link'>8146663</a>:</span> <span class='sentence-part'>Soluble beta-amyloid induction of Alzheimer's phenotype for human fibroblast K+ channels. In Alzheimer's disease, then, beta-amyloid might alter potassium channels and thus impair neuronal function to produce symptoms such as memory loss by a means other than plaque formation.</span></div></div>
<div class='streamlined-assertion'><div class='streamlined-header sticky-relation-header'><span class='label-text'>Subject:</span> <strong>Alzheimers</strong> <span class='label-text'>Subject CUI:</span> <strong>C0002395</strong> â†’ <span class='label-text predicate-text'>CAUSES</span> â†’ <span class='label-text'>Object:</span> <strong>Syndrome</strong> <span class='label-text'>Object CUI:</span> <strong>C0039082</strong></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/11574902' target='_blank' class='pmid-link'>11574902</a>:</span> <span class='sentence-part'>The syndrome of dementia is most commonly caused by Alzheimer's disease (AD), an age-related neurodegenerative process that primarily affects the cortex.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/12137606' target='_blank' class='pmid-link'>12137606</a>:</span> <span class='sentence-part'>BACKGROUND: Dementia is an age-associated syndrome most commonly due to Alzheimer's disease (AD) and/or cerebrovascular disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/1590915' target='_blank' class='pmid-link'>1590915</a>:</span> <span class='sentence-part'>This case, together with other reports, points to the existence of neurologically defined subgroups of AD with unusual clinical deficits that are correlated with the regional and laminar distribution of NP and NFT, and further supports the hypothesis that the symptomatology presented by AD patients results from the loss of specific neuronal populations leading to a syndrome of global cortical disconnection.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/16300967' target='_blank' class='pmid-link'>16300967</a>:</span> <span class='sentence-part'>Semantic dementia (SD) and Alzheimer's disease (AD) are both disorders in which early pathology affects the temporal lobe yet they produce distinct syndromes of declarative memory impairment-loss of established semantic knowledge with relatively preserved episodic memory in the former and the converse in the latter.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17898010' target='_blank' class='pmid-link'>17898010</a>:</span> <span class='sentence-part'>AD is a much commoner cause of focal cortical syndromes than previously recognised, particularly in PCA, PNFA and CBS, but rarely causes SD or bvFTD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20098809' target='_blank' class='pmid-link'>20098809</a>:</span> <span class='sentence-part'>Posterior cortical atrophy (PCA) is a neurodegenerative syndrome, usually due to Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22766737' target='_blank' class='pmid-link'>22766737</a>:</span> <span class='sentence-part'>The first two relate to clinico-pathological studies which established that Alzheimer's disease (AD) is a relatively common cause of focal cortical syndromes, notably progressive aphasia (largely nonfluent), progressive apraxia, and posterior cortical atrophy with complex visual symptoms.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23300102' target='_blank' class='pmid-link'>23300102</a>:</span> <span class='sentence-part'>In CBS due to FTLD, atrophy extended into the prefrontal cortex, striatum, and brainstem, whereas in CBS due to AD, atrophy extended into the temporoparietal cortex and precuneus.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24291869' target='_blank' class='pmid-link'>24291869</a>:</span> <span class='sentence-part'>In CBS due to frontotemporal lobar degeneration (FTLD), atrophy extended into prefrontal cortex, striatum, and brainstem, whereas in CBS due to Alzheimer's disease (AD), atrophy extended into temporoparietal cortex and precuneus.No functional imaging study in pathology-proven CBD or CBS with known histopathology has been published today.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24994944' target='_blank' class='pmid-link'>24994944</a>:</span> <span class='sentence-part'>BACKGROUND: \Posterior shift\ of the neuropathological changes of Alzheimer's disease (AD) produces a syndrome (posterior cortical atrophy) (PCA) dominated by high-level visual deficits.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26200048' target='_blank' class='pmid-link'>26200048</a>:</span> <span class='sentence-part'>Cortical correlates of affective syndrome in dementia due to Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26377458' target='_blank' class='pmid-link'>26377458</a>:</span> <span class='sentence-part'>UNLABELLED: Posterior cortical atrophy (PCA) is a rare focal neurodegenerative syndrome characterized by progressive visuoperceptual and visuospatial deficits, most often due to atypical Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26483753' target='_blank' class='pmid-link'>26483753</a>:</span> <span class='sentence-part'>Different neurodegenerative disorders, such as Alzheimer's disease (AD) and frontotemporal dementia (FTD), lead to dementia syndromes.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29695292' target='_blank' class='pmid-link'>29695292</a>:</span> <span class='sentence-part'>BACKGROUND: Mild cognitive impairment (MCI) is a heterogeneous syndrome resulting from Alzheimer's disease (AD) as well as to non-AD and non-neurodegenerative conditions.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30083812' target='_blank' class='pmid-link'>30083812</a>:</span> <span class='sentence-part'>PCA is a clinico-radiological syndrome that is often caused by Alzheimer's disease and other neurodegenerative diseases as Lewy body dementia and corticobasal degeneration.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30799336' target='_blank' class='pmid-link'>30799336</a>:</span> <span class='sentence-part'>Mixed Alzheimer's and Lewy-related Pathology Can Cause Corticobasal Syndrome with Visual Hallucinations.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30799371' target='_blank' class='pmid-link'>30799371</a>:</span> <span class='sentence-part'>Authors' Reply: Mixed Alzheimer's and Lewy-related Pathology Can Cause Corticobasal Syndrome with Visual Hallucinations.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30997705' target='_blank' class='pmid-link'>30997705</a>:</span> <span class='sentence-part'>Despite its low prevalence, PCA should be considered a syndrome caused by Alzheimer's disease, dementia with Lewy bodies, or other dementias.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31264318' target='_blank' class='pmid-link'>31264318</a>:</span> <span class='sentence-part'>One had been diagnosed with subjective cognitive impairment, 13 with mild cognitive impairment with or without depression, and 17 with dementia syndrome due to Alzheimer's and/or cerebrovascular disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32810333' target='_blank' class='pmid-link'>32810333</a>:</span> <span class='sentence-part'>Some aged community dogs acquire a degenerative syndrome termed Canine Cognitive Dysfunction (CCD) that resembles human dementia due to Alzheimer's Disease (AD), with comparable cognitive and behavioural deficits.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32925054' target='_blank' class='pmid-link'>32925054</a>:</span> <span class='sentence-part'>The ROI with the maximal hypometabolism was the dominant middle temporal gyrus in the language variant of AD (mean z score -2.28), middle occipital gyrus in PCA (-3.24), middle temporal gyrus in frontal AD (-2.70), and angular gyrus in corticobasal syndrome due to AD (-2.31).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33206389' target='_blank' class='pmid-link'>33206389</a>:</span> <span class='sentence-part'>OBJECTIVE: To investigate if individual brain [     18       F]fluorodeoxyglucose-positron emission tomography (FDG-PET) patterns could distinguish CBS due to Alzheimer's disease (AD) from other pathologies based on [     11       C]Pittsburgh Compound-B (PIB)-PET.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35670835' target='_blank' class='pmid-link'>35670835</a>:</span> <span class='sentence-part'>For the differentiation of Alzheimer's disease from other etiologies of dementia syndromes, established biological markers could be helpful to confirm a distinctive neuropathology.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/38261145' target='_blank' class='pmid-link'>38261145</a>:</span> <span class='sentence-part'>PURPOSE OF THE STUDY: Posterior cortical atrophy is a clinico-radiographical syndrome that presents with higher-order visual dysfunction and is most commonly due to Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/6835874' target='_blank' class='pmid-link'>6835874</a>:</span> <span class='sentence-part'>Alzheimer's disease is one of a number of conditions that can cause the syndrome of dementia.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/9363830' target='_blank' class='pmid-link'>9363830</a>:</span> <span class='sentence-part'>Dementia is one of the most common organic mental syndromes, usually caused by Alzheimer's disease (AD) or vascular dementia (VD) or both.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/9434673' target='_blank' class='pmid-link'>9434673</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) is by far the most common cause of the Type 1 syndrome.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/9652488' target='_blank' class='pmid-link'>9652488</a>:</span> <span class='sentence-part'>Early alexia and higher visual impairments characterize Posterior cortical atrophy (PCA), a progressive dementing syndrome most often caused by Alzheimer disease.</span></div></div>
<div class='streamlined-assertion'><div class='streamlined-header sticky-relation-header'><span class='label-text'>Subject:</span> <strong>Amyloid</strong> <span class='label-text'>Subject CUI:</span> <strong>C0002716</strong> â†’ <span class='label-text predicate-text'>CAUSES</span> â†’ <span class='label-text'>Object:</span> <strong>Alzheimers</strong> <span class='label-text'>Object CUI:</span> <strong>C0002395</strong></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/10219973' target='_blank' class='pmid-link'>10219973</a>:</span> <span class='sentence-part'>Abnormal processing of amyloid precursor protein (APP), in particular the generation of beta-amyloid (Abeta) peptides, has been implicated in the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/10589538' target='_blank' class='pmid-link'>10589538</a>:</span> <span class='sentence-part'>Genetic evidence strongly supports the view that Abeta amyloid production is central to the cause of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/10670439' target='_blank' class='pmid-link'>10670439</a>:</span> <span class='sentence-part'>The deposition of beta amyloid is a critical event in the pathogenesis of Alzheimer's disease. Further studies are required to determine the clinical significance of these physiological changes in plasma amyloid precursor protein and the implications for Alzheimer's disease pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/10818502' target='_blank' class='pmid-link'>10818502</a>:</span> <span class='sentence-part'>The beta-amyloid (A beta) peptide is believed to play a central role in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/10899442' target='_blank' class='pmid-link'>10899442</a>:</span> <span class='sentence-part'>Although there remains controversy as to whether Abeta deposited as classic amyloid or a smaller, aggregated, form causes AD, the relevance of studying the amyloid deposits has certainly been proven.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/11019859' target='_blank' class='pmid-link'>11019859</a>:</span> <span class='sentence-part'>Chemical and conformational early modifications of the beta-amyloid peptide are critical steps in AD pathogenesis and have been widely investigated.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/11145990' target='_blank' class='pmid-link'>11145990</a>:</span> <span class='sentence-part'>Converging lines of evidence implicate the beta-amyloid peptide (Ass) as causative in Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/11181832' target='_blank' class='pmid-link'>11181832</a>:</span> <span class='sentence-part'>A large body of evidence suggests that an increase in the brain beta-amyloid (Abeta) burden contributes to the etiology of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/11388427' target='_blank' class='pmid-link'>11388427</a>:</span> <span class='sentence-part'>Microglial activation induced by beta-amyloid (A beta) is an important cellular response in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/11455613' target='_blank' class='pmid-link'>11455613</a>:</span> <span class='sentence-part'>Microglial interaction with beta-amyloid: implications for the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/11475420' target='_blank' class='pmid-link'>11475420</a>:</span> <span class='sentence-part'>Recent studies suggest melatonin, due to its antioxidant and free-radical-scavenging actions, may play a role in the neuroprotection against amyloid, which is implicated in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/11496136' target='_blank' class='pmid-link'>11496136</a>:</span> <span class='sentence-part'>The beta-amyloid peptide (A beta) is a key player in the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/11602326' target='_blank' class='pmid-link'>11602326</a>:</span> <span class='sentence-part'>Substantial evidence suggests that the accumulation of beta-amyloid (Abeta)-derived peptides contributes to the aetiology of Alzheimer's disease (AD) by stimulating formation of free radicals.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/11701593' target='_blank' class='pmid-link'>11701593</a>:</span> <span class='sentence-part'>Cerebral amyloid angiopathy is a pathogenic lesion in Alzheimer's disease due to a novel presenilin 1 mutation. This was unusually severe CAA reminiscent of the Flemish amyloid precursor protein (A692G) mutation we reported previously, which causes Alzheimer's disease and/or cerebral haemorrhages. Here, we report a family (family GB) in which early-onset Alzheimer's disease was caused by a novel presenilin 1 mutation (L282V). Nevertheless, in &gt; 90% of cases of Alzheimer's disease amyloid is also deposited in cerebral blood vessel walls (congophilic amyloid angiopathy; CAA) but its role in Alzheimer's disease pathogenesis remains enigmatic.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/11818564' target='_blank' class='pmid-link'>11818564</a>:</span> <span class='sentence-part'>beta-amyloid (A beta), derived form the beta-amyloid precursor protein (APP), is important for the pathogenesis of Alzheimer's disease (AD), which is characterized by progressive decline of cognitive functions, formation of A beta plaques and neurofibrillary tangles, and loss of neurons.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/11848621' target='_blank' class='pmid-link'>11848621</a>:</span> <span class='sentence-part'>Investigation of the interactions of nerve cells with human apolipoprotein E (apoE), beta-amyloid (Abeta), and their complex, which are known to be included in senile plaques, is necessary to clarify the functional role of apoE in the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/11886820' target='_blank' class='pmid-link'>11886820</a>:</span> <span class='sentence-part'>Aggregation of amyloid peptide (Abeta) has been identified as a major feature of the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/11967228' target='_blank' class='pmid-link'>11967228</a>:</span> <span class='sentence-part'>Moreover, our findings indicate that beta-sheet breaker peptides provide a valuable tool for evaluating further the importance of amyloid in the etiology of AD and suggest that these peptides or some of their derivatives might be good candidates for AD treatment.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/12119153' target='_blank' class='pmid-link'>12119153</a>:</span> <span class='sentence-part'>The amyloid and tangle cascade hypothesis is the dominant explanation for the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/12214051' target='_blank' class='pmid-link'>12214051</a>:</span> <span class='sentence-part'>The biogenesis and degradation/clearance of Abeta amyloid lies at the centre of the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/12423367' target='_blank' class='pmid-link'>12423367</a>:</span> <span class='sentence-part'>While BACE1 processes the amyloid precursor protein (APP) at a key step in generating the beta-amyloid peptide and presumably causes Alzheimer's disease (AD), BACE2 has not been demonstrated to be directly involved in APP processing, and its physiological functions remain to be determined.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/12496118' target='_blank' class='pmid-link'>12496118</a>:</span> <span class='sentence-part'>The amyloid precursor protein (APP) is the precursor of the beta-amyloid peptide (Abeta), which is centrally related to the genesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/12598899' target='_blank' class='pmid-link'>12598899</a>:</span> <span class='sentence-part'>Amyloid precursor protein (APP) processing and the generation of beta-amyloid peptide (Abeta) are important in the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/12600718' target='_blank' class='pmid-link'>12600718</a>:</span> <span class='sentence-part'>Increased formation of the beta-amyloid peptide (Abeta) is a central event in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/12751917' target='_blank' class='pmid-link'>12751917</a>:</span> <span class='sentence-part'>The evidence indicates that abnormal processing and extracellular deposition of the longer form of the beta-amyloid (Abeta) peptide (Abeta(1-42), a proteolytic derivative of the amyloid precursor protein [APP]) is implicated in the pathogenesis of Alzheimer's disease. This research strongly supports the notion that abnormal Abeta processing is essential to the pathogenesis of Alzheimer's disease and provides a crucial platform for the development and detailed testing of potential treatments in experimental models before each of these approaches can be proposed as a therapy for Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/12821522' target='_blank' class='pmid-link'>12821522</a>:</span> <span class='sentence-part'>The accumulation of beta-amyloid (A beta) in neuritic plaques is thought to be causative for the progression of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/12970358' target='_blank' class='pmid-link'>12970358</a>:</span> <span class='sentence-part'>Increased production and deposition of the 40-42-amino acid beta-amyloid peptide (Abeta) is believed to be central to the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/13130516' target='_blank' class='pmid-link'>13130516</a>:</span> <span class='sentence-part'>Current Alzheimer's disease (AD) research has established the fact that excessive genesis of Abeta derived from amyloidogenic processing of beta-amyloid (Abeta) precursor protein is fundamental to AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/14511676' target='_blank' class='pmid-link'>14511676</a>:</span> <span class='sentence-part'>Deposition of amyloid in the brain is important in the pathogenesis of Alzheimer's disease (AD), but it remains to be determined if deposition is due to increased production or decreased clearance of fibrillogenic forms of beta-amyloid (Abeta).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/14640701' target='_blank' class='pmid-link'>14640701</a>:</span> <span class='sentence-part'>Deposition of beta-amyloid (Abeta) is considered an important early event in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/14713297' target='_blank' class='pmid-link'>14713297</a>:</span> <span class='sentence-part'>Beta-amyloid (Abeta) peptide has been suggested to play important roles in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/15071107' target='_blank' class='pmid-link'>15071107</a>:</span> <span class='sentence-part'>Multiple lines of evidence implicate beta-amyloid (Abeta) in the pathogenesis of Alzheimer's disease (AD), but the mechanisms whereby Abeta is involved remain unclear.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/15099019' target='_blank' class='pmid-link'>15099019</a>:</span> <span class='sentence-part'>The formation of amyloid-containing senile plaques and tau-rich neurofibrillary tangles are central events in Alzheimer disease (AD) pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/15181252' target='_blank' class='pmid-link'>15181252</a>:</span> <span class='sentence-part'>We will continue to investigate the effect of apoE isoform and Abeta conformation on the structural and functional interactions between these two proteins in relation to the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/15189029' target='_blank' class='pmid-link'>15189029</a>:</span> <span class='sentence-part'>Recent studies have indicated that the most important role of beta-amyloid peptide (Abeta) in the etiology of Alzheimer's disease may not be in plaque formation but in the formation of soluble, metastable Abeta(1-42) neurotoxic intermediates (called ADDLs).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/15240683' target='_blank' class='pmid-link'>15240683</a>:</span> <span class='sentence-part'>Human formyl peptide receptor-like 1 and its mouse homologue formyl peptide receptor 2 (FPR2) are G protein-coupled receptors used by a number of exogenous and host-derived chemotactic peptides, including the 42 aa form of beta amyloid peptide, a causative factor of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/15340356' target='_blank' class='pmid-link'>15340356</a>:</span> <span class='sentence-part'>Cerebral accumulation of beta-amyloid peptide (A beta) is a central event in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/15452193' target='_blank' class='pmid-link'>15452193</a>:</span> <span class='sentence-part'>gamma-Secretase inhibitors reduce brain beta-amyloid peptide (Abeta), which is believed to be a major contributor in the etiology of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/15474359' target='_blank' class='pmid-link'>15474359</a>:</span> <span class='sentence-part'>Understanding the molecular mechanism of beta-amyloid (Abeta) generation is crucial for Alzheimer's disease pathogenesis as well as for normal APP function.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/15565529' target='_blank' class='pmid-link'>15565529</a>:</span> <span class='sentence-part'>According to the beta-amyloid cascade hypothesis, the accumulation of beta-amyloid (Abeta) deposits as amyloid plaques in the patient's brain is the primary event in the pathogenesis of Alzheimer's disease (AD). The majority of known APP and presenilin mutations responsible for familial early onset AD affect APP processing causing overproduction of Abeta, especially Abeta42.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/15974916' target='_blank' class='pmid-link'>15974916</a>:</span> <span class='sentence-part'>Previous studies from our lab also showed that TGF-beta1 can reduce accumulation of beta-amyloid peptide (Abeta), which appears to be central to Alzheimer's disease (AD) pathogenesis, and we therefore initiated a search for small molecule chemical compounds that could mimic this effect.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/16170650' target='_blank' class='pmid-link'>16170650</a>:</span> <span class='sentence-part'>Genetic evidence indicates a central role of cerebral accumulation of beta-amyloid (Abeta) in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/16271725' target='_blank' class='pmid-link'>16271725</a>:</span> <span class='sentence-part'>Polymerization of the soluble beta-amyloid peptide into highly ordered fibrils is hypothesized to be a causative event in the development of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/16289381' target='_blank' class='pmid-link'>16289381</a>:</span> <span class='sentence-part'>Accumulation of the beta-amyloid peptide (Abeta) is a primary event in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/16420415' target='_blank' class='pmid-link'>16420415</a>:</span> <span class='sentence-part'>Considering the deleterious role of beta-amyloid (Abeta) in the aetiology of Alzheimer's disease (AD), we investigated green and black tea extracts and flavan-3-ols (present as monomers and dimers in green and black forms, respectively) against toxicity induced by Abeta-derived peptides using primary cultures of rat hippocampal cells as model.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/16539391' target='_blank' class='pmid-link'>16539391</a>:</span> <span class='sentence-part'>Activation of alpha-secretase upon PKC stimulation by ligands causes increased degradation of the amyloid precursor protein (APP), resulting in enhanced secretion of sAPPalpha and reduced deposition of beta-amyloid peptide (Abeta), which is implicated in the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/16542055' target='_blank' class='pmid-link'>16542055</a>:</span> <span class='sentence-part'>The amyloid hypothesis, which states that beta-amyloid (Abeta) aggregates cause the onset and progression of Alzheimer's disease (AD), is a leading proposal to explain AD aetiology.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/16581185' target='_blank' class='pmid-link'>16581185</a>:</span> <span class='sentence-part'>Production and accumulation of beta-amyloid peptide (Abeta) is central to the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/16624948' target='_blank' class='pmid-link'>16624948</a>:</span> <span class='sentence-part'>Increasing evidence links intraneuronal beta-amyloid (Abeta42) accumulation with the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/16626708' target='_blank' class='pmid-link'>16626708</a>:</span> <span class='sentence-part'>In addition to the role of beta-amyloid peptide (Abeta) in the pathogenesis of AD, reduced glucose oxidative metabolism and decreased mitochondrial activity have been suggested as associated factors.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/1669714' target='_blank' class='pmid-link'>1669714</a>:</span> <span class='sentence-part'>Amyloid precursor protein (APP) and beta A4 amyloid in the etiology of Alzheimer's disease: precursor-product relationships in the derangement of neuronal function.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/16723396' target='_blank' class='pmid-link'>16723396</a>:</span> <span class='sentence-part'>beta-Amyloid (Abeta) polypeptide plays a critical role in the pathogenesis of Alzheimer's disease (AD), which is characterized by progressive decline of cognitive functions, formation of Abeta deposits and neurofibrillary tangles, and loss of neurons.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/16762454' target='_blank' class='pmid-link'>16762454</a>:</span> <span class='sentence-part'>beta-Amyloid (Abeta) is a hydrophobic peptide that drives the pathogenesis of Alzheimer's disease (AD) due to its aberrant aggregation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/16822591' target='_blank' class='pmid-link'>16822591</a>:</span> <span class='sentence-part'>Cerebral accumulation of beta-amyloid peptide (Abeta) is a central event in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/16908985' target='_blank' class='pmid-link'>16908985</a>:</span> <span class='sentence-part'>The accumulation of the beta-amyloid peptide (Abeta) is a central event in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/16945610' target='_blank' class='pmid-link'>16945610</a>:</span> <span class='sentence-part'>BACKGROUND: Growing evidence suggests that oxidative damage caused by the beta-amyloid peptide in the pathogenesis of Alzheimer's disease may be hydrogen peroxide mediated.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/16962711' target='_blank' class='pmid-link'>16962711</a>:</span> <span class='sentence-part'>Recent studies indicate that the deposition of beta-amyloid (Abeta) is related in the pathogenesis of Alzheimer's disease (AD), but the underlying mechanism is still not clear.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17013614' target='_blank' class='pmid-link'>17013614</a>:</span> <span class='sentence-part'>A contributing factor to the pathology of Alzheimer's disease is the generation of reactive oxygen species, most probably a consequence of the beta-amyloid (Abeta) peptide coordinating copper ions.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17050537' target='_blank' class='pmid-link'>17050537</a>:</span> <span class='sentence-part'>Understanding the intracellular transport of the beta-amyloid precursor protein (APP) is a major key to elucidate the regulation of APP processing and thus beta-amyloid peptide generation in Alzheimer disease pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17086547' target='_blank' class='pmid-link'>17086547</a>:</span> <span class='sentence-part'>Based on the central dogma of beta-amyloid (Abeta) as a key seeding event in the pathogenesis of Alzheimer disease (AD), immunoneutralization strategies have been actively pursued both in AD and in models of AD as a potential means for treating AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17287054' target='_blank' class='pmid-link'>17287054</a>:</span> <span class='sentence-part'>Beta-amyloid peptide (AbetaP) aggregation, an essentially early event in Alzheimer's disease (AD) pathogenesis, became a target for therapeutics.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17374949' target='_blank' class='pmid-link'>17374949</a>:</span> <span class='sentence-part'>Evidence supports an important role for beta-amyloid (Abeta) in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17517969' target='_blank' class='pmid-link'>17517969</a>:</span> <span class='sentence-part'>Subcutaneous administration of G-CSF into two different beta-amyloid (Abeta)-induced AD mouse models substantially rescued their cognitive/memory functions.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17531157' target='_blank' class='pmid-link'>17531157</a>:</span> <span class='sentence-part'>The involvement of beta-amyloid (Abeta) in the pathogenesis of Alzheimer's disease (AD) has been well documented.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17553417' target='_blank' class='pmid-link'>17553417</a>:</span> <span class='sentence-part'>BACE initiates the production of beta-amyloid (Abeta), the likely cause of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17566645' target='_blank' class='pmid-link'>17566645</a>:</span> <span class='sentence-part'>Beta-site amyloid precursor protein cleaving enzyme 1 (BACE1) is a key protease in the generation of beta-amyloid, an important trigger protein in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17620492' target='_blank' class='pmid-link'>17620492</a>:</span> <span class='sentence-part'>BACKGROUND: Deposition of the beta-amyloid peptide Abeta(42) is thought to be an important initial step in the pathogenesis of Alzheimer disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17650113' target='_blank' class='pmid-link'>17650113</a>:</span> <span class='sentence-part'>The beta amyloid (Abeta) cascade has been at the forefront of the hypothesis used to describe the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17722071' target='_blank' class='pmid-link'>17722071</a>:</span> <span class='sentence-part'>To elucidate whether myricetin could counter the progress of AD, we examined the effects of myricetin on neurotoxicity induced by beta-amyloid (A beta), a component of senile plaques in the AD brain.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17907956' target='_blank' class='pmid-link'>17907956</a>:</span> <span class='sentence-part'>The ageing brain becomes increasingly less able to destroy or eject toxic amyloid (A) beta42 peptide byproducts of normal neuronal activity that consequently accumulate to induce Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/18167346' target='_blank' class='pmid-link'>18167346</a>:</span> <span class='sentence-part'>Amyloid formation may mediate aberrant protein interactions that culminate in neurodegeneration in Alzheimer, Huntington, and Parkinson diseases and in prion encephalopathies.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/18304698' target='_blank' class='pmid-link'>18304698</a>:</span> <span class='sentence-part'>The amyloid precursor protein (APP) is the source of beta-amyloid, a pivotal peptide in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/18357680' target='_blank' class='pmid-link'>18357680</a>:</span> <span class='sentence-part'>While such amyloid mechanism contributes to Alzheimer's pathological conditions, recent studies from a number of laboratories suggest that defective axonal transport may represent an early stage in AD pathogenesis because axonal swellings and reduced axonal transport were observed before apparent AD hallmarks.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/18395981' target='_blank' class='pmid-link'>18395981</a>:</span> <span class='sentence-part'>Amyloid precursor protein (APP) is a precursor protein for beta-amyloid, an important trigger protein in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/18413473' target='_blank' class='pmid-link'>18413473</a>:</span> <span class='sentence-part'>Most of these mutations may also cause cognitive impairment, but the Arctic APP mutation is the only known intra-beta-amyloid mutation to date causing the more typical clinical picture of Alzheimer disease. Clinical and neuropathological features of the arctic APP gene mutation causing early-onset Alzheimer disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/18422968' target='_blank' class='pmid-link'>18422968</a>:</span> <span class='sentence-part'>The interaction of the beta-amyloid peptide (Abeta) with neuronal membranes could play a key role in the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/18452319' target='_blank' class='pmid-link'>18452319</a>:</span> <span class='sentence-part'>Extracellular beta-amyloid (A beta) deposit is considered as one of the primary factors that induce Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/18473932' target='_blank' class='pmid-link'>18473932</a>:</span> <span class='sentence-part'>Beta-amyloid (Abeta)likely plays a pivotal role in the etiology of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/18855672' target='_blank' class='pmid-link'>18855672</a>:</span> <span class='sentence-part'>In line with the growing body of evidence of the pivotal role of the beta-amyloid peptide (Abeta) in the pathogenesis of AD, alternative classes of drugs targeting mainly the formation or the aggregation of Abeta are actively pursued by the pharmaceutical industry, as they could positively modify the course of AD, stopping or slowing down disease progression.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/19270530' target='_blank' class='pmid-link'>19270530</a>:</span> <span class='sentence-part'>Extracellular accumulation of beta-amyloid peptide has been reported to be a major cause of Alzheimer disease (AD) and large numbers of autophagic vacuoles accumulate in the brain of AD patient.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/19360426' target='_blank' class='pmid-link'>19360426</a>:</span> <span class='sentence-part'>Beta-amyloid (Abeta) is thought to be a key contributor to the pathogenesis of Alzheimer disease (AD) in the general population and in adults with Down syndrome (DS).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/19572401' target='_blank' class='pmid-link'>19572401</a>:</span> <span class='sentence-part'>Deposition of beta-amyloid (A beta) is considered as an important early event in the pathogenesis of Alzheimer's Disease (AD), and reduction of A beta levels by various therapeutic approaches is actively being pursued.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/19594760' target='_blank' class='pmid-link'>19594760</a>:</span> <span class='sentence-part'>BACKGROUND AND PURPOSE: Orally administered withanoside IV (a compound isolated from the roots of Withania somnifera) improved memory deficits in mice with a model of Alzheimer's disease induced by the amyloid peptide Abeta(25-35).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/19610108' target='_blank' class='pmid-link'>19610108</a>:</span> <span class='sentence-part'>The significance of intracellular beta-amyloid (Abeta(42)) accumulation is increasingly recognized in Alzheimer's disease (AD) pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/19631265' target='_blank' class='pmid-link'>19631265</a>:</span> <span class='sentence-part'>The role of beta-amyloid (A beta) in the pathogenesis of Alzheimer's disease (AD) is frequently reported in the literature.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/19634775' target='_blank' class='pmid-link'>19634775</a>:</span> <span class='sentence-part'>A wide range of diseases are associated with amyloidosis such as Alzheimer's disease, multiple myeloma, other plasma cell disorders, and chronic inflammation, either as a cause, or result, of amyloid production.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/19657023' target='_blank' class='pmid-link'>19657023</a>:</span> <span class='sentence-part'>Recent evidence supports an important role for intraneuronal beta-amyloid in the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/19678545' target='_blank' class='pmid-link'>19678545</a>:</span> <span class='sentence-part'>The neurotoxicity induced by beta-amyloid (Abeta), which is one of the major causes of Alzheimer's disease (AD), leads to synaptic loss and subsequent neuronal death.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/19699263' target='_blank' class='pmid-link'>19699263</a>:</span> <span class='sentence-part'>The neurotoxicity of aggregated beta-amyloid (Abeta) has been implicated as a critical cause in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/19794916' target='_blank' class='pmid-link'>19794916</a>:</span> <span class='sentence-part'>In Alzheimer's disease tauopathy is considered secondary to amyloid, and the duality obscures their relation and the definition of their respective contributions.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/19827625' target='_blank' class='pmid-link'>19827625</a>:</span> <span class='sentence-part'>Anomalous accumulation of beta-amyloid peptide in cerebral neurons plays central role in pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/19843960' target='_blank' class='pmid-link'>19843960</a>:</span> <span class='sentence-part'>The beta-amyloid (Abeta) peptide is associated with the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/19903023' target='_blank' class='pmid-link'>19903023</a>:</span> <span class='sentence-part'>Genetic and biological studies provide strong support for the hypothesis that accumulation of beta amyloid peptide (Abeta) contributes to the etiology of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/19957250' target='_blank' class='pmid-link'>19957250</a>:</span> <span class='sentence-part'>Withanamides in Withania somnifera fruit protect PC-12 cells from beta-amyloid responsible for Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20074226' target='_blank' class='pmid-link'>20074226</a>:</span> <span class='sentence-part'>Beta-amyloid (Abeta) peptides are thought to play a major role in the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20101562' target='_blank' class='pmid-link'>20101562</a>:</span> <span class='sentence-part'>Increased beta-amyloid (Abeta) production and its aggregation to the oligomeric state is considered to be a major cause of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20101719' target='_blank' class='pmid-link'>20101719</a>:</span> <span class='sentence-part'>The design of future immunomodulatory approaches that are more focused is dependent on addressing a number of questions, including when is the best time to start immunization, what are the most appropriate targets for vaccination, and is amyloid central to the pathogenesis of Alzheimer's disease or is it critical to target tau-related pathology also.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20164555' target='_blank' class='pmid-link'>20164555</a>:</span> <span class='sentence-part'>Controversy still exists about the amyloid pathway as the initiating mechanism or a mere consequence of the events leading to AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/2025422' target='_blank' class='pmid-link'>2025422</a>:</span> <span class='sentence-part'>Hypothesis regarding amyloid and zinc in the pathogenesis of Alzheimer disease: potential for preventive intervention.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20306540' target='_blank' class='pmid-link'>20306540</a>:</span> <span class='sentence-part'>Although Alzheimer's disease (AD) is characterized by the extracellular deposition of fibrillar aggregates of beta-amyloid (Abeta), transient oligomeric species of Abeta are increasingly implicated in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20348021' target='_blank' class='pmid-link'>20348021</a>:</span> <span class='sentence-part'>Research in genetics, pathology, epidemiology, biochemistry, and cell biology, as well as in animal models, suggests that cholesterol, its transporter in the brain, apolipoprotein E, amyloid precursor protein, and amyloid-beta all interact in AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20362424' target='_blank' class='pmid-link'>20362424</a>:</span> <span class='sentence-part'>Beta-amyloid (Abeta) aggregation, believed to be responsible for Alzheimer's disease, is monitored using its intrinsic fluorescence decay.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20429609' target='_blank' class='pmid-link'>20429609</a>:</span> <span class='sentence-part'>Deposition of beta-amyloid (Abeta) is considered an important early event in the pathogenesis of Alzheimer's disease (AD), and reduction of Abeta levels in the brain could be a viable therapeutic approach.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20456003' target='_blank' class='pmid-link'>20456003</a>:</span> <span class='sentence-part'>Presenilin 1 (PS1) is a key component of the gamma-secretase complex in the generation of beta-amyloid (Abeta), an important trigger protein in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20583856' target='_blank' class='pmid-link'>20583856</a>:</span> <span class='sentence-part'>Inhibiting the PAS is desirable for prevention of aggregation of the amyloid peptide Abeta, a major causative factor in the progression of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20637185' target='_blank' class='pmid-link'>20637185</a>:</span> <span class='sentence-part'>In AD, activated microglia may facilitate the clearance of beta-amyloid (Abeta), a neurotoxic component in AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20665950' target='_blank' class='pmid-link'>20665950</a>:</span> <span class='sentence-part'>Galantamine, which is currently used in the treatment of patients with Alzheimer's disease (AD), has been shown to have a neuroprotective effect against beta-amyloid (Abeta) peptide-induced toxicity, which is involved in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20674676' target='_blank' class='pmid-link'>20674676</a>:</span> <span class='sentence-part'>The neurotoxicity of aggregated beta-amyloid (Abeta) has been implicated as a critical cause in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20675873' target='_blank' class='pmid-link'>20675873</a>:</span> <span class='sentence-part'>[Involvement of beta-amyloid in the etiology of Alzheimer's disease].</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20972410' target='_blank' class='pmid-link'>20972410</a>:</span> <span class='sentence-part'>Accumulation of the beta-amyloid peptide (Abeta) is generally believed to be central to the induction of Alzheimer's disease, but the relevant mechanism(s) of toxicity are still unclear.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21222605' target='_blank' class='pmid-link'>21222605</a>:</span> <span class='sentence-part'>Proteolytic processing of APP to generate beta-amyloid, the principle component of amyloid plaques, can occur in membrane rafts, implicating them in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21233670' target='_blank' class='pmid-link'>21233670</a>:</span> <span class='sentence-part'>The first article on Alzheimer's disease (AD) outlines the major evidence available to date that links Abeta-amyloid peptide as a proximal cause of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21270904' target='_blank' class='pmid-link'>21270904</a>:</span> <span class='sentence-part'>beta-Amyloid (Abeta) over-expression and tau hyperphosphorylation are considered to be the central events in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21315759' target='_blank' class='pmid-link'>21315759</a>:</span> <span class='sentence-part'>Metabolism of beta-amyloid peptide (Abeta) is closely associated with the pathology and etiology of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21318523' target='_blank' class='pmid-link'>21318523</a>:</span> <span class='sentence-part'>A large body of evidence suggests a causative role of beta-amyloid (Abeta) in the pathogenesis of Alzheimer's disease (reviewed in refs. 1 and 2).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21395066' target='_blank' class='pmid-link'>21395066</a>:</span> <span class='sentence-part'>[Formation and participation of nano-amyloids in pathogenesis of Alzheimer's disease and other amyloidogenic diseases].</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21472290' target='_blank' class='pmid-link'>21472290</a>:</span> <span class='sentence-part'>Excessive accumulation of beta-amyloid (Abeta) has been proposed as a pivotal event in the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21476939' target='_blank' class='pmid-link'>21476939</a>:</span> <span class='sentence-part'>The beta-amyloid (Abeta) peptide, which plays a crucial role in the pathogenesis of Alzheimer's disease, alters hippocampal-dependent synaptic plasticity and memory and mediates synapse loss through the CREB signaling pathway.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21480689' target='_blank' class='pmid-link'>21480689</a>:</span> <span class='sentence-part'>The production of beta-amyloid is thought to be a major and early contributor to the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21504387' target='_blank' class='pmid-link'>21504387</a>:</span> <span class='sentence-part'>Solanezumab is a monoclonal antibody that binds to beta-amyloid (Abeta), a protein that plays a key role in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21706413' target='_blank' class='pmid-link'>21706413</a>:</span> <span class='sentence-part'>beta-amyloid (Abeta) and copper play important roles in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21839813' target='_blank' class='pmid-link'>21839813</a>:</span> <span class='sentence-part'>It is recognized that the main trigger of Alzheimer disease related neurodegeneration is beta-amyloid peptide, which subsequently generates different metabolic disorders in neuron and finally leads to neuronal death.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21897007' target='_blank' class='pmid-link'>21897007</a>:</span> <span class='sentence-part'>These results support the idea that a link between glucose dysmetabolism and the amyloid pathway may exist in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21961303' target='_blank' class='pmid-link'>21961303</a>:</span> <span class='sentence-part'>Excess production and accumulation of beta-amyloid peptide (betaAP) are central for pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22031884' target='_blank' class='pmid-link'>22031884</a>:</span> <span class='sentence-part'>Impaired beta-amyloid secretion in Alzheimer's disease pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22042506' target='_blank' class='pmid-link'>22042506</a>:</span> <span class='sentence-part'>Beta-amyloid peptide (Abeta), a major protein component of senile plaques, has been considered as a critical cause in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22202113' target='_blank' class='pmid-link'>22202113</a>:</span> <span class='sentence-part'>Generation of Amyloid peptide (Abeta) is at the beginning of a cascade that leads to Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22288451' target='_blank' class='pmid-link'>22288451</a>:</span> <span class='sentence-part'>Solanezumab (LY2062430) is a humanized monoclonal antibody that binds to the central region of beta-amyloid, a peptide believed to play a key role in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22342932' target='_blank' class='pmid-link'>22342932</a>:</span> <span class='sentence-part'>It has been more than a century since the first evidence linking the process of amyloid formation to the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22351073' target='_blank' class='pmid-link'>22351073</a>:</span> <span class='sentence-part'>Generation of amyloid peptide (Abeta) is at the beginning of a cascade that leads to Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22702727' target='_blank' class='pmid-link'>22702727</a>:</span> <span class='sentence-part'>beta-Amyloid peptide (1) (Abeta) aggregates are toxic to neuron and the main cause of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22727791' target='_blank' class='pmid-link'>22727791</a>:</span> <span class='sentence-part'>AIMS: Multiple lines of evidence have implicated beta-amyloid (Abeta) in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22833976' target='_blank' class='pmid-link'>22833976</a>:</span> <span class='sentence-part'>BACKGROUND: Excessive accumulation of beta-amyloid (Abeta) has been proposed as a pivotal event in the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23036978' target='_blank' class='pmid-link'>23036978</a>:</span> <span class='sentence-part'>The abnormal production and accumulation of beta-amyloid peptide (Abeta), which is produced from amyloid precursor protein (APP) by the sequential actions of beta-secretase and gamma-secretase, are thought to be the initial causative events in the development of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23134284' target='_blank' class='pmid-link'>23134284</a>:</span> <span class='sentence-part'>CONTEXT: The beta-amyloid (Abeta) peptide aggregation with accompanying oxidative stress plays the major role in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23300647' target='_blank' class='pmid-link'>23300647</a>:</span> <span class='sentence-part'>Beta-amyloid (Abeta ) neurotoxicity is important in Alzheimer's disease (AD) pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23383341' target='_blank' class='pmid-link'>23383341</a>:</span> <span class='sentence-part'>Unraveling the normal physiologic role of beta-amyloid is likely crucial to understanding the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23420027' target='_blank' class='pmid-link'>23420027</a>:</span> <span class='sentence-part'>IMPORTANCE: Current hypothetical models emphasize the importance of beta-amyloid in Alzheimer disease (AD) pathogenesis, although amyloid alone is not sufficient to account for the dementia syndrome.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23512986' target='_blank' class='pmid-link'>23512986</a>:</span> <span class='sentence-part'>The extracellular accumulation of beta-amyloid peptide is a key trigger in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23516302' target='_blank' class='pmid-link'>23516302</a>:</span> <span class='sentence-part'>Alzheimer's disease is thought to be caused by beta-amyloid peptide (Abeta)-dependent synaptic dysfunction.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23662474' target='_blank' class='pmid-link'>23662474</a>:</span> <span class='sentence-part'>At current review we represented state-of-art views on the processes of production and aggregation of betaAP in organism, cellular and molecular mechanisms of betaAP influence on physiological functions of excitable cells, the role of betaAP in pathogenesis of neurodegenerative diseases (Alzheimer's disease and others), as well as the results of our own studies in this field.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23794448' target='_blank' class='pmid-link'>23794448</a>:</span> <span class='sentence-part'>Amylin amyloid formation in the wall of cerebral blood vessels may also induce failure of elimination of Abeta from the brain, thus contributing to the etiology of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23942088' target='_blank' class='pmid-link'>23942088</a>:</span> <span class='sentence-part'>BACKGROUND: Beta-amyloid (Abeta) protein is a key factor in the pathogenesis of Alzheimer's disease (AD) and it has been reported that mitochondria is involved in the biochemical pathway by which Abeta can lead to neuronal dysfunction.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24162852' target='_blank' class='pmid-link'>24162852</a>:</span> <span class='sentence-part'>Notably, CD36 is also a receptor for modified lipoproteins and beta-amyloid, and has been implicated in the pathogenesis of atherosclerosis and of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24277156' target='_blank' class='pmid-link'>24277156</a>:</span> <span class='sentence-part'>The current study was carried out to investigate the effects of chronic administration of pioglitazone, a PPAR-gamma agonist, on cognitive impairment in an animal model of Alzheimer's disease induced by beta-amyloid.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24287378' target='_blank' class='pmid-link'>24287378</a>:</span> <span class='sentence-part'>The toxicity of amyloid beta-peptide (Abeta) has been implicated as a critical cause in the development of AD, and Abeta-amyloid-induced toxicity is typically associated with apoptosis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24491999' target='_blank' class='pmid-link'>24491999</a>:</span> <span class='sentence-part'>Many evidences are starting to cast doubt on Abeta as the primary causative factor in AD. The dark sides of amyloid in Alzheimer's disease pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24985739' target='_blank' class='pmid-link'>24985739</a>:</span> <span class='sentence-part'>The disruption of Abeta homeostasis, which results in the accumulation of neurotoxic amyloids, is the fundamental cause of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25066110' target='_blank' class='pmid-link'>25066110</a>:</span> <span class='sentence-part'>Implicating the role of lycopene in restoration of mitochondrial enzymes and BDNF levels in beta-amyloid induced Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25108368' target='_blank' class='pmid-link'>25108368</a>:</span> <span class='sentence-part'>Aberrant accumulation of beta-amyloid (Abeta) is thought to be an early event in a biological cascade that eventually leads to Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25639816' target='_blank' class='pmid-link'>25639816</a>:</span> <span class='sentence-part'>An interesting target is the beta-amyloid peptide (Abeta), whose accumulation and progressive deposition into amyloid plaques are key events in AD aetiology.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25686760' target='_blank' class='pmid-link'>25686760</a>:</span> <span class='sentence-part'>Even in Alzheimer disease, which is thought to be primarily caused by amyloid, vascular pathology, such as small vessel disease, may be of greater importance than amyloid itself in terms of influencing the disease course, especially in older individuals.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25686800' target='_blank' class='pmid-link'>25686800</a>:</span> <span class='sentence-part'>Extracellular beta-amyloid peptide accumulation is reported as a major cause in Alzheimer's disease (AD) pathogenesis; large numbers of autophagic vacuoles accumulate in patients' brains.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25714795' target='_blank' class='pmid-link'>25714795</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) and Parkinson's disease (PD) are caused by beta-amyloid (Abeta) and alpha-synuclein (alphaS), respectively.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26073444' target='_blank' class='pmid-link'>26073444</a>:</span> <span class='sentence-part'>Aggregation of beta-amyloid (Abeta) is central to the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26244661' target='_blank' class='pmid-link'>26244661</a>:</span> <span class='sentence-part'>Autophagy is a vital pathway for the removal of beta-amyloid peptide (Abeta) and the aggregated proteins that cause Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26411291' target='_blank' class='pmid-link'>26411291</a>:</span> <span class='sentence-part'>Although amyloids are best known for their role in the etiology of diseases such as Alzheimer's, Parkinson's, and diabetes by forming toxic protein aggregates, our findings show that cells can utilize amyloid-like protein aggregates to function as central regulators of gametogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26440073' target='_blank' class='pmid-link'>26440073</a>:</span> <span class='sentence-part'>The accumulation of extracellular beta-amyloid (Abeta) is crucial in AD pathogenesis, and Abeta-initiated secondary pathological processes could independently lead to neuronal degeneration and pathogenesis in AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26594145' target='_blank' class='pmid-link'>26594145</a>:</span> <span class='sentence-part'>Strong evidence showed neurotoxic properties of beta amyloid (Abeta) and its pivotal role in the Alzheimer's disease (AD) pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26618706' target='_blank' class='pmid-link'>26618706</a>:</span> <span class='sentence-part'>OBJECTIVE: To assess the role attributed to amyloid in AD pathogenesis by Italian dementia experts, and whether this modulates the impact of amyloid PET results in their diagnostic workup. RESULTS: 55% of the experts assigned a dominant role to amyloid, and 32% attributed a similar role to amyloid and tau in AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26786779' target='_blank' class='pmid-link'>26786779</a>:</span> <span class='sentence-part'>Accumulation of oxidized proteins, and especially beta-amyloid (Abeta), is thought to be one of the common causes of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26883101' target='_blank' class='pmid-link'>26883101</a>:</span> <span class='sentence-part'>The processing of amyloid beta precursor protein (APP) to beta-amyloid peptide (Abeta) is one of the critical events in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27018282' target='_blank' class='pmid-link'>27018282</a>:</span> <span class='sentence-part'>beta-Amyloid (Abeta) oligomers may play an important role in the early pathogenesis of Alzheimer's disease: cognitive impairment caused by synaptic dysfunction.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27071404' target='_blank' class='pmid-link'>27071404</a>:</span> <span class='sentence-part'>Protein misfolding, aggregation and deposition in the brain, in the form of amyloid, are implicated in the etiology of several neurodegenerative disorders, such as Alzheimer's, Parkinson's and prion diseases.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27072891' target='_blank' class='pmid-link'>27072891</a>:</span> <span class='sentence-part'>The processing of amyloid precursor protein (APP) into beta-amyloid peptide (Abeta) is a key step in the pathogenesis of Alzheimer's disease (AD), and trafficking dysregulations of APP and its secretases contribute significantly to altered APP processing.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27072999' target='_blank' class='pmid-link'>27072999</a>:</span> <span class='sentence-part'>Because of the increased lifetime of phosphorylated beta-amyloid aggregates, phosphorylation can promote the spreading of beta-amyloid in Alzheimer pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27106205' target='_blank' class='pmid-link'>27106205</a>:</span> <span class='sentence-part'>Several lines of evidence indicate that beta amyloid (beta-A) production, neurofibrillary tangles and neuroinflammation are interrelated in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27303604' target='_blank' class='pmid-link'>27303604</a>:</span> <span class='sentence-part'>INTRODUCTION: To study the effect of gallic acid (GA) on hippocampal long-term potentiation (LTP) and histological changes in animal model of Alzheimer disease (AD) induced by beta-amyloid (Abeta).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27318146' target='_blank' class='pmid-link'>27318146</a>:</span> <span class='sentence-part'>The misfolding and accumulation of the protein fragment beta-amyloid (Abeta) is an early and essential event in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27481595' target='_blank' class='pmid-link'>27481595</a>:</span> <span class='sentence-part'>Given its role in the formation of amyloids leading to Alzheimer's disease, it has been a major therapeutic target for intervention and has been a challenge in the past and the progress has been very slow.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27634977' target='_blank' class='pmid-link'>27634977</a>:</span> <span class='sentence-part'>This review examines the possible role of the gut in the dissemination of amyloids, the role of the gut microbiota in the regulation of the gut-brain axis, the potential amyloidogenic properties of gut bacteria, and the possible impact of nutrients on modulation of microbiota composition and amyloid formation in relation to the pathogenesis of Alzheimer disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27710900' target='_blank' class='pmid-link'>27710900</a>:</span> <span class='sentence-part'>Misfolded beta-sheet-rich protein aggregates termed amyloid, deposit in vivo leading to debilitating diseases such as Alzheimer's, prion and renal amyloidosis diseases etc.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27867033' target='_blank' class='pmid-link'>27867033</a>:</span> <span class='sentence-part'>The prevailing beta-amyloid (Abeta)-cascade hypothesis is the most classical Alzheimer's disease (AD) pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27922847' target='_blank' class='pmid-link'>27922847</a>:</span> <span class='sentence-part'>The objective of this article is to review the recent findings about the metabolism of apolipoprotein E (ApoE) and amyloid beta and other possible mechanisms by which ApoE contributes to the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28261990' target='_blank' class='pmid-link'>28261990</a>:</span> <span class='sentence-part'>AIMS: Axonal degeneration is a pathological symbol in the early stage of Alzheimer's disease (AD), which can be triggered by amyloid-?</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28271324' target='_blank' class='pmid-link'>28271324</a>:</span> <span class='sentence-part'>Beta-amyloid peptide (Abeta) induced neurotoxicity is considered as a hallmark of the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28320296' target='_blank' class='pmid-link'>28320296</a>:</span> <span class='sentence-part'>Here we (i) highlight the latest data on mechanisms of amyloid formation and further discuss a hypothesis on the amyloid cascade as a primary mechanism of AD pathogenesis and (ii) review the evolutionary aspects of amyloidosis, which allow new insight on human-specific mechanisms of dementia development.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28352309' target='_blank' class='pmid-link'>28352309</a>:</span> <span class='sentence-part'>The present study aimed to investigate the effects of asiaticoside (AS) on the pathology and associated mechanisms of beta-amyloid (Abeta)-induced Alzheimer's disease (AD) in rats. According to the findings of the observed study, AS has a marked protective effect on Abeta-induced AD pathology, and the underlying mechanism may be associated with the alleviation of the mitochondrial injuries, the anti-inflammatory activities, and the influence on the expression levels of apoptosis-associated proteins.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28509380' target='_blank' class='pmid-link'>28509380</a>:</span> <span class='sentence-part'>OBJECTIVE: The aim of this study is to examine the hypotheses stating the importance of amyloid or of its oligomers in the pathogenesis of Alzheimer's disease (AD). RESULTS: The importance of amyloid in the pathogenesis of AD is well established, yet accepting it as the main cause for AD is problematic, because amyloid-centric treatments have provided no clinical benefit and about one-third of cognitively normal, older persons have cerebral amyloid plaques.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28592267' target='_blank' class='pmid-link'>28592267</a>:</span> <span class='sentence-part'>BACKGROUND: ?-Amyloid peptide (A?) oligomers are initial factors used to induce Alzheimer's disease (AD) development, and A? monomers have normal physiological function.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28756148' target='_blank' class='pmid-link'>28756148</a>:</span> <span class='sentence-part'>Excessive accumulation of beta-amyloid (Abeta) has been proposed as a pivotal event in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28774853' target='_blank' class='pmid-link'>28774853</a>:</span> <span class='sentence-part'>Maintenance of normal biochemical levels in brain tissue demonstrated the potential of these coated MWCNTs in reducing beta-amyloid induced AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28815614' target='_blank' class='pmid-link'>28815614</a>:</span> <span class='sentence-part'>The amyloid hypothesis suggests that the progressive accumulation and deposition of central nervous system (CNS) amyloid with aging is the proximate cause of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28866757' target='_blank' class='pmid-link'>28866757</a>:</span> <span class='sentence-part'>Experimental data suggest that the cerebrospinal fluid (CSF) dynamic is involved in the clearance of beta-amyloid, a key event in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28900376' target='_blank' class='pmid-link'>28900376</a>:</span> <span class='sentence-part'>Also, various experimental and clinical studies are in progress to prove exercise role in the beta-amyloid (Abeta) pathology as a most prevailing hypothesis explaining AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/2890206' target='_blank' class='pmid-link'>2890206</a>:</span> <span class='sentence-part'>Furthermore, no significant allelic association was detected between AD and any of the loci, including the amyloid and SODI genes, providing no support for the hypothesis that defects in these specific genes are the primary cause of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28993924' target='_blank' class='pmid-link'>28993924</a>:</span> <span class='sentence-part'>The role of beta-amyloid (Abeta) in the pathogenesis of Alzheimer's disease (AD) is still considered crucial.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29158049' target='_blank' class='pmid-link'>29158049</a>:</span> <span class='sentence-part'>We therefore evaluated the effects of tanshinone IIA (TIIA) and cryptotanshinone (CRY) (the two major lipophilic compounds of Danshen) in a non-genetic mouse model of beta-amyloid (Abeta)-induced AD, which is mainly characterized by reactive gliosis and neuro-inflammation in the brain.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29191087' target='_blank' class='pmid-link'>29191087</a>:</span> <span class='sentence-part'>Deranged beta-amyloid (Abeta) trafficking across the blood-brain barrier is known to be a critical element in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29311595' target='_blank' class='pmid-link'>29311595</a>:</span> <span class='sentence-part'>Excessive accumulation of beta-amyloid (Abeta) is thought to be a major causative factor in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29427089' target='_blank' class='pmid-link'>29427089</a>:</span> <span class='sentence-part'>However, the role of ER stress in beta-amyloid (Abeta)-induced AD pathology remains elusive, and data obtained from different animal models and under different experimental conditions are sometimes controversial.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29444819' target='_blank' class='pmid-link'>29444819</a>:</span> <span class='sentence-part'>BACE1 initiates the generation of the beta-amyloid peptide, which likely causes Alzheimer's disease (AD) when accumulated abnormally.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29966723' target='_blank' class='pmid-link'>29966723</a>:</span> <span class='sentence-part'>beta-Amyloid (Abeta) plays an important role in the early pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30126231' target='_blank' class='pmid-link'>30126231</a>:</span> <span class='sentence-part'>Increasing evidence suggests that amyloid formation, i.e., self-assembly of proteins and the resulting conformational changes, is linked with the pathogenesis of various neurodegenerative disorders such as Alzheimer's disease, prion diseases, and Lewy body diseases.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30127003' target='_blank' class='pmid-link'>30127003</a>:</span> <span class='sentence-part'>Amyloid peptide-related inflammation is thought to be an important aspect of AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30220236' target='_blank' class='pmid-link'>30220236</a>:</span> <span class='sentence-part'>In light of recent evidence that the cascade is driven by the misfolding and templated aggregation of Abeta and tau, we believe that an empirically grounded Standard Model of Alzheimer's pathogenesis is within reach. By affirming markers of abnormal Abeta and tau proteins as the essential pathobiological signature of Alzheimer's disease, the Framework tacitly reinforces the amyloid (Abeta) cascade as the leading theory of Alzheimer pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30232325' target='_blank' class='pmid-link'>30232325</a>:</span> <span class='sentence-part'>In Alzheimer's disease (AD), the canonical Wnt inhibitor Dickkopf-1 (Dkk1) is induced by beta-amyloid (Abeta) and shifts the balance from canonical towards non-canonical Wnt signalling.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30483749' target='_blank' class='pmid-link'>30483749</a>:</span> <span class='sentence-part'>Cytotoxicity of beta-Amyloid (Abeta) is a major contributor to the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30572184' target='_blank' class='pmid-link'>30572184</a>:</span> <span class='sentence-part'>beta-Amyloid (Abeta) accumulation is an early event of Alzheimer's disease (AD) pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30723404' target='_blank' class='pmid-link'>30723404</a>:</span> <span class='sentence-part'>Effects of BIS-MEP on Reversing Amyloid Plaque Deposition and Spatial Learning and Memory Impairments in a Mouse Model of beta-Amyloid Peptide- and Ibotenic Acid-Induced Alzheimer's Disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30786665' target='_blank' class='pmid-link'>30786665</a>:</span> <span class='sentence-part'>Alzheimer's disease neuropathologic change (ADNC) in the form of ?-amyloid (A?) deposits is important not only in the pathogenesis of Alzheimer's disease (AD) and Down's syndrome (DS) but also as a 'co-pathology' in disorders such as dementia with Lewy bodies (DLB), corticobasal degeneration (CBD), and chronic traumatic encephalopathy (CTE).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30868421' target='_blank' class='pmid-link'>30868421</a>:</span> <span class='sentence-part'>Does HIV infection contribute to increased beta-amyloid synthesis and plaque formation leading to neurodegeneration and Alzheimer's disease?</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30936829' target='_blank' class='pmid-link'>30936829</a>:</span> <span class='sentence-part'>Literary evidence depicts that aggregated beta-amyloid (Abeta) leads to the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30946834' target='_blank' class='pmid-link'>30946834</a>:</span> <span class='sentence-part'>Beta-amyloid (Abeta) has pivotal functions in the pathogenesis of Alzheimer's Disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30959405' target='_blank' class='pmid-link'>30959405</a>:</span> <span class='sentence-part'>beta-amyloid (Abeta) plays an essential role in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31095505' target='_blank' class='pmid-link'>31095505</a>:</span> <span class='sentence-part'>Accumulation of beta-amyloid peptide (Abeta) is regarded as a primary cause of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31108937' target='_blank' class='pmid-link'>31108937</a>:</span> <span class='sentence-part'>beta-site APP-cleaving enzyme 1 (BACE1) initiates amyloid precursor protein (APP) cleavage and beta-amyloid (Abeta) production, a critical step in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31164812' target='_blank' class='pmid-link'>31164812</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) is one of the most common neurodegenerative diseases, and beta-amyloid (Abeta) plays a leading role in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31193333' target='_blank' class='pmid-link'>31193333</a>:</span> <span class='sentence-part'>They are infectious such as prions or noninfectious such as beta-amyloid (Abeta) fibrils causing Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31211853' target='_blank' class='pmid-link'>31211853</a>:</span> <span class='sentence-part'>The abnormal accumulation of beta-amyloid peptide (Abeta) is recognized as a central component in the pathogenesis of Alzheimer disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31299145' target='_blank' class='pmid-link'>31299145</a>:</span> <span class='sentence-part'>Tracing the GSAP-APP C-99 Interaction Site in the beta-Amyloid Pathway Leading to Alzheimer's Disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31301179' target='_blank' class='pmid-link'>31301179</a>:</span> <span class='sentence-part'>Activation of Nrf2 signaling by sitagliptin and quercetin combination against beta-amyloid induced Alzheimer's disease in rats. Pretreatment with QCR potentiates the action of Sita in Abeta induced AD in rats.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31332160' target='_blank' class='pmid-link'>31332160</a>:</span> <span class='sentence-part'>Beta-amyloid (Abeta) peptide accumulation is considered as a primary cause of AD pathogenesis, with defective autophagy in patients' brains.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31458243' target='_blank' class='pmid-link'>31458243</a>:</span> <span class='sentence-part'>During the early stages of beta amyloid (Ab) peptide aggregation, toxic oligomers form which have been recognized as a likely cause of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31482248' target='_blank' class='pmid-link'>31482248</a>:</span> <span class='sentence-part'>Beta amyloid (Abeta) peptide aggregation and phosphorylated tau protein accumulation are considered as one of the causes for AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31629115' target='_blank' class='pmid-link'>31629115</a>:</span> <span class='sentence-part'>Beta-amyloid (Abeta) peptide accumulation has long been implicated in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31639294' target='_blank' class='pmid-link'>31639294</a>:</span> <span class='sentence-part'>Previous studies have shown that fascaplysin might act on acetylcholinesterase and beta-amyloid (Abeta) to produce anti-AD properties.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31722781' target='_blank' class='pmid-link'>31722781</a>:</span> <span class='sentence-part'>Both amyloid and tau pathologies have an impact upon mitochondria through physical interaction or indirect signaling pathways, resulting in the disruption of mitochondrial function and dynamics which can trigger AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31876283' target='_blank' class='pmid-link'>31876283</a>:</span> <span class='sentence-part'>Zinc ions and glycosaminoglycans (GAGs) are found in amyloid deposits and are known to modulate the beta-amyloid peptide (Abeta) aggregation, which is thought to be a key event in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32035959' target='_blank' class='pmid-link'>32035959</a>:</span> <span class='sentence-part'>Sodium tanshinone IIA sulfonate protects against Abeta     1-42      -induced cellular toxicity by modulating Abeta-degrading enzymes in HT22 cells.beta-Amyloid (Abeta) plays an important role in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32046518' target='_blank' class='pmid-link'>32046518</a>:</span> <span class='sentence-part'>This study investigated the mechanism which postulates that intraneuronal accumulation of amyloid aggregates for pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32350803' target='_blank' class='pmid-link'>32350803</a>:</span> <span class='sentence-part'>CONCLUSIONS: The current ATN model of AD does not specify the subtype of beta-amyloid to be considered, which may be overlooking the differential roles that these two subtypes serve in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32353422' target='_blank' class='pmid-link'>32353422</a>:</span> <span class='sentence-part'>The fibrillar peptide beta-amyloid (Abeta) has a chief function in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32508629' target='_blank' class='pmid-link'>32508629</a>:</span> <span class='sentence-part'>Emerging evidence reveals that an aberrant accumulation of beta-amyloid (Abeta) is the main reason of Alzheimer's disease (AD) pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32831200' target='_blank' class='pmid-link'>32831200</a>:</span> <span class='sentence-part'>Dickkopf-1 Overexpression in vitro Nominates Candidate Blood Biomarkers Relating to Alzheimer's Disease Pathology.BACKGROUND: Previous studies suggest that Dickkopf-1 (DKK1), an inhibitor of Wnt signaling, plays a role in amyloid-induced toxicity and hence Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/3288032' target='_blank' class='pmid-link'>3288032</a>:</span> <span class='sentence-part'>Theories pertinent to the origins of brain amyloid and its role in the pathogenesis of Alzheimer disease are discussed in relation to theories of the cause of this dementia.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32907613' target='_blank' class='pmid-link'>32907613</a>:</span> <span class='sentence-part'>Peroxiredoxin 6 mediates protective function of astrocytes in Abeta proteostasis.BACKGROUND: Disruption of beta-amyloid (Abeta) homeostasis is the initial culprit in Alzheimer's disease (AD) pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33092519' target='_blank' class='pmid-link'>33092519</a>:</span> <span class='sentence-part'>Amyloid-beta peptides slightly affect lifespan or antimicrobial peptide gene expression in Drosophila melanogaster.BACKGROUND: Beta-amyloid peptide (Abeta) is the key protein in the pathogenesis of Alzheimer's disease, the most common age-related neurodegenerative disorder in humans.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33186671' target='_blank' class='pmid-link'>33186671</a>:</span> <span class='sentence-part'>With this viewpoint article, we aim to challenge the traditional view of amyloid as the leading cause of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33480241' target='_blank' class='pmid-link'>33480241</a>:</span> <span class='sentence-part'>Injection of ?-amyloid peptide (A?1-42) into the lateral ventricle was used to induce AD in rats.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33509204' target='_blank' class='pmid-link'>33509204</a>:</span> <span class='sentence-part'>Despite extensive research on the amyloid-based mechanism of AD pathogenesis, the underlying cause of AD is not fully understood.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34123738' target='_blank' class='pmid-link'>34123738</a>:</span> <span class='sentence-part'>Amyloid and tau protein abnormalities have been identified as the main causes of Alzheimer's disease but exact mechanisms remain to be revealed.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34299592' target='_blank' class='pmid-link'>34299592</a>:</span> <span class='sentence-part'>Beta (beta)-amyloid (Abeta) is a causative protein of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34488020' target='_blank' class='pmid-link'>34488020</a>:</span> <span class='sentence-part'>These three amyloidogenic proteins forming amyloids under physiological conditions (pH 7.4 and 37C) served as model and are thought to be the causative proteins of AD, type 2 diabetes, and insulin-derived amyloidosis, respectively.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34520451' target='_blank' class='pmid-link'>34520451</a>:</span> <span class='sentence-part'>Synthesis of human amyloid restricted to liver results in an Alzheimer disease-like neurodegenerative phenotype.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35109309' target='_blank' class='pmid-link'>35109309</a>:</span> <span class='sentence-part'>BACKGROUND: The amyloid channel theory readily explains primary molecular damage induced by beta-amyloid (Abeta) but cannot interpret multiple major phenomena associated with Alzheimer's Disease such as autophagy failure and decreased metabolism.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36420978' target='_blank' class='pmid-link'>36420978</a>:</span> <span class='sentence-part'>Betaeta-amyloid (Abeta) is a neurotoxic protein that deposits early in the pathogenesis of preclinical Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36856252' target='_blank' class='pmid-link'>36856252</a>:</span> <span class='sentence-part'>Effect of silibinin and trans-chalcone in an Alzheimer's disease-like model generated by insulin amyloids.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37774681' target='_blank' class='pmid-link'>37774681</a>:</span> <span class='sentence-part'>Our integrative analysis provides an organizing framework for targeting circuit dysfunction, neuroinflammation, and amyloid production early in AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/38352874' target='_blank' class='pmid-link'>38352874</a>:</span> <span class='sentence-part'>Methods: Here, we evaluated the    in vivo     role of microglia-selective and full body inflammasome signalling in several mouse models of ss-amyloid-induced AD neuropathology.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/38473975' target='_blank' class='pmid-link'>38473975</a>:</span> <span class='sentence-part'>New data suggest that the aggregation of misfolded native proteins initiates and drives the pathogenic cascade that leads to Alzheimer's disease (AD) and other age-related neurodegenerative disorders. An extensive body of genetic evidence suggests soluble aggregates of beta-amyloid (Abeta) as the primary neurotoxin in the pathogenesis of AD. Understanding the distinct roles of soluble and insoluble amyloid aggregates on AD pathogenesis has been the key missing piece of the Alzheimer's puzzle.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/7491048' target='_blank' class='pmid-link'>7491048</a>:</span> <span class='sentence-part'>Our study suggests that the size of cortical area affected by beta-amyloid deposition is an important factor in the clinical manifestation of dementia, and lends support to the possibility that beta-amyloid is central to the aetiology of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/7565212' target='_blank' class='pmid-link'>7565212</a>:</span> <span class='sentence-part'>Amyloid, aluminium and the aetiology of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/7708775' target='_blank' class='pmid-link'>7708775</a>:</span> <span class='sentence-part'>Normal control fibroblasts exposed to 10 nM beta-amyloid, the same concentration that induced AD-like K+ changes in control fibroblasts, showed a similar decrease in Cp20.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/7750567' target='_blank' class='pmid-link'>7750567</a>:</span> <span class='sentence-part'>The non-enzymatic glycosylation of beta-amyloid is implicated in the aetiology of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/7763339' target='_blank' class='pmid-link'>7763339</a>:</span> <span class='sentence-part'>Consequences of the molecular mechanism of amyloid formation for the understanding of the pathogenesis of Alzheimer's disease and the development of therapeutic strategies.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/7812796' target='_blank' class='pmid-link'>7812796</a>:</span> <span class='sentence-part'>These observations have direct consequences for the interpretation of Alz-50 staining in diagnostic usage and for the assessment of Alzheimer's disease-like changes induced by beta-amyloid in experimental animal brains.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/7822152' target='_blank' class='pmid-link'>7822152</a>:</span> <span class='sentence-part'>PURPOSE: Increased immunoreactivity (IR) of beta-amyloid and the amyloid-associated proteins tau and amyloid precursor protein (APP) in the brain have been linked to the pathogenesis of neurodegenerative disorders such as Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/8131745' target='_blank' class='pmid-link'>8131745</a>:</span> <span class='sentence-part'>Accumulation of the amyloid A beta peptide, which is derived from a larger precursor protein (APP), and the formation of plaques, are major events believed to be involved in the etiology of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/8146663' target='_blank' class='pmid-link'>8146663</a>:</span> <span class='sentence-part'>Soluble beta-amyloid induction of Alzheimer's phenotype for human fibroblast K+ channels. In Alzheimer's disease, then, beta-amyloid might alter potassium channels and thus impair neuronal function to produce symptoms such as memory loss by a means other than plaque formation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/8159255' target='_blank' class='pmid-link'>8159255</a>:</span> <span class='sentence-part'>We probed serial and near serial sections of cerebellum from 13 Alzheimer's disease (AD), 10 older Down's syndrome (DS) patients, and 9 age-matched, non-AD controls, using single and double labeling immunohistochemistry to investigate the pathologic consequences of beta-amyloid or A4 (A beta) deposits in cerebellum and their relationship to Purkinje cells (PCs).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/8185566' target='_blank' class='pmid-link'>8185566</a>:</span> <span class='sentence-part'>Besides the neurotoxic properties of beta-amyloid (beta A4), apolipoprotein E polymorphism seems to play an important role in the pathogenesis of sporadic Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/8489324' target='_blank' class='pmid-link'>8489324</a>:</span> <span class='sentence-part'>CONCLUSION: The results of the study indicate the importance of neurofibrillary degeneration, not the deposition of amyloid, in the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/8604204' target='_blank' class='pmid-link'>8604204</a>:</span> <span class='sentence-part'>Amyloid, aluminum and the aetiology of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/8606673' target='_blank' class='pmid-link'>8606673</a>:</span> <span class='sentence-part'>Amyloid, aluminium and the aetiology of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/8706841' target='_blank' class='pmid-link'>8706841</a>:</span> <span class='sentence-part'>The overproduction of beta-amyloid (A beta) appears to be a primary cause of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/8740984' target='_blank' class='pmid-link'>8740984</a>:</span> <span class='sentence-part'>The occurrence and effects of the mutations in APP and the fact that the epsilon 4 allele of ApoE are genetic risk factors point to the hypothesis that the extracellular deposition of beta-amyloid is the key initiating event in the pathogenesis of AD. Four genes have thus far been implicated in the etiology of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/8761337' target='_blank' class='pmid-link'>8761337</a>:</span> <span class='sentence-part'>Soluble beta-amyloid induces Alzheimer's disease features in human fibroblasts and in neuronal tissues.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/8997415' target='_blank' class='pmid-link'>8997415</a>:</span> <span class='sentence-part'>The importance of the beta-amyloid peptide in the pathogenesis of AD has been strengthened by the identification of pathogenic mutations in the APP gene on chromosome 21.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/9116244' target='_blank' class='pmid-link'>9116244</a>:</span> <span class='sentence-part'>Since administration of anti-inflammatory drugs has been reported to possibly slow the progression of Alzheimer's disease, an effort was made to define effector functions induced by beta-amyloid (A beta) which may be inhibited by these drugs.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/9168112' target='_blank' class='pmid-link'>9168112</a>:</span> <span class='sentence-part'>Although most of the molecular mechanisms involving beta-amyloid and APP in the aetiology of Alzheimer's disease are still unclear, changes in APP metabolism may be important in the pathogenesis of the disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/9348103' target='_blank' class='pmid-link'>9348103</a>:</span> <span class='sentence-part'>Since the identification in 1984 of the amyloid beta protein (Abeta) as the major component of senile plaques and cerebrovascular amyloid in Alzheimer's disease (AD) brains, it is well accepted that the production of this protein is a crucial factor in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/9399697' target='_blank' class='pmid-link'>9399697</a>:</span> <span class='sentence-part'>These findings indicate that changes in cerebral betaA4 levels contribute to temporal lobe atrophy in AD and support the possibility that betaA4 is central to the etiology of AD. Pathological and biochemical studies indicate that beta-amyloid (betaA4) deposition is a hallmark in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/9630681' target='_blank' class='pmid-link'>9630681</a>:</span> <span class='sentence-part'>Experimental evidence increasingly implicates the beta-amyloid peptide in the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/9683325' target='_blank' class='pmid-link'>9683325</a>:</span> <span class='sentence-part'>Formation of beta-amyloid and neurofibrillary tangles in the brain due to genetic or other factors is the most frequent cause of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/9794144' target='_blank' class='pmid-link'>9794144</a>:</span> <span class='sentence-part'>The particular contribution of muscarinic receptors, beta-amyloid and tau proteins in the pathogenesis of Alzheimer's disease remains still unclear. Probably Alzheimer's disease could be due to a progressive degeneration in the relationship between the three components covered in this review.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/9865931' target='_blank' class='pmid-link'>9865931</a>:</span> <span class='sentence-part'>An increased beta-amyloid (Abeta) peptide is believed to play a central role in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/9928821' target='_blank' class='pmid-link'>9928821</a>:</span> <span class='sentence-part'>Strong genetic evidence has been accumulated in favor of a central role of beta-amyloid precursor protein (APP) and beta-amyloid peptide (betaA4) in the pathogenesis of Alzheimer's disease (AD).</span></div></div>
<div class='streamlined-assertion'><div class='streamlined-header sticky-relation-header'><span class='label-text'>Subject:</span> <strong>Amyloid_Fibrils</strong> <span class='label-text'>Subject CUI:</span> <strong>C1449651</strong> â†’ <span class='label-text predicate-text'>CAUSES</span> â†’ <span class='label-text'>Object:</span> <strong>Alzheimers</strong> <span class='label-text'>Object CUI:</span> <strong>C0002395</strong></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/11374584' target='_blank' class='pmid-link'>11374584</a>:</span> <span class='sentence-part'>The formation of amyloid fibrils is considered to be an important step in the aetiology of Alzheimer's disease and other amyloidoses.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/11570871' target='_blank' class='pmid-link'>11570871</a>:</span> <span class='sentence-part'>The assembly of the beta-amyloid peptide (Abeta) into amyloid fibrils is essential to the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/11714802' target='_blank' class='pmid-link'>11714802</a>:</span> <span class='sentence-part'>These observations provide direct evidence of the ability of beta-amyloid fibrils to trigger activation of the classical C pathway and further support the hypothesis that C activation may be a component of the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/14640676' target='_blank' class='pmid-link'>14640676</a>:</span> <span class='sentence-part'>Protofibrils are transient structures observed during in vitro formation of mature amyloid fibrils and have been implicated as the toxic species responsible for cell dysfunction and neuronal loss in Alzheimer's disease (AD) and other protein aggregation diseases.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/15980593' target='_blank' class='pmid-link'>15980593</a>:</span> <span class='sentence-part'>Elucidating the structural properties of early intermediates (protofibrils) on the fibril formation pathway of Abeta and alpha-synuclein, the structural relationship among the different intermediates and their relationship to the structure of the amyloid fibrils is critical for understanding the roles of amyloid fibril formation in the pathogenesis of Alzheimer's and Parkinson's diseases.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/16178030' target='_blank' class='pmid-link'>16178030</a>:</span> <span class='sentence-part'>Mutations in AbetaPP cause deposition of Abeta amyloid fibrils in brain parenchyma and cerebral vessels, resulting in Alzheimer's disease (AD) and/or cerebral amyloid angiopathy (CAA).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/16186179' target='_blank' class='pmid-link'>16186179</a>:</span> <span class='sentence-part'>Protein aggregation--and, more specifically, amyloid fibril formation--has been implicated as a primary cause of neurodegeneration in Alzheimer's disease, Parkinson's disease, and related disorders, but the mechanism by which this process triggers neuronal death is unknown.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/16233815' target='_blank' class='pmid-link'>16233815</a>:</span> <span class='sentence-part'>Structure of beta-amyloid fibrils and its relevance to their neurotoxicity: implications for the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22271749' target='_blank' class='pmid-link'>22271749</a>:</span> <span class='sentence-part'>Amyloid fibrils are known to be responsible for diseases such as Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22468636' target='_blank' class='pmid-link'>22468636</a>:</span> <span class='sentence-part'>The misfolding and aggregation of amyloid-beta (Abeta) peptides into amyloid fibrils in solution and on the cell membrane has been linked to the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22528091' target='_blank' class='pmid-link'>22528091</a>:</span> <span class='sentence-part'>The elucidation of the structure of amyloid fibrils and related aggregates is an important step towards understanding the pathogenesis of diseases such as Alzheimer's and Parkinson's, which feature protein misfolding and/or aggregation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23415897' target='_blank' class='pmid-link'>23415897</a>:</span> <span class='sentence-part'>The formation of amyloid beta (Abeta) fibrils is crucial in initiating the cascade of pathological events that culminates in Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23506133' target='_blank' class='pmid-link'>23506133</a>:</span> <span class='sentence-part'>The misfolding and aggregation of amyloid-beta (Abeta) peptides into amyloid fibrils is regarded as one of the causative events in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23650245' target='_blank' class='pmid-link'>23650245</a>:</span> <span class='sentence-part'>Amyloid fibril formation is a critical step in Alzheimer's disease (AD) pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24247242' target='_blank' class='pmid-link'>24247242</a>:</span> <span class='sentence-part'>The interconversion of monomers, oligomers, and amyloid fibrils of the amyloid-beta peptide (Abeta) has been implicated in the pathogenesis of Alzheimer disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25343100' target='_blank' class='pmid-link'>25343100</a>:</span> <span class='sentence-part'>Aggregation of Abeta under the form of amyloid fibrils has long been considered central to the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25874995' target='_blank' class='pmid-link'>25874995</a>:</span> <span class='sentence-part'>The misfolding and aggregation of amyloid beta (Abeta) peptides into amyloid fibrils are key events in the amyloid cascade hypothesis for the etiology of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26206266' target='_blank' class='pmid-link'>26206266</a>:</span> <span class='sentence-part'>Finally, the surface-enhanced Raman scattering (SERS) activity of these HNS was investigated by using thioflavin T, a biomarker of the beta-amyloid fibril formation, responsible for Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28750656' target='_blank' class='pmid-link'>28750656</a>:</span> <span class='sentence-part'>Although amyloid fibrils were originally considered responsible for AD pathogenesis, recent convincing evidence strongly implicates soluble oligomeric Abeta as the primary neurotoxic species driving disease progression.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29107146' target='_blank' class='pmid-link'>29107146</a>:</span> <span class='sentence-part'>The NABi blocks Abeta-fibril formation in vitro and in vivo and prevents neuronal cell death, a hallmark of AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29704282' target='_blank' class='pmid-link'>29704282</a>:</span> <span class='sentence-part'>Taken together, this study illustrates dysfunction of hippocampal silent synapse in the rodent model of AD, which might result from the impairments of actin cytoskeleton and postsynaptic scaffolding proteins induced by amyloid fibrils.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30264484' target='_blank' class='pmid-link'>30264484</a>:</span> <span class='sentence-part'>Beta-secretase 1 (BACE-1) is an aspartyl protease implicated in the overproduction of beta-amyloid fibrils responsible for Alzheimer disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30979271' target='_blank' class='pmid-link'>30979271</a>:</span> <span class='sentence-part'>The formation of amyloid fibrils is considered to be one of the main causes for many neurodegenerative diseases, such as Alzheimer's, Parkinson's or Huntington's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31291354' target='_blank' class='pmid-link'>31291354</a>:</span> <span class='sentence-part'>Accumulation of amyloid beta (Abeta) peptides, the major component of amyloid fibrils in senile plaques, is one of the main causes of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34480905' target='_blank' class='pmid-link'>34480905</a>:</span> <span class='sentence-part'>Accumulating evidence indicates that amyloid oligomers, not amyloid fibrils, are the most toxic species that causes Alzheimer's disease (AD) and Parkinson's disease (PD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35213966' target='_blank' class='pmid-link'>35213966</a>:</span> <span class='sentence-part'>The Use of Bioactive Compounds in Hyperglycemia- and Amyloid Fibrils-Induced Toxicity in Type 2 Diabetes and Alzheimer's Disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35458686' target='_blank' class='pmid-link'>35458686</a>:</span> <span class='sentence-part'>Alzheimer's disease is understood to be caused by amyloid fibrils and oligomers formed by aggregated amyloid-beta (Abeta) peptides.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36297599' target='_blank' class='pmid-link'>36297599</a>:</span> <span class='sentence-part'>Senile plaques composed of amyloid beta (Abeta) fibrils are considered the leading cause of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36305141' target='_blank' class='pmid-link'>36305141</a>:</span> <span class='sentence-part'>Alzheimer's disease is caused by extracellular amyloid fibrils containing the peptide Amyloid beta (Abeta) accumulating in the brain.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/8621479' target='_blank' class='pmid-link'>8621479</a>:</span> <span class='sentence-part'>Polymerization of amyloid beta-peptide (Abeta) into amyloid fibrils is a critical step in the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/9689467' target='_blank' class='pmid-link'>9689467</a>:</span> <span class='sentence-part'>The aggregation of soluble A beta into insoluble amyloid fibrils is believed to be an important step in the pathogenesis of Alzheimer's disease (AD) and the prevention of this process therefore seems to be a promising strategy for the treatment of AD.</span></div></div>
<div class='streamlined-assertion'><div class='streamlined-header sticky-relation-header'><span class='label-text'>Subject:</span> <strong>Amyloid_beta</strong> <span class='label-text'>Subject CUI:</span> <strong>C3484390</strong> â†’ <span class='label-text predicate-text'>CAUSES</span> â†’ <span class='label-text'>Object:</span> <strong>Alzheimers</strong> <span class='label-text'>Object CUI:</span> <strong>C0002395</strong></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31901901' target='_blank' class='pmid-link'>31901901</a>:</span> <span class='sentence-part'>A novel rhamnoside derivative PL402 up-regulates matrix metalloproteinase 3/9 to promote Abeta degradation and alleviates Alzheimer's-like pathology.The accumulation of amyloid-beta (Abeta), considered as the major cause of Alzheimer's disease (AD) pathogenesis, relays on the rate of its biosynthesis and degradation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31951717' target='_blank' class='pmid-link'>31951717</a>:</span> <span class='sentence-part'>Amyloid beta is of particular interest as its oligomerization and aggregation are major events in the etiology of Alzheimer's disease, and it is known that interactions between the peptide and bioavailable metal cations have the potential to significantly damage neurons.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32061803' target='_blank' class='pmid-link'>32061803</a>:</span> <span class='sentence-part'>The response of astrocytes to the presence of Abeta as well astrocytic and microglial interaction and inflammatory cytokine release is also discussed, highlighting a cyclical behaviour of these cells in contributing to AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32144141' target='_blank' class='pmid-link'>32144141</a>:</span> <span class='sentence-part'>Thus, we reveal the Abeta-burdened neuron as a primary proinflammatory agent, implicating the intraneuronal accumulation of Abeta as a significant immunological component in the AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32146679' target='_blank' class='pmid-link'>32146679</a>:</span> <span class='sentence-part'>Microglial dysregulation, pertaining to impairment in phagocytosis, clearance and containment of amyloid-beta (Abeta), and activation of neuroinflammation, has been posited to contribute to the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32154567' target='_blank' class='pmid-link'>32154567</a>:</span> <span class='sentence-part'>Neuronal Aquaporin 1 inhibits amyloidogenesis by suppressing the interaction between beta-secretase and amyloid precursor protein.The accumulation of amyloid beta (Abeta) is a characteristic event in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32165044' target='_blank' class='pmid-link'>32165044</a>:</span> <span class='sentence-part'>Defective immune cell-mediated clearance of amyloid-beta (Abeta) and Abeta-associated inflammatory activation of immune cells are key contributors in pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32229231' target='_blank' class='pmid-link'>32229231</a>:</span> <span class='sentence-part'>Nanogold neuroprotection in human neural stem cells against Amyloid-beta-induced mitochondrial dysfunction.Alzheimer's disease (AD) is a neuronal dementia with progressive memory loss.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32238175' target='_blank' class='pmid-link'>32238175</a>:</span> <span class='sentence-part'>CONCLUSIONS: Overall, our RNA-seq data provide a valuable resource for future investigations into the roles of microglia and astrocytes in aging- and amyloid-beta-induced AD pathologies.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32244832' target='_blank' class='pmid-link'>32244832</a>:</span> <span class='sentence-part'>The cerebral accumulation of amyloid-beta (Abeta) is a critical molecular event in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32381118' target='_blank' class='pmid-link'>32381118</a>:</span> <span class='sentence-part'>Amyloid-beta (Abeta) is suggested to play a pivotal role in the pathogenesis of AD, and clearance of Abeta from the brain becomes a main therapeutic strategy for AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32403399' target='_blank' class='pmid-link'>32403399</a>:</span> <span class='sentence-part'>Amyloid-beta and tau proteins are triggers for AD pathogenesis, and usually used as AD candidate biomarkers in the clinical research.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32525440' target='_blank' class='pmid-link'>32525440</a>:</span> <span class='sentence-part'>Fluid transport in the perivascular space by the glia-lymphatic (glymphatic) system is important for the removal of solutes from the brain parenchyma, including peptides such as amyloid-beta which are implicated in the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32559516' target='_blank' class='pmid-link'>32559516</a>:</span> <span class='sentence-part'>Amyloid beta (Abeta) is an intricate molecule that interacts with several biomolecules and/or produces insoluble assemblies and eventually the nonphysiological depositions of its alternate with normal neuronal conditions leading to Alzheimer's disease (AD). Revisiting the role of brain and peripheral Abeta in the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32569471' target='_blank' class='pmid-link'>32569471</a>:</span> <span class='sentence-part'>Neuroprotective Effects of Triterpenoids from    Camellia japonica     against Amyloid beta-Induced Neuronal Damage.Alzheimer's disease (AD), a neurocognitive impairment affecting human mental capacity, is related to the accumulation of amyloid-beta peptide (Abeta) and the hyperphosphorylation of tau protein.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32588983' target='_blank' class='pmid-link'>32588983</a>:</span> <span class='sentence-part'>An agnostic reevaluation of the amyloid cascade hypothesis of Alzheimer's disease pathogenesis: The role of APP homeostasis.OBJECTIVE: To reassess the role of amyloid beta (Abeta) and the amyloid precursor protein (APP) system in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32599720' target='_blank' class='pmid-link'>32599720</a>:</span> <span class='sentence-part'>Evaluation of Amyloid beta     42       Aggregation Inhibitory Activity of Commercial Dressings by A Microliter-Scale High-Throughput Screening System Using Quantum-Dot Nanoprobes.The aggregation and accumulation of amyloid beta (Abeta) in the brain is a trigger of pathogenesis for Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32601313' target='_blank' class='pmid-link'>32601313</a>:</span> <span class='sentence-part'>Analyzing microglial-associated Abeta in Alzheimer's disease transgenic mice with a novel mid-domain Abeta-antibody.The mechanisms of amyloid-beta (Abeta)-degradation and clearance in Alzheimer's disease (AD) pathogenesis have been relatively little studied.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32649026' target='_blank' class='pmid-link'>32649026</a>:</span> <span class='sentence-part'>Alzheimer's Disease risk modifier genes do not affect tau aggregate uptake, seeding or maintenance in cell models.Alzheimer's disease (AD) afflicts millions of people worldwide and is caused by accumulated amyloid beta and tau pathology.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32725265' target='_blank' class='pmid-link'>32725265</a>:</span> <span class='sentence-part'>Increasing activity of post-synaptic kinase p38gamma that targets T205 in tau reduced memory deficits in symptomatic Abeta-induced AD models.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32804091' target='_blank' class='pmid-link'>32804091</a>:</span> <span class='sentence-part'>APOE-E4 reduces the levels of neuronal cholesterol, interferes with the transportation of cholesterol, impairs repair of synapses, decreases the clearance of neurotoxic peptide amyloid-beta (Abeta), and promotes the deposition of amyloid plaque, and eventually may cause development of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32816241' target='_blank' class='pmid-link'>32816241</a>:</span> <span class='sentence-part'>Dimethyl Fumarate Mitigates Tauopathy in Abeta-Induced Neuroblastoma SH-SY5Y Cells.Alzheimer's disease pathogenesis is measured by two key hallmarks viz extracellular senile plaques composed of insoluble amyloid beta (Abeta) and neurofibrillary tangles composed of hyperphosphorylated tau, resulting in microtubule destabilization, synaptic damage and neurodegeneration.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32832007' target='_blank' class='pmid-link'>32832007</a>:</span> <span class='sentence-part'>Amyloid    beta    - (A   beta    -) induced mitochondrial dysfunction may be a primary process triggering all the cascades of events that lead to AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32926328' target='_blank' class='pmid-link'>32926328</a>:</span> <span class='sentence-part'>5-N-ethyl Carboxamidoadenosine Stimulates Adenosine-2b Receptor-Mediated Mitogen-Activated Protein Kinase Pathway to Improve Brain Mitochondrial Function in Amyloid Beta-Induced Cognitive Deficit Mice.Alzheimer's disease (AD) is a progressive neurodegenerative disorder with loss in memory as one of the cardinal features.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32949547' target='_blank' class='pmid-link'>32949547</a>:</span> <span class='sentence-part'>Cerebral amyloid angiopathy can cause life-threatening brain haemorrhages; yet, there is no proof that the transmission of amyloid beta can also lead to Alzheimer's dementia.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32985682' target='_blank' class='pmid-link'>32985682</a>:</span> <span class='sentence-part'>Gut amyloid-beta induces cognitive deficits and Alzheimer's disease-related histopathology in a mouse model.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32993092' target='_blank' class='pmid-link'>32993092</a>:</span> <span class='sentence-part'>Lupeol, a Plant-Derived Flavonoid, Protects Mice Brains against Abeta-Induced Oxidative Stress and Neurodegeneration.Alzheimer's disease (AD) is a progressive neurodegenerative disorder that represents 60-70% of all dementia cases.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33014538' target='_blank' class='pmid-link'>33014538</a>:</span> <span class='sentence-part'>Besides extracellular deposition of amyloid beta and formation of phosphorylated tau in the brains of patients with Alzheimer's disease (AD), the pathogenesis of AD is also thought to involve mitochondrial dysfunctions and altered neurotransmission systems.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33059154' target='_blank' class='pmid-link'>33059154</a>:</span> <span class='sentence-part'>Cobalt(III) Schiff base complexes stabilize non-fibrillar amyloid-beta aggregates with reduced toxicity.The aggregation of amyloid-beta (Abeta) is believed to be foundational to the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33106917' target='_blank' class='pmid-link'>33106917</a>:</span> <span class='sentence-part'>Amyloid-beta (Abeta) plays a pivotal role in the pathogenesis of Alzheimer's disease (AD) and has been regarded as the main therapeutic target for AD.</span></div></div>
<div class='streamlined-assertion'><div class='streamlined-header sticky-relation-header'><span class='label-text'>Subject:</span> <strong>Amyloid_beta_Peptides</strong> <span class='label-text'>Subject CUI:</span> <strong>C0078939</strong> â†’ <span class='label-text predicate-text'>CAUSES</span> â†’ <span class='label-text'>Object:</span> <strong>Alzheimers</strong> <span class='label-text'>Object CUI:</span> <strong>C0002395</strong></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31949779' target='_blank' class='pmid-link'>31949779</a>:</span> <span class='sentence-part'>The abnormal accumulation and deposition of amyloid-beta peptide (Abeta) in senile plaques and cerebral vasculature is widely recognized to be the most likely culprit in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31991578' target='_blank' class='pmid-link'>31991578</a>:</span> <span class='sentence-part'>AD mutations contribute to the generation of toxic amyloid beta (Abeta) peptides and the formation of cerebral plaques, leading to the formulation of the amyloid cascade hypothesis for AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32028683' target='_blank' class='pmid-link'>32028683</a>:</span> <span class='sentence-part'>Amyloid-beta (Abeta) peptides play a crucial role in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32046252' target='_blank' class='pmid-link'>32046252</a>:</span> <span class='sentence-part'>Interaction of Abeta42 with Membranes Triggers the Self-Assembly into Oligomers.The self-assembly of amyloid beta (Abeta) proteins into oligomers is the major pathogenic event leading to Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32142821' target='_blank' class='pmid-link'>32142821</a>:</span> <span class='sentence-part'>Abeta-ganglioside interactions in the pathogenesis of Alzheimer's disease.It is widely accepted that the abnormal self-association of amyloid beta-protein (Abeta) is central to the pathogenesis of Alzheimer's disease, the most common form of dementia.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32210564' target='_blank' class='pmid-link'>32210564</a>:</span> <span class='sentence-part'>Purpose: Amyloid-beta protein (Abeta) is one of the causative proteins of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32272441' target='_blank' class='pmid-link'>32272441</a>:</span> <span class='sentence-part'>Multiple lines of evidence indicate that amyloid beta (Abeta) peptide is responsible for the pathological devastation caused in Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32307772' target='_blank' class='pmid-link'>32307772</a>:</span> <span class='sentence-part'>Identification of calcium and integrin-binding protein 1 as a novel regulator of production of amyloid beta peptide using CRISPR/Cas9-based screening system.The aberrant metabolism of amyloid beta peptide (Abeta) has been implicated in the etiology of Alzheimer disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32354467' target='_blank' class='pmid-link'>32354467</a>:</span> <span class='sentence-part'>Successive cleavage of beta-amyloid precursor protein by gamma-secretase.gamma-Secretase is a multimeric aspartyl protease that cleaves the membrane-spanning region of the beta-carboxyl terminal fragment (betaCTF) generated from beta-amyloid precursor protein. gamma-Secretase defines the generated molecular species of amyloid beta-protein (Abeta), a critical molecule in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32372339' target='_blank' class='pmid-link'>32372339</a>:</span> <span class='sentence-part'>BACKGROUND: Acetylcholine deficiencies in hippocampus and cortex, aggregation of beta-amyloid, and beta-secretase over activity have been introduced as main reasons in pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32444869' target='_blank' class='pmid-link'>32444869</a>:</span> <span class='sentence-part'>Amyloidogenic processing of Alzheimer's disease beta-amyloid precursor protein induces cellular iron retention.The proteolytic cleavage of beta-amyloid precursor protein (APP) to form the amyloid beta (Abeta) peptide is related to the pathogenesis of Alzheimer's disease (AD) because APP mutations that influence this processing either induce familial AD or mitigate the risk of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32580638' target='_blank' class='pmid-link'>32580638</a>:</span> <span class='sentence-part'>Salt bridges for the APOE correct folding are missing in APOE4, resulting in an increased deposition of the amyloid-beta peptide, compared to APOE3, which can lead to the AD. Herein, using both molecular dynamics and quantum mechanics, the binding mechanisms of APOE4 leading to the AD are unraveled and now available for drug design.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32683653' target='_blank' class='pmid-link'>32683653</a>:</span> <span class='sentence-part'>Amyloid-beta (Abeta) peptides play a significant role in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32733240' target='_blank' class='pmid-link'>32733240</a>:</span> <span class='sentence-part'>The Neuroprotective Action of Amidated-Kyotorphin on Amyloid beta Peptide-Induced Alzheimer's Disease Pathophysiology.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32848600' target='_blank' class='pmid-link'>32848600</a>:</span> <span class='sentence-part'>Major efforts in AD drug were devoted to the interference with the production and accumulation of amyloid-beta peptide (Abeta), which plays a causal role in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32973471' target='_blank' class='pmid-link'>32973471</a>:</span> <span class='sentence-part'>Studies focused on nonpharmacological treatment for AD have been developed to act on brain plasticity and minimize the neurotoxicity caused by the amyloid-beta (Abeta) peptide.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32975365' target='_blank' class='pmid-link'>32975365</a>:</span> <span class='sentence-part'>Moreover, upregulation of fl-APP protein and products may drive downstream events that dysregulate tau homeostasis and inflammatory responses that contribute to propagation of AD pathogenesis. NEW/UPDATED HYPOTHESIS: We hypothesize that the increase in APP gene dose in DS initiates a process in which increased levels of full-length APP (fl-APP) and its products, including beta-CTF and possibly Abeta peptides (Abeta42 and Abeta40), drive AD pathogenesis through an endosome-dependent mechanism(s), which compromises transport of neurotrophic signals. Evidence that in Down syndrome (DS), a population markedly predisposed to develop early onset AD, increased APP gene dose is necessary for both AD neuropathology and dementia points to normalization of the levels of the amyloid precursor protein (APP) and its products as a route to further define AD pathogenesis and discovering novel treatments.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32990912' target='_blank' class='pmid-link'>32990912</a>:</span> <span class='sentence-part'>Amyloid beta protein (Abeta) deposition is the main pathogenesis of AD, and many studies have shown that Abeta accumulation is toxic to neurons, leading to the inflammatory reaction, neuronal apoptosis, and neurofibrillary tangles.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33010207' target='_blank' class='pmid-link'>33010207</a>:</span> <span class='sentence-part'>Aggregation, fibril formation, and deposition of amyloid beta (Abeta) protein are believed to be the central pathogeneses of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33066971' target='_blank' class='pmid-link'>33066971</a>:</span> <span class='sentence-part'>This study investigated whether early-life and chronic exposure to DEHP affects AD via the toxicity of amyloid-beta (Abeta), which has been implicated in the pathogenesis of AD, using Caenorhabditis elegans AD models (strains CL4176 and CL2006).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33074279' target='_blank' class='pmid-link'>33074279</a>:</span> <span class='sentence-part'>Excess aggregation of amyloid beta peptide (Abeta) is a fatal cause of Alzheimer's disease (AD), which leads to physiological toxicity.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33132896' target='_blank' class='pmid-link'>33132896</a>:</span> <span class='sentence-part'>Accumulation of amyloid beta is a key event in Alzheimer's disease pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33189440' target='_blank' class='pmid-link'>33189440</a>:</span> <span class='sentence-part'>Further spatial memory assays in Abeta-induced AD model showed that 22 enhanced the ability of learning and memory.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33208229' target='_blank' class='pmid-link'>33208229</a>:</span> <span class='sentence-part'>The accumulation and aggregation of amyloid-beta (Abeta) are critical factors in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33224974' target='_blank' class='pmid-link'>33224974</a>:</span> <span class='sentence-part'>Particularly, the aggregation of misfolded amyloid-   beta     and hyperphosphorylated tau and    alpha    -synuclein are linked to the pathogenesis of AD and PD, respectively.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33225679' target='_blank' class='pmid-link'>33225679</a>:</span> <span class='sentence-part'>The accumulation and deposition of beta-amyloid (Abeta) is one postulated cause of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33238667' target='_blank' class='pmid-link'>33238667</a>:</span> <span class='sentence-part'>[Roles of amyloid-beta in the pathogenesis of cerebral amyloid angiopathy and Alzheimer's disease should be clarified].</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33258115' target='_blank' class='pmid-link'>33258115</a>:</span> <span class='sentence-part'>A variety of findings from in vitro experiments and animal models support the hypothesis that one contribution to pathogenesis in Alzheimer's disease (AD) is enhanced phosphorylation of tau protein, which may be triggered by amyloid beta (Abeta) and mediated by impaired activity of the PI3K/Akt signaling pathway.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33279620' target='_blank' class='pmid-link'>33279620</a>:</span> <span class='sentence-part'>The amyloid beta protein cascade hypothesis places the formation of amyloid beta protein aggregates on the first position in the complex pathological cascade leading to neurodegeneration, and therefore AD might be considered to be a protein-misfolding disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33310049' target='_blank' class='pmid-link'>33310049</a>:</span> <span class='sentence-part'>In the present study, we tested whether pinoresinol reduces learning and memory and excitatory synaptic deficits in an amyloid beta (Abeta)-induced AD-like mouse model.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33353018' target='_blank' class='pmid-link'>33353018</a>:</span> <span class='sentence-part'>We evaluated the effects of a grain diet rich in anthocyanins in a mouse model of Alzheimer's disease induced by amyloid-beta (Abeta) and a transgenic mouse model of Parkinson's disease (PD) with overexpression of human alpha-synuclein.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33359145' target='_blank' class='pmid-link'>33359145</a>:</span> <span class='sentence-part'>Accumulating evidences suggest that amyloid beta (Abeta)-peptide plays a key role in pathogenesis of Alzheimer's disease (AD) through aggregation and deposition into plaques in neuronal cells.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33386802' target='_blank' class='pmid-link'>33386802</a>:</span> <span class='sentence-part'>Such stress provides the activation energy needed to induce conformational changes of both Abeta and tau within the lower brain and brainstem region, producing unique neurotoxic oligomer molecule conformations that induce AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33400522' target='_blank' class='pmid-link'>33400522</a>:</span> <span class='sentence-part'>Cu, Zn, and amyloid-beta (Abeta) peptides play an important role in the etiology of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33401892' target='_blank' class='pmid-link'>33401892</a>:</span> <span class='sentence-part'>Cu     2+      -mediated amyloid beta-protein (Abeta) aggregation is implicated in the pathogenesis of Alzheimer's disease, so it is of significance to understand Cu     2+      -mediated conformational transitions of Abeta.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33414705' target='_blank' class='pmid-link'>33414705</a>:</span> <span class='sentence-part'>Misfolding and extracellular aggregation of Amyloid-beta (Abeta) peptides are recognized as the main cause of AD progression, leading to the formation of toxic Abeta oligomers and to the deposition of beta-amyloid plaques in the brain, representing the hallmarks of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33426095' target='_blank' class='pmid-link'>33426095</a>:</span> <span class='sentence-part'>Amyloid beta peptides (A   beta    1-42) have been found to be associated with the cause of Alzheimer's disease (AD) and dementia.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33495810' target='_blank' class='pmid-link'>33495810</a>:</span> <span class='sentence-part'>The generation of beta-amyloid protein (Abeta) is considered a key step in the pathogenesis of Alzheimer's disease (AD) and the regulation of its production is an important therapeutic strategy.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33503934' target='_blank' class='pmid-link'>33503934</a>:</span> <span class='sentence-part'>Aggregation of amyloid-beta (abeta) peptides into toxic oligomers, fibrils, and plaques is central in the molecular pathogenesis of Alzheimer's disease (AD) and is the primary focus of AD diagnostics.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33508037' target='_blank' class='pmid-link'>33508037</a>:</span> <span class='sentence-part'>Intraneuronal rise of amyloid beta in its oligomeric forms (iAbetaOs), has been linked to the pathogenesis of AD by disrupting cytosolic Ca2+ homeostasis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33535469' target='_blank' class='pmid-link'>33535469</a>:</span> <span class='sentence-part'>Amyloid beta (Abeta) peptide is an important pathological factor that triggers the progression of AD through accumulation and aggregation, which leads to AD-related pathologies that consequently affect cognitive functions.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33560154' target='_blank' class='pmid-link'>33560154</a>:</span> <span class='sentence-part'>Areas covered    : Considering the significance of Abeta and Tau in AD pathogenesis, these proteins have currently been adopted as the core biomarkers of AD, and their quantification has provided precise diagnostic information to develop next-generation AD therapeutic approaches.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33571523' target='_blank' class='pmid-link'>33571523</a>:</span> <span class='sentence-part'>Beta-amyloid (Abeta) has been recognized as an early trigger in the pathogenesis of Alzheimer's disease (AD) leading to synaptic and cognitive impairments.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33571524' target='_blank' class='pmid-link'>33571524</a>:</span> <span class='sentence-part'>gamma-secretase is responsible for the proteolysis of amyloid precursor protein (APP) into amyloid-beta (Abeta) peptides, which are centrally implicated in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33624157' target='_blank' class='pmid-link'>33624157</a>:</span> <span class='sentence-part'>METHODS: For the induction of Alzheimer's disease, amyloid beta (Abeta) 1-42 was injected in the CA1 region of the hippocampus.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33716668' target='_blank' class='pmid-link'>33716668</a>:</span> <span class='sentence-part'>(Dys)regulation of Synaptic Activity and Neurotransmitter Release by beta-Amyloid: A Look Beyond Alzheimer's Disease Pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33727592' target='_blank' class='pmid-link'>33727592</a>:</span> <span class='sentence-part'>Amyloid plaques are small (~ 50 MUm), highly-dense aggregates of amyloid beta (Abeta) protein in brain tissue, supposed to play a key role in pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33750486' target='_blank' class='pmid-link'>33750486</a>:</span> <span class='sentence-part'>We hypothesized that Alzheimer's-like disease (AD) exacerbates osteoarthritis and that intermittent fasting(IMF) with a high-protein(H-P) diet would enhance memory function and relieve osteoarthritis symptoms in estrogen-deficient animals with surgically induced AD and osteoarthritis. Ovariectomized Sprague-Dawley rats were fed high-fat(H-F) or H-P diets for two weeks, and then they had a hippocampal infusion of beta-amyloid(25-35) for 4 weeks to induce AD and an injection of monoidoacetate(MIA) into the articular cartilage to induce osteoarthritis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33785017' target='_blank' class='pmid-link'>33785017</a>:</span> <span class='sentence-part'>BACKGROUND: Alzheimer's disease (AD), an age-related neurodegenerative disorder and a serious public health concern, is mainly caused by beta-amyloid (Abeta)-induced toxicity.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33803769' target='_blank' class='pmid-link'>33803769</a>:</span> <span class='sentence-part'>The aggregation of amyloid beta (Abeta) peptides and deposition of amyloid plaques are implicated in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33828600' target='_blank' class='pmid-link'>33828600</a>:</span> <span class='sentence-part'>AD was induced by amyloid-beta (Abeta     1-42      ) (10 MUg/2 MUL, intracerebroventricular injection, icv) and then BVS at 20, 40, and 80 mg/kg were injected intraperitoneally (ip) in six equal intervals over 21 days.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33845371' target='_blank' class='pmid-link'>33845371</a>:</span> <span class='sentence-part'>Here, we review novel findings that have shifted our understanding of the role of Abeta in the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33848635' target='_blank' class='pmid-link'>33848635</a>:</span> <span class='sentence-part'>The imbalance between production and clearance of amyloid beta (Abeta) peptides and their resulting accumulation in the brain is an early and crucial step in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33851209' target='_blank' class='pmid-link'>33851209</a>:</span> <span class='sentence-part'>Amyloid formation and the deposition of the amyloid-beta peptide are hallmarks of Alzheimer's disease pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33875089' target='_blank' class='pmid-link'>33875089</a>:</span> <span class='sentence-part'>Recent studies found that the cellular uptake of extracellular amyloid beta (Abeta) peptides can lead to a build-up of intracellular Abeta in certain neuronal cells, which consequently lead to the onset of AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33876786' target='_blank' class='pmid-link'>33876786</a>:</span> <span class='sentence-part'>A comparative study of the effects of phosphatidylserine rich in DHA and EPA on Abeta-induced Alzheimer's disease using cell models.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33898246' target='_blank' class='pmid-link'>33898246</a>:</span> <span class='sentence-part'>Korean traditional herbal formula Soshiho-tang attenuates memory impairment and neuronal damage in mice with amyloid-beta-induced Alzheimer's disease. In the present study, we report that SST has preventive effects on memory impairment and neuronal cell changes in an Abeta-induced AD-like mouse model.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33908427' target='_blank' class='pmid-link'>33908427</a>:</span> <span class='sentence-part'>The accumulation of toxic soluble oligomers of the amyloid-beta peptide (Abeta) is a key step in the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33935701' target='_blank' class='pmid-link'>33935701</a>:</span> <span class='sentence-part'>Leaves Ameliorate Cognitive Deficit and Neuronal Damage in a Mouse Model of Amyloid-beta-Induced Alzheimer's Disease. Here, we investigated the neuroprotective effects of    F. erecta     Thunb. against cognitive deficit and neuronal damage in a mouse model of amyloid-beta (Abeta)-induced AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33967797' target='_blank' class='pmid-link'>33967797</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) is one of the most common neurodegenerative diseases and accumulating evidences suggest a key role of amyloid-beta (Abeta) peptide in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33976546' target='_blank' class='pmid-link'>33976546</a>:</span> <span class='sentence-part'>The amyloid cascade hypothesis, claiming that excess production or reduced clearance of amyloid-beta (Abeta) and its aggregation into amyloid plaques, was accepted for a long time as the main cause of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33977265' target='_blank' class='pmid-link'>33977265</a>:</span> <span class='sentence-part'>Accumulation of amyloid beta peptides is thought to initiate the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34006557' target='_blank' class='pmid-link'>34006557</a>:</span> <span class='sentence-part'>As amyloid-beta (Abeta) is regarded as the core pathological change and the trigger mechanism of AD, anti-Abeta therapy may be an effective therapy.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34051062' target='_blank' class='pmid-link'>34051062</a>:</span> <span class='sentence-part'>Based on existing literature, as a signaling molecule, Abeta is proposed to modulate its own turnover and synaptic plasticity through what is currently believed to be the cause of AD: the transient formation of pore-like oligomers. An emerging concept is that the amyloid-beta (Abeta) peptide, which was until recently deemed a major player in the cause of AD, may instead modulate synaptic plasticity and protect against excitotoxicity. The link between Abeta-mediated synaptic plasticity and Abeta trafficking is central for understanding AD pathogenesis and remains a perplexing relationship.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34053209' target='_blank' class='pmid-link'>34053209</a>:</span> <span class='sentence-part'>Treadmill Running Improves Spatial Learning Memory Through Inactivation of Nuclear Factor Kappa B/Mitogen-Activated Protein Kinase Signaling Pathway in Amyloid-beta-Induced Alzheimer Disease Rats.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34078792' target='_blank' class='pmid-link'>34078792</a>:</span> <span class='sentence-part'>Amyloid beta (Abeta) is one of the causative proteins of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34080759' target='_blank' class='pmid-link'>34080759</a>:</span> <span class='sentence-part'>The relationship between neuronal loss and Abeta deposits is one of the fundamental questions in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34084446' target='_blank' class='pmid-link'>34084446</a>:</span> <span class='sentence-part'>The excessive production and deposition of amyloid-beta (Abeta) is one of the most important etiologies of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34086399' target='_blank' class='pmid-link'>34086399</a>:</span> <span class='sentence-part'>The aggregation and deposition of amyloid beta (Abeta) peptide onto neuronal cells, with consequent cellular membrane perturbation, are central to the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34099032' target='_blank' class='pmid-link'>34099032</a>:</span> <span class='sentence-part'>BACKGROUND: The aggregation of amyloid beta (Abeta) is central in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34133880' target='_blank' class='pmid-link'>34133880</a>:</span> <span class='sentence-part'>The aggregation of amyloid beta (Abeta) peptide with subsequent formation of fibrils which deposit in senile plaques is considered one of the key triggers of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34151790' target='_blank' class='pmid-link'>34151790</a>:</span> <span class='sentence-part'>Sustained Hippocampal Neural Plasticity Questions the Reproducibility of an Amyloid-beta-Induced Alzheimer's Disease Model.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34280181' target='_blank' class='pmid-link'>34280181</a>:</span> <span class='sentence-part'>Oligomers of the amyloid beta-protein (Abeta) have been implicated in the pathogenesis of Alzheimer's disease (AD) through their toxicity towards neurons.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34285489' target='_blank' class='pmid-link'>34285489</a>:</span> <span class='sentence-part'>Purpose: Amyloid-beta (Abeta) is a brain protein that causes Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34286787' target='_blank' class='pmid-link'>34286787</a>:</span> <span class='sentence-part'>Additionally, they were able to inhibit the aggregation of amyloid-beta, one of the hallmarks in AD pathogenesis, and to exhibit considerable antioxidant capacity.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34294676' target='_blank' class='pmid-link'>34294676</a>:</span> <span class='sentence-part'>Failures of clinical trials targeting amyloid-beta protein (Abeta), a key trigger of AD, have been explained by drug inefficiency regardless of the mechanisms of amyloid neurotoxicity, which are very difficult to address by available technologies.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34299316' target='_blank' class='pmid-link'>34299316</a>:</span> <span class='sentence-part'>In addition, since toxic aggregates of amyloid-beta (Abeta) have been proposed as one of the major causes of the disease, the mechanism of clearing Abeta is also required to be investigated to reveal the etiology of AD clearly. Dyshomeostasis of these redox-active metal ions in the brain could cause Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34343891' target='_blank' class='pmid-link'>34343891</a>:</span> <span class='sentence-part'>The accumulation of amyloid beta (Abeta) peptides in the human brain leads to AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34407949' target='_blank' class='pmid-link'>34407949</a>:</span> <span class='sentence-part'>Synapse loss at early stages of Alzheimer's disease is thought to be induced by beta-amyloid (Abeta) pathology.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34411643' target='_blank' class='pmid-link'>34411643</a>:</span> <span class='sentence-part'>Chemical inhibition of sEH by TPPU, a selective sEH inhibitor, alleviated spatial learning and memory deficits, and elevated levels of neurotransmitters in Abeta-induced AD mice. In this study, we evaluated the vital role of sEH in amyloid beta (Abeta)-induced AD mice, and revealed a possible molecular mechanism for inhibition of sEH in the treatment of AD. The results showed that the sEH expression and activity were remarkably increased in the hippocampus of Abeta-induced AD mice.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34446574' target='_blank' class='pmid-link'>34446574</a>:</span> <span class='sentence-part'>Using mixed gender human temporal cortex and cultured hippocampal neurons from rats we further show that this balance is perturbed during Alzheimer's disease (AD) because of amyloid beta (Abeta)-driven reduction in Ly6h, with severe reduction leading to increased phosphorylated tau and alpha7-mediated neurotoxicity.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34502282' target='_blank' class='pmid-link'>34502282</a>:</span> <span class='sentence-part'>To investigate its therapeutic effects on AD pathology, we administered aripiprazole to 5xFAD AD model mice and examined beta-amyloid (betaA)-induced AD-like phenotypes, including betaA production, neuroinflammation, and cerebral glucose metabolism.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34628876' target='_blank' class='pmid-link'>34628876</a>:</span> <span class='sentence-part'>BACKGROUND: Alzheimer's disease (AD) is a progressive dementia, and beta-amyloid (Abeta) accumulation is widely regarded as the primary pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34654465' target='_blank' class='pmid-link'>34654465</a>:</span> <span class='sentence-part'>METHODS: We examined relationships between CSF p-Tau/Abeta     40      , and CSF Abeta     42      /Abeta     40      , Abeta PET, and white matter hyperintensities (WMH) as well as vascular risk factors in 149 cognitively unimpaired and 52 impaired individuals who were presumably not on the Alzheimer's disease (AD) pathway due to negative Abeta status on both CSF and PET.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34669098' target='_blank' class='pmid-link'>34669098</a>:</span> <span class='sentence-part'>Moreover, plant-based foods containing flavonoids were previously reported to show neuroprotective effects by modulating self-aggregation of amyloid-beta (Abeta)/or tau peptide into oligomers and fibrils, associated with the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34671708' target='_blank' class='pmid-link'>34671708</a>:</span> <span class='sentence-part'>According to the glymphatic hypothesis, in physiological conditions, cerebrospinal fluid flows primarily during sleep and serves to remove metabolic wastes like the amyloid-beta and tau proteins whose accumulation is believed to cause Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34677321' target='_blank' class='pmid-link'>34677321</a>:</span> <span class='sentence-part'>Abnormal amyloid beta protein (Abeta) accumulation is believed to be the most common cause of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34695393' target='_blank' class='pmid-link'>34695393</a>:</span> <span class='sentence-part'>This study explored the effects of chronic stimulation of 5-HT4R on cognition, memory, long-term potentiation (LTP), paired-pulse ratio (PPR), and neuronal apoptosis in a rat model of amyloid-beta (Abeta)-induced AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34715093' target='_blank' class='pmid-link'>34715093</a>:</span> <span class='sentence-part'>Here we investigate the potential of concurrent exercise to prevent recognition memory deficits in an Alzheimer's disease-like model induced by the hippocampal beta-amyloid (Abeta) injection in Wistar rats.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34733055' target='_blank' class='pmid-link'>34733055</a>:</span> <span class='sentence-part'>Background: Alzheimer's disease (AD), a prevalent neurodegenerative disease with progressive dementia and neurotransmission (NT)-dysfunction-related complications in older adults, is known to be caused by abnormal Amyloid-beta (Abeta) peptide and associated amyloid plaques in the brain.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34789556' target='_blank' class='pmid-link'>34789556</a>:</span> <span class='sentence-part'>Erratum: Medeiros et al., \Connecting TNF-alpha Signaling Pathways to iNOS Expression in a Mouse Model of Alzheimer's Disease: Relevance for the Behavioral and Synaptic Deficits Induced by Amyloid beta Protein\.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34798299' target='_blank' class='pmid-link'>34798299</a>:</span> <span class='sentence-part'>Coenzyme Q10, which scavenges FA, was shown to ameliorate Abeta-induced AD pathological phenotypes, thus suggesting a causative relation between FA toxicity and AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34801648' target='_blank' class='pmid-link'>34801648</a>:</span> <span class='sentence-part'>In our study, our established 3D gelatin scaffold model and a well characterized in vivo (APP/PS1) murine model of AD were used to directly investigate the molecular, biochemical and behavioural effects of neuronal stem cell exposure to Abeta to improve understanding of the in vivo etiology of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34832029' target='_blank' class='pmid-link'>34832029</a>:</span> <span class='sentence-part'>Amyloid beta (Abeta) is a transmembrane protein known to play a major role in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34838849' target='_blank' class='pmid-link'>34838849</a>:</span> <span class='sentence-part'>MAIN METHODS: Neuroblastoma cell line SH-SY5Y was treated with beta-amyloid (Abeta) to induce AD-like pathological changes, which serves as Alzheimer's disease model.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34856900' target='_blank' class='pmid-link'>34856900</a>:</span> <span class='sentence-part'>However, given the well-described role of misfolding peptides, particularly beta-amyloid (Abeta), in the pathogenesis of AD, the need for a broad-based conceptualization of AD, coalescing different theories into a single harmonized explanation emerges as a viable alternative.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34861133' target='_blank' class='pmid-link'>34861133</a>:</span> <span class='sentence-part'>Mounting evidence suggests that amyloid-beta (Abeta) and vascular etiologies are intertwined in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34867177' target='_blank' class='pmid-link'>34867177</a>:</span> <span class='sentence-part'>Amyloid beta (Abeta) and alpha-synuclein are two of the most investigated proteins, whose pathological aggregation and spreading are crucial to the pathogenesis of AD and PD, respectively.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34878807' target='_blank' class='pmid-link'>34878807</a>:</span> <span class='sentence-part'>The main pathological phenomena of AD are the accumulation of beta-amyloid (Abeta), neurofibrillary tangles, and neuroinflammation, however, the specific molecular mechanism of pathogenesis of AD is not fully clear.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34943094' target='_blank' class='pmid-link'>34943094</a>:</span> <span class='sentence-part'>The abnormal extracellular accumulation and deposition of the peptide amyloid-beta (Abeta) is considered as an early toxic event in AD pathogenesis, which initiates a series of events leading to neuronal dysfunction and death.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34971171' target='_blank' class='pmid-link'>34971171</a>:</span> <span class='sentence-part'>Fibroblast Growth Factor 21 and Autophagy Modulation Ameliorates Amyloid beta-Induced Alzheimer Disease Pathology in Rats.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35013124' target='_blank' class='pmid-link'>35013124</a>:</span> <span class='sentence-part'>All together, these findings suggest that L1-70 contributes to the clearance of Abeta in AD, thereby adding a novel perspective in understanding AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35019536' target='_blank' class='pmid-link'>35019536</a>:</span> <span class='sentence-part'>Two major amyloid-beta peptide (Abeta) variants, Abeta     42       and Abeta     40      , play a pivotal role in the etiology of AD and the concentration ratio of which (i.e., Abeta     42      %) has been suggested to be the superior biomarker for AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35043380' target='_blank' class='pmid-link'>35043380</a>:</span> <span class='sentence-part'>Amyloid-beta-induced Alzheimer's disease (AD) and its further complications are well-established models in preclinical studies and demonstrated by many researchers. Avicularin Attenuates Memory Impairment in Rats with Amyloid Beta-Induced Alzheimer's Disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35108926' target='_blank' class='pmid-link'>35108926</a>:</span> <span class='sentence-part'>Transport across the BBB is an important mediator of beta-amyloid (Abeta) accumulation in the brain and a contributing factor in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35109138' target='_blank' class='pmid-link'>35109138</a>:</span> <span class='sentence-part'>Microglia, specialized phagocytic cells of the brain, likewise play a critical role in the clearance of cellular debris, particularly amyloid beta, which is involved in the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35109187' target='_blank' class='pmid-link'>35109187</a>:</span> <span class='sentence-part'>Increasing activity of post-synaptic kinase p38gamma that targets T205 in tau reduced memory deficits in symptomatic Abeta-induced AD models.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35122611' target='_blank' class='pmid-link'>35122611</a>:</span> <span class='sentence-part'>Optimal Formula of Angelica sinensis Ameliorates Memory Deficits in beta-amyloid Protein-induced Alzheimer's Disease Rat Model.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35134462' target='_blank' class='pmid-link'>35134462</a>:</span> <span class='sentence-part'>PINK1 regulates mitochondrial fission/fusion and neuroinflammation in beta-amyloid-induced Alzheimer's disease models.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35148068' target='_blank' class='pmid-link'>35148068</a>:</span> <span class='sentence-part'>Abnormal aggregation and subsequent fibrillogenesis of amyloid-beta protein (Abeta) can cause Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35156141' target='_blank' class='pmid-link'>35156141</a>:</span> <span class='sentence-part'>For the purpose of discovering potential inhibitors of beta-amyloid (BACE1), which is a crucial element in Alzheimer's disease (AD) pathogenesis, an in silico study of naturally occurring compounds was performed using precise computational approaches.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35212149' target='_blank' class='pmid-link'>35212149</a>:</span> <span class='sentence-part'>Here, we aim to refocus the amyloid cascade hypothesis on its original premise that the accumulation of amyloid beta (Abeta) peptide is the primary and earliest event in AD pathogenesis as based on current evidence, initiating several pathological events and ultimately leading to AD dementia.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35214143' target='_blank' class='pmid-link'>35214143</a>:</span> <span class='sentence-part'>Neurofibrillary tangles (NFTs) composed of tau rather than senile plaques composed of Abeta are correlated with AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35281253' target='_blank' class='pmid-link'>35281253</a>:</span> <span class='sentence-part'>The aggregation of beta-amyloid peptide (Abeta) is one potential cause for Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35294796' target='_blank' class='pmid-link'>35294796</a>:</span> <span class='sentence-part'>INTRODUCTION: Amyloid beta (Abeta) is a brain protein that causes Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35306343' target='_blank' class='pmid-link'>35306343</a>:</span> <span class='sentence-part'>Here, we analyzed the process of aggregation and accumulation of amyloid beta (Abeta), which causes the development of Alzheimer's disease (AD), by real-time 3D imaging under physiological conditions using a quantum dot nanoprobe that we previously developed.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35372522' target='_blank' class='pmid-link'>35372522</a>:</span> <span class='sentence-part'>The cytotoxic self-aggregation of beta-amyloid (Abeta) peptide and islet amyloid polypeptide (IAPP) is implicated in the pathogenesis of Alzheimer's disease (AD) and Type 2 diabetes (T2D), respectively.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35443153' target='_blank' class='pmid-link'>35443153</a>:</span> <span class='sentence-part'>Amyloid-beta and tau are key molecules in the pathogenesis of Alzheimer's disease, but it remains unclear how these proteins interact to promote disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35443198' target='_blank' class='pmid-link'>35443198</a>:</span> <span class='sentence-part'>The present study was aimed to evaluate the effect of HIIT exercise and ecdy consumption synergistically on the changes in learning and memory functions, activities of hippocampal antioxidant enzymes, and neuronal population after AD induced by Abeta in male rats.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35459147' target='_blank' class='pmid-link'>35459147</a>:</span> <span class='sentence-part'>These observations have given rise to the theory that Abeta is the primary trigger of AD, and induces proinflammatory activation of immune brain cells (i.e., microglia), which culminates in neuronal damage and cognitive decline.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35474400' target='_blank' class='pmid-link'>35474400</a>:</span> <span class='sentence-part'>The accumulation of amyloid-beta at the neuronal sites is a major pathological hallmark involved in the etiology of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35531555' target='_blank' class='pmid-link'>35531555</a>:</span> <span class='sentence-part'>The development of hQC inhibitors could prevent the self-aggregation of Abeta peptides, resulting in impeding AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35631608' target='_blank' class='pmid-link'>35631608</a>:</span> <span class='sentence-part'>Subsequently, beta-amyloid (Abeta) was added into the brain-on-a-chip system to generate an AD-on-a-chip model, and toxic effects on neurons and the degeneration of synapses were observed.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35656096' target='_blank' class='pmid-link'>35656096</a>:</span> <span class='sentence-part'>While AD research is dominated by protein/peptide-centric research based on the amyloid hypothesis, a theory that designates dysfunction in beta-amyloid production, accumulation, or disposal as the primary cause of AD, many studies focus on metabolomics as a means of understanding the biological processes behind AD progression.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35663520' target='_blank' class='pmid-link'>35663520</a>:</span> <span class='sentence-part'>In this paper, we follow up with our preliminary biological studies that showed that Repeated electromagnetic field stimulation (REMFS) decreased the toxic amyloid-beta (A   beta    ) levels, which is considered to be the cause of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35666692' target='_blank' class='pmid-link'>35666692</a>:</span> <span class='sentence-part'>These studies will enhance the physicochemical understanding of the structural changes of Abeta at the heterogeneous interfaces and the mechanism of Alzheimer's disease pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35741166' target='_blank' class='pmid-link'>35741166</a>:</span> <span class='sentence-part'>Accumulation of aggregated amyloid-beta (Abeta) in the brain is considered the first pathological event within the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35742862' target='_blank' class='pmid-link'>35742862</a>:</span> <span class='sentence-part'>Disposition of amyloid beta (Abeta) into the perivascular space of the cerebral cortex has been recently suggested as a major source of its clearance, and its disturbance may be involved in the pathogenesis of cerebral amyloid angiopathy and Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35759136' target='_blank' class='pmid-link'>35759136</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) is a type of dementia characterized by the deposition of amyloid beta, a causative protein of AD, in the brain.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35762411' target='_blank' class='pmid-link'>35762411</a>:</span> <span class='sentence-part'>Excessive accumulation of amyloid-beta (Abeta) is the leading cause of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35928227' target='_blank' class='pmid-link'>35928227</a>:</span> <span class='sentence-part'>C99 is the immediate precursor for amyloid beta (Abeta) and therefore is a central intermediate in the pathway that is believed to result in Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35956985' target='_blank' class='pmid-link'>35956985</a>:</span> <span class='sentence-part'>In this study, the neuroprotective effects of 4-(4-(heptyloxy)phenyl)-2,4-dihydro-3   H    -1,2,4-triazol-3-one (W112) against beta-amyloid (Abeta)-induced AD pathology and its possible mechanism were explored both in vitro and in vivo. Anti-Inflammatory Activity of 4-(4-(Heptyloxy)phenyl)-2,4-dihydro-3   H    -1,2,4-triazol-3-one via Repression of MAPK/NF-kappaB Signaling Pathways in beta-Amyloid-Induced Alzheimer's Disease Models. The results showed that W112 exhibits a neuroprotective role against Abeta-induced cytotoxicity in PC12 cells and improves the learning and memory abilities of Abeta-induced AD-like rats.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36015135' target='_blank' class='pmid-link'>36015135</a>:</span> <span class='sentence-part'>Pretreatment with the KBD formula for 14 days significantly improved the short- and long-term memory performance of Abeta-induced AD rats as assessed by the Morris Water Maze (MWM) and object-recognition tests. The main purpose of the present study was to determine the protective effect and mechanism of KBD in amyloid beta (Abeta)-induced AD rats and its toxicity profiles.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36044812' target='_blank' class='pmid-link'>36044812</a>:</span> <span class='sentence-part'>Due to the hugely important roles of neurotransmitter acetylcholine (ACh) and amyloid-beta (Abeta) in the pathogenesis of Alzheimer's disease (AD), the development of multi-target directed ligands (MTDLs) focused on cholinesterase (ChE) and Abeta becomes one of the most attractive strategies for combating AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36058175' target='_blank' class='pmid-link'>36058175</a>:</span> <span class='sentence-part'>CONCLUSIONS: Our findings indicate that Abeta peptide induces AD-like molecular changes at certain doses, and these changes could be detected by evaluating brain oscillations.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36084891' target='_blank' class='pmid-link'>36084891</a>:</span> <span class='sentence-part'>The present study was designed to investigate the potential protective effects of minocycline against beta-amyloid (Abeta)-induced Alzheimer's disease (AD), recognition memory decline, and the possible involved anti-apoptotic mechanisms.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36093396' target='_blank' class='pmid-link'>36093396</a>:</span> <span class='sentence-part'>Herpes Simplex Virus Infection Increases Beta-Amyloid Production and Induces the Development of Alzheimer's Disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36120782' target='_blank' class='pmid-link'>36120782</a>:</span> <span class='sentence-part'>BACKGROUND: Amyloid-beta (Abeta) and tau protein accumulation in the brain is thought to be one of the causes of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36144245' target='_blank' class='pmid-link'>36144245</a>:</span> <span class='sentence-part'>The transitional expression and aggregation of amyloid beta (Abeta) are the most important causative factors leading to the deterioration of Alzheimer's disease (AD), a commonly occurring metabolic disease among older people.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36155521' target='_blank' class='pmid-link'>36155521</a>:</span> <span class='sentence-part'>The amyloid cascade hypothesis attributes a vital role to amyloid-beta protein (Abeta) in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36214002' target='_blank' class='pmid-link'>36214002</a>:</span> <span class='sentence-part'>BACKGROUND: Amyloid-beta (Abeta) is important in the etiology of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36221865' target='_blank' class='pmid-link'>36221865</a>:</span> <span class='sentence-part'>Since Abeta plays an important role in the etiology of AD, therefore Abeta-linked pathways are mainly targeted in order to develop potential AD therapies.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36284704' target='_blank' class='pmid-link'>36284704</a>:</span> <span class='sentence-part'>Amyloid beta-peptide (Abeta) misfolding into beta-sheet structures triggers neurotoxicity inducing Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36361906' target='_blank' class='pmid-link'>36361906</a>:</span> <span class='sentence-part'>Amyloid beta (Abeta) peptide is suspected to be a major cause of AD, and therefore, simultaneously blocking its formation and aggregation by inhibition of the enzymes BACE-1 (beta-secretase) and AChE (acetylcholinesterase) by a single inhibitor may be an effective therapeutic approach, as compared to blocking one of these targets or by combining two drugs, one for each of these targets.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36362046' target='_blank' class='pmid-link'>36362046</a>:</span> <span class='sentence-part'>This study could reveal the role of a highly toxic Abeta on AD pathogenesis, thereby contributing to the development of a novel therapeutic strategy targeting the toxic conformer.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36422822' target='_blank' class='pmid-link'>36422822</a>:</span> <span class='sentence-part'>New therapies under development include agents that target amyloid-beta (Abeta), a key component in AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36438603' target='_blank' class='pmid-link'>36438603</a>:</span> <span class='sentence-part'>Given the promising data on the additive effect of combination therapy with donepezil (Aricept), an acetylcholinesterase inhibitor (AChEI), and regarding the similar neuronal mechanisms through which donepezil (DON) and environmental enrichment (EE) exert their enhancing effects on cognition; we asked whether simultaneous treatment with two paradigms in amyloid-beta-induced AD rats may lead to greater protection against the cognitive impairments than either treatment individually. AD was induced by intrahippocampal injection of amyloid-beta (1-42, 6 MUg), and DON was orally administrated (4 mg/kg) for 21 days.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36510132' target='_blank' class='pmid-link'>36510132</a>:</span> <span class='sentence-part'>PirB deletion has been shown to suppress Abeta-induced synaptic dysfunction and behavioral deficits in AD model mice, implying that PirB mediates Abeta-induced AD pathology. Our findings revealed that LOTUS may be a promising therapeutic agent in counteracting Abeta-induced AD pathologies.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36544574' target='_blank' class='pmid-link'>36544574</a>:</span> <span class='sentence-part'>Oligomers of amyloid beta (Abeta) represent an early aggregative form that causes neurotoxicity in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36549596' target='_blank' class='pmid-link'>36549596</a>:</span> <span class='sentence-part'>However, the effect of naringin in AD caused by Abeta has not been clearly studied, and there are few studies on the electrophysiological aspect. Naringin enhances long-term potentiation and recovers learning and memory deficits of amyloid-beta induced Alzheimer's disease-like behavioral rat model.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36596482' target='_blank' class='pmid-link'>36596482</a>:</span> <span class='sentence-part'>The production of amyloid beta peptide (Abeta) is an important process relating to the pathogenesis of Alzheimer disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36610160' target='_blank' class='pmid-link'>36610160</a>:</span> <span class='sentence-part'>Esculentoside A (EsA), isolated from Phytolacca esculenta, exhibits pharmacotherapeutic efficacy in mice with amyloid beta-induced AD. BACKGROUND: Neurofibrillary tangles comprising hyperphosphorylated tau are vital factors associated with the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36623626' target='_blank' class='pmid-link'>36623626</a>:</span> <span class='sentence-part'>Hesperidin methylchalcone (HMC) hinders amyloid-beta induced Alzheimer's disease by attenuating cholinesterase activity, macromolecular damages, oxidative stress and apoptosis via regulating NF-kappaB and Nrf2/HO-1 pathways.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36630532' target='_blank' class='pmid-link'>36630532</a>:</span> <span class='sentence-part'>Impact of nanoparticles on amyloid beta-induced Alzheimer's disease, tuberculosis, leprosy and cancer: A systematic review.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36651694' target='_blank' class='pmid-link'>36651694</a>:</span> <span class='sentence-part'>Oxidative stress due to Cu     2+      -triggered aggregation of beta-amyloid protein (Abeta) and reactive oxygen species (ROS) overexpression in the brain is an important hallmark of early stages of Alzheimer's disease (AD) pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36674792' target='_blank' class='pmid-link'>36674792</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) is known to be caused by amyloid beta-peptide (Abeta) misfolded into beta-sheets, but this knowledge has not yet led to treatments to prevent AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36680733' target='_blank' class='pmid-link'>36680733</a>:</span> <span class='sentence-part'>Intriguingly, PCO treatment improved all the above-mentioned neuropathological changes in the Abeta-induced AD rats.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36704637' target='_blank' class='pmid-link'>36704637</a>:</span> <span class='sentence-part'>Overproduction and accumulation of beta-amyloid and its improper clearance can cause neurotoxicity leading to Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36803816' target='_blank' class='pmid-link'>36803816</a>:</span> <span class='sentence-part'>The amyloid hypothesis, that established amyloid-beta (Abeta) peptide as the primary cause of Alzheimer's disease (AD) and related dementia, has driven the development of treatments for neurodegeneration for 30 years.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36816173' target='_blank' class='pmid-link'>36816173</a>:</span> <span class='sentence-part'>The effect of ghrelin on antioxidant status in the rat's model of Alzheimer's disease induced by amyloid-beta. This study is going on to examine the effect of ghrelin on antioxidant status in the rat's model of AD induced by Abeta.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36866639' target='_blank' class='pmid-link'>36866639</a>:</span> <span class='sentence-part'>It is proven that protein aggregation like amyloid beta (Abeta) is one of the critical factors causing AD and, its diagnosis in the early stages of the disease is important for the treatment or prevention of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36868776' target='_blank' class='pmid-link'>36868776</a>:</span> <span class='sentence-part'>The \amyloid cascade hypothesis\ stablishes that the aggregation of the beta-amyloid protein (Abeta     42      ) is the first event that subsequently triggers AD development.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36878848' target='_blank' class='pmid-link'>36878848</a>:</span> <span class='sentence-part'>Mounting evidence suggests that the accumulation and aggregation of amyloid-beta peptides (Abeta), which constitute amyloid plaques in the brain, is critical for initiating and accelerating AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36889654' target='_blank' class='pmid-link'>36889654</a>:</span> <span class='sentence-part'>However, it has been suggested that rather than the fibrillary amyloid beta (Abeta) deposits, it is smaller, soluble Abeta aggregates that exert a neurotoxic effect and trigger AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36945328' target='_blank' class='pmid-link'>36945328</a>:</span> <span class='sentence-part'>Our preliminary biological studies showed that Repeated Electromagnetic Field Stimulation (REFMS) applying an EM frequency of 64 MHz and a specific absorption rate (SAR) of 0.4 - 0.9 W/kg decrease the level of amyloid-   beta     peptides (A   beta    ), which is the most likely etiology of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36945751' target='_blank' class='pmid-link'>36945751</a>:</span> <span class='sentence-part'>In this review, we first discuss the importance of Abeta in the pathogenesis of AD, then summarize the latest progress of Abeta-related targets and compounds.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36978955' target='_blank' class='pmid-link'>36978955</a>:</span> <span class='sentence-part'>The current study aims to investigate the effect of baicalein in combination with memantine in beta-amyloid-induced AD in albino Wistar rats. The Combination of Baicalein and Memantine Reduces Oxidative Stress and Protects against beta-amyloid-Induced Alzheimer's Disease in Rat Model.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37068195' target='_blank' class='pmid-link'>37068195</a>:</span> <span class='sentence-part'>Brain-targeted lycopene-loaded microemulsion modulates neuroinflammation, oxidative stress, apoptosis and synaptic plasticity in beta-amyloid-induced Alzheimer's disease mice.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37101809' target='_blank' class='pmid-link'>37101809</a>:</span> <span class='sentence-part'>Polymerization of soluble amyloid beta (Abeta) peptide into protease-stable insoluble fibrillary aggregates is a critical step in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37105250' target='_blank' class='pmid-link'>37105250</a>:</span> <span class='sentence-part'>Administraction of HPS ameliorated age-related symptoms such as imbalanced intestinal homeostasis, sleep disturbances, and beta-amyloid (Abeta) induced Alzheimer's disease (AD) in flies, but did not modulate neurobehavioral deficits in the AD model of tauopathy and the Parkinson's disease (PD) model of Pink1 mutation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37173803' target='_blank' class='pmid-link'>37173803</a>:</span> <span class='sentence-part'>Remarkably, hIAPP has structural similarity with amyloid beta (Abeta) and can engage in the pathogenesis of T2DM and Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37179042' target='_blank' class='pmid-link'>37179042</a>:</span> <span class='sentence-part'>Minocycline effects on memory and learning impairment in the beta-amyloid-induced Alzheimer's disease model in male rats using behavioral, biochemical, and histological methods. This study investigated the effect of minocycline on the changes in learning and memory functions, activities of blood serum antioxidant enzymes, neuronal loss, and the number of Abeta plaques after AD induced by Abeta in male rats.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37212117' target='_blank' class='pmid-link'>37212117</a>:</span> <span class='sentence-part'>Interestingly, pretreatment with CoQ10, HIIT, or both, could markedly improve the oxidative status and cognitive decline in the MWM and NOR tests, and hinder neuronal loss in the hippocampus of Abeta-induced AD rats. The Protective Effects of High-Intensity Interval Training Combined with Q10 Supplementation on Learning and Memory Impairments in Male Rats with Amyloid-beta-Induced Alzheimer's Disease. OBJECTIVE: This study was done to determine the protective effects of coenzyme Q10 (CoQ10) and high-intensity interval training (HIIT) alone and in combination for eight continuous weeks, on oxidative status, cognitive functions, and histological changes in the hippocampus in amyloid-beta (Abeta)-induced AD rats.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37239068' target='_blank' class='pmid-link'>37239068</a>:</span> <span class='sentence-part'>Emerging evidence over the past few decades supports the critical role of Abeta and tau in AD pathogenesis and the participation of glial cells in different molecular and cellular pathways.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37245024' target='_blank' class='pmid-link'>37245024</a>:</span> <span class='sentence-part'>CONCLUSIONS: Together, these findings indicate the protective functions of the N-terminal Abeta fragments extend to reactive gliosis and gliotoxicity induced by Abeta, by preventing or reversing glial reactive states indicative of neuroinflammation and synaptic loss central to AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37263123' target='_blank' class='pmid-link'>37263123</a>:</span> <span class='sentence-part'>This study provides basic data for the effects of Abeta and donepezil on plasma and urine metabolites in Abeta-induced AD rat models. Effects of donepezil treatment on plasma and urine metabolites in amyloid beta-induced Alzheimer's disease rats.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37307834' target='_blank' class='pmid-link'>37307834</a>:</span> <span class='sentence-part'>Decades of research have demonstrated an incontrovertible role of amyloid-beta (Abeta) in the etiology of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37348174' target='_blank' class='pmid-link'>37348174</a>:</span> <span class='sentence-part'>This study aimed to evaluate whether preconditioning MSCs with dimethyl fumarate (DMF), a Nrf2 inducer, could enhance MSC therapeutic efficacy in an amyloid-beta (Abeta     1-42      )-induced AD rat model.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37506558' target='_blank' class='pmid-link'>37506558</a>:</span> <span class='sentence-part'>The abnormal accumulation of amyloid beta protein (Abeta) is one of the most important causes of Alzheimer's disease (AD) and is usually a detecting biomarker.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37607046' target='_blank' class='pmid-link'>37607046</a>:</span> <span class='sentence-part'>Recent studies have found that beta-amyloid (Abeta) oligomers may play much more important roles than amyloid plaques in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37609338' target='_blank' class='pmid-link'>37609338</a>:</span> <span class='sentence-part'>Microglial cGAS deletion protects against amyloid-beta induced Alzheimer's disease pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37619312' target='_blank' class='pmid-link'>37619312</a>:</span> <span class='sentence-part'>Dose-dependent neuroprotective effects of adipose-derived mesenchymal stem cells on amyloid beta-induced Alzheimer's disease in rats.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37626631' target='_blank' class='pmid-link'>37626631</a>:</span> <span class='sentence-part'>Amyloid-beta (Abeta) is one of the causes of Alzheimer's disease (AD), damaging nerve membranes and inducing neurotoxicity.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37628913' target='_blank' class='pmid-link'>37628913</a>:</span> <span class='sentence-part'>In conclusion, this study demonstrates the neuroprotective effects of NACA against beta-amyloid induced AD-like pathology.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37654789' target='_blank' class='pmid-link'>37654789</a>:</span> <span class='sentence-part'>The question of how Abeta relates to neurovascular function and which is the trigger for AD has recently come into sharp focus.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37663321' target='_blank' class='pmid-link'>37663321</a>:</span> <span class='sentence-part'>Aggregation of amyloid-beta peptide (Abeta) is hypothesized to be the primary cause of Alzheimer's disease (AD) progression.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37667395' target='_blank' class='pmid-link'>37667395</a>:</span> <span class='sentence-part'>However, it is still a challenge to understand the DNs of specific neurons that are vulnerable to Abeta in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37718800' target='_blank' class='pmid-link'>37718800</a>:</span> <span class='sentence-part'>Probabilistic and parsimony-based arguments regarding available genetics data are used to propose that Hardy and Higgin's amyloid cascade hypothesis is valid but is commonly interpreted too narrowly to support, incorrectly, the primacy of the amyloid-beta peptide (Abeta) in driving Alzheimer's disease pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37728399' target='_blank' class='pmid-link'>37728399</a>:</span> <span class='sentence-part'>The accumulation of amyloid-beta (Abeta) into senile plaques and the resulting continuous oxidative stress are major pathogenic mechanisms in Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37758932' target='_blank' class='pmid-link'>37758932</a>:</span> <span class='sentence-part'>This study aimed to assess the defensive properties of rosavin against Alzheimer's disease induced by amyloid-beta, utilizing experimental models.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37853914' target='_blank' class='pmid-link'>37853914</a>:</span> <span class='sentence-part'>Sequential proteolysis of the amyloid precursor protein (APP) by gamma-secretases generates amyloid-beta (Abeta) peptides and defines the proportion of short-to-long Abeta peptides, which is tightly connected to Alzheimer's disease (AD) pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37905874' target='_blank' class='pmid-link'>37905874</a>:</span> <span class='sentence-part'>ABSTRACT: The aggregation of amyloid-beta peptide and tau protein dysregulation are implicated to play key roles in Alzheimer's disease pathogenesis and are considered the main pathological hallmarks of this devastating disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37921143' target='_blank' class='pmid-link'>37921143</a>:</span> <span class='sentence-part'>METHODS: The present study reviews the arsenic role in the generation of amyloid-beta from its precursor that leads to Alzheimer's disease through the published article from Pubmed and Scopus.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37935338' target='_blank' class='pmid-link'>37935338</a>:</span> <span class='sentence-part'>Although the validation of the long standing amyloid cascade hypothesis would seem to be at hand, what remains is the puzzling issue of why - if Abeta indeed causes AD - does removing it from the brain not stop the disease entirely.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37976283' target='_blank' class='pmid-link'>37976283</a>:</span> <span class='sentence-part'>Oligomers formed from monomers of the amyloid beta-protein (Abeta) are thought to be central to the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37983764' target='_blank' class='pmid-link'>37983764</a>:</span> <span class='sentence-part'>Amyloid-beta (Abeta) and its assemblies play important roles in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/38053635' target='_blank' class='pmid-link'>38053635</a>:</span> <span class='sentence-part'>Oligomeric amyloid beta (oAbeta) is considered a major synaptotoxic trigger for AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/38071408' target='_blank' class='pmid-link'>38071408</a>:</span> <span class='sentence-part'>AD was induced using amyloid beta (Abeta) and confirmed through the Morris water maze (MWM) behavioural test and Congo red staining.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/38143280' target='_blank' class='pmid-link'>38143280</a>:</span> <span class='sentence-part'>Amelioration of Amyloid-beta Induced Alzheimer's Disease by Bacopa monnieri through Modulation of Mitochondrial Dysfunction and GSK-3beta/Wnt/beta-Catenin Signaling.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/38163326' target='_blank' class='pmid-link'>38163326</a>:</span> <span class='sentence-part'>Amyloid-beta (Abeta) forms heterogeneous oligomers, which are implicated in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/38188833' target='_blank' class='pmid-link'>38188833</a>:</span> <span class='sentence-part'>Retracted: Herpes Simplex Virus Infection Increases Beta-Amyloid Production and Induces the Development of Alzheimer's Disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/38194817' target='_blank' class='pmid-link'>38194817</a>:</span> <span class='sentence-part'>Abnormal aggregation and fibrillogenesis of amyloid-beta protein (Abeta) can cause Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/38211684' target='_blank' class='pmid-link'>38211684</a>:</span> <span class='sentence-part'>Potential links between platelets and amyloid-beta in the pathogenesis of Alzheimer's disease: Evidence from in vitro, in vivo, and clinical studies.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/38242524' target='_blank' class='pmid-link'>38242524</a>:</span> <span class='sentence-part'>The undifferentiated OE-MSCs were transplanted either by intranasal (IN) or intrahippocampal (IH) injection to rat models of AD, which were induced by injecting amyloid-beta (Abeta) intrahippocampally.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/38287166' target='_blank' class='pmid-link'>38287166</a>:</span> <span class='sentence-part'>Compelling genetic and biomarker evidence supports Abeta as the root cause of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/38344035' target='_blank' class='pmid-link'>38344035</a>:</span> <span class='sentence-part'>Aggregates of amyloid-beta (Abeta) peptides are thought to cause Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/38455162' target='_blank' class='pmid-link'>38455162</a>:</span> <span class='sentence-part'>Accumulation of beta-amyloid peptide (Abeta) induces neurotoxicity, which is the primary risk factor in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/38473727' target='_blank' class='pmid-link'>38473727</a>:</span> <span class='sentence-part'>The perivascular space has been proposed as a clearance pathway for degradation products in the brain, including amyloid beta, the accumulation of which may induce Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/38475929' target='_blank' class='pmid-link'>38475929</a>:</span> <span class='sentence-part'>BACKGROUND: Although abnormal accumulation of amyloid beta (Abeta) protein is thought to be the main cause of Alzheimer's disease (AD), emerging evidence suggests a pivotal vascular contribution to AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/38497073' target='_blank' class='pmid-link'>38497073</a>:</span> <span class='sentence-part'>The beta-amyloid (Abeta) accumulation triggers AD pathogenesis, though clinical trials lowering Abeta have not altered disease outcomes suggesting other interacting factors to be identified for drug design of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/38534427' target='_blank' class='pmid-link'>38534427</a>:</span> <span class='sentence-part'>One of the most accepted theories in AD, the amyloid beta (Abeta) hypothesis, assumes that the buildup of the peptide Abeta is the root cause of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/38615460' target='_blank' class='pmid-link'>38615460</a>:</span> <span class='sentence-part'>This review summarizes the research on beta-hairpins in Abeta peptides and discusses the relevance of this conformation in AD pathogenesis and drug development.</span></div></div>
<div class='streamlined-assertion'><div class='streamlined-header sticky-relation-header'><span class='label-text'>Subject:</span> <strong>Amyloid_beta_Protein_Precursor</strong> <span class='label-text'>Subject CUI:</span> <strong>C0085151</strong> â†’ <span class='label-text predicate-text'>CAUSES</span> â†’ <span class='label-text'>Object:</span> <strong>Alzheimers</strong> <span class='label-text'>Object CUI:</span> <strong>C0750901</strong></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/12472904' target='_blank' class='pmid-link'>12472904</a>:</span> <span class='sentence-part'>The proliferation and survival of NPC in the dentate gyrus of the hippocampus was reduced in mice transgenic for a mutated form of amyloid precursor protein that causes early onset familial AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/12476348' target='_blank' class='pmid-link'>12476348</a>:</span> <span class='sentence-part'>Studies of the pathogenic actions of mutations in presenilins and amyloid precursor protein that cause early-onset familial AD have established central roles for perturbed cellular calcium homeostasis and oxidative stress in the neurodegenerative process. The clinical presentation of patients with AD is dominated by cognitive deficits and emotional disturbances that result from dysfunction and degeneration of neurons in the limbic system and cerebral cortex.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/12849363' target='_blank' class='pmid-link'>12849363</a>:</span> <span class='sentence-part'>Mutant genes for amyloid precursor protein (APP) or presenilin cause early-onset familial Alzheimer's disease (&lt;1% of all cases) and have helped to elucidate APP processing and amyloid-peptide formation by alpha, beta, and gamma secretases.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/14518509' target='_blank' class='pmid-link'>14518509</a>:</span> <span class='sentence-part'>Studies of the pathogenic mutations in presenilins 1 and 2 (PS1 and PS2) and amyloid precursor protein (APP) responsible for early onset familial AD have estabilished central roles for perturbed cellular Ca2+ homeostasis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/15565529' target='_blank' class='pmid-link'>15565529</a>:</span> <span class='sentence-part'>According to the beta-amyloid cascade hypothesis, the accumulation of beta-amyloid (Abeta) deposits as amyloid plaques in the patient's brain is the primary event in the pathogenesis of Alzheimer's disease (AD). The majority of known APP and presenilin mutations responsible for familial early onset AD affect APP processing causing overproduction of Abeta, especially Abeta42.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/15987951' target='_blank' class='pmid-link'>15987951</a>:</span> <span class='sentence-part'>PDAPP transgenic mice overexpress a mutant form of human amyloid precursor protein under control of the platelet-derived growth factor promoter in CNS neurons that causes early onset, familial Alzheimer's disease in humans.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/16478525' target='_blank' class='pmid-link'>16478525</a>:</span> <span class='sentence-part'>Mutations in the PS-1 and APP genes, which increase production of the highly amyloidogenic amyloid beta-peptide (Abeta42), are the major causes of early onset familial AD. Several lines of evidence suggest that enhanced oxidative stress, inflammation, and apoptosis play important roles in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/1791986' target='_blank' class='pmid-link'>1791986</a>:</span> <span class='sentence-part'>A mutation within exon 17 at codon 717 of the beta-amyloid protein precursor (APP) gene is one cause of early onset familial Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/18187157' target='_blank' class='pmid-link'>18187157</a>:</span> <span class='sentence-part'>Atypical early-onset Alzheimer's disease caused by the Iranian APP mutation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/18585407' target='_blank' class='pmid-link'>18585407</a>:</span> <span class='sentence-part'>To provide additional information about the effects of these oligomers on memory, the present study examined the memory of groups of rats exposed to ICV injections of the culture media (CM) of Chinese Hamster Ovary cells that were (7PA2) and were not (CHO-) transfected with a human mutation of amyloid precursor protein that appears to cause early-onset Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/19101658' target='_blank' class='pmid-link'>19101658</a>:</span> <span class='sentence-part'>AD occurs sporadically (SAD), or is caused by hereditary missense mutations in the amyloid precursor protein (APP) or presenilin-1 and -2 (PSEN1 and PSEN2) genes, leading to early-onset familial AD (FAD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/19804379' target='_blank' class='pmid-link'>19804379</a>:</span> <span class='sentence-part'>The Swedish mutation within the amyloid precursor protein (APP) causes early-onset Alzheimer's disease due to increased cleavage of APP by BACE1.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20080541' target='_blank' class='pmid-link'>20080541</a>:</span> <span class='sentence-part'>An additional copy of the beta-amyloid precursor protein (APP) gene causes early-onset Alzheimer's disease (AD) in trisomy 21 (DS).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21605030' target='_blank' class='pmid-link'>21605030</a>:</span> <span class='sentence-part'>Apo E is the major component of lipoprotein particles in the brain that mediate transport of cholesterol and other lipids between neurons and glial cells, indicating an implication of cerebral lipid metabolism in the pathogenesis of AD. Importantly, mutations in the genes of APP and the two homologous PS proteins are a major cause of familial early onset AD, indicating that the metabolism of APP and generation of Abeta play critical roles in the initiation of the disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21909359' target='_blank' class='pmid-link'>21909359</a>:</span> <span class='sentence-part'>Cerebrovascular integrity was characterized in Tg2576 AD model mice that overexpress the human amyloid precursor protein (APP) containing the double missense mutations, APPsw, found in a Swedish family, that causes early-onset AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22044463' target='_blank' class='pmid-link'>22044463</a>:</span> <span class='sentence-part'>BACKGROUND: Missense mutations in three different genes encoding amyloid-beta precursor protein, presenilin 1 and presenilin 2 are recognized to cause familial early-onset Alzheimer disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22491860' target='_blank' class='pmid-link'>22491860</a>:</span> <span class='sentence-part'>OBJECTIVES: More than 30 different rare mutations, including copy number variants (CNVs), in the amyloid precursor protein gene (APP) cause early-onset familial Alzheimer disease (EOFAD), whereas the contribution of common APP variants to disease risk remains controversial. CONCLUSION: Our study shows that APP mutations and locus duplications are a very rare cause of EOFAD and that the contribution of common APP variants to AD susceptibility is insignificant.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23102935' target='_blank' class='pmid-link'>23102935</a>:</span> <span class='sentence-part'>Pathogenic mutations of the APP gene, leading to early-onset Alzheimer's disease (AD) have been known for more than 20 years.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23142261' target='_blank' class='pmid-link'>23142261</a>:</span> <span class='sentence-part'>Mutations in the genes encoding amyloid precursor protein (APP), presenilin 1 (PSEN1) and presenilin 2 (PSEN2) are responsible for early-onset autosomal dominant AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23752245' target='_blank' class='pmid-link'>23752245</a>:</span> <span class='sentence-part'>Over 200 rare and fully penetrant pathogenic mutations in amyloid precursor protein (APP), presenilin 1 and 2 (PSEN1 and PSEN2) cause a subset of early-onset familial Alzheimer's disease (EO-FAD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23907250' target='_blank' class='pmid-link'>23907250</a>:</span> <span class='sentence-part'>Pathological amino-acid substitutions in the amyloid precursor protein (APP) and chemical gamma-secretase modulators affect the processing of APP by the gamma-secretase complex and the production of the amyloid-beta peptide Abeta42, the accumulation of which is considered causative of Alzheimer's disease. Here we demonstrate that mutations in the transmembrane domain of APP causing aggressive early-onset familial Alzheimer's disease affect both gamma- and epsilon-cleavage sites, by raising the Abeta42/40 ratio and inhibiting the production of AICD50-99, one of the two physiological APP intracellular domains (ICDs).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24838203' target='_blank' class='pmid-link'>24838203</a>:</span> <span class='sentence-part'>Mutations in the genes encoding amyloid precursor protein (APP), presenilin 1 (PSEN1) and presenilin 2 (PSEN2) are responsible for early-onset autosomal dominant AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24964199' target='_blank' class='pmid-link'>24964199</a>:</span> <span class='sentence-part'>Swedish double mutation (KM670/671NL) of amyloid precursor protein (APP) is reported to increase toxic amyloid beta (Abeta) production via aberrant cleavage at the beta-secretase site and thereby cause early-onset Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26141474' target='_blank' class='pmid-link'>26141474</a>:</span> <span class='sentence-part'>To date, mutations in three different genes, the Amyloid precursor protein (APP), Presenilin 1 (PS1), and Presenilin 2 (PS2), have been identified as causative in early-onset AD, making predictive testing possible.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26402764' target='_blank' class='pmid-link'>26402764</a>:</span> <span class='sentence-part'>BACKGROUND: Mutations within exons 16 and 17 of the amyloid-beta protein precursor (AbetaPP) gene were the first known causes of early-onset familial Alzheimer's disease (EOFAD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29578479' target='_blank' class='pmid-link'>29578479</a>:</span> <span class='sentence-part'>Many of these models express mutant versions of human amyloid-beta protein precursor (AbetaPP) that are associated with amyloid-beta protein (Abeta)-induced early onset familial AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30041064' target='_blank' class='pmid-link'>30041064</a>:</span> <span class='sentence-part'>Seizures have traditionally been related to neuronal loss in the late stages of AD as a consequence of neurodegeneration, however, recent studies indicated that seizures may contribute to the emergence of AD symptoms in early stages of the disease, mainly in familial AD. Mutations in genes encoding presenilin 1 (PSEN1), presenilin 2 (PSEN2) and amyloid precursor protein (APP) are responsible for early-onset familial AD (EOFAD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30763650' target='_blank' class='pmid-link'>30763650</a>:</span> <span class='sentence-part'>Mutations in the genes encoding amyloid precursor protein (APP) or presenilin (PS) cause early onset familial Alzheimer's disease (AD), and sequential cleavages of the APP by beta-secretase and gamma-secretase/presenilin generate amyloid beta protein (Abeta), the major component of pathological hallmark, neuritic plaques, in brains of AD patients.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31440394' target='_blank' class='pmid-link'>31440394</a>:</span> <span class='sentence-part'>Presenilin 1 (PSEN1), presenilin 2 (PSEN2), and amyloid precursor protein (APP) mutations are responsible for autosomal dominant early-onset Alzheimer's disease (AD-EOAD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31625391' target='_blank' class='pmid-link'>31625391</a>:</span> <span class='sentence-part'>Dominant mutations in APP and presenilin cause early onset familial Alzheimer's disease (FAD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/8395665' target='_blank' class='pmid-link'>8395665</a>:</span> <span class='sentence-part'>A mutation at codons 670 and 671 of exon 16 of the amyloid precursor protein has recently been identified as a cause of early onset familial Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/8811169' target='_blank' class='pmid-link'>8811169</a>:</span> <span class='sentence-part'>In early 1993, the genetic data implicating the amyloid precursor protein as one of the loci leading to early onset Alzheimer's disease were reviewed (Hardy and Duff, Annals of Medicine, 25: 437-440), together with the evidence implicating abnormal deposition of beta-amyloid as the initiating point of the process leading to the disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/8878479' target='_blank' class='pmid-link'>8878479</a>:</span> <span class='sentence-part'>Mutations in the genes encoding amyloid-beta precursor protein (APP), presenilin 1 (PS1) and presenilin 2 (PS2) are known to cause early-onset, autosomal dominant Alzheimer's disease. These results indicate that the presenilin mutations probably cause Alzheimer's disease through a gain of deleterious function that increases the amount of A beta42(43) in the brain.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/8915610' target='_blank' class='pmid-link'>8915610</a>:</span> <span class='sentence-part'>Six different single base mutations in the APP gene have been reported causing early-onset Alzheimer's disease (age at onset &lt; or = 65 years) or related amyloidosis in a small number of families.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/9106355' target='_blank' class='pmid-link'>9106355</a>:</span> <span class='sentence-part'>Various mutations in the amyloid protein precursor and presenilin genes can lead to early onset, autosomal Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/9328472' target='_blank' class='pmid-link'>9328472</a>:</span> <span class='sentence-part'>We report a novel mutation in the amyloid precursor protein gene (APP I716V) which probably leads to familial early onset Alzheimer's disease with an onset age in the mid 50s.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/9811864' target='_blank' class='pmid-link'>9811864</a>:</span> <span class='sentence-part'>The importance of the amyloid precursor protein (APP) in the pathogenesis of Alzheimer's disease (AD) became apparent through the identification of distinct mutations in the APP gene, causing early onset familial AD with the accumulation of a 4-kDa peptide fragment (betaA4) in amyloid plaques and vascular deposits.</span></div></div>
<div class='streamlined-assertion'><div class='streamlined-header sticky-relation-header'><span class='label-text'>Subject:</span> <strong>Amyloid_deposition</strong> <span class='label-text'>Subject CUI:</span> <strong>C0011560</strong> â†’ <span class='label-text predicate-text'>CAUSES</span> â†’ <span class='label-text'>Object:</span> <strong>Alzheimers</strong> <span class='label-text'>Object CUI:</span> <strong>C0002395</strong></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/14558486' target='_blank' class='pmid-link'>14558486</a>:</span> <span class='sentence-part'>Cerebral amyloid angiopathy (CAA), a condition affecting the elderly in a way similar to that of Alzheimer's disease, results from amyloid deposition within small and medium arteries of the cerebral leptomeninges and cerebral cortex.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/14747300' target='_blank' class='pmid-link'>14747300</a>:</span> <span class='sentence-part'>Evidence is growing to link precursors of amyloid deposition in the brain and pancreas with the pathogenesis of Alzheimer disease and type 2 diabetes, respectively.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/16863248' target='_blank' class='pmid-link'>16863248</a>:</span> <span class='sentence-part'>The identification and characterization of possible environmental factors that may influence amyloid deposition in vivo are important to unveil the underlying etiology of AD. According to the amyloid cascade hypothesis, diffuse plaques are initial and visual deposits in the early event of AD, leading to amyloid plaques.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/1763432' target='_blank' class='pmid-link'>1763432</a>:</span> <span class='sentence-part'>Amyloid deposition as the central event in the aetiology of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/1776729' target='_blank' class='pmid-link'>1776729</a>:</span> <span class='sentence-part'>At the cellular level, Alzheimer's disease (AD) must be the result of neuronal dysfunction and degeneration leading to a reduction in synaptic density. As elucidation of the reasons behind amyloid deposition must shed some light on the pathogenesis of AD, we review the current state of knowledge on the nature of the AD amyloid protein, its origin, and its formation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/18157656' target='_blank' class='pmid-link'>18157656</a>:</span> <span class='sentence-part'>Amyloid beta (Abeta) deposition and neurodegeneration are the two related events in the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/18547682' target='_blank' class='pmid-link'>18547682</a>:</span> <span class='sentence-part'>We propose that ASM activation is an important pathological event leading to AD, perhaps due to Abeta deposition.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/19084047' target='_blank' class='pmid-link'>19084047</a>:</span> <span class='sentence-part'>Bone marrow-derived mesenchymal stem cells reduce brain amyloid-beta deposition and accelerate the activation of microglia in an acutely induced Alzheimer's disease mouse model.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20061626' target='_blank' class='pmid-link'>20061626</a>:</span> <span class='sentence-part'>The relationship between amyloid-beta (Abeta) deposition and tau-related neurofibrillary changes is a key issue in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20538375' target='_blank' class='pmid-link'>20538375</a>:</span> <span class='sentence-part'>Despite the central role of amyloid deposition in the development of Alzheimer's disease (AD), the pathogenesis of AD still remains elusive at the molecular level.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21352095' target='_blank' class='pmid-link'>21352095</a>:</span> <span class='sentence-part'>Evidence is growing linking precursors of amyloid deposition in the brain and pancreas to the pathogenesis of AD and T2DM, respectively.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21683932' target='_blank' class='pmid-link'>21683932</a>:</span> <span class='sentence-part'>BACKGROUND: The hypothesis that amyloid deposition is the leading cause of Alzheimer's disease (AD) is supported by findings in transgenic animal models and forms the basis of clinical trials of anti-amyloid agents.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21705422' target='_blank' class='pmid-link'>21705422</a>:</span> <span class='sentence-part'>The similar topography of fibrillar amyloid-beta deposition between typical Alzheimer's disease and posterior cortical atrophy groups suggests that, although amyloid-beta accumulation plays a critical role in the pathogenesis of Alzheimer's disease, other factors such as neurofibrillary tangles may contribute to the different clinical features observed in posterior cortical atrophy.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23624169' target='_blank' class='pmid-link'>23624169</a>:</span> <span class='sentence-part'>BACKGROUND: Although it is well known that many clinical and genetic factors have been associated with beta-amyloid deposition, few studies have examined the interactions of such factors across different stages of Alzheimer's pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23788007' target='_blank' class='pmid-link'>23788007</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) is a consequence of degenerative brain pathology with amyloid plaque deposition and neurofibrillary tangle formation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25662507' target='_blank' class='pmid-link'>25662507</a>:</span> <span class='sentence-part'>Considering the role of proinflammatory molecules and microglial activation in the pathogenesis of AD, the current study aimed to elucidate the effects of donepezil on microglial activation induced by amyloid deposition in transgenic mice.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26283673' target='_blank' class='pmid-link'>26283673</a>:</span> <span class='sentence-part'>The early pretangle disease phase is a focus of increasing interest because only abnormal forms of the microtubule-associated protein tau are involved at that point and, in contrast to late-stage disease when amyloid-beta deposition is present, this phase is temporally closer to the prevailing conditions that induce the pathological process underlying Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27395454' target='_blank' class='pmid-link'>27395454</a>:</span> <span class='sentence-part'>This suggests that APOE epsilon4 facilitates amyloid deposition during the very early phase of AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27776263' target='_blank' class='pmid-link'>27776263</a>:</span> <span class='sentence-part'>The pathway leading from amyloid-beta deposition to cognitive impairment is believed to be a cornerstone of the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27996029' target='_blank' class='pmid-link'>27996029</a>:</span> <span class='sentence-part'>Accumulation of amyloid-beta (Abeta) peptides and amyloid plaque deposition in brain is postulated as a cause of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28460142' target='_blank' class='pmid-link'>28460142</a>:</span> <span class='sentence-part'>This study suggested that AgNP exposure might cause Abeta deposition and inflammation for subsequent neuronal cell apoptosis to potentially induce AD progression. AgNP exposure can increase amyloid beta (Abeta) deposition in neuronal cells to potentially induce Alzheimer's disease (AD) progression.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28669880' target='_blank' class='pmid-link'>28669880</a>:</span> <span class='sentence-part'>Amyloid beta (Abeta) deposition is considered to be one of the primary reason to trigger Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29406914' target='_blank' class='pmid-link'>29406914</a>:</span> <span class='sentence-part'>In Alzheimer Disease, impaired vasoreactivity has been reported as the results of vascular amyloid deposition.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30958361' target='_blank' class='pmid-link'>30958361</a>:</span> <span class='sentence-part'>Abeta deposition is the most frequently hypothesized initiating factor of AD, and Abeta clearance during the pathogenesis of AD may be an optional strategy to suppress AD development.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31219699' target='_blank' class='pmid-link'>31219699</a>:</span> <span class='sentence-part'>Interestingly, knockdown of Trem2 at the early-middle stage of AD (2-6 mo) prevents synaptic loss through directly inhibiting microglial phagocytosis, whereas knockdown of Trem2 at the middle-late stage of AD (6-10 mo) accelerates synaptic dysfunction because of more severe amyloid deposition caused by the depression of microglial phagocytosis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31223308' target='_blank' class='pmid-link'>31223308</a>:</span> <span class='sentence-part'>Therefore, revealing the underlying mechanism of BACE1 in the pathogenesis of AD might have a significant impact on the future development of therapeutic agents targeting dementia. Increased amyloid-beta (Abeta) plaque deposition is thought to be the main cause of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32108008' target='_blank' class='pmid-link'>32108008</a>:</span> <span class='sentence-part'>Senile plaques and amyloid deposition is one of the main causes of AD, amyloid deposition isconsidered as a central event which induces the link between the production of beta amyloid and vascular changes.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32796236' target='_blank' class='pmid-link'>32796236</a>:</span> <span class='sentence-part'>Amyloid deposition can lead to Alzheimer disease and cerebral amyloid angiopathy.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33318676' target='_blank' class='pmid-link'>33318676</a>:</span> <span class='sentence-part'>According to the prevailing amyloid cascade hypothesis, amyloid-beta (Abeta) deposition in the brain is the initiating event in AD, although evidence is accumulating that this hypothesis is insufficient to explain many aspects of AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34108650' target='_blank' class='pmid-link'>34108650</a>:</span> <span class='sentence-part'>Predicting cerebral amyloid deposition is considered the key for AD diagnosis because a cerebral amyloid deposition is the hallmark of AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34405526' target='_blank' class='pmid-link'>34405526</a>:</span> <span class='sentence-part'>Amyloid-beta (Abeta) deposition in the brain has been implicated in the development of Alzheimer's disease (AD), and neuroinflammation generates AD progression.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/3477820' target='_blank' class='pmid-link'>3477820</a>:</span> <span class='sentence-part'>Progressive amyloid deposition in senile plaques and cortical blood vessels may play a central role in the pathogenesis of Alzheimer disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34823269' target='_blank' class='pmid-link'>34823269</a>:</span> <span class='sentence-part'>Improved insight into these pathomechanisms may allow to shed light on the role of Abeta deposition as a primary vs. a secondary event in the complex pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35575872' target='_blank' class='pmid-link'>35575872</a>:</span> <span class='sentence-part'>The pathological characteristics of Alzheimer's disease (AD) include formation of senile plaques resulting from amyloid-beta (Abeta) deposition and neurofibrillary tangles caused by tau hyperphosphorylation. The above-mentioned proteins were then evaluated in an okadaic acid (OKA)-induced AD cell model to verify the results.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35986296' target='_blank' class='pmid-link'>35986296</a>:</span> <span class='sentence-part'>CONCLUSIONS: The reciprocal effects of amyloid deposition and systemic infectious burden may lead to a vicious cycle fueling Alzheimer's disease pathogenesis. The infectious theory linked various infectious agents with the development of AD, raising the possibility that they serve as etiological causes of the disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36996958' target='_blank' class='pmid-link'>36996958</a>:</span> <span class='sentence-part'>Previous research has established amyloid plaque deposition as the leading cause of Alzheimer's disease (AD) pathogenesis, detected mainly in aged population.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37188840' target='_blank' class='pmid-link'>37188840</a>:</span> <span class='sentence-part'>In preclinical Alzheimer's disease, neuro-functional changes due to amyloid-beta (Abeta) deposition are not synchronized in different brain lobes and subcortical nuclei.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37864249' target='_blank' class='pmid-link'>37864249</a>:</span> <span class='sentence-part'>Impaired autophagy in plaque-associated microglia (PAM) has been reported to accelerate amyloid plaque deposition and cognitive impairment in AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37895161' target='_blank' class='pmid-link'>37895161</a>:</span> <span class='sentence-part'>While conventional pathophysiological models of AD have primarily emphasized the significance of amyloid-beta (Abeta) deposition and tau protein hyperphosphorylation, this targeted systematic review meticulously aggregates and rigorously appraises seminal contributions from the past year elucidating the complex mechanisms of H     2      S in AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/38076912' target='_blank' class='pmid-link'>38076912</a>:</span> <span class='sentence-part'>Overall, this contextualized understanding of proteomic changes and their interplay with amyloid deposition provides valuable insights into the complexity of AD pathogenesis and potential biomarkers and therapeutic targets.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/7651609' target='_blank' class='pmid-link'>7651609</a>:</span> <span class='sentence-part'>Rats with lesions induced by beta-peptides may be a useful animal model of amyloid deposition for investigation of the pathogenetic mechanisms leading to Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/8620894' target='_blank' class='pmid-link'>8620894</a>:</span> <span class='sentence-part'>Here functional implications of these mutations on the processing of the precursor protein and the beta A4 amyloid deposition will be discussed with respect to the pathogenesis of Alzheimer's disease and related disorders. Alzheimer's disease is a senile dementia caused by progressive neurodegeneration of the central nervous system.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/9168248' target='_blank' class='pmid-link'>9168248</a>:</span> <span class='sentence-part'>Mechanisms of neurotoxicity associated with amyloid beta deposition and the role of free radicals in the pathogenesis of Alzheimer's disease: a critical appraisal.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/9223085' target='_blank' class='pmid-link'>9223085</a>:</span> <span class='sentence-part'>The association of astrocytes with plaques is a well-established feature of Alzheimer's disease (AD) and has generally been interpreted as a secondary reaction to amyloid deposition or neuronal degeneration.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/9399697' target='_blank' class='pmid-link'>9399697</a>:</span> <span class='sentence-part'>These findings indicate that changes in cerebral betaA4 levels contribute to temporal lobe atrophy in AD and support the possibility that betaA4 is central to the etiology of AD. Pathological and biochemical studies indicate that beta-amyloid (betaA4) deposition is a hallmark in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/9678319' target='_blank' class='pmid-link'>9678319</a>:</span> <span class='sentence-part'>CONCLUSION: Our results differ from the data from AD due to mutations in presenilin 1 and presenilin 2 genes and the amyloid precursor protein and suggest that the APOE epsilon4 genotype mediates increased Abeta deposition by a mechanism that differs from that found in other genetic causes of AD.</span></div></div>
<div class='streamlined-assertion'><div class='streamlined-header sticky-relation-header'><span class='label-text'>Subject:</span> <strong>Amyloidosis</strong> <span class='label-text'>Subject CUI:</span> <strong>C0002726</strong> â†’ <span class='label-text predicate-text'>CAUSES</span> â†’ <span class='label-text'>Object:</span> <strong>Alzheimers</strong> <span class='label-text'>Object CUI:</span> <strong>C0002395</strong></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/15017581' target='_blank' class='pmid-link'>15017581</a>:</span> <span class='sentence-part'>Cerebral Abeta amyloidosis and postmenopausal hormone deficiency: roles in the genesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/15265270' target='_blank' class='pmid-link'>15265270</a>:</span> <span class='sentence-part'>Atherosclerosis, vascular amyloidosis and brain hypoperfusion in the pathogenesis of sporadic Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/16399644' target='_blank' class='pmid-link'>16399644</a>:</span> <span class='sentence-part'>Neuropathological and genetic studies provide strong evidence of a key role for A beta amyloidosis in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21044348' target='_blank' class='pmid-link'>21044348</a>:</span> <span class='sentence-part'>CONCLUSIONS: Our present data indicate that there is a close link between insulin deficient diabetes and cerebral amyloidosis in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21426072' target='_blank' class='pmid-link'>21426072</a>:</span> <span class='sentence-part'>BACKGROUND: beta-amyloidosis and oxidative stress have been implicated as root causes of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21911660' target='_blank' class='pmid-link'>21911660</a>:</span> <span class='sentence-part'>BACKGROUND: The amyloid hypothesis predicts that increased production or decreased clearance of beta-amyloid (Abeta) leads to amyloidosis, which ultimately culminates in Alzheimer disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22813736' target='_blank' class='pmid-link'>22813736</a>:</span> <span class='sentence-part'>Our findings thus reveal a role of MAGL in modulating neuroinflammation and amyloidosis in AD etiology and put forth MAGL inhibitors as a potential next-generation strategy for combating AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24228859' target='_blank' class='pmid-link'>24228859</a>:</span> <span class='sentence-part'>CONCLUSIONS: Our study suggests that there is a close linkage of DM and cerebral amyloidosis in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24373429' target='_blank' class='pmid-link'>24373429</a>:</span> <span class='sentence-part'>Despite compelling genetic evidence indicating that cerebral amyloidosis can be, at least sometimes, the primary cause of Alzheimer's disease (AD), clinical trials for symptomatic AD with amyloid-reducing agents have succeeded at target engagement but failed to cause clinical benefit.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24852227' target='_blank' class='pmid-link'>24852227</a>:</span> <span class='sentence-part'>We review the genetics, epidemiology and pathology of sporadic AD and give an updated account of what is currently known about the molecular pathogenesis of the disease. The amyloid beta (Abeta) hypothesis posits that cerebral beta-amyloidosis is a critical early event in AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28490901' target='_blank' class='pmid-link'>28490901</a>:</span> <span class='sentence-part'>Amyloidosis, the aggregation of amyloid proteins to form amyloid bodies, plays a central role in the pathogenesis of AD and other human neuropathies by forming intracellular fibrillary proteins. Breast cancer and Alzheimer's disease (AD) are major causes of death in older women.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30053949' target='_blank' class='pmid-link'>30053949</a>:</span> <span class='sentence-part'>This landmark paper laid the foundation for extensive research in the following decades that ultimately established the role of beta-amyloidosis as a player in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31156159' target='_blank' class='pmid-link'>31156159</a>:</span> <span class='sentence-part'>These results provide mechanistic insight into the beneficial effects of insulin, and a possible link between insulin deficient diabetes and cerebral amyloidosis in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31162811' target='_blank' class='pmid-link'>31162811</a>:</span> <span class='sentence-part'>Amyloid-like peptides are an ideal model for the mechanistic study of amyloidosis, which may lead to many human diseases, such as Alzheimer disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33947453' target='_blank' class='pmid-link'>33947453</a>:</span> <span class='sentence-part'>CONCLUSIONS: Our results indicate that plasma and CSF p-tau181 abnormalities associated with amyloidosis occur simultaneously in the progression of AD pathogenesis and related cognitive decline, before tau-PET turns positive.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35202955' target='_blank' class='pmid-link'>35202955</a>:</span> <span class='sentence-part'>The protective innate immune response of beta-amyloid peptide (Abeta) has been indicated as a risk factor for Alzheimer's disease (AD) due to the rapid amyloidosis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/7579788' target='_blank' class='pmid-link'>7579788</a>:</span> <span class='sentence-part'>Recent molecular biological, biochemical and immunohistochemical studies have revealed various novel facts about beta-amyloidosis including its role in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/8885836' target='_blank' class='pmid-link'>8885836</a>:</span> <span class='sentence-part'>A mechanism is proposed, whereby nicotine retards amyloidosis by preventing an alpha-helix--&gt;beta-sheet conformational transformation that is important in the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/9099821' target='_blank' class='pmid-link'>9099821</a>:</span> <span class='sentence-part'>Based on the homology of human and monkey amyloid precursor proteins and the derived beta-amyloid peptides (A beta) the investigation of brains from old monkeys might be useful for the understanding of beta-amyloidosis in the aetiology of Alzheimer's disease.</span></div></div>
<div class='streamlined-assertion'><div class='streamlined-header sticky-relation-header'><span class='label-text'>Subject:</span> <strong>Antioxidants</strong> <span class='label-text'>Subject CUI:</span> <strong>C0003402</strong> â†’ <span class='label-text predicate-text'>CAUSES</span> â†’ <span class='label-text'>Object:</span> <strong>Alzheimers</strong> <span class='label-text'>Object CUI:</span> <strong>C0002395</strong></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/16311508' target='_blank' class='pmid-link'>16311508</a>:</span> <span class='sentence-part'>Deregulation of GRX1 and TRX1 antioxidant systems could be important events in AD pathogenesis. Strong evidence indicates oxidative stress in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21166677' target='_blank' class='pmid-link'>21166677</a>:</span> <span class='sentence-part'>Recent findings suggest that 'aged garlic extract' (AGE) may be a therapeutic agent for AD because of its antioxidant and Abeta lowering properties.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22042981' target='_blank' class='pmid-link'>22042981</a>:</span> <span class='sentence-part'>BACKGROUND: Serum plasmalogens (Pls) have gained interest in several clinical symptoms such as metabolic syndrome/atherosclerosis or Alzheimer's disease possibly because of their antioxidant properties.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23645386' target='_blank' class='pmid-link'>23645386</a>:</span> <span class='sentence-part'>Curcumin, a dietary polyphenol, has shown a potential to act on the symptoms of neurodegenerative disorders, including Alzheimer's and Parkinson's diseases, as a consequence of its antioxidant, anti-inflammatory and anti-protein aggregation properties.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24426241' target='_blank' class='pmid-link'>24426241</a>:</span> <span class='sentence-part'>In Conclusion, melatonin significantly ameliorates the neurodegeneration characteristic of AD in experimental animal model due to its antioxidant, antiapoptotic, neurotrophic and anti-amyloidogenic activities.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28049401' target='_blank' class='pmid-link'>28049401</a>:</span> <span class='sentence-part'>Many dietary components, including different types of fruits, vegetables, spices, and marine products as well as a Mediterranean diet, are a good source of antioxidants and have anti-inflammatory properties, with many showing substantial potential against AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30021335' target='_blank' class='pmid-link'>30021335</a>:</span> <span class='sentence-part'>In conclusion, 4-PSQ protected against learning and memory impairment and anxiety in a mouse model of AD induced by Abeta, and anticholinesterase and antioxidant actions are involved in the pharmacological effect of the compound.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30596810' target='_blank' class='pmid-link'>30596810</a>:</span> <span class='sentence-part'>Objectives: In order to infer whether long-term circulating antioxidant exposure plays a role in AD etiology, we tested the hypothesis that AD risk would be lower in individuals with lifelong, genetically predicted increases in concentrations of 4 circulating antioxidants that are modifiable by diet.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31561062' target='_blank' class='pmid-link'>31561062</a>:</span> <span class='sentence-part'>Trans-crocin 4 (TC4) is an important carotenoid constituent of saffron showing potential activity against Alzheimer's Disease (AD) due to its antioxidant and antiamyloidogenic properties.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31778363' target='_blank' class='pmid-link'>31778363</a>:</span> <span class='sentence-part'>They are new promising compounds against AD due to their antioxidant, anti-inflammatory and acetylcholinesterase inhibitory activities in the neural system.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32391472' target='_blank' class='pmid-link'>32391472</a>:</span> <span class='sentence-part'>Effects of alpha-Mangostin Derivatives on the Alzheimer's Disease Model of Rats and Their Mechanism: A Combination of Experimental Study and Computational Systems Pharmacology Analysis.alpha-Mangostin (alpha-M) is a natural xanthone from the pericarp of fruit    Garcinia mangostana     and possesses versatile biological activities. alpha-M has a therapeutic potential to treat Alzheimer's disease (AD) because of its anti-inflammatory, antioxidative, and neuroprotective activities.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33384986' target='_blank' class='pmid-link'>33384986</a>:</span> <span class='sentence-part'>The findings in this review suggest that probiotics, prebiotics or synbiotics have potential as novel biological prophylactics in treatment of AD, due to their anti-inflammatory and antioxidant properties, their ability to improve cognition and metabolic activity, as well as their capacity of producing essential metabolites for gut and brain barrier permeability.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33399852' target='_blank' class='pmid-link'>33399852</a>:</span> <span class='sentence-part'>Human apolipoprotein-D (apoD) is a glycosylated lipocalin that plays a protective role in Alzheimer's disease due to its antioxidant function.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33971493' target='_blank' class='pmid-link'>33971493</a>:</span> <span class='sentence-part'>Natural antioxidants enhance the power of physical and mental activities versus risk factors inducing progression of Alzheimer's disease in rats. METHODS: Aluminum chloride (70 mg/kg, I.P for 5 weeks) was used to induce AD in rats that either normally fed or socially isolated and protein malnourished (SI&amp;PM).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34553117' target='_blank' class='pmid-link'>34553117</a>:</span> <span class='sentence-part'>Conclusion: According to our results, we suggested that insufficient apelin-13 and TAS levels may contribute to the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35327563' target='_blank' class='pmid-link'>35327563</a>:</span> <span class='sentence-part'>This review highlights the neuroinflammatory and neuroprotective role of epigallocatechin-3-gallate (EGCG): the medicinal component of green tea, a known nutraceutical that has shown promise in modulating AD progression due to its antioxidant, anti-inflammatory, and anti-aging abilities. Using Alzheimer's disease (AD) as the archetype, the pathological findings include the aggregation of Amyloid Beta (Abeta) peptides, mitochondrial dysfunction, synaptic degradation caused by inflammation, elevated reactive oxygen species (ROS), and cerebrovascular dysregulation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35412308' target='_blank' class='pmid-link'>35412308</a>:</span> <span class='sentence-part'>Furthermore, two-photon microscopic imaging of various regions in Alzheimer's disease (AD) mice brains revealed a down-regulated Msrs levels compared with that in normal brains, especially in the cornuammonis of the hippocampus region, which may in turn lead to an aggravation of AD pathogenesis due to the weakened antioxidant and self-repair capability of neurons.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36143299' target='_blank' class='pmid-link'>36143299</a>:</span> <span class='sentence-part'>The results of the studies showed that the use of phytochemicals against AD has gained relevance due to their antioxidant, anti-neuroinflammatory, anti-amyloid, and anti-hyperphosphorylation properties of Tau protein.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36277497' target='_blank' class='pmid-link'>36277497</a>:</span> <span class='sentence-part'>Mesenchymal stem/stromal cells (MSCs) could be a potential therapeutic option for treating AD due to their immunomodulatory, anti-inflammatory, regenerative, antioxidant, anti-apoptotic, and neuroprotective effects.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37659206' target='_blank' class='pmid-link'>37659206</a>:</span> <span class='sentence-part'>In recent years, natural compounds sourced from diverse origins have garnered considerable attention as potential therapeutic agents for AD, owing to their anti-inflammatory, antioxidant, and neuroprotective properties.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37877008' target='_blank' class='pmid-link'>37877008</a>:</span> <span class='sentence-part'>Recently, natural medicines, especially Chinese herbal medicines, have gained attention in the treatment of AD due to their antioxidant, anti-inflammatory, and neuroprotective effects.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37927255' target='_blank' class='pmid-link'>37927255</a>:</span> <span class='sentence-part'>These phytocompounds are widely available and a multitude of holistic therapeutic efficiencies for treating AD owing to their antioxidant, anti-inflammatory, and biological activities.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/38151890' target='_blank' class='pmid-link'>38151890</a>:</span> <span class='sentence-part'>Consuming hazelnut may attenuate the risk of neurodegenerative disorders including Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, multiple sclerosis, and Huntington's disease due to its anti-inflammatory and anti-oxidant qualities.</span></div></div>
<div class='streamlined-assertion'><div class='streamlined-header sticky-relation-header'><span class='label-text'>Subject:</span> <strong>Apolipoprotein_E4</strong> <span class='label-text'>Subject CUI:</span> <strong>C0052201</strong> â†’ <span class='label-text predicate-text'>CAUSES</span> â†’ <span class='label-text'>Object:</span> <strong>Alzheimers</strong> <span class='label-text'>Object CUI:</span> <strong>C0002395</strong></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32163130' target='_blank' class='pmid-link'>32163130</a>:</span> <span class='sentence-part'>This suggests that structural vulnerability in neuronal networks associated with APOE-epsilon4 may be an early event in AD pathogenesis, possibly upstream of amyloid deposition.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32308396' target='_blank' class='pmid-link'>32308396</a>:</span> <span class='sentence-part'>Conclusions: Our findings suggested that APOE epsilon4 might affect CSF VILIP-1 level in preclinical AD, indicating an important role of APOE epsilon4 in neuron injury leading to AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32986665' target='_blank' class='pmid-link'>32986665</a>:</span> <span class='sentence-part'>OBJECTIVE: This study aimed to investigate the interactive role of androgen decline and APOEE4 genotype in the pathogenesis of amnestic mild cognitive impairment (aMCI) and AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33331110' target='_blank' class='pmid-link'>33331110</a>:</span> <span class='sentence-part'>AIM: Heredity plays an important role in the pathogenesis of Alzheimer's disease (AD) especially for single-nucleotide polymorphism (SNPs) of susceptible genes, which is one of the significant factors in the pathogenesis of AD. In addition, apolipoprotein E epsilon4 status promotes them to result in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33748578' target='_blank' class='pmid-link'>33748578</a>:</span> <span class='sentence-part'>Apolipoprotein E4 (ApoE4) is the main genetic risk factor for Alzheimer's disease (AD), but the exact way in which it causes AD remains unclear.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34743630' target='_blank' class='pmid-link'>34743630</a>:</span> <span class='sentence-part'>Congruence across language and episodic memory results as well as hippocampal and inferior lateral ventricle volume findings suggest that    APOE    -epsilon4 may interact with cerebral oxygen metabolism in the pathogenesis of Alzheimer's disease and related neurodegeneration.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35088039' target='_blank' class='pmid-link'>35088039</a>:</span> <span class='sentence-part'>Several studies suggests that    APOE        E    4 causes AD via different processes like neurofibrillary tangle formation by amyloid-beta accumulation, exacerbated neuroinflammation, cerebrovascular disease, and synaptic loss.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36396603' target='_blank' class='pmid-link'>36396603</a>:</span> <span class='sentence-part'>DISCUSSION: Since HLA-DRB1 and APOE are expressed in the BBB, blood MCP-1 released in the peripheral inflammatory cascade may function as a mediator of the effects of HLA-DRB1 rs9271192-AC/CC and APOE epsilon4 genotypes on AD pathogenesis in the brain via the BBB pathways.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37018391' target='_blank' class='pmid-link'>37018391</a>:</span> <span class='sentence-part'>Our results support that the    APOE    epsilon4 genotype exerts Abeta-independent effects on AD pathogenesis by activating microglia in brain regions associated with early tau deposition.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37947590' target='_blank' class='pmid-link'>37947590</a>:</span> <span class='sentence-part'>Detrimental Effects of ApoE epsilon4 on Blood-Brain Barrier Integrity and Their Potential Implications on the Pathogenesis of Alzheimer's Disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/38014339' target='_blank' class='pmid-link'>38014339</a>:</span> <span class='sentence-part'>Despite strong evidence supporting the involvement of both apolipoprotein E4 (APOE4) and microglia in Alzheimer's Disease (AD) pathogenesis, the effects of microglia on neuronal APOE4-driven AD pathogenesis remain elusive. These findings highlight the concerted roles of neuronal APOE, especially APOE4, and microglia in AD pathogenesis.</span></div></div>
<div class='streamlined-assertion'><div class='streamlined-header sticky-relation-header'><span class='label-text'>Subject:</span> <strong>Apolipoprotein_E_APOE</strong> <span class='label-text'>Subject CUI:</span> <strong>C0003595|348</strong> â†’ <span class='label-text predicate-text'>CAUSES</span> â†’ <span class='label-text'>Object:</span> <strong>Alzheimers</strong> <span class='label-text'>Object CUI:</span> <strong>C0002395</strong></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/10420066' target='_blank' class='pmid-link'>10420066</a>:</span> <span class='sentence-part'>More specifically, it seems undisputed that the APOE*4 allele plays an important role in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/10655544' target='_blank' class='pmid-link'>10655544</a>:</span> <span class='sentence-part'>Our human apoE4 knock-in mice will be useful in clarifying the role of apoE in the etiologies of AD and cardiovascular diseases in relation to cholesterol and lipid metabolism.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/10775884' target='_blank' class='pmid-link'>10775884</a>:</span> <span class='sentence-part'>Apolipoprotein E (protein: apo E; gene: APOE) plays an important role in the multifactorial etiology of both Alzheimer's disease (AD) and lipid level concentrations.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/10818522' target='_blank' class='pmid-link'>10818522</a>:</span> <span class='sentence-part'>We propose that ischemic-reperfusion processes in brain are the fountain-head of a cycle of molecular and cellular events that have neurodegenerative consequences which finally lead to AD. Our data suggest that ApoE modulates the outcome following cerebral ischemia via molecular events in common with AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/10899434' target='_blank' class='pmid-link'>10899434</a>:</span> <span class='sentence-part'>This review summarizes part of an experimental approach to identify biological pathways influenced by the different APOE polymorphisms that are relevant to the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/11005255' target='_blank' class='pmid-link'>11005255</a>:</span> <span class='sentence-part'>While the relevance of these proposed functions to the etiology of AD remains a mystery, these and other hypotheses will be tested as the field of apoE neurobiology grows, adding relevant new data to the functions of apoE in health and in the pathogenic mechanisms leading to AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/11145984' target='_blank' class='pmid-link'>11145984</a>:</span> <span class='sentence-part'>To further investigate the potential interaction between apoE and A beta in the pathogenesis of AD, we have determined the effect of apoE isoforms on the neurotoxicity of non-fibrillar A beta peptides.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/11165374' target='_blank' class='pmid-link'>11165374</a>:</span> <span class='sentence-part'>Apolipoprotein E (apoE) is a lipid transport molecule, which has been linked to the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/11212354' target='_blank' class='pmid-link'>11212354</a>:</span> <span class='sentence-part'>However, no clear explanation of the pathogenesis of apoE-induced AD has been provided.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/11980062' target='_blank' class='pmid-link'>11980062</a>:</span> <span class='sentence-part'>Hypotheses about apolipoprotein E function that may lead to Alzheimer's disease are also discussed.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/12214015' target='_blank' class='pmid-link'>12214015</a>:</span> <span class='sentence-part'>Since inheritance of different alleles of the apolipoprotein (apo) E gene is a risk factor for AD and apoE is the major lipoprotein trafficking molecule in brain, we hypothesized that apoE may modify the pathogenesis of AD by directing the delivery of oxidized CSF lipoproteins to neurons.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/12355988' target='_blank' class='pmid-link'>12355988</a>:</span> <span class='sentence-part'>Many of these are controversial and studies have shown conflicting results, but apoE polymorphism seems to be only one of the possible genetic factors suggested to play a role in the multifactoral pathogenesis of AD. First, the three genes in which mutations are known to result in early onset autosomal dominant familial AD (presenilins 1 and 2, and amyloid beta protein precursor [APP]): well characterized but that account for only a small proportion of AD cases.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/12573540' target='_blank' class='pmid-link'>12573540</a>:</span> <span class='sentence-part'>Recent evidence strongly suggests a role for cholesterol and apolipoprotein E in the etiology of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/12661900' target='_blank' class='pmid-link'>12661900</a>:</span> <span class='sentence-part'>Understanding how apoE participates in the formation of senile plaques is necessary to clarify the pathogenesis of AD; however, the mechanism remains unknown.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/14511323' target='_blank' class='pmid-link'>14511323</a>:</span> <span class='sentence-part'>Consequently, NSAID-induced increases in apoE protein may enhance apoE-mediated immunosuppression and compensatory synaptic plasticity, potentially resulting in decreased AD risk and delay of disease onset.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/14757931' target='_blank' class='pmid-link'>14757931</a>:</span> <span class='sentence-part'>These results suggest that apoE and transferrin may be part of a complex mechanism in the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/15159602' target='_blank' class='pmid-link'>15159602</a>:</span> <span class='sentence-part'>In particular, polymorphisms within the ApoE and alpha1-ACT gene have been implicated in the aetiology of AD and s-IBM.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/15634227' target='_blank' class='pmid-link'>15634227</a>:</span> <span class='sentence-part'>Accumulating evidence suggests that genetic factors such as apolipoprotein E (APOE), can act in different ways in the pathogenesis of cerebral amyloid angiopathy (CAA) and Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/15716586' target='_blank' class='pmid-link'>15716586</a>:</span> <span class='sentence-part'>This review examines the current evidence for diet, lipid homeostasis, and apoE in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/16198584' target='_blank' class='pmid-link'>16198584</a>:</span> <span class='sentence-part'>The mechanism of action of APOE in the etiology of AD remains unclear.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/16641890' target='_blank' class='pmid-link'>16641890</a>:</span> <span class='sentence-part'>Presenilins and apolipoprotein E are other neurotoxic agents involved in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17166269' target='_blank' class='pmid-link'>17166269</a>:</span> <span class='sentence-part'>Since apoE is important in the pathogenesis of Alzheimer's disease (AD), we tested whether apoE treatment of neurons affected molecules important to phosphorylation of tau, such as GSK 3beta, P35, and CDK5, and the phosphorylation of tau itself.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17854398' target='_blank' class='pmid-link'>17854398</a>:</span> <span class='sentence-part'>Apolipoprotein E (ApoE), encoded by the apolipoprotein E gene (APOE), plays an important role in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/18205697' target='_blank' class='pmid-link'>18205697</a>:</span> <span class='sentence-part'>This large body of evidence suggest that apoE is a key player in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/18430993' target='_blank' class='pmid-link'>18430993</a>:</span> <span class='sentence-part'>Further investigation of the genetic influence of these loci on apoE expression levels in the central nervous system is likely to provide new insight into apoE regulation as well as AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/18580587' target='_blank' class='pmid-link'>18580587</a>:</span> <span class='sentence-part'>These findings suggest that small HC limits educational attainment only among individuals who have greater risk of AD owing to their APOE genotype or who are destined to develop this illness later in life.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/19116777' target='_blank' class='pmid-link'>19116777</a>:</span> <span class='sentence-part'>However, exactly how apoE functions in the pathogenesis of AD remains to be fully determined. These studies show that the lipid binding capacity of apoE is a major mechanism of its function in the pathogenesis of AD, and suggest that increasing apoE lipidation may be of therapeutic importance for this devastating disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/19472365' target='_blank' class='pmid-link'>19472365</a>:</span> <span class='sentence-part'>Although apolipoprotein E (apoE) is the most common genetic risk factor for Alzheimer's Disease (AD), how apoE participates in AD pathogenesis remains incompletely understood.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20348021' target='_blank' class='pmid-link'>20348021</a>:</span> <span class='sentence-part'>Research in genetics, pathology, epidemiology, biochemistry, and cell biology, as well as in animal models, suggests that cholesterol, its transporter in the brain, apolipoprotein E, amyloid precursor protein, and amyloid-beta all interact in AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20538374' target='_blank' class='pmid-link'>20538374</a>:</span> <span class='sentence-part'>The findings suggest that abnormally high levels of ApoE may play a causative role in the pathological events of AD, particularly those involving the early cholinergic deficit in the AD brain, through modulation of cholinesterases activities, hence disturbing the acetylcholine-dependent activity of neurons and nonexcitable cells such as glial cells.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21676498' target='_blank' class='pmid-link'>21676498</a>:</span> <span class='sentence-part'>Despite the considerable converging evidence that implicates ApoE and LRP in the pathogenesis of AD, the precise mechanism by which ApoE and LRP modulate the risk for AD remains elusive.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22482075' target='_blank' class='pmid-link'>22482075</a>:</span> <span class='sentence-part'>Three genes, SORL1, APP, and APOE, are suspected to cause Alzheimer's whereas the other 21 genes are related to other diseases but may also be found to be associated with Alzheimer's, and these are TMEM59, CCT4, IGF2R, SFPQ, PRDX3, RNF14, IDS, SSBP1, SYNE2, TXNL4A, STXBP3, SMARCB1, ULK2, AGTPBP1, FABP7, CALB1, H2AFY, COPA, SAP18, ATIC and SYNCRIP.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22502767' target='_blank' class='pmid-link'>22502767</a>:</span> <span class='sentence-part'>This 'double whammy' result opens up a new direction for studies aimed at elucidating the relevant neurobiological activities of APOE isoforms in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22883744' target='_blank' class='pmid-link'>22883744</a>:</span> <span class='sentence-part'>While apoE isoforms differentially interact with amyloid beta (Abeta), a pleiotropic neurotoxin key to AD etiology, more recent work has focused on immune regulation in AD pathogenesis and on the mechanisms of innate immunomodulatory effects associated with inheritance of different APOE alleles.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23541982' target='_blank' class='pmid-link'>23541982</a>:</span> <span class='sentence-part'>Analysis of side chain oxysterols in the CSF is likely to provided useful information about cholesterol metabolism and ApoE function in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24154541' target='_blank' class='pmid-link'>24154541</a>:</span> <span class='sentence-part'>To directly determine the effects of APOE genotype on intraneuronal accumulation of Abeta1-42 at the onset of AD pathogenesis, we introduced lentiviral Abeta1-42 into the cortex of APOE targeted replacement (TR) mice at the age of 8-9 months.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24894353' target='_blank' class='pmid-link'>24894353</a>:</span> <span class='sentence-part'>Evidence suggests that the ApoE protein, a major lipid transporter, plays a key role in the pathogenesis of AD, and its role in both normal and aberrant lipid metabolism warrants further extensive investigation. Here, we review ApoE-lipid interactions, as well as the roles that lipids may play in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24971061' target='_blank' class='pmid-link'>24971061</a>:</span> <span class='sentence-part'>In this review we will summarize the evidence supporting a role for metals in the function of ApoE and its consequent role in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26401939' target='_blank' class='pmid-link'>26401939</a>:</span> <span class='sentence-part'>BACKGROUND/OBJECTIVE: Apolipoprotein E (ApoE) has an active part in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26413387' target='_blank' class='pmid-link'>26413387</a>:</span> <span class='sentence-part'>Among those factors, altered circulating cholesterol homeostasis, independent of the APOE genotype, continues to be implicated in brain deposition of amyloid beta protein (Abeta) and the pathogenesis of AD. Here, we will further discuss the linkage between elevated levels of LDL cholesterol and AD pathogenesis, and explore the underlying mechanisms whereby elevated levels of plasma LDL cholesterol promote amyloidogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26582899' target='_blank' class='pmid-link'>26582899</a>:</span> <span class='sentence-part'>Apolipoprotein E (ApoE) is an important modifier of Alzheimer's disease (AD) pathogenesis, and its abundance has been linked to the clearance of beta-amyloid (Abeta) in the brain.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27104063' target='_blank' class='pmid-link'>27104063</a>:</span> <span class='sentence-part'>The Role of Upregulated APOE in Alzheimer's Disease Etiology.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27922847' target='_blank' class='pmid-link'>27922847</a>:</span> <span class='sentence-part'>The objective of this article is to review the recent findings about the metabolism of apolipoprotein E (ApoE) and amyloid beta and other possible mechanisms by which ApoE contributes to the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28218653' target='_blank' class='pmid-link'>28218653</a>:</span> <span class='sentence-part'>The role of different genotypes of apolipoprotein E (apoE) in the etiology of Alzheimer's disease is widely recognized.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29376871' target='_blank' class='pmid-link'>29376871</a>:</span> <span class='sentence-part'>This suggests a vicious cycle between inflammation, RA signaling, and ApoE homeostasis in AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30032423' target='_blank' class='pmid-link'>30032423</a>:</span> <span class='sentence-part'>This review also highlighted utmost ApoE targeting therapeutic tactics that are crucial for controlling Alzheimer's pathogenesis. Regardless of widespread indispensable studies, the appropriate function of APOE in AD etiology stays ambiguous. Existing proof recommends that the disparate outcomes of ApoE isoforms on Abeta accretion and clearance have a distinct function in AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30140051' target='_blank' class='pmid-link'>30140051</a>:</span> <span class='sentence-part'>Here, we review the rapidly growing literature on the role of disease-associated microglia, TREM2 and APOE in the pathogenesis of Alzheimer disease and present an integrated view of innate immune function in Alzheimer disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30194628' target='_blank' class='pmid-link'>30194628</a>:</span> <span class='sentence-part'>Herein, (1) we identified the aggregation prone sequence in Abeta40 and Abeta42 as 'HHQKLVFFAE' and 'SGYEVHHQKLVFFAEDVG/KGAIIGLMVGGV' respectively with critical lysine (K) at 16 and 28 for stabilizing the aggregates; (2) elucidated the interaction pattern of AbetaPP with other Alzheimer's related proteins BACE1, APOE, SNCA, APBB1, CASP8, NAE1, ADAM10, and PSEN1 to describe the pathophysiology; (3) found APOE as commonly interacting factor between amyloid beta and Tau for governing AD pathogenesis; (4) reported K224, K351, K363, K377, K601, K662, K751, and K763 as potential putative lysine for facilitating AbetaPP clearance through ubiquitination thereby arresting Abeta formation; and (5) observed conserved glutamine (Q), glutamic acid (E), and alpha-helical conformation as few crucial factors for lysine selectivity in the ubiquitination of AbetaPP.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30804776' target='_blank' class='pmid-link'>30804776</a>:</span> <span class='sentence-part'>APOE in the brain is primarily expressed by astrocytes and microglia, cell types that are now widely appreciated to play key roles in the pathogenesis of AD; thus, a picture is emerging wherein APOE4 disrupts normal glial cell biology, intersecting with changes that occur during normal aging to ultimately cause neurodegeneration and cognitive dysfunction.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31062326' target='_blank' class='pmid-link'>31062326</a>:</span> <span class='sentence-part'>The Roles of Apolipoprotein E, Lipids, and Glucose in the Pathogenesis of Alzheimer's Disease. In this chapter, we discuss the roles of ApoE, lipids, and glucose in the pathogenesis of AD by considering their potential interactions.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31623648' target='_blank' class='pmid-link'>31623648</a>:</span> <span class='sentence-part'>However, the specific contributions of different apoE pools to AD pathogenesis remain unknown.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32027932' target='_blank' class='pmid-link'>32027932</a>:</span> <span class='sentence-part'>Here we review the critical role of APOE in the pathogenesis of AD and some of the most promising therapeutic approaches that focus on the APOE-Abeta interaction.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35639372' target='_blank' class='pmid-link'>35639372</a>:</span> <span class='sentence-part'>However, the mechanisms linking APOE to AD-particularly the apoE protein's role in AD pathogenesis and how this is affected by APOE variants-remain poorly understood.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/7615568' target='_blank' class='pmid-link'>7615568</a>:</span> <span class='sentence-part'>These findings, together with the strong genetic association between late onset AD and the E4 allele of apoE, have strengthened the hypothesis that apoE may have a central role in the pathogenesis of AD by modulating A beta cerebral accumulation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/7619525' target='_blank' class='pmid-link'>7619525</a>:</span> <span class='sentence-part'>Thus, we conclude that A beta-apoE complexes are principal components of AD-associated brain amyloid and that the data presented here support a role for apoE in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/7695621' target='_blank' class='pmid-link'>7695621</a>:</span> <span class='sentence-part'>In this study we sought to understand the role that ApoE protein could play in the pathogenesis of AD. These findings suggest that the interaction of ApoE with tau and amyloid-beta proteins in AD could play a important role in the formation of NFT and SP, respectively, contributing to the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/7761390' target='_blank' class='pmid-link'>7761390</a>:</span> <span class='sentence-part'>These and other isoform-specific interactions of apoE give rise to testable hypotheses for the mechanism(s) of pathogenesis of Alzheimer disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/8809843' target='_blank' class='pmid-link'>8809843</a>:</span> <span class='sentence-part'>We suggest that microglia might be one of the sources of apoE in the brain, and that apoE synthesized in microglia might be closely related to the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/8813351' target='_blank' class='pmid-link'>8813351</a>:</span> <span class='sentence-part'>However, apoE levels vary in different brain regions, and local factors related to the synthesis and metabolism of apoE may be crucial in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/8832646' target='_blank' class='pmid-link'>8832646</a>:</span> <span class='sentence-part'>Apolipoprotein E (Apo E), one of the major structural and functional apolipoproteins, has recently been implicated in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/9073026' target='_blank' class='pmid-link'>9073026</a>:</span> <span class='sentence-part'>To evaluate the usefulness of apoE concentration in pathogenesis of AD, we measured the cerebrospinal fluid (CSF) levels of apoE.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/9307253' target='_blank' class='pmid-link'>9307253</a>:</span> <span class='sentence-part'>In the 162 patients for whom autopsy and ApoE genotype data were available, the clinical diagnosis of AD was verified as the primary cause of dementia in 139 cases (139 of 162, or 86%).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/9326451' target='_blank' class='pmid-link'>9326451</a>:</span> <span class='sentence-part'>Apolipoprotein E (apoE) and certain peptides derived from it have been shown to exert neurotoxic effects in vitro, and apoE has been linked to the etiology of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/9523562' target='_blank' class='pmid-link'>9523562</a>:</span> <span class='sentence-part'>To further investigate the potential interaction of apoE and A beta in the pathogenesis of AD, we have determined the binding, internalization, and degradation of human apoE isoforms in the presence and absence of A beta peptides to rat primary hippocampal neurons.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/9700208' target='_blank' class='pmid-link'>9700208</a>:</span> <span class='sentence-part'>These data indicate that in addition to the qualitative effect of the APOE epsilon2/epsilon3/epsilon4 polymorphisms on the AD occurrence, the quantitative variation of expression of these alleles due to functional APOE promoter mutations, is a key determinant of AD development.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/9740234' target='_blank' class='pmid-link'>9740234</a>:</span> <span class='sentence-part'>ApoE might play an important part in the etiology of Alzheimer's disease by functioning as a \pathologic chaperone\ to promote the formation of amyloid filaments.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/9751198' target='_blank' class='pmid-link'>9751198</a>:</span> <span class='sentence-part'>In parallel, we determined the concentrations of apolipoprotein E (apoE), another apolipoprotein also implicated in nerve regeneration and in the etiology of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/9844032' target='_blank' class='pmid-link'>9844032</a>:</span> <span class='sentence-part'>This patient group was thought to be separable from those with Alzheimer's disease based on the results of ApoE allele analysis in addition to the substantial absence of amyloid beta deposits and has been designated as senile dementia of the tangle type (SDT).</span></div></div>
<div class='streamlined-assertion'><div class='streamlined-header sticky-relation-header'><span class='label-text'>Subject:</span> <strong>Atrial_Fibrillation</strong> <span class='label-text'>Subject CUI:</span> <strong>C0004238</strong> â†’ <span class='label-text predicate-text'>CAUSES</span> â†’ <span class='label-text'>Object:</span> <strong>Atrial_Remodeling</strong> <span class='label-text'>Object CUI:</span> <strong>C3658220</strong></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31941982' target='_blank' class='pmid-link'>31941982</a>:</span> <span class='sentence-part'>We have adapted a human SAN model to characterize the SND conditions by incorporating experimental data on AF-induced electrical remodelling, and then integrated actions of drugs into the modified model to assess their efficacy. Reductions in pacing rate upon the implementation of AF-induced electrical remodelling associated with SND agreed with the clinical observations.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31977017' target='_blank' class='pmid-link'>31977017</a>:</span> <span class='sentence-part'>Role of atrial arrhythmia and ventricular response in atrial fibrillation induced atrial remodeling.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32074201' target='_blank' class='pmid-link'>32074201</a>:</span> <span class='sentence-part'>Extent of Left Atrial Ablation Lesions and Atrial Fibrillation Recurrence after Catheter Ablation - A Systematic Review and Meta-Analysis.BACKGROUND: Atrial fibrillation (AF) is known to induce atrial remodeling, which promotes fibrosis related to arrhythmogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33098411' target='_blank' class='pmid-link'>33098411</a>:</span> <span class='sentence-part'>TRANSLATIONAL PERSPECTIVE: Increased atrial ROS production is associated with both incident and prevalent AF, with experimental findings suggesting it may have a causal role in AF induction and AF-induced electrical remodelling.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33099748' target='_blank' class='pmid-link'>33099748</a>:</span> <span class='sentence-part'>In summary, our study confirmed that AF induced by hyperuricemic rats occurred primarily via induction of atrial remodeling, thereby providing a novel potential treatment approach for hyperuricemia-related AF.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33232809' target='_blank' class='pmid-link'>33232809</a>:</span> <span class='sentence-part'>OBJECTIVE: To investigate the electrophysiological effects of ranolazine in atria with AF-induced electrical remodeling in a model of lone AF in awake goats.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33516398' target='_blank' class='pmid-link'>33516398</a>:</span> <span class='sentence-part'>Atrial fibrillation progression parallels progressive atrial remodeling induced by atrial fibrillation risk factors and atrial fibrillation itself, and is associated with worse clinical outcomes.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33989382' target='_blank' class='pmid-link'>33989382</a>:</span> <span class='sentence-part'>Strong evidence from animal models and clinical patients demonstrates that parasympathetic and sympathetic activity within this neuraxis may trigger AF, and the autonomic nervous system may either induce atrial remodeling or undergo remodeling itself to serve as a substrate for AF.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34803158' target='_blank' class='pmid-link'>34803158</a>:</span> <span class='sentence-part'>CONCLUSIONS With the development of atrial fibrillation, the serum ss2-MG levels increase and are closely related to the left atrial remodeling due to AF.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35095062' target='_blank' class='pmid-link'>35095062</a>:</span> <span class='sentence-part'>We have previously reported that atrial endocardial remodeling is induced by atrial fibrillation (AF), and the endocardial dysfunction may be partly responsible for the thrombus formation in the left atrium associated with AF.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35370645' target='_blank' class='pmid-link'>35370645</a>:</span> <span class='sentence-part'>The Sirt3 could regulate acetylated modification of key metabolic enzymes, and the increase of Sirt3 rescued AF induced atrial metabolic remodeling.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36356298' target='_blank' class='pmid-link'>36356298</a>:</span> <span class='sentence-part'>Besides the electrical recurrence of atrial tachyarrhythmia after ablation, left atrial (LA) remodeling has received attention as a consequence of AF.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37258220' target='_blank' class='pmid-link'>37258220</a>:</span> <span class='sentence-part'>CONCLUSIONS: An electrophysiological link via interatrial ECs might attenuate the hierarchical nature of activation frequencies of AF, leading to advanced electrical remodeling of the atria.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37569470' target='_blank' class='pmid-link'>37569470</a>:</span> <span class='sentence-part'>However, little is known about the role of lncRNAs in AF-induced electrical remodeling.</span></div></div>
<div class='streamlined-assertion'><div class='streamlined-header sticky-relation-header'><span class='label-text'>Subject:</span> <strong>Atrial_Fibrillation</strong> <span class='label-text'>Subject CUI:</span> <strong>C0004238</strong> â†’ <span class='label-text predicate-text'>CAUSES</span> â†’ <span class='label-text'>Object:</span> <strong>Cardioembolic_stroke</strong> <span class='label-text'>Object CUI:</span> <strong>C1531624</strong></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/12601493' target='_blank' class='pmid-link'>12601493</a>:</span> <span class='sentence-part'>We investigated the effect of prothrombin complex concentrate (PCC) on the international normalized ratio (INR) and blood coagulation system in two emergent patients treated with warfarin for secondary prevention of cardioembolic stroke due to nonvalvular atrial fibrillation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/12679765' target='_blank' class='pmid-link'>12679765</a>:</span> <span class='sentence-part'>BACKGROUND: Atrial fibrillation (AF) is widely accepted as a direct cause of cardioembolic stroke from left atrial (LA) thrombus formation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/12711853' target='_blank' class='pmid-link'>12711853</a>:</span> <span class='sentence-part'>Atrial fibrillation is identified as the most frequent cause of stroke. Diurnal and seasonal variation of stroke incidence in patients with cardioembolic stroke due to atrial fibrillation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/14574075' target='_blank' class='pmid-link'>14574075</a>:</span> <span class='sentence-part'>BACKGROUND: Atrial fibrillation is a major cause of cardioembolic stroke.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/15155965' target='_blank' class='pmid-link'>15155965</a>:</span> <span class='sentence-part'>BACKGROUND AND PURPOSE: Although atrial fibrillation is the most frequent cause of cardioembolic stroke, this arrhythmia remains underdiagnosed, as it is often asymptomatic or intermittent and, thus, may not be detected on standard 12-lead ECG or even 24-hour ECG recording (Holter).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/16822397' target='_blank' class='pmid-link'>16822397</a>:</span> <span class='sentence-part'>Nonvalvular atrial fibrillation remains the most common cause of cardioembolic stroke.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/16833031' target='_blank' class='pmid-link'>16833031</a>:</span> <span class='sentence-part'>Nonvalvular atrial fibrillation (NVAF) is the most frequent cause of cardioembolic stroke.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17239801' target='_blank' class='pmid-link'>17239801</a>:</span> <span class='sentence-part'>Hypertension and atrial fibrillation were the most common risk factor and cause, respectively, of ischemic stroke in this population. Hypertension was the most common cardiovascular risk factor in all subtypes and atrial fibrillation was the most common cause of cardioembolic stroke.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/19026905' target='_blank' class='pmid-link'>19026905</a>:</span> <span class='sentence-part'>Much of the increase may be attributed to atrial fibrillation, the most common cause of cardioembolic stroke and one that plays a substantial role in aging adults.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/19267052' target='_blank' class='pmid-link'>19267052</a>:</span> <span class='sentence-part'>The selected domains include cardiovascular disease, for example the management of hypertension in very old patients, the effects of blockade of the renin-angiotensin-aldosterone system, and the use of biomarkers in cardiology; neurovascular pathology, specifically the prognosis of transient ischemic attacks and some aspects of cardioembolic stroke due to atrial fibrillation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20671249' target='_blank' class='pmid-link'>20671249</a>:</span> <span class='sentence-part'>However, it remains unclear whether 4q25 associates with all the stroke subtypes or with cardioembolic stroke in particular, which is often attributable to atrial fibrillation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20727789' target='_blank' class='pmid-link'>20727789</a>:</span> <span class='sentence-part'>Atrial fibrillation (AF) is the major cause of cardioembolic stroke.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20832823' target='_blank' class='pmid-link'>20832823</a>:</span> <span class='sentence-part'>BACKGROUND: Atrial fibrillation (AF), which is the most common etiology of cardioembolic stroke, may be accompanied by other cardiac sources of embolism.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21031583' target='_blank' class='pmid-link'>21031583</a>:</span> <span class='sentence-part'>A separate 37-gene profile differentiated cardioembolic stroke due to atrial fibrillation from nonatrial fibrillation causes with &gt;90% sensitivity and specificity.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21804776' target='_blank' class='pmid-link'>21804776</a>:</span> <span class='sentence-part'>Atrial fibrillation is the most common cause of cardioembolic stroke.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21822469' target='_blank' class='pmid-link'>21822469</a>:</span> <span class='sentence-part'>Nonvalvular atrial fibrillation is the most frequent cause of cardioembolic stroke.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22788384' target='_blank' class='pmid-link'>22788384</a>:</span> <span class='sentence-part'>BACKGROUND AND PURPOSE: Atrial fibrillation (AF) is amongst the most important etiologies of ischaemic stroke. RESULTS: In total, 187 of 626 patients with FEIS suffered from cardioembolic stroke owing to AF, which was newly diagnosed in 57 (31%) patients. Stroke due to atrial fibrillation in a population-based stroke registry (Ludwigshafen Stroke Study) CHADS(2) , CHA(2) DS(2) -VASc score, underuse of oral anticoagulation, and implications for preventive measures. METHODS: Within the Ludwigshafen Stroke Study (LuSSt), a prospective ongoing population-based stroke register, we analyzed all patients with a first-ever ischaemic stroke (FEIS) owing to AF in 2006 and 2007.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23625310' target='_blank' class='pmid-link'>23625310</a>:</span> <span class='sentence-part'>Since a large proportion of patients do not receive OAC despite an indication (because of contraindications or mere fear of bleeding) and since the majority of patients have to stop OAC during the course of 2 years, mostly due to bleeding, the LAA occluder may play an important role in the long-term prophylaxis of cardioembolic stroke due to atrial fibrillation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24119617' target='_blank' class='pmid-link'>24119617</a>:</span> <span class='sentence-part'>Elevated serum brain natriuretic peptide (BNP) levels are associated with cardioembolic stroke mainly because of atrial fibrillation (AF).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24699483' target='_blank' class='pmid-link'>24699483</a>:</span> <span class='sentence-part'>Atrial fibrillation is the most common cause of cardioembolic stroke and typically justifies anticoagulation therapy.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25294056' target='_blank' class='pmid-link'>25294056</a>:</span> <span class='sentence-part'>CONCLUSIONS: Patients with PeAF and cardioembolic stroke due to NVAF had more severe neurologic deficits on admission, more frequent major arterial occlusion, and poorer outcomes than those with PAF. BACKGROUND: We compared the clinical outcomes of persistent atrial fibrillation (PeAF) and paroxysmal atrial fibrillation (PAF) in patients with cardioembolic stroke caused by nonvalvular atrial fibrillation (NVAF) because the nature of the fibrillation can cause persistent cerebral infarction.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25294430' target='_blank' class='pmid-link'>25294430</a>:</span> <span class='sentence-part'>BACKGROUND: Cardioembolic stroke (CES) due to atrial fibrillation (AF) is associated with high stroke mortality. METHODS: Within the Ludwigshafen Stroke Study (LuSSt), a prospective population-based stroke register, we analysed all patients with a first ever ischemic stroke or TIA due to AF from 2006 until 2010. RESULTS: In total 479 patients had a first-ever ischemic stroke (n = 394) or TIA (n = 85) due to AF. We analysed whether treatment or non-treatment with OAC and initiation of OAC-therapy during and after hospitalization influenced stroke mortality within 500 days after stroke/TIA due to AF.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25906935' target='_blank' class='pmid-link'>25906935</a>:</span> <span class='sentence-part'>Thus, 653 patients were evaluated, dividing them into 2 groups for comparison (164 with stroke due to atrial fibrillation and 489 with atherothrombotic/lacunar stroke). BACKGROUND: Basing on easily available clinical and instrumental data, we aimed to define an \atrial fibrillation profile\ able to discriminate cases of stroke due to atrial fibrillation from cases due to atherothrombosis of large vessels or small-vessel disease. CONCLUSIONS: A simple profile, based on commonly available data, seems suitable to characterize patients with stroke due to atrial fibrillation. Binary multiple logistic regression identified age older than 75 years, female sex, left atrial dilation, cortical-subcortical cerebral index infarct, ischemic lesions in multiple vascular grounds, and spontaneous hemorrhagic transformation of brain infarction as significant predictors of cardioembolic stroke due to atrial fibrillation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26070218' target='_blank' class='pmid-link'>26070218</a>:</span> <span class='sentence-part'>The most severe consequence of atrial fibrillation (AF) is a cardioembolic stroke.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26376341' target='_blank' class='pmid-link'>26376341</a>:</span> <span class='sentence-part'>Atrial fibrillation (AF), the most frequent cause of cardioembolic stroke, is increasing in prevalence as the population ages, and presents with a broad spectrum of symptoms and severity.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27256218' target='_blank' class='pmid-link'>27256218</a>:</span> <span class='sentence-part'>Various cardiac disorders including atrial fibrillation, ventricular thrombus, valvular heart disease, cardiac tumors, and structural heart defects can cause cardioembolic stroke.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27407055' target='_blank' class='pmid-link'>27407055</a>:</span> <span class='sentence-part'>BACKGROUND: Atrial fibrillation is an important cause of cardioembolic stroke.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27909476' target='_blank' class='pmid-link'>27909476</a>:</span> <span class='sentence-part'>While a majority of risk can be attributed to cardioembolic stroke secondary to atrial fibrillation, additional risk is apparent, and may be driven by vascular inflammation and changes in cerebral perfusion.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28148612' target='_blank' class='pmid-link'>28148612</a>:</span> <span class='sentence-part'>Atrial fibrillation is the most common cause of cardioembolic strokes, and its prevalence increases substantially with age. This case study discusses the course of illness, treatment, and prevention strategies for patients who have suffered cardioembolic stroke due to atrial fibrillation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28157747' target='_blank' class='pmid-link'>28157747</a>:</span> <span class='sentence-part'>Atrial fibrillation is the most common cause of cardioembolic stroke, and anticoagulation is usually recommended.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28468926' target='_blank' class='pmid-link'>28468926</a>:</span> <span class='sentence-part'>BACKGROUND AND PURPOSE: Atrial fibrillation (AF) is a leading cause of cardioembolic stroke, but the relationship between AF and noncardioembolic stroke subtypes are unclear.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28566189' target='_blank' class='pmid-link'>28566189</a>:</span> <span class='sentence-part'>Association between leukoaraiosis and hemorrhagic transformation after cardioembolic stroke due to atrial fibrillation and/or rheumatic heart disease. Cardioembolic stroke due to atrial fibrillation (AF) and/or rheumatic heart disease (RHD) often involves hemorrhagic transformation (HT), and we examined whether leukoaraiosis (LA) was associated with HT in these cases.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28702271' target='_blank' class='pmid-link'>28702271</a>:</span> <span class='sentence-part'>Atrial fibrillation was the most common cause of cardioembolic strokes (48%) and large-artery atherosclerosis (LAA) was the cause in 8% among those aged &lt;35 years.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28924104' target='_blank' class='pmid-link'>28924104</a>:</span> <span class='sentence-part'>Methods Sixty-two patients with nonvalvular AF-induced cardioembolic stroke underwent cognitive testing, including the Japanese version of the Montreal Cognitive Assessment (MoCA-J), Mini-Mental State Examination (MMSE), and Apathy Scale.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29886716' target='_blank' class='pmid-link'>29886716</a>:</span> <span class='sentence-part'>Atrial fibrillation remains the prototypical cause of cardioembolic strokes.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30051391' target='_blank' class='pmid-link'>30051391</a>:</span> <span class='sentence-part'>Other risk factors, although present in both sexes, have a higher prevalence in elderly females, such as atrial fibrillation leading to cardioembolic strokes.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30113487' target='_blank' class='pmid-link'>30113487</a>:</span> <span class='sentence-part'>This prospective observational study provides new evidence of the potential relationship of cardiac biomarkers with WMHs in patients with cardioembolic stroke due to AF and/or RHD. It remains unclear whether cardiac biomarkers are associated with WMHs.To investigate this question, we prospectively recruited patients with cardioembolic stroke due to atrial fibrillation (AF) and/or rheumatic heart disease (RHD). Relationship of cardiac biomarkers with white matter hyperintensities in cardioembolic stroke due to atrial fibrillation and/or rheumatic heart disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30122707' target='_blank' class='pmid-link'>30122707</a>:</span> <span class='sentence-part'>AIM: Atrial fibrillation (AF), which can lead to cardioembolic stroke, is often not properly diagnosed in hospital outpatient departments or medical clinics.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30355194' target='_blank' class='pmid-link'>30355194</a>:</span> <span class='sentence-part'>We included 941 survivors of ICH in the setting of active oral anticoagulation therapy for prevention of cardioembolic stroke because of nonvalvular atrial fibrillation and without evidence of ischemic stroke and recurrent ICH at 1 year from the index event.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30459853' target='_blank' class='pmid-link'>30459853</a>:</span> <span class='sentence-part'>Smoking and atrial fibrillation both were associated with unknown etiology of stroke (P = 0.001 and P = 0.039, respectively). Most common etiology of stroke was cardioembolism (40%), and atrial fibrillation is found to be the most common cause of cardioembolic stroke with 30.6% incidence. Atrial fibrillation is found to be the most common cause of cardioembolic stroke.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30878151' target='_blank' class='pmid-link'>30878151</a>:</span> <span class='sentence-part'>Atrial fibrillation (AF) is a significant cause of cardioembolic strokes.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30953905' target='_blank' class='pmid-link'>30953905</a>:</span> <span class='sentence-part'>BACKGROUND: Atrial fibrillation (AF) is the leading cause of cardioembolic stroke (CES), and patients with stroke and AF are frequently assumed to have CES.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31236725' target='_blank' class='pmid-link'>31236725</a>:</span> <span class='sentence-part'>Atrial fibrillation (AF) is the leading cause of CES, and as the population ages, the incidence of CES is anticipated to rise.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31475302' target='_blank' class='pmid-link'>31475302</a>:</span> <span class='sentence-part'>Several studies pointed out the usefulness of circulating gene expression markers to discriminate cardioembolic (CE) strokes, mainly due to atrial fibrillation (AF), while only exploring them in small cohorts.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31505594' target='_blank' class='pmid-link'>31505594</a>:</span> <span class='sentence-part'>AIMS: Atrial fibrillation (AF) is the most common tachyarrhythmia and a significant cause of cardioembolic strokes.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31520437' target='_blank' class='pmid-link'>31520437</a>:</span> <span class='sentence-part'>Cardioembolic stroke secondary to AF is a devastating event, but is largely preventable with appropriate oral anticoagulation (OAC).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31540308' target='_blank' class='pmid-link'>31540308</a>:</span> <span class='sentence-part'>Conclusions: Anticoagulant use in secondary prevention predicts better functional outcome and higher survival rate in patients with severe cardioembolic stroke due to non-valvular atrial fibrillation (NVAF), therefore severe neurological deficit must not be a reason of restriction of anticoagulation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31890906' target='_blank' class='pmid-link'>31890906</a>:</span> <span class='sentence-part'>Serum B-type natriuretic peptide level and timing of its measurement as a predictor of acute ischemic stroke outcome.An increased B-type natriuretic peptide (BNP) level is associated with cardioembolic stroke because of atrial fibrillation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31893142' target='_blank' class='pmid-link'>31893142</a>:</span> <span class='sentence-part'>We diagnosed him with synchronous cardioembolic stroke and acute myocardial infarction due to atrial fibrillation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32201103' target='_blank' class='pmid-link'>32201103</a>:</span> <span class='sentence-part'>Patients without diabetes who had FHG were older, had higher glucose on admission, higher prevalence of atrial fibrillation, cardioembolic stroke etiology and bleeding brain complications compared with the group with normal fasting glucose.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32722170' target='_blank' class='pmid-link'>32722170</a>:</span> <span class='sentence-part'>The purpose of this study was to analyze the prevalence of    MTHFR     gene polymorphisms correlated with cardiovascular risk factors in a selected population of patients with CES due to non-valvular AF (NVAF).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32755246' target='_blank' class='pmid-link'>32755246</a>:</span> <span class='sentence-part'>Atrial fibrillation is the leading cause of cardioembolic stroke, with emboli most commonly originating from the left atrial appendage.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/7631338' target='_blank' class='pmid-link'>7631338</a>:</span> <span class='sentence-part'>The study participants were limited to elderly patients with cardioembolic stroke due to nonvalvular atrial fibrillation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/7845828' target='_blank' class='pmid-link'>7845828</a>:</span> <span class='sentence-part'>UNLABELLED: Atrial fibrillation is considered the main cause of cardioembolic strokes.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/8261696' target='_blank' class='pmid-link'>8261696</a>:</span> <span class='sentence-part'>In order to evaluate the efficacy of warfarin for the secondary prevention of cardioembolic stroke due to nonvalvular atrial fibrillation (NVAF), we retrospectively investigated the frequencies of recurrent brain embolism and hemorrhagic complications in 68 subjects (62 +/- 9 years old, 54 men and 14 women), who had experienced at least one cardioembolic stroke prior to the study period.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/9614684' target='_blank' class='pmid-link'>9614684</a>:</span> <span class='sentence-part'>Anticoagulation with warfarin can prevent cardioembolic stroke resulting from atrial fibrillation.</span></div></div>
<div class='streamlined-assertion'><div class='streamlined-header sticky-relation-header'><span class='label-text'>Subject:</span> <strong>Atrial_Fibrillation</strong> <span class='label-text'>Subject CUI:</span> <strong>C0004238</strong> â†’ <span class='label-text predicate-text'>CAUSES</span> â†’ <span class='label-text'>Object:</span> <strong>Cardiomyopathies</strong> <span class='label-text'>Object CUI:</span> <strong>C0878544</strong></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/10834128' target='_blank' class='pmid-link'>10834128</a>:</span> <span class='sentence-part'>In fact, there is current evidence that AF may be the cause of cardiomyopathy.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/11828182' target='_blank' class='pmid-link'>11828182</a>:</span> <span class='sentence-part'>Difficult cases in heart failure: reversible cardiomyopathy due to atrial fibrillation in a 46-year-old patient.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/11918174' target='_blank' class='pmid-link'>11918174</a>:</span> <span class='sentence-part'>Atrial cardiomyopathy as a consequence of atrial fibrillation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/11975840' target='_blank' class='pmid-link'>11975840</a>:</span> <span class='sentence-part'>A fast ventricular rate associated with atrial fibrillation may cause tachycardia-related cardiomyopathy.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/12023264' target='_blank' class='pmid-link'>12023264</a>:</span> <span class='sentence-part'>AF with a rapid ventricular rate may cause a tachycardia-related cardiomyopathy.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17599446' target='_blank' class='pmid-link'>17599446</a>:</span> <span class='sentence-part'>At baseline, there were no significant differences between patients with SPWMD &gt;130 or &lt;130 ms in age, drug therapy, permanent atrial fibrillation, New York Heart Association functional class, underlying cause of cardiomyopathy, QRS duration, left ventricular (LV) ejection fraction, LV dimensions, or neurohormonal activation (norepinephrine and atrial and brain natriuretic peptide).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/18562808' target='_blank' class='pmid-link'>18562808</a>:</span> <span class='sentence-part'>AF with a rapid ventricular rate may cause a tachycardia-related cardiomyopathy.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/19182738' target='_blank' class='pmid-link'>19182738</a>:</span> <span class='sentence-part'>AF with a rapid ventricular rate may cause a tachycardia-related cardiomyopathy.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/19367229' target='_blank' class='pmid-link'>19367229</a>:</span> <span class='sentence-part'>AF can lead to the worsening of left ventricular filling, contribute to loss of atrioventricular synchrony, affect cardiac remodeling, and even cause a tachycardia-induced cardiomyopathy.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20567637' target='_blank' class='pmid-link'>20567637</a>:</span> <span class='sentence-part'>CONDENSED ABSTRACT: The prevalence and prognostic importance of CM occurring as a consequence of AF is poorly defined. The prevalence and prognostic importance of CM occurring as a consequence of AF is poorly defined.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21087435' target='_blank' class='pmid-link'>21087435</a>:</span> <span class='sentence-part'>Untreated sustained atrial fibrillation may lead to tachycardia-induced cardiomyopathy and/or systemic thromboembolization.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24049031' target='_blank' class='pmid-link'>24049031</a>:</span> <span class='sentence-part'>We described a case of47-year-old female with atypical form of TTC due to fast atrial fibrillation that converted into ventricular fibrillation in WPW syndrome.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24643151' target='_blank' class='pmid-link'>24643151</a>:</span> <span class='sentence-part'>Tachycardia-induced cardiomyopathy (TIC) due to persistent AF developing on the basis of Wolff-Parkinson-White (WPW) syndrome was considered.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24694484' target='_blank' class='pmid-link'>24694484</a>:</span> <span class='sentence-part'>Transthoracic echocardiography revealed a severely reduced left ventricular systolic function (ejection fraction: 32%), suggesting tachycardia-induced cardiomyopathy (TIC) due to AF.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28363618' target='_blank' class='pmid-link'>28363618</a>:</span> <span class='sentence-part'>Although tachycardia-induced cardiomyopathy (TIC) due to atrial fibrillation occurs frequently, it is under-recognized in clinical settings.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28496617' target='_blank' class='pmid-link'>28496617</a>:</span> <span class='sentence-part'>AF with a rapid ventricular rate may cause a tachycardia-related cardiomyopathy.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/2942933' target='_blank' class='pmid-link'>2942933</a>:</span> <span class='sentence-part'>[Severe dilated myocardiopathy caused by auricular fibrillation].</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29706180' target='_blank' class='pmid-link'>29706180</a>:</span> <span class='sentence-part'>Atrial Fibrillation, an Under-Appreciated Reversible Cause of Cardiomyopathy: Implications for Clinical Practice From the CAMERA-MRI Study.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30404750' target='_blank' class='pmid-link'>30404750</a>:</span> <span class='sentence-part'>This contemporary review summarizes the current understanding of pathophysiological mechanisms underlying AIC, discusses the clinical implications, and offers a general approach to management, with a particular focus on AF-induced cardiomyopathy.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30928552' target='_blank' class='pmid-link'>30928552</a>:</span> <span class='sentence-part'>BACKGROUND: Atrial fibrillation (AF) is a common cause of tachycardia-induced cardiomyopathy (TIC).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31384361' target='_blank' class='pmid-link'>31384361</a>:</span> <span class='sentence-part'>Prolonged Ventricular Dyssynchrony Due to Atrial Fibrillation and Pre-Excitation Syndrome Induced Cardiomyopathy.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31585589' target='_blank' class='pmid-link'>31585589</a>:</span> <span class='sentence-part'>Atrial Fibrillation and Morbidity and Mortality in Stress-Induced Cardiomyopathy.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31585590' target='_blank' class='pmid-link'>31585590</a>:</span> <span class='sentence-part'>In reply-Atrial Fibrillation and Morbidity and Mortality in Stress-Induced Cardiomyopathy.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33000736' target='_blank' class='pmid-link'>33000736</a>:</span> <span class='sentence-part'>Tachycardia, atrial fibrillation and premature ventricular contractions can trigger a reversible cardiomyopathy, which can result in clinical heart failure.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34988528' target='_blank' class='pmid-link'>34988528</a>:</span> <span class='sentence-part'>AF with rapid ventricular conduction can lead to tachycardia-mediated cardiomyopathy, which is a reversible cause of cardiomyopathy.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35306799' target='_blank' class='pmid-link'>35306799</a>:</span> <span class='sentence-part'>This association may put both AF and thyrotoxicosis treatment into a vicious circle, leading to AI cardiomyopathy.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/9638394' target='_blank' class='pmid-link'>9638394</a>:</span> <span class='sentence-part'>In addition to stroke, both AF and atrial flutter may cause cardiomyopathy, which may be fully reversible with effective treatment of the arrhythmia. It is well recognised that AF is a major cause of stroke, even in the absence of underlying heart disease.</span></div></div>
<div class='streamlined-assertion'><div class='streamlined-header sticky-relation-header'><span class='label-text'>Subject:</span> <strong>Atrial_Fibrillation</strong> <span class='label-text'>Subject CUI:</span> <strong>C0004238</strong> â†’ <span class='label-text predicate-text'>CAUSES</span> â†’ <span class='label-text'>Object:</span> <strong>Cardiovascular_morbidity</strong> <span class='label-text'>Object CUI:</span> <strong>C1301700</strong></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/11286527' target='_blank' class='pmid-link'>11286527</a>:</span> <span class='sentence-part'>AIMS: Atrial fibrillation is a common and important cause of cardiovascular morbidity and mortality that may become more prevalent due to an ageing population and more prolonged exposure to predisposing cardiovascular disease states.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/11602543' target='_blank' class='pmid-link'>11602543</a>:</span> <span class='sentence-part'>OBJECTIVES: Though atrial fibrillation (AF) is an important cause of cardiovascular morbidity, there are few large epidemiological studies of its prevalence, incidence, and risk factors.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/11911910' target='_blank' class='pmid-link'>11911910</a>:</span> <span class='sentence-part'>BACKGROUND: Although atrial fibrillation (AF) is an important cause of cardiovascular morbidity and mortality there is a paucity of data describing hospitalisation rates and case-fatality associated with this common arrhythmia.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/15058848' target='_blank' class='pmid-link'>15058848</a>:</span> <span class='sentence-part'>BACKGROUND: Atrial fibrillation (AF), the most common chronic cardiac dysrhythmia, is an important cause of cardiovascular morbidity and mortality.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/16790700' target='_blank' class='pmid-link'>16790700</a>:</span> <span class='sentence-part'>BACKGROUND: Atrial fibrillation is the most common type of cardiac arrhythmia and a leading cause of cardiovascular morbidity, particularly stroke.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17243937' target='_blank' class='pmid-link'>17243937</a>:</span> <span class='sentence-part'>Atrial fibrillation is the most common cardiac arrhythmia and is a major cause of cardiovascular morbidity and mortality in the Western world.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17271663' target='_blank' class='pmid-link'>17271663</a>:</span> <span class='sentence-part'>Despite advances in cardiac arrhythmia management, atrial fibrillation remains a major cause of cardiovascular morbidity and mortality.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/18313602' target='_blank' class='pmid-link'>18313602</a>:</span> <span class='sentence-part'>BACKGROUND: Atrial fibrillation (AF) is the most common clinical arrhythmia and a major cause of cardiovascular morbidity and mortality.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21070616' target='_blank' class='pmid-link'>21070616</a>:</span> <span class='sentence-part'>Cardiac arrhythmias including atrial fibrillation, ventricular tachycardia, and ventricular fibrillation are important causes of cardiovascular morbidity and mortality.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21884873' target='_blank' class='pmid-link'>21884873</a>:</span> <span class='sentence-part'>BACKGROUND: Atrial fibrillation (AF) is common and is an important cause of cardiovascular morbidity and mortality.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22920475' target='_blank' class='pmid-link'>22920475</a>:</span> <span class='sentence-part'>Similarly we have witnessed a parallel rise in the incidence of atrial fibrillation (AF), the commonest sustained cardiac arrhythmia, which is also a significant cause of cardiovascular morbidity and mortality.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24054478' target='_blank' class='pmid-link'>24054478</a>:</span> <span class='sentence-part'>There is clear interaction between AF and HF, with evidence that HF can lead to AF and AF exacerbates HF. Atrial fibrillation (AF) is an important and often-underrecognized cause of cardiovascular morbidity and mortality.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25193873' target='_blank' class='pmid-link'>25193873</a>:</span> <span class='sentence-part'>BACKGROUND: Atrial fibrillation and heart failure often coexist, causing substantial cardiovascular morbidity and mortality. beta blockers are indicated in patients with symptomatic heart failure with reduced ejection fraction; however, the efficacy of these drugs in patients with concomitant atrial fibrillation is uncertain.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25431922' target='_blank' class='pmid-link'>25431922</a>:</span> <span class='sentence-part'>Atrial fibrillation (AF) has been recognized as a major cause of cardiovascular-related morbidity and mortality.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25697868' target='_blank' class='pmid-link'>25697868</a>:</span> <span class='sentence-part'>BACKGROUND: Atrial fibrillation (AF) is the most common cardiac arrhythmia, causing substantial cardiovascular morbidity and mortality.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28496876' target='_blank' class='pmid-link'>28496876</a>:</span> <span class='sentence-part'>Similarly, there has been a parallel increase in the incidence of atrial fibrillation (AF), itself a significant cause of cardiovascular morbidity and mortality.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28500480' target='_blank' class='pmid-link'>28500480</a>:</span> <span class='sentence-part'>Although there are established pharmaceutical treatment options, atrial fibrillation is one of the major causes of stroke, heart failure and cardiovascular morbidity and mortality.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28662919' target='_blank' class='pmid-link'>28662919</a>:</span> <span class='sentence-part'>Atrial fibrillation (AF) is a leading cause of cardiovascular morbidity and mortality worldwide.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29059821' target='_blank' class='pmid-link'>29059821</a>:</span> <span class='sentence-part'>Atrial fibrillation (AF) is one of the major causes of stroke, heart failure, sudden death, and cardiovascular morbidity and the most common type of arrhythmia.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29655845' target='_blank' class='pmid-link'>29655845</a>:</span> <span class='sentence-part'>INTRODUCTION: Atrial fibrillation (AF) is nowadays considered to be one of the most important causes of heart failure, stroke, cognitive decline, vascular dementia, sudden death and overall cardiovascular morbidity.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30879840' target='_blank' class='pmid-link'>30879840</a>:</span> <span class='sentence-part'>Atrial fibrillation (AF) is a major cause of stroke, heart failure, sudden death and cardiovascular morbidity.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31191353' target='_blank' class='pmid-link'>31191353</a>:</span> <span class='sentence-part'>Background: Atrial fibrillation (AF) is a prevalent cause of cardiovascular morbidity, including thromboembolism and heart failure.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31673388' target='_blank' class='pmid-link'>31673388</a>:</span> <span class='sentence-part'>Objective: Atrial fibrillation (AF) is a growing problem internationally and a recognised cause of cardiovascular morbidity and mortality.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31691981' target='_blank' class='pmid-link'>31691981</a>:</span> <span class='sentence-part'>BACKGROUND: Atrial fibrillation (AF) is the most common clinical arrhythmia and one of the major causes of stroke, heart failure, sudden death, and cardiovascular morbidity.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31895877' target='_blank' class='pmid-link'>31895877</a>:</span> <span class='sentence-part'>Atrial fibrillation (AF) is an important cause of cardiovascular morbidity and mortality.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33516402' target='_blank' class='pmid-link'>33516402</a>:</span> <span class='sentence-part'>Atrial fibrillation (AF) is the most common cardiac arrythmia and a major cause of stroke, heart failure, sudden death, and cardiovascular morbidity. Oral anticoagulation is effective in prevention of strokes secondary to AF, reducing overall stroke numbers by approximately 64%.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34240286' target='_blank' class='pmid-link'>34240286</a>:</span> <span class='sentence-part'>BACKGROUND: Atrial fibrillation (AF) is a leading cause of cardiovascular morbidity and mortality.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34453577' target='_blank' class='pmid-link'>34453577</a>:</span> <span class='sentence-part'>Atrial fibrillation (AF) is a major cause of cardiovascular morbidity and mortality.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35393944' target='_blank' class='pmid-link'>35393944</a>:</span> <span class='sentence-part'>Although atrial fibrillation (AF) is a leading cause of cardiovascular morbidity and mortality, current platforms to generate iPSC-atrial (a) CMs are inadequate for modeling AF.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/8686300' target='_blank' class='pmid-link'>8686300</a>:</span> <span class='sentence-part'>Atrial fibrillation, a common arrhythmia, is responsible for considerable cardiovascular morbidity.</span></div></div>
<div class='streamlined-assertion'><div class='streamlined-header sticky-relation-header'><span class='label-text'>Subject:</span> <strong>Atrial_Fibrillation</strong> <span class='label-text'>Subject CUI:</span> <strong>C0004238</strong> â†’ <span class='label-text predicate-text'>CAUSES</span> â†’ <span class='label-text'>Object:</span> <strong>Cerebral_Embolism</strong> <span class='label-text'>Object CUI:</span> <strong>C0007780</strong></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/11096756' target='_blank' class='pmid-link'>11096756</a>:</span> <span class='sentence-part'>Atrial fibrillation, acute myocardial infarction, valvular heart disease, infective endocarditis, nonbacterial thrombotic endocarditis, and atrial myxoma are the main cardiac causes of cerebral embolism.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/1284251' target='_blank' class='pmid-link'>1284251</a>:</span> <span class='sentence-part'>These results suggest that the D-dimer and PAP levels in younger-aged patients with Af indicate the existence of cerebral emboli due to Af.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/15098362' target='_blank' class='pmid-link'>15098362</a>:</span> <span class='sentence-part'>Cerebral embolism due to atrial fibrillation associated with BMD-related DCM was diagnosed.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/18774361' target='_blank' class='pmid-link'>18774361</a>:</span> <span class='sentence-part'>PURPOSE: To assess the feasibility and efficacy of catheter-directed thrombolysis with recombinant tissue plasminogen activator (rt-PA) for acute limb embolism in patients with recent cerebral embolism due to atrial fibrillation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21297320' target='_blank' class='pmid-link'>21297320</a>:</span> <span class='sentence-part'>OBJECTIVE: This study aimed to identify factors associated with the functional outcomes of patients with cerebral embolism due to nonvalvular atrial fibrillation. Factors associated with functional outcomes of patients with cerebral embolism due to nonvalvular atrial fibrillation. METHODS: We retrospectively investigated the short-term functional outcomes of 134 patients diagnosed with cardiogenic cerebral embolism due to nonvalvular atrial fibrillation during the period of May 2006 to August 2008.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21916172' target='_blank' class='pmid-link'>21916172</a>:</span> <span class='sentence-part'>Atrial fibrillation was frequent and troublesome arrhythmia, which caused cerebral embolism and heart failure.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22451325' target='_blank' class='pmid-link'>22451325</a>:</span> <span class='sentence-part'>CHF patients are also at increased risk of atrial fibrillation (AF) that also leads to cerebral embolism.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23832979' target='_blank' class='pmid-link'>23832979</a>:</span> <span class='sentence-part'>Atrial fibrillation (Af) is the most important cause of cerebral embolisms, and the effects of anticoagulation therapy have been firmly established.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29603540' target='_blank' class='pmid-link'>29603540</a>:</span> <span class='sentence-part'>AIM: Atrial fibrillation (AF) is the most common underlying cause of cardiogenic cerebral embolism.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30940095' target='_blank' class='pmid-link'>30940095</a>:</span> <span class='sentence-part'>CONCLUSIONS: Antithrombotic therapy in patients with CMBs and cardiogenic cerebral embolism due to nonvalvular atrial fibrillation did not have increased risks of a cerebral hemorrhage event and all-cause death. We investigated the safety of antithrombotic therapy in patients with cerebral microbleeds and cardiogenic cerebral embolism caused by nonvalvular atrial fibrillation. The safety of antithrombotic therapy in patients with cerebral microbleeds and cardiogenic cerebral embolism due to nonvalvular atrial fibrillation. METHODS: This retrospective study enrolled patients with acute cardiogenic cerebral embolism due to nonvalvular atrial fibrillation in the stroke unit of the Department of Neurology at the Beijing Tiantan Hospital, the Capital Medical University, from January 2015 to January 2018.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33277821' target='_blank' class='pmid-link'>33277821</a>:</span> <span class='sentence-part'>Early neurological deterioration in cardiogenic cerebral embolism due to nonvalvular atrial fibrillation: Predisposing factors and clinical implications.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33663178' target='_blank' class='pmid-link'>33663178</a>:</span> <span class='sentence-part'>[A case of cerebral embolism caused by atrial fibrillation combined with superior mesenteric artery embolism and hepatic portal vein gas in a short time].</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34296210' target='_blank' class='pmid-link'>34296210</a>:</span> <span class='sentence-part'>Cardiac arrhythmias are an important cause of sudden cardiac death-a devastating manifestation of many underlying causes, such as heart failure and ischemic heart disease leading to ventricular tachyarrhythmias and ventricular fibrillation, and atrial fibrillation causing cerebral embolism.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/3738949' target='_blank' class='pmid-link'>3738949</a>:</span> <span class='sentence-part'>Atrial fibrillation was the presumed cause of cerebral embolism in 6.9% of patients.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/38084104' target='_blank' class='pmid-link'>38084104</a>:</span> <span class='sentence-part'>Prognostic Value of Platelet-to-Lymphocyte Ratio Combined with CHA     2      DS     2      -VAS     c       Score for Nonvalvular Atrial Fibrillation Induced Cardiogenic Cerebral Embolism.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/8120458' target='_blank' class='pmid-link'>8120458</a>:</span> <span class='sentence-part'>In case of nonrheumatismal atrial fibrillation (AF), the most frequent cause of cerebral embolism of cardiac origin, the benefits of a long-standing anticoagulant treatment in comparison with a placebo or with aspirin for the prevention of recurrence is being investigated in a European multicenter trial.</span></div></div>
<div class='streamlined-assertion'><div class='streamlined-header sticky-relation-header'><span class='label-text'>Subject:</span> <strong>Atrial_Fibrillation</strong> <span class='label-text'>Subject CUI:</span> <strong>C0004238</strong> â†’ <span class='label-text predicate-text'>CAUSES</span> â†’ <span class='label-text'>Object:</span> <strong>Cerebral_Infarction</strong> <span class='label-text'>Object CUI:</span> <strong>C0007785</strong></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/13129429' target='_blank' class='pmid-link'>13129429</a>:</span> <span class='sentence-part'>While a 74-year-old man with a past history of cerebral infarction was undergoing surface echocardiography due to transient atrial fibrillation, an unstable, pedunculated tumor was detected in the left ventricular outflow tract.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/19494781' target='_blank' class='pmid-link'>19494781</a>:</span> <span class='sentence-part'>BACKGROUND: Atrial fibrillation (AF) is a major cause of cerebral infarction.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22820358' target='_blank' class='pmid-link'>22820358</a>:</span> <span class='sentence-part'>[An update on the secondary prevention of cerebral infarction due to atrial fibrillation].</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/2595728' target='_blank' class='pmid-link'>2595728</a>:</span> <span class='sentence-part'>Nonvalvular atrial fibrillation as a cause of fatal massive cerebral infarction in the elderly. Our study shows that nonvalvular atrial fibrillation is a very important cause of fatal massive cerebral infarction in the elderly.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31627722' target='_blank' class='pmid-link'>31627722</a>:</span> <span class='sentence-part'>BACKGROUND: Atrial fibrillation (AF) is a common cause of cerebral infarction, which could lead to endothelial dysfunction, increased reactive oxygen species (ROS) and oxidized low density lipoprotein (Ox-LDL).AF is associated with higher mortality and more severe neurologic disability.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35049192' target='_blank' class='pmid-link'>35049192</a>:</span> <span class='sentence-part'>PATIENT CONCERNS: A case of cricopharyngeal dysfunction and swallowing apraxia due to cerebral infarction caused by atrial fibrillation in a 63-year-old woman who was followed up for 1 year.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35839007' target='_blank' class='pmid-link'>35839007</a>:</span> <span class='sentence-part'>BACKGROUND: Atrial fibrillation (AF) has been a leading cause of cerebral infarction, but the association with motor outcome after cerebral infarction remains unreported.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36039720' target='_blank' class='pmid-link'>36039720</a>:</span> <span class='sentence-part'>BACKGROUND: Atrial fibrillation (AF) is a major cause of cerebral ischemia, and its early detection may impact on health.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37176490' target='_blank' class='pmid-link'>37176490</a>:</span> <span class='sentence-part'>Atrial fibrillation-induced cerebral infarcts, hypoperfusion, systemic inflammation, and anticoagulant therapy-induced cerebral microbleeds, have been proposed to explain the link between these conditions.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/6605447' target='_blank' class='pmid-link'>6605447</a>:</span> <span class='sentence-part'>The origin of the cerebral infarct is presumably a vertebrobasilar insufficiency due to congestive cardiomyopathy and atrial fibrillation.</span></div></div>
<div class='streamlined-assertion'><div class='streamlined-header sticky-relation-header'><span class='label-text'>Subject:</span> <strong>Atrial_Fibrillation</strong> <span class='label-text'>Subject CUI:</span> <strong>C0004238</strong> â†’ <span class='label-text predicate-text'>CAUSES</span> â†’ <span class='label-text'>Object:</span> <strong>Cerebrovascular_accident</strong> <span class='label-text'>Object CUI:</span> <strong>C0038454</strong></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/11253857' target='_blank' class='pmid-link'>11253857</a>:</span> <span class='sentence-part'>Atrial fibrillation (AF) is common after cardiac surgery and may result in stroke, need for permanent pacemaker, hemodynamic instability, and sustained AF.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/11997272' target='_blank' class='pmid-link'>11997272</a>:</span> <span class='sentence-part'>BACKGROUND: Thromboembolism due to atrial fibrillation (AF) is a frequent cause of stroke.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/12062327' target='_blank' class='pmid-link'>12062327</a>:</span> <span class='sentence-part'>Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia and the major cardiac cause of stroke.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/12104061' target='_blank' class='pmid-link'>12104061</a>:</span> <span class='sentence-part'>Sudden cardiac deaths contribute substantially to the excessive mortality in congestive heart failure and so does atrial fibrillation as one of the major causes of stroke in elderly persons.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/12137410' target='_blank' class='pmid-link'>12137410</a>:</span> <span class='sentence-part'>By 1999, BIBR-1048 was in phase II clinical trials for thromboembolism and the prevention of stroke due to atrial fibrillation [331881]; by April 2002, proof-of-principle had been demonstrated in phase II trials in deep vein thrombosis [446554].</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/12464526' target='_blank' class='pmid-link'>12464526</a>:</span> <span class='sentence-part'>Most patients were eligible for anticoagulation before stroke because of previously known AF (80%), high risk for stroke (80%), absence of contraindications (83.3%), and good clinical compliance (90%).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/12574552' target='_blank' class='pmid-link'>12574552</a>:</span> <span class='sentence-part'>BACKGROUND AND PURPOSE: Atrial fibrillation (AF) is a major cause of stroke among the elderly.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/12624219' target='_blank' class='pmid-link'>12624219</a>:</span> <span class='sentence-part'>METHODS: Forty-two consecutive patients with ischemic stroke caused by nonvalvular atrial fibrillation and admitted within the first day of symptom onset were included. CONCLUSIONS: High plasma homocysteine conveys an independent risk for LA thrombus formation in patients with stroke caused by nonvalvular atrial fibrillation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/12698012' target='_blank' class='pmid-link'>12698012</a>:</span> <span class='sentence-part'>Long-term outcome after stroke due to atrial fibrillation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/12711853' target='_blank' class='pmid-link'>12711853</a>:</span> <span class='sentence-part'>Atrial fibrillation is identified as the most frequent cause of stroke. Diurnal and seasonal variation of stroke incidence in patients with cardioembolic stroke due to atrial fibrillation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/12796543' target='_blank' class='pmid-link'>12796543</a>:</span> <span class='sentence-part'>An 87-year-old artist experienced a top-of-the-basilar-artery embolic stroke secondary to atrial fibrillation and manifested a visual agnosia.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/1462916' target='_blank' class='pmid-link'>1462916</a>:</span> <span class='sentence-part'>Recent randomized trials have consistently demonstrated the marked efficacy of warfarin in reducing the risk of stroke caused by nonrheumatic atrial fibrillation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/14632953' target='_blank' class='pmid-link'>14632953</a>:</span> <span class='sentence-part'>More than 15% of all strokes are due to atrial fibrillation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/15063244' target='_blank' class='pmid-link'>15063244</a>:</span> <span class='sentence-part'>Postoperative atrial fibrillation is a major cause of stroke after on-pump coronary artery bypass surgery.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/15194993' target='_blank' class='pmid-link'>15194993</a>:</span> <span class='sentence-part'>The most disabling consequence of atrial fibrillation (AF) is stroke. In the elderly, AF is the single most important cause of stroke.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/15596564' target='_blank' class='pmid-link'>15596564</a>:</span> <span class='sentence-part'>Approximately 15% of all strokes are caused by AF.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/15619477' target='_blank' class='pmid-link'>15619477</a>:</span> <span class='sentence-part'>BACKGROUND: Three medical conditions--cervical carotid artery disease, atrial fibrillation, and hypertension--cause the majority of strokes.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/15853176' target='_blank' class='pmid-link'>15853176</a>:</span> <span class='sentence-part'>Atrial fibrillation (AF) is an important cause of stroke, and stroke risk stratification is critical to the management of patients with AF.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/16004852' target='_blank' class='pmid-link'>16004852</a>:</span> <span class='sentence-part'>\Evidence-based\ recommendations for warfarin prescription in patients with history of ischemic stroke limit its use to prevention of stroke due to atrial fibrillation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/16752514' target='_blank' class='pmid-link'>16752514</a>:</span> <span class='sentence-part'>Atrial fibrillation and severe carotid artery stenosis are the most common causes of stroke.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/16786467' target='_blank' class='pmid-link'>16786467</a>:</span> <span class='sentence-part'>Atrial fibrillation is associated with a relevant risk for ischemic stroke: Observational studies suggest that one in four to five strokes is due to atrial fibrillation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17000914' target='_blank' class='pmid-link'>17000914</a>:</span> <span class='sentence-part'>The case of a disappearing left atrial appendage thrombus: direct visualization of left atrial thrombus migration, captured by echocardiography, in a patient with atrial fibrillation, resulting in a stroke.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17356097' target='_blank' class='pmid-link'>17356097</a>:</span> <span class='sentence-part'>We hypothesized the following: (1) PMP levels are elevated in patients with AF compared to levels in both healthy control subjects (ie, patients without cardiovascular diseases who are in sinus rhythm) and disease control subjects (ie, patients with hypertension, CAD, diabetes or stroke, but who are in sinus rhythm); (2) PMP levels correlate with levels of soluble P-selectin (sP-selectin) [a marker of platelet activation]; and (3) PMP levels are related to the underlying factors in patients with AF that contribute to the overall risk of stroke secondary to AF.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17505170' target='_blank' class='pmid-link'>17505170</a>:</span> <span class='sentence-part'>Atrial fibrillation (AF) is the most common sustained arrhythmia and a leading cause of stroke.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17627564' target='_blank' class='pmid-link'>17627564</a>:</span> <span class='sentence-part'>Observational studies suggest that one in four to five strokes is due to AF.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17895200' target='_blank' class='pmid-link'>17895200</a>:</span> <span class='sentence-part'>CONCLUSIONS: Strokes caused by CHF or AF tend to be larger and are more likely to lead to death.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17903944' target='_blank' class='pmid-link'>17903944</a>:</span> <span class='sentence-part'>Atrial fibrillation (AF) and paroxysmal AF (PAF) are common causes of stroke which may not be detected by a single electrocardiogram (EKG).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/18061002' target='_blank' class='pmid-link'>18061002</a>:</span> <span class='sentence-part'>AF is the most common and important cause of stroke resulting from any cause.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/18180653' target='_blank' class='pmid-link'>18180653</a>:</span> <span class='sentence-part'>The WATCHMAN device was implanted in 75 patients that were eligible for long-term anticoagulation therapy with a moderate risk for thrombembolic stroke due to nonvalvular atrial fibrillation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/18560796' target='_blank' class='pmid-link'>18560796</a>:</span> <span class='sentence-part'>OBJECTIVE: This study investigated the attitude to prescribing OAC in patients with AF observed in an Italian Stroke Unit (SU) and the severity of ischemic stroke due to AF in comparison with that of other etiologies. Stroke due to atrial fibrillation and the attitude to prescribing anticoagulant prevention in Italy.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/18788834' target='_blank' class='pmid-link'>18788834</a>:</span> <span class='sentence-part'>Among patients with ischaemic stroke, AF is more likely to be implicated as the cause of stroke in the White population than in other racial/ethnic groups.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/19111769' target='_blank' class='pmid-link'>19111769</a>:</span> <span class='sentence-part'>AF is the most common and important cause of stroke.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/19160031' target='_blank' class='pmid-link'>19160031</a>:</span> <span class='sentence-part'>Advanced age is also a potent risk factor for stroke in patients with AF, and the proportion of strokes attributable to AF increases exponentially with age.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/19478793' target='_blank' class='pmid-link'>19478793</a>:</span> <span class='sentence-part'>METHODS: The sphygmomanometer incorporates an algorithm for detecting AF while reducing false positive readings due to premature beats. BACKGROUND: Hypertension is a major risk factor for the development of atrial fibrillation (AF) and for stroke due to AF. Asymptomatic AF can result in a stroke, in patients with risk factors, if it is not detected and treated appropriately.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/19739042' target='_blank' class='pmid-link'>19739042</a>:</span> <span class='sentence-part'>Atrial fibrillation is already the most common clinically significant cardiac arrhythmia and a common cause of stroke.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/19949330' target='_blank' class='pmid-link'>19949330</a>:</span> <span class='sentence-part'>For preventing recurrent stroke due to atrial fibrillation, warfarin is cost-effective.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20003345' target='_blank' class='pmid-link'>20003345</a>:</span> <span class='sentence-part'>BACKGROUND: Atrial fibrillation (AFib) is one of the prominent causes of stroke, and its risk increases with age.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/2046162' target='_blank' class='pmid-link'>2046162</a>:</span> <span class='sentence-part'>Therefore, the major etiology of cardio-cerebral apoplexy was a simultaneous embolism to the brain and heart due to Af, NBTE or, DIC.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20673913' target='_blank' class='pmid-link'>20673913</a>:</span> <span class='sentence-part'>Atrial fibrillation (AF) is the main cause of stroke and the most common sustained arrhythmia, afflicting about 2.3 million Americans.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20720410' target='_blank' class='pmid-link'>20720410</a>:</span> <span class='sentence-part'>BACKGROUND: Atrial fibrillation (AF) is a frequent cause of stroke, but detecting paroxysmal AF (pAF) poses a challenge.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20829515' target='_blank' class='pmid-link'>20829515</a>:</span> <span class='sentence-part'>BACKGROUND AND PURPOSE: Atrial fibrillation is a common cause of stroke with a known preventive treatment.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21211620' target='_blank' class='pmid-link'>21211620</a>:</span> <span class='sentence-part'>AF may cause stroke and heart failure but the relationship between AF and mortality is less clear.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21307613' target='_blank' class='pmid-link'>21307613</a>:</span> <span class='sentence-part'>The population attributable fraction (PAF) of stroke caused by AF was 2.2%; the PAFs were 1.0% and 3.6% in men and women, respectively.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21499792' target='_blank' class='pmid-link'>21499792</a>:</span> <span class='sentence-part'>Identifying atrial fibrillation (AF) as the cause of stroke is important because it may trigger a change from therapy with antiplatelet agents to proven superior therapy with anticoagulants.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21533567' target='_blank' class='pmid-link'>21533567</a>:</span> <span class='sentence-part'>Atrial fibrillation (AF) is well known as one of the leading causes of stroke and systemic embolism.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21559225' target='_blank' class='pmid-link'>21559225</a>:</span> <span class='sentence-part'>Given the large proportion of strokes caused by AF as well as the associated morbidity and mortality, reducing stroke burden is the most important part of AF management.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21684113' target='_blank' class='pmid-link'>21684113</a>:</span> <span class='sentence-part'>BACKGROUND: In addition to sudden death, heart failure and stroke due to atrial fibrillation are important in patients with hypertrophic cardiomyopathy (HCM).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21774762' target='_blank' class='pmid-link'>21774762</a>:</span> <span class='sentence-part'>Ischemic heart disease is the most common cause underlying 1) the development of ventricular fibrillation that results in sudden cardiac death and 2) atrial fibrillation that can lead to heart failure and stroke.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21788962' target='_blank' class='pmid-link'>21788962</a>:</span> <span class='sentence-part'>Atrial fibrillation (AF) is a major cause of stroke and thromboembolism, resulting in substantial morbidity and mortality.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22041550' target='_blank' class='pmid-link'>22041550</a>:</span> <span class='sentence-part'>Atrial fibrillation is a frequent cause of stroke; in the elderly, more than 20% of strokes are attributed to this common arrhythmia.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22094310' target='_blank' class='pmid-link'>22094310</a>:</span> <span class='sentence-part'>Atrial fibrillation (AF) is an important and potentially modifiable cause of stroke.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22125529' target='_blank' class='pmid-link'>22125529</a>:</span> <span class='sentence-part'>Multifocal and recurrent strokes are usually caused by embolic diseases, i.e. atrial fibrillation, but rare causes like cerebral vasculitis and clotting disorders are also well known.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22323896' target='_blank' class='pmid-link'>22323896</a>:</span> <span class='sentence-part'>Strokes due to atrial fibrillation tend to be more severe and disabling and are more often fatal than strokes due to other causes.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22541031' target='_blank' class='pmid-link'>22541031</a>:</span> <span class='sentence-part'>These results show a potential to increase the proportion of AF patients adequately anticoagulated, which will represent a significant advance in the prevention of stroke attributable to AF. Of every six ischemic strokes, one is due to AF, but the proportion of ischemic strokes attributable to AF increases with age.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22682205' target='_blank' class='pmid-link'>22682205</a>:</span> <span class='sentence-part'>[Social impact of stroke due to atrial fibrillation].</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22690880' target='_blank' class='pmid-link'>22690880</a>:</span> <span class='sentence-part'>AREAS COVERED: In ARISTOTLE (Apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation) apixaban was compared to warfarin in subjects with atrial fibrillation, and shown to cause a lower rate of stroke or systemic embolism and of major bleeding, than warfarin.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22715346' target='_blank' class='pmid-link'>22715346</a>:</span> <span class='sentence-part'>RESULTS: Stroke in myopathies is most frequently cardioembolic due to atrial fibrillation or atrial flutter, dilated cardio-myopathy, or left-ventricular hypertrabeculation (noncompaction).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22752615' target='_blank' class='pmid-link'>22752615</a>:</span> <span class='sentence-part'>A clinical decision aid for the selection of antithrombotic therapy for the prevention of stroke due to atrial fibrillation. CONCLUSION: The use of a clinical decision aid that considers both patient factors and evidence-based medicine will serve to bridge the knowledge gap and provide practical guidance to clinicians in the prevention of stroke due to atrial fibrillation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22770423' target='_blank' class='pmid-link'>22770423</a>:</span> <span class='sentence-part'>DISCUSSION: The STOP STROKE in AF study aims to evaluate a feasible intervention via distance education to prevent avoidable stroke due to atrial fibrillation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22788384' target='_blank' class='pmid-link'>22788384</a>:</span> <span class='sentence-part'>BACKGROUND AND PURPOSE: Atrial fibrillation (AF) is amongst the most important etiologies of ischaemic stroke. RESULTS: In total, 187 of 626 patients with FEIS suffered from cardioembolic stroke owing to AF, which was newly diagnosed in 57 (31%) patients. Stroke due to atrial fibrillation in a population-based stroke registry (Ludwigshafen Stroke Study) CHADS(2) , CHA(2) DS(2) -VASc score, underuse of oral anticoagulation, and implications for preventive measures. METHODS: Within the Ludwigshafen Stroke Study (LuSSt), a prospective ongoing population-based stroke register, we analyzed all patients with a first-ever ischaemic stroke (FEIS) owing to AF in 2006 and 2007.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22791299' target='_blank' class='pmid-link'>22791299</a>:</span> <span class='sentence-part'>Atrial fibrillation (AF) is important because it is common and is a major cause of stroke unless treated with oral anticoagulant.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22801431' target='_blank' class='pmid-link'>22801431</a>:</span> <span class='sentence-part'>Conditions such as hypertension, diabetes, atrial fibrillation, ischemic heart disease, dyslipidaemia and obesity have propensity to induce strokes, which increase risk of dementia up to five-fold in the elderly.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22825670' target='_blank' class='pmid-link'>22825670</a>:</span> <span class='sentence-part'>Atrial fibrillation is an important cause of preventable, disabling stroke and is particularly frequent in patients with chronic kidney disease (CKD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22871192' target='_blank' class='pmid-link'>22871192</a>:</span> <span class='sentence-part'>The occurrence of disabling stroke, the major fatal consequence of atrial fibrillation, can be reduced by almost two-thirds with warfarin oral anticoagulation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22923355' target='_blank' class='pmid-link'>22923355</a>:</span> <span class='sentence-part'>This will also be an option in patients who had a stroke due to atrial fibrillation and had no history of cerebral bleeding.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23083683' target='_blank' class='pmid-link'>23083683</a>:</span> <span class='sentence-part'>Fragmental or massive embolization in cardiogenic stroke caused by nonvalvular atrial fibrillation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23237139' target='_blank' class='pmid-link'>23237139</a>:</span> <span class='sentence-part'>BACKGROUND: Atrial fibrillation and flutter (AF, collectively) cause stroke.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23319965' target='_blank' class='pmid-link'>23319965</a>:</span> <span class='sentence-part'>INTRODUCTION: Thromboembolism, usually originating from the left atrium (LA) and left atrial appendage (LAA), is a major complication of atrial fibrillation and may result in transient ischemic attack and stroke.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23323132' target='_blank' class='pmid-link'>23323132</a>:</span> <span class='sentence-part'>However, how the CHADS(2) score is related to stroke severity and outcome in patients with strokes due to atrial fibrillation has not yet been elucidated.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23473948' target='_blank' class='pmid-link'>23473948</a>:</span> <span class='sentence-part'>Vitamin K antagonists are widely used for the prevention of stroke due to atrial fibrillation, treatment and secondary prevention of venous thromboembolism, prevention of valvular thromboembolism in patients with prosthetic heart valves, and secondary prevention of acute myocardial infarction.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23499278' target='_blank' class='pmid-link'>23499278</a>:</span> <span class='sentence-part'>Asymptomatic atrial fibrillation (AF) is a common cause of strokes. Home screening for AF may increase the likelihood of detecting asymptomatic AF in patients at risk for stroke because of AF.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23513777' target='_blank' class='pmid-link'>23513777</a>:</span> <span class='sentence-part'>Stroke due to atrial fibrillation are frequent, severe, with high mortality rate during hospitalization and during the following year.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23615428' target='_blank' class='pmid-link'>23615428</a>:</span> <span class='sentence-part'>CONCLUSION: The use of dabigatran would lead to a significant reduction of strokes and deaths attributable to AF in France. BACKGROUND: Atrial fibrillation (AF) is the main direct cause of stroke.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23615539' target='_blank' class='pmid-link'>23615539</a>:</span> <span class='sentence-part'>The purpose of this study was to assess the relationship between isolated aphasia and atrial fibrillation (AF) as the cause of presumed cardioembolic TIA or stroke within the setting of 2 large multicenter trials.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23631167' target='_blank' class='pmid-link'>23631167</a>:</span> <span class='sentence-part'>But regardless of types or symptoms of AF, AF is notorious for potentially causing stroke and heart failure, which increase morbidity and mortality.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23721623' target='_blank' class='pmid-link'>23721623</a>:</span> <span class='sentence-part'>Increasing age of the population is associated with a higher rate of cerebrovascular diseases, and every sixth stroke is the consequence of atrial fibrillation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23735694' target='_blank' class='pmid-link'>23735694</a>:</span> <span class='sentence-part'>BACKGROUND: Atrial fibrillation (AF) is a common, treatable cause of stroke.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23790597' target='_blank' class='pmid-link'>23790597</a>:</span> <span class='sentence-part'>Stroke is the most devastating consequence of AF, and can be prevented with effective oral anticoagulation in patients at increased stroke risk. Recent developments in understanding epidemiology and risk determinants of atrial fibrillation as a cause of stroke.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23864134' target='_blank' class='pmid-link'>23864134</a>:</span> <span class='sentence-part'>Atrial fibrillation (AF) is the most common arrhythmia and among the leading causes of stroke and heart failure in Western populations.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23866305' target='_blank' class='pmid-link'>23866305</a>:</span> <span class='sentence-part'>BACKGROUND: Atrial fibrillation (AF) is the most common form of heart arrhythmia and a leading cause of stroke and systemic embolism.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23920553' target='_blank' class='pmid-link'>23920553</a>:</span> <span class='sentence-part'>Twenty percent of all strokes are caused by AF.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23953910' target='_blank' class='pmid-link'>23953910</a>:</span> <span class='sentence-part'>Atrial fibrillation (AF) is a common arrhythmia and the leading cause of stroke, an event with high human and economic burden.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23991534' target='_blank' class='pmid-link'>23991534</a>:</span> <span class='sentence-part'>Early diagnosis is essential to reduce mortality and improve quality of life--the most common arrhythmia--atrial fibrillation--can cause a stroke if left untreated or inadequately treated.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23997448' target='_blank' class='pmid-link'>23997448</a>:</span> <span class='sentence-part'>Balancing efficacy and bleeding risk in the prevention of stroke due to atrial fibrillation with newer oral anticoagulants.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24060583' target='_blank' class='pmid-link'>24060583</a>:</span> <span class='sentence-part'>Atrial fibrillation (AF) is the most common type of cardiac arrhythmia and a major cause of stroke.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24072002' target='_blank' class='pmid-link'>24072002</a>:</span> <span class='sentence-part'>BACKGROUND AND PURPOSE: Subclinical atrial fibrillation (AF) and patent foramen ovale (PFO) are the major causes of cryptogenic stroke, and neuroimaging may help distinguish the cause.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24076444' target='_blank' class='pmid-link'>24076444</a>:</span> <span class='sentence-part'>BACKGROUND: Atrial fibrillation (AF) is an important cause of stroke.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24109470' target='_blank' class='pmid-link'>24109470</a>:</span> <span class='sentence-part'>Anticoagulation is highly effective in preventing stroke due to atrial fibrillation, but numerous studies have demonstrated low utilization of anticoagulation for these patients.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24234513' target='_blank' class='pmid-link'>24234513</a>:</span> <span class='sentence-part'>Specifically, the use of the NOACs in the geriatric population, who are more likely to have an increased risk of stroke due to atrial fibrillation and other medical comorbidities, is not without risk.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24322948' target='_blank' class='pmid-link'>24322948</a>:</span> <span class='sentence-part'>Recommendations for the use of new oral anticoagulants (NOACs) after TIA or stroke caused by atrial fibrillation (AF), after a consensus conference among Italian neurologists (the Venice group).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24337399' target='_blank' class='pmid-link'>24337399</a>:</span> <span class='sentence-part'>Patient's values and preferences regarding the relative importance of preventing strokes and avoiding bleeding are now recognised to be of great importance in deciding on therapy for the prevention of stroke due to atrial fibrillation (SPAF).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24605405' target='_blank' class='pmid-link'>24605405</a>:</span> <span class='sentence-part'>Patients with AF have a 5-fold increased risk of stroke, and 15%-20% of all strokes are attributable to AF.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24655745' target='_blank' class='pmid-link'>24655745</a>:</span> <span class='sentence-part'>The challenge for patients with ACS and AFib is that their ACS will probably require antiplatelet therapy, and addition of anticoagulation therapy as prophylaxis against stroke and systemic embolism because of the AFib creates the problem of so-called \triple therapy.\</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24659084' target='_blank' class='pmid-link'>24659084</a>:</span> <span class='sentence-part'>In patients at risk of stroke due to atrial fibrillation, rivaroxaban was noninferior compared to warfarin in preventing stroke/systemic embolism in the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET-AF) trial and was associated with a similar risk of major bleeding; the incidence of intracranial hemorrhage was 33% lower with rivaroxaban.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24683059' target='_blank' class='pmid-link'>24683059</a>:</span> <span class='sentence-part'>Non-valvular atrial fibrillation (NVAF) is the most common clinically significant cardiac arrhythmia and is a common cause of stroke.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24687081' target='_blank' class='pmid-link'>24687081</a>:</span> <span class='sentence-part'>Atrial fibrillation (AF) causes a third of all strokes, but often goes undetected before stroke.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24771841' target='_blank' class='pmid-link'>24771841</a>:</span> <span class='sentence-part'>BACKGROUND: Atrial fibrillation (AF) is a cause of stroke, and undertreatment with anticoagulants is a persistent issue despite their effectiveness.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24790796' target='_blank' class='pmid-link'>24790796</a>:</span> <span class='sentence-part'>Atrial fibrillation is a common, potentially preventable cause of disabling stroke in the elderly, particularly in elderly women, resulting from embolism of stasis-precipitated thrombi formed in the left atrial appendage.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24842559' target='_blank' class='pmid-link'>24842559</a>:</span> <span class='sentence-part'>Atrial fibrillation (AF) is the most common cardiac arrhythmia that can potentially result in stroke.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24963566' target='_blank' class='pmid-link'>24963566</a>:</span> <span class='sentence-part'>BACKGROUND: Atrial fibrillation is a leading preventable cause of recurrent stroke for which early detection and treatment are critical.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24973113' target='_blank' class='pmid-link'>24973113</a>:</span> <span class='sentence-part'>BACKGROUND: Atrial fibrillation is the main cause of stroke, but the risk can be reduced, usually with vitamin K antagonists (VKAs) such as warfarin.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25051131' target='_blank' class='pmid-link'>25051131</a>:</span> <span class='sentence-part'>Atrial fibrillation (AF) is a major cause of stroke and systemic embolism.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25066488' target='_blank' class='pmid-link'>25066488</a>:</span> <span class='sentence-part'>Atrial fibrillation (AF) is the most commonly sustained arrhythmia and is a major cause of stroke and systemic embolism.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25072906' target='_blank' class='pmid-link'>25072906</a>:</span> <span class='sentence-part'>Now, in two new studies involving long-term electrocardiogram monitoring, investigators from the EMBRACE and CRYSTAL-AF trials suggest that many instances of cryptogenic stroke might be caused by undetected atrial fibrillation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25135392' target='_blank' class='pmid-link'>25135392</a>:</span> <span class='sentence-part'>Atrial fibrillation (AF) is an important cause of preventable, disabling stroke and is increasingly prevalent with advancing age.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25179484' target='_blank' class='pmid-link'>25179484</a>:</span> <span class='sentence-part'>BACKGROUND AND AIM: Atrial fibrillation (AF) is a common arrhythmia in elderly people, and in many cases it is responsible for stroke or pulmonary embolism.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25192579' target='_blank' class='pmid-link'>25192579</a>:</span> <span class='sentence-part'>Atrial fibrillation is currently a very prevalent disease and it represents one of the most common causes of disabling stroke.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25276118' target='_blank' class='pmid-link'>25276118</a>:</span> <span class='sentence-part'>Previous studies have identified isolated aphasia as a risk factor for AF as the cause of the stroke.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25364886' target='_blank' class='pmid-link'>25364886</a>:</span> <span class='sentence-part'>BACKGROUND: Atrial fibrillation (AF) is a common cause of stroke.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25544820' target='_blank' class='pmid-link'>25544820</a>:</span> <span class='sentence-part'>Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia and a major preventable cause of stroke and hospitalization. Despite the fact that oral anticoagulation is effective in preventing strokes due to AF, there is extensive evidence suggesting this therapy remains underused.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25555394' target='_blank' class='pmid-link'>25555394</a>:</span> <span class='sentence-part'>These data are compelling in convincing us that long-term ECG technologies have superior sensitivity for the detection of AF in CS; however, clinical specificity for the definition of CS etiology of such findings cannot be established and can be lower than expected, leaving open questions about the etiologic weight of AF in CS.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25561824' target='_blank' class='pmid-link'>25561824</a>:</span> <span class='sentence-part'>Stroke is the most devastating consequence of atrial fibrillation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25635565' target='_blank' class='pmid-link'>25635565</a>:</span> <span class='sentence-part'>Atrial fibrillation (AF) is the most common abnormal heart rhythm and the single biggest cause of stroke.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25639643' target='_blank' class='pmid-link'>25639643</a>:</span> <span class='sentence-part'>BACKGROUND: Atrial fibrillation (AF) is a major cause of stroke.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25713737' target='_blank' class='pmid-link'>25713737</a>:</span> <span class='sentence-part'>Atrial fibrillation (AF) is a frequent cause of stroke.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25792720' target='_blank' class='pmid-link'>25792720</a>:</span> <span class='sentence-part'>The consequences of AF include an increased rate of death, stroke and heart failure.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25906935' target='_blank' class='pmid-link'>25906935</a>:</span> <span class='sentence-part'>Thus, 653 patients were evaluated, dividing them into 2 groups for comparison (164 with stroke due to atrial fibrillation and 489 with atherothrombotic/lacunar stroke). BACKGROUND: Basing on easily available clinical and instrumental data, we aimed to define an \atrial fibrillation profile\ able to discriminate cases of stroke due to atrial fibrillation from cases due to atherothrombosis of large vessels or small-vessel disease. CONCLUSIONS: A simple profile, based on commonly available data, seems suitable to characterize patients with stroke due to atrial fibrillation. Binary multiple logistic regression identified age older than 75 years, female sex, left atrial dilation, cortical-subcortical cerebral index infarct, ischemic lesions in multiple vascular grounds, and spontaneous hemorrhagic transformation of brain infarction as significant predictors of cardioembolic stroke due to atrial fibrillation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25935765' target='_blank' class='pmid-link'>25935765</a>:</span> <span class='sentence-part'>Accordingly, occult AF may cause stroke before it is clinically diagnosed.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25965590' target='_blank' class='pmid-link'>25965590</a>:</span> <span class='sentence-part'>BACKGROUND: Atrial fibrillation (AF) is a leading cause of preventable stroke in Australia.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26062790' target='_blank' class='pmid-link'>26062790</a>:</span> <span class='sentence-part'>BACKGROUND: In the 1990s, epidemiological studies estimated the prevalence of stroke caused by atrial fibrillation (AF) at about 15 %.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26062914' target='_blank' class='pmid-link'>26062914</a>:</span> <span class='sentence-part'>Atrial fibrillation (AF) is an increasingly common cause of stroke and systemic embolism.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26231476' target='_blank' class='pmid-link'>26231476</a>:</span> <span class='sentence-part'>Although strokes caused by atrial fibrillation carry the highest mortality when compared with other etiologies, it is not known whether the CHADS2 score predicts stroke-related mortality in patients with atrial fibrillation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26241302' target='_blank' class='pmid-link'>26241302</a>:</span> <span class='sentence-part'>AF causes thrombus formation in the LAA due to both the loss of atrial systole and the unique anatomic features of the LAA. Stroke or systemic embolism is a devastating consequence of atrial fibrillation (AF) due to thrombus formation in the left atrial appendage (LAA).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26270886' target='_blank' class='pmid-link'>26270886</a>:</span> <span class='sentence-part'>BACKGROUND: Dabigatran, a direct thrombin inhibitor, is effective for the treatment of venous thromboembolism and the prevention of stroke and systemic embolism resulting from atrial fibrillation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26322338' target='_blank' class='pmid-link'>26322338</a>:</span> <span class='sentence-part'>If elderly and with multiple risk factors, non-AF patients may have a risk of incident ischaemic stroke that is comparable or even higher than patients with AF, suggesting that the incremental stroke risk attributable to AF is marginal in such 'high risk' patients.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26335221' target='_blank' class='pmid-link'>26335221</a>:</span> <span class='sentence-part'>Atrial fibrillation (AF) is an important cause of stroke and risk factor for heart failure and death.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26378211' target='_blank' class='pmid-link'>26378211</a>:</span> <span class='sentence-part'>Atrial fibrillation is the most common cause of stroke.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26488098' target='_blank' class='pmid-link'>26488098</a>:</span> <span class='sentence-part'>Atrial fibrillation is one of the major causes of stroke and should be treated with anticoagulation depending on the CHA2DS2-VASc score.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26499449' target='_blank' class='pmid-link'>26499449</a>:</span> <span class='sentence-part'>BACKGROUND: Atrial fibrillation is a common cause of stroke and other morbidity.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26608637' target='_blank' class='pmid-link'>26608637</a>:</span> <span class='sentence-part'>Patients with isolated dysphasia had a longer onset to treatment time, lower proportion of visible infarctions on admission imaging scan and atrial fibrillation, and were less often classified as having large vessels causing strokes, in comparison with the rest of the SITS-ISTR.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26641808' target='_blank' class='pmid-link'>26641808</a>:</span> <span class='sentence-part'>RECENT FINDINGS: Three typical case vignettes are presented and the associated dilemmas are discussed: a patient with an anticoagulant-related intracranial hemorrhage: would you restart anticoagulation?, an anticoagulated patient with a previous stroke because of atrial fibrillation is scheduled for an elective polyp removal: how would you handle anticoagulation perioperatively?, and a patient presents with an ischemic stroke because of atrial fibrillation: how soon would you start anticoagulation for secondary stroke prevention?</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26655548' target='_blank' class='pmid-link'>26655548</a>:</span> <span class='sentence-part'>BACKGROUND: Stroke is the most serious clinical consequence of atrial fibrillation, which is the most common cardiac arrhythmia.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26707792' target='_blank' class='pmid-link'>26707792</a>:</span> <span class='sentence-part'>BACKGROUND: Atrial fibrillation (AF) is a leading cause of stroke, but not all cases of stroke in patients with AF are due to AF.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26756697' target='_blank' class='pmid-link'>26756697</a>:</span> <span class='sentence-part'>However, about 25% of cryptogenic strokes are caused by asymptomatic atrial fibrillation showing a significant risk of thromboembolism by this condition.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26932564' target='_blank' class='pmid-link'>26932564</a>:</span> <span class='sentence-part'>CONCLUSIONS: AF is an important and treatable cause of recurrent stroke and needs to be ruled out by thorough evaluation before the diagnosis of cryptogenic stroke is assigned.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26935273' target='_blank' class='pmid-link'>26935273</a>:</span> <span class='sentence-part'>CONCLUSION: Left atrial appendage closure in NVAF in a real-world setting may result in lower stroke and major bleeding rates than reported in LAAC clinical trials.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27022272' target='_blank' class='pmid-link'>27022272</a>:</span> <span class='sentence-part'>Approximately one-third of all strokes are caused by AF and, due to thromboembolic cause, these strokes are often more severe than those caused by other etiologies.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27026394' target='_blank' class='pmid-link'>27026394</a>:</span> <span class='sentence-part'>BACKGROUND: Atrial fibrillation (AF) is a common and preventable cause of stroke.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27063831' target='_blank' class='pmid-link'>27063831</a>:</span> <span class='sentence-part'>Strokes caused by atrial fibrillation (AF) are thromboembolic, and AF is the leading cause of ischemic stroke.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27283277' target='_blank' class='pmid-link'>27283277</a>:</span> <span class='sentence-part'>Atrial fibrillation is a major cardiac cause of stroke, and a pathogenesis involving thrombus formation in patients with atrial fibrillation is well established.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27326208' target='_blank' class='pmid-link'>27326208</a>:</span> <span class='sentence-part'>INTRODUCTION: Atrial fibrillation (AF) is a well-known cause of strokes and all major society guidelines recommend oral anticoagulants (OAC) such as vitamin K antagonists (VKA) for patients with concomitant risk factors to prevent them.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27347225' target='_blank' class='pmid-link'>27347225</a>:</span> <span class='sentence-part'>Paroxys-mal atrial fibrillation (PAF) has been suggested as a major etiology of these cryptogenic strokes [2, 3].</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27450623' target='_blank' class='pmid-link'>27450623</a>:</span> <span class='sentence-part'>Atrial fibrillation (AF) is a frequent cause of stroke.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27514627' target='_blank' class='pmid-link'>27514627</a>:</span> <span class='sentence-part'>AF is the most important cause of stroke in patients &gt;75years.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27521536' target='_blank' class='pmid-link'>27521536</a>:</span> <span class='sentence-part'>One in every five strokes is due to atrial fibrillation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27571335' target='_blank' class='pmid-link'>27571335</a>:</span> <span class='sentence-part'>About 20% of strokes are attributable to AF and AF patients are at 5-fold increased risk of stroke.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27621674' target='_blank' class='pmid-link'>27621674</a>:</span> <span class='sentence-part'>Up to 20% of all strokes are caused by AF.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27775782' target='_blank' class='pmid-link'>27775782</a>:</span> <span class='sentence-part'>When we compared apoplexy and heart failure caused by atrial fibrillation in the two groups, the difference was not statistically significant (Apoplexy: p = 0.186; Heart failure: p = 0.170).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27783556' target='_blank' class='pmid-link'>27783556</a>:</span> <span class='sentence-part'>BACKGROUND: Non-vitamin K antagonist oral anticoagulants (NOACs) are widely used for prevention of stroke secondary to nonvalvular atrial fibrillation (NVAF).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27817241' target='_blank' class='pmid-link'>27817241</a>:</span> <span class='sentence-part'>In particular, detecting atrial fibrillation in cryptogenic stroke patients may shed insight into the cause of the index stroke, but is also important to identify an important cause of secondary stroke.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27898406' target='_blank' class='pmid-link'>27898406</a>:</span> <span class='sentence-part'>BACKGROUND: Atrial fibrillation (AF) is a major cause of stroke.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28041720' target='_blank' class='pmid-link'>28041720</a>:</span> <span class='sentence-part'>Atrial fibrillation is a major cause of stroke in apneic patients: a prospective study.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28087552' target='_blank' class='pmid-link'>28087552</a>:</span> <span class='sentence-part'>INTRODUCTION: Atrial fibrillation (AF) is a cause of stroke and a marker of atherosclerosis and of all patients with stroke, around 17% have AF.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28215062' target='_blank' class='pmid-link'>28215062</a>:</span> <span class='sentence-part'>INTRODUCTION: Atrial fibrillation (AF) is one of the leading causes of stroke.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28289746' target='_blank' class='pmid-link'>28289746</a>:</span> <span class='sentence-part'>Atrial fibrillation (AF) is a major cause of stroke.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28500480' target='_blank' class='pmid-link'>28500480</a>:</span> <span class='sentence-part'>Although there are established pharmaceutical treatment options, atrial fibrillation is one of the major causes of stroke, heart failure and cardiovascular morbidity and mortality.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28592963' target='_blank' class='pmid-link'>28592963</a>:</span> <span class='sentence-part'>The consequences of AF have been clearly established in multiple large observational cohort studies and include increased stroke and systemic embolism rates if no oral anticoagulation is prescribed, with increased morbidity and mortality.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28702113' target='_blank' class='pmid-link'>28702113</a>:</span> <span class='sentence-part'>The incremental cost-effectiveness ratio for stroke due to AF was -150, 201, 26$ per prevention of stroke recurrence (p-values &lt;= 0/05). This study was carried out aiming at analyzing the cost effectiveness of LMWH versus UFH in hospitalized patients with stroke due to AF with respect to the Iranian population. CONCLUSION: The results of the cost-effectiveness analysis of LMWH versus UFH showed that LMWH is a dominant strategy for patients with stroke due to AF in Iranian population. Cost-Effectiveness Analysis of the Unfractionated Heparin versus Low-Molecular-Weight Heparin in Hospitalized Patients with Stroke Due to Atrial Fibrillation in Shiraz, South of Iran. The number of prevention of new strokes due to AF in LMWH and UFH was 2 and 0, respectively.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28751849' target='_blank' class='pmid-link'>28751849</a>:</span> <span class='sentence-part'>About 20% of strokes are attributable to AF and AF patients are at five-fold increased risk of stroke.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28765648' target='_blank' class='pmid-link'>28765648</a>:</span> <span class='sentence-part'>The results demonstrated that curvature pattern of aorta can play a determinant role in AF-induced stroke propensity alteration. We performed computational fluid dynamics (CFD) simulations to determine the variations of AF-induced stroke propensity over various image-based patient-dependent aorta models.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28821351' target='_blank' class='pmid-link'>28821351</a>:</span> <span class='sentence-part'>Long-term residents of skilled nursing facilities frequently have multiple risk factors for strokes due to AF and may benefit from screening for AF.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28940166' target='_blank' class='pmid-link'>28940166</a>:</span> <span class='sentence-part'>Although anticoagulation therapy is usually chosen for cardiogenic stroke due to atrial fibrillation, it is inappropriate for acute aortic dissection.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29059821' target='_blank' class='pmid-link'>29059821</a>:</span> <span class='sentence-part'>Atrial fibrillation (AF) is one of the major causes of stroke, heart failure, sudden death, and cardiovascular morbidity and the most common type of arrhythmia.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29069008' target='_blank' class='pmid-link'>29069008</a>:</span> <span class='sentence-part'>The CHADS2, CHA2DS2-VASc, and R2CHADS2 scores are well-known predictors of stroke caused by atrial fibrillation (AF), but no studies have evaluated their use for stratifying all-cause mortality risk in patients discharged for systolic heart failure (SHF) with or without AF.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29105079' target='_blank' class='pmid-link'>29105079</a>:</span> <span class='sentence-part'>AF causes stroke or systemic embolism, leading to increased mortality.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29132510' target='_blank' class='pmid-link'>29132510</a>:</span> <span class='sentence-part'>The use of anticoagulation in the prevention of strokes due to atrial fibrillation or the treatment of venous thromboembolic disease has been on the rise.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29141778' target='_blank' class='pmid-link'>29141778</a>:</span> <span class='sentence-part'>This could result in fewer recurrent strokes and deaths, a reduction or delay in dementia onset, and in the lessening of the functional, structural, and metabolic consequences of atrial fibrillation on the heart.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29279710' target='_blank' class='pmid-link'>29279710</a>:</span> <span class='sentence-part'>We report a case of a male patient with stroke caused by atrial fibrillation (AF) due to thyrotoxicosis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29284897' target='_blank' class='pmid-link'>29284897</a>:</span> <span class='sentence-part'>Atrial fibrillation remains one of the major causes of stroke, heart failure, sudden death all over the world.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29289494' target='_blank' class='pmid-link'>29289494</a>:</span> <span class='sentence-part'>Despite recent advance in management of patients with AF, AF remains one of the main causes of stroke or systemic embolism.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29297178' target='_blank' class='pmid-link'>29297178</a>:</span> <span class='sentence-part'>Seven days after, stroke as AF consequence was chosen by 74/94 (78.7%) vs.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29328506' target='_blank' class='pmid-link'>29328506</a>:</span> <span class='sentence-part'>Atrial fibrillation (AF) is a leading cause of stroke.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29332603' target='_blank' class='pmid-link'>29332603</a>:</span> <span class='sentence-part'>A silent AF is also the possible cause of many cryptogenic strokes.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29341881' target='_blank' class='pmid-link'>29341881</a>:</span> <span class='sentence-part'>AF is the leading cause of stroke among patients older than 75 years and is responsible for at least 15% of all strokes.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29402843' target='_blank' class='pmid-link'>29402843</a>:</span> <span class='sentence-part'>BACKGROUND: Atrial fibrillation (AF) is an important cause of stroke.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29459990' target='_blank' class='pmid-link'>29459990</a>:</span> <span class='sentence-part'>In the last two to three years, significant progress has been made in acute treatment, secondary prophylaxis in patients with patent foramen ovale, and the interdisciplinary evaluation of atrial fibrillation as the cause of the stroke.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29474715' target='_blank' class='pmid-link'>29474715</a>:</span> <span class='sentence-part'>Aims: Atrial fibrillation (AF) is a common condition that is a major cause of stroke.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29544401' target='_blank' class='pmid-link'>29544401</a>:</span> <span class='sentence-part'>Objective Stroke due to atrial fibrillation (AF) is common and frequently devastating.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29552925' target='_blank' class='pmid-link'>29552925</a>:</span> <span class='sentence-part'>The significantly increased incidence of stroke and systemic embolisation caused by atrial fibrillation can be prevented by adequately adjusted anticoagulant therapy.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29575965' target='_blank' class='pmid-link'>29575965</a>:</span> <span class='sentence-part'>Atrial fibrillation (AF) is the commonest persistent cardiac arrhythmia with an estimated incidence rate of between 1.5-2% and an important cause of strokes.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29590383' target='_blank' class='pmid-link'>29590383</a>:</span> <span class='sentence-part'>AF is a major cause of stroke, and its prevalence is increasing.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29655845' target='_blank' class='pmid-link'>29655845</a>:</span> <span class='sentence-part'>INTRODUCTION: Atrial fibrillation (AF) is nowadays considered to be one of the most important causes of heart failure, stroke, cognitive decline, vascular dementia, sudden death and overall cardiovascular morbidity.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29680999' target='_blank' class='pmid-link'>29680999</a>:</span> <span class='sentence-part'>PURPOSE OF REVIEW: Atrial fibrillation (AF), the most common sustained arrhythmia, is a major cause of stroke and systemic embolism, and is increasing in prevalence.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29702842' target='_blank' class='pmid-link'>29702842</a>:</span> <span class='sentence-part'>However, literature suggested that AF-induced strokes are highly preventable with drugs and clinical procedures, which highlights the importance of optimal clinical management of stroke prevention in patients with AF.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29894355' target='_blank' class='pmid-link'>29894355</a>:</span> <span class='sentence-part'>AIMS: Stroke due to atrial fibrillation has been associated with a high risk of disability and mortality.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29910583' target='_blank' class='pmid-link'>29910583</a>:</span> <span class='sentence-part'>The incidence of stroke secondary to atrial fibrillation in patients across the MENA region is higher than rates reported globally, and this might be attributed to a higher incidence of vascular risk factors and underuse of anticoagulants in patients in the MENA.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30041778' target='_blank' class='pmid-link'>30041778</a>:</span> <span class='sentence-part'>BACKGROUND: Atrial fibrillation is a common cause of stroke, and diabetes increases stroke risk.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30159163' target='_blank' class='pmid-link'>30159163</a>:</span> <span class='sentence-part'>Patent foramen ovale and atrial fibrillation as causes of cryptogenic stroke: is treatment with surgery superior to device closure and anticoagulation?</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30254772' target='_blank' class='pmid-link'>30254772</a>:</span> <span class='sentence-part'>Nonvalvular atrial fibrillation (AF) is a common age-related arrthymia and a leading cause of stroke in the elderly; with an aging hemophilia population, the number of patients developing AF is increasing.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30292336' target='_blank' class='pmid-link'>30292336</a>:</span> <span class='sentence-part'>A better awareness of current usage of anticoagulant therapy would enable prevention of stroke secondary to AF. This highlights the need for improvement of prevention of ischemic stroke secondary to AF.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30347966' target='_blank' class='pmid-link'>30347966</a>:</span> <span class='sentence-part'>Two-thirds of strokes due to AF are preventable with suitable anticoagulant therapy.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30360887' target='_blank' class='pmid-link'>30360887</a>:</span> <span class='sentence-part'>Left atrial appendage (LAA) thrombus in nonvalvular atrial fibrillation or flutter (AF) is a major cause of stroke and presents a therapeutic dilemma in a rhythm-control strategy.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30418608' target='_blank' class='pmid-link'>30418608</a>:</span> <span class='sentence-part'>Oral anticoagulation is highly effective at preventing stroke due to AF; however, AF remains undetected in a large number of individuals. Even when asymptomatic, AF remains a major cause of stroke, particularly among the elderly.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30441699' target='_blank' class='pmid-link'>30441699</a>:</span> <span class='sentence-part'>AF can lead to strokes, heart failures, and even death if it is not diagnosed and treated on time, therefore automatic detection of AF is an urgent need, particularly using Internet- connected devices that can alert healthcare services.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30459853' target='_blank' class='pmid-link'>30459853</a>:</span> <span class='sentence-part'>Smoking and atrial fibrillation both were associated with unknown etiology of stroke (P = 0.001 and P = 0.039, respectively). Most common etiology of stroke was cardioembolism (40%), and atrial fibrillation is found to be the most common cause of cardioembolic stroke with 30.6% incidence. Atrial fibrillation is found to be the most common cause of cardioembolic stroke.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30480476' target='_blank' class='pmid-link'>30480476</a>:</span> <span class='sentence-part'>There is growing evidence that most of these cryptogenic strokes are thromboembolic and caused by an undetected atrial fibrillation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30496756' target='_blank' class='pmid-link'>30496756</a>:</span> <span class='sentence-part'>Atrial fibrillation (AF), the most frequently encountered cardiac arrhythmia in the clinical setting and the foremost cause of stroke, results from a progressive decrease in atrial refractoriness.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30584597' target='_blank' class='pmid-link'>30584597</a>:</span> <span class='sentence-part'>Studies are warranted to determine whether AF genetic risk can serve as a biomarker for strokes caused by AF.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30873623' target='_blank' class='pmid-link'>30873623</a>:</span> <span class='sentence-part'>BACKGROUND: Atrial fibrillation (AF) is an important preventable cause of stroke.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30879840' target='_blank' class='pmid-link'>30879840</a>:</span> <span class='sentence-part'>Atrial fibrillation (AF) is a major cause of stroke, heart failure, sudden death and cardiovascular morbidity.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30949352' target='_blank' class='pmid-link'>30949352</a>:</span> <span class='sentence-part'>Atrial fibrillation is a leading cause of stroke and early detection and treatment of the condition are critical.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31022824' target='_blank' class='pmid-link'>31022824</a>:</span> <span class='sentence-part'>While anticoagulation is associated with increased risk of intracranial bleeding after a fall, the risk of suffering a further stroke due to atrial fibrillation outweigh the risk of bleeding from a recurrent fall.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31236691' target='_blank' class='pmid-link'>31236691</a>:</span> <span class='sentence-part'>METHODS AND RESULTS: Patients with acute ischemic stroke [baseline diagnosis of ESUS (n = 69), stroke of macro- or microvascular cause (n = 16/25), stroke caused by AF (n = 5)] and controls with paroxysmal AF without acute ischemic stroke (n = 22) as well as healthy controls of young and old age (n = 21/17) in sinus rhythm were included (overall n = 175).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31256311' target='_blank' class='pmid-link'>31256311</a>:</span> <span class='sentence-part'>BACKGROUND: Although atrial fibrillation (AF) causes one-third of strokes in Ireland, studies have shown that public awareness and knowledge of AF are poor.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31258288' target='_blank' class='pmid-link'>31258288</a>:</span> <span class='sentence-part'>D-dimer, a degraded product of fibrin polymer, is a useful indicator of hypercoagulability, which frequently increases in cancer-associated stroke, but not in stroke resulted from atrial fibrillation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31315471' target='_blank' class='pmid-link'>31315471</a>:</span> <span class='sentence-part'>Objective: Atrial fibrillation (AF) is a major cause for recurrent stroke, has severe impact on a patient's health and imposes a high economic burden for society.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31353245' target='_blank' class='pmid-link'>31353245</a>:</span> <span class='sentence-part'>Prevalence of Nonstenotic Carotid Plaque in Stroke Due to Atrial Fibrillation Compared to Embolic Stroke of Undetermined Source. Patients with unilateral anterior circulation embolic stroke due to atrial fibrillation (AF) or consistent with ESUS who underwent computed tomographic neck angiography were included.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31409855' target='_blank' class='pmid-link'>31409855</a>:</span> <span class='sentence-part'>Covert atrial fibrillation (AF) accounts for cryptogenic stroke aetiology in elderly patients and in younger populations.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31503373' target='_blank' class='pmid-link'>31503373</a>:</span> <span class='sentence-part'>BACKGROUND: Silent atrial fibrillation is a frequent etiology of cryptogenic stroke.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31503549' target='_blank' class='pmid-link'>31503549</a>:</span> <span class='sentence-part'>Atrial fibrillation (AF) is the most common heart rhythm disorder and a major cause of stroke.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31517456' target='_blank' class='pmid-link'>31517456</a>:</span> <span class='sentence-part'>Background and purpose: The aim of this study is to evaluate utility of CHADS2 score to estimate stroke severity and prognosis in patients with ischemic stroke due to non-valvular atrial fibrillation (AF) in addition to evaluate effects of hematologic and echocardiographic findings on stroke severity and prognosis. Effects of CHADS2 score, echocardiographic and haematologic parameters on stroke severity and prognosis in patients with stroke due to nonvalvular atrial fibrillation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31526683' target='_blank' class='pmid-link'>31526683</a>:</span> <span class='sentence-part'>A number of recent studies appear to detach AF as a direct cause of stroke.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31535493' target='_blank' class='pmid-link'>31535493</a>:</span> <span class='sentence-part'>This review highlights the interplay of both clinician's awareness of guideline recommendations and understanding of individual patient-level factors which impact adherence and persistence, which are required to reduce the incidence of preventable stroke attributable to AF.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31587756' target='_blank' class='pmid-link'>31587756</a>:</span> <span class='sentence-part'>BACKGROUND: Although atrial fibrillation (AF) is a significant population health burden, and an avoidable cause of stroke, AF screening remains controversial.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31687065' target='_blank' class='pmid-link'>31687065</a>:</span> <span class='sentence-part'>Atrial fibrillation (AF) is the most common sustained arrhythmia encountered in practice and is the leading cause of debilitating strokes with significant economic burden.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31691981' target='_blank' class='pmid-link'>31691981</a>:</span> <span class='sentence-part'>BACKGROUND: Atrial fibrillation (AF) is the most common clinical arrhythmia and one of the major causes of stroke, heart failure, sudden death, and cardiovascular morbidity.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31719011' target='_blank' class='pmid-link'>31719011</a>:</span> <span class='sentence-part'>Atrial fibrillation is a common type of arrhythmia and is an important cause of stroke and heart failure. vitamin D is an emerging risk factor of AF, and is implicated in the pathophysiology of atrial fibrillation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31728874' target='_blank' class='pmid-link'>31728874</a>:</span> <span class='sentence-part'>Insightful association between PSVT and stroke from a National Inpatient Database Study.BACKGROUND: Atrial fibrillation and flutter are well-known causes of stroke.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31767526' target='_blank' class='pmid-link'>31767526</a>:</span> <span class='sentence-part'>Letter to the Editor regarding \Prevalence of Nonstenotic Carotid Plaque in Stroke due to Atrial Fibrillation Compared to Embolic Stroke of Undetermined Source\.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31791056' target='_blank' class='pmid-link'>31791056</a>:</span> <span class='sentence-part'>Atrial fibrillation is an important cause of stroke, and without anticoagulant treatment, patients with AFib have approximately a 5-fold increased risk for stroke.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31809335' target='_blank' class='pmid-link'>31809335</a>:</span> <span class='sentence-part'>Atrial fibrillation and stroke: how much atrial fibrillation is enough to cause a stroke?</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31843351' target='_blank' class='pmid-link'>31843351</a>:</span> <span class='sentence-part'>Lattanzi and Silvestrini Re: Prevalence of Nonstenotic Carotid Plaque in Stroke Due to Atrial Fibrillation Compared to Embolic Stroke of Undetermined Source.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31885372' target='_blank' class='pmid-link'>31885372</a>:</span> <span class='sentence-part'>A major goal in preventive medicine is the reduction of cardiovascular death by early detection of atrial fibrillation (AF), which may cause stroke, or early detection of life-threatening myocardial ischemia in acute coronary syndrome.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31903036' target='_blank' class='pmid-link'>31903036</a>:</span> <span class='sentence-part'>Effective INR Level May Be Delayed in Secondary Prevention of Stroke Due to Atrial Fibrillation with Warfarin in the Patients with Diabetes Mellitus.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31909178' target='_blank' class='pmid-link'>31909178</a>:</span> <span class='sentence-part'>Left atrial (LA) remodelling, a substrate for atrial fibrillation (AF) and stroke development, may play a role in identification of the aetiology of cryptogenic stroke.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31933524' target='_blank' class='pmid-link'>31933524</a>:</span> <span class='sentence-part'>Introduction: Atrial fibrillation (AF) is the commonest arrhythmia and a major cause of stroke and health care utilization.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32002111' target='_blank' class='pmid-link'>32002111</a>:</span> <span class='sentence-part'>Background: Atrial fibrillation (AF) is a leading source of emboli that precipitate cerebrovascular accident (CVA) which is correlated with left atrial appendage (LAA) morphology.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32264806' target='_blank' class='pmid-link'>32264806</a>:</span> <span class='sentence-part'>Atrial fibrillation is a major cause of debilitating strokes and anticoagulation is an established and indispensable therapy for reducing their rate.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32332662' target='_blank' class='pmid-link'>32332662</a>:</span> <span class='sentence-part'>Dabigatran-induced esophagitis: A case report.RATIONALE: Dabigatran is an anticoagulant medication that has been widely used to prevent strokes caused by atrial fibrillation, deep vein thrombosis, and pulmonary embolism.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32600783' target='_blank' class='pmid-link'>32600783</a>:</span> <span class='sentence-part'>Comparison of the Effect of Atrial Fibrillation Detection Algorithms in Patients With Cryptogenic Stroke Using Implantable Loop Recorders.Occult atrial fibrillation (AF) can be the underlying cause for cryptogenic stroke (CS).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32628401' target='_blank' class='pmid-link'>32628401</a>:</span> <span class='sentence-part'>Sophisticated catheter techniques for ablating cardiac arrhythmias have become state of the art; Watchman procedure gaining position in the prevention of stroke resulting from atrial fibrillation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32684980' target='_blank' class='pmid-link'>32684980</a>:</span> <span class='sentence-part'>Most of strokes are due to atrial fibrillation (AF).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32686471' target='_blank' class='pmid-link'>32686471</a>:</span> <span class='sentence-part'>Background:     Atrial fibrillation (AF) is the most common heart rhythm disorder in adults and a major cause of stroke.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32756054' target='_blank' class='pmid-link'>32756054</a>:</span> <span class='sentence-part'>RESULTS: Of 7,175 patients admitted between January 2009 and December 2018, 1,812 (25.3%) suffered stroke caused by AF. Modification of In-Hospital Recommendation and Prescription of Anticoagulants for Secondary Prevention of Stroke after Launch of Direct Oral Anticoagulants and Change of National Guidelines.INTRODUCTION: Approximately 1 out of 4 stroke patients suffers ischemic stroke secondary to atrial fibrillation (AF).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32912570' target='_blank' class='pmid-link'>32912570</a>:</span> <span class='sentence-part'>Anticoagulation Choice and Timing in Stroke Due to Atrial Fibrillation: A Survey of US Stroke Specialists (ACT-SAFe).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32970956' target='_blank' class='pmid-link'>32970956</a>:</span> <span class='sentence-part'>Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia and a major cause of stroke and heart failure.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33022807' target='_blank' class='pmid-link'>33022807</a>:</span> <span class='sentence-part'>Initially, the ESUS definition was based on the hypothesis that atrial fibrillation would be the main cause for stroke in this subpopulation of cryptogenic stroke.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33024492' target='_blank' class='pmid-link'>33024492</a>:</span> <span class='sentence-part'>The majority of strokes are ischemic and a subset of these are due to atrial fibrillation (AF).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33252411' target='_blank' class='pmid-link'>33252411</a>:</span> <span class='sentence-part'>Studies have shown that these strokes may be caused by occult atrial fibrillation, occult malignancy, and other hypercoagulable states but are often identified after hospital discharge.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33346822' target='_blank' class='pmid-link'>33346822</a>:</span> <span class='sentence-part'>BACKGROUND: Atrial fibrillation (AF) is the most common sustained heart arrhythmia and a major preventable cause of stroke, heart failure and dementia.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33401327' target='_blank' class='pmid-link'>33401327</a>:</span> <span class='sentence-part'>BACKGROUND: Undocumented atrial fibrillation (AF) is suspected as a main stroke cause in patients with ESUS, but its prevalence is largely unknown.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33487413' target='_blank' class='pmid-link'>33487413</a>:</span> <span class='sentence-part'>CONCLUSIONS: For patients with atrial fibrillation, the removal of the left atrial appendage can effectively prevent stroke caused by atrial fibrillation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33516401' target='_blank' class='pmid-link'>33516401</a>:</span> <span class='sentence-part'>Atrial fibrillation (AF) is a major, preventable cause of stroke, whose prevalence is increasing with the aging of the population.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33516402' target='_blank' class='pmid-link'>33516402</a>:</span> <span class='sentence-part'>Atrial fibrillation (AF) is the most common cardiac arrythmia and a major cause of stroke, heart failure, sudden death, and cardiovascular morbidity. Oral anticoagulation is effective in prevention of strokes secondary to AF, reducing overall stroke numbers by approximately 64%.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33625468' target='_blank' class='pmid-link'>33625468</a>:</span> <span class='sentence-part'>Importance: Atrial fibrillation (AF) is a major cause of preventable strokes.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33629410' target='_blank' class='pmid-link'>33629410</a>:</span> <span class='sentence-part'>BACKGROUND: Atrial fibrillation (AF) is the major cause of stroke since approximately 25% of all strokes are of cardioembolic-origin.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33634195' target='_blank' class='pmid-link'>33634195</a>:</span> <span class='sentence-part'>Opportunistic screening for AF applied to the above clinical situation can save lives, since the strokes that occur as a result of AF are often large, severely debilitating or fatal.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33752143' target='_blank' class='pmid-link'>33752143</a>:</span> <span class='sentence-part'>We allocated patients with strokes caused by small vessel occlusion, large artery atherosclerosis, atrial fibrillation, or aortic atheroma to Group A and those with strokes of other causes to Group B which included dissection, Trousseau syndrome and cerebral sinus thrombosis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34053133' target='_blank' class='pmid-link'>34053133</a>:</span> <span class='sentence-part'>Atrial fibrillation (AF) is the most common heart rhythm disorder in adults and a major cause of stroke.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34113853' target='_blank' class='pmid-link'>34113853</a>:</span> <span class='sentence-part'>Background: Atrial fibrillation (AF), a common cause of stroke, often is asymptomatic.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34192898' target='_blank' class='pmid-link'>34192898</a>:</span> <span class='sentence-part'>Occult atrial fibrillation (AF) is a leading cause of stroke of unclear cause.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34240675' target='_blank' class='pmid-link'>34240675</a>:</span> <span class='sentence-part'>BACKGROUND: Ischaemic stroke or cerebrovascular accident (CVA) due to occult atrial fibrillation (AF) may cause severe morbidity and mortality.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34291659' target='_blank' class='pmid-link'>34291659</a>:</span> <span class='sentence-part'>Atrial fibrillation is a major cause of stroke.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34355779' target='_blank' class='pmid-link'>34355779</a>:</span> <span class='sentence-part'>BACKGROUND: Atrial fibrillation (AF) is the leading cause of stroke.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34416866' target='_blank' class='pmid-link'>34416866</a>:</span> <span class='sentence-part'>Cardioembolism related to atrial fibrillation is the major cause of stroke in this population.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34555558' target='_blank' class='pmid-link'>34555558</a>:</span> <span class='sentence-part'>BACKGROUND: Atrial fibrillation (AF) is the most common preventable cause of stroke.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34565689' target='_blank' class='pmid-link'>34565689</a>:</span> <span class='sentence-part'>Atrial fibrillation (AF) is responsible for cardiogenic stroke.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34807935' target='_blank' class='pmid-link'>34807935</a>:</span> <span class='sentence-part'>BACKGROUND/AIM: Atrial fibrillation (AF) is a major health problem and causes heart failure and stroke.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34883983' target='_blank' class='pmid-link'>34883983</a>:</span> <span class='sentence-part'>Cardiovascular diseases with high mortality rates, such as strokes, are frequently caused by atrial fibrillation without subjective symptoms.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34884381' target='_blank' class='pmid-link'>34884381</a>:</span> <span class='sentence-part'>Atrial fibrillation (AF) is a major cause of heart failure and stroke.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34939547' target='_blank' class='pmid-link'>34939547</a>:</span> <span class='sentence-part'>Atrial fibrillation (AF) can be a cause of stroke by causing blood clots in the chambers of the heart.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35080356' target='_blank' class='pmid-link'>35080356</a>:</span> <span class='sentence-part'>Prospective data have demonstrated the benefits of long-term cardiac monitoring to identify AF in association with cryptogenic stroke, as most strokes are presumed to result from AF.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35114252' target='_blank' class='pmid-link'>35114252</a>:</span> <span class='sentence-part'>Atrial fibrillation (AF) affects over 1% of the population and is a leading cause of stroke and heart failure in the elderly.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35138372' target='_blank' class='pmid-link'>35138372</a>:</span> <span class='sentence-part'>BACKGROUND: Atrial Fibrillation (AF) is the most common sustained heart arrhythmia and a major preventable cause of stroke.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35155858' target='_blank' class='pmid-link'>35155858</a>:</span> <span class='sentence-part'>AF affects a substantial proportion of patient days and may be an underappreciated cause of stroke in KF-HD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35176666' target='_blank' class='pmid-link'>35176666</a>:</span> <span class='sentence-part'>Atrial fibrillation (AF) is a known cause of stroke.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35232217' target='_blank' class='pmid-link'>35232217</a>:</span> <span class='sentence-part'>Background:     Undiagnosed atrial fibrillation (AF) may cause preventable strokes.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35322290' target='_blank' class='pmid-link'>35322290</a>:</span> <span class='sentence-part'>OBJECTIVE: Atrial fibrillation (AF) is a major cause of stroke with lifetime risks.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35361456' target='_blank' class='pmid-link'>35361456</a>:</span> <span class='sentence-part'>Atrial fibrillation is one of the most important stroke causes.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35517873' target='_blank' class='pmid-link'>35517873</a>:</span> <span class='sentence-part'>We examined the relation between area deprivation index (ADI) and anticoagulation in individuals at risk of stroke due to AF.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35909711' target='_blank' class='pmid-link'>35909711</a>:</span> <span class='sentence-part'>In the univariate analysis, FPE was associated with RBC clot area, atrial fibrillation, and occlusion location but not with fibrin clot area, mixed clot area, stroke etiology, thrombectomy technique, distal emboli, or 90-day mRS.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36003419' target='_blank' class='pmid-link'>36003419</a>:</span> <span class='sentence-part'>Importance: Undiagnosed atrial fibrillation (AF) is an important cause of stroke.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36105228' target='_blank' class='pmid-link'>36105228</a>:</span> <span class='sentence-part'>Atrial arrhythmias, such as atrial fibrillation (AF), are a major mortality risk and a leading cause of stroke.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36118256' target='_blank' class='pmid-link'>36118256</a>:</span> <span class='sentence-part'>Conclusion: Guideline-recommended anticoagulant therapy for prevention of stroke due to AF may not be optimally implemented among RA patients, and requires special attention.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36121557' target='_blank' class='pmid-link'>36121557</a>:</span> <span class='sentence-part'>INTRODUCTION: Atrial fibrillation (AF) is a major cause of stroke.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36268397' target='_blank' class='pmid-link'>36268397</a>:</span> <span class='sentence-part'>Conclusion: Our case highlights the importance of cardiac embolus as a diagnosis in a patient with a history of stroke secondary to atrial fibrillation as a cause of acute STEMI and its management.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36537565' target='_blank' class='pmid-link'>36537565</a>:</span> <span class='sentence-part'>Strokes caused by AF more often are fatal or result in severe disability.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36645969' target='_blank' class='pmid-link'>36645969</a>:</span> <span class='sentence-part'>INTRODUCTION: Atrial fibrillation (AF) is suspected as the main cause of stroke in the majority of patients presenting with cryptogenic stroke (CS).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36757910' target='_blank' class='pmid-link'>36757910</a>:</span> <span class='sentence-part'>CONCLUSIONS: Screening for NVAF at &gt;=75 years of age could result in fewer NVAF-related strokes.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36863334' target='_blank' class='pmid-link'>36863334</a>:</span> <span class='sentence-part'>INTRODUCTION:  Atrial fibrillation (AF) is a common cause of stroke.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36882886' target='_blank' class='pmid-link'>36882886</a>:</span> <span class='sentence-part'>With respect to the cause of stroke, this is multifactorial, due to atherosclerotic heart disease,    inflammation    , atrial fibrillation, and hypertension    with the latter     being the most important cause.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36971961' target='_blank' class='pmid-link'>36971961</a>:</span> <span class='sentence-part'>Thus, a high index of suspicion for more common causes of stroke is needed, especially given that treatment for valvular lesions typically involves cardiac surgery whereas secondary prevention of stroke due to occult atrial fibrillation is readily accomplished with anticoagulation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37076223' target='_blank' class='pmid-link'>37076223</a>:</span> <span class='sentence-part'>Atrial fibrillation is one of the most important stroke causes.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37080450' target='_blank' class='pmid-link'>37080450</a>:</span> <span class='sentence-part'>Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia and a major cause of stroke and morbidity.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37092856' target='_blank' class='pmid-link'>37092856</a>:</span> <span class='sentence-part'>BACKGROUND: Atrial fibrillation is a common cause of stroke among older adults and is often first detected during hospitalization, given frequent use of cardiac telemetry.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37096200' target='_blank' class='pmid-link'>37096200</a>:</span> <span class='sentence-part'>Purpose: Atrial fibrillation (AF) is a significant cause of stroke, and newly diagnosed AF (NDAF) is typically detected in the early period of stroke onset.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37363945' target='_blank' class='pmid-link'>37363945</a>:</span> <span class='sentence-part'>Atrial fibrillation (AF) is a common cause of stroke but may not be detectable at the time of stroke. Polygenic risk of AF may be a useful biomarker for identifying strokes caused by AF.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37422010' target='_blank' class='pmid-link'>37422010</a>:</span> <span class='sentence-part'>BACKGROUND: Atrial fibrillation (AF) is one of the most frequent causes of stroke.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37701476' target='_blank' class='pmid-link'>37701476</a>:</span> <span class='sentence-part'>As the population of Delaware ages, atrial fibrillation is a growing cause of stroke.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37818120' target='_blank' class='pmid-link'>37818120</a>:</span> <span class='sentence-part'>AFib can result in the formation of blood clots in the atria, which may subsequently embolize the brain, causing a stroke.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37898714' target='_blank' class='pmid-link'>37898714</a>:</span> <span class='sentence-part'>Paradoxically, lower rates of stroke and all-cause mortality secondary to AF in people with obesity and sepsis warrant further investigation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37990153' target='_blank' class='pmid-link'>37990153</a>:</span> <span class='sentence-part'>BACKGROUND: Atrial Fibrillation (AF) is the leading cause of stroke, which can be reduced by 70% with appropriate oral anticoagulation (OAC) therapy.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/38015598' target='_blank' class='pmid-link'>38015598</a>:</span> <span class='sentence-part'>BACKGROUND: Atrial fibrillation (AF) is a common cause of stroke, and timely diagnosis is critical for secondary prevention.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/38025532' target='_blank' class='pmid-link'>38025532</a>:</span> <span class='sentence-part'>Atrial fibrillation (AF) is a common critical cause of stroke and cardiac dysfunction worldwide with lifetime risks.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/38133621' target='_blank' class='pmid-link'>38133621</a>:</span> <span class='sentence-part'>Left atrial (LA) blood flow plays an important role in diseases such as atrial fibrillation (AF) and atrial cardiomyopathy since alterations in the blood flow might lead to thrombus formation and stroke.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/38151689' target='_blank' class='pmid-link'>38151689</a>:</span> <span class='sentence-part'>BACKGROUND: Atrial fibrillation (AF) is a major cause of stroke in older people.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/38326254' target='_blank' class='pmid-link'>38326254</a>:</span> <span class='sentence-part'>INTRODUCTION: Atrial fibrillation (AF) is a significant cause of perioperative stroke in aortic and mitral valve surgeries.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/38395298' target='_blank' class='pmid-link'>38395298</a>:</span> <span class='sentence-part'>METHODS: We performed a retrospective cohort study of consecutive patients receiving acute recanalization treatment for acute ischemic stroke between January 2016 and August 2022, with AF as a potential stroke cause.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/38541270' target='_blank' class='pmid-link'>38541270</a>:</span> <span class='sentence-part'>Frailty status on admission with stroke due to AF can help identify those more likely to have poorer outcomes, to benefit from intervention, to require prolonged rehabilitation, and to avail of ESD. Frailty is prevalent among patients with cardioembolic stroke due to AF and was associated with poorer functional outcomes. Stroke due to atrial fibrillation (AF) is more common in older adults. Impact of Frailty on Healthcare Outcomes after Cardioembolic Ischaemic Stroke Due to Atrial Fibrillation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/38672245' target='_blank' class='pmid-link'>38672245</a>:</span> <span class='sentence-part'>Strokes and thromboembolisms are also common consequences of AF.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/7660392' target='_blank' class='pmid-link'>7660392</a>:</span> <span class='sentence-part'>Did AF precede and precipitate the stroke, or did the arrhythmia appear as a result of stroke?</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/7786120' target='_blank' class='pmid-link'>7786120</a>:</span> <span class='sentence-part'>Fifteen per cent of cerebrovascular accidents have a cardiac origin, two thirds of which are due to atrial fibrillation (AF).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/8745546' target='_blank' class='pmid-link'>8745546</a>:</span> <span class='sentence-part'>[Complete arrhythmia, caused by atrial fibrillation, causing ischemic cerebral vascular accident following acute alcoholic intoxication in a young subject].</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/8834062' target='_blank' class='pmid-link'>8834062</a>:</span> <span class='sentence-part'>Stroke due to AF is preventable.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/9474682' target='_blank' class='pmid-link'>9474682</a>:</span> <span class='sentence-part'>From a clinical point of view, AIDA is a valuable tool to evaluate the efficacy of antiarrhythmic therapy, particularly as it pertains to the prevention of stroke due to atrial fibrillation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/9619696' target='_blank' class='pmid-link'>9619696</a>:</span> <span class='sentence-part'>Poststroke atrial fibrillation bursts with sinus rhythm at stroke onset: what was the cause of stroke?</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/9638394' target='_blank' class='pmid-link'>9638394</a>:</span> <span class='sentence-part'>In addition to stroke, both AF and atrial flutter may cause cardiomyopathy, which may be fully reversible with effective treatment of the arrhythmia. It is well recognised that AF is a major cause of stroke, even in the absence of underlying heart disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/9672497' target='_blank' class='pmid-link'>9672497</a>:</span> <span class='sentence-part'>A major consequence of atrial fibrillation (AF) is stroke.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/9725923' target='_blank' class='pmid-link'>9725923</a>:</span> <span class='sentence-part'>BACKGROUND: Atrial fibrillation, the most common sustained cardiac arrhythmia and a major cause of stroke, results from simultaneous reentrant wavelets.</span></div></div>
<div class='streamlined-assertion'><div class='streamlined-header sticky-relation-header'><span class='label-text'>Subject:</span> <strong>Atrial_Fibrillation</strong> <span class='label-text'>Subject CUI:</span> <strong>C0004238</strong> â†’ <span class='label-text predicate-text'>CAUSES</span> â†’ <span class='label-text'>Object:</span> <strong>Cessation_of_life</strong> <span class='label-text'>Object CUI:</span> <strong>C0011065</strong></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/11978585' target='_blank' class='pmid-link'>11978585</a>:</span> <span class='sentence-part'>The multiple-causes mortality files from 1980 through 1998 were analyzed for decedents, with atrial fibrillation (International Classification of Diseases, Ninth Revision, code 427.3) listed as one of up to 20 conditions causing death.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/12617537' target='_blank' class='pmid-link'>12617537</a>:</span> <span class='sentence-part'>The findings indicate that AF as a contributing cause of death and hospitalization affects primarily persons aged &gt; or = 75 years and that death and hospitalization rates vary by state. Atrial fibrillation as a contributing cause of death and Medicare hospitalization--United States, 1999. The frequency with which AF is reported on death certificates as a contributing cause of death has increased since 1980.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/15746706' target='_blank' class='pmid-link'>15746706</a>:</span> <span class='sentence-part'>These findings support AF as a contributing cause of cardiovascular death independent of clinically associated risk factors, such as hypertension, diabetes mellitus, smoking, congestive heart failure, and prior myocardial infarction.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/15845559' target='_blank' class='pmid-link'>15845559</a>:</span> <span class='sentence-part'>CONCLUSION: Death due to LV dysfunction was not frequent and cardioembolic events due to AF were the leading cause for cardiac death.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/16627459' target='_blank' class='pmid-link'>16627459</a>:</span> <span class='sentence-part'>The primary long-term objective is to show the non-inferiority of IC AADs compared with amiodarone in terms of time to first occurrence of a composite endpoint (death, atrial cardioversion, hospitalizations due to AF or heart failure, or change of AADs).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17198809' target='_blank' class='pmid-link'>17198809</a>:</span> <span class='sentence-part'>OBJECTIVE: The study objective was to describe the independent effect of preoperative atrial fibrillation on the outcome of coronary artery bypass grafting, including the causes of death (cardiac vs noncardiac).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17526974' target='_blank' class='pmid-link'>17526974</a>:</span> <span class='sentence-part'>Cox's regression analysis was carried out to estimate the hazard ratios (HRs) of each cause of death attributable to AF after adjusting for other risk factors.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/18391094' target='_blank' class='pmid-link'>18391094</a>:</span> <span class='sentence-part'>The occurrence of atrial fibrillation and cardiovascular events over 4.7 years as well as the determination of cause of death at 4.7 and 14.3 years were followed.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/2003280' target='_blank' class='pmid-link'>2003280</a>:</span> <span class='sentence-part'>The risk of death attributable to atrial fibrillation, adjusted for the effect of other prognostic factors, was significant at 1 month (relative risk = 1.55) and at 6 months (relative risk = 1.74).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21599901' target='_blank' class='pmid-link'>21599901</a>:</span> <span class='sentence-part'>DISCUSSION: Successful translation of evidence into clinical practice can reduce avoidable stroke, death, and disability due to nonvalvular atrial fibrillation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21933802' target='_blank' class='pmid-link'>21933802</a>:</span> <span class='sentence-part'>Secondary endpoints were cardiovascular death, hospitalization because of AF, or worsening HF.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24016454' target='_blank' class='pmid-link'>24016454</a>:</span> <span class='sentence-part'>BACKGROUND: Atrial fibrillation is associated with increased mortality, but the specific causes of death and their predictors have not been described among patients on effective anticoagulant therapy.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24381330' target='_blank' class='pmid-link'>24381330</a>:</span> <span class='sentence-part'>CONCLUSION: Atrial fibrillation has become much more common as a certified cause of death. Atrial fibrillation as a cause of death increased steeply in England between 1995 and 2010. Atrial fibrillation was given as the underlying cause of death in 21.4% of all deaths in which it was mentioned (41 298 of 192 770).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26220013' target='_blank' class='pmid-link'>26220013</a>:</span> <span class='sentence-part'>AIMS: Diabetes mellitus (DM) and atrial fibrillation (AF) are worldwide public health challenges and major causes of death and cardiovascular events.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26701216' target='_blank' class='pmid-link'>26701216</a>:</span> <span class='sentence-part'>Despite remarkable advances in antiarrhythmic drugs, ablation procedures, and stroke-prevention strategies, atrial fibrillation (AF) remains an important cause of death and disability in middle-aged and elderly individuals.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27476087' target='_blank' class='pmid-link'>27476087</a>:</span> <span class='sentence-part'>BACKGROUND: Atrial fibrillation is associated with a higher mortality, but causes of death of atrial fibrillation patients and their specific predictors have been less well defined.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28153995' target='_blank' class='pmid-link'>28153995</a>:</span> <span class='sentence-part'>Female sex is an independent risk factor for death or stroke attributable to AF.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28826448' target='_blank' class='pmid-link'>28826448</a>:</span> <span class='sentence-part'>Except for three patients (0.8%) lost to follow-up with unknown cause of death, 3 (0.8%, 95%CI 0.2-2.4) adverse cardiac events were documented: atrial fibrillation, cardiac tamponade due to TB pericarditis and cardiac arrest, which was determined to not have been caused by QT drugs.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28916640' target='_blank' class='pmid-link'>28916640</a>:</span> <span class='sentence-part'>AF is an uncommon primary cause of death in HCM virtually limited to embolic stroke, supporting a low threshold for initiating anticoagulation therapy.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28964382' target='_blank' class='pmid-link'>28964382</a>:</span> <span class='sentence-part'>Rates were calculated for AF as primary diagnosis or underlying cause of death (primary AF), as well as secondary diagnosis or contributing cause of death (co-morbid AF), and standardized by age to the 2010 US population.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29165583' target='_blank' class='pmid-link'>29165583</a>:</span> <span class='sentence-part'>Conclusion: This modelling analysis suggests that the transition from VKA to NOACs may greatly help in reducing the burden of IS and death caused by AF in the East Asian region.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29250283' target='_blank' class='pmid-link'>29250283</a>:</span> <span class='sentence-part'>AF is a major cause of death and disability, as it is associated with a 4-5 fold increase in the risk of ischemic stroke[2].</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29605142' target='_blank' class='pmid-link'>29605142</a>:</span> <span class='sentence-part'>HCM-related events were defined as sudden death, implantable cardioverter-defibrillator discharge with successful recovery from cardiopulmonary arrest, death due to heart failure, hospitalization for heart failure, myocardial infarction, and thrombosis caused by atrial fibrillation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29893840' target='_blank' class='pmid-link'>29893840</a>:</span> <span class='sentence-part'>Atrial fibrillation is increasing in frequency and is a major cause of death, stroke, heart failure, cognitive decline, and hospitalizations.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30310328' target='_blank' class='pmid-link'>30310328</a>:</span> <span class='sentence-part'>The analysis included demographics, posttransplant medication, length of the initial hospital stay after HTX, early posttransplant atrial fibrillation (AF), mortality, and causes of death.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30442001' target='_blank' class='pmid-link'>30442001</a>:</span> <span class='sentence-part'>Atrial fibrillation is a frequent cause, ventricular arrhythmias a frequent consequence and ventricular fibrillation a frequent cause of death in patients with heart failure.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30536543' target='_blank' class='pmid-link'>30536543</a>:</span> <span class='sentence-part'>Cardiac complications including arrhythmia and especially atrial fibrillation (AF) are common causes of death in beta-thalassemia patients.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30586468' target='_blank' class='pmid-link'>30586468</a>:</span> <span class='sentence-part'>METHODS: A total of 15,411 patients with atrial fibrillation from the Korean National Health Insurance Service-National Sample Cohort were enrolled, and causes of death were identified according to codes of the 10th revision of the International Classification of Diseases. There is a paucity of population-based studies about the impact of atrial fibrillation on the mortality risk stratified by age, sex, and detailed causes of death.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30794758' target='_blank' class='pmid-link'>30794758</a>:</span> <span class='sentence-part'>Despite available drug and electrophysical treatments, death and functional restrictions due to AF are still common.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31876019' target='_blank' class='pmid-link'>31876019</a>:</span> <span class='sentence-part'>From all ischemic stroke subtypes, those attributed to atrial fibrillation are known to present with increased neurological severity resulting in death or major long-term disability [1].</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31999778' target='_blank' class='pmid-link'>31999778</a>:</span> <span class='sentence-part'>The association between AF and echocardiographic parameters, causes of death were also investigated. The association between AF and sepsis-related death suggested the role of systemic inflammation on the pathogenesis of AF.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32159116' target='_blank' class='pmid-link'>32159116</a>:</span> <span class='sentence-part'>Stroke and Systemic Thromboembolism Prevention in People Living With Human Immunodeficiency Virus With Atrial Fibrillation: A Review of Its Implications for Clinical Practice.In the last few decades, types of diseases affecting people living with human immunodeficiency virus (PLHIV) have shifted as the population ages, with cardiovascular disease becoming a leading cause of death in this population.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32608191' target='_blank' class='pmid-link'>32608191</a>:</span> <span class='sentence-part'>Analysis included patient characteristics, medication, echocardiographic features, heart rates, permanent pacemaker implantation, atrial fibrillation, and post-transplant survival including causes of death.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33978991' target='_blank' class='pmid-link'>33978991</a>:</span> <span class='sentence-part'>BACKGROUND AND AIM: Atrial fibrillation is a major cause of death and disability due to stroke.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34320819' target='_blank' class='pmid-link'>34320819</a>:</span> <span class='sentence-part'>Methods and Results We performed serial cross-sectional analyses of national death certificate data for cardiovascular mortality related to AF, whereby cardiovascular disease was listed as underlying cause of death and AF as multiple cause of death among adults aged 35 to 84 years using the Centers for Disease Control and Prevention's Wide-Ranging Online Data for Epidemiologic Research.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35791086' target='_blank' class='pmid-link'>35791086</a>:</span> <span class='sentence-part'>AF can put one's life at risk and eventually lead to death.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36577318' target='_blank' class='pmid-link'>36577318</a>:</span> <span class='sentence-part'>BACKGROUND: Atrial Fibrillation (AF) is a major risk factor for stroke, which is the second leading cause of death worldwide.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36603885' target='_blank' class='pmid-link'>36603885</a>:</span> <span class='sentence-part'>During a follow-up of (14.4+/-6.8) months (range: 3 to 22 months), no death occurred, and 1 patient was readmitted for endocardial radiofrequency ablation due to atrial fibrillation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37536787' target='_blank' class='pmid-link'>37536787</a>:</span> <span class='sentence-part'>Cardioembolic stroke from atrial fibrillation causes substantial death and disability in the United States.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/38205729' target='_blank' class='pmid-link'>38205729</a>:</span> <span class='sentence-part'>The model projected both clinical consequences and costs associated with, among others, AF, heart failure (HF), strokes, and deaths due to AF or AF related complications. Results:     STAI was advantageous versus AADs on all 4 main clinical outcomes evaluated; AF: 25.83% lower (12.84% vs 38.67%), HF: 2.22% lower (1.33% vs 3.55%), stroke or post stroke: 1.82% lower (10.00% vs 11.82%) and deaths due to AF or AF related complications: 0.64% lower (4.11% vs 4.75%).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/38606645' target='_blank' class='pmid-link'>38606645</a>:</span> <span class='sentence-part'>The incidence rate of CV death due to IHD was highest in HFrEF while incidence rates of CV death due to pulmonary vascular disease, stroke, valvular heart disease and atrial fibrillation increased with increasing EF.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/9040681' target='_blank' class='pmid-link'>9040681</a>:</span> <span class='sentence-part'>This study was undertaken to determine the influence of AF on the mortality of stroke patients and on the causes of death after a stroke event.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/9361653' target='_blank' class='pmid-link'>9361653</a>:</span> <span class='sentence-part'>OBJECTIVES: The objective of this study was to determine the association of atrial fibrillation (AF) with stroke recurrence and mortality and with the causes of death in ischemic stroke patients aged 75 years and older.</span></div></div>
<div class='streamlined-assertion'><div class='streamlined-header sticky-relation-header'><span class='label-text'>Subject:</span> <strong>Atrial_Fibrillation</strong> <span class='label-text'>Subject CUI:</span> <strong>C0004238</strong> â†’ <span class='label-text predicate-text'>CAUSES</span> â†’ <span class='label-text'>Object:</span> <strong>Complication</strong> <span class='label-text'>Object CUI:</span> <strong>C0009566</strong></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28582906' target='_blank' class='pmid-link'>28582906</a>:</span> <span class='sentence-part'>BACKGROUND: Atrial fibrillation (AF) is a common type of arrhythmia disease, which has a high morbidity and can lead to some serious complications.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33019201' target='_blank' class='pmid-link'>33019201</a>:</span> <span class='sentence-part'>Clinical Relevance-This paper confirms that AF can be detected in compressive sensed ECG using deep learning, This will facilitate long-term ECG monitoring using wearable devices and will reduce adverse complications resulting from undiagnosed AF.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35669184' target='_blank' class='pmid-link'>35669184</a>:</span> <span class='sentence-part'>Atrial fibrillation (AF) is always in high incidence in the population, which can lead to serious complications.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35978763' target='_blank' class='pmid-link'>35978763</a>:</span> <span class='sentence-part'>Anticoagulation is utilized to prevent and reduce AF-induced complications such as stroke, heart failure, and death.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36568557' target='_blank' class='pmid-link'>36568557</a>:</span> <span class='sentence-part'>Background and objective: Around 33.5 million patients suffered from atrial fibrillation (AF), causing complications and increasing mortality and disability rate.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37115683' target='_blank' class='pmid-link'>37115683</a>:</span> <span class='sentence-part'>These patients both have a risk of cardioembolic complications due to atrial fibrillation, and a risk of cerebral haemorrhage from cerebral amyloid angiopathy.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37522088' target='_blank' class='pmid-link'>37522088</a>:</span> <span class='sentence-part'>AF not only affects patients' quality of life, but also causes thrombosis, heart failure and other complications in severe cases.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37836479' target='_blank' class='pmid-link'>37836479</a>:</span> <span class='sentence-part'>The AF can cause life-threatening thromboembolic complications.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/38132169' target='_blank' class='pmid-link'>38132169</a>:</span> <span class='sentence-part'>The reasons are the increasing prevalence and thromboembolic complications caused by AF.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/38206235' target='_blank' class='pmid-link'>38206235</a>:</span> <span class='sentence-part'>Although cardioembolic stroke remains the most feared and widely studied complication of AF, AIC is also a clinically important consequence of AF that portends significant morbidity and mortality to patients with AF.</span></div></div>
<div class='streamlined-assertion'><div class='streamlined-header sticky-relation-header'><span class='label-text'>Subject:</span> <strong>Atrial_Fibrillation</strong> <span class='label-text'>Subject CUI:</span> <strong>C0004238</strong> â†’ <span class='label-text predicate-text'>CAUSES</span> â†’ <span class='label-text'>Object:</span> <strong>Congestive_heart_failure</strong> <span class='label-text'>Object CUI:</span> <strong>C0018802</strong></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/10067370' target='_blank' class='pmid-link'>10067370</a>:</span> <span class='sentence-part'>The combination of atrial fibrillation (Af) and tricuspid regurgitation (TR) may induce the congestive heart failure (HF) due to insufficient output.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/10936003' target='_blank' class='pmid-link'>10936003</a>:</span> <span class='sentence-part'>Improved diagnosis and an ageing population with an increased likelihood of underlying cardiac disease results in AF in more than 1% of population. AF is associated with an approximately two-fold increase in mortality, largely due to stroke which occurs at an annual rate of 5-7%. Studies in patients with little or no awareness of their arrhythmia condition indicate that unrecognized and untreated AF may cause congestive heart failure.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/14688506' target='_blank' class='pmid-link'>14688506</a>:</span> <span class='sentence-part'>These two conditions seem to be linked together, and congestive heart failure may either be the cause or the consequence of atrial fibrillation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/14708411' target='_blank' class='pmid-link'>14708411</a>:</span> <span class='sentence-part'>Atrial fibrillation (AF) and tricuspid regurgitation (TR) may induce congestive heart failure (CHD). Congestive heart failure induced by the combination of atrial fibrillation and tricuspid regurgitation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/15106182' target='_blank' class='pmid-link'>15106182</a>:</span> <span class='sentence-part'>Excluded were trials in which the prevalence of atrial fibrillation was 2% or greater, or in which any arrhythmia that might compromise cardiac function or any potentially reversible cause of CHF such as acute ischemic heart disease or myocarditis was present.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17342365' target='_blank' class='pmid-link'>17342365</a>:</span> <span class='sentence-part'>We report the case of a 25-year-old man with WS, who suffered congestive heart failure caused by severe mitral insufficiency and atrial fibrillation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23126050' target='_blank' class='pmid-link'>23126050</a>:</span> <span class='sentence-part'>The patient was already known to have liver cirrhosis of ethylic etiology, cardiac decompensation caused by hypertensive heart disease with permanent atrial fibrillation, chronic obstructive pulmonary disease, diabetes mellitus type 2, and cholelithiasis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25774257' target='_blank' class='pmid-link'>25774257</a>:</span> <span class='sentence-part'>We report the case of a 75-year-old female patient with a history of Hashimoto's thyroiditis who presented with congestive heart failure caused by atrial fibrillation associated with isolated adrenocorticotropic hormone (ACTH) deficiency. Heart Failure Caused by Atrial Fibrillation in a Patient with Isolated Adrenocorticotropic Hormone Deficiency and Hashimoto's Thyroiditis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28496733' target='_blank' class='pmid-link'>28496733</a>:</span> <span class='sentence-part'>AF causes congestive heart failure, thromboembolic events such as stroke and intolerable symptoms in some patients.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29844916' target='_blank' class='pmid-link'>29844916</a>:</span> <span class='sentence-part'>A 94 year-old Japanese woman with renal dysfunction was admitted to our hospital for congestive heart failure caused by atrial fibrillation with rapid ventricular response.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/3379031' target='_blank' class='pmid-link'>3379031</a>:</span> <span class='sentence-part'>The authors present a case of a 62-year-old woman who was hospitalized with severe medical problems that included congestive heart failure secondary to mitral stenosis and atrial fibrillation, coronary artery disease, chronic renal failure, and a recent history of a right cerebral lacunar infarction.</span></div></div>
<div class='streamlined-assertion'><div class='streamlined-header sticky-relation-header'><span class='label-text'>Subject:</span> <strong>Atrial_Fibrillation</strong> <span class='label-text'>Subject CUI:</span> <strong>C0004238</strong> â†’ <span class='label-text predicate-text'>CAUSES</span> â†’ <span class='label-text'>Object:</span> <strong>Disease</strong> <span class='label-text'>Object CUI:</span> <strong>C0012634</strong></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/11892422' target='_blank' class='pmid-link'>11892422</a>:</span> <span class='sentence-part'>On another hand, newly discovered antiarrhythmic virtues of atrial pacing are of a great interest for a certain type of atrial fibrillations such as vagal induced fibrillations, atrial diseases and atypical flutters.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/12821245' target='_blank' class='pmid-link'>12821245</a>:</span> <span class='sentence-part'>CONCLUSIONS: Familial AF is more common than previously recognized, highlighting the importance of genetics in disease pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/15989549' target='_blank' class='pmid-link'>15989549</a>:</span> <span class='sentence-part'>Atrial fibrillation causes disease for three reasons: i) the ventricular rate is often high, which leads to symptoms ranging from discomfort to life threatening heart failure; ii) the rhythm causes loss of atrioventricular synchrony, which reduces diastolic filling and may lead to heart failure; and iii) atrial contraction is lost leading to stagnant blood that again may lead to atrial thrombi and peripheral embolism.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/16253356' target='_blank' class='pmid-link'>16253356</a>:</span> <span class='sentence-part'>OBJECTIVE: Previous research has demonstrated that patients with atrial fibrillation (AF) possess very little knowledge of their disease, the consequences of AF and the benefits/risks of anti-coagulant therapy.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17113662' target='_blank' class='pmid-link'>17113662</a>:</span> <span class='sentence-part'>CONCLUSIONS: This study highlights the role of ACE gene in predisposing to both lone and secondary NVAF, further contributing to penetrate the genetic mechanisms responsible for this complex disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/18446268' target='_blank' class='pmid-link'>18446268</a>:</span> <span class='sentence-part'>Patients with mesenteric ischaemia secondary to a prothrombotic state such as that rendered by the Factor V Leiden mutation, are substantially younger than the typical elderly patient in whom embolic disease triggered by atrial fibrillation is the main underlying cause.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21562376' target='_blank' class='pmid-link'>21562376</a>:</span> <span class='sentence-part'>While recognizing that AF is a heterogeneous disorder, we submit that the parallels between AF and HF may arise because many cases of AF and HF result from the cumulative exposure of the atria and ventricles to a common set of systemic cardiovascular risk factors.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22318757' target='_blank' class='pmid-link'>22318757</a>:</span> <span class='sentence-part'>To date, the precise mechanism of atrial fibrillation (AF) as a possible cause of reflux disease remains uncertain, although some possibilities can be postulated.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24709949' target='_blank' class='pmid-link'>24709949</a>:</span> <span class='sentence-part'>The purpose of this review is to describe the burden of atrial fibrillation in patients with chronic kidney disease (CKD) and end-stage renal disease (ESRD), postulate possible mechanisms to explain this burden of disease, understand the clinical consequences of atrial fibrillation and review the treatment options for atrial fibrillation specific to patients with kidney disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25534665' target='_blank' class='pmid-link'>25534665</a>:</span> <span class='sentence-part'>In total, the burden of disease attributable to atrial fibrillation was estimated at 23,084 DALYs: 10,521 resulting from premature deaths (1.7% of the total DALYs due to death in 2010 in Portugal), and 12,563 resulting from disability.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26304517' target='_blank' class='pmid-link'>26304517</a>:</span> <span class='sentence-part'>The appropriate initial treatment of a middle-aged individual with symptomatic paroxysms of atrial fibrillation, diabetes, and hypertension should focus on eliminating the underlying causes of disease to safely reduce morbidity and prolong life.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26460925' target='_blank' class='pmid-link'>26460925</a>:</span> <span class='sentence-part'>Atrial fibrillation (AF) consequences on the heart valve dynamics are usually studied along with a valvular disfunction or disease, since in medical monitoring, the two pathologies are often concomitant.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27446629' target='_blank' class='pmid-link'>27446629</a>:</span> <span class='sentence-part'>Atrial fibrillation (AF) is the most common arrhythmia and is responsible for significant disease burden worldwide.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29714131' target='_blank' class='pmid-link'>29714131</a>:</span> <span class='sentence-part'>CONCLUSION: Although genetic variation of sodium channel modifiers may contribute to development of AF at a molecular level, it is unlikely a monogenic cause of the disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31354391' target='_blank' class='pmid-link'>31354391</a>:</span> <span class='sentence-part'>AF is a heterogenous disease both in terms of the pathophysiologic mechanisms that lead to the disease, and in terms of symptom presentation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34957757' target='_blank' class='pmid-link'>34957757</a>:</span> <span class='sentence-part'>FTR is a multifactorial disorder, resulting from maladaptive right ventricular remodeling secondary to pulmonary hypertension or from atrial fibrillation leading to dilation of the right atrium, tricuspid annulus and base of the right ventricle, with pathological TV coaptation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37162626' target='_blank' class='pmid-link'>37162626</a>:</span> <span class='sentence-part'>The obtained data confirm the presence of myocardial edema of the interatrial septum in CHF patients and persistent form of atrial fibrillation, which expands the understanding of the pathogenesis of this condition.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37371680' target='_blank' class='pmid-link'>37371680</a>:</span> <span class='sentence-part'>The reported AF required patient hospitalization in 35% of cases and resulted in a life-threatening condition in 10% of cases.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/9247903' target='_blank' class='pmid-link'>9247903</a>:</span> <span class='sentence-part'>A hypertensive black male, at risk for episodic attacks of pseudo-malignant hypertension and self-induced atrial fibrillation, seeks to discover possible clues to the pathogeneses of these strange disorders through self-study and concludes they might be associated with impaired oxygen intake, secondary to sleeping position in bed.</span></div></div>
<div class='streamlined-assertion'><div class='streamlined-header sticky-relation-header'><span class='label-text'>Subject:</span> <strong>Atrial_Fibrillation</strong> <span class='label-text'>Subject CUI:</span> <strong>C0004238</strong> â†’ <span class='label-text predicate-text'>CAUSES</span> â†’ <span class='label-text'>Object:</span> <strong>Embolic_stroke</strong> <span class='label-text'>Object CUI:</span> <strong>C0262469</strong></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/10711089' target='_blank' class='pmid-link'>10711089</a>:</span> <span class='sentence-part'>Atrial fibrillation (AF) is a common cardiac arrhythmia in older adults and the most common cause of embolic stroke.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/11461736' target='_blank' class='pmid-link'>11461736</a>:</span> <span class='sentence-part'>BACKGROUND: Electrical cardioversion of atrial fibrillation (AF) to sinus rhythm is associated with transient left atrial dysfunction and this phenomenon may lead to thrombus formation and embolic stroke.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/12712813' target='_blank' class='pmid-link'>12712813</a>:</span> <span class='sentence-part'>The authors present the case of a 64-year-old German man admitted to the emergency care unit with a diagnosis of embolic stroke due to atrial fibrillation with fast ventricular rate.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/16076267' target='_blank' class='pmid-link'>16076267</a>:</span> <span class='sentence-part'>Atrial fibrillation is the most common sustained cardiac arrhythmia and the most frequently encountered cause of embolic stroke.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/1878825' target='_blank' class='pmid-link'>1878825</a>:</span> <span class='sentence-part'>In the elderly population embolic stroke, particularly that due to nonvalvular atrial fibrillation, is seen with increasing frequency.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/18929320' target='_blank' class='pmid-link'>18929320</a>:</span> <span class='sentence-part'>BACKGROUND: Nonrheumatic atrial fibrillation (AF) is a common cause of embolic stroke.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20562072' target='_blank' class='pmid-link'>20562072</a>:</span> <span class='sentence-part'>Embolic stroke due to atrial fibrillation is a common observation, especially in the elderly.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22281071' target='_blank' class='pmid-link'>22281071</a>:</span> <span class='sentence-part'>Recent studies have highlighted its effectiveness in the prevention of venous thrombosis and embolic stroke due to atrial fibrillation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23062528' target='_blank' class='pmid-link'>23062528</a>:</span> <span class='sentence-part'>BACKGROUND: Embolic stroke is the most devastating consequence of atrial fibrillation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24054537' target='_blank' class='pmid-link'>24054537</a>:</span> <span class='sentence-part'>BACKGROUND: Atrial fibrillation is the most common cause of embolic stroke associated to heart disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24363753' target='_blank' class='pmid-link'>24363753</a>:</span> <span class='sentence-part'>Although atrial fibrillation is the most frequent cause of embolic stroke, coronary embolism from atrial fibrillation is a very rare cause of acute myocardial infarction.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24874974' target='_blank' class='pmid-link'>24874974</a>:</span> <span class='sentence-part'>Atrial fibrillation (AF), the most common cardiac arrhythmia, is a significant cause of embolic stroke.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25740380' target='_blank' class='pmid-link'>25740380</a>:</span> <span class='sentence-part'>Early Anti-Coagulation after Ischemic Stroke due to Atrial Fibrillation is Safe and Prevents Recurrent Stroke. RESULTS: Between 2009-2011, 324 patients were identified with cardio-embolic stroke secondary to AF.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27264227' target='_blank' class='pmid-link'>27264227</a>:</span> <span class='sentence-part'>Atrial fibrillation (AF) is common, increasing as the population ages, and a major cause of embolic stroke.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27403222' target='_blank' class='pmid-link'>27403222</a>:</span> <span class='sentence-part'>We compared safety, efficacy, and tolerability of low-molecular-weight heparin (LMWH) and unfractionated heparin (UFH) as a bridging method in patients with recent ischemic stroke due to atrial fibrillation. Unfractionated Heparin as Bridging Therapy in Patients with Embolic Stroke due to Atrial Fibrillation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27513654' target='_blank' class='pmid-link'>27513654</a>:</span> <span class='sentence-part'>BACKGROUND: Although atrial fibrillation (AF) is a leading cause of recurrent embolic stroke, secondary AF after stroke has been reported frequently.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29609876' target='_blank' class='pmid-link'>29609876</a>:</span> <span class='sentence-part'>Covert atrial fibrillation and atrial high-rate episodes as a potential cause of embolic strokes of undetermined source: Their detection and possible management strategy. In this review, we focus on the roles of covert AF and AHRE in the pathogenesis of cryptogenic ischemic stroke or ESUS.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29728202' target='_blank' class='pmid-link'>29728202</a>:</span> <span class='sentence-part'>Atrial fibrillation (AF) accounts for most embolic strokes, especially in elderly individuals.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29921647' target='_blank' class='pmid-link'>29921647</a>:</span> <span class='sentence-part'>Atrial fibrillation is a highly prevalent cardiac arrhythmia and the most important cause of embolic stroke.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30564337' target='_blank' class='pmid-link'>30564337</a>:</span> <span class='sentence-part'>In older patients, atrial fibrillation is a more common cause of embolic stroke.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31015048' target='_blank' class='pmid-link'>31015048</a>:</span> <span class='sentence-part'>BACKGROUND: Atrial fibrillation (AF) is the most common cardiac arrhythmia and the most important cause of embolic stroke, requiring new technologies for its better understanding and therapies.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31155304' target='_blank' class='pmid-link'>31155304</a>:</span> <span class='sentence-part'>Atrial fibrillation was the leading cause of CES.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31353245' target='_blank' class='pmid-link'>31353245</a>:</span> <span class='sentence-part'>Prevalence of Nonstenotic Carotid Plaque in Stroke Due to Atrial Fibrillation Compared to Embolic Stroke of Undetermined Source. Patients with unilateral anterior circulation embolic stroke due to atrial fibrillation (AF) or consistent with ESUS who underwent computed tomographic neck angiography were included.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31369664' target='_blank' class='pmid-link'>31369664</a>:</span> <span class='sentence-part'>BACKGROUND: Atrial fibrillation (AF) is the most common cardiac arrhythmia and is a major cause of embolic stroke.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31511980' target='_blank' class='pmid-link'>31511980</a>:</span> <span class='sentence-part'>The findings were compared to a reference group with related stroke etiology, i.e., 166 patients with embolic stroke due to AF detected for the first time by long-term ECG.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32001107' target='_blank' class='pmid-link'>32001107</a>:</span> <span class='sentence-part'>The Use of Oral Anticoagulants in Patients with Atrial Fibrillation in the Emergency Department.BACKGROUND AND AIM: Atrial Fibrillation is the leading cause of embolic stroke, yet less than half of high-risk patients with atrial fibrillation are on adequate stroke prevention with oral anticoagulants.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33024465' target='_blank' class='pmid-link'>33024465</a>:</span> <span class='sentence-part'>Nine-year trend of oral anticoagulant use in patients with embolic stroke due to nonvalvular atrial fibrillation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/8037127' target='_blank' class='pmid-link'>8037127</a>:</span> <span class='sentence-part'>Atrial fibrillation (AF) is a common arrhythmia in elderly persons and a common cause of embolic stroke.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/8316191' target='_blank' class='pmid-link'>8316191</a>:</span> <span class='sentence-part'>Embolic stroke is a common result of atrial fibrillation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/9518970' target='_blank' class='pmid-link'>9518970</a>:</span> <span class='sentence-part'>Approximately 4.5% of nonembolic and 28.7% of embolic strokes among hospitalized Medicare patients aged 65 years and older were attributable to atrial fibrillation.</span></div></div>
<div class='streamlined-assertion'><div class='streamlined-header sticky-relation-header'><span class='label-text'>Subject:</span> <strong>Atrial_Fibrillation</strong> <span class='label-text'>Subject CUI:</span> <strong>C0004238</strong> â†’ <span class='label-text predicate-text'>CAUSES</span> â†’ <span class='label-text'>Object:</span> <strong>Fibrosis</strong> <span class='label-text'>Object CUI:</span> <strong>C0016059</strong></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32003313' target='_blank' class='pmid-link'>32003313</a>:</span> <span class='sentence-part'>The Role of Atrial Fibrosis Detected by Delayed - Enhancement MRI in Atrial Fibrillation Ablation.INTRODUCTION: Atrial Fibrillation (AF) is associated with remodeling of the atrial tissue, which leads to fibrosis that can contribute to the initiation and maintenance of AF.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32130618' target='_blank' class='pmid-link'>32130618</a>:</span> <span class='sentence-part'>Moreover, MIAT knockdown effectively reduced AF-induced atrial fibrosis by detecting reduced collagen in the right atria and inhibited expression of fibrosis-related gene expression of collagen I, collagen III, connective tissue growth factor (CTGF) and transforming growth factor-beta1 (TGF-beta1) in rats with AF, these findings were in contrast with the findings for rats with inhibition of miR-133a-3p.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32330625' target='_blank' class='pmid-link'>32330625</a>:</span> <span class='sentence-part'>The EAT in patients with atrial fibrillation (AF) induced a more significant atrial fibrosis than in those without.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33516409' target='_blank' class='pmid-link'>33516409</a>:</span> <span class='sentence-part'>Cardiac adipose tissue, such as epicardial fat, is a powerful predictor of AF and leads to myocardial fatty infiltration and adipokine-induced fibrosis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34303273' target='_blank' class='pmid-link'>34303273</a>:</span> <span class='sentence-part'>H     2      S inhibits atrial fibrillation-induced atrial fibrosis through miR-133a/CTGF axis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34670668' target='_blank' class='pmid-link'>34670668</a>:</span> <span class='sentence-part'>Overexpression of c-Ski significantly inhibited alpha-SMA and Col3 levels, as well as levels of inflammatory cytokines IL-18 and TLR4 in serum and atrial tissues, and alleviated AF induced atrial fibrosis by inhibiting TGF-beta1-Smad pathway and p38 MAPK pathway in the canine atrial rapid pacing model.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35651726' target='_blank' class='pmid-link'>35651726</a>:</span> <span class='sentence-part'>The pathogenesis of AF is linked to inflammatory reaction and oxidative stress, which leads to fibrosis of the atria and progression of the disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36552815' target='_blank' class='pmid-link'>36552815</a>:</span> <span class='sentence-part'>Although there is a well-established relationship between thyroid disease (especially hyperthyroidism) and AF, the underlying biochemical mechanisms leading to atrial fibrosis and atrial arrhythmias are poorly understood in thyrotoxicosis. Studies have shown that disorders associated with endocrine dysregulation are potential underlying causes of AF.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37593150' target='_blank' class='pmid-link'>37593150</a>:</span> <span class='sentence-part'>Conclusion: Cfa-circ002203 might serve as an active promoter of the proliferation, migration, and fibrosis of atrial fibroblasts and is involved in AF-induced fibroblast fibrosis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37969261' target='_blank' class='pmid-link'>37969261</a>:</span> <span class='sentence-part'>Background: Atrial fibrosis caused by long-term atrial fibrillation influences the outcomes of clinical treatment.</span></div></div>
<div class='streamlined-assertion'><div class='streamlined-header sticky-relation-header'><span class='label-text'>Subject:</span> <strong>Atrial_Fibrillation</strong> <span class='label-text'>Subject CUI:</span> <strong>C0004238</strong> â†’ <span class='label-text predicate-text'>CAUSES</span> â†’ <span class='label-text'>Object:</span> <strong>Functional_mitral_regurgitation</strong> <span class='label-text'>Object CUI:</span> <strong>C0340369</strong></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20868842' target='_blank' class='pmid-link'>20868842</a>:</span> <span class='sentence-part'>We report a case of significant functional mitral regurgitation and functional tricuspid regurgitation arising from isolated annular dilatation secondary to atrial fibrillation and associated atrial remodeling.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21939832' target='_blank' class='pmid-link'>21939832</a>:</span> <span class='sentence-part'>CONCLUSIONS: AF can result in \atrial functional MR\ that improves if sinus rhythm is restored. Evidence of atrial functional mitral regurgitation due to atrial fibrillation: reversal with arrhythmia control.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27535338' target='_blank' class='pmid-link'>27535338</a>:</span> <span class='sentence-part'>BACKGROUND: Left atrial remodeling caused by persistent atrial fibrillation (AF) causes atrial functional mitral regurgitation (MR), even though left ventricular (LV) remodeling and organic changes of the mitral leaflets are lacking.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28750997' target='_blank' class='pmid-link'>28750997</a>:</span> <span class='sentence-part'>INTRODUCTION AND OBJECTIVES: Atrial fibrillation can lead to left atrium remodelling and induce functional mitral regurgitation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30126422' target='_blank' class='pmid-link'>30126422</a>:</span> <span class='sentence-part'>BACKGROUND: Atrial fibrillation (AF) can result in atrial functional mitral regurgitation (MR), but the mechanism remains controversial.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31233252' target='_blank' class='pmid-link'>31233252</a>:</span> <span class='sentence-part'>BACKGROUND: Surgical ring annuloplasty is generally performed in patients with symptomatic atrial functional mitral regurgitation (MR) caused by long-standing atrial fibrillation (AF).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32951140' target='_blank' class='pmid-link'>32951140</a>:</span> <span class='sentence-part'>Efficacy of left atrial plication for atrial functional mitral regurgitation.OBJECTIVE: Atrial functional mitral regurgitation (AFMR) is caused by atrial fibrillation and left atrial enlargement.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33526277' target='_blank' class='pmid-link'>33526277</a>:</span> <span class='sentence-part'>BACKGROUND: Atrial functional mitral regurgitation (FMR) occurs because of left atrial dilatation or atrial fibrillation in heart failure with preserved left ventricular (LV) function, contrary to ventricular FMR, which occurs because of LV dysfunction.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33906059' target='_blank' class='pmid-link'>33906059</a>:</span> <span class='sentence-part'>BACKGROUND: Atrial fibrillation (AF) induces functional mitral regurgitation (FMR) and tricuspid regurgitation (FTR) during atrial remodeling.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35456162' target='_blank' class='pmid-link'>35456162</a>:</span> <span class='sentence-part'>Functional mitral regurgitation (fMR) can be both a cause and a consequence of AF and may influence rhythm restoration procedures.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37273859' target='_blank' class='pmid-link'>37273859</a>:</span> <span class='sentence-part'>In atrial functional MR, MR occurs in patients with left atrial dilation and altered mitral annular geometry due to atrial fibrillation.</span></div></div>
<div class='streamlined-assertion'><div class='streamlined-header sticky-relation-header'><span class='label-text'>Subject:</span> <strong>Atrial_Fibrillation</strong> <span class='label-text'>Subject CUI:</span> <strong>C0004238</strong> â†’ <span class='label-text predicate-text'>CAUSES</span> â†’ <span class='label-text'>Object:</span> <strong>Heart_failure</strong> <span class='label-text'>Object CUI:</span> <strong>C0018801</strong></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/10885295' target='_blank' class='pmid-link'>10885295</a>:</span> <span class='sentence-part'>The prognosis was generally good, but atrial fibrillation caused heart failure in 4 cases.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/11279775' target='_blank' class='pmid-link'>11279775</a>:</span> <span class='sentence-part'>Excluded were trials in which the prevalence of atrial fibrillation was 2% or greater, or in which any arrhythmia that might compromise cardiac function or any potentially reversible cause of heart failure such as acute ischemic heart disease or myocarditis was present.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/11687032' target='_blank' class='pmid-link'>11687032</a>:</span> <span class='sentence-part'>Excluded were trials in which the prevalence of atrial fibrillation was 2% or greater, or in which any arrhythmia that might compromise cardiac function or any potentially reversible cause of heart failure such as acute ischemic heart disease or myocarditis was present.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/12034150' target='_blank' class='pmid-link'>12034150</a>:</span> <span class='sentence-part'>It is well known that atrial fibrillation can lead to heart failure, and is attributed to rapid ventricular rate (tachycardia-induced cardiomyopathy).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/12215733' target='_blank' class='pmid-link'>12215733</a>:</span> <span class='sentence-part'>The prevalence of atrial fibrillation rises as a function of severity of cardiac failure, but it is also in known that persistent atrial fibrillation with an uncontrolled ventricular response may induce heart failure.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/14618033' target='_blank' class='pmid-link'>14618033</a>:</span> <span class='sentence-part'>For these patients, safer and more effective methods of maintaining sinus rhythm are needed to reduce morbidity related to palpitations and atrial fibrillation-induced heart failure.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/14978909' target='_blank' class='pmid-link'>14978909</a>:</span> <span class='sentence-part'>Occurrence of atrial fibrillation was supposed to be the cause of heart failure rather than L-R shunt of ASD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17174237' target='_blank' class='pmid-link'>17174237</a>:</span> <span class='sentence-part'>BACKGROUND: Heart failure increases the risk of atrial fibrillation (AF), which frequently results in heart failure progression.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17174599' target='_blank' class='pmid-link'>17174599</a>:</span> <span class='sentence-part'>A logistic model indicated that AF was associated with a 2.5 OR of being in NYHA class III-IV vs I-II while accounting for age, gender, left ventricular ejection fraction (LVEF), and aetiology of HF.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/19102036' target='_blank' class='pmid-link'>19102036</a>:</span> <span class='sentence-part'>PURPOSE OF REVIEW: The present review will examine the prognostic importance of atrial fibrillation and heart failure, explore the different therapeutic options for treating atrial fibrillation and present the results of the Atrial Fibrillation and Congestive Heart Failure (AF-CHF) trial.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/19717850' target='_blank' class='pmid-link'>19717850</a>:</span> <span class='sentence-part'>Atrial fibrillation occurrence was defined as the presence of AF in the electrocardiogram (ECG) performed at each visit during the trial or AF as a cause of worsening HF or hospital admission or as an event during hospitalization.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20103171' target='_blank' class='pmid-link'>20103171</a>:</span> <span class='sentence-part'>AF can be the cause of HF, especially by leading to a tachycardia-induced cardiomyopathy, either isolated or associated to an underlying heart disease. HF is a common cause of AF.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21211620' target='_blank' class='pmid-link'>21211620</a>:</span> <span class='sentence-part'>AF may cause stroke and heart failure but the relationship between AF and mortality is less clear.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21684113' target='_blank' class='pmid-link'>21684113</a>:</span> <span class='sentence-part'>BACKGROUND: In addition to sudden death, heart failure and stroke due to atrial fibrillation are important in patients with hypertrophic cardiomyopathy (HCM).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21774762' target='_blank' class='pmid-link'>21774762</a>:</span> <span class='sentence-part'>Ischemic heart disease is the most common cause underlying 1) the development of ventricular fibrillation that results in sudden cardiac death and 2) atrial fibrillation that can lead to heart failure and stroke.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21781599' target='_blank' class='pmid-link'>21781599</a>:</span> <span class='sentence-part'>From 1993 - 1998 to 2003 - 2007, atrial fibrillation was the most common cause of heart failure, and the rate of myocardial infarction, pneumonia and renal failure rose from 11.0%, 8.9% and 5.2% to 14.7%, 14.5% and 9.1%, respectively (all P &lt; 0.05) and the rate of COPD fell from 12.9% to 8.4% (P &lt; 0.05).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21916172' target='_blank' class='pmid-link'>21916172</a>:</span> <span class='sentence-part'>Atrial fibrillation was frequent and troublesome arrhythmia, which caused cerebral embolism and heart failure.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22350697' target='_blank' class='pmid-link'>22350697</a>:</span> <span class='sentence-part'>From May 2010 to November 2011, 112 outpatients who were receiving antithrombotic agents because of their high-risk status for a thromboembolic event (after implantation of coronary stent, after valve replacement, or a previous history of thromboembolic event or heart failure due to atrial fibrillation) were enrolled.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23631167' target='_blank' class='pmid-link'>23631167</a>:</span> <span class='sentence-part'>But regardless of types or symptoms of AF, AF is notorious for potentially causing stroke and heart failure, which increase morbidity and mortality.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23678530' target='_blank' class='pmid-link'>23678530</a>:</span> <span class='sentence-part'>AF can induce HF and persistence over time of high rate AF may result in tachycardiomyopathy, a form of dilated cardiomyopathy characterized by severe left ventricular dysfunction.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23864134' target='_blank' class='pmid-link'>23864134</a>:</span> <span class='sentence-part'>Atrial fibrillation (AF) is the most common arrhythmia and among the leading causes of stroke and heart failure in Western populations.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24439981' target='_blank' class='pmid-link'>24439981</a>:</span> <span class='sentence-part'>Compared with the QRS 120-149 ms group, cardiac mortality was highest in the QRS &gt;=200 ms group (hazard ratio [HR] 1.72 [95% CI 1.35-2.19], P &lt; .001), independent of age, gender, New York Heart Association class, presence of atrial fibrillation, heart failure etiology, and left ventricular ejection fraction.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24565821' target='_blank' class='pmid-link'>24565821</a>:</span> <span class='sentence-part'>Atrial fibrillation is a common, often symptomatic, and concerning arrhythmia that can lead to heart failure, decreased athletic tolerance, and thromboembolic events; it has also been associated with increased mortality.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24771511' target='_blank' class='pmid-link'>24771511</a>:</span> <span class='sentence-part'>Excluded were trials in which the prevalence of atrial fibrillation was 2% or greater, or in which any arrhythmia that might compromise cardiac function or any potentially reversible cause of HF such as acute ischemic heart disease or myocarditis was present.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24931393' target='_blank' class='pmid-link'>24931393</a>:</span> <span class='sentence-part'>CONCLUSIONS: In addition to being a discrete electrophysiologic event, in heart failure patients, new-onset atrial fibrillation is a predictor of and trigger for clinical heart failure progression.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25089233' target='_blank' class='pmid-link'>25089233</a>:</span> <span class='sentence-part'>Despite antithyroid medication, he developed rapid ventricular rate from his atrial fibrillation that resulted in decompensated heart failure and multiple hospitalizations.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25774257' target='_blank' class='pmid-link'>25774257</a>:</span> <span class='sentence-part'>We report the case of a 75-year-old female patient with a history of Hashimoto's thyroiditis who presented with congestive heart failure caused by atrial fibrillation associated with isolated adrenocorticotropic hormone (ACTH) deficiency. Heart Failure Caused by Atrial Fibrillation in a Patient with Isolated Adrenocorticotropic Hormone Deficiency and Hashimoto's Thyroiditis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25792720' target='_blank' class='pmid-link'>25792720</a>:</span> <span class='sentence-part'>The consequences of AF include an increased rate of death, stroke and heart failure.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25972381' target='_blank' class='pmid-link'>25972381</a>:</span> <span class='sentence-part'>She was initially thought to have decompensated heart failure secondary to atrial fibrillation and was initiated on diuretic therapy.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26318825' target='_blank' class='pmid-link'>26318825</a>:</span> <span class='sentence-part'>BACKGROUND: Delay in seeking treatment for symptoms of atrial fibrillation (AF) at onset results in a missed opportunity for vital early treatment of AF which is important for reducing stroke, tachycardia induced heart failure, and treatment-resistant AF.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26658575' target='_blank' class='pmid-link'>26658575</a>:</span> <span class='sentence-part'>Although we now have a clear picture of how HF promotes AF, gaps remain in our knowledge of how AF exacerbates or even causes HF, and how the development of HF affects the outcome of patients with AF.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27775782' target='_blank' class='pmid-link'>27775782</a>:</span> <span class='sentence-part'>When we compared apoplexy and heart failure caused by atrial fibrillation in the two groups, the difference was not statistically significant (Apoplexy: p = 0.186; Heart failure: p = 0.170).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28500480' target='_blank' class='pmid-link'>28500480</a>:</span> <span class='sentence-part'>Although there are established pharmaceutical treatment options, atrial fibrillation is one of the major causes of stroke, heart failure and cardiovascular morbidity and mortality.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29059821' target='_blank' class='pmid-link'>29059821</a>:</span> <span class='sentence-part'>Atrial fibrillation (AF) is one of the major causes of stroke, heart failure, sudden death, and cardiovascular morbidity and the most common type of arrhythmia.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29061566' target='_blank' class='pmid-link'>29061566</a>:</span> <span class='sentence-part'>BACKGROUND: Atrial fibrillation (AF) is a highly prevalent disorder leading to heart failure, stroke, and death.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29518782' target='_blank' class='pmid-link'>29518782</a>:</span> <span class='sentence-part'>BACKGROUND/AIMS: Cardiac interstitial fibrosis is an abnormality of various cardiovascular diseases, including myocardial infarction, hypertrophy, and atrial fibrillation, and it can ultimately lead to heart failure.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29655845' target='_blank' class='pmid-link'>29655845</a>:</span> <span class='sentence-part'>INTRODUCTION: Atrial fibrillation (AF) is nowadays considered to be one of the most important causes of heart failure, stroke, cognitive decline, vascular dementia, sudden death and overall cardiovascular morbidity.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29725548' target='_blank' class='pmid-link'>29725548</a>:</span> <span class='sentence-part'>Toxicity included atrial fibrillation that ultimately led to heart failure as well as sepsis which ultimately led to the patient's demise.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29988259' target='_blank' class='pmid-link'>29988259</a>:</span> <span class='sentence-part'>Atrial Fibrillation as a Cause of Incident Heart Failure: A Discrete Clinical Phenotype.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29997004' target='_blank' class='pmid-link'>29997004</a>:</span> <span class='sentence-part'>In multivariable Cox model (functional class, LV ejection fraction, LV end-diastolic dimension, permanent atrial fibrillation, age, gender, heart failure etiology, creatinine level, diabetes mellitus), LV-paced QRS duration remained a significant determinant of both endpoints.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30236398' target='_blank' class='pmid-link'>30236398</a>:</span> <span class='sentence-part'>RESULTS: During a median follow-up of 942 days (interquartile range: 379 to 1,464 days) a total of 22 patients, including 59% of CRT responders, developed heart failure (HF) due to a transient AF attack itself, and that accounted for 21% of all HF events. CONCLUSIONS: A substantial number of patients developed HF due to transient AF attacks themselves even in the CRT responders, and the reason was mainly due to the loss of the BIVP%.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30404749' target='_blank' class='pmid-link'>30404749</a>:</span> <span class='sentence-part'>Asymptomatic left ventricular systolic or diastolic dysfunction can exacerbate or be exacerbated by AF, resulting in HF with reduced ejection fraction or preserved ejection fraction.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30541355' target='_blank' class='pmid-link'>30541355</a>:</span> <span class='sentence-part'>A multivariable prognostic model included normalized QRSd together with age, atrial fibrillation, renal function, and heart failure cause, whereas sex, diabetes mellitus, strict left bundle branch block morphology, and LV end-diastolic volumes were expelled from the model.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30814385' target='_blank' class='pmid-link'>30814385</a>:</span> <span class='sentence-part'>Sleep disordered breathing (SDB), which causes sleep deprivation, intermittent hypoxia, and negative intrathoracic pressure swings, can be accompanied by other harmful pathophysiologies relating to cardiovascular diseases (CVD), including sudden death, atrial fibrillation, stroke, and coronary artery disease leading to heart failure.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30879840' target='_blank' class='pmid-link'>30879840</a>:</span> <span class='sentence-part'>Atrial fibrillation (AF) is a major cause of stroke, heart failure, sudden death and cardiovascular morbidity.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31049749' target='_blank' class='pmid-link'>31049749</a>:</span> <span class='sentence-part'>We examine this clinical problem by interpreting the relationships between these two entities: the mechanism of tachycardia-induced cardiomyopathy (TIC), past opinions about rhythm control and rate control of AF, discrimination of HF-related AF and AF-induced HF, how to identify the AF patients that could benefit from invasive therapies, and how to select invasive therapies for different AF patients and peri-operative treatments.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31249590' target='_blank' class='pmid-link'>31249590</a>:</span> <span class='sentence-part'>As a potential factor for ischemic stroke, AF could also cause heart failure.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31691981' target='_blank' class='pmid-link'>31691981</a>:</span> <span class='sentence-part'>BACKGROUND: Atrial fibrillation (AF) is the most common clinical arrhythmia and one of the major causes of stroke, heart failure, sudden death, and cardiovascular morbidity.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31719011' target='_blank' class='pmid-link'>31719011</a>:</span> <span class='sentence-part'>Atrial fibrillation is a common type of arrhythmia and is an important cause of stroke and heart failure. vitamin D is an emerging risk factor of AF, and is implicated in the pathophysiology of atrial fibrillation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32071625' target='_blank' class='pmid-link'>32071625</a>:</span> <span class='sentence-part'>Effectiveness of catheter ablation of atrial fibrillation according to heart failure etiology.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32071626' target='_blank' class='pmid-link'>32071626</a>:</span> <span class='sentence-part'>Editorial to \effectiveness of catheter ablation of atrial fibrillation according to heart failure etiology\.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32970956' target='_blank' class='pmid-link'>32970956</a>:</span> <span class='sentence-part'>Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia and a major cause of stroke and heart failure.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32989791' target='_blank' class='pmid-link'>32989791</a>:</span> <span class='sentence-part'>Relationship between device-detected subclinical atrial fibrillation and heart failure in patients with cardiac resynchronization therapy defibrillator.BACKGROUND: Atrial fibrillation (AF) is a leading preventable cause of heart failure (HF) for which early detection and treatment is critical.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33002464' target='_blank' class='pmid-link'>33002464</a>:</span> <span class='sentence-part'>CA did not reduce mortality and HF readmission at one year irrespective of the type of HF, but significantly reduce readmission due to AF.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33346822' target='_blank' class='pmid-link'>33346822</a>:</span> <span class='sentence-part'>BACKGROUND: Atrial fibrillation (AF) is the most common sustained heart arrhythmia and a major preventable cause of stroke, heart failure and dementia.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33516402' target='_blank' class='pmid-link'>33516402</a>:</span> <span class='sentence-part'>Atrial fibrillation (AF) is the most common cardiac arrythmia and a major cause of stroke, heart failure, sudden death, and cardiovascular morbidity. Oral anticoagulation is effective in prevention of strokes secondary to AF, reducing overall stroke numbers by approximately 64%.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33736761' target='_blank' class='pmid-link'>33736761</a>:</span> <span class='sentence-part'>Atrial fibrillation (AF) causes heart failure, ischemic strokes, and poor quality of life.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34051969' target='_blank' class='pmid-link'>34051969</a>:</span> <span class='sentence-part'>Sleep disorder may contribute to left ventricular diastolic dysfunction via left atrial overload, left ventricular remodeling, pulmonary hypertension, and atrial fibrillation, which lead to HF with preserved left ventricular ejection fraction.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34220978' target='_blank' class='pmid-link'>34220978</a>:</span> <span class='sentence-part'>A case of applying left bundle branch pacing combined with atrioventricular node ablation to treat atrial fibrillation-induced heart failure.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34251579' target='_blank' class='pmid-link'>34251579</a>:</span> <span class='sentence-part'>AF can cause heart failure and myocardial infarction and increase the risk of stroke, disability, and thromboembolic events.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34807935' target='_blank' class='pmid-link'>34807935</a>:</span> <span class='sentence-part'>BACKGROUND/AIM: Atrial fibrillation (AF) is a major health problem and causes heart failure and stroke.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34884381' target='_blank' class='pmid-link'>34884381</a>:</span> <span class='sentence-part'>Atrial fibrillation (AF) is a major cause of heart failure and stroke.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35114252' target='_blank' class='pmid-link'>35114252</a>:</span> <span class='sentence-part'>Atrial fibrillation (AF) affects over 1% of the population and is a leading cause of stroke and heart failure in the elderly.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35295255' target='_blank' class='pmid-link'>35295255</a>:</span> <span class='sentence-part'>Early identification of AF patients at risk for AF-induced heart failure (AF-HF) is desirable to reduce both morbidity and mortality as well as health care costs. Machine Learning Using a Single-Lead ECG to Identify Patients With Atrial Fibrillation-Induced Heart Failure. Conclusion: Beat-to-beat-analysis using a machine learning classifier identifies patients with AF-induced heart failure with clinically relevant diagnostic properties.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35566639' target='_blank' class='pmid-link'>35566639</a>:</span> <span class='sentence-part'>It often remains unclear if HF is the cause or consequence of AF due to the complexity of the processes that are involved in both the perpetuation of AF and the development of HF.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36007727' target='_blank' class='pmid-link'>36007727</a>:</span> <span class='sentence-part'>BACKGROUND: Little is known about genome-wide changes in the atrial transcriptome as a cause or consequence of atrial fibrillation (AF), and the effect of its common and clinically relevant comorbidity, heart failure (HF).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36120239' target='_blank' class='pmid-link'>36120239</a>:</span> <span class='sentence-part'>Physical examination and complementary diagnostic tests helped diagnose acutely decompensated heart failure due to atrial fibrillation (AF) with a rapid ventricular response, and IV amiodarone was started.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36246770' target='_blank' class='pmid-link'>36246770</a>:</span> <span class='sentence-part'>The clinical consequences of AF can often include emboli, heart failure, and early mortality.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36456901' target='_blank' class='pmid-link'>36456901</a>:</span> <span class='sentence-part'>BACKGROUND: The exact mechanism of atrial fibrillation (AF)-induced heart failure (HF) remains unclear. CONCLUSIONS: This study provides novel insights to understanding the mechanisms of AF-induced HF progression and identifying novel biomarkers for prognosis of AF with HF by using metabolomics and proteomics analyses. Integration of proteomic and metabolomic characterization in atrial fibrillation-induced heart failure.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36589918' target='_blank' class='pmid-link'>36589918</a>:</span> <span class='sentence-part'>Key inclusion criteria include a previous CRT implant (with atrial lead) for dyssynchronous heart failure, and biventricular pacing &lt;95% secondary to AF.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36712260' target='_blank' class='pmid-link'>36712260</a>:</span> <span class='sentence-part'>Background: Atrial fibrillation (AF) and atrial flutter (AFL) induced tachycardiomyopathy (TCM) has been known to cause reversible heart failure (HF) for many years.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37161971' target='_blank' class='pmid-link'>37161971</a>:</span> <span class='sentence-part'>AIMS: Atrial natriuretic peptide (ANP) deficiency is thought to be one of the causes of heart failure induced by atrial fibrillation (AF).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37522088' target='_blank' class='pmid-link'>37522088</a>:</span> <span class='sentence-part'>AF not only affects patients' quality of life, but also causes thrombosis, heart failure and other complications in severe cases.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/6819639' target='_blank' class='pmid-link'>6819639</a>:</span> <span class='sentence-part'>Among the total of 26 patients requiring further digitalization an absolute indication was found only in 12 (14%), 8 due to progressive cardiac insufficiency and 4 due to atrial fibrillation. Six patients were re-instituted on digoxin therapy, 3 due to progressive cardiac insufficiency, 2 due to atrial fibrillation, and 1 at his own request.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/9616075' target='_blank' class='pmid-link'>9616075</a>:</span> <span class='sentence-part'>A new model of sustained atrial fibrillation in conscious dogs with pacing induced heart failure.</span></div></div>
<div class='streamlined-assertion'><div class='streamlined-header sticky-relation-header'><span class='label-text'>Subject:</span> <strong>Atrial_Fibrillation</strong> <span class='label-text'>Subject CUI:</span> <strong>C0004238</strong> â†’ <span class='label-text predicate-text'>CAUSES</span> â†’ <span class='label-text'>Object:</span> <strong>Hospitalization</strong> <span class='label-text'>Object CUI:</span> <strong>C0019993</strong></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32028229' target='_blank' class='pmid-link'>32028229</a>:</span> <span class='sentence-part'>We fit Cox regressions to investigate the association between OSA severity and a cardiovascular composite outcome (all-cause mortality or hospitalization due to myocardial infarction, stroke, heart failure or atrial fibrillation), controlling for risk factors and stratifying by sex.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32255385' target='_blank' class='pmid-link'>32255385</a>:</span> <span class='sentence-part'>Therefore, interventions aimed at improvement of clinical management and reduction of direct and indirect healthcare costs, related to AF, would be strongly recommended in view of their potential increase.An integrated approach to healthcare delivery is a suitable approach for AF patients: the SAFETY intervention is a nurse-led home management approach aimed at reducing all-cause of unplanned hospitalizations and at prolonging survival in AF patients.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32857834' target='_blank' class='pmid-link'>32857834</a>:</span> <span class='sentence-part'>METHODS AND RESULTS: Using Danish nationwide registers we included patients &gt;= 70 years of age between 2010 and 2017 at their first hospitalization due to AF.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33895768' target='_blank' class='pmid-link'>33895768</a>:</span> <span class='sentence-part'>During these follow-up periods, 2 hospitalizations were required due to pneumonia and atrial fibrillation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34612056' target='_blank' class='pmid-link'>34612056</a>:</span> <span class='sentence-part'>RCTs of cardiovascular outcomes of marine omega-3 fatty acids that reported results for AF, either as pre-specified outcome, adverse event, or a cause for hospitalization, with a minimum sample size of 500 patients and a median followup of at least one year were included.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34627574' target='_blank' class='pmid-link'>34627574</a>:</span> <span class='sentence-part'>OBJECTIVE: In the United States, atrial fibrillation (AF) accounts for over 400,000 hospitalizations annually.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35140628' target='_blank' class='pmid-link'>35140628</a>:</span> <span class='sentence-part'>The treatment of atrial fibrillation and other cardiac arrhythmias as a major cause of cardiovascular hospitalization has remained a challenge predominantly for patients with severely remodeled substrate.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35283016' target='_blank' class='pmid-link'>35283016</a>:</span> <span class='sentence-part'>AIMS: Atrial fibrillation (AF) is a leading cause of hospitalisations, yet little is known about 30-day readmissions following discharge despite increasing policy focus on reducing readmissions.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35752454' target='_blank' class='pmid-link'>35752454</a>:</span> <span class='sentence-part'>A Call to Action to Reduce Preventable Hospitalisations and Health Care Burden Due to Atrial Fibrillation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36237290' target='_blank' class='pmid-link'>36237290</a>:</span> <span class='sentence-part'>He developed atrial fibrillation with a rapid ventricular response and non-ST-segment-elevation myocardial infarction, leading to hospitalization.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36713012' target='_blank' class='pmid-link'>36713012</a>:</span> <span class='sentence-part'>The percentage of days lost due to unplanned cardiovascular hospitalization or death of any cause (primary endpoint of TIM-HF2), the rate of newly detected AF, and the hospitalization rate due to AF were analysed.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36730485' target='_blank' class='pmid-link'>36730485</a>:</span> <span class='sentence-part'>Atrial fibrillation (AF) is a prevalent problem worldwide and a common cause of hospitalization, poor quality of life, and increased mortality.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37330162' target='_blank' class='pmid-link'>37330162</a>:</span> <span class='sentence-part'>The rates/100 patient-years of death, hospitalization due to AF, AF ablation, cardioversion, stroke, systemic embolism, and major bleeding were 5.76 (5.12-6.47), 15.8 (14.6-17.0), 5.0 (4.4-5.7), 1.8 (1.4-2.2), 2.77 (2.32-3.32), 1.01 (0.75-1.36), and 2.21 (1.81-2.70).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37373655' target='_blank' class='pmid-link'>37373655</a>:</span> <span class='sentence-part'>The secondary goals of this study are to prove the superiority of flecainide over amiodarone in the reduction in hospitalizations from the Emergency Department due to atrial fibrillation in the time taken to achieve cardioversion, and in the reduction in the need to conduct electrical cardioversion.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37421392' target='_blank' class='pmid-link'>37421392</a>:</span> <span class='sentence-part'>OBJECTIVE: Atrial fibrillation (AF) is a potentially lethal complication that leads to increased hospitalization, disability, and mortality.</span></div></div>
<div class='streamlined-assertion'><div class='streamlined-header sticky-relation-header'><span class='label-text'>Subject:</span> <strong>Atrial_Fibrillation</strong> <span class='label-text'>Subject CUI:</span> <strong>C0004238</strong> â†’ <span class='label-text predicate-text'>CAUSES</span> â†’ <span class='label-text'>Object:</span> <strong>Ischemic_stroke</strong> <span class='label-text'>Object CUI:</span> <strong>C0948008</strong></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/12624219' target='_blank' class='pmid-link'>12624219</a>:</span> <span class='sentence-part'>METHODS: Forty-two consecutive patients with ischemic stroke caused by nonvalvular atrial fibrillation and admitted within the first day of symptom onset were included. CONCLUSIONS: High plasma homocysteine conveys an independent risk for LA thrombus formation in patients with stroke caused by nonvalvular atrial fibrillation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/12629277' target='_blank' class='pmid-link'>12629277</a>:</span> <span class='sentence-part'>The odds ratio for bedridden state following ischemic stroke due to AF was 2.23 (95% CI = 1.87-2.59, p &lt; 0.0005) by multivariate logistic regression.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/15228390' target='_blank' class='pmid-link'>15228390</a>:</span> <span class='sentence-part'>BACKGROUND: Atrial fibrillation (AF), an important and treatable cause of ischaemic stroke, can occur as a sustained or a paroxysmal arrhythmia.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/16221372' target='_blank' class='pmid-link'>16221372</a>:</span> <span class='sentence-part'>Atrial fibrillation is an important cause of disabling ischemic stroke, and adjusted-dose warfarin is highly effective for prevention and remains the therapy of choice for high-risk patients.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17239801' target='_blank' class='pmid-link'>17239801</a>:</span> <span class='sentence-part'>Hypertension and atrial fibrillation were the most common risk factor and cause, respectively, of ischemic stroke in this population. Hypertension was the most common cardiovascular risk factor in all subtypes and atrial fibrillation was the most common cause of cardioembolic stroke.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17903798' target='_blank' class='pmid-link'>17903798</a>:</span> <span class='sentence-part'>PURPOSE: Although it is well established that atrial fibrillation (AF) causes ischemic stroke, the relationship between AF and cognitive impairment is unclear.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/18560796' target='_blank' class='pmid-link'>18560796</a>:</span> <span class='sentence-part'>OBJECTIVE: This study investigated the attitude to prescribing OAC in patients with AF observed in an Italian Stroke Unit (SU) and the severity of ischemic stroke due to AF in comparison with that of other etiologies. Stroke due to atrial fibrillation and the attitude to prescribing anticoagulant prevention in Italy.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/18807225' target='_blank' class='pmid-link'>18807225</a>:</span> <span class='sentence-part'>Ischemic strokes secondary to AF carry twice the risk of death when compared with strokes from other causes.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/18993153' target='_blank' class='pmid-link'>18993153</a>:</span> <span class='sentence-part'>Atrial fibrillation (AF) is a common cause of ischemic stroke.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/19255811' target='_blank' class='pmid-link'>19255811</a>:</span> <span class='sentence-part'>CONCLUSION: For patients at average risk for ischemic stroke due to AF and at average risk for major hemorrhage, treatment based on genetic testing offers no benefit compared to warfarin initiation without testing.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20170841' target='_blank' class='pmid-link'>20170841</a>:</span> <span class='sentence-part'>For patients with TIA and ischaemic stroke of cardiac origin due to atrial fibrillation, vitamin K antagonists (VKAs) are highly effective in preventing recurrent ischaemic stroke but have important limitations and are thus underused.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20425224' target='_blank' class='pmid-link'>20425224</a>:</span> <span class='sentence-part'>Atrial fibrillation (AF) causes nearly 10% of all ischemic strokes.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21086074' target='_blank' class='pmid-link'>21086074</a>:</span> <span class='sentence-part'>Atrial fibrillation is the most common cause of cardioembolic ischemic stroke and has a rising prevalence worldwide.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21286676' target='_blank' class='pmid-link'>21286676</a>:</span> <span class='sentence-part'>Atrial fibrillation (AF) causes at least 20% of all ischemic strokes.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21546265' target='_blank' class='pmid-link'>21546265</a>:</span> <span class='sentence-part'>Failure to expeditiously diagnose atrial fibrillation (AF) as the cause of ischemic stroke has unclear consequences.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21822468' target='_blank' class='pmid-link'>21822468</a>:</span> <span class='sentence-part'>Since atrial fibrillation can result in ischemic stroke, one might assume that genetic determinants of this cardiac arrhythmia are also implicated in cerebrovascular disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21861923' target='_blank' class='pmid-link'>21861923</a>:</span> <span class='sentence-part'>BACKGROUND: Atrial fibrillation (AF) is a leading cause of fatal ischemic stroke.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21893980' target='_blank' class='pmid-link'>21893980</a>:</span> <span class='sentence-part'>BACKGROUND: Atrial fibrillation (AF) is a common cause of ischemic stroke and transient ischemic attack (TIA).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22103748' target='_blank' class='pmid-link'>22103748</a>:</span> <span class='sentence-part'>BACKGROUND: Atrial fibrillation is one of the most important causes of ischemic stroke.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22341670' target='_blank' class='pmid-link'>22341670</a>:</span> <span class='sentence-part'>BACKGROUND: Atrial fibrillation (AF) is a major cause of ischemic stroke.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22382136' target='_blank' class='pmid-link'>22382136</a>:</span> <span class='sentence-part'>Atrial fibrillation is the most common form of arrhythmia and one of the most frequent causes of ischemic stroke.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22458577' target='_blank' class='pmid-link'>22458577</a>:</span> <span class='sentence-part'>Atrial fibrillation (AF) is a major cause of ischemic stroke, especially in the elderly.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22541031' target='_blank' class='pmid-link'>22541031</a>:</span> <span class='sentence-part'>These results show a potential to increase the proportion of AF patients adequately anticoagulated, which will represent a significant advance in the prevention of stroke attributable to AF. Of every six ischemic strokes, one is due to AF, but the proportion of ischemic strokes attributable to AF increases with age.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22565207' target='_blank' class='pmid-link'>22565207</a>:</span> <span class='sentence-part'>For patients with ischaemic stroke of cardiac origin due to atrial fibrillation, long-term warfarin treatment reduces the risk of recurrent stroke by two-thirds compared with control, and by half compared with antiplatelet therapy.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22788384' target='_blank' class='pmid-link'>22788384</a>:</span> <span class='sentence-part'>BACKGROUND AND PURPOSE: Atrial fibrillation (AF) is amongst the most important etiologies of ischaemic stroke. RESULTS: In total, 187 of 626 patients with FEIS suffered from cardioembolic stroke owing to AF, which was newly diagnosed in 57 (31%) patients. Stroke due to atrial fibrillation in a population-based stroke registry (Ludwigshafen Stroke Study) CHADS(2) , CHA(2) DS(2) -VASc score, underuse of oral anticoagulation, and implications for preventive measures. METHODS: Within the Ludwigshafen Stroke Study (LuSSt), a prospective ongoing population-based stroke register, we analyzed all patients with a first-ever ischaemic stroke (FEIS) owing to AF in 2006 and 2007.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23391669' target='_blank' class='pmid-link'>23391669</a>:</span> <span class='sentence-part'>Atrial fibrillation (AF) is an important cause of ischemic stroke and is the underlying cause of &gt; 20% of all strokes, with increasing age being a risk factor.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23535494' target='_blank' class='pmid-link'>23535494</a>:</span> <span class='sentence-part'>Atrial fibrillation (AF), a well-established cause of ischemic stroke, is found in up to 25% of first strokes.(1,2) Most patients with stroke from AF will benefit from anticoagulation for secondary stroke prevention, so finding AF as a cause of ischemic stroke is critical.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23773494' target='_blank' class='pmid-link'>23773494</a>:</span> <span class='sentence-part'>Non-valvular atrial fibrillation (AF) is the commonest cardiac arrhythmia which causes ischemic stroke.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23790598' target='_blank' class='pmid-link'>23790598</a>:</span> <span class='sentence-part'>Atrial fibrillation (AF) is an important cause of ischemic stroke, especially in older individuals.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23929293' target='_blank' class='pmid-link'>23929293</a>:</span> <span class='sentence-part'>A large proportion of ischemic strokes caused by atrial fibrillation could be prevented if patients receive optimal prophylactic treatment.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23984177' target='_blank' class='pmid-link'>23984177</a>:</span> <span class='sentence-part'>Adverse outcome of early recurrent ischemic stroke secondary to atrial fibrillation after repeated systemic thrombolysis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24357657' target='_blank' class='pmid-link'>24357657</a>:</span> <span class='sentence-part'>Awareness of the role of atrial fibrillation as a cause of ischemic stroke.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24380488' target='_blank' class='pmid-link'>24380488</a>:</span> <span class='sentence-part'>AF is the leading preventable cause of ischaemic stroke, and strokes due to AF have a higher mortality and morbidity.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24484463' target='_blank' class='pmid-link'>24484463</a>:</span> <span class='sentence-part'>Adequate antiplatelet therapy is recommended for secondary prevention after cerebral ischaemia of presumed arterial origin, whether for patients with TIA and ischaemic stroke of cardiac origin, mainly due to atrial fibrillation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24532115' target='_blank' class='pmid-link'>24532115</a>:</span> <span class='sentence-part'>PURPOSE: Atrial fibrillation (AF) is a major cause of ischemic strokes, and it is assumed that occult intermittent episodes of AF are responsible for some of the seemingly cryptogenic strokes.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24968547' target='_blank' class='pmid-link'>24968547</a>:</span> <span class='sentence-part'>Till date, 150mg dabigatran is the only NOAC offering a superior reduction in most commonly seen ischemic strokes due to AF compared to warfarin.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25161388' target='_blank' class='pmid-link'>25161388</a>:</span> <span class='sentence-part'>BACKGROUND: Atrial fibrillation (AF) is a common cardiac arrhythmia, and leading cause of ischemic stroke.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25294430' target='_blank' class='pmid-link'>25294430</a>:</span> <span class='sentence-part'>BACKGROUND: Cardioembolic stroke (CES) due to atrial fibrillation (AF) is associated with high stroke mortality. METHODS: Within the Ludwigshafen Stroke Study (LuSSt), a prospective population-based stroke register, we analysed all patients with a first ever ischemic stroke or TIA due to AF from 2006 until 2010. RESULTS: In total 479 patients had a first-ever ischemic stroke (n = 394) or TIA (n = 85) due to AF. We analysed whether treatment or non-treatment with OAC and initiation of OAC-therapy during and after hospitalization influenced stroke mortality within 500 days after stroke/TIA due to AF.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25377999' target='_blank' class='pmid-link'>25377999</a>:</span> <span class='sentence-part'>BACKGROUND: Atrial fibrillation (AF) is a cause of ischemic stroke and is associated with recurrence and with acute multi-vessel territory non lacunar stroke.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25440347' target='_blank' class='pmid-link'>25440347</a>:</span> <span class='sentence-part'>BACKGROUND: Patients with ischemic stroke caused by atrial fibrillation (AF) have a high risk of recurrence without adequate secondary prevention with oral anticoagulation (OAC).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25537233' target='_blank' class='pmid-link'>25537233</a>:</span> <span class='sentence-part'>AIMS: Atrial fibrillation (AF) is the most common cause of ischemic stroke.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25604070' target='_blank' class='pmid-link'>25604070</a>:</span> <span class='sentence-part'>Atrial fibrillation (AF) is currently one of the major causes of ischemic stroke with an estimated stroke risk of 5% per year.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25740380' target='_blank' class='pmid-link'>25740380</a>:</span> <span class='sentence-part'>Early Anti-Coagulation after Ischemic Stroke due to Atrial Fibrillation is Safe and Prevents Recurrent Stroke. RESULTS: Between 2009-2011, 324 patients were identified with cardio-embolic stroke secondary to AF.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25782122' target='_blank' class='pmid-link'>25782122</a>:</span> <span class='sentence-part'>OBJECTIVES: Atrial fibrillation (AF) is one of the most common causes of preventable ischemic stroke and is related to increased cardiovascular morbidity and mortality.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25847305' target='_blank' class='pmid-link'>25847305</a>:</span> <span class='sentence-part'>BACKGROUND: Atrial fibrillation (AF) is a cardiac arrhythmia that frequently induces ischemic strokes.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25912470' target='_blank' class='pmid-link'>25912470</a>:</span> <span class='sentence-part'>Atrial fibrillation is an important cause of ischemic stroke and its prevention is efficient with oral anticoagulation. CONCLUSION: The technique of left atrial appendage occlusion is a very interesting and promising technique for ischemic stroke prevention in patient with high risk of cardio-embolic complication because of atrial fibrillation, but high risk of bleeding and contraindication for oral anticoagulation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25916280' target='_blank' class='pmid-link'>25916280</a>:</span> <span class='sentence-part'>BACKGROUND: Atrial fibrillation is known very frequent cause of ischemic stroke.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26235450' target='_blank' class='pmid-link'>26235450</a>:</span> <span class='sentence-part'>BACKGROUND AND RATIONALE: The increasing use of oral anticoagulants, mostly to prevent ischemic stroke due to atrial fibrillation in an ageing population, has been associated with a fivefold increased incidence of oral anticoagulant-associated intracerebral hemorrhage: a rare, serious, and unpredictable complication. EXPECTED OUTCOMES: We will identify the factors associated with increased intracranial hemorrhage risk after oral anticoagulants for secondary prevention after ischemic stroke due to atrial fibrillation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26641808' target='_blank' class='pmid-link'>26641808</a>:</span> <span class='sentence-part'>RECENT FINDINGS: Three typical case vignettes are presented and the associated dilemmas are discussed: a patient with an anticoagulant-related intracranial hemorrhage: would you restart anticoagulation?, an anticoagulated patient with a previous stroke because of atrial fibrillation is scheduled for an elective polyp removal: how would you handle anticoagulation perioperatively?, and a patient presents with an ischemic stroke because of atrial fibrillation: how soon would you start anticoagulation for secondary stroke prevention?</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26981569' target='_blank' class='pmid-link'>26981569</a>:</span> <span class='sentence-part'>Ischaemic strokes resulting from atrial fibrillation (AF) constitute a devastating condition for patients and their carers with huge burden on health care systems.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27063831' target='_blank' class='pmid-link'>27063831</a>:</span> <span class='sentence-part'>Strokes caused by atrial fibrillation (AF) are thromboembolic, and AF is the leading cause of ischemic stroke.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27105568' target='_blank' class='pmid-link'>27105568</a>:</span> <span class='sentence-part'>Although atrial fibrillation (AF) is one of the most frequent causes of ischemic stroke, coronary artery embolism (CE) from AF is rare, and 2.9% of all myocardial infarctions are caused by CE.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27234866' target='_blank' class='pmid-link'>27234866</a>:</span> <span class='sentence-part'>Atrial fibrillation (AF) is the most common cause of ischemic strokes.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27403222' target='_blank' class='pmid-link'>27403222</a>:</span> <span class='sentence-part'>We compared safety, efficacy, and tolerability of low-molecular-weight heparin (LMWH) and unfractionated heparin (UFH) as a bridging method in patients with recent ischemic stroke due to atrial fibrillation. Unfractionated Heparin as Bridging Therapy in Patients with Embolic Stroke due to Atrial Fibrillation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27507860' target='_blank' class='pmid-link'>27507860</a>:</span> <span class='sentence-part'>BACKGROUND AND PURPOSE: Atrial fibrillation (AF) is increasingly recognized as the single most important cause of disabling ischemic stroke in the elderly.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27936187' target='_blank' class='pmid-link'>27936187</a>:</span> <span class='sentence-part'>New atrial fibrillation seems to be predominantly the cause of the ischemic stroke and not triggered by the acute cerebrovascular event.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28093965' target='_blank' class='pmid-link'>28093965</a>:</span> <span class='sentence-part'>A 22% prevalence of subdiaphragmatic visceral infarction (SDVI) among patients with ischemic stroke (IS) due to AF has been reported, using abdominal MRI. Methods In consecutive patients admitted to our hospital, we compared SDVI prevalence in three groups: patients with IS due to AF (IS+/AF+ group), patients with stroke of another determined cause (IS+/AF- group) and patients with AF without stroke (IS-/AF+ group).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28118928' target='_blank' class='pmid-link'>28118928</a>:</span> <span class='sentence-part'>Atrial fibrillation (AF) is the most common cardiac cause of ischemic stroke and transient ischemic attack (IS/TIA).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28158768' target='_blank' class='pmid-link'>28158768</a>:</span> <span class='sentence-part'>1.14-2.3) in middle-aged and elderly septicemia survivors with new-onset AF induced IS.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28208140' target='_blank' class='pmid-link'>28208140</a>:</span> <span class='sentence-part'>BACKGROUND: Atrial fibrillation (AF) is a major cause of ischemic stroke.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28513116' target='_blank' class='pmid-link'>28513116</a>:</span> <span class='sentence-part'>BACKGROUND: Atrial fibrillation (AF) is the most common arrhythmia and a common cause of ischemic stroke.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28596457' target='_blank' class='pmid-link'>28596457</a>:</span> <span class='sentence-part'>It is not known whether statins have similar effects in ischemic stroke caused by atrial fibrillation (AFib).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28904820' target='_blank' class='pmid-link'>28904820</a>:</span> <span class='sentence-part'>Ten days later, she presented with an ischemic stroke of the left middle cerebral artery territory due to new-onset atrial fibrillation (NOAF).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29201334' target='_blank' class='pmid-link'>29201334</a>:</span> <span class='sentence-part'>Atrial fibrillation (AF) is a major cause of ischaemic stroke.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29202727' target='_blank' class='pmid-link'>29202727</a>:</span> <span class='sentence-part'>BACKGROUND: Atrial fibrillation (AF) is reported to be a less frequent cause of ischemic stroke in China than in Europe and North America, but it is not clear whether this is due to underestimation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29378729' target='_blank' class='pmid-link'>29378729</a>:</span> <span class='sentence-part'>Cox regression models, with AF as a time-dependent variable, were used to calculate cause-specific hazard ratios (HRs) with 95% confidence intervals (CIs) for PE and IS.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29445431' target='_blank' class='pmid-link'>29445431</a>:</span> <span class='sentence-part'>Conclusions: IS secondary to NVAF has a high rate of stroke recurrence and mortality in our population, with the absence of OAC and major stroke as the main risk factors.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29553306' target='_blank' class='pmid-link'>29553306</a>:</span> <span class='sentence-part'>Generalized linear model with log link and least-square means were utilized to estimate the incremental inpatient cost and length of stay in ischemic stroke due to atrial fibrillation after controlling for sociodemographic, clinical, and hospital characteristics.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29609876' target='_blank' class='pmid-link'>29609876</a>:</span> <span class='sentence-part'>Covert atrial fibrillation and atrial high-rate episodes as a potential cause of embolic strokes of undetermined source: Their detection and possible management strategy. In this review, we focus on the roles of covert AF and AHRE in the pathogenesis of cryptogenic ischemic stroke or ESUS.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29615448' target='_blank' class='pmid-link'>29615448</a>:</span> <span class='sentence-part'>INTRODUCTION: Atrial fibrillation (AF) causes ischaemic stroke and based on risk factor evaluation warrants anticoagulation therapy.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29808758' target='_blank' class='pmid-link'>29808758</a>:</span> <span class='sentence-part'>Background Atrial fibrillation is the most common serious abnormal heart rhythm, and a frequent cause of ischaemic stroke.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29853275' target='_blank' class='pmid-link'>29853275</a>:</span> <span class='sentence-part'>Nowadays the non-vitamin K antagonist oral anticoagulants (NOACs) may represent a valid alternative to vitamin K antagonists (VKA) in the prevention of ischemic stroke due to AF with a better safety profile.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30292336' target='_blank' class='pmid-link'>30292336</a>:</span> <span class='sentence-part'>A better awareness of current usage of anticoagulant therapy would enable prevention of stroke secondary to AF. This highlights the need for improvement of prevention of ischemic stroke secondary to AF.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30483820' target='_blank' class='pmid-link'>30483820</a>:</span> <span class='sentence-part'>About every fifth ischemic stroke is caused by atrial fibrillation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30737948' target='_blank' class='pmid-link'>30737948</a>:</span> <span class='sentence-part'>Detection of atrial fibrillation is of great importance because ischaemic stroke due to atrial fibrillation is characterized by a tendency to recurrence, worse prognosis, longer hospitalization and higher mortality. Atrial fibrillation is one of the most common causes of ischaemic stroke, especially among the elderly.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30760287' target='_blank' class='pmid-link'>30760287</a>:</span> <span class='sentence-part'>Meanwhile, AF is considered to be a major cause of ischemic strokes due to irregular heart-rhythm, coexisting chronic vascular inflammation, and renal insufficiency, and blood stasis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30826740' target='_blank' class='pmid-link'>30826740</a>:</span> <span class='sentence-part'>Neurologists and stroke physicians will be familiar with atrial fibrillation as a major cause of ischaemic stroke, and the role of anticoagulation in preventing cardioembolic stroke.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30857284' target='_blank' class='pmid-link'>30857284</a>:</span> <span class='sentence-part'>Atrial fibrillation (AF) is a common cardiac arrhythmia and is one of the major causes of ischemic stroke.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30935808' target='_blank' class='pmid-link'>30935808</a>:</span> <span class='sentence-part'>INTRODUCTION: Atrial fibrillation (AF) is a major cause of ischemic stroke and Transient Ischemic Attack (TIA) and investigation for paroxysmal AF is recommended following an embolic brain event.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31000364' target='_blank' class='pmid-link'>31000364</a>:</span> <span class='sentence-part'>The consequences of AF included in the model were ischaemic stroke, intracranial haemorrhage, extracranial haemorrhage, and myocardial infarction.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31019998' target='_blank' class='pmid-link'>31019998</a>:</span> <span class='sentence-part'>Methods: Pre-endovascular treatment gradient echo (GRE) images from consecutive patients with middle cerebral artery occlusion were utilized to develop and validate an ML system to predict whether atrial fibrillation (AF) was the underlying cause of ischemic stroke.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31076823' target='_blank' class='pmid-link'>31076823</a>:</span> <span class='sentence-part'>Atrial fibrillation is the most frequent cardiac arrhythmia worldwide, causing approximately 20% of all ischemic strokes.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31084325' target='_blank' class='pmid-link'>31084325</a>:</span> <span class='sentence-part'>Background and Purpose- Ischemic stroke (IS) secondary to atrial fibrillation (AF) is largely preventable with the use of anticoagulation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31143079' target='_blank' class='pmid-link'>31143079</a>:</span> <span class='sentence-part'>Atrial fibrillation (AF) is a leading preventable cause of ischemic stroke for which early detection and treatment are critical.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31517456' target='_blank' class='pmid-link'>31517456</a>:</span> <span class='sentence-part'>Background and purpose: The aim of this study is to evaluate utility of CHADS2 score to estimate stroke severity and prognosis in patients with ischemic stroke due to non-valvular atrial fibrillation (AF) in addition to evaluate effects of hematologic and echocardiographic findings on stroke severity and prognosis. Effects of CHADS2 score, echocardiographic and haematologic parameters on stroke severity and prognosis in patients with stroke due to nonvalvular atrial fibrillation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31572466' target='_blank' class='pmid-link'>31572466</a>:</span> <span class='sentence-part'>Introduction: Atrial fibrillation (AF) is the most common cause of ischemic stroke (IS).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31580732' target='_blank' class='pmid-link'>31580732</a>:</span> <span class='sentence-part'>We analyzed the rates of stroke and systemic embolic events as defined as ischemic stroke, pulmonary embolism (PE), deep vein thrombosis (DVT), and myocardial infarction (MI) as well as major bleeding in morbidly obese patients receiving apixaban, dabigatran, or rivaroxaban in comparison to warfarin for anticoagulation due to nonvalvular atrial fibrillation, postoperative thrombus prophylaxis, or DVT/PE treatment and/or reduction in risk for recurrence.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31681159' target='_blank' class='pmid-link'>31681159</a>:</span> <span class='sentence-part'>Background and aims: Atrial fibrillation (AF) is a major cause of ischemic stroke; however, detailed clinical data and prognostic factors for stroke patients with AF are lacking in Korea.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32000854' target='_blank' class='pmid-link'>32000854</a>:</span> <span class='sentence-part'>Determination of the increased risk of developing atrial fibrillation in fibromyalgia syndrome.INTRODUCTION: Atrial fibrillation (AF) is the leading cause of ischemic stroke and is one of the most common arrhythmias.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32028277' target='_blank' class='pmid-link'>32028277</a>:</span> <span class='sentence-part'>METHODS: Plasma samples were collected from patients aged 18 years and older with ischemic stroke or TIA due to AF (n = 9) and large artery atherosclerosis (LAA) with ipsilateral carotid stenosis (n = 8) and age- and sex-matched controls (n = 10).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32415343' target='_blank' class='pmid-link'>32415343</a>:</span> <span class='sentence-part'>Atrial fibrillation (AF) is one of the most frequent causes of ischemic stroke.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32423155' target='_blank' class='pmid-link'>32423155</a>:</span> <span class='sentence-part'>ED visits due to ischemic stroke, intracranial hemorrhage, and myocardial infarction decreased, whereas ED visits due to AF, gastrointestinal bleeding, and other major bleeding slightly increased among total AF population over 12 years.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32434472' target='_blank' class='pmid-link'>32434472</a>:</span> <span class='sentence-part'>Concurrently, ischaemic stroke caused by nonvalvular atrial fibrillation (AF) has attracted increasing attention.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32451109' target='_blank' class='pmid-link'>32451109</a>:</span> <span class='sentence-part'>Atrial fibrillation is a leading cause of ischemic stroke.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32664115' target='_blank' class='pmid-link'>32664115</a>:</span> <span class='sentence-part'>The patients with ischemic stroke caused by AF and LAA were recruited to this study.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32724734' target='_blank' class='pmid-link'>32724734</a>:</span> <span class='sentence-part'>Background Atrial fibrillation causes ischemic stroke when thrombi dislodge from a cardiac outpouching, the left atrial appendage (LAA), and embolize to the brain.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32811392' target='_blank' class='pmid-link'>32811392</a>:</span> <span class='sentence-part'>Initial Stroke Severity in Patients With Atrial Fibrillation According to Antithrombotic Therapy Before Ischemic Stroke.BACKGROUND AND PURPOSE: Atrial fibrillation (AF) is the leading cause of ischemic stroke.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33200948' target='_blank' class='pmid-link'>33200948</a>:</span> <span class='sentence-part'>CONCLUSION: We showed that atrial fibrillation was a common cause of ischemic stroke in young adults with migraine with aura.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33304313' target='_blank' class='pmid-link'>33304313</a>:</span> <span class='sentence-part'>Since about 90% of patients with ischemic stroke due to atrial fibrillation have thrombus in left atrial appendage (LAA) we sought to explore the possibility that resistant stroke could have a LAA morphology resistant to anticoagulants.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33736761' target='_blank' class='pmid-link'>33736761</a>:</span> <span class='sentence-part'>Atrial fibrillation (AF) causes heart failure, ischemic strokes, and poor quality of life.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33782701' target='_blank' class='pmid-link'>33782701</a>:</span> <span class='sentence-part'>AIMS: Atrial fibrillation (AF) is a preventable cause of ischaemic stroke but it is often undiagnosed and undertreated.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34240675' target='_blank' class='pmid-link'>34240675</a>:</span> <span class='sentence-part'>BACKGROUND: Ischaemic stroke or cerebrovascular accident (CVA) due to occult atrial fibrillation (AF) may cause severe morbidity and mortality.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34469764' target='_blank' class='pmid-link'>34469764</a>:</span> <span class='sentence-part'>BACKGROUND: Atrial fibrillation is a leading cause of ischaemic stroke.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34589224' target='_blank' class='pmid-link'>34589224</a>:</span> <span class='sentence-part'>Atrial fibrillation is a frequently detected cardiac arrhythmia in the etiology of ischemic stroke. The incidence of atrial fibrillation and the risk of it causing ischemic stroke increase significantly with age; it is rare in young people. It is clear that atrial fibrillation, which is highly unlikely to cause ischemic stroke in young adults, may develop due to hyperthyroidism.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34985732' target='_blank' class='pmid-link'>34985732</a>:</span> <span class='sentence-part'>Atrial fibrillation (AF) is a major cause of ischemic stroke and the number of AF patients is increasing.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35962815' target='_blank' class='pmid-link'>35962815</a>:</span> <span class='sentence-part'>OBJECTIVES: Atrial fibrillation (AF), a significant cause of ischemic stroke, often goes undetected because of its asymptomatic nature. KEY POINTS: * Atrial fibrillation is not only a significant cause of ischemic stroke but is also often masked because of its atypical and asymptomatic features.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36003904' target='_blank' class='pmid-link'>36003904</a>:</span> <span class='sentence-part'>Groups were divided as follows: healthy individuals (Control), suspected AF (Sus-AF), first diagnosed AF (Fir-AF), paroxysmal AF (Par-AF), persistent AF (Per-AF), and AF causing a cardiogenic ischemic stroke (Car-AF).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36380809' target='_blank' class='pmid-link'>36380809</a>:</span> <span class='sentence-part'>The most fearful complication of AF is represented by cardio-embolic stroke and 30% of ischaemic strokes are attributable to AF.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36506510' target='_blank' class='pmid-link'>36506510</a>:</span> <span class='sentence-part'>Background:     Atrial fibrillation (AF) is the leading cause of ischemic stroke and treatment has focused on reducing this risk through anticoagulation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37055252' target='_blank' class='pmid-link'>37055252</a>:</span> <span class='sentence-part'>INTRODUCTION: Cryptogenic stroke constitutes 25% of all ischemic strokes, of which 20-30% are due to atrial fibrillation (AF).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37060045' target='_blank' class='pmid-link'>37060045</a>:</span> <span class='sentence-part'>In the Nordic Atrial Fibrillation and Stroke (NOR-FIB) study, the causes of ischemic stroke were identified in 43% of cryptogenic stroke patients monitored with implantable cardiac monitor (ICM), but one-third of these patients had non-cardioembolic causes.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37128146' target='_blank' class='pmid-link'>37128146</a>:</span> <span class='sentence-part'>Relatively few studies have focused on the risk factors and clinical features of ischemic stroke caused by NVAF combined with ICAS.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37160136' target='_blank' class='pmid-link'>37160136</a>:</span> <span class='sentence-part'>BACKGROUND:  Atrial fibrillation (AF) is an important cause of cardioembolic stroke, and population aging has increased its prevalence. CONCLUSION:  During the analyzed period, ischemic stroke caused by AF was a significant burden on the population of Joinville, and a considerable number of patients had undiagnosed or untreated AF. OBJECTIVE:  To evaluate the incidence of cardioembolic stroke caused by AF in the city of Joinville, Brazil, as well as previous diagnoses and use of medication.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37263975' target='_blank' class='pmid-link'>37263975</a>:</span> <span class='sentence-part'>Bioinformatics-based analysis of mechanistic differences in vascular endothelial injury ischemic stroke induced by atrial fibrillation and atherosclerosis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37526798' target='_blank' class='pmid-link'>37526798</a>:</span> <span class='sentence-part'>METHODS: We are presenting a case of ischemic stroke involving the right striatum due to atrial fibrillation and associated in a few days with the neuroimaging finding of hyperintensity of the ipsilateral substantia nigra and striatonigral tract on T2-fluid attenuated inversion recovery and diffusion-weighted imaging sequences of brain magnetic resonance imaging.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37600060' target='_blank' class='pmid-link'>37600060</a>:</span> <span class='sentence-part'>This study was conducted to predict the risk of IS occurring secondary to AF based on multi-spectrum fundus images using deep learning. Predicting the risk of IS occurring secondary to AF, based on subtle differences in fundus images of different wavelengths, is yet to be explored. Conclusions: The probability of IS secondary to AF could be predicted based on multi-spectrum fundus images using deep learning, and combinations of multi-spectrum images improved the performance of DNNs.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37655405' target='_blank' class='pmid-link'>37655405</a>:</span> <span class='sentence-part'>Atrial fibrillation (AF) is a serious medical and social problem, being a common cause of ischemic stroke (IS) and cognitive impairment (CI), often reaching the degree of dementia.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37771031' target='_blank' class='pmid-link'>37771031</a>:</span> <span class='sentence-part'>The proportion all total IS due to AF decreased by 15.3% (31.3%-26.5%, chi-square = 24.6, p &lt; 0.0001).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37809237' target='_blank' class='pmid-link'>37809237</a>:</span> <span class='sentence-part'>Cardiovascular disease, including atrial fibrillation and atrial flutter, is a frequent cause of ischemic strokes.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37899899' target='_blank' class='pmid-link'>37899899</a>:</span> <span class='sentence-part'>Materials and methods In this study, we included patients over 65 years of age who had suffered an ischemic stroke caused by atrial fibrillation within 30 days after the onset of symptoms.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37964899' target='_blank' class='pmid-link'>37964899</a>:</span> <span class='sentence-part'>As GPVI-dimer is elevated in AF patients' platelets, the exploration of targeted GPVI-dimer inhibition for stroke prevention in patients at high risk of IS due to AF is supported.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/38134250' target='_blank' class='pmid-link'>38134250</a>:</span> <span class='sentence-part'>Atrial fibrillation is a major cause of ischemic stroke.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/38188314' target='_blank' class='pmid-link'>38188314</a>:</span> <span class='sentence-part'>Cardioembolism associated with atrial fibrillation is a major cause of ischemic stroke.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/38640772' target='_blank' class='pmid-link'>38640772</a>:</span> <span class='sentence-part'>BACKGROUND: Atrial Fibrillation (AF) is a common cause of ischemic stroke (IS), and is associated with cognitive impairment in the general population.</span></div></div>
<div class='streamlined-assertion'><div class='streamlined-header sticky-relation-header'><span class='label-text'>Subject:</span> <strong>Atrial_Fibrillation</strong> <span class='label-text'>Subject CUI:</span> <strong>C0004238</strong> â†’ <span class='label-text predicate-text'>CAUSES</span> â†’ <span class='label-text'>Object:</span> <strong>Thromboembolism</strong> <span class='label-text'>Object CUI:</span> <strong>C0040038</strong></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31169698' target='_blank' class='pmid-link'>31169698</a>:</span> <span class='sentence-part'>RATIONALE: Atrial fibrillation (AF) is a common arrhythmia disease that can cause thromboembolic disease and/or heart failure, resulting in increased mortality.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33766975' target='_blank' class='pmid-link'>33766975</a>:</span> <span class='sentence-part'>Patients with platelet disorders are at a higher risk for bleeding; however, that does not prevent such patients from thromboembolic events secondary to AF.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34276010' target='_blank' class='pmid-link'>34276010</a>:</span> <span class='sentence-part'>Patients would undergo physical examinations, echocardiography, and 24-hour dynamic electrocardiogram in a local or in our hospital to determine whether there was a recurrence of atrial fibrillation (AF) or thromboembolism caused by AF.In total, 124 patients were included in this study (male: 88 (71.0%); mean age: 62.3 years).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35450462' target='_blank' class='pmid-link'>35450462</a>:</span> <span class='sentence-part'>AF precipitates thromboembolic (TE) events.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35699230' target='_blank' class='pmid-link'>35699230</a>:</span> <span class='sentence-part'>Etiology was later revealed to be thromboembolism secondary to atrial fibrillation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36636509' target='_blank' class='pmid-link'>36636509</a>:</span> <span class='sentence-part'>Left atrial appendage (LAA) closure may prevent atrial fibrillation (AF)-induced thromboembolism.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36874296' target='_blank' class='pmid-link'>36874296</a>:</span> <span class='sentence-part'>Postoperative atrial fibrillation (POAF) can lead to thromboembolic events and prolong hospital stays.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37337492' target='_blank' class='pmid-link'>37337492</a>:</span> <span class='sentence-part'>Postoperative atrial fibrillation (POAF) can lead to thromboembolic events, hemodynamic instability, and prolonged hospital stay, affecting morbidity and influencing short and long-term outcomes after CABG.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37385172' target='_blank' class='pmid-link'>37385172</a>:</span> <span class='sentence-part'>Recent evidence suggests that an intrinsically prothrombotic atrial substrate may precede and promote AF and lead to thromboembolic events independent of the arrhythmia, allowing for a window of intervention before arrhythmia detection and development of ischemic stroke.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37938523' target='_blank' class='pmid-link'>37938523</a>:</span> <span class='sentence-part'>Atrial fibrillation (AF) is the most common cardiac arrhythmia and the cause of thromboembolic events in elderly patients worldwide.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/38350188' target='_blank' class='pmid-link'>38350188</a>:</span> <span class='sentence-part'>BACKGROUND AND OBJECTIVE: Atrial Fibrillation (AF) is a supraventricular tachyarrhythmia that can lead to thromboembolism, hearlt failure, ischemic stroke, and a decreased quality of life.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/38672245' target='_blank' class='pmid-link'>38672245</a>:</span> <span class='sentence-part'>Strokes and thromboembolisms are also common consequences of AF.</span></div></div>
<div class='streamlined-assertion'><div class='streamlined-header sticky-relation-header'><span class='label-text'>Subject:</span> <strong>Atrial_Fibrillation</strong> <span class='label-text'>Subject CUI:</span> <strong>C0004238</strong> â†’ <span class='label-text predicate-text'>CAUSES</span> â†’ <span class='label-text'>Object:</span> <strong>Thrombus</strong> <span class='label-text'>Object CUI:</span> <strong>C0087086</strong></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/11461736' target='_blank' class='pmid-link'>11461736</a>:</span> <span class='sentence-part'>BACKGROUND: Electrical cardioversion of atrial fibrillation (AF) to sinus rhythm is associated with transient left atrial dysfunction and this phenomenon may lead to thrombus formation and embolic stroke.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/15451156' target='_blank' class='pmid-link'>15451156</a>:</span> <span class='sentence-part'>Inflammation, arrhythmia burden and the thrombotic consequences of atrial fibrillation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/15931346' target='_blank' class='pmid-link'>15931346</a>:</span> <span class='sentence-part'>Masses that are most commonly seen in the atrial chambers include thrombi due to atrial fibrillation, cardiac myxomas often located in the atria, and valvular vegetations of infective endocarditis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/18951871' target='_blank' class='pmid-link'>18951871</a>:</span> <span class='sentence-part'>Atrial fibrillation (AF) may cause thrombus formation in the left atrial appendage (LAA).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20549522' target='_blank' class='pmid-link'>20549522</a>:</span> <span class='sentence-part'>The main causes of perioperative ischemic stroke include cerebral atherothrombosis; lacuna stroke; cardiac thrombi due to atrial fibrillation; dehydration; hypotension; and perioperative systemic hypercoagulability.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22447005' target='_blank' class='pmid-link'>22447005</a>:</span> <span class='sentence-part'>BACKGROUND: The anti-thrombotic strategy during coronary stenting is challenging in patients on long-term oral anticoagulation (OAC) because of atrial fibrillation (AF).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/2373815' target='_blank' class='pmid-link'>2373815</a>:</span> <span class='sentence-part'>To clarify whether the formation of thrombi could be induced by atrial fibrillation itself or by factors predisposing to atrial fibrillation such as mitral stenosis, plasma D-dimer levels (cross-linked fibrin degradation products) were measured in 73 patients without atrial fibrillation (Group 2).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23919268' target='_blank' class='pmid-link'>23919268</a>:</span> <span class='sentence-part'>Giant left atrial appandage thrombus due to atrial fibrillation: successful treatment with warfarin.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25504982' target='_blank' class='pmid-link'>25504982</a>:</span> <span class='sentence-part'>The majority of thrombi that arise due to atrial fibrillation occur in the left atrial appendage.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25534207' target='_blank' class='pmid-link'>25534207</a>:</span> <span class='sentence-part'>We cover the epidemiology of concomitant presentation of AF and CAD as well as differences in the pathogenesis of thrombus formation in both conditions.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26241302' target='_blank' class='pmid-link'>26241302</a>:</span> <span class='sentence-part'>AF causes thrombus formation in the LAA due to both the loss of atrial systole and the unique anatomic features of the LAA. Stroke or systemic embolism is a devastating consequence of atrial fibrillation (AF) due to thrombus formation in the left atrial appendage (LAA).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28620869' target='_blank' class='pmid-link'>28620869</a>:</span> <span class='sentence-part'>Echocardiography helps to establish the diagnosis and can differentiate between right heart thrombi that result from atrial fibrillation and those originating from deep venous thrombosis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29336400' target='_blank' class='pmid-link'>29336400</a>:</span> <span class='sentence-part'>Successful resolution with apixaban of a massive left atrial appendage thrombus due to nonrheumatic atrial fibrillation: A case report and review.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32999792' target='_blank' class='pmid-link'>32999792</a>:</span> <span class='sentence-part'>In these cases, we recommend putting left atrial appendage (LAA) to prevent thrombus formation in the left atrium due to AF.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33931840' target='_blank' class='pmid-link'>33931840</a>:</span> <span class='sentence-part'>Thrombus formation due to atrial fibrillation is the most common cause of embolic stroke.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34061226' target='_blank' class='pmid-link'>34061226</a>:</span> <span class='sentence-part'>Atrial fibrillation (AF) is the most frequent arrhythmic disease in humans, which leads to thrombus formation in the left atrial appendage and stroke through peripheral embolization.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37073479' target='_blank' class='pmid-link'>37073479</a>:</span> <span class='sentence-part'>Atrial fibrillation (AF) can cause thrombi formation and subsequent emboli deposition in systemic arteries, leading to various organ ischemia and infarction.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37583380' target='_blank' class='pmid-link'>37583380</a>:</span> <span class='sentence-part'>Taken together, it was considered that a massive-free thrombus from the left atrium, which was caused by atrial fibrillation, had first obstructed the left ventricular outflow tract, resulting in cardiac arrest.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/38133621' target='_blank' class='pmid-link'>38133621</a>:</span> <span class='sentence-part'>Left atrial (LA) blood flow plays an important role in diseases such as atrial fibrillation (AF) and atrial cardiomyopathy since alterations in the blood flow might lead to thrombus formation and stroke.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/8753102' target='_blank' class='pmid-link'>8753102</a>:</span> <span class='sentence-part'>Contributional factors possibly growing of such huge thrombus formation explained resulting from atrial fibrillation and decreased contractile force of the hypertrophied ventricle.</span></div></div>
<div class='streamlined-assertion'><div class='streamlined-header sticky-relation-header'><span class='label-text'>Subject:</span> <strong>Atrial_Fibrillation</strong> <span class='label-text'>Subject CUI:</span> <strong>C0004238</strong> â†’ <span class='label-text predicate-text'>CAUSES</span> â†’ <span class='label-text'>Object:</span> <strong>Transient_Ischemic_Attack</strong> <span class='label-text'>Object CUI:</span> <strong>C0007787</strong></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/19262366' target='_blank' class='pmid-link'>19262366</a>:</span> <span class='sentence-part'>These complications consisted of fractured leads requiring lead revision in 36 (3.4%) patients, lead infection requiring antibiotics in 5 (0.5%) patients, device replacement because of malfunction in 5 (0.5%) patients, repositioning of leads in 3 (0.3%) patients, a hematoma at the time of implantation in 3 (0.3%) patients, pneumothorax at the time of implantation in 2 (0.2%) patients, repair of a defective generator in 1 (0.1%) patient, replacement of the device because of atrophy of the skin over the device in 1 (0.1%) patient, a transient ischemic attack because of atrial fibrillation developing during implantation in 1 (0.1%) patient, device replacement because of a recall from Guidant in 1 (0.1%) patient, pocket revision because of pain when lying on the side of the pacemaker in 1 (0.1%) patient, and pacemaker infection in 1 (0.1%) patient.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20170841' target='_blank' class='pmid-link'>20170841</a>:</span> <span class='sentence-part'>For patients with TIA and ischaemic stroke of cardiac origin due to atrial fibrillation, vitamin K antagonists (VKAs) are highly effective in preventing recurrent ischaemic stroke but have important limitations and are thus underused.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21893980' target='_blank' class='pmid-link'>21893980</a>:</span> <span class='sentence-part'>BACKGROUND: Atrial fibrillation (AF) is a common cause of ischemic stroke and transient ischemic attack (TIA).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23319965' target='_blank' class='pmid-link'>23319965</a>:</span> <span class='sentence-part'>INTRODUCTION: Thromboembolism, usually originating from the left atrium (LA) and left atrial appendage (LAA), is a major complication of atrial fibrillation and may result in transient ischemic attack and stroke.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23615539' target='_blank' class='pmid-link'>23615539</a>:</span> <span class='sentence-part'>The purpose of this study was to assess the relationship between isolated aphasia and atrial fibrillation (AF) as the cause of presumed cardioembolic TIA or stroke within the setting of 2 large multicenter trials.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24322948' target='_blank' class='pmid-link'>24322948</a>:</span> <span class='sentence-part'>Recommendations for the use of new oral anticoagulants (NOACs) after TIA or stroke caused by atrial fibrillation (AF), after a consensus conference among Italian neurologists (the Venice group).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24484463' target='_blank' class='pmid-link'>24484463</a>:</span> <span class='sentence-part'>Adequate antiplatelet therapy is recommended for secondary prevention after cerebral ischaemia of presumed arterial origin, whether for patients with TIA and ischaemic stroke of cardiac origin, mainly due to atrial fibrillation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25027667' target='_blank' class='pmid-link'>25027667</a>:</span> <span class='sentence-part'>The etiology of the TIA was defined according to the results of complementary examinations performed at admission as follows: large artery atherosclerosis (LAA-TIA) TIA, TIA due to atrial fibrillation (AF-TIA), other causes, and undetermined TIA.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25294430' target='_blank' class='pmid-link'>25294430</a>:</span> <span class='sentence-part'>BACKGROUND: Cardioembolic stroke (CES) due to atrial fibrillation (AF) is associated with high stroke mortality. METHODS: Within the Ludwigshafen Stroke Study (LuSSt), a prospective population-based stroke register, we analysed all patients with a first ever ischemic stroke or TIA due to AF from 2006 until 2010. RESULTS: In total 479 patients had a first-ever ischemic stroke (n = 394) or TIA (n = 85) due to AF. We analysed whether treatment or non-treatment with OAC and initiation of OAC-therapy during and after hospitalization influenced stroke mortality within 500 days after stroke/TIA due to AF.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28118928' target='_blank' class='pmid-link'>28118928</a>:</span> <span class='sentence-part'>Atrial fibrillation (AF) is the most common cardiac cause of ischemic stroke and transient ischemic attack (IS/TIA).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30935808' target='_blank' class='pmid-link'>30935808</a>:</span> <span class='sentence-part'>INTRODUCTION: Atrial fibrillation (AF) is a major cause of ischemic stroke and Transient Ischemic Attack (TIA) and investigation for paroxysmal AF is recommended following an embolic brain event.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32028277' target='_blank' class='pmid-link'>32028277</a>:</span> <span class='sentence-part'>METHODS: Plasma samples were collected from patients aged 18 years and older with ischemic stroke or TIA due to AF (n = 9) and large artery atherosclerosis (LAA) with ipsilateral carotid stenosis (n = 8) and age- and sex-matched controls (n = 10).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36212791' target='_blank' class='pmid-link'>36212791</a>:</span> <span class='sentence-part'>Atrial fibrillation (AF) is a major cause of recurrent stroke and transient ischaemic attack (TIA) in the UK.</span></div></div>
<div class='streamlined-assertion'><div class='streamlined-header sticky-relation-header'><span class='label-text'>Subject:</span> <strong>Atrial_Fibrillation</strong> <span class='label-text'>Subject CUI:</span> <strong>C0004238</strong> â†’ <span class='label-text predicate-text'>CAUSES</span> â†’ <span class='label-text'>Object:</span> <strong>Ventricular_Fibrillation</strong> <span class='label-text'>Object CUI:</span> <strong>C0042510</strong></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/10648491' target='_blank' class='pmid-link'>10648491</a>:</span> <span class='sentence-part'>MAIN OUTCOME MEASURES: Frequency of atrial fibrillation after induction of ventricular fibrillation; clinical characteristics of patients with and without induced atrial fibrillation; frequency of atrial fibrillation induced by rapid atrial bursts during predischarge testing.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/12227703' target='_blank' class='pmid-link'>12227703</a>:</span> <span class='sentence-part'>Ventricular fibrillation in a patient with ventricular preexcitation is usually due to atrial fibrillation with an extremely rapid ventricular rate from which it degenerates.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/16174019' target='_blank' class='pmid-link'>16174019</a>:</span> <span class='sentence-part'>BACKGROUND: The pattern of FF intervals during atrial fibrillation (AF) has been analyzed in induced and spontaneous AF episodes, after the induction of ventricular fibrillation (VF) and after atrial shock, in order to suggest practical considerations for AF management in patients implanted with antitachycardia devices.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/16932087' target='_blank' class='pmid-link'>16932087</a>:</span> <span class='sentence-part'>We report the case of a young patient with hypertrophic cardiomyopathy in whom an episode of atrial fibrillation triggered ventricular fibrillation and cardiac arrest.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20225635' target='_blank' class='pmid-link'>20225635</a>:</span> <span class='sentence-part'>BACKGROUND/AIM: The occurrence of atrial fibrillation (AF) in the presence of an accessory pathway (AP) that conducts rapidly is potentially lethal because the rapid ventricular response may lead to ventricular fibrillation (VF).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/2710202' target='_blank' class='pmid-link'>2710202</a>:</span> <span class='sentence-part'>The mechanism of sudden death is usually ventricular fibrillation, which is triggered by atrial fibrillation with a rapid ventricular response rate.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/2740877' target='_blank' class='pmid-link'>2740877</a>:</span> <span class='sentence-part'>We report the case of a patient with WPW syndrome in whom inappropriate administration of verapamil during an episode of atrial fibrillation and rapid ventricular response caused ventricular fibrillation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28392310' target='_blank' class='pmid-link'>28392310</a>:</span> <span class='sentence-part'>Simultaneous stimulation of both the sympathetic and parasympathetic systems is thought to lead to atrial fibrillation whereas increased sympathetic stimulation is thought to lead to ventricular fibrillation or ventricular tachycardia.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31126668' target='_blank' class='pmid-link'>31126668</a>:</span> <span class='sentence-part'>Here, we report a unique case where during electrical cardioversion of pre-excited AF with inappropriate synchronization on the T wave inadvertently resulted in ventricular fibrillation (VF), and review the literature.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34662385' target='_blank' class='pmid-link'>34662385</a>:</span> <span class='sentence-part'>There were two intra-procedural adverse events in one patient, including reaction to anaesthesia and an episode of transient atrial fibrillation during ventricular fibrillation induction.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/8472715' target='_blank' class='pmid-link'>8472715</a>:</span> <span class='sentence-part'>The mechanism of sudden death in these patients is believed to result from ventricular fibrillation due to atrial fibrillation with rapid anterograde conduction over the accessory pathway.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/872319' target='_blank' class='pmid-link'>872319</a>:</span> <span class='sentence-part'>Digitalis could be directly related to the onset of ventricle fibrillation resulting from atrial fibrillation in 9/21 patients.</span></div></div>
<div class='streamlined-assertion'><div class='streamlined-header sticky-relation-header'><span class='label-text'>Subject:</span> <strong>Atrial_Premature_Complexes</strong> <span class='label-text'>Subject CUI:</span> <strong>C0033036</strong> â†’ <span class='label-text predicate-text'>CAUSES</span> â†’ <span class='label-text'>Object:</span> <strong>Atrial_Fibrillation</strong> <span class='label-text'>Object CUI:</span> <strong>C0004238</strong></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/10402438' target='_blank' class='pmid-link'>10402438</a>:</span> <span class='sentence-part'>Before Atrioverter implantation, AF was induced by 1 atrial premature beat in 3 patients and not induced in the remaining patient.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/10455082' target='_blank' class='pmid-link'>10455082</a>:</span> <span class='sentence-part'>In most episodes, ERAF was triggered by short coupling atrial premature beats with preceding normal heart rate.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/10961097' target='_blank' class='pmid-link'>10961097</a>:</span> <span class='sentence-part'>To overcome the difficulties in reproducing the maze operation with catheter ablation, new alternatives have appeared, such as energy application inside the pulmonary veins, known as the source of most ectopic atrial beats that trigger AF episodes.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/11227964' target='_blank' class='pmid-link'>11227964</a>:</span> <span class='sentence-part'>A simple method of mapping atrial premature depolarizations triggering atrial fibrillation. Atrial premature depolarizations (APDs) originating from focal sites, particularly the pulmonary veins (PV), may become triggers of atrial fibrillation (AF).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/11282080' target='_blank' class='pmid-link'>11282080</a>:</span> <span class='sentence-part'>The class III antiarrhythmic drugs dofetilide and sotalol prevent AF induction by atrial premature complexes at doses that fail to terminate AF.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/11797990' target='_blank' class='pmid-link'>11797990</a>:</span> <span class='sentence-part'>High-resolution noncontact mapping can map a single beat, should help identify the sites of spontaneously occurring PACs and PACs induced following cardioversion of spontaneous or induced AF, and could help correlate the trigger sites for AF induction. Cardioversion of spontaneous or induced AF could be used as an electrophysiologic parameter for guiding therapy. In all patients, AF was induced and subsequently cardioverted to assess and map isolated PACs or PACs that induced AF.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/12062732' target='_blank' class='pmid-link'>12062732</a>:</span> <span class='sentence-part'>In 22 patients (73%), AF was reproducibly induced by APCs from a single focus (59 episodes). APCs inducing AF had shorter coupling intervals than APCs not inducing AF (307 +/- 54 vs 409 +/- 76 ms, p &lt;0.001).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/12084595' target='_blank' class='pmid-link'>12084595</a>:</span> <span class='sentence-part'>However, the procedure may be challenging due to the complex anatomy of the left atrium and PVs, uncertain catheter positioning within the PVs and difficulties in mapping atrial extrasystoles, which may be rare or repeatedly induce AF and require cardioversion.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/12843685' target='_blank' class='pmid-link'>12843685</a>:</span> <span class='sentence-part'>CONCLUSIONS: Oral amiodarone increases conversion rates, prolongs fibrillatory cycle length and atrial effective refractory period and preserves sinus rhythm after cardioversion in persistent AF patients by suppressing the atrial ectopics that trigger AF.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/12862301' target='_blank' class='pmid-link'>12862301</a>:</span> <span class='sentence-part'>HYPOTHESIS: Atrial fibrillation may be induced by atrial ectopic beats originating in the pulmonary veins, and premature P-wave (PPW) patterns may help to identify the source of firing.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/15817085' target='_blank' class='pmid-link'>15817085</a>:</span> <span class='sentence-part'>Also during SR, single APBs did not induce AF (0 +/- 0 sec, P &lt; 0.05 vs pacing at RA) whereas multiple APBs invariably induced AF (39 +/- 74 sec, NS).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/15936622' target='_blank' class='pmid-link'>15936622</a>:</span> <span class='sentence-part'>The fewest number of APDs from the RSPV required to induce AF during AG stimulation was as follows: control (no stimulation) 7 +/- 4, 2.4 V; 3 +/- 1, p &lt;/=0.05.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/16387051' target='_blank' class='pmid-link'>16387051</a>:</span> <span class='sentence-part'>The role of premature atrial contractions as the main triggers of postoperative atrial fibrillation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/16643393' target='_blank' class='pmid-link'>16643393</a>:</span> <span class='sentence-part'>Although AF was frequently triggered by an atrial premature beat that emerged during normal sinus rhythm, most patients demonstrated a variety of onset patterns.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/16677524' target='_blank' class='pmid-link'>16677524</a>:</span> <span class='sentence-part'>RESULTS: In the baseline state, S1S1 programmed stimulation on all the sites evoked single or multiple atrial premature beats and short runs of atrial tachycardia, only a few sites induced AF.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/16903959' target='_blank' class='pmid-link'>16903959</a>:</span> <span class='sentence-part'>Electroanatomic characteristics of atrial premature beats triggering atrial fibrillation in patients with persistent versus paroxysmal atrial fibrillation. METHODS: We mapped 75 APBs (53 APBs triggering AF, 22 isolated APBs) from the LA and PVs in 26 patients with AF (age: 49.5 +/- 9.6, males: 23, PAF = 17, PeAF = 9), using a noncontact endocardial mapping (NCM) system. We hypothesized that the origin of the atrial premature beats (APBs) that trigger AF and the pattern of their breakthrough into the LA differ between PAF and PeAF. PCs were more commonly found with APBs inducing AF (63.3%) than with those not inducing AF (35.2%, P = 0.01).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17302699' target='_blank' class='pmid-link'>17302699</a>:</span> <span class='sentence-part'>Consequently, the more positive TO preceding spontaneous atrial fibrillation episodes might be an epiphenomenon of incidental short-coupled APCs with delayed AV conduction, likely to trigger atrial fibrillation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17562750' target='_blank' class='pmid-link'>17562750</a>:</span> <span class='sentence-part'>The percentage of AF induced by premature atrial contractions (PACs) was significantly reduced by rate soothing from 25 to 17% (P &lt; 0.05).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17694471' target='_blank' class='pmid-link'>17694471</a>:</span> <span class='sentence-part'>Since during AVNRT a few short coupled atrial ectopic beats appeared, we hypothesized that AVNRT did not trigger AF directly but by inducing ectopic beats form a pulmonary vein or an atrial focus that became a direct trigger of AF.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24322420' target='_blank' class='pmid-link'>24322420</a>:</span> <span class='sentence-part'>In summary, ATP provoked AF or atrial ectopic beats in 88.9 % of PVI patients, 36.1 % of whose triggering sites matched that of the spontaneous AF, while 79.4 % of spontaneous AF trigger sites matched ATP-provoked AF or ectopic beat sites.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27702869' target='_blank' class='pmid-link'>27702869</a>:</span> <span class='sentence-part'>There was significant difference in CoIs of PACs triggering AF and those from PVs and non-PV areas but without causing AF (362.8 +/- 23.0 ms vs. 470.6 +/- 60.1 ms vs. 515.6 +/- 77.2 ms, P&lt; 0.001).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27892888' target='_blank' class='pmid-link'>27892888</a>:</span> <span class='sentence-part'>The incidence and characteristics of both PoAF and supraventricular premature beats triggering PoAF, their interrelationship and alterations over time have never been examined.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28705381' target='_blank' class='pmid-link'>28705381</a>:</span> <span class='sentence-part'>Atrial premature complexes (APCs) serve as acute triggers for atrial fibrillation (AF), but it is currently unknown whether the association between APCs and AF varies by race or sex.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29250296' target='_blank' class='pmid-link'>29250296</a>:</span> <span class='sentence-part'>During ablation of the pulmonary veins (PV), right atrial ectopics were noted to repeatedly trigger AF and atrial tachycardia (AT).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29660447' target='_blank' class='pmid-link'>29660447</a>:</span> <span class='sentence-part'>After PV isolation was performed, AF was induced by atrial premature contraction (APC) from the PLSVC, and AF storm occurred.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30871832' target='_blank' class='pmid-link'>30871832</a>:</span> <span class='sentence-part'>Atrial premature depolarizations are usually not associated with poor performance, but are a potential trigger for atrial fibrillation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31753439' target='_blank' class='pmid-link'>31753439</a>:</span> <span class='sentence-part'>After PV isolation, we infused isoproterenol to provoke non-PV AF triggers and/or non-PV PACs. BACKGROUND: Residual atrial ectopic beats that trigger AF from non-PVs (non-PV AF triggers) after catheter ablation are among the major causes of AF recurrence.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33153949' target='_blank' class='pmid-link'>33153949</a>:</span> <span class='sentence-part'>BACKGROUND: Premature atrial complexes from pulmonary veins are the main triggers for atrial fibrillation in the early stages.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33775981' target='_blank' class='pmid-link'>33775981</a>:</span> <span class='sentence-part'>This study aimed to test the hypothesis that in patients with reproducible atrial fibrillation (AF) triggered by premature atrial contractions originating only from PVs, PVI alone can be sufficient to maintain sinus rhythm.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34869625' target='_blank' class='pmid-link'>34869625</a>:</span> <span class='sentence-part'>Twenty-three patients in the ATP group demonstrated additional electrophysiological entities due to ATP administration, including reappearance of the ablated APs in 16 patients, discovery of PES-undetected APs in 5, induction of atrial fibrillation in 5, premature atrial contractions in 1, and premature ventricular contractions in another.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36003566' target='_blank' class='pmid-link'>36003566</a>:</span> <span class='sentence-part'>Objectives: Atrial extrasystoles are usually benign; however, they can also trigger atrial fibrillation. The findings of this pilot study provide a possible explanation for enhanced vulnerability for postoperative atrial extrasystoles to induce postoperative atrial fibrillation in patients after cardiac surgery.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37482964' target='_blank' class='pmid-link'>37482964</a>:</span> <span class='sentence-part'>INTRODUCTION: Atrial premature beats (APBs) are the trigger for atrial fibrillation (AF).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/8760170' target='_blank' class='pmid-link'>8760170</a>:</span> <span class='sentence-part'>Thus, premature beats cause AF by initiating a single macroreentrant cycle that degenerates into multiple wavefronts, regional refractoriness is the primary determinant of AF induction by premature beats, and variability in refractoriness may be an important determinant of the ability of AF to sustain itself. The site of atrial extrasystoles determined their ability to induce AF.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/9727692' target='_blank' class='pmid-link'>9727692</a>:</span> <span class='sentence-part'>Multisite pacing methods reduce the ability to initiate AF with atrial premature beats by reducing the window for AF induction and minimizing the dispersion of atrial refractoriness.</span></div></div>
<div class='streamlined-assertion'><div class='streamlined-header sticky-relation-header'><span class='label-text'>Subject:</span> <strong>Atrial_Remodeling</strong> <span class='label-text'>Subject CUI:</span> <strong>C3658220</strong> â†’ <span class='label-text predicate-text'>CAUSES</span> â†’ <span class='label-text'>Object:</span> <strong>Atrial_Fibrillation</strong> <span class='label-text'>Object CUI:</span> <strong>C0004238</strong></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32197906' target='_blank' class='pmid-link'>32197906</a>:</span> <span class='sentence-part'>Dysregulation of peroxisome proliferators-activated receptor alpha and glutathione metabolism pathways related to metabolic remodeling and redox imbalance-associated electrical remodeling may play a key role in the pathogenesis of POAF.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32476808' target='_blank' class='pmid-link'>32476808</a>:</span> <span class='sentence-part'>Mechanisms such as atrial structural remodeling and electrical remodeling have been implicated in the pathogenesis of AF.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32601674' target='_blank' class='pmid-link'>32601674</a>:</span> <span class='sentence-part'>Most likely the lack of fibrosis and/or advanced electrical remodelling explain why pulmonary veins remain the dominant trigger for AF in this patient cohort.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32982180' target='_blank' class='pmid-link'>32982180</a>:</span> <span class='sentence-part'>Purpose: Atrial remodeling takes part in the pathogenesis of atrial fibrillation (AF).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33119551' target='_blank' class='pmid-link'>33119551</a>:</span> <span class='sentence-part'>We hypothesized that TRPV4 blockade alleviates atrial remodeling and reduces AF induction in sterile pericarditis (SP) rats.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33516408' target='_blank' class='pmid-link'>33516408</a>:</span> <span class='sentence-part'>Risk factors including cardiometabolic and endocrine disorders have a significant impact on atrial remodeling causing atrial fibrillation (AF).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35092224' target='_blank' class='pmid-link'>35092224</a>:</span> <span class='sentence-part'>Hemodynamic changes due to stiffening of the arteries may cause cardiac structural and electrical remodeling that induces AF.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36388100' target='_blank' class='pmid-link'>36388100</a>:</span> <span class='sentence-part'>In conclusion, Ang II mediated atrial electrical and structural remodeling develop earlier and more extensively in the left atrium compared to the right atrium, providing insight into how atrial remodeling leads to enhanced AF susceptibility in Ang II mediated hypertension.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37518343' target='_blank' class='pmid-link'>37518343</a>:</span> <span class='sentence-part'>Arterial stiffness has been reported to cause left atrial (LA) remodeling due to increased left ventricular filling pressure, resulting in atrial fibrillation (AF).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37810107' target='_blank' class='pmid-link'>37810107</a>:</span> <span class='sentence-part'>Conclusions: These findings suggest that 5-MTP administration decreases the vulnerability of ibrutinib-related AF mainly caused by ameliorated maladaptive left atrial remodeling and dysregulation of calcium handling proteins.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/38022420' target='_blank' class='pmid-link'>38022420</a>:</span> <span class='sentence-part'>Objectives: Atrial fibrillation (AF) is the most frequent arrhythmia, and myocardial fibrosis (MF) has a close association with atrial remodeling and leads to AF.</span></div></div>
<div class='streamlined-assertion'><div class='streamlined-header sticky-relation-header'><span class='label-text'>Subject:</span> <strong>Atrial_effective_refractory_period</strong> <span class='label-text'>Subject CUI:</span> <strong>C0428938</strong> â†’ <span class='label-text predicate-text'>CAUSES</span> â†’ <span class='label-text'>Object:</span> <strong>Atrial_Fibrillation</strong> <span class='label-text'>Object CUI:</span> <strong>C0004238</strong></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/12062336' target='_blank' class='pmid-link'>12062336</a>:</span> <span class='sentence-part'>A shorter atrial effective refractory period, greater dispersion of the atrial refractoriness and atrial conduction delay are also of electrophysiologic significance in the genesis of AF.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/19709509' target='_blank' class='pmid-link'>19709509</a>:</span> <span class='sentence-part'>CONCLUSIONS: Although shortening of the AERP may play a fundamental role, it is not in itself responsible for cholinergically induced AF.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22371231' target='_blank' class='pmid-link'>22371231</a>:</span> <span class='sentence-part'>The AF inducibility after ablation was significantly lower than that before ablation in the two groups (98% vs. 28%, p &lt; 0.01, in the CPVa group; 97% vs.14%, p &lt; 0.01, in the BOXa group), and the induced AF lasting time after ablation was significantly shorter than that before ablation in both groups (233 +/- 40 vs. 70 +/- 29 s, p &lt; 0.01, in the CPVa group; 240 +/- 41 vs. 34 +/- 22 s, p &lt; 0.01, in the BOXa group). Before-and-after ablation left atrial effective refractory period (LAERP), AF inducibility, and induced AF lasting time were measured in both groups.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25404650' target='_blank' class='pmid-link'>25404650</a>:</span> <span class='sentence-part'>RESULTS: Aged dogs exhibited a higher induction rate of atrial fibrillation (AF) in response to electrical stimulation, longer AF duration after induction, longer SNRTc, longer right atrial effective refractory period (AERP), shorter left AERP, and increased AERP dispersion compared to adults.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26078277' target='_blank' class='pmid-link'>26078277</a>:</span> <span class='sentence-part'>CONCLUSIONS: Ganglionated plexi ablation effectively prolonged atrial effective refractory period for a short period, but the long-term effects on atrial effective refractory period and the suppression of atrial fibrillation induction were not persistent.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26130614' target='_blank' class='pmid-link'>26130614</a>:</span> <span class='sentence-part'>RESULTS: After pacing for 7 days, beta3-AR was significantly upregulated, AERP was reduced, and the AF induction rate was increased.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26625514' target='_blank' class='pmid-link'>26625514</a>:</span> <span class='sentence-part'>Main predictors of late AF recurrence were age &gt; 65 years, AF duration &gt; 5 years, preoperative atrial effective refractory period &lt; 240 ms, frequency threshold of AF induction &lt; 400 counts/min, anteroposterior left atrial size &gt; 50 mm, glomerular filtration rate &lt; 60 ml/min/1.73 m2.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29864240' target='_blank' class='pmid-link'>29864240</a>:</span> <span class='sentence-part'>In group 2, LOMLSPV ablation prolonged atrial ERP, decreased ?WOV, eliminated AF induction.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30297578' target='_blank' class='pmid-link'>30297578</a>:</span> <span class='sentence-part'>The AF induction rate, AF duration, atrial effective refractory period (ERP), and dispersion of ERP (dERP) were compared after every 2 h of RAP or/and RVTS.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/8636559' target='_blank' class='pmid-link'>8636559</a>:</span> <span class='sentence-part'>In addition, decremental rapid atrial stimulation was applied to the site of shortest and longest atrial effective refractory periods until atrial fibrillation induction in a subgroup of nine dogs.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/9326992' target='_blank' class='pmid-link'>9326992</a>:</span> <span class='sentence-part'>MAIN OUTCOME MEASURES: Changes in left and right atrial effective refractory periods, atrial activation times, and frequency of induction of atrial fibrillation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/9815876' target='_blank' class='pmid-link'>9815876</a>:</span> <span class='sentence-part'>Combined mapping of AF induction and atrial ERP showed that premature extrastimuli induced AF at sites with short ERP by causing local conduction slowing and/or block in adjacent zones with longer ERP values. CONCLUSIONS: Atrial tachycardia causes nonuniform remodeling of atrial refractoriness that plays an important role in increasing atrial vulnerability to AF induction and the duration of induced AF.</span></div></div>
<div class='streamlined-assertion'><div class='streamlined-header sticky-relation-header'><span class='label-text'>Subject:</span> <strong>Atrophic</strong> <span class='label-text'>Subject CUI:</span> <strong>C0333641</strong> â†’ <span class='label-text predicate-text'>CAUSES</span> â†’ <span class='label-text'>Object:</span> <strong>Alzheimers</strong> <span class='label-text'>Object CUI:</span> <strong>C0002395</strong></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/12919717' target='_blank' class='pmid-link'>12919717</a>:</span> <span class='sentence-part'>Reduced coherence between central and temporal cortex is discussed in light of a neurological model of AD that hypothesizes reduced electrocortical efficiency and a breakdown of neural network communication to temporal lobes possibly resulting from temporal lobe atrophy.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/14745078' target='_blank' class='pmid-link'>14745078</a>:</span> <span class='sentence-part'>White matter lesions (WML) and hippocampal atrophy (HA) on MRI commonly co-occur in Alzheimer's disease (AD) and are thought to play a role in the etiology of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/15377431' target='_blank' class='pmid-link'>15377431</a>:</span> <span class='sentence-part'>BACKGROUND: Neurone atrophy and loss are major causes of chronic neurodegenerative disorders such as Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/18646617' target='_blank' class='pmid-link'>18646617</a>:</span> <span class='sentence-part'>Atrophy of the hippocampus can lead to Alzheimer disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/19596405' target='_blank' class='pmid-link'>19596405</a>:</span> <span class='sentence-part'>Hippocampal atrophy is the key marker in the pathogenesis of Alzheimer's disease (AD), which is associated with white matter (WM) disruption.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20371138' target='_blank' class='pmid-link'>20371138</a>:</span> <span class='sentence-part'>Present findings suggest that most DTI-derived changes in AD and a-MCI are largely secondary to gray matter atrophy.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21174483' target='_blank' class='pmid-link'>21174483</a>:</span> <span class='sentence-part'>Indeed, the available evidence suggests that hippocampal atrophy is the starting point of the pathogenesis of Alzheimer's disease and a significant number of patients with hippocampal atrophy will develop Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21391278' target='_blank' class='pmid-link'>21391278</a>:</span> <span class='sentence-part'>BACKGROUND: Cerebral small vessel disease (SVD) and hippocampal atrophy are related to verbal memory failures and may ultimately result in Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29984299' target='_blank' class='pmid-link'>29984299</a>:</span> <span class='sentence-part'>Introduction: Current models posit a sequence of amyloid beta (Abeta), tau, atrophy, and cognitive change leading to Alzheimer's disease, but ambiguities remain.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37009529' target='_blank' class='pmid-link'>37009529</a>:</span> <span class='sentence-part'>It often starts with abnormal aggregation and deposition of    beta     amyloid and tau, followed by neuronal damage such as atrophy of the hippocampi, leading to Alzheimers Disease (AD).</span></div></div>
<div class='streamlined-assertion'><div class='streamlined-header sticky-relation-header'><span class='label-text'>Subject:</span> <strong>Brain_Injuries</strong> <span class='label-text'>Subject CUI:</span> <strong>C0270611</strong> â†’ <span class='label-text predicate-text'>CAUSES</span> â†’ <span class='label-text'>Object:</span> <strong>Alzheimers</strong> <span class='label-text'>Object CUI:</span> <strong>C0002395</strong></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/10652986' target='_blank' class='pmid-link'>10652986</a>:</span> <span class='sentence-part'>Brain regional oxidative damage is thought to be a central mechanism in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/11404403' target='_blank' class='pmid-link'>11404403</a>:</span> <span class='sentence-part'>Because LPO precedes amyloid plaque formation in Tg2576 mice, this suggests that brain oxidative damage contributes to AD pathogenesis before Abeta accumulation in the AD brain.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/12202836' target='_blank' class='pmid-link'>12202836</a>:</span> <span class='sentence-part'>Finally, different hypotheses link the origin of Alzheimer's disease to that of progressive cerebrovascular dementia caused by cerebral microcirculation damage.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/12574667' target='_blank' class='pmid-link'>12574667</a>:</span> <span class='sentence-part'>Finally, different hypotheses link the origin of Alzheimer's disease to that of progressive cerebrovascular dementia caused by cerebral microcirculation damage.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/1461171' target='_blank' class='pmid-link'>1461171</a>:</span> <span class='sentence-part'>Beta amyloid protein appears to be the principal active constituent of senile plaques thought to be a probable cause of brain damage resulting in AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28926722' target='_blank' class='pmid-link'>28926722</a>:</span> <span class='sentence-part'>There is now an unprecedented opportunity to improve the care of the over 5 million people who are living with Alzheimer's disease and related dementias and many more with cognitive impairment due to brain injury, systemic diseases, and other causes.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29843241' target='_blank' class='pmid-link'>29843241</a>:</span> <span class='sentence-part'>It proposed that the brain damage leading to Alzheimer's disease (AD) was instigated by soluble, ligand-like AbetaOs.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33292860' target='_blank' class='pmid-link'>33292860</a>:</span> <span class='sentence-part'>Since the brain is a sterile organ, neuroinflammation in Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS) is triggered by cerebral cellular damage or the abnormal accumulation of inflammatogenic molecules in CNS tissue through the activation of innate and acquired immunity.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37712394' target='_blank' class='pmid-link'>37712394</a>:</span> <span class='sentence-part'>In astrocytes, dysregulation of P2X7Rs has been associated with neurodegenerative illnesses such as Alzheimer's disease (AD), as well as the consequences of cerebral ischemic injury and status epilepticus (SE).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37714710' target='_blank' class='pmid-link'>37714710</a>:</span> <span class='sentence-part'>SIGNIFICANCE STATEMENT     Alzheimer's disease (AD)-associated cognitive dysfunction is hypothesized to be a consequence of brain network damage.</span></div></div>
<div class='streamlined-assertion'><div class='streamlined-header sticky-relation-header'><span class='label-text'>Subject:</span> <strong>Cardiac_ablation</strong> <span class='label-text'>Subject CUI:</span> <strong>C0162563</strong> â†’ <span class='label-text predicate-text'>CAUSES</span> â†’ <span class='label-text'>Object:</span> <strong>Atrial_Fibrillation</strong> <span class='label-text'>Object CUI:</span> <strong>C0004238</strong></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/10816796' target='_blank' class='pmid-link'>10816796</a>:</span> <span class='sentence-part'>(iv) Finally, pacemakers and catheter ablation may be used to suppress the triggers for atrial fibrillation episodes.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/15185487' target='_blank' class='pmid-link'>15185487</a>:</span> <span class='sentence-part'>Catheter ablation of the triggers of AF, which mainly originate at the pulmonary veins and the \substrate modification\ have been introduced in the last couple of years and is performed increasingly in specialized EP centers.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/15534799' target='_blank' class='pmid-link'>15534799</a>:</span> <span class='sentence-part'>Identification of AF trigger sites using the surface electrocardiogram (ECG) P wave morphology is feasible but conventional 12-lead scalar recordings do not offer the resolving power to provide discrete regional localization to potentially target catheter ablation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17367350' target='_blank' class='pmid-link'>17367350</a>:</span> <span class='sentence-part'>CONCLUSION: Computer simulation of various ablation patterns in persistent AF is feasible and can reproduce clinical results of catheter ablation. After induction of AF by burst pacing, progressively broader ablation patterns were applied: (A) individual pulmonary vein isolation (PVI); (B) double ipsilateral PVI; (C) double PVI with a roofline; (D) double PVI with a lateral mitral isthmus line, and (E) double PVI with both linear lesions.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/18465217' target='_blank' class='pmid-link'>18465217</a>:</span> <span class='sentence-part'>The ability to terminate AF by catheter ablation has provided additional clues to explain AF induction and sustenance.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23258139' target='_blank' class='pmid-link'>23258139</a>:</span> <span class='sentence-part'>The aim of this study was to investigate whether effective RA linear lesions can terminate AF and render it noninducible in a canine model of rapid atrial pacing-induced sustained AF. Linear catheter ablation of the right atrium for rapid atrial pacing-induced sustained atrial fibrillation in dogs.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23486416' target='_blank' class='pmid-link'>23486416</a>:</span> <span class='sentence-part'>One such approach is catheter ablation (CA), a procedure in which a radiofrequency electrical current is applied to regions of the heart to create small ablation lesions that electrically isolate potential AF triggers.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26477712' target='_blank' class='pmid-link'>26477712</a>:</span> <span class='sentence-part'>These results support the current recommendations for PV isolation as the cornerstone of catheter ablation to eliminate AF triggers in PerAF and LSPAF.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28259694' target='_blank' class='pmid-link'>28259694</a>:</span> <span class='sentence-part'>In these patients, triggers can typically be elicited using standardized induction protocols, which include cardioversion of spontaneous and/or induced AF and infusion of high-dose isoproterenol. Pulmonary vein (PV) isolation is the cornerstone of catheter ablation approaches for eliminating AF triggers.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29043080' target='_blank' class='pmid-link'>29043080</a>:</span> <span class='sentence-part'>Catheter ablation of the AF triggers is more effective than anti-arrhythmic drugs at maintaining sinus rhythm.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30139009' target='_blank' class='pmid-link'>30139009</a>:</span> <span class='sentence-part'>Methods: Between August 2010 and May 2016, 48 AF (8 proximal AF, 15 persistent AF and 25 long-standing persistent AF) patients (29 males, 19 females, mean age: (62.5+/-7.3) years old) with previously 1-3 failed catheter ablation results were treated with Mei mini maze procedure in our department.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32451104' target='_blank' class='pmid-link'>32451104</a>:</span> <span class='sentence-part'>In such circumstances, one may pursue catheter ablation of AF triggers, if present, or proceed with empiric posterior left atrial wall ablation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32827450' target='_blank' class='pmid-link'>32827450</a>:</span> <span class='sentence-part'>Catheter ablation (CA) was developed as a potentially curative procedure through electrical isolation of the pulmonary veins to isolate the main triggers of atrial fibrillation (AF).</span></div></div>
<div class='streamlined-assertion'><div class='streamlined-header sticky-relation-header'><span class='label-text'>Subject:</span> <strong>Cerebral_Amyloid_Angiopathy</strong> <span class='label-text'>Subject CUI:</span> <strong>C0085220</strong> â†’ <span class='label-text predicate-text'>CAUSES</span> â†’ <span class='label-text'>Object:</span> <strong>Alzheimers</strong> <span class='label-text'>Object CUI:</span> <strong>C0002395</strong></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/11004129' target='_blank' class='pmid-link'>11004129</a>:</span> <span class='sentence-part'>Further insight into the relationship between CAA and Alzheimer's disease may provide clues about the aetiology of Alzheimer's disease. Several mutations in the amyloid precursor protein (APP) gene may lead to either Alzheimer's disease or cerebral haemorrhage due to congophilic amyloid angiopathy (CAA).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/19822028' target='_blank' class='pmid-link'>19822028</a>:</span> <span class='sentence-part'>In this review we focus on the pathology and pathogenesis of CAA, its role in the aetiology of AD and its impact on immunotherapy for AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20359779' target='_blank' class='pmid-link'>20359779</a>:</span> <span class='sentence-part'>Epidemiologic evidence and postmortem studies of cerebral amyloid angiopathy suggest that vascular dysfunction may play an important role in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21037967' target='_blank' class='pmid-link'>21037967</a>:</span> <span class='sentence-part'>Cerebral amyloid angiopathy (CAA) is increasingly recognized as a major contributor of Alzheimer's disease (AD) pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21239853' target='_blank' class='pmid-link'>21239853</a>:</span> <span class='sentence-part'>The accumulation of amyloid-beta (Abeta) peptides as toxic oligomers, amyloid plaques, and cerebral amyloid angiopathy (CAA) is critical in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21760540' target='_blank' class='pmid-link'>21760540</a>:</span> <span class='sentence-part'>The relevance of cerebral amyloid angiopathy (CAA) to the pathogenesis of Alzheimer disease (AD) and dementia in general emphasizes the importance of developing novel targeting approaches for detecting and treating cerebrovascular amyloid (CVA) deposits.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29620941' target='_blank' class='pmid-link'>29620941</a>:</span> <span class='sentence-part'>Cerebral amyloid angiopathy (CAA) is a major contributor to Alzheimer's disease (AD) pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29770843' target='_blank' class='pmid-link'>29770843</a>:</span> <span class='sentence-part'>In this study, we have compared the severity of amyloid plaque formation and cerebral amyloid angiopathy (CAA), and the subtype pattern of CAA pathology itself, between APP genetic causes of AD (APPdup, APP mutations), older individuals with Down syndrome (DS) showing the pathology of Alzheimer's disease (AD) and individuals with sporadic (early and late onset) AD (sEOAD and sLOAD, respectively).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31727169' target='_blank' class='pmid-link'>31727169</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD)-related amyloid beta-peptide (Abeta) pathology in the form of amyloid plaques and cerebral amyloid angiopathy (CAA) spreads in its topographical distribution, increases in quantity, and undergoes qualitative changes in its composition of modified Abeta species throughout the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33590547' target='_blank' class='pmid-link'>33590547</a>:</span> <span class='sentence-part'>VSI and mVD increased in Tg mice; these findings indicated microvascular disruption in the brain that could be related to damage to the neurovascular unit in AD caused by cerebral amyloid angiopathy.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35367207' target='_blank' class='pmid-link'>35367207</a>:</span> <span class='sentence-part'>Compared with the pathology of CAA in humans, the pathology in most mouse models of AD is not as evident, making it difficult to examine the contribution of CAA to the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/7780697' target='_blank' class='pmid-link'>7780697</a>:</span> <span class='sentence-part'>Deposits of beta A4 amyloid in a form of amyloid (senile) plaques, diffuse amyloid deposits and congophilic angiopathy is central to the pathogenesis of AD.</span></div></div>
<div class='streamlined-assertion'><div class='streamlined-header sticky-relation-header'><span class='label-text'>Subject:</span> <strong>Cerebral_atrophy</strong> <span class='label-text'>Subject CUI:</span> <strong>C0235946</strong> â†’ <span class='label-text predicate-text'>CAUSES</span> â†’ <span class='label-text'>Object:</span> <strong>Alzheimers</strong> <span class='label-text'>Object CUI:</span> <strong>C0002395</strong></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/11255453' target='_blank' class='pmid-link'>11255453</a>:</span> <span class='sentence-part'>BACKGROUND: Brain glucose metabolic rates measured by positron emission tomography can be more affected by partial volume effects in Alzheimer disease (AD) than in healthy aging because of disease-associated brain atrophy.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/15110003' target='_blank' class='pmid-link'>15110003</a>:</span> <span class='sentence-part'>In eight patients with probable AD and eight age-matched normal control subjects, the IPCA was comparable to the established but partly manual digital subtraction (DS) method in characterizing annual rates of whole-brain atrophy: resulting rates were correlated (Spearman rank correlation = 0.94, P &lt; 0.0005) and comparable in distinguishing probable AD from normal aging (IPCA-detected atrophy rates: 2.17 +/- 0.52% per year in the patients vs.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/15345807' target='_blank' class='pmid-link'>15345807</a>:</span> <span class='sentence-part'>There was a 25% increase (not statistically significant) in vessel density in mm/mm2 in AD subjects (AD = 11.88 +/- 0.87; control = 9.53 +/- 0.78; p = 0.06), presumably due to brain atrophy in the white matter.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22011258' target='_blank' class='pmid-link'>22011258</a>:</span> <span class='sentence-part'>Abstract   Posterior cortical atrophy (PCA) is a visual-cognitive syndrome caused by Creutzfeldt-Jakob disease (CJD), Alzheimer's disease (AD), or subcortical gliosis. Clinical manifestations of PCA caused by AD included visual agnosia, cortical blindness, optic apraxla, delusions, hallucinations, agitation, depression, amnestic deficit, Wernicke's aphasia, acalculia, and left/right disorientation. Posterior cortical atrophy produced by AD can be demonstrated on magnetic resonance imaging, positron emission tomography, and electroencephalography; determination of the etiology requires tissue examination.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23634965' target='_blank' class='pmid-link'>23634965</a>:</span> <span class='sentence-part'>Specifically, since MCI coincides with the onset of clinical symptoms and brain atrophy, and LC pathology is already present at this early stage of AD pathogenesis, MCI may offer a critical window of time to initiate novel noradrenergic-based therapies aimed at the secondary wave of events that lead to progressive neurodegeneration.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26222866' target='_blank' class='pmid-link'>26222866</a>:</span> <span class='sentence-part'>Nevertheless, mild DAT in illiterate participants seems to be due to brain atrophy.In this study, we compared the impact of brain metabolism efficiency in healthy participants and less-educated patients with mild DAT using 2-fluoro-2-deoxy-D-glucose (F-FDG-PET) positron emission tomography.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27879212' target='_blank' class='pmid-link'>27879212</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) is a progressive and irreversible neurodegenerative disease causing neural cell degeneration and brain atrophy and is considered to be the most common form of dementia.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30582529' target='_blank' class='pmid-link'>30582529</a>:</span> <span class='sentence-part'>Structural magnetic resonance imaging (sMRI) has been widely used for computer-aided diagnosis of neurodegenerative disorders, e.g., Alzheimer's disease (AD), due to its sensitivity to morphological changes caused by brain atrophy.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32183332' target='_blank' class='pmid-link'>32183332</a>:</span> <span class='sentence-part'>Alzheimer's disease is an age-related disease characterized by the progressive loss of memory and cognitive function, caused by the unstoppable neurodegeneration and brain atrophy.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33327913' target='_blank' class='pmid-link'>33327913</a>:</span> <span class='sentence-part'>RESULTS: These data highlight the importance of the role of olfactory cortical atrophy in the pathogenesis of AD and the interplay between the olfactory deficits and degeneration of olfactory regions in the brain.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36294870' target='_blank' class='pmid-link'>36294870</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) is a neurologic disorder causing brain atrophy and the death of brain cells.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/38102439' target='_blank' class='pmid-link'>38102439</a>:</span> <span class='sentence-part'>The deposition of Abeta is believed to initiate a detrimental cascade, including cerebral hypometabolism, accelerated brain atrophy, and cognitive problems-ultimately resulting in AD.</span></div></div>
<div class='streamlined-assertion'><div class='streamlined-header sticky-relation-header'><span class='label-text'>Subject:</span> <strong>Cerebrospinal_Fluid</strong> <span class='label-text'>Subject CUI:</span> <strong>C0007806</strong> â†’ <span class='label-text predicate-text'>CAUSES</span> â†’ <span class='label-text'>Object:</span> <strong>Alzheimers</strong> <span class='label-text'>Object CUI:</span> <strong>C0002395</strong></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/12218644' target='_blank' class='pmid-link'>12218644</a>:</span> <span class='sentence-part'>Cerebrospinal fluid (CSF) contains proteins known to be involved in the pathogenesis of Alzheimer disease (AD), including amyloid-related proteins, tau protein and apolipoprotein E.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/15288699' target='_blank' class='pmid-link'>15288699</a>:</span> <span class='sentence-part'>Upregulation of MCP-1 may occur in the brain of subjects affected by Alzheimer's disease (AD) and MCP-1 levels in plasma and cerebrospinal fluid have been proposed as biological markers for the inflammatory process that accompanies AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/19026494' target='_blank' class='pmid-link'>19026494</a>:</span> <span class='sentence-part'>Stasis of cerebrospinal fluid (CSF) has been previously suggested to be a factor in the etiology of AD, but it has generated little attention among researchers.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/19363993' target='_blank' class='pmid-link'>19363993</a>:</span> <span class='sentence-part'>In cerebro-spinal fluid (CSF), it is the second most abundant protein, and is considered as an important protein in the pathogenesis of Alzheimer's disease, depression, and lead intoxication.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20727007' target='_blank' class='pmid-link'>20727007</a>:</span> <span class='sentence-part'>We here analysed adiponectin, one of the most important adipocytokines, in plasma and cerebrospinal fluid (CSF) from cognitive normal controls (NC), mild cognitive impairment (MCI) subjects, and patients with Alzheimer's disease (AD) and discussed if/how adiponectin could relate to the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21880396' target='_blank' class='pmid-link'>21880396</a>:</span> <span class='sentence-part'>Furthermore, continuous sampling of CSF proved to be a useful and robust method, which may also be used to investigate AD pathogenesis and to evaluate pharmacotherapeutic interventions.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23186986' target='_blank' class='pmid-link'>23186986</a>:</span> <span class='sentence-part'>Diagnoses of AD and other dementias were established by multidisciplinary expert teams, based on neuropsychological exams and structural brain imaging, blinded from CSF results.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24311739' target='_blank' class='pmid-link'>24311739</a>:</span> <span class='sentence-part'>Zinc (Zn) is an essential element for normal brain function; an abnormal Zn homeostasis in brain and the cerebrospinal fluid (CSF) has been implied in the etiology of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25079796' target='_blank' class='pmid-link'>25079796</a>:</span> <span class='sentence-part'>Vitamin D binding protein (VDBP), a multifunctional protein, has been found to be elevated in the cerebrospinal fluid (CSF) of neurodegenerative disorder cases, implicating it in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25946191' target='_blank' class='pmid-link'>25946191</a>:</span> <span class='sentence-part'>The current study indicates that reduction in water influx into the CSF may disturb the clearance rate of beta-amyloid, and therefore be linked to the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30297997' target='_blank' class='pmid-link'>30297997</a>:</span> <span class='sentence-part'>The parameters other than CSF results were included to study the difference between high- and low-AD-risk subjects in NC or MCI groups, based on CSF results.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32225073' target='_blank' class='pmid-link'>32225073</a>:</span> <span class='sentence-part'>Importantly, there is also clinical evidence supporting their potential use as biomarker candidates for AD, due to reduced serum and CSF levels that correlate with amyloid burden in AD patients compared with controls. Although the exact etiology of the disease remains elusive, accumulating evidence highlights the key role of lipid rafts, as well as the endocytic pathways in amyloidogenic amyloid precursor protein (APP) processing and AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35344967' target='_blank' class='pmid-link'>35344967</a>:</span> <span class='sentence-part'>Demographics, cognitive measurements, AD phenotypes, apolipoprotein E status, and results from cerebrospinal fluid and amyloid positron emission tomography analyses were included as explanatory variables of the hippocampal subtypes.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36171657' target='_blank' class='pmid-link'>36171657</a>:</span> <span class='sentence-part'>In this regard, the search for new protein markers and studies of proteomic changes in CSF and blood plasma are of particular interest and may consequentially identify particular pathways involved in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37355215' target='_blank' class='pmid-link'>37355215</a>:</span> <span class='sentence-part'>Recently, it was suggested that dysregulated microRNA-485-3p (miRNA-485-3p) in the brain and cerebrospinal fluid is closely related to pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/38043012' target='_blank' class='pmid-link'>38043012</a>:</span> <span class='sentence-part'>CONCLUSIONS: Our comprehensive analyses identified the cells in cerebrospinal fluid from AD patients are expanded TEMRA or TEM cells and the TEMRA cells communicating with other immune cells is weakened, which may be an important immune feature that leads to AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/9086466' target='_blank' class='pmid-link'>9086466</a>:</span> <span class='sentence-part'>Hence, it is concluded that increases in cerebrospinal fluid (CSF) levels of apoE are not involved in the pathogenesis of Alzheimer's disease and that measurement of CSF apoE levels does not seem to be useful as a diagnostic procedure.</span></div></div>
<div class='streamlined-assertion'><div class='streamlined-header sticky-relation-header'><span class='label-text'>Subject:</span> <strong>Cerebrovascular_accident</strong> <span class='label-text'>Subject CUI:</span> <strong>C0038454</strong> â†’ <span class='label-text predicate-text'>CAUSES</span> â†’ <span class='label-text'>Object:</span> <strong>Atrial_Fibrillation</strong> <span class='label-text'>Object CUI:</span> <strong>C0004238</strong></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/10936003' target='_blank' class='pmid-link'>10936003</a>:</span> <span class='sentence-part'>Improved diagnosis and an ageing population with an increased likelihood of underlying cardiac disease results in AF in more than 1% of population. AF is associated with an approximately two-fold increase in mortality, largely due to stroke which occurs at an annual rate of 5-7%. Studies in patients with little or no awareness of their arrhythmia condition indicate that unrecognized and untreated AF may cause congestive heart failure.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/16076273' target='_blank' class='pmid-link'>16076273</a>:</span> <span class='sentence-part'>The burden of morbidity in atrial fibrillation is mostly due to stroke, one of the major causes of death and the leading cause of long-term disability.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/16239992' target='_blank' class='pmid-link'>16239992</a>:</span> <span class='sentence-part'>Stroke is the major clinical cause of atrial fibrillation (AF).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17371199' target='_blank' class='pmid-link'>17371199</a>:</span> <span class='sentence-part'>Atrial fibrillation is the most common sustained cardiac arrhythmia that is observed in clinical practice and is associated with increased morbidity and mortality, resulting from stroke and exacerbation of heart failure.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17945152' target='_blank' class='pmid-link'>17945152</a>:</span> <span class='sentence-part'>Atrial fibrillation (AF) is a common arrhythmia that is associated with substantial morbidity and mortality, particularly due to stroke and thromboembolism.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21153001' target='_blank' class='pmid-link'>21153001</a>:</span> <span class='sentence-part'>Much of the morbidity and mortality in AF is due to stroke and thromboembolism.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21998467' target='_blank' class='pmid-link'>21998467</a>:</span> <span class='sentence-part'>Atrial fibrillation is the most common arrhythmia in clinical practice and is associated with significant mortality and morbidity due to stroke.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22989780' target='_blank' class='pmid-link'>22989780</a>:</span> <span class='sentence-part'>OBJECTIVE: Atrial fibrillation (AF) is associated with poor outcome after intravenous thrombolysis probably due to greater pretreatment stroke severity.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23227423' target='_blank' class='pmid-link'>23227423</a>:</span> <span class='sentence-part'>AF is correlated with an increased morbidity and mortality, mainly due to stroke and heart failure.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25587048' target='_blank' class='pmid-link'>25587048</a>:</span> <span class='sentence-part'>Atrial fibrillation (AF) is the most common sustained clinical arrhythmia and is associated with significant morbidity, mostly secondary to heart failure and stroke, and an estimated two-fold increase in premature death.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27325333' target='_blank' class='pmid-link'>27325333</a>:</span> <span class='sentence-part'>All patients with a hospital diagnosis of AF were identified, and propensity score-matched analyses were used to estimate costs attributable to first-incident stroke among patients with AF in the period 2002 to 2012.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27780804' target='_blank' class='pmid-link'>27780804</a>:</span> <span class='sentence-part'>Atrial fibrillation is the most common cardiac arrhythmia and conveys a significant risk of morbidity and mortality due to related stroke and systemic embolism.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28496725' target='_blank' class='pmid-link'>28496725</a>:</span> <span class='sentence-part'>Atrial fibrillation (AF) is the commonest sustained cardiac arrhythmia and is associated with increased morbidity and mortality due to stroke and thrombo-embolism.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29369958' target='_blank' class='pmid-link'>29369958</a>:</span> <span class='sentence-part'>CASE REPORT: An 89-year-old woman requiring upper abdominal surgery presented with multiple comorbidities, including a prior cerebrovascular accident resulting in a left-sided hemiparesis and atrial fibrillation requiring anticoagulation with rivaroxaban.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29878481' target='_blank' class='pmid-link'>29878481</a>:</span> <span class='sentence-part'>Atrial fibrillation is the most common heart-rhythm disorder, affecting about 1.5% to 2% of the population with an increased risk of mortality and morbidity due to stroke, thromboembolism, and heart failure.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30076825' target='_blank' class='pmid-link'>30076825</a>:</span> <span class='sentence-part'>Some studies show a close relationship between atrial fibrillation and dementia due to silent stroke, in the absence of overt stroke.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32241245' target='_blank' class='pmid-link'>32241245</a>:</span> <span class='sentence-part'>Atrial fibrillation (AF) is more commonly diagnosed in the elderly.The aim of the study was the assessment of the manifestations of AF in patients hospitalized due to cerebral stroke, with particular attention paid to newly diagnosed AF.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33723575' target='_blank' class='pmid-link'>33723575</a>:</span> <span class='sentence-part'>AF is a serious clinical problem associated with increased morbidity and mortality, mainly due to stroke and heart failure.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35163340' target='_blank' class='pmid-link'>35163340</a>:</span> <span class='sentence-part'>The prevention of cardiac life-threatening ventricular fibrillation and stroke-provoking atrial fibrillation remains a serious global clinical issue, with ongoing need for novel approaches.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/8296526' target='_blank' class='pmid-link'>8296526</a>:</span> <span class='sentence-part'>We propose that the AF was the consequence of the stroke.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/9809899' target='_blank' class='pmid-link'>9809899</a>:</span> <span class='sentence-part'>Nonvalvular atrial fibrillation (AF) is the most common cardiac disorder causing stroke and systemic emboli.</span></div></div>
<div class='streamlined-assertion'><div class='streamlined-header sticky-relation-header'><span class='label-text'>Subject:</span> <strong>Cholesterol</strong> <span class='label-text'>Subject CUI:</span> <strong>C0008377</strong> â†’ <span class='label-text predicate-text'>CAUSES</span> â†’ <span class='label-text'>Object:</span> <strong>Alzheimers</strong> <span class='label-text'>Object CUI:</span> <strong>C0002395</strong></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/12515903' target='_blank' class='pmid-link'>12515903</a>:</span> <span class='sentence-part'>Previous studies employing the cholesterol-fed rabbit model of AD demonstrated that induction of AD-like Abeta accumulation in brain could be reversed by co-administration of cholesterol lowering drugs or removing cholesterol, prompted initiation of an AD Cholesterol-Lowering (Statin) Treatment Trial.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/12573540' target='_blank' class='pmid-link'>12573540</a>:</span> <span class='sentence-part'>Recent evidence strongly suggests a role for cholesterol and apolipoprotein E in the etiology of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/12668899' target='_blank' class='pmid-link'>12668899</a>:</span> <span class='sentence-part'>Since apoE is a regulator of lipid metabolism, it is reasonable to assume that lipids such as cholesterol are involved in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/12737522' target='_blank' class='pmid-link'>12737522</a>:</span> <span class='sentence-part'>Use of in vivo models to study the role of cholesterol in the etiology of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/12843267' target='_blank' class='pmid-link'>12843267</a>:</span> <span class='sentence-part'>Epidemiology, in vitro, and in vivo studies strongly implicate a role for cholesterol in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/12920183' target='_blank' class='pmid-link'>12920183</a>:</span> <span class='sentence-part'>Despite the crucial role played by cholesterol and copper in nutrition and normal brain function, recent evidence indicates that they may both be important factors in the etiology of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/15212822' target='_blank' class='pmid-link'>15212822</a>:</span> <span class='sentence-part'>This review focuses on the newly recognized importance of cholesterol and its oxygenated metabolites in the pathogenesis of ischemic stroke and AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/15270198' target='_blank' class='pmid-link'>15270198</a>:</span> <span class='sentence-part'>Although early studies recognized the loss of cholesterol and other lipids in the brain, these findings have been poorly connected with AD pathogenesis, despite the identification of the epsilon4 allele of APOE as a major risk factor in AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/15351438' target='_blank' class='pmid-link'>15351438</a>:</span> <span class='sentence-part'>Epidemiological and biochemical studies strongly implicate a role for cholesterol in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/15844755' target='_blank' class='pmid-link'>15844755</a>:</span> <span class='sentence-part'>AD is a complex multifactorial disorder that involves numerous susceptibility genes, but the exact pathogenesis and biochemical basis of AD is not well understood Cholesterol is receiving a great deal of attention as a potentially crucial factor in the etiology of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/16096813' target='_blank' class='pmid-link'>16096813</a>:</span> <span class='sentence-part'>Cholesterol regulates the production of amyloid beta (Abeta), which is central to the pathogenesis of Alzheimer's disease (AD), with high cellular cholesterol promoting and low cellular cholesterol reducing Abeta in vitro and in vivo.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/16786033' target='_blank' class='pmid-link'>16786033</a>:</span> <span class='sentence-part'>It can be seen that abnormal lipid, cholesterol and glucose metabolism are consistently indicated as central in the pathophysiology, and possibly the pathogenesis of AD. ApoE has roles in cholesterol metabolism and Abeta clearance, both of which are thought to be significant in AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/18387175' target='_blank' class='pmid-link'>18387175</a>:</span> <span class='sentence-part'>High levels of serum cholesterol and disruptions of the blood brain barrier (BBB) have all been implicated as underlying mechanisms in the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/19239689' target='_blank' class='pmid-link'>19239689</a>:</span> <span class='sentence-part'>Growing evidence suggests an important function for cholesterol in the pathogenesis of AD, particularly in APP metabolism and production of A beta peptides.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/19293239' target='_blank' class='pmid-link'>19293239</a>:</span> <span class='sentence-part'>In conclusion, long-term, low-level cholesterol feeding was sufficient to promote the formation of extracellular beta-amyloid plaque formation in rabbits, supporting the integral role of cholesterol in the aetiology of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/19297055' target='_blank' class='pmid-link'>19297055</a>:</span> <span class='sentence-part'>A growing body of evidence implicates low membrane cholesterol in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/19996111' target='_blank' class='pmid-link'>19996111</a>:</span> <span class='sentence-part'>Significantly, LXR activation has been found to reduce the symptoms of Alzheimer disease (Fan, J., Donkin, J., and Wellington C. (2009) Biofactors 35, 239-248); thus, cholesterol metabolites may play an important role in the etiology of Alzheimer disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20138836' target='_blank' class='pmid-link'>20138836</a>:</span> <span class='sentence-part'>It has been suggested that cholesterol may modulate amyloid-beta (Abeta) formation, a causative factor of Alzheimer's disease (AD), by regulating distribution of the three key proteins in the pathogenesis of AD (beta-amyloid precursor protein (APP), beta-secretase (BACE1) and/or presenilin 1 (PS1)) within lipid rafts.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20157255' target='_blank' class='pmid-link'>20157255</a>:</span> <span class='sentence-part'>Our results suggest that cholesterol-enriched diets and cholesterol metabolites induce AD-like pathology by altering leptin signaling.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20304094' target='_blank' class='pmid-link'>20304094</a>:</span> <span class='sentence-part'>Many preclinical and clinical studies have implied a role for cholesterol in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20638472' target='_blank' class='pmid-link'>20638472</a>:</span> <span class='sentence-part'>However, the effects of caffeine on cholesterol-induced sporadic AD pathology have not been determined.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21091943' target='_blank' class='pmid-link'>21091943</a>:</span> <span class='sentence-part'>High-fat diabetogenic diets, cholesterol, and the omega-6 fatty acid arachidonate and its prostaglandin metabolites have all been implicated in promoting the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21590435' target='_blank' class='pmid-link'>21590435</a>:</span> <span class='sentence-part'>Additionally, excess brain cholesterol has been associated with increased formation and deposition of amyloid-beta peptide from amyloid precursor protein which may contribute to the risk and pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21605030' target='_blank' class='pmid-link'>21605030</a>:</span> <span class='sentence-part'>Apo E is the major component of lipoprotein particles in the brain that mediate transport of cholesterol and other lipids between neurons and glial cells, indicating an implication of cerebral lipid metabolism in the pathogenesis of AD. Importantly, mutations in the genes of APP and the two homologous PS proteins are a major cause of familial early onset AD, indicating that the metabolism of APP and generation of Abeta play critical roles in the initiation of the disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21741455' target='_blank' class='pmid-link'>21741455</a>:</span> <span class='sentence-part'>In this review, we aim to provide a background on AD and the contribution of cholesterol in the etiology of Alzheimer's. Cholesterol seems to be intimately linked with the generation of amyloid plaques, which is central to the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21851605' target='_blank' class='pmid-link'>21851605</a>:</span> <span class='sentence-part'>Epidemiological studies correlated high plasma cholesterol levels with high incidence of AD, and feeding rabbits with a diet rich in cholesterol has been shown to induce AD-like pathology in rabbit brain.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21965313' target='_blank' class='pmid-link'>21965313</a>:</span> <span class='sentence-part'>The aim of this review is to summarize the findings of epidemiological and cell biological studies to elucidate the role of cholesterol in AD etiology. The role of cholesterol in the etiology of Alzheimer's disease (AD) is still controversial.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22046282' target='_blank' class='pmid-link'>22046282</a>:</span> <span class='sentence-part'>We have previously shown that the cholesterol oxidized metabolite 27-hydroxycholesterol (27-OHC) triggers AD-like pathology in organotypic slices.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22108168' target='_blank' class='pmid-link'>22108168</a>:</span> <span class='sentence-part'>Cholesterol in the plasma membrane plays an important role in the pathogenesis of Alzheimer's disease, but the exact function of cholesterol in the regulation of amyloid-beta (Abeta) generation, aggregation, and toxicity remains elusive.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22367100' target='_blank' class='pmid-link'>22367100</a>:</span> <span class='sentence-part'>This review summarizes the current state of our knowledge of the influence of cholesterol and lipid pathways in AD pathogenesis in vitro and in vivo.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22580286' target='_blank' class='pmid-link'>22580286</a>:</span> <span class='sentence-part'>Endolysosome involvement in LDL cholesterol-induced Alzheimer's disease-like pathology in primary cultured neurons.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24155031' target='_blank' class='pmid-link'>24155031</a>:</span> <span class='sentence-part'>Here, we first provide a brief overview of cholesterol-protein interactions and then offer our perspective on how and why binding of cholesterol to APP and its C99 domain (beta-CTF) promotes the amyloidogenic pathway, which is closely related to the etiology of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24329875' target='_blank' class='pmid-link'>24329875</a>:</span> <span class='sentence-part'>Cholesterol as a causative factor in Alzheimer's disease: a debatable hypothesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24754001' target='_blank' class='pmid-link'>24754001</a>:</span> <span class='sentence-part'>The significant up regulation of miR-26b is consistent with the decrease of leptin levels in the brains of cholesterol fed rabbit model for AD, confirming that miR-26b is indeed regulated by leptin and that both leptin and miR-26b may be involved in cholesterol induced AD-like pathology.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25859562' target='_blank' class='pmid-link'>25859562</a>:</span> <span class='sentence-part'>Role of endolysosomes and cholesterol in the pathogenesis of Alzheimer's disease: Insights into why statins might not provide clinical benefit.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26413387' target='_blank' class='pmid-link'>26413387</a>:</span> <span class='sentence-part'>Among those factors, altered circulating cholesterol homeostasis, independent of the APOE genotype, continues to be implicated in brain deposition of amyloid beta protein (Abeta) and the pathogenesis of AD. Here, we will further discuss the linkage between elevated levels of LDL cholesterol and AD pathogenesis, and explore the underlying mechanisms whereby elevated levels of plasma LDL cholesterol promote amyloidogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26944571' target='_blank' class='pmid-link'>26944571</a>:</span> <span class='sentence-part'>Although numerous studies have shown the important function of cholesterol in AD pathogenesis and development, the underlying mechanism remains unclear.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27687218' target='_blank' class='pmid-link'>27687218</a>:</span> <span class='sentence-part'>A significant body of evidence indicates that oxidized cholesterol, in the form of oxysterols, is one of the main triggers of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28461971' target='_blank' class='pmid-link'>28461971</a>:</span> <span class='sentence-part'>Cholesterol in the Pathogenesis of Alzheimer's, Parkinson's Diseases and Autism: Link to Synaptic Dysfunction.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29736006' target='_blank' class='pmid-link'>29736006</a>:</span> <span class='sentence-part'>Although increasing evidence implicates cholesterol in the pathogenesis of Alzheimer's disease, the detailed mechanistic link between this lipid molecule and the disease process remains to be fully established.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30684043' target='_blank' class='pmid-link'>30684043</a>:</span> <span class='sentence-part'>Accumulating evidence suggests that cholesterol may play a role in the pathogenesis of Alzheimer's disease since abnormal deposits of cholesterol surrounding senile plaques have been described in animal transgenic models and patients with Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30689571' target='_blank' class='pmid-link'>30689571</a>:</span> <span class='sentence-part'>Epidemiologic and experimental evidence also suggests that cholesterol (CH) contributes to the pathogenesis of AD, particularly the formation of amyloid plaques.</span></div></div>
<div class='streamlined-assertion'><div class='streamlined-header sticky-relation-header'><span class='label-text'>Subject:</span> <strong>Chronic_inflammation</strong> <span class='label-text'>Subject CUI:</span> <strong>C0021376</strong> â†’ <span class='label-text predicate-text'>CAUSES</span> â†’ <span class='label-text'>Object:</span> <strong>Alzheimers</strong> <span class='label-text'>Object CUI:</span> <strong>C0002395</strong></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/10446805' target='_blank' class='pmid-link'>10446805</a>:</span> <span class='sentence-part'>In addition, increasing data claim the importance of chronic inflammation in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/12189211' target='_blank' class='pmid-link'>12189211</a>:</span> <span class='sentence-part'>Similar observations in Alzheimer's disease (AD) have lead to the hypothesis that chronic localized inflammation is an important element of AD pathogenesis, with significant neurodegenerative consequences.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/15931589' target='_blank' class='pmid-link'>15931589</a>:</span> <span class='sentence-part'>In conclusion, neurodegenerative diseases such as Alzheimer's disease, which is caused primarily by cell death due to chronic inflammation and cell stress, might be controlled by proper doses of non-toxic, natural Rg1 and Rb1.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/15979880' target='_blank' class='pmid-link'>15979880</a>:</span> <span class='sentence-part'>Chronic inflammation is known to play an important role in the heterogeneous pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/19320056' target='_blank' class='pmid-link'>19320056</a>:</span> <span class='sentence-part'>Using novel engineered dominant negative TNF inhibitors (DN-TNFs) selective for soluble TNF (solTNF), we investigated whether blocking TNF signaling with chronic infusion of the recombinant DN-TNF XENP345 or a single injection of a lentivirus encoding DN-TNF prevented the acceleration of AD-like pathology induced by chronic systemic inflammation in 3xTgAD mice.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/19946744' target='_blank' class='pmid-link'>19946744</a>:</span> <span class='sentence-part'>Glycated proteins can induce activation of microglia, which exacerbate the pathology of Alzheimer's disease by causing chronic inflammation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20080314' target='_blank' class='pmid-link'>20080314</a>:</span> <span class='sentence-part'>CLU, CR1 and PICALM support existing hypotheses about the amyloid, lipid, chaperone and chronic inflammatory pathways in AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20629514' target='_blank' class='pmid-link'>20629514</a>:</span> <span class='sentence-part'>These susceptibility loci support existing hypotheses about the amyloid, lipid, chaperone and chronic inflammatory mechanisms in AD pathogenesis, and are therefore likely to provide the basis for the development of hypothesis-driven novel biomarker candidates.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28448946' target='_blank' class='pmid-link'>28448946</a>:</span> <span class='sentence-part'>INTRODUCTION: There is increasing evidence for the involvement of chronic inflammation and oxidative stress in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29134678' target='_blank' class='pmid-link'>29134678</a>:</span> <span class='sentence-part'>Chronic inflammation represents a central component in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30657587' target='_blank' class='pmid-link'>30657587</a>:</span> <span class='sentence-part'>OBJECTIVE: the role of microbes and chronic inflammation in the pathogenesis of Alzheimer' disease (AD) has been postulated by many authors.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31797529' target='_blank' class='pmid-link'>31797529</a>:</span> <span class='sentence-part'>In particular, chronic inflammation plays a central role in Alzheimer's disease (AD) etiology, and dysregulated LX production and activities have been reported in a variety of AD rodent models and clinical tissue samples, yet with complex and sometimes conflicting results.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32035419' target='_blank' class='pmid-link'>32035419</a>:</span> <span class='sentence-part'>Oxidative stress and chronic inflammation have been suggested as causes of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33408815' target='_blank' class='pmid-link'>33408815</a>:</span> <span class='sentence-part'>Chronic inflammation is thought to contribute to the early pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35717405' target='_blank' class='pmid-link'>35717405</a>:</span> <span class='sentence-part'>Microglia cells play a key role in the pathology of Alzheimer's disease by causing chronic inflammation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35892582' target='_blank' class='pmid-link'>35892582</a>:</span> <span class='sentence-part'>Amyloid-beta (Abeta)-peptide production or deposition in the neuropathology of Alzheimer's disease (AD) was shown to be caused by chronic inflammation that may be induced by infection, but the role of pathogenic-bacteria-related AD-associated Abeta is not yet clearly understood.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37059510' target='_blank' class='pmid-link'>37059510</a>:</span> <span class='sentence-part'>The detrimental role that chronic inflammation plays in the pathogenesis of Alzheimer's disease is increasingly recognised; however, it is largely ascribed to the accumulation of amyloid beta, leaving the effect of chronic inflammation on tau pathology and neurofibrillary tangle-related pathways greatly overlooked.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/38622351' target='_blank' class='pmid-link'>38622351</a>:</span> <span class='sentence-part'>This study hypothesized that chronic aseptic inflammation might lead to AD in KOA patients.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/9790168' target='_blank' class='pmid-link'>9790168</a>:</span> <span class='sentence-part'>Chronic inflammatory reactions in the brain appear to be one of the primary etiological factors in the pathogenesis of Alzheimer's disease (AD).</span></div></div>
<div class='streamlined-assertion'><div class='streamlined-header sticky-relation-header'><span class='label-text'>Subject:</span> <strong>Congestive_heart_failure</strong> <span class='label-text'>Subject CUI:</span> <strong>C0018802</strong> â†’ <span class='label-text predicate-text'>CAUSES</span> â†’ <span class='label-text'>Object:</span> <strong>Atrial_Fibrillation</strong> <span class='label-text'>Object CUI:</span> <strong>C0004238</strong></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/10880422' target='_blank' class='pmid-link'>10880422</a>:</span> <span class='sentence-part'>Dofetilide was highly effective in preventing AF induction by atrial burst pacing in dogs with CHF but was totally ineffective in dogs with RAP.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/14708411' target='_blank' class='pmid-link'>14708411</a>:</span> <span class='sentence-part'>Atrial fibrillation (AF) and tricuspid regurgitation (TR) may induce congestive heart failure (CHD). Congestive heart failure induced by the combination of atrial fibrillation and tricuspid regurgitation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/14976404' target='_blank' class='pmid-link'>14976404</a>:</span> <span class='sentence-part'>Differential alterations of receptor densities of three muscarinic acetylcholine receptor subtypes and current densities of the corresponding K+ channels in canine atria with atrial fibrillation induced by experimental congestive heart failure.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/16271942' target='_blank' class='pmid-link'>16271942</a>:</span> <span class='sentence-part'>Atrial fibrillation itself does not lead to structural remodeling, whereas this is frequently produced by hypertension or CHF, even in the absence of AF.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/16697402' target='_blank' class='pmid-link'>16697402</a>:</span> <span class='sentence-part'>Atrial dysfunction, sino-atrial and nodal ischemia, congestive heart failure, sympathetic stimulation, iatrogenic factors are the possible causes of AF especially in patients undergoing primary PCI.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17270161' target='_blank' class='pmid-link'>17270161</a>:</span> <span class='sentence-part'>Statin-induced inhibition of profibrotic atrial fibroblast responses and attenuation of left-ventricular dysfunction may contribute to preventing the CHF-induced fibrotic AF substrate. BACKGROUND: Congestive heart failure (CHF) is a common cause of atrial fibrillation (AF).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/19808399' target='_blank' class='pmid-link'>19808399</a>:</span> <span class='sentence-part'>BACKGROUND: Congestive heart failure (CHF) is a common cause of atrial fibrillation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23192509' target='_blank' class='pmid-link'>23192509</a>:</span> <span class='sentence-part'>We report the case of a 64-year-old Chinese man who presented with atrial fibrillation and fluid overload due to congestive cardiac failure.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24393590' target='_blank' class='pmid-link'>24393590</a>:</span> <span class='sentence-part'>We observed a lower proportion of admissions due to AF in OP2 (63%) than in OP1 (87%) and a higher proportion of admissions due to congestive heart failure (16% versus 3%) and of days of inpatient care due to ischaemic stroke (25% versus 7%).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29250263' target='_blank' class='pmid-link'>29250263</a>:</span> <span class='sentence-part'>A 86-year-old woman with first diagnosed atrial fibrillation (AF) underwent mitral valve annuloplasty 10 years before was admitted to our Unit due to congestive heart failure.</span></div></div>
<div class='streamlined-assertion'><div class='streamlined-header sticky-relation-header'><span class='label-text'>Subject:</span> <strong>Copper</strong> <span class='label-text'>Subject CUI:</span> <strong>C0009968</strong> â†’ <span class='label-text predicate-text'>CAUSES</span> â†’ <span class='label-text'>Object:</span> <strong>Alzheimers</strong> <span class='label-text'>Object CUI:</span> <strong>C0002395</strong></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/10448050' target='_blank' class='pmid-link'>10448050</a>:</span> <span class='sentence-part'>Recent studies have also implicated copper in the pathogenesis of neuronal injury in Alzheimer's disease and the prion-mediated encephalopathies, suggesting that further elucidation of the mechanisms of copper trafficking and metabolism within the nervous system will be of direct relevance to our understanding of the pathophysiology and treatment of neurodegenerative disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/12920183' target='_blank' class='pmid-link'>12920183</a>:</span> <span class='sentence-part'>Despite the crucial role played by cholesterol and copper in nutrition and normal brain function, recent evidence indicates that they may both be important factors in the etiology of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17119285' target='_blank' class='pmid-link'>17119285</a>:</span> <span class='sentence-part'>Metals such as aluminum (Al), copper (Cu), zinc and iron have been implicated in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17408857' target='_blank' class='pmid-link'>17408857</a>:</span> <span class='sentence-part'>The decrease in loosely bound iron in mild-moderate AD patients may be associated with myelin breakdown seen in the beginning stages of AD and implicates that iron dysregulation is an early event in AD pathogenesis. Accumulating evidence implicates a role for altered iron and copper metabolism in the pathogenesis of neurodegenerative disorders such as Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/18376063' target='_blank' class='pmid-link'>18376063</a>:</span> <span class='sentence-part'>Recent studies also point to redox active metals such as iron, copper and zinc in mediating oxidative stress in AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21303349' target='_blank' class='pmid-link'>21303349</a>:</span> <span class='sentence-part'>Despite the crucial role of redox active metals like copper and iron in central biological reactions, their elevated levels are involved in the pathogenesis of Alzheimer's Disease (AD). Iron, copper, and zinc are some of the metals, which intensify this process and contribute for the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21514009' target='_blank' class='pmid-link'>21514009</a>:</span> <span class='sentence-part'>It is now accepted that transition metals, such as iron and copper, are involved in the pathogenesis of the Alzheimer's disease (AD) through their participation in toxic oxidative phenomena.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23669644' target='_blank' class='pmid-link'>23669644</a>:</span> <span class='sentence-part'>These results suggest that the action of copper may be profoundly associated with the pathway of Abeta production in AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24343096' target='_blank' class='pmid-link'>24343096</a>:</span> <span class='sentence-part'>In addition, it should be noted the important role that low molecular mass fractions of iron, copper, aluminium and cobalt appear to play in pathogenesis of Alzheimer.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27983558' target='_blank' class='pmid-link'>27983558</a>:</span> <span class='sentence-part'>BACKGROUND: Defective copper regulation, primarily referred to as chelatable redox active Cu(II), has been involved in the etiology of diabetes, and Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28644490' target='_blank' class='pmid-link'>28644490</a>:</span> <span class='sentence-part'>Mounting evidence suggests that copper, a crucial element in normal brain function, plays an important role in the etiology of Alzheimer's disease, which is known as a neurodegenerative mitochondrial disorder.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30598025' target='_blank' class='pmid-link'>30598025</a>:</span> <span class='sentence-part'>Moreover, it is already established that metals (particularly copper, zinc and iron) have a key role in the pathogenesis of AD.</span></div></div>
<div class='streamlined-assertion'><div class='streamlined-header sticky-relation-header'><span class='label-text'>Subject:</span> <strong>DNA_Mitochondrial</strong> <span class='label-text'>Subject CUI:</span> <strong>C0012929</strong> â†’ <span class='label-text predicate-text'>CAUSES</span> â†’ <span class='label-text'>Object:</span> <strong>Alzheimers</strong> <span class='label-text'>Object CUI:</span> <strong>C0002395</strong></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/15247418' target='_blank' class='pmid-link'>15247418</a>:</span> <span class='sentence-part'>To determine whether mtDNA mutations contribute more generally to the etiology of AD, we have investigated the sequence of the mtDNA control region (CR) from AD brains for possible disease-causing mutations.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/16408223' target='_blank' class='pmid-link'>16408223</a>:</span> <span class='sentence-part'>We report here the analyses of complete mtDNA coding region sequences from more than 270 Alzheimer's disease (AD) patients and normal controls to determine if inherited mtDNA mutations contribute to the etiology of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/16886726' target='_blank' class='pmid-link'>16886726</a>:</span> <span class='sentence-part'>Mitochondrial DNA in pathogenesis of Alzheimer's and Parkinson's diseases.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20798880' target='_blank' class='pmid-link'>20798880</a>:</span> <span class='sentence-part'>In this review we discuss the role of the mitochondria, and especially of the mtDNA, in the cascade of events leading to neurodegeneration, dementia, and AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21925769' target='_blank' class='pmid-link'>21925769</a>:</span> <span class='sentence-part'>Future research is needed to clarify the role mtDNA deletions have in normal aging and investigate the relationship between mtDNA deletions and the pathogenesis of sporadic AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22442439' target='_blank' class='pmid-link'>22442439</a>:</span> <span class='sentence-part'>OBJECTIVE: Although several studies have described an association between Alzheimer disease (AD) and genetic variation of mitochondrial DNA (mtDNA), each has implicated different mtDNA variants, so the role of mtDNA in the etiology of AD remains uncertain.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26881032' target='_blank' class='pmid-link'>26881032</a>:</span> <span class='sentence-part'>In conclusion these data confirmed peripheral mitochondria impairment in AD and demonstrated that TFAM and mtDNA amount reduction could be two features of early events occurring in AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33221353' target='_blank' class='pmid-link'>33221353</a>:</span> <span class='sentence-part'>The current review will focus on alterations and variation in mitochondria/mitochondrial DNA (mtDNA) and the rationale for involvement of related abnormalities in pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/8937782' target='_blank' class='pmid-link'>8937782</a>:</span> <span class='sentence-part'>There is increasing evidence for a role of defects of mitochondrial DNA in the etiology of neurodegenerative disorders such as Parkinson's and Alzheimer's disease as well as in normal aging.</span></div></div>
<div class='streamlined-assertion'><div class='streamlined-header sticky-relation-header'><span class='label-text'>Subject:</span> <strong>Degenerative_abnormality</strong> <span class='label-text'>Subject CUI:</span> <strong>C0011164</strong> â†’ <span class='label-text predicate-text'>CAUSES</span> â†’ <span class='label-text'>Object:</span> <strong>Alzheimers</strong> <span class='label-text'>Object CUI:</span> <strong>C0002395</strong></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/10668988' target='_blank' class='pmid-link'>10668988</a>:</span> <span class='sentence-part'>Two of the most prevalent neurologic disorders that result from degeneration are Alzheimer's and Parkinson's diseases.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/11793352' target='_blank' class='pmid-link'>11793352</a>:</span> <span class='sentence-part'>The long-held belief that degeneration of the cholinergic basal forebrain was central to Alzheimer's disease (AD) pathogenesis and occurred early in the disease process has been questioned recently.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/12476348' target='_blank' class='pmid-link'>12476348</a>:</span> <span class='sentence-part'>Studies of the pathogenic actions of mutations in presenilins and amyloid precursor protein that cause early-onset familial AD have established central roles for perturbed cellular calcium homeostasis and oxidative stress in the neurodegenerative process. The clinical presentation of patients with AD is dominated by cognitive deficits and emotional disturbances that result from dysfunction and degeneration of neurons in the limbic system and cerebral cortex.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/1508410' target='_blank' class='pmid-link'>1508410</a>:</span> <span class='sentence-part'>Alzheimer's, Parkinson's, and Huntington's diseases present unique constellations of behavioral and neurological abnormalities which result from the degeneration of neurons in specific regions of the brain.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/15190683' target='_blank' class='pmid-link'>15190683</a>:</span> <span class='sentence-part'>While glutamatergic transmission is severely altered by early degeneration of cortico-cortical connections and hippocampal projections in Alzheimer's disease (AD), the role of glutamate receptors in the pathogenesis of AD is not yet defined clearly.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/16125326' target='_blank' class='pmid-link'>16125326</a>:</span> <span class='sentence-part'>Alzheimer disease is regarded as a disorder of neural input modulation caused by the degeneration of four modulatory amine transmitter (MAT) systems, namely the serotoninergic, the noradrenergic, the histaminergic, and the cholinergic systems with ascending projections.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/16404228' target='_blank' class='pmid-link'>16404228</a>:</span> <span class='sentence-part'>In Alzheimer's disease, the posterior cingulate cortex itself shows little neuropathologic degeneration, and a hypothesis explaining such a discrepancy is that the functional impairment in the posterior cingulate cortex reflects remote effects caused by degeneration in distant but connected areas, such as the entorhinal cortex.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/16963164' target='_blank' class='pmid-link'>16963164</a>:</span> <span class='sentence-part'>We conclude that the intraneuronal accumulation of Abeta-amyloid peptides is followed by axonal degeneration, and thus might be a causative factor for the axonal changes seen in AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17378753' target='_blank' class='pmid-link'>17378753</a>:</span> <span class='sentence-part'>They suggest that degeneration of microglia is a factor in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/1776729' target='_blank' class='pmid-link'>1776729</a>:</span> <span class='sentence-part'>At the cellular level, Alzheimer's disease (AD) must be the result of neuronal dysfunction and degeneration leading to a reduction in synaptic density. As elucidation of the reasons behind amyloid deposition must shed some light on the pathogenesis of AD, we review the current state of knowledge on the nature of the AD amyloid protein, its origin, and its formation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/18569738' target='_blank' class='pmid-link'>18569738</a>:</span> <span class='sentence-part'>We describe a 56-year-old woman with Alzheimer's disease with left hemispatial neglect and left homonymous hemianopsia with macular sparing considered a manifestation of Alzheimer's disease resulting from severe degenerative change in the right primary visual cortex.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/19718893' target='_blank' class='pmid-link'>19718893</a>:</span> <span class='sentence-part'>The different organs age in different ways: vessel walls become rigid due to protein glycation and develop atheroma; the heart is invaded by fibrosis; the brain suffers from neurofibrillar degeneration and senile plaques (responsible for Alzheimer's disease); the retina undergoes macular degeneration; renal function declines in parallel with the fall in the glomerular filtration rate due to a gradual decrease in the nephron pool; and immune defenses become less effective due to the functional degradation of B and T lymphocytes and thymus involution.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20032460' target='_blank' class='pmid-link'>20032460</a>:</span> <span class='sentence-part'>Synaptic degeneration, including impairment of synaptic plasticity and loss of synapses, is an important feature of Alzheimer disease pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20575007' target='_blank' class='pmid-link'>20575007</a>:</span> <span class='sentence-part'>These data support the idea that by inducing degeneration of the DG, GSK3beta could be involved in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20698821' target='_blank' class='pmid-link'>20698821</a>:</span> <span class='sentence-part'>Numerous studies have indicated that Alzheimer's amyloid-beta protein (Abeta) causes the degeneration of synapses and neurons, finally inducing the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20858975' target='_blank' class='pmid-link'>20858975</a>:</span> <span class='sentence-part'>When considering degeneration (ratio to synaptophysin and the post-synaptic marker PSD95), GR expression was similar between controls and AD, suggesting that GR loss was due to synaptic degeneration in AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21460623' target='_blank' class='pmid-link'>21460623</a>:</span> <span class='sentence-part'>Genetic, molecular and biochemical evidence indicates that the accumulation of toxic Abeta aggregates plays a critical role in the degeneration of neurons during the pathogenesis of Alzheimer disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23670960' target='_blank' class='pmid-link'>23670960</a>:</span> <span class='sentence-part'>Degeneration of the corpus callosum (CC) is evident in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/2412232' target='_blank' class='pmid-link'>2412232</a>:</span> <span class='sentence-part'>Degeneration of cholinergic neurons from the basal forebrain nuclei is suspected to be the cause of Alzheimer disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/2463283' target='_blank' class='pmid-link'>2463283</a>:</span> <span class='sentence-part'>In SDAT, there is a primary loss of cholinergic neurons compounded by a secondary reaction of the remaining cholinergic neurons to the terminal degeneration in the cortex.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25045655' target='_blank' class='pmid-link'>25045655</a>:</span> <span class='sentence-part'>Since synaptic dysfunction and degeneration are early events during the pathogenesis of AD, we aim to investigate the effects of testosterone on oligomeric Abeta-induced synaptic changes.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25512503' target='_blank' class='pmid-link'>25512503</a>:</span> <span class='sentence-part'>The dementia of Alzheimer's disease (AD) results primarily from degeneration of neurons that furnish glutamatergic corticocortical connections that subserve cognition.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/2582270' target='_blank' class='pmid-link'>2582270</a>:</span> <span class='sentence-part'>These neurones have previously been shown to respond to substance P3 and are analogous to the nucleus basalis of Meynert in man, which gives a diffuse projection to the cerebral cortex and whose degeneration is the likely cause of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26025658' target='_blank' class='pmid-link'>26025658</a>:</span> <span class='sentence-part'>The progressive cognitive decline that is associated with Alzheimer's disease has been mainly attributed to a deficit in cholinergic neurotransmission due to the continuous degeneration of cholinergic neurons e.g. in the basal forebrain.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26415025' target='_blank' class='pmid-link'>26415025</a>:</span> <span class='sentence-part'>Progressive degeneration and death of neurons are main causes of neurodegenerative disorders such as Parkinson's disease and Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/2655587' target='_blank' class='pmid-link'>2655587</a>:</span> <span class='sentence-part'>Alzheimer's disease results from the degeneration of neurons.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26608462' target='_blank' class='pmid-link'>26608462</a>:</span> <span class='sentence-part'>Neurological diseases such as Alzheimer's and Parkinson's diseases are incurable progressive neurological disorders caused by the degeneration of neuronal cells and characterized by motor and non-motor symptoms.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26981406' target='_blank' class='pmid-link'>26981406</a>:</span> <span class='sentence-part'>Alzheimer's disease is the prevalent cause of premature senility, a progressive mental disorder due to degeneration in brain and deposition of amyloid beta peptide (1-42, a misfolded protein) in the form of aggregation that prevails for a prolonged time and obstructs every aspect of life. One of the primary hallmarks of the neuropathological disease is the accretion of amyloid beta peptide in the brain that leads to Alzheimer's disease, but the mechanism is still a mystery.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27023706' target='_blank' class='pmid-link'>27023706</a>:</span> <span class='sentence-part'>AD manifests by progressive decline in cognitive functions and alterations in behaviour, which are the result of the extensive degeneration of brain neurons.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/2742360' target='_blank' class='pmid-link'>2742360</a>:</span> <span class='sentence-part'>Insomnia associated with progressive supranuclear palsy appears to be worse than the insomnia of Parkinson's disease or Alzheimer's disease and may be due to degenerative changes in brain structures responsible for sleep maintenance.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27458373' target='_blank' class='pmid-link'>27458373</a>:</span> <span class='sentence-part'>The dysfunction of neurogenesis and increased degeneration of neurons contribute to the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28133526' target='_blank' class='pmid-link'>28133526</a>:</span> <span class='sentence-part'>OBJECTIVES: Alzheimer's disease (AD) as progressive cognitive decline and the most common form of dementia is due to degeneration of the cholinergic neurons in the brain.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28265241' target='_blank' class='pmid-link'>28265241</a>:</span> <span class='sentence-part'>In association with the amyloid deposits, increasing impairments in learning and memory as well as the degeneration of neurons especially in the hippocampus formation are hallmarks of the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28671131' target='_blank' class='pmid-link'>28671131</a>:</span> <span class='sentence-part'>Thus, the olfactory activation deficits present in AD and MCI patients are most likely caused by degeneration of the central olfactory nervous system.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29602022' target='_blank' class='pmid-link'>29602022</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) is a severe neurodegenerative disorder characterized by loss of memory and reduction in cognitive functions due to progressive degeneration of neurons and their connections, eventually leading to death.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30524269' target='_blank' class='pmid-link'>30524269</a>:</span> <span class='sentence-part'>Conclusion: The HPA axis may play a crucial role in synaptic degeneration in AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30528858' target='_blank' class='pmid-link'>30528858</a>:</span> <span class='sentence-part'>Synaptic degeneration is central in Alzheimer's disease (AD) pathogenesis and biomarkers to monitor this pathophysiology in living patients are warranted.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31117343' target='_blank' class='pmid-link'>31117343</a>:</span> <span class='sentence-part'>This excellent piece of work identifies a potent hexapeptide, which has exceptional ability to protect neurons as well as microtubule from degeneration and may become potent therapeutics against AD pathogenesis in the future.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31507373' target='_blank' class='pmid-link'>31507373</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) is the most common type of dementia which characterized by a progressive loss of memory and cognitive function due to degeneration of synapses and axons. Till now, it is far from clear what role autophagy plays in AD, a causative role, a protective role, or just a consequence of the disease process itself.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31605783' target='_blank' class='pmid-link'>31605783</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) is a progressive dementia caused by degeneration of the central nervous system with a high incidence in the elderly.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34590507' target='_blank' class='pmid-link'>34590507</a>:</span> <span class='sentence-part'>Neurodegenerative disorders such as Alzheimer's Disease (AD) and Parkinson's Disease (PD), have been majorly resulted due to degeneration of neurons and neuroinflammation progressively.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/7143014' target='_blank' class='pmid-link'>7143014</a>:</span> <span class='sentence-part'>Is the loss of cerebral cortical choline acetyl transferase activity in Alzheimer's disease due to degeneration of ascending cholinergic nerve cells.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/7509608' target='_blank' class='pmid-link'>7509608</a>:</span> <span class='sentence-part'>A substantial body of literature has suggested that the memory and learning deficits associated with Alzheimer's disease are attributable to degeneration of the cholinergic magnocellular neurons of the nucleus basalis of Meynert (nbM).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/9111743' target='_blank' class='pmid-link'>9111743</a>:</span> <span class='sentence-part'>Pathological comparison between cases with Alzheimer-type dementia (ATD) and the non-demented cases with infarct showed that hippocampal atrophy in ATD could be caused mainly by degeneration of the stratum lacunosum-radiatum rather than neuronal loss in the pyramidal layer of the hippocampus, and that degeneration of the stratum lacunosum-radiatum could be secondary mainly to the entorhinal cortical degeneration.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/9527715' target='_blank' class='pmid-link'>9527715</a>:</span> <span class='sentence-part'>These findings led to consider cholinergic deficit as the main disturbance in AD, due to degeneration of presynaptic cholinergic neurons, and that replacement of acetylcholine could restore the cognitive alterations characteristic of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/9619150' target='_blank' class='pmid-link'>9619150</a>:</span> <span class='sentence-part'>OBJECTIVE: Diffuse brain atrophy is one of the gross pathological features of Alzheimer's disease and is a result of degenerative changes.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/9632306' target='_blank' class='pmid-link'>9632306</a>:</span> <span class='sentence-part'>The system may eventually be applicable to the development of pharmaceutical agents that interfere with formation and/or degeneration of PHF-tau in Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/9794144' target='_blank' class='pmid-link'>9794144</a>:</span> <span class='sentence-part'>The particular contribution of muscarinic receptors, beta-amyloid and tau proteins in the pathogenesis of Alzheimer's disease remains still unclear. Probably Alzheimer's disease could be due to a progressive degeneration in the relationship between the three components covered in this review.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/9854137' target='_blank' class='pmid-link'>9854137</a>:</span> <span class='sentence-part'>Alzheimer's disease, the most common form of senile dementia, affects more than 15 million people world-wide and is characterized by a marked deterioration in memory and all cognitive functions, as a result of a progressive degeneration and loss of cortical and limbic neurons.</span></div></div>
<div class='streamlined-assertion'><div class='streamlined-header sticky-relation-header'><span class='label-text'>Subject:</span> <strong>Dementia</strong> <span class='label-text'>Subject CUI:</span> <strong>C0497327</strong> â†’ <span class='label-text predicate-text'>CAUSES</span> â†’ <span class='label-text'>Object:</span> <strong>Alzheimers</strong> <span class='label-text'>Object CUI:</span> <strong>C0002395</strong></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/10867221' target='_blank' class='pmid-link'>10867221</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) and cerebrovascular dementia (CVD) are two major causes of senile dementia in elderly individuals.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/12480441' target='_blank' class='pmid-link'>12480441</a>:</span> <span class='sentence-part'>Different forms of dementia are now distinguished-Alzheimer's disease, dementia with Lewy bodies, frontotemporal dementia, and dementia secondary to disease, such as AIDS dementia.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/15608634' target='_blank' class='pmid-link'>15608634</a>:</span> <span class='sentence-part'>A central unresolved problem in research on Alzheimer disease is the nature of the molecular entity causing dementia.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/16037976' target='_blank' class='pmid-link'>16037976</a>:</span> <span class='sentence-part'>These results suggest that the activation of this enzyme occurs early in the course of AD, before the onset of overt dementia, thereby implicating 12/15LOX-mediated lipid peroxidation in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/16046825' target='_blank' class='pmid-link'>16046825</a>:</span> <span class='sentence-part'>They are consistent with the hypothesis that brain hypoperfusion contributes to dementia, possibly to AD pathogenesis, and raise the possibility that the APOE allele epsilon 4 contributes directly to heart valve and myocardial damage.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/16092095' target='_blank' class='pmid-link'>16092095</a>:</span> <span class='sentence-part'>PD-dementia (PDD) and dementia with Lewy bodies (DLB) are second to Alzheimer's disease in causing degenerative dementia in the elderly.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/16401890' target='_blank' class='pmid-link'>16401890</a>:</span> <span class='sentence-part'>BACKGROUND: Although QOL is an important indicator to assess multiple facets of life, the QOL of Alzheimer's disease (AD) subjects with impaired cognitive ability due to dementia has not yet been fully investigated.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17143085' target='_blank' class='pmid-link'>17143085</a>:</span> <span class='sentence-part'>Significant changes in personality are typically associated with frontotemporal lobar degeneration (e.g., slowly progressive sociopathy), Alzheimer's disease, mild cognitive impairment due to incipient dementia or underlying medical illness.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/18041446' target='_blank' class='pmid-link'>18041446</a>:</span> <span class='sentence-part'>At present, different forms of dementia are distinguished, including Alzheimer's disease (AD), dementia with Lewy bodies, frontotemporal dementia, and dementia secondary to diseases, such as AIDS dementia.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/19672571' target='_blank' class='pmid-link'>19672571</a>:</span> <span class='sentence-part'>Homonymous visual field disorders, impaired elementary visual capacities (e.g. acuity, contrast sensitivity, convergent fusion, oculomotor disorders), visual neglect, Balint-Holmes syndrome or dementia (e.g. Alzheimer's disease) are the most frequent causes of such disorders.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20596916' target='_blank' class='pmid-link'>20596916</a>:</span> <span class='sentence-part'>Various innovative diagnostic methods for Alzheimer's disease (AD) have been developed in view of the increasing prevalence and consequences of later-life dementia.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21542885' target='_blank' class='pmid-link'>21542885</a>:</span> <span class='sentence-part'>The clinical and scientific study of dementia in adults with Down syndrome led to the development of the amyloid hypothesis as a fundamental concept in Alzheimer's disease pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22492589' target='_blank' class='pmid-link'>22492589</a>:</span> <span class='sentence-part'>The ROSA and four standard instruments -- the Alzheimer's disease Assessment Scale-cognitive (ADAS-cog), Severe Impairment Battery (SIB), Disability Assessment for Dementia (DAD), and the Neuropsychiatric Inventory (NPI) -- were used in an open-label, multicenter, single-arm clinical study to assess treatment-induced changes in cognitive, functional, and behavioral symptoms in patients with AD at different severity stages.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22574282' target='_blank' class='pmid-link'>22574282</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD), the most common form of dementia, is an age-dependent progressive neurodegenerative disorder. beta-amyloid, a metabolic product of the amyloid precursor protein (APP), plays an important role in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23100439' target='_blank' class='pmid-link'>23100439</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) is the most common progressive neurodegenerative disorder causing dementia.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23338285' target='_blank' class='pmid-link'>23338285</a>:</span> <span class='sentence-part'>Dementia in 2012: Further insights into Alzheimer disease pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23707728' target='_blank' class='pmid-link'>23707728</a>:</span> <span class='sentence-part'>The clinical syndrome of dementia has several aetiologies of which Alzheimer's disease (AD) is the most common.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23828739' target='_blank' class='pmid-link'>23828739</a>:</span> <span class='sentence-part'>Therefore, a disorder primarily affecting structures in medial temporal lobe, with accumulation of amyloid beta and abnormal tau, neuritic plaques and tangles, progressive loss of memory and/or other cognitive deficits, ultimately resulting in dementia should be classified as AD. Alzheimer's disease (AD), the most prevalent disorder causing dementia, is considered a neurodegenerative disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24505903' target='_blank' class='pmid-link'>24505903</a>:</span> <span class='sentence-part'>30 % of the cases are wrongly diagnosed with Alzheimer, being in fact other forms of dementia, or that we deal with several biologic processes, generating rather an Alzheimer's syndrome, meanwhile others are unsatisfied by a poor diagnosed disease and its popular receipt as a part of the normal aging process.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25083748' target='_blank' class='pmid-link'>25083748</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) is the most prevalent form of dementia, and aggregation of amyloid beta-proteins (Abeta) into soluble oligomers and fibrils has been implicated in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25435921' target='_blank' class='pmid-link'>25435921</a>:</span> <span class='sentence-part'>The aim of this study was to examine the relation between AD pathologies and early death in AD caused by dementia.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/2545826' target='_blank' class='pmid-link'>2545826</a>:</span> <span class='sentence-part'>The relatively small difference in the prevalence of Lewy bodies between controls and Alzheimer's disease could be explained by the additive effects of Lewy body and tangle pathology causing dementia, rather than a greater than chance association between Parkinson's disease and Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26161148' target='_blank' class='pmid-link'>26161148</a>:</span> <span class='sentence-part'>Emerging evidence for the potential co-contributions of small vessel vasculopathy to dementia has resulted in a more nuanced view of Alzheimer's disease (AD) pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26862951' target='_blank' class='pmid-link'>26862951</a>:</span> <span class='sentence-part'>Molecular alterations in ITM2B are associated with 2 neurodegenerative diseases, Familial British and Danish dementia, and dysregulation of ITM2B function has been implicated in the pathogenesis of Alzheimer disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26882509' target='_blank' class='pmid-link'>26882509</a>:</span> <span class='sentence-part'>BACKGROUND AND AIMS: Caregivers of individuals with neurodegenerative diseases, including frontotemporal dementia (FTD), Lewy body dementia (DLB), and Alzheimer's disease (AD), experience high levels of psychological and physical stress, likely due to behavioral and psychological symptoms of dementia (BPSD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27040140' target='_blank' class='pmid-link'>27040140</a>:</span> <span class='sentence-part'>AD is a neurodegenerative disorder causing dementia with no cure nor means for definitive diagnosis during life.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27554603' target='_blank' class='pmid-link'>27554603</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) is the general consequence of dementia and is diagnostic neuropathology by the cumulation of amyloid-beta (Abeta) protein aggregates, which are thought to promote mitochondrial dysfunction processes leading to neurodegeneration.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27890830' target='_blank' class='pmid-link'>27890830</a>:</span> <span class='sentence-part'>Vascular cognitive impairment and dementia (VCID) is the second leading cause of dementia behind Alzheimer's disease (AD) and is a frequent co-morbidity with AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28522216' target='_blank' class='pmid-link'>28522216</a>:</span> <span class='sentence-part'>DISCUSSION: This large prospective study of French older adults suggests that maintaining adequate vitamin D status in older age could contribute to slow down cognitive decline and to delay or prevent the onset of dementia, especially of AD etiology.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28729192' target='_blank' class='pmid-link'>28729192</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) is the most common neurodegenerative disorder causing dementia.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29226870' target='_blank' class='pmid-link'>29226870</a>:</span> <span class='sentence-part'>Despite the wide knowledge on factors influencing dementia risk, little is known on what accounts for AD progression.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29383688' target='_blank' class='pmid-link'>29383688</a>:</span> <span class='sentence-part'>APP is involved in the pathology of Alzheimer's disease (AD), the most common neurodegenerative disorder causing dementia.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29389553' target='_blank' class='pmid-link'>29389553</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) is the most common cause of dementia in the elderly. beta-Amyloid (Abeta) has been proposed to play a role in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29957266' target='_blank' class='pmid-link'>29957266</a>:</span> <span class='sentence-part'>When hospitalizations were classified according to the main diagnosis, chronic skin ulcers, functional impairment and daily urinary incontinence were associated with hospitalization due to infectious diseases; impaired cognitive capacity, Alzheimer's disease or other dementia and polypharmacy (protective effect) were associated with hospitalizations due to dementia; age of &gt;=90 years, congestive heart failure, coronary artery disease and using &gt;=10 drugs with hospitalizations due to heart diseases; and moderate or strong pain with hospitalization due to musculoskeletal disorders.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30424485' target='_blank' class='pmid-link'>30424485</a>:</span> <span class='sentence-part'>Hallmarks of Alzheimer's disease (AD), a progressive neurodegenerative disease causing dementia, include protein aggregates such as amyloid beta plaques and tau neurofibrillary tangles in a patient's brain.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30696930' target='_blank' class='pmid-link'>30696930</a>:</span> <span class='sentence-part'>Dementia was further categorised into Alzheimer's disease (AD), vascular dementia (VaD), and dementia caused by other diseases (ODs).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30942758' target='_blank' class='pmid-link'>30942758</a>:</span> <span class='sentence-part'>The brain ventricles are surrounded by periventricular structures that are affected by dementia which results in neurodegenerative disorder such as Alzheimer's Disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30949934' target='_blank' class='pmid-link'>30949934</a>:</span> <span class='sentence-part'>Molecular Docking and Cognitive Impairment Attenuating Effect of Phenolic Compound Rich Fraction of Trianthema portulacastrum in Scopolamine Induced Alzheimer's Disease Like Condition. Dementia is considered as the frequent cause of neurodegenerative mental disorder such as Alzheimer's disease (AD) amongst elderly people.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30998476' target='_blank' class='pmid-link'>30998476</a>:</span> <span class='sentence-part'>Mild cognitive impairment (MCI) is the preliminary stage of dementia, which may lead to Alzheimer's disease (AD) in the elderly people.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31182772' target='_blank' class='pmid-link'>31182772</a>:</span> <span class='sentence-part'>Many mutations in the amyloid precursor protein (APP) and presenilin 1 and 2 (PSEN1 and PSEN2) have been reported as the pathogenic causes of early-onset AD (EOAD), which accounts for up to 5% of all AD cases. Alzheimer's disease (AD) is the most common type of neurodegenerative dementia, but the cause of AD remained poorly understood.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31248465' target='_blank' class='pmid-link'>31248465</a>:</span> <span class='sentence-part'>METHOD: Data from the initial administration of the MINT were obtained on NACC participants who were cognitively normal (N = 3,981) or diagnosed with mild cognitive impairment (N = 852) or dementia (N = 1,148) with presumed etiology of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31356838' target='_blank' class='pmid-link'>31356838</a>:</span> <span class='sentence-part'>BACKGROUND: Alzheimer's disease (AD) is the most common neurodegenerative disease causing dementia in the elderly population.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31486140' target='_blank' class='pmid-link'>31486140</a>:</span> <span class='sentence-part'>Recognition of the long-term detrimental consequences of migraines for AD and dementia has implications for migraine management, as well as for our understanding of AD etiology.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32615251' target='_blank' class='pmid-link'>32615251</a>:</span> <span class='sentence-part'>Increased GABAergic Development in iPSC-Derived Neurons from Patients with Sporadic Alzheimer's Disease.Alzheimer's disease (AD) is the most common cause of dementia in the elderly, and the underlying molecular mechanisms of this neurodegenerative disorder are still unclear. gamma-aminobutyric acid (GABA) neurons play an essential role in the excitatory/inhibitory (E/I) balance in the brain, and the GABAergic system may contribute to the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33126501' target='_blank' class='pmid-link'>33126501</a>:</span> <span class='sentence-part'>Alzheimer's Disease (AD) is a progressive multifactorial age-related neurodegenerative disorder that causes the majority of deaths due to dementia in the elderly.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33207563' target='_blank' class='pmid-link'>33207563</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) is a fatal neurodegenerative disorder caused by protein misfolding and aggregation, affecting brain function and causing dementia.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33396415' target='_blank' class='pmid-link'>33396415</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) is the most prevalent neurodegenerative disease causing dementia and poses significant health risks to middle-aged and elderly people.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33472953' target='_blank' class='pmid-link'>33472953</a>:</span> <span class='sentence-part'>Advances in molecular positron emission tomography (PET) have enabled anatomic tracking of brain pathology in longitudinal studies of normal aging and dementia, including assessment of the central model of Alzheimer's disease (AD) pathogenesis, according to which TAU pathology begins focally but expands catastrophically under the influence of amyloid-beta (Abeta) pathology to mediate neurodegeneration and cognitive decline.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34237255' target='_blank' class='pmid-link'>34237255</a>:</span> <span class='sentence-part'>In 2016, YLDs due to Alzheimer's dementia, vascular dementia, and MCI composed 37% (177 per 100,000), 18% (85 per 100,000), and 15% (70 per 100,000), respectively, of the total YLDs due to MCI and all-cause dementia. In 2016, DALYs attributed to Alzheimer's dementia, vascular dementia, and MCI accounted for 33% (423 per 100,000), 20% (316 per 100,000), and 24% (123 per 100,000), respectively, of the total DALYs due to MCI and all-cause dementia. In 2065, YLDs due to Alzheimer's dementia, vascular dementia, and MCI will account for 48% (1358 per 100,000), 15% (410 per 100,000), and 10% (290 per 100,000), respectively, of total YLDs due to MCI and all-cause dementia. In 2065, DALYs due to Alzheimer's dementia, vascular dementia, and MCI will account for 38% (3654 per 100,000), 17% (1654 per 100,000), and 27% (2585 per 100,000) of total DALYs due to MCI and all-cause dementia, respectively.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35493944' target='_blank' class='pmid-link'>35493944</a>:</span> <span class='sentence-part'>Mild Cognitive Impairment (MCI) is an early stage of dementia, which may lead to Alzheimer's disease (AD) in older adults.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36113115' target='_blank' class='pmid-link'>36113115</a>:</span> <span class='sentence-part'>Despite early mentions of dementia in the ancient literature and the first patient diagnosed in 1906, the underlying causes of AD are not well understood.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36254682' target='_blank' class='pmid-link'>36254682</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) is the most common form of dementia, and risk-influencing genetics implicates microglia and neuroimmunity in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36362376' target='_blank' class='pmid-link'>36362376</a>:</span> <span class='sentence-part'>The biological plausibility of the link between high adiposity, insulin resistance, and dementia is central for understanding AD etiology, and to form bases for prevention efforts to decrease the disease burden.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37223834' target='_blank' class='pmid-link'>37223834</a>:</span> <span class='sentence-part'>Conclusions: We identified a gap in the literature on the description of the psychotic symptoms of dementia, mainly in those of non-AD etiologies.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37425748' target='_blank' class='pmid-link'>37425748</a>:</span> <span class='sentence-part'>ABri plaques are accompanied by tau pathology, neuronal cell death and progressive dementia, with striking parallels to the aetiology and pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37543811' target='_blank' class='pmid-link'>37543811</a>:</span> <span class='sentence-part'>In particular, Alzheimer disease, the most common type causing dementia, remains an incurable disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37629545' target='_blank' class='pmid-link'>37629545</a>:</span> <span class='sentence-part'>Considering the results obtained, DTZ might have a potential therapeutic role in treating and managing AD and related dementia pathologies due to its anti-dementia activity in SAD-type conditions in rats induced by ICV-STZ. Repurposing Diltiazem for Its Neuroprotective Anti-Dementia Role against Intra-Cerebroventricular Streptozotocin-Induced Sporadic Alzheimer's Disease-Type Rat Model. In the present study, the neuroprotective anti-dementia effects of DTZ against intra-cerebroventricular-streptozotocin (ICV-STZ)-induced sporadic AD (SAD)-type rat model was investigated.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/38491393' target='_blank' class='pmid-link'>38491393</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) is the most prevailing form of dementia, with long-term high-fat diet (HFD) consumption being a pivotal contributor to AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/8739399' target='_blank' class='pmid-link'>8739399</a>:</span> <span class='sentence-part'>This paper summarizes results of the Vienna Longitudinal Study on Dementia obtained during the past few years and presents a critical discussion on the relevance of clinicopathological correlation studies for the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/9058061' target='_blank' class='pmid-link'>9058061</a>:</span> <span class='sentence-part'>In spite of this progress, the pathogenetic events that differentiate normal brain aging from the early stages of dementia and may lead eventually to AD are not completely understood.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/9625186' target='_blank' class='pmid-link'>9625186</a>:</span> <span class='sentence-part'>CONCLUSIONS: In a population aged 75 to 85 years, the presence of an apoE e4 allele is associated with impaired cognitive function, clinical dementia, AD, and excess 5-year mortality resulting from dementia and all causes.</span></div></div>
<div class='streamlined-assertion'><div class='streamlined-header sticky-relation-header'><span class='label-text'>Subject:</span> <strong>Deterioration</strong> <span class='label-text'>Subject CUI:</span> <strong>C0868945</strong> â†’ <span class='label-text predicate-text'>CAUSES</span> â†’ <span class='label-text'>Object:</span> <strong>Alzheimers</strong> <span class='label-text'>Object CUI:</span> <strong>C0002395</strong></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/11244216' target='_blank' class='pmid-link'>11244216</a>:</span> <span class='sentence-part'>It may also represent, reflect or account for the impaired neuronal transmission in DS and AD, caused by deterioration of the exocytic machinery.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/12214126' target='_blank' class='pmid-link'>12214126</a>:</span> <span class='sentence-part'>Because AD is a disease of neuronal and synaptic deterioration, APP may be involved during the course of AD pathogenesis, perhaps secondarily. The presence of mutations around the A beta sequence in APP provides strong argument for the involvement of APP, and A beta in particular, in pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/12657430' target='_blank' class='pmid-link'>12657430</a>:</span> <span class='sentence-part'>There is much evidence suggesting that there is a strong relationship between the deterioration of brain lipid homeostasis, vascular changes and the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21809745' target='_blank' class='pmid-link'>21809745</a>:</span> <span class='sentence-part'>In it EN provides evidence that in true Alzheimer dementia (AD), memory loss is the initially dominating problem due to deterioration of the circulation in the hippocampus, which has a vulnerable blood supply to begin with.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23512996' target='_blank' class='pmid-link'>23512996</a>:</span> <span class='sentence-part'>BACKGROUND: Relating to Alzheimer's disease (AD), dependence has been defined as the increased need for assistance due to deterioration in cognition, physical functioning, and behavior.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24499794' target='_blank' class='pmid-link'>24499794</a>:</span> <span class='sentence-part'>The deterioration of subcellular organelles, including the mitochondria, is another major ultrastructural characteristic of AD pathogenesis, in addition to amyloid plaque deposition.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29042514' target='_blank' class='pmid-link'>29042514</a>:</span> <span class='sentence-part'>Our results suggest deterioration of DNA integrity as a central contributing factor in AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29604402' target='_blank' class='pmid-link'>29604402</a>:</span> <span class='sentence-part'>BACKGROUND: Alzheimer's disease is a neurodegenerative brain disease resulting from the deterioration of neuronal cells and vascular dementia, the latter of which results from cerebrovascular disorders.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/2965684' target='_blank' class='pmid-link'>2965684</a>:</span> <span class='sentence-part'>It is concluded that at this age Down's and mentally retarded with different etiologies generally have rather similar cognitive abilities and that the intellectual deterioration of Down's, which at a later age inevitably leads to Alzheimer's disease, indeed starts only at a later CA.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36056872' target='_blank' class='pmid-link'>36056872</a>:</span> <span class='sentence-part'>The progressive deterioration of neurons leads to Alzheimer's disease (AD), and developing a drug for this disorder is challenging.</span></div></div>
<div class='streamlined-assertion'><div class='streamlined-header sticky-relation-header'><span class='label-text'>Subject:</span> <strong>Diabetes</strong> <span class='label-text'>Subject CUI:</span> <strong>C0011847</strong> â†’ <span class='label-text predicate-text'>CAUSES</span> â†’ <span class='label-text'>Object:</span> <strong>Alzheimers</strong> <span class='label-text'>Object CUI:</span> <strong>C0002395</strong></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/14702004' target='_blank' class='pmid-link'>14702004</a>:</span> <span class='sentence-part'>Does diabetes protect or provoke Alzheimer's disease?</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17130475' target='_blank' class='pmid-link'>17130475</a>:</span> <span class='sentence-part'>These results show that insulin deficiency causes rapid and large increases in tau phosphorylation, a condition that could prime tau for the neuropathology of Alzheimer's disease, thereby contributing to the increased susceptibility to Alzheimer's disease caused by diabetes.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/19188609' target='_blank' class='pmid-link'>19188609</a>:</span> <span class='sentence-part'>The finding that synapse vulnerability to ADDLs can be mitigated by insulin suggests that bolstering brain insulin signaling, which can decline with aging and diabetes, could have significant potential to slow or deter AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21044348' target='_blank' class='pmid-link'>21044348</a>:</span> <span class='sentence-part'>CONCLUSIONS: Our present data indicate that there is a close link between insulin deficient diabetes and cerebral amyloidosis in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22785400' target='_blank' class='pmid-link'>22785400</a>:</span> <span class='sentence-part'>AD-type pathology demonstrated in genetically unmodified rabbits calls attention to the considerable potential of the model for investigation of AD pathogenesis, diagnostics, and therapeutics. Amyloid-beta and tau pathology of Alzheimer's disease induced by diabetes in a rabbit animal model.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23020846' target='_blank' class='pmid-link'>23020846</a>:</span> <span class='sentence-part'>Diabetes is a risk factor in the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25096625' target='_blank' class='pmid-link'>25096625</a>:</span> <span class='sentence-part'>Diabetes is considered to be a risk factor in Alzheimer's disease (AD) pathogenesis. To determine whether mitochondrial perturbation is associated with the contribution of diabetes to AD progression, we characterized mouse models of streptozotocin (STZ)-induced type 1 diabetes and transgenic AD mouse models with diabetes.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25976367' target='_blank' class='pmid-link'>25976367</a>:</span> <span class='sentence-part'>Several preclinical and epidemiological studies have linked metabolic risk factors such as hypertension, obesity, dyslipidemia, and diabetes to the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26969101' target='_blank' class='pmid-link'>26969101</a>:</span> <span class='sentence-part'>Interestingly, recent epidemiological studies indicate that diabetes significantly increases the risk of developing AD, suggesting that diabetes may play a causative role in the development of AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28957663' target='_blank' class='pmid-link'>28957663</a>:</span> <span class='sentence-part'>Diabetes and impaired brain insulin signaling are linked to the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30043289' target='_blank' class='pmid-link'>30043289</a>:</span> <span class='sentence-part'>Even though the relationship between diabetes and AD was indicated by significant evidences, the critical mechanisms and metabolic alterations in diabetes induced AD are not clear until now. Iron metabolism in diabetes-induced Alzheimer's disease: a focus on insulin resistance in the brain.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30225625' target='_blank' class='pmid-link'>30225625</a>:</span> <span class='sentence-part'>Correction to: Iron metabolism in diabetes-induced Alzheimer's disease: a focus on insulin resistance in the brain.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30364261' target='_blank' class='pmid-link'>30364261</a>:</span> <span class='sentence-part'>Increased risks for Alzheimer's disease (AD) are a well-recognized consequence of diabetes, insulin resistance (IR), and hyperinsulinemia.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30958383' target='_blank' class='pmid-link'>30958383</a>:</span> <span class='sentence-part'>Moreover, diabetes-induced AD-like behavioral and pathological changes were associated with a decrease in neuronal cell autophagy.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31068802' target='_blank' class='pmid-link'>31068802</a>:</span> <span class='sentence-part'>Docosahexaenoic Acid Increases the Potency of Soluble Epoxide Hydrolase Inhibitor in Alleviating Streptozotocin-Induced Alzheimer's Disease-Like Complications of Diabetes. Also, we evaluated the effect of edaravone, an antioxidant on diabetes-induced Alzheimer's-like complications and the additive effect of docosahexaenoic acid (DHA) on the efficacy of TPPU.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31156159' target='_blank' class='pmid-link'>31156159</a>:</span> <span class='sentence-part'>These results provide mechanistic insight into the beneficial effects of insulin, and a possible link between insulin deficient diabetes and cerebral amyloidosis in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32436237' target='_blank' class='pmid-link'>32436237</a>:</span> <span class='sentence-part'>Thus, targeting PICALM and mTORC1 to prevent endosomal disorders is a promising strategy for managing diabetes-induced AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34256527' target='_blank' class='pmid-link'>34256527</a>:</span> <span class='sentence-part'>Additionally, the risk of increased progression of AD was revealed due to pre-diabetes, T2DM and gut dysbiosis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34347307' target='_blank' class='pmid-link'>34347307</a>:</span> <span class='sentence-part'>In view of its wide range of pharmacological activities, bergapten is expected to be a potential drug candidate for the treatment of diabetes and diabetes-induced osteoporosis, epilepsy, Alzheimer's disease, depression, and cancer.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34609116' target='_blank' class='pmid-link'>34609116</a>:</span> <span class='sentence-part'>The complications that are discussed in this article are diabetic nephropathy, diabetes induced cardiovascular disease, diabetic neuropathy, Diabetic Foot Ulcer (DFU) and Alzheimer's disease. The progression of AD can be due to the change in DNA methylation of CLOCK gene, followed with worsening of AD by APOE4 gene due to dyslipidaemia condition in T2DM patients. Insulin resistance is also a factor that contributes to pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36262805' target='_blank' class='pmid-link'>36262805</a>:</span> <span class='sentence-part'>Our findings provide insight of targeting ERK as a therapeutic application for diabetes-induced AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37414154' target='_blank' class='pmid-link'>37414154</a>:</span> <span class='sentence-part'>Furthermore, we have presented an overview of the main pathways that can be targeted to mitigate the progression of AD and the cognitive impairment caused by diabetes.</span></div></div>
<div class='streamlined-assertion'><div class='streamlined-header sticky-relation-header'><span class='label-text'>Subject:</span> <strong>Diabetes_Mellitus_Non_Insulin_Dependent</strong> <span class='label-text'>Subject CUI:</span> <strong>C0011860</strong> â†’ <span class='label-text predicate-text'>CAUSES</span> â†’ <span class='label-text'>Object:</span> <strong>Alzheimers</strong> <span class='label-text'>Object CUI:</span> <strong>C0002395</strong></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22829447' target='_blank' class='pmid-link'>22829447</a>:</span> <span class='sentence-part'>Thus, the insulin resistance that underlies the pathogenesis of T2DM might also trigger accumulation of autophagosomes, leading to increased Abeta generation, which might be involved in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24121970' target='_blank' class='pmid-link'>24121970</a>:</span> <span class='sentence-part'>Experimental induction of type 2 diabetes in aging-accelerated mice triggered Alzheimer-like pathology and memory deficits.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25082505' target='_blank' class='pmid-link'>25082505</a>:</span> <span class='sentence-part'>Additionally, we provide up-to-date perspectives on critical areas of AD research with special reference to common NO-related etiological factors linking Type 2 diabetes to the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25230234' target='_blank' class='pmid-link'>25230234</a>:</span> <span class='sentence-part'>With an abundance of common mechanisms underpinning both disorders, a significant question that can be posed is whether T2DM leads to AD in aged individuals and the associations between other protein misfolding diseases.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27810390' target='_blank' class='pmid-link'>27810390</a>:</span> <span class='sentence-part'>Previous studies in high-fat diet-induced AD animal models have shown that brain insulin resistance in these animals leads to the accumulation of amyloid beta (Abeta) and the reduction in GSK-3beta phosphorylation, which promotes tau phosphorylation to cause AD. The aim of this study was to investigate the ability of agmatine to treat AD induced by brain insulin resistance. Agmatine ameliorates type 2 diabetes induced-Alzheimer's disease-like alterations in high-fat diet-fed mice via reactivation of blunted insulin signalling.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29382127' target='_blank' class='pmid-link'>29382127</a>:</span> <span class='sentence-part'>Interestingly, epidemiological studies have described a relationship between type 2 diabetes mellitus (T2DM) and this pathology, being one of the risk factors for the development of AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30964050' target='_blank' class='pmid-link'>30964050</a>:</span> <span class='sentence-part'>On the other hand, the increased phosphorylation of IRS1 at several serine sites is observed in the brains from patients with AD and animal models of AD or cognitive impairment induced by type 2 diabetes.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31817238' target='_blank' class='pmid-link'>31817238</a>:</span> <span class='sentence-part'>Human pathologies such as Alzheimer's disease, type 2 diabetes-induced insulin resistance, cancer, and cardiovascular diseases have altered lipid homeostasis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32602568' target='_blank' class='pmid-link'>32602568</a>:</span> <span class='sentence-part'>However, lack of any significant effect on P-tau load, oxidative stress, neuroinflammation, and insulin resistance raise the question about the ability of donepezil to delay the development or arrest the progression of T2D-induced AD and it is still a matter of debate that require further studies.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33797062' target='_blank' class='pmid-link'>33797062</a>:</span> <span class='sentence-part'>The prevalence of T2D leading to AD is approximately 50-70%.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34256527' target='_blank' class='pmid-link'>34256527</a>:</span> <span class='sentence-part'>Additionally, the risk of increased progression of AD was revealed due to pre-diabetes, T2DM and gut dysbiosis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35639033' target='_blank' class='pmid-link'>35639033</a>:</span> <span class='sentence-part'>Protective effects of L-arginine on cognitive deficits and biochemical parameters in an experimental model of type-2 diabetes mellitus induced Alzheimer's disease in rats.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36505102' target='_blank' class='pmid-link'>36505102</a>:</span> <span class='sentence-part'>Can Alzheimer's Disease Be Secondary to Type-2 Diabetes Mellitus?</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36849855' target='_blank' class='pmid-link'>36849855</a>:</span> <span class='sentence-part'>Therefore, large-scale prospective and comparative studies involving long-term metformin therapy in both diabetic and non-diabetic patients are required to exclude the effect of T2DM-induced AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37554106' target='_blank' class='pmid-link'>37554106</a>:</span> <span class='sentence-part'>Molecular docking was used to predict possible protein targets for T2DM-induced AD. Aim:     The purpose of this study was to elucidate the potential mechanisms of Alzheimer's disease (AD) induced by Type 2 diabetes mellitus (T2DM) through bioinformatics analysis, to provide new treatment targets for this disease. Results:     The direct interaction of CD44 and STAT3 may play a significant role in the development of T2DM-induced AD. Exploring the molecular targets for Type 2 diabetes-induced Alzheimer's disease through bioinformatics analysis.</span></div></div>
<div class='streamlined-assertion'><div class='streamlined-header sticky-relation-header'><span class='label-text'>Subject:</span> <strong>Diet</strong> <span class='label-text'>Subject CUI:</span> <strong>C0012155</strong> â†’ <span class='label-text predicate-text'>CAUSES</span> â†’ <span class='label-text'>Object:</span> <strong>Alzheimers</strong> <span class='label-text'>Object CUI:</span> <strong>C0002395</strong></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22406440' target='_blank' class='pmid-link'>22406440</a>:</span> <span class='sentence-part'>We have previously demonstrated that cholesterol-enriched diet causes AD-like pathology with iron deposition in rabbit brain.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22533436' target='_blank' class='pmid-link'>22533436</a>:</span> <span class='sentence-part'>Alzheimer disease (AD) and metabolic syndrome are two highly prevalent pathological conditions of Western society due to incorrect diet, lifestyle, and vascular risk factors.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22914588' target='_blank' class='pmid-link'>22914588</a>:</span> <span class='sentence-part'>Diet is an important lifestyle factor implicated in the etiology of Alzheimer's disease (AD), but so far it is not fully elucidated to which nutrients the suggested protective effect of diet can be attributed.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23530509' target='_blank' class='pmid-link'>23530509</a>:</span> <span class='sentence-part'>The more common sporadic form of Alzheimer disease (SAD) and the metabolic syndrome are two highly prevalent pathological conditions of Western society due to incorrect diet, lifestyle, and vascular risk factors.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24286859' target='_blank' class='pmid-link'>24286859</a>:</span> <span class='sentence-part'>The ameliorating effects of the diet on the OBX-induced changes were comparable to those of the NMDA receptor antagonist, memantine, a drug used for the management of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26075716' target='_blank' class='pmid-link'>26075716</a>:</span> <span class='sentence-part'>The fact that genetic factors account for less than 50% cases of sporadic Alzheimer's disease (AD) highlights the important contribution of environmental factors, such as high-salt diet, in AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28575011' target='_blank' class='pmid-link'>28575011</a>:</span> <span class='sentence-part'>Here, we tested this hypothesis by assessing the efficacy of HT against diet-induced obesity and AD-related pathology in female 3xTg-AD mice at early versus late middle-age.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30704467' target='_blank' class='pmid-link'>30704467</a>:</span> <span class='sentence-part'>Overall, our study provides intriguing evidence for the role of diet, as an important environmental factor, in AD etiology.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30954605' target='_blank' class='pmid-link'>30954605</a>:</span> <span class='sentence-part'>Increasing evidence has revealed that vascular risk factors influence the midlife development of AD and that diet-induced obesity accelerates tau phosphorylation in tau transgenic mice and increases the level of serum leptin receptor (leptin-R).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31240575' target='_blank' class='pmid-link'>31240575</a>:</span> <span class='sentence-part'>This literature review indicated that adherence to a healthy dietary pattern has neuroprotective effects on AD prevention, while unhealthy diet can cause neurodegenerative effects in AD etiology.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31600762' target='_blank' class='pmid-link'>31600762</a>:</span> <span class='sentence-part'>Poor Diet, Stress, and Inactivity Converge to Form a \Perfect Storm\ That Drives Alzheimer's Disease Pathogenesis. It is thus likely that lifestyle and environmental factors contribute to neurodegenerative processes implicated in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33750486' target='_blank' class='pmid-link'>33750486</a>:</span> <span class='sentence-part'>We hypothesized that Alzheimer's-like disease (AD) exacerbates osteoarthritis and that intermittent fasting(IMF) with a high-protein(H-P) diet would enhance memory function and relieve osteoarthritis symptoms in estrogen-deficient animals with surgically induced AD and osteoarthritis. Ovariectomized Sprague-Dawley rats were fed high-fat(H-F) or H-P diets for two weeks, and then they had a hippocampal infusion of beta-amyloid(25-35) for 4 weeks to induce AD and an injection of monoidoacetate(MIA) into the articular cartilage to induce osteoarthritis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33880134' target='_blank' class='pmid-link'>33880134</a>:</span> <span class='sentence-part'>High Methionine Diet-Induced Alzheimer's Disease like Symptoms Are Accompanied by 5-Methylcytosine Elevated Levels in the Brain.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34370639' target='_blank' class='pmid-link'>34370639</a>:</span> <span class='sentence-part'>Alkaloids on Alzheimer's Disease-like Symptoms Induced by High-methionine Diet. OBJECT: Whether DNLA can improve AD-like symptoms induced by HMD is to be explored. BACKGROUND: High methionine-diet (HMD) causes Alzheimer's disease (AD)-like symptoms. CONCLUSIONS: DNLA alleviated AD-like symptoms induced by HMD via the DNA methylation pathway.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35205079' target='_blank' class='pmid-link'>35205079</a>:</span> <span class='sentence-part'>Moreover, there has been growing evidence that a combination of antioxidants in conjugation with a nutrient-rich diet might be more effective in tackling AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36463453' target='_blank' class='pmid-link'>36463453</a>:</span> <span class='sentence-part'>OBJECTIVE: The purpose of this study was to evaluate the effects of a low-dose lithium supplementation on GSK3 activity in the brain of an early, diet-induced Alzheimer's disease model.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36894557' target='_blank' class='pmid-link'>36894557</a>:</span> <span class='sentence-part'>N-acetylneuraminic acid links immune exhaustion and accelerated memory deficit in diet-induced obese Alzheimer's disease mouse model.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/8940575' target='_blank' class='pmid-link'>8940575</a>:</span> <span class='sentence-part'>This can be further evidence that Hg from amalgam restorations or diet is not related to etiology and pathogenesis of AD.</span></div></div>
<div class='streamlined-assertion'><div class='streamlined-header sticky-relation-header'><span class='label-text'>Subject:</span> <strong>Disease</strong> <span class='label-text'>Subject CUI:</span> <strong>C0012634</strong> â†’ <span class='label-text predicate-text'>CAUSES</span> â†’ <span class='label-text'>Object:</span> <strong>Alzheimers</strong> <span class='label-text'>Object CUI:</span> <strong>C0002395</strong></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/10570621' target='_blank' class='pmid-link'>10570621</a>:</span> <span class='sentence-part'>UNLABELLED: BASIC: The loss of verbal fluency in Alzheimer's disease (AD) has been related to the cognitive and functional impairment caused by the disorder.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/10879068' target='_blank' class='pmid-link'>10879068</a>:</span> <span class='sentence-part'>These novel findings regarding the protein aggregates and causative genes for AD and related disorders will facilitate our understanding of the pathogenesis of AD, as well as development of therapeutic strategies against it.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/11006125' target='_blank' class='pmid-link'>11006125</a>:</span> <span class='sentence-part'>As NSP-C was also reduced in AD frontal cortex, NSP-C deficits in these disorders may be reflecting neurodegenerative changes rather than a primary and specific finding of DS or AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/11741391' target='_blank' class='pmid-link'>11741391</a>:</span> <span class='sentence-part'>In addition, it has revealed differences in apoC-I expression based on site, genotype, and disease status that may reflect a role for apoC-I in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/12480441' target='_blank' class='pmid-link'>12480441</a>:</span> <span class='sentence-part'>Different forms of dementia are now distinguished-Alzheimer's disease, dementia with Lewy bodies, frontotemporal dementia, and dementia secondary to disease, such as AIDS dementia.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/12740808' target='_blank' class='pmid-link'>12740808</a>:</span> <span class='sentence-part'>Despite the dramatic progress that has been made in understanding the disease, the exact cause of Alzheimer's disease is still unknown. The enigmatic proteases alpha-,beta-, and gamma-secretase are the three executioners of amyloid precursor protein processing, and disruption of their delicate balance is suspected to result in Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/14758627' target='_blank' class='pmid-link'>14758627</a>:</span> <span class='sentence-part'>For the first time the Alzheimer disease in monkeys was shown to entail a deficit of operative memory due to disorders in the sensory and cognitive components of the memory.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/15340159' target='_blank' class='pmid-link'>15340159</a>:</span> <span class='sentence-part'>Because enhanced neurogenesis occurs in both AD and an animal model of AD, it seems to be caused by the disease itself and not by confounding clinical factors.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/16120299' target='_blank' class='pmid-link'>16120299</a>:</span> <span class='sentence-part'>Mitochondrial dysfunction causes dozens of debilitating diseases, and is implicated in the etiology of type 2 diabetes, Parkinson's, and Alzheimer's diseases, among others.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17337008' target='_blank' class='pmid-link'>17337008</a>:</span> <span class='sentence-part'>However, evidence from epidemiological, neuropathological, clinical, pharmacological, and functional studies suggest considerable overlap in risk factors and pathological changes suggesting shared common pathogenic mechanisms between these two diseases such that vascular factors play a vital role in the pathogenesis of Alzheimer disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17892369' target='_blank' class='pmid-link'>17892369</a>:</span> <span class='sentence-part'>The onset of disease is not manifested clinically and little is known regarding the cause of nonfamiliar AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17922309' target='_blank' class='pmid-link'>17922309</a>:</span> <span class='sentence-part'>Moreover, accumulating evidence that mitochondria failure, reduced glucose utilization and deficient energy metabolism occur already very early in the course of the disease suggests a role of impaired insulin signalling in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/18041446' target='_blank' class='pmid-link'>18041446</a>:</span> <span class='sentence-part'>At present, different forms of dementia are distinguished, including Alzheimer's disease (AD), dementia with Lewy bodies, frontotemporal dementia, and dementia secondary to diseases, such as AIDS dementia.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/1976213' target='_blank' class='pmid-link'>1976213</a>:</span> <span class='sentence-part'>Disorders in somatostatin metabolism have been proposed to contribute to the pathogenesis of Alzheimer's disease, epilepsy, GI motility disorders, and diabetes.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/19777328' target='_blank' class='pmid-link'>19777328</a>:</span> <span class='sentence-part'>The markers of oxidative stress have been localized in the brain regions of AD and MCI that show pathological hallmarks of this disease, suggesting the possible role of Abeta in the initiation of the free-radical mediated process and consequently to the build up oxidative stress and AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20059701' target='_blank' class='pmid-link'>20059701</a>:</span> <span class='sentence-part'>For example, in neurodegenerative diseases such as Alzheimer disease (AD), evidence for abnormal cell cycle re-entry precedes other hallmarks of disease and as such, implicates cell cycle aberrations in the aetiology of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20305996' target='_blank' class='pmid-link'>20305996</a>:</span> <span class='sentence-part'>BACKGROUND: During the course of the Alzheimer's disease (AD), many patients need to be hospitalized either due to the direct consequences of the disease itself, or due to associated diseases or life event.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20413848' target='_blank' class='pmid-link'>20413848</a>:</span> <span class='sentence-part'>The accumulation of toxic amyloid-beta42 (Abeta42) peptide oligomers and aggregates in AD brain has been proposed to be primarily responsible for the pathology of the disease, an idea dubbed the 'amyloid hypothesis' of AD etiology.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20442493' target='_blank' class='pmid-link'>20442493</a>:</span> <span class='sentence-part'>Since its proposal in 1992, the amyloid cascade hypothesis implicates Abeta overproduction as a causative event in disease pathogenesis, and this thinking has predominated the field's understanding of AD pathogenesis and the development of potential therapeutics (i.e., Abeta-reducing agents).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20552018' target='_blank' class='pmid-link'>20552018</a>:</span> <span class='sentence-part'>In neurodegenerative disorders such as Alzheimer's disease (AD), brain miRNA profiles are altered; thus miRNA dysfunction could be both a cause and a consequence of disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20601643' target='_blank' class='pmid-link'>20601643</a>:</span> <span class='sentence-part'>While partially effective in improving symptoms, currently available treatments approved by the US Food and Drug Administration (FDA) do not halt progression of AD, or address the underlying mechanism of the disease, in part because the etiology of AD is still an active area of investigation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21391278' target='_blank' class='pmid-link'>21391278</a>:</span> <span class='sentence-part'>BACKGROUND: Cerebral small vessel disease (SVD) and hippocampal atrophy are related to verbal memory failures and may ultimately result in Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21504127' target='_blank' class='pmid-link'>21504127</a>:</span> <span class='sentence-part'>Mild cognitive impairment (MCI) is recognized as a prodromal phase of dementing disorders, and it has been suggested that oxidative stress may play a role in the pathogenesis of Alzheimer's disease (AD), and in predicting progression of MCI to AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22886015' target='_blank' class='pmid-link'>22886015</a>:</span> <span class='sentence-part'>While macroscopic stroke can clearly produce cognitive deficits and accelerate Alzheimer's disease, the prevalence and implications of microvascular disease in Alzheimer's disease pathogenesis has been harder to define.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/2313044' target='_blank' class='pmid-link'>2313044</a>:</span> <span class='sentence-part'>Alzheimer's disease is a major public health problem, yet little is known about the potential oral consequences of the disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23811083' target='_blank' class='pmid-link'>23811083</a>:</span> <span class='sentence-part'>Some significant novel genes and other variants for various biological processes have been reported as being associated with AD, AG, and other diseases, and these could be implicated in biochemical events leading to AD from AG through pathways, interactions, and associations. The present study aimed to identify genes with differential topology and their further association with other biological processes that regulate causative factors for AD, ageing (AG) and other diseases.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24059308' target='_blank' class='pmid-link'>24059308</a>:</span> <span class='sentence-part'>Our findings implicate diabetic disorders in the pathogenesis of AD, and provide a basis for future candidate studies based on specific pathways.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24899710' target='_blank' class='pmid-link'>24899710</a>:</span> <span class='sentence-part'>Few animal models of AD have been capable of isolating the relative contribution made by soluble and insoluble forms of Abeta to the behavioral symptoms and biochemical consequences of the disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25435363' target='_blank' class='pmid-link'>25435363</a>:</span> <span class='sentence-part'>Within this group, the top five leading causes of DALYs were: depressive disorders, Alzheimer's disease, migraine, substance-use disorders, and anxiety disorder, which accounted for 70.9% of all DALYs due to neuropsychiatric disorders.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26283893' target='_blank' class='pmid-link'>26283893</a>:</span> <span class='sentence-part'>Although no single model of AD is capable of providing the solution to the growing epidemic of the disease, we encourage a comprehensive approach that acknowledges the complex etiology of AD with the goal of enhancing the bidirectional translatability from bench to bedside and vice versa.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26618971' target='_blank' class='pmid-link'>26618971</a>:</span> <span class='sentence-part'>Tests of processing speed, working memory, verbal symbolic functions, and visuoperceptual and visuospatial judgment and problem solving are sensitive to the severity of TBI and AD, as well as to the functional consequences of these disorders, including ability to work, financial and medical decision-making capacities, and driving ability.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27094492' target='_blank' class='pmid-link'>27094492</a>:</span> <span class='sentence-part'>Mitochondrial dysfunction has been widely associated with the pathology of Alzheimer's disease, but there is no consensus on whether it is a cause or consequence of disease, nor on the precise mechanism(s).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27313503' target='_blank' class='pmid-link'>27313503</a>:</span> <span class='sentence-part'>Whether these changes are an initial cause for the onset of AD or occur as a result of the disease in late stages is still under debate.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27699087' target='_blank' class='pmid-link'>27699087</a>:</span> <span class='sentence-part'>Evidence from rodent and cell models show a number of neurotrophic and neuroprotective effects of guanosine preventing deleterious consequences of seizures, spinal cord injury, pain, mood disorders and aging-related diseases, such as ischemia, Parkinson's and Alzheimer's diseases.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28122529' target='_blank' class='pmid-link'>28122529</a>:</span> <span class='sentence-part'>Because the burden of AD on patients, families, healthcare providers, and society is substantial and increasing, it is important and necessary to understand the economic burden caused by this disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28261376' target='_blank' class='pmid-link'>28261376</a>:</span> <span class='sentence-part'>Studying AD from a metabolic perspective provides new insights into AD pathogenesis and may lead to the discovery of dietary metabolite supplements that can partially compensate for alterations of enzymatic function to delay AD or alleviate some of the suffering caused by the disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28387677' target='_blank' class='pmid-link'>28387677</a>:</span> <span class='sentence-part'>To date, neither any effective treatment nor prevention of Alzheimer's disease (AD), a major dementia causing disorder, are available.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29301530' target='_blank' class='pmid-link'>29301530</a>:</span> <span class='sentence-part'>OBJECTIVES: To understand AMD pathogenesis by analogy and suggest ideas for future research, this study summarizes main commonalities in disease pathogenesis of AMD, Alzheimer's disease, atherosclerosis and glomerulonephritis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/2941815' target='_blank' class='pmid-link'>2941815</a>:</span> <span class='sentence-part'>The theories put forward to explain the association between these two disorders and their possible significance to the understanding of the aetiology of Alzheimer's disease are discussed.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30546389' target='_blank' class='pmid-link'>30546389</a>:</span> <span class='sentence-part'>Although both amyloid beta peptide deposition and neurofibrillary tangle formation in the AD brain have been established as pathological hallmarks of the disease, many other factors contribute in a complex manner to the pathogenesis of AD before clinical symptoms of the disease become apparent.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30696930' target='_blank' class='pmid-link'>30696930</a>:</span> <span class='sentence-part'>Dementia was further categorised into Alzheimer's disease (AD), vascular dementia (VaD), and dementia caused by other diseases (ODs).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30740049' target='_blank' class='pmid-link'>30740049</a>:</span> <span class='sentence-part'>Nevertheless, the relationships between the morphological and functional changes of dendrodendritic synapses, particularly the local field potentials (LFPs) as a consequence of olfactory disorders in patients with AD have not been investigated.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30937343' target='_blank' class='pmid-link'>30937343</a>:</span> <span class='sentence-part'>The identification of the molecular underpinning of the disease not only provided the framework of AD pathogenesis but also targets for therapeutic inventions.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31127574' target='_blank' class='pmid-link'>31127574</a>:</span> <span class='sentence-part'>BER deficiency is associated with development of diseases causing neurodegenerative disorders, such as Alzheimer's disease (AD) and amyotrophic lateral sclerosis (ALS).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31228376' target='_blank' class='pmid-link'>31228376</a>:</span> <span class='sentence-part'>Despite the fact that this disease is considered, of course, age-associated pathology, which is the main cause of senile dementia, its diagnosis in Russia is exhibited rather rarely compared with dementia, for example, of vascular origin.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31456206' target='_blank' class='pmid-link'>31456206</a>:</span> <span class='sentence-part'>Increasing evidence suggests that disorders of metal ion metabolism in the brain are one of the risk factors for the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31521231' target='_blank' class='pmid-link'>31521231</a>:</span> <span class='sentence-part'>Amyloid-beta (Abeta) and alpha-synuclein (alphaS) are two intrinsically disordered proteins (IDPs) at the centers of the pathogenesis of Alzheimer's and Parkinson's diseases, respectively. Intrinsically disordered proteins in various hypotheses on the pathogenesis of Alzheimer's and Parkinson's diseases.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31605538' target='_blank' class='pmid-link'>31605538</a>:</span> <span class='sentence-part'>While Abeta has been suggested to be critical in inducing and, potentially, driving the disease, the molecular basis of AD pathogenesis is still under debate.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31607780' target='_blank' class='pmid-link'>31607780</a>:</span> <span class='sentence-part'>Similar to other complex disorders, the etiology of Alzheimer disease is multifactorial and characterized by an interplay of biological and environmental risk and protective factors.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31894361' target='_blank' class='pmid-link'>31894361</a>:</span> <span class='sentence-part'>Knowing the intrinsic disorder status and disorder-based functionality of proteins associated with amyloid cascade signaling pathway may help to untangle the mechanisms of AD pathogenesis and help identify therapeutic targets.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31900899' target='_blank' class='pmid-link'>31900899</a>:</span> <span class='sentence-part'>Excitotoxicity is a modern clinical condition included in the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32225073' target='_blank' class='pmid-link'>32225073</a>:</span> <span class='sentence-part'>Importantly, there is also clinical evidence supporting their potential use as biomarker candidates for AD, due to reduced serum and CSF levels that correlate with amyloid burden in AD patients compared with controls. Although the exact etiology of the disease remains elusive, accumulating evidence highlights the key role of lipid rafts, as well as the endocytic pathways in amyloidogenic amyloid precursor protein (APP) processing and AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32696388' target='_blank' class='pmid-link'>32696388</a>:</span> <span class='sentence-part'>Measuring Interactions Between Tau and Aggregation Inducers with Single-Molecule Forster Resonance Energy Transfer.Tau is an intrinsically disordered protein implicated in the pathogenesis of Alzheimer's disease and other neurodegenerative disorders.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33302541' target='_blank' class='pmid-link'>33302541</a>:</span> <span class='sentence-part'>AD is considered a multifactorial disease: two main hypotheses were proposed as a cause for AD, cholinergic and amyloid hypotheses.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33457489' target='_blank' class='pmid-link'>33457489</a>:</span> <span class='sentence-part'>Models or combinations of new models are needed that incorporate genetics with environmental interactions, timing of disease development, heterogeneous mechanisms and pathways, comorbidities, and other pathologies that lead to AD and related dementias.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33512819' target='_blank' class='pmid-link'>33512819</a>:</span> <span class='sentence-part'>Although it has not been possible to determine the origin of this disease, the amyloid hypothesis is one of the most accepted to explain the etiology of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33629978' target='_blank' class='pmid-link'>33629978</a>:</span> <span class='sentence-part'>Although it has not been possible to determine the origin of this disease, the amyloid hypothesis is one of the most accepted to explain the etiology of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33806317' target='_blank' class='pmid-link'>33806317</a>:</span> <span class='sentence-part'>Identifying the molecular characteristics of the disease is imperative to understanding the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34439596' target='_blank' class='pmid-link'>34439596</a>:</span> <span class='sentence-part'>No drug class was associated with the least severe AD (cluster-1), likely due to lesser antecedent disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34609116' target='_blank' class='pmid-link'>34609116</a>:</span> <span class='sentence-part'>The complications that are discussed in this article are diabetic nephropathy, diabetes induced cardiovascular disease, diabetic neuropathy, Diabetic Foot Ulcer (DFU) and Alzheimer's disease. The progression of AD can be due to the change in DNA methylation of CLOCK gene, followed with worsening of AD by APOE4 gene due to dyslipidaemia condition in T2DM patients. Insulin resistance is also a factor that contributes to pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35463002' target='_blank' class='pmid-link'>35463002</a>:</span> <span class='sentence-part'>Background: Recent Alzheimer's disease (AD) hypotheses implicate that hepatic metabolic disorders might contribute to the disease pathogenesis of AD, but the mechanism remains unclear.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35563253' target='_blank' class='pmid-link'>35563253</a>:</span> <span class='sentence-part'>As research progresses, it has become known that AD can be caused by diseases that have been experienced over the course of a lifetime, which could also affect other organs.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36430144' target='_blank' class='pmid-link'>36430144</a>:</span> <span class='sentence-part'>The identification signatures overlapping for AD, PD, and MS raise the question of whether these reflect a common etiology or rather common consequence of these diseases.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36431219' target='_blank' class='pmid-link'>36431219</a>:</span> <span class='sentence-part'>This state of affairs has made neuroscientists suspicious, so much so that for several years the idea has gained ground that AD is not a direct neuropathological consequence taking place downstream of the deposition of the two toxic proteins, but rather a multifactorial disease, including mitochondrial dysfunction as an early event in the pathogenesis of AD, occurring even before clinical symptoms.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36436686' target='_blank' class='pmid-link'>36436686</a>:</span> <span class='sentence-part'>Animal model of Alzheimer's disease induced by streptozotocin: new insights about cholinergic pathway. Disorders of the cholinergic system are well known to be involved in the pathogenesis of AD, characterized by increased acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) and decreased acetyltransferase (ChAT) enzymatic activities.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37000425' target='_blank' class='pmid-link'>37000425</a>:</span> <span class='sentence-part'>Although it is largely unclear whether dysfunctions in sleep and circadian rhythms contribute to the etiology of AD or are a consequence of the disease, there is evidence that these conditions are involved in a complex self-reinforcing bidirectional relationship.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37693644' target='_blank' class='pmid-link'>37693644</a>:</span> <span class='sentence-part'>We suggest that Abeta is not a culprit of Alzheimer's disease, but merely a byproduct of autophagy/lysosomal failure resulting from hydroxynonenal-induced Hsp70.1 disorder.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37811614' target='_blank' class='pmid-link'>37811614</a>:</span> <span class='sentence-part'>Furthermore, despite the disease hallmarks commonly manifested in all AD cases, considerable evidence suggests complex heterogeneity of AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37934647' target='_blank' class='pmid-link'>37934647</a>:</span> <span class='sentence-part'>For Alzheimer's Disease, the proposed method demonstrated remarkable performance in predicting the brain ventricle changes induced by the disease, achieving the state-of-the-art result on TADPOLE cross-sectional prediction challenge dataset.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/38064104' target='_blank' class='pmid-link'>38064104</a>:</span> <span class='sentence-part'>Even though a century has passed since the discovery of AD, the exact cause of the disease still remains unknown. Since dysregulation of this kinase affects all the major characteristic features of the disease, such as tau phosphorylation, amyloid formation, memory, and synaptic function, it is thought to be a major player in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/38203429' target='_blank' class='pmid-link'>38203429</a>:</span> <span class='sentence-part'>After several years of research in the field of Alzheimer's disease (AD), it is still unclear how amyloid-beta (Abeta) and Tau, two key hallmarks of the disease, mediate the neuropathogenic events that lead to AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/38549636' target='_blank' class='pmid-link'>38549636</a>:</span> <span class='sentence-part'>Background: Increasing evidence suggests that both amyloid-beta metabolism disorders in the liver and cerebral hypoperfusion play an important role in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/7542917' target='_blank' class='pmid-link'>7542917</a>:</span> <span class='sentence-part'>CONCLUSION: These results indicate that optic nerve degeneration is not a feature of AD and suggest that the visual deficits in the disease result from cortical dysfunction.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/8198393' target='_blank' class='pmid-link'>8198393</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD), the most common dementing disorder of late life, is a major cause of disability and death in the elderly.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/8290042' target='_blank' class='pmid-link'>8290042</a>:</span> <span class='sentence-part'>This mutation was present in DNA from all four examined affected individuals and linked to the disease with a lod score of 3.25, and was the most probable cause of AD in this family.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/8871938' target='_blank' class='pmid-link'>8871938</a>:</span> <span class='sentence-part'>Despite a large amount of evidence that suggests an association between oxidative stress and the pathogenesis of AD, it is not yet known whether oxidative stress is a cause or consequence of the disorder.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/8912490' target='_blank' class='pmid-link'>8912490</a>:</span> <span class='sentence-part'>Further studies will determine whether this alteration could provide a peripheral biochemical marker of the disorder and whether it could intervene in the pathogenesis of Alzheimer disease.</span></div></div>
<div class='streamlined-assertion'><div class='streamlined-header sticky-relation-header'><span class='label-text'>Subject:</span> <strong>Disease</strong> <span class='label-text'>Subject CUI:</span> <strong>C0012634</strong> â†’ <span class='label-text predicate-text'>CAUSES</span> â†’ <span class='label-text'>Object:</span> <strong>Atrial_Fibrillation</strong> <span class='label-text'>Object CUI:</span> <strong>C0004238</strong></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/10077887' target='_blank' class='pmid-link'>10077887</a>:</span> <span class='sentence-part'>In this study, high-frequency atrial activity to clarify the electrophysiologic background for the predisposition to have proximal right coronary artery disease leading to atrial fibrillation after coronary revascularization was investigated.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/16499161' target='_blank' class='pmid-link'>16499161</a>:</span> <span class='sentence-part'>Many diseases can lead to atrial fibrillation and one of these is thyroid disfunction.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17245405' target='_blank' class='pmid-link'>17245405</a>:</span> <span class='sentence-part'>In the absence of traditional risk factors for disease, a genetic defect in electrical homeostasis underlying stress-induced AF was explored.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17435813' target='_blank' class='pmid-link'>17435813</a>:</span> <span class='sentence-part'>About one in four cerebral infarctions are due to embolism from the heart to the brain, mainly because of atrial fibrillation, but also because of diseases such as acute myocardial infarction, dilated cardiomyopathy and prosthetic heart valves (cardioembolic stroke).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17882807' target='_blank' class='pmid-link'>17882807</a>:</span> <span class='sentence-part'>The data of the study evidence a cyclic character of the disease and stresses an important role in AF pathogenesis played by disturbances associated with the functional condition of non-specific temporal-limbic and reticular brain structures, especially in patients without organic myocardial alterations.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/19804171' target='_blank' class='pmid-link'>19804171</a>:</span> <span class='sentence-part'>The Cox-maze procedure for the surgical treatment of atrial fibrillation has proven to be the most effective means of addressing the adverse consequences of the disease, including rhythm, hemodynamics, and thromboembolic risk.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21423470' target='_blank' class='pmid-link'>21423470</a>:</span> <span class='sentence-part'>Further studies may clarify whether atrial delayed gadolinium enhancement is seen in rheumatic heart disease more often than in other diseases that cause atrial fibrillation, and the diagnostic and prognostic significance of such a finding.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24333117' target='_blank' class='pmid-link'>24333117</a>:</span> <span class='sentence-part'>However, AF is a genetically heterogeneous disease and the genetic defects responsible for AF in an overwhelming majority of patients remain unclear.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24378975' target='_blank' class='pmid-link'>24378975</a>:</span> <span class='sentence-part'>As bee venom activates some inflammatory and vascular events resulting in occlusion in vessels or diseases in electrical system of heart, it may cause myocardial infarction or atrial fibrillation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24978663' target='_blank' class='pmid-link'>24978663</a>:</span> <span class='sentence-part'>BACKGROUND: In hemodynamically stable patients, mortality and morbidity related to atrial fibrillation are mainly due to cardioembolic disorder.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25175086' target='_blank' class='pmid-link'>25175086</a>:</span> <span class='sentence-part'>Atrial fibrillation may be encountered in young otherwise healthy individuals, due to the isolated electrophysiological disorder limited mostly to the pulmonary veins and posterior left atrial wall, or associated with the presence of advanced underlying heart disease and numerous cardiac and non-cardiac comorbidities with significant structural remodeling of the atrial myocardium.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25773299' target='_blank' class='pmid-link'>25773299</a>:</span> <span class='sentence-part'>In this study, we have presented a novel transgenic mouse model of AF that mimics human disease and characterized the mechanisms of atrial electroanatomical remodeling in the genesis of AF.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25994868' target='_blank' class='pmid-link'>25994868</a>:</span> <span class='sentence-part'>AF can develop secondary to other diseases, but there is also evidence of a heritable component.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26169204' target='_blank' class='pmid-link'>26169204</a>:</span> <span class='sentence-part'>Whole-exome sequencing analysis identified a mutation in TNNI3, R186Q, that co-segregated with the disease in the family, but did not exist in &gt;1583 controls, suggesting that R186Q causes AF and HCM.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28028946' target='_blank' class='pmid-link'>28028946</a>:</span> <span class='sentence-part'>BACKGROUND: Patients treated for sick sinus syndrome may have interatrial conduction disorder leading to atrial fibrillation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28760209' target='_blank' class='pmid-link'>28760209</a>:</span> <span class='sentence-part'>CONCLUSION: This trial will provide information on the value of ICMs to detect subclinical AF in patients with stroke presumed due to large vessel atherosclerosis or small vessel disease, which will have implications for guiding treatment with oral anticoagulation for secondary stroke prevention.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29929399' target='_blank' class='pmid-link'>29929399</a>:</span> <span class='sentence-part'>However, further studies are needed to elucidate whether NAFLD has a causative role in the development of AF.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30405438' target='_blank' class='pmid-link'>30405438</a>:</span> <span class='sentence-part'>While the initiation of pathogenic pathways leading to AF varies with disease (including increased glycosylation in diabetes, increased renin angiotensin aldosterone system activation in hypertension, atrial ischemia in coronary artery disease, and sleep apnea) the pathogenesis of AF is united by shared mediators of altered conduction in the atria. Due to the wealth of epidemiologic data linking AF with obesity-related disease, mechanisms of AF pathogenesis in the context of obesity are an area of ongoing investigation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31622581' target='_blank' class='pmid-link'>31622581</a>:</span> <span class='sentence-part'>NAFLD and NASH lead to an expansion of epicardial adipose tissue and the release of proinflammatory adipocytokines that cause microcirculatory dysfunction and fibrosis of the adjoining myocardium, resulting in atrial fibrillation as well as heart failure with a preserved ejection fraction (HFpEF).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31938982' target='_blank' class='pmid-link'>31938982</a>:</span> <span class='sentence-part'>Atrial fibrillation is a multi-facet malady and it may occur as a result of other diseases or it may trigger other problems.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32365521' target='_blank' class='pmid-link'>32365521</a>:</span> <span class='sentence-part'>The development of an automated and efficient method that monitors AF in real time would likely become a key component for meeting public health goals regarding the reduction of fatalities caused by the disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34270327' target='_blank' class='pmid-link'>34270327</a>:</span> <span class='sentence-part'>Conclusions     - Our results capture molecular events that occur at an early stage of disease development using well-characterized animal models, and may therefore inform future studies that aim to further dissect the causes of AF in humans.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34548541' target='_blank' class='pmid-link'>34548541</a>:</span> <span class='sentence-part'>However, whether AF is a cause or consequence of these diseases is uncertain.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34692988' target='_blank' class='pmid-link'>34692988</a>:</span> <span class='sentence-part'>Background: Atrial fibrillation (AF) is a heterogeneous condition caused by various underlying disorders and comorbidities.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35402340' target='_blank' class='pmid-link'>35402340</a>:</span> <span class='sentence-part'>LEARNING POINTS: Atrial fibrillation usually occurs secondary to intrinsic disorders such as hypertension, coronary artery disease, abnormal heart valves, thyroid dysfunction and medication side effects.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36552815' target='_blank' class='pmid-link'>36552815</a>:</span> <span class='sentence-part'>Although there is a well-established relationship between thyroid disease (especially hyperthyroidism) and AF, the underlying biochemical mechanisms leading to atrial fibrosis and atrial arrhythmias are poorly understood in thyrotoxicosis. Studies have shown that disorders associated with endocrine dysregulation are potential underlying causes of AF.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37641724' target='_blank' class='pmid-link'>37641724</a>:</span> <span class='sentence-part'>Health-related quality of life suffers from AF, and patients often find themselves less active as a result of their condition.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37892626' target='_blank' class='pmid-link'>37892626</a>:</span> <span class='sentence-part'>AF is associated with substantial mortality and morbidity, due to the disease itself and its specific complications, such as the increased risk of stroke and thromboembolic events associated with AF.</span></div></div>
<div class='streamlined-assertion'><div class='streamlined-header sticky-relation-header'><span class='label-text'>Subject:</span> <strong>Down_Syndrome</strong> <span class='label-text'>Subject CUI:</span> <strong>C0013080</strong> â†’ <span class='label-text predicate-text'>CAUSES</span> â†’ <span class='label-text'>Object:</span> <strong>Alzheimers</strong> <span class='label-text'>Object CUI:</span> <strong>C0002395</strong></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/11447838' target='_blank' class='pmid-link'>11447838</a>:</span> <span class='sentence-part'>There are two pieces of supporting data for this: first, APP is overexpressed in Down's syndrome, which leads to AD-like neuropathology by the age of 40 in virtually all affected individuals; secondly, specific point mutations in APP cause some forms of familial AD. We have hypothesized that AD results from a progressive dysfunction of APP.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/11755021' target='_blank' class='pmid-link'>11755021</a>:</span> <span class='sentence-part'>Results support the hypothesis that in a group of persons at risk for AD because of DS, olfactory impairment is greater in older individuals, suggesting progressive impairment over time.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/15834031' target='_blank' class='pmid-link'>15834031</a>:</span> <span class='sentence-part'>OBJECTIVE: Down's syndrome (DS) is the most frequent genetic cause of Alzheimer-type dementia.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/18676989' target='_blank' class='pmid-link'>18676989</a>:</span> <span class='sentence-part'>Enlarged early endosomes in the neurons of young Down syndrome (DS) and pre-Alzheimer's disease (AD) brains suggest that a disturbance in endocytosis is one of the earliest hallmarks of AD pathogenesis in both conditions.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/19509306' target='_blank' class='pmid-link'>19509306</a>:</span> <span class='sentence-part'>Regulator of calcineurin 1 (RCAN1), a gene identified from the critical region of Down syndrome, has been implied in pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21944886' target='_blank' class='pmid-link'>21944886</a>:</span> <span class='sentence-part'>Transfer of the amyloid beta and/or of beta-amyloid precursor protein of the fetus with trisomy 21 to the maternal blood stream and its possible contribution to the pathogenesis of the maternal Alzheimer's Disease. The evidence that is derived from several sources--genetic, among them--suggests that the Abeta participates in the pathogenesis of Alzheimer's Disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24888381' target='_blank' class='pmid-link'>24888381</a>:</span> <span class='sentence-part'>The amyloid precursor protein gene is on chromosome 21, and so is over-expressed in Down syndrome, leading to amyloid beta (Abeta) over-production, a major upstream pathway leading to Alzheimer disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24962069' target='_blank' class='pmid-link'>24962069</a>:</span> <span class='sentence-part'>Individuals with Down syndrome (DS) are at increased risk of developing AD in adulthood as a result of chromosome 21 trisomy and triplication of the amyloid precursor protein (APP) gene.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/2534160' target='_blank' class='pmid-link'>2534160</a>:</span> <span class='sentence-part'>These results indicate that neither the normal aging processes, Alzheimer's disease, nor the increased in vitro lipid peroxidation reported in fetuses with Down's syndrome result from a gross lack of alpha-tocopherol, or cause a significant depletion of the vitamin.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/2563716' target='_blank' class='pmid-link'>2563716</a>:</span> <span class='sentence-part'>A lot of recent molecular genetic experiments and many neuropathological analogies of Alzheimer's dementia and Down's syndrome indicate a damage on the chromosome 21 as possible cause of Alzheimer's dementia.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27867340' target='_blank' class='pmid-link'>27867340</a>:</span> <span class='sentence-part'>DS is also the most frequent genetic cause of Alzheimer's disease (AD), and ~50% of those with DS will develop AD-related dementia.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34182407' target='_blank' class='pmid-link'>34182407</a>:</span> <span class='sentence-part'>This early detection of tau can help characterize the tau accumulation phase during preclinical Alzheimer's disease progression in Down syndrome and suggests that there may be a relatively narrow window after Abeta accumulation begins to prevent the downstream cascade of events that leads to Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35596914' target='_blank' class='pmid-link'>35596914</a>:</span> <span class='sentence-part'>Correlating Alzheimer's disease biomarkers in Down syndrome and cognitive function scores while considering the effect of psychosocial risk factors helps us identify the mechanisms leading to Alzheimer's disease at an early age.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/9732570' target='_blank' class='pmid-link'>9732570</a>:</span> <span class='sentence-part'>This article, the first of two parts, considers the link between Down's syndrome and Alzheimer's disease and how this link has been a significant factor with regards to research into the aetiology of Alzheimer's disease.</span></div></div>
<div class='streamlined-assertion'><div class='streamlined-header sticky-relation-header'><span class='label-text'>Subject:</span> <strong>Electric_Countershock</strong> <span class='label-text'>Subject CUI:</span> <strong>C0013778</strong> â†’ <span class='label-text predicate-text'>CAUSES</span> â†’ <span class='label-text'>Object:</span> <strong>Atrial_Fibrillation</strong> <span class='label-text'>Object CUI:</span> <strong>C0004238</strong></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/11797990' target='_blank' class='pmid-link'>11797990</a>:</span> <span class='sentence-part'>High-resolution noncontact mapping can map a single beat, should help identify the sites of spontaneously occurring PACs and PACs induced following cardioversion of spontaneous or induced AF, and could help correlate the trigger sites for AF induction. Cardioversion of spontaneous or induced AF could be used as an electrophysiologic parameter for guiding therapy. In all patients, AF was induced and subsequently cardioverted to assess and map isolated PACs or PACs that induced AF.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/1378592' target='_blank' class='pmid-link'>1378592</a>:</span> <span class='sentence-part'>atrial fibrillation induced by cardioversion therapy; 3.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17000635' target='_blank' class='pmid-link'>17000635</a>:</span> <span class='sentence-part'>After confirmation of successful induction of sustained AF, defibrillation was attempted.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/19083330' target='_blank' class='pmid-link'>19083330</a>:</span> <span class='sentence-part'>Furthermore, this encouraging result of a pharmacologic cardioversion suggests that further investigation would be of interest to ascertain the effectiveness and mechanism of the antiarrhythmic action of lidocaine in vagally induced AF.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/19140908' target='_blank' class='pmid-link'>19140908</a>:</span> <span class='sentence-part'>Successful cardioversion occurred in 137 of the 138 induced-AF episodes (86.1% with 12 joule (J), 13.1% with 24 J, and 0.7% with 35 J).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/19880410' target='_blank' class='pmid-link'>19880410</a>:</span> <span class='sentence-part'>Sinus rhythm was restored with electrical cardioversion and maintained for 10 min before re-induction of AF and repeat mapping.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20964739' target='_blank' class='pmid-link'>20964739</a>:</span> <span class='sentence-part'>In total, 59.7% qualified for history of AF because of successful cardioversion, 11.8% because of two or more episodes of AF in the 6 months preceding randomization and 28.5% because of both.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25947079' target='_blank' class='pmid-link'>25947079</a>:</span> <span class='sentence-part'>However, it is still unclear whether induction of HSPs also prolongs the arrhythmia-free interval after, for example, cardioversion of AF.In this review, we discuss the role of HSPs in the pathophysiology of AF and give an outline of the HALT&amp;REVERSE project, initiated by the HALT&amp;REVERSE Consortium and the AF Innovation Platform.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28259694' target='_blank' class='pmid-link'>28259694</a>:</span> <span class='sentence-part'>In these patients, triggers can typically be elicited using standardized induction protocols, which include cardioversion of spontaneous and/or induced AF and infusion of high-dose isoproterenol. Pulmonary vein (PV) isolation is the cornerstone of catheter ablation approaches for eliminating AF triggers.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30133839' target='_blank' class='pmid-link'>30133839</a>:</span> <span class='sentence-part'>CONCLUSIONS AND CLINICAL IMPORTANCE: Flecainide is effective for cardioversion of short-term induced AF, but the effect decreases with AF duration.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32180722' target='_blank' class='pmid-link'>32180722</a>:</span> <span class='sentence-part'>Aims: To describe the effects of the K     Ca      2 channel inhibitor AP30663 in pigs regarding tolerability, cardiac electrophysiology, pharmacokinetics, atrial functional selectivity, effectiveness in cardioversion of tachy-pacing induced vernakalant-resistant atrial fibrillation (AF), and prevention of reinduction of AF.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/38296010' target='_blank' class='pmid-link'>38296010</a>:</span> <span class='sentence-part'>NPVTs were defined as non-pulmonary vein ectopic beats triggering AF or focal atrial tachycardia. Isoproterenol infusion and cardioversion of spontaneous or induced AF can provoke NPVTs but typically require vasopressor support and increased procedure time.</span></div></div>
<div class='streamlined-assertion'><div class='streamlined-header sticky-relation-header'><span class='label-text'>Subject:</span> <strong>Endopeptidases</strong> <span class='label-text'>Subject CUI:</span> <strong>C0030946</strong> â†’ <span class='label-text predicate-text'>CAUSES</span> â†’ <span class='label-text'>Object:</span> <strong>Alzheimers</strong> <span class='label-text'>Object CUI:</span> <strong>C0002395</strong></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/15727865' target='_blank' class='pmid-link'>15727865</a>:</span> <span class='sentence-part'>beta-Secretase is an important protease in the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/16293708' target='_blank' class='pmid-link'>16293708</a>:</span> <span class='sentence-part'>As an essential protease in the generation of amyloid beta, gamma-secretase is believed to play an important role in the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17098871' target='_blank' class='pmid-link'>17098871</a>:</span> <span class='sentence-part'>Rare familial forms of Alzheimer's disease (AD) are thought to be caused by elevated proteolytic production of the Abeta42 peptide from the beta-amyloid-precursor protein (APP).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/19544621' target='_blank' class='pmid-link'>19544621</a>:</span> <span class='sentence-part'>Mitochondrial dysfunction is one of the key characteristics of AD pathogenesis. Growing evidence suggests a causative role for intracellular accumulation of amyloid precursor protein (APP) and its proteolytic products in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21331224' target='_blank' class='pmid-link'>21331224</a>:</span> <span class='sentence-part'>Amyloid Precursor Protein (APP) and its proteolytic product amyloid beta (Abeta) are critical in the pathogenesis of Alzheimer's Disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21354962' target='_blank' class='pmid-link'>21354962</a>:</span> <span class='sentence-part'>Ubiquitin ligase was an important protease in the pathogenesis of Alzheimer's Disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22464639' target='_blank' class='pmid-link'>22464639</a>:</span> <span class='sentence-part'>DESIGN: Sixty female Sprague Dawley rats were divided into four groups n=15, (1) normal control group (con), (2) group underwent surgery to remove ovaries (ovx control group), (3) ovx group received aluminum chloride in a dose of 17 mg/kg daily for 2 months to induce AD (AD group), (4) AD group treated with alpha-chymotrypcin (alpha-ch) at dose (8.1 unit/rat/day) which is equivalent to the recommended human dose (alpha-ch-treated group) for three months. CONCLUSION: This study revealed that alpha-chymotrypcin significantly ameliorates the neuroinflammation characterizing Alzheimer's disease in ovariectomized rats due to it's proteolytic activity as well as it's anti-inflammatory effect.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25528641' target='_blank' class='pmid-link'>25528641</a>:</span> <span class='sentence-part'>The amyloid precursor protein (APP) and its proteolytic cleavage product Abeta are widely believed to be central to the etiology of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28826672' target='_blank' class='pmid-link'>28826672</a>:</span> <span class='sentence-part'>Delta-secretase, a lysosomal asparagine endopeptidase (AEP), simultaneously cleaves both APP and tau, controlling the onset of pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/8773762' target='_blank' class='pmid-link'>8773762</a>:</span> <span class='sentence-part'>The imbalance of an extracellular protease system may participate in the pathogenesis of Alzheimer's disease.</span></div></div>
<div class='streamlined-assertion'><div class='streamlined-header sticky-relation-header'><span class='label-text'>Subject:</span> <strong>Enzymes</strong> <span class='label-text'>Subject CUI:</span> <strong>C0014442</strong> â†’ <span class='label-text predicate-text'>CAUSES</span> â†’ <span class='label-text'>Object:</span> <strong>Alzheimers</strong> <span class='label-text'>Object CUI:</span> <strong>C0002395</strong></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/10651647' target='_blank' class='pmid-link'>10651647</a>:</span> <span class='sentence-part'>Since SPs are composed predominantly of Abeta1-42, which is more amyloidogenic in vitro, the enzymes involved in generating Abeta1-42 may be particularly important to the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/11032903' target='_blank' class='pmid-link'>11032903</a>:</span> <span class='sentence-part'>To define the enzymes involved in the etiology of Alzheimer's disease, we compared in mouse and human brain the mRNA levels and cellular localization of the ubiquitous beta-amyloid precursor protein (beta-APP) with those of the putative alpha-secretases ADAM10 and ADAM17 and the beta-secretases BACE and BACE2.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/15275956' target='_blank' class='pmid-link'>15275956</a>:</span> <span class='sentence-part'>The PGF(2 alpha), an enzymatic product of arachidonic acid, may affect the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/15665036' target='_blank' class='pmid-link'>15665036</a>:</span> <span class='sentence-part'>Each of the genotypes (Tg ABAD, Tg mAPP and Tg mAPP/ABAD mice, and non-TG littermates) displayed normal reproductive fitness, development and lifespan (1) These findings link ABAD-induced oxidant stress to critical aspects of Alzheimer's disease (AD)-associated cellular dysfunction, suggesting a pivotal role for this enzyme in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/15917100' target='_blank' class='pmid-link'>15917100</a>:</span> <span class='sentence-part'>Any change in the fine balance between these enzymes and their substrate may contribute to the etio-pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/18565755' target='_blank' class='pmid-link'>18565755</a>:</span> <span class='sentence-part'>In order to access beta-secretase (BACE1), and enzyme strongly implicated in the cause of Alzheimer's disease, inhibitors must possess sufficient lipophilicity to traverse two lipid bilayers.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/19321181' target='_blank' class='pmid-link'>19321181</a>:</span> <span class='sentence-part'>Statins inhibit HMG-CoA reductase, the enzyme that catalyzes the rate-limiting step in cholesterol biosynthesis thus inserting itself into the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/19579178' target='_blank' class='pmid-link'>19579178</a>:</span> <span class='sentence-part'>This enzyme is pivotal in the generation of beta-amyloid (A beta), a neurotoxic endogenous peptide believed to be involved in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20066010' target='_blank' class='pmid-link'>20066010</a>:</span> <span class='sentence-part'>Dysregulation of beta-site APP-cleaving enzyme (BACE) and/or gamma-secretase leads to anomalous production of amyloid-beta peptide (Abeta) and contributes to the etiology of Alzheimer's disease (AD). Since these secretases mediate proteolytic processing of numerous proteins, little success has been achieved to treat AD by secretase inhibitors because of inevitable undesired side effects.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23410524' target='_blank' class='pmid-link'>23410524</a>:</span> <span class='sentence-part'>In addition to MAO inhibition, PLZ also inhibits primary amine oxidase (PrAO), an enzyme implicated in the etiology of Alzheimer's disease, diabetes and cardiovascular disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26940238' target='_blank' class='pmid-link'>26940238</a>:</span> <span class='sentence-part'>The CYP17A1 gene encodes cytochrome P450c17alpha, an enzyme that catalyzes the formation of sex hormones, which have been linked to the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27784218' target='_blank' class='pmid-link'>27784218</a>:</span> <span class='sentence-part'>Uleine Disrupts Key Enzymatic and Non-Enzymatic Biomarkers that Leads to Alzheimer's Disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29303784' target='_blank' class='pmid-link'>29303784</a>:</span> <span class='sentence-part'>Acetylcholinesterase (AChE) is an enzyme that metabolises the ACh at synaptic cleft resulting in Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29851073' target='_blank' class='pmid-link'>29851073</a>:</span> <span class='sentence-part'>?-Secretase is the enzyme that generates various forms of A?, such as A?40 and A?42, the latter being an aggregation-prone toxic peptide that is involved in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31353736' target='_blank' class='pmid-link'>31353736</a>:</span> <span class='sentence-part'>AChE is an important therapeutic target because excessive activity of this enzyme is a causative factor of neurodegenerative diseases such as dementia and Alzheimer's.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32239935' target='_blank' class='pmid-link'>32239935</a>:</span> <span class='sentence-part'>Compounds    1    -   9     were found to exhibit potent inhibitory activity in the 1.0 * 10     -3       to 2.2 MUM range against acetylcholinesterase, an enzyme directly involved in the etiology of Alzheimer's disease and senile dementia.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34263703' target='_blank' class='pmid-link'>34263703</a>:</span> <span class='sentence-part'>The molecular docking analysis reveals that the studied molecule under interest can act as a potent inhibitor against the amyloid beta-protein (Abeta) enzyme, which causes the Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35013923' target='_blank' class='pmid-link'>35013923</a>:</span> <span class='sentence-part'>In Silico Molecular Docking Approach Against Enzymes Causing Alzheimer's Disease Using Borassus flabellifer Linn.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37148523' target='_blank' class='pmid-link'>37148523</a>:</span> <span class='sentence-part'>Since the activity of dopamine b hydroxylase (DbetaH) is reduced in the hippocampus and neocortex in the brain, changes in the physiological status of dopamine have been reported in Alzheimer's disease (AD) induced by this enzyme.</span></div></div>
<div class='streamlined-assertion'><div class='streamlined-header sticky-relation-header'><span class='label-text'>Subject:</span> <strong>FRAGMENTS</strong> <span class='label-text'>Subject CUI:</span> <strong>C0486805</strong> â†’ <span class='label-text predicate-text'>CAUSES</span> â†’ <span class='label-text'>Object:</span> <strong>Alzheimers</strong> <span class='label-text'>Object CUI:</span> <strong>C0002395</strong></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/10094144' target='_blank' class='pmid-link'>10094144</a>:</span> <span class='sentence-part'>Numerous lines of evidence suggest that some of the neurotoxicity associated with Alzheimer's disease (AD) is due to proteolytic fragments of the amyloid precursor protein (APP).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/10928985' target='_blank' class='pmid-link'>10928985</a>:</span> <span class='sentence-part'>Numerous lines of evidence indicate that some of the neurotoxicity associated with Alzheimer's disease (AD) is due to proteolytic fragments of the amyloid precursor protein (APP).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/12507755' target='_blank' class='pmid-link'>12507755</a>:</span> <span class='sentence-part'>Amyloid peptide (Abeta) is a 40/42-residue proteolytic fragment of a precursor protein (APP), implicated in the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/12708616' target='_blank' class='pmid-link'>12708616</a>:</span> <span class='sentence-part'>The regulated intramembrane proteolysis of the amyloid precursor protein (APP) that results in the generation of a toxic 40 to 42 amino acid fragment, Abeta, and a C-terminal intracellular fragment stands central in the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/1438289' target='_blank' class='pmid-link'>1438289</a>:</span> <span class='sentence-part'>The peptide comprising the carboxyl-terminal 100 amino acids of the beta-amyloid precursor protein (beta APP) has been shown to aggregate into amyloid-like fibrils in vitro and to be neurotoxic, suggesting that this fragment may play a role in the etiology of Alzheimer disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/15145073' target='_blank' class='pmid-link'>15145073</a>:</span> <span class='sentence-part'>Micromolar concentrations of beta-amyloid (Abeta), a 40/42-amino-acid-long proteolytic fragment (Abeta(1-40/42)) of the amyloid precursor protein, was shown previously to play a crucial role in pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/15821343' target='_blank' class='pmid-link'>15821343</a>:</span> <span class='sentence-part'>Several lines of evidence suggest that some of the neurotoxicity in Alzheimer's disease (AD) is attributed to proteolytic fragments of amyloid precursor protein (APP) and beta-amyloid (Abeta) may not be the sole active component involved in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/16087241' target='_blank' class='pmid-link'>16087241</a>:</span> <span class='sentence-part'>It is a fragment of the presynaptic protein alpha-synuclein and, as such, it is implicated in the aetiologies of both Alzheimer's (AD) and Parkinson's (PD) disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/16480887' target='_blank' class='pmid-link'>16480887</a>:</span> <span class='sentence-part'>These findings provide the first evidence that APP-betaCTF can accumulate in the axons of OA-treated neurons, and may suggest that APP-betaCTF is involved in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/16820299' target='_blank' class='pmid-link'>16820299</a>:</span> <span class='sentence-part'>Amyloid-beta peptide (Abeta), a proteolytic fragment generated from the amyloid precursor protein, has been implicated as the toxic molecule involved in the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17714184' target='_blank' class='pmid-link'>17714184</a>:</span> <span class='sentence-part'>However, an increased level of APP intracellular domain was also observed, highlighting the need to increase our knowledge about the relevance of this fragment in Alzheimer's disease pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/19733011' target='_blank' class='pmid-link'>19733011</a>:</span> <span class='sentence-part'>We propose that the electrical activity of neurons causes a structural destabilization of the fragments, which could lead to fibril formation, and thereby contributes to the pathogenesis of Alzheimer's Disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/19901559' target='_blank' class='pmid-link'>19901559</a>:</span> <span class='sentence-part'>Surprisingly, a recent report suggests that PrP is a receptor for toxic oligomeric species of a-beta, a pathogenic fragment of the amyloid precursor protein, and likely contributes to disease pathogenesis of Alzheimer disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20412390' target='_blank' class='pmid-link'>20412390</a>:</span> <span class='sentence-part'>These apoE4 fragments have been hypothesized to be involved in the pathogenesis of AD, although the mechanism is not clear.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21960299' target='_blank' class='pmid-link'>21960299</a>:</span> <span class='sentence-part'>While physiological function(s) of APP still remain a matter of debate, consensus exists that the proteolytic processing of this protein represents a critical event in the life of neurons and that abnormalities in this process are instrumental in Alzheimer's disease (AD) pathogenesis. Understanding neuron-specific mechanisms of APP processing would help illuminating the physiological roles of APP-derived proteolytic fragments and provide novel insights on AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23517619' target='_blank' class='pmid-link'>23517619</a>:</span> <span class='sentence-part'>Processing of beta-amyloid precursor protein (APP) by beta- and gamma-secretases in neurons produces amyloid-beta (Abeta), whose excess accumulation leads to Alzheimer's disease (AD). Knowledge on subcellular trafficking pathways of APP and its fragments is important for the understanding of AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25150572' target='_blank' class='pmid-link'>25150572</a>:</span> <span class='sentence-part'>Although full-length APP has been thoroughly studied, the role of the cleavage fragments especially the N-terminal fragments (N-APPs) in Alzheimer's disease pathogenesis was still elusive.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27697033' target='_blank' class='pmid-link'>27697033</a>:</span> <span class='sentence-part'>It has been demonstrated that recombinant antibody fragments may neutralize toxic extra- and intracellular misfolded proteins involved in the pathogenesis of AD, PD, DLB, FTD, HD or TSEs and may target toxic immune cells participating in the pathogenesis of MS.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29848690' target='_blank' class='pmid-link'>29848690</a>:</span> <span class='sentence-part'>One of the most active fragments of the pathological \endogen\ substrate responsible for AD was investigated in the presence of amyloid-beta fragment on the reversal of multidrug resistance and apoptosis induction on multidrug-resistant tumor cells in model experiments.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31649526' target='_blank' class='pmid-link'>31649526</a>:</span> <span class='sentence-part'>The amyloid beta (Abeta)-peptide, its amyloid precursor protein (APP) and the intermediate APP-c-terminal fragments (APP-CTFs) are all important players in AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/7588622' target='_blank' class='pmid-link'>7588622</a>:</span> <span class='sentence-part'>Due to the capacity of these cells to secrete and accumulate intracellular amyloid fragments, we hypothesize that in the pathogenesis of AD there is a positive feed-back loop where neurons are both producers and victims of amyloid, leading to neuronal degeneration and dementia.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/8687017' target='_blank' class='pmid-link'>8687017</a>:</span> <span class='sentence-part'>Excessive amyloidogenic pathway of APP processing may be the final common pathway involved in the pathogenesis of AD. There is mounting evidence that at least some of the neurotoxicity associated with AD is due to fragments from APP.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/8780033' target='_blank' class='pmid-link'>8780033</a>:</span> <span class='sentence-part'>There is mounting evidence that at least some of the neurotoxicity associated with Alzheimer's disease (AD) is due to proteolytic fragments of the beta-amyloid precursor protein (beta APP).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/8888112' target='_blank' class='pmid-link'>8888112</a>:</span> <span class='sentence-part'>Synthetic peptides homologous to beta A and its fragments contribute to investigate the mechanisms of beta A deposit formation and the role played by beta A in AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/8954102' target='_blank' class='pmid-link'>8954102</a>:</span> <span class='sentence-part'>Our finding that PHF-like structures assemble from a MAP-2 fragment raises new questions about MAP-2's role in the etiology of Alzheimer's Disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/9219695' target='_blank' class='pmid-link'>9219695</a>:</span> <span class='sentence-part'>In cells expressing PS2 containing the asparagine-141 FAD mutant, the ratio of alternative to normal PS2 cleavage fragments was increased relative to wild-type PS2-expressing cells, suggesting a potential role for apoptosis-associated cleavage of presenilins in the pathogenesis of Alzheimer's disease. Most cases of early-onset familial Alzheimer's disease (FAD) are caused by mutations in the genes encoding the presenilin 1 (PS1) and PS2 proteins, both of which undergo regulated endoproteolytic processing.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/9312066' target='_blank' class='pmid-link'>9312066</a>:</span> <span class='sentence-part'>Fractionation studies revealed that the C-terminal fragment generated by expression of the Alzheimer mutations, like C100, partitioned into membrane fractions and was particularly enriched in synaptosomes.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/9358827' target='_blank' class='pmid-link'>9358827</a>:</span> <span class='sentence-part'>The aim of the present study was: (i) to investigate the conditions determining the toxicity of Al and A beta 25-35; and (ii) to assess whether melatonin could attenuate the damage done by both aluminium and the amyloid fragment, thus suggesting a pathway for the aetiology of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/9875721' target='_blank' class='pmid-link'>9875721</a>:</span> <span class='sentence-part'>Numerous lines of evidence suggest that some of the neurotoxicity associated with Alzheimer's disease (AD) is due to proteolytic fragments of the amyloid precursor protein (APP).</span></div></div>
<div class='streamlined-assertion'><div class='streamlined-header sticky-relation-header'><span class='label-text'>Subject:</span> <strong>Free_Radicals</strong> <span class='label-text'>Subject CUI:</span> <strong>C0016693</strong> â†’ <span class='label-text predicate-text'>CAUSES</span> â†’ <span class='label-text'>Object:</span> <strong>Alzheimers</strong> <span class='label-text'>Object CUI:</span> <strong>C0002395</strong></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/10093929' target='_blank' class='pmid-link'>10093929</a>:</span> <span class='sentence-part'>Role of free radicals and metal ions in the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/10462121' target='_blank' class='pmid-link'>10462121</a>:</span> <span class='sentence-part'>The ability of homogenates from Alzheimer and control brains to inhibit formation of thiobarbituric acid reactive products (TBAR) induced by free radicals was compared.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/16447689' target='_blank' class='pmid-link'>16447689</a>:</span> <span class='sentence-part'>Short-term study mostly involved of newly evaluated assay methods for important substances such as the second level in the cell life span in the variation of lipid metabolite of cardiovascular diseases based on atherosclerosis, Alzheimer disease, and their evaluation by homogeneous assay of HDL-C, LDL-C, enzymatic assay for choline relating metabolites, and lipoperoxide as the results of free radical reactions.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/19361273' target='_blank' class='pmid-link'>19361273</a>:</span> <span class='sentence-part'>Mitochondrial dysfunction, which is closely related to intracellular calcium overload and excessive free radicals, is an important cause of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20648652' target='_blank' class='pmid-link'>20648652</a>:</span> <span class='sentence-part'>The oxidative stress observed in brains of subjects with AD and MCI may be due, either fully or in part, to increased free radicals mediated by amyloid-beta peptide (Abeta).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23326794' target='_blank' class='pmid-link'>23326794</a>:</span> <span class='sentence-part'>BACKGROUND: Alzheimer's disease is a neurodegenerative disease appearing as a result of free radicals and oxidative stress.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26606243' target='_blank' class='pmid-link'>26606243</a>:</span> <span class='sentence-part'>Previous studies in Down's syndrome (DS) and Alzheimer's disease (AD) suggested that the accumulation of protein oxidative damage results from the increased free radical production, mainly related to metabolic alterations, mitochondrial degeneration and amyloid-beta deposition, and aberrant activity of protein degradative systems.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27796744' target='_blank' class='pmid-link'>27796744</a>:</span> <span class='sentence-part'>Genistein has been mainly focused because of its potential on amelioration of Abeta-induced impairment and its antioxidant capacity to scavenge the free radicals produced in AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33781589' target='_blank' class='pmid-link'>33781589</a>:</span> <span class='sentence-part'>In particular, Fe     2+       has been hypothesized to produce free radicals that induce oxidative damage and eventually cause Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35538829' target='_blank' class='pmid-link'>35538829</a>:</span> <span class='sentence-part'>Here we reviewed some of the key findings that have shown the function of Abeta peptide, oxidative stress, free radical damage Triggering Receptors Expressed on Myeloid Cells 2 (TREM2), Nitric Oxide (NO), and gut microbiota in the aetiology of AD. RESULTS: Findings suggested that channels of free radicals, such as transition metal accumulation, and genetic factors are mainly accountable for the redox imbalance that assist to understand better the pathogenesis of AD and incorporate new therapeutic approaches.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/38527587' target='_blank' class='pmid-link'>38527587</a>:</span> <span class='sentence-part'>This may lead to iron accumulation in the brain and the catalysis of free radicals that damage cerebral neurons and eventually lead to Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/7643122' target='_blank' class='pmid-link'>7643122</a>:</span> <span class='sentence-part'>Recent studies revealed that A beta can be neurotoxic by a mechanism involving free radical production and loss of cellular ion homeostasis, thus implicating A beta as a key factor in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/7866588' target='_blank' class='pmid-link'>7866588</a>:</span> <span class='sentence-part'>Substantial evidence has accumulated implicating metals and free radicals in the pathogenesis of the major neurodegenerative disorders (Parkinson's disease, Alzheimer's disease, and amyotrophic lateral sclerosis).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/8239316' target='_blank' class='pmid-link'>8239316</a>:</span> <span class='sentence-part'>Free radicals in the genesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/8847550' target='_blank' class='pmid-link'>8847550</a>:</span> <span class='sentence-part'>We present evidence to support the premise that many of the pathological correlates of Alzheimer's disease are precipitated by free radical- and oxidative stress-induced mechanisms.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/9298634' target='_blank' class='pmid-link'>9298634</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) and vascular dementia (VaD) share several features such as overactivation of microglial cells, damage induced by free radicals, glutamate and calcium overload.</span></div></div>
<div class='streamlined-assertion'><div class='streamlined-header sticky-relation-header'><span class='label-text'>Subject:</span> <strong>Functional_disorder</strong> <span class='label-text'>Subject CUI:</span> <strong>C0277785</strong> â†’ <span class='label-text predicate-text'>CAUSES</span> â†’ <span class='label-text'>Object:</span> <strong>Alzheimers</strong> <span class='label-text'>Object CUI:</span> <strong>C0002395</strong></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/10737603' target='_blank' class='pmid-link'>10737603</a>:</span> <span class='sentence-part'>These results support the hypothesis that cathepsin D links lysosomal dysfunction to the etiology of Alzheimer's disease and suggest a new approach to treating the disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/10790719' target='_blank' class='pmid-link'>10790719</a>:</span> <span class='sentence-part'>Decreased melatonin production with malfunction of REM sleep is proposed to be a cause of sudden infant death syndrome and Alzheimer's disease, because the loss of the antioxidant function of melatonin allows brain injury to occur.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/11447838' target='_blank' class='pmid-link'>11447838</a>:</span> <span class='sentence-part'>There are two pieces of supporting data for this: first, APP is overexpressed in Down's syndrome, which leads to AD-like neuropathology by the age of 40 in virtually all affected individuals; secondly, specific point mutations in APP cause some forms of familial AD. We have hypothesized that AD results from a progressive dysfunction of APP.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/12387703' target='_blank' class='pmid-link'>12387703</a>:</span> <span class='sentence-part'>Neuronal cell dysfunction and cell death due to oxidative stress may causally contribute to the pathogenesis of progressive neurodegenerative disorders, such as Alzheimer's disease and Parkinson's disease, as well as acute syndromes of neurodegeneration, such as ischaemic and haemorrhagic stroke.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/12453672' target='_blank' class='pmid-link'>12453672</a>:</span> <span class='sentence-part'>This raises a question whether Alzheimer's dementia is secondary to vascular dysfunction in the central nervous system (CNS) and, therefore, the neurodegeneration that follows is a consequence of inadequate cerebral blood flow, altered brain metabolism and failure in physiological functions of brain endothelium which represents a site at the blood-brain barrier (BBB).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/12476348' target='_blank' class='pmid-link'>12476348</a>:</span> <span class='sentence-part'>Studies of the pathogenic actions of mutations in presenilins and amyloid precursor protein that cause early-onset familial AD have established central roles for perturbed cellular calcium homeostasis and oxidative stress in the neurodegenerative process. The clinical presentation of patients with AD is dominated by cognitive deficits and emotional disturbances that result from dysfunction and degeneration of neurons in the limbic system and cerebral cortex.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/1453480' target='_blank' class='pmid-link'>1453480</a>:</span> <span class='sentence-part'>Finally, disfunction of the lysosomal system may play a role in the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/14689635' target='_blank' class='pmid-link'>14689635</a>:</span> <span class='sentence-part'>This adaptation in Alzheimer's disease may be caused by dysfunction of the mechanism in adaptation of a quickly recovering central process.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/15639790' target='_blank' class='pmid-link'>15639790</a>:</span> <span class='sentence-part'>Selective dysfunction of mGlu II receptors may also lead to abnormal protein phosphorylation (i.e., tau phosphorylation), culminating in neurodegenerative disorders (i.e., Alzheimer disease).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/15781969' target='_blank' class='pmid-link'>15781969</a>:</span> <span class='sentence-part'>Accumulation of cytoplasmic inclusion bodies in many neurodegenerative diseases, including Alzheimer's disease (AD), might result from dysfunction of the ubiquitin-proteasome system. Phospho-beta-catenin accumulation in Alzheimer's disease and in aggresomes attributable to proteasome dysfunction.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/15847115' target='_blank' class='pmid-link'>15847115</a>:</span> <span class='sentence-part'>CONCLUSIONS: Spectrophotometric enzymatic analyses of respiratory complexes in brain homogenates do not support the primary contribution of mitochondrial RC dysfunction in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/16002400' target='_blank' class='pmid-link'>16002400</a>:</span> <span class='sentence-part'>Synaptic dysfunction is one of the earliest events in the pathogenesis of Alzheimer disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/16078048' target='_blank' class='pmid-link'>16078048</a>:</span> <span class='sentence-part'>Since mitochondrial dysfunction has been proposed as an underlying cause of AD and a specific haplogroup was found to affect AD susceptibility in Caucasians, we investigated whether inherited mitochondrial haplogroups affect risk of developing AD dementia in Ohio and Indiana Amish communities.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/16178023' target='_blank' class='pmid-link'>16178023</a>:</span> <span class='sentence-part'>There is strong evidence from genetics and transgenic mouse models that mitochondrial dysfunction results in neurodegeneration and may contribute to the pathogenesis of Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, hereditary spastic paraplegia, and cerebellar degenerations.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/16569229' target='_blank' class='pmid-link'>16569229</a>:</span> <span class='sentence-part'>BACKGROUND: Alzheimer's disease is a neurodegenerative disorder characterized by a progressive cognitive impairment, the consequence of neuronal dysfunction and ultimately the death of neurons.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/16814428' target='_blank' class='pmid-link'>16814428</a>:</span> <span class='sentence-part'>A pathological feature of Alzheimer's disease (AD) is an area-specific neuronal loss that may be caused by excitotoxicity-related synaptic dysfunction.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17168642' target='_blank' class='pmid-link'>17168642</a>:</span> <span class='sentence-part'>Today, we know that Abeta-degrading proteases are critical regulators of brain Abeta levels in vivo, with evidence accumulating that their dysfunction may play a role in the etiology of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17512984' target='_blank' class='pmid-link'>17512984</a>:</span> <span class='sentence-part'>Oxidative stress, bioenergetic failure and mitochondrial dysfunction are all implicated in the etiology of neurodegenerative diseases such as Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17558294' target='_blank' class='pmid-link'>17558294</a>:</span> <span class='sentence-part'>Tau is an axonal microtubule-associated protein, whose dysfunction causes neurodegenerative diseases such as Alzheimer's disease and other tauopathies.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17678440' target='_blank' class='pmid-link'>17678440</a>:</span> <span class='sentence-part'>Extensive literature exists supporting a role for mitochondrial dysfunction and oxidative damage in the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17696767' target='_blank' class='pmid-link'>17696767</a>:</span> <span class='sentence-part'>This article discusses critical issues of mitochondria causing dysfunction in aging and AD and discusses the strategies to protect neurons caused by mitochondrial dysfunction.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/1776729' target='_blank' class='pmid-link'>1776729</a>:</span> <span class='sentence-part'>At the cellular level, Alzheimer's disease (AD) must be the result of neuronal dysfunction and degeneration leading to a reduction in synaptic density. As elucidation of the reasons behind amyloid deposition must shed some light on the pathogenesis of AD, we review the current state of knowledge on the nature of the AD amyloid protein, its origin, and its formation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17786024' target='_blank' class='pmid-link'>17786024</a>:</span> <span class='sentence-part'>Extensive literature exists supporting a role for mitochondrial dysfunction and oxidative damage in the pathogenesis of Alzheimer disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17911214' target='_blank' class='pmid-link'>17911214</a>:</span> <span class='sentence-part'>Growing evidence suggests that mitochondrial dysfunction is one of the key intracellular lesions associated with the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17959149' target='_blank' class='pmid-link'>17959149</a>:</span> <span class='sentence-part'>Our results provide a template for the design of curcuminoid-based synthetic small-molecule fold catalysts that accelerate the folding of ER-processed proteins; this assumes significance given that nitrosative stress and dysfunction of the ER-resident oxidoreductase protein disulfide isomerise due to S-nitrosylation are factors associated with the pathogenesis of Alzheimer's and Parkinson's diseases.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17986027' target='_blank' class='pmid-link'>17986027</a>:</span> <span class='sentence-part'>The epidemiological finding of an increased risk of dementia in patients with diabetes mellitus has raised the hypothesis that a dysfunction of the insulin receptors plays a role in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/18322383' target='_blank' class='pmid-link'>18322383</a>:</span> <span class='sentence-part'>Structural and functional genomics studies demonstrate that genomic factors, probably induced by environmental factors, cerebrovascular dysfunction, and epigenetic phenomena, might be responsible for AD pathogenesis leading to premature neuronal death.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/18641892' target='_blank' class='pmid-link'>18641892</a>:</span> <span class='sentence-part'>In Alzheimer's disease, pathological and neuroimaging data indicate that apathy is likely due to a dysfunction of the medial prefrontal cortex.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/18949251' target='_blank' class='pmid-link'>18949251</a>:</span> <span class='sentence-part'>BACKGROUND: Subjects with Alzheimer's disease (AD) have elevated cortisol levels as a result of hypothalamic-pituitary-adrenal (HPA) axis dysfunction.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/19182481' target='_blank' class='pmid-link'>19182481</a>:</span> <span class='sentence-part'>When AD or DLB patients walk with incongruent visual information, they may increase their postural sway or instability, because of their executive dysfunction.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/19389700' target='_blank' class='pmid-link'>19389700</a>:</span> <span class='sentence-part'>Caspase-cleaved tau expression induces mitochondrial dysfunction in immortalized cortical neurons: implications for the pathogenesis of Alzheimer disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/19417214' target='_blank' class='pmid-link'>19417214</a>:</span> <span class='sentence-part'>Mitochondrial dysfunction is a hallmark of beta-amyloid (Abeta)-induced neuronal injury in the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/19496804' target='_blank' class='pmid-link'>19496804</a>:</span> <span class='sentence-part'>There is strong evidence that beta-amyloid (Abeta) causes oxidative stress and induces mitochondrial dysfunction in the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/19519498' target='_blank' class='pmid-link'>19519498</a>:</span> <span class='sentence-part'>However, there is growing evidence that early stages of AD may be due to neuronal network dysfunction produced by the actions of soluble forms of Abeta.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/19544621' target='_blank' class='pmid-link'>19544621</a>:</span> <span class='sentence-part'>Mitochondrial dysfunction is one of the key characteristics of AD pathogenesis. Growing evidence suggests a causative role for intracellular accumulation of amyloid precursor protein (APP) and its proteolytic products in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/19682326' target='_blank' class='pmid-link'>19682326</a>:</span> <span class='sentence-part'>The current clinical criteria for diagnosis of AD are focused mostly on cognitive deficits produced by dysfunction of hippocampal and high-order neocortical areas, whereas noncognitive, behavioural and psychological symptoms of dementia such as disturbances in mood, emotion, appetite, and wake-sleep cycle, confusion, agitation and depression have been less considered.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/19853658' target='_blank' class='pmid-link'>19853658</a>:</span> <span class='sentence-part'>Mitochondrial dysfunction is a trigger of Alzheimer's disease pathophysiology. Extensive literature exists supporting a role for mitochondrial dysfunction and oxidative damage in the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/19907182' target='_blank' class='pmid-link'>19907182</a>:</span> <span class='sentence-part'>BACKGROUND/AIM: The contribution of mitochondrial dysfunction and oxidative stress to the pathogenesis of Alzheimer's disease (AD) has previously been described.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20016833' target='_blank' class='pmid-link'>20016833</a>:</span> <span class='sentence-part'>Whether mitochondrial dysfunctions are merely a consequence of AD pathology, or are early seminal events in AD pathogenesis remains to be determined.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20061648' target='_blank' class='pmid-link'>20061648</a>:</span> <span class='sentence-part'>Although increasing evidence supports a role for mitochondrial dysfunction in the pathogenesis of AD, there have been few studies that simultaneously evaluate changes in multiple mitochondrial proteins.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20107079' target='_blank' class='pmid-link'>20107079</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) is attributable to synapse dysfunction and loss, but the nature and progression of the presynaptic structural and functional changes in AD are essentially unknown.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20127811' target='_blank' class='pmid-link'>20127811</a>:</span> <span class='sentence-part'>Recent studies suggest that synaptic dysfunction is one of the earliest events in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20463402' target='_blank' class='pmid-link'>20463402</a>:</span> <span class='sentence-part'>Increasing evidence is implicating mitochondrial dysfunction as a central factor in the etiology of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20512543' target='_blank' class='pmid-link'>20512543</a>:</span> <span class='sentence-part'>Cognitive impairment symptoms of AD are induced by limbic system dysfunction, and an early-stage AD brain without dementia has the potential for atrophy in the hippocampal region.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20553766' target='_blank' class='pmid-link'>20553766</a>:</span> <span class='sentence-part'>The dysfunction and loss of basal forebrain cholinergic neurons and their cortical projections are among the earliest pathological events in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20555132' target='_blank' class='pmid-link'>20555132</a>:</span> <span class='sentence-part'>Although mitochondrial dysfunction and the resultant oxidative stress are believed to play a major role in the pathogenesis of both early- and late-onset AD, it is conceivable that the altered physiological state of the cells leading to sporadic AD could involve additional mechanisms.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20661404' target='_blank' class='pmid-link'>20661404</a>:</span> <span class='sentence-part'>Mitochondrial dysfunction has surfaced as one of the most discussed hypotheses acting as a trigger for the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20730022' target='_blank' class='pmid-link'>20730022</a>:</span> <span class='sentence-part'>Studies in mice expressing both human amyloid precursor protein and human tau have provided clear evidence that amyloid-beta and tau interact in the pathogenesis of AD. A defined effort must be made to develop therapies that directly address the impact of tau dysfunction in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20840064' target='_blank' class='pmid-link'>20840064</a>:</span> <span class='sentence-part'>We also cover the recent findings on cellular and animal models that highlight mitochondrial dysfunction as a fundamental mechanism in AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21046564' target='_blank' class='pmid-link'>21046564</a>:</span> <span class='sentence-part'>The case for blood-brain barrier dysfunction in the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21112383' target='_blank' class='pmid-link'>21112383</a>:</span> <span class='sentence-part'>This review proposes the hypothesis that a chronic mild longlasting cerebrovascular dysfunction could initiate a cascade of events leading to AD. Chronic mild cerebrovascular dysfunction as a cause for Alzheimer's disease?</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21143177' target='_blank' class='pmid-link'>21143177</a>:</span> <span class='sentence-part'>Dysfunction of one or more of these proteins is hypothesized to contribute to the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21244356' target='_blank' class='pmid-link'>21244356</a>:</span> <span class='sentence-part'>Mitochondrial dysfunction has been widely implicated in the etiology of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21336338' target='_blank' class='pmid-link'>21336338</a>:</span> <span class='sentence-part'>The analyses of the similarities and differences of these dysfunctional pathways provide insights into understanding the dynamics of AD progression in six brain regions from a network perspective, which will further shed light on the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21450370' target='_blank' class='pmid-link'>21450370</a>:</span> <span class='sentence-part'>Mitochondrial dysfunction is likely a significant contributing factor to Alzheimer disease pathogenesis, and both amyloid peptide (Abeta) and pathological forms of tau may contribute to this impairment.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21514369' target='_blank' class='pmid-link'>21514369</a>:</span> <span class='sentence-part'>Especially in the context that mitochondrial dysfunction is an early and prominent characteristic of Alzheimer's pathogenesis, EMF treatment could have profound value in the disease's prevention and treatment through intervention at the mitochondrial level.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/2165009' target='_blank' class='pmid-link'>2165009</a>:</span> <span class='sentence-part'>The hypothesis that the symptomatology of Alzheimer's disease is attributable to cholinergic dysfunction is supported by postmortem studies that have demonstrated reduced choline acetyltransferase (ChAT) activity across all areas of cerebral cortex and diminished numbers of perikarya in the basal forebrain nucleus basalis of Meynert.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22024748' target='_blank' class='pmid-link'>22024748</a>:</span> <span class='sentence-part'>Primary lysosomal dysfunction causes cargo-specific deficits of axonal transport leading to Alzheimer-like neuritic dystrophy.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22391273' target='_blank' class='pmid-link'>22391273</a>:</span> <span class='sentence-part'>Mitochondrial dysfunction is considered a major causative factor in Alzheimer's disease (AD), Parkinson's disease (PD) and Huntington's disease (HD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22539855' target='_blank' class='pmid-link'>22539855</a>:</span> <span class='sentence-part'>Oxidative stress, mitochondrial dysfunction, and Ca2+ dysregulation are key factors in the pathogenesis of AD, but the causal relationship between these factors and synaptic dysfunction is not clearly understood. Alzheimer's disease (AD) in the early stages is characterized by memory impairment, which may be attributable to synaptic dysfunction.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22751174' target='_blank' class='pmid-link'>22751174</a>:</span> <span class='sentence-part'>The evidence that neurovascular dysfunction is an integral part of Alzheimer's disease (AD) pathogenesis has continued to emerge in the last decade.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22833458' target='_blank' class='pmid-link'>22833458</a>:</span> <span class='sentence-part'>From mitochondrial dysfunction to amyloid beta formation: novel insights into the pathogenesis of Alzheimer's disease. Furthermore, there is cumulating evidence that Abeta formation impairs mitochondrial function and that mitochondrial dysfunction is an early event in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22914888' target='_blank' class='pmid-link'>22914888</a>:</span> <span class='sentence-part'>Several lines of evidence point to synaptic dysfunction as a cause of AD and that synapse loss is a pathological correlate associated with cognitive decline.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22922216' target='_blank' class='pmid-link'>22922216</a>:</span> <span class='sentence-part'>The recognition that G(1)/S checkpoint dysfunctions in Alzheimer's disease (AD) has opened a novel avenue for better understanding the pathogenesis of AD, as well as for searching for new biomarkers for early diagnosis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22961084' target='_blank' class='pmid-link'>22961084</a>:</span> <span class='sentence-part'>Our data indicate that insulin dysfunction in NOD mice leads to AD-like tau hyperphosphorylation in the brain, with molecular mechanisms likely involving a deregulation of PP2A.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22995655' target='_blank' class='pmid-link'>22995655</a>:</span> <span class='sentence-part'>Mitochondrial dysfunction and synaptic damage have been described as early events in Alzheimer's disease (AD) pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23107435' target='_blank' class='pmid-link'>23107435</a>:</span> <span class='sentence-part'>Increasing evidence demonstrates that amyloid beta (Abeta) elicits mitochondrial dysfunction and oxidative stress, which contributes to the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23126372' target='_blank' class='pmid-link'>23126372</a>:</span> <span class='sentence-part'>Thus, deficiency in mural vascular cells may contribute to disrupted vascular barrier properties and resultant neuronal dysfunction during AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23151073' target='_blank' class='pmid-link'>23151073</a>:</span> <span class='sentence-part'>Oxidative damage and mitochondrial dysfunction have been also implicated in the pathogenesis of AD, but the question as to whether they are involved in the onset and progression of the pathology or rather represent a consequence of neurodegeneration is still debated. Vascular factors and mitochondrial dysfunction: a central role in the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23382999' target='_blank' class='pmid-link'>23382999</a>:</span> <span class='sentence-part'>Abnormal mitochondrial motility and mitochondrial dysfunction within axons are critical for amyloid beta (Abeta)-induced synaptic stress and the loss of synapses relevant to the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23494712' target='_blank' class='pmid-link'>23494712</a>:</span> <span class='sentence-part'>The dysfunction of the Neurovascular Unit (NVU) has been proposed to be causative in AD development, due to an impaired clearance of Abeta from the brain.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23756733' target='_blank' class='pmid-link'>23756733</a>:</span> <span class='sentence-part'>Their dysfunction may cause various life-threatening disorders, such as Parkinson's, Alzheimer's, and cardiovascular diseases.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23948929' target='_blank' class='pmid-link'>23948929</a>:</span> <span class='sentence-part'>Dysfunction of this signaling process may underlie glia-based aspects of AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24171818' target='_blank' class='pmid-link'>24171818</a>:</span> <span class='sentence-part'>Here, we provide an overview of current research focused on the relevance of autophagic/lysosomal dysfunction in AD pathogenesis as well as potential therapeutic targets aimed at restoring autophagic/lysosomal pathway function.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24252187' target='_blank' class='pmid-link'>24252187</a>:</span> <span class='sentence-part'>As such, NVU/BBB dysfunction, associated to irregularities in cerebral blood flow (CBF), has been proposed to contribute in the pathogenesis of Alzheimer's disease (AD), mainly by impairing cerebral Abeta clearance.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24450113' target='_blank' class='pmid-link'>24450113</a>:</span> <span class='sentence-part'>Currently, AD is believed to begin with synaptic dysfunction caused by soluble Abeta oligomers, playing a more important role in the etiology of AD than insoluble Abeta ibrils ('oligomer hypothesis').</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24512632' target='_blank' class='pmid-link'>24512632</a>:</span> <span class='sentence-part'>Dysfunction of retromer is a risk factor for the pathogenesis of Parkinson's disease (PD) and Alzheimer's disease (AD), both neuro-degeneration disorders.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24610177' target='_blank' class='pmid-link'>24610177</a>:</span> <span class='sentence-part'>Increasing evidence has implicated autophagic dysfunction in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24664866' target='_blank' class='pmid-link'>24664866</a>:</span> <span class='sentence-part'>The brain is more vulnerable than other organs to oxidative stress, and most of the components of neurons (lipids, proteins, and nucleic acids) can be oxidized in AD due to mitochondrial dysfunction, increased metal levels, inflammation, and beta-amyloid (Abeta) peptides.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24684730' target='_blank' class='pmid-link'>24684730</a>:</span> <span class='sentence-part'>Synaptic dysfunction and synapse loss are key features of Alzheimer's pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24713000' target='_blank' class='pmid-link'>24713000</a>:</span> <span class='sentence-part'>Together, our results support the role of tau and calcineurin as two intermediate signaling molecules between Abeta initiation and eventual synaptic dysfunction early in AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24728903' target='_blank' class='pmid-link'>24728903</a>:</span> <span class='sentence-part'>Human studies show that besides loss of cognition/learning ability, neuropsychological symptoms such as anxiety and seizures are seen as high as 70 and 17 % respectively in AD patients, suggesting dysfunction of GABAergic neurotransmission contributes to pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24902900' target='_blank' class='pmid-link'>24902900</a>:</span> <span class='sentence-part'>Evidence indicates that nitrosative stress and mitochondrial dysfunction participate in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25045655' target='_blank' class='pmid-link'>25045655</a>:</span> <span class='sentence-part'>Since synaptic dysfunction and degeneration are early events during the pathogenesis of AD, we aim to investigate the effects of testosterone on oligomeric Abeta-induced synaptic changes.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25062013' target='_blank' class='pmid-link'>25062013</a>:</span> <span class='sentence-part'>Soluble oligomeric amyloid beta (oAbeta) causes synaptic dysfunction and neuronal cell death, which are involved in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25106114' target='_blank' class='pmid-link'>25106114</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) has historically been considered to arise due to the specific dysfunction and pathology of neurons in brain areas related to cognition.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25322927' target='_blank' class='pmid-link'>25322927</a>:</span> <span class='sentence-part'>BACKGROUND: Specific mechanisms behind the role of oxidative/nitrosative stress and mitochondrial dysfunction in Alzheimer's disease (AD) pathogenesis remain elusive.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25400096' target='_blank' class='pmid-link'>25400096</a>:</span> <span class='sentence-part'>Although it is well documented that soluble beta amyloid (Abeta) oligomers are critical factors in the pathogenesis of Alzheimer's disease (AD) by causing synaptic dysfunction and neuronal death, the primary mechanisms by which Abeta oligomers trigger neurodegeneration are not entirely understood.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25465240' target='_blank' class='pmid-link'>25465240</a>:</span> <span class='sentence-part'>Olfactory dysfunction is a recognized risk factor for the pathogenesis of Alzheimer's disease (AD), while the mechanisms are still not clear.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25511446' target='_blank' class='pmid-link'>25511446</a>:</span> <span class='sentence-part'>Although pathological hallmarks of AD are senile plaques, neurofibrillary tangles, and neuronal degeneration which are associated with increased oxidative stress, synaptic loss is an early event in the pathogenesis of AD. Mechanism of Oxidative Stress and Synapse Dysfunction in the Pathogenesis of Alzheimer's Disease: Understanding the Therapeutics Strategies.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25531259' target='_blank' class='pmid-link'>25531259</a>:</span> <span class='sentence-part'>This review explores the potential role of mitochondrial epigenetic dysfunction in Alzheimer's disease etiology and discusses some technical issues pertinent to the study of these processes.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25533203' target='_blank' class='pmid-link'>25533203</a>:</span> <span class='sentence-part'>INTRODUCTION: Synaptic dysfunction is an early event in Alzheimer's disease (AD) pathogenesis and directly related to cognitive impairment.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25688079' target='_blank' class='pmid-link'>25688079</a>:</span> <span class='sentence-part'>Despite widespread recognition of the significance of vascular dysfunction in Alzheimer's disease aetiology and progression, much uncertainty still surrounds the mechanism underlying Alzheimer's disease vascular injury.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26075247' target='_blank' class='pmid-link'>26075247</a>:</span> <span class='sentence-part'>Diabetes is associated with various nervous disorders, such as cognitive deficits, depression, and Alzheimer's disease, and that may be caused by neural stem cell dysfunction.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26126792' target='_blank' class='pmid-link'>26126792</a>:</span> <span class='sentence-part'>Dysfunction of protein transport contributes to pathogenesis of AD and other neurodegenerative diseases.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26186010' target='_blank' class='pmid-link'>26186010</a>:</span> <span class='sentence-part'>Additionally, oxidative damage and the dysfunction of the antioxidant system play important roles in the pathogenesis of osteoporosis and AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26311408' target='_blank' class='pmid-link'>26311408</a>:</span> <span class='sentence-part'>Vascular dysfunction in the pathogenesis of Alzheimer's disease--A review of endothelium-mediated mechanisms and ensuing vicious circles. This study reviews the current literature of in vitro and ex vivo studies on endothelium-mediated mechanisms underlying vascular dysfunction in AD pathogenesis, with the aim of presenting a comprehensive overview of the complex network of causative relationships.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26359500' target='_blank' class='pmid-link'>26359500</a>:</span> <span class='sentence-part'>Alzheimer disease (AD) is a progressive neurodegenerative disorder characterized by loss of neurons and formation of pathological extracellular deposits induced by amyloid-beta peptide (Abeta). Thus, this study suggests that GAPDH aggregates accelerate Abeta amyloidogenesis, subsequently leading to mitochondrial dysfunction and neuronal cell death in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26380416' target='_blank' class='pmid-link'>26380416</a>:</span> <span class='sentence-part'>[THE ROLE OF beta-AMYLOID AND MITOCHONDRIAL DYSFUNCTION IN THE PATHOGENESIS OF ALZHEIMER'S DISEASE].</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26440450' target='_blank' class='pmid-link'>26440450</a>:</span> <span class='sentence-part'>In Alzheimer's disease (AD), the deposition of beta-amyloid (Abeta) is hypothesized to result in a series of secondary neurodegenerative processes, leading ultimately to synaptic dysfunction and neuronal loss.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26500157' target='_blank' class='pmid-link'>26500157</a>:</span> <span class='sentence-part'>This study demonstrates for the first time mitochondrial dysfunction in transgenic mice with a mutation within the Abeta peptide (the Arctic APP mutation), and confirms previous studies suggesting that mitochondrial dysfunction and oxidative stress is an early event in the pathogenesis of Alzheimer disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26601965' target='_blank' class='pmid-link'>26601965</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) and Parkinson's disease (PD) are the two most widespread neurological disorders (NDs) characterized by degeneration of cognitive and motor functions due to malfunction and loss of neurons in the central nervous system (CNS).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26647379' target='_blank' class='pmid-link'>26647379</a>:</span> <span class='sentence-part'>This multi-sensor system measured mitochondrial parameters in the brain of transgenic mice that model Alzheimer's disease (AD), because mitochondrial dysfunction is believed to be a primary event in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26829765' target='_blank' class='pmid-link'>26829765</a>:</span> <span class='sentence-part'>Characterizing the early NVU damage and identifying biomarkers of neurovascular dysfunction may provide a fresh insight into Alzheimer pathogenesis and open opportunities for pediatric neuroprotection.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26869037' target='_blank' class='pmid-link'>26869037</a>:</span> <span class='sentence-part'>Mounting evidence has implicated autophagic dysfunction in the pathogenesis of several major neurodegenerative disorders, such as Parkinson's disease, Alzheimer's disease and Huntington's disease, where deficient elimination of abnormal and toxic protein aggregates promotes cellular stress, failure and death.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26949964' target='_blank' class='pmid-link'>26949964</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) and Parkinson's disease (PD) are such kind of killer CDs that occur due to dysfunction of cholinergic and dopaminergic neurons.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26976084' target='_blank' class='pmid-link'>26976084</a>:</span> <span class='sentence-part'>Its dysfunction and aggregation into insoluble paired helical filaments is involved in the pathogenesis of Alzheimer's disease (AD), constituting, together with accumulated beta-amyloid (Abeta) peptides, a hallmark of the disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27073745' target='_blank' class='pmid-link'>27073745</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) is the most common neurodegenerative disorder, characterized by cognitive impairment and dementia, resulting from progressive synaptic dysfunction, loss and neuronal cell death.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27340665' target='_blank' class='pmid-link'>27340665</a>:</span> <span class='sentence-part'>Cellular dysfunctions involving specific subcellular compartments, such as mitochondria and endoplasmic reticulum (ER), are emerging as crucial players in the pathogenesis of AD, as well as increased oxidative stress and dysregulation of calcium homeostasis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27439966' target='_blank' class='pmid-link'>27439966</a>:</span> <span class='sentence-part'>It is well known that cognitive deficit of AD is caused by synaptic dysfunction.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27556379' target='_blank' class='pmid-link'>27556379</a>:</span> <span class='sentence-part'>On the other hand, experimental findings and human observations signal that some of the primary degenerative diseases of the CNS, like frontotemporal dementia, Parkinson's disease, Alzheimer's dementia, Huntington's dementia, primary cerebellar ataxias and amyotrophic lateral sclerosis, all of which affect the human species exclusively, may be due to astroglial dysfunction.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27581448' target='_blank' class='pmid-link'>27581448</a>:</span> <span class='sentence-part'>UNLABELLED: Microglial dysfunction is increasingly recognized as a key contributor to the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27599716' target='_blank' class='pmid-link'>27599716</a>:</span> <span class='sentence-part'>Mitochondrial dysfunction is known as one of causative factors in Alzheimer's disease (AD), inducing neuronal cell death.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27629410' target='_blank' class='pmid-link'>27629410</a>:</span> <span class='sentence-part'>These results further implicate endolysosome dysfunction in the pathogenesis of AD and HAND, and by virtue of its ability to prevent and/or block neuropathological features associated with AD and HAND caffeine might find use as an effective adjunctive therapeutic agent.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27634555' target='_blank' class='pmid-link'>27634555</a>:</span> <span class='sentence-part'>Mitochondrial dysfunction and ensuing oxidative damage is typically thought to be a primary cause of Huntington's disease, Alzheimer's disease, and Parkinson disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27634936' target='_blank' class='pmid-link'>27634936</a>:</span> <span class='sentence-part'>Cerebrovascular dysfunction is a critical component of Alzheimer's disease (AD) pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27653553' target='_blank' class='pmid-link'>27653553</a>:</span> <span class='sentence-part'>Mitochondrial dysfunction and impaired energy metabolism are important components of AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27834780' target='_blank' class='pmid-link'>27834780</a>:</span> <span class='sentence-part'>Therefore, to elucidate the causative mechanisms of mitochondrial dysfunction in aging brains is of paramount importance for our understanding of the pathogenesis of AD, in particular its sporadic form.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27987381' target='_blank' class='pmid-link'>27987381</a>:</span> <span class='sentence-part'>Hypoxia/ischemia activate processing of Amyloid Precursor Protein: impact of vascular dysfunction in the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28131207' target='_blank' class='pmid-link'>28131207</a>:</span> <span class='sentence-part'>BACKGROUND: Potential role of vascular dysfunction has been suggested in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28237964' target='_blank' class='pmid-link'>28237964</a>:</span> <span class='sentence-part'>Microvascular dysfunction is considered an integral part of Alzheimer disease (AD) pathogenesis, but the possible relationship between amyloid pathology, microvascular dysfunction and cell death is still unclear.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28299814' target='_blank' class='pmid-link'>28299814</a>:</span> <span class='sentence-part'>They further support the concept of subtypes of Alzheimer's disease with distinct cognitive profiles due to prominent neocortical dysfunction early in the disease course.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28531191' target='_blank' class='pmid-link'>28531191</a>:</span> <span class='sentence-part'>Recent studies have shown that mitochondrial dysfunction is a causative factor of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28934248' target='_blank' class='pmid-link'>28934248</a>:</span> <span class='sentence-part'>Dysfunction of retromer is a risk factor for the pathogenesis of Parkinson's disease (PD) and Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28956268' target='_blank' class='pmid-link'>28956268</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) is a progressive neurodegenerative disorder leading to dementia caused by advanced neuronal dysfunction and death.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28988799' target='_blank' class='pmid-link'>28988799</a>:</span> <span class='sentence-part'>Dysfunction of autophagy and endosomal-lysosomal pathways: Roles in pathogenesis of Down syndrome and Alzheimer's Disease. The same genetic factors that cause or increase AD risk are also direct causes of endosomal-lysosomal dysfunction, underscoring the essential partnership between this dysfunction and APP metabolites in AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29089996' target='_blank' class='pmid-link'>29089996</a>:</span> <span class='sentence-part'>Alzheimer's disease, a progressive neurodegenerative disease, affects learning and memory resulting from cholinergic dysfunction. These findings revealed the underlying mechanisms of scopolamine-induced Alzheimer's disease-like cellular dysfunctions, which provide evidence for developing drugs for the treatment of this debilitating disease. Scopolamine has been employed to induce Alzheimer's disease-like pathology in vivo and in vitro through alteration of cholinergic system.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29124106' target='_blank' class='pmid-link'>29124106</a>:</span> <span class='sentence-part'>(A?) accumulation and A?-related neural network dysfunction are considered central to the pathogenesis of Alzheimer's disease (AD) at the early stage.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29127191' target='_blank' class='pmid-link'>29127191</a>:</span> <span class='sentence-part'>Recent studies on Alzheimer's disease (AD) pathogenesis have suggested that accumulation of aggregated beta-amyloid (Abeta) peptides in the AD brain results from a dysfunction in these cellular clearance systems.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29255835' target='_blank' class='pmid-link'>29255835</a>:</span> <span class='sentence-part'>Mitochondrial dysfunction has been found to play an important role in the initiation of both aging and the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29320772' target='_blank' class='pmid-link'>29320772</a>:</span> <span class='sentence-part'>This article examines the available evidence for a role of mTOR-driven cerebrovascular dysfunction in the pathogenesis of AD and of vascular cognitive impairment and dementia (VCID) and highlights the therapeutic potential of targeting mTOR and/or specific downstream effectors for vasculoprotection in AD, VCID, and other age-associated neurological diseases with cerebrovascular etiology.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29354787' target='_blank' class='pmid-link'>29354787</a>:</span> <span class='sentence-part'>We suggest that complex I dysfunction accelerate amyloid toxicity and mitochondrial complex I dysfunction in aging may contribute to the pathogenesis of sporadic AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29516292' target='_blank' class='pmid-link'>29516292</a>:</span> <span class='sentence-part'>Along with brain amyloid-beta (Abeta) deposits and neurofibrillary tangles, cerebrovascular dysfunction is increasingly recognized as fundamental to the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29551631' target='_blank' class='pmid-link'>29551631</a>:</span> <span class='sentence-part'>Mitochondrial dysfunction has been identified as an early event in AD pathogenesis and is reflected by reduced metabolism, disruption of Ca2+ homeostasis, and increased levels of reactive oxygen species, lipid peroxidation, and apoptosis. Although an accumulation of brain amyloid-beta (Abeta) peptide and hyperphosphorylated tau protein have been implicated in the pathogenesis of AD, the etiology of the disease remains unclear.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29777753' target='_blank' class='pmid-link'>29777753</a>:</span> <span class='sentence-part'>Recent studies suggest that neurovascular dysfunction may be an integral part of AD pathogenesis, contributing to the onset and development of AD pathologies such as neuronal death, inflammatory response, and breakdown of blood-brain barrier (BBB).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29863022' target='_blank' class='pmid-link'>29863022</a>:</span> <span class='sentence-part'>These findings indicate that the involvement of early demyelination at 3 months and the oligodendrocyte dysfunction at 6 months in APP/PS1 mice are in association with Alzheimer's disease pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29992725' target='_blank' class='pmid-link'>29992725</a>:</span> <span class='sentence-part'>While both Abeta plaques and tau aggregates could in turn enhance the dysfunction of these proteostatic pathways, eventually leading to apoptotic or necrotic neuronal death and pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30009706' target='_blank' class='pmid-link'>30009706</a>:</span> <span class='sentence-part'>Dysfunction of the cholinergic system plays an important role in pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30144541' target='_blank' class='pmid-link'>30144541</a>:</span> <span class='sentence-part'>In summary, APOE epsilon4 may affect CSF SNAP levels in MCI patients, suggesting an important role of APOE epsilon4 in synaptic dysfunction leading to AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30292394' target='_blank' class='pmid-link'>30292394</a>:</span> <span class='sentence-part'>CONCLUSIONS: Our results reveal a role for RPS23RG1 in maintaining synaptic integrity and function and provide a new mechanism for synaptic dysfunction in AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30296191' target='_blank' class='pmid-link'>30296191</a>:</span> <span class='sentence-part'>CONCLUSION: Endogenous n-3 PUFAs delayed the onset of Alzheimer's disease caused by tau protein dysfunction, alleviating related symptoms and significantly prolonging survival in vivo.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30352630' target='_blank' class='pmid-link'>30352630</a>:</span> <span class='sentence-part'>Amyloid beta (Abeta)-mediated synapse dysfunction and spine loss are considered to be early events in Alzheimer's disease (AD) pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30362531' target='_blank' class='pmid-link'>30362531</a>:</span> <span class='sentence-part'>Autophagic dysfunction in Alzheimer's disease: Cellular and molecular mechanistic approaches to halt Alzheimer's pathogenesis. This review highlights the critical linkage of autophagy in the pathogenesis of AD, and avows a new insight to search for therapeutic target for blocking Alzheimer's pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30472149' target='_blank' class='pmid-link'>30472149</a>:</span> <span class='sentence-part'>Overtaken of High-fat, high-glucose or high-cholesterol diet may hasten the incidence of AD in later life, due to the metabolic dysfunction.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30478411' target='_blank' class='pmid-link'>30478411</a>:</span> <span class='sentence-part'>Moreover, our findings strongly suggest that mitochondrial dysfunction, NF-kappaB signalling and iNOS signalling are important dysregulated pathways in AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30481567' target='_blank' class='pmid-link'>30481567</a>:</span> <span class='sentence-part'>Importantly, dysfunction of such postsynaptic receptor trafficking can lead to severe brain diseases such as Alzheimer's Disease, autism spectrum disorder, and intellectual disability, yet underlying mechanisms remain elusive.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/3539000' target='_blank' class='pmid-link'>3539000</a>:</span> <span class='sentence-part'>Two principal features of Alzheimer's disease (AD) are (1) the occurrence of neurofibrillary tangles (NFTs) and senile plaques, and (2) the loss of cortical cholinergic activity because of dysfunction of neurons in the basal forebrain cholinergic system.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/7280699' target='_blank' class='pmid-link'>7280699</a>:</span> <span class='sentence-part'>The effects of diffuse cerebral dysfunction on oculomotor reaction time were assessed in patients with dementia of presumed Alzheimer's etiology and in normal age-matched control subjects.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/8892355' target='_blank' class='pmid-link'>8892355</a>:</span> <span class='sentence-part'>Thus, the decrease we observe in overall PGSH-2 mRNA levels is likely to reflect both the known decline in numbers of neurons in AD as well as a lowered capacity for neuronal synthesis of PGHS-2, perhaps due to dysfunction or a loss of synaptic input.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/9452785' target='_blank' class='pmid-link'>9452785</a>:</span> <span class='sentence-part'>Hypertension may also give rise to a blood-brain barrier dysfunction, which has been suggested to be involved in the aetiology and pathogenesis of Alzheimer's disease.</span></div></div>
<div class='streamlined-assertion'><div class='streamlined-header sticky-relation-header'><span class='label-text'>Subject:</span> <strong>Gene_Mutation</strong> <span class='label-text'>Subject CUI:</span> <strong>C0596611</strong> â†’ <span class='label-text predicate-text'>CAUSES</span> â†’ <span class='label-text'>Object:</span> <strong>Alzheimers</strong> <span class='label-text'>Object CUI:</span> <strong>C0750901</strong></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/10037734' target='_blank' class='pmid-link'>10037734</a>:</span> <span class='sentence-part'>The amyloid precursor protein (APP) has been associated with Alzheimer's disease (AD) because APP is processed into the beta-peptide that accumulates in amyloid plaques, and APP gene mutations can cause early onset AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/10913280' target='_blank' class='pmid-link'>10913280</a>:</span> <span class='sentence-part'>Elevated levels of A beta(42) peptide formation have been linked to early-onset familial AD-causing gene mutations in the amyloid beta-protein precursor (A beta PP) and the presenilins.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/12862394' target='_blank' class='pmid-link'>12862394</a>:</span> <span class='sentence-part'>Amyloid precursor protein gene mutations responsible for early-onset autosomal dominant Alzheimer's disease. The imbalance between A beta production and A beta clearance releases a cascade of subsequent cellular processes leading to AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/16713961' target='_blank' class='pmid-link'>16713961</a>:</span> <span class='sentence-part'>To assess the potential of Drosophila to analyze clinically graded aspects of human disease, we developed a transgenic fly model to characterize Presenilin (PS) gene mutations that cause early-onset familial Alzheimer's disease (FAD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/18413473' target='_blank' class='pmid-link'>18413473</a>:</span> <span class='sentence-part'>Most of these mutations may also cause cognitive impairment, but the Arctic APP mutation is the only known intra-beta-amyloid mutation to date causing the more typical clinical picture of Alzheimer disease. Clinical and neuropathological features of the arctic APP gene mutation causing early-onset Alzheimer disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/19276550' target='_blank' class='pmid-link'>19276550</a>:</span> <span class='sentence-part'>Presenilin 1 (PS1) gene mutations are the major causes of early-onset familial Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/19276551' target='_blank' class='pmid-link'>19276551</a>:</span> <span class='sentence-part'>Presenilin 1 (PS1) gene mutations are the major causes of early-onset familial Alzheimer's disease and are known to increase amyloid-beta42 (Abeta42) production as well as to promote apoptosis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22491860' target='_blank' class='pmid-link'>22491860</a>:</span> <span class='sentence-part'>OBJECTIVES: More than 30 different rare mutations, including copy number variants (CNVs), in the amyloid precursor protein gene (APP) cause early-onset familial Alzheimer disease (EOFAD), whereas the contribution of common APP variants to disease risk remains controversial. CONCLUSION: Our study shows that APP mutations and locus duplications are a very rare cause of EOFAD and that the contribution of common APP variants to AD susceptibility is insignificant.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24114635' target='_blank' class='pmid-link'>24114635</a>:</span> <span class='sentence-part'>Gene mutations influence the outcome of age-related neuronal degeneration to cause early onset familial AD (EO-FAD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25927677' target='_blank' class='pmid-link'>25927677</a>:</span> <span class='sentence-part'>Rare forms of early onset familial Alzheimer's disease are due to gene mutations.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26757189' target='_blank' class='pmid-link'>26757189</a>:</span> <span class='sentence-part'>Studies of presenilin (PSEN) gene mutations producing early onset Alzheimer's disease (AD) have helped elucidate the pathogenic mechanisms of dementia and guided clinical trials of potential therapeutic interventions.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29562513' target='_blank' class='pmid-link'>29562513</a>:</span> <span class='sentence-part'>In fact, while early-onset AD is a clear consequence of gene mutations, late-onset AD is more likely due to a gradual accumulation of age-related damages.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31296348' target='_blank' class='pmid-link'>31296348</a>:</span> <span class='sentence-part'>\Presenilin 1\ (PSEN1) gene mutations are the major known genetic cause of early-onset Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34189411' target='_blank' class='pmid-link'>34189411</a>:</span> <span class='sentence-part'>One consistent observation for all    PRESENILIN     gene mutations causing EOfAD is that a transcript is produced with a reading frame terminated by the normal stop codon-the \reading frame preservation rule\. Background: Mutations in    PRESENILIN 2     (   PSEN2    ) cause early onset familial Alzheimer's disease (EOfAD) but their mode of action remains elusive.</span></div></div>
<div class='streamlined-assertion'><div class='streamlined-header sticky-relation-header'><span class='label-text'>Subject:</span> <strong>Genes</strong> <span class='label-text'>Subject CUI:</span> <strong>C0017337</strong> â†’ <span class='label-text predicate-text'>CAUSES</span> â†’ <span class='label-text'>Object:</span> <strong>Alzheimers</strong> <span class='label-text'>Object CUI:</span> <strong>C0750901</strong></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/10195399' target='_blank' class='pmid-link'>10195399</a>:</span> <span class='sentence-part'>Three genes responsible for early-onset autosomal dominant AD have been identified, and one gene, apolipoprotein E, has been confirmed as a susceptibility gene for late-onset forms of the disorder.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/10349334' target='_blank' class='pmid-link'>10349334</a>:</span> <span class='sentence-part'>Amyloid precursor protein (APP), presenilin I (PS 1) and presenilin II (PS 2) genes have been identified as the causative genes for early-onset familial Alzheimer's disease. Although these data suggest that accumulation of A beta is an essential step in the pathogenesis of Alzheimer's disease, it still remains to be elucidated whether such process is causative for Alzheimer's disease. Recently another gene on chromosome 12 has been suggested to be involved in the development of late-onset Alzheimer's disease, and identification of the gene on chromosome 12 may bring a new insight into the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/10404731' target='_blank' class='pmid-link'>10404731</a>:</span> <span class='sentence-part'>The Asn141Ile mutation of the presenilin 2 gene is responsible for familial early-onset Alzheimer disease found in Volga-German kindreds.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/10488446' target='_blank' class='pmid-link'>10488446</a>:</span> <span class='sentence-part'>Mutations in any one of three genes can cause autosomal dominant, early-onset Alzheimer's disease: these genes are the amyloid precursor protein (APP) gene on chromosome 21, the presenilin-1 (PS-1) gene on chromosome 14 and the presenilin-2 (PS-2) gene on chromosome 1.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/10507458' target='_blank' class='pmid-link'>10507458</a>:</span> <span class='sentence-part'>At least 50 different mutations in the presenilin 1 gene have been shown to cause early onset familial Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/10768621' target='_blank' class='pmid-link'>10768621</a>:</span> <span class='sentence-part'>BACKGROUND: Pathogenic mutations in the presenilin 1 (PS1) gene leading to early-onset Alzheimer disease have been described in various populations.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/11216203' target='_blank' class='pmid-link'>11216203</a>:</span> <span class='sentence-part'>Rare mutations in at least 3 genes are responsible for early-onset familial AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/12604663' target='_blank' class='pmid-link'>12604663</a>:</span> <span class='sentence-part'>Discovery of mutations in three genes leading to severe early onset AD was critical in focusing attention on the role of amyloid peptides (Abeta) in neuronal cell death, and enhanced understanding of the biology of these peptides has led to an array of mechanism-based drug discovery strategies.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/15010344' target='_blank' class='pmid-link'>15010344</a>:</span> <span class='sentence-part'>Three genes have been implicated in the etiology of early-onset autosomal-dominant Alzheimer disease (AD): the amyloid precursor protein, the presenilin-1, and presenilin-2 genes.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/15119738' target='_blank' class='pmid-link'>15119738</a>:</span> <span class='sentence-part'>The beta-amyloid precursor protein (APP) gene (on chromosome 21), Presenilin 1 (PS1) gene (on chromosome 14) and Presenilin 2 (PS2) gene (on chromosome 1) are responsible for autosomal dominant early-onset Alzheimer's disease (EOAD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/15205973' target='_blank' class='pmid-link'>15205973</a>:</span> <span class='sentence-part'>Two siblings with the R269G mutation in the presenilin-1 gene causing early-onset Alzheimer's disease are presented, only the second family with this mutation to be reported.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/15654674' target='_blank' class='pmid-link'>15654674</a>:</span> <span class='sentence-part'>With the identification of the genes responsible for autosomal dominant early-onset familial Alzheimer's disease (FAD genes), there is a considerable interest in the application of this genetic information in medical practice through genetic testing and counseling.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/16628450' target='_blank' class='pmid-link'>16628450</a>:</span> <span class='sentence-part'>Founder effect for the Ala431Glu mutation of the presenilin 1 gene causing early-onset Alzheimer's disease in Mexican families.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17334805' target='_blank' class='pmid-link'>17334805</a>:</span> <span class='sentence-part'>Three genes have been identified causing earlier onset AD, and a fourth has been shown to be a risk factor for late onset AD (LOAD), while many more yet unrecognized genes are thought to contribute to susceptibility.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17645236' target='_blank' class='pmid-link'>17645236</a>:</span> <span class='sentence-part'>Over 100 mutations in the presenilin-1 gene (PSEN1) have been shown to result in familial early onset Alzheimer disease (EOAD), but only a relatively few give rise to plaques with an appearance like cotton wool (CWP) and/or spastic paraparesis (SP). A single point mutation, p.L420R (g.1508T &gt; G) that gives rise to a missense mutation in the eighth transmembrane (TM8) domain of PS1 was identified in two affected members of the family. p.L420R (g.1508T &gt; G) is the mutation responsible for EOAD, seizures and CWP without SP in this family.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/19101658' target='_blank' class='pmid-link'>19101658</a>:</span> <span class='sentence-part'>AD occurs sporadically (SAD), or is caused by hereditary missense mutations in the amyloid precursor protein (APP) or presenilin-1 and -2 (PSEN1 and PSEN2) genes, leading to early-onset familial AD (FAD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20097758' target='_blank' class='pmid-link'>20097758</a>:</span> <span class='sentence-part'>Four genes have been established to either cause familial early onset AD (APP, PSEN1, and PSEN2) or to increase susceptibility for late onset AD (APOE).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20594621' target='_blank' class='pmid-link'>20594621</a>:</span> <span class='sentence-part'>Three genes have been identified as the cause of early onset familial AD (EOAD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21463452' target='_blank' class='pmid-link'>21463452</a>:</span> <span class='sentence-part'>Familial forms of CAA are because of mutations in the gene encoding the beta-amyloid precursor protein (APP) and duplications of this gene can cause early-onset Alzheimer's disease associated with CAA.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23575824' target='_blank' class='pmid-link'>23575824</a>:</span> <span class='sentence-part'>We have developed a Tg rat model (line TgF344-AD) expressing mutant human amyloid precursor protein (APPsw) and presenilin 1 (PS1DeltaE9) genes, each independent causes of early-onset familial AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25998699' target='_blank' class='pmid-link'>25998699</a>:</span> <span class='sentence-part'>This review summarizes CSF biomarker findings from studies on symptomatic and presymptomatic individuals carrying a mutation in one of the genes known to cause early-onset familial AD or FTD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27540966' target='_blank' class='pmid-link'>27540966</a>:</span> <span class='sentence-part'>Mutations in the amyloid-beta protein precursor gene (AbetaPP), the presenilin 1 gene (PSEN1) or the presenilin 2 gene (PSEN2) that increase production of the AbetaPP-derived peptide Abeta42 cause early-onset Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29945247' target='_blank' class='pmid-link'>29945247</a>:</span> <span class='sentence-part'>Triplication of APP, a gene on chromosome 21, is sufficient to cause early-onset Alzheimer's disease in the absence of Down syndrome. This indicates that triplication of chromosome 21 genes other than APP is likely to have an important role to play in Alzheimer's disease pathogenesis in individuals who have Down syndrome.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31862541' target='_blank' class='pmid-link'>31862541</a>:</span> <span class='sentence-part'>Genetic variants in presenilin (PSEN) 1 and 2 genes lead to autosomal dominant early-onset AD (ADAD); patients with PSEN gene variants also report seizures.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34193504' target='_blank' class='pmid-link'>34193504</a>:</span> <span class='sentence-part'>Pathogenic variants in the presenilin 1 (PSEN1) gene are the most frequent cause of early-onset AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37996068' target='_blank' class='pmid-link'>37996068</a>:</span> <span class='sentence-part'>Mutations in the Presenilin (PSEN) genes are the most common cause of early-onset familial Alzheimer's disease (FAD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/7550356' target='_blank' class='pmid-link'>7550356</a>:</span> <span class='sentence-part'>Genetic linkage studies place a gene causing early onset familial Alzheimer's disease (FAD) on chromosome 14q24.3 (refs 1-4).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/8710164' target='_blank' class='pmid-link'>8710164</a>:</span> <span class='sentence-part'>The rat homologue of the presenilin-1 (PS-1) gene, which is responsible for early-onset familial Alzheimer's disease linked to chromosome 14, was cloned and sequenced.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/8742474' target='_blank' class='pmid-link'>8742474</a>:</span> <span class='sentence-part'>A series of mutations has been reported in the presenilin-1 (PS-1) gene which cause early onset Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/9044502' target='_blank' class='pmid-link'>9044502</a>:</span> <span class='sentence-part'>Genes responsible for the early-onset familial AD have been cloned and found to be membrane associated transport proteins.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/9180219' target='_blank' class='pmid-link'>9180219</a>:</span> <span class='sentence-part'>To investigate whether presenilin 1 (PS1) gene, a major causative gene of familial early-onset Alzheimer's disease (AD), also contributes to the etiology of sporadic AD, we evaluated associations between Japanese AD and polymorphisms located at 14q24.3.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/9197277' target='_blank' class='pmid-link'>9197277</a>:</span> <span class='sentence-part'>Immunohistochemical analysis of two A beta species (A beta 42/43 and A beta 40) deposition was undertaken using the carboxyl end-specific antibodies to determine the molecular alteration of these species in the brains of patients whose presenilin 1 (PS-1) gene, the major causative gene for the early-onset familial AD, bears the point mutation (H163R) and the deletion of exon 9.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/9368568' target='_blank' class='pmid-link'>9368568</a>:</span> <span class='sentence-part'>BACKGROUND AND PURPOSE: An intronic polymorphism of presenilin-1 (PS-1), a gene responsible for early-onset familial Alzheimer's disease, has been reported to be associated with late-onset sporadic Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/9834545' target='_blank' class='pmid-link'>9834545</a>:</span> <span class='sentence-part'>The second part describes the three genes, amyloid precusor protein (APP), presenilin 1 (PS1) and presenilin 2 (PS2) genes, which when mutated cause early-onset autosomal dominant AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/9852298' target='_blank' class='pmid-link'>9852298</a>:</span> <span class='sentence-part'>Presenilin 2 (PS2) is a gene responsible for the early-onset familial Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/9923762' target='_blank' class='pmid-link'>9923762</a>:</span> <span class='sentence-part'>OBJECTIVE: To disclose a novel mutation of the presenilin 1 (PS1) gene responsible for early-onset Alzheimer disease and to clarify genotype-phenotype correlation that should help to establish the function of this protein. CONCLUSION: These results demonstrate that a missense mutation in a region not conserved between PS1 and PS2 can cause Alzheimer disease.</span></div></div>
<div class='streamlined-assertion'><div class='streamlined-header sticky-relation-header'><span class='label-text'>Subject:</span> <strong>Glycogen_Synthase_Kinase_3</strong> <span class='label-text'>Subject CUI:</span> <strong>C0244989</strong> â†’ <span class='label-text predicate-text'>CAUSES</span> â†’ <span class='label-text'>Object:</span> <strong>Alzheimers</strong> <span class='label-text'>Object CUI:</span> <strong>C0002395</strong></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/12180271' target='_blank' class='pmid-link'>12180271</a>:</span> <span class='sentence-part'>As lithium is a relatively specific inhibitor of glycogen synthase kinase-3 (in comparison with other protein kinases), and other studies also point to a relevant role of this enzyme, we favor the view that glycogen synthase kinase-3 is a crucial element in the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/1336152' target='_blank' class='pmid-link'>1336152</a>:</span> <span class='sentence-part'>Glycogen synthase kinase-3 induces Alzheimer's disease-like phosphorylation of tau: generation of paired helical filament epitopes and neuronal localisation of the kinase.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/14643380' target='_blank' class='pmid-link'>14643380</a>:</span> <span class='sentence-part'>Among the different kinases that are able to phosphorylate tau in these sites, GSK-3 has emerged as a key effector of AD pathogenesis in view of its interaction with many of the proteins involved in the ethiology of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/15959856' target='_blank' class='pmid-link'>15959856</a>:</span> <span class='sentence-part'>Activation of glycogen synthase kinase-3 induces Alzheimer-like tau hyperphosphorylation in rat hippocampus slices in culture.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/16914869' target='_blank' class='pmid-link'>16914869</a>:</span> <span class='sentence-part'>GSK-3 is essential in the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17456772' target='_blank' class='pmid-link'>17456772</a>:</span> <span class='sentence-part'>Glycogen synthase kinase 3 (GSK-3) is a major kinase implicated in the pathogenesis of Alzheimer's disease (AD), and reducing its activity may have therapeutic efficacy.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22966039' target='_blank' class='pmid-link'>22966039</a>:</span> <span class='sentence-part'>Thus the inflammation, insulin resistance, GSK-3, and mitochondrial dysfunction hypotheses are not opposing ideas but stages of the same fundamental, overarching, pathway of Alzheimer's disease pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23621307' target='_blank' class='pmid-link'>23621307</a>:</span> <span class='sentence-part'>In particular, the involvement of GSK-3 in several key pathophysiological pathways leading to AD and neurodegenerative diseases has placed this enzyme in a central position in this disorder.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24099155' target='_blank' class='pmid-link'>24099155</a>:</span> <span class='sentence-part'>In particular, the involvement of GSK-3 in several key pathophysiological pathways leading to AD and neurodegenerative diseases has placed this enzyme in a central position in this disorder.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26562543' target='_blank' class='pmid-link'>26562543</a>:</span> <span class='sentence-part'>In this review, we have enlightened Glycogen Synthase Kinase-3 which has been considered as a concrete cause for Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26708942' target='_blank' class='pmid-link'>26708942</a>:</span> <span class='sentence-part'>This article also highlights Drp1 and its relationships to glycogen synthase kinase 3, cyclin-dependent kinase 5, p53, and microRNAs in AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28485573' target='_blank' class='pmid-link'>28485573</a>:</span> <span class='sentence-part'>Dysfunction of glycogen synthase kinase 3 (GSK-3) is implicated in the etiology of Alzheimer's disease, Parkinson's disease, diabetes, pain, and cancer.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31054862' target='_blank' class='pmid-link'>31054862</a>:</span> <span class='sentence-part'>Glycogen synthase kinase 3 (GSK-3) has become known for its multifactorial involvement in the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34423266' target='_blank' class='pmid-link'>34423266</a>:</span> <span class='sentence-part'>Glycogen synthase kinase-3 (GSK-3) is a positron emission tomography (PET) imaging target with implications in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37893156' target='_blank' class='pmid-link'>37893156</a>:</span> <span class='sentence-part'>Tau hyperphosphorylation is susceptible to GSK-3, which has led to an emerging hypothesis regarding the pathogenesis of AD.</span></div></div>
<div class='streamlined-assertion'><div class='streamlined-header sticky-relation-header'><span class='label-text'>Subject:</span> <strong>Glycosylation_End_Products_Advanced</strong> <span class='label-text'>Subject CUI:</span> <strong>C0162574</strong> â†’ <span class='label-text predicate-text'>CAUSES</span> â†’ <span class='label-text'>Object:</span> <strong>Alzheimers</strong> <span class='label-text'>Object CUI:</span> <strong>C0002395</strong></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/18473848' target='_blank' class='pmid-link'>18473848</a>:</span> <span class='sentence-part'>Continuous hyperglycemia is a causative factor for diabetic vascular complications, and it enhances the generation of AGEs through the non-enzymatic glycation, thereby being involved in the pathogenesis of AD as well.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/19275211' target='_blank' class='pmid-link'>19275211</a>:</span> <span class='sentence-part'>Many of the pathological components of diabetes, atherosclerosis, cancer, macular degeneration, Alzheimer's disease, and even the normal aging process are attributable to AGEs and their potential for aggregate formation in the vasculature.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21264887' target='_blank' class='pmid-link'>21264887</a>:</span> <span class='sentence-part'>Among these compounds, methylglyoxal (MG) can yield advanced glycation end products (AGEs), which are crucial in AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23799541' target='_blank' class='pmid-link'>23799541</a>:</span> <span class='sentence-part'>Recent studies have increasingly suggested that a high concentration of advanced glycation end products (AGEs) may be important in AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25556063' target='_blank' class='pmid-link'>25556063</a>:</span> <span class='sentence-part'>In conclusion, QFY could attenuate AGEs-induced, Alzheimer-like pathophysiological changes. Qifu-Yin attenuates AGEs-induced Alzheimer-like pathophysiological changes through the RAGE/NF-kappaB pathway.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26045684' target='_blank' class='pmid-link'>26045684</a>:</span> <span class='sentence-part'>RESULTS: Behavioral results showed that PG (1 g/kg, 0.5 g/kg, and 0.25 g/kg) significantly shortened the escape latency, remarkably increased the number of crossing times, significantly decreased the number of errors, and prolonged the latency in rats with AGE-induced AD. The present study evaluated the neuroprotective effects of PG and its possible neuroprotective mechanisms in advanced glycation end product (AGE)-induced AD in a rat model.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26587989' target='_blank' class='pmid-link'>26587989</a>:</span> <span class='sentence-part'>However, the role played by AGEs in the pathogenesis of AD remains unclear.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26738988' target='_blank' class='pmid-link'>26738988</a>:</span> <span class='sentence-part'>AGEs and receptor for AGEs (RAGE) play important roles in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28210868' target='_blank' class='pmid-link'>28210868</a>:</span> <span class='sentence-part'>Impaired insulin signaling, inflammation, the accumulation of advanced glycation end-products and oxidative stress all play an essential role in the pathogenesis of both AD and diabetic complications.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29885514' target='_blank' class='pmid-link'>29885514</a>:</span> <span class='sentence-part'>Advanced glycation end products (AGEs) are known to play a leading part in the pathogenesis of human diseases, such as diabetes, Alzheimer's disease, lateral sclerosis, and atherosclerosis.</span></div></div>
<div class='streamlined-assertion'><div class='streamlined-header sticky-relation-header'><span class='label-text'>Subject:</span> <strong>Heart_Diseases</strong> <span class='label-text'>Subject CUI:</span> <strong>C0018799</strong> â†’ <span class='label-text predicate-text'>CAUSES</span> â†’ <span class='label-text'>Object:</span> <strong>Atrial_Fibrillation</strong> <span class='label-text'>Object CUI:</span> <strong>C0004238</strong></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/10342138' target='_blank' class='pmid-link'>10342138</a>:</span> <span class='sentence-part'>Considering efficacy, antiarrhythmic agents should be selected depending on the following factors: cardiac function, renal or hepatic function, underlying heart disease, exercise-induced or enhanced mental condition, cholinergic induced, drug-resistant atrial fibrillation or not.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/10371789' target='_blank' class='pmid-link'>10371789</a>:</span> <span class='sentence-part'>The following parameters were evaluated: age, underlying cardiac disease, duration and etiology of atrial fibrillation, mode of cardioversion, left ventricular diameters and function, left atrial diameters and function, assessed as atrial ejection force.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/10752183' target='_blank' class='pmid-link'>10752183</a>:</span> <span class='sentence-part'>Two had primary AF and 59 AF secondary to heart disease (2 atrial septal defects, 57 mitral).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/10936003' target='_blank' class='pmid-link'>10936003</a>:</span> <span class='sentence-part'>Improved diagnosis and an ageing population with an increased likelihood of underlying cardiac disease results in AF in more than 1% of population. AF is associated with an approximately two-fold increase in mortality, largely due to stroke which occurs at an annual rate of 5-7%. Studies in patients with little or no awareness of their arrhythmia condition indicate that unrecognized and untreated AF may cause congestive heart failure.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/14571312' target='_blank' class='pmid-link'>14571312</a>:</span> <span class='sentence-part'>RFAs of atrial fibrillation and ventricular tachycardia secondary to underlying structural heart disease are currently considered experimental procedures because there remains insufficient published data to draw conclusions about their clinical efficacy and safety profile.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/1603141' target='_blank' class='pmid-link'>1603141</a>:</span> <span class='sentence-part'>Thyrotoxicosis can aggravate preexisting cardiac disease and can also lead to atrial fibrillation, congestive heart failure, or worsening of angina pectoris.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17967594' target='_blank' class='pmid-link'>17967594</a>:</span> <span class='sentence-part'>Thus, progression to persistent AF is probably related to an AF substrate, which is undergoing progressive structural remodeling owing to heart disease and other factors and is now suddenly capable of sustaining prolonged or multiple ATs.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32715669' target='_blank' class='pmid-link'>32715669</a>:</span> <span class='sentence-part'>Proarrhythmogenic Effect of the L532P and N588K    KCNH2     Mutations in the Human Heart Using a 3D Electrophysiological Model.BACKGROUND: Atrial arrhythmia is a cardiac disorder caused by abnormal electrical signaling and transmission, which can result in atrial fibrillation and eventual death.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/38546222' target='_blank' class='pmid-link'>38546222</a>:</span> <span class='sentence-part'>HYPOTHESES: RHD generates electrophysiological and morphological remodelling affecting the CM, leading to atrial inflammation and increased AF susceptibility.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/9064982' target='_blank' class='pmid-link'>9064982</a>:</span> <span class='sentence-part'>Those patients who are presently proposed to receive radio frequency catheter ablation usually continue to be symptomatic despite pharmacological therapy and/or have a potential risk for sudden cardiac death due to atrial fibrillation in WPW syndrome, or rate-dependent hemodynamic compromise secondary to cardiac disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/9825363' target='_blank' class='pmid-link'>9825363</a>:</span> <span class='sentence-part'>In patients with structural heart disease, induced atrial fibrillation shortens the atrial ERP as well as the atrial APD90.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/9856921' target='_blank' class='pmid-link'>9856921</a>:</span> <span class='sentence-part'>The following parameters were evaluated: patient age, cardiac disease, duration and etiology of atrial fibrillation, mode of cardioversion, left ventricular diameters and function, and left atrial diameter and function assessed as atrial ejection force.</span></div></div>
<div class='streamlined-assertion'><div class='streamlined-header sticky-relation-header'><span class='label-text'>Subject:</span> <strong>Heart_failure</strong> <span class='label-text'>Subject CUI:</span> <strong>C0018801</strong> â†’ <span class='label-text predicate-text'>CAUSES</span> â†’ <span class='label-text'>Object:</span> <strong>Atrial_Fibrillation</strong> <span class='label-text'>Object CUI:</span> <strong>C0004238</strong></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/10363868' target='_blank' class='pmid-link'>10363868</a>:</span> <span class='sentence-part'>Prognostic significance of atrial fibrillation in patients at a tertiary medical center referred for heart transplantation because of severe heart failure.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/11072543' target='_blank' class='pmid-link'>11072543</a>:</span> <span class='sentence-part'>INTRODUCTION: Atrial fibrillation could be a consequence of heart failure as well as arrhythmia may cause deterioration of left ventricle systolic function.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/11684069' target='_blank' class='pmid-link'>11684069</a>:</span> <span class='sentence-part'>Whereas in ATR, electrophysiological remodeling is of prime importance in AF promotion, structural remodeling (as reflected in changes in atrial size and contraction) appears much more important in HF-induced AF.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/1261580' target='_blank' class='pmid-link'>1261580</a>:</span> <span class='sentence-part'>CONCLUSIONS: (1) in the absence of HF, AF may be the consequence of pericarditis; (2) in patients with mild HF, AF may be consequence of HF; (3) the contribution of AF to the subsequent clinical course is only of prognostic significance in patients with mild HF.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/15921810' target='_blank' class='pmid-link'>15921810</a>:</span> <span class='sentence-part'>In most patients, AF occurred secondary to HF.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17704207' target='_blank' class='pmid-link'>17704207</a>:</span> <span class='sentence-part'>Heart failure (HF) commonly results in atrial fibrillation (AF) and fibrosis, but how the distribution of fibrosis impacts AF dynamics has not been studied.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/18456193' target='_blank' class='pmid-link'>18456193</a>:</span> <span class='sentence-part'>Heart failure, a major cause of AF, may involve arrhythmogenic atrial electrical remodeling, but the pattern is unclear in humans.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/19960186' target='_blank' class='pmid-link'>19960186</a>:</span> <span class='sentence-part'>Heart failure (HF), a major cause of AF, causes adrenergic activation and adaptational changes, remodelling, of atrial electrophysiology, Ca(2+) homeostasis, and adrenergic responses.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20103171' target='_blank' class='pmid-link'>20103171</a>:</span> <span class='sentence-part'>AF can be the cause of HF, especially by leading to a tachycardia-induced cardiomyopathy, either isolated or associated to an underlying heart disease. HF is a common cause of AF.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20495015' target='_blank' class='pmid-link'>20495015</a>:</span> <span class='sentence-part'>BACKGROUND: Atrial fibrillation (AF) promotes atrial remodeling and can develop secondary to heart failure or mitral valve disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20662987' target='_blank' class='pmid-link'>20662987</a>:</span> <span class='sentence-part'>The HF group had demonstrable moderate global HF (left ventricular ejection fraction [LVEF]: 37.1 vs 46.4%; P = 0.003) and showed the following compared to controls: left atrial dilatation (P = 0.02) and dysfunction (P = 0.005); longer P-wave duration (P &lt; 0.05); higher ERP at all cycle lengths (P ? 0.002) and locations (P &lt; 0.001); slower conduction velocity (P &lt; 0.001); increased conduction heterogeneity index (P &lt; 0.001); increased atrial fibrosis (right atrial [RA]: 5.9 +/- 2.6 vs 2.8 +/- 0.9%; P &lt; 0.0001, left atrial [LA]: 3.7 +/- 2.2 vs 2.4 +/- 1.1%; P = 0.002), and longer induced atrial fibrillation (AF) episodes (16 +/- 22 vs 2 +/- 3 seconds; P = 0.04).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20693125' target='_blank' class='pmid-link'>20693125</a>:</span> <span class='sentence-part'>Heart failure induces AF, AF aggravates HF and therefore they generally coexist.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21097807' target='_blank' class='pmid-link'>21097807</a>:</span> <span class='sentence-part'>Such models should be relevant to and accurately reproduce the important substrates associated with ageing and with diseases such as hypertension, heart failure, and ischaemic heart disease which cause AF in the vast majority of patients.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21562376' target='_blank' class='pmid-link'>21562376</a>:</span> <span class='sentence-part'>While recognizing that AF is a heterogeneous disorder, we submit that the parallels between AF and HF may arise because many cases of AF and HF result from the cumulative exposure of the atria and ventricles to a common set of systemic cardiovascular risk factors.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22201041' target='_blank' class='pmid-link'>22201041</a>:</span> <span class='sentence-part'>The association of AF to progressive heart failure, reinfarction, and cardiovascular death underlines the need for an intensive follow-up of post-MI patients with new-onset AF in order to reveal underlying causes of AF such as progressive left ventricular dysfunction or myocardial ischemia.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23227423' target='_blank' class='pmid-link'>23227423</a>:</span> <span class='sentence-part'>AF is correlated with an increased morbidity and mortality, mainly due to stroke and heart failure.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24054478' target='_blank' class='pmid-link'>24054478</a>:</span> <span class='sentence-part'>There is clear interaction between AF and HF, with evidence that HF can lead to AF and AF exacerbates HF. Atrial fibrillation (AF) is an important and often-underrecognized cause of cardiovascular morbidity and mortality.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24589281' target='_blank' class='pmid-link'>24589281</a>:</span> <span class='sentence-part'>In hypertrophic cardiomyopathy (HC), atrial fibrillation (AF) is an important determinant of clinical deterioration due to heart failure or embolic stroke.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24722816' target='_blank' class='pmid-link'>24722816</a>:</span> <span class='sentence-part'>F 16915 prevents heart failure-induced atrial fibrillation: a promising new drug as upstream therapy.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24794785' target='_blank' class='pmid-link'>24794785</a>:</span> <span class='sentence-part'>CASE REPORT: A 88-years-old female (body-mass-index = 19.95) with AF, hypertension and diabetes mellitus, hospitalized because of heart failure and a non-convulsive epileptic state, was treated by valproate, mirtazepin, nebivolol, digitoxin, lisinopril, gliclazide and amlodipine.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25112657' target='_blank' class='pmid-link'>25112657</a>:</span> <span class='sentence-part'>INTRODUCTION: Atrial fibrillation (AF) is the most common arrhythmia and brings about significant mortality and morbidity as a result of heart failure and ischemic stroke.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25587048' target='_blank' class='pmid-link'>25587048</a>:</span> <span class='sentence-part'>Atrial fibrillation (AF) is the most common sustained clinical arrhythmia and is associated with significant morbidity, mostly secondary to heart failure and stroke, and an estimated two-fold increase in premature death.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26495822' target='_blank' class='pmid-link'>26495822</a>:</span> <span class='sentence-part'>Although the occurrence of AF rarely poses an immediate threat to patient's survival, the arrhythmia is associated with significant cardiovascular morbidity and mortality mostly resulting from ischemic stroke or systemic thromboembolism, or heart failure.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26771573' target='_blank' class='pmid-link'>26771573</a>:</span> <span class='sentence-part'>LA strain decreased with HF (p = 0.025) and further decreased after induction of AF (p = 0.0001).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27571932' target='_blank' class='pmid-link'>27571932</a>:</span> <span class='sentence-part'>BACKGROUND: Heart failure (HF) plays a critical role in the genesis of atrial fibrillation (AF).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28169950' target='_blank' class='pmid-link'>28169950</a>:</span> <span class='sentence-part'>RECENT FINDINGS: Diseases such as hypertension, valvular heart disease, and heart failure may induce atrial fibrillation, which increases the risk of stroke and sudden cardiac death.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29878481' target='_blank' class='pmid-link'>29878481</a>:</span> <span class='sentence-part'>Atrial fibrillation is the most common heart-rhythm disorder, affecting about 1.5% to 2% of the population with an increased risk of mortality and morbidity due to stroke, thromboembolism, and heart failure.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30528622' target='_blank' class='pmid-link'>30528622</a>:</span> <span class='sentence-part'>Both MI and HF can trigger development of AF, mainly by promoting structural and electrical atrial remodeling.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30835325' target='_blank' class='pmid-link'>30835325</a>:</span> <span class='sentence-part'>Relationship between the CHA2DS2-VASc score and atrial fibrillation in patients hospitalised due to heart failure.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30915767' target='_blank' class='pmid-link'>30915767</a>:</span> <span class='sentence-part'>AF is a cause as well as a consequence of HF, with complicated interactions resulting in impairment of cardiac systolic and diastolic function.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31530276' target='_blank' class='pmid-link'>31530276</a>:</span> <span class='sentence-part'>However, the role of AVP in HF-induced AF still remains unclear.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32150669' target='_blank' class='pmid-link'>32150669</a>:</span> <span class='sentence-part'>In patients with LGE, atrial fibrillation (HR, 19.10; 95% CI, 2.97-123.09), and mid-linear LGE (HR, 12.96; 95% CI, 2.02-82.94) were independent predictors of readmission because of HF.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32603556' target='_blank' class='pmid-link'>32603556</a>:</span> <span class='sentence-part'>Heart failure is one of the causes of AF as well.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33346136' target='_blank' class='pmid-link'>33346136</a>:</span> <span class='sentence-part'>We also tested 3 chronic models: pacemaker implantation followed by either 4 weeks of AT and subsequent atrial burst pacing, or intermittent long-term AT for up to 4-5 months to generate AF &gt;= 4.5 hours, and finally ventricular tachypacing to induce heart failure followed by atrial burst pacing to induce AF.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33723575' target='_blank' class='pmid-link'>33723575</a>:</span> <span class='sentence-part'>AF is a serious clinical problem associated with increased morbidity and mortality, mainly due to stroke and heart failure.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33777158' target='_blank' class='pmid-link'>33777158</a>:</span> <span class='sentence-part'>In contrast, heart diseases can affect the liver, heart failure may lead to cardiogenic hypoxic hepatitis and cardiac cirrhosis, and atrial fibrillation (AF) markedly alters the hepatic gene expression profile and induces AF-related hypercoagulation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34078775' target='_blank' class='pmid-link'>34078775</a>:</span> <span class='sentence-part'>Aldosterone accelerated the progression from asymptomatic heart failure to overt heart failure and induced sustained AF resistant to electrical fibrillation in one out of six rats.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34129347' target='_blank' class='pmid-link'>34129347</a>:</span> <span class='sentence-part'>Atrial fibrillation can precipitate and can be a consequence of heart failure with reduced ejection fraction and cardiomyopathy.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34186046' target='_blank' class='pmid-link'>34186046</a>:</span> <span class='sentence-part'>MATERIALS AND METHODS: HDAC and ion channel expression was quantified in a porcine model of early HF induced by short-term atrial tachypacing, resulting in atrial fibrillation with rapid ventricular rate response.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34296210' target='_blank' class='pmid-link'>34296210</a>:</span> <span class='sentence-part'>Cardiac arrhythmias are an important cause of sudden cardiac death-a devastating manifestation of many underlying causes, such as heart failure and ischemic heart disease leading to ventricular tachyarrhythmias and ventricular fibrillation, and atrial fibrillation causing cerebral embolism.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34600904' target='_blank' class='pmid-link'>34600904</a>:</span> <span class='sentence-part'>BACKGROUND: Patients with Fontan circulation may develop heart failure resulting in atrial fibrillation during the late phase.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34912871' target='_blank' class='pmid-link'>34912871</a>:</span> <span class='sentence-part'>Post-AVR AF had a worse impact on admission due to heart failure (log rank    P     = 0.008) and composite outcome in the TAVR group. Post-AVR AF had a worse impact on admission due to heart failure (log rank    P     = 0.049) and composite outcomes in the SAVR group.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35210075' target='_blank' class='pmid-link'>35210075</a>:</span> <span class='sentence-part'>BACKGROUND: AF is a common comorbidity in HF; however, it is unclear if HF triggers AF, or vice-versa.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/9155607' target='_blank' class='pmid-link'>9155607</a>:</span> <span class='sentence-part'>Thus heart failure may cause atrial fibrillation, with electromechanical feedback and neurohumoral activation playing an important mediating role.</span></div></div>
<div class='streamlined-assertion'><div class='streamlined-header sticky-relation-header'><span class='label-text'>Subject:</span> <strong>Herpesvirus_1_Human</strong> <span class='label-text'>Subject CUI:</span> <strong>C0206679</strong> â†’ <span class='label-text predicate-text'>CAUSES</span> â†’ <span class='label-text'>Object:</span> <strong>Alzheimers</strong> <span class='label-text'>Object CUI:</span> <strong>C0002395</strong></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/11258753' target='_blank' class='pmid-link'>11258753</a>:</span> <span class='sentence-part'>The peripheral and central nervous system are harbouring herpes simplex virus type 1 (HSV-1) and this virus has been proposed to be implicated in the aetiology of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/15607565' target='_blank' class='pmid-link'>15607565</a>:</span> <span class='sentence-part'>To further examine the role of HSV-1 in the etiology of AD, we have formulated a Neuroinvasive Score that quantifies the presence and viral load of HSV-1 in eight brain regions.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17725689' target='_blank' class='pmid-link'>17725689</a>:</span> <span class='sentence-part'>There is growing evidence that herpes simplex virus type 1 (HSV-1), together with the apolipoprotein E 4 (APOE4) allele, contribute to the pathogenesis of Alzheimer's disease (AD), although the mechanism of their interaction remains uncertain.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/18300070' target='_blank' class='pmid-link'>18300070</a>:</span> <span class='sentence-part'>Following the authors' previous studies implicating herpes simplex virus type 1 (HSV1) in brain of APOE-epsilon 4 carriers as a major cause of AD, the authors propose here, on the basis of their and others' recent studies, that not only does HSV1 generate the main components of amyloid plaques and neurofibrillary tangles (NFTs) - beta-amyloid (A beta) and abnormally phosphorylated tau but also, by disrupting autophagy, it prevents degradation of these aberrant proteins, leading to their accumulation and deposition, and eventually to AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/19542624' target='_blank' class='pmid-link'>19542624</a>:</span> <span class='sentence-part'>There is growing body of evidence for the involvement of herpes simplex virus type 1 (HSV1) in the etiology of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20450378' target='_blank' class='pmid-link'>20450378</a>:</span> <span class='sentence-part'>Herpes simplex virus type 1 persists in the brain of most aged individuals and may contribute to the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20674092' target='_blank' class='pmid-link'>20674092</a>:</span> <span class='sentence-part'>These findings indicate that HSV-1 causes functional changes in cortical neurons that promote APP processing and Abeta production, and they are compatible with the co-factorial role for HSV-1 in the pathogenesis of AD suggested by previous findings.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21085580' target='_blank' class='pmid-link'>21085580</a>:</span> <span class='sentence-part'>Epidemiological and experimental findings suggest that HSV-1 might contribute to the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22252837' target='_blank' class='pmid-link'>22252837</a>:</span> <span class='sentence-part'>Given that HSV-1 is considered a risk factor for AD, our results suggest a new way in which to understand the relationships between HSV-1 infection and the pathogenic mechanisms leading to AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22475795' target='_blank' class='pmid-link'>22475795</a>:</span> <span class='sentence-part'>Moreover, HSV-1 has been related to the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25963683' target='_blank' class='pmid-link'>25963683</a>:</span> <span class='sentence-part'>Herpes simplex virus-1 has been proposed as potential cause of AD because of its ability to form beta amyloid(Abeta) and neurofibrillary tangles due to tau hyperphosphorylation and action of beta &amp; gamma secretase on amyloid precursor protein(APP) together with genetic association with apolipoprotein-E4(ApoE-E4), which points out to latent Herpes Simplex virus-1 as an agent causing AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26401998' target='_blank' class='pmid-link'>26401998</a>:</span> <span class='sentence-part'>Herpes Simplex Virus Type 1 and Other Pathogens are Key Causative Factors in Sporadic Alzheimer's Disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27470229' target='_blank' class='pmid-link'>27470229</a>:</span> <span class='sentence-part'>These results reinforce the hypothesis for a role for HSV-1 in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27664135' target='_blank' class='pmid-link'>27664135</a>:</span> <span class='sentence-part'>Herpes simplex virus (HSV) type 1 affects a majority of the population and recent evidence suggests involvement in Alzheimer's disease aetiology.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28765170' target='_blank' class='pmid-link'>28765170</a>:</span> <span class='sentence-part'>Recent studies that provide further support for the occurrence of repeated reactivation of latent HSV1 in the brain in AD pathogenesis are also discussed.-Itzhaki, R.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29559905' target='_blank' class='pmid-link'>29559905</a>:</span> <span class='sentence-part'>Studies are reviewed supporting subclinical chronic reactivation of latent HSV-1 in the brain as significant in the pathogenesis of AD. This review focuses on research in the areas of epidemiology, neuropathology, molecular biology and genetics that implicates herpes simplex virus type 1 (HSV-1) as a causative agent in the pathogenesis of sporadic Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30250480' target='_blank' class='pmid-link'>30250480</a>:</span> <span class='sentence-part'>Itzhaki presented her work on the role of viruses, specifically HSV-1, in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31455413' target='_blank' class='pmid-link'>31455413</a>:</span> <span class='sentence-part'>Several evidences suggest that, together with inflammation, an immunological response incapable to counteract HSV-1 reactivation plays a role in the pathogenesis of Alzheimer's (AD) and Parkinson's (PD) diseases.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/9219743' target='_blank' class='pmid-link'>9219743</a>:</span> <span class='sentence-part'>CONCLUSION: The presence of one neurotropic virus--HSV1--and the absence of another--VZV--in aged human brains is consistent with a role for HSV1 in the aetiology of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/9789723' target='_blank' class='pmid-link'>9789723</a>:</span> <span class='sentence-part'>In this review, we consider the arguments implicating HSV1 in the pathogenesis of AD.</span></div></div>
<div class='streamlined-assertion'><div class='streamlined-header sticky-relation-header'><span class='label-text'>Subject:</span> <strong>Hypertensive_disease</strong> <span class='label-text'>Subject CUI:</span> <strong>C0020538</strong> â†’ <span class='label-text predicate-text'>CAUSES</span> â†’ <span class='label-text'>Object:</span> <strong>Alzheimers</strong> <span class='label-text'>Object CUI:</span> <strong>C0002395</strong></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/12480731' target='_blank' class='pmid-link'>12480731</a>:</span> <span class='sentence-part'>Hypertension and related factors in the etiology of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17362841' target='_blank' class='pmid-link'>17362841</a>:</span> <span class='sentence-part'>In recent years the renin-angiotensin system, already of recognised importance in the pathogenesis of hypertension, has become a source of interest in the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/19555872' target='_blank' class='pmid-link'>19555872</a>:</span> <span class='sentence-part'>Cumulative evidence implicates hypertension in the pathogenesis of Alzheimer disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22615109' target='_blank' class='pmid-link'>22615109</a>:</span> <span class='sentence-part'>Interestingly, RAGE inhibition protected from hypertension-induced Alzheimer pathology, as showed by rescue from cognitive impairment and parenchymal Abeta deposition. Overall we demonstrate that RAGE activation in brain vessels is a crucial pathogenetic event in hypertension-induced Alzheimer disease, suggesting that inhibiting this target can limit the onset of vascular-related Alzheimer disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25976367' target='_blank' class='pmid-link'>25976367</a>:</span> <span class='sentence-part'>Several preclinical and epidemiological studies have linked metabolic risk factors such as hypertension, obesity, dyslipidemia, and diabetes to the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29568075' target='_blank' class='pmid-link'>29568075</a>:</span> <span class='sentence-part'>In conclusion, eNOS downregulation contributed to hypertension-induced Alzheimer pathology and cognitive impairment.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30854970' target='_blank' class='pmid-link'>30854970</a>:</span> <span class='sentence-part'>Chronic, low-level environmental lead (Pb) exposure is associated with cognitive impairment, hypertension and mortality, and has been proposed as a potential cause of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31889399' target='_blank' class='pmid-link'>31889399</a>:</span> <span class='sentence-part'>Dipeptide IF prevents the effects of hypertension-induced Alzheimer's disease on long-term memory in the cortex of spontaneously hypertensive rats. The study result showed that HTN-induced AD regulated long-term memory (LTM) loss and neuronal degeneration in the SHR animals.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34897090' target='_blank' class='pmid-link'>34897090</a>:</span> <span class='sentence-part'>Hypertension is a major risk factor for the pathogenesis of vascular dementia and Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/38062190' target='_blank' class='pmid-link'>38062190</a>:</span> <span class='sentence-part'>This implies that approximately 55% of the risk of AD owing to hypertension can be attributed to stroke. The results suggest that the increased risk of AD owing to hypertension is mediated through stroke.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/9894287' target='_blank' class='pmid-link'>9894287</a>:</span> <span class='sentence-part'>A possible consequence of these findings would be to prevent, or to postpone, AD by an early treatment of arterial hypertension.</span></div></div>
<div class='streamlined-assertion'><div class='streamlined-header sticky-relation-header'><span class='label-text'>Subject:</span> <strong>Hypertensive_disease</strong> <span class='label-text'>Subject CUI:</span> <strong>C0020538</strong> â†’ <span class='label-text predicate-text'>CAUSES</span> â†’ <span class='label-text'>Object:</span> <strong>Atrial_Fibrillation</strong> <span class='label-text'>Object CUI:</span> <strong>C0004238</strong></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/11558841' target='_blank' class='pmid-link'>11558841</a>:</span> <span class='sentence-part'>Hypertension is perhaps the most common cardiovascular antecedent cause of AF, and particularly a disproportionate cause of morbidity and mortality among blacks.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/15913489' target='_blank' class='pmid-link'>15913489</a>:</span> <span class='sentence-part'>Other cardiovascular diseases, such as atrial fibrillation, congestive heart failure, and left ventricular hypertrophy, which may occur as a result of untreated hypertension, can also activate the prothrombotic state.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/16157832' target='_blank' class='pmid-link'>16157832</a>:</span> <span class='sentence-part'>Hypertension (n = 48; 35%) was the most common primary cause of AF, followed by alcohol related (n = 23; 17%), coronary artery disease (n = 20; 15%), and valvular heart disease (n = 17; 12%).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/16271942' target='_blank' class='pmid-link'>16271942</a>:</span> <span class='sentence-part'>Atrial fibrillation itself does not lead to structural remodeling, whereas this is frequently produced by hypertension or CHF, even in the absence of AF.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/16607602' target='_blank' class='pmid-link'>16607602</a>:</span> <span class='sentence-part'>Cardiovascular diseases which are associated with an activation of the renin-angiotensin-system -- myocardial infarction, heart failure, hypertension -- often induce atrial fibrillation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17664857' target='_blank' class='pmid-link'>17664857</a>:</span> <span class='sentence-part'>Arterial hypertension (HTN) represents one of the major causes of atrial fibrillation, a cardiac arrhythmia with high prevalence and comorbidity.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/18765964' target='_blank' class='pmid-link'>18765964</a>:</span> <span class='sentence-part'>Hypertension was the most common cause of AF, followed by advanced age.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20185115' target='_blank' class='pmid-link'>20185115</a>:</span> <span class='sentence-part'>OBJECTIVE: The purpose of this study was to characterize the atrial substrate predisposing to AF due to short-duration hypertension.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20466075' target='_blank' class='pmid-link'>20466075</a>:</span> <span class='sentence-part'>BACKGROUND: Hypertension accounts for more atrial fibrillation (AF) than any other predisposing factor.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21097807' target='_blank' class='pmid-link'>21097807</a>:</span> <span class='sentence-part'>Such models should be relevant to and accurately reproduce the important substrates associated with ageing and with diseases such as hypertension, heart failure, and ischaemic heart disease which cause AF in the vast majority of patients.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22198902' target='_blank' class='pmid-link'>22198902</a>:</span> <span class='sentence-part'>This study was designed to compare the diagnostic accuracy of two widely diffused home BP monitoring devices in detecting AF in an unselected population of outpatients referred to a hypertension clinic because of high BP.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26259287' target='_blank' class='pmid-link'>26259287</a>:</span> <span class='sentence-part'>Obesity is associated with numerous comorbidities, including hypertension, lipid disorders and type II diabetes, and is also a major cause of cardiovascular disease, coronary disease, heart failure, atrial fibrillation, and sudden death.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28169950' target='_blank' class='pmid-link'>28169950</a>:</span> <span class='sentence-part'>RECENT FINDINGS: Diseases such as hypertension, valvular heart disease, and heart failure may induce atrial fibrillation, which increases the risk of stroke and sudden cardiac death.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28290877' target='_blank' class='pmid-link'>28290877</a>:</span> <span class='sentence-part'>Arterial hypertension (AH) occupies the first place among causes of atrial fibrillation (AF) in general population.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29049041' target='_blank' class='pmid-link'>29049041</a>:</span> <span class='sentence-part'>There is emerging evidence to suggest that the successful management of several cardiovascular risk factors [obesity, hypertension (HTN), diabetes mellitus, and obstructive sleep apnea (OSA)] can lead to fewer complications and atrial fibrillation prevention.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29670471' target='_blank' class='pmid-link'>29670471</a>:</span> <span class='sentence-part'>Methods: The sample of the study included 170 patients with AF caused by hypertension. Purpose: to explore patients' characteristics associated with AF caused by hypertension.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32196618' target='_blank' class='pmid-link'>32196618</a>:</span> <span class='sentence-part'>Correlation analysis between ADAMTS-13 gene polymorphism and hypertension-induced atrial fibrillation.OBJECTIVE: The aim of this study was to explore the relationships between ADAMTS-13 gene polymorphisms and hypertension-induced atrial fibrillation (AF). Correlation analysis between ADAMTS-13 gene polymorphism and hypertension-induced atrial fibrillation. CONCLUSIONS: ADAMTS-13 gene polymorphism is correlated with the susceptibility and procession of hypertension-induced AF.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32395776' target='_blank' class='pmid-link'>32395776</a>:</span> <span class='sentence-part'>Assessment of atrial conduction time by Doppler tissue imaging in hypertensive patients.BACKGROUND: Hypertension is the first cause of atrial fibrillation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32613146' target='_blank' class='pmid-link'>32613146</a>:</span> <span class='sentence-part'>Highly Reactive Isolevuglandins Promote Atrial Fibrillation Caused by Hypertension.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32614933' target='_blank' class='pmid-link'>32614933</a>:</span> <span class='sentence-part'>Removing the Stress From Hypertension-Induced Atrial Fibrillation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/3285783' target='_blank' class='pmid-link'>3285783</a>:</span> <span class='sentence-part'>Hypertension, ischemic heart disease, and rheumatic valvular disease are the commonest causes of atrial fibrillation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33390040' target='_blank' class='pmid-link'>33390040</a>:</span> <span class='sentence-part'>Aggressive blood pressure management in patients with known AF reduces overall arrhythmia burden, but it remains unclear whether hypertension is causative for AF.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33516406' target='_blank' class='pmid-link'>33516406</a>:</span> <span class='sentence-part'>Hypertension (HT) confers the highest population-attributable risk among factors leading to atrial fibrillation (AF).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35726314' target='_blank' class='pmid-link'>35726314</a>:</span> <span class='sentence-part'>Conclusion: In China, hypertension is the leading preventable cause of AF, and more than half of these cases can be prevented through improving those modifiable risk factors.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36026686' target='_blank' class='pmid-link'>36026686</a>:</span> <span class='sentence-part'>OBJECTIVE: It is known, that arterial hypertension (AH) is the main cause of atrial fibrillation (AF).The aim of our study was to assess the parameters of systemic hemodynamics as a predictor of AF development after coronavirus infection (CI).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37652577' target='_blank' class='pmid-link'>37652577</a>:</span> <span class='sentence-part'>Mediating effect of subclinical inflammation on the process of morning hypertension leading to atrial fibrillation in community-based older adults.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/9809895' target='_blank' class='pmid-link'>9809895</a>:</span> <span class='sentence-part'>Because of its high prevalence in the population, hypertension was responsible for more AF in the population (14%) than any other risk factor.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/9926906' target='_blank' class='pmid-link'>9926906</a>:</span> <span class='sentence-part'>Although rheumatic valvular diseases are still common in Saudi Arabia, ischemic heart disease and hypertension are emerging as important causes of AF in this developing nation, and therefore require prevention and control.</span></div></div>
<div class='streamlined-assertion'><div class='streamlined-header sticky-relation-header'><span class='label-text'>Subject:</span> <strong>Hyperthyroidism</strong> <span class='label-text'>Subject CUI:</span> <strong>C0020550</strong> â†’ <span class='label-text predicate-text'>CAUSES</span> â†’ <span class='label-text'>Object:</span> <strong>Atrial_Fibrillation</strong> <span class='label-text'>Object CUI:</span> <strong>C0004238</strong></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/10090139' target='_blank' class='pmid-link'>10090139</a>:</span> <span class='sentence-part'>A 44-year-old man with atrial fibrillation caused by hyperthyroidism is described.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/12647553' target='_blank' class='pmid-link'>12647553</a>:</span> <span class='sentence-part'>The authors report on the case history of a 61 year old woman with hyperthyroidism induced atrial fibrillation, tachycardiomyopathy and congestive heart failure, in whom life threatening ventricular proarrhythmia (torsades de pointes) developed in response to intravenous amiodarone.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/1417379' target='_blank' class='pmid-link'>1417379</a>:</span> <span class='sentence-part'>CONCLUSIONS: Hyperthyroidism is not a common cause of atrial fibrillation in male nursing home residents. Hyperthyroidism as a cause of atrial fibrillation in long-term care.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/16208264' target='_blank' class='pmid-link'>16208264</a>:</span> <span class='sentence-part'>The morbidity and mortality associated with hypothyroidism are apparently related to the atherogenic and prothrombotic vascular modifications that follow thyroid hormone deficiency, whereas heart failure and particularly atrial fibrillation and its thromboembolic complications are the primary consequences of hyperthyroidism.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/16755962' target='_blank' class='pmid-link'>16755962</a>:</span> <span class='sentence-part'>We report a case of a 31-year-old man in whom a non obstructive cor triatrium was discovered while evaluation for an atrial fibrillation secondary to a hyperthyroidism.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/1802392' target='_blank' class='pmid-link'>1802392</a>:</span> <span class='sentence-part'>This work was performed in order to evaluate the weight of hyperthyroidism on the genesis of atrial fibrillation in elderly subjects.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/18307779' target='_blank' class='pmid-link'>18307779</a>:</span> <span class='sentence-part'>INTRODUCTION: Hyperthyroidism is a well established cause of atrial fibrillation (AF).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/18407192' target='_blank' class='pmid-link'>18407192</a>:</span> <span class='sentence-part'>The most serious consequences of subclinical hyperthyroidism are atrial fibrillation and osteoporosis, to which elderly patients are particularly predisposed.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/19079440' target='_blank' class='pmid-link'>19079440</a>:</span> <span class='sentence-part'>AIM: Subclinical and overt hyperthyroidism is a known trigger of atrial fibrillation and flutter (AF).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/19187905' target='_blank' class='pmid-link'>19187905</a>:</span> <span class='sentence-part'>OBJECTIVE: This study sought to investigate the clinical outcome of hyperthyroidism-induced AF with regard to risk of ischemic stroke risk. BACKGROUND: Hyperthyroidism is one of the most common reversible causes of atrial fibrillation (AF); nevertheless, the risk of ischemic stroke in patients with hyperthyroidism who present with new-onset AF is unclear. METHODS: We prospectively studied the incidence, time course, and clinical predictors for ischemic stroke in patients with hyperthyroidism-induced AF (n = 160).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/19195517' target='_blank' class='pmid-link'>19195517</a>:</span> <span class='sentence-part'>The long-term outcome of hyperthyroidism-induced persistent AF after successful cardioversion remains unclear. The study group consisted of 58 patients with hyperthyroidism-induced persistent AF (mean age 57 +/- 2 years, 72% men) who had undergone successful electrical cardioversion. Hyperthyroidism-induced atrial fibrillation (AF) often spontaneously reverts to sinus rhythm after the return of euthyroid state, but a significant number of patients remain in persistent AF, which requires electrical cardioversion. In conclusion, hyperthyroidism-induced persistent AF carries a lower recurrence rate after conversion to sinus rhythm than non-hyperthyroidism-induced persistent AF, and early electrical cardioversion should be considered. Cox regression analysis showed that long AF duration was the only predictor of AF recurrence in patients with hyperthyroidism-induced persistent AF.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20708873' target='_blank' class='pmid-link'>20708873</a>:</span> <span class='sentence-part'>INTRODUCTION: Hyperthyroidism is a relative uncommon but important cause of atrial fibrillation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21234757' target='_blank' class='pmid-link'>21234757</a>:</span> <span class='sentence-part'>These findings provide an important mechanistic insight into hyperthyroidism-induced AF.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22813838' target='_blank' class='pmid-link'>22813838</a>:</span> <span class='sentence-part'>BACKGROUND: Hyperthyroidism is usually regarded as a reversible cause of atrial fibrillation (AF); however, one-third of patients remain in AF despite euthyroid restoration.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23238902' target='_blank' class='pmid-link'>23238902</a>:</span> <span class='sentence-part'>METHODS AND RESULTS: Sixty-two patients with hyperthyroidism-induced persistent AF were treated with bepridil. BACKGROUND: Hyperthyroidism is one of the common causes of atrial fibrillation (AF), and AF is associated with increased morbidity and mortality due to thromboembolism. The sinus rhythm maintenance rate of hyperthyroidism-induced AF patients after conversion to sinus rhythm is excellent. The present study was undertaken to assess the efficacy and safety of bepridil, a multichannel blocker, in patients with hyperthyroidism-induced persistent AF. CONCLUSIONS: Bepridil is as beneficial treatment to convert AF for the patients with hyperthyroidism-induced persistent AF as it is for the patients with AF due to other causes.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23253416' target='_blank' class='pmid-link'>23253416</a>:</span> <span class='sentence-part'>We describe the case of a patient presented with isolated right heart failure with atrial fibrillation and severe tricuspid regurgitation due to hyperthyroidism.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23742676' target='_blank' class='pmid-link'>23742676</a>:</span> <span class='sentence-part'>AIM: Hyperthyroidism is a well-known cause of atrial fibrillation (AF) which is associated with increased morbidity and mortality.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/2509297' target='_blank' class='pmid-link'>2509297</a>:</span> <span class='sentence-part'>Diagnostic algorithm for atrial fibrillation caused by occult hyperthyroidism.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26049050' target='_blank' class='pmid-link'>26049050</a>:</span> <span class='sentence-part'>BACKGROUND: Hyperthyroidism is a known reversible cause of atrial fibrillation (AF).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26537235' target='_blank' class='pmid-link'>26537235</a>:</span> <span class='sentence-part'>Hyperthyroidism can induce atrial fibrillation, a harmful arrhythmia which can precipitate heart failure and cause stroke.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/2799447' target='_blank' class='pmid-link'>2799447</a>:</span> <span class='sentence-part'>Embolic occlusion of lower extremity arteries caused by hyperthyroidism-induced atrial fibrillation occurs rarely.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28822529' target='_blank' class='pmid-link'>28822529</a>:</span> <span class='sentence-part'>Hyperthyroidism is a well-known cause of atrial fibrillation with a 16%-60% prevalence of atrial fibrillation in patients with known hyperthyroidism Ross et al. While hyperthyroidism as a causative factor of atrial fibrillation is well established, this literature review aims to answer several questions on this topic including: 1.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/2912608' target='_blank' class='pmid-link'>2912608</a>:</span> <span class='sentence-part'>Atrial fibrillation due to hyperthyroidism is characterized by a rapid ventricular response which is typically resistant to digoxin therapy.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30032140' target='_blank' class='pmid-link'>30032140</a>:</span> <span class='sentence-part'>A markedly increased risk of atrial fibrillation is a well-established consequence of subclinical hyperthyroidism in patients in the sixth decade of life and beyond.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34009499' target='_blank' class='pmid-link'>34009499</a>:</span> <span class='sentence-part'>PURPOSE: Thyrotropin-secreting pituitary adenoma (TSHoma) is rare but occasionally causes cardiovascular complications such as atrial fibrillation (AF) due to hyperthyroidism.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34589224' target='_blank' class='pmid-link'>34589224</a>:</span> <span class='sentence-part'>Atrial fibrillation is a frequently detected cardiac arrhythmia in the etiology of ischemic stroke. The incidence of atrial fibrillation and the risk of it causing ischemic stroke increase significantly with age; it is rare in young people. It is clear that atrial fibrillation, which is highly unlikely to cause ischemic stroke in young adults, may develop due to hyperthyroidism.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35414842' target='_blank' class='pmid-link'>35414842</a>:</span> <span class='sentence-part'>These findings indicated that the decreased gene expression of K     ACh       and K     ATP       may be related to hyperthyroidism-induced cardiac hypertrophy and atrial fibrillation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36874762' target='_blank' class='pmid-link'>36874762</a>:</span> <span class='sentence-part'>Benefit and Preference of Propranolol Over Metoprolol in Thyrotoxicosis-Induced Atrial Fibrillation: A Case Report and Review of Literature. The aim of our review is to highlight that propranolol should be used over metoprolol in patients with hyperthyroidism-induced atrial fibrillation due to the effect of propranolol on blocking the activity of T4 conversion to active T3 and, as such, blocking its effect on cardiac myocytes, terminating reentrant atrial excitation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37199311' target='_blank' class='pmid-link'>37199311</a>:</span> <span class='sentence-part'>Sympathetic activation promotes apoptosis in cardiomyocytes with hyperthyroidism-induced AF via the p38 MAPK signaling pathway. A rabbit susceptibility model of hyperthyroidism-induced AF was constructed, and metoprolol treatment was administered. The present study investigated the molecular mechanisms of hyperthyroidism-induced AF.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37220445' target='_blank' class='pmid-link'>37220445</a>:</span> <span class='sentence-part'>Hyperthyroidism is a prevalent cause of atrial fibrillation (AF). The Outcome of Electrical Cardioversion in Hyperthyroid Induced Atrial Fibrillation. This review article compares the recurrence rate of AF as an outcome of ECV in Hyperthyroid induced atrial fibrillation. Early ECV before the antithyroid medication should be explored for hyperthyroidism-induced AF to reduce the risk of thromboembolic consequences. After returning to euthyroid status, hyperthyroidism-induced AF generally spontaneously reverts to sinus rhythm (SR), and a significant number of patients remain in chronic AF and require electrical cardioversion (ECV).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37954707' target='_blank' class='pmid-link'>37954707</a>:</span> <span class='sentence-part'>We included all patients with atrial fibrillation due to hyperthyroidism in KAMC-R and patients' records from 2015 to 2020. Objectives Our study aims to investigate the percentage of people with atrial fibrillation that is caused by hyperthyroidism in the National Guard Hospital.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/4162998' target='_blank' class='pmid-link'>4162998</a>:</span> <span class='sentence-part'>Hyperthyroidism causing atrial fibrillation in a young man.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/6476993' target='_blank' class='pmid-link'>6476993</a>:</span> <span class='sentence-part'>We hypothesized that hyperthyroidism would be an infrequent cause of atrial fibrillation in older persons because atherosclerotic, hypertensive, and degenerative heart disorders are more prevalent with aging.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/7606691' target='_blank' class='pmid-link'>7606691</a>:</span> <span class='sentence-part'>Atrial fibrillation with a rapid ventricular rate due to hyperthyroidism should be treated with propranolol to control the rapid ventricular rate.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/8509809' target='_blank' class='pmid-link'>8509809</a>:</span> <span class='sentence-part'>Hyperthyroidism is a frequently misdiagnosed cause of atrial fibrillation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/8686967' target='_blank' class='pmid-link'>8686967</a>:</span> <span class='sentence-part'>After iodine restriction, however, she became severely thyrotoxic and developed cerebral embolism associated with atrial fibrillation due to Graves' hyperthyroidism.</span></div></div>
<div class='streamlined-assertion'><div class='streamlined-header sticky-relation-header'><span class='label-text'>Subject:</span> <strong>Hypoxia</strong> <span class='label-text'>Subject CUI:</span> <strong>C0242184</strong> â†’ <span class='label-text predicate-text'>CAUSES</span> â†’ <span class='label-text'>Object:</span> <strong>Alzheimers</strong> <span class='label-text'>Object CUI:</span> <strong>C0002395</strong></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/15681798' target='_blank' class='pmid-link'>15681798</a>:</span> <span class='sentence-part'>One of the logical approaches to this problem is to study the effects of ischemia and hypoxia on the metabolism of amyloid precursor protein, which plays one of the key roles in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17121991' target='_blank' class='pmid-link'>17121991</a>:</span> <span class='sentence-part'>Taken together, our results clearly demonstrate that hypoxia can facilitate AD pathogenesis, and they provide a molecular mechanism linking vascular factors to AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17999180' target='_blank' class='pmid-link'>17999180</a>:</span> <span class='sentence-part'>Hypoxia is one of the major common components of vascular risk factors for pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/18063223' target='_blank' class='pmid-link'>18063223</a>:</span> <span class='sentence-part'>The greatly increased incidence of AD following stroke and cerebral ischemia suggests that hypoxia is a risk factor which may accelerate AD pathogenesis by altering amyloid precursor protein (APP) processing.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21909359' target='_blank' class='pmid-link'>21909359</a>:</span> <span class='sentence-part'>Cerebrovascular integrity was characterized in Tg2576 AD model mice that overexpress the human amyloid precursor protein (APP) containing the double missense mutations, APPsw, found in a Swedish family, that causes early-onset AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22886562' target='_blank' class='pmid-link'>22886562</a>:</span> <span class='sentence-part'>Owing to the pathological impact of hypoxia, hypertension, hypoperfusion and impaired glucose metabolism, the adverse cardiovascular, neurocirculatory and metabolic consequences upregulate amyloid beta generation and tau phosphorylation, and lead to memory/cognitive impairment-culminating in AD. This article systematically delineates the steps in the complex cascade leading to AD, focusing on pathology caused by chronic intermittent hypoxia, hypertension, brain hypoperfusion, glucose dysmetabolism, and endothelial dysfunction.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23345083' target='_blank' class='pmid-link'>23345083</a>:</span> <span class='sentence-part'>However, the mechanism of hypoxia in the pathogenesis of AD remains unclear.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23400634' target='_blank' class='pmid-link'>23400634</a>:</span> <span class='sentence-part'>Strong evidence underscores that cerebral amyloidogenesis and tau phosphorylation--two cardinal features of Alzheimer's disease (AD), are triggered by hypoxia.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24650677' target='_blank' class='pmid-link'>24650677</a>:</span> <span class='sentence-part'>Our previous studies have documented that chronic hypoxia is one of the environmental factors that may trigger the AD development and aggravate the disease progression.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26351108' target='_blank' class='pmid-link'>26351108</a>:</span> <span class='sentence-part'>This study suggests that there is an association between chronic intermittent hypoxia and increased Abeta levels, implying that hypoxia may contribute to the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26617286' target='_blank' class='pmid-link'>26617286</a>:</span> <span class='sentence-part'>Hypoxia and GABA shunt activation in the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28562318' target='_blank' class='pmid-link'>28562318</a>:</span> <span class='sentence-part'>Intermittent hypoxia produces Alzheimer disease?</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29423001' target='_blank' class='pmid-link'>29423001</a>:</span> <span class='sentence-part'>Hypoxia promotes the accumulation of amyloid-beta (Abeta), which is related to the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29867325' target='_blank' class='pmid-link'>29867325</a>:</span> <span class='sentence-part'>In summary, all these findings suggest that acute hypoxia could induce the AD-like pathological damages in the brain of APPswe/PS1dE9 mice and Wt mice to some extent.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29931858' target='_blank' class='pmid-link'>29931858</a>:</span> <span class='sentence-part'>OBJECTIVE: To further study the regulation of hypoxia on Alzheimer's disease (AD) pathogenesis, we investigate the effect of hypoxia on the effect of cell survival and expression of related proteins in HEK293 cells stably expressing APP695 Swedish mutantK595N/M596L (HEK293-APP695 cells).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31934303' target='_blank' class='pmid-link'>31934303</a>:</span> <span class='sentence-part'>In the present study, a cellular model of hypoxia-induced AD was established by exposing HT-22 mouse hippocampal neurons to the chemical hypoxia-mimicking agent cobalt chloride (CoCl     2      ).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32548235' target='_blank' class='pmid-link'>32548235</a>:</span> <span class='sentence-part'>Introduction: It has been reported that environmental factors such as hypoxia could contribute to the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34130857' target='_blank' class='pmid-link'>34130857</a>:</span> <span class='sentence-part'>CONCLUSIONS: CIH-induced increase in pathologic human tau seeding and spread and exacerbation of other AD-related impairments provide new insights into the role of CIH and obstructive sleep apnea in AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35799509' target='_blank' class='pmid-link'>35799509</a>:</span> <span class='sentence-part'>Hypoxia is one of the important factors that contribute to the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37490963' target='_blank' class='pmid-link'>37490963</a>:</span> <span class='sentence-part'>This review summarizes the effects of normoxia and hypoxia on AD pathogenesis and discusses the underlying mechanisms.</span></div></div>
<div class='streamlined-assertion'><div class='streamlined-header sticky-relation-header'><span class='label-text'>Subject:</span> <strong>IMPACT_gene</strong> <span class='label-text'>Subject CUI:</span> <strong>C1825598</strong> â†’ <span class='label-text predicate-text'>CAUSES</span> â†’ <span class='label-text'>Object:</span> <strong>Alzheimers</strong> <span class='label-text'>Object CUI:</span> <strong>C0002395</strong></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32479244' target='_blank' class='pmid-link'>32479244</a>:</span> <span class='sentence-part'>CONCLUSION: Examining the impact, as well as the consequences of protein misfolding, could help to uncover the molecular etiologies behind the complicated AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33679375' target='_blank' class='pmid-link'>33679375</a>:</span> <span class='sentence-part'>Over the last few years, remarkable efforts have been made to investigate the impact on the pathogenesis of Alzheimer's disease (AD) of various forms of mitochondrial dysfunction, such as excessive reactive oxygen species (ROS) production, mitochondrial Ca     2+       dyshomeostasis, loss of ATP, and defects in mitochondrial dynamics and transport, and mitophagy. In this review, we focus on recent progress that highlights the crucial role of alterations in mitochondrial function and oxidative stress in the pathogenesis of AD, emphasizing a framework of existing and potential therapeutic approaches.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34052817' target='_blank' class='pmid-link'>34052817</a>:</span> <span class='sentence-part'>New theories on the link between sleep and beta-amyloid and tau secretion, accumulation and clearance, and its interaction with hypocretins/orexins (key neuropeptides regulating wakefulness) suggest mechanistic ways to better understand the impact of sleep alterations in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34292312' target='_blank' class='pmid-link'>34292312</a>:</span> <span class='sentence-part'>Finally, we outline future directions for delineating the microglial impact in AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34685649' target='_blank' class='pmid-link'>34685649</a>:</span> <span class='sentence-part'>Here, we investigated the impact of NF-kappaB-initiated neuroinflammation on AD pathogenesis using the APP23 mouse model of AD in combination with conditional activation of IKK2/NF-kappaB signaling in astrocytes.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35034901' target='_blank' class='pmid-link'>35034901</a>:</span> <span class='sentence-part'>The combination of biochemical/biophysical and 'omics-based studies of these variants needed to elucidate their downstream impact and molecular contributions to AD pathogenesis is highlighted.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35109353' target='_blank' class='pmid-link'>35109353</a>:</span> <span class='sentence-part'>CONCLUSION: There are some evidences of common molecular pathways involved in AD and ischemic stroke, which require further investigations to evaluate cerebral vascular impacts on the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35289012' target='_blank' class='pmid-link'>35289012</a>:</span> <span class='sentence-part'>We consider how abnormalities of the constituent cells of the neurovascular unit - particularly of endothelial cells and pericytes - and impairment of the blood-brain barrier (BBB) impact on the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35572126' target='_blank' class='pmid-link'>35572126</a>:</span> <span class='sentence-part'>The following review will explore the impact of p53 PTMs on its function and consequential involvement in AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35624892' target='_blank' class='pmid-link'>35624892</a>:</span> <span class='sentence-part'>The provocative question arising is the following: is it possible that the beneficial effects of regular exercise on AD are due to the systemic impact of training, rather than just the effects of exercise on the brain?</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36395955' target='_blank' class='pmid-link'>36395955</a>:</span> <span class='sentence-part'>Here, we generated a novel AD mouse model deficient for Neil3 to study the impact of impaired oxidative base lesion repair on the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37176104' target='_blank' class='pmid-link'>37176104</a>:</span> <span class='sentence-part'>Many preclinical and clinical trials have explored the impact of adjusting the whole-body and intracellular metabolism on the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37556014' target='_blank' class='pmid-link'>37556014</a>:</span> <span class='sentence-part'>This study aims to determine if two distinct doses of myco-fabricated ZnO-NPs have a positive impact on behavioral impairment and several biochemical markers associated with inflammation and oxidative stress in mice that have been treated by aluminum chloride (AlCl     3      ) to induce AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37801071' target='_blank' class='pmid-link'>37801071</a>:</span> <span class='sentence-part'>To assess the impact of vitamin D3 (Vit.D) on neurogenesis, we investigated its role in mitigating cognitive impairment and mitochondrial dysfunction through calcium/calmodulin-dependent protein kinase kinase 2 (CAMKK2)-mediated phosphorylation of Sirtuin1 (SIRT1) in an aluminum-chloride-D-galactose (AlCl3-D-gal)-induced AD rat model.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37878335' target='_blank' class='pmid-link'>37878335</a>:</span> <span class='sentence-part'>We investigated the impact of BHB on Abeta oligomer (AbetaO)-stimulated human iPS-derived microglia (hiMG), a model relevant to the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/38617186' target='_blank' class='pmid-link'>38617186</a>:</span> <span class='sentence-part'>Future studies exploring this impact on the pathogenesis of AD and related biomarkers are needed.</span></div></div>
<div class='streamlined-assertion'><div class='streamlined-header sticky-relation-header'><span class='label-text'>Subject:</span> <strong>Impaired_cognition</strong> <span class='label-text'>Subject CUI:</span> <strong>C0338656</strong> â†’ <span class='label-text predicate-text'>CAUSES</span> â†’ <span class='label-text'>Object:</span> <strong>Alzheimers</strong> <span class='label-text'>Object CUI:</span> <strong>C0002395</strong></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21504127' target='_blank' class='pmid-link'>21504127</a>:</span> <span class='sentence-part'>Mild cognitive impairment (MCI) is recognized as a prodromal phase of dementing disorders, and it has been suggested that oxidative stress may play a role in the pathogenesis of Alzheimer's disease (AD), and in predicting progression of MCI to AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32804131' target='_blank' class='pmid-link'>32804131</a>:</span> <span class='sentence-part'>The Contribution of Vascular Pathology Toward Cognitive Impairment in Older Individuals with Intermediate Braak Stage Tau Pathology.BACKGROUND: The pathological features of Alzheimer's disease (AD) are well described but little is known as to how both neurodegeneration and vascular changes might interact in causing cognitive impairment.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32847949' target='_blank' class='pmid-link'>32847949</a>:</span> <span class='sentence-part'>1       This represents an important advance because it allows us to investigate the relationship of risk factors with cognitive impairment at the level of the etiology of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33206363' target='_blank' class='pmid-link'>33206363</a>:</span> <span class='sentence-part'>Many evidence confirms that amyloid beta 1-42 fragment (Abeta     1-42      ) causes neuroinflammation, oxidative stress, and cell death, which are related to progressive memory loss, cognitive impairments and mental disorders that will lead to Alzheimer's disease (AD) progression.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33670778' target='_blank' class='pmid-link'>33670778</a>:</span> <span class='sentence-part'>The Role of Butyrylcholinesterase and Iron in the Regulation of Cholinergic Network and Cognitive Dysfunction in Alzheimer's Disease Pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33941272' target='_blank' class='pmid-link'>33941272</a>:</span> <span class='sentence-part'>Meanwhile, COVID-19 has also been reported to cause various neurologic symptoms including cognitive impairment that may ultimately result in AD, probably through the invasion of SARS-CoV-2 into the central nervous system, COVID-19-induced inflammation, long-term hospitalization and delirium, and post-COVID-19 syndrome.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36270437' target='_blank' class='pmid-link'>36270437</a>:</span> <span class='sentence-part'>In conclusion, this study demonstrates the importance of early-stage prevention of microgliosis on the development of cognitive impairment in APP/PS1 mice, which might be clinically relevant in preventing memory loss and delaying AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36949264' target='_blank' class='pmid-link'>36949264</a>:</span> <span class='sentence-part'>Emerging evidence recommended that resistance in insulin production develops cognitive dysfunction, which generally leads to AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37481287' target='_blank' class='pmid-link'>37481287</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) brings with it the need to think about the loss of autonomy caused by cognitive impairment, and how to manage it.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37864249' target='_blank' class='pmid-link'>37864249</a>:</span> <span class='sentence-part'>Impaired autophagy in plaque-associated microglia (PAM) has been reported to accelerate amyloid plaque deposition and cognitive impairment in AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/38158451' target='_blank' class='pmid-link'>38158451</a>:</span> <span class='sentence-part'>Altered empathic mechanisms observed in AD may be a consequence of cognitive impairment, more specifically of reduced mental flexibility and self-regulation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/38159199' target='_blank' class='pmid-link'>38159199</a>:</span> <span class='sentence-part'>Downregulation of ATF-4 Attenuates the Endoplasmic Reticulum Stress-Mediated Neuroinflammation and Cognitive Impairment in Experimentally Induced Alzheimer's Disease Model.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/38212861' target='_blank' class='pmid-link'>38212861</a>:</span> <span class='sentence-part'>APOE modifies microstructural patterns associated with aging and cognitive impairment, which may advance the development of biomarkers to distinguish microstructural changes characteristic of normal brain aging, APOE-dependent pathways, and non-AD etiologies.</span></div></div>
<div class='streamlined-assertion'><div class='streamlined-header sticky-relation-header'><span class='label-text'>Subject:</span> <strong>Induction</strong> <span class='label-text'>Subject CUI:</span> <strong>C0857127</strong> â†’ <span class='label-text predicate-text'>CAUSES</span> â†’ <span class='label-text'>Object:</span> <strong>Atrial_Fibrillation</strong> <span class='label-text'>Object CUI:</span> <strong>C0004238</strong></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/18402824' target='_blank' class='pmid-link'>18402824</a>:</span> <span class='sentence-part'>After 4 weeks of rapid ventricular stimulation (185 bpm) for CHF induction, additional rapid atrial stimulation (500 bpm) was maintained for 7 weeks to induce AF.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/18476546' target='_blank' class='pmid-link'>18476546</a>:</span> <span class='sentence-part'>There was no significant difference in the AF induction rate among the most points, however, the AF induction rate of the RIPV was significantly lower than those of the other points (all P &lt; 0.05).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22528047' target='_blank' class='pmid-link'>22528047</a>:</span> <span class='sentence-part'>Each induction was performed after a waiting time that exceeded twice the duration of induced AF from the preceding induction.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22878806' target='_blank' class='pmid-link'>22878806</a>:</span> <span class='sentence-part'>Although acute atrial dilation facilitates the induction of atrial fibrillation (AF) in the normal heart, little is known about whether the induction of AF due to acute atrial dilation increases in the diseased heart.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23148120' target='_blank' class='pmid-link'>23148120</a>:</span> <span class='sentence-part'>Orthodromic AVRT induction was as frequent (55.5 vs. 55%), but AF induction (41 vs. 24%; P &lt; 0.002) and electrophysiological malignant form were more frequent (22 vs. 12%; P &lt; 0.02).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25929601' target='_blank' class='pmid-link'>25929601</a>:</span> <span class='sentence-part'>Nevertheless, the spontaneous induction may generate an undesired AFib, which may induce risk for patient and thus a critical issue for physicians.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26005035' target='_blank' class='pmid-link'>26005035</a>:</span> <span class='sentence-part'>These electrophysiological changes may contribute to the induction of ectopic premature beats that trigger atrial fibrillation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26391145' target='_blank' class='pmid-link'>26391145</a>:</span> <span class='sentence-part'>The most plausible explanation for these findings, in our view, is that beta-blockers exert similar benefits through similar mechanisms regardless of intrinsic heart rhythm but that the benefits of beta-blockers are neutralized in patients with atrial fibrillation due to the induction of pauses that may impair cardiac function leading to worsening heart failure or cause arrhythmias resulting in death.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30413767' target='_blank' class='pmid-link'>30413767</a>:</span> <span class='sentence-part'>MI induction caused atrial fibrillation which was prevented by pretreatment of metoprolol or CurNisNp.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/8512728' target='_blank' class='pmid-link'>8512728</a>:</span> <span class='sentence-part'>No differences were obtained among the anterograde refractory period, the induction of atrial fibrillation independently of the type of atrioventricular conduction, and the induction of atrioventricular reentrant tachycardia and or atrial flutter.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/9612655' target='_blank' class='pmid-link'>9612655</a>:</span> <span class='sentence-part'>Repeated induction of AF by rapid atrial pacing leads to a shortening of atrial refractoriness with loss of rate adaptation, which favours the induction and maintenance of AF.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/9815876' target='_blank' class='pmid-link'>9815876</a>:</span> <span class='sentence-part'>Combined mapping of AF induction and atrial ERP showed that premature extrastimuli induced AF at sites with short ERP by causing local conduction slowing and/or block in adjacent zones with longer ERP values. CONCLUSIONS: Atrial tachycardia causes nonuniform remodeling of atrial refractoriness that plays an important role in increasing atrial vulnerability to AF induction and the duration of induced AF.</span></div></div>
<div class='streamlined-assertion'><div class='streamlined-header sticky-relation-header'><span class='label-text'>Subject:</span> <strong>Inflammasomes</strong> <span class='label-text'>Subject CUI:</span> <strong>C2936529</strong> â†’ <span class='label-text predicate-text'>CAUSES</span> â†’ <span class='label-text'>Object:</span> <strong>Alzheimers</strong> <span class='label-text'>Object CUI:</span> <strong>C0002395</strong></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32564756' target='_blank' class='pmid-link'>32564756</a>:</span> <span class='sentence-part'>Alzheimer's disease: new concepts on the role of autoimmunity and of NLRP3 inflammasome in the pathogenesis of the disease.Alzheimer's disease (AD), recognized as the most common neurodegenerative disorder, is clinically characterized by the presence of extracellular beta amyloid (Abeta) plaques and by intracellular neurofibrillary tau tangles, accompanied by glial activation and neuroinflammation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33181351' target='_blank' class='pmid-link'>33181351</a>:</span> <span class='sentence-part'>The NLRP3 inflammasome triggers sterile neuroinflammation and Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34209586' target='_blank' class='pmid-link'>34209586</a>:</span> <span class='sentence-part'>This review summarizes the current literature on the role of the NLRP3 inflammasome in the pathogenesis of AD, and its involvement in infections, particularly SARS-CoV-2.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34219728' target='_blank' class='pmid-link'>34219728</a>:</span> <span class='sentence-part'>Among the known inflammasomes, the NOD-like receptor family pyrin domain containing 3 (NLRP3) inflammasome plays a critical role in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34381452' target='_blank' class='pmid-link'>34381452</a>:</span> <span class='sentence-part'>By researching the activation or inactivation of NLRP3 inflammasome, it is possible to reveal the pathogenesis of AD from a new perspective and provide a new idea for the prevention and treatment of AD. Activation of the NLRP3 inflammasome play a key role in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35250595' target='_blank' class='pmid-link'>35250595</a>:</span> <span class='sentence-part'>In this review, we summarize current literatures on the activation of NLRP3 inflammasome and activation-related regulation mechanisms, and discuss its possible roles in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35382471' target='_blank' class='pmid-link'>35382471</a>:</span> <span class='sentence-part'>Amyloid beta-peptide (Abeta) aggregation and nucleotide-binding oligomerization domain (NOD)-like receptor protein 3 (NLRP3) inflammasome play crucial roles in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35966798' target='_blank' class='pmid-link'>35966798</a>:</span> <span class='sentence-part'>Here, we studied the expressional change of HECT-E3 ligase using M01 on autophagy and inflammasome pathways in the context of AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36802053' target='_blank' class='pmid-link'>36802053</a>:</span> <span class='sentence-part'>Mechanistic and therapeutic role of NLRP3 inflammasome in the pathogenesis of Alzheimer's Disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37055801' target='_blank' class='pmid-link'>37055801</a>:</span> <span class='sentence-part'>However, the specific mechanism of NLRP1 inflammasome in the pathogenesis of AD is still unclear.</span></div></div>
<div class='streamlined-assertion'><div class='streamlined-header sticky-relation-header'><span class='label-text'>Subject:</span> <strong>Inflammation</strong> <span class='label-text'>Subject CUI:</span> <strong>C0021368</strong> â†’ <span class='label-text predicate-text'>CAUSES</span> â†’ <span class='label-text'>Object:</span> <strong>Alzheimers</strong> <span class='label-text'>Object CUI:</span> <strong>C0002395</strong></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/10869806' target='_blank' class='pmid-link'>10869806</a>:</span> <span class='sentence-part'>Further, as inflammation is reported to play a prominent role is AD pathogenesis, IL-6, a known mediator of inflammation, is another candidate gene proposed to be associated with the risk of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/11715204' target='_blank' class='pmid-link'>11715204</a>:</span> <span class='sentence-part'>They could have a role in the neurotoxicity observed in AD because of the inflammatory reaction they generate.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/11738475' target='_blank' class='pmid-link'>11738475</a>:</span> <span class='sentence-part'>Further, in diseases such as progressive supranuclear palsy, Huntington's, Alzheimer's and Parkinson's diseases, the aberrant activation of TGases may be caused by oxidative stress and inflammation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/11754998' target='_blank' class='pmid-link'>11754998</a>:</span> <span class='sentence-part'>The limited number of studies that have investigated chemokine and chemokine receptor expression in Alzheimer's disease (AD) brain and in cell culture models seem to support a role for inflammation in AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/11755000' target='_blank' class='pmid-link'>11755000</a>:</span> <span class='sentence-part'>Biochemical, genetic, and epidemiological evidence indicates that inflammation is an essential part of the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/12099698' target='_blank' class='pmid-link'>12099698</a>:</span> <span class='sentence-part'>Transforming growth factor-beta-1 (TGF-beta), a key regulator of the brain responses to injury and inflammation, has been implicated in upregulating the expression of the Alzheimer amyloid precursor protein (APP) and Alzheimer's disease (AD) pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/12973747' target='_blank' class='pmid-link'>12973747</a>:</span> <span class='sentence-part'>Moreover, doses leading to similar brain/serum levels provided neuroprotection in animal models relevant for neurodegeneration in AD such as neurotoxicity produced by inflammation in the NBM or beta-amyloid injection to the hippocampus.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/15473667' target='_blank' class='pmid-link'>15473667</a>:</span> <span class='sentence-part'>Expression of the NF-kappaB-dependent genes responsible for inflammation, such as TNF-alpha, IL-1beta, and nitric oxide synthase (NOS), contributes to chronic inflammation which is a major cause of neurodegenerative diseases (i.e. Alzheimer's disease).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/15644140' target='_blank' class='pmid-link'>15644140</a>:</span> <span class='sentence-part'>But simultaneous with the arrival of a more complex view of microglia, evidence that inflammation plays a causal or exacerbating role in AD etiology has been boosted by genetic, physiological, and epidemiological studies.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/15665405' target='_blank' class='pmid-link'>15665405</a>:</span> <span class='sentence-part'>These then cause a cytokine cascade and microlocalized inflammation in the CNS, that in time results in clinical Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/15681802' target='_blank' class='pmid-link'>15681802</a>:</span> <span class='sentence-part'>Inflammation is a critical component of the pathogenesis of Alzheimer's disease (AD), consisting of the activation of both microglia and astrocytes.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/15748779' target='_blank' class='pmid-link'>15748779</a>:</span> <span class='sentence-part'>The importance of the role of inflammation has been suggested in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/16192374' target='_blank' class='pmid-link'>16192374</a>:</span> <span class='sentence-part'>Inflammation is a critical component of the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/16384684' target='_blank' class='pmid-link'>16384684</a>:</span> <span class='sentence-part'>The initial stages of Alzheimer's disease pathology in the neocortex show upregulation of cell cycle proteins, adhesion and inflammation related factors, indicating the early involvement of inflammatory and regenerating pathways in Alzheimer's disease pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/16478525' target='_blank' class='pmid-link'>16478525</a>:</span> <span class='sentence-part'>Mutations in the PS-1 and APP genes, which increase production of the highly amyloidogenic amyloid beta-peptide (Abeta42), are the major causes of early onset familial AD. Several lines of evidence suggest that enhanced oxidative stress, inflammation, and apoptosis play important roles in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/16602061' target='_blank' class='pmid-link'>16602061</a>:</span> <span class='sentence-part'>DEVELOPMENT: Inflammation is considered an important, although secondary, element in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/16787834' target='_blank' class='pmid-link'>16787834</a>:</span> <span class='sentence-part'>In vivo, doses leading to similar brain/serum levels produce neuroprotection in animal models relevant for neurodegeneration in Alzheimer's disease such as neurotoxicity produced by inflammation in the NBM or beta-amyloid injection to the hippocampus.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17027528' target='_blank' class='pmid-link'>17027528</a>:</span> <span class='sentence-part'>Although the precise molecular and cellular relationship between AD and inflammation remains unclear, interleukins and cytokines might induce activation of signaling pathways leading to futher inflammation and neuronal injury. Epidemiologic data as well as clinical trial evidence suggest that nonsteroidal anti-inflammatory drug (NSAID) use may decrease the incidence of AD, further supporting a role for inflammation in AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17262990' target='_blank' class='pmid-link'>17262990</a>:</span> <span class='sentence-part'>The importance of inflammation in the pathogenesis of AD was indirectly confirmed by epidemiological investigations that revealed a decreased incidence of AD in subjects using anti-inflammatory drugs, especially the non-steroidal anti-inflammatory drugs (NSAIDs).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17767011' target='_blank' class='pmid-link'>17767011</a>:</span> <span class='sentence-part'>Inflammation is also believed to be integral to the pathogenesis of AD. Amyloid-beta peptides (Abeta), generated by proteolysis of the beta-amyloid precursor protein (APP) by beta- and gamma-secretases, play an important role in the pathogenesis of Alzheimer disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17949824' target='_blank' class='pmid-link'>17949824</a>:</span> <span class='sentence-part'>Increasing evidence supports a propensity towards inflammation in Alzheimer's disease (AD) pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/19914323' target='_blank' class='pmid-link'>19914323</a>:</span> <span class='sentence-part'>A large body of evidence suggests the importance of inflammation and oxidative or nitrosative stress in Alzheimer's disease (AD) pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20011709' target='_blank' class='pmid-link'>20011709</a>:</span> <span class='sentence-part'>The importance of inflammation in the pathogenesis of neurodegenerative diseases, such as Alzheimer's disease, is increasingly being recognized.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20160456' target='_blank' class='pmid-link'>20160456</a>:</span> <span class='sentence-part'>OBJECTIVES: To show that the interest in inflammation in Alzheimer's disease (AD) is not only an early event in the history of AD but that inflammation is also an early event in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20195797' target='_blank' class='pmid-link'>20195797</a>:</span> <span class='sentence-part'>How the regulation of inflammation loses its effectiveness during AD pathogenesis remains largely unclear.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20205641' target='_blank' class='pmid-link'>20205641</a>:</span> <span class='sentence-part'>Morbidities of aging and Alzheimer's disease (AD) have been related to defective functions of both T cells and macrophages leading to brain amyloidosis and inflammation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20933033' target='_blank' class='pmid-link'>20933033</a>:</span> <span class='sentence-part'>The Abeta aggregate-induced neurotoxicity, inflammatory reactions and oxidative stress are linked strongly to the etiology of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21143138' target='_blank' class='pmid-link'>21143138</a>:</span> <span class='sentence-part'>This strongly indicates that inflammation plays a central role in the aetiology of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21567187' target='_blank' class='pmid-link'>21567187</a>:</span> <span class='sentence-part'>Inflammation including microglial activation may contribute in AD pathogenesis, and biomarkers for this process may thus be of value to study AD pathogenesis and might facilitate development of therapies targeting these cells.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21920632' target='_blank' class='pmid-link'>21920632</a>:</span> <span class='sentence-part'>Inflammation is believed to be integral to the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21951392' target='_blank' class='pmid-link'>21951392</a>:</span> <span class='sentence-part'>Beta-amyloid (Abeta) plaques and local inflammation are central to the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22342162' target='_blank' class='pmid-link'>22342162</a>:</span> <span class='sentence-part'>Inflammation within the CNS is part of the pathogenesis of neurodegenerative diseases, in particular Alzheimer's disease, multiple sclerosis and Parkinson's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23046210' target='_blank' class='pmid-link'>23046210</a>:</span> <span class='sentence-part'>There is a great deal of evidence suggesting an important role for systemic inflammation in the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23533697' target='_blank' class='pmid-link'>23533697</a>:</span> <span class='sentence-part'>Although much attention has been devoted concerning the contribution of the microscopic lesions, senile plaques, and neurofibrillary tangles to the disease process, inflammation has long been suspected to play a major role in the etiology of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23566485' target='_blank' class='pmid-link'>23566485</a>:</span> <span class='sentence-part'>BACKGROUND: Immune activation and inflammation represent critical factors in the pathogenesis of Alzheimer's disease (AD) and are associated with increased blood concentrations of markers like neopterin and the kynurenine to tryptophan ratio (Kyn/Trp).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24369524' target='_blank' class='pmid-link'>24369524</a>:</span> <span class='sentence-part'>The presence of activated microglia and astrocytes in the vicinity of amyloid plaques in the brains of Alzheimer's disease (AD) patients and mouse models implicates inflammation as a contributor to AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24384767' target='_blank' class='pmid-link'>24384767</a>:</span> <span class='sentence-part'>Amyloid beta or Abeta plaques and neurofibrillary tangles define AD pathologically but do not fully explain it, because dementia may also be caused by inflammation resulting in neuronal, axonal synaptic loss and dysfunction.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24413537' target='_blank' class='pmid-link'>24413537</a>:</span> <span class='sentence-part'>Alzheimer's disease may result from low-grade inflammation of the brain, and the characteristic amyloid beta may be a protective response.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24557039' target='_blank' class='pmid-link'>24557039</a>:</span> <span class='sentence-part'>Immune activation and inflammation, likely triggered by amyloid-beta (Abeta) deposition, play a remarkable role in the pathogenesis of Alzheimer's disease (AD), which is the most frequent cause of dementia in the elderly.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24631395' target='_blank' class='pmid-link'>24631395</a>:</span> <span class='sentence-part'>The current study was designed to further our understanding of peripheral inflammation-induced AD-like pathology, by administering polyinosinic:polycytidylic acid (poly I:C), a viral mimetic.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25051986' target='_blank' class='pmid-link'>25051986</a>:</span> <span class='sentence-part'>BACKGROUND: Aging is characterized by a low-grade systemic inflammation that contributes to the pathogenesis of neurodegenerative disorders such as Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25554493' target='_blank' class='pmid-link'>25554493</a>:</span> <span class='sentence-part'>In Alzheimer's disease (AD), large populations of endothelial cells undergo angiogenesis due to brain hypoxia and inflammation. Substantial evidence from epidemiologic, pathologic, and clinical reports suggests that vascular factors are critical for the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26103884' target='_blank' class='pmid-link'>26103884</a>:</span> <span class='sentence-part'>There is relatively little information about inflammation in the DS brain and how the genetics of DS may alter inflammatory responses and modify the course of AD pathogenesis in this disorder.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26587902' target='_blank' class='pmid-link'>26587902</a>:</span> <span class='sentence-part'>BACKGROUND: The critical role of neuro-inflammation and oxidative stress in the pathogenesis of neurodegenerative diseases such as Alzheimer's disease (AD) has become evident.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26899953' target='_blank' class='pmid-link'>26899953</a>:</span> <span class='sentence-part'>Clusterin (CLU) is recognized as a secreted protein that is related to the processes of inflammation and immunity in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26910914' target='_blank' class='pmid-link'>26910914</a>:</span> <span class='sentence-part'>Neuro-inflammation is associated with activation of astrocyte and amyloid-beta (Abeta) generations that lead to pathogenesis of Alzheimer disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26913031' target='_blank' class='pmid-link'>26913031</a>:</span> <span class='sentence-part'>In this article, we consider how current imaging techniques can help to unravel new inflammation mechanisms in the pathogenesis of AD and identify novel therapeutic strategies to treat the disease by interfering with leukocyte trafficking mechanisms.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27010693' target='_blank' class='pmid-link'>27010693</a>:</span> <span class='sentence-part'>BACKGROUND: One of the factors that contribute to Alzheimer's disease (AD) is the DNA damage caused by oxidative stress and inflammation that occurs in nerve cells.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27357286' target='_blank' class='pmid-link'>27357286</a>:</span> <span class='sentence-part'>Inflammation is becoming increasingly recognized as an important contributor to Alzheimer's disease (AD) pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27412235' target='_blank' class='pmid-link'>27412235</a>:</span> <span class='sentence-part'>Inflammation is one of the main causes of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27829994' target='_blank' class='pmid-link'>27829994</a>:</span> <span class='sentence-part'>In conclusion, astrocytes have been shown to exert a direct role in Abeta clearance and undergo functional impair associated with inflammation in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28460142' target='_blank' class='pmid-link'>28460142</a>:</span> <span class='sentence-part'>This study suggested that AgNP exposure might cause Abeta deposition and inflammation for subsequent neuronal cell apoptosis to potentially induce AD progression. AgNP exposure can increase amyloid beta (Abeta) deposition in neuronal cells to potentially induce Alzheimer's disease (AD) progression.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28977138' target='_blank' class='pmid-link'>28977138</a>:</span> <span class='sentence-part'>Innate immunity and inflammation in Alzheimer's disease pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29249963' target='_blank' class='pmid-link'>29249963</a>:</span> <span class='sentence-part'>A working hypothesis links extrinsic inflammation as a secondary cause of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29393440' target='_blank' class='pmid-link'>29393440</a>:</span> <span class='sentence-part'>Although the pathologic mechanism remains to be fully elucidated, inflammation has been shown to be critical in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29562537' target='_blank' class='pmid-link'>29562537</a>:</span> <span class='sentence-part'>The production of soluble amyloid-beta oligomers (AbetaOs) and the activation of inflammation are two important early steps in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29628886' target='_blank' class='pmid-link'>29628886</a>:</span> <span class='sentence-part'>Furthermore, the CCR might be mechanistically linked to inflammation, a critical factor in the AD etiology according to the genetic evidence.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30403186' target='_blank' class='pmid-link'>30403186</a>:</span> <span class='sentence-part'>OBJECTIVE: The dysregulation of neuro-inflammation is one of the attributes of the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30564548' target='_blank' class='pmid-link'>30564548</a>:</span> <span class='sentence-part'>The cognitive impairment that is a hallmark of AD may be caused by inflammation in the brain triggered and maintained by the presence of Abeta protein, ultimately leading to neuronal dysfunction and loss.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30661858' target='_blank' class='pmid-link'>30661858</a>:</span> <span class='sentence-part'>Inflammation increases beta-amyloid burden and is thought to drive Alzheimer's disease pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30777084' target='_blank' class='pmid-link'>30777084</a>:</span> <span class='sentence-part'>Given the role played by inflammation in AD pathogenesis and the established efficacy of IFNbeta1a in the treatment of inflammatory diseases of the central nervous system such as multiple sclerosis, its use may be a viable strategy to inhibit the pro-inflammatory cytokine and oxidative stress cascade associated with Abeta deposition in the hippocampus of AD patients.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30929586' target='_blank' class='pmid-link'>30929586</a>:</span> <span class='sentence-part'>BACKGROUND: An imbalance of free radicals and antioxidant defense systems in physiological processes can result in protein/DNA damage, inflammation, and cellular apoptosis leading to neurodegenerative disorders such as Alzheimer's disease (AD), Parkinson's disease (PD), and Huntington's disease (HD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30968773' target='_blank' class='pmid-link'>30968773</a>:</span> <span class='sentence-part'>Evidence also suggests that inflammation may lead to atherosclerosis, Alzheimer's, hypertension, stroke, cysts and cancers.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31233762' target='_blank' class='pmid-link'>31233762</a>:</span> <span class='sentence-part'>According to the critical role of inflammation in pathogenesis of AD and memory deficits, a cytokine with anti-inflammatory properties like interferon beta (IFNbeta), currently used to slow down disease progression and protect against cognitive disturbance in multiple sclerosis, might be also an effective treatment in AD condition.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31312547' target='_blank' class='pmid-link'>31312547</a>:</span> <span class='sentence-part'>A central role for inflammation has been implicated in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31451750' target='_blank' class='pmid-link'>31451750</a>:</span> <span class='sentence-part'>Regulator of calcineurin 1 (RCAN1) is a multifunctional protein involved in neurodegeneration, mitochondrial dysfunction, inflammation and protein glycosylation, and plays an important role in the pathogenesis of Down syndrome and Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31680874' target='_blank' class='pmid-link'>31680874</a>:</span> <span class='sentence-part'>Accumulating evidences suggest an active role of inflammation in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31865964' target='_blank' class='pmid-link'>31865964</a>:</span> <span class='sentence-part'>We believe this review will provide new insights into biomarker candidates for the early diagnosis of AD with systemic relevance to inflammation during AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31867568' target='_blank' class='pmid-link'>31867568</a>:</span> <span class='sentence-part'>Human and animal studies have shown that chronic immune response and inflammation are important factors in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32444542' target='_blank' class='pmid-link'>32444542</a>:</span> <span class='sentence-part'>Tenuifolin Attenuates Amyloid-beta42-Induced Neuroinflammation in Microglia Through the NF-kappaB Signaling Pathway.BACKGROUND: Inflammation and oxidative stress are believed to play an important role in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32606694' target='_blank' class='pmid-link'>32606694</a>:</span> <span class='sentence-part'>Background: beta-Amyloid (Abeta) induces oxidative stress and inflammation of microglial cells, thus leading to Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32765394' target='_blank' class='pmid-link'>32765394</a>:</span> <span class='sentence-part'>Thus, ORC may exert a protective role in AD through attenuating the damage caused by inflammation and oxidative stress.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32781098' target='_blank' class='pmid-link'>32781098</a>:</span> <span class='sentence-part'>Evidence suggests that hyperglycemia induces oxidative stress, mitochondrial dysfunction, inflammation and excitotoxicity, all of which play important roles in the onset and progression of AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32916195' target='_blank' class='pmid-link'>32916195</a>:</span> <span class='sentence-part'>Chronic airway allergy induces pro-inflammatory responses in the brain of wildtype mice but not 3xTgAD mice.The effects of systemic inflammation on the pathogenesis of Alzheimer's disease (AD) are not clarified, both beneficial and deleterious effects being reported.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33422142' target='_blank' class='pmid-link'>33422142</a>:</span> <span class='sentence-part'>BACKGROUND: Both serotonergic signalling disruption and systemic inflammation have been associated with the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33737171' target='_blank' class='pmid-link'>33737171</a>:</span> <span class='sentence-part'>INTRODUCTION: Systemic inflammation has been increasingly implicated in the pathogenesis of Alzheimer's disease (AD), yet the mechanistic and temporal specificity of this relationship is poorly understood.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33881288' target='_blank' class='pmid-link'>33881288</a>:</span> <span class='sentence-part'>PURPOSE: Systemic inflammation is characteristic for the pathogenesis of Alzheimer's disease (AD) and is responsible for the accumulation of its disease-specific Tau-protein and beta-amyloid plaques.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33977208' target='_blank' class='pmid-link'>33977208</a>:</span> <span class='sentence-part'>Here, we explain how vascular dysfunction mechanistically contributes to thrombosis as well as inflammation and neurodegeneration in AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34023945' target='_blank' class='pmid-link'>34023945</a>:</span> <span class='sentence-part'>Chronic exposure to metals like aluminium and copper causes accumulation of Abeta plaques, promotes oxidative stress, neuro-inflammation, and degeneration of cholinergic neurons results in AD-like symptoms.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34025357' target='_blank' class='pmid-link'>34025357</a>:</span> <span class='sentence-part'>Recent studies have shown that inflammation plays early and perhaps causal roles in the pathogenesis of AD related to NVU damage, possibly in part by overactivating the aspartic acid protease activity of beta-site amyloid precursor protein-cleaving enzyme 1 (BACE1), which until now has almost solely been studied in the context of the beta-amyloid cascade.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34032945' target='_blank' class='pmid-link'>34032945</a>:</span> <span class='sentence-part'>BACKGROUND: Numerous studies have indicated the role of inflammation in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34245502' target='_blank' class='pmid-link'>34245502</a>:</span> <span class='sentence-part'>It was noted, that the capacities of the tenuigenin to decrease the secretion of beta amyloid and to protect of neurons from damage by already made beta ameloids, to inhibit the processes of the tau proteins' hyperphosphorylation and inflammations in microglia, as well as increase the main synaptic transmission can be used by the development of effective therapeutic drugs aimed to reduce the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34260075' target='_blank' class='pmid-link'>34260075</a>:</span> <span class='sentence-part'>Inflammation plays an important role in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34340010' target='_blank' class='pmid-link'>34340010</a>:</span> <span class='sentence-part'>Increasing evidence has placed inflammation and immune dysfunction at the center of the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34384901' target='_blank' class='pmid-link'>34384901</a>:</span> <span class='sentence-part'>Although the mechanisms are still not fully elucidated, studies have revealed that these highly conserved ncRNAs are important modulators of gene expression, amyloid-beta production, tau phosphorylation, inflammation, synaptic plasticity and neuronal survival, all features considered central to AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34403662' target='_blank' class='pmid-link'>34403662</a>:</span> <span class='sentence-part'>CONCLUSION: CircLPAR1 promotes Abeta25-35-induced apoptosis, inflammation, and oxidative stress via miR-212-3p/ZNF217 axis, suggesting a new insight into the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34856902' target='_blank' class='pmid-link'>34856902</a>:</span> <span class='sentence-part'>Inflammation in the CNS - understanding various aspects of the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35145898' target='_blank' class='pmid-link'>35145898</a>:</span> <span class='sentence-part'>Objective: Sustained inflammation, which could be promoted by Abeta aggregation and tau hyperphosphorylation, is a critical player in Alzheimer's disease (AD) pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35327563' target='_blank' class='pmid-link'>35327563</a>:</span> <span class='sentence-part'>This review highlights the neuroinflammatory and neuroprotective role of epigallocatechin-3-gallate (EGCG): the medicinal component of green tea, a known nutraceutical that has shown promise in modulating AD progression due to its antioxidant, anti-inflammatory, and anti-aging abilities. Using Alzheimer's disease (AD) as the archetype, the pathological findings include the aggregation of Amyloid Beta (Abeta) peptides, mitochondrial dysfunction, synaptic degradation caused by inflammation, elevated reactive oxygen species (ROS), and cerebrovascular dysregulation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35601620' target='_blank' class='pmid-link'>35601620</a>:</span> <span class='sentence-part'>Background: Inflammation and immune dysfunction play significant roles in the pathogenesis of Alzheimer's disease (AD)-related dementia.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36204826' target='_blank' class='pmid-link'>36204826</a>:</span> <span class='sentence-part'>Secondly, we outlined key aspects of glial cell-associated inflammation in Alzheimer's disease pathogenesis and provided the latest evidence on the roles of microglia and astrocytes in Alzheimer's disease pathology.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36340795' target='_blank' class='pmid-link'>36340795</a>:</span> <span class='sentence-part'>Combining animal pharmacodynamic experiments with network pharmacology analysis, we confirmed the importance of inflammation in pathogenesis of AD, clarified the pharmacodynamic characteristics of QZZD in treating AD, and proved its neuroprotective effects through the regulation of TNFR1-ERK1/2-NF-kappaBp65 signaling pathway, which might provide reference for studies on treatment of AD in the future.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36675125' target='_blank' class='pmid-link'>36675125</a>:</span> <span class='sentence-part'>SIRT3 downregulation leads to mitochondrial dysfunction, neuroinflammation, and inflammation, potentially triggering factors of AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36982996' target='_blank' class='pmid-link'>36982996</a>:</span> <span class='sentence-part'>This review is aimed at summarizing the effects of dietary supplementation on cognitive decline, neuroinflammation and oxidative stress in AD-like animal models with a focus on neuroinflammation induced by lipopolysaccharide (LPS) injection, which mimics systemic inflammation in animals. Evidence suggests that systemic inflammation, dysregulation of the immune response and the resulting neuroinflammation and neurodegeneration play a significant role in AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37251647' target='_blank' class='pmid-link'>37251647</a>:</span> <span class='sentence-part'>Recent advances highlight that inflammation is critical to Alzheimer Disease (AD) pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37332353' target='_blank' class='pmid-link'>37332353</a>:</span> <span class='sentence-part'>Cumulative studies have shown inflammation as one of the main contributors to the pathogenesis of AD, leading to the recognition of a specific role of neuroinflammation synergic with the Abeta and NFTs cascades.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37337817' target='_blank' class='pmid-link'>37337817</a>:</span> <span class='sentence-part'>Specifically, we have shown that acrolein, acting as a diffusive factor of secondary injury, is both critical and sufficient in promoting inflammation (TNF-alpha) and Abeta42 aggregation, two known contributors of AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/38157740' target='_blank' class='pmid-link'>38157740</a>:</span> <span class='sentence-part'>It suggests that the therapeutic effect of nervonic acid on AD is likely to be produced by ameliorating inflammation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/8712791' target='_blank' class='pmid-link'>8712791</a>:</span> <span class='sentence-part'>Abundant circumstantial evidence implicates inflammation in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/8892340' target='_blank' class='pmid-link'>8892340</a>:</span> <span class='sentence-part'>The present review addresses these issues by showing that 1) inflammatory molecules and mechanisms are uniquely present or significantly elevated in the AD brain, 2) inflammation may be a necessary component of AD pathogenesis, 3) inflammation may be sufficient to cause AD neurodegeneration, and 4) retrospective and direct clinical trials suggest a therapeutic benefit of conventional antiinflammatory medications in slowing the progress or even delaying the onset of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/8892348' target='_blank' class='pmid-link'>8892348</a>:</span> <span class='sentence-part'>Recent evidence suggests that inflammation in the central nervous system plays an important role in the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/8996832' target='_blank' class='pmid-link'>8996832</a>:</span> <span class='sentence-part'>Largely this review presents current opinions which support the concept that inflammation and similar immune mechanisms need to be considered as participating in AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/9545438' target='_blank' class='pmid-link'>9545438</a>:</span> <span class='sentence-part'>The essential role of inflammation and induced gene expression in the pathogenic pathway of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/9550286' target='_blank' class='pmid-link'>9550286</a>:</span> <span class='sentence-part'>It has been suggested that inflammation may be a possible cause of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/9651139' target='_blank' class='pmid-link'>9651139</a>:</span> <span class='sentence-part'>Several converging lines of evidence suggest that beta-amyloid and inflammation may be linked in the pathogenesis of Alzheimer disease (AD), but the mechanism of beta-amyloid neurotoxicity is unclear.</span></div></div>
<div class='streamlined-assertion'><div class='streamlined-header sticky-relation-header'><span class='label-text'>Subject:</span> <strong>Inflammation</strong> <span class='label-text'>Subject CUI:</span> <strong>C0021368</strong> â†’ <span class='label-text predicate-text'>CAUSES</span> â†’ <span class='label-text'>Object:</span> <strong>Atrial_Fibrillation</strong> <span class='label-text'>Object CUI:</span> <strong>C0004238</strong></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31999778' target='_blank' class='pmid-link'>31999778</a>:</span> <span class='sentence-part'>The association between AF and echocardiographic parameters, causes of death were also investigated. The association between AF and sepsis-related death suggested the role of systemic inflammation on the pathogenesis of AF.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32072262' target='_blank' class='pmid-link'>32072262</a>:</span> <span class='sentence-part'>Atrial inflammation in different atrial fibrillation subtypes and its relation with clinical risk factors.OBJECTIVE: Inflammation of the atria is an important factor in the pathogenesis of atrial fibrillation (AF).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32152730' target='_blank' class='pmid-link'>32152730</a>:</span> <span class='sentence-part'>Uneven distribution of EAT may imply the direct contribution of EAT-related inflammation to the pathogenesis of AF or CAD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32275023' target='_blank' class='pmid-link'>32275023</a>:</span> <span class='sentence-part'>The incidence of postoperative atrial fibrillation (POAF) may also be reduced because of less ischemia and inflammation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32524234' target='_blank' class='pmid-link'>32524234</a>:</span> <span class='sentence-part'>Inflammation has been suggested to play a key role in the pathogenesis of atrial fibrillation (AF).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32539447' target='_blank' class='pmid-link'>32539447</a>:</span> <span class='sentence-part'>Inflammation is a large component in the pathogenesis of both atrial fibrillation (AF) and sepsis and may link these conditions in CKD5-HD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32623472' target='_blank' class='pmid-link'>32623472</a>:</span> <span class='sentence-part'>Inflammation may be an important factor for the pathogenesis of POAF, and increased preoperative levels of C-reactive protein (CRP) are associated with the development of POAF.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32946846' target='_blank' class='pmid-link'>32946846</a>:</span> <span class='sentence-part'>Inflammation has been implicated as an etiology of POAF.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33102683' target='_blank' class='pmid-link'>33102683</a>:</span> <span class='sentence-part'>Mechanisms including apnea-induced hypoxia with intermittent arousal, fluctuating levels of carbon dioxide, enhanced sympathetic/neurohormonal activation and oxidative stress causing inflammation have been implicated as etiologic causes of AF within this subpopulation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33664879' target='_blank' class='pmid-link'>33664879</a>:</span> <span class='sentence-part'>It has become clear that AF causes structural alterations in the atrial myocardium that propagate further AF, and that some of these alterations are the result of inflammation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33737532' target='_blank' class='pmid-link'>33737532</a>:</span> <span class='sentence-part'>Systemic inflammation is assumed to be the consequence and the cause of atrial fibrillation (AF); however, the underlying mechanism remains unclear.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33765041' target='_blank' class='pmid-link'>33765041</a>:</span> <span class='sentence-part'>BACKGROUND: Emerging evidence has implicated that inflammation contributes to the pathogenesis of atrial fibrillation (AF).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33837408' target='_blank' class='pmid-link'>33837408</a>:</span> <span class='sentence-part'>AIMS: Inflammation plays a role in the pathogenesis of atrial fibrillation (AF).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34002134' target='_blank' class='pmid-link'>34002134</a>:</span> <span class='sentence-part'>BACKGROUND: Studies have suggested that atrial fibrillation (AF) in patients with rheumatic diseases (RD) may be due to inflammation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35023045' target='_blank' class='pmid-link'>35023045</a>:</span> <span class='sentence-part'>Is glucose metabolism in the atria in patients with atrial fibrillation due to inflammation or remodeling?</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36110442' target='_blank' class='pmid-link'>36110442</a>:</span> <span class='sentence-part'>Given the importance of systemic inflammation in the pathogenesis of AF, an increased risk of the development of other diseases related to systemic inflammation can be expected.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36741841' target='_blank' class='pmid-link'>36741841</a>:</span> <span class='sentence-part'>Although underlying inflammatory atrial cardiomyopathy may contribute to the development of AF, the arrhythmogenic remodeling caused by atrial inflammation has not been elucidated in detail.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37293559' target='_blank' class='pmid-link'>37293559</a>:</span> <span class='sentence-part'>The present review article aims to provide an updated overview and focus on the basic role of different biomarkers of inflammation in the pathophysiological aspects of the pathogenesis of AF.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37384420' target='_blank' class='pmid-link'>37384420</a>:</span> <span class='sentence-part'>Almost half of patients recovering from open-chest surgery experience atrial fibrillation (AF) that results principally from inflammation in the pericardial space surrounding the heart.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37516824' target='_blank' class='pmid-link'>37516824</a>:</span> <span class='sentence-part'>In this review, we discuss the epidemiology of obesity and AF, summarize the mechanisms by which obesity triggers AF, and explain how weight loss improves the prognosis of AF. Weight loss reduced the risk and reversed natural progression of AF, which may be due to its anti-fibrosis and inflammation effect.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/38247541' target='_blank' class='pmid-link'>38247541</a>:</span> <span class='sentence-part'>The aim of this paper is to provide a comprehensive view of the close relationship between obesity-induced oxidative stress, inflammation, and mitochondrial dysfunction and the pathogenesis of AF. The triad inflammation, oxidative stress, and mitochondrial dysfunction are critical for AF pathogenesis in the setting of obesity via multiple structural and functional proarrhythmic changes at the level of the atria.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/38639701' target='_blank' class='pmid-link'>38639701</a>:</span> <span class='sentence-part'>Specifically, we aimed to assess the efficacy of amiodarone (a classic antiarrhythmic drug), colchicine (an anti-inflammatory agent), and EVs derived from human heart-derived cells, which possess anti-inflammatory and antifibrotic properties, on AF induction, inflammation, and fibrosis progression.</span></div></div>
<div class='streamlined-assertion'><div class='streamlined-header sticky-relation-header'><span class='label-text'>Subject:</span> <strong>Inflammatory_Response</strong> <span class='label-text'>Subject CUI:</span> <strong>C1155266</strong> â†’ <span class='label-text predicate-text'>CAUSES</span> â†’ <span class='label-text'>Object:</span> <strong>Alzheimers</strong> <span class='label-text'>Object CUI:</span> <strong>C0002395</strong></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/12923064' target='_blank' class='pmid-link'>12923064</a>:</span> <span class='sentence-part'>In most neurodegenerative disorders, including multiple sclerosis, Parkinson's disease, and Alzheimer's disease, a massive neuronal cell death occurs as a consequence of an uncontrolled inflammatory response, where activated microglia and its cytotoxic agents play a crucial pathologic role.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/15817469' target='_blank' class='pmid-link'>15817469</a>:</span> <span class='sentence-part'>In most neurodegenerative disorders, including multiple sclerosis, Parkinson disease, and Alzheimer disease, a massive neuronal cell death occurs as a consequence of an uncontrolled inflammatory response, where activated astrocytes and microglia and their cytotoxic agents play a crucial pathological role.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/15880353' target='_blank' class='pmid-link'>15880353</a>:</span> <span class='sentence-part'>Several lines of neuroimmunological evidence correlate the development of the inflammatory responses of the brain with the formation of amyloid plaques associated with the pathogenesis of neurodegenerative disorders such as Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17048151' target='_blank' class='pmid-link'>17048151</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) is the most commonly diagnosed etiology of dementia and may be caused by the progressive accumulation and deposition of neurotoxic Abeta/amyloid plaques and aggregates in brain with aging-the amyloid hypothesis of AD. However, Abeta/amyloid deposition is likely necessary but not sufficient to cause AD, and other putative downstream pathologies, including the aggregation of phospho-tau in neurofibrillary tangles, synaptic and neuronal loss, and glial and inflammatory responses, are likely equally important to AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/18539391' target='_blank' class='pmid-link'>18539391</a>:</span> <span class='sentence-part'>The expression level of cortical glial fibrillary acidic protein (GFAP) increased in an age-related manner, in particular in 2-month PS cDKO mice, suggesting that the interaction relationship between oxidative stress and inflammatory response may be closely associated with the underlying loss-of-function pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/19557827' target='_blank' class='pmid-link'>19557827</a>:</span> <span class='sentence-part'>In addition, innate inflammatory responses, such as those mediated by microglia, are integral to the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/19650431' target='_blank' class='pmid-link'>19650431</a>:</span> <span class='sentence-part'>It regulates blood pressure and inflammatory response, takes part in the pathogenesis of Alzheimer disease, influences cellular proliferation and differentiation, as well as neoplastic progression.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/19996595' target='_blank' class='pmid-link'>19996595</a>:</span> <span class='sentence-part'>BACKGROUND/AIMS: Abnormal inflammatory response has been associated to the pathogenesis of Alzheimer's disease (AD) and may be a marker of an ongoing neurodegenerative process.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21683531' target='_blank' class='pmid-link'>21683531</a>:</span> <span class='sentence-part'>However, the underlying mechanism of how inflammatory response induces AD is unknown.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24052108' target='_blank' class='pmid-link'>24052108</a>:</span> <span class='sentence-part'>It proposes that abnormal production of beta amyloid protein (Abeta) is the cause of AD and that the neurotoxicity is due to Abeta itself or its oligomeric forms. AD probably results from the inflammatory response induced by extracellular Abeta deposits, which later become enhanced by aggregates of tau.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24561250' target='_blank' class='pmid-link'>24561250</a>:</span> <span class='sentence-part'>Accumulating evidence demonstrates that inflammasomes, which cleave precursors of interleukin-1beta (IL-1beta) and IL-18 to generate their active forms, play an important role in the inflammatory response in the CNS and in AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25620241' target='_blank' class='pmid-link'>25620241</a>:</span> <span class='sentence-part'>Oxidative stress and inflammatory response are important elements of Alzheimer's disease (AD) pathogenesis, but the role of redox signaling cascade and its cross-talk with inflammatory mediators have not been elucidated in details in this disorder. The biology of NF-kappaB and its activation by reactive oxygen species (ROS) and proinflammatory cytokines in the pathogenesis of AD have been specially highlighted citing evidence both from post-mortem studies in AD brain and experimental research in animal or cell-based models of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27351675' target='_blank' class='pmid-link'>27351675</a>:</span> <span class='sentence-part'>Our findings suggest that oxidative stress and inflammatory responses could result in abnormal SET gene expression, contributing to the tauopathy in AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28253985' target='_blank' class='pmid-link'>28253985</a>:</span> <span class='sentence-part'>Extensive research has revealed that multiple cellular pathways involved, including amyloid beta production, mitochondrial structural and functional changes, hyperphosphorylation of Tau and NFT formation, inflammatory responses, and neuronal loss in AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29667667' target='_blank' class='pmid-link'>29667667</a>:</span> <span class='sentence-part'>Accumulating evidence has shown that activated microglia cause inflammatory immune response, which could lead to neurodegenerative diseases such as Parkinson's disease and Alzheimer's disease. alpha-Cyperone, one of the main ingredients of Cyperus rotundus oil, has been reported to possess anti-inflammatory activity in activated macrophages.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29676229' target='_blank' class='pmid-link'>29676229</a>:</span> <span class='sentence-part'>Viral induced oxidative and inflammatory response in Alzheimer's disease pathogenesis with identification of potential drug candidates: A systematic review using systems biology approach.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30646475' target='_blank' class='pmid-link'>30646475</a>:</span> <span class='sentence-part'>The convergence of gut-derived inflammatory response together with aging and poor diet in the elderly contribute to the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32452370' target='_blank' class='pmid-link'>32452370</a>:</span> <span class='sentence-part'>Infection of the brain with various types of pathogens, and the resulting inflammatory response, is becoming increasingly important in our understanding of the etiology of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32975365' target='_blank' class='pmid-link'>32975365</a>:</span> <span class='sentence-part'>Moreover, upregulation of fl-APP protein and products may drive downstream events that dysregulate tau homeostasis and inflammatory responses that contribute to propagation of AD pathogenesis. NEW/UPDATED HYPOTHESIS: We hypothesize that the increase in APP gene dose in DS initiates a process in which increased levels of full-length APP (fl-APP) and its products, including beta-CTF and possibly Abeta peptides (Abeta42 and Abeta40), drive AD pathogenesis through an endosome-dependent mechanism(s), which compromises transport of neurotrophic signals. Evidence that in Down syndrome (DS), a population markedly predisposed to develop early onset AD, increased APP gene dose is necessary for both AD neuropathology and dementia points to normalization of the levels of the amyloid precursor protein (APP) and its products as a route to further define AD pathogenesis and discovering novel treatments.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33105802' target='_blank' class='pmid-link'>33105802</a>:</span> <span class='sentence-part'>Remarkably, the significant increase in expression of    Lcn2    ,    S100a8    ,    S100a9     and also    Saa3     and    Ch25h    , was found in AD brains suggesting that early changes of immune-response genes evoked by mild SIR could be crucial in AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34456729' target='_blank' class='pmid-link'>34456729</a>:</span> <span class='sentence-part'>Toxic Abeta oligomers (AbetaOs) can trigger inflammatory response and play an important role in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35944080' target='_blank' class='pmid-link'>35944080</a>:</span> <span class='sentence-part'>Moreover, MT1-MMP was described as a key player in cancer progression and it is involved in various inflammatory processes, as well as in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36145197' target='_blank' class='pmid-link'>36145197</a>:</span> <span class='sentence-part'>Moreover, based on thioflavin-T-based fluorometric assays, we elucidated that coumestrol effectively prevented self-aggregation of amyloid beta (Abeta), which induces an inflammatory response in the central nervous system (CNS) and is a major cause of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36165619' target='_blank' class='pmid-link'>36165619</a>:</span> <span class='sentence-part'>Upstream lipid and metabolic systems are potential causes of Alzheimer's disease, Parkinson's disease and dementias. Using microglia as an example, we review data that suggest increased lipid concentrations cause dysfunctional inflammatory responses to immune challenges, leading to Alzheimer's disease, Parkinson's disease and dementia.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36286438' target='_blank' class='pmid-link'>36286438</a>:</span> <span class='sentence-part'>Neuroinflammation is a condition associated with several types of dementia, such as Alzheimer's disease (AD), mainly caused by an inflammatory response to amyloid peptides that induce microglial activation, with subsequent cytokine release.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36394096' target='_blank' class='pmid-link'>36394096</a>:</span> <span class='sentence-part'>The GO and KEGG enrichment analyses revealed that TCFW mainly acted on oxidative response, inflammatory response, insulin secretion, amyloid fibril formation, neurodegenerative pathway-multiple diseases, Alzheimer's disease, longevity regulation pathway, PI3K-Akt signaling pathway, MAPK signaling pathway, etc, which were the main pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37416769' target='_blank' class='pmid-link'>37416769</a>:</span> <span class='sentence-part'>beta-amyloid binds to microglia Dectin-1 to induce inflammatory response in the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/38201258' target='_blank' class='pmid-link'>38201258</a>:</span> <span class='sentence-part'>An increasing amount of basic scientific data and clinical studies underscore the importance of inflammatory processes and subsequent glial activation in the pathogenesis of AD.</span></div></div>
<div class='streamlined-assertion'><div class='streamlined-header sticky-relation-header'><span class='label-text'>Subject:</span> <strong>Injection</strong> <span class='label-text'>Subject CUI:</span> <strong>C1272883</strong> â†’ <span class='label-text predicate-text'>CAUSES</span> â†’ <span class='label-text'>Object:</span> <strong>Alzheimers</strong> <span class='label-text'>Object CUI:</span> <strong>C0002395</strong></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31914623' target='_blank' class='pmid-link'>31914623</a>:</span> <span class='sentence-part'>Using an acute model of AD induced by the intracerebroventricular injection of amyloid-beta oligomers (oAbeta), we analyzed cellular and behavioral hallmarks of AD, GR signaling pathways, processing of amyloid precursor protein, and enzymes involved in Tau phosphorylation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31991177' target='_blank' class='pmid-link'>31991177</a>:</span> <span class='sentence-part'>Sixty male adult Wistar rats were randomly divided into 6 groups (n = 10 per group) as follows: 1; control, 2; sham, 3; Abeta, 4; pre-treatment (vinpocetine + Abeta): oral gavage administration of vinpocetine at 4 mg/kg for 30 days followed by intracerebroventricular (ICV) injection of Abeta, 5; treatment (Abeta + vinpocetine): Abeta ICV injection followed by vinpocetine administration for 30 days, 6; pre-treatment + treatment (vinpocetine + Abeta + vinpocetine): vinpocetine administration for 30 days before and 30 days after AD induction.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32048245' target='_blank' class='pmid-link'>32048245</a>:</span> <span class='sentence-part'>Sixty-three rats were divided into nine groups: (1) healthy, (2-4) sham, and (5-9) AD models: (5) AD was induced by intracerebroventricular injection of amyloid beta (Abeta) 1-42.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32488543' target='_blank' class='pmid-link'>32488543</a>:</span> <span class='sentence-part'>Induction of AD was performed in ovariectomized female rats with high-fat high fructose diet (HFFD) feeding after 4 weeks following D-galactose injection (150 mg/kg).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32681248' target='_blank' class='pmid-link'>32681248</a>:</span> <span class='sentence-part'>This study aimed to investigate the protective effect of GSPE on the cognitive and synaptic impairments of AD using a sporadic AD rat model induced by intracerebroventricular (ICV) injection of streptozotocin (STZ) (ICV-STZ).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33383443' target='_blank' class='pmid-link'>33383443</a>:</span> <span class='sentence-part'>Hence, rat model of AD was induced by intra-hippocampal injection of beta-amyloid     1-42      .</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33715084' target='_blank' class='pmid-link'>33715084</a>:</span> <span class='sentence-part'>AD was induced by intra-cerebroventricular injection of Abeta1-42 peptide.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33974953' target='_blank' class='pmid-link'>33974953</a>:</span> <span class='sentence-part'>AD was induced by the intra-cerebroventricular injection of Abeta1-42 peptide.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34000331' target='_blank' class='pmid-link'>34000331</a>:</span> <span class='sentence-part'>We examined the efficacy of L. glauca in a mouse model of AD, which was induced by intrahippocampal injection of Abeta     1-42      .</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34802394' target='_blank' class='pmid-link'>34802394</a>:</span> <span class='sentence-part'>AD was induced by the injection of STZ (3 mg/kg, bilaterally, ICV). This study investigated the neuroprotective effect of green tea (GT) on cognitive disorder, inflammation, and oxidative stress in the streptozotocin (STZ)- induced AD model.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34929632' target='_blank' class='pmid-link'>34929632</a>:</span> <span class='sentence-part'>This study aimed to determine the effect of 4 weeks of aerobic rehabilitation exercise (RhExe) on the genes expression of BDNF and TGF-beta1 in the hippocampus tissue of rats with the AD induced by injection of amyloid-beta (Abeta     1-42      ).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34992853' target='_blank' class='pmid-link'>34992853</a>:</span> <span class='sentence-part'>Here, we investigated whether natural products from    Chrysophyllum perpulchrum     as catechin and two dimeric procyanidins (catechin + hexose) could prevent progression of oxidative stress and cognitive changes using an AD-like rat model induced by Abeta     1-40       injection into the hippocampal CA1 subfield.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35281502' target='_blank' class='pmid-link'>35281502</a>:</span> <span class='sentence-part'>Impact of Donepezil on Brain Glucose Metabolism Assessed Using [     18      F]2-Fluoro-2-deoxy-D-Glucose Positron Emission Tomography Imaging in a Mouse Model of Alzheimer's Disease Induced by Intracerebroventricular Injection of Amyloid-Beta Peptide.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35527550' target='_blank' class='pmid-link'>35527550</a>:</span> <span class='sentence-part'>Experimental Periodontitis Deteriorates Cognitive Function and Impairs Insulin Signaling in a Streptozotocin-Induced Alzheimer's Disease Rat Model. OBJECTIVE: To assess the impact of experimental periodontitis on cognitive function deficits in a rat model of streptozotocin-induced AD and determine the mechanisms underlying these effects. METHODS: Rats were randomly assigned to the control (C), experimental periodontitis (P), Alzheimer's disease (AD), and experimental periodontitis with streptozotocin-induced AD (AD-P) groups. In the AD-P group, AD was induced by intracerebroventricular injection of streptozotocin after 6 weeks of experimental periodontitis induction.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35532618' target='_blank' class='pmid-link'>35532618</a>:</span> <span class='sentence-part'>Protective Effect of L-Arginine in an Animal Model of Alzheimer's Disease Induced by Intra-Hippocampal Injection of AlCl3.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35556434' target='_blank' class='pmid-link'>35556434</a>:</span> <span class='sentence-part'>The streptozotocin (STZ) -induced AD model mimics respiratory problems seen in humans and exhibits neuronal hyperactivity in the nucleus tractus solitarii (nTS), the central integration site for respiratory afferents in the brainstem. AD was induced by intracerebroventricular injection of 2 mg/kg STZ in 6-week old male Sprague Dawley rats.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36271966' target='_blank' class='pmid-link'>36271966</a>:</span> <span class='sentence-part'>AD was induced by an intracerebroventricular (ICV) injection of streptozotocin (STZ).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36438603' target='_blank' class='pmid-link'>36438603</a>:</span> <span class='sentence-part'>Given the promising data on the additive effect of combination therapy with donepezil (Aricept), an acetylcholinesterase inhibitor (AChEI), and regarding the similar neuronal mechanisms through which donepezil (DON) and environmental enrichment (EE) exert their enhancing effects on cognition; we asked whether simultaneous treatment with two paradigms in amyloid-beta-induced AD rats may lead to greater protection against the cognitive impairments than either treatment individually. AD was induced by intrahippocampal injection of amyloid-beta (1-42, 6 MUg), and DON was orally administrated (4 mg/kg) for 21 days.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36442692' target='_blank' class='pmid-link'>36442692</a>:</span> <span class='sentence-part'>The aim of this study was evaluated the effects of 2-(4-(methylthio)phenyl)-3-(3-(piperidin-1-yl)propyl) thiazolidin-4-one (DS12) on memory and neurochemical parameters in a model of AD induced by an intracerebroventricular injection of streptozotocin (STZ).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36927298' target='_blank' class='pmid-link'>36927298</a>:</span> <span class='sentence-part'>In this research, we investigated the neuroprotective and therapeutic effects of Vin through hippocampal synaptic plasticity on a rat's model of Alzheimer's disease (AD) induced by an intracerebroventricular (ICV) injection of beta-amyloid (Abeta).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36982996' target='_blank' class='pmid-link'>36982996</a>:</span> <span class='sentence-part'>This review is aimed at summarizing the effects of dietary supplementation on cognitive decline, neuroinflammation and oxidative stress in AD-like animal models with a focus on neuroinflammation induced by lipopolysaccharide (LPS) injection, which mimics systemic inflammation in animals. Evidence suggests that systemic inflammation, dysregulation of the immune response and the resulting neuroinflammation and neurodegeneration play a significant role in AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37895841' target='_blank' class='pmid-link'>37895841</a>:</span> <span class='sentence-part'>Dapagliflozin/Hesperidin Combination Mitigates Lipopolysaccharide-Induced Alzheimer's Disease in Rats. The aim of this study was to elucidate the potential ameliorative effects of dapagliflozin and/or hesperidin on Alzheimer's disease (AD) induced by lipopolysaccharide (LPS) injection in rats.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37970437' target='_blank' class='pmid-link'>37970437</a>:</span> <span class='sentence-part'>AD was produced by injection of amyloid-beta (1-42, 6 ug) intrahippocampally, and a daily treadmill for 3 consecutive weeks was used for EX animals.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37978479' target='_blank' class='pmid-link'>37978479</a>:</span> <span class='sentence-part'>The groups were pretreated with vehicle and propolis at a dose of 100, 300 and 900 mg/kg body weight for 8 days, then AD-like phenotypes were induced by intracerebroventricular (ICV) injection of Abeta     25-35      . This study aimed to investigate the effect of Brazilian green propolis on cognitive impairment using a mouse model of Alzheimer's disease (AD) induced by intracerebroventricular injection of amyloid beta (Abeta)     25-35      .</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/38091207' target='_blank' class='pmid-link'>38091207</a>:</span> <span class='sentence-part'>We administered Abeta 1-42 oligomers in rats via intracerebroventricular (i.c.v.) injection to induce AD-like conditions.</span></div></div>
<div class='streamlined-assertion'><div class='streamlined-header sticky-relation-header'><span class='label-text'>Subject:</span> <strong>Injection_procedure</strong> <span class='label-text'>Subject CUI:</span> <strong>C1533685</strong> â†’ <span class='label-text predicate-text'>CAUSES</span> â†’ <span class='label-text'>Object:</span> <strong>Alzheimers</strong> <span class='label-text'>Object CUI:</span> <strong>C0002395</strong></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/15151831' target='_blank' class='pmid-link'>15151831</a>:</span> <span class='sentence-part'>CONCLUSION: The differentially displayed proteins in the brain identified between the rats with intrahippocampal amyloid beta injection and control rats may provide further insight into the pathogenesis of Alzheimer's disease and useful clues for developing new drugs for its treatment.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/18687381' target='_blank' class='pmid-link'>18687381</a>:</span> <span class='sentence-part'>The rat model of Alzheimer's disease used in the present study was induced by the intracerebroventricular (ICV) injection of streptozotocin (STZ) using a stereotaxic instrument.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20030829' target='_blank' class='pmid-link'>20030829</a>:</span> <span class='sentence-part'>CONCLUSIONS: These findings indicate efficacy for NPC transplantation in an animal model of AD with effects consistent with cellular actions to attenuate inflammatory reactivity induced by intrahippocampal peptide injection.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20384276' target='_blank' class='pmid-link'>20384276</a>:</span> <span class='sentence-part'>Rats with AD-like cognitive deficiency was induced by injection of ibotenic acid into Nucleus Basalis of Meynert (NBM) bilaterally (5 microg 0.5 microL(-1), each side).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20838863' target='_blank' class='pmid-link'>20838863</a>:</span> <span class='sentence-part'>A nonhuman primate model of Alzheimer's disease generated by intracranial injection of amyloid-beta42 and thiorphan.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20933058' target='_blank' class='pmid-link'>20933058</a>:</span> <span class='sentence-part'>The present work explored the anti-neuroinflammation effects of Ginseng Rb1 in a rat model of Alzheimer disease produced by ventricle injection of Abeta1-42.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21689771' target='_blank' class='pmid-link'>21689771</a>:</span> <span class='sentence-part'>The present study utilized a mouse model of AD induced by intrahippocampal injection of AbetaO (10 MUM) to investigate the effects of Gami-Chunghyuldan (GCD), a standardized multi-herbal medicinal formula, on the presentation of memory deficits and neurohistological pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22235318' target='_blank' class='pmid-link'>22235318</a>:</span> <span class='sentence-part'>The current study was designed to further investigate the protective effect of the RCE on neurogenesis in a rat model of Alzheimer's disease (AD) induced by an intracerebroventricular injection of streptozotocin (STZ), and to determine whether this neuroprotective effect is induced by the antioxidative activity of salidroside.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22562026' target='_blank' class='pmid-link'>22562026</a>:</span> <span class='sentence-part'>METHODS: Two weeks after induction of AD by injection of Amyloid-beta1-40 into CA1 area of rat hippocamp, Y-maze and single-trial passive avoidance tests were used to show deficit of learning and memory abilities.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23061885' target='_blank' class='pmid-link'>23061885</a>:</span> <span class='sentence-part'>This study aimed to show that the rat model of sporadic Alzheimer's disease (sAD) generated by the intracerebroventricular (icv) injection of a sub-diabetogenic dose of streptozotocin (icvSTZ) is characterized by brain mitochondrial abnormalities.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23156675' target='_blank' class='pmid-link'>23156675</a>:</span> <span class='sentence-part'>The intranasal administration of glutamate antibodies in the dose of 300 microg/kg one hour after damage on the level of mRNA expression of Dffb gene which codes caspase-activated DNase which participates in intranucleosome fragmentation of genome DNA in apoptosis was investigated in experimental Alzheimer's disease induced by injection of neurotoxic fragment of beta-amyloid protein Abeta25-35 in Meynert basal magnocellular nuclei on rats.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23244235' target='_blank' class='pmid-link'>23244235</a>:</span> <span class='sentence-part'>We investigated the effect of thalidomide on AD-like cognitive deficits caused by intracerebroventricular injection of streptozotocin (STZ).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23726868' target='_blank' class='pmid-link'>23726868</a>:</span> <span class='sentence-part'>Short-term and long-term treatments with sodium hydrosulfide and/or Tabiano's spa-water significantly protected against impairment in learning and memory in rat models of AD induced by brain injection of beta-amyloid1-40 (Abeta) or streptozotocin, and in an AD mouse model harboring human transgenes APPSwe, PS1M146V and tauP301L (3xTg-AD mice).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24648641' target='_blank' class='pmid-link'>24648641</a>:</span> <span class='sentence-part'>[Purpose] This study examined the effect of the application of transcranial direct current stimulation (tDCS) on neurologic recovery and cognitive function of rats with Alzheimer-like dementia induced by scopolamine injections.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24678498' target='_blank' class='pmid-link'>24678498</a>:</span> <span class='sentence-part'>The rat model of Alzheimer's disease was induced by the intracerebroventricular (ICV) injection of Abeta25-35, using a stereotaxic instrument.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24877042' target='_blank' class='pmid-link'>24877042</a>:</span> <span class='sentence-part'>The rat model of Alzheimer's disease was induced by intracerebroventricular (ICV) injection of streptozotocin (STZ) using a stereotaxic instrument. Treadmill exercise alleviates impairment of spatial learning ability through enhancing cell proliferation in the streptozotocin-induced Alzheimer's disease rats. Decreased cell proliferation with decrement of BDNF and TrkB expressions in the hippocampus were observed in the STZ-induced Alzheimer's disease rats.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25290208' target='_blank' class='pmid-link'>25290208</a>:</span> <span class='sentence-part'>Perindopril, an angiotensin converting enzyme inhibitor, has been reported to improve learning and memory in a mouse or rat model of Alzheimer's disease (AD) induced by injection of beta-amyloid protein.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25714979' target='_blank' class='pmid-link'>25714979</a>:</span> <span class='sentence-part'>This study aimed to investigate the neuroprotective effects of different extract fractions from AGR against Alzheimer disease-like symptoms induced by Amyloid Beta (Abeta) 1-42 intra-hippocampal injection.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25849905' target='_blank' class='pmid-link'>25849905</a>:</span> <span class='sentence-part'>In the present study, we investigated the effects of hippocampal BDNF in a rat model of AD produced by a ventricle injection of amyloid-beta1-42 (Abeta1-42).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25881906' target='_blank' class='pmid-link'>25881906</a>:</span> <span class='sentence-part'>Characterization of Cerebral Damage in a Monkey Model of Alzheimer's Disease Induced by Intracerebroventricular Injection of Streptozotocin.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26166589' target='_blank' class='pmid-link'>26166589</a>:</span> <span class='sentence-part'>OBJECTIVE: To evaluate the effects of Catechin (CAT) on memory acquisition and retrieval in the animal model of sporadic alzheimer's disease (sAD) induced by intracerebroventricular (icv) injection of streptozotocin (STZ) in passive avoidance memory test.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26386305' target='_blank' class='pmid-link'>26386305</a>:</span> <span class='sentence-part'>The selective sigma1 agonist PRE-084, or the non-selective sigma1 drug ANAVEX2-73 was combined with the acetylcholinesterase inhibitor donepezil or the NMDA receptor antagonist memantine in the nontransgenic mouse model of AD-like memory impairments induced by intracerebroventricular injection of oligomeric Abeta25-35 peptide.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26511841' target='_blank' class='pmid-link'>26511841</a>:</span> <span class='sentence-part'>In the present study, we tested PUE in a sporadic AD (SAD) mouse model which was induced by the intracerebroventricular injection of streptozotocin (STZ).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27023127' target='_blank' class='pmid-link'>27023127</a>:</span> <span class='sentence-part'>Intracerebroventricular Injection of Amyloid-beta Peptides in Normal Mice to Acutely Induce Alzheimer-like Cognitive Deficits.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27516988' target='_blank' class='pmid-link'>27516988</a>:</span> <span class='sentence-part'>CONCLUSION: The results indicate that chronic administration of frankincense has the potential to improve dementia type of AD induced by i.c.v injection of streptozotocin in a time-dependent manner.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28101460' target='_blank' class='pmid-link'>28101460</a>:</span> <span class='sentence-part'>AD was induced by the injections of streptozotocin (3mg/kg, bilateral intracerebroventricular) at days 1&amp;3.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28158298' target='_blank' class='pmid-link'>28158298</a>:</span> <span class='sentence-part'>Adult male ddY mice were used in this study, and an animal model of AD was induced by intracerebroventricular (ICV) injection of Abeta1-42.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28255862' target='_blank' class='pmid-link'>28255862</a>:</span> <span class='sentence-part'>Fourty adult male Wistar rats were randomly assigned to 5 groups:(n = 8 rats/group): group 1, control, consumed an ordinary diet, group 2 consumed a HFD for 8 weeks, then received phosphate-buffered saline (PBS) via intrahippocampal (IHP) injection, group 3 consumed HFD for 8 weeks, then received beta-amyloid (Abeta)1-42 via IHP injections to induce AD, group 4 consumed HFD for 8 weeks, then received Abeta1-42, and was treated by thymol (30 mg/kg in sunflower oil) daily for 4 weeks, and group 5 consumed HFD for 8 week, then received Abeta1-42 after what sunflower oil was administered by oral gavage daily for 4 weeks.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28397428' target='_blank' class='pmid-link'>28397428</a>:</span> <span class='sentence-part'>Twelve rats with Alzheimer's disease, induced by STZ injection (3 mg/kg) into both lateral ventricles using a stereotaxic frame (bilaterally ICV-STZ), were divided into 2 groups 5 days after the STZ injection: one treated with rhEPO 5000 (IU/kg/day, i.p.) and the other with 0.9% NaCl (1 mL/kg/day, i.p.) for 2 weeks.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28511119' target='_blank' class='pmid-link'>28511119</a>:</span> <span class='sentence-part'>Hence, A HPLC-QTOF-MS based plasma metabonomics approach was applied to investigate the neuroprotective effects of breviscapine on intracerebroventricular injection of aggregated Abeta 1-42 induced AD mice for the first time in the study.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29104777' target='_blank' class='pmid-link'>29104777</a>:</span> <span class='sentence-part'>These results are fully consistent with the data obtained in animal models of Alzheimer's disease induced by the injection of the beta-amyloid (betaA) fragment 25-35 into the giant-cell nucleus basalis of Meynert or by co-injection of the betaA fragment 25-35 and ibotenic acid into the hippocampus, and the model of ischemia stroke (chronic bilateral occlusion of carotids, 2VO).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29174415' target='_blank' class='pmid-link'>29174415</a>:</span> <span class='sentence-part'>Mucin-type O-glycosylation has been associated with inflammation of brain tissues in AD, thus in this work, we aimed at identifying changes in the glycosylation profile generated by the injection of Abeta25-35 into the CA1 of the hippocampus of rats, using histochemistry with lectins.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29270738' target='_blank' class='pmid-link'>29270738</a>:</span> <span class='sentence-part'>Our previous study has identified that injection of soluble H.pylori filtrate could induce AD-like pathologic changes and cognitive impairment in SD rats.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29493157' target='_blank' class='pmid-link'>29493157</a>:</span> <span class='sentence-part'>This study was aimed to investigate the protective effect and mechanism of beta-asarone on the animal model of Alzheimer's disease(AD) which was induced by intracerebroventricular injection of Abeta1-42 combined cerebral ischemia.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29710724' target='_blank' class='pmid-link'>29710724</a>:</span> <span class='sentence-part'>Homocysteine (Hcy) injection for 14 days was used to induce AD-like pathology. Moringa Oleifera Alleviates Homocysteine-Induced Alzheimer's Disease-Like Pathology and Cognitive Impairments.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29881705' target='_blank' class='pmid-link'>29881705</a>:</span> <span class='sentence-part'>Materials and Methods: Hippocampal injection of amyloid beta (Abeta) was used to induce Alzheimer's disease in male Wistar rats, followed by intra peritoneal administrations of 5 and 10 mg/kg thymoquinone on a daily basis for 4 weeks.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29948724' target='_blank' class='pmid-link'>29948724</a>:</span> <span class='sentence-part'>Here, we evaluated the effect of a 4-week moderate treadmill exercise on spatial memory via central and peripheral Abeta clearance mechanisms following developed AD-like neuropathology induced by intra-hippocampal Abeta1-42 injection in male Wistar rats.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30178892' target='_blank' class='pmid-link'>30178892</a>:</span> <span class='sentence-part'>The protective effect of betulinic acid on microvascular responsivity and protein expression in alzheimer disease induced by cerebral micro-injection of beta-amyloid and streptozotocin.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30412728' target='_blank' class='pmid-link'>30412728</a>:</span> <span class='sentence-part'>In our study, model mice with AD induced by intracerebroventricular injection of Abeta1-42 were used to determine the role of TEC on memory retrieval.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30701598' target='_blank' class='pmid-link'>30701598</a>:</span> <span class='sentence-part'>This paper aims to investigate the effects of KF on cognitive function impairment and neurodegeneration in the mouse model of Alzheimer's disease induced by intracerebroventricular (ICV) injection of Abeta1-42 .</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30760053' target='_blank' class='pmid-link'>30760053</a>:</span> <span class='sentence-part'>We investigated the effects of different doses of hCG on hCG receptor density in the prefrontal cortex and cerebellum in a rat model of STZ-induced AD. Administration of hCG ameliorated the lowered density of hCG receptor-ir neurons in the cerebellum and prefrontal cortex in STZ-induced AD rats. AD was induced by intracerebroventricular injection of 3 mg/kg STZ.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30814820' target='_blank' class='pmid-link'>30814820</a>:</span> <span class='sentence-part'>Conclusion: Aerobic and resistance exercise could improve recognition memory and decrease AChE activity in Abeta-induced AD in rats. AD was induced by intracerebroventricular injection of Abeta25-35 peptide.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30822517' target='_blank' class='pmid-link'>30822517</a>:</span> <span class='sentence-part'>Herein, we investigated the neurogenesis potential of quercetin in a rat model of Alzheimer's disease induced by amyloid-beta injection.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31325424' target='_blank' class='pmid-link'>31325424</a>:</span> <span class='sentence-part'>This study investigated the neuroprotective effects of curcumin loaded lipid-core nanocapsules (LNC) in a model of Alzheimer's disease (AD) induced by intracerebroventricular injections of beta-amyloid1-42 (Abeta1-42) peptide in aged female mice, and compared these effects with those from free curcumin.</span></div></div>
<div class='streamlined-assertion'><div class='streamlined-header sticky-relation-header'><span class='label-text'>Subject:</span> <strong>Injury</strong> <span class='label-text'>Subject CUI:</span> <strong>C0175677</strong> â†’ <span class='label-text predicate-text'>CAUSES</span> â†’ <span class='label-text'>Object:</span> <strong>Alzheimers</strong> <span class='label-text'>Object CUI:</span> <strong>C0002395</strong></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/11462768' target='_blank' class='pmid-link'>11462768</a>:</span> <span class='sentence-part'>The amyloid beta-peptides have been implicated in the excitotoxic mechanism of neuronal injury in the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/12099698' target='_blank' class='pmid-link'>12099698</a>:</span> <span class='sentence-part'>Transforming growth factor-beta-1 (TGF-beta), a key regulator of the brain responses to injury and inflammation, has been implicated in upregulating the expression of the Alzheimer amyloid precursor protein (APP) and Alzheimer's disease (AD) pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/16159194' target='_blank' class='pmid-link'>16159194</a>:</span> <span class='sentence-part'>Peroxynitrite (ONOO(-)), formed from the reaction of superoxide ((*)O(2)(-)) and nitric oxide ((*)NO), induces cellular and tissue injury, resulting in several human diseases such as stroke, Alzheimer's disease, and atherosclerosis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/16355213' target='_blank' class='pmid-link'>16355213</a>:</span> <span class='sentence-part'>Angiogenesis factors, especially vascular endothelial growth factor, are now known to have roles in the birth of new neurons (neurogenesis), the prevention or mitigation of neuronal injury (neuroprotection), and the pathogenesis of stroke, Alzheimer's disease and motor neuron disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/16534775' target='_blank' class='pmid-link'>16534775</a>:</span> <span class='sentence-part'>CONCLUSION: This study showed that oxidative injuries could be involved in the pathogenesis of AD, as well as indicating that some antioxidant might be associated with the cognitive functions in AD. OBJECTIVES: It has been suggested that oxidative injuries have an important role in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17602566' target='_blank' class='pmid-link'>17602566</a>:</span> <span class='sentence-part'>ONOO- induces cellular and tissue injury, resulting in several human diseases such as Alzheimer's disease, atherosclerosis, and stroke.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/19950527' target='_blank' class='pmid-link'>19950527</a>:</span> <span class='sentence-part'>CONCLUSION: R. rosea extract can protect rats against cognitive deficits, neuronal injury and oxidative stress induced by intracerebroventricular injection of streptozotocin, and may be used as a potential agent in treatment of neurodegenerative diseases such as AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22540007' target='_blank' class='pmid-link'>22540007</a>:</span> <span class='sentence-part'>In addition, DG could alleviate lipid peroxidation and partially restore the mitochondrial function in Abeta(1-42)-induced AD mice. Furthermore, DG significantly decreased the escape latency and search distance and increased the target crossing times of Abeta(1-42)-induced AD mice in the Morris water maze test. Therefore, these results demonstrated that DG could attenuate Abeta(1-42)-induced neuronal injury by preventing mitochondrial dysfunction and oxidative stress and improved cognitive impairment in Abeta(1-42)-induced AD mice, indicating that DG exerted potential beneficial effects on AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23877934' target='_blank' class='pmid-link'>23877934</a>:</span> <span class='sentence-part'>Increasing evidence has demonstrated that white matter (WM) disruptions, due to the injury of the axon and myelin, play an important role in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25362039' target='_blank' class='pmid-link'>25362039</a>:</span> <span class='sentence-part'>BACKGROUND: It has been suggested that oxidative injuries have a role in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26166438' target='_blank' class='pmid-link'>26166438</a>:</span> <span class='sentence-part'>Studies have revealed that astrocyte response to gross tissue damaging injury leads to anisomorphic astrogliosis reinforcing a cascade of events, eventually increasing the pathogenesis of AD and many other neurodegenerative disorders.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26221414' target='_blank' class='pmid-link'>26221414</a>:</span> <span class='sentence-part'>In this review, we will discuss evidence that supports the importance of mitochondrial injury in the pathogenesis of AD and how studying these mechanisms could lead us to suggest new targets for diagnostic and therapeutic intervention against neurodegeneration.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27793193' target='_blank' class='pmid-link'>27793193</a>:</span> <span class='sentence-part'>Recent diffusion tensor imaging studies in AD suggest that increased diffusion in the fornix secondary to p-MAPT-related axonal injury could serve as a predictive biomarker of the risk of disease progression.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28702899' target='_blank' class='pmid-link'>28702899</a>:</span> <span class='sentence-part'>INTRODUCTION: Oxidative injury to the brain and aging are theoretical co-causes of Alzheimer's Disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29630554' target='_blank' class='pmid-link'>29630554</a>:</span> <span class='sentence-part'>While plasma NFL may not reflect NAL in individuals with normal global cognition, the current observations indicate that onset of axonal injury, reflected by increased plasma NFL, within the preclinical phase of AD may contribute to the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29978424' target='_blank' class='pmid-link'>29978424</a>:</span> <span class='sentence-part'>Pretreatment of neurons with Klotho protein can avoid neuronal injury related to the toxic amyloid-beta and glutamate, centrally related to the pathogenesis of Alzheimer's disease (AD), in order that Klotho protein could play a neuroprotective role in AD patients.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/3561662' target='_blank' class='pmid-link'>3561662</a>:</span> <span class='sentence-part'>The results do not support the hypothesized roles of blood-brain barrier disruption or of immunologically-mediated injury of the central nervous system in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/7777136' target='_blank' class='pmid-link'>7777136</a>:</span> <span class='sentence-part'>Increasing evidence supports the involvement of amyloid beta-peptide (A beta) and an excitotoxic mechanism of neuronal injury in the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/9883847' target='_blank' class='pmid-link'>9883847</a>:</span> <span class='sentence-part'>Excitotoxicity, a form of neuronal injury in which excessive activation of glutamate receptors results in cellular calcium overload, has been implicated in the pathogenesis of Alzheimer disease (AD), although direct evidence is lacking.</span></div></div>
<div class='streamlined-assertion'><div class='streamlined-header sticky-relation-header'><span class='label-text'>Subject:</span> <strong>Insulin_Resistance</strong> <span class='label-text'>Subject CUI:</span> <strong>C0021655</strong> â†’ <span class='label-text predicate-text'>CAUSES</span> â†’ <span class='label-text'>Object:</span> <strong>Alzheimers</strong> <span class='label-text'>Object CUI:</span> <strong>C0002395</strong></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17049785' target='_blank' class='pmid-link'>17049785</a>:</span> <span class='sentence-part'>Insulin resistance is central to Type II diabetes and is also implicated in the pathogenesis of Alzheimer's Disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17982898' target='_blank' class='pmid-link'>17982898</a>:</span> <span class='sentence-part'>Central insulin resistance as a trigger for sporadic Alzheimer-like pathology: an experimental approach.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/19705099' target='_blank' class='pmid-link'>19705099</a>:</span> <span class='sentence-part'>Accordingly, metabolic and cognitive disorders such as obesity, type 2 diabetes mellitus and Alzheimer's disease are associated with resistance of central nervous structures to the effects of insulin, which may derive from genetic polymorphisms as well as from long-term exposure to excess amounts of circulating insulin due to peripheral insulin resistance.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21435176' target='_blank' class='pmid-link'>21435176</a>:</span> <span class='sentence-part'>Possible implications of insulin resistance and glucose metabolism in Alzheimer's disease pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22201977' target='_blank' class='pmid-link'>22201977</a>:</span> <span class='sentence-part'>Growing evidence supports roles for brain insulin and insulin-like growth factor (IGF) resistance and metabolic dysfunction in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22610992' target='_blank' class='pmid-link'>22610992</a>:</span> <span class='sentence-part'>Given the potential relationship between insulin resistance and pathogenesis of Alzheimer's disease (AD) in elderly life, we investigated the relationship between perinatal DEHP exposure and AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24333407' target='_blank' class='pmid-link'>24333407</a>:</span> <span class='sentence-part'>Impaired insulin signaling and insulin resistance in brain have been found to play an important role in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25755673' target='_blank' class='pmid-link'>25755673</a>:</span> <span class='sentence-part'>CONCLUSIONS: The extracts of moderate and severe red peppers were found to prevent the memory deficit and exacerbation of insulin resistance by blocking tau phosphorylation and beta-amyloid accumulation in diabetic rats with experimentally induced Alzheimer's-like dementia.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26136993' target='_blank' class='pmid-link'>26136993</a>:</span> <span class='sentence-part'>In conclusion, the expression of BACE1 in the brain tissue of insulin-resistant rats increased, and IR was indicated to participate in the pathogenesis of AD. The aim of this study was to investigate the expression of beta-site APP-cleaving enzyme 1 (BACE1) in the hippocampal tissue of an insulin-resistant rat model, and thereby explore the roles of BACE1 and insulin resistance (IR) in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26240147' target='_blank' class='pmid-link'>26240147</a>:</span> <span class='sentence-part'>Insulin resistance and neuroinflammation have emerged as two likely key contributors in the pathogenesis of Alzheimer disease (AD), especially in those sporadic AD cases compromised by diabetes or cardiovascular disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26268336' target='_blank' class='pmid-link'>26268336</a>:</span> <span class='sentence-part'>Impaired brain insulin signaling or brain insulin resistance and its role in the molecular pathogenesis of sporadic AD have been demonstrated.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27466310' target='_blank' class='pmid-link'>27466310</a>:</span> <span class='sentence-part'>Deficits in glucose, impaired insulin signalling and brain insulin resistance are common in the pathogenesis of Alzheimer's disease (AD); therefore, some scholars even called AD type 3 diabetes mellitus.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27810390' target='_blank' class='pmid-link'>27810390</a>:</span> <span class='sentence-part'>Previous studies in high-fat diet-induced AD animal models have shown that brain insulin resistance in these animals leads to the accumulation of amyloid beta (Abeta) and the reduction in GSK-3beta phosphorylation, which promotes tau phosphorylation to cause AD. The aim of this study was to investigate the ability of agmatine to treat AD induced by brain insulin resistance. Agmatine ameliorates type 2 diabetes induced-Alzheimer's disease-like alterations in high-fat diet-fed mice via reactivation of blunted insulin signalling.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27988872' target='_blank' class='pmid-link'>27988872</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) should be regarded as a degenerative metabolic disease caused by brain insulin resistance and deficiency, and overlapping with the molecular, biochemical, pathophysiological, and metabolic dysfunctions in diabetes mellitus, non-alcoholic fatty liver disease, and metabolic syndrome.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29132997' target='_blank' class='pmid-link'>29132997</a>:</span> <span class='sentence-part'>AIMS: Diabetes mellitus (DM) and impairments of glucose metabolism and insulin resistance in the brain have been suggested as a likely etiology of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29163128' target='_blank' class='pmid-link'>29163128</a>:</span> <span class='sentence-part'>In this review, we will discuss insulin resistance as a contributing factor to the pathogenesis of AD, as well as the metabolic and bioenergetic disruptions linking insulin resistance and AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29712510' target='_blank' class='pmid-link'>29712510</a>:</span> <span class='sentence-part'>DISCUSSION: GCBE exerted neuroprotective effects against IR-induced AD mediated by alleviating IR and modulating brain insulin signaling cascade.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29951404' target='_blank' class='pmid-link'>29951404</a>:</span> <span class='sentence-part'>Disruption of insulin signaling cascade and insulin resistance can induce AD; and central insulin resistance causes systemic alterations in serum insulin, FBS levels, and lipid profile.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30364261' target='_blank' class='pmid-link'>30364261</a>:</span> <span class='sentence-part'>Increased risks for Alzheimer's disease (AD) are a well-recognized consequence of diabetes, insulin resistance (IR), and hyperinsulinemia.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30804755' target='_blank' class='pmid-link'>30804755</a>:</span> <span class='sentence-part'>We further highlight the deleterious consequences of Tau pathology-induced insulin resistance to the brain and/or peripheral tissues, suggesting that these are key events mediating cognitive decline in Alzheimer's disease (AD) and other tauopathies.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32829453' target='_blank' class='pmid-link'>32829453</a>:</span> <span class='sentence-part'>In this narrative review, we provide an overview of gut microbiota and their dysregulation in the pathogenesis of AD. Although a causal relationship between gut dysbiosis and neural dysfunction remains elusive, emerging evidence indicates that gut dysbiosis may promote amyloid-beta aggregation, neuroinflammation, oxidative stress, and insulin resistance in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33164543' target='_blank' class='pmid-link'>33164543</a>:</span> <span class='sentence-part'>In this study, the probable role of insulin resistance in the pathogenesis of AD was investigated in patients with Type 2 Diabetes Mellitus (T2DM). OBJECTIVE: Recent evidence suggests that insulin resistance may play an important role in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33552476' target='_blank' class='pmid-link'>33552476</a>:</span> <span class='sentence-part'>This model predicts that any condition leading to an increase of [Ca      2+      ]      i       may trigger central insulin resistance and explains why central insulin resistance is implicated in the pathogenesis of AD, with which glutamate excitotoxicity is a comorbid condition.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33816504' target='_blank' class='pmid-link'>33816504</a>:</span> <span class='sentence-part'>Insulin resistance is a kind of pathological state, which is important in the pathogeneses of type 2 diabetes mellitus (T2DM), gestational diabetes mellitus and Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34524376' target='_blank' class='pmid-link'>34524376</a>:</span> <span class='sentence-part'>Disturbances in the action of GSK-3 enzyme may leads to various disease conditions that include insulin resistance leading to diabetes, neurological disease like Alzheimer's disease and cancer.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34609116' target='_blank' class='pmid-link'>34609116</a>:</span> <span class='sentence-part'>The complications that are discussed in this article are diabetic nephropathy, diabetes induced cardiovascular disease, diabetic neuropathy, Diabetic Foot Ulcer (DFU) and Alzheimer's disease. The progression of AD can be due to the change in DNA methylation of CLOCK gene, followed with worsening of AD by APOE4 gene due to dyslipidaemia condition in T2DM patients. Insulin resistance is also a factor that contributes to pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34686782' target='_blank' class='pmid-link'>34686782</a>:</span> <span class='sentence-part'>CONCLUSION: The present paper proposes the hypothesis that hypercoagulation might amplify MetS associated insulin resistance, neuroinflammation, BBB disruption, and amyloid beta accumulation which eventually leads to AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35533773' target='_blank' class='pmid-link'>35533773</a>:</span> <span class='sentence-part'>Therefore, activation of alpha7nAChR through GTS-21 might be the potential target for the amelioration of central insulin resistance induced AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36118711' target='_blank' class='pmid-link'>36118711</a>:</span> <span class='sentence-part'>Overall, this pattern is reminiscent of neural abnormalities previously observed in Alzheimer's disease, suggesting that similar neurobiological mechanisms, secondary to insulin resistance and manifesting as NVC alterations, might be developing in T2DM pathology.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36162508' target='_blank' class='pmid-link'>36162508</a>:</span> <span class='sentence-part'>Taken together, our results suggest that CX3CL1-ICD may have translational potential for neuroprotection in Alzheimer's disease and for disorders resulting from insulin resistance.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36362376' target='_blank' class='pmid-link'>36362376</a>:</span> <span class='sentence-part'>The biological plausibility of the link between high adiposity, insulin resistance, and dementia is central for understanding AD etiology, and to form bases for prevention efforts to decrease the disease burden.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36404813' target='_blank' class='pmid-link'>36404813</a>:</span> <span class='sentence-part'>Objectives: Glucose intolerance and insulin resistance are hallmarks of metabolic syndrome and lead to Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36626931' target='_blank' class='pmid-link'>36626931</a>:</span> <span class='sentence-part'>In humans, central insulin resistance is at least part of the formal pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36630734' target='_blank' class='pmid-link'>36630734</a>:</span> <span class='sentence-part'>PP2Calpha aggravates neuronal insulin resistance leading to AD-like phenotype in vitro. Our study thereby demonstrates escalation of hyperinsulinemia mediated neuronal insulin resistance leading to AD-like pathogenesis by PP2Calpha in vitro and hints a novel molecule, PP2Calpha, linking AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37985011' target='_blank' class='pmid-link'>37985011</a>:</span> <span class='sentence-part'>In conclusion, brain insulin resistance could lead to AD and vice versa.</span></div></div>
<div class='streamlined-assertion'><div class='streamlined-header sticky-relation-header'><span class='label-text'>Subject:</span> <strong>Intestinal_Microbiome</strong> <span class='label-text'>Subject CUI:</span> <strong>C2985398</strong> â†’ <span class='label-text predicate-text'>CAUSES</span> â†’ <span class='label-text'>Object:</span> <strong>Alzheimers</strong> <span class='label-text'>Object CUI:</span> <strong>C0002395</strong></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32319677' target='_blank' class='pmid-link'>32319677</a>:</span> <span class='sentence-part'>However, studies related to gut microbiota have been mostly restricted to comparisons of amyloid deposits, while investigations on neurobehavioral changes and the pathogenesis of AD are limited.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32829453' target='_blank' class='pmid-link'>32829453</a>:</span> <span class='sentence-part'>In this narrative review, we provide an overview of gut microbiota and their dysregulation in the pathogenesis of AD. Although a causal relationship between gut dysbiosis and neural dysfunction remains elusive, emerging evidence indicates that gut dysbiosis may promote amyloid-beta aggregation, neuroinflammation, oxidative stress, and insulin resistance in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32876860' target='_blank' class='pmid-link'>32876860</a>:</span> <span class='sentence-part'>Roles of Gut Microbiota in Pathogenesis of Alzheimer's Disease and Therapeutic Effects of Chinese Medicine. Hence, the purpose of this review is to outline the roles of GM and its core metabolites in the pathogenesis of AD. Roles of Gut Microbiota in Pathogenesis of Alzheimer's Disease and Therapeutic Effects of Chinese Medicine.Alzheimer's disease (AD) is the most common neurodegenerative disease characterized by progressive cognitive impairment.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33814442' target='_blank' class='pmid-link'>33814442</a>:</span> <span class='sentence-part'>Recent studies showed that gut microbiota might play an important role in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33829390' target='_blank' class='pmid-link'>33829390</a>:</span> <span class='sentence-part'>This review discusses the gut microbiota and epigenetics connection in the pathogenesis of AD and aims to highlight vast opportunities for diagnosis and therapeutics of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33916001' target='_blank' class='pmid-link'>33916001</a>:</span> <span class='sentence-part'>Recent studies suggested that gut microbiota can influence AD progression; however, potential mechanisms linking the gut microbiota with AD pathogenesis remain obscure. Alzheimer's disease (AD), a progressive neurodegenerative disorder characterized by memory loss and cognitive decline, is a major cause of death and disability among the older population.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34365962' target='_blank' class='pmid-link'>34365962</a>:</span> <span class='sentence-part'>As supported by a growing amount of evidence in recent years, the gut microbiota plays an important role in the pathogenesis of Alzheimer's disease through the brain-gut-microbiota axis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34384375' target='_blank' class='pmid-link'>34384375</a>:</span> <span class='sentence-part'>This study aims to investigate metabolic output of the dysbiosis of GMB in AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34411603' target='_blank' class='pmid-link'>34411603</a>:</span> <span class='sentence-part'>The initial stage of the involvement of gut microbiota in the pathogenesis of AD may be the dysfunction of the blood-brain barrier (BBB).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34520319' target='_blank' class='pmid-link'>34520319</a>:</span> <span class='sentence-part'>Finally, we discuss the possible interactions between SCRD and GM in AD pathogenesis, as well as several methodological improvements that are necessary for future research.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34735921' target='_blank' class='pmid-link'>34735921</a>:</span> <span class='sentence-part'>Recently, the roles of short-chain fatty acids (SCFAs), the main metabolites generated by fermentation of dietary fiber by gut microbiota, in the pathogenesis of AD have attracted considerable interest.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35070441' target='_blank' class='pmid-link'>35070441</a>:</span> <span class='sentence-part'>This article aims to review the leading-edge knowledge concerning potential roles of GM in AD pathogenesis and of probiotics in its treatment and prevention.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35213369' target='_blank' class='pmid-link'>35213369</a>:</span> <span class='sentence-part'>Gut Microbiota as a Hidden Player in the Pathogenesis of Alzheimer's Disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35248147' target='_blank' class='pmid-link'>35248147</a>:</span> <span class='sentence-part'>CONCLUSIONS: There is strong increasing evidence supporting a role for the gut microbiome in the pathogenesis of Alzheimer's disease, including effects on synaptic dysfunction and neuroinflammation, which contribute to cognitive decline.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35440320' target='_blank' class='pmid-link'>35440320</a>:</span> <span class='sentence-part'>The Role of the Gut Microbiota and Microbial Metabolites in the Pathogenesis of Alzheimer's Disease. As proposed by scientists and supported by a growing amount of evidence in recent years, the gut microbiota plays an important role in the pathogenesis of Alzheimer's disease via a constant bidirectional communication through the brain-gut-microbiota axis which is a multifunctional network involving the nervous system and the peripheral circulatory system.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35538829' target='_blank' class='pmid-link'>35538829</a>:</span> <span class='sentence-part'>Here we reviewed some of the key findings that have shown the function of Abeta peptide, oxidative stress, free radical damage Triggering Receptors Expressed on Myeloid Cells 2 (TREM2), Nitric Oxide (NO), and gut microbiota in the aetiology of AD. RESULTS: Findings suggested that channels of free radicals, such as transition metal accumulation, and genetic factors are mainly accountable for the redox imbalance that assist to understand better the pathogenesis of AD and incorporate new therapeutic approaches.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35634849' target='_blank' class='pmid-link'>35634849</a>:</span> <span class='sentence-part'>Accumulating evidence from experimental and animal studies also show potential effects of gut microbiome on AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35754271' target='_blank' class='pmid-link'>35754271</a>:</span> <span class='sentence-part'>BACKGROUND: Dysbiosis of gut microbiota has been reported to be enrolled in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35992591' target='_blank' class='pmid-link'>35992591</a>:</span> <span class='sentence-part'>Aims: To explore the possible pathways of the involvement of gut microbiota in AD pathogenesis through metabolites and to identify new AD biomarkers.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36047913' target='_blank' class='pmid-link'>36047913</a>:</span> <span class='sentence-part'>Neuroinflammation and intestinal microbiota cause pathological progression of Alzheimer's disease (AD), leading to neurodegeneration and cognitive decline.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36578263' target='_blank' class='pmid-link'>36578263</a>:</span> <span class='sentence-part'>Evidence that the gut microbiota plays a key role in the pathogenesis of Alzheimer's disease is already un-ravelling.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36683147' target='_blank' class='pmid-link'>36683147</a>:</span> <span class='sentence-part'>The current study focused on uncovering the potential interactions among gut-derived Abeta in aging, gut microbiota, and AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36736919' target='_blank' class='pmid-link'>36736919</a>:</span> <span class='sentence-part'>Growing evidence suggests that the gut microbiome (GM) plays a pivotal role in the pathogenesis of AD through the microbiota-gut-brain axis (MGB).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36914812' target='_blank' class='pmid-link'>36914812</a>:</span> <span class='sentence-part'>Our findings demonstrate that gut microbiota mainly modulate the mutual transformation of microglial subtypes, which may lead to new insights into the pathogenesis of AD and MDD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37511841' target='_blank' class='pmid-link'>37511841</a>:</span> <span class='sentence-part'>Convincing evidence has demonstrated the roles of GM in the pathogenesis of AD, which are partly mediated by modified microglial activity in the brain.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/38031265' target='_blank' class='pmid-link'>38031265</a>:</span> <span class='sentence-part'>SCOPE: Recent studies have highlighted the vital role of gut microbiota in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/38452948' target='_blank' class='pmid-link'>38452948</a>:</span> <span class='sentence-part'>Recently, the role of gut microbiota has been implicated in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/38479921' target='_blank' class='pmid-link'>38479921</a>:</span> <span class='sentence-part'>Recent research has revealed that the gut microbiota (GM) plays an important role in the pathogenesis of AD through the microbiota-gut-brain axis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/38606018' target='_blank' class='pmid-link'>38606018</a>:</span> <span class='sentence-part'>Conclusion: Dietary vitamin A supplementation modulates the gut microbiota, intestinal permeability, inflammatory factors, and Abeta protein formation, offering insights into the pathogenesis of AD and potential therapeutic avenues for further exploration.</span></div></div>
<div class='streamlined-assertion'><div class='streamlined-header sticky-relation-header'><span class='label-text'>Subject:</span> <strong>Ions</strong> <span class='label-text'>Subject CUI:</span> <strong>C0022023</strong> â†’ <span class='label-text predicate-text'>CAUSES</span> â†’ <span class='label-text'>Object:</span> <strong>Alzheimers</strong> <span class='label-text'>Object CUI:</span> <strong>C0002395</strong></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/10093929' target='_blank' class='pmid-link'>10093929</a>:</span> <span class='sentence-part'>Role of free radicals and metal ions in the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/16267663' target='_blank' class='pmid-link'>16267663</a>:</span> <span class='sentence-part'>Two of the defining hallmarks of Alzheimer's disease (AD) are deposits of the beta-amyloid peptide, Abeta, and the generation of reactive oxygen species, both of which may be due to the Abeta peptide coordinating metal ions.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/18289347' target='_blank' class='pmid-link'>18289347</a>:</span> <span class='sentence-part'>There is evidence that binding of metal ions like Zn2+ and Cu2+ to amyloid beta-peptides (Abeta) may contribute to the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/19540003' target='_blank' class='pmid-link'>19540003</a>:</span> <span class='sentence-part'>As for aluminum, a role for this ion in AD pathogenesis is still controversial.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/19808086' target='_blank' class='pmid-link'>19808086</a>:</span> <span class='sentence-part'>AIM OF THE STUDY: To determine the effect of alcoholic extract of Bacopa monnieri on cognitive function and neurodegeneration in animal model of Alzheimer's disease induced by ethylcholine aziridinium ion (AF64A).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21209855' target='_blank' class='pmid-link'>21209855</a>:</span> <span class='sentence-part'>The metals hypothesis implicates redox-active copper ions in the pathogenesis of AD and the Cu(2+) coordination of various Abeta peptides has been widely studied.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21280585' target='_blank' class='pmid-link'>21280585</a>:</span> <span class='sentence-part'>The role of metal ions in Alzheimer's disease etiology is unresolved.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22452395' target='_blank' class='pmid-link'>22452395</a>:</span> <span class='sentence-part'>Abnormal interactions of Cu and Zn ions with the amyloid beta (Abeta) peptide are proposed to play an important role in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23043377' target='_blank' class='pmid-link'>23043377</a>:</span> <span class='sentence-part'>The copper ion, Cu(2+), is found at high concentrations in plaques, but its role in AD etiology is unclear.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23416043' target='_blank' class='pmid-link'>23416043</a>:</span> <span class='sentence-part'>Several lines of evidence have supported the potential involvement of metal ions in the etiology of Alzheimer's Disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23506614' target='_blank' class='pmid-link'>23506614</a>:</span> <span class='sentence-part'>Herein, we present current understanding on the roles of Abeta, tau, and metal ions, placing equal emphasis on each of these proposed features, as well as their inter-relationships in AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23793644' target='_blank' class='pmid-link'>23793644</a>:</span> <span class='sentence-part'>Abeta aggregation, possibly modulated by metal ions, is now considered as an important factor in AD aetiology.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23841511' target='_blank' class='pmid-link'>23841511</a>:</span> <span class='sentence-part'>The interaction of Cu(II) and Zn(II) ions with amyloid-beta (Abeta) plays an important role in the etiology of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24954589' target='_blank' class='pmid-link'>24954589</a>:</span> <span class='sentence-part'>Disbalance of zinc (Zn2+) and copper (Cu2+) ions in the central nervous system is involved in the pathogenesis of numerous neurodegenerative disorders such as multisystem atrophy, amyotrophic lateral sclerosis, Creutzfeldt-Jakob disease, Wilson-Konovalov disease, Alzheimer's disease, and Parkinson's disease. Analysis of the literature suggests that the main factors of AD and PD pathogenesis (oxidative stress, structural disorders and aggregation of proteins, mitochondrial dysfunction, energy deficiency) that initiate a cascade of events resulting finally in the dysfunction of neuronal networks are mediated by the disbalance of Zn2+ and Cu2+.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24970207' target='_blank' class='pmid-link'>24970207</a>:</span> <span class='sentence-part'>Metal ions, including copper and zinc, have been implicated in the pathogenesis of Alzheimer's disease through a variety of mechanisms including increased amyloid-beta affinity and redox effects.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25014537' target='_blank' class='pmid-link'>25014537</a>:</span> <span class='sentence-part'>Revealing molecular level details of subcomponents in metal ion coordination is critical in understanding the role of metal ions in Alzheimer's disease etiology.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25051063' target='_blank' class='pmid-link'>25051063</a>:</span> <span class='sentence-part'>Dysfunctional interaction of amyloid-beta (Abeta) with excess metal ions is proved to be related to the etiology of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25633876' target='_blank' class='pmid-link'>25633876</a>:</span> <span class='sentence-part'>Metal ions may play a role in the etiology of neurodegenerative disorders such as AD, and in this work we explore the metal ion induced folding and aggregation of Bri2-23 using Hg(ii) and Ag(i) as spectroscopic probes with structural and ligand preferences similar to those of Cu(i), while not displaying redox activity under the experimental conditions.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25968625' target='_blank' class='pmid-link'>25968625</a>:</span> <span class='sentence-part'>Dysfunctional interactions of amyloid-beta (Abeta) with Zn and Cu ions are proved to be related to the etiology of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27044837' target='_blank' class='pmid-link'>27044837</a>:</span> <span class='sentence-part'>Misbalance of zinc (Zn(2+)) ions in the central nervous system is involved in the pathogenesis of numerous neurodegenerative disorders such as Alzheimer's disease, Depression, and Epilepsy.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27591874' target='_blank' class='pmid-link'>27591874</a>:</span> <span class='sentence-part'>Al(3+) ions are the most probable etiological cause of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27591943' target='_blank' class='pmid-link'>27591943</a>:</span> <span class='sentence-part'>Dysfunctional interaction of amyloid-beta (Abeta) with excess metal ions is proved to be related to the etiology of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29111371' target='_blank' class='pmid-link'>29111371</a>:</span> <span class='sentence-part'>The accumulation of the extracellular beta-amyloid (Abeta) aggregates with metal ions in conjunction with reactive oxygen species (ROS) is closely related to the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29596976' target='_blank' class='pmid-link'>29596976</a>:</span> <span class='sentence-part'>Abnormal interaction of amyloid-beta peptide (Abeta) and metal ions is proved to be related to the etiology of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30882825' target='_blank' class='pmid-link'>30882825</a>:</span> <span class='sentence-part'>Copper ions have high relevance to AD pathogenesis, causing Cu(ii)-mediated Abeta aggregation and oxidative damage to neuronal cells.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32261634' target='_blank' class='pmid-link'>32261634</a>:</span> <span class='sentence-part'>Metal ions play an important role in amyloid aggregation and neurotoxicity in the AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32266063' target='_blank' class='pmid-link'>32266063</a>:</span> <span class='sentence-part'>Current understanding of metal ions in the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33617717' target='_blank' class='pmid-link'>33617717</a>:</span> <span class='sentence-part'>The high concentration of zinc metal ions in Abeta aggregations is one of the most cited hallmarks of Alzheimer's disease (AD), and several substantial pieces of evidence emphasize the key role of zinc metal ions in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34299316' target='_blank' class='pmid-link'>34299316</a>:</span> <span class='sentence-part'>In addition, since toxic aggregates of amyloid-beta (Abeta) have been proposed as one of the major causes of the disease, the mechanism of clearing Abeta is also required to be investigated to reveal the etiology of AD clearly. Dyshomeostasis of these redox-active metal ions in the brain could cause Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36082494' target='_blank' class='pmid-link'>36082494</a>:</span> <span class='sentence-part'>Aggregation and fibrillation of beta-amyloid peptides (Abeta) as well as accumulation of toxic metal ions have been believed to be the central events to cause Alzheimer's disease (AD).</span></div></div>
<div class='streamlined-assertion'><div class='streamlined-header sticky-relation-header'><span class='label-text'>Subject:</span> <strong>Iron</strong> <span class='label-text'>Subject CUI:</span> <strong>C0302583</strong> â†’ <span class='label-text predicate-text'>CAUSES</span> â†’ <span class='label-text'>Object:</span> <strong>Alzheimers</strong> <span class='label-text'>Object CUI:</span> <strong>C0002395</strong></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/11232594' target='_blank' class='pmid-link'>11232594</a>:</span> <span class='sentence-part'>This furthers the evidence that redox-active iron and subsequent Fenton reaction generating reactive oxygen are critical factors in the pathogenesis of AD. Multiple lines of evidence indicate that oxidative stress is an integral component of the pathogenesis of Alzheimer disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/16122736' target='_blank' class='pmid-link'>16122736</a>:</span> <span class='sentence-part'>Excess of iron in the brain has been implicated in the pathogenesis of several human neurodegenerative diseases, for example Alzheimer's disease and Parkinson's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17029598' target='_blank' class='pmid-link'>17029598</a>:</span> <span class='sentence-part'>Hypercholesterolemia is a potential trigger of Alzheimer's disease, and is thought to increase brain levels of beta-amyloid (Abeta) and iron.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17408857' target='_blank' class='pmid-link'>17408857</a>:</span> <span class='sentence-part'>The decrease in loosely bound iron in mild-moderate AD patients may be associated with myelin breakdown seen in the beginning stages of AD and implicates that iron dysregulation is an early event in AD pathogenesis. Accumulating evidence implicates a role for altered iron and copper metabolism in the pathogenesis of neurodegenerative disorders such as Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17628213' target='_blank' class='pmid-link'>17628213</a>:</span> <span class='sentence-part'>Iron is a reactive oxygen species and has been implicated in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/18376063' target='_blank' class='pmid-link'>18376063</a>:</span> <span class='sentence-part'>Recent studies also point to redox active metals such as iron, copper and zinc in mediating oxidative stress in AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/19195795' target='_blank' class='pmid-link'>19195795</a>:</span> <span class='sentence-part'>Body iron stores that increase with age could be pivotal to AD pathogenesis and progression. This communication explores the temporal link between the age-associated increase in body iron stores and the age-related incidence of Alzheimer's disease (AD), the most prevalent cause of senile dementia.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21303349' target='_blank' class='pmid-link'>21303349</a>:</span> <span class='sentence-part'>Despite the crucial role of redox active metals like copper and iron in central biological reactions, their elevated levels are involved in the pathogenesis of Alzheimer's Disease (AD). Iron, copper, and zinc are some of the metals, which intensify this process and contribute for the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21514009' target='_blank' class='pmid-link'>21514009</a>:</span> <span class='sentence-part'>It is now accepted that transition metals, such as iron and copper, are involved in the pathogenesis of the Alzheimer's disease (AD) through their participation in toxic oxidative phenomena.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21902663' target='_blank' class='pmid-link'>21902663</a>:</span> <span class='sentence-part'>In addition, disruption of iron regulation plays a key role in the etiology of Alzheimer's disease, Parkinson's disease, Huntington's disease, Friedreich's ataxia and other neurological disorders, cancer (lung cancer, breast cancer, colon cancer), Fanconi anemia, stroke and ageing.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22746342' target='_blank' class='pmid-link'>22746342</a>:</span> <span class='sentence-part'>Disruption of iron regulation also plays a key role in the etiology of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23887894' target='_blank' class='pmid-link'>23887894</a>:</span> <span class='sentence-part'>Better knowledge of the distribution of iron in the brains of Alzheimer's disease (AD) patients may facilitate the development of an in vivo magnetic resonance (MR) marker for AD and may cast light on the role of this potentially toxic molecule in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24343096' target='_blank' class='pmid-link'>24343096</a>:</span> <span class='sentence-part'>In addition, it should be noted the important role that low molecular mass fractions of iron, copper, aluminium and cobalt appear to play in pathogenesis of Alzheimer.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25557378' target='_blank' class='pmid-link'>25557378</a>:</span> <span class='sentence-part'>Future investigation of CO and iron in the pathogenesis of Alzheimer's disease is warranted.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30598025' target='_blank' class='pmid-link'>30598025</a>:</span> <span class='sentence-part'>Moreover, it is already established that metals (particularly copper, zinc and iron) have a key role in the pathogenesis of AD.</span></div></div>
<div class='streamlined-assertion'><div class='streamlined-header sticky-relation-header'><span class='label-text'>Subject:</span> <strong>Ischemia</strong> <span class='label-text'>Subject CUI:</span> <strong>C0022116</strong> â†’ <span class='label-text predicate-text'>CAUSES</span> â†’ <span class='label-text'>Object:</span> <strong>Alzheimers</strong> <span class='label-text'>Object CUI:</span> <strong>C0002395</strong></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/11132936' target='_blank' class='pmid-link'>11132936</a>:</span> <span class='sentence-part'>Therefore, it was concluded that the WM lesions in DAT are the result of ischemia rather than wallerian degeneration.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/15681798' target='_blank' class='pmid-link'>15681798</a>:</span> <span class='sentence-part'>One of the logical approaches to this problem is to study the effects of ischemia and hypoxia on the metabolism of amyloid precursor protein, which plays one of the key roles in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23319188' target='_blank' class='pmid-link'>23319188</a>:</span> <span class='sentence-part'>The identification of the genes involved in sporadic Alzheimer's disease induced by ischemia will enable to further define the events leading to Alzheimer's disease-related abnormalities.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23519520' target='_blank' class='pmid-link'>23519520</a>:</span> <span class='sentence-part'>The identification of the genes involved in Alzheimer's disease induced by ischemia will enable to further define the events leading to sporadic Alzheimer's disease-related abnormalities.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25232510' target='_blank' class='pmid-link'>25232510</a>:</span> <span class='sentence-part'>However, since May 1998, we know that a progressive ischemia in the medial temporal lobes and subcommissural regions can cause Alzheimer's disease; because, in contrast to this, its revascularization by means of omental tissue can cure or improve this disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27699087' target='_blank' class='pmid-link'>27699087</a>:</span> <span class='sentence-part'>Evidence from rodent and cell models show a number of neurotrophic and neuroprotective effects of guanosine preventing deleterious consequences of seizures, spinal cord injury, pain, mood disorders and aging-related diseases, such as ischemia, Parkinson's and Alzheimer's diseases.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33608912' target='_blank' class='pmid-link'>33608912</a>:</span> <span class='sentence-part'>Here, we review recent evidence that microglial phagocytosis of live neurons and synapses causes neurodegeneration in animal models of Alzheimer's disease and other tauopathies, Parkinson's disease, frontotemporal dementias, multiple sclerosis, retinal degeneration, and neurodegeneration induced by ischaemia, infection or ageing.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35903609' target='_blank' class='pmid-link'>35903609</a>:</span> <span class='sentence-part'>Because excess copper and zinc may be present in the synaptic clefts during ischemia, it is possible that secreted copper and copper-induced reactive oxygen species may enhance zinc neurotoxicity and eventually contribute to the pathogenesis of vascular type senile dementia.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36225888' target='_blank' class='pmid-link'>36225888</a>:</span> <span class='sentence-part'>Ischemia as a common trigger for Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36892020' target='_blank' class='pmid-link'>36892020</a>:</span> <span class='sentence-part'>Cerebral ischemic injury, one of the leading causes of morbidity and mortality worldwide, triggers various central nervous system (CNS) diseases, including acute ischemic stroke (AIS) and chronic ischemia-induced Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37326114' target='_blank' class='pmid-link'>37326114</a>:</span> <span class='sentence-part'>Cerebral ischemic injury, one of the leading causes of morbidity and mortality worldwide, triggers various central nervous system (CNS) diseases, including acute ischemic stroke (AIS) and chronic ischemia-induced Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37357280' target='_blank' class='pmid-link'>37357280</a>:</span> <span class='sentence-part'>In AD, white matter hyperintensities (WMH) which are postulated to develop as a result of chronic ischemia from small vessel CVD are shown to play a role in the aetiology.</span></div></div>
<div class='streamlined-assertion'><div class='streamlined-header sticky-relation-header'><span class='label-text'>Subject:</span> <strong>Ischemia</strong> <span class='label-text'>Subject CUI:</span> <strong>C0022116</strong> â†’ <span class='label-text predicate-text'>CAUSES</span> â†’ <span class='label-text'>Object:</span> <strong>Atrial_Fibrillation</strong> <span class='label-text'>Object CUI:</span> <strong>C0004238</strong></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17316585' target='_blank' class='pmid-link'>17316585</a>:</span> <span class='sentence-part'>Flecainide and dofetilide failed to prevent ischemia-induced AF promotion (e.g. AF duration at 3-hour ischemia 779+/-417 and 801+/-414 respectively, p=NS vs control) and failed to alter ischemia-induced conduction slowing.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/18852714' target='_blank' class='pmid-link'>18852714</a>:</span> <span class='sentence-part'>The mechanisms that underlie the remodeling process in atrial fibrillation have not yet been completely elucidated, although experimental and clinical investigations have indicated a number of signaling systems, inflammation, oxidative stress, atrial stretching and ischemia as factors involved in the cascade of events that leads to atrial fibrillation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20103202' target='_blank' class='pmid-link'>20103202</a>:</span> <span class='sentence-part'>BACKGROUND: Atrial ischemia, and sinus node ischemia in particular, may be involved in the pathogenesis of atrial fibrillation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24431317' target='_blank' class='pmid-link'>24431317</a>:</span> <span class='sentence-part'>Nevertheless, AF is diagnosed in 60-95% of patients operated on due to acute limb ischemia, 31% of patients with splenic artery embolization, 55% with acute renal ischemia and 47% with mesenteric ischemia.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27317981' target='_blank' class='pmid-link'>27317981</a>:</span> <span class='sentence-part'>CONCLUSION: Selective inhibition of cardiac late INa with eleclazine confers dual protection against vulnerability to ischemia-induced AF and reduces atrial and ventricular repolarization abnormalities before and during adrenergic stimulation without negative inotropic effects. OBJECTIVE: The purpose of this study was to investigate whether selective inhibition of the cardiac late sodium current (INa) with eleclazine decreases susceptibility to ischemia-induced atrial fibrillation (AF) and atrial and ventricular repolarization abnormalities before and after epinephrine infusion.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28379023' target='_blank' class='pmid-link'>28379023</a>:</span> <span class='sentence-part'>AFib in cancer patients may develop secondary to ischaemia in anaemic patients, metabolic disorders caused by cancer or treatment, pulmonary embolism, sepsis or even as a result of direct impact of cytotoxic treatment (cisplatin, ifosfamide, gemcitabine, 5-fluorouracil, etoposide).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29540372' target='_blank' class='pmid-link'>29540372</a>:</span> <span class='sentence-part'>CONCLUSIONS: Atrial ischemia causes spontaneous AF episodes in sheep, caused by SFDs that initiate reentry.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31719941' target='_blank' class='pmid-link'>31719941</a>:</span> <span class='sentence-part'>Our case indicated that 5-FU predisposed vasospasm in RCA and the subsequent atrial ischemia may lead to AF.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32275023' target='_blank' class='pmid-link'>32275023</a>:</span> <span class='sentence-part'>The incidence of postoperative atrial fibrillation (POAF) may also be reduced because of less ischemia and inflammation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37240950' target='_blank' class='pmid-link'>37240950</a>:</span> <span class='sentence-part'>AF can be caused by ischemia, and MI can be caused by AF.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37274376' target='_blank' class='pmid-link'>37274376</a>:</span> <span class='sentence-part'>CAD adversely affects AF by promoting progression    via     re-entry and increasing excitability of atrial tissue as a result of ischemia and electrical inhomogeneity.</span></div></div>
<div class='streamlined-assertion'><div class='streamlined-header sticky-relation-header'><span class='label-text'>Subject:</span> <strong>Isolation_procedure</strong> <span class='label-text'>Subject CUI:</span> <strong>C0204727</strong> â†’ <span class='label-text predicate-text'>CAUSES</span> â†’ <span class='label-text'>Object:</span> <strong>Atrial_Fibrillation</strong> <span class='label-text'>Object CUI:</span> <strong>C0004238</strong></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/12142112' target='_blank' class='pmid-link'>12142112</a>:</span> <span class='sentence-part'>In the first 21 patients (group 1), distal isolation (&gt; or = 5 mm from the ostium) was achieved targeting veins triggering AF.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/18462325' target='_blank' class='pmid-link'>18462325</a>:</span> <span class='sentence-part'>METHODS: Over a 7-year period we studied 1,165 consecutive patients undergoing 1,506 AF ablation procedures using a consistent ablation protocol that included proximal ostial pulmonary vein (PV) isolation and focal ablation of non-PV AF triggers.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26939965' target='_blank' class='pmid-link'>26939965</a>:</span> <span class='sentence-part'>Atrial fibrillation is uncommon owing to obligatory surgical pulmonary vein isolation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28496917' target='_blank' class='pmid-link'>28496917</a>:</span> <span class='sentence-part'>Utility of the Pulmonary Vein Ablation Catheter for Electrical Isolation of A Left Sided Vena Cava Triggering Atrial Fibrillation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29458408' target='_blank' class='pmid-link'>29458408</a>:</span> <span class='sentence-part'>Selective ablation of cardiac tissues resulting in isolation of areas causing atrial fibrillation is another treatment strategy which can be delivered by two minimally invasive interventions: percutaneous catheter ablation and thoracoscopic surgical ablation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30711378' target='_blank' class='pmid-link'>30711378</a>:</span> <span class='sentence-part'>BACKGROUND: Catheter ablation of atrial fibrillation (AF) by means of pulmonary vein isolation (PVI) focuses on the PVs as the putative trigger of AF.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31407347' target='_blank' class='pmid-link'>31407347</a>:</span> <span class='sentence-part'>The second ablation procedure included re-isolation of reconnected pulmonary veins (PVs) and elimination of clinical or induced non-PV AF triggers and atrial tachycardia (AT).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31753439' target='_blank' class='pmid-link'>31753439</a>:</span> <span class='sentence-part'>After PV isolation, we infused isoproterenol to provoke non-PV AF triggers and/or non-PV PACs. BACKGROUND: Residual atrial ectopic beats that trigger AF from non-PVs (non-PV AF triggers) after catheter ablation are among the major causes of AF recurrence.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32494445' target='_blank' class='pmid-link'>32494445</a>:</span> <span class='sentence-part'>The Role of Superior Vena Cava Isolation in the Management of Atrial Fibrillation.The superior vena cava (SVC) has been identified as one of the most common sources of non-pulmonary vein triggers for atrial fibrillation (AF).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33490363' target='_blank' class='pmid-link'>33490363</a>:</span> <span class='sentence-part'>Conclusion: Pulmonary vein isolation and vagal denervation lead to low AF incidence in OHT recipients.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33545152' target='_blank' class='pmid-link'>33545152</a>:</span> <span class='sentence-part'>CONCLUSIONS: In patients with persistent AF indicated for non-mitral valve surgery, a concomitant Cox-Maze procedure resulted in superior AF- and event-free survival as compared to PVI without increased risk of early mortality.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35689513' target='_blank' class='pmid-link'>35689513</a>:</span> <span class='sentence-part'>Since the seminal observations demonstrating pulmonary veins (PVs) as the most common sites of atrial fibrillation (AF) triggers,     1       PV isolation has become the standard of care for catheter ablation of AF This article is protected by copyright.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37260106' target='_blank' class='pmid-link'>37260106</a>:</span> <span class='sentence-part'>We report a case of atrial fibrillation (AF) recurrence after pulmonary vein isolation, which patient had AF trigger in the superior vena cava (SVC) near the sinus node (SN).</span></div></div>
<div class='streamlined-assertion'><div class='streamlined-header sticky-relation-header'><span class='label-text'>Subject:</span> <strong>Isoproterenol</strong> <span class='label-text'>Subject CUI:</span> <strong>C0022245</strong> â†’ <span class='label-text predicate-text'>CAUSES</span> â†’ <span class='label-text'>Object:</span> <strong>Atrial_Fibrillation</strong> <span class='label-text'>Object CUI:</span> <strong>C0004238</strong></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/11211447' target='_blank' class='pmid-link'>11211447</a>:</span> <span class='sentence-part'>A malignant form of the condition was defined as the demonstration of two abnormalities: rapid conduction in the bundle of Kent (over 240/min) under basal conditions or over 300/min after Isoprenaline, and if it induced sustained atrial fibrillation (&gt; 1 min).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/12036217' target='_blank' class='pmid-link'>12036217</a>:</span> <span class='sentence-part'>Focal activity was present spontaneously or was elicited by isoprenaline, burst pacing or AF induction and cardioversion.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/12741705' target='_blank' class='pmid-link'>12741705</a>:</span> <span class='sentence-part'>PV triggers were provoked by isoproterenol, adenosine, and AF induction followed by cardioversion.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/15013134' target='_blank' class='pmid-link'>15013134</a>:</span> <span class='sentence-part'>Beta-blockade by propranolol (1 mg/kg) did not prevent ACh-induced AF, but increased the threshold ACh concentration for AF induction to 23.5 +/- 3.4 micromol/l (p &lt; 0.05). METHODS: Perfusion of catecholamines and acetylcholine (ACh), as well as their combination, through the sinus node artery was used to induce AF in 20 anesthetized open-chest dogs without electrical stimulation of atria. Acetylcholine-mediated AF was facilitated by isoproterenol (1 to 2 and 10 micromol/l), which decreased the threshold ACh concentration for AF induction to 0.5 +/- 0.1 and 0.4 +/- 0.1 micromol/l, respectively (p &lt; 0.05) and increased the AF duration (from 25 +/- 7 to 141 +/- 54 and 233 +/- 60 s, respectively; p &lt; 0.05). RESULTS: Isoproterenol and adrenaline (10 to 100 micromol/l) induced AF in 21% (3 of 14) and 17% (1 of 6) of dogs, respectively. Acetylcholine (2.8 +/- 0.3 micromol/l) induced AF in all dogs.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/15158364' target='_blank' class='pmid-link'>15158364</a>:</span> <span class='sentence-part'>Isoproterenol treatment showed antagonistic effect against endothelin-1 induced MAP duration prolongation, early after depolarisation and ventricular fibrillation formation, while endothelin-1 showed protective effect against the development of isoproterenol induced atrial fibrillation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17895559' target='_blank' class='pmid-link'>17895559</a>:</span> <span class='sentence-part'>Atrial fibrillation (Af) was induced by isoproterenol infusion in 2 patients.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/18266669' target='_blank' class='pmid-link'>18266669</a>:</span> <span class='sentence-part'>However, no studies have determined the sensitivity and specificity of isoproterenol for the induction of AF. RESULTS: Among the 20 control subjects, AF was induced by isoproterenol in one patient (5%). OBJECTIVE: To determine the sensitivity and specificity of isoproterenol for the induction of atrial fibrillation (AF). Isoproterenol induced AF in 15 of 17 patients (88%) with vagotonic AF, 11 of 11 patients (100%) with adrenergic AF, and 41 of 52 patients (79%) with random episodes of AF (P = 0.2).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/18284496' target='_blank' class='pmid-link'>18284496</a>:</span> <span class='sentence-part'>Atrial fibrillation induction with isoproterenol: teaching an old drug new tricks.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/2036596' target='_blank' class='pmid-link'>2036596</a>:</span> <span class='sentence-part'>Isoproterenol produced a 6-25% increase of the atrial rate in 6 out of 14 trials of atrial flutter and induced atrial fibrillation in 4.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20676970' target='_blank' class='pmid-link'>20676970</a>:</span> <span class='sentence-part'>While the PVI did not completely suppress the AF induced by an isoproterenol infusion, the Holter monitor recordings demonstrated a major decrease in the clinical episodes of AF and ventricular tachyarrhythmias in association with a reduced high-frequency (HF) component and ratio of the low-frequency (LF) component power to the HF component (LF/HF) after the PVI.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21692897' target='_blank' class='pmid-link'>21692897</a>:</span> <span class='sentence-part'>This suggests that at least part of the beneficial effect achieved by CFAE ablation reflects elimination of non-PV AF triggers. OBJECTIVE: We compared the impact of CFAE ablation on the prevalence of non-PV atrial triggers inducing AF in 2 groups of patients with LS persistent AF. After ablation, infusion of isoproterenol up to 30 mcg/min was given to reveal non PV foci inducing AF.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23099358' target='_blank' class='pmid-link'>23099358</a>:</span> <span class='sentence-part'>Infusion of acetylcholine (1 uM) and isoproterenol (1 uM) led to AF in all failing hearts and in 11 sham hearts.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/2330864' target='_blank' class='pmid-link'>2330864</a>:</span> <span class='sentence-part'>When isoproterenol was infused, it was difficult to induce atrial fibrillation; when the arrhythmia was initiated, it could not be sustained even with concomitant electrical vagal stimulation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25244538' target='_blank' class='pmid-link'>25244538</a>:</span> <span class='sentence-part'>Burst pacing and isoproterenol induced a greater AF occurrence (50% vs. 100%; P = 0.009) and a longer AF duration (26 +/- 9 vs. 5 +/- 3 seconds; P &lt; 0.05) in the LA (n = 8) with IS (100 MUM) than without IS.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26432585' target='_blank' class='pmid-link'>26432585</a>:</span> <span class='sentence-part'>Infusions of isoproterenol and adenosine triphosphate (ATP) were used to induce AF.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28575293' target='_blank' class='pmid-link'>28575293</a>:</span> <span class='sentence-part'>AF induction by isoproterenol occurred only in 3/70 (4%) patients of whom 2/3 (66%) patients with an EPVR of a triggering vein.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30375070' target='_blank' class='pmid-link'>30375070</a>:</span> <span class='sentence-part'>Ado-induced AF episodes originated from the left PVs in 6 of 12 (50%), from the right atrium (RA) in 4 of 12 (33%), and from the CS in 2 of 12 (17%) cases. Is adenosine useful for the identification of atrial fibrillation triggers? Altogether, Iso-induced AF was more likely initiated from the PVs (93%) compared with Ado (50%) ( P?=?0.02). INTRODUCTION: Both isoproterenol (Iso) and adenosine (Ado) are used to induce atrial fibrillation (AF) in the electrophysiology lab.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31175534' target='_blank' class='pmid-link'>31175534</a>:</span> <span class='sentence-part'>Administration of ACh/Iso provoked more episodes of AF (baseline: 26 episodes, Iso/Ach: 48 episodes).</span></div></div>
<div class='streamlined-assertion'><div class='streamlined-header sticky-relation-header'><span class='label-text'>Subject:</span> <strong>Lipids</strong> <span class='label-text'>Subject CUI:</span> <strong>C0023779</strong> â†’ <span class='label-text predicate-text'>CAUSES</span> â†’ <span class='label-text'>Object:</span> <strong>Alzheimers</strong> <span class='label-text'>Object CUI:</span> <strong>C0002395</strong></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/12419469' target='_blank' class='pmid-link'>12419469</a>:</span> <span class='sentence-part'>These results support the hypothesis that oxidative damage to lipid, protein, and DNA is an important early event in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/12668899' target='_blank' class='pmid-link'>12668899</a>:</span> <span class='sentence-part'>Since apoE is a regulator of lipid metabolism, it is reasonable to assume that lipids such as cholesterol are involved in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/15270198' target='_blank' class='pmid-link'>15270198</a>:</span> <span class='sentence-part'>Although early studies recognized the loss of cholesterol and other lipids in the brain, these findings have been poorly connected with AD pathogenesis, despite the identification of the epsilon4 allele of APOE as a major risk factor in AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/16344479' target='_blank' class='pmid-link'>16344479</a>:</span> <span class='sentence-part'>Thus, the lipid- and receptor-binding regions in apoE4 fragments act together to cause mitochondrial dysfunction and neurotoxicity, which may be important in Alzheimer's disease pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21605030' target='_blank' class='pmid-link'>21605030</a>:</span> <span class='sentence-part'>Apo E is the major component of lipoprotein particles in the brain that mediate transport of cholesterol and other lipids between neurons and glial cells, indicating an implication of cerebral lipid metabolism in the pathogenesis of AD. Importantly, mutations in the genes of APP and the two homologous PS proteins are a major cause of familial early onset AD, indicating that the metabolism of APP and generation of Abeta play critical roles in the initiation of the disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22367100' target='_blank' class='pmid-link'>22367100</a>:</span> <span class='sentence-part'>This review summarizes the current state of our knowledge of the influence of cholesterol and lipid pathways in AD pathogenesis in vitro and in vivo.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24575399' target='_blank' class='pmid-link'>24575399</a>:</span> <span class='sentence-part'>This review summarizes lipid alterations found in AD postmortem brains, AD transgenic mouse models, and the current understanding of how lipids influence the molecular mechanisms leading to AD and A beta generation, focusing especially on cholesterol, docosahexaenoic acid (DHA), and sphingolipids/glycosphingolipids.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24894353' target='_blank' class='pmid-link'>24894353</a>:</span> <span class='sentence-part'>Evidence suggests that the ApoE protein, a major lipid transporter, plays a key role in the pathogenesis of AD, and its role in both normal and aberrant lipid metabolism warrants further extensive investigation. Here, we review ApoE-lipid interactions, as well as the roles that lipids may play in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24898654' target='_blank' class='pmid-link'>24898654</a>:</span> <span class='sentence-part'>The probable auto-antigenic role of lipids (anti-ganglioside antibodies) in the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28002106' target='_blank' class='pmid-link'>28002106</a>:</span> <span class='sentence-part'>As the brain has a high lipid content, lipidomics may offer novel insights into the underlying pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29522770' target='_blank' class='pmid-link'>29522770</a>:</span> <span class='sentence-part'>SIGNIFICANCE: Therefore, this solid lipid nanoparticle of quercetin can be used as future nanomedicine for various neurodegenerative disorders like Alzheimer and Parkinson disorders due to its potential anti-oxidative, anti-lipid peroxidative and acetylcholinesterase inhibitory actions.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29526709' target='_blank' class='pmid-link'>29526709</a>:</span> <span class='sentence-part'>This, we believe, will refocus our thinking on the influence of lipids and open new approaches in delineating the mechanisms of AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30207230' target='_blank' class='pmid-link'>30207230</a>:</span> <span class='sentence-part'>Lipids participate in Amyloid Precursor Protein (APP) trafficking and processing - important factors in the initiation of Alzheimer's disease (AD) pathogenesis and influence the formation of neurotoxic beta-amyloid (Abeta) peptides. The Role of Lipids and Membranes in the Pathogenesis of Alzheimer's Disease: A Comprehensive View.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31062326' target='_blank' class='pmid-link'>31062326</a>:</span> <span class='sentence-part'>The Roles of Apolipoprotein E, Lipids, and Glucose in the Pathogenesis of Alzheimer's Disease. In this chapter, we discuss the roles of ApoE, lipids, and glucose in the pathogenesis of AD by considering their potential interactions.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33550528' target='_blank' class='pmid-link'>33550528</a>:</span> <span class='sentence-part'>A recent surge in research on lipid handling and metabolism in glia and neurons has established defective lipid clearance from endolysosomes as a central driver of AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34483892' target='_blank' class='pmid-link'>34483892</a>:</span> <span class='sentence-part'>Introduction: Prior evidence suggested    Apolipoprotein E (APOE)    , lipids, and glucose metabolism may act through the same pathways on the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36165619' target='_blank' class='pmid-link'>36165619</a>:</span> <span class='sentence-part'>Upstream lipid and metabolic systems are potential causes of Alzheimer's disease, Parkinson's disease and dementias. Using microglia as an example, we review data that suggest increased lipid concentrations cause dysfunctional inflammatory responses to immune challenges, leading to Alzheimer's disease, Parkinson's disease and dementia.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36570536' target='_blank' class='pmid-link'>36570536</a>:</span> <span class='sentence-part'>In this cross-sectional study, we attempted to elucidate the associations of these bioactive lipids with the pathogenesis/pathology of AD through postmortem studies of human brains.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37398438' target='_blank' class='pmid-link'>37398438</a>:</span> <span class='sentence-part'>Our study of circulating lipids and central AD biomarkers enabled identification of lipids that play potential roles in the cascade of AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/38203341' target='_blank' class='pmid-link'>38203341</a>:</span> <span class='sentence-part'>Several studies in recent years have shown that lipid metabolic dysregulation and neuroinflammation are associated with the pathogenesis of AD.</span></div></div>
<div class='streamlined-assertion'><div class='streamlined-header sticky-relation-header'><span class='label-text'>Subject:</span> <strong>Lipopolysaccharides</strong> <span class='label-text'>Subject CUI:</span> <strong>C0023810</strong> â†’ <span class='label-text predicate-text'>CAUSES</span> â†’ <span class='label-text'>Object:</span> <strong>Alzheimers</strong> <span class='label-text'>Object CUI:</span> <strong>C0002395</strong></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22211682' target='_blank' class='pmid-link'>22211682</a>:</span> <span class='sentence-part'>For instance, lipopolysaccharides in PD and amyloid beta in AD trigger microglia and astrocytes to release reactive oxygen species (ROS) and proinflammatory cytokines.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25454121' target='_blank' class='pmid-link'>25454121</a>:</span> <span class='sentence-part'>RESULTS: Systemic LPS induced AD, as shown by cognitive impairment; increased levels of Abeta and concomitant increase in the brain NO concentrations.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29447949' target='_blank' class='pmid-link'>29447949</a>:</span> <span class='sentence-part'>RESULTS: It was found that successive intragastric administration of AOF (360 mg/kg) extracts for 14 days showed different degrees of improvement on LPS-induced AD model as measured by Y-maze test, Morris water maze test, and Histopathological examination.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31073286' target='_blank' class='pmid-link'>31073286</a>:</span> <span class='sentence-part'>Design: We explored to investigate the effects of GA on neuroinflammation and memory impairment in an LPS-induced Alzheimer's mouse model.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31463498' target='_blank' class='pmid-link'>31463498</a>:</span> <span class='sentence-part'>Our data showed that SEO improved the cognitive ability of mice with Abeta1-42 or lipopolysaccharides (LPS)-induced Alzheimer's disease (AD) and suppressed the production of tumor necrosis factor-a (TNF-a), interleukin-6 (IL-6), and interleukin-1beta (IL-1beta) in the hippocampus.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32045690' target='_blank' class='pmid-link'>32045690</a>:</span> <span class='sentence-part'>Nasal timosaponin BII dually sensitive in situ hydrogels for the prevention of Alzheimer's disease induced by lipopolysaccharides.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32925065' target='_blank' class='pmid-link'>32925065</a>:</span> <span class='sentence-part'>Systemic Exposure to Lipopolysaccharide from Porphyromonas gingivalis Induces Bone Loss-Correlated Alzheimer's Disease-Like Pathologies in Middle-Aged Mice.BACKGROUND: Alzheimer's disease (AD) and bone loss are clinically exacerbated. Systemic Exposure to Lipopolysaccharide from Porphyromonas gingivalis Induces Bone Loss-Correlated Alzheimer's Disease-Like Pathologies in Middle-Aged Mice.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33191624' target='_blank' class='pmid-link'>33191624</a>:</span> <span class='sentence-part'>Here, we identified a non-equilibrium state of interaction between supramolecular lipopolysaccharide (LPS) and Abeta42, an aggregate-prone protein that causes Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33481268' target='_blank' class='pmid-link'>33481268</a>:</span> <span class='sentence-part'>Thirty female Wistar albino rats aged 6 months to 1 year were equally divided into five groups; control group, LPS-induced AD group, LPS + MVs group, LPS + NaHS group, and LPS + MVs and NaHS group. In conclusion, downregulation of TNF-alpha, miR-155, and pAkt and increased SHIP-1 could improve the neuro-inflammatory state and cognitive function of LPS-induced Alzheimer's disease. The current study was conducted to evaluate the role of miR-155 in a rat model of lipopolysaccharide (LPS)-induced AD and to investigate the effect of using MVs and H     2       S that were given either separately or combined in regulating pro-inflammatory signaling. Hydrogen sulfide and mesenchymal stem cells-extracted microvesicles attenuate LPS-induced Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33816329' target='_blank' class='pmid-link'>33816329</a>:</span> <span class='sentence-part'>In recent years, as the infectious theory and endotoxin hypothesis of AD has gained substantial attention, several studies have proposed that    Porphyromonas gingivalis     (   P. gingivalis    ), one of the main pathogenic bacteria of chronic periodontitis, and the lipopolysaccharide (LPS) of    P. gingivalis     may lead to AD-like pathological changes and cognition impairment.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34091099' target='_blank' class='pmid-link'>34091099</a>:</span> <span class='sentence-part'>These results underline the significance of microbial/ inflammatory involvement in dementia and offer novel perspectives on the roles of LPSs and COX in pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34971183' target='_blank' class='pmid-link'>34971183</a>:</span> <span class='sentence-part'>The role of lycopene on the hippocampus of rat model of lipopolysaccharide-induced Alzheimer's disease. This study was designed to investigate the role of lycopene on hippocampus in lipopolysaccharide- induced Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35273209' target='_blank' class='pmid-link'>35273209</a>:</span> <span class='sentence-part'>Subsequently, we used the CBN and transcriptomic data to identify key molecular pathways driving the astrocyte phenotype in four CNS pathologies: samples from mouse models of lipopolysaccharide-induced endotoxemia, Alzheimer's disease, and amyotrophic lateral sclerosis; and samples from multiple sclerosis patients.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35429976' target='_blank' class='pmid-link'>35429976</a>:</span> <span class='sentence-part'>Further, a transcriptomic meta-analysis revealed that IL-6 and IFN-alpha both contribute to the formation of a core microglia response in animal models of neurodegenerative and neuroinflammatory disorders, such as Alzheimer's disease, tauopathy, multiple sclerosis and lipopolysaccharide-induced endotoxemia.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35890426' target='_blank' class='pmid-link'>35890426</a>:</span> <span class='sentence-part'>DC against Lipopolysaccharide Induced Alzheimer's Disease in Mice.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36499428' target='_blank' class='pmid-link'>36499428</a>:</span> <span class='sentence-part'>Furthermore, systemic treatment of    Porphyromonas gingivalis     (   Pg    ) lipopolysaccharide (LPS) induced Alzheimer's disease-like neuropathological changes in middle-aged mice.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36642360' target='_blank' class='pmid-link'>36642360</a>:</span> <span class='sentence-part'>In conclusion, the study provides evidence that the treatment with Bacterial protease can improve the memory and learning impairments of LPS-induced AD and may be used as a promising therapeutic agent to manage AD since it has anti-inflammatory and antioxidant effect.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37895841' target='_blank' class='pmid-link'>37895841</a>:</span> <span class='sentence-part'>Dapagliflozin/Hesperidin Combination Mitigates Lipopolysaccharide-Induced Alzheimer's Disease in Rats. The aim of this study was to elucidate the potential ameliorative effects of dapagliflozin and/or hesperidin on Alzheimer's disease (AD) induced by lipopolysaccharide (LPS) injection in rats.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/38051653' target='_blank' class='pmid-link'>38051653</a>:</span> <span class='sentence-part'>In-depth analyses of lncRNA and circRNA expression in the hippocampus of LPS-induced AD mice by Byu d Mar 25.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/38533683' target='_blank' class='pmid-link'>38533683</a>:</span> <span class='sentence-part'>In the present study, the neuroprotective effects of four    Morus     extracts were assessed in LPS-induced AD in mice.</span></div></div>
<div class='streamlined-assertion'><div class='streamlined-header sticky-relation-header'><span class='label-text'>Subject:</span> <strong>MAPT</strong> <span class='label-text'>Subject CUI:</span> <strong>4137</strong> â†’ <span class='label-text predicate-text'>CAUSES</span> â†’ <span class='label-text'>Object:</span> <strong>Alzheimers</strong> <span class='label-text'>Object CUI:</span> <strong>C0002395</strong></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/15615644' target='_blank' class='pmid-link'>15615644</a>:</span> <span class='sentence-part'>Whether Abeta or tau filaments cause AD is still an open question, as a wide variety of proteins and pathways have been implicated in the initiation and advancement of the disease--processes such as apoptosis, oxidative stress, and protein degradation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/16262633' target='_blank' class='pmid-link'>16262633</a>:</span> <span class='sentence-part'>Abnormal hyperphosphorylation of tau is believed to lead to neurofibrillary degeneration in Alzheimer's disease (AD) and other tauopathies.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/16953147' target='_blank' class='pmid-link'>16953147</a>:</span> <span class='sentence-part'>Hence, the abnormal hyperphosphorylation of tau appears to be critical to the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17044033' target='_blank' class='pmid-link'>17044033</a>:</span> <span class='sentence-part'>The degradation of aberrantly phosphorylated tau in neurons plays an important role in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17077307' target='_blank' class='pmid-link'>17077307</a>:</span> <span class='sentence-part'>These studies describe a novel mechanism for MPTP neurotoxicity, namely a MPTP-inducible, strictly alpha-Syn-dependent, increased formation of PHF-1-reactive Tau, suggesting convergent overlapping pathways in the genesis of clinically divergent diseases such as AD and PD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17360920' target='_blank' class='pmid-link'>17360920</a>:</span> <span class='sentence-part'>These findings, in combination with evidence for cell cycle regulation of amyloid precursor protein and tau, has led to the hypothesis that reentry into the cell cycle underlies AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17361031' target='_blank' class='pmid-link'>17361031</a>:</span> <span class='sentence-part'>The positive correlation trend in MCI and the robust correlation in AD between Pin1 activity and phosphorylated tau implies that increasing phosphorylated tau during AD pathogenesis may induce the compensatory activation/up-regulation of Pin1, while the inverse correlation between Pin1 activity and phosphorylated tau in NCI group implies that decreased Pin1 may play a role in the initial accumulation of phosphorylated tau in AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17562708' target='_blank' class='pmid-link'>17562708</a>:</span> <span class='sentence-part'>A combination of casein kinase 1delta and glycogen synthase kinase-3beta activities could account for over three-quarters of the serine/threonine phosphorylation sites identified in PHF-tau, indicating that casein kinase 1delta may have a role, together with glycogen synthase kinase-3beta, in the pathogenesis of Alzheimer disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/18583940' target='_blank' class='pmid-link'>18583940</a>:</span> <span class='sentence-part'>An altered tau produces cytoskeleton pathology resulting in neurodegenerative diseases such as Alzheimer's disease and tauopathies.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/18690834' target='_blank' class='pmid-link'>18690834</a>:</span> <span class='sentence-part'>Mechanism of tau-induced neurodegeneration in Alzheimer disease and related tauopathies.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/18855662' target='_blank' class='pmid-link'>18855662</a>:</span> <span class='sentence-part'>Recent studies have suggested that abnormal hyperphosphorylation of tau in the brain plays a vital role in the molecular pathogenesis of AD and in neurodegeneration. Furthermore, several therapeutic strategies for treating AD on the basis of the important role of tau hyperphosphorylation in the pathogenesis of the disease are described.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/19742193' target='_blank' class='pmid-link'>19742193</a>:</span> <span class='sentence-part'>The mismetabolism of APP and the defective clearance of beta amyloid generate a cascade of events including hyperphosphorylated tau (tau) mediated breakdown of microtubular assembly and resultant synaptic failure which results in AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20422200' target='_blank' class='pmid-link'>20422200</a>:</span> <span class='sentence-part'>Hallmark cellular pathology of Alzheimer's disease induced by mutant human tau expression in cultured Aplysia neurons.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20683187' target='_blank' class='pmid-link'>20683187</a>:</span> <span class='sentence-part'>Dementia mimicking Alzheimer's disease Owing to a tau mutation: CSF and PET findings.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20730022' target='_blank' class='pmid-link'>20730022</a>:</span> <span class='sentence-part'>Studies in mice expressing both human amyloid precursor protein and human tau have provided clear evidence that amyloid-beta and tau interact in the pathogenesis of AD. A defined effort must be made to develop therapies that directly address the impact of tau dysfunction in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20926667' target='_blank' class='pmid-link'>20926667</a>:</span> <span class='sentence-part'>Our results strongly support a convergent role for PS and tau in axonal transport and neuronal survival and function and implicate their misregulation as a contributor to AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21348938' target='_blank' class='pmid-link'>21348938</a>:</span> <span class='sentence-part'>However, given the increasing evidence that pathological forms of tau can compromise neuronal function and that tau is likely an important mediator of Abeta toxicity, there is a growing awareness that tau is a central player in AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22401494' target='_blank' class='pmid-link'>22401494</a>:</span> <span class='sentence-part'>The misfolding and aggregation of the intrinsically disordered, microtubule-associated tau protein into neurofibrillary tangles is implicated in the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22922102' target='_blank' class='pmid-link'>22922102</a>:</span> <span class='sentence-part'>Tau, a microtubule-associated protein and substrate for GSK3beta, has been implicated in the pathogenesis of tauopathies such as Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23052602' target='_blank' class='pmid-link'>23052602</a>:</span> <span class='sentence-part'>The cerebrospinal fluid (CSF) biomarker profile in Alzheimer's disease (AD) is characterized by decreased beta amyloid (Abeta(1-42)), increased total and hyperphosphorylated tau (t-tau and p-tau, respectively), which is a useful diagnostic tool and gives insight in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23517246' target='_blank' class='pmid-link'>23517246</a>:</span> <span class='sentence-part'>Both pro-aggregant Tau variants cause Alzheimer-like features, including synapse loss, mis-localization of Tau into the somatodendritic compartment, conformational changes and hyperphosphorylation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23659495' target='_blank' class='pmid-link'>23659495</a>:</span> <span class='sentence-part'>In addition to amyloid-beta (Abeta) peptide and phosphorylated tau, lipid dysregulation is suggested to participate in AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23828739' target='_blank' class='pmid-link'>23828739</a>:</span> <span class='sentence-part'>Therefore, a disorder primarily affecting structures in medial temporal lobe, with accumulation of amyloid beta and abnormal tau, neuritic plaques and tangles, progressive loss of memory and/or other cognitive deficits, ultimately resulting in dementia should be classified as AD. Alzheimer's disease (AD), the most prevalent disorder causing dementia, is considered a neurodegenerative disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23904623' target='_blank' class='pmid-link'>23904623</a>:</span> <span class='sentence-part'>Tau, a microtubule-associated protein, is implicated in the pathogenesis of Alzheimer's Disease (AD) in regard to both neurofibrillary tangle formation and neuronal network hyperexcitability.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24027553' target='_blank' class='pmid-link'>24027553</a>:</span> <span class='sentence-part'>Tau clearance mechanisms and their possible role in the pathogenesis of Alzheimer disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24076336' target='_blank' class='pmid-link'>24076336</a>:</span> <span class='sentence-part'>Understanding the role of tau in both normal and degenerating synapses is crucial for the development of therapeutic strategies designed to ameliorate synapse loss and prevent AD pathogenesis. A role for tau at the synapse in Alzheimer's disease pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24493463' target='_blank' class='pmid-link'>24493463</a>:</span> <span class='sentence-part'>Amyloid-beta and tau: the trigger and bullet in Alzheimer disease pathogenesis. Therefore, Abeta is upstream of tau in AD pathogenesis and triggers the conversion of tau from a normal to a toxic state, but there is also evidence that toxic tau enhances Abeta toxicity via a feedback loop.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24785461' target='_blank' class='pmid-link'>24785461</a>:</span> <span class='sentence-part'>Heat shock protein 90 (Hsp90alpha) is a molecular chaperone which was found to regulate the function of number of client proteins including tau that is involved in the cause of the AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24936619' target='_blank' class='pmid-link'>24936619</a>:</span> <span class='sentence-part'>Changes in spatial learning ability and memory and induction of AD-like pathogenesis were not detected by in vivo brain imaging for amyloid-beta peptide accumulation and by immunohistochemical staining of amyloid precursor protein, amyloid-beta protein, tau, and phosphorylated tau protein.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25169677' target='_blank' class='pmid-link'>25169677</a>:</span> <span class='sentence-part'>Activated human microglia stimulate neuroblastoma cells to upregulate production of beta amyloid protein and tau: implications for Alzheimer's disease pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25442111' target='_blank' class='pmid-link'>25442111</a>:</span> <span class='sentence-part'>The interaction of amyloid-beta (Abeta) and tau in the pathogenesis of Alzheimer's disease is a subject of intense inquiry, with the bulk of evidence indicating that changes in tau are downstream of Abeta.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26563932' target='_blank' class='pmid-link'>26563932</a>:</span> <span class='sentence-part'>Accumulation of beta-amyloid (Abeta) and phosphorylated tau in the brain are central events underlying Alzheimer's disease (AD) pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26943044' target='_blank' class='pmid-link'>26943044</a>:</span> <span class='sentence-part'>Our findings reveal a novel mechanism underlying the htau-induced neuronal toxicities in AD and other tauopathies.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27034421' target='_blank' class='pmid-link'>27034421</a>:</span> <span class='sentence-part'>According to published research, the inverted tau concentration gradient may be one of the reasons leading to AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27079722' target='_blank' class='pmid-link'>27079722</a>:</span> <span class='sentence-part'>This is a reasonable assumption because amyloid-beta peptide (Abeta) accumulation and tau hyperphosphorylation are the defining histological features in AD, and because AbetaPP and tau mutations can cause AD in humans or AD-like features in animal models. Alzheimer's disease (AD) has long been viewed as a pathology that must be caused either by aberrant amyloid-beta protein precursor (AbetaPP) processing, dysfunctional tau protein processing, or a combination of these two factors.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27152883' target='_blank' class='pmid-link'>27152883</a>:</span> <span class='sentence-part'>Tau is a microtubule-associated protein implicated in the pathogenesis of Alzheimer's disease and other related tauopathies.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27651066' target='_blank' class='pmid-link'>27651066</a>:</span> <span class='sentence-part'>Tau is a microtubule-associated protein that plays an important role in the pathogenesis of neurodegenerative diseases such as Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28186985' target='_blank' class='pmid-link'>28186985</a>:</span> <span class='sentence-part'>Hyperphosphorylation of Tau forming neurofibrillary tangles has been considered as a crucial event in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28420695' target='_blank' class='pmid-link'>28420695</a>:</span> <span class='sentence-part'>Cyclin-dependent kinase 5 (Cdk5), which binds to and is activated by p35, phosphorylates multiple substrates and plays an essential role in the development and function of the CNS; however, proteolytic production of p25 from p35 under stress conditions leads to the inappropriate activation of Cdk5 and contributes to hyperphosphorylation of tau and other substrates that are related to the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28580182' target='_blank' class='pmid-link'>28580182</a>:</span> <span class='sentence-part'>There is growing evidence that in addition to Abeta deposition, accumulation of hyperphosphorylated oligomeric tau contributes significantly to AD etiology.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28655349' target='_blank' class='pmid-link'>28655349</a>:</span> <span class='sentence-part'>BACKGROUND: Finding ways to reverse or prevent the consequences of pathogenic tau in the brain is of considerable importance for treatment of Alzheimer's disease and other tauopathies.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29237931' target='_blank' class='pmid-link'>29237931</a>:</span> <span class='sentence-part'>OBJECTIVE: To review recent research advances on tau, a major player in Alzheimer's disease (AD) pathogenesis, a biomarker for AD onset, and potential target for AD therapy.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29278891' target='_blank' class='pmid-link'>29278891</a>:</span> <span class='sentence-part'>We investigated the CSF levels of Abeta and tau, another pathological hallmark in the AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29554190' target='_blank' class='pmid-link'>29554190</a>:</span> <span class='sentence-part'>Conclusions and Relevance: Alzheimer disease CSF core biomarkers can be used with high specificity for the in vivo identification of patients with pure FTLD-TDP and FTLD-tau when accounting for comorbid AD and genetic status.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29782836' target='_blank' class='pmid-link'>29782836</a>:</span> <span class='sentence-part'>Structural studies show interaction modes of Hsp90 with the intrinsically disordered Alzheimer's disease-causing protein Tau, the kinase Cdk4 in a partially unfolded state and the folded ligand-binding domain of a steroid receptor.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29954063' target='_blank' class='pmid-link'>29954063</a>:</span> <span class='sentence-part'>However, the roles of A&amp;beta; and Tau in AD pathology are being questioned and other causes of AD are postulated.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30278184' target='_blank' class='pmid-link'>30278184</a>:</span> <span class='sentence-part'>These findings have implications for further studies of tau under the conditions of protein phosphatase downregulation, aiming to explain mechanisms involved in early events leading to AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30382187' target='_blank' class='pmid-link'>30382187</a>:</span> <span class='sentence-part'>Here we show that the fragments of delta-secretase-cleavage, APP (586-695) and Tau(1-368), additively drive AD pathogenesis and cognitive dysfunctions.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30744518' target='_blank' class='pmid-link'>30744518</a>:</span> <span class='sentence-part'>Given that accumulation of hyperphosphorylated MAPT contributes to the pathogenesis of Alzheimer disease and other tauopathies, decreasing endogenous MAPT levels has been shown to be beneficial to neuronal health in models of these diseases.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30864847' target='_blank' class='pmid-link'>30864847</a>:</span> <span class='sentence-part'>Recent studies imply that sleep-wake cycles affect brain tau more significantly than Abeta levels, leading to accelerated AD progression and cognitive decline.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31016584' target='_blank' class='pmid-link'>31016584</a>:</span> <span class='sentence-part'>As the HIV-infected population is aging, it is becoming increasingly important to understand how HIV-Tat may interact with proteins such as amyloid beta and Tau which accumulate in the aging brain and eventually result in Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31308793' target='_blank' class='pmid-link'>31308793</a>:</span> <span class='sentence-part'>Mitochondrial dysfunction is also a prominent feature in AD, and the extracellular Abeta and phosphorylated tau result in the impaired mitochondrial dynamics.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31524157' target='_blank' class='pmid-link'>31524157</a>:</span> <span class='sentence-part'>This finding provides further evidence for a mechanistic connection between Abeta and tau at seminal stages of AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31796124' target='_blank' class='pmid-link'>31796124</a>:</span> <span class='sentence-part'>These findings shed light on early PTM changes of tau during AD pathogenesis in human brains.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/7532213' target='_blank' class='pmid-link'>7532213</a>:</span> <span class='sentence-part'>Several PDPKs can phosphorylate tau in vitro and induce Alzheimer-like epitopes to many phosphorylation-dependent antibodies.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/7533559' target='_blank' class='pmid-link'>7533559</a>:</span> <span class='sentence-part'>These results suggest that abnormal phosphorylation at Ser-202 of PHF-tau in DNs represents one of the earliest neuropathological changes within the neurites of vulnerable neurons and may have a pivotal role in the initial pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/7566354' target='_blank' class='pmid-link'>7566354</a>:</span> <span class='sentence-part'>It is unclear whether levels of nuclear tau can be correlated to pathologic events in AD, but its insoluble nature along with reports of intranuclear PHFs warrant further studies of nuclear tau as a molecular candidate in the genesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/7822152' target='_blank' class='pmid-link'>7822152</a>:</span> <span class='sentence-part'>PURPOSE: Increased immunoreactivity (IR) of beta-amyloid and the amyloid-associated proteins tau and amyloid precursor protein (APP) in the brain have been linked to the pathogenesis of neurodegenerative disorders such as Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/7891887' target='_blank' class='pmid-link'>7891887</a>:</span> <span class='sentence-part'>Isoform-specific interactions of apoE with the microtubule-associated proteins MAP2c and tau might affect intracellular maintenance of microtubules and could contribute to a time-dependent pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/8764598' target='_blank' class='pmid-link'>8764598</a>:</span> <span class='sentence-part'>The ability of GSK-3beta to phosphorylate APPcyt and tau provides a putative link between the two lesions and indicates a critical role of GSK-3beta in the pathogenesis of Alzheimer's disease.</span></div></div>
<div class='streamlined-assertion'><div class='streamlined-header sticky-relation-header'><span class='label-text'>Subject:</span> <strong>MAPT_protein_human_MAPT</strong> <span class='label-text'>Subject CUI:</span> <strong>C1454489|4137</strong> â†’ <span class='label-text predicate-text'>CAUSES</span> â†’ <span class='label-text'>Object:</span> <strong>Alzheimers</strong> <span class='label-text'>Object CUI:</span> <strong>C0002395</strong></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31941827' target='_blank' class='pmid-link'>31941827</a>:</span> <span class='sentence-part'>Here, we reveal a previously unappreciated direct role of norepinephrine signaling in connecting beta-amyloid (Abeta) and tau, two key pathological components of AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31961372' target='_blank' class='pmid-link'>31961372</a>:</span> <span class='sentence-part'>Elevation of CSF P-tau appears to precede flortaucipir-PET positivity in the progression of AD pathogenesis and related cognitive decline.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31997800' target='_blank' class='pmid-link'>31997800</a>:</span> <span class='sentence-part'>In this review, we emphasize the recent studies about the toxic and shape-shifting nature of tau in the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32226410' target='_blank' class='pmid-link'>32226410</a>:</span> <span class='sentence-part'>Given the importance of tau to AD pathogenesis and therapies, it is important to understand non-classic physiological functions for this protein inside and outside the central nervous system (CNS).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32404183' target='_blank' class='pmid-link'>32404183</a>:</span> <span class='sentence-part'>Under the synergistic effects of T807, T807/RPCNP can not only effectively penetrate the blood-brain barrier (BBB), but they also possess high binding affinity to hyperphosphorylated tau in nerve cells where they inhibit multiple key pathways in tau-associated AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32572101' target='_blank' class='pmid-link'>32572101</a>:</span> <span class='sentence-part'>Cellular polyamines condense hyperphosphorylated Tau, triggering Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32649026' target='_blank' class='pmid-link'>32649026</a>:</span> <span class='sentence-part'>Alzheimer's Disease risk modifier genes do not affect tau aggregate uptake, seeding or maintenance in cell models.Alzheimer's disease (AD) afflicts millions of people worldwide and is caused by accumulated amyloid beta and tau pathology.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32780352' target='_blank' class='pmid-link'>32780352</a>:</span> <span class='sentence-part'>Hyperphosphorylation Renders Tau Prone to Aggregate and to Cause Cell Death.Alzheimer's disease (AD) is a neurodegenerative disorder without a cure or prevention to date.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32784025' target='_blank' class='pmid-link'>32784025</a>:</span> <span class='sentence-part'>This review will divulge the importance of tau in AD pathogenesis, the interplay of Abeta and tau, the pathological functions of tau, and potential therapeutic strategies for an effective management of neuronal disorders.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32827351' target='_blank' class='pmid-link'>32827351</a>:</span> <span class='sentence-part'>DISCUSSION: Refining the molecular mechanisms connecting tau, Abeta, and apoE with cerebrovascular pathologies is critical for greater understanding of AD pathogenesis and establishing effective therapeutic interventions for the disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32967303' target='_blank' class='pmid-link'>32967303</a>:</span> <span class='sentence-part'>The present review will focus on the mechanisms that lead to cytosolic and especially mitochondrial Ca     2+       disturbances occurring in AD and tau-induced FTD, and propose possible therapeutic interventions for these disorders.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32972344' target='_blank' class='pmid-link'>32972344</a>:</span> <span class='sentence-part'>However, much attention has been given to the link between tau and beta-amyloid hypothesis in AD pathogenesis/prognosis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33013321' target='_blank' class='pmid-link'>33013321</a>:</span> <span class='sentence-part'>Overexpression of GSK-3beta in Adult Tet-OFF GSK-3beta Transgenic Mice, and Not During Embryonic or Postnatal Development, Induces Tau Phosphorylation, Neurodegeneration and Learning Deficits.GSK-3beta or tau-kinase I is particularly abundant in the central nervous system (CNS), playing a key role in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33168053' target='_blank' class='pmid-link'>33168053</a>:</span> <span class='sentence-part'>Although tau is recognized to play a central role in pathogenesis of AD, the precise mechanisms by which these abnormal PTMs contribute to the neural toxicity of tau is unclear.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33224974' target='_blank' class='pmid-link'>33224974</a>:</span> <span class='sentence-part'>Particularly, the aggregation of misfolded amyloid-   beta     and hyperphosphorylated tau and    alpha    -synuclein are linked to the pathogenesis of AD and PD, respectively.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33328854' target='_blank' class='pmid-link'>33328854</a>:</span> <span class='sentence-part'>Neurofibrillary tangles (NFTs) are pathological hallmarks of AD and due to accumulated phosphorylated Tau.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33386802' target='_blank' class='pmid-link'>33386802</a>:</span> <span class='sentence-part'>Such stress provides the activation energy needed to induce conformational changes of both Abeta and tau within the lower brain and brainstem region, producing unique neurotoxic oligomer molecule conformations that induce AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33425704' target='_blank' class='pmid-link'>33425704</a>:</span> <span class='sentence-part'>Glycogen synthase kinase 3 beta (GSK3 beta) plays a key role in pathologic hyper phosphorylation of tau and plays an important role in the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33560154' target='_blank' class='pmid-link'>33560154</a>:</span> <span class='sentence-part'>Areas covered    : Considering the significance of Abeta and Tau in AD pathogenesis, these proteins have currently been adopted as the core biomarkers of AD, and their quantification has provided precise diagnostic information to develop next-generation AD therapeutic approaches.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33665647' target='_blank' class='pmid-link'>33665647</a>:</span> <span class='sentence-part'>Here, we review emerging evidence for a critical nexus among Abeta, tau, and the lysosomal protease cathepsin D (CatD) that we hypothesize may play a pivotal role in the etiology of AD. Future research into these novel mechanistic links among Abeta, tau and CatD promises to expand our understanding of the etiology of AD and could potentially lead to novel therapeutic approaches for combatting this devastating disease of brain and mind. Despite a wealth of experimental and genetic evidence implicating both Abeta and tau in the pathogenesis of AD, the precise molecular links between these two pathological hallmarks have remained surprisingly elusive.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33809978' target='_blank' class='pmid-link'>33809978</a>:</span> <span class='sentence-part'>The self-assembly of tau into paired helical filaments (PHFs) in neurofibrillary tangles (NFTs) is a significant event in Alzheimer's disease (AD) pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34015458' target='_blank' class='pmid-link'>34015458</a>:</span> <span class='sentence-part'>Excessive accumulation of amyloid beta-protein (Abeta) is one of the primary mechanisms that leads to neuronal death with phosphorylated tau in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34283221' target='_blank' class='pmid-link'>34283221</a>:</span> <span class='sentence-part'>On the other hand, ELISAs combining antibodies against the later-middle to C-terminal regions of tau produced substantially increased signals from AD samples, compared to those from non-AD controls.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34738809' target='_blank' class='pmid-link'>34738809</a>:</span> <span class='sentence-part'>This study not only provides a further insight into the involvement of subchronic Cd     2+       exposure in the tau etiology of AD but also offers more comprehensive and effective information about the asymptomatic stage of AD upon environmental risk, which has potential applications in the early diagnosis and therapy.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34751792' target='_blank' class='pmid-link'>34751792</a>:</span> <span class='sentence-part'>The hyperphosphorylation of tau is a central mechanism in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35443153' target='_blank' class='pmid-link'>35443153</a>:</span> <span class='sentence-part'>Amyloid-beta and tau are key molecules in the pathogenesis of Alzheimer's disease, but it remains unclear how these proteins interact to promote disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35786817' target='_blank' class='pmid-link'>35786817</a>:</span> <span class='sentence-part'>CONCLUSION: The tau deletion mutation significantly improved the synaptic damage caused by Abeta, and tau protein played an indispensable role in the synaptic dysfunction caused by Abeta, suggesting that Abeta and tau have close interactions in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35864434' target='_blank' class='pmid-link'>35864434</a>:</span> <span class='sentence-part'>It boosts the antioxidant enzyme activities, prevents Tau-induced oxidative stress, ameliorates eye degeneration, and inhibits cholinesterase activities in Tau-induced AD model.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35928283' target='_blank' class='pmid-link'>35928283</a>:</span> <span class='sentence-part'>However, it is still not clear to what extent DYRK1A overexpression by itself leads to AD-like phenotypes and how these compare to Tau and Amyloid-beta mediated pathology.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36066633' target='_blank' class='pmid-link'>36066633</a>:</span> <span class='sentence-part'>Amyloid-beta 42 (Abeta42) and phosphorylated tau (pTau) levels in cerebrospinal fluid (CSF) reflect core features of the pathogenesis of Alzheimer's disease (AD) more directly than clinical diagnosis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36399096' target='_blank' class='pmid-link'>36399096</a>:</span> <span class='sentence-part'>Modulation of the effect of the epsilon4 alleles by    TOMM40     and    APOC1     variants indicates the potential genetic mechanism of differential roles of Abeta and tau in AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36634842' target='_blank' class='pmid-link'>36634842</a>:</span> <span class='sentence-part'>Misfolded hyperphosphorylated tau (p-tau) is considered a pivotal point in the pathogenesis of AD and other tauopathies.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36967088' target='_blank' class='pmid-link'>36967088</a>:</span> <span class='sentence-part'>Extracellular tau has been highlighted in the pathogenesis of Alzheimer disease (AD), which is the most common neurodegenerative disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37239068' target='_blank' class='pmid-link'>37239068</a>:</span> <span class='sentence-part'>Emerging evidence over the past few decades supports the critical role of Abeta and tau in AD pathogenesis and the participation of glial cells in different molecular and cellular pathways.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37332018' target='_blank' class='pmid-link'>37332018</a>:</span> <span class='sentence-part'>Therefore, in this review, we will discuss for the first time the importance of truncated tau by caspases activation in the pathogenesis of AD and how its negative actions could impact neuronal function.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37333306' target='_blank' class='pmid-link'>37333306</a>:</span> <span class='sentence-part'>A major driver of AD progression is the spreading of pathogenic Tau protein between brain regions, precipitated by neuronal Tau secretion.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37371067' target='_blank' class='pmid-link'>37371067</a>:</span> <span class='sentence-part'>Herein, we investigated the effects of TREM2 deficiency on tau spreading using a mouse model in which endogenous tau is seeded to produce AD-like tau features.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37503224' target='_blank' class='pmid-link'>37503224</a>:</span> <span class='sentence-part'>A major driver of AD progression is the spreading of pathogenic Tau protein between brain regions, precipitated by neuronal Tau secretion.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37777806' target='_blank' class='pmid-link'>37777806</a>:</span> <span class='sentence-part'>Accumulating evidence suggests that TDP-43 and p-tau interact and exhibit pathological synergy during AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/38110916' target='_blank' class='pmid-link'>38110916</a>:</span> <span class='sentence-part'>The neuronal aggregated tau observed in AD cells suggests that the protein folding problem is a major cause of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/38178136' target='_blank' class='pmid-link'>38178136</a>:</span> <span class='sentence-part'>And the relation between the peripheral blood Abeta and tau tangles of brain, another crucial pathologic factor contributing to the pathogenesis of AD, is also ambiguous. More recently, the anti-Abeta monoclonal antibodies are approved for treatment of AD patients through declining the peripheral blood Abeta mechanism of action to enhance plasma and central nervous system (CNS) Abeta clearance, leading to a decrease Abeta burden in brain and improving cognitive function, which clearly indicates that the levels of the peripheral blood Abeta impacted on the Abeta burden in brain and involved in the pathogenesis of AD. In the present review, we summarize recent studies on the roles of peripheral blood Abeta and the peripheral innate immune cells in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/38238309' target='_blank' class='pmid-link'>38238309</a>:</span> <span class='sentence-part'>A major driver of AD progression is the spreading of pathogenic Tau protein between brain regions, precipitated by neuronal Tau secretion.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/38281031' target='_blank' class='pmid-link'>38281031</a>:</span> <span class='sentence-part'>CONCLUSIONS: This work establishes a tau-induced AD-like NHP model with many key pathological and behavioural features of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/38434588' target='_blank' class='pmid-link'>38434588</a>:</span> <span class='sentence-part'>This observation, along with the failure of previous clinical trials targeting Abeta or Tau and the modest success of recent trials using Abeta monoclonal antibodies, has led to a reappraisal of the view that Abeta accumulation is the sole factor in the pathogenesis of AD.</span></div></div>
<div class='streamlined-assertion'><div class='streamlined-header sticky-relation-header'><span class='label-text'>Subject:</span> <strong>Memory_impairment</strong> <span class='label-text'>Subject CUI:</span> <strong>C0233794</strong> â†’ <span class='label-text predicate-text'>CAUSES</span> â†’ <span class='label-text'>Object:</span> <strong>Alzheimers</strong> <span class='label-text'>Object CUI:</span> <strong>C0002395</strong></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/10730508' target='_blank' class='pmid-link'>10730508</a>:</span> <span class='sentence-part'>The first stage of Alzheimer's disease commonly is marked by anxiety and depression secondary to memory impairment, and delusions.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/11966459' target='_blank' class='pmid-link'>11966459</a>:</span> <span class='sentence-part'>Thus far, the clinical utility of muscarinic agonists remains unproven, yet recent studies suggest that muscarinic agonists might be useful in treating not only memory deficits, but also psychiatric disturbances and some of the underlying causes of Alzheimer's disease, such as the deposition of Abeta.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/14503018' target='_blank' class='pmid-link'>14503018</a>:</span> <span class='sentence-part'>These preliminary findings may be important in understanding, at least in part, the molecular mechanisms that precede memory impairment during chronic brain ischemia and as such, the pre-clinical stage leading to Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17197420' target='_blank' class='pmid-link'>17197420</a>:</span> <span class='sentence-part'>First, conditional inactivation of PS in the adult mouse brain causes progressive memory loss and neurodegeneration resembling AD, whereas mouse models based on overproduction of Abeta have failed to produce neurodegeneration. Based on these and other observations, we propose that partial loss of PS function may underlie memory impairment and neurodegeneration in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21535936' target='_blank' class='pmid-link'>21535936</a>:</span> <span class='sentence-part'>Since Abeta and glucocorticoids increase with aging, DEX potentiating Abeta-induced learning and memory impairment may be one of the etiology of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22886562' target='_blank' class='pmid-link'>22886562</a>:</span> <span class='sentence-part'>Owing to the pathological impact of hypoxia, hypertension, hypoperfusion and impaired glucose metabolism, the adverse cardiovascular, neurocirculatory and metabolic consequences upregulate amyloid beta generation and tau phosphorylation, and lead to memory/cognitive impairment-culminating in AD. This article systematically delineates the steps in the complex cascade leading to AD, focusing on pathology caused by chronic intermittent hypoxia, hypertension, brain hypoperfusion, glucose dysmetabolism, and endothelial dysfunction.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25788560' target='_blank' class='pmid-link'>25788560</a>:</span> <span class='sentence-part'>Paradoxically, we found an attenuated stimulus-response function, compared to controls, suggesting that AD dementia interferes with pain ratings over time, most likely due to memory impairment.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26724580' target='_blank' class='pmid-link'>26724580</a>:</span> <span class='sentence-part'>These pathological changes have complex internal relations with one other, causing memory impairment and participating in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28159908' target='_blank' class='pmid-link'>28159908</a>:</span> <span class='sentence-part'>Amyloid-beta (Abeta) peptides play a key role in synaptic damage and memory deficits in the early pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32198621' target='_blank' class='pmid-link'>32198621</a>:</span> <span class='sentence-part'>Hyperglycemia is one of the major risk factors responsible for memory impairment in diabetes which may lead to Alzheimer's disease (AD) at a later stage.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34102642' target='_blank' class='pmid-link'>34102642</a>:</span> <span class='sentence-part'>These may be explained whereby awareness of/fear of falling increases with AD due to a preserved emotional awareness, whereas awareness of cognitive impairment is impaired due to memory deficits.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36116555' target='_blank' class='pmid-link'>36116555</a>:</span> <span class='sentence-part'>In addition, MT exerted a superior effect on ameliorating the learning ability of senescence-related and metabolic AD models, and corrected the memory deficit of the toxin-induced AD model.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36915078' target='_blank' class='pmid-link'>36915078</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) is the most prevalent cause of dementia and is primarily associated with memory impairment and cognitive decline, but the etiology of AD has not been elucidated.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37627238' target='_blank' class='pmid-link'>37627238</a>:</span> <span class='sentence-part'>Since A     2A      R overfunction is sufficient to trigger memory deficits, we tested if A     2A      R were upregulated in hippocampal synapses before the onset of memory deficits to support the hypothesis that A     2A      R overfunction could be a trigger of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37685895' target='_blank' class='pmid-link'>37685895</a>:</span> <span class='sentence-part'>SAMP8 mice have been proposed as a model for studying late-onset AD, since they show age-related learning and memory deficits as well as several features of AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/38532080' target='_blank' class='pmid-link'>38532080</a>:</span> <span class='sentence-part'>In the context of Alzheimer's disease, this is particularly relevant for patients who seek medical advice due to memory problems.</span></div></div>
<div class='streamlined-assertion'><div class='streamlined-header sticky-relation-header'><span class='label-text'>Subject:</span> <strong>Mental_deterioration</strong> <span class='label-text'>Subject CUI:</span> <strong>C0234985</strong> â†’ <span class='label-text predicate-text'>CAUSES</span> â†’ <span class='label-text'>Object:</span> <strong>Alzheimers</strong> <span class='label-text'>Object CUI:</span> <strong>C0002395</strong></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32982937' target='_blank' class='pmid-link'>32982937</a>:</span> <span class='sentence-part'>As AD results in a complex disease process for cognitive decline, various theories have been suggested as the cause of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36195639' target='_blank' class='pmid-link'>36195639</a>:</span> <span class='sentence-part'>Associations of higher brain copper levels with slower cognitive decline and with less AD pathology support a role for copper dyshomeostasis in AD pathogenesis and suggest that lower brain copper may exacerbate or indicate disease severity.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36336928' target='_blank' class='pmid-link'>36336928</a>:</span> <span class='sentence-part'>OBJECTIVE: Investigating brain topologies would help to mine the neuromechanisms of SCD and provide new insights into the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36915078' target='_blank' class='pmid-link'>36915078</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) is the most prevalent cause of dementia and is primarily associated with memory impairment and cognitive decline, but the etiology of AD has not been elucidated.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37074955' target='_blank' class='pmid-link'>37074955</a>:</span> <span class='sentence-part'>Exposure to traffic-related air pollution consisting of particulate matter (PM) is associated with cognitive decline leading to Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37310581' target='_blank' class='pmid-link'>37310581</a>:</span> <span class='sentence-part'>Thus, this study showed that the decline in renal function was correlated with abnormal AD biomarkers and cognitive decline, which provides human evidence that renal function may be involved in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37349795' target='_blank' class='pmid-link'>37349795</a>:</span> <span class='sentence-part'>Increasing the number of participants with harmonized cognitive domain scores will enhance the discovery of additional genetic factors of cognitive decline leading to AD and related dementias.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/38139415' target='_blank' class='pmid-link'>38139415</a>:</span> <span class='sentence-part'>It appears that the dynamics of AbetaPP-derived    i    Abeta accumulation is the determining factor that either drives Aging-Associated Cognitive Decline (AACD) and triggers AD or confers the resistance to both.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/38334675' target='_blank' class='pmid-link'>38334675</a>:</span> <span class='sentence-part'>Cathepsin B (CatB) is thought to be essential for the induction of    Porphyromonas gingivalis     lipopolysaccharide (   Pg     LPS)-induced Alzheimer's disease-like pathologies in mice, including interleukin-1beta (IL-1beta) production and cognitive decline.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/38460555' target='_blank' class='pmid-link'>38460555</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) poses a complex challenge, with abnormal protein accumulation in the brain causing memory loss and cognitive decline.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/38593020' target='_blank' class='pmid-link'>38593020</a>:</span> <span class='sentence-part'>Index Terms- Cognitive impairment, longitudinal data, multimodal data, encoder-decoder LSTM, progression prediction Clinical relevance The proposed approach has the potential to improve understanding of Alzheimer's disease progression in diagnostics, facilitating early identification of various stages of cognitive decline leading to AD by considering its clinical variability.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/38639833' target='_blank' class='pmid-link'>38639833</a>:</span> <span class='sentence-part'>CMHs are closely associated with accelerated cognitive decline and are increasingly recognized as key contributors to the pathogenesis of vascular cognitive impairment and dementia (VCID) and Alzheimer's disease (AD).</span></div></div>
<div class='streamlined-assertion'><div class='streamlined-header sticky-relation-header'><span class='label-text'>Subject:</span> <strong>Metals</strong> <span class='label-text'>Subject CUI:</span> <strong>C0025552</strong> â†’ <span class='label-text predicate-text'>CAUSES</span> â†’ <span class='label-text'>Object:</span> <strong>Alzheimers</strong> <span class='label-text'>Object CUI:</span> <strong>C0002395</strong></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/15105262' target='_blank' class='pmid-link'>15105262</a>:</span> <span class='sentence-part'>The emergence of redox-active metals as key players in AD pathogenesis strongly argues that amyloid-specific metal-complexing agents and antioxidants be investigated as possible disease-modifying agents for treating this horrible disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/16672274' target='_blank' class='pmid-link'>16672274</a>:</span> <span class='sentence-part'>The conformational change and associated aggregation of beta amyloid (Abeta) with or without metals is the main cause of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17522444' target='_blank' class='pmid-link'>17522444</a>:</span> <span class='sentence-part'>The role of metals in the etiology of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17612380' target='_blank' class='pmid-link'>17612380</a>:</span> <span class='sentence-part'>OBJECTIVE: Aluminium has lately been implicated as one of the possible causal factors contributing to Alzheimer's disease and other neurodegenerative disorders due to this metal is conducive to oxidative stress in the brain.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/18228200' target='_blank' class='pmid-link'>18228200</a>:</span> <span class='sentence-part'>Aluminium (Al) is a neurotoxic metal and Al exposure may be a factor in the aetiology of various neurodegenerative diseases such as Alzheimer's disease (AD). Aluminium exposure induces Alzheimer's disease-like histopathological alterations in mouse brain.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/18376063' target='_blank' class='pmid-link'>18376063</a>:</span> <span class='sentence-part'>Recent studies also point to redox active metals such as iron, copper and zinc in mediating oxidative stress in AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20308778' target='_blank' class='pmid-link'>20308778</a>:</span> <span class='sentence-part'>Metal ions are known to catalyze the production of free radicals and induce mental retardation or dementia, and several studies have also identified metals such as Pb, Fe, Al, Cu, and Zn in AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21303349' target='_blank' class='pmid-link'>21303349</a>:</span> <span class='sentence-part'>Despite the crucial role of redox active metals like copper and iron in central biological reactions, their elevated levels are involved in the pathogenesis of Alzheimer's Disease (AD). Iron, copper, and zinc are some of the metals, which intensify this process and contribute for the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22342404' target='_blank' class='pmid-link'>22342404</a>:</span> <span class='sentence-part'>Exposure to environmental neurotoxic metals, pesticides and other chemicals is increasingly recognized as a key risk factor in the pathogenesis of chronic neurodegenerative disorders such as Parkinson's and Alzheimer's diseases.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22370090' target='_blank' class='pmid-link'>22370090</a>:</span> <span class='sentence-part'>The key points of this review are that metals are implicated in the etiology or pathogenesis of Alzheimer's disease and other protein folding disorders, metals induce the expression GRP78, often associated with oxidative stress, some metals bind to GRP78, and lead (Pb) impairs GRP78 function when it binds to GRP78.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24682942' target='_blank' class='pmid-link'>24682942</a>:</span> <span class='sentence-part'>This metal progressively accumulates in the pathogenesis of Alzheimer's (AD) and Parkinson's (PD) diseases.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25894020' target='_blank' class='pmid-link'>25894020</a>:</span> <span class='sentence-part'>The present studies utilized synchrotron radiation X-ray fluorescence (SRXRF) and focused primarily on zinc and iron, two abundant metals in neurons that have been implicated in the pathogenesis of neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30598025' target='_blank' class='pmid-link'>30598025</a>:</span> <span class='sentence-part'>Moreover, it is already established that metals (particularly copper, zinc and iron) have a key role in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34502369' target='_blank' class='pmid-link'>34502369</a>:</span> <span class='sentence-part'>The existing data also demonstrate that AGE toxicity seems to mediate the involvement of copper (Cu) and potentially other metals in AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35727933' target='_blank' class='pmid-link'>35727933</a>:</span> <span class='sentence-part'>Disruption of the homeostasis of redox-active metals, iron and copper, is an integral part of the pathogenesis of Alzheimer's disease and Parkinson's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36613911' target='_blank' class='pmid-link'>36613911</a>:</span> <span class='sentence-part'>To further assess the involvement of heavy and essential metals in AD pathogenesis, we compared cerebrospinal fluid (CSF) AD biomarkers to macro- and microelements measured in CSF and plasma.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/7866588' target='_blank' class='pmid-link'>7866588</a>:</span> <span class='sentence-part'>Substantial evidence has accumulated implicating metals and free radicals in the pathogenesis of the major neurodegenerative disorders (Parkinson's disease, Alzheimer's disease, and amyotrophic lateral sclerosis).</span></div></div>
<div class='streamlined-assertion'><div class='streamlined-header sticky-relation-header'><span class='label-text'>Subject:</span> <strong>MicroRNAs</strong> <span class='label-text'>Subject CUI:</span> <strong>C1101610</strong> â†’ <span class='label-text predicate-text'>CAUSES</span> â†’ <span class='label-text'>Object:</span> <strong>Alzheimers</strong> <span class='label-text'>Object CUI:</span> <strong>C0002395</strong></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/18525125' target='_blank' class='pmid-link'>18525125</a>:</span> <span class='sentence-part'>We used experimental validation in addition to literature to reveal how the deregulated brain microRNAs are biomarkers for known and novel pathways in AD pathogenesis related to amyloid processing, neurogenesis, insulin resistance, and innate immunity.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21945006' target='_blank' class='pmid-link'>21945006</a>:</span> <span class='sentence-part'>This review is conducted to summarize accumulating studies focused on aberrant miRNA expression in AD brains, and to propose the systems biological view that abnormal regulation of cell cycle progression as a result of deregulation of miRNA target networks plays a central role in the pathogenesis of AD. Aberrant expression and dysfunction of brain-enriched miRNAs induce development of neurodegenerative diseases, such as Alzheimer's disease (AD) and Parkinson's disease (PD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22985563' target='_blank' class='pmid-link'>22985563</a>:</span> <span class='sentence-part'>OBJECTIVE: To observe the changes of miRNA expression profiles in APPswe/PSdeltaE9 transgenic mice and explore the possible roles of miRNA in the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23443129' target='_blank' class='pmid-link'>23443129</a>:</span> <span class='sentence-part'>These results demonstrated that oxidative stress alters the miRNA expression profile of hippocampal neurons, and the deregulated miRNAs might play a potential role in the pathogenesis of neurodegenerative diseases, such as Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23450482' target='_blank' class='pmid-link'>23450482</a>:</span> <span class='sentence-part'>Research on microRNA will facilitate in depth understanding of the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23922807' target='_blank' class='pmid-link'>23922807</a>:</span> <span class='sentence-part'>Pathway analysis, taking into account enriched target mRNAs for these signature miRNAs was also carried out, suggesting that the disturbance of multiple enzymatic pathways including lipid metabolism could play a role in AD etiology.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23962497' target='_blank' class='pmid-link'>23962497</a>:</span> <span class='sentence-part'>In conclusion, the abnormal expression of several miRNAs in hippocampus of intermediate- and late-stage AD patients suggests their involvement in AD pathogenesis, and low levels of miR-146a in CSF were associated with AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24027266' target='_blank' class='pmid-link'>24027266</a>:</span> <span class='sentence-part'>MicroRNA (miRNA) functions in the pathogenesis of major neurodegenerative diseases such as Alzheimer's disease (AD) are only beginning to emerge.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24423585' target='_blank' class='pmid-link'>24423585</a>:</span> <span class='sentence-part'>These results suggested that oxidative stress alters the miRNA expression profile of hippocampal neurons, and the deregulated miRNAs might play potential roles in the pathogenesis of neurodegenerative diseases, such as Alzheimer's disease (AD). Oxidative stress plays a critical role in the etiology and pathogenesis of Alzheimer's disease (AD), and the molecular mechanisms that control the neuron response to oxidative stress have been extensively studied.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26345540' target='_blank' class='pmid-link'>26345540</a>:</span> <span class='sentence-part'>Recent efforts have revealed the microRNA (miRNA) pathways in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26402112' target='_blank' class='pmid-link'>26402112</a>:</span> <span class='sentence-part'>Dysregulation of specific miRNAs leads to impaired synaptic plasticity resulting in Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26708942' target='_blank' class='pmid-link'>26708942</a>:</span> <span class='sentence-part'>This article also highlights Drp1 and its relationships to glycogen synthase kinase 3, cyclin-dependent kinase 5, p53, and microRNAs in AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26856603' target='_blank' class='pmid-link'>26856603</a>:</span> <span class='sentence-part'>miR-603, a novel primate-specific miRNA and an intronic miRNA of a human brain highly expressed gene KIAA1217, is implicated in the risk and pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27213057' target='_blank' class='pmid-link'>27213057</a>:</span> <span class='sentence-part'>Our data implicate dysregulation of miRNA methylation as contributor to the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27396304' target='_blank' class='pmid-link'>27396304</a>:</span> <span class='sentence-part'>Recently, an increasing number of studies revealed that the dysregulation of microRNAs (miRNAs) may be involved in the etiology of cognitive disorders as Alzheimer, Parkinson, and Huntington's diseases, Schizophrenia and Autism spectrum disorders.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27964992' target='_blank' class='pmid-link'>27964992</a>:</span> <span class='sentence-part'>This review briefly describes the studies on changes in the expressions of microRNAs in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30881384' target='_blank' class='pmid-link'>30881384</a>:</span> <span class='sentence-part'>AD is a multifactorial disorder, and accumulating evidence shows that microRNAs play a critical role in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30887246' target='_blank' class='pmid-link'>30887246</a>:</span> <span class='sentence-part'>Recently, non-coding RNAs such as microRNAs (miRNAs) and circular RNAs (circRNAs) have been reported to contribute to the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30890906' target='_blank' class='pmid-link'>30890906</a>:</span> <span class='sentence-part'>There is also emerging evidence that miRNAs play an important role in the pathogenesis of neurodegenerative diseases such as Alzheimer's disease (AD) or Parkinson's disease (PD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31685236' target='_blank' class='pmid-link'>31685236</a>:</span> <span class='sentence-part'>The role of microRNAs (miRNAs) in the pathogenesis of Alzheimer's disease (AD) is currently extensively investigated.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31965936' target='_blank' class='pmid-link'>31965936</a>:</span> <span class='sentence-part'>We found that 3, 11, or 8 neuronal development related miRNAs from the brain tissue, 13, 16 or 14 miRNAs from the blood of patient with AD, depression and schizophrenia respectively were also involved in radiation-induced brain pathological changes, suggesting a possibly specific involvement of these miRNAs in radiation-induced development of AD, depression and schizophrenia respectively.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33220166' target='_blank' class='pmid-link'>33220166</a>:</span> <span class='sentence-part'>BACKGROUND: Numerous microRNAs (miRNAs) have been identified as functional molecules in Alzheimer's disease (AD) pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33307856' target='_blank' class='pmid-link'>33307856</a>:</span> <span class='sentence-part'>OBJECTIVE: It is believed that microRNAs (miRNAs) participate in the pathogenesis of Alzheimer's disease (AD), but the specified function of miR-10b-5p in the disease has not been thoroughly understood.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33529652' target='_blank' class='pmid-link'>33529652</a>:</span> <span class='sentence-part'>Non-coding microRNAs (miRNAs or miRs) have been linked to the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33548978' target='_blank' class='pmid-link'>33548978</a>:</span> <span class='sentence-part'>Many studies have shown that microRNAs (miRNAs) are implicated in the pathogenesis of AD, and alterations of their levels in blood make them potential biomarkers for AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33672031' target='_blank' class='pmid-link'>33672031</a>:</span> <span class='sentence-part'>Cx/Panx HCs are also expressed by astrocytes and are likely involved in the release of critical toxic amounts of soluble factors-such as glutamate, adenosine triphosphate (ATP), complement component 3 derivate C3a, tumor necrosis factor (TNFalpha), apoliprotein E (ApoE), and certain miRNAs-known to play a role in the pathogenesis of AD, ALS, and other neurodegenerative disorders.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33771994' target='_blank' class='pmid-link'>33771994</a>:</span> <span class='sentence-part'>Aberrant regulation of microRNAs (miRNAs) has been implicated in the pathogenesis of Alzheimer's disease (AD), but most abnormally expressed miRNAs found in AD are not regulated by synaptic activity.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33790780' target='_blank' class='pmid-link'>33790780</a>:</span> <span class='sentence-part'>The Eminent Role of microRNAs in the Pathogenesis of Alzheimer's Disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35273693' target='_blank' class='pmid-link'>35273693</a>:</span> <span class='sentence-part'>In order to further understand the potential roles of miRNAs in the pathogenesis of AD, we analyzed Down syndrome (DS), a special model of AD, by using a TaqMan microRNA array and found that miRNA let-7c was up-regulated in both DS and AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35532940' target='_blank' class='pmid-link'>35532940</a>:</span> <span class='sentence-part'>BACKGROUND: Roles for extracellular vesicles (EVs) enriched with micro-RNAs (miRNAs) have been proposed in Alzheimer's disease (AD) pathogenesis, leading to the discovery of blood miRNAs as AD biomarkers.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35615589' target='_blank' class='pmid-link'>35615589</a>:</span> <span class='sentence-part'>Deciphering the Link Between ER     UPR       Signaling and MicroRNA in Pathogenesis of Alzheimer's Disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35783137' target='_blank' class='pmid-link'>35783137</a>:</span> <span class='sentence-part'>To identify the AD-specific differentially expressed miRNAs and mRNAs, we used bioinformatics analysis to study candidate miRNA-mRNA pairs involved in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35993941' target='_blank' class='pmid-link'>35993941</a>:</span> <span class='sentence-part'>MicroRNAs are reported to correlate with synaptic plasticity and exert functions in Alzheimer's disease (AD) pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36110561' target='_blank' class='pmid-link'>36110561</a>:</span> <span class='sentence-part'>Several lncRNAs and miRNAs play crucial roles in both these hallmarks of the AD pathogenesis and other AD-related pathological procedures such as neuronal and synaptic plasticity, neuroinflammation, neuronal differentiation and neuronal apoptosis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36453506' target='_blank' class='pmid-link'>36453506</a>:</span> <span class='sentence-part'>Finally, we constructed lncRNA-miRNA-mRNA and lncRNA-mRNA co-expression networks to reveal the potential regulator roles in AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36902178' target='_blank' class='pmid-link'>36902178</a>:</span> <span class='sentence-part'>The aim of this review was to describe the molecular interactions between miRNAs and MAPKs during AD pathogenesis by selecting evidence from experimental AD models.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/38501059' target='_blank' class='pmid-link'>38501059</a>:</span> <span class='sentence-part'>Mounting evidence has revealed critical roles of microRNAs (miRNAs) in AD pathogenesis; however, the miRNAs directly targeting    presenilin1     (   PSEN1    ), which encodes the catalytic core subunit of gamma-secretase that limits the production of Abeta from amyloid precursor protein (APP), are extremely understudied.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/38516808' target='_blank' class='pmid-link'>38516808</a>:</span> <span class='sentence-part'>RESULTS: Molecules involving in OLs' differentiation or maturation, including various transcriptional factors, cholesterol homeostasis regulators, and microRNAs could also participate in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/38558361' target='_blank' class='pmid-link'>38558361</a>:</span> <span class='sentence-part'>The interconnectedness between membrane transporters (SLCs) and microRNAs (miRNAs) in AD pathogenesis has gained increasing attention.</span></div></div>
<div class='streamlined-assertion'><div class='streamlined-header sticky-relation-header'><span class='label-text'>Subject:</span> <strong>Molecule</strong> <span class='label-text'>Subject CUI:</span> <strong>C0567416</strong> â†’ <span class='label-text predicate-text'>CAUSES</span> â†’ <span class='label-text'>Object:</span> <strong>Alzheimers</strong> <span class='label-text'>Object CUI:</span> <strong>C0002395</strong></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/10880397' target='_blank' class='pmid-link'>10880397</a>:</span> <span class='sentence-part'>Endocytosis is critical to the function and fate of molecules important to Alzheimer's disease (AD) etiology, including the beta protein precursor (betaPP), amyloid beta (Abeta) peptide, and apolipoprotein E (ApoE).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/11785012' target='_blank' class='pmid-link'>11785012</a>:</span> <span class='sentence-part'>INTRODUCTION: With their discovery in 1995, presenilins were put forward as molecules of unknown function but central to the aetiology of Alzheimer s disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/12826739' target='_blank' class='pmid-link'>12826739</a>:</span> <span class='sentence-part'>It has been suggested that a number of molecules associated with inflammation are involved in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/15004329' target='_blank' class='pmid-link'>15004329</a>:</span> <span class='sentence-part'>AIDA-1 proteins are expressed at high levels in the brain; thus, studying their involvement in AbetaPP processing and AID function might give new insights regarding a possible role for these molecules in normal brain development and in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17644432' target='_blank' class='pmid-link'>17644432</a>:</span> <span class='sentence-part'>The beta-amyloid peptide (A beta) is widely considered to be the molecule that causes Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21380836' target='_blank' class='pmid-link'>21380836</a>:</span> <span class='sentence-part'>In this regard, recent studies have shown that molecules involved in the pathogenesis of Alzheimer's disease (AD) in fact have a synaptic location.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22675504' target='_blank' class='pmid-link'>22675504</a>:</span> <span class='sentence-part'>We also demonstrate a slower turnover rate for CSF ApoE than that for amyloid beta, another molecule critically important in AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24130920' target='_blank' class='pmid-link'>24130920</a>:</span> <span class='sentence-part'>A series of studies on Abeta clearance mechanism provide new insight into the pathogenesis of AD at the molecular level and suggest a new target for the development of novel therapeutics. Amyloid-beta peptide (Abeta) is still best known as a molecule to cause Alzheimer's disease (AD) through accumulation and deposition within the frontal cortex and hippocampus in the brain.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/2507928' target='_blank' class='pmid-link'>2507928</a>:</span> <span class='sentence-part'>The regulation of extracellular proteolysis by PN-II and the deposition of at least parts of the molecule in senile plaques is consistent with previous reports that implicate altered proteolysis in the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25675299' target='_blank' class='pmid-link'>25675299</a>:</span> <span class='sentence-part'>Given the dual behavior of this molecule, there is some controversy regarding its contribution to the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26934981' target='_blank' class='pmid-link'>26934981</a>:</span> <span class='sentence-part'>Our recent work has shown that the intracellular domain of the amyloid precursor protein (APP), a molecule central to the aetiology of Alzheimer's disease binds to VAC14 and enhances PIKfyve function.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29729150' target='_blank' class='pmid-link'>29729150</a>:</span> <span class='sentence-part'>These molecules can mediate neuron-microglia interactions in a contact-dependent manner and contribute to the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30770921' target='_blank' class='pmid-link'>30770921</a>:</span> <span class='sentence-part'>Because the blood-brain barrier tightly regulates the exchange of molecules between brain and blood and maintains brain homeostasis, its impairment is increasingly recognized as a critical factor contributing to Alzheimer's disease pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32123823' target='_blank' class='pmid-link'>32123823</a>:</span> <span class='sentence-part'>As the number of stored light chains in the above protein bank has reached the hundreds, in this study, we screened them against amyloid-beta (Abeta), which is well-known as one of the molecules causing Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35791032' target='_blank' class='pmid-link'>35791032</a>:</span> <span class='sentence-part'>Specifically, we delineate how various aspects of the brain immune microenvironment, including immune gateways, immune cells, and molecules, and the interplay between immune cells and neural cells, accelerate AD pathogenesis during aging.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36140198' target='_blank' class='pmid-link'>36140198</a>:</span> <span class='sentence-part'>Despite these possibilities, improved knowledge of the relative contribution of the different innate immune cells and molecules comprising the chronically inflamed brain network to AD pathogenesis, and elucidation of the network hierarchy, are needed for planning potent preventive and/or therapeutic interventions.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37569296' target='_blank' class='pmid-link'>37569296</a>:</span> <span class='sentence-part'>In this review, we focus on the role of cells (microglia, astrocytes, and oligodendrocytes) and molecules (TREM2, tau, and beta-amyloid) of the innate immune system in the pathogenesis of Alzheimer's disease and their possible exploitation as disease biomarkers and targets of therapeutical approaches.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/9015824' target='_blank' class='pmid-link'>9015824</a>:</span> <span class='sentence-part'>The main objective of the manuscript is to review the current progress in understanding the functions of apoE in the nervous system and how malfunctioning of this molecule might result in neurodegenerative disorders such as Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/9206974' target='_blank' class='pmid-link'>9206974</a>:</span> <span class='sentence-part'>A number of molecules have been implicated in the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/9298769' target='_blank' class='pmid-link'>9298769</a>:</span> <span class='sentence-part'>Here, mice deficient in apolipoprotein E (ApoE), a molecule associated with the etiology of Alzheimer's disease, served as a model to investigate the developmental and protective effects of SNV.</span></div></div>
<div class='streamlined-assertion'><div class='streamlined-header sticky-relation-header'><span class='label-text'>Subject:</span> <strong>Mutation</strong> <span class='label-text'>Subject CUI:</span> <strong>C0026882</strong> â†’ <span class='label-text predicate-text'>CAUSES</span> â†’ <span class='label-text'>Object:</span> <strong>Alzheimers</strong> <span class='label-text'>Object CUI:</span> <strong>C0750901</strong></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/10025714' target='_blank' class='pmid-link'>10025714</a>:</span> <span class='sentence-part'>Many cases of early-onset familial Alzheimer's disease (FAD) are caused by mutations in the presenilin 1 (PS1) and PS2 genes.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/10051671' target='_blank' class='pmid-link'>10051671</a>:</span> <span class='sentence-part'>Mutations in the human presenilin genes PS1 and PS2 cause early-onset Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/10193509' target='_blank' class='pmid-link'>10193509</a>:</span> <span class='sentence-part'>First, the three genes in which mutations are known to result in early onset autosomal dominant familial Alzheimer's disease will be discussed.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/10439444' target='_blank' class='pmid-link'>10439444</a>:</span> <span class='sentence-part'>Mutation in the presenilin-1 (PS-1) gene at chromosome 14q24.3 is the most common cause of autosomal dominant early-onset Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/10549825' target='_blank' class='pmid-link'>10549825</a>:</span> <span class='sentence-part'>Autosomal dominant early-onset Alzheimer's disease results mainly from mutations of the presenilin 1 (PSEN1) gene, which codes for an integral membrane protein of 467 amino acids.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/10594046' target='_blank' class='pmid-link'>10594046</a>:</span> <span class='sentence-part'>Mutations in presenilin (PS) genes cause early onset familial Alzheimer's disease (FAD) by increasing production of the amyloidogenic form of amyloid beta peptides ending at residue 42 (Abeta42).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/10854108' target='_blank' class='pmid-link'>10854108</a>:</span> <span class='sentence-part'>Mutations in the presenilin-1 (PS-1) gene have been shown to cause early onset Alzheimer's disease (EOAD) in an autosomal dominant manner.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/10963361' target='_blank' class='pmid-link'>10963361</a>:</span> <span class='sentence-part'>Mutations in the amyloid precursor protein (APP) gene cause one form of early onset familial Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/11122949' target='_blank' class='pmid-link'>11122949</a>:</span> <span class='sentence-part'>Mutations in the amyloid precursor protein and presenilin 1 (PS1) genes are fully penetrant and cause early-onset AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/11124892' target='_blank' class='pmid-link'>11124892</a>:</span> <span class='sentence-part'>APP is a transmembrane precursor of beta-amyloid, and its mutations cause early-onset familial Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/11126202' target='_blank' class='pmid-link'>11126202</a>:</span> <span class='sentence-part'>BACKGROUND: Mutations in the presenilin proteins cause early-onset, familial Alzheimer's disease (FAD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/11161700' target='_blank' class='pmid-link'>11161700</a>:</span> <span class='sentence-part'>Most cases of familial early-onset Alzheimer's disease are caused by mutations in the presenilin 1 (PS1) gene.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/11432849' target='_blank' class='pmid-link'>11432849</a>:</span> <span class='sentence-part'>Mutations in presenilin (PS) genes cause early-onset familial Alzheimer's disease by increasing production of the amyloidogenic form of amyloid beta peptides ending at residue 42 (Abeta42).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/11444983' target='_blank' class='pmid-link'>11444983</a>:</span> <span class='sentence-part'>Mutations in the presenilin genes PS1 and PS2 cause early-onset Alzheimer's disease by altering gamma-secretase cleavage of the amyloid precursor protein, the last step in the generation of Abeta peptide.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/11489281' target='_blank' class='pmid-link'>11489281</a>:</span> <span class='sentence-part'>Most familial early-onset Alzheimer's disease (FAD) is caused by mutations in the presenilin-1 (PS1) gene.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/11710891' target='_blank' class='pmid-link'>11710891</a>:</span> <span class='sentence-part'>This genetic change may be a prevalent cause of early-onset familial AD in the Caribbean Hispanic population. A founder mutation in presenilin 1 causing early-onset Alzheimer disease in unrelated Caribbean Hispanic families.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/11816789' target='_blank' class='pmid-link'>11816789</a>:</span> <span class='sentence-part'>Amyloid plaques, primarily composed of Abeta, progressively develop in the brains of AD patients, and mutations in three genes (APP, PS1, and PS2) cause early onset familial AD (FAD) by directly increasing synthesis of the toxic, plaque-promoting Abeta42 peptide.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/11817902' target='_blank' class='pmid-link'>11817902</a>:</span> <span class='sentence-part'>Mutations in the presenilin genes PS1 and PS2 are a major cause of early onset familial Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/11898555' target='_blank' class='pmid-link'>11898555</a>:</span> <span class='sentence-part'>To date, mutations in three genes (APP, PSEN1, PSEN2) have been described to cause familial early-onset AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/11992262' target='_blank' class='pmid-link'>11992262</a>:</span> <span class='sentence-part'>Nicastrin regulates gamma-secretase cleavage of the amyloid precursor protein by forming complexes with presenilins, in which most mutations causing familial early-onset Alzheimer disease (EOAD) have been found.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/12052536' target='_blank' class='pmid-link'>12052536</a>:</span> <span class='sentence-part'>The E693G (Arctic) mutation of the amyloid precursor protein was recently found to lead to early-onset Alzheimer's disease in a Swedish family.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/12059037' target='_blank' class='pmid-link'>12059037</a>:</span> <span class='sentence-part'>Mutations in the amyloid precursor protein (APP) gene are known as causative factors in the pathogenesis of early-onset familial Alzheimer's disease (FAD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/12139484' target='_blank' class='pmid-link'>12139484</a>:</span> <span class='sentence-part'>A significant proportion of early onset Alzheimer's disease (AD) is caused by mutations in human genes for amyloid precursor protein (APP), presenilins 1 and 2 (PSEN1,2).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/12154011' target='_blank' class='pmid-link'>12154011</a>:</span> <span class='sentence-part'>We report the identification of a novel rat cDNA encoding a peptide homologous to Humanin, a secreted peptide that specifically protects against neuronal cell death induced by beta-amyloid peptide (Ab) or by mutations causing early-onset familial Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/12223532' target='_blank' class='pmid-link'>12223532</a>:</span> <span class='sentence-part'>The autosomal-dominant inherited forms of early-onset Alzheimer's disease are caused by mutations in the genes encoding APP, presenilin-1 (chromosome 14), and presenilin-2 (chromosome 1). This review covers the trafficking and processing of APP, amyloid cascade hypothesis in AD pathogenesis, physiological and pathological roles of presenilins, molecular characteristics of alpha-synuclein, their interactions, and therapeutic strategies for AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/12355988' target='_blank' class='pmid-link'>12355988</a>:</span> <span class='sentence-part'>Many of these are controversial and studies have shown conflicting results, but apoE polymorphism seems to be only one of the possible genetic factors suggested to play a role in the multifactoral pathogenesis of AD. First, the three genes in which mutations are known to result in early onset autosomal dominant familial AD (presenilins 1 and 2, and amyloid beta protein precursor [APP]): well characterized but that account for only a small proportion of AD cases.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/12390529' target='_blank' class='pmid-link'>12390529</a>:</span> <span class='sentence-part'>Mutations in the presenilin-1 (PS1) gene cause early onset familial Alzheimer's disease (FAD) by a mechanism believed to involve perturbed endoplasmic reticulum (ER) function and altered proteolytic processing of the amyloid precursor protein.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/12540060' target='_blank' class='pmid-link'>12540060</a>:</span> <span class='sentence-part'>The identification of the neurotoxic effects of beta-amyloid and the discovery of mutations responsible for early-onset Alzheimer's disease (EOAD) and their linkage to beta-amyloid overproduction, has made the amyloid hypothesis of AD the predominant influence for therapeutic targets.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/12558063' target='_blank' class='pmid-link'>12558063</a>:</span> <span class='sentence-part'>AD appears to have a heterogeneous etiology with a large percentage termed sporadic AD arising from unknown causes and a smaller fraction of early onset familial AD (FAD) caused by mutations in one of several genes, such as the beta-amyloid precursor protein (APP) and presenilins (PS1, PS2).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/12605888' target='_blank' class='pmid-link'>12605888</a>:</span> <span class='sentence-part'>Mutations in the presenilin (PS) genes, PS1 and PS2, are a major cause of early-onset familial Alzheimer's disease (FAD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/12629906' target='_blank' class='pmid-link'>12629906</a>:</span> <span class='sentence-part'>Mutations in the amyloid precursor protein gene (APP) and the presenilin genes (PSEN1 en PSEN2) cause early onset Alzheimer's disease. Research in the field of Alzheimer's disease has shown that genetic factors play an important role in the aetiology of the disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/1303172' target='_blank' class='pmid-link'>1303172</a>:</span> <span class='sentence-part'>These data suggest that mutations in APP are a rare cause of familial early onset AD (3/21 families tested) and that within APP most, possibly all, mutations which cause AD are in exon 17.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/14610118' target='_blank' class='pmid-link'>14610118</a>:</span> <span class='sentence-part'>BACKGROUND: Plasma amyloid [beta]-peptide (A[beta]) 40 and A[beta]42 levels are increased in persons with mutations causing early-onset familial Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/14643748' target='_blank' class='pmid-link'>14643748</a>:</span> <span class='sentence-part'>Most familial early-onset Alzheimer's disease (FAD) is caused by mutations in the presenilin-1 (PS1) gene.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/14769392' target='_blank' class='pmid-link'>14769392</a>:</span> <span class='sentence-part'>Mutations in three causative genes have been identified in patients with an autosomal-dominant form of early-onset Alzheimer's disease (EOAD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/15038915' target='_blank' class='pmid-link'>15038915</a>:</span> <span class='sentence-part'>Familial early onset AD is a heterogeneous disorder that can be caused by mutations in at least three different genes.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/15126696' target='_blank' class='pmid-link'>15126696</a>:</span> <span class='sentence-part'>Data that have accumulated for well over a decade have implicated the beta-amyloid (Abeta) peptide as a central player in the pathogenesis of Alzheimer's disease (AD). Amyloid plaques, composed primarily of Abeta progressively form in the brains of AD patients, and mutations in three genes (amyloid precursor protein [APP] and presenilin 1 and 2 [PS1 and PS2]) cause early-onset familial AD (FAD) by directly increasing production of the toxic, plaque-promoting Abeta42 peptide.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/15249849' target='_blank' class='pmid-link'>15249849</a>:</span> <span class='sentence-part'>Early-onset AD can be due to mutations in several autosomal dominant genes.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/15337637' target='_blank' class='pmid-link'>15337637</a>:</span> <span class='sentence-part'>Mutations in the presenilin-1 (PS-1) gene are the main cause of autosomal-dominant early onset Alzheimer's disease (EOAD) and show a high penetrance of symptoms. Genotype-phenotype analysis in early-onset Alzheimer's disease due to presenilin-1 mutations at codon 139.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/15534188' target='_blank' class='pmid-link'>15534188</a>:</span> <span class='sentence-part'>BACKGROUND: Early-onset familial Alzheimer disease is caused by mutations in the amyloid precursor protein (APP), presenilin-1 (PSEN1), or presenilin-2 (PSEN2) genes.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/15544501' target='_blank' class='pmid-link'>15544501</a>:</span> <span class='sentence-part'>These studies together with findings that A beta is neurotoxic in vitro, provide evidence that some aggregates of this peptide are the key to the pathogenesis of AD. A small fraction of early onset familial AD (FAD) is caused by mutations in genes, such as the beta-amyloid precursor protein (APP) and presenilins that increase the load of A beta in the brain.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/15663477' target='_blank' class='pmid-link'>15663477</a>:</span> <span class='sentence-part'>In support of our hypothesis, the four verified PS2 FAD mutations cause substantial changes in the Abeta 42/40 ratio, comparable with PS1 mutations that cause very-early-onset FAD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/15950763' target='_blank' class='pmid-link'>15950763</a>:</span> <span class='sentence-part'>The pathogenesis of Alzheimer's disease (AD) is now thought to be tightly linked to Abeta deposition and oxidative stress, but it is still unknown how these factors result in neuronal dysfunction and cell death. Mutations of presenilin 1 (PS1) gene are the causative gene for early onset familial AD (FAD) due to the overproduction and deposition of pathogenic Abeta1-42 peptides.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/16857570' target='_blank' class='pmid-link'>16857570</a>:</span> <span class='sentence-part'>Plasma concentrations of Abeta(1-40) and Abeta(1-42) rise with age and are increased in people with mutations that cause early-onset Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/16897084' target='_blank' class='pmid-link'>16897084</a>:</span> <span class='sentence-part'>In the current letter, we expand this observation by describing an additional 15 independent families with the Ala431Glu substitution in the PSEN1 gene and conclude that this mutation is not an uncommon cause of early-onset autosomal dominant AD in persons of Mexican origin.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17131822' target='_blank' class='pmid-link'>17131822</a>:</span> <span class='sentence-part'>Most cases of familial early-onset Alzheimer's disease are caused by mutations in the presenilin 1 (PS1) gene.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17169464' target='_blank' class='pmid-link'>17169464</a>:</span> <span class='sentence-part'>Mutations in the presenilin 1 gene cause most early onset familial Alzheimer's disease (FAD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17645236' target='_blank' class='pmid-link'>17645236</a>:</span> <span class='sentence-part'>Over 100 mutations in the presenilin-1 gene (PSEN1) have been shown to result in familial early onset Alzheimer disease (EOAD), but only a relatively few give rise to plaques with an appearance like cotton wool (CWP) and/or spastic paraparesis (SP). A single point mutation, p.L420R (g.1508T &gt; G) that gives rise to a missense mutation in the eighth transmembrane (TM8) domain of PS1 was identified in two affected members of the family. p.L420R (g.1508T &gt; G) is the mutation responsible for EOAD, seizures and CWP without SP in this family.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17728018' target='_blank' class='pmid-link'>17728018</a>:</span> <span class='sentence-part'>Mutations in presenilin (PS) genes cause majority of early onset Alzheimer's disease (AD), an age related neurodegenerative disorder.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17920016' target='_blank' class='pmid-link'>17920016</a>:</span> <span class='sentence-part'>Mutations in the amyloid precursor protein (APP) cause early-onset Alzheimer's disease (AD), but the only genetic risk factor for late-onset AD is the varepsilon4 allele of apolipoprotein E (apoE), a major cholesterol carrier.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17927985' target='_blank' class='pmid-link'>17927985</a>:</span> <span class='sentence-part'>Mutations in presenilin which result in early-onset Alzheimer disease (AD) cause both increased calcium release from intracellular stores, primarily endoplasmic reticulum (ER), and changes in NF-kappaB activation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/18367332' target='_blank' class='pmid-link'>18367332</a>:</span> <span class='sentence-part'>Presenilin (PS1 and PS2) mutations cause early-onset familial Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/18403054' target='_blank' class='pmid-link'>18403054</a>:</span> <span class='sentence-part'>Mutations in amyloid precursor protein (APP) and presenilin (PSEN) genes are known to cause familial early-onset Alzheimer's disease (AD), which account for around 5% of AD cases.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/18437002' target='_blank' class='pmid-link'>18437002</a>:</span> <span class='sentence-part'>Although mutations in three genes, amyloid precursor protein (APP), presenilin 1 (PSEN1), and presenilin 2 (PSEN2), have been identified as genetic causes of early-onset Alzheimer s disease (EOAD), there has been a single report on a PSEN1 mutation in Koreans.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/18580586' target='_blank' class='pmid-link'>18580586</a>:</span> <span class='sentence-part'>OBJECTIVE: Early onset familial Alzheimer disease (EOFAD) can be caused by mutations in genes for amyloid precursor protein, presenilin 1 (PSEN1), or presenilin 2 (PSEN2). CONCLUSIONS: This is the first description of neuropathologic findings in EOFAD owing to N135S PSEN1 mutation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/18973685' target='_blank' class='pmid-link'>18973685</a>:</span> <span class='sentence-part'>ZAbeta3 coexpression moreover permits the recombinant production of Abeta(1-42) carrying the Arctic (E22G) mutation, which causes early onset familial AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/19076441' target='_blank' class='pmid-link'>19076441</a>:</span> <span class='sentence-part'>CMRglc reductions were observed on FDG-PET before the onset of disease in several groups of at-risk individuals, including patients with mild cognitive impairment (MCI), often a prodrome to AD; presymptomatic individuals carrying mutations responsible for early-onset familial AD; cognitively normal elderly individuals followed for several years until they declined to MCI and eventually to AD; normal, middle-aged individuals who expressed subjective memory complaints and were carriers of the apolipoprotein E epsilon-4 allele, a strong genetic risk factor for late-onset AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/19196715' target='_blank' class='pmid-link'>19196715</a>:</span> <span class='sentence-part'>Mutations of the presenilin 1 (PS1) gene are the most common cause of early onset familial Alzheimer disease (FAD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/19363265' target='_blank' class='pmid-link'>19363265</a>:</span> <span class='sentence-part'>Mutations in the amyloid-beta protein precursor (AbetaPP) gene can cause autosomal dominant early-onset Alzheimer's disease, or Alzheimer's disease (AD) associated with cerebral amyloid angiopathy (CAA), cerebral hemorrhage, or both.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/1944558' target='_blank' class='pmid-link'>1944558</a>:</span> <span class='sentence-part'>Early-onset Alzheimer's disease caused by mutations at codon 717 of the beta-amyloid precursor protein gene.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/19524115' target='_blank' class='pmid-link'>19524115</a>:</span> <span class='sentence-part'>Mutations in presenilin (PS) and amyloid precursor protein (APP) genes are a predominant cause for early-onset familial Alzheimer disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/19659892' target='_blank' class='pmid-link'>19659892</a>:</span> <span class='sentence-part'>To date, three genes have been identified in which mutations cause early-onset autosomal dominant inherited AD: APP, PSEN1, and PSEN2.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/19716367' target='_blank' class='pmid-link'>19716367</a>:</span> <span class='sentence-part'>Studies of mutations that cause early onset AD and promote Abeta accumulation in the brain strongly support the notion that inhibiting Abeta aggregation will prevent AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/19853579' target='_blank' class='pmid-link'>19853579</a>:</span> <span class='sentence-part'>Presenilin is the catalytic member of the gamma-secretase proteolytic complex and mutations in presenilins are the major cause of early-onset familial Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20076796' target='_blank' class='pmid-link'>20076796</a>:</span> <span class='sentence-part'>This review will give an overview of FDG-PET results in individuals at risk for developing dementia, including: presymptomatic individuals carrying mutations responsible for early-onset familial AD; patients with Mild Cognitive Impairment (MCI), often a prodrome to late-onset sporadic AD; non-demented carriers of the Apolipoprotein E (ApoE) epsilon4 allele, a strong genetic risk factor for late-onset AD; cognitively normal subjects with a family history of AD; subjects with subjective memory complaints; and normal elderly followed longitudinally until they expressed the clinical symptoms and received post-mortem confirmation of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20119496' target='_blank' class='pmid-link'>20119496</a>:</span> <span class='sentence-part'>MAIN METHODS: Here, we have explored the anti-amyloid properties of these SMAbetaBA's in mice doubly transgenic for human prensenilin-1 (PS1) and APP gene mutations that cause early-onset AD. AIMS: One promising approach for treatment of Alzheimer's disease (AD) is use of anti-amyloid therapies, based on the hypothesis that increases in amyloid-beta (Abeta) deposits in brain are a major cause of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20129170' target='_blank' class='pmid-link'>20129170</a>:</span> <span class='sentence-part'>Mutations in the presenilin genes cause early-onset familial Alzheimer's disease, but mutation carriers have substantial phenotypic heterogeneity.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20213228' target='_blank' class='pmid-link'>20213228</a>:</span> <span class='sentence-part'>Mutations in the presenilin 1 (PSEN1) gene are more commonly identified as genetic causes of early-onset familial Alzheimer's disease than mutations in the amyloid precursor protein (APP) and the presenilin 2 (PSEN2) genes.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20541250' target='_blank' class='pmid-link'>20541250</a>:</span> <span class='sentence-part'>PS1 mutations causing early-onset AD produce a similar lysosomal/autophagy phenotype in fibroblasts from AD patients.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20559464' target='_blank' class='pmid-link'>20559464</a>:</span> <span class='sentence-part'>By contrast, mutations in the presenilin genes responsible for early onset familial AD cause rapid disease progression and accentuate clinical and pathological features including inflammation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20586737' target='_blank' class='pmid-link'>20586737</a>:</span> <span class='sentence-part'>Approximately 0.5% of those with Alzheimer's disease have an autosomal dominant inherited early onset Alzheimer's disease, caused by mutations in the APP, PSEN1 or PSEN2 gene.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21130746' target='_blank' class='pmid-link'>21130746</a>:</span> <span class='sentence-part'>Mutations in APP (amyloid-beta precursor protein), which flanks the Abeta sequence, cause early-onset familial AD, and evidence has pointed to the APP-to-Abeta conversion as a possible therapeutic target.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21297272' target='_blank' class='pmid-link'>21297272</a>:</span> <span class='sentence-part'>Studies in carriers of mutations that cause early-onset familial Alzheimer's disease (eoFAD) are of significant interest.We showed previously that regional glucose hypometabolism could be detected many years before disease onset in presenilin 1(PSEN1) mutation carriers.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21524270' target='_blank' class='pmid-link'>21524270</a>:</span> <span class='sentence-part'>Mutations in the presenilin genes cause the majority of early-onset familial Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21544564' target='_blank' class='pmid-link'>21544564</a>:</span> <span class='sentence-part'>Mutations in the presenilin 2 (PSEN2) gene are less commonly identified as genetic causes of early-onset familial Alzheimer's disease than mutations in the amyloid precursor protein (APP) and the presenilin 1 (PSEN1) genes.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21784978' target='_blank' class='pmid-link'>21784978</a>:</span> <span class='sentence-part'>Mutations in presenilins (PS) account for most early-onset familial Alzheimer's disease (FAD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21785673' target='_blank' class='pmid-link'>21785673</a>:</span> <span class='sentence-part'>Amyloid precursor protein, presenilin 1 and presenilin 2 mutations are known to cause familial early-onset AD, whereas apolipoprotein E (APOE) epsilon4 is a susceptibility gene for late-onset AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22033785' target='_blank' class='pmid-link'>22033785</a>:</span> <span class='sentence-part'>Mutations in these genes have been found to cause mainly early-onset AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22221884' target='_blank' class='pmid-link'>22221884</a>:</span> <span class='sentence-part'>To date, more than 200 mutations in three genes have been identified as cause of early-onset autosomal dominant inherited AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22359955' target='_blank' class='pmid-link'>22359955</a>:</span> <span class='sentence-part'>Although most cases of early-onset familial Alzheimer's disease are caused by mutations in the presenilin 1 (PS1) gene, the functions of PS1 and its role in synaptic disfunction are not yet completely understood.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22766738' target='_blank' class='pmid-link'>22766738</a>:</span> <span class='sentence-part'>Presenilin 1 (PS1) mutations are the most common cause of early-onset familial Alzheimer's disease (EOFAD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22815225' target='_blank' class='pmid-link'>22815225</a>:</span> <span class='sentence-part'>Mutations in the PSEN1 gene are the most common genetic cause of early onset Alzheimer's disease, whereas APP and PSEN2 gene mutations are less frequent.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22867970' target='_blank' class='pmid-link'>22867970</a>:</span> <span class='sentence-part'>Mutations in presenilins are the major cause of early onset familial Alzheimer disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22872014' target='_blank' class='pmid-link'>22872014</a>:</span> <span class='sentence-part'>Plasma concentrations of Abeta40 and Abeta42 rise with age and are increased in people with mutations that cause early-onset Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23123781' target='_blank' class='pmid-link'>23123781</a>:</span> <span class='sentence-part'>BACKGROUND: Mutations in the gene for presenilin-1 cause familial, early-onset Alzheimer's disease. CONCLUSIONS: This novel presenilin-1 sequence variant cosegregated with early onset dementia in the proband and at least one other affected family member, and likely represents a mutation causing familial, early-onset Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23593396' target='_blank' class='pmid-link'>23593396</a>:</span> <span class='sentence-part'>Mutations in the presenilin 1 gene, affecting the function of gamma-secretase, are the most common genetic cause of familial, early-onset Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23707529' target='_blank' class='pmid-link'>23707529</a>:</span> <span class='sentence-part'>Mutations in presenilins (PS1 and PS2) have been linked to the pathogenesis of early onset familial Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23850332' target='_blank' class='pmid-link'>23850332</a>:</span> <span class='sentence-part'>BACKGROUND: Early-onset familial Alzheimer disease (AD) is an autosomal dominant disorder caused by mutations in the amyloid precursor protein, presenilin 1 (PSEN1), or presenilin 2 gene.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24416243' target='_blank' class='pmid-link'>24416243</a>:</span> <span class='sentence-part'>Presenilin 1 (PSEN1) encodes the catalytic subunit of gamma-secretase, and PSEN1 mutations are the most common cause of early onset familial Alzheimer's disease (FAD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24599465' target='_blank' class='pmid-link'>24599465</a>:</span> <span class='sentence-part'>Rare, familial, early-onset autosomal dominant forms of familial Alzheimer's disease (FAD) are caused by mutations in genes encoding beta-amyloid (Abeta) precursor protein (APP), presenilin-1 (PS1), and presenilin-2.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24650794' target='_blank' class='pmid-link'>24650794</a>:</span> <span class='sentence-part'>Mutations of 3 causative genes, namely presenilin 1 (PSEN1), presenilin 2 (PSEN2), and amyloid precursor protein (APP), have been identified as the major causes of early-onset familial Alzheimer's disease (EOFAD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24669286' target='_blank' class='pmid-link'>24669286</a>:</span> <span class='sentence-part'>Mutations in APP, PS1, and PS2 genes are causes for early onset AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24773620' target='_blank' class='pmid-link'>24773620</a>:</span> <span class='sentence-part'>U1 small nuclear ribonucleoproteins (snRNPs) aggregate in Alzheimer's disease due to autosomal dominant genetic mutations and trisomy 21. However little is known about snRNP biology in early onset AD due to autosomal dominant genetic mutations or trisomy 21 in Down syndrome.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24838186' target='_blank' class='pmid-link'>24838186</a>:</span> <span class='sentence-part'>The mutations in the presenilin 2 (PSEN2) gene as causes of early-onset familial Alzheimer's disease (AD) have never been reported in Asia.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24844686' target='_blank' class='pmid-link'>24844686</a>:</span> <span class='sentence-part'>Mutations in the gene PSEN2 are a rare cause of early onset Alzheimer's disease (EOAD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24906965' target='_blank' class='pmid-link'>24906965</a>:</span> <span class='sentence-part'>Clinical presentation of early-onset Alzheimer's disease as a result of mutation in exon 12 of the PSEN-1 gene. INTRODUCTION: Mutations in the gene for presenilin 1 (PSEN-1) cause familial, early-onset Alzheimer's disease (EOAD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25045597' target='_blank' class='pmid-link'>25045597</a>:</span> <span class='sentence-part'>Early-onset AD (EOAD) is caused by mutations in the genes APP, PSEN1 and PSEN2.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25138979' target='_blank' class='pmid-link'>25138979</a>:</span> <span class='sentence-part'>Mutations in the amyloid precursor protein (APP), presenilin-1 and presenilin-2 genes have been recognized to be the cause of EOAD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25589721' target='_blank' class='pmid-link'>25589721</a>:</span> <span class='sentence-part'>Presenilin 1 (PS1) mutations are responsible for many early-onset familial AD (FAD) cases.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25720399' target='_blank' class='pmid-link'>25720399</a>:</span> <span class='sentence-part'>While early-onset familial Alzheimer's disease (AD) is caused by a genetic mutation, the vast majority of late-onset AD is likely caused by the combination of genetic and environmental factors.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25933409' target='_blank' class='pmid-link'>25933409</a>:</span> <span class='sentence-part'>Early onset AD (EOAD) is commonly caused by mutations in amyloid precursor protein (APP) or genes involved in the processing of APP including the presenilins (e.g. PSEN1 or PSEN2).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26092625' target='_blank' class='pmid-link'>26092625</a>:</span> <span class='sentence-part'>A large, genetically-isolated community in Antioquia, Colombia, with early-onset familial Alzheimer's disease due to a presenilin-1 mutation is ideally suited for the study of molecular mechanisms of AD, and hence accelerate the discovery of new or alternative treatment approaches.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26268329' target='_blank' class='pmid-link'>26268329</a>:</span> <span class='sentence-part'>Its subunit, presenilin (PS) is the catalytic component, of which mutations are a major cause of early onset familial Alzheimer disease (FAD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27120160' target='_blank' class='pmid-link'>27120160</a>:</span> <span class='sentence-part'>Using this approach, we generated human induced pluripotent stem cells with heterozygous and homozygous dominant early onset Alzheimer's disease-causing mutations in amyloid precursor protein (APP(Swe)) and presenilin 1 (PSEN1(M146V)) and derived cortical neurons, which displayed genotype-dependent disease-associated phenotypes.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27128372' target='_blank' class='pmid-link'>27128372</a>:</span> <span class='sentence-part'>Mutations in the presenilin 2 gene (PS2) are an extremely rare cause of early-onset autosomal dominant Alzheimer's disease (AD), accounting for only 5% of these families.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28065273' target='_blank' class='pmid-link'>28065273</a>:</span> <span class='sentence-part'>In recent years, we have successfully generated high-affinity, conformation-sensitive anti-gamma-secretase Nanobodies. gamma-Secretase is a multimeric membrane protease involved in processing of the amyloid precursor protein with high clinical relevance as mutations in its catalytic subunit (Presenilin) cause early-onset Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28461250' target='_blank' class='pmid-link'>28461250</a>:</span> <span class='sentence-part'>Presenilin 1 (PSEN1) mutations are the main cause of autosomal dominant Early-onset Alzheimer Disease (EOAD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28550254' target='_blank' class='pmid-link'>28550254</a>:</span> <span class='sentence-part'>BACKGROUND: Presenilin-1 (PSEN1) mutations are the most common cause of familial early onset Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28623607' target='_blank' class='pmid-link'>28623607</a>:</span> <span class='sentence-part'>Presenilin-1 gene (psen1) mutations are the main cause of early-onset autosomal-dominant Familial Alzheimer Disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28764909' target='_blank' class='pmid-link'>28764909</a>:</span> <span class='sentence-part'>A novel PSEN1 (S230N) mutation causing early-onset Alzheimer's Disease associated with prosopagnosia, hoarding, and Parkinsonism.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28781776' target='_blank' class='pmid-link'>28781776</a>:</span> <span class='sentence-part'>Early onset AD is caused by mutations in three genes: Amyloid-beta precursor protein, presenilin 1 (PSEN1) and PSEN2.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29404783' target='_blank' class='pmid-link'>29404783</a>:</span> <span class='sentence-part'>The majority (~ 55%) of early onset familial Alzheimer disease (FAD) is caused by mutations in the presenilin 1 gene (PSEN1).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29740579' target='_blank' class='pmid-link'>29740579</a>:</span> <span class='sentence-part'>Mutations in the APP, PSEN1, and PSEN2 genes cause early onset Alzheimer's disease (EOAD) that follows a Mendelian inheritance pattern.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31153663' target='_blank' class='pmid-link'>31153663</a>:</span> <span class='sentence-part'>Mutations in PSEN1 are the most common cause of early-onset Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31182772' target='_blank' class='pmid-link'>31182772</a>:</span> <span class='sentence-part'>Many mutations in the amyloid precursor protein (APP) and presenilin 1 and 2 (PSEN1 and PSEN2) have been reported as the pathogenic causes of early-onset AD (EOAD), which accounts for up to 5% of all AD cases. Alzheimer's disease (AD) is the most common type of neurodegenerative dementia, but the cause of AD remained poorly understood.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32354700' target='_blank' class='pmid-link'>32354700</a>:</span> <span class='sentence-part'>Mutations in the PS genes are a major cause of familial early-onset Alzheimer disease and affect the cleavage of the amyloid precursor protein, thereby altering the production of the amyloid beta-peptide.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32767553' target='_blank' class='pmid-link'>32767553</a>:</span> <span class='sentence-part'>Gene mutations associated with early onset familial Alzheimer's disease in China: An overview and current status.BACKGROUND: Mutations of three causative genes, namely presenilin 1 (PSEN1), presenilin 2 (PSEN2), and amyloid precursor protein (APP), have been identified as the major causes of early-onset familial Alzheimer's disease (EOFAD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32957903' target='_blank' class='pmid-link'>32957903</a>:</span> <span class='sentence-part'>AD can be of two types; early-onset and late-onset, where late-onset AD occurs sporadically whereas early-onset AD results from a mutation in any of the three genes that include amyloid precursor protein (APP), presenilin 1 (PSEN 1) and presenilin 2 (PSEN 2).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33274538' target='_blank' class='pmid-link'>33274538</a>:</span> <span class='sentence-part'>Mutations in three genes (APP, PSEN1, and PSEN2) are the main cause of the autosomal dominant early-onset Alzheimer's disease (AD-EOAD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34189411' target='_blank' class='pmid-link'>34189411</a>:</span> <span class='sentence-part'>One consistent observation for all    PRESENILIN     gene mutations causing EOfAD is that a transcript is produced with a reading frame terminated by the normal stop codon-the \reading frame preservation rule\. Background: Mutations in    PRESENILIN 2     (   PSEN2    ) cause early onset familial Alzheimer's disease (EOfAD) but their mode of action remains elusive.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35203497' target='_blank' class='pmid-link'>35203497</a>:</span> <span class='sentence-part'>We also know that mutations in certain proteins generate early-onset Alzheimer's disease (EOAD), and many other genes modulate the disease in its sporadic form.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35354048' target='_blank' class='pmid-link'>35354048</a>:</span> <span class='sentence-part'>Here, we examine synaptic and sleep homeostasis in a Drosophila model by overexpressing human amyloid precursor protein (APP), whose duplication and mutations cause familial early-onset AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35366787' target='_blank' class='pmid-link'>35366787</a>:</span> <span class='sentence-part'>The etiology of AD is complex with a substantial portion of sporadic AD emerging from unknown reasons and a lesser proportion of early-onset familial AD (FAD) caused by mutation in several genes, such as the amyloid precursor protein (APP), presenilin 1 (PS1) and presenilin 2 (PS2) genes.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36361714' target='_blank' class='pmid-link'>36361714</a>:</span> <span class='sentence-part'>AD occurs in two forms, early onset familial and late-onset sporadic; genetic mutations in PS1, PS2, and APP genes cause early onset familial AD, and a combination of lifestyle, environment and genetic factors causes the late-onset sporadic form of the disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36555791' target='_blank' class='pmid-link'>36555791</a>:</span> <span class='sentence-part'>Mutations in the PS1 gene (   PSEN1    ) are the most common cause of early onset familial Alzheimer's disease (FAD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37108607' target='_blank' class='pmid-link'>37108607</a>:</span> <span class='sentence-part'>The etiology of early-onset Alzheimer's disease (EOAD) is associated with alterations in the production of amyloid beta (Abeta) species caused by mutations in the    APP    ,    PSEN1    , and    PSEN2     genes.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/38396302' target='_blank' class='pmid-link'>38396302</a>:</span> <span class='sentence-part'>We review here the structure, function, and pathobiology of gamma-secretases, with a focus on how mutations in presenilin genes result in early-onset AD. The GSAS represent, in theory, a precision medicine approach to the prevention of amyloid deposition, as they specifically target a discrete aspect in a complex cell biological signalling mechanism that initiates the pathological processes leading to Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/38607732' target='_blank' class='pmid-link'>38607732</a>:</span> <span class='sentence-part'>Early-onset AD is a rare (~1%), autosomal dominant, caused by mutations in presenilin-1, presenilin-2, and amyloid precursor protein genes and the other is a late-onset, prevalent and is evolved due to age-associated complex interactions between environmental and genetic factors, in addition to apolipoprotein E4 polymorphism.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/7567974' target='_blank' class='pmid-link'>7567974</a>:</span> <span class='sentence-part'>Mutations in the amyloid precursor protein gene (APP) can cause early-onset autosomal dominant AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/8357039' target='_blank' class='pmid-link'>8357039</a>:</span> <span class='sentence-part'>Mutations in the amyloid precursor protein (APP) gene on chromosome (CHR) 21 have been shown to cause early-onset AD in a small number of pedigrees.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/8410047' target='_blank' class='pmid-link'>8410047</a>:</span> <span class='sentence-part'>On the other hand, our data suggest that this mutation is not a common cause of Japanese early-onset FAD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/8574969' target='_blank' class='pmid-link'>8574969</a>:</span> <span class='sentence-part'>Mutations in two recently identified genes appear to cause the majority of early-onset familial Alzheimer's disease (FAD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/8766720' target='_blank' class='pmid-link'>8766720</a>:</span> <span class='sentence-part'>The majority of cases of early-onset familial Alzheimer disease are caused by mutations in the recently identified presenilin 1 (PS1) gene, located on chromosome 14.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/8799182' target='_blank' class='pmid-link'>8799182</a>:</span> <span class='sentence-part'>Mutations in the recently identified presenilin 1 gene on chromosome 14 cause early onset familial Alzheimer disease (FAD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/8858181' target='_blank' class='pmid-link'>8858181</a>:</span> <span class='sentence-part'>Early data suggest that mutations found within the two genes cause early onset Alzheimer's disease by influencing the proteolytic processing of amyloid beta-peptide in a pathological manner.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/8881379' target='_blank' class='pmid-link'>8881379</a>:</span> <span class='sentence-part'>This review reports the different genetic factors that have been identified either as risk factor for Alzheimer's disease (AD) or directly causing the disease. The second part describes the mutations responsible for early-onset autosomal dominant AD found in three different genes.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/8972483' target='_blank' class='pmid-link'>8972483</a>:</span> <span class='sentence-part'>Mutations in the recently cloned Presenilin genes (PS-1 and PS-2) are by far the most common cause of early onset familial AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/8986743' target='_blank' class='pmid-link'>8986743</a>:</span> <span class='sentence-part'>Our data demonstrate that the presenilin mutations cause a dominant gain of function and may induce AD by enhancing A beta 42 production, thus promoting cerebral beta-amyloidosis. The mechanism by which mutations in the presenilin (PS) genes cause the most aggressive form of early-onset Alzheimer's disease (AD) is unknown, but fibroblasts from mutation carriers secrete increased levels of the amyloidogenic A beta 42 peptide, the main component of AD plaques.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/9129725' target='_blank' class='pmid-link'>9129725</a>:</span> <span class='sentence-part'>Mutations in the Presenilin 1 (PS1) gene on chromosome 14 cause most early-onset familial Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/9151738' target='_blank' class='pmid-link'>9151738</a>:</span> <span class='sentence-part'>Most autosomal dominant inherited forms of early onset Alzheimer's disease (AD) are caused by mutations in the presenilin-1 (PS-1) gene on chromosome 14.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/9169406' target='_blank' class='pmid-link'>9169406</a>:</span> <span class='sentence-part'>Most cases of early-onset familial Alzheimer's disease are caused by mutations in the presenilin genes.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/9185547' target='_blank' class='pmid-link'>9185547</a>:</span> <span class='sentence-part'>Mutations in the presenilin-1 (PS1) gene is a cause of early- onset familial Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/9219695' target='_blank' class='pmid-link'>9219695</a>:</span> <span class='sentence-part'>In cells expressing PS2 containing the asparagine-141 FAD mutant, the ratio of alternative to normal PS2 cleavage fragments was increased relative to wild-type PS2-expressing cells, suggesting a potential role for apoptosis-associated cleavage of presenilins in the pathogenesis of Alzheimer's disease. Most cases of early-onset familial Alzheimer's disease (FAD) are caused by mutations in the genes encoding the presenilin 1 (PS1) and PS2 proteins, both of which undergo regulated endoproteolytic processing.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/9371838' target='_blank' class='pmid-link'>9371838</a>:</span> <span class='sentence-part'>Mutations in the amyloid precursor protein (APP) gene cause early-onset familial Alzheimer disease (AD) by affecting the formation of the amyloid beta (A beta) peptide, the major constituent of AD plaques.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/9422341' target='_blank' class='pmid-link'>9422341</a>:</span> <span class='sentence-part'>Many cases of autosomal dominant inherited forms of early-onset Alzheimer's disease are caused by mutations in the genes encoding presenilin-1 (PS-1; chromosome 14) and presenilin-2 (PS-2; chromosome 1).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/9485068' target='_blank' class='pmid-link'>9485068</a>:</span> <span class='sentence-part'>Mutations in the presenilin 1 (PS1) gene on chromosome 14 are a major cause of autosomal dominant, early-onset Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/9500965' target='_blank' class='pmid-link'>9500965</a>:</span> <span class='sentence-part'>Mutations in the presenilin-1 gene (PS-1) on chromosome 14 are causative for early-onset familial Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/9521423' target='_blank' class='pmid-link'>9521423</a>:</span> <span class='sentence-part'>Mutations in the presenilin genes (PS-1 and PS-2) cause early onset autosomal dominant Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/9535737' target='_blank' class='pmid-link'>9535737</a>:</span> <span class='sentence-part'>Mutations in presenilin 1 (PS1) gene are the major cause of early-onset familial Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/9546349' target='_blank' class='pmid-link'>9546349</a>:</span> <span class='sentence-part'>Mutations of the newly discovered PS1 gene are responsible for early-onset familial Alzheimer disease (AD), and PS1 is abnormally accumulated in sporadic and familial AD brain.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/9652956' target='_blank' class='pmid-link'>9652956</a>:</span> <span class='sentence-part'>The majority of cases of early-onset familial Alzheimer disease are caused by mutations in the recently identified presenilin 1 (PS 1) gene, located on chromosome 14.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/9728730' target='_blank' class='pmid-link'>9728730</a>:</span> <span class='sentence-part'>Mutations in the presenilin-1 gene (PS-1 gene) on chromosome 14 have recently been identified as a cause of familial early-onset Alzheimer's disease (EOAD). Early-onset Alzheimer's disease due to mutations of the presenilin-1 gene on chromosome 14: a 7-year follow-up of a patient with a mutation at codon 139.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/9751187' target='_blank' class='pmid-link'>9751187</a>:</span> <span class='sentence-part'>Mutations in the presenilin genes PS1 and PS2 cause the most common form of early-onset familial Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/9790190' target='_blank' class='pmid-link'>9790190</a>:</span> <span class='sentence-part'>Mutations of the presenilin-1 gene are a major cause of familial early-onset Alzheimer's disease.</span></div></div>
<div class='streamlined-assertion'><div class='streamlined-header sticky-relation-header'><span class='label-text'>Subject:</span> <strong>Need_for_isolation</strong> <span class='label-text'>Subject CUI:</span> <strong>C0260397</strong> â†’ <span class='label-text predicate-text'>CAUSES</span> â†’ <span class='label-text'>Object:</span> <strong>Atrial_Fibrillation</strong> <span class='label-text'>Object CUI:</span> <strong>C0004238</strong></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/15599328' target='_blank' class='pmid-link'>15599328</a>:</span> <span class='sentence-part'>The endpoint is the electrical isolation of the PVs from the left atrium, as they house foci triggering AF in 80% to 95% of cases and seem to play a key role in arrhythmia maintenance.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/15637082' target='_blank' class='pmid-link'>15637082</a>:</span> <span class='sentence-part'>However, complete isolation is necessary to prevent AF induction by triggering from the isolated area.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/16443526' target='_blank' class='pmid-link'>16443526</a>:</span> <span class='sentence-part'>METHODS: In 74 patients (age 53 +/- 8 years) with paroxysmal AF, PV isolation was performed during induced or spontaneous AF.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17367350' target='_blank' class='pmid-link'>17367350</a>:</span> <span class='sentence-part'>CONCLUSION: Computer simulation of various ablation patterns in persistent AF is feasible and can reproduce clinical results of catheter ablation. After induction of AF by burst pacing, progressively broader ablation patterns were applied: (A) individual pulmonary vein isolation (PVI); (B) double ipsilateral PVI; (C) double PVI with a roofline; (D) double PVI with a lateral mitral isthmus line, and (E) double PVI with both linear lesions.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/18626758' target='_blank' class='pmid-link'>18626758</a>:</span> <span class='sentence-part'>Our current intracardiac echo-guided approach to PV antra isolation, including the adjunct of superior vena cava isolation, has likely accounted for higher success rates by electrically isolating further AF trigger sites, modifying the substrate for AF maintenance and possibly by modulating a dysfunctional autonomic cardiac nervous system.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20335557' target='_blank' class='pmid-link'>20335557</a>:</span> <span class='sentence-part'>Patients with recurrent AF &gt;or=5 years after index PVI were older, had larger left atrial size, more AF triggers and more likely had persistent AF.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21791333' target='_blank' class='pmid-link'>21791333</a>:</span> <span class='sentence-part'>After isolation of ipsilateral PVs, venous activity was observed in 68 (79.1%) and 178 (68.5%) PVs among the 86 PVs with AF triggers and 260 PVs without AF triggers, respectively (p = 0.06).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22509772' target='_blank' class='pmid-link'>22509772</a>:</span> <span class='sentence-part'>CONCLUSIONS: PVAI with non-PVTA for longstanding persistent AF provides good long-term AF control in over 70% of patients with infrequent (5%) AFL.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22583843' target='_blank' class='pmid-link'>22583843</a>:</span> <span class='sentence-part'>CONCLUSION: HFS increases the incidence of ER in patients with persistent AF despite a partial GP modification resulting from the pulmonary vein isolation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22972873' target='_blank' class='pmid-link'>22972873</a>:</span> <span class='sentence-part'>BACKGROUND: Electric isolation of the pulmonary veins and posterior left atrium with a single ring of radiofrequency lesions (single-ring isolation [SRI]) may result in fewer atrial fibrillation (AF) recurrences than wide antral pulmonary vein isolation (wide antral isolation [WAI]) by abolishing extravenous AF triggers.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24243786' target='_blank' class='pmid-link'>24243786</a>:</span> <span class='sentence-part'>CONCLUSIONS: Adenosine-induced PV ectopy is a predictor of recurrent AF after PV isolation and may be a marker of increased susceptibility to autonomic triggers of AF.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25091566' target='_blank' class='pmid-link'>25091566</a>:</span> <span class='sentence-part'>CONCLUSION: DPV activity occurred in 12% of PVs after PVI and was observed more frequently in PVs identified as AF triggers.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26051530' target='_blank' class='pmid-link'>26051530</a>:</span> <span class='sentence-part'>However, in patients with PAF and structural atrial disease, PVI may fail and cause progressive atrial remodeling, often leading to persistent/permanent atrial fibrillation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26297786' target='_blank' class='pmid-link'>26297786</a>:</span> <span class='sentence-part'>In group B, PVI was performed with the patient either in spontaneous or in induced AF.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26581316' target='_blank' class='pmid-link'>26581316</a>:</span> <span class='sentence-part'>Catheter ablation procedure is a method for treatment of AF, which involves 3D electroanatomic mapping of the patient's left atrium (LA) by maneuvering a conventional multipolar diagnostic catheter (MPDC) along the LA endocardial surface after which pulmonary vein (PV) isolation is performed, thus eliminating the AF triggers originating from the PVs.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27296156' target='_blank' class='pmid-link'>27296156</a>:</span> <span class='sentence-part'>RESULTS: Pulmonary vein isolation was completed in all patients without serious complications and with similar procedural (170.60 +/- 14.80 vs. 158.18 +/- 9.06 min; p = 0.062) and X-ray exposure (16.48 +/- 2.15 vs. 15.36 +/- 1.57 min; p = 0.058) time in AIT vs. control groups; however, upon coronary sinus catheter pacing (from 300 ms to 200 ms) after intrave-nous isoproterenol administration 30 min post PVI, rates of induction of AF (35% vs. 3.33%; p = 0.005) and of non-pulmonary vein-related atrial tachyarrhythmias (50% vs. 6.67%; p = 0.01) were higher, while those for atrial flutter (15% vs. 3.33%; p = 0.17) and atrial tachycardia (15% vs. 6.67%; p = 0.31) were similar, as was the recovery of conduction of pulmonary vein potential (15% vs. 30%; p = 0.191).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27614378' target='_blank' class='pmid-link'>27614378</a>:</span> <span class='sentence-part'>Fibrillatory pattern of dissociated venous activity after pulmonary vein isolation: Novel characteristics for remnant foci of a trigger ectopy for atrial fibrillation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27909520' target='_blank' class='pmid-link'>27909520</a>:</span> <span class='sentence-part'>The cornerstone of catheter ablation is electrical isolation of the pulmonary veins, since the pulmonary veins are the most common location for triggers of AF.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27957201' target='_blank' class='pmid-link'>27957201</a>:</span> <span class='sentence-part'>The Late Electrophysiological Consequences Of Posterior Wall Isolation In Patients With Atrial Fibrillation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27991673' target='_blank' class='pmid-link'>27991673</a>:</span> <span class='sentence-part'>Since the seminal observation in 1998 that pulmonary veins host the triggers of AF in the majority of cases, electrical isolation of all pulmonary veins constitutes the cornerstone of ablation in patients with symptomatic AF.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29988245' target='_blank' class='pmid-link'>29988245</a>:</span> <span class='sentence-part'>Introduction: The efficacy of thoracic vein isolation (TVI), an approach to trigger atrial fibrillation (AF), for the management of AF has been established.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30347332' target='_blank' class='pmid-link'>30347332</a>:</span> <span class='sentence-part'>Pulmonary vein isolation (PVI) is a common procedure for the treatment of atrial fibrillation (AF) since the initial trigger for AF frequently originates in the pulmonary veins.</span></div></div>
<div class='streamlined-assertion'><div class='streamlined-header sticky-relation-header'><span class='label-text'>Subject:</span> <strong>Nerve_Degeneration</strong> <span class='label-text'>Subject CUI:</span> <strong>C0027746</strong> â†’ <span class='label-text predicate-text'>CAUSES</span> â†’ <span class='label-text'>Object:</span> <strong>Alzheimers</strong> <span class='label-text'>Object CUI:</span> <strong>C0002395</strong></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/10928742' target='_blank' class='pmid-link'>10928742</a>:</span> <span class='sentence-part'>As the previous studies have almost always used the visual modality for presentation, they speculate that auditory presentation, especially of nonverbal material, may be compromised in AD because of neural degeneration in auditory areas in the temporal lobes.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/11226152' target='_blank' class='pmid-link'>11226152</a>:</span> <span class='sentence-part'>Our results demonstrate that in vivo overexpression of GSK-3beta results in neurodegeneration and suggest that these mice can be used as an animal model to study the relevance of GSK-3beta deregulation to the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/15036597' target='_blank' class='pmid-link'>15036597</a>:</span> <span class='sentence-part'>While many studies have addressed the atherogenic or anti-atherogenic potential of this polymorphism, little is known about its effect on neurodegeneration, despite the fact that CETP is expressed in the brain and the disturbance of cholesterol homeostasis appears to be an important factor in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/15197750' target='_blank' class='pmid-link'>15197750</a>:</span> <span class='sentence-part'>The most visible and, until very recently, the only hypothesis regarding the involvement of microglial cells in Alzheimer's disease (AD) pathogenesis is centered around the notion that activated microglia are neurotoxin-producing immune effector cells actively involved in causing the neurodegeneration that is the cause for AD dementia.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/15704193' target='_blank' class='pmid-link'>15704193</a>:</span> <span class='sentence-part'>To elucidate the involvement of protein citrullination in human neuronal degeneration, we examined whether citrullinated proteins are produced during Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17017913' target='_blank' class='pmid-link'>17017913</a>:</span> <span class='sentence-part'>We will review recent findings in in vitro cell models, in vivo mouse models, and post mortem AD brain tissue in view of the effects of different Abeta peptide species on neurodegeneration during AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17197420' target='_blank' class='pmid-link'>17197420</a>:</span> <span class='sentence-part'>First, conditional inactivation of PS in the adult mouse brain causes progressive memory loss and neurodegeneration resembling AD, whereas mouse models based on overproduction of Abeta have failed to produce neurodegeneration. Based on these and other observations, we propose that partial loss of PS function may underlie memory impairment and neurodegeneration in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/18067990' target='_blank' class='pmid-link'>18067990</a>:</span> <span class='sentence-part'>Elucidation of the events that control the transitions from neuroprotection to neurodegeneration should be a critical point toward elucidation of AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/18157656' target='_blank' class='pmid-link'>18157656</a>:</span> <span class='sentence-part'>Amyloid beta (Abeta) deposition and neurodegeneration are the two related events in the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/18645613' target='_blank' class='pmid-link'>18645613</a>:</span> <span class='sentence-part'>The neuroinflammatory response during the course of Alzheimer's disease (AD) is triggered by the neurodegeneration and the deposition of the beta-amyloid peptide in extracellular plaques.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/18648646' target='_blank' class='pmid-link'>18648646</a>:</span> <span class='sentence-part'>Analysis of postmortem brain tissue from AD patients can provide information on molecular alterations present at the end of the disease process, but cannot discriminate between changes that are specifically involved in AD versus those that are simply a consequence of neuronal degeneration.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/19114068' target='_blank' class='pmid-link'>19114068</a>:</span> <span class='sentence-part'>Cell cycle re-entry mediated neurodegeneration and its treatment role in the pathogenesis of Alzheimer's disease. As one of the earliest pathologic changes, the aberrant re-expression of many cell cycle-related proteins and inappropriate cell cycle control in specific vulnerable neuronal populations in Alzheimer's disease (AD) is emerging as an important component in the pathogenesis leading to AD and other neurodegenerative diseases.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/19264902' target='_blank' class='pmid-link'>19264902</a>:</span> <span class='sentence-part'>Together, these data indicate that UPR activation in AD neurons occurs at an early stage of neurofibrillary degeneration and suggest that the prolonged activation of the UPR is involved in both tau phosphorylation and neurodegeneration in AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/19373562' target='_blank' class='pmid-link'>19373562</a>:</span> <span class='sentence-part'>Here, we will review reports of host and viral factors associated with HAND and place these studies in the context of the data employed to support current theories regarding the molecular and cellular mechanisms that lead to HIV-induced neurodegeneration with additional focus on mechanisms common to AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/19683527' target='_blank' class='pmid-link'>19683527</a>:</span> <span class='sentence-part'>Similar type of intraneuronal Abeta accumulation, which precedes senile plaque formation, may link Abeta to tauopathy and neurodegeneration in Alzheimer's disease pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/19685437' target='_blank' class='pmid-link'>19685437</a>:</span> <span class='sentence-part'>The most prevalent form of neurodegeneration is Alzheimer's disease(AD) reaching a prevalence of over 30 % above age 80.The question is reviewed whether nutrients may protect or slow down the age associated mental decline due to neuronal degeneration.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/19801631' target='_blank' class='pmid-link'>19801631</a>:</span> <span class='sentence-part'>Evidence from both in vitro and in vivo studies indicates that increased GSK3beta activity contributes to neurodegeneration and to the pathogenesis of Alzheimer disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/19903025' target='_blank' class='pmid-link'>19903025</a>:</span> <span class='sentence-part'>AD usually shows poor prognosis owing to progressive neuronal degeneration, while depression is basically reversible.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20080301' target='_blank' class='pmid-link'>20080301</a>:</span> <span class='sentence-part'>The accumulation of toxic amyloid-beta (Abeta) peptide aggregates in AD brain are thought to trigger the extensive synaptic loss and neurodegeneration linked to cognitive decline, an idea that underlies the 'amyloid hypothesis' of AD etiology in both the familal (FAD) and sporadic forms of the disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20594619' target='_blank' class='pmid-link'>20594619</a>:</span> <span class='sentence-part'>AD is caused by severe neurodegeneration in the hippocampus and neocortical regions of the brain but the cause of this neuronal loss is unclear.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21371450' target='_blank' class='pmid-link'>21371450</a>:</span> <span class='sentence-part'>Apoptosis or programmed cell death has been suggested as an important mode of neurodegeneration in Alzheimer's disease pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21547225' target='_blank' class='pmid-link'>21547225</a>:</span> <span class='sentence-part'>Oligomerization, conformational changes, and the consequent neurodegeneration of Alzheimer's beta-amyloid protein (AbetaP) play crucial roles in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21663966' target='_blank' class='pmid-link'>21663966</a>:</span> <span class='sentence-part'>The accumulation of toxic amyloid-beta (Abeta) peptide aggregates in AD brain is thought to trigger the extensive synaptic loss and neurodegeneration linked to cognitive decline, an idea that underlies the 'amyloid hypothesis' of AD etiology in both the familal (FAD) and sporadic forms of the disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21786197' target='_blank' class='pmid-link'>21786197</a>:</span> <span class='sentence-part'>Our latest work on studies of ER Ca(2+) leak channel function of presenilins and implications of these findings for understanding AD pathogenesis are discussed in this article. The accumulation of toxic amyloid-beta (Abeta) peptide aggregates in AD brain is thought to trigger the extensive synaptic loss and neurodegeneration linked to cognitive decline, an idea that underlies the 'amyloid hypothesis' of AD etiology in both the familal (FAD) and sporadic forms of the disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22232001' target='_blank' class='pmid-link'>22232001</a>:</span> <span class='sentence-part'>With regards to Alzheimer's disease (AD) pathogenesis, it is not yet established whether entangled tau represents a cause or a consequence of neurodegeneration.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22266106' target='_blank' class='pmid-link'>22266106</a>:</span> <span class='sentence-part'>The result that APP proteins and specifically their soluble alpha-cleaved ectodomains can protect against progressive neurodegeneration in vivo provides support for the hypothesis that a disruption of the physiological function of APP could play a role in the pathogenesis of Alzheimer's Disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22505366' target='_blank' class='pmid-link'>22505366</a>:</span> <span class='sentence-part'>The lack of differences between AD and controls may result from a relatively advanced neurodegeneration in AD brains.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23151073' target='_blank' class='pmid-link'>23151073</a>:</span> <span class='sentence-part'>Oxidative damage and mitochondrial dysfunction have been also implicated in the pathogenesis of AD, but the question as to whether they are involved in the onset and progression of the pathology or rather represent a consequence of neurodegeneration is still debated. Vascular factors and mitochondrial dysfunction: a central role in the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23701948' target='_blank' class='pmid-link'>23701948</a>:</span> <span class='sentence-part'>However, the biological mechanisms underlying this association are still unclear because of the complexity of the pathological processes that cause AD. We argue that the interaction between the APOE-dependent non-pathological vulnerabilities and age-related pathological changes is one mechanism that can trigger neurodegeneration, resulting in AD and other complex phenotypes.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23783773' target='_blank' class='pmid-link'>23783773</a>:</span> <span class='sentence-part'>RATIONALE: Acetylcholinesterase inhibitors (AChEIs) are approved to treat the symptoms of mild to moderate Alzheimer's disease by restoring acetylcholine levels at synapses where the neurotransmitter has been depleted due to neurodegeneration.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24514870' target='_blank' class='pmid-link'>24514870</a>:</span> <span class='sentence-part'>We highlight how structural network damage caused by axonal injury might interact with neuroinflammation and neurodegeneration in the pathogenesis of Alzheimer disease and chronic traumatic encephalopathy, which are late complications of TBI.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25399848' target='_blank' class='pmid-link'>25399848</a>:</span> <span class='sentence-part'>Neurodegeneration is the progressive loss of neuronal structure and function, which ultimately leads to neurological disorders such as Alzheimer's disease (AD), Parkinson's disease (PD), multiple sclerosis, and Huntington's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25511446' target='_blank' class='pmid-link'>25511446</a>:</span> <span class='sentence-part'>Although pathological hallmarks of AD are senile plaques, neurofibrillary tangles, and neuronal degeneration which are associated with increased oxidative stress, synaptic loss is an early event in the pathogenesis of AD. Mechanism of Oxidative Stress and Synapse Dysfunction in the Pathogenesis of Alzheimer's Disease: Understanding the Therapeutics Strategies.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25713139' target='_blank' class='pmid-link'>25713139</a>:</span> <span class='sentence-part'>Brain accumulation of neurotoxic amyloid beta (Abeta) peptide because of increased processing of amyloid precursor protein (APP), resulting in loss of synapses and neurodegeneration, is central to the pathogenesis of Alzheimer disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26083882' target='_blank' class='pmid-link'>26083882</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) is a clinical syndrome caused by neurodegeneration and characterized by a progressive deterioration in cognitive ability and capacity for independent living.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26555572' target='_blank' class='pmid-link'>26555572</a>:</span> <span class='sentence-part'>Despite recent advances criticized the direct role in neurodegeneration of cortical neurons, Abeta is considered responsible for synaptopathy and impairment of neurotransmission and therefore remains the major trigger of AD and future pharmacological treatment remain Abeta oriented.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26557086' target='_blank' class='pmid-link'>26557086</a>:</span> <span class='sentence-part'>Here, we review the emerging evidence regarding the roles of lipid and glucose metabolism in the modulation of beta-amyloid, tau, and neurodegeneration during the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26880859' target='_blank' class='pmid-link'>26880859</a>:</span> <span class='sentence-part'>The anxiety status is changed along with memory impairments in intracerebroventricular colchicine injected rat model of Alzheimer Disease (cAD) due to neurodegeneration, which has been indicated to be mediated by inflammation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26898910' target='_blank' class='pmid-link'>26898910</a>:</span> <span class='sentence-part'>Thus, pSer26Abeta could represent a critical species in the neurodegeneration during AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27111252' target='_blank' class='pmid-link'>27111252</a>:</span> <span class='sentence-part'>OBJECTIVE: Alzheimer's disease (AD) is the result of neurodegeneration, which manifests clinically as deficits in memory, thinking, and behavior.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27776205' target='_blank' class='pmid-link'>27776205</a>:</span> <span class='sentence-part'>Neuroinflammatory mechanisms mediated by activated glial and cytokines (TNF-alpha, IL-1beta) might contribute to neuronal degeneration leading to Alzheimer's (AD) and Parkinson's disease (PD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27879212' target='_blank' class='pmid-link'>27879212</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) is a progressive and irreversible neurodegenerative disease causing neural cell degeneration and brain atrophy and is considered to be the most common form of dementia.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28094792' target='_blank' class='pmid-link'>28094792</a>:</span> <span class='sentence-part'>Our in silico analysis, suggesting a novel function for APOE4 at the DNA level, offers a potential mechanism for the observed tissue specific neurodegeneration and the role of environmental factors in Alzheimer's disease etiology.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28157684' target='_blank' class='pmid-link'>28157684</a>:</span> <span class='sentence-part'>These results were confirmed in an Alzheimer's disease mouse model, which exhibited increased levels and nuclear localization of Foxo3 in hippocampal neurons, which preceded neurodegeneration and Abeta plaque formation, indicating this phenomenon is an early event in Alzheimer's disease pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28861684' target='_blank' class='pmid-link'>28861684</a>:</span> <span class='sentence-part'>Amyloid beta (Abeta) peptide deposition is the primary cause of neurodegeneration in Alzheimer's disease (AD) pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29159058' target='_blank' class='pmid-link'>29159058</a>:</span> <span class='sentence-part'>The relationships between beta-amyloid (Abeta), tau and neurodegeneration within Alzheimer's Disease pathogenesis are not fully understood.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30041064' target='_blank' class='pmid-link'>30041064</a>:</span> <span class='sentence-part'>Seizures have traditionally been related to neuronal loss in the late stages of AD as a consequence of neurodegeneration, however, recent studies indicated that seizures may contribute to the emergence of AD symptoms in early stages of the disease, mainly in familial AD. Mutations in genes encoding presenilin 1 (PSEN1), presenilin 2 (PSEN2) and amyloid precursor protein (APP) are responsible for early-onset familial AD (EOFAD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30058479' target='_blank' class='pmid-link'>30058479</a>:</span> <span class='sentence-part'>Alzheimer's is an age-related disease with a hallmark of progressive loss of memory formation followed by a damage in the brain function due to the neural degeneration and extracellular beta-amyloid (Abeta) plaques accumulation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30120962' target='_blank' class='pmid-link'>30120962</a>:</span> <span class='sentence-part'>Symptoms of AD worsen over time due to progressive neurodegeneration, requiring institutional care at the later stage and resulting in a heavy burden on patients, caregivers, and the public-health system.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30595042' target='_blank' class='pmid-link'>30595042</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) is considered as a potential risk factor for the development of seizure due to neurodegeneration and imbalance between stimulatory and inhibitory circuits in the brain.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31121578' target='_blank' class='pmid-link'>31121578</a>:</span> <span class='sentence-part'>AD results from progressive neurodegeneration leading to dysfunctional synaptic transmission in the brain.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31686097' target='_blank' class='pmid-link'>31686097</a>:</span> <span class='sentence-part'>BACKGROUND: The National Institute on Aging and Alzheimer's Association (NIA-AA) have proposed a new Research Framework: Towards a biological definition of Alzheimer's disease, which uses a three-biomarker construct: Abeta-amyloid, tau and neurodegeneration AT(N), to generate a biomarker based definition of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31689310' target='_blank' class='pmid-link'>31689310</a>:</span> <span class='sentence-part'>BACKGROUND AND PURPOSE: The loss of retinal ganglion cells observed in Alzheimer's disease (AD) may be attributable to a neurodegeneration of the neuro-retinal structure.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32143546' target='_blank' class='pmid-link'>32143546</a>:</span> <span class='sentence-part'>RECENT ADVANCES: Solid recent evidence clearly suggest that metabolic factors, systemic infections, Microbiota dysbiosis, and oxidative stress are implicated, although at different extent, in the development in brain diseases CRITICAL ISSUE: Here, we reviewed the most solid published evidence supporting the implication of the axis systemic inflammation-neuroinflammation-neurodegeneration in the pathogenesis of AD, VAD, PD and MS, highlighting the possible cause of the putative downstream component of the axis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32183332' target='_blank' class='pmid-link'>32183332</a>:</span> <span class='sentence-part'>Alzheimer's disease is an age-related disease characterized by the progressive loss of memory and cognitive function, caused by the unstoppable neurodegeneration and brain atrophy.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32651317' target='_blank' class='pmid-link'>32651317</a>:</span> <span class='sentence-part'>Neurodegeneration of Trigeminal Mesencephalic Neurons by the Tooth Loss Triggers the Progression of Alzheimer's Disease in 3*Tg-AD Model Mice.BACKGROUND: The mesencephalic trigeminal nucleus (Vmes) is not only anatomically adjacent to the locus coeruleus (LC) but is also tightly associated with the function of the LC. Neurodegeneration of Trigeminal Mesencephalic Neurons by the Tooth Loss Triggers the Progression of Alzheimer's Disease in 3*Tg-AD Model Mice.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32795415' target='_blank' class='pmid-link'>32795415</a>:</span> <span class='sentence-part'>Dysregulated microglia are intimately involved in neurodegeneration, including Alzheimer's disease (AD) pathogenesis, but the mechanisms controlling pathogenic microglial gene expression remain poorly understood.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32813239' target='_blank' class='pmid-link'>32813239</a>:</span> <span class='sentence-part'>Neurodegeneration leading to Parkinson's disease (PD) and Alzheimer's disease (AD) has become a major health burden globally.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32903806' target='_blank' class='pmid-link'>32903806</a>:</span> <span class='sentence-part'>PARP-1 inhibition may also exert a protective effect against neurodegeneration by its action to diminish neuroinflammation and microglial activation which are also implicated in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33180216' target='_blank' class='pmid-link'>33180216</a>:</span> <span class='sentence-part'>Failure of this machinery and any alterations during mitochondrial biogenesis underlies neurodegeneration resulting in Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and Parkinson's disease (PD) etc.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33290860' target='_blank' class='pmid-link'>33290860</a>:</span> <span class='sentence-part'>In conclusion, we provide clinical trial evidence to confirm that restoration of BMI1 activity through EVOO administration in MCI patients constitutes a potential therapeutic approach against neurodegeneration leading to AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33337366' target='_blank' class='pmid-link'>33337366</a>:</span> <span class='sentence-part'>BACKGROUND: Alzheimer's disease (AD) is the most common type of dementia caused by irreversible neurodegeneration, with the onset mechanisms elusive.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33459705' target='_blank' class='pmid-link'>33459705</a>:</span> <span class='sentence-part'>In the subgroup of 19 AD and 19 NC with ATN results, AD-RAI results matched completely with ATN classification.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33495355' target='_blank' class='pmid-link'>33495355</a>:</span> <span class='sentence-part'>Molecular mechanisms of neurodegeneration in the entorhinal cortex that underlie its selective vulnerability during the pathogenesis of Alzheimer's disease. Defining the mechanisms underlying molecular neurodegeneration in the EC is crucial to determining its contributions to the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33788812' target='_blank' class='pmid-link'>33788812</a>:</span> <span class='sentence-part'>OBJECTIVE: Alzheimer disease is characterized by progressive decline in cognitive function due to neurodegeneration induced by accumulation of Abeta and hyperphosphorylated tau protein.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33977208' target='_blank' class='pmid-link'>33977208</a>:</span> <span class='sentence-part'>Here, we explain how vascular dysfunction mechanistically contributes to thrombosis as well as inflammation and neurodegeneration in AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34072862' target='_blank' class='pmid-link'>34072862</a>:</span> <span class='sentence-part'>After a brief summary of the molecular and cell biology of AD and HD this review covers what is known about the role of these three groups of kinases in the brain and in the pathogenesis of the two neurodegenerative disorders. Alzheimer's disease (AD) is a mostly sporadic brain disorder characterized by cognitive decline resulting from selective neurodegeneration in the hippocampus and cerebral cortex whereas Huntington's disease (HD) is a monogenic inherited disorder characterized by motor abnormalities and psychiatric disturbances resulting from selective neurodegeneration in the striatum.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34087544' target='_blank' class='pmid-link'>34087544</a>:</span> <span class='sentence-part'>One of the major causes of neurodegeneration in the pathogenesis of Alzheimer's disease is the accumulation of cytotoxic amyloid species within the intercellular compartments of the brain.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34100423' target='_blank' class='pmid-link'>34100423</a>:</span> <span class='sentence-part'>Therefore, an imbalance caused by mutations in presenilin 1/gamma-secretase might cause aberrant signaling, synaptic dysfunction, memory impairment, and increased Abeta     42      /Abeta     40       ratio, contributing to neurodegeneration during the initial stages of Alzheimer's disease pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34681867' target='_blank' class='pmid-link'>34681867</a>:</span> <span class='sentence-part'>Chronic Rhinosinusitis and Alzheimer's Disease-A Possible Role for the Nasal Microbiome in Causing Neurodegeneration in the Elderly.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35283778' target='_blank' class='pmid-link'>35283778</a>:</span> <span class='sentence-part'>The ischemic injury in the brain starts a cascade of events that lead to neuronal death, inducing neurodegeneration which could lead to Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35346299' target='_blank' class='pmid-link'>35346299</a>:</span> <span class='sentence-part'>BACKGROUND: Increased total tau (t-tau) in cerebrospinal fluid (CSF) is a key characteristic of Alzheimer's disease (AD) and is considered to result from neurodegeneration.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36012707' target='_blank' class='pmid-link'>36012707</a>:</span> <span class='sentence-part'>Neurodegeneration leading to Alzheimer's disease results from a complex interplay of a variety of processes including misfolding and aggregation of amyloid beta and tau proteins, neuroinflammation or oxidative stress.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36091826' target='_blank' class='pmid-link'>36091826</a>:</span> <span class='sentence-part'>Disturbed retinoic acid signaling causes inflammatory responses, mitochondrial impairment, oxidative stress, and neurodegeneration, leading to Alzheimer's disease (AD) progression. We outlined the physiology of retinoids in this review, focusing on their possible neuroprotective actions, which will aid in elucidating the critical function of such receptors in AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37190116' target='_blank' class='pmid-link'>37190116</a>:</span> <span class='sentence-part'>While attention has been focused on neurodegeneration in AD pathogenesis, recent decades have provided evidence of the importance of microglia, and resident immune cells in the central nervous system.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37477796' target='_blank' class='pmid-link'>37477796</a>:</span> <span class='sentence-part'>Recent studies have shown that, coupled with other environmental factors, aluminium exposure may lead to neurodegeneration resulting in cognitive impairment resembling Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/38020769' target='_blank' class='pmid-link'>38020769</a>:</span> <span class='sentence-part'>Autophagy acts as a proteostasis process to remove protein clumps, although it progressively weakens with aging and AD, thus facilitating the accumulation of toxic proteins and causing neurodegeneration.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/38542219' target='_blank' class='pmid-link'>38542219</a>:</span> <span class='sentence-part'>This model, highlighting microglia as a pivotal player in risk factor-mediated neurodegeneration, offers a new point of view on the complex associations of modifiable risk factors and proteinopathy in AD pathogenesis, which may act in parallel to the thoroughly studied amyloid-driven Tau pathology, and strengthens the therapeutic rationale of combining immune modulation with tight control of risk factor-driven insults.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/8423065' target='_blank' class='pmid-link'>8423065</a>:</span> <span class='sentence-part'>These results suggest that microglial activation in AD may be secondary to neurodegeneration and that, once activated, microglia may participate in a local inflammatory cascade that promotes tissue damage and contributes to amyloid formation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/8620894' target='_blank' class='pmid-link'>8620894</a>:</span> <span class='sentence-part'>Here functional implications of these mutations on the processing of the precursor protein and the beta A4 amyloid deposition will be discussed with respect to the pathogenesis of Alzheimer's disease and related disorders. Alzheimer's disease is a senile dementia caused by progressive neurodegeneration of the central nervous system.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/9223085' target='_blank' class='pmid-link'>9223085</a>:</span> <span class='sentence-part'>The association of astrocytes with plaques is a well-established feature of Alzheimer's disease (AD) and has generally been interpreted as a secondary reaction to amyloid deposition or neuronal degeneration.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/9514829' target='_blank' class='pmid-link'>9514829</a>:</span> <span class='sentence-part'>These findings indicate that nNOS expressing neurons are highly susceptible to neurodegeneration and that nNOS might contribute to the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/9700651' target='_blank' class='pmid-link'>9700651</a>:</span> <span class='sentence-part'>Alzheimer's disease entails multiple neuronal systems and results from neuronal cytoskeletal degeneration of only a few types of nerve cells.</span></div></div>
<div class='streamlined-assertion'><div class='streamlined-header sticky-relation-header'><span class='label-text'>Subject:</span> <strong>Neurodegenerative_Disorders</strong> <span class='label-text'>Subject CUI:</span> <strong>C0524851</strong> â†’ <span class='label-text predicate-text'>CAUSES</span> â†’ <span class='label-text'>Object:</span> <strong>Alzheimers</strong> <span class='label-text'>Object CUI:</span> <strong>C0002395</strong></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/12570697' target='_blank' class='pmid-link'>12570697</a>:</span> <span class='sentence-part'>Recently, interest in the therapeutic potential of CDKIs has expanded to include neurodegenerative diseases, where dysregulated CDK activity has been linked to the pathogenesis of Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and stroke.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/16955484' target='_blank' class='pmid-link'>16955484</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) is a neurodegenerative disease of the central nervous system characterized by two major lesions: extracellular senile plaques and intraneuronal neurofibrillary tangles. beta-Amyloid (Abeta) is known to play a major role in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/18778193' target='_blank' class='pmid-link'>18778193</a>:</span> <span class='sentence-part'>Although clinical management of neurodegenerative diseases usually involves symptomatic treatment, Colostrinin() (CLN), which has efficacy in counteracting neural degradation and in stimulating neural growth, might prove to be a more effective means to deal with the causes of Alzheimer's and other neurodegenerative diseases.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/18781980' target='_blank' class='pmid-link'>18781980</a>:</span> <span class='sentence-part'>Nevertheless, the available data indicate that endocannabinoids are likely to play in this disorder a role similar to that suggested in other neurodegenerative diseases, that is, to represent an endogenous adaptive response aimed at counteracting both the neurochemical and inflammatory consequences of beta-amyloid-induced tau protein hyperactivity, possibly the most important underlying cause of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/19042040' target='_blank' class='pmid-link'>19042040</a>:</span> <span class='sentence-part'>Parkinson's disease (PD) is the second most common neurodegenerative disorder after Alzheimer's disease and is an important cause of chronic disability.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20810758' target='_blank' class='pmid-link'>20810758</a>:</span> <span class='sentence-part'>The 4 most common neurodegenerative disorders that cause dementia-Alzheimer disease, frontotemporal dementia, dementia with Lewy bodies, and dementia in Parkinson disease-have different underlying etiologies and pathogenetic mechanisms.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21210060' target='_blank' class='pmid-link'>21210060</a>:</span> <span class='sentence-part'>Many neurodegenerative diseases including Parkinson's disease (PD) and Alzheimer's disease (AD) are the result of neurodegenerative processes. In this review, we discuss the role of metals in neurodegenerative diseases with emphasis on the utility of Caenorhabditis elegans (C. elegans) genetic models in deciphering mechanisms associated with the etiology of PD and AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22647475' target='_blank' class='pmid-link'>22647475</a>:</span> <span class='sentence-part'>In the last 30 years, the elucidation of the molecular pathogenesis of neurodegenerative diseases has undergone remarkable progress, including the discoveries of the causative genes and risk factors of Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22870188' target='_blank' class='pmid-link'>22870188</a>:</span> <span class='sentence-part'>BDNF has recently garnered significant attention as a potential therapeutic target for neurodegenerative diseases such as Alzheimer disease (AD), but emerging evidence suggests that BDNF may also be mechanistically involved in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23303475' target='_blank' class='pmid-link'>23303475</a>:</span> <span class='sentence-part'>The activity of metabotropic glutamate receptors (mGluRs) is known to be altered as the consequence of neurodegenerative diseases such as Alzheimer, Parkinson, and Huntington disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23678459' target='_blank' class='pmid-link'>23678459</a>:</span> <span class='sentence-part'>INTRODUCTION: Alzheimer's disease (AD) is a common neurodegenerative disorder in elderly people with an impairment of cognitive decline and memory loss. beta-amyloid (Abeta) as a potent neurotoxic peptide has a pivotal role in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24680827' target='_blank' class='pmid-link'>24680827</a>:</span> <span class='sentence-part'>My findings may provide new directions not only for investigating the role of APP in neuropathology associated with HPRT-deficiency in LNS but also for the research in neurodevelopmental and neurodegenerative disorders by which various APP isoforms involved in the pathogenesis of the diseases such as Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24747741' target='_blank' class='pmid-link'>24747741</a>:</span> <span class='sentence-part'>Although Alzheimer's disease (AD) is the most common neurodegenerative disease, the etiology of AD is not well understood.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25719338' target='_blank' class='pmid-link'>25719338</a>:</span> <span class='sentence-part'>Also, these findings may be of significance for research in neurodevelopmental and neurodegenerative disorders in which the APP gene is involved in the pathogenesis of diseases such as autism, fragile X syndrome (FXS) and AD, with its diversity and complexity, SAD in particular.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25999816' target='_blank' class='pmid-link'>25999816</a>:</span> <span class='sentence-part'>Growing evidence indicates that mitochondrial dysfunction is a common feature of neurodegenerative diseases and is observed at an early stage in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26295822' target='_blank' class='pmid-link'>26295822</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) is a neurodegenerative disease characterized by deposit of amyloid plaques and neurofibrillary tangles and oxidative stress plays an essential role in the pathogenesis of AD. These results indicate that JAT may be the potential target to treat AD induced by oxidative stress and apoptosis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26398526' target='_blank' class='pmid-link'>26398526</a>:</span> <span class='sentence-part'>My findings accounted for epigenetic mechanism in the regulation of alternative APP pre-mRNA splicing as well as for epigenetic control of genomic rearrangements of APP gene may provide therefore new directions not only for investigating the role of APP in neuropathology associated with HGprt-deficiency in LNS and LNVs patients but also for the research in neurodevelopmental and neurodegenerative disorders by which APP gene involved in the pathogenesis of the diseases such as autism, fragile X syndrome (FXS), and Alzheimer's disease (AD) with its diversity and complexity, especially for sporadic form of AD (SAD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27166223' target='_blank' class='pmid-link'>27166223</a>:</span> <span class='sentence-part'>Impaired protein degradation has been discussed as a cause or consequence of various neurodegenerative diseases, such as Alzheimer's, Parkinson's and Huntington's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28192196' target='_blank' class='pmid-link'>28192196</a>:</span> <span class='sentence-part'>The method is useful for identifying the defective APP-mRNA isoform in LND patients, and in neurodevelopmental and neurodegenerative disorders in which the APP gene is involved in the pathogenesis of diseases such as autism, fragile X syndrome, amyotrophic lateral sclerosis, and Alzheimer's disease, and may pave the way for new strategies applicable to rational antisense drugs design.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28694424' target='_blank' class='pmid-link'>28694424</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) is a major and devastating neurodegenerative disease, and the amyloid-beta (Abeta) hypothesis is still the central theory for AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29933008' target='_blank' class='pmid-link'>29933008</a>:</span> <span class='sentence-part'>This review summarizes the current knowledge and concepts regarding the connection between long-term consequences of TBI and aging-associated neurodegenerative disorders including Alzheimer's disease (AD), chronic traumatic encephalopathy (CTE), and Parkinsonism, with implications for novel therapy targets.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30083812' target='_blank' class='pmid-link'>30083812</a>:</span> <span class='sentence-part'>PCA is a clinico-radiological syndrome that is often caused by Alzheimer's disease and other neurodegenerative diseases as Lewy body dementia and corticobasal degeneration.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30250265' target='_blank' class='pmid-link'>30250265</a>:</span> <span class='sentence-part'>Animal models of adult-onset neurodegenerative diseases have enhanced the understanding of the molecular pathogenesis of Alzheimer's disease, Parkinson's disease, frontotemporal dementia, and amyotrophic lateral sclerosis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30605723' target='_blank' class='pmid-link'>30605723</a>:</span> <span class='sentence-part'>Although tau plays important physiological roles in neurons, its involvement in neurodegenerative diseases, and most prominently in the pathogenesis of Alzheimer disease (AD), has directed the majority of tau studies.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30983949' target='_blank' class='pmid-link'>30983949</a>:</span> <span class='sentence-part'>Nervous tissues from both humans with neurodegenerative diseases (NDD) and animals with genetic models of human NDD, such as rare monogenic causes of Amyotrophic Lateral Sclerosis (ALS), Alzheimer's disease (AD), and Parkinson's disease (PD), show activated microglia, suggesting a potential causal role for inflammation in pathogenesis of NDD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32275992' target='_blank' class='pmid-link'>32275992</a>:</span> <span class='sentence-part'>Molecular insights into the inhibitory mechanisms of gallate moiety on the Abeta     1-40       amyloid aggregation: A molecular dynamics simulation study.Alzheimer's disease is the most common form of neurodegenerative disease and the formation of Abeta amyloid aggregates has been widely demonstrated to be the principal cause of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32968718' target='_blank' class='pmid-link'>32968718</a>:</span> <span class='sentence-part'>Both Alzheimer's disease (AD) and HIV-associated neurocognitive disorders (HAND) could progress to dementia, a severe consequence of neurodegenerative diseases.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33204697' target='_blank' class='pmid-link'>33204697</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) is a chronic progressive neurodegenerative disease that affects the quality of life of elderly individuals, while the pathogenesis of AD is still unclear.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35114208' target='_blank' class='pmid-link'>35114208</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) is a progressive memory related neurodegenerative disease, for which the current Food and drug administration approved therapeutics are only meant for a symptomatic management rather than targeting the root cause of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35207764' target='_blank' class='pmid-link'>35207764</a>:</span> <span class='sentence-part'>Mild cognitive impairment (MCI), a neurodegenerative disease leading to Alzheimer's disease or dementia, is often associated with physical complaints.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35243650' target='_blank' class='pmid-link'>35243650</a>:</span> <span class='sentence-part'>John Hardy's research identified key mutations linked to prevalent neurodegenerative diseases in humans and contributed to our understanding of the molecular pathogenesis of Alzheimer disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35347731' target='_blank' class='pmid-link'>35347731</a>:</span> <span class='sentence-part'>Since Abeta is an important hallmark of Alzheimer's disease (AD), which is a socially significant neurodegenerative disorder of the elderly worldwide, analysis of its endogenous variations is of particular importance for elucidating the pathogenesis of AD, predicting increased risks of the disease onset, and developing effective therapy.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35601340' target='_blank' class='pmid-link'>35601340</a>:</span> <span class='sentence-part'>Neurodegenerative disorders, caused by prone-to-aggregation proteins, such as Alzheimer disease or Huntington disease, share other traits such as disrupted homeostasis of essential metal ions, like copper.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35756499' target='_blank' class='pmid-link'>35756499</a>:</span> <span class='sentence-part'>Thus, in this review, we focus on summarizing the consequences of ROS NDs, while taking the four prevalent NDs as examples, including Alzheimer's disease (AD), Parkinson's disease (PD), Amyotrophic lateral sclerosis (ALS), and Huntington's disease (HD), to illustrate the key signaling pathways and relevant drugs.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37380605' target='_blank' class='pmid-link'>37380605</a>:</span> <span class='sentence-part'>As a neurodegenerative disease that is difficult to prevent and cure, the pathogenesis of AD is complex and there is no effective cure.</span></div></div>
<div class='streamlined-assertion'><div class='streamlined-header sticky-relation-header'><span class='label-text'>Subject:</span> <strong>Neurotoxins</strong> <span class='label-text'>Subject CUI:</span> <strong>C0027934</strong> â†’ <span class='label-text predicate-text'>CAUSES</span> â†’ <span class='label-text'>Object:</span> <strong>Alzheimers</strong> <span class='label-text'>Object CUI:</span> <strong>C0002395</strong></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/10519044' target='_blank' class='pmid-link'>10519044</a>:</span> <span class='sentence-part'>Aluminum is a recognized neurotoxin in dialysis encephalopathy and may also be implicated in the etiology of neurodegenerative disease, particularly Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/12853325' target='_blank' class='pmid-link'>12853325</a>:</span> <span class='sentence-part'>This paper explores the effect of MPP(+) and beta-amyloid fragment 25-35, neurotoxins that are known to generate Parkinson's-like syndrome and Alzheimer's disease, on the regulation of the mitochondrial pores.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17202404' target='_blank' class='pmid-link'>17202404</a>:</span> <span class='sentence-part'>beta-Amyloid peptides, tentatively regarded as the principal neurotoxins responsible for Alzheimer's Disease, make up a set of products that varies significantly among different biological systems.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21071869' target='_blank' class='pmid-link'>21071869</a>:</span> <span class='sentence-part'>There have been many reports suggesting that soluble oligomers of amyloid beta (Abeta) are neurotoxins causing Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/2680002' target='_blank' class='pmid-link'>2680002</a>:</span> <span class='sentence-part'>A review of published reports on conventional and unconventional viruses, aluminum, neurotoxic metals and trace elements, neurotoxins of biological origin and immune systems, suggest that environmental factors, possibly multiple ones, play a significant role in the etiology of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28918635' target='_blank' class='pmid-link'>28918635</a>:</span> <span class='sentence-part'>There is a serious dispute on the existence of beta-N-methylamino-l-alanine (BMAA) in water, which is a neurotoxin that may cause amyotrophic lateral sclerosis/Parkinson's disease (ALS/PDC) and Alzheimer' disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29889206' target='_blank' class='pmid-link'>29889206</a>:</span> <span class='sentence-part'>Among various aggregates, Abeta oligomer is widely accepted as the leading neurotoxin in the progress of Alzheimer's disease (AD) and is considered to be the crucial event in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30551539' target='_blank' class='pmid-link'>30551539</a>:</span> <span class='sentence-part'>D-galactose (D-gal) is a senescence agent, while aluminium is a known neurotoxin linked to pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31363819' target='_blank' class='pmid-link'>31363819</a>:</span> <span class='sentence-part'>Aluminum (Al) is a neurotoxin and is associated with the etiology of neurodegenerative diseases, such as Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32030485' target='_blank' class='pmid-link'>32030485</a>:</span> <span class='sentence-part'>The comparison is based on the selectivity of the neurotoxins which cause experimental PD and AD, towards the cellular membrane and intracellular molecular targets as well as towards the selective neurons/non-neuronal cells, and the particular brain regions.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33687726' target='_blank' class='pmid-link'>33687726</a>:</span> <span class='sentence-part'>Zebrafish as a Promising Tool for Modeling Neurotoxin-Induced Alzheimer's Disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/3666247' target='_blank' class='pmid-link'>3666247</a>:</span> <span class='sentence-part'>Are Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis caused by neurotoxins?</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/38473975' target='_blank' class='pmid-link'>38473975</a>:</span> <span class='sentence-part'>New data suggest that the aggregation of misfolded native proteins initiates and drives the pathogenic cascade that leads to Alzheimer's disease (AD) and other age-related neurodegenerative disorders. An extensive body of genetic evidence suggests soluble aggregates of beta-amyloid (Abeta) as the primary neurotoxin in the pathogenesis of AD. Understanding the distinct roles of soluble and insoluble amyloid aggregates on AD pathogenesis has been the key missing piece of the Alzheimer's puzzle.</span></div></div>
<div class='streamlined-assertion'><div class='streamlined-header sticky-relation-header'><span class='label-text'>Subject:</span> <strong>Nicotinic_Receptors</strong> <span class='label-text'>Subject CUI:</span> <strong>C0034830</strong> â†’ <span class='label-text predicate-text'>CAUSES</span> â†’ <span class='label-text'>Object:</span> <strong>Alzheimers</strong> <span class='label-text'>Object CUI:</span> <strong>C0002395</strong></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/12446934' target='_blank' class='pmid-link'>12446934</a>:</span> <span class='sentence-part'>Other studies show complex interactions between nAChR, nicotinic agonists, and agents implicated in AD etiology.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17069698' target='_blank' class='pmid-link'>17069698</a>:</span> <span class='sentence-part'>[Effect of beta-amyloid peptides on alpha-7 nicotinic receptor status in astrocytes and neurons, and its relationship to pathogenesis of Alzheimer's disease].</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17493709' target='_blank' class='pmid-link'>17493709</a>:</span> <span class='sentence-part'>In order to examine the neuroprotective effects of the alpha7 nicotinic receptor (nAChR) in relationship to the pathogenesis of Alzheimer's disease (AD), neuroblastoma (SH-SY5Y) cells were transfected with small interference RNAs (siRNAs) that targets specifically towards alpha7 nAChR or exposed to 20microM 3-[2,4-dimethoxybenzylidene] anabaseine (DMXB), a selective agonist of this same receptor. These findings indicate that alpha7 nAChR may play a significant neuroprotective role by enhancing cleavage of APP by alpha-secretase, regulating signal transduction, improving antioxidant defenses and inhibiting the toxicity of Abeta, which is connected with the pathogenesis of AD. The consequences of reducing expression of the alpha7 nicotinic receptor by RNA interference and of stimulating its activity with an alpha7 agonist in SH-SY5Y cells indicate that this receptor plays a neuroprotective role in connection with the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17569627' target='_blank' class='pmid-link'>17569627</a>:</span> <span class='sentence-part'>Elevated amyloid-beta peptide (Abeta) and loss of nicotinic acetylcholine receptors (nAChRs) stand prominently in the etiology of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/18509986' target='_blank' class='pmid-link'>18509986</a>:</span> <span class='sentence-part'>OBJECTIVES: To investigate the neuroprotective function of alpha7 nicotinic receptor (nAChR) and its roles in the pathogenesis of Alzheimer's disease (AD). CONCLUSION: The findings indicate that alpha7 nAChR may play a significant neuroprotective role by enhancing cleavage of APP, improving antioxidant defenses and limiting the toxicity of Abeta, which has been implied in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/18647633' target='_blank' class='pmid-link'>18647633</a>:</span> <span class='sentence-part'>In order to examine the effects of alpha3 nicotinic acetylcholine receptor (nAChR) in connection with the pathogenesis of Alzheimer's disease (AD), neuroblastoma (SH-SY5Y) cells were transfected with small interference RNAs (siRNAs) that target specifically towards alpha3 nAChR.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20205670' target='_blank' class='pmid-link'>20205670</a>:</span> <span class='sentence-part'>Elevated amyloid-beta peptide (Abeta) and loss of nicotinic acetylcholine receptors (nAChRs) stand prominently in the etiology of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21763291' target='_blank' class='pmid-link'>21763291</a>:</span> <span class='sentence-part'>Aberrant amyloid-beta peptide (Abeta) accumulation along with altered expression and function of nicotinic acetylcholine receptors (nAChRs) stand prominently in the etiology of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27396406' target='_blank' class='pmid-link'>27396406</a>:</span> <span class='sentence-part'>The purpose of this study was to investigate the alterations in the levels of nuclear factor kappaBp65 (NF-kappaBp65), monocyte chemoattractant protein 1 (MCP-1/CCL-2) and macrophage inflammatory protein 1alpha (MIP-1alpha/CCL-3) in relationship to the expression of alpha3 nicotinic acetylcholine receptor (nAChR) during the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27498631' target='_blank' class='pmid-link'>27498631</a>:</span> <span class='sentence-part'>Nicotinic acetylcholine receptors of alpha7 subtype (alpha7 nAChRs) attenuate the inflammatory cytokines production by macrophages and are involved in pathogenesis of Alzheimer disease by directly influencing the processing of amyloid-beta (Abeta) precursor protein in the brain.</span></div></div>
<div class='streamlined-assertion'><div class='streamlined-header sticky-relation-header'><span class='label-text'>Subject:</span> <strong>Nitric_Oxide</strong> <span class='label-text'>Subject CUI:</span> <strong>C0028128</strong> â†’ <span class='label-text predicate-text'>CAUSES</span> â†’ <span class='label-text'>Object:</span> <strong>Alzheimers</strong> <span class='label-text'>Object CUI:</span> <strong>C0002395</strong></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/10567488' target='_blank' class='pmid-link'>10567488</a>:</span> <span class='sentence-part'>There is a growing evidence that NO is involved in neuronal death in Alzheimer's disease, and the oxidative stress caused by NO in the brain could be a pathogenic mechanism in Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/11110032' target='_blank' class='pmid-link'>11110032</a>:</span> <span class='sentence-part'>Interleukin-1 (IL-1) is known to trigger induction of inducible nitric oxide synthase (iNOS) to persistently mass produce nitric oxide (NO) to induce various diseases such as cancer, inflammation, Alzheimer's disease and eye diseases, including uveitis, retinopathy, age-related macular degeneration, glaucoma and myopia.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/1381038' target='_blank' class='pmid-link'>1381038</a>:</span> <span class='sentence-part'>A possible role for nitric oxide in glutamate (MSG)-induced Chinese restaurant syndrome, glutamate-induced asthma, 'hot-dog headache', pugilistic Alzheimer's disease, and other disorders.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/16253246' target='_blank' class='pmid-link'>16253246</a>:</span> <span class='sentence-part'>This is the first direct evidence demonstrating that nitric oxide induces AD-like tau hyperphosphorylation in vitro, and GSK-3beta activation is partially responsible for the nitric oxide-induced tau hyperphosphorylation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17560043' target='_blank' class='pmid-link'>17560043</a>:</span> <span class='sentence-part'>Several studies suggest a pivotal role of amyloid beta (Abeta)(1-42) and nitric oxide (NO) in the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20082297' target='_blank' class='pmid-link'>20082297</a>:</span> <span class='sentence-part'>The elevation of nitric oxide (NO) within the central nervous system (CNS) is known to be associated with the pathogenesis of neurodegenerative diseases such as HIV-associated dementia (HAD), brain ischemia, Parkinson's disease, and Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22445961' target='_blank' class='pmid-link'>22445961</a>:</span> <span class='sentence-part'>The Abeta aggregate-induced neurotoxicity, inflammatory reactions, oxidative stress, and nitric oxide (NO) generation are strongly linked to the etiology of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23745722' target='_blank' class='pmid-link'>23745722</a>:</span> <span class='sentence-part'>This suggests chronic loss of endothelial NO may be an important contributor to the pathogenesis of sporadic AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27806872' target='_blank' class='pmid-link'>27806872</a>:</span> <span class='sentence-part'>Our results showed that LPS treatment (500MUg/kg/day) for 7days disturbed memory, enhanced systemic NO production, NOS2 and Abeta 1-42 cerebral expression and generated an Alzheimer's disease (AD)-like neuronal degeneration.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29300354' target='_blank' class='pmid-link'>29300354</a>:</span> <span class='sentence-part'>The overproduction of nitric oxide (NO) and prostaglandin E2 (PGE2) by microglia may cause neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31531065' target='_blank' class='pmid-link'>31531065</a>:</span> <span class='sentence-part'>Nitric oxide (NO) is a key mediator that plays an important role in pathogenesis of various chronic diseases like Alzheimer's disease and Parkinson's disease.</span></div></div>
<div class='streamlined-assertion'><div class='streamlined-header sticky-relation-header'><span class='label-text'>Subject:</span> <strong>Obesity</strong> <span class='label-text'>Subject CUI:</span> <strong>C0028754</strong> â†’ <span class='label-text predicate-text'>CAUSES</span> â†’ <span class='label-text'>Object:</span> <strong>Alzheimers</strong> <span class='label-text'>Object CUI:</span> <strong>C0002395</strong></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25976367' target='_blank' class='pmid-link'>25976367</a>:</span> <span class='sentence-part'>Several preclinical and epidemiological studies have linked metabolic risk factors such as hypertension, obesity, dyslipidemia, and diabetes to the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28582856' target='_blank' class='pmid-link'>28582856</a>:</span> <span class='sentence-part'>Diabetes mellitus and AD have received particular attention due to their prominence in Western societies as a result of the ongoing obesity epidemic and the aging populations.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29257910' target='_blank' class='pmid-link'>29257910</a>:</span> <span class='sentence-part'>Evidence suggests that neurological diseases such as Parkinson's disease and Alzheimer's disease could be initiated by various metabolic changes, related to CNS damage, caused by obesity.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30257330' target='_blank' class='pmid-link'>30257330</a>:</span> <span class='sentence-part'>Raspberry ketone preserved cholinergic activity and antioxidant defense in obesity induced Alzheimer disease in rats.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32313838' target='_blank' class='pmid-link'>32313838</a>:</span> <span class='sentence-part'>The objectives of EMIF included providing a unified platform to support a wide range of studies within two verification programmes-Alzheimer's disease (EMIF-AD), and metabolic consequences of obesity (EMIF-MET).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32555166' target='_blank' class='pmid-link'>32555166</a>:</span> <span class='sentence-part'>Although sodium butyrate (NaB) has emerged as the potential therapeutic substance in AD, there is a lack of detailed results into what signaling pathways affect amyloidogenesis in AD induced by obesity.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33728019' target='_blank' class='pmid-link'>33728019</a>:</span> <span class='sentence-part'>In this review, we have shown that obesity may induce T2D-mediated AD and assessed the recent therapeutic advances, especially the use of anthocyanin, against T2D-mediated AD pathology.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36362376' target='_blank' class='pmid-link'>36362376</a>:</span> <span class='sentence-part'>The biological plausibility of the link between high adiposity, insulin resistance, and dementia is central for understanding AD etiology, and to form bases for prevention efforts to decrease the disease burden.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37231172' target='_blank' class='pmid-link'>37231172</a>:</span> <span class='sentence-part'>Therapeutic potential of flavonoids in the management of obesity-induced Alzheimer's disease: an overview of preclinical and clinical studies. Obesity has also been linked to neurological diseases such as cognitive decline, dementia, and Alzheimer's disease (AD), caused by oxidative stress, pro-inflammatory cytokines, and the production of reactive oxygen free radicals (ROS). Thus, flavonoid-rich nutraceuticals can be a potential cost-effective therapeutic option for treating obesity-induced AD, but further well-designed, randomized, and placebo-controlled clinical studies are needed to assess their optimal dosages, efficacy, and long-term safety of flavonoids in humans.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37686334' target='_blank' class='pmid-link'>37686334</a>:</span> <span class='sentence-part'>Thus, this study innovatively utilized bioinformatics and Mendelian randomization (MR) to explore the key targets of obesity-induced AD, and investigate the causal associations between different types of obesity and key targets. APOE3 carriers may be more susceptible to obesity, while the risk of AD caused by APOE2 and APOE4 may not be induced by obesity. Bioinformatics analysis revealed Apolipoprotein E (APOE) as the key target of obesity-induced AD.</span></div></div>
<div class='streamlined-assertion'><div class='streamlined-header sticky-relation-header'><span class='label-text'>Subject:</span> <strong>Obesity</strong> <span class='label-text'>Subject CUI:</span> <strong>C0028754</strong> â†’ <span class='label-text predicate-text'>CAUSES</span> â†’ <span class='label-text'>Object:</span> <strong>Atrial_Fibrillation</strong> <span class='label-text'>Object CUI:</span> <strong>C0004238</strong></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22886089' target='_blank' class='pmid-link'>22886089</a>:</span> <span class='sentence-part'>Adipocytes modulate the electrophysiology of atrial myocytes: implications in obesity-induced atrial fibrillation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28733051' target='_blank' class='pmid-link'>28733051</a>:</span> <span class='sentence-part'>BACKGROUND AND AIM: Obesity plays a dominant role in the etiology of atrial fibrillation (AF), and the maintenance of a normal body mass index (BMI) seems to prevent and even reduce the incidence of the arrhythmia's recurrence.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29049041' target='_blank' class='pmid-link'>29049041</a>:</span> <span class='sentence-part'>There is emerging evidence to suggest that the successful management of several cardiovascular risk factors [obesity, hypertension (HTN), diabetes mellitus, and obstructive sleep apnea (OSA)] can lead to fewer complications and atrial fibrillation prevention.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31682014' target='_blank' class='pmid-link'>31682014</a>:</span> <span class='sentence-part'>Obesity plays an important role in the pathogenesis of atrial fibrillation (AF).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32629939' target='_blank' class='pmid-link'>32629939</a>:</span> <span class='sentence-part'>The present study aims to test whether there is a role of Nampt/NAD axis in the pathogenesis of obesity-induced AF.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32654503' target='_blank' class='pmid-link'>32654503</a>:</span> <span class='sentence-part'>Mitochondrial antioxidant therapy abrogated the ion channel and structural remodeling and reversed the obesity-induced AF burden.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33319222' target='_blank' class='pmid-link'>33319222</a>:</span> <span class='sentence-part'>AIMS: Adiposity plays a key role in the pathogenesis of atrial fibrillation (AF).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33500550' target='_blank' class='pmid-link'>33500550</a>:</span> <span class='sentence-part'>METHODS: Here, we investigated a possible role for CaMKII-dependent I     Na,L       in obesity-induced AF using wild-type (WT) and whole-body knock-in mice that ablates phosphorylation of the Na     v      1.5 sodium channel and prevents augmentation of the late sodium current (S571A; SA mice).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33523143' target='_blank' class='pmid-link'>33523143</a>:</span> <span class='sentence-part'>In this study, we hypothesized that the NLRP3 inflammasome is a key driver of obesity-induced AF.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34113869' target='_blank' class='pmid-link'>34113869</a>:</span> <span class='sentence-part'>AF is thought to occur in association with electrical remodeling due to changes in ion channel expression or function as well as structural remodeling due to fibrosis, myocyte hypertrophy, or adiposity.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36084771' target='_blank' class='pmid-link'>36084771</a>:</span> <span class='sentence-part'>However, whether the gut microbiota is involved in regulating obesity-induced AF has not been studied.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36639364' target='_blank' class='pmid-link'>36639364</a>:</span> <span class='sentence-part'>Herein, using a mouse model of obesity-induced atrial fibrillation (AF), we tentatively explored whether exogenous melatonin supplementation could increase AF susceptibility in the context of obesity.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37516824' target='_blank' class='pmid-link'>37516824</a>:</span> <span class='sentence-part'>In this review, we discuss the epidemiology of obesity and AF, summarize the mechanisms by which obesity triggers AF, and explain how weight loss improves the prognosis of AF. Weight loss reduced the risk and reversed natural progression of AF, which may be due to its anti-fibrosis and inflammation effect.</span></div></div>
<div class='streamlined-assertion'><div class='streamlined-header sticky-relation-header'><span class='label-text'>Subject:</span> <strong>Okadaic_Acid</strong> <span class='label-text'>Subject CUI:</span> <strong>C0069389</strong> â†’ <span class='label-text predicate-text'>CAUSES</span> â†’ <span class='label-text'>Object:</span> <strong>Alzheimers</strong> <span class='label-text'>Object CUI:</span> <strong>C0002395</strong></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/10681533' target='_blank' class='pmid-link'>10681533</a>:</span> <span class='sentence-part'>By using metabolically competent rat brain slices as a model, we found that selective inhibition of protein phosphatase 2A by okadaic acid induced an Alzheimer-like hyperphosphorylation and accumulation of tau.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/10774752' target='_blank' class='pmid-link'>10774752</a>:</span> <span class='sentence-part'>Previous studies have shown that okadaic acid (OA) evokes tau phosphorylation and neurofibrillary changes in vivo, and in cultured neurons, that resemble Alzheimer's disease pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/12242084' target='_blank' class='pmid-link'>12242084</a>:</span> <span class='sentence-part'>Comparison of melatonin versus vitamin C on oxidative stress and antioxidant enzyme activity in Alzheimer's disease induced by okadaic acid in neuroblastoma cells.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/15000877' target='_blank' class='pmid-link'>15000877</a>:</span> <span class='sentence-part'>Melatonin ameliorated okadaic-acid induced Alzheimer-like lesions.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22459049' target='_blank' class='pmid-link'>22459049</a>:</span> <span class='sentence-part'>Here, we showed that Drp1 phosphorylation and mitochondrial fission were also increased in rat cortical neurons treated with okadaic acid (OA), which inhibits protein phosphatase-2A (PP2A) and induces AD-like tau phosphorylation and neuronal death.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22515493' target='_blank' class='pmid-link'>22515493</a>:</span> <span class='sentence-part'>Here, we examined the efficacy of memantine (MN) pretreatment on reducing OA-induced AD-like phenotypes in rats.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23944061' target='_blank' class='pmid-link'>23944061</a>:</span> <span class='sentence-part'>[Study on protective effect of acteoside on cellular model of Alzheimer's disease induced by okadaic acid].</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25317137' target='_blank' class='pmid-link'>25317137</a>:</span> <span class='sentence-part'>In this study, we pretreated rat brain tissue sections with ginsenoside Rg1, and established brain slice models of Alzheimer's disease induced by okadaic acid.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25393881' target='_blank' class='pmid-link'>25393881</a>:</span> <span class='sentence-part'>We have investigated the protective effects of ITH91/IQM157, a hybrid of melatonin and N,N-dibenzyl(N-methyl)amine, in an in vitro model of Alzheimer's disease (AD)-like pathology that combines amyloid beta (Abeta) and tau hyperphosphorylation induced by okadaic acid (OA), in the human neuroblastoma cell line SH-SY5Y.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26295819' target='_blank' class='pmid-link'>26295819</a>:</span> <span class='sentence-part'>Development of a Novel and Robust Pharmacological Model of Okadaic Acid-induced Alzheimer's Disease in Zebrafish. OKA-induced AD in zebrafish can become a cost efficient model to study drug discovery for AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29475037' target='_blank' class='pmid-link'>29475037</a>:</span> <span class='sentence-part'>Lanthionine ketimine-5-ethyl ester provides neuroprotection in a zebrafish model of okadaic acid-induced Alzheimer's disease. In this study, a recently established zebrafish OKA-induced AD model was utilized to further elucidate the neuroprotective and neurotrophic properties of LKE in the context of an AD-like condition.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30127109' target='_blank' class='pmid-link'>30127109</a>:</span> <span class='sentence-part'>This demonstrated the ability of the okadaic acid-induced AD zebrafish model to be implemented in the drug discovery process for therapeutics against AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30392874' target='_blank' class='pmid-link'>30392874</a>:</span> <span class='sentence-part'>This further corroborates the use of GSKbeta inhibitors in the treatment against AD and bolsters the use of the OKA-induced AD-like zebrafish model for drug discovery. The GSK3beta inhibitor, TDZD-8, rescues cognition in a zebrafish model of okadaic acid-induced Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30500552' target='_blank' class='pmid-link'>30500552</a>:</span> <span class='sentence-part'>SIGNIFICANCE: In this study, we found that the administration of the CB2 receptor agonist JWH-133 in this study reduced neurodegeneration, neuroinflammation, and spatial memory impairment in the OKA-induced Alzheimer's Disease model.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32397764' target='_blank' class='pmid-link'>32397764</a>:</span> <span class='sentence-part'>Here, we developed plasma exosomes (Exo) loaded with Que (Exo-Que) to improve the drug bioavailability, enhance the brain targeting of Que and potently ameliorate cognitive dysfunction in okadaic acid (OA)-induced AD mice.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33818056' target='_blank' class='pmid-link'>33818056</a>:</span> <span class='sentence-part'>A mouse model of okadaic-acid-induced AD-like pathology was used    in vivo     and    in vitro    .</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33957218' target='_blank' class='pmid-link'>33957218</a>:</span> <span class='sentence-part'>In the present study, the effects of PF11 on AD, in particular the underlying mechanisms related with protein phosphatase 2A (PP2A), were investigated in a rat model induced by okadaic acid (OA), a selective inhibitor of PP2A. The results showed that PF11 treatment dose-dependently improved the learning and memory impairments in OA-induced AD rats.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35447926' target='_blank' class='pmid-link'>35447926</a>:</span> <span class='sentence-part'>A few studies have used OA to trigger AD in zebrafish, providing an opportunity to test in vivo the effectiveness of new drugs in treating or attenuating AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35575872' target='_blank' class='pmid-link'>35575872</a>:</span> <span class='sentence-part'>The pathological characteristics of Alzheimer's disease (AD) include formation of senile plaques resulting from amyloid-beta (Abeta) deposition and neurofibrillary tangles caused by tau hyperphosphorylation. The above-mentioned proteins were then evaluated in an okadaic acid (OKA)-induced AD cell model to verify the results.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36594931' target='_blank' class='pmid-link'>36594931</a>:</span> <span class='sentence-part'>This study investigated the effect of cucurbitacin E (CuE), one of the bioactive components of    Ecballium elaterium    , on TAU fibril formation in okadaic acid-induced AD in rats.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37100105' target='_blank' class='pmid-link'>37100105</a>:</span> <span class='sentence-part'>To explore the driving mechanisms of AD development, we stretch out further to study time-dependant changes after Okadaic acid (OKA)-induced AD-like conditions in zebrafish. In the case of protein expression, the heatmap suggested an important role of some common proteins identified in both groups, which can be explored further to investigate their mechanism in OKA-induced AD pathology. Both time course OKA-induced AD models have shown significant memory impairment, as evident from T-Maze.</span></div></div>
<div class='streamlined-assertion'><div class='streamlined-header sticky-relation-header'><span class='label-text'>Subject:</span> <strong>Oxidation</strong> <span class='label-text'>Subject CUI:</span> <strong>C0030011</strong> â†’ <span class='label-text predicate-text'>CAUSES</span> â†’ <span class='label-text'>Object:</span> <strong>Alzheimers</strong> <span class='label-text'>Object CUI:</span> <strong>C0002395</strong></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/10100423' target='_blank' class='pmid-link'>10100423</a>:</span> <span class='sentence-part'>[Is the lesion produced by oxidation a central part in the pathogenesis of Alzheimer's disease?].</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/10699746' target='_blank' class='pmid-link'>10699746</a>:</span> <span class='sentence-part'>Oxidation has been proposed to be an important factor in the pathogenesis of Alzheimer's disease (AD) and amyloid beta is considered to induce oxidation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/12832513' target='_blank' class='pmid-link'>12832513</a>:</span> <span class='sentence-part'>This may implicate the potential contribution of RNA oxidation in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/12926540' target='_blank' class='pmid-link'>12926540</a>:</span> <span class='sentence-part'>This mini review gives a brief overview over the oxidation mechanism of methionine (Met), relevant for processes which may lead to the oxidation of amyloid beta-peptide (betaAP), involved in the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/15203119' target='_blank' class='pmid-link'>15203119</a>:</span> <span class='sentence-part'>In particular, it is well known that oxidation of methionine 35, is strongly related to the pathogenesis of Alzheimer's disease, since it represents the residue in the beta-amyloid peptide most susceptible to oxidation \in vivo\.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/15207347' target='_blank' class='pmid-link'>15207347</a>:</span> <span class='sentence-part'>In particular, it is well known that oxidation of methionine 35, is strongly related to the pathogenesis of AD, since it represents the residue in AbetaP most susceptible to oxidation in vivo.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/15635660' target='_blank' class='pmid-link'>15635660</a>:</span> <span class='sentence-part'>Metal-catalysed oxidation (MCO) may play a causative role in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20836858' target='_blank' class='pmid-link'>20836858</a>:</span> <span class='sentence-part'>We have recently shown that the cholesterol oxidation metabolite 27-hydroxycholesterol (27-OHC) causes AD-like pathology in human neuroblastoma SH-SY5Y cells and in organotypic hippocampal slices.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21272192' target='_blank' class='pmid-link'>21272192</a>:</span> <span class='sentence-part'>All three cholesterol oxidation products implicated thus far in the pathogenesis of Alzheimer's disease, 7beta-hydroxycholesterol, 24-hydroxycholesterol, and 27-hydroxycholesterol, markedly enhance the binding of amyloid-beta (Abeta) to human differentiated neuronal cell lines (SK-N-BE and NT-2) by up-regulating net expression and synthesis of CD36 and beta1-integrin receptors.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22460333' target='_blank' class='pmid-link'>22460333</a>:</span> <span class='sentence-part'>These results provide new insights and are supportive of our hypothesis that DeMPs are a newly identified trigger of neurodegenerative diseases such as Alzheimer's disease, which are known to be associated with early stage inflammation and oxidation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22758637' target='_blank' class='pmid-link'>22758637</a>:</span> <span class='sentence-part'>Over the last decade, growing evidence supports the idea that cholesterol oxidation products, known as oxysterols, may be the missing link between altered brain cholesterol metabolism and AD pathogenesis, as their involvement in neurotoxicity, mainly by interacting with Abeta peptides, is reported.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23261179' target='_blank' class='pmid-link'>23261179</a>:</span> <span class='sentence-part'>Aluminum may mediate Alzheimer's disease through liver toxicity, with aberrant hepatic synthesis of ceruloplasmin and ATPase7B, the resultant excess free copper causing brain oxidation, beta-amyloid aggregation and Alzheimer disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25261765' target='_blank' class='pmid-link'>25261765</a>:</span> <span class='sentence-part'>In this review, we will provide results from our laboratory and data from literature that converge to strongly suggest the involvement of cholesterol and cholesterol oxidation products in the pathogenesis of AD and PD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25630716' target='_blank' class='pmid-link'>25630716</a>:</span> <span class='sentence-part'>We aimed to investigate the toxicity and mechanism of AD-like pathology caused by cholesterol oxidation metabolite 27-hydroxycholesterol (27-OHC) in astrocyte cells.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29883958' target='_blank' class='pmid-link'>29883958</a>:</span> <span class='sentence-part'>It is now established that cholesterol oxidation products (oxysterols) are involved in several events underlying Alzheimer's disease (AD) pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/9737846' target='_blank' class='pmid-link'>9737846</a>:</span> <span class='sentence-part'>Oxidation of Met35 may have implications in the aetiology of Alzheimer's disease.</span></div></div>
<div class='streamlined-assertion'><div class='streamlined-header sticky-relation-header'><span class='label-text'>Subject:</span> <strong>Oxidative_Stress</strong> <span class='label-text'>Subject CUI:</span> <strong>C0242606</strong> â†’ <span class='label-text predicate-text'>CAUSES</span> â†’ <span class='label-text'>Object:</span> <strong>Alzheimers</strong> <span class='label-text'>Object CUI:</span> <strong>C0002395</strong></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/10507060' target='_blank' class='pmid-link'>10507060</a>:</span> <span class='sentence-part'>Oxidative stress and its sequelae are likely related to both necrotic and apoptotic mechanisms of neurotoxicity, and A beta-associated free radical oxidative stress may be of fundamental importance in Alzheimer's disease etiology and pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/10568522' target='_blank' class='pmid-link'>10568522</a>:</span> <span class='sentence-part'>The provided data appear to be in accordance with the known alteration of GSH levels in central nervous system and strengthen the hypothesis of oxidative stress as an important, possibly crucial mechanism in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/10681271' target='_blank' class='pmid-link'>10681271</a>:</span> <span class='sentence-part'>Many lines of evidence suggest that oxidative stress is important in the pathogenesis of Alzheimer disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/10850732' target='_blank' class='pmid-link'>10850732</a>:</span> <span class='sentence-part'>Because of the proximal role that oxidative stress mechanisms seem to play in the pathogenesis of Alzheimer disease, further investigation in this realm may lead to novel therapeutic strategies.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/10867210' target='_blank' class='pmid-link'>10867210</a>:</span> <span class='sentence-part'>The relationships shown to exist between hemorheology, blood flow, amyloids, oxidative stress, and cognitive function suggest that these factors may be one of the mechanisms operating in the complex etiology of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/10899439' target='_blank' class='pmid-link'>10899439</a>:</span> <span class='sentence-part'>Determining which of the proposed sources of free radicals, which include mitochondrial dysfunction, amyloid-beta-mediated processes, transition metal accumulation and genetic factors like apolipoprotein E and presenilins, is responsible for redox imbalance will lead to a better understanding of Alzheimer's disease pathogenesis and novel therapeutic approaches. While this suggests that oxidative stress is a proximal event in Alzheimer's disease pathogenesis, the mechanisms by which redox balance is altered in the disease remains elusive.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/11068183' target='_blank' class='pmid-link'>11068183</a>:</span> <span class='sentence-part'>The present study may help to explain the pathogenesis of neurodegeneration in AD disorders caused by metal-generated oxidative stress.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/11079778' target='_blank' class='pmid-link'>11079778</a>:</span> <span class='sentence-part'>To begin to address these issues, we investigated p38 kinase, which is induced by oxidative stress, in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/11232594' target='_blank' class='pmid-link'>11232594</a>:</span> <span class='sentence-part'>This furthers the evidence that redox-active iron and subsequent Fenton reaction generating reactive oxygen are critical factors in the pathogenesis of AD. Multiple lines of evidence indicate that oxidative stress is an integral component of the pathogenesis of Alzheimer disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/11578751' target='_blank' class='pmid-link'>11578751</a>:</span> <span class='sentence-part'>On the other hand, there is cumulative evidence from studies in cultured brain cells and on brains that oxidative stress constitutes a main factor in the modification of normal signaling pathways in neuronal cells, leading to biochemical and structural abnormalities and neurodegeneration as related to the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/11640950' target='_blank' class='pmid-link'>11640950</a>:</span> <span class='sentence-part'>There are multiple lines of evidence showing that oxidative stress and aberrant mitogenic signaling play an important role in the pathogenesis of Alzheimer disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/11708617' target='_blank' class='pmid-link'>11708617</a>:</span> <span class='sentence-part'>Oxidative stress may contribute to the aetiology of AD by dysregulation of APP metabolism.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/11738475' target='_blank' class='pmid-link'>11738475</a>:</span> <span class='sentence-part'>Further, in diseases such as progressive supranuclear palsy, Huntington's, Alzheimer's and Parkinson's diseases, the aberrant activation of TGases may be caused by oxidative stress and inflammation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/11771743' target='_blank' class='pmid-link'>11771743</a>:</span> <span class='sentence-part'>Oxidative stress is considered to be crucial in the pathogenesis of Alzheimer's disease-like neurodegeneration. An elevation of carbonyl compounds that are biomarkers of and leading to oxidative stress has been demonstrated in Down Syndrome (DS) and Alzheimer's Disease (AD) brains and seems to be the result of a multifactorial process.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/11884366' target='_blank' class='pmid-link'>11884366</a>:</span> <span class='sentence-part'>In addition, oxidative stress in the mitochondria is associated with the pathogenesis of Alzheimer's disease, Parkinson's disease, prion diseases, and amyotrophic lateral sclerosis (ALS) as well as aging itself.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/11890747' target='_blank' class='pmid-link'>11890747</a>:</span> <span class='sentence-part'>Oxidative stress and quasi-inflammatory processes recently have been recognized as contributing factors in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/12488575' target='_blank' class='pmid-link'>12488575</a>:</span> <span class='sentence-part'>Further investigation into the role that oxidative stress mechanisms seem to play in the pathogenesis of Alzheimer disease may lead to novel clinical interventions.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/12870699' target='_blank' class='pmid-link'>12870699</a>:</span> <span class='sentence-part'>There is strong evidence that oxidative stress participates in the etiology of neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/12893008' target='_blank' class='pmid-link'>12893008</a>:</span> <span class='sentence-part'>Hopefully, the following discussion will help elucidate the relationship between oxidative stress, protein modification and the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/14656990' target='_blank' class='pmid-link'>14656990</a>:</span> <span class='sentence-part'>These results support the hypothesis that oxidative stress is an important early event in AD pathogenesis, and antioxidant therapy may be beneficial only if given at this stage of the disease process.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/14661103' target='_blank' class='pmid-link'>14661103</a>:</span> <span class='sentence-part'>However, increasing evidence indicates that factors such as oxidative stress and disturbed protein metabolism and their interaction in a vicious cycle are central to AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/15036353' target='_blank' class='pmid-link'>15036353</a>:</span> <span class='sentence-part'>A growing body of evidence supports an important role for oxidative stress in the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/15039034' target='_blank' class='pmid-link'>15039034</a>:</span> <span class='sentence-part'>There are many lines of evidence showing that oxidative stress and aberrant mitogenic changes have important roles in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/15096699' target='_blank' class='pmid-link'>15096699</a>:</span> <span class='sentence-part'>Although several studies show the importance of oxidative stress in the pathogenesis of Alzheimer's disease (AD), there are few evidences on the role of free radicals in Mild Cognitive Impairment (MCI).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/15105265' target='_blank' class='pmid-link'>15105265</a>:</span> <span class='sentence-part'>Many lines of evidence indicate that oxidative stress is one of the earliest events in the genesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/15120069' target='_blank' class='pmid-link'>15120069</a>:</span> <span class='sentence-part'>A growing body of evidence suggests that oxidative stress is a common underlying mechanism in the pathogenesis of neurodegenerative disorders such as Alzheimer's, Huntington's, Creutzfeld-Jakob and Parkinson's diseases.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/15141484' target='_blank' class='pmid-link'>15141484</a>:</span> <span class='sentence-part'>However, increasing evidence indicates that factors such as oxidative stress and disturbed protein metabolism and their interaction in a vicious cycle are central to AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/15370876' target='_blank' class='pmid-link'>15370876</a>:</span> <span class='sentence-part'>Although the role of oxidative stress in the aetiology of Alzheimer's disease is still not clear, the detection of an increased damage status in the cells of patients could have important therapeutic implications.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/15380154' target='_blank' class='pmid-link'>15380154</a>:</span> <span class='sentence-part'>There is evidence that oxidative stress, homocysteine-related vitamins, fats, and alcohol have a role in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/15500684' target='_blank' class='pmid-link'>15500684</a>:</span> <span class='sentence-part'>BACKGROUND: An increasing body of evidence implicates both brain inflammation and oxidative stress in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/15614428' target='_blank' class='pmid-link'>15614428</a>:</span> <span class='sentence-part'>Oxidative stress has been shown to affect A(beta) generation in the AD pathogenesis and the mechanism of such effect is unknown. Thus, upregulation of BACE1 transcription by oxidative stress may contribute to the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/15635602' target='_blank' class='pmid-link'>15635602</a>:</span> <span class='sentence-part'>Despite the mounting evidence, however, for the causal role of mitogenic abnormalities and oxidative stress in AD pathogenesis, the effect of the converging relevant pathways due to chronic stimulation in AD remains largely unknown.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/15723615' target='_blank' class='pmid-link'>15723615</a>:</span> <span class='sentence-part'>Oxidative stress, bioenergetic impairment and mitochondrial failure have all been implicated in the etiology of neurodegenerative diseases such as Alzheimer's disease (AD), Parkinson's disease (PD) and Huntington's disease (HD), as well as retinal degeneration in glaucoma and retinitis pigmentosa.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/15753151' target='_blank' class='pmid-link'>15753151</a>:</span> <span class='sentence-part'>Oxidative stress is important in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/16181112' target='_blank' class='pmid-link'>16181112</a>:</span> <span class='sentence-part'>Evidence indicates that in the initial phase of Alzheimer's disease development, amyloid-beta deposition and hyperphosphorylated tau are consequences of oxidative stress and function as a primary line of antioxidant defense.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/16271804' target='_blank' class='pmid-link'>16271804</a>:</span> <span class='sentence-part'>The identification of common oxidized proteins in different brain regions of AD brain suggests a potential role for these oxidized proteins and thereby oxidative stress in the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/16298240' target='_blank' class='pmid-link'>16298240</a>:</span> <span class='sentence-part'>There is a large body of evidence highlighting the importance of oxidative stress in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/16311508' target='_blank' class='pmid-link'>16311508</a>:</span> <span class='sentence-part'>Deregulation of GRX1 and TRX1 antioxidant systems could be important events in AD pathogenesis. Strong evidence indicates oxidative stress in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/16337883' target='_blank' class='pmid-link'>16337883</a>:</span> <span class='sentence-part'>These results supported the hypothesis that oxidative stress was an early event in AD pathogenesis and that antioxidant therapy may be beneficial only if given at this stage of the disease process.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/16399210' target='_blank' class='pmid-link'>16399210</a>:</span> <span class='sentence-part'>Cortical and hippocampal oxidative stress is a very early event in the pathogenesis of sporadic AD and correlates with the development of specific cognitive deficits in this condition. We determined whether oxidative stress is an early event in the pathogenesis of sporadic Alzheimer disease (AD), and correlated oxidative stress with neuropsychological functions and neurofibrillary pathology in AD and mild cognitive impairment (MCI).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/16538519' target='_blank' class='pmid-link'>16538519</a>:</span> <span class='sentence-part'>Several studies have documented the involvement of oxidative stress represented by lipid peroxidation in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/16624449' target='_blank' class='pmid-link'>16624449</a>:</span> <span class='sentence-part'>Besides the genetic, biochemical and neuropathological analogies between Down's syndrome (DS) and Alzheimer's disease (AD), there is ample evidence of the involvement of oxidative stress (OS) in the pathogenesis of both disorders.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/16703529' target='_blank' class='pmid-link'>16703529</a>:</span> <span class='sentence-part'>Glutamatergic excitatory neurotransmission, an important process in learning and memory, is severely disrupted in AD, probably due to the oxidative stress associated with the beta-amyloid peptide (1-42) increase.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/16860790' target='_blank' class='pmid-link'>16860790</a>:</span> <span class='sentence-part'>Evidence has suggested a critical role for amyloid-beta peptide metabolism and oxidative stress in Alzheimer's disease pathogenesis and progression.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/16873963' target='_blank' class='pmid-link'>16873963</a>:</span> <span class='sentence-part'>Dysfunction of mitochondria and oxidative stress in the pathogenesis of Alzheimer's disease: on defects in the cytochrome c oxidase complex and aldehyde detoxification.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/16930434' target='_blank' class='pmid-link'>16930434</a>:</span> <span class='sentence-part'>This indicates that truncation of tau may precede oxidative stress in the pathogenesis of neurodegenerative diseases such as AD and other tauopathies.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17121373' target='_blank' class='pmid-link'>17121373</a>:</span> <span class='sentence-part'>This review will focus on some of the mediators of oxidative stress occurring in AD pathology and their possible role in the AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17210195' target='_blank' class='pmid-link'>17210195</a>:</span> <span class='sentence-part'>There is substantial evidence implicating increased production of the hydroxyl radical and oxidative stress in the pathogenesis of neurodegenerative diseases such as Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17279615' target='_blank' class='pmid-link'>17279615</a>:</span> <span class='sentence-part'>Recent studies implicating Abeta oligomers and protofibrils in the neurotoxic process that ultimately leads to AD suggest that the Abeta aggregates induced by 4-HNE may be important in the pathogenesis of AD. Although it remains an open question as to whether oxidative stress is a causative factor or a consequence of AD, we show here that 4-HNE, putatively resulting from the peroxidation of lipids, covalently modifies Abeta, triggering its aggregation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17460216' target='_blank' class='pmid-link'>17460216</a>:</span> <span class='sentence-part'>Evidence suggests that oxidative stresses are involved in the mechanism of Abeta-induced neurotoxicity and AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17664130' target='_blank' class='pmid-link'>17664130</a>:</span> <span class='sentence-part'>Roles of amyloid beta-peptide-associated oxidative stress and brain protein modifications in the pathogenesis of Alzheimer's disease and mild cognitive impairment.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17707551' target='_blank' class='pmid-link'>17707551</a>:</span> <span class='sentence-part'>Recent reports on amyloid beta peptide (A beta) binding-alcohol dehydrogenase (ABAD) have revealed the link of A beta with oxidative stress derived from mitochondria in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17761673' target='_blank' class='pmid-link'>17761673</a>:</span> <span class='sentence-part'>There is substantial evidence that oxidative stress elicited by amyloid beta (Abeta) accumulation is a causative factor in the pathogenesis of Alzheimer disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17764625' target='_blank' class='pmid-link'>17764625</a>:</span> <span class='sentence-part'>There is evidence that oxidative stress, homo-cysteine-related vitamins, fats, and alcohol have a role in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17996678' target='_blank' class='pmid-link'>17996678</a>:</span> <span class='sentence-part'>Inflammatory injury and induction of oxidative stress have been implicated as causative factors in neurodegenerative diseases such as Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/18084903' target='_blank' class='pmid-link'>18084903</a>:</span> <span class='sentence-part'>Oxidative stress is considered one of the causative pathomechanisms of nervous system diseases such as Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, stroke and excitotoxicity.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/18297609' target='_blank' class='pmid-link'>18297609</a>:</span> <span class='sentence-part'>Several studies show the importance of oxidative stress in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/18427999' target='_blank' class='pmid-link'>18427999</a>:</span> <span class='sentence-part'>Glutathione S-transferase omega 1 and 2 (GSTO1 and 2) protect from oxidative stress, a possible pathogenic mechanism underlying the pathogenesis of neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS) and Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/18524497' target='_blank' class='pmid-link'>18524497</a>:</span> <span class='sentence-part'>The premise that the event that initiates plaque formation is vascular explains why the risk factors for ALDs and cardiovascular diseases overlap; why drugs and lifestyle changes with vaso-protective effects protect against dementia; and why oxidative stress is prominent early in the genesis of Alzheimer-like dementias.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/18539391' target='_blank' class='pmid-link'>18539391</a>:</span> <span class='sentence-part'>The expression level of cortical glial fibrillary acidic protein (GFAP) increased in an age-related manner, in particular in 2-month PS cDKO mice, suggesting that the interaction relationship between oxidative stress and inflammatory response may be closely associated with the underlying loss-of-function pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/18565274' target='_blank' class='pmid-link'>18565274</a>:</span> <span class='sentence-part'>Cross-talk between oxidative stress and modifications of cholinergic and glutaminergic receptors in the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/18662010' target='_blank' class='pmid-link'>18662010</a>:</span> <span class='sentence-part'>There is strong evidence that oxidative stress participates in the etiology of neurodegenerative diseases such as Parkinson's, and Alzheimer's diseases.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/18762245' target='_blank' class='pmid-link'>18762245</a>:</span> <span class='sentence-part'>These results are discussed with reference to the importance of Abeta42-associated oxidative stress in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/18780972' target='_blank' class='pmid-link'>18780972</a>:</span> <span class='sentence-part'>Oxidative stress has been shown to be a triggering event in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/18822368' target='_blank' class='pmid-link'>18822368</a>:</span> <span class='sentence-part'>Oxidative stress is one of the hypotheses involved in the etiology of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/19166318' target='_blank' class='pmid-link'>19166318</a>:</span> <span class='sentence-part'>GSH deficiency or a decrease in the GSH/glutathione disulfide ratio manifests itself largely through an increased susceptibility to oxidative stress, and the resulting damage is thought to be involved in diseases, such as cancer, Parkinson's disease, and Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/19200343' target='_blank' class='pmid-link'>19200343</a>:</span> <span class='sentence-part'>Oxidative stress is one of the earliest events in the pathogenesis of Alzheimer's disease (AD) and can markedly exacerbate amyloid pathology.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/19250756' target='_blank' class='pmid-link'>19250756</a>:</span> <span class='sentence-part'>The basic pathophysiological difference is that AD is caused by oxidative stress alone, whereas PD is caused by oxidative stress plus failure of energy production.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/19345730' target='_blank' class='pmid-link'>19345730</a>:</span> <span class='sentence-part'>Oxidative stress has been reported to be a common underlying mechanism in the pathogenesis of many neurodegenerative disorders such as Alzheimer, Huntington, Creutzfeld-Jakob, and Parkinson disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/19907182' target='_blank' class='pmid-link'>19907182</a>:</span> <span class='sentence-part'>BACKGROUND/AIM: The contribution of mitochondrial dysfunction and oxidative stress to the pathogenesis of Alzheimer's disease (AD) has previously been described.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/19950527' target='_blank' class='pmid-link'>19950527</a>:</span> <span class='sentence-part'>CONCLUSION: R. rosea extract can protect rats against cognitive deficits, neuronal injury and oxidative stress induced by intracerebroventricular injection of streptozotocin, and may be used as a potential agent in treatment of neurodegenerative diseases such as AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20026169' target='_blank' class='pmid-link'>20026169</a>:</span> <span class='sentence-part'>There is significant evidence that oxidative stress is a critical event in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20236039' target='_blank' class='pmid-link'>20236039</a>:</span> <span class='sentence-part'>Genetic mutations and genetic, acquired and environmental risk factors, particularly neuroinflammation and oxidative stress, are the main causes of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20302830' target='_blank' class='pmid-link'>20302830</a>:</span> <span class='sentence-part'>Oxidative stress is known to play a key role in the initiation and promotion of the neurodegeneration that characterizes the pathogenesis of Alzheimer disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20381316' target='_blank' class='pmid-link'>20381316</a>:</span> <span class='sentence-part'>There is evidence that malnutrition, oxidative stress, and homocysteine-related vitamins play a role in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20541661' target='_blank' class='pmid-link'>20541661</a>:</span> <span class='sentence-part'>Metabolic derangements and oxidative stress are early events in Alzheimer's disease pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20555132' target='_blank' class='pmid-link'>20555132</a>:</span> <span class='sentence-part'>Although mitochondrial dysfunction and the resultant oxidative stress are believed to play a major role in the pathogenesis of both early- and late-onset AD, it is conceivable that the altered physiological state of the cells leading to sporadic AD could involve additional mechanisms.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20564553' target='_blank' class='pmid-link'>20564553</a>:</span> <span class='sentence-part'>It is strongly suggested that D-aspartic acid (D-Asp)-containing proteins are spontaneously generated by oxidative stress and would cause many aging-related misfolding diseases, such as cataracts, prion disease, and Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20586698' target='_blank' class='pmid-link'>20586698</a>:</span> <span class='sentence-part'>Oxidative stress is an important factor, and one that acts in the earliest stages, of Alzheimer's disease (AD) pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20691758' target='_blank' class='pmid-link'>20691758</a>:</span> <span class='sentence-part'>The changes in the levels of homocysteine and DHEA-S in aged rat brain have been related to associated glutathione depletion and oxidative stress and the implications of the results highlighted in the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20933033' target='_blank' class='pmid-link'>20933033</a>:</span> <span class='sentence-part'>The Abeta aggregate-induced neurotoxicity, inflammatory reactions and oxidative stress are linked strongly to the etiology of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20966918' target='_blank' class='pmid-link'>20966918</a>:</span> <span class='sentence-part'>Oxidative stress is an important determinant not only in the pathogenesis of Alzheimer's disease (AD), but also in insulin resistance (InsRes) and diabetic complications.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21357903' target='_blank' class='pmid-link'>21357903</a>:</span> <span class='sentence-part'>Oxidative stress and cell membranes in the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21426072' target='_blank' class='pmid-link'>21426072</a>:</span> <span class='sentence-part'>BACKGROUND: beta-amyloidosis and oxidative stress have been implicated as root causes of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21463622' target='_blank' class='pmid-link'>21463622</a>:</span> <span class='sentence-part'>Increasing evidence indicates that factors such as oxidative-nitrergic stress, glutathione depletion, impaired protein metabolism and cholinergic deficit can interact in a vicious cycle, which is central to Alzheimer's disease pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21551909' target='_blank' class='pmid-link'>21551909</a>:</span> <span class='sentence-part'>Moreover, since alpha1-antitrypsin, the principal inhibitor of elastase, is highly susceptible to oxidative stress, our findings suggest a link between proteolytic imbalance and oxidative stress in the pathogenesis of Alzheimer disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21605062' target='_blank' class='pmid-link'>21605062</a>:</span> <span class='sentence-part'>Oxidative stress is considered one of the earliest events in AD pathogenesis and is thought to contribute largely to neuronal cell death.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21631359' target='_blank' class='pmid-link'>21631359</a>:</span> <span class='sentence-part'>Punica granatum protects against oxidative stress in PC12 cells and oxidative stress-induced Alzheimer's symptoms in mice.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22008267' target='_blank' class='pmid-link'>22008267</a>:</span> <span class='sentence-part'>The down-regulation of energy metabolism in AD has been considered by many as a consequence of mitochondrion damage due to oxidative stress.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22137893' target='_blank' class='pmid-link'>22137893</a>:</span> <span class='sentence-part'>Specific adducts of lipid peroxidation have been demonstrated in intimate association with the pathological lesions of Alzheimer disease (AD), suggesting that oxidative stress is a major component of AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22172527' target='_blank' class='pmid-link'>22172527</a>:</span> <span class='sentence-part'>In addition, studies from mild cognitive impairment patients suggest that oxidative stress is an early event in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22406441' target='_blank' class='pmid-link'>22406441</a>:</span> <span class='sentence-part'>Our results confirm a critical role for oxidative stress in AD pathogenesis and progression and suggest the potential usefulness of EUK-207 in AD treatment.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22430645' target='_blank' class='pmid-link'>22430645</a>:</span> <span class='sentence-part'>The activation of PARP-1 by oxidative stress seems to be an early and important event in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22500616' target='_blank' class='pmid-link'>22500616</a>:</span> <span class='sentence-part'>Do proteomics analyses provide insights into reduced oxidative stress in the brain of an Alzheimer disease transgenic mouse model with an M631L amyloid precursor protein substitution and thereby the importance of amyloid-beta-resident methionine 35 in Alzheimer disease pathogenesis?</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22539855' target='_blank' class='pmid-link'>22539855</a>:</span> <span class='sentence-part'>Oxidative stress, mitochondrial dysfunction, and Ca2+ dysregulation are key factors in the pathogenesis of AD, but the causal relationship between these factors and synaptic dysfunction is not clearly understood. Alzheimer's disease (AD) in the early stages is characterized by memory impairment, which may be attributable to synaptic dysfunction.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22541290' target='_blank' class='pmid-link'>22541290</a>:</span> <span class='sentence-part'>Mitochondrial abnormalities contribute to oxidative stress which is part of AD pathogenesis in DS as well as AD in the general population.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22664577' target='_blank' class='pmid-link'>22664577</a>:</span> <span class='sentence-part'>It is well known that oxidative stress is one of the earliest events in Alzheimer's disease pathogenesis, indicating that may play a key role in this disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22708607' target='_blank' class='pmid-link'>22708607</a>:</span> <span class='sentence-part'>Copper and oxidative stress in the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22811764' target='_blank' class='pmid-link'>22811764</a>:</span> <span class='sentence-part'>Oxidative stress in the central nervous system is strongly associated with neuronal cell death in the pathogenesis of several neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, Huntington's disease, and amyotrophic lateral sclerosis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22998047' target='_blank' class='pmid-link'>22998047</a>:</span> <span class='sentence-part'>Consequences of oxidative stress thought to contribute to the development of a wide range of diseases including Alzheimer's disease, Parkinson's disease, diabetes, rheumatoid arthritis, neurodegeneration in motor neuron diseases and many cancer types.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23107435' target='_blank' class='pmid-link'>23107435</a>:</span> <span class='sentence-part'>Increasing evidence demonstrates that amyloid beta (Abeta) elicits mitochondrial dysfunction and oxidative stress, which contributes to the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23200807' target='_blank' class='pmid-link'>23200807</a>:</span> <span class='sentence-part'>In this review, we focus on changes in mitochondrial DNA and mitochondrial dynamics, two aspects critical to the maintenance of mitochondrial homeostasis and function, in relationship with oxidative stress in the pathogenesis of AD and PD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23228953' target='_blank' class='pmid-link'>23228953</a>:</span> <span class='sentence-part'>There are many evidences suggesting that oxidative stress is one of the earliest events in Alzheimer disease (AD) pathogenesis and plays a key role in the development of the AD pathology.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23254632' target='_blank' class='pmid-link'>23254632</a>:</span> <span class='sentence-part'>Oxidative stress is an early event in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23420079' target='_blank' class='pmid-link'>23420079</a>:</span> <span class='sentence-part'>Significant bodies of evidences have shown different mechanisms known to be the etiological cause of Alzheimer's disease (AD) involving amyloid-beta protein accumulation, chronic inflammatory reactions, oxidative stress, proteasome inhibition, and high-cholesterol level, but the presize etiology of AD still remains enigmatic.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23480224' target='_blank' class='pmid-link'>23480224</a>:</span> <span class='sentence-part'>BACKGROUND: Oxidative stress represents a key event in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23849337' target='_blank' class='pmid-link'>23849337</a>:</span> <span class='sentence-part'>Another hypothesis proposed by the late Mark Smith and colleagues is that oxidative stress, rather than Abeta, precipitates the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24372221' target='_blank' class='pmid-link'>24372221</a>:</span> <span class='sentence-part'>Oxidative stress mediated mitochondrial and vascular lesions as markers in the pathogenesis of Alzheimer disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24423585' target='_blank' class='pmid-link'>24423585</a>:</span> <span class='sentence-part'>These results suggested that oxidative stress alters the miRNA expression profile of hippocampal neurons, and the deregulated miRNAs might play potential roles in the pathogenesis of neurodegenerative diseases, such as Alzheimer's disease (AD). Oxidative stress plays a critical role in the etiology and pathogenesis of Alzheimer's disease (AD), and the molecular mechanisms that control the neuron response to oxidative stress have been extensively studied.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24788773' target='_blank' class='pmid-link'>24788773</a>:</span> <span class='sentence-part'>Thus, oxidative stress-induced HRD1 insolubilization might be involved in a vicious cycle of increased amyloid beta production and amyloid beta-induced oxidative stress in Alzheimer's disease pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24846973' target='_blank' class='pmid-link'>24846973</a>:</span> <span class='sentence-part'>Aggregation of Abeta induces neurotoxicities manifested by apoptosis, neuroin-flammation, oxidative stress and mitochondrial dysfunction etc., which consequently provoke the pathological progression of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25322927' target='_blank' class='pmid-link'>25322927</a>:</span> <span class='sentence-part'>BACKGROUND: Specific mechanisms behind the role of oxidative/nitrosative stress and mitochondrial dysfunction in Alzheimer's disease (AD) pathogenesis remain elusive.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25462645' target='_blank' class='pmid-link'>25462645</a>:</span> <span class='sentence-part'>Protein carbonylation is a well-documented and quantifiable consequence of oxidative stress in several neuropathologies, including multiple sclerosis, Alzheimer's disease, and Parkinson's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25511446' target='_blank' class='pmid-link'>25511446</a>:</span> <span class='sentence-part'>Although pathological hallmarks of AD are senile plaques, neurofibrillary tangles, and neuronal degeneration which are associated with increased oxidative stress, synaptic loss is an early event in the pathogenesis of AD. Mechanism of Oxidative Stress and Synapse Dysfunction in the Pathogenesis of Alzheimer's Disease: Understanding the Therapeutics Strategies.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25620241' target='_blank' class='pmid-link'>25620241</a>:</span> <span class='sentence-part'>Oxidative stress and inflammatory response are important elements of Alzheimer's disease (AD) pathogenesis, but the role of redox signaling cascade and its cross-talk with inflammatory mediators have not been elucidated in details in this disorder. The biology of NF-kappaB and its activation by reactive oxygen species (ROS) and proinflammatory cytokines in the pathogenesis of AD have been specially highlighted citing evidence both from post-mortem studies in AD brain and experimental research in animal or cell-based models of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26171115' target='_blank' class='pmid-link'>26171115</a>:</span> <span class='sentence-part'>Oxidative stress is a prominent early event in the pathogenesis of AD and is therefore believed to contribute to tau hyperphosphorylation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26295822' target='_blank' class='pmid-link'>26295822</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) is a neurodegenerative disease characterized by deposit of amyloid plaques and neurofibrillary tangles and oxidative stress plays an essential role in the pathogenesis of AD. These results indicate that JAT may be the potential target to treat AD induced by oxidative stress and apoptosis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26500157' target='_blank' class='pmid-link'>26500157</a>:</span> <span class='sentence-part'>This study demonstrates for the first time mitochondrial dysfunction in transgenic mice with a mutation within the Abeta peptide (the Arctic APP mutation), and confirms previous studies suggesting that mitochondrial dysfunction and oxidative stress is an early event in the pathogenesis of Alzheimer disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26587902' target='_blank' class='pmid-link'>26587902</a>:</span> <span class='sentence-part'>BACKGROUND: The critical role of neuro-inflammation and oxidative stress in the pathogenesis of neurodegenerative diseases such as Alzheimer's disease (AD) has become evident.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26629876' target='_blank' class='pmid-link'>26629876</a>:</span> <span class='sentence-part'>Oxidative stress is considered as an important factor and an early event in the etiology of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26890100' target='_blank' class='pmid-link'>26890100</a>:</span> <span class='sentence-part'>These changes include chronic astrocytic and microglial gliosis, oxidative stress, and altered metabolism of a number of proteins associated with the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27010693' target='_blank' class='pmid-link'>27010693</a>:</span> <span class='sentence-part'>BACKGROUND: One of the factors that contribute to Alzheimer's disease (AD) is the DNA damage caused by oxidative stress and inflammation that occurs in nerve cells.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27040443' target='_blank' class='pmid-link'>27040443</a>:</span> <span class='sentence-part'>CONCLUSION: Recent studies have shown that oxidative stress is the one of the molecular changes underlying the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27129593' target='_blank' class='pmid-link'>27129593</a>:</span> <span class='sentence-part'>In a novel sporadic mouse model that manifests AD-like pathology caused by accelerated oxidative stress in the absence of any familial AD mutation, oral administration of NMZ attenuated hallmark AD pathology and restored biomarkers of synaptic and neuronal function.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27252059' target='_blank' class='pmid-link'>27252059</a>:</span> <span class='sentence-part'>In conclusion, oxidative stress-induced HRD1 insolubilization might be involved in a vicious cycle of increased Abeta production and Abeta-induced oxidative stress in Alzheimer's disease pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27351675' target='_blank' class='pmid-link'>27351675</a>:</span> <span class='sentence-part'>Our findings suggest that oxidative stress and inflammatory responses could result in abnormal SET gene expression, contributing to the tauopathy in AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27386059' target='_blank' class='pmid-link'>27386059</a>:</span> <span class='sentence-part'>BACKGROUND: Recent studies have shown that oxidative stress (OS) is the most important indicator in the pathogenesis of Alzheimer's disease (AD), but the results in previous studies are conflicting.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27498145' target='_blank' class='pmid-link'>27498145</a>:</span> <span class='sentence-part'>Evidence suggests that oxidative stress and apoptosis are involved in the mechanism of Abeta-induced neurotoxicity and AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27774420' target='_blank' class='pmid-link'>27774420</a>:</span> <span class='sentence-part'>At the same time, aggregated Abeta-induced oxidative stress is the trigger in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27796749' target='_blank' class='pmid-link'>27796749</a>:</span> <span class='sentence-part'>Oxidative stress is considered a major contributor to the pathogenesis of AD, and accumulating evidence indicates that high levels of reactive oxygen species (ROS) are involved in Abeta-induced neurodegeneration. Amyloid-beta peptide (Abeta) is one of the major players in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28332351' target='_blank' class='pmid-link'>28332351</a>:</span> <span class='sentence-part'>Oxidative stress is known to be induced by Abeta and NFTs, and we suggest that oxidative stress caused by metabolic alterations in the body induce brain metabolic alterations, resulting in AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28448946' target='_blank' class='pmid-link'>28448946</a>:</span> <span class='sentence-part'>INTRODUCTION: There is increasing evidence for the involvement of chronic inflammation and oxidative stress in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28970897' target='_blank' class='pmid-link'>28970897</a>:</span> <span class='sentence-part'>Oxidative stress is linked to the etiology of Alzheimer's disease (AD), the most common cause of dementia in the elderly.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29090409' target='_blank' class='pmid-link'>29090409</a>:</span> <span class='sentence-part'>Oxidative stress and cytotoxic damage induced by amyloid beta (Abeta) have been considered pivotal in the pathogenesis of Alzheimer's disease (AD) and may represent a target for treatment.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29109370' target='_blank' class='pmid-link'>29109370</a>:</span> <span class='sentence-part'>Our results suggest that olive biophenols potentially serve as agents for the prevention of neurodegenerative diseases such as AD, and other neurodegenerative ailments that are caused by oxidative stress.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29112116' target='_blank' class='pmid-link'>29112116</a>:</span> <span class='sentence-part'>Increased evidence suggests neuroinflammation and oxidative stress may cause AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29512790' target='_blank' class='pmid-link'>29512790</a>:</span> <span class='sentence-part'>Oxidative stress may contribute to the underlying mechanisms causing Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29574628' target='_blank' class='pmid-link'>29574628</a>:</span> <span class='sentence-part'>Increasing evidence indicates that sirtuin 3 (Sirt3) has neuroprotective effects in regulating oxidative stress and energy metabolism, both of which are involved in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29951441' target='_blank' class='pmid-link'>29951441</a>:</span> <span class='sentence-part'>This paper outlines possible protective consequences of LDR in preventing the pathogenesis of AD through mechanisms such as restoring the myelin sheath and preventing neurodegeneration caused by oxidative stress.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30112360' target='_blank' class='pmid-link'>30112360</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) and multiple sclerosis are major neurodegenerative diseases, which are characterized by the accumulation of abnormal pathogenic proteins due to oxidative stress, mitochondrial dysfunction, impaired autophagy, and pathogens, leading to neurodegeneration and behavioral deficits.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30151968' target='_blank' class='pmid-link'>30151968</a>:</span> <span class='sentence-part'>Transition-metal-catalyzed oxidative stress is a widespread concern in the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30498443' target='_blank' class='pmid-link'>30498443</a>:</span> <span class='sentence-part'>Several factors like tau protein hyperphosphorylation, amyloid-beta (Abeta) peptide aggregation, decline in acetyl cholinesterase and oxidative stress might be contributing toward the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30689517' target='_blank' class='pmid-link'>30689517</a>:</span> <span class='sentence-part'>Oxidative stress has also been known as an important cause of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30694418' target='_blank' class='pmid-link'>30694418</a>:</span> <span class='sentence-part'>Oxidative stress and the presence of ApoEepsilon4 allele has been reported to play a major role in the pathogenesis of AD, but the contribution of oxidative stress and ApoEepsilon4 in macrophage dysfunction leading to ineffective Abeta phagocytosis needs to be analyzed.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30729451' target='_blank' class='pmid-link'>30729451</a>:</span> <span class='sentence-part'>This combinatorial model also exhibited cognitive deficiency which was assessed by Morris water maze and avoidance tests along with enhanced oxidative stress which is thought to be a major player in AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30984280' target='_blank' class='pmid-link'>30984280</a>:</span> <span class='sentence-part'>For this reason, OS is considered a key factor in Alzheimer's Disease (AD) development and recent evidence correlated oxidative stress with vascular lesion in the pathogenesis of AD, but the mechanism still need to be fully clarified.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31006097' target='_blank' class='pmid-link'>31006097</a>:</span> <span class='sentence-part'>Oxidative stress is a key factor of and closely implicated in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31022822' target='_blank' class='pmid-link'>31022822</a>:</span> <span class='sentence-part'>The detrimental effects of oxidative stress and chronic neuroinflammation on neuronal cell death have been implicated in the pathogenesis of neurodegenerative disorders such as Alzheimer's disease (AD) and Parkinson's disease (PD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31057691' target='_blank' class='pmid-link'>31057691</a>:</span> <span class='sentence-part'>In this review, we outline and discuss the mitochondrial and oxidative stress factors causing degenerative diseases, such as Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, Huntington's disease, and Friedreich's ataxia.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31117312' target='_blank' class='pmid-link'>31117312</a>:</span> <span class='sentence-part'>It is believed that oxidative stress and cholinergic deficit are the leading causes of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31151322' target='_blank' class='pmid-link'>31151322</a>:</span> <span class='sentence-part'>Oxidative stress is believed to be one of the main causes of neurodegenerative diseases such as Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31165850' target='_blank' class='pmid-link'>31165850</a>:</span> <span class='sentence-part'>Cholinergic dysfunction and oxidative stress are the most common causes of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31173752' target='_blank' class='pmid-link'>31173752</a>:</span> <span class='sentence-part'>The protective effects of liraglutide on AD-like neurodegeneration induced by oxidative stress in human neuroblastoma SH-SY5Y cells.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31247877' target='_blank' class='pmid-link'>31247877</a>:</span> <span class='sentence-part'>They indeed impact the aggregation pathways of Abeta and are involved in the catalytic generation of reactive oxygen species (ROS) that participate in oxidative stress, while Abeta aggregation and oxidative stress are regarded as two key events in AD etiology.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31403949' target='_blank' class='pmid-link'>31403949</a>:</span> <span class='sentence-part'>These findings suggest that EDA possesses clinical and pathological benefits for AD with CCH in the present mouse model and has a potential as a therapeutic agent for AD with CCH via targeting multiple key pathways of the disease pathogenesis. The hallmarks of AD including amyloid-beta (Abeta)/phosphorylated tau (pTau) and pathology-related events such as neural oxidative stress and neuroinflammation play critical roles in pathogenesis of AD with CCH.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31424393' target='_blank' class='pmid-link'>31424393</a>:</span> <span class='sentence-part'>Ischemic postconditioning protects against post-ischemic excitotoxicity, oxidative stress, and inflammatory process that have also been implicated in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31462605' target='_blank' class='pmid-link'>31462605</a>:</span> <span class='sentence-part'>Oxidative stress is closely related to the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31495239' target='_blank' class='pmid-link'>31495239</a>:</span> <span class='sentence-part'>Oxidative stress is implicated in pathogenesis of neurodegenerative disorders, such as Alzheimer's and Parkinson's diseases.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31521745' target='_blank' class='pmid-link'>31521745</a>:</span> <span class='sentence-part'>These findings support a role for the involvement of mitochondria-derived oxidative stress in the etiology of AD and suggest that mitochondria-targeted antioxidants may lessen symptoms in AD patients.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31585875' target='_blank' class='pmid-link'>31585875</a>:</span> <span class='sentence-part'>The pathophysiology involved in AD is intra-neuronal accumulation of hyper-phosphorylated tau protein as neurofibrillary tangle and extra cellular beta amyloid plaque deposition, which is due to oxidative stress.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31607444' target='_blank' class='pmid-link'>31607444</a>:</span> <span class='sentence-part'>Dysregulation of the blood brain barrier due to oxidative stress causes neurological disorders, such as Alzheimer's and Parkinson's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31686372' target='_blank' class='pmid-link'>31686372</a>:</span> <span class='sentence-part'>However, the molecular mechanisms underlying the aberrant expression levels of these proteins in the pathogenesis of AD are still not completely understood. Mitochondrial dysfunctions and oxidative stress play important roles in the early pathogenesis of Alzheimer's disease (AD), which also involves the aberrant expression levels of mitochondrial proteins.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31766696' target='_blank' class='pmid-link'>31766696</a>:</span> <span class='sentence-part'>This study presents a literature review of ANTs from different berries and their potential therapeutic value, with particular emphasis on neurodegenerative AD, which owing to oxidative stress.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31939658' target='_blank' class='pmid-link'>31939658</a>:</span> <span class='sentence-part'>Oxidative stress is known to play an important role in the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31945778' target='_blank' class='pmid-link'>31945778</a>:</span> <span class='sentence-part'>The oxidative stress is one of the main causative factors of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32035419' target='_blank' class='pmid-link'>32035419</a>:</span> <span class='sentence-part'>Oxidative stress and chronic inflammation have been suggested as causes of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32124703' target='_blank' class='pmid-link'>32124703</a>:</span> <span class='sentence-part'>Oxidative stress in the pathogenesis of Alzheimer's disease and cerebrovascular disease with therapeutic implications.The significant gain in life expectancy led to an increase in the incidence and prevalence of dementia. Oxidative stress in the pathogenesis of Alzheimer's disease and cerebrovascular disease with therapeutic implications.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32171783' target='_blank' class='pmid-link'>32171783</a>:</span> <span class='sentence-part'>Indeed, the burden of amyloid beta (Abeta), neurofibrillary tangles (NFTs), neuroinflammation, oxidative stress, and dysfunction of circadian rhythms may lead to AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32180930' target='_blank' class='pmid-link'>32180930</a>:</span> <span class='sentence-part'>Moreover, BACE1 was also found to be closely related to AD pathogenesis caused by oxidative stress.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32277437' target='_blank' class='pmid-link'>32277437</a>:</span> <span class='sentence-part'>Uric acid and late-onset Alzheimer's disease: results from the ReGAl 2.0 project.BACKGROUND: It has been suggested that oxidative stress may have a role in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32329360' target='_blank' class='pmid-link'>32329360</a>:</span> <span class='sentence-part'>Nutritional supplementation of GA preserve the morphological and physiological integrity of the hippocampus against environmental neurotoxins (AlCl     3      ) by mopping up free radicals associated with oxidative stress induced AD. This study aimed at investigating the neuroprotective effects of Gallic Acid (GA) against aluminum-chloride induced AD in adult Wistar rats.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32444542' target='_blank' class='pmid-link'>32444542</a>:</span> <span class='sentence-part'>Tenuifolin Attenuates Amyloid-beta42-Induced Neuroinflammation in Microglia Through the NF-kappaB Signaling Pathway.BACKGROUND: Inflammation and oxidative stress are believed to play an important role in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32504391' target='_blank' class='pmid-link'>32504391</a>:</span> <span class='sentence-part'>Protective Effects of Co-administration of Zinc and Selenium Against Streptozotocin-Induced Alzheimer's Disease: Behavioral, Mitochondrial Oxidative Stress, and GPR39 Expression Alterations in Rats. Findings of the current study showed that ZnR/GPR39 receptor, mitochondrial dysfunction, and oxidative stress play important roles in the pathogenesis of AD. Co-treatment of Zn and Se improved the cognitive performance, mitochondrial dysfunction, and oxidative stress caused by STZ-induced AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32594052' target='_blank' class='pmid-link'>32594052</a>:</span> <span class='sentence-part'>Amyloid beta (Abeta)-induced neurotoxicity and oxidative stress plays an important role in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32606694' target='_blank' class='pmid-link'>32606694</a>:</span> <span class='sentence-part'>Background: beta-Amyloid (Abeta) induces oxidative stress and inflammation of microglial cells, thus leading to Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32730855' target='_blank' class='pmid-link'>32730855</a>:</span> <span class='sentence-part'>Oxidative stress is considered as one of the pathogenesis of Alzheimer's disease (AD) and plays an important role in the occurrence and development of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32737764' target='_blank' class='pmid-link'>32737764</a>:</span> <span class='sentence-part'>Oxidative stress is thought to be central in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32765394' target='_blank' class='pmid-link'>32765394</a>:</span> <span class='sentence-part'>Thus, ORC may exert a protective role in AD through attenuating the damage caused by inflammation and oxidative stress.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32829453' target='_blank' class='pmid-link'>32829453</a>:</span> <span class='sentence-part'>In this narrative review, we provide an overview of gut microbiota and their dysregulation in the pathogenesis of AD. Although a causal relationship between gut dysbiosis and neural dysfunction remains elusive, emerging evidence indicates that gut dysbiosis may promote amyloid-beta aggregation, neuroinflammation, oxidative stress, and insulin resistance in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32920833' target='_blank' class='pmid-link'>32920833</a>:</span> <span class='sentence-part'>It has long been recognized that mitochondrial dysfunction and oxidative stress contribute to the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33052996' target='_blank' class='pmid-link'>33052996</a>:</span> <span class='sentence-part'>Oxidative stress and metal dyshomeostasis are considered as crucial factors in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33081348' target='_blank' class='pmid-link'>33081348</a>:</span> <span class='sentence-part'>Copper Toxicity Links to Pathogenesis of Alzheimer's Disease and Therapeutics Approaches. Several studies have indicated that oxidative stress plays a crucial role in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33114450' target='_blank' class='pmid-link'>33114450</a>:</span> <span class='sentence-part'>Amongst the dysregulated pathophysiological pathways in AD, oxidative stress seems to play a critical role in the pathogenesis progression of AD, with a dominant role of nuclear factor erythroid 2-related factor 2 (Nrf2)/Kelch-like ECH-associated protein-1 (Keap1)/antioxidant responsive elements (ARE) pathway.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33239403' target='_blank' class='pmid-link'>33239403</a>:</span> <span class='sentence-part'>Abeta accumulation affects mitochondrial redox balance, increasing oxidative stress status, which in turn is proposed as a primary culprit in AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33264657' target='_blank' class='pmid-link'>33264657</a>:</span> <span class='sentence-part'>Hypoxia causes oxidative stress with severe and detrimental effects on brain function and acts as a critical initiating factor in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33476985' target='_blank' class='pmid-link'>33476985</a>:</span> <span class='sentence-part'>Oxidative stress is a prominent early event in the pathogenesis of AD and is therefore believed to contribute to tau hyperphosphorylation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33488846' target='_blank' class='pmid-link'>33488846</a>:</span> <span class='sentence-part'>beta    -Amyloid (A   beta    ), a strong inducer of oxidative stress, plays a crucial role in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33567524' target='_blank' class='pmid-link'>33567524</a>:</span> <span class='sentence-part'>Oxidative stress has been implicated in the pathogenesis of Alzheimer's disease, and brains with the disease examined in this study also exhibited higher carbonylated proteins, as well as an increased thiol oxidation state of peroxiredoxin 6 (Prx6).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33633844' target='_blank' class='pmid-link'>33633844</a>:</span> <span class='sentence-part'>Conclusions:     Our findings indicate that oxidative stress, apoptosis, and inflammation/immune system processes likely underlie the pathogenesis of AD and DS.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33679375' target='_blank' class='pmid-link'>33679375</a>:</span> <span class='sentence-part'>Over the last few years, remarkable efforts have been made to investigate the impact on the pathogenesis of Alzheimer's disease (AD) of various forms of mitochondrial dysfunction, such as excessive reactive oxygen species (ROS) production, mitochondrial Ca     2+       dyshomeostasis, loss of ATP, and defects in mitochondrial dynamics and transport, and mitophagy. In this review, we focus on recent progress that highlights the crucial role of alterations in mitochondrial function and oxidative stress in the pathogenesis of AD, emphasizing a framework of existing and potential therapeutic approaches.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33774476' target='_blank' class='pmid-link'>33774476</a>:</span> <span class='sentence-part'>Oxidative stress has been implicated in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33811448' target='_blank' class='pmid-link'>33811448</a>:</span> <span class='sentence-part'>In addition, oxidative stress is considered as an important factor in the etiology of AD and a multitude of metalloproteins and transporters are affected, leading to metal ion misregulation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33897425' target='_blank' class='pmid-link'>33897425</a>:</span> <span class='sentence-part'>The toxic aggregates of amyloid beta (Abeta) disrupt the cell membrane, induce oxidative stress and mitochondrial dysfunction, and eventually lead to Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34107282' target='_blank' class='pmid-link'>34107282</a>:</span> <span class='sentence-part'>We have found that HSV-1 induces the main neuropathological hallmarks of AD, including the accumulation of intracellular amyloid beta (Abeta), hyperphosphorylated tau protein and autophagic vesicles, that OS exacerbates these effects, and that matrix metalloproteinase 14 (MMP-14) participates in the alterations induced by OS.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34403662' target='_blank' class='pmid-link'>34403662</a>:</span> <span class='sentence-part'>CONCLUSION: CircLPAR1 promotes Abeta25-35-induced apoptosis, inflammation, and oxidative stress via miR-212-3p/ZNF217 axis, suggesting a new insight into the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34662512' target='_blank' class='pmid-link'>34662512</a>:</span> <span class='sentence-part'>Expanding literature suggests that oxidative stress (OS) is a vital factor contributing to the pathogenesis of AD such that biometals (e.g., iron, zinc, copper) are believed to play a crucial role in Abeta formation and neurodegeneration.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34932880' target='_blank' class='pmid-link'>34932880</a>:</span> <span class='sentence-part'>Oxidative stress and cholinergic system dysfunction are two widely studied pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35049930' target='_blank' class='pmid-link'>35049930</a>:</span> <span class='sentence-part'>As the major clinical indications (CI) of AD are extracellular plaques formed by beta-amyloid (Abeta) protein, intracellular neurofibrillary tangles (NFTs) formed by hyper phosphorylated tau-protein, uncommon inflammatory response and neuron apoptosis and death caused by oxidative stress, alkaloids that may decrease CI, might be used against AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35226474' target='_blank' class='pmid-link'>35226474</a>:</span> <span class='sentence-part'>Oxidative stress is important for the etiology and pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35280979' target='_blank' class='pmid-link'>35280979</a>:</span> <span class='sentence-part'>Background/Aim: Apoptosis and oxidative stress have been considered as key events in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35341471' target='_blank' class='pmid-link'>35341471</a>:</span> <span class='sentence-part'>The accumulation of aluminum in brain is reported to be associated with cholinergic dysfunction, oxidative stress and neuronal damage, that may ultimately cause Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35395415' target='_blank' class='pmid-link'>35395415</a>:</span> <span class='sentence-part'>Taking oxidative stress as the central point, this review comprehensively expands on the roles of oxidative stress that are involved in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35411685' target='_blank' class='pmid-link'>35411685</a>:</span> <span class='sentence-part'>Hence, this study was designed to investigate the possible therapeutic effect of betanin against SCO-induced AD on Wistar rats. SCO (1 mg/kg) was administrated intraperitoneally to induce the AD in Wistar rats. Mitochondrial dysfunction and oxidative stress are identified to contribute to the mechanisms responsible for the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35474814' target='_blank' class='pmid-link'>35474814</a>:</span> <span class='sentence-part'>Identifying specific interactive effects of MI with cellular antioxidant enzymes would represent an essential step in understanding the oxidative stress-induced AD pathogenicity.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35961386' target='_blank' class='pmid-link'>35961386</a>:</span> <span class='sentence-part'>Oxidative stress is an early event during AD pathogenesis and is associated with tau-mediated AD pathology.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36014181' target='_blank' class='pmid-link'>36014181</a>:</span> <span class='sentence-part'>The antioxidant, anti-cholinesterase, and anti-diabetic potential of the prepared nanoparticles were high in comparison to other areas of biological potential, indicating that the FeNPs are capable of targeting meditators of oxidative stress leading to diabetes and Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36091821' target='_blank' class='pmid-link'>36091821</a>:</span> <span class='sentence-part'>Conclusion:     This study suggests that AOF had the potential to treat AD by suppressing apoptosis induced by oxidative stress via the PI3K/Akt pathway.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36091826' target='_blank' class='pmid-link'>36091826</a>:</span> <span class='sentence-part'>Disturbed retinoic acid signaling causes inflammatory responses, mitochondrial impairment, oxidative stress, and neurodegeneration, leading to Alzheimer's disease (AD) progression. We outlined the physiology of retinoids in this review, focusing on their possible neuroprotective actions, which will aid in elucidating the critical function of such receptors in AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36139869' target='_blank' class='pmid-link'>36139869</a>:</span> <span class='sentence-part'>Oxidative stress in the brain is highly related to the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36476438' target='_blank' class='pmid-link'>36476438</a>:</span> <span class='sentence-part'>These molecules protect neurons against oxidative stress and deposition of amyloid-beta (Abeta) and tau proteins which play a vital role in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36587558' target='_blank' class='pmid-link'>36587558</a>:</span> <span class='sentence-part'>Although the pathogenesis of AD is unclear, neurotoxicity induced by oxidative stress plays an important role in the progression of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36635346' target='_blank' class='pmid-link'>36635346</a>:</span> <span class='sentence-part'>Oxidative stress and neuroinflammation play important roles in the pathogenesis of AD. Our study identified 9 key genes associated with oxidative stress and immune reaction in AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36744334' target='_blank' class='pmid-link'>36744334</a>:</span> <span class='sentence-part'>OBJECTIVE: The goal of the present study was to uncover the oxidative stress mechanisms causing AD, as well as the potential therapeutic targets and neuroprotective drugs against oxidative stress mechanisms.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36999542' target='_blank' class='pmid-link'>36999542</a>:</span> <span class='sentence-part'>Oxidative stress is an important contributor to the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37231172' target='_blank' class='pmid-link'>37231172</a>:</span> <span class='sentence-part'>Therapeutic potential of flavonoids in the management of obesity-induced Alzheimer's disease: an overview of preclinical and clinical studies. Obesity has also been linked to neurological diseases such as cognitive decline, dementia, and Alzheimer's disease (AD), caused by oxidative stress, pro-inflammatory cytokines, and the production of reactive oxygen free radicals (ROS). Thus, flavonoid-rich nutraceuticals can be a potential cost-effective therapeutic option for treating obesity-induced AD, but further well-designed, randomized, and placebo-controlled clinical studies are needed to assess their optimal dosages, efficacy, and long-term safety of flavonoids in humans.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37385075' target='_blank' class='pmid-link'>37385075</a>:</span> <span class='sentence-part'>In the present study, we reported a new phosphodiester containing diaminonaphthalene compound, POZL, designed to target the PPI interface using a structure-based design strategy to combat oxidative stress in AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37453560' target='_blank' class='pmid-link'>37453560</a>:</span> <span class='sentence-part'>Brain acetylcholine deficit and oxidative stress may be considered the key pathogenic causes for AD, even though the basic etiology is still unknown.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37465125' target='_blank' class='pmid-link'>37465125</a>:</span> <span class='sentence-part'>Oxidative stress in the brain is considered as one of the contributing factors to the pathogenesis of AD, and thus, antioxidants have attracted much interest as potential therapeutic agents against the disorder.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37516225' target='_blank' class='pmid-link'>37516225</a>:</span> <span class='sentence-part'>Amyloid fibrils are associated with various neurodegenerative diseases (ND) such as Alzheimer's disease (AD) and Parkinson's disease (PD), which are caused by oxidative stress and impaired protein homeostasis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37718506' target='_blank' class='pmid-link'>37718506</a>:</span> <span class='sentence-part'>BACKGROUND: Oxidative stress is an early event in the development of Alzheimer's disease (AD) and maybe a pivotal point of interaction governing AD pathogenesis; oxidative stress contributes to metabolism imbalance, protein misfolding, neuroinflammation and apoptosis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37962427' target='_blank' class='pmid-link'>37962427</a>:</span> <span class='sentence-part'>The redox-active metal ions, especially Cu     2+      , are highly correlated to Alzheimer's disease (AD) by causing metal ion-mediated oxidative stress and toxic metal-bound beta-amyloid (Abeta) aggregates.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37979715' target='_blank' class='pmid-link'>37979715</a>:</span> <span class='sentence-part'>This study provides evidence to support the essential roles of OS in pathogenesis of AD, and the application of Pls in relieving AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/38057817' target='_blank' class='pmid-link'>38057817</a>:</span> <span class='sentence-part'>A body of evidence suggest that oxidative stress and autophagy are involved in the pathogenesis of AD. However, its effects on aluminum-induced AD model have not been studied much.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/38251163' target='_blank' class='pmid-link'>38251163</a>:</span> <span class='sentence-part'>The primary pathological hallmark of Alzheimer's disease (AD) is the formation and accumulation of neurofibrillary tangles and plaques, which result from the aggregation of amyloid-   beta     (A   beta    ) induced by oxidative stress.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/38396988' target='_blank' class='pmid-link'>38396988</a>:</span> <span class='sentence-part'>Oxidative stress is involved in the impaired clearance of amyloid beta (Abeta), and Abeta-induced oxidative stress causes AD by inducing the formation of neurofibrillary tangles.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/38565372' target='_blank' class='pmid-link'>38565372</a>:</span> <span class='sentence-part'>Multiple complex pathways, such as oxidative stress, tau and amyloid-beta (Abeta) pathology, and cholinergic dysfunction, are involved in the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/38571463' target='_blank' class='pmid-link'>38571463</a>:</span> <span class='sentence-part'>It is one of the beneficial compounds used to prevent and treat the oxidative stress induced neurological disorders like stress, depression and Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/8871938' target='_blank' class='pmid-link'>8871938</a>:</span> <span class='sentence-part'>Despite a large amount of evidence that suggests an association between oxidative stress and the pathogenesis of AD, it is not yet known whether oxidative stress is a cause or consequence of the disorder.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/8871940' target='_blank' class='pmid-link'>8871940</a>:</span> <span class='sentence-part'>We and other investigators recently demonstrated that several mechanisms related to oxidative stress and free-radical reactions could play a crucial role in the pathogenesis of AD and, specifically, in the formation of senile plaques and neurofibrillary tangles (NFT).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/9562500' target='_blank' class='pmid-link'>9562500</a>:</span> <span class='sentence-part'>Recent studies have implicated increased oxidative stress in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/9887447' target='_blank' class='pmid-link'>9887447</a>:</span> <span class='sentence-part'>In this review article, we will discuss the evidence suggesting that estrogen may have a protective role against AD, mainly through its action as: a trophic factor for cholinergic neurons, a modulator for the expression of apolipoprotein E (ApoE) in the brain, an antioxidant compound decreasing the neuronal damage caused by oxidative stress, and a promoter of the physiological nonamyloidogenic processing of the amyloid precursor protein (APP), decreasing the production of the amyloid-beta-peptide (A beta), a key factor in the pathogenesis of AD.</span></div></div>
<div class='streamlined-assertion'><div class='streamlined-header sticky-relation-header'><span class='label-text'>Subject:</span> <strong>PS2_protein_alzheimer_associated_PSEN2</strong> <span class='label-text'>Subject CUI:</span> <strong>C0528480|5664</strong> â†’ <span class='label-text predicate-text'>CAUSES</span> â†’ <span class='label-text'>Object:</span> <strong>Alzheimers</strong> <span class='label-text'>Object CUI:</span> <strong>C0750901</strong></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/10078973' target='_blank' class='pmid-link'>10078973</a>:</span> <span class='sentence-part'>Mutations in two related genes, presenilin 1 and presenilin 2 (PS1 and PS2), cause a subset of early-onset familial Alzheimer's disease (FAD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/10340748' target='_blank' class='pmid-link'>10340748</a>:</span> <span class='sentence-part'>Because distinct mutations in presenilin 1 and presenilin 2 are a major cause of early-onset familial Alzheimer's disease, we generated four monoclonal antibodies for the identification, localization, and investigation of presenilins in various cell lines and tissues from patients and controls.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22044463' target='_blank' class='pmid-link'>22044463</a>:</span> <span class='sentence-part'>BACKGROUND: Missense mutations in three different genes encoding amyloid-beta precursor protein, presenilin 1 and presenilin 2 are recognized to cause familial early-onset Alzheimer disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22702962' target='_blank' class='pmid-link'>22702962</a>:</span> <span class='sentence-part'>Mutations in genes such as those encoding amyloid precursor protein (APP), presenilin 1 and presenilin 2, are responsible for early-onset familial AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23142261' target='_blank' class='pmid-link'>23142261</a>:</span> <span class='sentence-part'>Mutations in the genes encoding amyloid precursor protein (APP), presenilin 1 (PSEN1) and presenilin 2 (PSEN2) are responsible for early-onset autosomal dominant AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24838203' target='_blank' class='pmid-link'>24838203</a>:</span> <span class='sentence-part'>Mutations in the genes encoding amyloid precursor protein (APP), presenilin 1 (PSEN1) and presenilin 2 (PSEN2) are responsible for early-onset autosomal dominant AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26141474' target='_blank' class='pmid-link'>26141474</a>:</span> <span class='sentence-part'>To date, mutations in three different genes, the Amyloid precursor protein (APP), Presenilin 1 (PS1), and Presenilin 2 (PS2), have been identified as causative in early-onset AD, making predictive testing possible.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30041064' target='_blank' class='pmid-link'>30041064</a>:</span> <span class='sentence-part'>Seizures have traditionally been related to neuronal loss in the late stages of AD as a consequence of neurodegeneration, however, recent studies indicated that seizures may contribute to the emergence of AD symptoms in early stages of the disease, mainly in familial AD. Mutations in genes encoding presenilin 1 (PSEN1), presenilin 2 (PSEN2) and amyloid precursor protein (APP) are responsible for early-onset familial AD (EOFAD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31440394' target='_blank' class='pmid-link'>31440394</a>:</span> <span class='sentence-part'>Presenilin 1 (PSEN1), presenilin 2 (PSEN2), and amyloid precursor protein (APP) mutations are responsible for autosomal dominant early-onset Alzheimer's disease (AD-EOAD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/8878479' target='_blank' class='pmid-link'>8878479</a>:</span> <span class='sentence-part'>Mutations in the genes encoding amyloid-beta precursor protein (APP), presenilin 1 (PS1) and presenilin 2 (PS2) are known to cause early-onset, autosomal dominant Alzheimer's disease. These results indicate that the presenilin mutations probably cause Alzheimer's disease through a gain of deleterious function that increases the amount of A beta42(43) in the brain.</span></div></div>
<div class='streamlined-assertion'><div class='streamlined-header sticky-relation-header'><span class='label-text'>Subject:</span> <strong>PSEN1</strong> <span class='label-text'>Subject CUI:</span> <strong>5663</strong> â†’ <span class='label-text predicate-text'>CAUSES</span> â†’ <span class='label-text'>Object:</span> <strong>Alzheimers</strong> <span class='label-text'>Object CUI:</span> <strong>C0750901</strong></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/12941610' target='_blank' class='pmid-link'>12941610</a>:</span> <span class='sentence-part'>Dominant mutations in presenilin1 (PS1) and presenilin2 (PS2) are a major cause of early-onset Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/18028191' target='_blank' class='pmid-link'>18028191</a>:</span> <span class='sentence-part'>L286P is a novel mutation in PSEN1 that causes familial early-onset AD and brain haematomas related to amyloid angiopathy.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20388456' target='_blank' class='pmid-link'>20388456</a>:</span> <span class='sentence-part'>CONCLUSIONS: E120G is a novel mutation in PSEN1 that probably causes early-onset autosomal dominant AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20955934' target='_blank' class='pmid-link'>20955934</a>:</span> <span class='sentence-part'>Positional cloning led to the identification of rare, disease-causing mutations in APP, PSEN1, and PSEN2 causing early-onset familial AD, followed by the discovery of APOE as the single most important risk factor for late-onset AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21094210' target='_blank' class='pmid-link'>21094210</a>:</span> <span class='sentence-part'>Biochemical, neuropathological, and neuroimaging characteristics of early-onset Alzheimer's disease due to a novel PSEN1 mutation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25220527' target='_blank' class='pmid-link'>25220527</a>:</span> <span class='sentence-part'>In addition to mutations in APP, PSEN1 and PSEN2 genes, that cause early onset autosomal dominant AD, several genetic risk factors for late onset AD are now known. Alzheimer's disease (AD) is the most common form of dementia characterized by deterioration of memory and other cognitive domains which leads to death in 3-9years after diagnosis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26830138' target='_blank' class='pmid-link'>26830138</a>:</span> <span class='sentence-part'>Over 200 highly penetrant pathogenic variants in the genes APP, PSEN1, and PSEN2 cause a subset of early-onset familial AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27274215' target='_blank' class='pmid-link'>27274215</a>:</span> <span class='sentence-part'>Linkage analysis was the first milestone in unraveling the mutations in APP, PSEN1, and PSEN2 that cause early-onset AD, followed by the discovery of apolipoprotein E-epsilon4 allele as the only one genetic risk factor for late-onset AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27535542' target='_blank' class='pmid-link'>27535542</a>:</span> <span class='sentence-part'>BACKGROUND: Pathogenic mutations in PSEN1 are known to cause familial early-onset Alzheimer's disease (EOAD) but common variants in PSEN1 have not been found to strongly influence late-onset AD (LOAD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28131463' target='_blank' class='pmid-link'>28131463</a>:</span> <span class='sentence-part'>The Val391Gly variation widens the number of PSEN1 mutations responsible for early-onset Alzheimer's disease with extrapyramidal phenotype and would help to establish a functional map of presenilin 1 protein architecture.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29478590' target='_blank' class='pmid-link'>29478590</a>:</span> <span class='sentence-part'>Genetically, the first clues were provided by genetic linkage studies that led to the identification of APP, PSEN1, and PSEN2 mutations as the main causes of autosomal-dominant early-onset AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29562504' target='_blank' class='pmid-link'>29562504</a>:</span> <span class='sentence-part'>The subjects are carriers of the PSEN1 mutation, which leads to early onset Alzheimer's disease, but at the time of EEG acquisition in 1999, these subjects were cognitively unimpaired.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30168435' target='_blank' class='pmid-link'>30168435</a>:</span> <span class='sentence-part'>PSEN1, APP and PSEN2 are the major causes of monogenic EOAD while GRN, MAPT and C9ORF72 are the most frequently mutated genes in familial FTLD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30909216' target='_blank' class='pmid-link'>30909216</a>:</span> <span class='sentence-part'>With the exception of rare mutations in APP, PSEN1, and PSEN2 genes causing autosomal dominant EOAD, little is known about the genetic factors underlying most of the EOAD cases.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31026686' target='_blank' class='pmid-link'>31026686</a>:</span> <span class='sentence-part'>The mutation E280A in PSEN1 (presenilin-1) is the most common cause of early-onset familial Alzheimer's Disease (fAD).</span></div></div>
<div class='streamlined-assertion'><div class='streamlined-header sticky-relation-header'><span class='label-text'>Subject:</span> <strong>Parkinson_Disease</strong> <span class='label-text'>Subject CUI:</span> <strong>C0030567</strong> â†’ <span class='label-text predicate-text'>CAUSES</span> â†’ <span class='label-text'>Object:</span> <strong>Alzheimers</strong> <span class='label-text'>Object CUI:</span> <strong>C0002395</strong></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/11684176' target='_blank' class='pmid-link'>11684176</a>:</span> <span class='sentence-part'>Experiment 2 compared letter fluency performance among NC, AD and IVD groups, and participants with dementia secondary to idiopathic Parkinson's disease (PD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/14722078' target='_blank' class='pmid-link'>14722078</a>:</span> <span class='sentence-part'>The genetic defects underlying several monogenic familial forms of AD and PD have recently been identified, however, the causes of other AD and PD cases, particularly sporadic cases, remain unclear.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20634620' target='_blank' class='pmid-link'>20634620</a>:</span> <span class='sentence-part'>Camptocormia can be due to central nervous system diseases, such as Parkinson's disease, dystonia, multisystem atrophy, or Alzheimer's disease, due to peripheral nervous system diseases, such as primary myopathy, secondary myopathy, motor neuron disease, myasthenia, or chronic inflammatory demyelinating polyneuropathy, due to side effects of drug treatment, due to disc herniation, arthritis or spinal trauma, or due to paraneoplasia.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23303475' target='_blank' class='pmid-link'>23303475</a>:</span> <span class='sentence-part'>The activity of metabotropic glutamate receptors (mGluRs) is known to be altered as the consequence of neurodegenerative diseases such as Alzheimer, Parkinson, and Huntington disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24503004' target='_blank' class='pmid-link'>24503004</a>:</span> <span class='sentence-part'>As the second most common age related neurodegenerative disease after Alzheimer's disease, the health, social and economic impact resulting from Parkinson's disease will continue to increase alongside the longevity of the population.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26528186' target='_blank' class='pmid-link'>26528186</a>:</span> <span class='sentence-part'>Neurodegenerative diseases such as Alzheimer's disease, Creutzfeldt-Jakob disease (CJD), Parkinson's disease, Huntington's disease, frontotemporal dementia (FTD), and amyotrophic lateral sclerosis (ALS) result from the loss of a specific subsets of neurons, which is closely associated with accumulation and deposition of specific protein aggregates.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27074540' target='_blank' class='pmid-link'>27074540</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) and Parkinson's disease (PD) are the leading causes of disability associated with neurodegeneration worldwide.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27166223' target='_blank' class='pmid-link'>27166223</a>:</span> <span class='sentence-part'>Impaired protein degradation has been discussed as a cause or consequence of various neurodegenerative diseases, such as Alzheimer's, Parkinson's and Huntington's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27699087' target='_blank' class='pmid-link'>27699087</a>:</span> <span class='sentence-part'>Evidence from rodent and cell models show a number of neurotrophic and neuroprotective effects of guanosine preventing deleterious consequences of seizures, spinal cord injury, pain, mood disorders and aging-related diseases, such as ischemia, Parkinson's and Alzheimer's diseases.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28839167' target='_blank' class='pmid-link'>28839167</a>:</span> <span class='sentence-part'>The ultra-sensitive IMR assay was applied to detect the plasma tau protein levels of subjects with prevalent neurodegenerative diseases, such as Alzheimer's disease (AD), mild cognitive impairment (MCI) due to AD, Parkinson's disease (PD), frontotemporal dementia (FTD) and vascular dementia (VD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30068225' target='_blank' class='pmid-link'>30068225</a>:</span> <span class='sentence-part'>This article reviewed the up-to-date evidence of MCI including the diagnostic criteria of MCI due to Alzheimer's disease, vascular cognitive impairment and MCI due to Parkinson disease, management and preventive intervention of MCI.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32107064' target='_blank' class='pmid-link'>32107064</a>:</span> <span class='sentence-part'>Choroid plexus volume is associated with levels of CSF proteins: relevance for Alzheimer's and Parkinson's disease.The choroid plexus (ChP) is a major source of cerebrospinal fluid (CSF) production, with a direct and indirect role in protein clearance, and pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33417216' target='_blank' class='pmid-link'>33417216</a>:</span> <span class='sentence-part'>Therapeutic Efficacy of Plasmalogens for Alzheimer's Disease, Mild Cognitive Impairment, and Parkinson's Disease in Conjunction with a New Hypothesis for the Etiology of Alzheimer's Disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33621313' target='_blank' class='pmid-link'>33621313</a>:</span> <span class='sentence-part'>Of 4498 records identified, 17 articles met the inclusion criteria with a total of 979 participants including studies on mild cognitive impairment (MCI; n = 6), multiple sclerosis (n = 4), Alzheimer's disease (n = 5), Parkinson's disease (n = 1), and MCI secondary to Parkinson's disease (n = 1).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36717892' target='_blank' class='pmid-link'>36717892</a>:</span> <span class='sentence-part'>We summarize the impact of COVID-19 infection on symptom severity, disease progression, and mortality rate of PD and AD, and discuss whether COVID-19 infection could trigger PD and AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/38036035' target='_blank' class='pmid-link'>38036035</a>:</span> <span class='sentence-part'>For AD and PD, an increased iron load was causative: the right pallidum for AD and the right caudate, left caudate and right accumbens for PD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/8033937' target='_blank' class='pmid-link'>8033937</a>:</span> <span class='sentence-part'>Lastly, degenerative cerebral diseases, such as Alzheimer's disease, Parkinson's disease, Huntington's disease, progressive supranuclear palsy and corticobasal degeneration result in more or less severe eye movement disturbances.</span></div></div>
<div class='streamlined-assertion'><div class='streamlined-header sticky-relation-header'><span class='label-text'>Subject:</span> <strong>Pathogenesis</strong> <span class='label-text'>Subject CUI:</span> <strong>C0699748</strong> â†’ <span class='label-text predicate-text'>CAUSES</span> â†’ <span class='label-text'>Object:</span> <strong>Alzheimers</strong> <span class='label-text'>Object CUI:</span> <strong>C0002395</strong></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/12446969' target='_blank' class='pmid-link'>12446969</a>:</span> <span class='sentence-part'>As evidence emerges concerning the role of insulin and insulin like growth factors (IGFs) in learning and memory, recent findings have suggested that insulin may have a significant role in the pathogenetic pathways leading to Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/15760652' target='_blank' class='pmid-link'>15760652</a>:</span> <span class='sentence-part'>The pathogenesis, which is primarily responsible for Alzheimer's disease (AD) and cerebrovascular accidents (CVA), seems to involve chronic hypoperfusion.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/16008818' target='_blank' class='pmid-link'>16008818</a>:</span> <span class='sentence-part'>Therefore the pathogenesis of Lytico-Bodig appears still to have most pertinence to the ongoing investigation of the pathogenesis of AD and other tauopathies.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17119287' target='_blank' class='pmid-link'>17119287</a>:</span> <span class='sentence-part'>The message between the lines of the following article is that the involvement of Al in the pathogenesis of AD should not be discarded, especially in these times when the amyloid dogma of AD etiology shows its myopia. Although objects of methodological controversies for scientists and oversimplification for lay spectators, several lines of evidence have strongly supported the involvement of Al as a secondary aggravating factor or risk factor in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/18827923' target='_blank' class='pmid-link'>18827923</a>:</span> <span class='sentence-part'>The pathogenesis that is primarily responsible for Alzheimer's disease (AD) and cerebrovascular accidents (CVA) appears to involve chronic hypoperfusion.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/19114068' target='_blank' class='pmid-link'>19114068</a>:</span> <span class='sentence-part'>Cell cycle re-entry mediated neurodegeneration and its treatment role in the pathogenesis of Alzheimer's disease. As one of the earliest pathologic changes, the aberrant re-expression of many cell cycle-related proteins and inappropriate cell cycle control in specific vulnerable neuronal populations in Alzheimer's disease (AD) is emerging as an important component in the pathogenesis leading to AD and other neurodegenerative diseases.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22610992' target='_blank' class='pmid-link'>22610992</a>:</span> <span class='sentence-part'>Given the potential relationship between insulin resistance and pathogenesis of Alzheimer's disease (AD) in elderly life, we investigated the relationship between perinatal DEHP exposure and AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22906543' target='_blank' class='pmid-link'>22906543</a>:</span> <span class='sentence-part'>The phosphoinositide 3-kinase (PI3K)/Akt pathway has been implicated in the pathogenesis of AD, however, potential functions and role of tumor suppressor phosphatase and tensin homologue deleted on chromosome 10 (PTEN) in AD pathogenesis have not been fully explored.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23318673' target='_blank' class='pmid-link'>23318673</a>:</span> <span class='sentence-part'>Although the pathogenesis of sporadic Alzheimer's disease (AD) is not clearly understood, neuroinflammation has been known to play a role in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23711354' target='_blank' class='pmid-link'>23711354</a>:</span> <span class='sentence-part'>Recent findings, however, have implicated altered function of ER-mitochondria contact sites and amyloid beta- and/or tau-induced defects in mitochondrial function and dynamics in the pathogenesis of AD, suggesting that mitochondrial defects may act as key mediators in the pathogenesis of AD as well.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23948893' target='_blank' class='pmid-link'>23948893</a>:</span> <span class='sentence-part'>The pathogenetic mechanism of Alzheimer's disease (AD) is still unknown; however, genetic variants play a critical role in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25019275' target='_blank' class='pmid-link'>25019275</a>:</span> <span class='sentence-part'>Although the pathogenetic mechanism of AD is still unknown, genetic variants play a critical role in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25809055' target='_blank' class='pmid-link'>25809055</a>:</span> <span class='sentence-part'>BACKGROUNDS AND AIMS: The pathogenetic mechanism of Alzheimer's disease (AD) is still unknown; however, gene polymorphism may play a critical role in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26438898' target='_blank' class='pmid-link'>26438898</a>:</span> <span class='sentence-part'>The following topics are reviewed: a role of beta-amyloid in the pathogenesis of AD, a role of tau-protein in the pathogenesis of AD, main hypotheses of the pathogenesis, the relationship between beta-amyloid and tau-protein, the dysfunction of synapses in AD, a neuroimmune hypothesis, treatment approaches.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26849355' target='_blank' class='pmid-link'>26849355</a>:</span> <span class='sentence-part'>Sphingolipids are widely known to have roles in the pathogenesis of inflammatory diseases, where the precise roles for sphingolipids in inflammation-associated pathogenesis of AD are not well understood. Alzheimer's disease (AD) is the most common cause of senile dementia.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28745240' target='_blank' class='pmid-link'>28745240</a>:</span> <span class='sentence-part'>CONCLUSION: In light of our understanding of the duality of the role of NF-?B in the pathogenesis of Alzheimer's disease, further studies are warranted to dissect and understand the basis of the dichotomous effects of NF-?B, so that certain selective benevolent and benign attributes of NF-?B can be spared while targeting its deleterious attributes and facets that are integral in the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30362531' target='_blank' class='pmid-link'>30362531</a>:</span> <span class='sentence-part'>Autophagic dysfunction in Alzheimer's disease: Cellular and molecular mechanistic approaches to halt Alzheimer's pathogenesis. This review highlights the critical linkage of autophagy in the pathogenesis of AD, and avows a new insight to search for therapeutic target for blocking Alzheimer's pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35282779' target='_blank' class='pmid-link'>35282779</a>:</span> <span class='sentence-part'>This review will highlight the pathogenesis of each of the stated microbial infection, their association in AD pathogenesis as well as the effect of chronic infection in AD progression.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36071897' target='_blank' class='pmid-link'>36071897</a>:</span> <span class='sentence-part'>Currently, the pathogenesis and underlying causative genes of AD remain unclear, and there exists no effective treatment for this disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36291068' target='_blank' class='pmid-link'>36291068</a>:</span> <span class='sentence-part'>The amyloid cascade hypothesis has predominately been used to describe the pathogenesis of Alzheimer's disease (AD) for decades, as Abeta oligomers are thought to be the prime cause of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37163426' target='_blank' class='pmid-link'>37163426</a>:</span> <span class='sentence-part'>These results not only provide a retrospective interpretation for understanding the pathogenesis of AD, but also provide a window of opportunity for more effective preventive and identifying therapeutic strategies for stress-induced AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/38450383' target='_blank' class='pmid-link'>38450383</a>:</span> <span class='sentence-part'>Animal models have provided important insights into the pathogenesis of AD and they have shown that different brain cell types including neurons, astrocytes and microglia have important functions in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/38474398' target='_blank' class='pmid-link'>38474398</a>:</span> <span class='sentence-part'>Firing Alterations of Neurons in Alzheimer's Disease: Are They Merely a Consequence of Pathogenesis or a Pivotal Component of Disease Progression?</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/7763324' target='_blank' class='pmid-link'>7763324</a>:</span> <span class='sentence-part'>As we begin to understand some of the underlying pathogenetic mechanisms and causes of AD, this most frequent dementing condition is well suited to serve as model system to study the common principles of neurodegenerative diseases.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/9539218' target='_blank' class='pmid-link'>9539218</a>:</span> <span class='sentence-part'>These results suggest that the co-injection of beta-amyloid with a small amount of ibotenic acid provides a useful model for investigation of the pathogenetic mechanisms leading to Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/9577653' target='_blank' class='pmid-link'>9577653</a>:</span> <span class='sentence-part'>Now that major genes involved in the pathogenesis of AD have been identified, future research should be directed toward elucidation of the molecular mechanisms of how these gene products are involved in the pathogenesis of AD on protein as well as cellular levels.</span></div></div>
<div class='streamlined-assertion'><div class='streamlined-header sticky-relation-header'><span class='label-text'>Subject:</span> <strong>Pathologic_Processes</strong> <span class='label-text'>Subject CUI:</span> <strong>C0030660</strong> â†’ <span class='label-text predicate-text'>CAUSES</span> â†’ <span class='label-text'>Object:</span> <strong>Alzheimers</strong> <span class='label-text'>Object CUI:</span> <strong>C0002395</strong></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/12914680' target='_blank' class='pmid-link'>12914680</a>:</span> <span class='sentence-part'>Although criteria for MCI are not a matter of secure agreement, a consensus is emerging that MCI is common, is associated with significant mortality and morbidity, particularly the development of AD, and is due, in large part, to the same pathologic processes responsible for Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/14520653' target='_blank' class='pmid-link'>14520653</a>:</span> <span class='sentence-part'>Our findings support the hypothesis that reductions in estrogens after menopause contribute to the cascade of pathological processes leading to AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/16926067' target='_blank' class='pmid-link'>16926067</a>:</span> <span class='sentence-part'>Our findings support the hypothesis that reductions in estrogen following menopause can contribute to the cascade of pathological processes leading to AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17000013' target='_blank' class='pmid-link'>17000013</a>:</span> <span class='sentence-part'>Lipoprotein receptors have important roles in pathological processes that lead to Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17168651' target='_blank' class='pmid-link'>17168651</a>:</span> <span class='sentence-part'>Since the pathological processes leading to AD are seen across the lifespan in DS, an opportunity is afforded for early pharmacological intervention in the disorder.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/18537547' target='_blank' class='pmid-link'>18537547</a>:</span> <span class='sentence-part'>Although cholinergic cell loss is clearly an important attribute of the pathological process, another well-described yet underappreciated early feature of AD pathogenesis is degeneration of the locus coeruleus (LC), which serves as the main source of norepinephrine (NE) supplying various cortical and subcortical areas that are affected in AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/19028146' target='_blank' class='pmid-link'>19028146</a>:</span> <span class='sentence-part'>This has contributed to the hypothesis that the menopause may contribute to the cascade of pathological processes leading to AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20182019' target='_blank' class='pmid-link'>20182019</a>:</span> <span class='sentence-part'>Evidence accumulating from biological and epidemiological studies suggests that high levels of serum cholesterol may promote the pathological processes that lead to Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22315714' target='_blank' class='pmid-link'>22315714</a>:</span> <span class='sentence-part'>As cause and effect relationships between inflammation and AD are being worked out, there is a realization that some components of this complex molecular and cellular machinery are most likely promoting pathological processes leading to AD, whereas other components serve to do the opposite.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22465174' target='_blank' class='pmid-link'>22465174</a>:</span> <span class='sentence-part'>Pretangle formation marks the beginning of the pathological process and is of particular interest because it is temporally closer to the prevailing conditions that induce the pathological process underlying Alzheimer's disease in contrast to late-stage disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22521584' target='_blank' class='pmid-link'>22521584</a>:</span> <span class='sentence-part'>These results suggest that alterations in the SM metabolism may contribute to early pathological processes leading to AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22699850' target='_blank' class='pmid-link'>22699850</a>:</span> <span class='sentence-part'>The formation of non-argyrophilic pretangles marks the beginning of the pathological process and is of increasing interest because it is temporally closer to the prevailing conditions that induce the pathological process underlying AD in contrast to late-stage disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22700814' target='_blank' class='pmid-link'>22700814</a>:</span> <span class='sentence-part'>CONCLUSIONS: The lack of fibrillar beta-amyloid (Abeta) as visualized by PiB PET in APParc mutation carriers suggests, given the reduced glucose metabolism and levels of Abeta(1-42) in CSF, that other forms of Abeta such as oligomers and protofibrils are important for the pathologic processes leading to clinical Alzheimer disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23553131' target='_blank' class='pmid-link'>23553131</a>:</span> <span class='sentence-part'>More than 100 years after description of Alzheimer's disease (AD), two major pathological processes observed already by Alois Alzheimer, remain as the main explanation of the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23701948' target='_blank' class='pmid-link'>23701948</a>:</span> <span class='sentence-part'>However, the biological mechanisms underlying this association are still unclear because of the complexity of the pathological processes that cause AD. We argue that the interaction between the APOE-dependent non-pathological vulnerabilities and age-related pathological changes is one mechanism that can trigger neurodegeneration, resulting in AD and other complex phenotypes.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24796109' target='_blank' class='pmid-link'>24796109</a>:</span> <span class='sentence-part'>It is understood that molecules involved in this inflammation promote pathological processes leading to AD, whereas other molecules work to protect neuron/brain function from toxicity found in AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26547034' target='_blank' class='pmid-link'>26547034</a>:</span> <span class='sentence-part'>Recent studies show that the pathological processes leading to AD cause characteristic alterations in blood and brain inflammatory proteins that are associated with the progression of AD, suggesting that these markers could be used to diagnosis and monitor disease progression.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27454811' target='_blank' class='pmid-link'>27454811</a>:</span> <span class='sentence-part'>IMPORTANCE: The amyloid hypothesis posits that disrupted beta-amyloid homeostasis initiates the pathological process resulting in Alzheimer disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28760504' target='_blank' class='pmid-link'>28760504</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD), which is the most commonly encountered neurodegenerative disease, causes synaptic dysfunction and neuronal loss due to various pathological processes that include tau abnormality and amyloid beta (Abeta) accumulation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28939668' target='_blank' class='pmid-link'>28939668</a>:</span> <span class='sentence-part'>CONCLUSIONS: Synaptic dysfunction (assessed via neurogranin) may be an early pathologic process in age-related neurodegeneration, and a sensitive marker of age-related cognitive abilities, potentially preceding or even acting independently from AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28993728' target='_blank' class='pmid-link'>28993728</a>:</span> <span class='sentence-part'>Future studies conducting comprehensive and integrative characterization of brain aging, including crosstalk with peripheral systems and factors, will be necessary to define the mechanisms underlying the shift from normal aging to pathological processes in the etiology of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29150293' target='_blank' class='pmid-link'>29150293</a>:</span> <span class='sentence-part'>The four major pathologic processes causing AD are: I. vascular hypoperfusion of the brain with associated mitochondrial dysfunction. It is felt that the main reason for this failure is that AD appears to be a disease caused by four major pathological processes.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30805871' target='_blank' class='pmid-link'>30805871</a>:</span> <span class='sentence-part'>beta-secretase (BACE1) and its naturally occurring anti-sense RNA (BACE1-AS) have established role in the pathologic process leading to Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31453786' target='_blank' class='pmid-link'>31453786</a>:</span> <span class='sentence-part'>BACKGROUND: Growing evidence suggests that pathological processes leading to Alzheimer's disease occurs gradually and begins to develop decades before the earliest clinical symptoms occur.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33268824' target='_blank' class='pmid-link'>33268824</a>:</span> <span class='sentence-part'>It is generally believed that AD is caused by multiple pathological processes resulting from Abeta abnormality, tau phosphorylation, neuroinflammation, neurotransmitter dysregulation, and oxidative stress.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35557359' target='_blank' class='pmid-link'>35557359</a>:</span> <span class='sentence-part'>Previous research has demonstrated that the pathological process leading to AD occurs years before a positive diagnosis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37126689' target='_blank' class='pmid-link'>37126689</a>:</span> <span class='sentence-part'>Impairment of its vesicular release by beta-amyloid (Abeta) oligomers is thought to participate in pathological processes leading to Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/38396302' target='_blank' class='pmid-link'>38396302</a>:</span> <span class='sentence-part'>We review here the structure, function, and pathobiology of gamma-secretases, with a focus on how mutations in presenilin genes result in early-onset AD. The GSAS represent, in theory, a precision medicine approach to the prevention of amyloid deposition, as they specifically target a discrete aspect in a complex cell biological signalling mechanism that initiates the pathological processes leading to Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/8375434' target='_blank' class='pmid-link'>8375434</a>:</span> <span class='sentence-part'>Because of the compelling evidence indicating common clinical and pathological findings in idiopathic parkinsonism, Alzheimer's disease, and amyotrophic lateral sclerosis, we believe that these conditions result from pathological processes with more similarity than diversity.</span></div></div>
<div class='streamlined-assertion'><div class='streamlined-header sticky-relation-header'><span class='label-text'>Subject:</span> <strong>Peptides</strong> <span class='label-text'>Subject CUI:</span> <strong>C0030956</strong> â†’ <span class='label-text predicate-text'>CAUSES</span> â†’ <span class='label-text'>Object:</span> <strong>Alzheimers</strong> <span class='label-text'>Object CUI:</span> <strong>C0002395</strong></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/10196523' target='_blank' class='pmid-link'>10196523</a>:</span> <span class='sentence-part'>Here we review genetic and molecular biological evidence suggesting that the peptide A beta 42 is central to the etiology of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/10440895' target='_blank' class='pmid-link'>10440895</a>:</span> <span class='sentence-part'>Substantial genetic and biochemical evidence implicates amyloid peptides (Abeta) in the etiology of Alzheimer's Disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/10825171' target='_blank' class='pmid-link'>10825171</a>:</span> <span class='sentence-part'>beta-(25-35) is a synthetic derivative of beta-amyloid, the peptide that is believed to cause Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/10940223' target='_blank' class='pmid-link'>10940223</a>:</span> <span class='sentence-part'>beta-Amyloid peptides are the main protein components of neuritic plaques and may be important in the pathogenesis of Alzheimer's Disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/11409035' target='_blank' class='pmid-link'>11409035</a>:</span> <span class='sentence-part'>The extracellular deposition of short amyloid peptides in the brain of patients is thought to be a central event in the pathogenesis of Alzheimer's Disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/11437372' target='_blank' class='pmid-link'>11437372</a>:</span> <span class='sentence-part'>Time-resolved anisotropy measurements (TRAMS) have been used to study the aggregation of the beta-amyloid (Abeta) peptide which is suspected of playing a central role in the pathogenesis of Alzheimer's Disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/11544033' target='_blank' class='pmid-link'>11544033</a>:</span> <span class='sentence-part'>In the case of amyloid precursor protein, this cleavage contributes to the generation of small, toxic amyloid peptides that trigger the pathological development of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/11606220' target='_blank' class='pmid-link'>11606220</a>:</span> <span class='sentence-part'>Beta-amyloid peptides (Abeta) are the main protein components of neuritic plaques and are important in the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/12182949' target='_blank' class='pmid-link'>12182949</a>:</span> <span class='sentence-part'>Here, we demonstrated that PACAP also protected against neuronal toxicity induced by beta-amyloid (Abeta) peptide, aggregation of which is a causative factor for Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/12414694' target='_blank' class='pmid-link'>12414694</a>:</span> <span class='sentence-part'>Neuronal plasma membranes are thought to be the primary target of the neurotoxic beta-amyloid peptides (Abeta) in the pathogenesis of the Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/12435726' target='_blank' class='pmid-link'>12435726</a>:</span> <span class='sentence-part'>Presenilins (PS1/PS2) play a critical role in proteolysis of beta-amyloid precursor protein (beta APP) to generate beta-amyloid, a peptide important in the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/12475558' target='_blank' class='pmid-link'>12475558</a>:</span> <span class='sentence-part'>The Abeta(1-42) peptide is widely considered to be of greatest significance in relation to the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/14766758' target='_blank' class='pmid-link'>14766758</a>:</span> <span class='sentence-part'>The proteolytic processing of the precursor of the beta-amyloid peptides (APP) is believed to be a key event in the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/15126696' target='_blank' class='pmid-link'>15126696</a>:</span> <span class='sentence-part'>Data that have accumulated for well over a decade have implicated the beta-amyloid (Abeta) peptide as a central player in the pathogenesis of Alzheimer's disease (AD). Amyloid plaques, composed primarily of Abeta progressively form in the brains of AD patients, and mutations in three genes (amyloid precursor protein [APP] and presenilin 1 and 2 [PS1 and PS2]) cause early-onset familial AD (FAD) by directly increasing production of the toxic, plaque-promoting Abeta42 peptide.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/15211591' target='_blank' class='pmid-link'>15211591</a>:</span> <span class='sentence-part'>The beta-amyloid peptides derived by proteolytic cleavage from the amyloid precursor protein (APP) play a major role in the pathogenesis of Alzheimer's disease (AD) by forming aggregated, fibrillary complexes that have been shown to be neurotoxic.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/15248287' target='_blank' class='pmid-link'>15248287</a>:</span> <span class='sentence-part'>This cleavage is responsible for a key biochemical step in signaling from several different cell-surface receptors, and it is also crucial in generating the neurotoxic amyloid peptides that are central to the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/15314264' target='_blank' class='pmid-link'>15314264</a>:</span> <span class='sentence-part'>Because accumulation of beta-amyloid (Abeta) peptide appears central to AD pathogenesis, large efforts have been directed at understanding and interfering with Abeta production or aggregation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/15326604' target='_blank' class='pmid-link'>15326604</a>:</span> <span class='sentence-part'>In the present study the transition from ideal alpha-helical to beta-hairpin conformations is revealed by long timescale molecular dynamics simulations in explicit water solvent, for two well-known amyloidogenic peptides: the H1 peptide from prion protein and the Abeta(12-28) fragment from the Abeta(1-42) peptide responsible for Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/15544501' target='_blank' class='pmid-link'>15544501</a>:</span> <span class='sentence-part'>These studies together with findings that A beta is neurotoxic in vitro, provide evidence that some aggregates of this peptide are the key to the pathogenesis of AD. A small fraction of early onset familial AD (FAD) is caused by mutations in genes, such as the beta-amyloid precursor protein (APP) and presenilins that increase the load of A beta in the brain.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/15878503' target='_blank' class='pmid-link'>15878503</a>:</span> <span class='sentence-part'>The polymerization of beta-amyloid (A beta) peptides into fibrillary plaques is implicated, in part, in the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/15909112' target='_blank' class='pmid-link'>15909112</a>:</span> <span class='sentence-part'>Peptides derived from proteolytic processing of the amyloid precursor protein (APP) are important for the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/16033885' target='_blank' class='pmid-link'>16033885</a>:</span> <span class='sentence-part'>Accumulation of beta-amyloid (Abeta) peptides in the cerebral cortex is considered a key event in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/16830133' target='_blank' class='pmid-link'>16830133</a>:</span> <span class='sentence-part'>The data are also consistent with the concept that a focally dysfunctional blood-brain barrier (BBB) that is unable to regulate the influx/efflux of neurotoxic amyloid peptides may participate in the pathogenesis of AD lesions.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/16880006' target='_blank' class='pmid-link'>16880006</a>:</span> <span class='sentence-part'>Beta-amyloid peptides (Abeta) have been genetically implicated as the cause of Alzheimer's disease, but the causality of amyloid deposited as plaques has been challenged.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17276414' target='_blank' class='pmid-link'>17276414</a>:</span> <span class='sentence-part'>Disruption of this homeostasis due to aging, injury or toxicant exposure may contribute to accumulation of beta-amyloid peptides in the brain fluids, leading to AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17348862' target='_blank' class='pmid-link'>17348862</a>:</span> <span class='sentence-part'>Excessive production and/or accumulation of beta-amyloid (Abeta) peptides that are proteolytically derived from the beta-amyloid precursor protein (APP) have been linked to the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17385278' target='_blank' class='pmid-link'>17385278</a>:</span> <span class='sentence-part'>Reportedly, beta-amyloid peptides (Abeta40 and Abeta42) induce the neurodegenerative changes of Alzheimer's disease (AD) both directly by interacting with components of the cell surface to trigger apoptogenic signaling and indirectly by activating astrocytes and microglia to produce excess amounts of inflammatory cytokines.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17559680' target='_blank' class='pmid-link'>17559680</a>:</span> <span class='sentence-part'>Mutations in amyloid precursor protein (APP) and presenilins alter APP metabolism resulting in accumulation of Abeta42, a peptide essential for the formation of amyloid deposits and proposed to initiate the cascade leading to AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17881287' target='_blank' class='pmid-link'>17881287</a>:</span> <span class='sentence-part'>Cellular cholesterol accumulation enhances the deposition of insoluble beta-amyloid peptides, which is considered a hallmark in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/18220930' target='_blank' class='pmid-link'>18220930</a>:</span> <span class='sentence-part'>In particular, a selective reduction of the longer Abeta(1-42) peptide which is widely believed to be causative of AD is currently seen as an attractive approach for a disease-modifying therapy.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/18221260' target='_blank' class='pmid-link'>18221260</a>:</span> <span class='sentence-part'>AIMS: The deposition of amyloid peptides (A beta) in the cortex and hippocampus is the primary trigger of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/18232509' target='_blank' class='pmid-link'>18232509</a>:</span> <span class='sentence-part'>Extensive studies suggest that the conversion of beta-amyloid (Abeta) peptide from soluble forms into fibrillar structure is a key factor in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/18284028' target='_blank' class='pmid-link'>18284028</a>:</span> <span class='sentence-part'>Amyloid beta (Abeta) is a peptide integral in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/18341423' target='_blank' class='pmid-link'>18341423</a>:</span> <span class='sentence-part'>The most studied hypothesis of development of the disease is that of the amyloid cascade, which states that overproduction of amyloid-beta peptide, or failure to clear this peptide, leads to Alzheimer's disease primarily through amyloid deposition, which is presumed to be involved in neurofibrillary tangle formation; these lesions are then associated with cell death, which is reflected in memory impairment, the hallmarks of this dementia.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/18544674' target='_blank' class='pmid-link'>18544674</a>:</span> <span class='sentence-part'>Increasing evidence suggests that the elevation of beta-amyloid (Abeta) peptides in the brain is central to the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/18634756' target='_blank' class='pmid-link'>18634756</a>:</span> <span class='sentence-part'>Androgen deprivation increases plasma Abeta levels, which indicate that androgens may reduce the levels of soluble Abeta, the peptide widely implicated in the initiation of AD pathogenesis; however, the underlying mechanisms are still poorly understood.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/19237574' target='_blank' class='pmid-link'>19237574</a>:</span> <span class='sentence-part'>Insulin modulates metabolism of beta-amyloid precursor protein (APP) in neurons, decreasing the intracellular accumulation of beta-amyloid (Abeta) peptides, which are pivotal in AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/19238376' target='_blank' class='pmid-link'>19238376</a>:</span> <span class='sentence-part'>A peptide with 42 amino acid residues (Abeta42) plays a key role in the pathogenesis of the Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/19442147' target='_blank' class='pmid-link'>19442147</a>:</span> <span class='sentence-part'>It is believed that the production and accumulation of beta-amyloid (Abeta) peptide is a critical step to the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/19509405' target='_blank' class='pmid-link'>19509405</a>:</span> <span class='sentence-part'>Excessive production of beta-amyloid (Abeta) peptides from proteolytic cleavage of amyloid precursor protein is believed to play a central role in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/19595795' target='_blank' class='pmid-link'>19595795</a>:</span> <span class='sentence-part'>Thus, the aggregation kinetics of these peptides is central to understanding the etiology of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/19939231' target='_blank' class='pmid-link'>19939231</a>:</span> <span class='sentence-part'>Pathological, genetic, biochemical and pharmacological studies support the hypothesis that brain accumulation of oligomeric species of beta-amyloid (Abeta) peptides may cause Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20371995' target='_blank' class='pmid-link'>20371995</a>:</span> <span class='sentence-part'>Increasing evidence suggests that the elevation of beta-amyloid (Abeta) peptides in the brain is central to AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20388523' target='_blank' class='pmid-link'>20388523</a>:</span> <span class='sentence-part'>The amyloid cascade hypothesis states that overproduction of amyloid-beta peptide (Abeta/AbetaP) or failure to clear this peptide, leads to Alzheimer's disease (AD) primarily through amyloid deposition, presumed to be involved in neurofibrillary tangle formation; these lesions are then associated with cell death which is reflected in memory impairment, the hallmarks of this dementia.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20418805' target='_blank' class='pmid-link'>20418805</a>:</span> <span class='sentence-part'>The anomalous folding and polymerization of the beta-amyloid (Abeta) peptide is thought to initiate the neurodegenerative cascade in Alzheimer's disease pathogenesis(1).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21383152' target='_blank' class='pmid-link'>21383152</a>:</span> <span class='sentence-part'>Amyloid-beta (Abeta), a peptide central to the pathogenesis of AD, has profound vascular effects mediated, for the most part, by reactive oxygen species produced by the enzyme NADPH oxidase.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21740063' target='_blank' class='pmid-link'>21740063</a>:</span> <span class='sentence-part'>Interactions of beta-amyloid (Abeta) peptides with neuronal membranes have been associated with the pathogenesis of Alzheimer's disease (AD); however, the molecular details remain unclear. The latter could represent a two-dimensional (2D) seeding template for the formation of toxic oligomeric Abeta in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21813692' target='_blank' class='pmid-link'>21813692</a>:</span> <span class='sentence-part'>The concentration of amyloid-beta (Abeta) within the brain extracellular space is one determinant of whether the peptide will aggregate into toxic species that are important in Alzheimer's disease (AD) pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21855336' target='_blank' class='pmid-link'>21855336</a>:</span> <span class='sentence-part'>Aggregation and fibril formation of beta-amyloid peptides (Abeta) is the key event in the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21889458' target='_blank' class='pmid-link'>21889458</a>:</span> <span class='sentence-part'>Assembly of beta-amyloid (Abeta) peptide into toxic oligomers is widely believed to initiate Alzheimer's disease pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21939202' target='_blank' class='pmid-link'>21939202</a>:</span> <span class='sentence-part'>The beta amyloid (Abeta) peptide aggregates to form beta-rich structures that are known to trigger Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22206488' target='_blank' class='pmid-link'>22206488</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) is characterized by pathological aggregation of beta-amyloid peptides and MAP-Tau protein. beta-Amyloid (Abeta) is a peptide responsible for extracellular Alzheimer's plaque formation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22351782' target='_blank' class='pmid-link'>22351782</a>:</span> <span class='sentence-part'>Accumulation of the neurotoxic beta-amyloid (Abeta) peptide in the brain is central to the pathogenesis of Alzheimer disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22468783' target='_blank' class='pmid-link'>22468783</a>:</span> <span class='sentence-part'>OBJECTIVE: The aggregation and formation of beta-amyloid peptides (Abeta) into fibrils are central events in the pathogenesis of Alzheimer's disease (AD), and overproduction and aggregation of Abeta into oligomers have been known to trigger neurotoxicity. In addition, the behavioral deficits accompanying Abeta(1-40)-induced AD were attenuated by inhalation of EOCO.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22552903' target='_blank' class='pmid-link'>22552903</a>:</span> <span class='sentence-part'>One important CSF biomarker is the amyloid beta 42 (Abeta(42)) peptide, a key player in AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22610977' target='_blank' class='pmid-link'>22610977</a>:</span> <span class='sentence-part'>Aggregated amyloid peptides (AP), major components of senile plaques, have been considered to play a very important and crucial role in the development and neuro-pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22711819' target='_blank' class='pmid-link'>22711819</a>:</span> <span class='sentence-part'>The aggregation and deposition of amyloid-beta (Abeta) peptides are believed to be central events in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22947874' target='_blank' class='pmid-link'>22947874</a>:</span> <span class='sentence-part'>The amyloid-beta(25-35) peptide plays a key role in the etiology of Alzheimer's disease due to its extreme toxicity even in the absence of aging.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23245572' target='_blank' class='pmid-link'>23245572</a>:</span> <span class='sentence-part'>Aggregation and fibril formation of beta-amyloid peptides (Abeta) are central events in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23262458' target='_blank' class='pmid-link'>23262458</a>:</span> <span class='sentence-part'>Aggregation of amyloid-beta (Abeta) peptides into oligomers and amyloid plaques in the human brain is considered a causative factor in Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23410038' target='_blank' class='pmid-link'>23410038</a>:</span> <span class='sentence-part'>The subsequent release of Abeta (amyloid beta) peptides is thought to be the major cause of the neurodegenerative Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23425062' target='_blank' class='pmid-link'>23425062</a>:</span> <span class='sentence-part'>INTRODUCTION: Genetic, physiological, and biochemical data indicate that agglomerates of the 42-amino acid form of the amyloid-beta (Abeta(42)) peptide are strongly linked to Alzheimer's disease (AD) etiology and thus represent a particularly attractive target for the development of an effective disease-modifying approach for AD treatment.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23573456' target='_blank' class='pmid-link'>23573456</a>:</span> <span class='sentence-part'>Substantial evidence implicates beta-amyloid (Abeta) peptides in the etiology of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23614719' target='_blank' class='pmid-link'>23614719</a>:</span> <span class='sentence-part'>Amyloid-beta (Abeta) peptides represent key players in the pathogenesis of Alzheimer's disease (AD), and mounting evidence indicates that soluble Abeta oligomers mediate the toxicity.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23708321' target='_blank' class='pmid-link'>23708321</a>:</span> <span class='sentence-part'>Aggregation of the beta-amyloid (Abeta) peptide into toxic oligomers is considered the primary event in the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23719722' target='_blank' class='pmid-link'>23719722</a>:</span> <span class='sentence-part'>These results, in conjunction with the finding that insulin mitigates hippocampal synapse vulnerability to beta amyloid, a peptide thought to be causative in the development of AD, provide a strong rationale for hypothesizing that pharmacological strategies bolstering brain insulin signaling, such as intranasal administration of insulin, could have significant potential in the treatment and prevention of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24192706' target='_blank' class='pmid-link'>24192706</a>:</span> <span class='sentence-part'>BACKGROUND: Accumulation of beta-amyloid peptides (Abeta) and its progressive deposition into amyloid plaques are key events in the aetiology of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24410826' target='_blank' class='pmid-link'>24410826</a>:</span> <span class='sentence-part'>The beta-amyloid (Abeta) peptide has been postulated to be a key determinant in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25504599' target='_blank' class='pmid-link'>25504599</a>:</span> <span class='sentence-part'>Copper-amyloid peptides are proposed to be the cause of Alzheimer's disease, presumably by oxidative stress.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25621019' target='_blank' class='pmid-link'>25621019</a>:</span> <span class='sentence-part'>beta-site amyloid precursor protein cleaving enzyme 1 (BACE1) is the beta-secretase enzyme required for the production of the neurotoxic beta-amyloid (Abeta) peptide that is widely considered to have a crucial early role in the etiology of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25809804' target='_blank' class='pmid-link'>25809804</a>:</span> <span class='sentence-part'>A growing body of evidence suggests that beta-amyloid peptides (Abeta) are unlikely to be the only factor involved in Alzheimer's disease (AD) aetiology.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26749845' target='_blank' class='pmid-link'>26749845</a>:</span> <span class='sentence-part'>In this study, we first provided evidence that A. arborescens extract protects IMR32, a neuroblastoma human cellular line, from toxicity induced by beta amyloid, the peptide responsible for Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26827638' target='_blank' class='pmid-link'>26827638</a>:</span> <span class='sentence-part'>There is a vast literature on the role of beta amyloid (Abeta) peptides in the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27030769' target='_blank' class='pmid-link'>27030769</a>:</span> <span class='sentence-part'>The accumulation of amyloid-beta (Abeta) peptides cleaved from amyloid precursor protein (APP) in the brain is a key event in AD pathogenesis and we also found that ABCA7 deficit exacerbated brain Abeta deposition in amyloid AD model APP/PS1 mice.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27044452' target='_blank' class='pmid-link'>27044452</a>:</span> <span class='sentence-part'>Over the past two decades, many studies have identified significant contributions of toxic beta-amyloid peptides (Abeta) to the etiology of Alzheimer's disease (AD), which is the most common age-dependent neurodegenerative disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27118677' target='_blank' class='pmid-link'>27118677</a>:</span> <span class='sentence-part'>This is important for understanding the Abeta25-35-Flavonoid (A-F) interaction as a therapeutic strategy to inhibit the neurotoxic effects that this peptide causes in AD, which currently is still considered an ambiguous process.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27565738' target='_blank' class='pmid-link'>27565738</a>:</span> <span class='sentence-part'>(A?) peptide, a key protein in Alzheimer's disease pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27721583' target='_blank' class='pmid-link'>27721583</a>:</span> <span class='sentence-part'>PURPOSE: This study is aimed at investigating the mechanism of reserpine action, which alleviates the toxicity of amyloid beta (Abeta) (AD-causing peptide) in Caenorhabditis elegans [1, 2].</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27807285' target='_blank' class='pmid-link'>27807285</a>:</span> <span class='sentence-part'>beta-Amyloid (Abeta) peptides are thought to be critically involved in the etiology of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28145081' target='_blank' class='pmid-link'>28145081</a>:</span> <span class='sentence-part'>AIMS: To clarify the correlation between chronic sleep restriction (CSR) and sporadic Alzheimer disease (AD), we determined in wild-type mice the impact of CSR, on cognitive performance, beta-amyloid (A?) peptides, and its feed-forward regulators regarding AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28193770' target='_blank' class='pmid-link'>28193770</a>:</span> <span class='sentence-part'>Aggregation of the beta-amyloid (Abeta) peptide within the brain is thought to be an initiating event in AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28795459' target='_blank' class='pmid-link'>28795459</a>:</span> <span class='sentence-part'>The oligomerization and fibrillation of beta-amyloid (Abeta) peptides are important events in the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28978359' target='_blank' class='pmid-link'>28978359</a>:</span> <span class='sentence-part'>(A?) peptides in plaques in the brain parenchyma and in cerebral blood vessels is considered to be a key event in Alzheimer's disease (AD) pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29337241' target='_blank' class='pmid-link'>29337241</a>:</span> <span class='sentence-part'>In conclusion, elevated brain Abeta levels and Abeta42:40 ratio apparent in the early stages of AD could perturb intraneuronal trafficking, augment the anomalous accumulation of amyloid peptides in AD brain, and drive AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/2950070' target='_blank' class='pmid-link'>2950070</a>:</span> <span class='sentence-part'>The following account traces the history of NPY and appraises some of the literature in an attempt to raise some speculation concerning its function; several reviews on this peptide already exist (Emson and de Quidt 1984; Solomon 1985; Allen and Bloom 1986; Gray and Morley 1986), Particular attention is paid to studies which have recently suggested that NPY might be involved with the pathogenesis of two neurodegenerative disorders, Huntington's chorea and Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29568268' target='_blank' class='pmid-link'>29568268</a>:</span> <span class='sentence-part'>Both peptides show enhanced aggregation and neurotoxicity in comparison to full-length Abeta, suggesting that these amyloid peptides may play an important role in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30605056' target='_blank' class='pmid-link'>30605056</a>:</span> <span class='sentence-part'>We review the role of the most important proteins and peptides in AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30624452' target='_blank' class='pmid-link'>30624452</a>:</span> <span class='sentence-part'>Fibrillation of amyloid peptides induces human diseases such as Alzheimer's disease, which has become a huge challenge.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31048034' target='_blank' class='pmid-link'>31048034</a>:</span> <span class='sentence-part'>Pre-administered IP before an ICV injection of amyloid Abeta25-35 peptide, a pharmacological model of Alzheimer's disease, OZP002 prevented the learning deficits induced by the peptide after one week in the Y-maze, passive avoidance and novel object tests.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31138770' target='_blank' class='pmid-link'>31138770</a>:</span> <span class='sentence-part'>Compelling evidence implicates self-assembly of amyloid-beta (Abeta 1-42) peptides into soluble oligomers and fibrils as a major underlying event in Alzheimer's disease (AD) pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31749959' target='_blank' class='pmid-link'>31749959</a>:</span> <span class='sentence-part'>Failure to clear these peptides appears to cause the development of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32093407' target='_blank' class='pmid-link'>32093407</a>:</span> <span class='sentence-part'>One- and Two-Electron Oxidations of beta-Amyloid     25-35       by Carbonate Radical Anion (CO     3           *-      ) and Peroxymonocarbonate (HCO     4           -      ): Role of Sulfur in Radical Reactions and Peptide Aggregation.The beta-amyloid (Abeta) peptide plays a key role in the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32827572' target='_blank' class='pmid-link'>32827572</a>:</span> <span class='sentence-part'>Accumulation of amyloid peptides in the brain plays a key role in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32845146' target='_blank' class='pmid-link'>32845146</a>:</span> <span class='sentence-part'>The Abeta     21-30       peptide fragment is a decapeptide fragment of the complete Abeta42 peptide which is a hypothesized cause of Alzheimer's disease via amyloid fibrillogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32857496' target='_blank' class='pmid-link'>32857496</a>:</span> <span class='sentence-part'>Deposition and aggregation of beta-amyloid (Abeta) peptides are demonstrated to be closely related to the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32973564' target='_blank' class='pmid-link'>32973564</a>:</span> <span class='sentence-part'>Though accumulation of neuron-derived Abeta peptides is considered the primary influence driving AD and CAA pathogenesis, recent studies highlighted the importance of the physiological role of the beta-amyloid precursor protein (APP) in endothelial cell homeostasis, suggesting a potential role of this protein in maintaining vascular stability.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33642533' target='_blank' class='pmid-link'>33642533</a>:</span> <span class='sentence-part'>Extracellular Zn     2+       dynamics, which serves bidirectionally and involved in cognitive activity and cognitive decline, is modified by extracellular glutamate signaling and the presence of amyloid-beta     1-42       (Abeta     1-42      ), a causative peptide in Alzheimer's disease (AD) pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33668038' target='_blank' class='pmid-link'>33668038</a>:</span> <span class='sentence-part'>Extracellular aggregation of the beta-amyloid (Abeta) peptide into toxic multimers in the brain is a prominent event occurring in the pathogenesis of Alzheimer's disease (AD), and a large amount of Abeta in the blood is derived from platelets.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33959916' target='_blank' class='pmid-link'>33959916</a>:</span> <span class='sentence-part'>These small peptides are attributed to the pathogenesis of both AD and CAA, suggesting an important index for disease stage and progression.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34219248' target='_blank' class='pmid-link'>34219248</a>:</span> <span class='sentence-part'>Age, hypercholesterolemia, and vitamin D deficiency are risk factors that increase the brain accumulation of pathogenic beta-amyloid peptides (40 and 42), precursors leading to Alzheimer's disease (AD) in humans.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34669098' target='_blank' class='pmid-link'>34669098</a>:</span> <span class='sentence-part'>Moreover, plant-based foods containing flavonoids were previously reported to show neuroprotective effects by modulating self-aggregation of amyloid-beta (Abeta)/or tau peptide into oligomers and fibrils, associated with the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34852746' target='_blank' class='pmid-link'>34852746</a>:</span> <span class='sentence-part'>BACKGROUND: Alzheimer's disease (AD) is a chronic neurodegenerative disease where no specific disease-modifying treatment is currently available. beta-secretase (BACE1) is considered the potential and rationale target because it is involved in the rate-limiting step, which produces toxic Abeta42 peptides leading to deposits in the form of amyloid plaques extracellularly leading to AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35006003' target='_blank' class='pmid-link'>35006003</a>:</span> <span class='sentence-part'>This study provides new molecular leads on altered protein dynamics relevant to neurodegeneration, neuroplasticity, and AD progression induced by Abeta42 toxicity. Production and deposition of beta-amyloid peptides (Abeta) are among the major hallmarks of the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35109277' target='_blank' class='pmid-link'>35109277</a>:</span> <span class='sentence-part'>ApoE binds to Sortilin, which mediates uptake of ApoE containing lipoproteins into neurons, and to amyloid-b (Ab) peptide, which is thought to play important roles in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35263093' target='_blank' class='pmid-link'>35263093</a>:</span> <span class='sentence-part'>Aggregation of beta-amyloid (Abeta42) peptide in the neural extracellular space leads to cellular dysfunction, resulting in Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35309680' target='_blank' class='pmid-link'>35309680</a>:</span> <span class='sentence-part'>Methods: Intracerebroventricular amyloid-beta [Abeta(1-42)] peptide was used to induce AD in Abeta rats.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35908946' target='_blank' class='pmid-link'>35908946</a>:</span> <span class='sentence-part'>Furthermore, human Abeta     1-42      , a causative peptide in Alzheimer's disease pathogenesis captures extracellular Zn     2+       and readily taken up into hippocampal neurons followed by intracellular Zn     2+       dysregulation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36641678' target='_blank' class='pmid-link'>36641678</a>:</span> <span class='sentence-part'>To date, conflicting pathogenic and neuroprotective roles for this peptide and its analogs for AD pathogenesis have been described.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37076912' target='_blank' class='pmid-link'>37076912</a>:</span> <span class='sentence-part'>CONCLUSIONS: In conclusion, 5-mer peptides prevent short-term memory deficit in Abeta25-35 induced AD model mouse by reducing the aggregated Abeta25-35.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37214891' target='_blank' class='pmid-link'>37214891</a>:</span> <span class='sentence-part'>Aggregation of Abeta peptides has been known as a key contributor to the etiology of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37265546' target='_blank' class='pmid-link'>37265546</a>:</span> <span class='sentence-part'>Aggregation of Abeta peptides is an initial event of AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37413816' target='_blank' class='pmid-link'>37413816</a>:</span> <span class='sentence-part'>Aggregation of Abeta peptides is a key contributor to the etiology of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37625763' target='_blank' class='pmid-link'>37625763</a>:</span> <span class='sentence-part'>Amyloid beta (Abeta), a peptide produced by the proteolytic processing of amyloid precursor protein (APP), is known as a key mediator of brain damage involved in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37741318' target='_blank' class='pmid-link'>37741318</a>:</span> <span class='sentence-part'>AIMS: Evidence indicates accumulating Abeta peptides in brain activates immune responses in neuronal and peripheral system, which may collaboratively influence pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/38142891' target='_blank' class='pmid-link'>38142891</a>:</span> <span class='sentence-part'>This review briefly elaborates on the pathogenesis of AD and analyzes the regulatory effects of endogenous and exogenous peptides on the pathogenesis of AD, thereby providing new therapeutic targets for AD and a theoretical basis for the application of bioactive peptides as adjunctive therapies for AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/38241093' target='_blank' class='pmid-link'>38241093</a>:</span> <span class='sentence-part'>Beta amyloid peptide Abeta 1-42 (Abeta42) has a unique dual role in the human organism, as both the peptide with an important physiological function and one of the most toxic biological compounds provoking Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/38292476' target='_blank' class='pmid-link'>38292476</a>:</span> <span class='sentence-part'>The self-assembly of Abeta peptides into toxic oligomers and fibrils is the primary cause of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/38578892' target='_blank' class='pmid-link'>38578892</a>:</span> <span class='sentence-part'>However, the poor track record of clinical trials based on this hypothesis suggests that the accumulation of these peptides is not the only cause of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/38630150' target='_blank' class='pmid-link'>38630150</a>:</span> <span class='sentence-part'>In the present study, we firstly found that Abeta peptides induced AD-like neuroinflammation upregulation and downregulated the level of autophagy.</span></div></div>
<div class='streamlined-assertion'><div class='streamlined-header sticky-relation-header'><span class='label-text'>Subject:</span> <strong>Pharmaceutical_Preparations</strong> <span class='label-text'>Subject CUI:</span> <strong>C0013227</strong> â†’ <span class='label-text predicate-text'>CAUSES</span> â†’ <span class='label-text'>Object:</span> <strong>Alzheimers</strong> <span class='label-text'>Object CUI:</span> <strong>C0002395</strong></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/10850725' target='_blank' class='pmid-link'>10850725</a>:</span> <span class='sentence-part'>The development of additional drugs requires greater basic research on the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/11212463' target='_blank' class='pmid-link'>11212463</a>:</span> <span class='sentence-part'>The prevalence of opioid administration, other drugs known to cause hallucinations, brain tumours, liver metastases, bone metastases, lung metastases, known renal failure, eye disease, Alzheimer's disease, Parkinson's disease, other neurodegenerative disorder, psychiatric disorder and epilepsy were also recorded.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/15025506' target='_blank' class='pmid-link'>15025506</a>:</span> <span class='sentence-part'>Thus, 1 has been suggested to play a role in the degeneration of serotonergic neurons in brain disorders such as Alzheimer's disease or evoked by amphetamine drugs.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/15917096' target='_blank' class='pmid-link'>15917096</a>:</span> <span class='sentence-part'>Considering the increase of Abeta42 plasma levels as a risk factor for AD, any changes induced by medication by long-term use in the peripheral and possibly also in the central compartment, could be of clinical relevance.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/16553493' target='_blank' class='pmid-link'>16553493</a>:</span> <span class='sentence-part'>Drugs that target metal beta-amyloid interactions can effect Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/16863459' target='_blank' class='pmid-link'>16863459</a>:</span> <span class='sentence-part'>Although donepezil was originally developed to inhibit the breakdown of the neurotransmitter acetylcholine as symptomatic therapy for AD, recent studies raise the possibility of other effects this drug has on the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20298170' target='_blank' class='pmid-link'>20298170</a>:</span> <span class='sentence-part'>These treatments are symptomatic, whereas drugs under development are supposed to modify pathological steps leading to AD, thus acting on the evolution of the disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21095183' target='_blank' class='pmid-link'>21095183</a>:</span> <span class='sentence-part'>Accordingly, these receptors may become therapeutic targets for the development of novel drugs to be used for reducing the inflammation induced injuries in asthma, rheumatoid arthritis, Alzheimer's disease, cardiovascular diseases and traumatic shock.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21765871' target='_blank' class='pmid-link'>21765871</a>:</span> <span class='sentence-part'>These treatments are symptomatic, whereas drugs under development are intended to modify the pathological steps leading to AD, thus acting on the evolution of the disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22442659' target='_blank' class='pmid-link'>22442659</a>:</span> <span class='sentence-part'>To combat this disease, the few therapies that are available rely on drugs that increase neurotransmission; however, this approach has had limited success as it has simply slowed an imminent decline and failed to target the root cause of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23299047' target='_blank' class='pmid-link'>23299047</a>:</span> <span class='sentence-part'>These treatments are symptomatic, whereas drugs under development are supposed to modify pathological steps leading to AD, thus acting on the evolution of the disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23762322' target='_blank' class='pmid-link'>23762322</a>:</span> <span class='sentence-part'>Among these medications, some might benefit, while others might exacerbate, the pathogenesis of AD. Alzheimer's disease (AD) is rapidly becoming one of the leading causes of disability and mortality in the elderly.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24353405' target='_blank' class='pmid-link'>24353405</a>:</span> <span class='sentence-part'>Treatment with acetylcholinesterase inhibitors or memantine aims at slowing progression and controlling symptoms, whereas drugs under development are intended to modify the pathologic steps leading to AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24379759' target='_blank' class='pmid-link'>24379759</a>:</span> <span class='sentence-part'>Thus, a platform of knowledge is provided for laboratory protocols that could be used to assess the efficacy of drugs designed to improve memory performance in rodents, including rodent models of neurodegenerative diseases that cause cognitive deficits, and Alzheimer's disease in particular.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28587340' target='_blank' class='pmid-link'>28587340</a>:</span> <span class='sentence-part'>The rats in the drug and control groups were treated to induce AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28955143' target='_blank' class='pmid-link'>28955143</a>:</span> <span class='sentence-part'>In the past 20 years, many new drugs that focus on the pathogenesis of Alzheimer's disease have been assessed in clinical trials.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29692948' target='_blank' class='pmid-link'>29692948</a>:</span> <span class='sentence-part'>Furthermore, we propose potential new drug targets that may modulate diverse pathways responsible for AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30124447' target='_blank' class='pmid-link'>30124447</a>:</span> <span class='sentence-part'>Here, we treated animals with intracerebroventricular streptozotocin (STZ, 2 mg/kg), a drug that has been described to cause Alzheimer-like behavioral and histopathological impairments.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30988761' target='_blank' class='pmid-link'>30988761</a>:</span> <span class='sentence-part'>As potential AD treatment drugs, SA and TB compounds have been demonstrated to alleviate the oxidative stress induced by Abeta25-35 via the regulation of intracellular calcium homeostasis and Calnexin, preventing AD development.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31092147' target='_blank' class='pmid-link'>31092147</a>:</span> <span class='sentence-part'>In this review, we advance the hypothesis that neuroinflammatory responses resulting from mast cell activation along with the accompanying risk factors such as age, gender, food habits, emotional status, stress, allergic tendency, chronic inflammatory diseases, and certain drugs can accelerate brain injury-associated neuroinflammation, neurodegeneration, and AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33515559' target='_blank' class='pmid-link'>33515559</a>:</span> <span class='sentence-part'>However, these medications were gradually discovered to be ineffective in removing the root of AD pathogenesis but merely targeting the symptoms so as to improve a patient's cognitive outcome.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35053277' target='_blank' class='pmid-link'>35053277</a>:</span> <span class='sentence-part'>Besides the mechanistic link, an overview of clinical studies utilizing vitamin B supplementation are given, and a potential link between diseases and medication resulting in a reduced vitamin B12 level and AD are discussed.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35204697' target='_blank' class='pmid-link'>35204697</a>:</span> <span class='sentence-part'>In summary, DOTA repositions promising drugs that target important biological pathways and are predicted to improve patient cognition, circadian rhythms, and AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35257810' target='_blank' class='pmid-link'>35257810</a>:</span> <span class='sentence-part'>Despite tremendous effort being involved, several anti-AD drugs come into clinical trials but with a moderate-to-poor success rate due to the complex AD pathogenesis and the blood-brain barrier (BBB).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36683856' target='_blank' class='pmid-link'>36683856</a>:</span> <span class='sentence-part'>We depict the cellular source, culture condition, differentiation methods, transfection methods, drugs inducing AD, general approaches (evaluation methods and metrics), and    in vitro     cellular models used in parallel with PC12 cells.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36931947' target='_blank' class='pmid-link'>36931947</a>:</span> <span class='sentence-part'>However, it was progressively found that these drugs did not address the underlying causes of AD pathogenesis; rather, they focused on the symptoms in order to enhance patients' cognitive outcomes.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37122620' target='_blank' class='pmid-link'>37122620</a>:</span> <span class='sentence-part'>The study provides a valuable epigenetic resource for identifying DNAm-based diagnostic biomarkers, developing effective drugs, and studying AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37183545' target='_blank' class='pmid-link'>37183545</a>:</span> <span class='sentence-part'>Then, via molecular docking, we further screened these drugs by examining their interaction with islet amyloid polypeptide (IAPP) and Abeta42 peptide, the key components involved in the pathogenesis of T2D or AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37824197' target='_blank' class='pmid-link'>37824197</a>:</span> <span class='sentence-part'>CONCLUSIONS: GBA interactions, along with systemic inflammation and the adverse effects of medication, might be a cause of MCI and AD development in patients with IBD.</span></div></div>
<div class='streamlined-assertion'><div class='streamlined-header sticky-relation-header'><span class='label-text'>Subject:</span> <strong>Pharmaceutical_Preparations</strong> <span class='label-text'>Subject CUI:</span> <strong>C0013227</strong> â†’ <span class='label-text predicate-text'>CAUSES</span> â†’ <span class='label-text'>Object:</span> <strong>Atrial_Fibrillation</strong> <span class='label-text'>Object CUI:</span> <strong>C0004238</strong></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/10072943' target='_blank' class='pmid-link'>10072943</a>:</span> <span class='sentence-part'>METHODS: Atrial fibrillations in vivo and in vitro were induced by arrhythmogenic drugs.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/10875733' target='_blank' class='pmid-link'>10875733</a>:</span> <span class='sentence-part'>Because local f-f intervals during atrial fibrillation correlate with the atrial refractory period, changes in mean f-f intervals in the right atrial appendage, His bundle region, coronary sinus ostium and distal coronary sinus were compared before and after injection of adenosine during induced Afib. However, bolus injection of these drugs has been reported to provoke atrial fibrillation (Afib).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/15582307' target='_blank' class='pmid-link'>15582307</a>:</span> <span class='sentence-part'>However, several classes of drugs may induce AF in patients without apparent heart disease or may precipitate the onset of AF in patients with preexisting heart disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17845143' target='_blank' class='pmid-link'>17845143</a>:</span> <span class='sentence-part'>Targeting non-ionic mechanisms may also provide new drugs directed towards the underlying mechanisms responsible for AF and possibly greater antiarrhythmic potency.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/18855351' target='_blank' class='pmid-link'>18855351</a>:</span> <span class='sentence-part'>First-line drug for conversion was continued up to a full dose, and was chosen by AF etiology, or in recurrent AF episodes, empirically.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/19246442' target='_blank' class='pmid-link'>19246442</a>:</span> <span class='sentence-part'>BACKGROUND: The hyperadrenergic condition following surgical stress and inotropic drugs have been identified as leading causes for postoperative atrial fibrillation (AF).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22428188' target='_blank' class='pmid-link'>22428188</a>:</span> <span class='sentence-part'>Evidence that a number of drugs can cause atrial fibrillation has been accumulating since the 2000s.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22724662' target='_blank' class='pmid-link'>22724662</a>:</span> <span class='sentence-part'>A myriad of drugs can induce AF.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23200060' target='_blank' class='pmid-link'>23200060</a>:</span> <span class='sentence-part'>Clinical reports indicate that an increasing number of cardiovascular (adenosine, positive inotropics) and non-cardiovascular (cancer chemotherapy, non-steroidal anti-inflammatory agents, high-dose methylprednisolone, and several respiratory medications) drugs can induce AF, increasing the number of hospitalizations.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27742566' target='_blank' class='pmid-link'>27742566</a>:</span> <span class='sentence-part'>Ideally, novel drugs should specifically correct the pathophysiological mechanisms responsible for atrial fibrillation with no other cardiac or extracardiac actions.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29043080' target='_blank' class='pmid-link'>29043080</a>:</span> <span class='sentence-part'>Catheter ablation of the AF triggers is more effective than anti-arrhythmic drugs at maintaining sinus rhythm.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/2926064' target='_blank' class='pmid-link'>2926064</a>:</span> <span class='sentence-part'>The drug was given during sustained atrial fibrillation (n = 45) or during sinus rhythm before induction of atrial fibrillation for patients whose atrial fibrillation was self-terminating in the control state (n = 9).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29995658' target='_blank' class='pmid-link'>29995658</a>:</span> <span class='sentence-part'>Potential ibrutinib users often have age-associated cardiovascular risk factors or conditions and the drug itself may trigger atrial fibrillation requiring antithrombotic therapy.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30505567' target='_blank' class='pmid-link'>30505567</a>:</span> <span class='sentence-part'>We propose an individualized approach aimed at rate control using initial incremental low dose beta-blocker or calcium channel blocker (CCB) therapy with close monitoring of a patient's response, and continuation of the drug that they respond to, along with simultaneous identification and reduction of triggers of AF, in order for spontaneous return to sinus rhythm.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31101572' target='_blank' class='pmid-link'>31101572</a>:</span> <span class='sentence-part'>After receiving drugs for 15 days, induced AF was observed, and left atrium (LA) tissues were obtained.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31748121' target='_blank' class='pmid-link'>31748121</a>:</span> <span class='sentence-part'>In particular, Session II not only focused on arterial thrombosis and venous thromboembolism, but also hypertension or cardiomyopathy or atrial fibrillation induced by many otherwise life-saving drugs.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34803149' target='_blank' class='pmid-link'>34803149</a>:</span> <span class='sentence-part'>This review briefly discusses AF caused by anticancer drugs and the underlying mechanisms. While anticancer drugs may induce AF in cancer patients without AF risk factors, it appears that most drug-associated AF develop when cancer drugs add or aggravate pre-cancer-existing and/or cancer-related pro-AF factors/alterations, additively or synergistically producing AF. Atrial fibrillation induced by anticancer drugs and underling mechanisms.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37581400' target='_blank' class='pmid-link'>37581400</a>:</span> <span class='sentence-part'>Four of these proteins have drugs targeting them that are approved or in development, and our results suggest the potential for these drugs to treat AF or cause AF.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/38244650' target='_blank' class='pmid-link'>38244650</a>:</span> <span class='sentence-part'>There is clinical evidence that an increasing number of cardiovascular and non-cardiovascular drugs, mainly anticancer drugs, can induce AF can induce AF either in patients with or without pre-existing cardiac disorders, but drug-induced AF (DIAF) has not received the attention that it might deserve.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/8449204' target='_blank' class='pmid-link'>8449204</a>:</span> <span class='sentence-part'>The effects of a single intravenous dose (1.4 +/- 0.3 mg.kg-1) of the new class I drug, cibenzoline, were studied in 20 patients with spontaneous (n = 11) or induced (n = 9) atrial fibrillation, during an electrophysiological study.</span></div></div>
<div class='streamlined-assertion'><div class='streamlined-header sticky-relation-header'><span class='label-text'>Subject:</span> <strong>Players</strong> <span class='label-text'>Subject CUI:</span> <strong>C5142959</strong> â†’ <span class='label-text predicate-text'>CAUSES</span> â†’ <span class='label-text'>Object:</span> <strong>Alzheimers</strong> <span class='label-text'>Object CUI:</span> <strong>C0002395</strong></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32048973' target='_blank' class='pmid-link'>32048973</a>:</span> <span class='sentence-part'>An emerging concept is that microglia, the innate immune cells of the brain, are major players in AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32130931' target='_blank' class='pmid-link'>32130931</a>:</span> <span class='sentence-part'>Aging-related cellular and molecular processes including low-grade inflammation are major players in the pathogenesis of cardiovascular disease (CVD) and Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32197653' target='_blank' class='pmid-link'>32197653</a>:</span> <span class='sentence-part'>Because astrocytes are key players in the pathogenesis of AD, we studied here if and how ES affects astrocytes in wildtype (WT) and APP/PS1 mice and how these relate to the previously reported amyloid pathology and microglial profile.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32251633' target='_blank' class='pmid-link'>32251633</a>:</span> <span class='sentence-part'>Circular RNAs (circRNAs) function as crucial players in AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32739006' target='_blank' class='pmid-link'>32739006</a>:</span> <span class='sentence-part'>MAM and C99, key players in the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33190798' target='_blank' class='pmid-link'>33190798</a>:</span> <span class='sentence-part'>Microglia, the resident immune cells of the brain, have recently emerged as key players in Alzheimer Disease (AD) pathogenesis, but their roles in AD remain largely elusive and require further investigation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33573255' target='_blank' class='pmid-link'>33573255</a>:</span> <span class='sentence-part'>In the search for new, more reliable biomarkers and potential therapeutic options, epigenetic modifications have emerged as important players in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33623128' target='_blank' class='pmid-link'>33623128</a>:</span> <span class='sentence-part'>Neuropeptides govern diverse pathophysiological processes and represent key players in AD pathogenesis, regulating synaptic plasticity, glial cell functions and amyloid pathology.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34211387' target='_blank' class='pmid-link'>34211387</a>:</span> <span class='sentence-part'>Amyloidogenicity and vascular dysfunction are the key players in the pathogenesis of Alzheimer's disease (AD), involving dysregulated cellular interactions. Overall, the current review informs about the interaction of neuronal and glial cell types in AD pathogenesis and its critical association with cerebrovascular dysfunction.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35247551' target='_blank' class='pmid-link'>35247551</a>:</span> <span class='sentence-part'>Microglia have been identified as key players in Alzheimer's disease pathogenesis, and other neurodegenerative diseases.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35348415' target='_blank' class='pmid-link'>35348415</a>:</span> <span class='sentence-part'>Microglia are critical players in the neuroimmune system, and their involvement in Alzheimer's disease (AD) pathogenesis is increasingly being recognized.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35527555' target='_blank' class='pmid-link'>35527555</a>:</span> <span class='sentence-part'>OBJECTIVE: The aim of this study was to use a differential co-expression analysis approach for analyzing a small RNA sequencing dataset from a well-established murine model in order to identify potentially new players in the etiology of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35771435' target='_blank' class='pmid-link'>35771435</a>:</span> <span class='sentence-part'>Extensive researches suggest the probable role of mitochondrial complex II and III dysfunction as underlying players in the pathogenesis of AD, PD, and HD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35893045' target='_blank' class='pmid-link'>35893045</a>:</span> <span class='sentence-part'>In the search for more reliable biomarkers, epigenetic mechanisms, able to mediate the interaction between the genome and the environment, are emerging as important players in AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36614325' target='_blank' class='pmid-link'>36614325</a>:</span> <span class='sentence-part'>Amyloid beta (Abeta) and protein Tau aggregates are disease hallmarks and key players in AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37587894' target='_blank' class='pmid-link'>37587894</a>:</span> <span class='sentence-part'>As amyloid b protein (Ab) is one of the key players responsible for the pathogenesis of AD, we sought to investigate the protective effects of fisetin in an Ab1-42-induced rat model of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/38219962' target='_blank' class='pmid-link'>38219962</a>:</span> <span class='sentence-part'>In conclusion, passive immunotherapy targeting key players in AD pathogenesis offers a promising strategy for effective AD treatment. Here, we review characteristics, clinical trial data, and mechanisms of action for monoclonal antibodies (mAbs) targeting key players in AD pathogenesis, including amyloid-beta (Abeta), tau and neuroinflammation modulators.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/38260408' target='_blank' class='pmid-link'>38260408</a>:</span> <span class='sentence-part'>Genetic variations have emerged as crucial players in the etiology of AD, enabling hope for a better understanding of the disease mechanisms; yet the specific mechanism of action for those genetic variants remain uncertain.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/38350636' target='_blank' class='pmid-link'>38350636</a>:</span> <span class='sentence-part'>This review explores the intricate interplay between two pivotal players in AD pathogenesis: beta-amyloid (Abeta) and tau protein.</span></div></div>
<div class='streamlined-assertion'><div class='streamlined-header sticky-relation-header'><span class='label-text'>Subject:</span> <strong>Polymorphism_Genetic</strong> <span class='label-text'>Subject CUI:</span> <strong>C0032529</strong> â†’ <span class='label-text predicate-text'>CAUSES</span> â†’ <span class='label-text'>Object:</span> <strong>Alzheimers</strong> <span class='label-text'>Object CUI:</span> <strong>C0002395</strong></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/10027555' target='_blank' class='pmid-link'>10027555</a>:</span> <span class='sentence-part'>To investigate the further contribution of the polymorphism to the etiology of sporadic AD, we evaluated associations between Japanese AD and -491 A/T polymorphism of APOE.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/10530514' target='_blank' class='pmid-link'>10530514</a>:</span> <span class='sentence-part'>Since reports about the relevance of these polymorphisms for the pathogenesis of AD have been contradictory, we performed an association study with some modifications.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/12214130' target='_blank' class='pmid-link'>12214130</a>:</span> <span class='sentence-part'>These findings suggested that genetic polymorphisms of the neuronal nAChR genes might be related to the pathogenesis of sporadic AD. To identify the possible mutations and/or polymorphisms of neuronal nicotinic acetylcholine receptor (nAChR) genes related to the pathogenesis of sporadic AD, we have performed mutational analyses of the major neuronal nAChR genes (CHRNA3, 4, 7 and CHRNB2) expressed in central nervous system.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/15200238' target='_blank' class='pmid-link'>15200238</a>:</span> <span class='sentence-part'>These results suggest that polymorphism in exon 11 of septin 3 may have a determinative role in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/15653174' target='_blank' class='pmid-link'>15653174</a>:</span> <span class='sentence-part'>In order to clarify the role of these polymorphisms in the complex pathogenesis of AD we examined genotype and haplotype frequencies of the two C-to-T SNPs at position -889 and -551 in the IL-1alpha and IL-1beta genes, respectively, and of the 86 bp VNTR intron-2 polymorphisms in the IL-1Ra gene.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/16999857' target='_blank' class='pmid-link'>16999857</a>:</span> <span class='sentence-part'>The Multi Drug Resistance (ABCB1) gene, encoding for P-gp, is highly polymorphic and this may result in a changed function of P-gp and may possibly interfere with the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/18033638' target='_blank' class='pmid-link'>18033638</a>:</span> <span class='sentence-part'>BACKGROUND AND PURPOSE: The role of N-acetyltransferase gene (NAT2) polymorphism in the aetiology of Alzheimer's disease (AD) and Parkinson's disease (PD) is an interesting issue; it is suggested that the slow acetylator genotype favours the damage of central nervous system cells by environmental toxins.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/18303265' target='_blank' class='pmid-link'>18303265</a>:</span> <span class='sentence-part'>Further investigations of polymorphisms in the gene encoding the NMDA receptor 2B subunit in AD patients with different genetic setting are needed to clarify their role in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21176999' target='_blank' class='pmid-link'>21176999</a>:</span> <span class='sentence-part'>These findings suggest that polymorphisms within the IGF-I gene could infer greater risk for AD through their effect on IGF-I levels, and confirm the physiological role IGF-I in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21840620' target='_blank' class='pmid-link'>21840620</a>:</span> <span class='sentence-part'>Finally, we discuss the possible impact of CR1 genetic polymorphisms in relation to the amyloid cascade hypothesis of AD and the way in which CR1 may lead to AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25538763' target='_blank' class='pmid-link'>25538763</a>:</span> <span class='sentence-part'>These results support the contribution of the polymorphisms of rs2227564 in the urokinase-type plasminogen gene to the pathogenesis of sporadic Alzheimer's disease in the Han Chinese population.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26809345' target='_blank' class='pmid-link'>26809345</a>:</span> <span class='sentence-part'>Since only ~30% of phenotypic diversity of AD can be explained by polymorphisms in risk genes, these and transgenic bioassay data argue that structurally distinct Abeta particles play a major role in the diverse pathogenesis of AD, and may behave as distinct prion-like strains encoding diverse phenotypes.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30026459' target='_blank' class='pmid-link'>30026459</a>:</span> <span class='sentence-part'>The odds ratios (ORs) and corresponding 95% confidence intervals (CI) were calculated to express the degree of risk of AD resulting from polymorphisms in the EGFR gene.</span></div></div>
<div class='streamlined-assertion'><div class='streamlined-header sticky-relation-header'><span class='label-text'>Subject:</span> <strong>Premature_Cardiac_Complex</strong> <span class='label-text'>Subject CUI:</span> <strong>C0340464</strong> â†’ <span class='label-text predicate-text'>CAUSES</span> â†’ <span class='label-text'>Object:</span> <strong>Atrial_Fibrillation</strong> <span class='label-text'>Object CUI:</span> <strong>C0004238</strong></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/11326144' target='_blank' class='pmid-link'>11326144</a>:</span> <span class='sentence-part'>INTRODUCTION: Most focal atrial fibrillation (AF) can be triggered by premature beats from pulmonary veins (PVs), and ablation of these foci could cure AF.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/11803931' target='_blank' class='pmid-link'>11803931</a>:</span> <span class='sentence-part'>Conduction time following premature beats that induced AF was shorter after PACAP than during vagal stimulation (P &lt; 0.01).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/12521345' target='_blank' class='pmid-link'>12521345</a>:</span> <span class='sentence-part'>After RPV fat pad RFA, premature beats induced AF by causing conduction block primarily in the HRA and macroreentrant activation around the block.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/16919674' target='_blank' class='pmid-link'>16919674</a>:</span> <span class='sentence-part'>The window of vulnerability (WOV), a measure of the propensity for AF inducibility, was determined by the longest coupling interval of the premature beat (S(1)-S(2)) minus the shortest S(1)-S(2), which induced AF.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/19478793' target='_blank' class='pmid-link'>19478793</a>:</span> <span class='sentence-part'>METHODS: The sphygmomanometer incorporates an algorithm for detecting AF while reducing false positive readings due to premature beats. BACKGROUND: Hypertension is a major risk factor for the development of atrial fibrillation (AF) and for stroke due to AF. Asymptomatic AF can result in a stroke, in patients with risk factors, if it is not detected and treated appropriately.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22051334' target='_blank' class='pmid-link'>22051334</a>:</span> <span class='sentence-part'>BACKGROUND: How rapid firings or premature beats trigger AF is not completely understood.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22234329' target='_blank' class='pmid-link'>22234329</a>:</span> <span class='sentence-part'>In porcine studies, atrial effective refractory period (AERP) was measured in pentobarbital-anesthetized thoracotomized pigs and atrial fibrillation (AF) was induced by a premature beat.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22407414' target='_blank' class='pmid-link'>22407414</a>:</span> <span class='sentence-part'>BACKGROUND: In addition to extrasystoles of pulmonary vein (PV) origin, those arising from the superior vena cava (SVC) can precipitate atrial fibrillation (AF).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/38296010' target='_blank' class='pmid-link'>38296010</a>:</span> <span class='sentence-part'>NPVTs were defined as non-pulmonary vein ectopic beats triggering AF or focal atrial tachycardia. Isoproterenol infusion and cardioversion of spontaneous or induced AF can provoke NPVTs but typically require vasopressor support and increased procedure time.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/8760170' target='_blank' class='pmid-link'>8760170</a>:</span> <span class='sentence-part'>Thus, premature beats cause AF by initiating a single macroreentrant cycle that degenerates into multiple wavefronts, regional refractoriness is the primary determinant of AF induction by premature beats, and variability in refractoriness may be an important determinant of the ability of AF to sustain itself. The site of atrial extrasystoles determined their ability to induce AF.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/9106433' target='_blank' class='pmid-link'>9106433</a>:</span> <span class='sentence-part'>While the ability to terminate AF is determined by refractoriness prolongation at rapid rates, refractoriness prolongation at slow rates (e.g., sinus rhythm) can prevent AF induction by premature beats.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/9704357' target='_blank' class='pmid-link'>9704357</a>:</span> <span class='sentence-part'>We propose that distal CS pacing eliminates the propensity of HRA extrasystoles to induce AF.</span></div></div>
<div class='streamlined-assertion'><div class='streamlined-header sticky-relation-header'><span class='label-text'>Subject:</span> <strong>Prions</strong> <span class='label-text'>Subject CUI:</span> <strong>C0033164</strong> â†’ <span class='label-text predicate-text'>CAUSES</span> â†’ <span class='label-text'>Object:</span> <strong>Alzheimers</strong> <span class='label-text'>Object CUI:</span> <strong>C0002395</strong></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/12463910' target='_blank' class='pmid-link'>12463910</a>:</span> <span class='sentence-part'>We were able to obtain functional information about two proteins, Amyloid Precursor Protein and Prion Protein, that have been implicated in the etiology of Alzheimer's Disease and Creutzfeldt-Jakob Disease, respectively.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20698011' target='_blank' class='pmid-link'>20698011</a>:</span> <span class='sentence-part'>Prion protein in Alzheimer's pathogenesis: a hot and controversial issue.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20930299' target='_blank' class='pmid-link'>20930299</a>:</span> <span class='sentence-part'>The cellular form of the prion protein (PrPC) has been shown to inhibit the production of amyloid-beta which is critically involved in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21968933' target='_blank' class='pmid-link'>21968933</a>:</span> <span class='sentence-part'>Our results suggest that some of the typical brain abnormalities associated with AD can be induced by a prion-like mechanism of disease transmission through propagation of protein misfolding.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23171056' target='_blank' class='pmid-link'>23171056</a>:</span> <span class='sentence-part'>Alzheimer's disease, naturally occurring transmissible spongiform encephalopathies (TSEs) and experimental disorders caused by misfolded prion protein (PrP) generated in vitro all share an imbalance of protein synthesis, aggregation and clearance that leads to protein aggregation, prompting some to suggest that Alzheimer's disease is caused by a prion-like mechanism.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23856335' target='_blank' class='pmid-link'>23856335</a>:</span> <span class='sentence-part'>Evidence has been mounting for an involvement of the prion protein (PrP) in a molecular pathway assumed to play a critical role in the etiology of Alzheimer disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25869610' target='_blank' class='pmid-link'>25869610</a>:</span> <span class='sentence-part'>Our results show that Abeta activates microglia and regulates microglial protein expression in a manner similar to prions and, thus, provide new insight into the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25888324' target='_blank' class='pmid-link'>25888324</a>:</span> <span class='sentence-part'>Oligomeric Abeta has recently been shown to form complexes with the glycosylphosphatidylinositol (GPI)-anchored membrane protein, cellular prion protein (PrP(c)), and these complexes are believed to play an important role in the progression of AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28246183' target='_blank' class='pmid-link'>28246183</a>:</span> <span class='sentence-part'>A wealth of recent data argues that both beta-amyloid (Abeta) and tau proteins form prions that cause Alzheimer's disease, and alpha-synuclein forms prions that cause multiple system atrophy and Parkinson's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29203673' target='_blank' class='pmid-link'>29203673</a>:</span> <span class='sentence-part'>Misfolding of tau proteins into prions and their propagation along neural circuits are thought to result in neurodegeneration causing Alzheimer's disease, progressive supranuclear palsy, chronic traumatic encephalopathy, and other tauopathies.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29887525' target='_blank' class='pmid-link'>29887525</a>:</span> <span class='sentence-part'>This study provides a second animal model linking PrPC expression with Abeta toxicity and supports a role for PrPC in AD pathogenesis. The cellular prion protein (PrPC) can act as a cell-surface receptor for beta-amyloid (Abeta) peptide; however, a role for PrPC in the pathogenesis of Alzheimer's disease (AD) is contested.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31093882' target='_blank' class='pmid-link'>31093882</a>:</span> <span class='sentence-part'>Binding between Prion Protein and Abeta Oligomers Contributes to the Pathogenesis of Alzheimer's Disease. In addition, we proposed a potential mechanism to explain why infectious agents, such as viruses, conduce AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31526227' target='_blank' class='pmid-link'>31526227</a>:</span> <span class='sentence-part'>Furthermore, evidence suggests that traditional infectious agents, including certain viruses and bacteria, may trigger AD. However, amyloid beta (Abeta) or tau, which can act like infectious proteins, or prions, might induce Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32677995' target='_blank' class='pmid-link'>32677995</a>:</span> <span class='sentence-part'>These observations argue against the hypothesis that the propagation of Tau pathology in AD is caused by the prion-like templated aggregation of Tau protein, transmitted via cell-to-cell spreading of Tau.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36399277' target='_blank' class='pmid-link'>36399277</a>:</span> <span class='sentence-part'>Using cellular bioassays for prions in postmortem samples, we found that both Abeta and tau proteins misfold into prions leading to AD, which is either a sporadic or familial dementing disorder. Abeta and Tau Prions Causing Alzheimer's Disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/38653354' target='_blank' class='pmid-link'>38653354</a>:</span> <span class='sentence-part'>miR-519a-3p, found to regulate cellular prion protein during Alzheimer's disease pathogenesis, as a biomarker of asymptomatic stages.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/6381559' target='_blank' class='pmid-link'>6381559</a>:</span> <span class='sentence-part'>The similarities in the regional metabolic alterations between CJD and AD provide additional evidence for the possibility that AD may be caused by a slow infectious prion.</span></div></div>
<div class='streamlined-assertion'><div class='streamlined-header sticky-relation-header'><span class='label-text'>Subject:</span> <strong>Process</strong> <span class='label-text'>Subject CUI:</span> <strong>C1522240</strong> â†’ <span class='label-text predicate-text'>CAUSES</span> â†’ <span class='label-text'>Object:</span> <strong>Alzheimers</strong> <span class='label-text'>Object CUI:</span> <strong>C0002395</strong></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/10210631' target='_blank' class='pmid-link'>10210631</a>:</span> <span class='sentence-part'>We discuss these findings in terms of a theory of reference processing, the Informational Load Hypothesis, which views referential impairments in AD as the consequence of normal discourse processing in the context of a working memory impairment.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/10349334' target='_blank' class='pmid-link'>10349334</a>:</span> <span class='sentence-part'>Amyloid precursor protein (APP), presenilin I (PS 1) and presenilin II (PS 2) genes have been identified as the causative genes for early-onset familial Alzheimer's disease. Although these data suggest that accumulation of A beta is an essential step in the pathogenesis of Alzheimer's disease, it still remains to be elucidated whether such process is causative for Alzheimer's disease. Recently another gene on chromosome 12 has been suggested to be involved in the development of late-onset Alzheimer's disease, and identification of the gene on chromosome 12 may bring a new insight into the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/10516307' target='_blank' class='pmid-link'>10516307</a>:</span> <span class='sentence-part'>Recent observations have begun to challenge this assumption by suggesting that earlier Abeta assemblies formed during the process of fibrillogenesis may also play a role in AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/10616034' target='_blank' class='pmid-link'>10616034</a>:</span> <span class='sentence-part'>The fact that IL-6 is detectable in early stage diffuse plaques encourages the speculation that the acute-phase process is crucial to the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/10818522' target='_blank' class='pmid-link'>10818522</a>:</span> <span class='sentence-part'>We propose that ischemic-reperfusion processes in brain are the fountain-head of a cycle of molecular and cellular events that have neurodegenerative consequences which finally lead to AD. Our data suggest that ApoE modulates the outcome following cerebral ischemia via molecular events in common with AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/10854253' target='_blank' class='pmid-link'>10854253</a>:</span> <span class='sentence-part'>This suggests that an altered function of mutated PSs accounts for a fundamental process leading to AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/10899439' target='_blank' class='pmid-link'>10899439</a>:</span> <span class='sentence-part'>Determining which of the proposed sources of free radicals, which include mitochondrial dysfunction, amyloid-beta-mediated processes, transition metal accumulation and genetic factors like apolipoprotein E and presenilins, is responsible for redox imbalance will lead to a better understanding of Alzheimer's disease pathogenesis and novel therapeutic approaches. While this suggests that oxidative stress is a proximal event in Alzheimer's disease pathogenesis, the mechanisms by which redox balance is altered in the disease remains elusive.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/11131295' target='_blank' class='pmid-link'>11131295</a>:</span> <span class='sentence-part'>Unregulated systemic immune processes are secondary but important as a driving-force role in AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/11140685' target='_blank' class='pmid-link'>11140685</a>:</span> <span class='sentence-part'>Evidence that A beta immunization also reduces cognitive dysfunction in murine models of Alzheimer's disease would support the hypothesis that abnormal A beta processing is essential to the pathogenesis of Alzheimer's disease, and would encourage the development of other strategies directed at the 'amyloid cascade'. Much evidence indicates that abnormal processing and extracellular deposition of amyloid-beta peptide (A beta), a proteolytic derivative of the beta-amyloid precursor protein (betaAPP), is central to the pathogenesis of Alzheimer's disease (reviewed in ref. 1).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/11378240' target='_blank' class='pmid-link'>11378240</a>:</span> <span class='sentence-part'>It also suggests that synaptic loss observed in pathological conditions such as Alzheimer's disease, may be the result of the disease process and not a consequence of normal aging.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/11755016' target='_blank' class='pmid-link'>11755016</a>:</span> <span class='sentence-part'>Chronic neuroinflammatory processes including glial activation may play a role in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/11771743' target='_blank' class='pmid-link'>11771743</a>:</span> <span class='sentence-part'>Oxidative stress is considered to be crucial in the pathogenesis of Alzheimer's disease-like neurodegeneration. An elevation of carbonyl compounds that are biomarkers of and leading to oxidative stress has been demonstrated in Down Syndrome (DS) and Alzheimer's Disease (AD) brains and seems to be the result of a multifactorial process.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/11976212' target='_blank' class='pmid-link'>11976212</a>:</span> <span class='sentence-part'>The different categories of AD may be due to processes that augment to different degrees the innate cellular aging rate, that is, mitochondrial superoxide radical (SO) formation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/12212771' target='_blank' class='pmid-link'>12212771</a>:</span> <span class='sentence-part'>In particular, they modulate processes that govern the function and metabolism of proteins key to the pathogenesis of AD, including tau and amyloid precursor protein (APP).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/12212799' target='_blank' class='pmid-link'>12212799</a>:</span> <span class='sentence-part'>Gamma-secretase processing of the amyloid-beta precursor protein (APP) releases the amyloid-beta peptide, which is widely held to be involved in the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/12392058' target='_blank' class='pmid-link'>12392058</a>:</span> <span class='sentence-part'>Because this process is a central event in the pathogenesis of AD, gamma-secretase is believed to be an excellent therapeutic target.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/12435432' target='_blank' class='pmid-link'>12435432</a>:</span> <span class='sentence-part'>Fe65 modulates trafficking and processing of APP, including production of the beta-amyloid peptide that is believed to be central to the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/12436384' target='_blank' class='pmid-link'>12436384</a>:</span> <span class='sentence-part'>With the advent of further understanding of the neurodegenerative processes that cause AD, new treatments that may slow down the progression of the disease will be available.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/12740808' target='_blank' class='pmid-link'>12740808</a>:</span> <span class='sentence-part'>Despite the dramatic progress that has been made in understanding the disease, the exact cause of Alzheimer's disease is still unknown. The enigmatic proteases alpha-,beta-, and gamma-secretase are the three executioners of amyloid precursor protein processing, and disruption of their delicate balance is suspected to result in Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/12751917' target='_blank' class='pmid-link'>12751917</a>:</span> <span class='sentence-part'>The evidence indicates that abnormal processing and extracellular deposition of the longer form of the beta-amyloid (Abeta) peptide (Abeta(1-42), a proteolytic derivative of the amyloid precursor protein [APP]) is implicated in the pathogenesis of Alzheimer's disease. This research strongly supports the notion that abnormal Abeta processing is essential to the pathogenesis of Alzheimer's disease and provides a crucial platform for the development and detailed testing of potential treatments in experimental models before each of these approaches can be proposed as a therapy for Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/12792666' target='_blank' class='pmid-link'>12792666</a>:</span> <span class='sentence-part'>Genetic and neuropathological studies suggest that processing of amyloid precursor protein (APP) to yield amyloid beta-protein (Abeta) plays an important role in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/1288358' target='_blank' class='pmid-link'>1288358</a>:</span> <span class='sentence-part'>The processing of the amyloid beta/A4 protein has been implicated in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/14501020' target='_blank' class='pmid-link'>14501020</a>:</span> <span class='sentence-part'>Calpains modulate processes that govern the function and metabolism of proteins key to the pathogenesis of Alzheimer's disease, including tau and amyloid precursor protein.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/14506131' target='_blank' class='pmid-link'>14506131</a>:</span> <span class='sentence-part'>These studies demonstrate that APP processing, A beta metabolism and A beta deposition are regulated by genetic background and that analysis of these phenotypes in mice should provide new insights into the factors that regulate AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/1467582' target='_blank' class='pmid-link'>1467582</a>:</span> <span class='sentence-part'>A fundamental process in the pathogenesis of Alzheimer's disease (AD) is the breakdown of the cytoskeleton.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/14716023' target='_blank' class='pmid-link'>14716023</a>:</span> <span class='sentence-part'>Data suggesting that late onset AD risk factors play a role in Abeta turnover in the brain have shifted some of the research focus to the study of Abeta clearance and degradation and the impact of these processes on the etiology of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/14746246' target='_blank' class='pmid-link'>14746246</a>:</span> <span class='sentence-part'>Angiogenic brain damage and Alzheimer's disease caused by a progressing degenerative process are listed among the most frequent causes of dementia.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/15342738' target='_blank' class='pmid-link'>15342738</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) may be caused by the abnormal processing of the amyloid precursor protein (APP) and the accumulation of beta-amyloid (Abeta).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/15377701' target='_blank' class='pmid-link'>15377701</a>:</span> <span class='sentence-part'>CONCLUSIONS: Polymorphisms within IL-1A influence the degree of brain microglial cell activation, especially in bearers of APOE epsilon4 allele, reinforcing the importance of neuroinflammatory processes in the pathogenesis of AD, and supporting the rationale for treating the disease with inflammation modulating drugs.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/15467394' target='_blank' class='pmid-link'>15467394</a>:</span> <span class='sentence-part'>Alzheimer's beta-secretase (BACE1) cleaves amyloid precursor protein to produce amyloid beta-peptide, which is a crucial initiation process of the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/15784960' target='_blank' class='pmid-link'>15784960</a>:</span> <span class='sentence-part'>Beta-amyloid (Abeta) peptides are derived from the endoproteolytic processing of amyloid precursor protein (APP) and play a key role in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/15949039' target='_blank' class='pmid-link'>15949039</a>:</span> <span class='sentence-part'>In some individuals this initially positive process becomes highly overregulated by genetic or/and epigenetic risk factors and after many years of accumulations lead eventually to AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/16109164' target='_blank' class='pmid-link'>16109164</a>:</span> <span class='sentence-part'>These data suggest that infection can directly alter the processing of a transmembranal protein intimately linked to the aetiology of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/16128148' target='_blank' class='pmid-link'>16128148</a>:</span> <span class='sentence-part'>The vast number of physiological parameters involved in the poorly understood processes responsible for AD yields a large combination of parameters that can be manipulated and studied.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/16251213' target='_blank' class='pmid-link'>16251213</a>:</span> <span class='sentence-part'>The reactivity of posterior cingulate and hippocampal structures to cholinergic challenge suggests a key role of the cholinergic system in the functional processes that lead to Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/16275806' target='_blank' class='pmid-link'>16275806</a>:</span> <span class='sentence-part'>It states that abnormal amyloid processing and accumulation is the primary causative factor of AD and other associated neuropathologic abnormalities are of secondary consequence.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/16641106' target='_blank' class='pmid-link'>16641106</a>:</span> <span class='sentence-part'>APP also is cleaved intracytoplasmically at Asp-664 to generate a second cytotoxic peptide, APP-C31, but whether this C-terminal processing of APP plays a role in the pathogenesis of AD is unknown.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/16766195' target='_blank' class='pmid-link'>16766195</a>:</span> <span class='sentence-part'>Overexpression of PCTAIRE 3 in cell culture suggests that the protein acts indirectly to stimulate phosphorylation at the pT231 and pS235 sites on tau, residues that are modified early in the process of AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/16785601' target='_blank' class='pmid-link'>16785601</a>:</span> <span class='sentence-part'>Evidence in the literature suggests that gonadotropins may be involved in processes that contribute to the etiology/pathogenesis of AD such as inflammation, cholesterol homeostasis, and insulin status.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/16869341' target='_blank' class='pmid-link'>16869341</a>:</span> <span class='sentence-part'>Recent understanding of this process has confirmed that interactions between AGEs and their receptor (RAGE) may play a role in the pathogenesis of diabetic complications and AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/16884489' target='_blank' class='pmid-link'>16884489</a>:</span> <span class='sentence-part'>In this review, we summarize the arguments showing that calpains modulate processes that govern the function and metabolism of these two key proteins in the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/16892365' target='_blank' class='pmid-link'>16892365</a>:</span> <span class='sentence-part'>A central element in the pathophysiology of Alzheimer's disease (AD) is the formation of amyloid plaques, which result from abnormal processing of the amyloid precursor protein (APP).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/16898674' target='_blank' class='pmid-link'>16898674</a>:</span> <span class='sentence-part'>In accord with this view, nonsteroidal anti-inflammatory drugs and antioxidants suppress early pathogenic processes leading to Alzheimer's disease, thus decreasing the risk of developing the disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17006763' target='_blank' class='pmid-link'>17006763</a>:</span> <span class='sentence-part'>Mild cognitive impairment (MCI) is regarded as a transition stage between the cognitive changes of normal aging and the more serious problems caused by Alzheimer's disease (AD). Since these proteins are involved directly or indirectly in microtubule destabilization and hyperphosphorylation of tau, and also in APP processing we hypothesize that cell cycle disturbance may be important contributor in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17009917' target='_blank' class='pmid-link'>17009917</a>:</span> <span class='sentence-part'>Clinicians and researchers in the AD field face great challenges: the pathophysiological processes that cause AD are not well understood, definite diagnosis of AD requires autopsy, and therapeutic options are limited to treating the symptoms rather than the cause of the disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17047298' target='_blank' class='pmid-link'>17047298</a>:</span> <span class='sentence-part'>Numerous studies now indicate that protein synthesis and protein degradation are significantly altered in Alzheimer's disease (AD), with impairments in these two processes potentially contributing to AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17261781' target='_blank' class='pmid-link'>17261781</a>:</span> <span class='sentence-part'>Evidence from experimental and epidemiological studies suggests a role of sex hormones in the pathogenic process leading to neurodegenerative diseases, (i.e., Alzheimer's and Parkinson's disease).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17279615' target='_blank' class='pmid-link'>17279615</a>:</span> <span class='sentence-part'>Recent studies implicating Abeta oligomers and protofibrils in the neurotoxic process that ultimately leads to AD suggest that the Abeta aggregates induced by 4-HNE may be important in the pathogenesis of AD. Although it remains an open question as to whether oxidative stress is a causative factor or a consequence of AD, we show here that 4-HNE, putatively resulting from the peroxidation of lipids, covalently modifies Abeta, triggering its aggregation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17400334' target='_blank' class='pmid-link'>17400334</a>:</span> <span class='sentence-part'>Processing of the amyloid precursor protein (APP) to produce amyloid-beta (Abeta) peptide is increasingly believed to be of central importance in AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17401045' target='_blank' class='pmid-link'>17401045</a>:</span> <span class='sentence-part'>This is in accordance with reports that lithium inhibits crucial processes in the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17512513' target='_blank' class='pmid-link'>17512513</a>:</span> <span class='sentence-part'>OBJECTIVES: A neuroinflammatory process, triggered by amyloid-beta (Abeta)-peptide, is thought to play a central role in the neurodegenerative process leading to Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17623998' target='_blank' class='pmid-link'>17623998</a>:</span> <span class='sentence-part'>Both estimates of controlled and to a lesser extent automatic uses of memory were greater for the EC than the AD subjects, indicating that the stem completion impairment in AD may not be entirely attributable to a deficiency in controlled memory processes but also due to reduced automatic processing.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17644063' target='_blank' class='pmid-link'>17644063</a>:</span> <span class='sentence-part'>Processing of APP by BACE1 plays a crucial role in the pathogenesis of Alzheimer disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/18024114' target='_blank' class='pmid-link'>18024114</a>:</span> <span class='sentence-part'>Alzheimer's disease is a pathology putting even at the moment multiple questioning as for its etiopathogeny, which results credibly from several processes.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/18081741' target='_blank' class='pmid-link'>18081741</a>:</span> <span class='sentence-part'>This process may play a significant role in the pathogenesis of AD and aging.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/18299393' target='_blank' class='pmid-link'>18299393</a>:</span> <span class='sentence-part'>Presenilin 1 (PS1) plays a critical role in the gamma-secretase processing of the amyloid precursor protein to generate the beta-amyloid peptide, which accumulates in plaques in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/18410513' target='_blank' class='pmid-link'>18410513</a>:</span> <span class='sentence-part'>In this study, we evaluated the cognitive performance in rodent models of hypercholesterolemia in relation to neuroinflammatory changes and amyloid precursor protein (APP) processing, the two key parameters of Alzheimer's disease pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/18487847' target='_blank' class='pmid-link'>18487847</a>:</span> <span class='sentence-part'>All these processes are involved in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/18577840' target='_blank' class='pmid-link'>18577840</a>:</span> <span class='sentence-part'>The key strategy for establishment of diagnostic and therapeutic approaches to AD is sensitive and specific detection of the incipient neuropathology characteristics of AD, combined with emerging treatments that counteract molecular processes in AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/18650430' target='_blank' class='pmid-link'>18650430</a>:</span> <span class='sentence-part'>Specifically, molecular characterization of the secretases involved in Abeta production has facilitated cell biological investigations on APP processing and advanced efforts to model AD pathogenesis in animal models.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/1890972' target='_blank' class='pmid-link'>1890972</a>:</span> <span class='sentence-part'>A number of neurological disorders including Alzheimer and Parkinson disease have been suggested to be caused by processes leading to lipid peroxidation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/19041409' target='_blank' class='pmid-link'>19041409</a>:</span> <span class='sentence-part'>In this review, we summarize the current understanding of the roles of lipoprotein receptors and cholesterol in APP trafficking and processing and their implication for AD pathogenesis and therapy.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/19271231' target='_blank' class='pmid-link'>19271231</a>:</span> <span class='sentence-part'>Alterations in amyloid precursor protein (APP) processing and amyloid-beta (Abeta) accumulation, key molecules associated with Alzheimer;s disease pathogenesis, may therefore contribute to retinal damage.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/19306098' target='_blank' class='pmid-link'>19306098</a>:</span> <span class='sentence-part'>Disruptions in Abeta processing have been hypothesised to be the major cause of AD (the amyloid cascade hypothesis).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/19355848' target='_blank' class='pmid-link'>19355848</a>:</span> <span class='sentence-part'>CONCLUSIONS: The present animal imaging system would substantially facilitate establishment of a safe and effective therapeutic strategy targeting multiple key processes in the AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/19357271' target='_blank' class='pmid-link'>19357271</a>:</span> <span class='sentence-part'>Understanding how APP processing is regulated under physiological conditions may provide new insights into AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/19589380' target='_blank' class='pmid-link'>19589380</a>:</span> <span class='sentence-part'>The data demonstrate that VEGF may affect APP processing, at least in vitro, suggesting a role of VEGF in the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/19642202' target='_blank' class='pmid-link'>19642202</a>:</span> <span class='sentence-part'>In AD, the extracellular deposition of fibrillogenic amyloid-beta peptides (Abeta) occurs as a result of aberrant processing of the full-length Abeta precursor protein (APP).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/19686046' target='_blank' class='pmid-link'>19686046</a>:</span> <span class='sentence-part'>By comparing to age-matched controls, we reasoned that such analysis could help in understanding potential mechanisms involved in upstream processes in AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20060898' target='_blank' class='pmid-link'>20060898</a>:</span> <span class='sentence-part'>In-vivo visualization of key molecular processes involved in Alzheimer's disease pathogenesis: Insights from neuroimaging research in humans and rodent models.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20061651' target='_blank' class='pmid-link'>20061651</a>:</span> <span class='sentence-part'>Our findings suggests that an imbalance in iron homeostasis is a precursor to the neurodegenerative processes leading to AD and that iron imbalance is not necessarily unique to affected regions.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20122289' target='_blank' class='pmid-link'>20122289</a>:</span> <span class='sentence-part'>This review aims to highlight the importance of the immune processes involved in AD pathogenesis based on the outcomes of the two major inflammation-relevant treatment strategies against AD developed and tested to date in animal studies and human clinical trials - the use of anti-inflammatory drugs and immunisation against Abeta.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20226030' target='_blank' class='pmid-link'>20226030</a>:</span> <span class='sentence-part'>Depression can be a risk factor for the development of AD or it can be developed secondary to the neurodegenerative process.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20463393' target='_blank' class='pmid-link'>20463393</a>:</span> <span class='sentence-part'>Mechanistically, recent reports suggest that mitochondrial fission/fusion and mitophagy are altered in AD and in in vitro models of disease, and since both processes are reported to be protective, this review will discuss the role of mitochondrial fission/fusion and mitophagy in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20580938' target='_blank' class='pmid-link'>20580938</a>:</span> <span class='sentence-part'>Experimental data show that cholesterol can modulate central processes in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20734314' target='_blank' class='pmid-link'>20734314</a>:</span> <span class='sentence-part'>The structural and mechanistic observations based on these simulations agree with the recent NMR experiments and provide the driving force and structural origin for the Abeta42 aggregation process to cause AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20948726' target='_blank' class='pmid-link'>20948726</a>:</span> <span class='sentence-part'>Because AD historically has been defined by neuropathologic criteria, treatment strategies have been aimed at diminishing the pathologic end result of the disease process, namely neurodegenerative changes associated with extracellular amyloid-beta-containing plaques, as well as intracellular neurofibrillary tangles of the hyper-phosphorylated microtubule protein, tau.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21085570' target='_blank' class='pmid-link'>21085570</a>:</span> <span class='sentence-part'>SIGNIFICANCE: Processes related to cholesterol metabolism and the innate immune response have previously been implicated by pathological and epidemiological studies of Alzheimer's disease, but it has been unclear whether those findings reflected primary aetiological events or consequences of the disease process.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21145918' target='_blank' class='pmid-link'>21145918</a>:</span> <span class='sentence-part'>These observations support the suggestion of a key role of the cholinergic system in the functional processes that lead to AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21210060' target='_blank' class='pmid-link'>21210060</a>:</span> <span class='sentence-part'>Many neurodegenerative diseases including Parkinson's disease (PD) and Alzheimer's disease (AD) are the result of neurodegenerative processes. In this review, we discuss the role of metals in neurodegenerative diseases with emphasis on the utility of Caenorhabditis elegans (C. elegans) genetic models in deciphering mechanisms associated with the etiology of PD and AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21257235' target='_blank' class='pmid-link'>21257235</a>:</span> <span class='sentence-part'>A recent publication suggested that hypocretin (Hcrt, orexin) may mediate the neuropathological process leading to Alzheimer's disease (AD) and that antagonism of hypocretin receptors decreases this process.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/2129870' target='_blank' class='pmid-link'>2129870</a>:</span> <span class='sentence-part'>Alteration in PUFA desaturation/elongation processes and resultant membrane abnormalities may play a key role in the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21303349' target='_blank' class='pmid-link'>21303349</a>:</span> <span class='sentence-part'>Despite the crucial role of redox active metals like copper and iron in central biological reactions, their elevated levels are involved in the pathogenesis of Alzheimer's Disease (AD). Iron, copper, and zinc are some of the metals, which intensify this process and contribute for the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21305033' target='_blank' class='pmid-link'>21305033</a>:</span> <span class='sentence-part'>BACKGROUND AND PURPOSE: Cognitive impairment resulting from cerebrovascular insufficiency has been termed vascular cognitive impairment, and is generally accepted to be distinct from Alzheimer's disease resulting from a neurodegenerative process.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21321391' target='_blank' class='pmid-link'>21321391</a>:</span> <span class='sentence-part'>Shift of AbetaPP processing in favor of the amyloidogenic pathway is a key event in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21567187' target='_blank' class='pmid-link'>21567187</a>:</span> <span class='sentence-part'>Inflammation including microglial activation may contribute in AD pathogenesis, and biomarkers for this process may thus be of value to study AD pathogenesis and might facilitate development of therapies targeting these cells.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21680755' target='_blank' class='pmid-link'>21680755</a>:</span> <span class='sentence-part'>While the general notion that vascular and metabolic dysfunctions contribute to the etiology of AD is becoming accepted, recent research suggests novel mechanisms by which these/such processes could possibly contribute to AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21693162' target='_blank' class='pmid-link'>21693162</a>:</span> <span class='sentence-part'>Beta-amyloid (Abeta) is a major pathogenic peptide for Alzheimer's disease (AD) and is generated by the processing of amyloid precursor protein (APP).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21829458' target='_blank' class='pmid-link'>21829458</a>:</span> <span class='sentence-part'>Abeta peptides, generated by processing of the Amyloid Precursor Protein (APP), are thought to play a central role in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21876254' target='_blank' class='pmid-link'>21876254</a>:</span> <span class='sentence-part'>Although it is still debatable whether tau aggregation is harmful or protective for the cell, detailed analysis of molecular mechanisms underlying this process seems to be of great importance for understanding AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21891862' target='_blank' class='pmid-link'>21891862</a>:</span> <span class='sentence-part'>Amyloid-beta (Abeta) aggregation is a recognized key process in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21942868' target='_blank' class='pmid-link'>21942868</a>:</span> <span class='sentence-part'>In addition, we showed that TMS has also been used to assess neuroplasticity changes in AD supporting the notion that cortical excitability is changed in AD due to the neurodegenerative process.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21960299' target='_blank' class='pmid-link'>21960299</a>:</span> <span class='sentence-part'>While physiological function(s) of APP still remain a matter of debate, consensus exists that the proteolytic processing of this protein represents a critical event in the life of neurons and that abnormalities in this process are instrumental in Alzheimer's disease (AD) pathogenesis. Understanding neuron-specific mechanisms of APP processing would help illuminating the physiological roles of APP-derived proteolytic fragments and provide novel insights on AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/2203106' target='_blank' class='pmid-link'>2203106</a>:</span> <span class='sentence-part'>This result suggests that the sprouting process may involve a reactivation of certain developmental mechanisms and that this may possibly contribute to the etiology of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22037310' target='_blank' class='pmid-link'>22037310</a>:</span> <span class='sentence-part'>This is illustrated by the exchange reaction between amyloid-beta (Abeta) monomers and polydisperse, NMR-invisible ('dark') protofibrils, a process of significant interest because the accumulation of toxic, aggregated forms of Abeta, from small oligomers to very large assemblies, has been implicated in the aetiology of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22045482' target='_blank' class='pmid-link'>22045482</a>:</span> <span class='sentence-part'>Chronic stress, associated with altered memory and other neurological processes, is thought to influence the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22144675' target='_blank' class='pmid-link'>22144675</a>:</span> <span class='sentence-part'>APP processing and amyloid-beta production play a central role in Alzheimer disease pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22170863' target='_blank' class='pmid-link'>22170863</a>:</span> <span class='sentence-part'>Processing of beta-CTF by gamma-secretase releases amyloid-beta (Abeta), which is assumed to cause AD. APP processing is linked to Alzheimer disease (AD) pathogenesis, which is consistent with a common mechanism involving toxic APP metabolites in both dementias.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22184106' target='_blank' class='pmid-link'>22184106</a>:</span> <span class='sentence-part'>The prolyl isomerase Pin1 and glycogen synthase kinase-3beta (GSK3beta) have been shown to have the opposite effects on APP processing and Tau hyperphosphorylation, relevant to the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22214391' target='_blank' class='pmid-link'>22214391</a>:</span> <span class='sentence-part'>The initial neurodegenerative process that causes AD is unknown.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22272623' target='_blank' class='pmid-link'>22272623</a>:</span> <span class='sentence-part'>Whether or not inflammation represents a possible cause of AD or occurs as a consequence of the disease process, or, alternatively, whether the inflammatory response might be beneficial to slow the disease progression remains to be elucidated.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22356903' target='_blank' class='pmid-link'>22356903</a>:</span> <span class='sentence-part'>Our investigation demonstrated the presence of loci of susceptibility for AD in the WD ATP7B gene, supporting a role of copper dysfunction in contributing or accelerating neurodegenerative processes leading to AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22450454' target='_blank' class='pmid-link'>22450454</a>:</span> <span class='sentence-part'>Four articles in the journal Alzheimer's and Dementia in 2011 describe new criteria for Alzheimer's disease (AD) dementia and mild cognitive impairment (MCI) due to the AD pathophysiological process (MCI due to AD), as well as the underlying rationale for them.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22454637' target='_blank' class='pmid-link'>22454637</a>:</span> <span class='sentence-part'>Inflammation is a complex process that has a key role to play in the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22479317' target='_blank' class='pmid-link'>22479317</a>:</span> <span class='sentence-part'>Membrane-imbedded Abeta-bundles generated by gamma-secretase could be neurotoxic and thus crucial for our understanding of the amyloid hypothesis and AD pathogenesis. CONCLUSIONS: Gradual saturation of gamma-secretase with its substrate can be the pathogenic process in different alleged causes of AD. Modulation of gamma-secretase activity by multiple enzyme-substrate interactions: implications in pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22558227' target='_blank' class='pmid-link'>22558227</a>:</span> <span class='sentence-part'>Although the pathogenic nature of this mutation needs further confirmation, our findings suggest that the Abeta N-terminal region potentially modulates APP processing and Abeta aggregation, and further provides a genetic indication of the importance of Zn(2+) and Cu(2+) in the etiology of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22594617' target='_blank' class='pmid-link'>22594617</a>:</span> <span class='sentence-part'>Interactions between miR-103 and miR-107 to genes were revealed playing a role in processes leading to AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22819647' target='_blank' class='pmid-link'>22819647</a>:</span> <span class='sentence-part'>Coordination of redox active metal ions such as copper or iron to the amyloid-beta (Abeta) peptide has been linked to deleterious processes encountered in the etiology of Alzheimer disease (AD), such as Abeta aggregation and reactive oxygen species (ROS) production.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22867901' target='_blank' class='pmid-link'>22867901</a>:</span> <span class='sentence-part'>Alzheimer's disease is the most common progressive neurodegenerative disorder characterized by the abnormal deposition of amyloid plaques, likely as a consequence of an incorrect processing of the amyloid-beta precursor protein (AbetaPP).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22899726' target='_blank' class='pmid-link'>22899726</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) could result from a multifactorial process involving both genetic predisposition and exposure to environmental factors like pesticides.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23020178' target='_blank' class='pmid-link'>23020178</a>:</span> <span class='sentence-part'>Processing of Abeta-precursor protein (APP) plays an important role in Alzheimer's disease (AD) pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23114667' target='_blank' class='pmid-link'>23114667</a>:</span> <span class='sentence-part'>CONCLUSIONS: These new criteria are immediately helpful to the practicing clinician, providing more accurate and specific guidelines for the diagnosis of AD dementia and MCI due to AD. REVIEW SUMMARY: Four articles in the journal Alzheimer's &amp; Dementia in 2011 describe new criteria for AD dementia and mild cognitive impairment (MCI) due to the AD pathophysiological process (MCI due to AD) and the underlying rationale for them.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23131555' target='_blank' class='pmid-link'>23131555</a>:</span> <span class='sentence-part'>During the process of fibrillation, the Abeta42 takes the form of protofibrils with strong neurotoxicity, and is thus believed to play a crucial role in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23142975' target='_blank' class='pmid-link'>23142975</a>:</span> <span class='sentence-part'>Cleavage of the amyloid precursor protein by enzymes commonly referred to as beta- and gamma-secretase constitute an important process in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23166730' target='_blank' class='pmid-link'>23166730</a>:</span> <span class='sentence-part'>These processes are implicated in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23365075' target='_blank' class='pmid-link'>23365075</a>:</span> <span class='sentence-part'>Inflammatory changes, typified by activated microglia, particularly adjacent to Abeta plaques, are also a characteristic of the disease, but it is unclear whether these contribute to the pathogenesis of AD or are a consequence of the progressive neurodegenerative processes.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23372648' target='_blank' class='pmid-link'>23372648</a>:</span> <span class='sentence-part'>Since synaptic alteration is the best pathologic correlate of cognitive dysfunction in AD, the spatial association of M/LMW Abeta peptide accumulation with pathology of MAP2 within neuronal processes and synaptic compartments early in the disease process reinforces the importance of intraneuronal Abeta accumulation in AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23623603' target='_blank' class='pmid-link'>23623603</a>:</span> <span class='sentence-part'>Amyloid beta (Abeta) plays a major role in Alzheimer's disease (AD), and neuroinflammatory processes mediated by Abeta plaque-induced microglial cells and astrocytes contribute to AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23809366' target='_blank' class='pmid-link'>23809366</a>:</span> <span class='sentence-part'>Scientists are investigating other molecular and cellular pathways and processes that contribute to AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23827971' target='_blank' class='pmid-link'>23827971</a>:</span> <span class='sentence-part'>We will shortly introduce the function of Beclin 1 interactome in autophagy and phagocytosis, review the recent evidence indicating that Beclin 1 regulates autophagy and APP processing in AD, and finally examine the potential mechanisms through which Beclin 1 dysfunction could be involved in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23831375' target='_blank' class='pmid-link'>23831375</a>:</span> <span class='sentence-part'>Alzheimer's disease and prion diseases are neuropathological disorders that are caused by abnormal processing and aggregation of amyloid and prion proteins.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/2386197' target='_blank' class='pmid-link'>2386197</a>:</span> <span class='sentence-part'>The focus of research on the neurofibrillary pathology (NFP) of Alzheimer disease has been not only to determine the component forming the paired helical filaments but also to determine whether they result from abnormal processes affecting a single protein.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24033439' target='_blank' class='pmid-link'>24033439</a>:</span> <span class='sentence-part'>AIMS: Phosphorylation, conformational changes and cleavage of tau protein have been widely suggested to contribute to abnormal tau processing in the pathogenesis of Alzheimer's disease, as well as in other tauopathies.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24205136' target='_blank' class='pmid-link'>24205136</a>:</span> <span class='sentence-part'>Soluble oligomeric amyloid beta peptide (Abeta) generated from processing of the amyloid precursor protein (APP) plays a central role in the pathogenesis of Alzheimer's Disease (AD) and through actions at glutamatergic synapses affects excitability and plasticity.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24279329' target='_blank' class='pmid-link'>24279329</a>:</span> <span class='sentence-part'>These processes may be important in AD pathogenesis, as proper intracellular sorting, processing and export of APP are affected by how it is glycosylated.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24333192' target='_blank' class='pmid-link'>24333192</a>:</span> <span class='sentence-part'>Converging evidence indicates that processes occurring in and around neuronal dendrites are central to the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24463342' target='_blank' class='pmid-link'>24463342</a>:</span> <span class='sentence-part'>Brain network dysfunction in Alzheimer's disease (AD) involves many proteins (enzymes), processes and pathways, which overlap and influence one another in AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24469452' target='_blank' class='pmid-link'>24469452</a>:</span> <span class='sentence-part'>Taken together, these results suggest that Fbxo2 regulates APP levels and processing in the brain and may play a role in modulating AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24476230' target='_blank' class='pmid-link'>24476230</a>:</span> <span class='sentence-part'>Recent research has thus focused on investigating the molecular and cellular pathways and processes involved in AD pathogenesis to support the development of effective disease-modifying agents.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24478167' target='_blank' class='pmid-link'>24478167</a>:</span> <span class='sentence-part'>Many neurodegenerative diseases, like Parkinson's, Alzheimer's, or Huntington's disease, occur as a result of amyloid protein fibril formation and cell death induced by this process.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24506061' target='_blank' class='pmid-link'>24506061</a>:</span> <span class='sentence-part'>TMS has been used to assess neuroplastic changes in Alzheimer's disease (AD), corroborating findings that cortical physiology is altered in AD due to the underlying neurodegenerative process.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24516000' target='_blank' class='pmid-link'>24516000</a>:</span> <span class='sentence-part'>The amyloid precursor protein (APP) and its processing are widely believed to be central for the etiology of Alzheimer's disease (AD) and appear essential for neuronal development and cell homeostasis in mammals.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24524150' target='_blank' class='pmid-link'>24524150</a>:</span> <span class='sentence-part'>One feasible approach to improve the diagnostic and prognostic performance of AD biomarkers is to measure upstream events of amyloid precursor protein (APP) processing, which are at the core of the initial phase of AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24559299' target='_blank' class='pmid-link'>24559299</a>:</span> <span class='sentence-part'>Such interactions between Abeta and ferrihydrite shed light upon the processes of AD pathogenesis, while providing potential targets for future therapies.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24578544' target='_blank' class='pmid-link'>24578544</a>:</span> <span class='sentence-part'>A better knowledge of long-term trajectories of cognitive decline is a central feature of the study of the process leading to Alzheimer's dementia.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24735980' target='_blank' class='pmid-link'>24735980</a>:</span> <span class='sentence-part'>The impairment of the PI3K/Akt/mTOR axis in DS population might represent a key-contributing factor to the neurodegenerative process that culminates in Alzheimer-like dementia.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25045220' target='_blank' class='pmid-link'>25045220</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) is the most common form of dementia caused by neurodegenerative process and is tightly related to amyloid beta (Abeta) and neurofibrillary tangles.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25053581' target='_blank' class='pmid-link'>25053581</a>:</span> <span class='sentence-part'>Therefore, this study indicates a regulatory role of D678H in APP sorting and processing, and provides genetic evidence for the importance of APP sorting in AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25118934' target='_blank' class='pmid-link'>25118934</a>:</span> <span class='sentence-part'>All these findings suggest that APP672-699 region is critical for human wild-type APP processing and may provide new clues for the pathogenesis of sporadic AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25281744' target='_blank' class='pmid-link'>25281744</a>:</span> <span class='sentence-part'>Abeta is generated by the proteolytic processing of the amyloid precursor protein (APP), and alterations to this processing can result in Alzheimer disease. Alzheimer disease (AD) is a progressive neurodegenerative disease leading to memory loss.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25316600' target='_blank' class='pmid-link'>25316600</a>:</span> <span class='sentence-part'>Amyloid precursor protein processing and the subsequent generation of amyloid beta (Abeta) are central to the pathogenesis of Alzheimer's disease, as soluble, oligomeric Abeta is thought to be the toxic species driving disease progression.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25352592' target='_blank' class='pmid-link'>25352592</a>:</span> <span class='sentence-part'>On the other hand, gamma-secretase-mediated processing of amyloid precursor protein leads to the production of amyloid beta (Abeta) peptides that play an important role in the pathogenesis of Alzheimer disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25365422' target='_blank' class='pmid-link'>25365422</a>:</span> <span class='sentence-part'>The aggregation of amyloid-beta (Abeta) peptide and its deposition in parts of the brain form the central processes in the etiology of Alzheimer disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25591151' target='_blank' class='pmid-link'>25591151</a>:</span> <span class='sentence-part'>Although aggregates can be functional under certain circumstances, this process often leads to the disruption of the cellular protein homeostasis (proteostasis), eventually leading to devastating diseases such as Alzheimer's disease (AD), Parkinson's disease (PD), Amyotrophic lateral sclerosis (ALS), or transmissible spongiform encephalopathies (TSEs).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25636033' target='_blank' class='pmid-link'>25636033</a>:</span> <span class='sentence-part'>Tumor suppressor molecules play a pivotal role in regulating DNA repair, cell proliferation, and cell death, which are also important processes in the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25727637' target='_blank' class='pmid-link'>25727637</a>:</span> <span class='sentence-part'>Such process might be important for the pathogenesis of AD, and inhibition of LPC generation could be a therapeutic target for the disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25766617' target='_blank' class='pmid-link'>25766617</a>:</span> <span class='sentence-part'>Disturbances in the sleep-wake cycle and circadian rhythms are common symptoms of Alzheimer Disease (AD), and they have generally been considered as late consequences of the neurodegenerative processes.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26227906' target='_blank' class='pmid-link'>26227906</a>:</span> <span class='sentence-part'>Cyclin-dependent kinase 5 (Cdk5), a unique member of the cyclin-dependent kinases (Cdks), is reported to intimately associate with the process of the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26242258' target='_blank' class='pmid-link'>26242258</a>:</span> <span class='sentence-part'>While the process leading to the development of AD is complex and multifactorial, and the etiology of AD is not completely known, it is nowadays clear that AD is a multifaceted illness requiring the combination of synergetic treatment strategies.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26270969' target='_blank' class='pmid-link'>26270969</a>:</span> <span class='sentence-part'>A major difference in the revised diagnostic criteria for Alzheimer's disease (AD) is the incorporation of biomarkers to support a clinical diagnosis and allow the identification of preclinical AD due to AD neuropathological processes.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26484900' target='_blank' class='pmid-link'>26484900</a>:</span> <span class='sentence-part'>CONCLUSION: Anxiety and irritability are associated with greater amyloid deposition in the neurodegenerative process leading to AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26519433' target='_blank' class='pmid-link'>26519433</a>:</span> <span class='sentence-part'>Most processes associated with AD pathogenesis, such as inflammation, synaptic dysfunction, and hyper-phosphorylation of tau are dependent on protein kinase activity.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26583091' target='_blank' class='pmid-link'>26583091</a>:</span> <span class='sentence-part'>Our study suggests that Abeta25-35 induces autophagy and the PI3K/AKT/mTOR/p70S6K pathway is involved in the process, which improves our understanding of the pathogenesis of AD and provides an additional model for AD research.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26629788' target='_blank' class='pmid-link'>26629788</a>:</span> <span class='sentence-part'>The conversion of soluble monomers to amyloid Abeta fibrils is a complicated process and involves several transient oligomeric species, which are widely believed to be highly toxic and play a crucial role in the etiology of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26642316' target='_blank' class='pmid-link'>26642316</a>:</span> <span class='sentence-part'>To investigate whether lipid peroxidation is only a consequence or might also influence the processes leading to AD, we analyzed 7 different oxidized lipid species including 5 oxidized DHA derivatives and the lipid peroxidation products of omega-3 and omega-6 PUFAs, HNE and 4-hydroxy-hexenal, in human neuroblastoma cells and mouse mixed cortical neurons. Previously it has been demonstrated that polyunsaturated fatty acids (PUFAs), especially docosahexaenoic acid (DHA), are associated with a reduced risk of AD caused by decreased Abeta production.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26792010' target='_blank' class='pmid-link'>26792010</a>:</span> <span class='sentence-part'>The neuropathological processes eventually leading to Alzheimer's disease (AD) are thought to start decades before the appearance of clinical symptoms and the clinical diagnosis of AD dementia.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26878581' target='_blank' class='pmid-link'>26878581</a>:</span> <span class='sentence-part'>In this review, we analyze issues concerning processes of generation of two proteins (beta-amyloid peptide and Tau-protein) in the cell, which are believed to play the key role in AD genesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26993139' target='_blank' class='pmid-link'>26993139</a>:</span> <span class='sentence-part'>The cellular and molecular mechanisms that govern presynaptic dystrophic neurite formation are unclear, and elucidating these processes may lead to novel AD therapeutic strategies.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27012953' target='_blank' class='pmid-link'>27012953</a>:</span> <span class='sentence-part'>APP is subjected to several PTMs (proteolytic processing, glycosylation, sulfation, and phosphorylation) during its course of processing, resulting in Abeta deposition, leading to AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27079722' target='_blank' class='pmid-link'>27079722</a>:</span> <span class='sentence-part'>This is a reasonable assumption because amyloid-beta peptide (Abeta) accumulation and tau hyperphosphorylation are the defining histological features in AD, and because AbetaPP and tau mutations can cause AD in humans or AD-like features in animal models. Alzheimer's disease (AD) has long been viewed as a pathology that must be caused either by aberrant amyloid-beta protein precursor (AbetaPP) processing, dysfunctional tau protein processing, or a combination of these two factors.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27183464' target='_blank' class='pmid-link'>27183464</a>:</span> <span class='sentence-part'>INTRODUCTION: Neuroinflammatory processes play an important role in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27196068' target='_blank' class='pmid-link'>27196068</a>:</span> <span class='sentence-part'>In this study, we examined the effects of ABCG1 and ABCG4 on amyloid precursor protein (APP) processing, the product of which, amyloid beta (Abeta), is involved in the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27454922' target='_blank' class='pmid-link'>27454922</a>:</span> <span class='sentence-part'>In the absence of Abeta, hippocampal tau deposition may be insufficient for the neurodegenerative process that leads to AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27524794' target='_blank' class='pmid-link'>27524794</a>:</span> <span class='sentence-part'>Characteristic features of Alzheimer's disease are memory loss, plaques resulting from abnormal processing of amyloid precursor protein (APP), and presence of neurofibrillary tangles and dystrophic neurites containing hyperphosphorylated tau.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27671345' target='_blank' class='pmid-link'>27671345</a>:</span> <span class='sentence-part'>BACKGROUND: It is widely accepted that neuroinflammatory processes play an important role in the pathogenesis of Alzheimer's disease (AD) and high levels of cytokines and chemokines are detected around Abeta plaques.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27713140' target='_blank' class='pmid-link'>27713140</a>:</span> <span class='sentence-part'>Although the mechanisms causing the neurodegenerative process are largely unknown, increasing evidence highlights a critical role of immunity in the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27723573' target='_blank' class='pmid-link'>27723573</a>:</span> <span class='sentence-part'>GTM-1 is a drug that reverses Alzheimer's Disease (AD) development specifically induced by thapsgargin (TG) and endoplasmic reticulum (ER) has been reported to be a pilot process that leads to AD formation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27856911' target='_blank' class='pmid-link'>27856911</a>:</span> <span class='sentence-part'>Our work provides insights into postsynaptic processes in AD pathogenesis and challenges a purely pathogenic role of tau phosphorylation in neuronal toxicity.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/2813376' target='_blank' class='pmid-link'>2813376</a>:</span> <span class='sentence-part'>The present data extend earlier findings of abnormal processing of neurofilaments and tau protein in Alzheimer disease and, together with reported abnormal processing of cerebrovascular amyloid beta-protein, suggest that inhibition of the processing of multiple proteins is basic to the pathogenesis of Alzheimer disease, whereas formation of plaques and tangles could be merely the most striking histologic result.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28157316' target='_blank' class='pmid-link'>28157316</a>:</span> <span class='sentence-part'>In conclusion, these data suggest dysregulation of the proteins and processes identified as early events in pathogenesis of AD following Abeta accumulation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28209190' target='_blank' class='pmid-link'>28209190</a>:</span> <span class='sentence-part'>BACKGROUND: Disturbed amyloid precursor protein (APP) processing is considered to be central to the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28569173' target='_blank' class='pmid-link'>28569173</a>:</span> <span class='sentence-part'>Together, these results indicate that an ApoE2 or ApoE3 mediated positive regulation of BDNF may be protective while ApoE4 related defects in BDNF processing could lead to AD pathophysiology.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28612181' target='_blank' class='pmid-link'>28612181</a>:</span> <span class='sentence-part'>This finding identifies a point mutation in LRP1 which slows LRP1-CT-mediated APP endocytosis and amyloidogenic processing, while enhancing APP alpha-secretase cleavage, thus demonstrating a potential novel target for slowing AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28626014' target='_blank' class='pmid-link'>28626014</a>:</span> <span class='sentence-part'>The results demonstrate that APP673 regulates APP processing, and the BACE1 cleavage site selection is critical for amyloidogenesis in AD pathogenesis, and implicate a pharmaceutical potential for targeting the APP673 site for AD drug development. The results demonstrate that APP673 regulates APP processing and the BACE1 cleavage site selection is critical for amyloidogenesis in AD pathogenesis, and implicate a pharmaceutical potential for targeting the APP673 site for AD drug development.SIGNIFICANCE STATEMENT beta-site APP cleaving enzyme 1 (BACE1) is essential for amyloid beta protein production.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28759721' target='_blank' class='pmid-link'>28759721</a>:</span> <span class='sentence-part'>The amyloid aggregation process of amyloid beta1-42 peptide is responsible for Alzheimer's disease, affecting millions of elderly people worldwide.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28812474' target='_blank' class='pmid-link'>28812474</a>:</span> <span class='sentence-part'>A number of studies demonstrated compelling evidence of the importance of oxidative processes in AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28825683' target='_blank' class='pmid-link'>28825683</a>:</span> <span class='sentence-part'>Given the importance of the GABAergic system in neuronal function and homeostasis, in the maintenance of the excitatory/inhibitory balance, and in the processes of learning and memory, such changes in GABAergic function could be an important factor in both early and later stages of AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28892789' target='_blank' class='pmid-link'>28892789</a>:</span> <span class='sentence-part'>Though the causes of Alzheimer's disease (AD) are yet to be understood, much evidence has suggested that excessive amyloid-beta (Abeta) accumulation due to abnormal amyloid-beta precursor protein (APP) processing and Abeta metabolism are crucial processes towards AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28965829' target='_blank' class='pmid-link'>28965829</a>:</span> <span class='sentence-part'>Reduced brain insulin signaling: A seminal process in Alzheimer's disease pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29079430' target='_blank' class='pmid-link'>29079430</a>:</span> <span class='sentence-part'>Insulin dysfunction is known as an essential process in the pathogenesis of sporadic Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29097202' target='_blank' class='pmid-link'>29097202</a>:</span> <span class='sentence-part'>However, abnormal processing of APP leads to excessive production of beta-amyloid (Abeta) in the central nervous system (CNS), an event which is regarded as a primary cause of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29124681' target='_blank' class='pmid-link'>29124681</a>:</span> <span class='sentence-part'>However, their single actions cannot explain the extent of brain damage observed in this disorder, and the characterization of co-adjuvant involved in the early toxic processes evoked in AD is essential.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29223769' target='_blank' class='pmid-link'>29223769</a>:</span> <span class='sentence-part'>The processes involved in the pathogenesis of AD have been shown to overlap with those found in cognitive decline in patients with Obstructive Sleep Apnoea (OSA).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29277576' target='_blank' class='pmid-link'>29277576</a>:</span> <span class='sentence-part'>Amyloid precursor protein (APP) processing is central in Alzheimer's disease (AD) pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29407908' target='_blank' class='pmid-link'>29407908</a>:</span> <span class='sentence-part'>Dysfunctional accumulation of amyloid-beta (Abeta) protein stimulated by Cu2+ is considered as a key process in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29410161' target='_blank' class='pmid-link'>29410161</a>:</span> <span class='sentence-part'>Minor species of amyloid beta-peptide (Abeta), such as Abeta-(1-43) and pyroglutaminated Abeta-(3-42) (Abeta-(3pE-42)), have been suggested to be involved in the initiation of the Abeta aggregation process, which is closely associated with the etiology of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29695619' target='_blank' class='pmid-link'>29695619</a>:</span> <span class='sentence-part'>The endoplasmic reticulum (ER) stress response is regarded as an important process in the aetiology of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30149452' target='_blank' class='pmid-link'>30149452</a>:</span> <span class='sentence-part'>These data suggest that A?-associated clinical progression is consistent with clinical-pathological models of AD, whereas progression in the absence of elevated A? deposition may be the result of neuropathological processes other than AD that accumulate with age.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30167602' target='_blank' class='pmid-link'>30167602</a>:</span> <span class='sentence-part'>Toxic aggregation of monomeric amyloid beta (Abeta) into oligomers followed by the formation of fibrils is a causative process in the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30200516' target='_blank' class='pmid-link'>30200516</a>:</span> <span class='sentence-part'>Considering the involvement of (mis)folding processes in AD aetiology, targeting molecular chaperones represents a promising therapeutic perspective.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30407837' target='_blank' class='pmid-link'>30407837</a>:</span> <span class='sentence-part'>The aggregation of amyloid beta-proteins (Abeta) has been recognized as a key process in the pathogenesis of Alzheimer's disease (AD), so inhibiting Abeta aggregation is an important strategy to prevent the onset and treatment of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30574086' target='_blank' class='pmid-link'>30574086</a>:</span> <span class='sentence-part'>There is general agreement that the neuropathological processes leading to Alzheimer's disease (AD) begin decades before the clinical onset.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30590039' target='_blank' class='pmid-link'>30590039</a>:</span> <span class='sentence-part'>Abnormalities of the endolysosomal and autophagy systems are found in Alzheimer's disease, but it is not clear whether defects in these systems are a cause or consequence of degenerative processes in the disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30662636' target='_blank' class='pmid-link'>30662636</a>:</span> <span class='sentence-part'>These results suggested that SQYZ has the ability to improve the cognitive impairment and ameliorate the neural pathological changes in AD, and the therapeutic mechanism may be related to the modulation of multiple processes related to AD pathogenesis, especially anti-neuroinflammation, promotion of stress recovery and improvement of energy metabolism.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30790387' target='_blank' class='pmid-link'>30790387</a>:</span> <span class='sentence-part'>BACKGROUND: In the past few decades, it has been demonstrated with animal models and clinical studies that a chronic inflammatory process significantly contributes to Alzheimer's disease (AD) pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30795987' target='_blank' class='pmid-link'>30795987</a>:</span> <span class='sentence-part'>Molecular studies in rodent models suggest a direct contribution of astrocytes to neuroinflammatory and neurodegenerative processes causing Alzheimer's disease; however, these models might insufficiently mimic the human disease, because rodent astrocytes differ considerably in morphology, functionality, and gene expression.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30949921' target='_blank' class='pmid-link'>30949921</a>:</span> <span class='sentence-part'>PURPOSE OF REVIEW: Nutrition is known to modulate the immune system and may alter neuroinflammatory processes implicated in the pathogenesis of Alzheimer's disease (AD) and progression of neurodegeneration.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31058201' target='_blank' class='pmid-link'>31058201</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) is a lifelong progressive neurodegenerativa disease related with accumulation of amyloid beta peptide (Abeta) produced by processing of amyloid precursor protein (APP) in the brain.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31086058' target='_blank' class='pmid-link'>31086058</a>:</span> <span class='sentence-part'>These compounds accompany thermal processing of protein-containing foods and are known to impact on ageing, pathogenesis of diabetes mellitus and Alzheimer's disease in mammals.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31465249' target='_blank' class='pmid-link'>31465249</a>:</span> <span class='sentence-part'>In late 2016, we solicited a series of reviews covering the variety of processes that appeared to be involved in the pathogenesis of neurodegenerative disorders, particularly Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31477183' target='_blank' class='pmid-link'>31477183</a>:</span> <span class='sentence-part'>BACKGROUND: Alzheimer's disease results from a neurodegenerative process that starts well before the diagnosis can be made.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31507373' target='_blank' class='pmid-link'>31507373</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) is the most common type of dementia which characterized by a progressive loss of memory and cognitive function due to degeneration of synapses and axons. Till now, it is far from clear what role autophagy plays in AD, a causative role, a protective role, or just a consequence of the disease process itself.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31583531' target='_blank' class='pmid-link'>31583531</a>:</span> <span class='sentence-part'>In this review, we discuss the current molecular understanding of how alterations in the AS process contribute to AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31600762' target='_blank' class='pmid-link'>31600762</a>:</span> <span class='sentence-part'>Poor Diet, Stress, and Inactivity Converge to Form a \Perfect Storm\ That Drives Alzheimer's Disease Pathogenesis. It is thus likely that lifestyle and environmental factors contribute to neurodegenerative processes implicated in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31704512' target='_blank' class='pmid-link'>31704512</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) is a progressive, chronic and severe neurodegenerative disorder linked with cognitive and memory impairment that eventually lead to death. There are several processes which can cause AD, including mitochondrial dysfunction-mediated oxidative stress (OS), intracellular buildup of hyper-phosphorylated tau as neurofibrillary tangles (NFTs) and excessive buildup of extracellular amyloid beta (Abeta) plaques, and/or genetic as well as the environmental factors.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31808139' target='_blank' class='pmid-link'>31808139</a>:</span> <span class='sentence-part'>Chronic cerebral hypoperfusion (CCH) is a major contributor to cognitive decline and degenerative processes leading to Alzheimer's disease, vascular dementia, and aging.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31911114' target='_blank' class='pmid-link'>31911114</a>:</span> <span class='sentence-part'>We propose that CNS APOE is involved in processes in the normal brains that in later years apply specifically to processes of AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32062666' target='_blank' class='pmid-link'>32062666</a>:</span> <span class='sentence-part'>Vascular processes even proceed AD neuropathology, implicating a causal role in the etiology of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32365768' target='_blank' class='pmid-link'>32365768</a>:</span> <span class='sentence-part'>We provide a comprehensive overview of processes associated with AD pathogenesis and biomarkers, current knowledge on AD-related biomarkers derived from on human and animal brains and body fluids, comparisons of biomarkers obtained in human AD and frequently used animal AD models, and emerging body-fluid-based biomarkers.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32415525' target='_blank' class='pmid-link'>32415525</a>:</span> <span class='sentence-part'>MiR-539-5p Decreases amyloid beta-protein production, hyperphosphorylation of Tau and Memory Impairment by Regulating PI3K/Akt/GSK-3beta Pathways in APP/PS1 Double Transgenic Mice.The production of amyloid beta (Abeta) and tau hyperphosphorylation have been identified as key processes in Alzheimer's disease (AD) pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32418657' target='_blank' class='pmid-link'>32418657</a>:</span> <span class='sentence-part'>The convergence of pathogenic mutations on one functional pathway, the amyloidogenic cleavage of APP, strongly supports the significance of this process in AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32468556' target='_blank' class='pmid-link'>32468556</a>:</span> <span class='sentence-part'>Detecting Common Pathways and Key Molecules of Neurodegenerative Diseases from the Topology of Molecular Networks.MotivationNeurodegenerative diseases (NDs), including amyotrophic lateral sclerosis, Parkinson's disease, Alzheimer's disease, and Huntington's disease, occur as a result of neurodegenerative processes.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32548880' target='_blank' class='pmid-link'>32548880</a>:</span> <span class='sentence-part'>Multitargeted directed ligands (MTDLs) have been considered to be a feasible way to treat AD due to the multiple neuropathological processes in AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32664217' target='_blank' class='pmid-link'>32664217</a>:</span> <span class='sentence-part'>Individuals residing close to busy roads are at higher risk of developing AD, and nanomaterials that are specifically generated by traffic-related processes have been detected in human brains.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33325586' target='_blank' class='pmid-link'>33325586</a>:</span> <span class='sentence-part'>The imbalance of amyloid-beta (Abeta) production and clearance causes aggregation of Abeta     1-42       monomers to form fibrils and amyloid plaques, which is an indispensable process in the pathogenesis of Alzheimer's disease (AD), and eventually leads to pathological changes and cognitive impairment.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33543132' target='_blank' class='pmid-link'>33543132</a>:</span> <span class='sentence-part'>These findings provide support for a causal relationship between two crucial processes in Alzheimer's disease pathogenesis and suggest that targeting inflammation, particularly tumour necrosis factor, may have beneficial downstream effects on ameliorating aberrant protein aggregation and accumulation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33887256' target='_blank' class='pmid-link'>33887256</a>:</span> <span class='sentence-part'>We monitor early stages of beta-amyloid (Abeta     1-40      ) aggregation, one of key processes leading to Alzheimer's disease (AD), in the presence of high glucose concentrations by measuring Abeta     1- 40       intrinsic fluorescence.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34118718' target='_blank' class='pmid-link'>34118718</a>:</span> <span class='sentence-part'>beta-Amyloid (Abeta) triggered proteopathic and immunopathic processes are a postulated cause of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34135909' target='_blank' class='pmid-link'>34135909</a>:</span> <span class='sentence-part'>Emerging evidence suggests that both central and peripheral immunological processes play an important role in the pathogenesis of Alzheimer's disease (AD), but regulatory mechanisms remain unknown.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34440878' target='_blank' class='pmid-link'>34440878</a>:</span> <span class='sentence-part'>Dysfunctions of both glucose metabolism and mitochondrial dynamics have been recognized as the main upstream events of the degenerative processes leading to AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34563212' target='_blank' class='pmid-link'>34563212</a>:</span> <span class='sentence-part'>BACKGROUND: Increasing evidence for a direct contribution of astrocytes to neuroinflammatory and neurodegenerative processes causing Alzheimer's disease comes from molecular and functional studies in rodent models.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35109055' target='_blank' class='pmid-link'>35109055</a>:</span> <span class='sentence-part'>BACKGROUND: There is a growing appreciation that systemic factors, such as chronic inflammation, metabolic disorders, vascular dysfunction and gut microbiota dysbiosis, are highly connected and traverse a complex route across multiple pathophysiological processes that play crucial roles in Alzheimer's disease (AD) pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35749963' target='_blank' class='pmid-link'>35749963</a>:</span> <span class='sentence-part'>Due to the central role of the amyloid aggregation process in the early phase of AD pathogenesis, we aimed at developing a lipidomic approach to evaluate the amyloid toxic effects on differentiated human neuroblastoma derived SH-SY5Y cells.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35780617' target='_blank' class='pmid-link'>35780617</a>:</span> <span class='sentence-part'>The review aims to provide a comprehensive understanding of the neuroinflammatory processes causing AD, giving a brief overview of the disease interventions.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35805958' target='_blank' class='pmid-link'>35805958</a>:</span> <span class='sentence-part'>Role of Impaired Mitochondrial Dynamics Processes in the Pathogenesis of Alzheimer's Disease. This review highlights aspects of altered mitochondrial dynamics in AD that may contribute to the etiology of this debilitating condition.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35821178' target='_blank' class='pmid-link'>35821178</a>:</span> <span class='sentence-part'>Mounting evidence indicates that intensified neuroinflammatory processes play a pivotal role in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36090249' target='_blank' class='pmid-link'>36090249</a>:</span> <span class='sentence-part'>This review attempts to elucidate the process of Regulated cell death, how it gets unregulated in response to different intra and extracellular stressors, various forms of unregulated cell death, their interplay and their role in pathogenesis of Alzheimer's Disease in both human and experimental models of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36464806' target='_blank' class='pmid-link'>36464806</a>:</span> <span class='sentence-part'>DISCUSSION: The identification of these novel gene-trait associations offers new perspectives into the role of rare coding variation in the distinct pathophysiological processes culminating in AD, which may lead to identification of novel therapeutic and diagnostic targets.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36551781' target='_blank' class='pmid-link'>36551781</a>:</span> <span class='sentence-part'>The processes that cause AD are still under investigation and there are no available therapies to halt it.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36702317' target='_blank' class='pmid-link'>36702317</a>:</span> <span class='sentence-part'>Liquid-liquid phase separation of protein tau: An emerging process in Alzheimer's disease pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37027506' target='_blank' class='pmid-link'>37027506</a>:</span> <span class='sentence-part'>This led to the alternative hypothesis that in AD, part of WMH may be secondary to AD-related processes.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37258519' target='_blank' class='pmid-link'>37258519</a>:</span> <span class='sentence-part'>Neuroinflammation is believed to be a key process in Alzheimer's disease (AD) pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37382195' target='_blank' class='pmid-link'>37382195</a>:</span> <span class='sentence-part'>The gene ontology (GO) analysis manifests that the included processes are close to the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37638691' target='_blank' class='pmid-link'>37638691</a>:</span> <span class='sentence-part'>Tau-dependent cell cycle re-entry and NiMA inhibition occur in cultured neurons within a few hours of exposure to AbetaOs, and thus may represent seminal processes in AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37759477' target='_blank' class='pmid-link'>37759477</a>:</span> <span class='sentence-part'>The results revealed that oxidative phosphorylation and mitochondrial-related pathways are significantly down-regulated in both tissues of Tg2576 mice, supporting the role of these processes in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/38479477' target='_blank' class='pmid-link'>38479477</a>:</span> <span class='sentence-part'>Besides this, agmatine has been shown to modulate amyloid beta (Abeta) production, aggregation, and clearance, key processes implicated in AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/7745947' target='_blank' class='pmid-link'>7745947</a>:</span> <span class='sentence-part'>BACKGROUND: Dysregulation in the processing of the Alzheimer precursor protein (APP) is thought to be central to the deposition of the beta-A4 peptide and to the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/7838304' target='_blank' class='pmid-link'>7838304</a>:</span> <span class='sentence-part'>APP processing, A beta-amyloidogenesis, and the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/8122883' target='_blank' class='pmid-link'>8122883</a>:</span> <span class='sentence-part'>The persistence of abnormalities in KGDHC and particularly in its E2k component in FAD fibroblasts indicates that abnormalities of this autosomally coded nuclear component are an intrinsic part of the AD process, and the possible role of this abnormality in the pathogenesis of AD is discussed.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/8157623' target='_blank' class='pmid-link'>8157623</a>:</span> <span class='sentence-part'>Based on these observations, we postulate that the accumulation of insoluble A beta N-42 in Alzheimer Disease is due to the anomalous processing of the C-terminal region.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/8250938' target='_blank' class='pmid-link'>8250938</a>:</span> <span class='sentence-part'>These results implicate PLA2 in regulating APP processing and secretion, which may have important implications for understanding the pathogenesis of Alzheimer's Disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/8326828' target='_blank' class='pmid-link'>8326828</a>:</span> <span class='sentence-part'>These data support and extend the hypothesis that complement mediated processes are related to beta-amyloid deposition and may be involved in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/8427604' target='_blank' class='pmid-link'>8427604</a>:</span> <span class='sentence-part'>Elucidation of the mechanisms regulating the expression of the human APP gene might therefore be an important step forward in understanding the processes leading to Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/8687017' target='_blank' class='pmid-link'>8687017</a>:</span> <span class='sentence-part'>Excessive amyloidogenic pathway of APP processing may be the final common pathway involved in the pathogenesis of AD. There is mounting evidence that at least some of the neurotoxicity associated with AD is due to fragments from APP.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/8841658' target='_blank' class='pmid-link'>8841658</a>:</span> <span class='sentence-part'>Abnormal processing of beta-amyloid precursor protein (APP) and precipitation of amyloidogenic beta A4 peptide have been implicated in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/8875116' target='_blank' class='pmid-link'>8875116</a>:</span> <span class='sentence-part'>The data presented here support the hypothesis that unpaired proteolytic processes could be involved in the pathogenesis of Alzheimer's disease and suggest that the levels of urinary acid-stable inhibitors may prove to be useful markers of the disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/8922411' target='_blank' class='pmid-link'>8922411</a>:</span> <span class='sentence-part'>apoE is involved in processes of degeneration and regeneration after nerve lesions as well as in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/9161470' target='_blank' class='pmid-link'>9161470</a>:</span> <span class='sentence-part'>Lowering of blood pressure in dementia, especially Alzheimer's disease, may be due to the dementia process itself or to the characteristics of the disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/9199880' target='_blank' class='pmid-link'>9199880</a>:</span> <span class='sentence-part'>Reactive oxygen-mediated processes are though to contribute to the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/9462872' target='_blank' class='pmid-link'>9462872</a>:</span> <span class='sentence-part'>In addition apoE has also been implicated in neural regenerative processes and in the etiology of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/9754878' target='_blank' class='pmid-link'>9754878</a>:</span> <span class='sentence-part'>The processing of beta-amyloid precursor protein (betaAPP) and its metabolites plays an important role in the pathogenesis of Alzheimer's disease (AD) and Down's syndrome.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/9809105' target='_blank' class='pmid-link'>9809105</a>:</span> <span class='sentence-part'>The pathogenic process that causes AD has not been fully delineated; however, it clearly leads to neuropathology characterized by neuritic plaques, neurofibrillary tangles, and loss of cholinergic neurons in the nucleus basalis of Meynert.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/9850931' target='_blank' class='pmid-link'>9850931</a>:</span> <span class='sentence-part'>Alzheimer's disease is a neurodegenerative disorder comprising multisystem atrophies probably caused by multifactorial processes.</span></div></div>
<div class='streamlined-assertion'><div class='streamlined-header sticky-relation-header'><span class='label-text'>Subject:</span> <strong>Proteins</strong> <span class='label-text'>Subject CUI:</span> <strong>C0033684</strong> â†’ <span class='label-text predicate-text'>CAUSES</span> â†’ <span class='label-text'>Object:</span> <strong>Alzheimers</strong> <span class='label-text'>Object CUI:</span> <strong>C0002395</strong></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/10079962' target='_blank' class='pmid-link'>10079962</a>:</span> <span class='sentence-part'>Approximately 30% of patients who die after a single episode of severe head injury show intracerebral deposition of beta-amyloid protein (A beta), a protein that is thought to be central to the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/10349860' target='_blank' class='pmid-link'>10349860</a>:</span> <span class='sentence-part'>These results suggest the possibility that altered presenilin gene products in stress conditions may also participate in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/10369525' target='_blank' class='pmid-link'>10369525</a>:</span> <span class='sentence-part'>This paper discusses the biochemical evidence that links each protein to AD, various animal and cell models that have been used in these investigations, and the putative interactions between these proteins that lead to AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/10867209' target='_blank' class='pmid-link'>10867209</a>:</span> <span class='sentence-part'>For example, apoE can interact with amyloid beta-protein and tau, proteins central to the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/11072133' target='_blank' class='pmid-link'>11072133</a>:</span> <span class='sentence-part'>Calsenilin was discovered by virtue of its interaction with both presenilin-1 and -2, proteins that are involved in the etiology of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/11973456' target='_blank' class='pmid-link'>11973456</a>:</span> <span class='sentence-part'>By comparing the CSF proteome between Alzheimer disease (AD) patients and controls it may be possible to identify proteins that play a role in the disease process and thus to study the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/12020852' target='_blank' class='pmid-link'>12020852</a>:</span> <span class='sentence-part'>Accumulation of beta-amyloid (Abeta) protein in brain is an important characteristic for the etiology of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/12419469' target='_blank' class='pmid-link'>12419469</a>:</span> <span class='sentence-part'>These results support the hypothesis that oxidative damage to lipid, protein, and DNA is an important early event in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/12429067' target='_blank' class='pmid-link'>12429067</a>:</span> <span class='sentence-part'>Although the precise molecular mechanism underlying presenilin function or dysfunction remains elusive, presenilins are thought to be part of a complex of proteins that has 'gamma-secretase cleavage' activity, which is clearly central in the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/12716134' target='_blank' class='pmid-link'>12716134</a>:</span> <span class='sentence-part'>Abnormal activity of these proteins in brain may contribute to the pathogenesis of Alzheimer's disease, a neurodegenerative condition characterized by focal amyloid deposits with neurofibrillary tangles.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/12893422' target='_blank' class='pmid-link'>12893422</a>:</span> <span class='sentence-part'>Since the HPC patients can be regarded as preclinical AD patients, our results suggest the accumulation of these proteins involved in the initial steps of AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/12972157' target='_blank' class='pmid-link'>12972157</a>:</span> <span class='sentence-part'>Recent biological studies indicate the importance of anterior-pharynx defective-1 (APH-1) proteins in Alzheimer's disease (AD) pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/15304237' target='_blank' class='pmid-link'>15304237</a>:</span> <span class='sentence-part'>The beta amyloid (A beta) protein is a key molecule in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/15456259' target='_blank' class='pmid-link'>15456259</a>:</span> <span class='sentence-part'>Beta-secretase (BACE) is a critical enzyme in the production of beta-amyloid, a protein that has been implicated as a potential cause of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/15663474' target='_blank' class='pmid-link'>15663474</a>:</span> <span class='sentence-part'>Increased damage to proteins by glycation, oxidation and nitration has been implicated in neuronal cell death leading to Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/15686969' target='_blank' class='pmid-link'>15686969</a>:</span> <span class='sentence-part'>These findings open new perspectives for the study of the possible crosstalk between these proteins in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/15975080' target='_blank' class='pmid-link'>15975080</a>:</span> <span class='sentence-part'>This article will review the current knowledge of PS1 function in protein trafficking and discuss its potential role in AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/16472206' target='_blank' class='pmid-link'>16472206</a>:</span> <span class='sentence-part'>After much initial debate for and against the role of amyloid in Alzheimer's disease (AD), mutations on the amyloid precursor protein (APP) and processing pathways that increase levels of the amyloid b peptide of 42 residues (Abeta42) have established that faulty function or processing of these proteins are responsible for AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/16883086' target='_blank' class='pmid-link'>16883086</a>:</span> <span class='sentence-part'>By comparing the CSF proteome of AD patients and controls it might be possible to identify proteins that play a role in the disease process and thus study the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17369839' target='_blank' class='pmid-link'>17369839</a>:</span> <span class='sentence-part'>Polyglutamine (polyQ) diseases are classified as conformational neurodegenerative diseases, like Alzheimer and Parkinson diseases, and they are caused by proteins with an abnormally expanded polyQ stretch.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17699523' target='_blank' class='pmid-link'>17699523</a>:</span> <span class='sentence-part'>Despite the functional importance of this protein in Alzheimer disease pathogenesis, the functional correlation to the structural domain of RTN3 remained unclear.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17761554' target='_blank' class='pmid-link'>17761554</a>:</span> <span class='sentence-part'>OBJECTIVE: Serine protease inhibitors (serpins), the acute phase reactants and regulators of the proteolytic processing of proteins, have been recognized as potential contributors to the pathogenesis of Alzheimer disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17904250' target='_blank' class='pmid-link'>17904250</a>:</span> <span class='sentence-part'>We provide evidence that normal aging involves loss of Reelin neurons, reduced production and elimination of the extracellular deposits, whereas a prenatal immune challenge or the expression of AD-causing gene products, result in earlier, higher, and more persistent levels of Reelin-positive deposits.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/1791973' target='_blank' class='pmid-link'>1791973</a>:</span> <span class='sentence-part'>It has been speculated that this protein, or the lack of it, may be involved in the aetiology of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/18374273' target='_blank' class='pmid-link'>18374273</a>:</span> <span class='sentence-part'>Thus, the study of the complex interplay of proteins that are involved in or modify Abeta production is very important to gain insight into the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/19478666' target='_blank' class='pmid-link'>19478666</a>:</span> <span class='sentence-part'>PURPOSE OF REVIEW: This article reviews recent developments in the field of amyloid imaging using PET, specifically the ability to quantify the amount and distribution of brain beta-amyloid, the protein that occupies a central position in leading theories of the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21248114' target='_blank' class='pmid-link'>21248114</a>:</span> <span class='sentence-part'>Presenilin 1 (PS1) is an integral component of gamma-secretase and is also a protein closely linked to the etiology of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/2128596' target='_blank' class='pmid-link'>2128596</a>:</span> <span class='sentence-part'>These data suggest that an intrinsic property of AD cells is the progressive reduced ability to interact with normal biologic signals provided by proteins such as interferons which in turn may contribute to the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21694447' target='_blank' class='pmid-link'>21694447</a>:</span> <span class='sentence-part'>The CD147 protein interacts with other proteins such as cyclophilin A (CyPA), Cyclophilin B (CyPB), sterol carrier protein (SCP), caveolin-1 and integrins, and can influence amyloid-beta (Abeta) peptide levels, a protein that is central to Alzheimer's disease (AD) pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21944696' target='_blank' class='pmid-link'>21944696</a>:</span> <span class='sentence-part'>The formation and accumulation of D-aspartate residue (D-Asp) in proteins caused by oxidative stress leads to dysfunction and/or denaturation of proteins, and is consequently responsible for aging-related misfolding diseases such as cataracts, prion disease, and Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22138302' target='_blank' class='pmid-link'>22138302</a>:</span> <span class='sentence-part'>The association between apolipoprotein E (apoE) and amyloid-beta peptide (Abeta) may significantly impact the function of both proteins, thus affecting the etiology of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22683528' target='_blank' class='pmid-link'>22683528</a>:</span> <span class='sentence-part'>Based on the studies that have been conducted so far amyloid beta-peptide (Abeta), a protein found in senile plaques, one of the key pathological hallmarks of AD, has been reported to be critical in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22926141' target='_blank' class='pmid-link'>22926141</a>:</span> <span class='sentence-part'>These observations led us to conclude that VDAC1 interacts with Abeta, and phosphorylated tau may in turn block mitochondrial pores, leading to mitochondrial dysfunction in AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22971592' target='_blank' class='pmid-link'>22971592</a>:</span> <span class='sentence-part'>Neuroprotective effect of sinapic acid in a mouse model of amyloid beta(1-42) protein-induced Alzheimer's disease. The neuroprotective effects of SA in a mouse model of amyloid beta (Abeta)(1-42) protein-induced Alzheimer's disease (AD) were investigated.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23600477' target='_blank' class='pmid-link'>23600477</a>:</span> <span class='sentence-part'>AREAS COVERED: Here, the properties and diverse functions of ubiquilin-1 protein in the context of the pathogenesis of AD and other neurodegenerative disorders are discussed.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23697802' target='_blank' class='pmid-link'>23697802</a>:</span> <span class='sentence-part'>Near-complete fragmentation of proteins up to 29 kDa is achieved with UVPD including the unambiguous localization of a single residue mutation and several protein modifications on Pin1 (Q13526), a protein implicated in the development of Alzheimer's disease and in cancer pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23748076' target='_blank' class='pmid-link'>23748076</a>:</span> <span class='sentence-part'>Here we have shown a novel function of Caspr in pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23866266' target='_blank' class='pmid-link'>23866266</a>:</span> <span class='sentence-part'>The discovery of neuroinflammatory changes, including dramatic proliferation of activated glia overexpressing a chromosome 2 gene product--the pluripotent immune cytokine interleukin-1 (IL-1)--and a chromosome 21 gene product--S100B--in the brains of fetuses, neonates, and children with DS opened the possibility that early events in Alzheimer pathogenesis were driven by cytokines.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24028865' target='_blank' class='pmid-link'>24028865</a>:</span> <span class='sentence-part'>In summary, we provide further evidence for interactions of PrP(C) with proteins that are known to be the key players in AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24269629' target='_blank' class='pmid-link'>24269629</a>:</span> <span class='sentence-part'>In the last five years our group has been involved in unraveling the neurobiology of this protein and investigating its relationship with cellular and molecular events of functional importance in AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25108596' target='_blank' class='pmid-link'>25108596</a>:</span> <span class='sentence-part'>The neuroprotective effects of baicalin on pathological changes and behavioral deficits were explored in a mouse model of amyloid beta (Abeta)(1-42) protein-induced Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25589722' target='_blank' class='pmid-link'>25589722</a>:</span> <span class='sentence-part'>Disturbances on AbetaPP and secretases intracellular trafficking and, consequently, in their localization may affect dynamic interactions between these proteins with consequences in the AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26438529' target='_blank' class='pmid-link'>26438529</a>:</span> <span class='sentence-part'>We review the literature regarding the biological functions of these six proteins and their putative role in AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27037841' target='_blank' class='pmid-link'>27037841</a>:</span> <span class='sentence-part'>The sialylation of proteins varies during development, aging, and pathogenesis of degenerative diseases such as Morbus Alzheimer, diabetes mellitus type II, or myopathies.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28217771' target='_blank' class='pmid-link'>28217771</a>:</span> <span class='sentence-part'>Amyloid fibrils are formed by the aberrant aggregation of proteins into highly ordered beta-sheet structures and are believed to be the root cause of several neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, Prion diseases, etc. and have been the subject of extensive biochemical, biophysical and clinical studies.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28415805' target='_blank' class='pmid-link'>28415805</a>:</span> <span class='sentence-part'>The dysregulation of these proteins can cause diseases such as Alzheimer's disease, tumorigenesis etc. and may also lead to drug resistance.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28550247' target='_blank' class='pmid-link'>28550247</a>:</span> <span class='sentence-part'>(A?), including A?42, proteins thought critical in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/2888020' target='_blank' class='pmid-link'>2888020</a>:</span> <span class='sentence-part'>The defect in the inherited autosomal dominant form of Alzheimer's disease, familial Alzheimer's disease (FAD), has been mapped to the same approximate region of chromosome 21 by genetic linkage to anonymous DNA markers, raising the possibility that this gene product, which could be important in the pathogenesis of Alzheimer's disease, is also the site of the inherited defect in FAD (ref. 5).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29076790' target='_blank' class='pmid-link'>29076790</a>:</span> <span class='sentence-part'>Misfolded beta-sheet structures of proteins leading to neurodegenerative diseases like Alzheimer's disease (AD) and Parkinson's disease (PD) are in the spotlight since long.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29774507' target='_blank' class='pmid-link'>29774507</a>:</span> <span class='sentence-part'>Here we focus on CALM, a protein containing an ANTH domain, which is implicated in the pathogenesis of blood cancers and Alzheimer disease, and discuss how alteration of CALM function is involved in these diseases.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30282354' target='_blank' class='pmid-link'>30282354</a>:</span> <span class='sentence-part'>Possible Role of Chitin-Like Proteins in the Etiology of Alzheimer's Disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30906244' target='_blank' class='pmid-link'>30906244</a>:</span> <span class='sentence-part'>The disruption of iron metabolism and iron transport proteins have been implicated in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31281238' target='_blank' class='pmid-link'>31281238</a>:</span> <span class='sentence-part'>Increasing evidence links proteins of the S100 family to the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31507405' target='_blank' class='pmid-link'>31507405</a>:</span> <span class='sentence-part'>Amyloid-beta (Abeta) deposits and some proteins play essential roles in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31686372' target='_blank' class='pmid-link'>31686372</a>:</span> <span class='sentence-part'>However, the molecular mechanisms underlying the aberrant expression levels of these proteins in the pathogenesis of AD are still not completely understood. Mitochondrial dysfunctions and oxidative stress play important roles in the early pathogenesis of Alzheimer's disease (AD), which also involves the aberrant expression levels of mitochondrial proteins.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33815938' target='_blank' class='pmid-link'>33815938</a>:</span> <span class='sentence-part'>Cleavage of this protein by beta-secretase can lead to the formation of amyloid-beta (Abeta) peptide plaque, which leads to Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33833046' target='_blank' class='pmid-link'>33833046</a>:</span> <span class='sentence-part'>Diverse gene products contribute to the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34129723' target='_blank' class='pmid-link'>34129723</a>:</span> <span class='sentence-part'>Continued evaluation of these proteins will determine to what extent they can aid in the discrimination of MCI patients with and without an underlying AD etiology, and if they have the potential to contribute to a better understanding of the AD continuum.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34627984' target='_blank' class='pmid-link'>34627984</a>:</span> <span class='sentence-part'>MATERIALS AND METHODS: 60 APP/PS1 double transgenic AD mice (Mt) and 60 Ass1-40 protein-induced AD mice (Mi) were divided into 3 groups according to the dose of BdNlRB: BdNlRB-100, BdNlRB-200 and BdNlRB-400, with 100, 200 and 400 mg/kg*weight, respectively.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35188507' target='_blank' class='pmid-link'>35188507</a>:</span> <span class='sentence-part'>Because long-lived proteins do not have the corrective regeneration capabilities of most other proteins, points of isomerism and epimerization that accumulate within the proteins can severely hamper their functions and can lead to serious diseases like Alzheimer's disease, cancer and cataracts.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35877305' target='_blank' class='pmid-link'>35877305</a>:</span> <span class='sentence-part'>Tau and beta-amyloid (Abeta) proteins are major contributors to the etiology of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36983903' target='_blank' class='pmid-link'>36983903</a>:</span> <span class='sentence-part'>Since the protein is able to establish protein-protein interaction (PPI) in different contexts and aggregation-prone proteins and the PPI networks are relevant for AD pathogenesis, and due to the relevance of finding new AD markers in peripheral biofluids, we thought it was interesting to study the possible involvement of cystatin B in PPIs in saliva and to evaluate differences and similarities between AD and age-matched elderly healthy controls (HC).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36994753' target='_blank' class='pmid-link'>36994753</a>:</span> <span class='sentence-part'>This article describes the Abeta protein and its role in AD, summarizing the evidence showing that altered Abeta clearance from the brain may lead to the imbalance, toxic buildup and misfolding of the protein - triggering a cascade of cellular, molecular and systematic events that ultimately lead to AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37127251' target='_blank' class='pmid-link'>37127251</a>:</span> <span class='sentence-part'>Accumulating evidence indicates that impaired autophagic function for removal of damaged mitochondria and protein aggregates such as amyloid and tau protein aggregates may contribute to the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37454217' target='_blank' class='pmid-link'>37454217</a>:</span> <span class='sentence-part'>We aimed at validating the potential value of these proteins as new CSF biomarkers for AD and their possible involvement in AD pathogenesis, with specific interest on the preclinical phase of the disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37724426' target='_blank' class='pmid-link'>37724426</a>:</span> <span class='sentence-part'>Further technical advancement of glial proteomics will enable us to identify proteins within individual cells and specific cell types, thus significantly enhancing our comprehension of AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/38151346' target='_blank' class='pmid-link'>38151346</a>:</span> <span class='sentence-part'>In this article, we conduct a comprehensive review on the primary functions of multiple Rab proteins and their involvement in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/38473975' target='_blank' class='pmid-link'>38473975</a>:</span> <span class='sentence-part'>New data suggest that the aggregation of misfolded native proteins initiates and drives the pathogenic cascade that leads to Alzheimer's disease (AD) and other age-related neurodegenerative disorders. An extensive body of genetic evidence suggests soluble aggregates of beta-amyloid (Abeta) as the primary neurotoxin in the pathogenesis of AD. Understanding the distinct roles of soluble and insoluble amyloid aggregates on AD pathogenesis has been the key missing piece of the Alzheimer's puzzle.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/7542371' target='_blank' class='pmid-link'>7542371</a>:</span> <span class='sentence-part'>The results are further discussed in view of the known or anticipated physiological functions of the proteins examined and of their possible role in the etiology of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/8856006' target='_blank' class='pmid-link'>8856006</a>:</span> <span class='sentence-part'>Two of these loci, encoding the beta-amyloid precursor protein and apolipoprotein E, have gene products that are well characterized and of evident significance in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/8910899' target='_blank' class='pmid-link'>8910899</a>:</span> <span class='sentence-part'>We suggest that this long transcript may alter the normal pathway for processing of amyloid precursor protein, the protein which appears to be central in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/9697696' target='_blank' class='pmid-link'>9697696</a>:</span> <span class='sentence-part'>A2M, LRP1 (encoding the alpha-2M receptor) and the genes for two other LRP ligands, APOE and APP (encoding the amyloid beta-protein precursor), have now all been genetically linked to AD, suggesting that these proteins may participate in a common neuropathogenic pathway leading to AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/9804283' target='_blank' class='pmid-link'>9804283</a>:</span> <span class='sentence-part'>Identification of these proteins and their binding affinities for Abeta are needed to assess their potential role in the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/9838173' target='_blank' class='pmid-link'>9838173</a>:</span> <span class='sentence-part'>An indirect role for these proteins has been previously suggested in the etiology of AD.</span></div></div>
<div class='streamlined-assertion'><div class='streamlined-header sticky-relation-header'><span class='label-text'>Subject:</span> <strong>Reactive_Oxygen_Species</strong> <span class='label-text'>Subject CUI:</span> <strong>C0162772</strong> â†’ <span class='label-text predicate-text'>CAUSES</span> â†’ <span class='label-text'>Object:</span> <strong>Alzheimers</strong> <span class='label-text'>Object CUI:</span> <strong>C0002395</strong></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/10699754' target='_blank' class='pmid-link'>10699754</a>:</span> <span class='sentence-part'>Increasing evidence supports the role of reactive oxygen species (ROS) in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/10875435' target='_blank' class='pmid-link'>10875435</a>:</span> <span class='sentence-part'>The preliminary segment is an introduction to reactive oxygen species and their potential involvement in the pathogenesis of AD and the generation of an inflammatory response.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/11992623' target='_blank' class='pmid-link'>11992623</a>:</span> <span class='sentence-part'>The discovery of the isoprostanes, recent studies performed in living patients, and the development of transgenic animal models of AD-amyloidosis are three important factors that are helping us to better understand and define the role that oxygen radicals might play in AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17365122' target='_blank' class='pmid-link'>17365122</a>:</span> <span class='sentence-part'>One major pathogenesis in degenerative disorders of the central nervous system (CNS), including Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, and ischemia, is the oxidative stress induced by reactive oxygen species (ROS).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/19035781' target='_blank' class='pmid-link'>19035781</a>:</span> <span class='sentence-part'>As a result, the AbetaCu(I) complex may be a critical reactant involved in ROS associated with AD etiology.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23041154' target='_blank' class='pmid-link'>23041154</a>:</span> <span class='sentence-part'>It has been suggested that excess accumulation of reactive oxygen species, termed oxidative stress, may lead to neuronal death resulting in neurodegenerative disorders such as Parkinson's and Alzheimer's diseases.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23417568' target='_blank' class='pmid-link'>23417568</a>:</span> <span class='sentence-part'>Identifying these differential behaviors and mechanisms of hydrogen peroxide and superoxide anion functions illuminates the possible therapeutic targets in the prevention or treatment of ROS-induced neurodegenerative diseases such as Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24189435' target='_blank' class='pmid-link'>24189435</a>:</span> <span class='sentence-part'>Since mitochondria are also vulnerable to oxidative stress, it is likely that a vicious downward spiral involving the interactions between mitochondrial dysfunction and oxidative stress contributes to the initiation and/or amplification of reactive oxygen species that is critical to the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24276282' target='_blank' class='pmid-link'>24276282</a>:</span> <span class='sentence-part'>Aberrant regulation of transition metals and the resultant disregulation of neuronal reactive oxygen species (ROS) are considered significant in the etiology of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24351276' target='_blank' class='pmid-link'>24351276</a>:</span> <span class='sentence-part'>These results indicate that dityrosine cross-links may play an important role in the pathogenesis of Alzheimer's disease and can be generated by reactive oxygen species catalyzed by Cu2+ ions.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25620241' target='_blank' class='pmid-link'>25620241</a>:</span> <span class='sentence-part'>Oxidative stress and inflammatory response are important elements of Alzheimer's disease (AD) pathogenesis, but the role of redox signaling cascade and its cross-talk with inflammatory mediators have not been elucidated in details in this disorder. The biology of NF-kappaB and its activation by reactive oxygen species (ROS) and proinflammatory cytokines in the pathogenesis of AD have been specially highlighted citing evidence both from post-mortem studies in AD brain and experimental research in animal or cell-based models of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27476701' target='_blank' class='pmid-link'>27476701</a>:</span> <span class='sentence-part'>We have previously shown that a specific apoE4 fragment, apoE4-165, promotes amyloid-peptide beta 42 (Abeta42) accumulation in human neuroblastoma SK-N-SH cells and increased intracellular reactive oxygen species formation, two events considered to occur early in AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28059794' target='_blank' class='pmid-link'>28059794</a>:</span> <span class='sentence-part'>While mounting evidence implicates ROS in the AD etiology, clinical trials with antioxidant therapies have not produced consistent results.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28618998' target='_blank' class='pmid-link'>28618998</a>:</span> <span class='sentence-part'>This paper reviews the role of mitochondrial produced ROS and pyrimidines in the aetiology of AD and their proposed role in oxidative degeneration of macromolecules, synthesis of essential phospholipids and maintenance of mitochondrial viability in the AD brain.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30688256' target='_blank' class='pmid-link'>30688256</a>:</span> <span class='sentence-part'>Proper regulation of mitophagy is crucial for maintaining homeostasis; conversely, inadequate removal of mitochondria through mitophagy leads to the generation of oxidative species, including reactive oxygen species and reactive nitrogen species, resulting in various neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease, Huntington's disease, and amyotrophic lateral sclerosis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31001602' target='_blank' class='pmid-link'>31001602</a>:</span> <span class='sentence-part'>Understanding the factors that give rise to tau aggregation and reactive oxygen species (ROS) is the key aspect in Alzheimer's disease pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31617375' target='_blank' class='pmid-link'>31617375</a>:</span> <span class='sentence-part'>Aims: Reactive oxygen species (ROS) generated during Alzheimer's disease (AD) pathogenesis through multiple sources are implicated in synaptic pathology observed in the disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33306995' target='_blank' class='pmid-link'>33306995</a>:</span> <span class='sentence-part'>The vulnerability of the brain to reactive oxygen species (ROS) is now emerging as a key detrimental factor driving AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35463198' target='_blank' class='pmid-link'>35463198</a>:</span> <span class='sentence-part'>CNDs were also found to inhibit the generation of multiple reactive oxygen species, which is an important contributor to AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37657763' target='_blank' class='pmid-link'>37657763</a>:</span> <span class='sentence-part'>Reactive Oxygen Species (ROS) and mitochondrial dysfunction are implicated in the pathogenesis of Alzheimer's disease (AD), a common neurodegenerative disorder characterized by abnormal metabolism of the amyloid precursor protein (APP) in brain tissue.</span></div></div>
<div class='streamlined-assertion'><div class='streamlined-header sticky-relation-header'><span class='label-text'>Subject:</span> <strong>SUCLA2_gene_SUCLA2</strong> <span class='label-text'>Subject CUI:</span> <strong>C1420510|8803</strong> â†’ <span class='label-text predicate-text'>CAUSES</span> â†’ <span class='label-text'>Object:</span> <strong>Alzheimers</strong> <span class='label-text'>Object CUI:</span> <strong>C0002395</strong></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31902262' target='_blank' class='pmid-link'>31902262</a>:</span> <span class='sentence-part'>Here, the effects of CGA on beta-amyloid protein (Abeta)-induced cell models were investigated, aiming to provide a direction for Abeta-induced AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31922154' target='_blank' class='pmid-link'>31922154</a>:</span> <span class='sentence-part'>This new analytical strategy allows the direct detection and identification of all possible Asp, isoAsp, and Ser stereoisomers in Abeta, and may contribute to a better understanding of the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31969500' target='_blank' class='pmid-link'>31969500</a>:</span> <span class='sentence-part'>Methods: After estradiol (E2) treatment in Abeta-induced AD cell model, reactive oxygen species (ROS), TXNIP, and apoptosis levels were detected.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32023927' target='_blank' class='pmid-link'>32023927</a>:</span> <span class='sentence-part'>Genetic studies, biochemical data, and animal models have suggested that Abeta is responsible for the pathogenesis of AD (i.e., the amyloid hypothesis).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32212051' target='_blank' class='pmid-link'>32212051</a>:</span> <span class='sentence-part'>Taken together, the results of this meta-analysis clarified circulating autoantibodies to Abeta levels in AD patients and suggested that endogenous IgG and IgM-class antibodies to Abeta may play a role in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32341098' target='_blank' class='pmid-link'>32341098</a>:</span> <span class='sentence-part'>Beta-amyloid (Abeta) is thought to play a critical role in Alzheimer's disease (AD), and application of soluble oligomeric forms of Abeta produce AD-like impairments in cognition and synaptic plasticity in experimental systems.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32355946' target='_blank' class='pmid-link'>32355946</a>:</span> <span class='sentence-part'>In this review, emerging evidence highlights the importance of the Abeta cascade hypothesis and indicates a significant role of Abeta and its aggregates as biomarkers in the pathogenesis of AD; we present an up-to-date summary on Abeta-based biosensor systems.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32375443' target='_blank' class='pmid-link'>32375443</a>:</span> <span class='sentence-part'>Conclusion:     The inhibitor of mTOR rapamycin can improve the cognitive dysfunction of mice with AD induced by Abeta(1-42) and reduce deposition of Abeta(1-42) in the hippocampus, and the possible mechanism is rapamycin depressing the phosphorylation of mTOR as the same as Up-regulation the expression level of Homer3.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32377164' target='_blank' class='pmid-link'>32377164</a>:</span> <span class='sentence-part'>A   beta     plays an important role in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32430275' target='_blank' class='pmid-link'>32430275</a>:</span> <span class='sentence-part'>The deposition of Abeta in the brain due to impaired Abeta clearance is considered as an important cause of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32479003' target='_blank' class='pmid-link'>32479003</a>:</span> <span class='sentence-part'>Effect of the King Oyster Culinary-Medicinal Mushroom Pleurotus eryngii (Agaricomycetes) Basidiocarps Powder to Ameliorate Memory and Learning Deficit in Ability in Abeta-Induced Alzheimer's Disease C57BL/6J Mice Model.One of the major causes of Alzheimer's disease (AD) is oxidative stress, which accelerates beta-amyloid peptide (AP) plaque and neurofibrillary tangle accumulation in the brain. Effect of the King Oyster Culinary-Medicinal Mushroom Pleurotus eryngii (Agaricomycetes) Basidiocarps Powder to Ameliorate Memory and Learning Deficit in Ability in Abeta-Induced Alzheimer's Disease C57BL/6J Mice Model. The aim of this study was to investigate the proximate and functional composition of P. eryngii, and evaluate the cognitive effects of low (LPE), medium (MPE), and high (HPE) P. eryngii dosages in an Abeta-induced Alzheimer's disease C57BL/6J mouse model.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32496898' target='_blank' class='pmid-link'>32496898</a>:</span> <span class='sentence-part'>Abeta (1-42) was injected intracerebroventricularly to healthy male mouse to induce AD-like behavioral manifestations on Day-1 (D-1) of the experimental protocol.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32531337' target='_blank' class='pmid-link'>32531337</a>:</span> <span class='sentence-part'>Ion channel formation by N-terminally truncated Abeta (4-42): relevance for the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32556928' target='_blank' class='pmid-link'>32556928</a>:</span> <span class='sentence-part'>As AD develops and progresses, mitophagy diminishes insoluble Abeta, and mitochondrial dysfunction seems to be a determining factor in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32587293' target='_blank' class='pmid-link'>32587293</a>:</span> <span class='sentence-part'>Such findings strongly implicate Abeta in the altered iron handling and increased oxidative stress observed in AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32592731' target='_blank' class='pmid-link'>32592731</a>:</span> <span class='sentence-part'>Activation of cannabinoid receptor 2 protects rat hippocampal neurons against Abeta-induced neuronal toxicity.Alzheimer's disease (AD) is a dementing, neurodegenerative disorder characterized by increased accumulation of beta-amyloid peptides (Abeta), degeneration of hippocampal neurons and the gradual development of learning and memory deficits.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32599696' target='_blank' class='pmid-link'>32599696</a>:</span> <span class='sentence-part'>We also summarize the characteristics and pathogenicity such as the size, morphology and cytotoxicity of dimers, trimers, Abeta*56 and spherical oligomers, and suggest that Abetaos may play a different role at different phases of AD pathogenesis, resulting in differential consequences on neuronal synaptotoxicity and survival.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32790274' target='_blank' class='pmid-link'>32790274</a>:</span> <span class='sentence-part'>Synthetic and biophysical studies on the toxic conformer in amyloid beta with the E22Delta mutation in Alzheimer pathology.The toxic conformer of the 40- or 42-mer-Abeta (Abeta40, Abeta42) with a turn at positions 22 and 23 plays a role in oligomer formation, leading to neurotoxicity as part of the pathogenesis of Alzheimer disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32827351' target='_blank' class='pmid-link'>32827351</a>:</span> <span class='sentence-part'>DISCUSSION: Refining the molecular mechanisms connecting tau, Abeta, and apoE with cerebrovascular pathologies is critical for greater understanding of AD pathogenesis and establishing effective therapeutic interventions for the disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32950104' target='_blank' class='pmid-link'>32950104</a>:</span> <span class='sentence-part'>Melatonin Induction of APP Intracellular Domain 50 SUMOylation Alleviates AD through Enhanced Transcriptional Activation and Abeta Degradation.The amyloid precursor protein (APP) intracellular domain (AICD) is implicated in the pathogenesis of Alzheimer's disease (AD), but post-translational modification of AICD has rarely been studied and its role in AD is unknown.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33665647' target='_blank' class='pmid-link'>33665647</a>:</span> <span class='sentence-part'>Here, we review emerging evidence for a critical nexus among Abeta, tau, and the lysosomal protease cathepsin D (CatD) that we hypothesize may play a pivotal role in the etiology of AD. Future research into these novel mechanistic links among Abeta, tau and CatD promises to expand our understanding of the etiology of AD and could potentially lead to novel therapeutic approaches for combatting this devastating disease of brain and mind. Despite a wealth of experimental and genetic evidence implicating both Abeta and tau in the pathogenesis of AD, the precise molecular links between these two pathological hallmarks have remained surprisingly elusive.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33912008' target='_blank' class='pmid-link'>33912008</a>:</span> <span class='sentence-part'>Evidence implicates elevated soluble oligomeric Abeta as one of the primary triggers during the prodromic phase leading to AD, effected largely via hyperphosphorylation of the microtubule-associated protein tau.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33953832' target='_blank' class='pmid-link'>33953832</a>:</span> <span class='sentence-part'>Oral Administration of Gintonin Protects the Brains of Mice against A   beta    -Induced Alzheimer Disease Pathology: Antioxidant and Anti-Inflammatory Effects.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34214643' target='_blank' class='pmid-link'>34214643</a>:</span> <span class='sentence-part'>Moreover, the concurrence of neuroinflammation and Abeta dyshomeostasis, which by reciprocal interactions drive the vicious cycle of neurodegeneration, contradicts Abeta as the primary trigger of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34272583' target='_blank' class='pmid-link'>34272583</a>:</span> <span class='sentence-part'>Our data indicate an essential role for intracellular prion-like Abeta and its synaptic spread in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34356865' target='_blank' class='pmid-link'>34356865</a>:</span> <span class='sentence-part'>AD has two significant pathological hallmarks: extracellular senile plaques composed of amyloid beta-peptide (Abeta) and intracellular neurofibrillary tangles composed of hyperphosphorylated tau protein, and the aggregation of Abeta, which starts in earlier stages, is usually claimed to be the primary cause of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34371202' target='_blank' class='pmid-link'>34371202</a>:</span> <span class='sentence-part'>Can platelet activation result in increased plasma Abeta levels and contribute to the pathogenesis of Alzheimer's disease?</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34435574' target='_blank' class='pmid-link'>34435574</a>:</span> <span class='sentence-part'>Moreover, the mechanism of action of L7 on improving Abeta-induced AD was preliminarily investigated, and the results uncovered that the neuroprotective effects of L7 was might exerte via intervening Abeta-induced pyroptosis through NLRP3-caspase-1-GSDMD axis and ameliorating neuronal apoptosis by mitochondrial apoptosis pathway.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34608607' target='_blank' class='pmid-link'>34608607</a>:</span> <span class='sentence-part'>However, intermediate soluble oligomers of Abeta are now recognized as initiators of the pathogenic cascade leading to AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34655726' target='_blank' class='pmid-link'>34655726</a>:</span> <span class='sentence-part'>Genetic studies, biochemical data, and animal models have suggested that Abeta is a critical species in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34672433' target='_blank' class='pmid-link'>34672433</a>:</span> <span class='sentence-part'>CONCLUSIONS: Our findings confirmed that 6D11 has a therapeutic effect in APP/PS1 transgenic AD mouse model and Abeta-induced AD cell model, and the effect exerted via increase of neurogenesis and cell differentiation by transduction of Abeta peptide signal.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34810230' target='_blank' class='pmid-link'>34810230</a>:</span> <span class='sentence-part'>Therefore, the predominant processing of C99 and enrichment of Abeta in late endosomes and lysosomes may be critical events in the molecular cascade leading to AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34946712' target='_blank' class='pmid-link'>34946712</a>:</span> <span class='sentence-part'>The complete characterization of the copper complexes made with phenHH, phenHGH and H'phenH' is reported, along with the ability of ligands to remove Cu from Abeta, and to prevent the formation of reactive oxygen species catalyzed by Cu and Cu-Abeta, including in presence of zinc, the second metal ions important in the etiology of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35098860' target='_blank' class='pmid-link'>35098860</a>:</span> <span class='sentence-part'>The mouse model of AD and the cell model induced by Abeta were established.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35181336' target='_blank' class='pmid-link'>35181336</a>:</span> <span class='sentence-part'>CBD was found to alleviate the progression of Abeta-induced AD but not tau protein-induced AD or alpha-syn-induced Parkinson's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35292372' target='_blank' class='pmid-link'>35292372</a>:</span> <span class='sentence-part'>Abeta     (1-42)       was injected into the hippocampus of the animals to induce AD-like pathology.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35452628' target='_blank' class='pmid-link'>35452628</a>:</span> <span class='sentence-part'>We found that: 1) Recognition memory impairment in Abeta-induced Alzheimer's disease model was associated with the reduction in TREM2 which induced microglial activation and neuroinflammation; 2) Exercise activated the TREM2 pathway, which was necessary for inhibiting microglial activation and neuroinflammation, leading to improved recognition memory in the Alzheimer's disease model.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35453040' target='_blank' class='pmid-link'>35453040</a>:</span> <span class='sentence-part'>Amyloid beta peptide (Abeta) is produced through the proteolytic processing of amyloid precursor protein (APP), and Abeta accumulation in the brain is proposed to be an early toxic event in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35786817' target='_blank' class='pmid-link'>35786817</a>:</span> <span class='sentence-part'>CONCLUSION: The tau deletion mutation significantly improved the synaptic damage caused by Abeta, and tau protein played an indispensable role in the synaptic dysfunction caused by Abeta, suggesting that Abeta and tau have close interactions in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35865745' target='_blank' class='pmid-link'>35865745</a>:</span> <span class='sentence-part'>Opinions are divided about whether there is enough evidence to definitely consider Abeta as a causative substance of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35956985' target='_blank' class='pmid-link'>35956985</a>:</span> <span class='sentence-part'>In this study, the neuroprotective effects of 4-(4-(heptyloxy)phenyl)-2,4-dihydro-3   H    -1,2,4-triazol-3-one (W112) against beta-amyloid (Abeta)-induced AD pathology and its possible mechanism were explored both in vitro and in vivo. Anti-Inflammatory Activity of 4-(4-(Heptyloxy)phenyl)-2,4-dihydro-3   H    -1,2,4-triazol-3-one via Repression of MAPK/NF-kappaB Signaling Pathways in beta-Amyloid-Induced Alzheimer's Disease Models. The results showed that W112 exhibits a neuroprotective role against Abeta-induced cytotoxicity in PC12 cells and improves the learning and memory abilities of Abeta-induced AD-like rats.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36074939' target='_blank' class='pmid-link'>36074939</a>:</span> <span class='sentence-part'>According to the amyloid cascade hypothesis, Abeta is the critical early initiator of AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36120034' target='_blank' class='pmid-link'>36120034</a>:</span> <span class='sentence-part'>More importantly,    1c     could ameliorate the impaired learning and memory in Abeta-induced AD mice.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36200197' target='_blank' class='pmid-link'>36200197</a>:</span> <span class='sentence-part'>Flavonoids from Stems and Leaves of Scutellaria baicalensis Georgi Improve Composited Abeta-induced Alzheimer's Disease Model Rats' Memory and Neuroplasticity Disorders.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36233130' target='_blank' class='pmid-link'>36233130</a>:</span> <span class='sentence-part'>Abeta and its isoforms are important factors in the Alzheimer's disease (AD) pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36321205' target='_blank' class='pmid-link'>36321205</a>:</span> <span class='sentence-part'>Abeta induced AD by Abeta plaques formation and increasing step-through latency time. Hippocampal injection of Abeta was used to induce AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36399096' target='_blank' class='pmid-link'>36399096</a>:</span> <span class='sentence-part'>Modulation of the effect of the epsilon4 alleles by    TOMM40     and    APOC1     variants indicates the potential genetic mechanism of differential roles of Abeta and tau in AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36399277' target='_blank' class='pmid-link'>36399277</a>:</span> <span class='sentence-part'>Using cellular bioassays for prions in postmortem samples, we found that both Abeta and tau proteins misfold into prions leading to AD, which is either a sporadic or familial dementing disorder. Abeta and Tau Prions Causing Alzheimer's Disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36549596' target='_blank' class='pmid-link'>36549596</a>:</span> <span class='sentence-part'>However, the effect of naringin in AD caused by Abeta has not been clearly studied, and there are few studies on the electrophysiological aspect. Naringin enhances long-term potentiation and recovers learning and memory deficits of amyloid-beta induced Alzheimer's disease-like behavioral rat model.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36809522' target='_blank' class='pmid-link'>36809522</a>:</span> <span class='sentence-part'>The present research aimed to investigate the possible protective effect of RJ on learning and memory in a rat model of Abeta-induced AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36856542' target='_blank' class='pmid-link'>36856542</a>:</span> <span class='sentence-part'>The exact pathogenic mechanisms linking Abeta to AD pathogenesis remain however not fully understood.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36899831' target='_blank' class='pmid-link'>36899831</a>:</span> <span class='sentence-part'>Of note, miRNA-146a-5p was exclusively dysregulated in the Abeta-induced AD model.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37179042' target='_blank' class='pmid-link'>37179042</a>:</span> <span class='sentence-part'>Minocycline effects on memory and learning impairment in the beta-amyloid-induced Alzheimer's disease model in male rats using behavioral, biochemical, and histological methods. This study investigated the effect of minocycline on the changes in learning and memory functions, activities of blood serum antioxidant enzymes, neuronal loss, and the number of Abeta plaques after AD induced by Abeta in male rats.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37264159' target='_blank' class='pmid-link'>37264159</a>:</span> <span class='sentence-part'>Extensive studies indicate that beta-amyloid (Abeta) aggregation is pivotal for Alzheimer's disease (AD) progression; however, cumulative evidence suggests that Abeta itself is not sufficient to trigger AD-associated degeneration, and whether other additional pathological factors drive AD pathogenesis remains unclear.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37342418' target='_blank' class='pmid-link'>37342418</a>:</span> <span class='sentence-part'>However, whether Abeta itself is a key toxic agent in AD pathogenesis and the precise mechanism of Abeta-elicited neurotoxicity are still debated.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37372012' target='_blank' class='pmid-link'>37372012</a>:</span> <span class='sentence-part'>Reactive oxygen species (ROS) and lipid peroxidation (LPO) assays were performed and showed that the levels of ROS and LPO were markedly reduced in the caffeic acid-treated mice, as compared to Abeta-induced AD mice brains.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37401257' target='_blank' class='pmid-link'>37401257</a>:</span> <span class='sentence-part'>However, the histidine behaviors of Abeta(1-42) are unconfirmed, which is the key point to understanding the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37849639' target='_blank' class='pmid-link'>37849639</a>:</span> <span class='sentence-part'>Within the framework of the ACH2.0, AD is triggered by amyloid-beta protein precursor (AbetaPP)-derived    intraneuronal     Abeta (   i    Abeta) and is driven by    i    Abeta produced in the AbetaPP-independent pathway and retained intraneuronally.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37858630' target='_blank' class='pmid-link'>37858630</a>:</span> <span class='sentence-part'>Examples include the self-assembly of phenylalanine, which causes phenylketonuria; Abeta, which causes Alzheimer's disease; the tau protein, which causes both Alzheimer's and Parkinson's diseases; and alpha-synuclein, which causes Parkinson's illness.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37886704' target='_blank' class='pmid-link'>37886704</a>:</span> <span class='sentence-part'>Retracted: Oral Administration of Gintonin Protects the Brains of Mice against A   beta    -Induced Alzheimer Disease Pathology: Antioxidant and Anti-Inflammatory Effects.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/38008888' target='_blank' class='pmid-link'>38008888</a>:</span> <span class='sentence-part'>We reported that UA treatment significantly alleviated memory decline in Abeta-induced AD model mice and APP23/PS45 double transgenic AD model mice.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/38178136' target='_blank' class='pmid-link'>38178136</a>:</span> <span class='sentence-part'>And the relation between the peripheral blood Abeta and tau tangles of brain, another crucial pathologic factor contributing to the pathogenesis of AD, is also ambiguous. More recently, the anti-Abeta monoclonal antibodies are approved for treatment of AD patients through declining the peripheral blood Abeta mechanism of action to enhance plasma and central nervous system (CNS) Abeta clearance, leading to a decrease Abeta burden in brain and improving cognitive function, which clearly indicates that the levels of the peripheral blood Abeta impacted on the Abeta burden in brain and involved in the pathogenesis of AD. In the present review, we summarize recent studies on the roles of peripheral blood Abeta and the peripheral innate immune cells in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/38434588' target='_blank' class='pmid-link'>38434588</a>:</span> <span class='sentence-part'>This observation, along with the failure of previous clinical trials targeting Abeta or Tau and the modest success of recent trials using Abeta monoclonal antibodies, has led to a reappraisal of the view that Abeta accumulation is the sole factor in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/38559176' target='_blank' class='pmid-link'>38559176</a>:</span> <span class='sentence-part'>It is well known that Abeta and tau proteins are deposited stereotypically in brain regions to cause Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/38612434' target='_blank' class='pmid-link'>38612434</a>:</span> <span class='sentence-part'>In conclusion, we have identified DDX24 as a protein with a potential role in Abeta-induced AD pathology.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/38612514' target='_blank' class='pmid-link'>38612514</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) is the fifth leading cause of death among adults aged 65 and older, yet the onset and progression of the disease is poorly understood. Interestingly, as AD progresses, less Abeta42 is detectable in the plasma, a phenomenon thought to result from Abeta becoming more aggregated in the brain and less Abeta42 and Abeta40 being transported from the brain to the plasma via the CSF.</span></div></div>
<div class='streamlined-assertion'><div class='streamlined-header sticky-relation-header'><span class='label-text'>Subject:</span> <strong>Single_Nucleotide_Polymorphism</strong> <span class='label-text'>Subject CUI:</span> <strong>C0752046</strong> â†’ <span class='label-text predicate-text'>CAUSES</span> â†’ <span class='label-text'>Object:</span> <strong>Alzheimers</strong> <span class='label-text'>Object CUI:</span> <strong>C0002395</strong></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/19668339' target='_blank' class='pmid-link'>19668339</a>:</span> <span class='sentence-part'>The quantitative trait analysis identified 21 genes or chromosomal areas with at least one SNP with a p-value &lt; or =10(-6), which can be considered potential \new\ candidate loci to explore in the etiology of sporadic AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20455082' target='_blank' class='pmid-link'>20455082</a>:</span> <span class='sentence-part'>To determine whether there is any single-nucleotide polymorphisms in the BACE1 gene promoter region affecting BACE1 expression in AD pathogenesis, in this study, we screened 2.6 kb of the human BACE1 gene promoter region from late-onset AD patients and found that there was no significant association between single-nucleotide polymorphisms and AD cases.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22167654' target='_blank' class='pmid-link'>22167654</a>:</span> <span class='sentence-part'>Genome-wide association studies (GWAS) identified multiple single-nucleotide polymorphisms (SNPs) that are associated with the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26095531' target='_blank' class='pmid-link'>26095531</a>:</span> <span class='sentence-part'>A single nucleotide polymorphism in primary-microRNA-146a reduces the expression of mature microRNA-146a in patients with Alzheimer's disease and is associated with the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29993426' target='_blank' class='pmid-link'>29993426</a>:</span> <span class='sentence-part'>Besides, the associated SNPs and brain regions found in this study have also been shown AD-related in previously studies, thus verifying the effectiveness and potential of the proposed method in AD pathogenesis study.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30361487' target='_blank' class='pmid-link'>30361487</a>:</span> <span class='sentence-part'>Functional analyses of these SNPs indicate their potential relevance with AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33331110' target='_blank' class='pmid-link'>33331110</a>:</span> <span class='sentence-part'>AIM: Heredity plays an important role in the pathogenesis of Alzheimer's disease (AD) especially for single-nucleotide polymorphism (SNPs) of susceptible genes, which is one of the significant factors in the pathogenesis of AD. In addition, apolipoprotein E epsilon4 status promotes them to result in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36140686' target='_blank' class='pmid-link'>36140686</a>:</span> <span class='sentence-part'>Brain imaging genetics examines associations between imaging quantitative traits (QTs) and genetic factors such as single nucleotide polymorphisms (SNPs) to provide important insights into the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37065064' target='_blank' class='pmid-link'>37065064</a>:</span> <span class='sentence-part'>A follow-up study to elucidate the impact of our identified m6a-SNPs in the experimental study would validate our findings for AD, which would contribute to the etiology of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37409680' target='_blank' class='pmid-link'>37409680</a>:</span> <span class='sentence-part'>DISCUSSION: The model successfully estimated the contribution of AD-risk SNPs that account for AD progression at the individual level.</span></div></div>
<div class='streamlined-assertion'><div class='streamlined-header sticky-relation-header'><span class='label-text'>Subject:</span> <strong>Sinus_rhythm</strong> <span class='label-text'>Subject CUI:</span> <strong>C0232201</strong> â†’ <span class='label-text predicate-text'>CAUSES</span> â†’ <span class='label-text'>Object:</span> <strong>Atrial_Fibrillation</strong> <span class='label-text'>Object CUI:</span> <strong>C0004238</strong></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/10506851' target='_blank' class='pmid-link'>10506851</a>:</span> <span class='sentence-part'>The changes in the duration of atrial electrograms during different atrial activation sequences from a sinus rhythm were evaluated to test the hypothesis that the prolongation of atrial electrogram duration caused by the different atrial activation sequence is more prominent at the site of atrial fibrillation (Afib) genesis (initiation site) than other areas.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/11817061' target='_blank' class='pmid-link'>11817061</a>:</span> <span class='sentence-part'>In a previous study, we determined the dosage of intravenously administered diltiazem necessary to reduce ventricular response (VR), cardiac output (CO), and mean systemic arterial pressure (P(Ao)) to values similar to those observed during sinus rhythm (SR) before induction of AF.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/11978000' target='_blank' class='pmid-link'>11978000</a>:</span> <span class='sentence-part'>METHODS AND RESULTS: In 16 patients (10 men, mean age 43+/-13 years) with normal coronary vessels, baseline and hyperaemic blood pressure and Doppler phasic coronary flow velocity were measured, using a 0.014 inch intracoronary Doppler flow wire, during sinus rhythm, experimentally induced atrial fibrillation, and right atrial pacing at a similar heart rate to that during atrial fibrillation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/1258735' target='_blank' class='pmid-link'>1258735</a>:</span> <span class='sentence-part'>ECG, atrial electrogram, phonocardiogram, and direct arterial blood pressure were recorded during periods of sinus rhythm and during periods of induced atrial fibrillation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/1279580' target='_blank' class='pmid-link'>1279580</a>:</span> <span class='sentence-part'>We were able to terminate atrial flutter in 136 of 162 patients by transesophageal rapid atrial stimulation (conversion to sinus rhythm in 75 cases, induction of atrial fibrillation in 61 cases).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/12815307' target='_blank' class='pmid-link'>12815307</a>:</span> <span class='sentence-part'>The aim of the study was to assess during implantation the efficacy of a custom-built free-floating single-pass defibrillation lead and to record sinus rhythm (SR), induced AF, and atrial flutter (Afl). Fifteen seconds recordings were made during SR and after the induction of AF and Afl as well as during induced ventricular fibrillation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/15028052' target='_blank' class='pmid-link'>15028052</a>:</span> <span class='sentence-part'>We studied the impact of electrical remodeling by comparing these findings with the unremodeled atria of patients in sinus rhythm during pacing-induced sustained AF (n = 17).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/1926983' target='_blank' class='pmid-link'>1926983</a>:</span> <span class='sentence-part'>We were able to terminate atrial flutter in 136 of 162 patients by transesophageal rapid atrial stimulation (conversion to sinus rhythm in 75 cases, induction of atrial fibrillation in 61 cases).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/19483437' target='_blank' class='pmid-link'>19483437</a>:</span> <span class='sentence-part'>Spontaneous reversion to sinus rhythm within 36 hours is in favor of new onset lightning induced AF.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20167615' target='_blank' class='pmid-link'>20167615</a>:</span> <span class='sentence-part'>Contact bipolar electrograms were recorded before PVAI, during SR, and subsequently during induced AF.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21824645' target='_blank' class='pmid-link'>21824645</a>:</span> <span class='sentence-part'>METHODS: Blood samples were obtained from patients with paroxysmal AF (n=14) at sinus rhythm and at 15 min after induction of AF during an electrophysiological study, and from control subjects (n=13) and patients with chronic AF (n=14) in the outpatient clinic.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22439013' target='_blank' class='pmid-link'>22439013</a>:</span> <span class='sentence-part'>In this subgroup, left atrial dilatation, increase of pulmonary capillary wedge pressure, PAP and RAP were more pronounced in AF than in SR, suggesting that more marked backward failure led to AF in this setting.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22586260' target='_blank' class='pmid-link'>22586260</a>:</span> <span class='sentence-part'>METHODS AND RESULTS: We recorded bilateral cervical vagal nerve activity (VNA) and IVC-IAGPNA during baseline sinus rhythm and during pacing-induced sustained AF in 6 ambulatory dogs.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23333141' target='_blank' class='pmid-link'>23333141</a>:</span> <span class='sentence-part'>METHODS: We studied 55 patients with AF who underwent catheter ablation while in sinus rhythm; 20 patients were induced into AF, 20 patients were atrial paced at 150 beats/min, and 15 were control patients.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27090869' target='_blank' class='pmid-link'>27090869</a>:</span> <span class='sentence-part'>Sustained pressure overload of the LA in SR could be a cause of the recurrent AF.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/2916892' target='_blank' class='pmid-link'>2916892</a>:</span> <span class='sentence-part'>We conclude that there are differences regarding gender, age, and possible conversion of AF to SR according to the different causes of AF.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/2919537' target='_blank' class='pmid-link'>2919537</a>:</span> <span class='sentence-part'>On a series of days, recordings were made from the atrial leads during sinus rhythm and induced sustained atrial fibrillation, both before and after administration of cardioactive drugs.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29221440' target='_blank' class='pmid-link'>29221440</a>:</span> <span class='sentence-part'>Flecainide caused a decrease in AFR in all animals and restored sinus rhythm in the animals with induced AF.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29519812' target='_blank' class='pmid-link'>29519812</a>:</span> <span class='sentence-part'>Knowledge of atrial excitation patterns during SR and its electropathological variations, as demonstrated in this study, is essential to further unravel the pathogenesis of AF.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29951149' target='_blank' class='pmid-link'>29951149</a>:</span> <span class='sentence-part'>An LVZ was found in the anteroseptal left atrium during sinus rhythm and was ablated during induced AF after a pulmonary vein antrum isolation, which terminated the AF and rendered it noninducible by rapid pacing and/or isoproterenol.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30573117' target='_blank' class='pmid-link'>30573117</a>:</span> <span class='sentence-part'>METHODS: High-density mapping was performed first in SR and afterward in induced AF/AFL.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/3339174' target='_blank' class='pmid-link'>3339174</a>:</span> <span class='sentence-part'>However, interruption of atrial flutter by rapid atrial pacing may not always produce sinus rhythm, but rather may result in atrial fibrillation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/7659571' target='_blank' class='pmid-link'>7659571</a>:</span> <span class='sentence-part'>A hemodynamic study was performed both during sinus rhythm and after the induction of AF.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/8227794' target='_blank' class='pmid-link'>8227794</a>:</span> <span class='sentence-part'>In the first study, hemodynamic variables were evaluated both during sinus rhythm and after the induction of atrial fibrillation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/8682029' target='_blank' class='pmid-link'>8682029</a>:</span> <span class='sentence-part'>We studied the effects of intravenous flecainide (2 mg.kg-1) on atrial and ventricular refractoriness and conduction during sinus rhythm, induced atrial fibrillation and atrial pacing at rates of 100, 120 and 150 ppm, in 14 patients with normal left ventricle.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/8985802' target='_blank' class='pmid-link'>8985802</a>:</span> <span class='sentence-part'>Ablation only in the right atrium is a safe technique providing limited success, whereas linear lesions in the left atrium significantly increase the incidence of stable restoration of sinus rhythm, the inability to induce sustained AF, and the final success rate.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/9167219' target='_blank' class='pmid-link'>9167219</a>:</span> <span class='sentence-part'>The best results were registered in patients over sixty, with stable sinus rhythm in 75% of cases, probably in relation to the ischemic etiology of AF and the anti-ischemic associated effect of amiodarone.</span></div></div>
<div class='streamlined-assertion'><div class='streamlined-header sticky-relation-header'><span class='label-text'>Subject:</span> <strong>Sleep_Apnea_Obstructive</strong> <span class='label-text'>Subject CUI:</span> <strong>C0520679</strong> â†’ <span class='label-text predicate-text'>CAUSES</span> â†’ <span class='label-text'>Object:</span> <strong>Atrial_Fibrillation</strong> <span class='label-text'>Object CUI:</span> <strong>C0004238</strong></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/16472270' target='_blank' class='pmid-link'>16472270</a>:</span> <span class='sentence-part'>Obstructive sleep apnoea induced atrial fibrillation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25015734' target='_blank' class='pmid-link'>25015734</a>:</span> <span class='sentence-part'>Our findings suggested that reversing atrial remodeling might be a potential therapeutic strategy for OSA-induced AF.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25440097' target='_blank' class='pmid-link'>25440097</a>:</span> <span class='sentence-part'>CONCLUSIONS: Chronically repeated OSA episodes cause AF-promoting cardiac remodeling, with conduction abnormalities related to connexin dysregulation and fibrosis playing a prominent role.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25533582' target='_blank' class='pmid-link'>25533582</a>:</span> <span class='sentence-part'>CONCLUSION: LLVS is capable of suppressing ERP shortening and AF induced by OSA. LLVS may serve as a new therapeutic approach to treat OSA-induced AF.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27652812' target='_blank' class='pmid-link'>27652812</a>:</span> <span class='sentence-part'>RECENT FINDINGS: The cardiovascular consequences of OSA include hypertension, strokes, atrial fibrillation, and heart failure.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28652027' target='_blank' class='pmid-link'>28652027</a>:</span> <span class='sentence-part'>Despite that lack of strong, randomised controlled trials, there is a considerable body of data indicating that not only does untreated OSA provide the substrates and triggers for AF but that OSA, itself, is also a therapeutic target for the management of cardiovascular disease in general and of AF in particular.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28903938' target='_blank' class='pmid-link'>28903938</a>:</span> <span class='sentence-part'>BACKGROUND: The mechanisms of atrial fibrillation (AF) induced by obstructive sleep apnea (OSA) are not completely understood. This study investigated the roles of the intrinsic and extrinsic cardiac autonomic nervous system in OSA-induced AF and provided noninvasive autonomic nervous modulation for the suppression of OSA-induced AF by using low-level transcutaneous electrical stimulation (LL-TS) of the auricular branch of the vagus nerve at the tragus. CONCLUSIONS: These findings suggest that the intrinsic and extrinsic cardiac autonomic nervous system plays crucial roles in the acute stage of OSA-induced AF. Noninvasive LL-TS suppressed shortening of atrial refractoriness and autonomic remodeling, which prevented OSA-induced AF.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29049041' target='_blank' class='pmid-link'>29049041</a>:</span> <span class='sentence-part'>There is emerging evidence to suggest that the successful management of several cardiovascular risk factors [obesity, hypertension (HTN), diabetes mellitus, and obstructive sleep apnea (OSA)] can lead to fewer complications and atrial fibrillation prevention.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29097705' target='_blank' class='pmid-link'>29097705</a>:</span> <span class='sentence-part'>Our results suggest a new and feasible treatment strategy for AF induced by OSA.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30772533' target='_blank' class='pmid-link'>30772533</a>:</span> <span class='sentence-part'>Female sex, Hispanic ethnicity, obstructive sleep apnea, and a family history of AF were each associated with a greater number of AF triggers.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31106116' target='_blank' class='pmid-link'>31106116</a>:</span> <span class='sentence-part'>Understanding the biology and regulatory mechanisms of connexins in OSA at the transcriptional, translational, and post-translational levels will undoubtedly require major efforts to decipher the breadth and complexity of connexin functions in OSA-induced AF.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33411188' target='_blank' class='pmid-link'>33411188</a>:</span> <span class='sentence-part'>BACKGROUND: Obstructive sleep apnoea (OSA) is closely related to atrial fibrillation (AF), and OSA-induced atrial structural remodelling is the basis of AF maintenance.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33516410' target='_blank' class='pmid-link'>33516410</a>:</span> <span class='sentence-part'>Obstructive sleep apnea (OSA) creates a complex and dynamic substrate for atrial fibrillation (AF), which is characterized by structural remodeling as a result of long-term OSA as well as transient and acute apnea-associated transient atrial electrophysiological changes.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33574766' target='_blank' class='pmid-link'>33574766</a>:</span> <span class='sentence-part'>Objective    : This study investigates the underlying electrophysiological, neural, and cardiomyocyte injury mechanisms on acute OSA-induced AF, examining whether LLVS can attenuate or reverse this remodeling. Conclusion    : LLVS decreased the inducibility of AF partly by ameliorating sympathetic hyperactivity and atrial myocyte injury after acute OSA-induced AF.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33606818' target='_blank' class='pmid-link'>33606818</a>:</span> <span class='sentence-part'>Here, we investigated the potential neural mechanism of AF induced by OSA.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34583808' target='_blank' class='pmid-link'>34583808</a>:</span> <span class='sentence-part'>Obstructive sleep apnea is a common cause of AF, and treating it effectively reduces AF episodes.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34931608' target='_blank' class='pmid-link'>34931608</a>:</span> <span class='sentence-part'>CONCLUSIONS: Compared to paroxysmal AF patients with M-NSA, those with OSA were far more likely to have a symptomatic AF attack during sleeping hours, supporting a causal role for OSA in the pathogenesis of AF in this population.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35508332' target='_blank' class='pmid-link'>35508332</a>:</span> <span class='sentence-part'>The evidence for other comorbidities, such as hypertension and atrial fibrillation, support these being more a consequence of OSA with limited evidence to support a bidirectional relationship.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35538180' target='_blank' class='pmid-link'>35538180</a>:</span> <span class='sentence-part'>PURPOSE: Obstructive sleep apnea (OSA) is a common, potentially modifiable condition implicated in the pathogenesis of atrial fibrillation (AF).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35673889' target='_blank' class='pmid-link'>35673889</a>:</span> <span class='sentence-part'>The main interest of this clinical review is to discuss the cardiovascular consequences of OSA with a special focus on left ventricular (LV) function and structure, arterial stiffness and atrial fibrillation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36419803' target='_blank' class='pmid-link'>36419803</a>:</span> <span class='sentence-part'>Objectives: Obstructive sleep apnea (OSA) is a common cause of atrial fibrillation (AF).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36524043' target='_blank' class='pmid-link'>36524043</a>:</span> <span class='sentence-part'>Experimental and clinical studies have shown that OSA pathophysiology is multifactorial, comprising of hypoxemia, hypercapnia, autonomic dysfunction, negative intrathoracic pressure changes, and arousals of OSA, and lead to AF.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36811692' target='_blank' class='pmid-link'>36811692</a>:</span> <span class='sentence-part'>However, the effect of RDN on chronic OSA (COSA)-induced AF is still unclear. RDN markedly suppressed the LSG hyperactivity and atrial sympathetic innervation, decreased the serum concentrations of Ang II and IL-6, further inhibited fibroblast-to-myofibroblast transformation via the TGF-beta1/Smad2/3/alpha-SMA pathway, and reduced the expression of MMP-9, thus decreasing OSA-induced AF.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37371131' target='_blank' class='pmid-link'>37371131</a>:</span> <span class='sentence-part'>Emerging clinical data cite adverse effects of OSA on AF induction, maintenance, disease severity, and responsiveness to treatment.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37694608' target='_blank' class='pmid-link'>37694608</a>:</span> <span class='sentence-part'>PURPOSE OF REVIEW: Obstructive sleep apnea (OSA) is highly prevalent in patients with atrial fibrillation and plays a causal role for OSA in the pathogenesis of atrial fibrillation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/38025517' target='_blank' class='pmid-link'>38025517</a>:</span> <span class='sentence-part'>Aim: Prolonged P-wave duration (PWD), which indicates atrial conduction delay, is a potent precursor of atrial fibrillation (AF) that may be induced by obstructive sleep apnea (OSA).</span></div></div>
<div class='streamlined-assertion'><div class='streamlined-header sticky-relation-header'><span class='label-text'>Subject:</span> <strong>Study_models</strong> <span class='label-text'>Subject CUI:</span> <strong>C0026336</strong> â†’ <span class='label-text predicate-text'>CAUSES</span> â†’ <span class='label-text'>Object:</span> <strong>Alzheimers</strong> <span class='label-text'>Object CUI:</span> <strong>C0002395</strong></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/11141480' target='_blank' class='pmid-link'>11141480</a>:</span> <span class='sentence-part'>The similar characteristics of microglia in the APP23 mice and in AD render the mouse model suitable to study the role of inflammatory processes during AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/11193142' target='_blank' class='pmid-link'>11193142</a>:</span> <span class='sentence-part'>The APP23 line is a suitable model to analyze the contribution of APP, A beta, and amyloid to the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/14769913' target='_blank' class='pmid-link'>14769913</a>:</span> <span class='sentence-part'>These findings suggest a new model of AD pathogenesis in which a genomically orchestrated up-regulation of tumor suppressor-mediated differentiation and involution processes induces the spread of pathology along myelinated axons.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/1497790' target='_blank' class='pmid-link'>1497790</a>:</span> <span class='sentence-part'>Mendelian genetics is a possible model for Alzheimer's disease etiology.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/1741393' target='_blank' class='pmid-link'>1741393</a>:</span> <span class='sentence-part'>Ts 16 provides a model of spontaneous, genetically determined neurodegeneration that may be used to understand better the molecular pathogenesis of neuronal dysfunction in Alzheimer disease and Down syndrome.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/18068305' target='_blank' class='pmid-link'>18068305</a>:</span> <span class='sentence-part'>The present study was designed to determine the time-course of the shift from neuronal to glial induction in the expression of these proteins in Down's syndrome, sometimes referred to as a human model of Alzheimer-like beta-amyloid (Abeta) deposition.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/19096160' target='_blank' class='pmid-link'>19096160</a>:</span> <span class='sentence-part'>Here, the neurochemical, neuropathological, and behavioral alterations, characterized in SAMP8 mice are critically reviewed and discussed in relation to the potential use of this mouse model in the study of AD pathogenesis. However, published data show that senescence-accelerated mouse (SAMP8), as a model of aging, display many features that are known to occur early in the pathogenesis of AD such as increased oxidative stress, amyloid-beta alterations, and tau phosphorylation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/2039382' target='_blank' class='pmid-link'>2039382</a>:</span> <span class='sentence-part'>The proposed model postulates a role for environmental agents in the pathogenesis of Alzheimer's disease and accounts for families that show an aggregation of cases but no apparent pattern of inheritance.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20682182' target='_blank' class='pmid-link'>20682182</a>:</span> <span class='sentence-part'>We propose an integrative model on the pathogenesis of AD that includes several damage signals such as Abeta oligomers, oxygen free radicals, iron overload, homocysteine, cholesterol and LDL species.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21471644' target='_blank' class='pmid-link'>21471644</a>:</span> <span class='sentence-part'>The findings demonstrate that the effect of icv-STZ is regionally specific, lending further support for the method as a model of AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22112803' target='_blank' class='pmid-link'>22112803</a>:</span> <span class='sentence-part'>We have proposed a model which is consistent with most of the published data and current notions of AD pathogenesis and can serve as a hypothesis which can be tested.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22203915' target='_blank' class='pmid-link'>22203915</a>:</span> <span class='sentence-part'>Together, these data support a model of AD pathogenesis in which soluble Abeta initiates synaptic dysfunction and loss, as well as pathological changes in tau, which contribute to both synaptic and neuronal loss.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22459153' target='_blank' class='pmid-link'>22459153</a>:</span> <span class='sentence-part'>This model will allow the study of AD pathogenesis and testing of therapeutic strategies in a more relevant environment without experimental artifacts due to the overexpression of a single-mutant AbetaPP isoform using exogenous promoters.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22523954' target='_blank' class='pmid-link'>22523954</a>:</span> <span class='sentence-part'>This model allowed us to study the role of amyloid-beta25-35 in the pathogenesis of Alzheimer's disease and to test anti-amyloid substances.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22723178' target='_blank' class='pmid-link'>22723178</a>:</span> <span class='sentence-part'>So it might not be suitable to utilize the knockout murine model to explore biological function of Calhm1 in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22735677' target='_blank' class='pmid-link'>22735677</a>:</span> <span class='sentence-part'>We integrate biomarker findings into a comprehensive model of AD pathogenesis from healthy aging to cognitive decline, the resilience to cerebral amyloid load (RECAL) matrix.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22785400' target='_blank' class='pmid-link'>22785400</a>:</span> <span class='sentence-part'>AD-type pathology demonstrated in genetically unmodified rabbits calls attention to the considerable potential of the model for investigation of AD pathogenesis, diagnostics, and therapeutics. Amyloid-beta and tau pathology of Alzheimer's disease induced by diabetes in a rabbit animal model.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22874668' target='_blank' class='pmid-link'>22874668</a>:</span> <span class='sentence-part'>Since in the brain and other tissues of these mice, wild-type human AbetaPP mRNA and protein levels are comparable to those of endogenous AbetaPP, this model may allow studies about the role of AbetaPP isoforms in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23011729' target='_blank' class='pmid-link'>23011729</a>:</span> <span class='sentence-part'>The significance of this data and accompanying model pertains to the role transport plays in neuronal function, connectivity, and survival, and has implications in the pathogenesis of neurological disorders, such as Alzheimer's, Huntington and Parkinson's diseases.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23276384' target='_blank' class='pmid-link'>23276384</a>:</span> <span class='sentence-part'>The 3xTgAD mouse model was used to test the hypothesis that a ketone ester-based diet can ameliorate AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23383380' target='_blank' class='pmid-link'>23383380</a>:</span> <span class='sentence-part'>In this review we analyze the current situation in the use of zebrafish as a model for AD, discussing the reasons to use this experimental paradigm in CNS investigation and analyzing the several strategies adopted to induce an AD-like pathology in zebrafish.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23419876' target='_blank' class='pmid-link'>23419876</a>:</span> <span class='sentence-part'>The expression of GxxxG motifs on either reactant under consideration is in line with this model of Alzheimer's disease pathogenesis, which clearly differs from the amyloid Abeta cascade theory, and which can, furthermore, be understood as a basic model for apoptosis induction.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24150111' target='_blank' class='pmid-link'>24150111</a>:</span> <span class='sentence-part'>Consequently, 3xTg-AD mice may be a useful model in elucidating the role of immune system in the etiology of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24239247' target='_blank' class='pmid-link'>24239247</a>:</span> <span class='sentence-part'>The aim of this study is to develop a predictive model using proton magnetic resonance spectroscopy (1H-MRS), a noninvasive technique that evaluates brain chemistry in vivo, for monitoring the clinical outcome of carriers of a fully penetrant mutation that causes AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24346216' target='_blank' class='pmid-link'>24346216</a>:</span> <span class='sentence-part'>We present a new model for etiology of Alzheimer's disease (AD) which postulates early involvement of specialized neuroprotective mechanisms in the pathology of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24910393' target='_blank' class='pmid-link'>24910393</a>:</span> <span class='sentence-part'>A hypothetical model for the role of sleep and the Abeta diurnal pattern in AD pathogenesis is proposed.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25008180' target='_blank' class='pmid-link'>25008180</a>:</span> <span class='sentence-part'>In this study, we investigated the interrelation between AD and diabetes using a high-fat diet (HFD) in a mouse model of genetically induced AD-like neuropathology (3xTg-AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25131634' target='_blank' class='pmid-link'>25131634</a>:</span> <span class='sentence-part'>The results of this single-population gene expression analysis at the time of septohippocampal deficits in a trisomic mouse model shed light on a vulnerable circuit that may cause the AD-like pathology invariably seen in DS that could help to identify mechanisms of degeneration, and provide novel gene targets for therapeutic interventions.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/2519521' target='_blank' class='pmid-link'>2519521</a>:</span> <span class='sentence-part'>The association of antibodies to cholinergic neurons with cognitive deficits in this rat model suggests that such antibodies may be involved in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25213090' target='_blank' class='pmid-link'>25213090</a>:</span> <span class='sentence-part'>Furthermore, our study identifies a number of genes already known to be altered in human AD, thus confirming the use of the 5XFAD strain as a valid model for understanding AD pathogenesis and for screening potential therapeutic molecules.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25297091' target='_blank' class='pmid-link'>25297091</a>:</span> <span class='sentence-part'>Thus, generation of a macaque model of AD that links Abeta oligomers to tau and synaptic pathology has the potential to greatly advance our understanding of mechanisms centrally implicated in AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25310732' target='_blank' class='pmid-link'>25310732</a>:</span> <span class='sentence-part'>The 'amyloid cascade hypothesis' (ACH) is the most influential model of the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25754641' target='_blank' class='pmid-link'>25754641</a>:</span> <span class='sentence-part'>RESULTS: Here, using a Drosophila model of AD, we provide evidence suggesting that changes in neuronal excitability underlie the effects of sleep loss on AD pathogenesis. beta-amyloid (Abeta) accumulation leads to reduced and fragmented sleep, while chronic sleep deprivation increases Abeta burden.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25864576' target='_blank' class='pmid-link'>25864576</a>:</span> <span class='sentence-part'>Based on the schema of a well-received model of biomarker dynamics in AD pathogenesis, it has been postulated that SCD symptoms may result from compensatory changes in response to beta-amyloid accumulation and neurodegeneration.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26295040' target='_blank' class='pmid-link'>26295040</a>:</span> <span class='sentence-part'>We used a mouse model of amyloid beta- (Abeta-) induced AD, which is characterized by reactive gliosis and neuroinflammation in the brain, and we evaluated the effect of pentamidine on the main S100B-mediated events.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26461298' target='_blank' class='pmid-link'>26461298</a>:</span> <span class='sentence-part'>Similar results were obtained by using a C.elegans model of Amyloid beta (Alphabeta) -induced toxicity mimicking Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26696886' target='_blank' class='pmid-link'>26696886</a>:</span> <span class='sentence-part'>Connectivity of Pathology: The Olfactory System as a Model for Network-Driven Mechanisms of Alzheimer's Disease Pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26759118' target='_blank' class='pmid-link'>26759118</a>:</span> <span class='sentence-part'>With this strategy, we identified a sequence of early events likely to account for disease onset and described a model that may facilitate efforts to decipher the factors triggering AD and to evaluate early neuroprotective strategies.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26918610' target='_blank' class='pmid-link'>26918610</a>:</span> <span class='sentence-part'>By using a new model of SCCH, our study unravels new insights into the implication of severe chronic cerebral hypoperfusion in AD pathogenesis, mainly by altering microglial cell activity and consequently Abeta clearance.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26959388' target='_blank' class='pmid-link'>26959388</a>:</span> <span class='sentence-part'>To establish a new mouse AD model that takes advantage of this benefit, we produced transgenic mice expressing amyloid-beta (Abeta), a causative element for AD, in their auditory hair cells.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27121378' target='_blank' class='pmid-link'>27121378</a>:</span> <span class='sentence-part'>METHODS: Wild-type (WT), TRPA1(-/-), amyloid precursor protein (APP)/presenilin 1 (PS1) transgenic (APP/PS1 Tg) mice, the mouse model of AD, and APP/PS1 Tg/TRPA1(-/-) mice were used to examine the role of TRPA1 in pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27569580' target='_blank' class='pmid-link'>27569580</a>:</span> <span class='sentence-part'>Collectively, our data show that the tTa:APPsi model is characterized by a lack of sex-related differences in APP expression, making this model useful in deciphering the mechanisms of sex differences in AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28186729' target='_blank' class='pmid-link'>28186729</a>:</span> <span class='sentence-part'>Although the amyloid (abeta peptide, Abeta) hypothesis is 25 years old, is the dominant model of Alzheimer's disease (AD) pathogenesis, and guides the development of potential treatments, it is still controversial.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28413635' target='_blank' class='pmid-link'>28413635</a>:</span> <span class='sentence-part'>The amyloid hypothesis has become the dominant model of AD pathogenesis; however, the details of the hypothesis are changing over time.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28459436' target='_blank' class='pmid-link'>28459436</a>:</span> <span class='sentence-part'>The findings in these index cases support a model in which early development of occult hippocampal hyperexcitability may contribute to the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28707174' target='_blank' class='pmid-link'>28707174</a>:</span> <span class='sentence-part'>The Puri-Li kinetic model is explored here to study the contribution of microglia and astroglia during the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29338754' target='_blank' class='pmid-link'>29338754</a>:</span> <span class='sentence-part'>Because the ADLPAPT mouse model recapitulates the main features of AD pathogenesis, the proteomic data derived from its hippocampus has significant utility as a novel resource for the research on the Abeta-tau axis and pathophysiological changes in vivo.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/2934737' target='_blank' class='pmid-link'>2934737</a>:</span> <span class='sentence-part'>This possibility suggests a model for the pathogenesis of Alzheimer disease involving beta protein.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29615895' target='_blank' class='pmid-link'>29615895</a>:</span> <span class='sentence-part'>For the first model, 7-month-old Lanyu-miniature-pigs were given the abdominal aortic constriction operation to induce hypertension and their AD-related pathologies were assessed at 1, 2, and 3 months after the operation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29754213' target='_blank' class='pmid-link'>29754213</a>:</span> <span class='sentence-part'>The Puri-Li kinetic model is modified to include neuronal calcium ion homeostasis to study the effect of calcium ions on the production of amyloid-beta peptides (Abeta), microglia, and astroglia during the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30043649' target='_blank' class='pmid-link'>30043649</a>:</span> <span class='sentence-part'>CONCLUSION: Our study on Drosophila model suggests that dysregulation of gut microbiota may participate in AD pathogenesis by influencing SCFA level.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30149447' target='_blank' class='pmid-link'>30149447</a>:</span> <span class='sentence-part'>The icv injection of STZ model and STZ exposed Neuro-2a cells may be potential experimental models for assessing molecules related to the pathogenesis of sAD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30220236' target='_blank' class='pmid-link'>30220236</a>:</span> <span class='sentence-part'>In light of recent evidence that the cascade is driven by the misfolding and templated aggregation of Abeta and tau, we believe that an empirically grounded Standard Model of Alzheimer's pathogenesis is within reach. By affirming markers of abnormal Abeta and tau proteins as the essential pathobiological signature of Alzheimer's disease, the Framework tacitly reinforces the amyloid (Abeta) cascade as the leading theory of Alzheimer pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30557391' target='_blank' class='pmid-link'>30557391</a>:</span> <span class='sentence-part'>We show that mini-brains obtained from a non-AD control cell line are responsive to chemical compound induction, producing a shift of physiological Abeta concentrations, suggesting that this model can be used to identify environmental agents that may initiate the cascade of events ultimately leading to sporadic AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30837279' target='_blank' class='pmid-link'>30837279</a>:</span> <span class='sentence-part'>The senescence-accelerated mouse-prone 8 (SAMP8) model has been used to study age-related neurodegenerative changes associated with aging and the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30982098' target='_blank' class='pmid-link'>30982098</a>:</span> <span class='sentence-part'>In addition, on the basis of the new genetic landscape, resulting from the recent high-throughput genomic approaches and emerging neurobiological information, we propose an over-arching model in which the focal adhesion pathway and the related cell signalling are key elements in AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31342431' target='_blank' class='pmid-link'>31342431</a>:</span> <span class='sentence-part'>In this chapter, we demonstrate the use of all-atom molecular dynamics simulations to model the self-aggregation of a six-residue amyloidogenic peptide derived from amyloid beta, a 39-43 residue-long peptide associated with the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31421155' target='_blank' class='pmid-link'>31421155</a>:</span> <span class='sentence-part'>In conclusion, we suggest that cerebral organoids are a suitable AD model for scientific study, and that will provide us a novel insight into the understanding of the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31450503' target='_blank' class='pmid-link'>31450503</a>:</span> <span class='sentence-part'>Blood platelets frequently serve as peripheral model for studying AD pathogenesis and might represent a reasonable biomarker source.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31551757' target='_blank' class='pmid-link'>31551757</a>:</span> <span class='sentence-part'>Studies on these biological mechanisms together with the use of the AOF model have the potential to shed light on key molecular pathways underlying AD pathogenesis for the development of precision medicine approaches that take sex and hormonal status into account.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31608251' target='_blank' class='pmid-link'>31608251</a>:</span> <span class='sentence-part'>This study assessed the effects of probiotic supplementation on spatial learning and memory, long-term potentiation (LTP), paired-pulse facilitation (PPF) ratios, nitric oxide (NO) concentrations, and lipid profiles in a rat model of amyloid beta (Abeta)(1-42)-induced Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34473990' target='_blank' class='pmid-link'>34473990</a>:</span> <span class='sentence-part'>This study establishes an excellent model to investigate the mechanism of activity-dependent hTau release and to better understand the role of phosphorylated tau release in the pathogenesis of AD since it relates to alterations in the early stage of neurodegeneration associated with increased neuronal activity.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34585626' target='_blank' class='pmid-link'>34585626</a>:</span> <span class='sentence-part'>An AD-like homocysteine (Hcy) rat model was established to evaluate the effects of miR-132-3p on AD pathogenesis    in vivo    .</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/7739409' target='_blank' class='pmid-link'>7739409</a>:</span> <span class='sentence-part'>A model is proposed to explain the aetiology of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/8450928' target='_blank' class='pmid-link'>8450928</a>:</span> <span class='sentence-part'>Here we review current evidence in support of the cortical disconnection/cortical connectivity model of Alzheimer disease (AD) pathogenesis, a model which predicts that one of the first events in AD is damage to the entorhinal cortex and/or subiculum resulting in the disconnection of the hippocampal formation and neocortex, and the subsequent progression of the disease in a stepwise fashion along cortico-cortical connections.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/9115271' target='_blank' class='pmid-link'>9115271</a>:</span> <span class='sentence-part'>This model provides important clues to the potential functions of different parts of the presenilin molecule and how these might relate to the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/9126173' target='_blank' class='pmid-link'>9126173</a>:</span> <span class='sentence-part'>The proposed mouse model may explain familial resistance to AD in man, provide extremely valuable insights into the etiology of AD, and suggest means for its prevention.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/9330979' target='_blank' class='pmid-link'>9330979</a>:</span> <span class='sentence-part'>Requiring urgent resolution is whether cellular changes seen in brains of aging normals represent merely the earliest phase of typical AD (and therefore a good model for Alzheimer pathogenesis), or rather reflect a totally different aging syndrome distinct from AD.</span></div></div>
<div class='streamlined-assertion'><div class='streamlined-header sticky-relation-header'><span class='label-text'>Subject:</span> <strong>Study_models</strong> <span class='label-text'>Subject CUI:</span> <strong>C0026336</strong> â†’ <span class='label-text predicate-text'>CAUSES</span> â†’ <span class='label-text'>Object:</span> <strong>Atrial_Fibrillation</strong> <span class='label-text'>Object CUI:</span> <strong>C0004238</strong></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/10715599' target='_blank' class='pmid-link'>10715599</a>:</span> <span class='sentence-part'>The model produces a persistent AF in 80% of animals paced at 400 beats/min for 6 weeks.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/10987620' target='_blank' class='pmid-link'>10987620</a>:</span> <span class='sentence-part'>OBJECTIVES: To test the hypothesis that when activation of Bachmann's bundle (BB) is critical to the unstable reentrant circuits that maintain atrial fibrillation (AF) in the sterile pericarditis canine model, a lesion in BB would prevent induction of stable AF. CONCLUSIONS: In this AF model, catheter ablation of BB terminates and prevents the induction of AF by preventing 1) formation of unstable reentrant circuits that involve BB, and 2) activation of the atrial-free walls after a nonactivation period. METHODS: Simultaneous multisite mapping studies during AF and after ablation of BB were performed by recording (384 to 396 electrodes) from both atria and the atrial septum during six induced AF episodes in six dogs with sterile pericarditis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/11041507' target='_blank' class='pmid-link'>11041507</a>:</span> <span class='sentence-part'>This model of pacing induced atrial fibrillation can be used to study the mechanisms leading to atrial fibrillation, its perpetuation and therapy.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/12181156' target='_blank' class='pmid-link'>12181156</a>:</span> <span class='sentence-part'>We conclude that nonreentrant focal activations are present in the PVs in a canine model of pacing-induced sustained AF.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/12900337' target='_blank' class='pmid-link'>12900337</a>:</span> <span class='sentence-part'>METHODS AND RESULTS: We used a stretch-related AF model in the sheep heart to induce stable episodes of AF (&gt;40 minutes) in 9 animals.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/16055519' target='_blank' class='pmid-link'>16055519</a>:</span> <span class='sentence-part'>We conclude that ibutilide reduces reentrant wave fronts but not PV FD in a canine model of pacing-induced sustained AF.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17199956' target='_blank' class='pmid-link'>17199956</a>:</span> <span class='sentence-part'>CONCLUSIONS: In canine RAP model, nifekalant inhibited ERP shortening and ERP heterogeneity increasing, decreased AF induction.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/18954643' target='_blank' class='pmid-link'>18954643</a>:</span> <span class='sentence-part'>Although several animal models focus on the initiating mechanisms of atrial fibrillation in dilated atria, a model of left atrial overload resulting in persistent atrial fibrillation in nonanesthetized animals has not been presented thus far.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22436870' target='_blank' class='pmid-link'>22436870</a>:</span> <span class='sentence-part'>Autonomic ganglionated plexi: characterization and effect of epicardial microwave ablation in a canine model of vagally induced acute atrial fibrillation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23258139' target='_blank' class='pmid-link'>23258139</a>:</span> <span class='sentence-part'>The aim of this study was to investigate whether effective RA linear lesions can terminate AF and render it noninducible in a canine model of rapid atrial pacing-induced sustained AF. Linear catheter ablation of the right atrium for rapid atrial pacing-induced sustained atrial fibrillation in dogs.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23465221' target='_blank' class='pmid-link'>23465221</a>:</span> <span class='sentence-part'>CONCLUSIONS: CFAE site with high DF had an arrhythmogenic property differing significantly from the other areas of LA in an HF rabbit model, which may contribute to the genesis of AF.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24109989' target='_blank' class='pmid-link'>24109989</a>:</span> <span class='sentence-part'>A bidomain Courtemanche model was used to simulate the 3D electric waves on the LA surface, and an S1-S2 protocol was applied to induce AF in the model.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24297188' target='_blank' class='pmid-link'>24297188</a>:</span> <span class='sentence-part'>The addition of PAC count to the Framingham model resulted in significant 10-year AF risk discrimination improvement (c-statistic, 0.65 vs. 0.72; P &lt; 0.001), net reclassification improvement (23.2% [CI, 12.8% to 33.6%]; P &lt; 0.001), and integrated discrimination improvement (5.6% [CI, 4.2% to 7.0%]; P &lt; 0.001).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26331943' target='_blank' class='pmid-link'>26331943</a>:</span> <span class='sentence-part'>METHODS AND RESULTS: In 6 closed-chest anesthetized pigs, AF was induced by intrapericardial acetylcholine (1 mL of 100 mM solution) followed within 1 minute by epinephrine (20 MUg/kg, i.v., bolus over 1 min). INTRODUCTION: The anti-atrial fibrillation (AF) effects of GS-458967 (GS-967), a selective, potent inhibitor of cardiac late Na(+) current (I(Na)), were evaluated in a novel model of AF induction that does not require electrical stimuli.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27056895' target='_blank' class='pmid-link'>27056895</a>:</span> <span class='sentence-part'>In each model, rapid pacing was applied to induce AF.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27217399' target='_blank' class='pmid-link'>27217399</a>:</span> <span class='sentence-part'>OBJECTIVE: We hypothesized that gene-based expression of dominant-negative type II TGF-beta receptor (TGF-beta-RII-DN) in the posterior left atrium in a canine heart failure model will sufficiently attenuate fibrosis-induced changes in atrial conduction and restitution to decrease AF.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27722784' target='_blank' class='pmid-link'>27722784</a>:</span> <span class='sentence-part'>In a Langendorff model of acutely induced AF on guinea pig hearts, it was investigated whether a combination of the SK channel blocker N-(pyridin-2-yl)-4-(pyridin-2-yl)thiazol-2-amine (ICA) together with either dofetilide or amiodarone provided a synergistic effect.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28901395' target='_blank' class='pmid-link'>28901395</a>:</span> <span class='sentence-part'>These results demonstrate that MMP-7 and BAX were highly expressed, while TIMP-2 and BCL-2 were downregulated in a Beagle dog model of AF, indicating that MMP-7 and apoptosis-associated genes (TIMP-2, BAX and BCL-2) may be associated with the pathogenesis of AF.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29068807' target='_blank' class='pmid-link'>29068807</a>:</span> <span class='sentence-part'>Antiarrhythmic Effects of Combining Dofetilide and Ranolazine in a Model of Acutely Induced Atrial Fibrillation in Horses.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30353147' target='_blank' class='pmid-link'>30353147</a>:</span> <span class='sentence-part'>In this study, we have developed and validated a novel human left atrial cellular model (TPA) based on the ten Tusscher-Panfilov ventricular cell model to systematically investigate how electrical remodeling induced by TBX5/PITX2 insufficiency leads to AF.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30661267' target='_blank' class='pmid-link'>30661267</a>:</span> <span class='sentence-part'>Effects of dofetilide and ranolazine on atrial fibrillatory rate in a horse model of acutely induced atrial fibrillation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31021331' target='_blank' class='pmid-link'>31021331</a>:</span> <span class='sentence-part'>Recently, we created a mouse model with spontaneous and sustained AF caused by a mutation in the NaV1.5 channel (F1759A) that enhances persistent Na+ current, thereby enabling the investigation of molecular mechanisms that cause AF and the identification of novel treatment strategies.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/8070492' target='_blank' class='pmid-link'>8070492</a>:</span> <span class='sentence-part'>In the other model, experimentally induced atrial fibrillation in the dog is regionally entrained by local rapid pacing.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/9386188' target='_blank' class='pmid-link'>9386188</a>:</span> <span class='sentence-part'>This goat model of AF offers a new approach to study the cascade of events leading to sustained AF and its maintenance.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/9727679' target='_blank' class='pmid-link'>9727679</a>:</span> <span class='sentence-part'>INTRODUCTION: We recently developed a goat model of sustained atrial fibrillation (AF) in which repetitive induction of AF by burst pacing shortened the atrial effective refractory period (AERP) (electrophysiologic remodeling) and progressively prolonged the paroxysms of AF to become sustained (24 hours) within 1 to 3 weeks (atrial fibrillation begets atrial fibrillation).</span></div></div>
<div class='streamlined-assertion'><div class='streamlined-header sticky-relation-header'><span class='label-text'>Subject:</span> <strong>Symptoms</strong> <span class='label-text'>Subject CUI:</span> <strong>C1457887</strong> â†’ <span class='label-text predicate-text'>CAUSES</span> â†’ <span class='label-text'>Object:</span> <strong>Alzheimers</strong> <span class='label-text'>Object CUI:</span> <strong>C0002395</strong></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/10464574' target='_blank' class='pmid-link'>10464574</a>:</span> <span class='sentence-part'>This paper provides a brief overview of the symptoms, progression, and etiology of AD, as well as of the prevalence and incidence of the disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/10862215' target='_blank' class='pmid-link'>10862215</a>:</span> <span class='sentence-part'>OBJECTIVES: To determine the accuracy of the MMSE in predicting emergent AD in a sample of patients who were referred because of symptoms suggestive of memory problems and to determine whether an abbreviated version of the MMSE could be developed that would be as accurate as the full MMSE in predicting emergent AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/16627930' target='_blank' class='pmid-link'>16627930</a>:</span> <span class='sentence-part'>Neurofibrillary degeneration characterized by abnormal hyperphosphorylation and aggregation of tau in affected neurons is directly associated with dementia symptoms and plays a pivotal role in the pathogenesis of Alzheimer disease (AD) and related tauopathies.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23634965' target='_blank' class='pmid-link'>23634965</a>:</span> <span class='sentence-part'>Specifically, since MCI coincides with the onset of clinical symptoms and brain atrophy, and LC pathology is already present at this early stage of AD pathogenesis, MCI may offer a critical window of time to initiate novel noradrenergic-based therapies aimed at the secondary wave of events that lead to progressive neurodegeneration.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25077345' target='_blank' class='pmid-link'>25077345</a>:</span> <span class='sentence-part'>Nutritional status of patients with certain neurological diseases such as stroke, Alzheimer's disease, Parkinson's disease, Epilepsy and Multiple Sclerosis can be altered because of symptoms associated with disease course, including certain micronutrient deficiency (folic acid, zinc, vitamin B6 and B12, vitamin D, vitamin E and vitamin C), changes in energy expenditure, intake decreased, gastrointestinal disorders and dysfunction of the bone mass.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26582973' target='_blank' class='pmid-link'>26582973</a>:</span> <span class='sentence-part'>Alterations in synaptic/neuronal activity and brain metabolism are considered among the earliest symptoms linked to the progression of AD, and lead to a central question in AD research: what is the role played by synaptic activity in AD pathogenesis?</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27247784' target='_blank' class='pmid-link'>27247784</a>:</span> <span class='sentence-part'>The main of present paper was to investigate symptoms and causes of alzheimer disease from the view point of Iranian traditional medicine.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29051137' target='_blank' class='pmid-link'>29051137</a>:</span> <span class='sentence-part'>Although AD symptoms (83/271, 30.6%), causes of AD (80/271, 29.5%), and treatment (76/271, 28.0%) were commonly addressed, quality of life of people with AD (34/271, 12.5%) had more views than those more commonly-covered content areas.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29384656' target='_blank' class='pmid-link'>29384656</a>:</span> <span class='sentence-part'>Novel Multitarget-Directed Ligands Aiming at Symptoms and Causes of Alzheimer's Disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29865070' target='_blank' class='pmid-link'>29865070</a>:</span> <span class='sentence-part'>These results suggest that HKL has therapeutic potential for delaying the onset of AD symptoms by alleviating mitochondrial impairment and increasing hyperactivation of SIRT3 in the pathogenesis of preclinical AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30620503' target='_blank' class='pmid-link'>30620503</a>:</span> <span class='sentence-part'>If the somatic symptoms caused by adverse effects appear as a lack of animation or irritation, the changes due to adverse effects will be likely misunderstood as symptoms caused by progression of AD, behavioral and psychological symptoms.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31699319' target='_blank' class='pmid-link'>31699319</a>:</span> <span class='sentence-part'>Therefore, MALDI IMS taking account of the brain's functional connectivity and the spread of AD symptoms should be a powerful strategy for uncovering molecular signatures related to the AD trigger(s).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31771066' target='_blank' class='pmid-link'>31771066</a>:</span> <span class='sentence-part'>BACKGROUND: Alzheimer's disease (AD) and dementia with Lewy bodies (DLB) are often misdiagnosed with each other because of similar symptoms including progressive memory loss.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32827867' target='_blank' class='pmid-link'>32827867</a>:</span> <span class='sentence-part'>In particular, defects in cerebral glucose metabolism, which have been often noted even before the occurrence of clinical symptoms and histopathological lesions, are now regarded as critical contributors to the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33092411' target='_blank' class='pmid-link'>33092411</a>:</span> <span class='sentence-part'>Multidirectional    in vitro     and    in cellulo     studies as a tool for identification of multi-target-directed ligands aiming at symptoms and causes of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34420966' target='_blank' class='pmid-link'>34420966</a>:</span> <span class='sentence-part'>BACKGROUND: The differentiation of idiopathic normal pressure hydrocephalus (iNPH) from neurodegenerative diseases such as Alzheimer's disease (AD) and dementia with Lewy bodies (DLB) is often challenging because of their non-specific symptoms.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37922187' target='_blank' class='pmid-link'>37922187</a>:</span> <span class='sentence-part'>Frontotemporal dementia (FTD) is frequently misdiagnosed as Alzheimer's disease (AD) due to similar clinical symptoms.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37988777' target='_blank' class='pmid-link'>37988777</a>:</span> <span class='sentence-part'>However, it is still a grand challenge to accurately diagnose AD at its early stage because of the indiscernible early symptoms and the lack of sensitive detection tools.</span></div></div>
<div class='streamlined-assertion'><div class='streamlined-header sticky-relation-header'><span class='label-text'>Subject:</span> <strong>Therapeutic_procedure</strong> <span class='label-text'>Subject CUI:</span> <strong>C0087111</strong> â†’ <span class='label-text predicate-text'>CAUSES</span> â†’ <span class='label-text'>Object:</span> <strong>Alzheimers</strong> <span class='label-text'>Object CUI:</span> <strong>C0002395</strong></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/10412794' target='_blank' class='pmid-link'>10412794</a>:</span> <span class='sentence-part'>A discussion of target therapy based on the proposed pathogenesis of AD is also briefly reviewed.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/10764737' target='_blank' class='pmid-link'>10764737</a>:</span> <span class='sentence-part'>Many cases of early-onset inherited Alzheimer's disease (AD) are caused by mutations in the presenilin-1 (PS1) gene. Caffeine treatment sensitizes neurons expressing mutant PS1 to apoptosis induced by amyloid beta-peptide, a neurotic peptide linked to the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/11193790' target='_blank' class='pmid-link'>11193790</a>:</span> <span class='sentence-part'>A brief discussion of target therapy based on the proposed pathogenesis of AD is also reviewed.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/12861345' target='_blank' class='pmid-link'>12861345</a>:</span> <span class='sentence-part'>Potential therapeutic strategies for AD treatment include palliative treatment with nonspecific neuroprotecting agents, symptomatic treatment with psychotropic drugs for noncognitive symptoms, cognitive treatment with cognition enhancers, substitutive treatment with cholinergic enhancers to improve memory deficits, multifactorial treatment using several drugs in combination and etiopathogenic treatment designed to regulate molecular factors potentially associated with AD pathogenesis. In our opinion, the pharmacological treatment of AD should rely on a better understanding of AD etiopathogenesis in order to use current drugs that protect the AD brain against deleterious events and/or to develop new drugs specifically designed to inhibit and/or regulate those factors responsible for premature neuronal death in AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/16472958' target='_blank' class='pmid-link'>16472958</a>:</span> <span class='sentence-part'>The implication of PPAR-gamma in the control of Abeta-induced inflammation suggests a new target for AD therapy and emphasize the contribution of neuroinflammatory mechanisms to the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17084014' target='_blank' class='pmid-link'>17084014</a>:</span> <span class='sentence-part'>This review will demonstrate data from humans and animals which promote NGF as a potential therapeutic target by (1) outlining the hypothesis behind using NGF for the treatment of AD, (2) reviewing both the normal and AD altered signaling pathways and effects of NGF in the central nervous system (CNS), and (3) examining the results of NGF treatment obtained from animal models of AD and AD patients.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/18542908' target='_blank' class='pmid-link'>18542908</a>:</span> <span class='sentence-part'>New treatment strategies have developed since publication in 1991 of the amyloid hypothesis on the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/19585951' target='_blank' class='pmid-link'>19585951</a>:</span> <span class='sentence-part'>Many of these new therapies are based on our best current understanding of the pathogenesis of Alzheimer's disease, and are designed to try to either slow or halt the progression of the disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20119496' target='_blank' class='pmid-link'>20119496</a>:</span> <span class='sentence-part'>MAIN METHODS: Here, we have explored the anti-amyloid properties of these SMAbetaBA's in mice doubly transgenic for human prensenilin-1 (PS1) and APP gene mutations that cause early-onset AD. AIMS: One promising approach for treatment of Alzheimer's disease (AD) is use of anti-amyloid therapies, based on the hypothesis that increases in amyloid-beta (Abeta) deposits in brain are a major cause of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22382658' target='_blank' class='pmid-link'>22382658</a>:</span> <span class='sentence-part'>Molecular approaches to the treatment, prophylaxis, and diagnosis of Alzheimer's disease: endoplasmic reticulum stress and immunological stress in pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22531418' target='_blank' class='pmid-link'>22531418</a>:</span> <span class='sentence-part'>Amyloid-beta (Abeta) producing enzymes are key targets for disease-modifying Alzheimer's disease (AD) therapies since Abeta trafficking is at the core of AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23474291' target='_blank' class='pmid-link'>23474291</a>:</span> <span class='sentence-part'>Lowering the production and accumulation of Abeta has been explored as treatment for Alzheimer's disease (AD), because Abeta is postulated to play an important role in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23954180' target='_blank' class='pmid-link'>23954180</a>:</span> <span class='sentence-part'>However, no cure or disease-modifying treatments are currently available, and the molecular and cellular mechanisms responsible for the etiology of AD remain under debate.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24040810' target='_blank' class='pmid-link'>24040810</a>:</span> <span class='sentence-part'>Thus Alzheimer disease (AD) treatment strategies based solely on the amyloid-beta clearance should be re-examined in light of the vast accumulating evidence that increased oxidative stress in the human brains is the key causative factor for AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24365186' target='_blank' class='pmid-link'>24365186</a>:</span> <span class='sentence-part'>Treatments for T2DM and AD attempt to slow cognitive decline, and recent investigations have focused on agents that may alter pathways common to AD and T2DM pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24599114' target='_blank' class='pmid-link'>24599114</a>:</span> <span class='sentence-part'>Our results indicate that by interacting with Abeta42 soluble species, delaying Abeta plaque formation, protecting against neuronal death and dendritic spine loss and preventing AD cognitive deficits, the Reelin pathway deserves consideration as a therapeutic target for the treatment of AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25027006' target='_blank' class='pmid-link'>25027006</a>:</span> <span class='sentence-part'>FAD hiPSCs harboring disease properties can be used as humanized models to test novel diagnostic methods and therapies and explore novel hypotheses for AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/2755560' target='_blank' class='pmid-link'>2755560</a>:</span> <span class='sentence-part'>3) While there is still a search for a symptomatic treatment for AD, the path to find a treatment for the Alzheimer disease process must first pass through a phase of basic research to find the cause of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27693185' target='_blank' class='pmid-link'>27693185</a>:</span> <span class='sentence-part'>A major obstacle to presymptomatic diagnosis and disease-modifying therapy for Alzheimer's disease (AD) is inadequate understanding of molecular mechanisms of AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28385651' target='_blank' class='pmid-link'>28385651</a>:</span> <span class='sentence-part'>Moreover, treatment with drugs that block AT1R (AT1R blockers, ARBs) ameliorates most of the clinical risk factors leading to AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28709498' target='_blank' class='pmid-link'>28709498</a>:</span> <span class='sentence-part'>Identifying specific signaling pathways involving Abeta has allowed for the development of more precise therapeutic interventions targeting the most relevant molecular mechanisms leading to AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29248451' target='_blank' class='pmid-link'>29248451</a>:</span> <span class='sentence-part'>Single modality of \One-molecule-one-target\ strategy for treating AD has failed and so future therapies on \Combination-drugs-multi-targets\ strategy (CDMT) will need to address multiple aspects to block the progression of pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29623038' target='_blank' class='pmid-link'>29623038</a>:</span> <span class='sentence-part'>In this review, we will describe how recent advances in stem cell technology have shed light on a novel treatment strategy and revolutionized the mechanistic investigation of AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30059692' target='_blank' class='pmid-link'>30059692</a>:</span> <span class='sentence-part'>Thus, there are urgent needs for the development of new therapies that target on the proximal cause of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30227819' target='_blank' class='pmid-link'>30227819</a>:</span> <span class='sentence-part'>The lack of effective treatments for AD stems mainly from the incomplete understanding of causes of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31818365' target='_blank' class='pmid-link'>31818365</a>:</span> <span class='sentence-part'>Currently available therapeutic agents for AD provide only symptomatic treatments, mainly because the complete mechanism of the AD pathogenesis is still unclear.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31824296' target='_blank' class='pmid-link'>31824296</a>:</span> <span class='sentence-part'>Therapeutic interventions aiming to restore mitophagy functions can be used as a strategy for ameliorating AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31960800' target='_blank' class='pmid-link'>31960800</a>:</span> <span class='sentence-part'>In order to find disease-modifying therapies to confront this challenge, a more complete understanding of the pathogenesis of Alzheimer's disease is necessary.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32898852' target='_blank' class='pmid-link'>32898852</a>:</span> <span class='sentence-part'>Systems-based proteomics to resolve the biology of Alzheimer's disease beyond amyloid and tau.The repeated failures of amyloid-targeting therapies have challenged our narrow understanding of Alzheimer's disease (AD) pathogenesis and inspired wide-ranging investigations into the underlying mechanisms of disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33188924' target='_blank' class='pmid-link'>33188924</a>:</span> <span class='sentence-part'>This review questions the major assumptions about Abeta on which therapies for AD were premised, and invites renewed interrogation into AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33417222' target='_blank' class='pmid-link'>33417222</a>:</span> <span class='sentence-part'>Therapeutic interventions aiming to restore mitophagy functions can be used as a strategy for ameliorating AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34160781' target='_blank' class='pmid-link'>34160781</a>:</span> <span class='sentence-part'>The Tg2576 is frequently used in AD research to test therapeutic interventions targeting cellular mechanisms contributing to the genesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36561895' target='_blank' class='pmid-link'>36561895</a>:</span> <span class='sentence-part'>There are just a few FDA-approved treatments without side effects in the market, and their efficacy is restricted due to their narrow target in the etiology of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37186274' target='_blank' class='pmid-link'>37186274</a>:</span> <span class='sentence-part'>This study sheds light on apoptotic pathways that are cardinal for neuronal survival and perform crucial role in the occurrence of AD along with the trends in therapeutics targeting apoptosis induced AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37833948' target='_blank' class='pmid-link'>37833948</a>:</span> <span class='sentence-part'>However, as reviewed in this article, results from the numerous clinical trials that have tested anti-Abeta therapies to date indicate that this peptide plays a minor role in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/3789676' target='_blank' class='pmid-link'>3789676</a>:</span> <span class='sentence-part'>These results indicate that cholinergic muscarinic binding by peripheral blood lymphocytes may be useful in the study of alterations associated with aging and SDAT, as well as in evaluating changes induced by certain cholinergic drug treatments.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/38003477' target='_blank' class='pmid-link'>38003477</a>:</span> <span class='sentence-part'>By providing an integrative perspective, we anticipate paving the way for future research and treatments focused on exploiting the BBB's role in AD pathogenesis and therapy.</span></div></div>
<div class='streamlined-assertion'><div class='streamlined-header sticky-relation-header'><span class='label-text'>Subject:</span> <strong>Therapeutic_procedure</strong> <span class='label-text'>Subject CUI:</span> <strong>C0087111</strong> â†’ <span class='label-text predicate-text'>CAUSES</span> â†’ <span class='label-text'>Object:</span> <strong>Atrial_Fibrillation</strong> <span class='label-text'>Object CUI:</span> <strong>C0004238</strong></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/10354972' target='_blank' class='pmid-link'>10354972</a>:</span> <span class='sentence-part'>Since suppression of inducible AF or atrial flutter is used as one of the endpoints of success of pharmacologic and ablation therapies, there is an obvious need to define a minimally appropriate electrical stimulation protocol for induction of AF or atrial flutter.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/11084094' target='_blank' class='pmid-link'>11084094</a>:</span> <span class='sentence-part'>Catheter ablation of triggers inducing paroxysms of atrial fibrillation (AF) is an emerging therapy for this common arrhythmia.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/12106941' target='_blank' class='pmid-link'>12106941</a>:</span> <span class='sentence-part'>When AT/AF terminated either because of a ventricular therapy or spontaneously, the median interdetection interval was prolonged to 71 h (p &lt; 0.001).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/12114844' target='_blank' class='pmid-link'>12114844</a>:</span> <span class='sentence-part'>Therapy should focus on identifying the specific substrate (underlying heart disease) and triggers for AF in each patient, making a more individualized therapy possible.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/12643434' target='_blank' class='pmid-link'>12643434</a>:</span> <span class='sentence-part'>This review describes contemporary and emerging surgical approaches to AF, synthesizes results of these operations, and proposes new standards for reporting results of AF treatment.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/12955433' target='_blank' class='pmid-link'>12955433</a>:</span> <span class='sentence-part'>Atrial fibrillation induced by simvastatin treatment in a 61-year-old man.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/1378592' target='_blank' class='pmid-link'>1378592</a>:</span> <span class='sentence-part'>atrial fibrillation induced by cardioversion therapy; 3.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/14574037' target='_blank' class='pmid-link'>14574037</a>:</span> <span class='sentence-part'>Thus, an \hybrid\ therapy prescription is more likely to address several of the etiologic factors culminating in clinical AF.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/15152746' target='_blank' class='pmid-link'>15152746</a>:</span> <span class='sentence-part'>The principles of treatment for this condition are to stabilize the patient hemodynamically, simultaneously determine whether a reversible cause of the AF exists, control the patient's heart rate, determine whether the patient should be cardioverted or maintained in AF, and then develop strategies to prevent the most important complications of stroke.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/15721499' target='_blank' class='pmid-link'>15721499</a>:</span> <span class='sentence-part'>BACKGROUND: Pacemaker treatment of known trigger mechanisms for atrial tachyarrhythmias (AT) and atrial fibrillation (AF) has shown reduction in the incidence of AF.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/16137503' target='_blank' class='pmid-link'>16137503</a>:</span> <span class='sentence-part'>PURPOSE: Ramp and burst pacing as treatment for atrial tachycardia (AT), one known trigger mechanism of atrial fibrillation (AF) are available in permanent pacemakers to reduce the burden of AF.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/1697949' target='_blank' class='pmid-link'>1697949</a>:</span> <span class='sentence-part'>Antiarrhythmic drug therapy in combination with a conservative antitachycardia pacing mode was required in four patients paced from the atrium to avoid pacing induced atrial fibrillation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17354577' target='_blank' class='pmid-link'>17354577</a>:</span> <span class='sentence-part'>Meanwhile, the upstream therapy of atrial fibrillation, the management of many components that lead to atrial fibrillation, has been paid much attention to, because its target would be the causes of atrial fibrillation itself.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17460420' target='_blank' class='pmid-link'>17460420</a>:</span> <span class='sentence-part'>Atrial fibrillation induced by gemcitabine treatment in a 65-year-old man.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17919572' target='_blank' class='pmid-link'>17919572</a>:</span> <span class='sentence-part'>CONCLUSIONS: Oral treatment with fish oils increased atrial n-3 PUFA levels and reduced vulnerability to induction of AF in this dog model.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/18281820' target='_blank' class='pmid-link'>18281820</a>:</span> <span class='sentence-part'>Ablation has emerged as a curative therapy that addresses the root causes of atrial fibrillation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/18442529' target='_blank' class='pmid-link'>18442529</a>:</span> <span class='sentence-part'>We hypothesized that the incidence of postoperative AF due to statin therapy is dose-related.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/19187919' target='_blank' class='pmid-link'>19187919</a>:</span> <span class='sentence-part'>The effect of mild VNS treatment on AF induction was further investigated in six chronically instrumented conscious dogs.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/19495681' target='_blank' class='pmid-link'>19495681</a>:</span> <span class='sentence-part'>Having venous sheaths already in place during electrophysiological studies, internal atrial cardioversion is a fast and uncomplicated procedure which may be the treatment of choice in case induced atrial fibrillation does not resolve spontaneously.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20384658' target='_blank' class='pmid-link'>20384658</a>:</span> <span class='sentence-part'>CONCLUSIONS: The focus of the management of AF may be changing as a consequence of new treatments based on the outcome improvements they offer.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20421888' target='_blank' class='pmid-link'>20421888</a>:</span> <span class='sentence-part'>Discovery of the role of pulmonary veins as a trigger has been an important breakthrough, leading to the development of pulmonary vein ablation-an established curative therapy for drug-resistant AF.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20570180' target='_blank' class='pmid-link'>20570180</a>:</span> <span class='sentence-part'>OBJECTIVE: To evaluate the incidence of postoperative atrial fibrillation (POAF), the predisposing factors, the results of treatment before discharge, and the impact on duration and costs of hospitalization.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20602551' target='_blank' class='pmid-link'>20602551</a>:</span> <span class='sentence-part'>Discovery of the role of pulmonary veins as a trigger has been an important breakthrough that has led to the development of catheter ablation, an established curative therapy for drug-resistant atrial fibrillation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23211770' target='_blank' class='pmid-link'>23211770</a>:</span> <span class='sentence-part'>AIMS: The aim of this study was to compare the clinical characteristics, treatment and outcome of elderly and younger patients hospitalized with AF in a Middle-Eastern country and examine the trends of AF etiologies over a 20-year period.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24814361' target='_blank' class='pmid-link'>24814361</a>:</span> <span class='sentence-part'>Rosiglitazone treatment significantly reduced the duration of induced AF in the treated rabbits (1.6 +/- 0.4 s vs. 1.2 +/- 0.05 s; P &lt; 0.05).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25660493' target='_blank' class='pmid-link'>25660493</a>:</span> <span class='sentence-part'>OBJECTIVES: We sought to determine the relationship between changes in natriuretic peptides and symptoms as a consequence of introducing beta-blocker therapy, in patients with chronic heart failure (CHF) and persistent atrial fibrillation (AF).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25819678' target='_blank' class='pmid-link'>25819678</a>:</span> <span class='sentence-part'>Case of atrial fibrillation induced by interferon beta treatment for melanoma.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25839622' target='_blank' class='pmid-link'>25839622</a>:</span> <span class='sentence-part'>Can treatment with beta blockers trigger episodes of atrial fibrillation in healthy patients?</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27637120' target='_blank' class='pmid-link'>27637120</a>:</span> <span class='sentence-part'>Ablation therapy is used to destroy abnormal foci responsible for atrial fibrillation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27699086' target='_blank' class='pmid-link'>27699086</a>:</span> <span class='sentence-part'>Atrial fibrillation (AF) is the most prevalent arrhythmia in the world, due both to its tenacious treatment resistance, and to the tremendous number of risk factors that set the stage for the atria to fibrillate.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27844147' target='_blank' class='pmid-link'>27844147</a>:</span> <span class='sentence-part'>Bradycardia and abnormal atrial refractoriness induced by ivabradine treatment may enhance vulnerability to AF induction, especially when vagal nerve is concurrently activated.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28132779' target='_blank' class='pmid-link'>28132779</a>:</span> <span class='sentence-part'>Of note, treatment with 0.25?M levosimendan resulted in induction of AF in 11 of 13 hearts (mean: 8.9+/-3.5 episodes).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28262346' target='_blank' class='pmid-link'>28262346</a>:</span> <span class='sentence-part'>Flecainide treatment also induced a significant increase of aPRR and resulted in induction of AF in 6 of 10 hearts (58 episodes) while 9 of 10 hearts were inducible during sole treatment with acetylcholine and isoproterenol (129 episodes).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28496795' target='_blank' class='pmid-link'>28496795</a>:</span> <span class='sentence-part'>There have been considerable advances in understanding the relationship of atrial fibrillation (AF) and atrial remodelling suggesting that remodelling states have a significant impact on treatment results.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29501704' target='_blank' class='pmid-link'>29501704</a>:</span> <span class='sentence-part'>A combined intravenous injection of CaCl2 (10 mg/mL) and acetylcholine (Ach; 66 ?g/mL) was administered to the model and treatment groups for 7 consecutive days to induce atrial fibrillation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29723895' target='_blank' class='pmid-link'>29723895</a>:</span> <span class='sentence-part'>AF may also develop as a consequence of anticancer therapy (chemotherapy or radiotherapy), a condition probably underestimated.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29885493' target='_blank' class='pmid-link'>29885493</a>:</span> <span class='sentence-part'>In experiment 2, dantrolene treatment (n = 8) was compared with placebo-control (n = 9) on SS-induced AF inducibility in HF.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30386232' target='_blank' class='pmid-link'>30386232</a>:</span> <span class='sentence-part'>In our review, we discuss these anticancer therapies and how they induce AF and consequently provide information on the precaution of AF during cancer treatment. Anticancer Therapy-Induced Atrial Fibrillation: Electrophysiology and Related Mechanisms.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32717176' target='_blank' class='pmid-link'>32717176</a>:</span> <span class='sentence-part'>Hereto, there is an urgent unmet need to develop mechanistic treatments directed at root causes of AF.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/3929907' target='_blank' class='pmid-link'>3929907</a>:</span> <span class='sentence-part'>Fast atrial fibrillation induced by treatment of psoriasis with azathioprine.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/5095935' target='_blank' class='pmid-link'>5095935</a>:</span> <span class='sentence-part'>Treatment of refractory supraventricular arrhythmias with induced permanent atrial fibrillation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/521298' target='_blank' class='pmid-link'>521298</a>:</span> <span class='sentence-part'>Treatment with additional propranolol leads to atrial fibrillation and paroxysmal atrial tachycardia with block.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/6087012' target='_blank' class='pmid-link'>6087012</a>:</span> <span class='sentence-part'>The variations in the content of endogenic prostanoids and cyclic nucleotides in the blood plasma of the coronary sinus and ascending aorta were studied in patients with the idiopathic stable form of atrial fibrillation before and after sinus rhythm recovery effected by electroimpulse therapy.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/6209190' target='_blank' class='pmid-link'>6209190</a>:</span> <span class='sentence-part'>When APCs are symptomatic or are a potential trigger for supraventricular tachycardia or atrial fibrillation, suppressive therapy with beta-blocking drugs or type I antiarrhythmic agents is indicated.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/7837694' target='_blank' class='pmid-link'>7837694</a>:</span> <span class='sentence-part'>[A case of atrial fibrillation induced by interferon treatment for chronic hepatitis C].</span></div></div>
<div class='streamlined-assertion'><div class='streamlined-header sticky-relation-header'><span class='label-text'>Subject:</span> <strong>Thyrotoxicosis</strong> <span class='label-text'>Subject CUI:</span> <strong>C0040156</strong> â†’ <span class='label-text predicate-text'>CAUSES</span> â†’ <span class='label-text'>Object:</span> <strong>Atrial_Fibrillation</strong> <span class='label-text'>Object CUI:</span> <strong>C0004238</strong></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/110126' target='_blank' class='pmid-link'>110126</a>:</span> <span class='sentence-part'>It would appear that clinically occult thyrotoxicosis can be identified consistently only with the thyrotropin-releasing hormone test and is the cause of \idiopathic\ atrial fibrillation in a significant proportion of patients.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/12555335' target='_blank' class='pmid-link'>12555335</a>:</span> <span class='sentence-part'>[Efficacy of cibenzoline in a case of atrial fibrillation due to cardiac thyrotoxicosis].</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17940989' target='_blank' class='pmid-link'>17940989</a>:</span> <span class='sentence-part'>Long-lasting thyrotoxicosis in patient with heart disease may result in atrial fibrillation, deterioration of angina pectoris or congestive heart failure.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/18854634' target='_blank' class='pmid-link'>18854634</a>:</span> <span class='sentence-part'>This is the first report of atrial fibrillation induced by post-parathyroidectomy transient thyrotoxicosis. Atrial fibrillation induced by post-parathyroidectomy transient thyrotoxicosis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/1905273' target='_blank' class='pmid-link'>1905273</a>:</span> <span class='sentence-part'>Is idiopathic atrial fibrillation caused by occult thyrotoxicosis?</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29279710' target='_blank' class='pmid-link'>29279710</a>:</span> <span class='sentence-part'>We report a case of a male patient with stroke caused by atrial fibrillation (AF) due to thyrotoxicosis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31942554' target='_blank' class='pmid-link'>31942554</a>:</span> <span class='sentence-part'>This case involves a 55-year-old male patient with systolic heart failure and refractory atrial fibrillation due to thyrotoxicosis, who was electrically cardioverted but then developed torsade de pointes and ventricular fibrillation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36483878' target='_blank' class='pmid-link'>36483878</a>:</span> <span class='sentence-part'>Renal infarction in a patient with thyrotoxicosis-induced atrial fibrillation treated successfully with dabigatran, a case report and literature review.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36874762' target='_blank' class='pmid-link'>36874762</a>:</span> <span class='sentence-part'>Benefit and Preference of Propranolol Over Metoprolol in Thyrotoxicosis-Induced Atrial Fibrillation: A Case Report and Review of Literature. The aim of our review is to highlight that propranolol should be used over metoprolol in patients with hyperthyroidism-induced atrial fibrillation due to the effect of propranolol on blocking the activity of T4 conversion to active T3 and, as such, blocking its effect on cardiac myocytes, terminating reentrant atrial excitation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/6531144' target='_blank' class='pmid-link'>6531144</a>:</span> <span class='sentence-part'>Comparison between ten patients with atrial fibrillation induced by thyrotoxicosis which reverted to sinus rhythm after return to a euthyroid state, and ten age-matched controls with treated hyperthyroidism who never developed atrial fibrillation, showed no significant difference in the incidence of underlying ischaemic heart disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/9036481' target='_blank' class='pmid-link'>9036481</a>:</span> <span class='sentence-part'>Thyrotoxicosis may precipitate atrial fibrillation, myocardial ischemia or heart failure if underlying heart disease is present.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/9492159' target='_blank' class='pmid-link'>9492159</a>:</span> <span class='sentence-part'>Thyrotoxicosis can aggravate pre-existing cardiac disease and can also lead to atrial fibrillation, congestive heart failure, worsening of angina, thromboembolism, and rarely, death.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/9920373' target='_blank' class='pmid-link'>9920373</a>:</span> <span class='sentence-part'>Thyrotoxicosis can aggravate pre-existing heart disease and can also lead to AF, congestive heart failure, or worsening of angina pectoris.</span></div></div>
<div class='streamlined-assertion'><div class='streamlined-header sticky-relation-header'><span class='label-text'>Subject:</span> <strong>Toxic_effect</strong> <span class='label-text'>Subject CUI:</span> <strong>C0600688</strong> â†’ <span class='label-text predicate-text'>CAUSES</span> â†’ <span class='label-text'>Object:</span> <strong>Alzheimers</strong> <span class='label-text'>Object CUI:</span> <strong>C0002395</strong></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/1423339' target='_blank' class='pmid-link'>1423339</a>:</span> <span class='sentence-part'>An elderly woman developed an Alzheimer-like subacute dementia as a result of propranolol toxicity.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/16866916' target='_blank' class='pmid-link'>16866916</a>:</span> <span class='sentence-part'>According to the amyloid cascade hypothesis, both familial and sporadic Alzheimer's disease (AD) is caused by the toxic effect of over-production and/or aggregation of beta-amyloid (Abeta).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17676931' target='_blank' class='pmid-link'>17676931</a>:</span> <span class='sentence-part'>Amyloid beta (Abeta) toxicity has been hypothesized to initiate the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17873593' target='_blank' class='pmid-link'>17873593</a>:</span> <span class='sentence-part'>Recent data also reveal that general anesthesia produces enduring cognitive impairment in aged but not young rodents and that halothane and isoflurane increase the generation and toxicity of amyloid beta, a protein strongly implicated in the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/18160097' target='_blank' class='pmid-link'>18160097</a>:</span> <span class='sentence-part'>Although neuronal apoptosis in Alzheimer's disease is generally interpreted as the consequence of the toxicity of extracellular beta-amyloid (Abeta) peptide aggregates, some experimental results provide evidence that the Abeta overproduction can be the result of a primary neuronal degeneration.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/19765580' target='_blank' class='pmid-link'>19765580</a>:</span> <span class='sentence-part'>Recently, modulation of beta-amyloid (Abeta) toxicity, one of the major potential causes of Alzheimer's disease, has emerged as a possible therapeutic approach to control the onset of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/19969390' target='_blank' class='pmid-link'>19969390</a>:</span> <span class='sentence-part'>Alternatively, our analysis of the specific effects of DR on neuronal toxicity downstream of Abeta and tau pathologies with negative results may simply confirm that the neuro-protective effects of DR are upstream of the initiating events involved in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20159774' target='_blank' class='pmid-link'>20159774</a>:</span> <span class='sentence-part'>Since accumulation of DNA damage has been detected in the brains of AD patients, our results suggest that the DNA damage-activated kinases Chk1 and Chk2 may be involved in tau phosphorylation and toxicity in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20466736' target='_blank' class='pmid-link'>20466736</a>:</span> <span class='sentence-part'>The amyloid-beta 42 (Abeta42) peptide has been suggested to promote tau phosphorylation and toxicity in Alzheimer's disease (AD) pathogenesis; however, the underlying mechanisms are not fully understood. Our results demonstrate that tau phosphorylation at Ser262 is crucial for Abeta42-induced tau toxicity in vivo, and suggest a new model of AD progression in which activation of DNA repair pathways is protective against Abeta42 toxicity but may trigger tau phosphorylation and toxicity in AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21876248' target='_blank' class='pmid-link'>21876248</a>:</span> <span class='sentence-part'>The entangled relationship of brain aging, mitochondrial dysfunction, and amyloid-beta peptide (Abeta42) toxicity occupies the center stage in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22565015' target='_blank' class='pmid-link'>22565015</a>:</span> <span class='sentence-part'>Recently, it has been hypothesized that copper toxicity may be a contributory factor in the etiology of the neurodegenerative disease AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22903022' target='_blank' class='pmid-link'>22903022</a>:</span> <span class='sentence-part'>Together these experiments allowed the discrimination of the intermediate states more responsible of oligomer toxicity, providing new insights on the correlation between the aggregation process and the toxicity and confirming the peculiar role in the pathogenesis of Alzheimer disease of Abetapy3-42 peptide.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22947874' target='_blank' class='pmid-link'>22947874</a>:</span> <span class='sentence-part'>The amyloid-beta(25-35) peptide plays a key role in the etiology of Alzheimer's disease due to its extreme toxicity even in the absence of aging.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22952452' target='_blank' class='pmid-link'>22952452</a>:</span> <span class='sentence-part'>Our results suggest that loss of axonal mitochondria may play an important role in tau phosphorylation and toxicity in the pathogenesis of AD. Abnormal phosphorylation and toxicity of a microtubule-associated protein tau are involved in the pathogenesis of Alzheimer's disease (AD); however, what pathological conditions trigger tau abnormality in AD is not fully understood.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23160010' target='_blank' class='pmid-link'>23160010</a>:</span> <span class='sentence-part'>Our results imply that Abeta-DNA interaction needs to be considered as a significant cause of the toxicity in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23550703' target='_blank' class='pmid-link'>23550703</a>:</span> <span class='sentence-part'>Since DNA damage is accumulated in diseased brains, Chk1 and Chk2 may be involved in tau phosphorylation and toxicity in AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23700270' target='_blank' class='pmid-link'>23700270</a>:</span> <span class='sentence-part'>In the present study, we showed neuroprotective effects of peptide derived from H. trimaculatus against amyloid-beta42 (Abeta42) toxicity which are central to the pathogenesis of Alzheimer's diseases (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24710686' target='_blank' class='pmid-link'>24710686</a>:</span> <span class='sentence-part'>Mitochondrial toxic effects of Abeta through mitofusins in the early pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24796109' target='_blank' class='pmid-link'>24796109</a>:</span> <span class='sentence-part'>It is understood that molecules involved in this inflammation promote pathological processes leading to AD, whereas other molecules work to protect neuron/brain function from toxicity found in AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24820962' target='_blank' class='pmid-link'>24820962</a>:</span> <span class='sentence-part'>These results demonstrate the neuroprotective effects of CHD through inhibition of microglia-mediated neuroinflammation in in-vitro and in-vivo AD-like models induced by Abeta oligomer1-42 toxicity.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25187042' target='_blank' class='pmid-link'>25187042</a>:</span> <span class='sentence-part'>These results support a role of Abeta administration in inducing age-dependent cholinergic loss and neuroinflammation, and additionally provide evidence for a more age-appropriate model of adult-onset Abeta toxicity demonstrating pathological changes that reflect the early stages of AD pathogenesis including neuroinflammation, cholinergic loss and beginning stages of memory impairment.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25212543' target='_blank' class='pmid-link'>25212543</a>:</span> <span class='sentence-part'>Huperzine A is isolated from Huperzia serrata and is used for treatment of Alzheimer's disease, due to its low toxicity and long effective period.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25595891' target='_blank' class='pmid-link'>25595891</a>:</span> <span class='sentence-part'>Nonetheless, it now seems increasingly unlikely that amyloid toxicity is the cause of sporadic AD, which leads to cognitive decline.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25707809' target='_blank' class='pmid-link'>25707809</a>:</span> <span class='sentence-part'>Carbohydrates have been earlier used in the treatment of AD because of their low toxicity, high efficiency, good biocompatibility, and easy permeability through the blood-brain barrier.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25964177' target='_blank' class='pmid-link'>25964177</a>:</span> <span class='sentence-part'>Abeta (25-35) is the smallest peptide in the amyloid peptide family that retains the toxicity of a full length peptide responsible for Alzheimer's disease and is chosen here as the model solute.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27055069' target='_blank' class='pmid-link'>27055069</a>:</span> <span class='sentence-part'>In addition, all of the new BAMs were capable of protecting differentiated SH-SY5Y neuroblastoma cells from toxicity and concomitant oxidative stress induced by AD-related aggregated Abeta (1-42) peptides.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27240009' target='_blank' class='pmid-link'>27240009</a>:</span> <span class='sentence-part'>Recently, soluble AbetaOs have been regarded as reliable molecular biomarkers for the diagnosis of AD because of their high toxicity for neuronal synapse and high concentration levels in the brains of AD patients.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27662318' target='_blank' class='pmid-link'>27662318</a>:</span> <span class='sentence-part'>This concept is further strengthened by the protective effect of mitochondrial medicine on synaptic function against the toxicity of amyloid-beta, a key player in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/2900537' target='_blank' class='pmid-link'>2900537</a>:</span> <span class='sentence-part'>Glutamate toxicity may play a role in the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29199234' target='_blank' class='pmid-link'>29199234</a>:</span> <span class='sentence-part'>However, the effects of EZJ on amyloid beta (Abeta) toxicity, which is a main cause of Alzheimer's disease (AD), remain to be elucidated.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29332042' target='_blank' class='pmid-link'>29332042</a>:</span> <span class='sentence-part'>The purpose of our article is to assess the current understanding of Indian spice, curcumin, against amyloid-beta (Abeta)-induced toxicity in Alzheimer's disease (AD) pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29736334' target='_blank' class='pmid-link'>29736334</a>:</span> <span class='sentence-part'>In this study, we tested hydroalcoholic extracts of S. scardica for their potential to counteract amyloid-beta toxicity and aggregation, which plays a crucial role in the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29888266' target='_blank' class='pmid-link'>29888266</a>:</span> <span class='sentence-part'>Here we focus on what is known about the role of autophagy in amyloid toxicity in AD from mammalian models and how Drosophila models can be used to further investigate AD pathogenesis. Using Drosophila Models of Amyloid Toxicity to Study Autophagy in the Pathogenesis of Alzheimer's Disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30016667' target='_blank' class='pmid-link'>30016667</a>:</span> <span class='sentence-part'>However, other amyloid peptides are now gaining considerable attention as potential key participants in AD due to their proposed higher neuronal toxicity.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30935198' target='_blank' class='pmid-link'>30935198</a>:</span> <span class='sentence-part'>The aggregation of Abeta16-22 peptide, the smallest fragment of full-length Abeta1-42 with seven residues, plays a very crucial role in Abeta toxicity, hence causing Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31183966' target='_blank' class='pmid-link'>31183966</a>:</span> <span class='sentence-part'>Taken together, this study revealed that Akt is involved in the aging process and Abeta toxicity, and manipulating Akt can restore both neuronal functions and improve behavioral activity during the processes of aging and AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31275419' target='_blank' class='pmid-link'>31275419</a>:</span> <span class='sentence-part'>The deposition of amyloid beta (Abeta) is the main hallmark of Alzheimer's disease (AD) and there is no effective drug to cure the progressive cognitive loss or memory deficits caused by the aggregative toxicity of Abeta protein.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31415717' target='_blank' class='pmid-link'>31415717</a>:</span> <span class='sentence-part'>BACKGROUND/AIMS: Amyloid plaques, generated during the progression of Alzheimer's disease, cause major neurological deficits due to substantial cell toxicity and death.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31926632' target='_blank' class='pmid-link'>31926632</a>:</span> <span class='sentence-part'>Natural products hold considerable interest for the development of preventive neuroprotectants to treat neurodegenerative disorders like AD, due to their low toxicity and general beneficial effects on human health with their anti-inflammatory and antioxidant features.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33081348' target='_blank' class='pmid-link'>33081348</a>:</span> <span class='sentence-part'>Copper Toxicity Links to Pathogenesis of Alzheimer's Disease and Therapeutics Approaches. Several studies have indicated that oxidative stress plays a crucial role in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33328884' target='_blank' class='pmid-link'>33328884</a>:</span> <span class='sentence-part'>How Microglia Manages Non-cell Autonomous Vicious Cycling of Abeta Toxicity in the Pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33482095' target='_blank' class='pmid-link'>33482095</a>:</span> <span class='sentence-part'>gamma-secretase is a promising therapeutic target for Alzheimer's disease, but all inhibitors and modulators have failed due to toxicity or low efficacy.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33642992' target='_blank' class='pmid-link'>33642992</a>:</span> <span class='sentence-part'>Since hypothesis put forward by Arispe and collegues in 1993 that amyloid-beta makes ion-conducting channels and that Alzheimer's disease may be due to the toxic effect of these channels, many studies have confirmed that APs are formed by prefibrillar oligomers of amyloidogenic proteins and are a common source of cytotoxicity.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33806326' target='_blank' class='pmid-link'>33806326</a>:</span> <span class='sentence-part'>Recent evidence suggests that the formation of soluble amyloid beta (Abeta) aggregates with high toxicity, such as oligomers and protofibrils, is a key event that causes Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34886786' target='_blank' class='pmid-link'>34886786</a>:</span> <span class='sentence-part'>There is great popularity gained by natural supplements as the treatment for AD, due to the higher toxicities of synthetic drugs.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35006003' target='_blank' class='pmid-link'>35006003</a>:</span> <span class='sentence-part'>This study provides new molecular leads on altered protein dynamics relevant to neurodegeneration, neuroplasticity, and AD progression induced by Abeta42 toxicity. Production and deposition of beta-amyloid peptides (Abeta) are among the major hallmarks of the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/3767535' target='_blank' class='pmid-link'>3767535</a>:</span> <span class='sentence-part'>The most common dementia diagnoses were Alzheimer's-type dementia (74.5%) and dementia due to toxic effects of drugs (9.5%).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/38551492' target='_blank' class='pmid-link'>38551492</a>:</span> <span class='sentence-part'>Soluble amyloid-beta protein oligomers (AbetaO) (mainly AbetaO     42      ) that circulate in biological fluids have been recognized as a molecular biomarker and therapeutic target of AD due to their high toxicity, and they are correlated much more strongly with AD compared to the insoluble Abeta monomers.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/8869917' target='_blank' class='pmid-link'>8869917</a>:</span> <span class='sentence-part'>The deficiency of selenium, which may act physiologically as an antagonist of tellurium, in the Alzheimer's disease brain would also be in keeping with the hypothesis of tellurium toxicity as a factor in the pathogenesis of Alzheimer's disease.</span></div></div>
<div class='streamlined-assertion'><div class='streamlined-header sticky-relation-header'><span class='label-text'>Subject:</span> <strong>Transesophageal_cardiac_pacing_procedure</strong> <span class='label-text'>Subject CUI:</span> <strong>C0472589</strong> â†’ <span class='label-text predicate-text'>CAUSES</span> â†’ <span class='label-text'>Object:</span> <strong>Atrial_Fibrillation</strong> <span class='label-text'>Object CUI:</span> <strong>C0004238</strong></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/12395207' target='_blank' class='pmid-link'>12395207</a>:</span> <span class='sentence-part'>Induction of atrial fibrillation in mice by rapid transesophageal atrial pacing.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/15175567' target='_blank' class='pmid-link'>15175567</a>:</span> <span class='sentence-part'>Atrial fibrillation in rats induced by rapid transesophageal atrial pacing during brief episodes of asphyxia: a new in vivo model. AF was induced by transesophageal atrial burst pacing during 35 seconds periods of asphyxia in anesthetized male Sprague-Dawley rats.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/15968140' target='_blank' class='pmid-link'>15968140</a>:</span> <span class='sentence-part'>Af was reproducibly induced by transesophageal atrial burst pacing for 30 s in each of the pentobarbital-anesthetized rats, whereas the cardiohemodynamic condition as well as the inducibility and duration of Af episode was stable over time.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17408377' target='_blank' class='pmid-link'>17408377</a>:</span> <span class='sentence-part'>AFL could be terminated by directed rapid TAP using an esophageal TO electrode, leading to induction of atrial fibrillation (AF) (n=6), induction of AF and spontaneous conversion to sinus rhythm (SR) (n=3), and with conversion to SR (n=1). AFL could also be terminated by directed rapid TAP using the TEE tube electrode, with induction of AF (n=3) or induction of AF and spontaneous conversion to SR (n=3).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/2076378' target='_blank' class='pmid-link'>2076378</a>:</span> <span class='sentence-part'>In the other seven patients, the ECG was not recorded during the symptoms, but an episode of atrial fibrillation was subsequently induced by transesophageal pacing.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22613983' target='_blank' class='pmid-link'>22613983</a>:</span> <span class='sentence-part'>AF was induced by transesophageal burst pacing.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25328683' target='_blank' class='pmid-link'>25328683</a>:</span> <span class='sentence-part'>AF was reproducibly induced by transesophageal atrial burst pacing in spontaneously hypertensive rats (SHR) and Wistar-Kyoto rats (WKY).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25352232' target='_blank' class='pmid-link'>25352232</a>:</span> <span class='sentence-part'>AF was induced by transesophageal burst pacing.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25955429' target='_blank' class='pmid-link'>25955429</a>:</span> <span class='sentence-part'>AF was induced by transesophageal burst pacing.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/2605586' target='_blank' class='pmid-link'>2605586</a>:</span> <span class='sentence-part'>Incremental TAP up to the occurrence of block in the AP was instituted, and attempts to induce atrial fibrillation (AF) with rapid burst pacing were made.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26203906' target='_blank' class='pmid-link'>26203906</a>:</span> <span class='sentence-part'>METHODS AND RESULTS: Trans-esophageal atrial burst pacing in mice could induce AF, as previously shown, but with only a short duration (29.0 +/- 8.1 sec).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28257569' target='_blank' class='pmid-link'>28257569</a>:</span> <span class='sentence-part'>While transesophageal burst pacing invariably induced AF (8/8, 100%) in WT-HFD mice, AF was induced less frequently (1/8, 12.5%) in Ob-HFD mice (P &lt; 0.01).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29291943' target='_blank' class='pmid-link'>29291943</a>:</span> <span class='sentence-part'>AF was induced by transesophageal atrial pacing in healthy mice and following a long-term high-fat-diet-induced insulin resistance.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32554248' target='_blank' class='pmid-link'>32554248</a>:</span> <span class='sentence-part'>AF was induced by transesophageal burst pacing on day 3 after surgery.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32682626' target='_blank' class='pmid-link'>32682626</a>:</span> <span class='sentence-part'>AF was induced either by transesophageal burst pacing in vivo or by burst/extrastimuli in isolated perfused hearts using a Langendorff apparatus. CONCLUSION: Our results demonstrated that RKT prevented atrial fibrosis and attenuated enhanced vulnerability to AF induced by AngII.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32792672' target='_blank' class='pmid-link'>32792672</a>:</span> <span class='sentence-part'>AF susceptibility, evaluated in terms of the duration of AF induced by transesophageal burst pacing, was significantly increased concomitantly with atrial remodeling, including fibrosis, myocyte apoptosis and oxidative DNA damage, in BO mice.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32903422' target='_blank' class='pmid-link'>32903422</a>:</span> <span class='sentence-part'>Transesophageal atrial pacing was used to induce AF in healthy, streptozotocin-induced insulin-deficient type 1 diabetic, and insulin-treated diabetic mice.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34515064' target='_blank' class='pmid-link'>34515064</a>:</span> <span class='sentence-part'>AF was induced by transesophageal burst pacing in vivo.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35225273' target='_blank' class='pmid-link'>35225273</a>:</span> <span class='sentence-part'>Transesophageal Atrial Burst Pacing for Atrial Fibrillation Induction in Rats.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37113690' target='_blank' class='pmid-link'>37113690</a>:</span> <span class='sentence-part'>Programmed electrical stimulation (PES) using intracardiac or transesophageal atrial pacing is used to induce AF as most mouse models do not develop spontaneous AF.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37795649' target='_blank' class='pmid-link'>37795649</a>:</span> <span class='sentence-part'>Transesophageal rapid atrial pacing was used to induce atrial fibrillation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37920527' target='_blank' class='pmid-link'>37920527</a>:</span> <span class='sentence-part'>Transesophageal burst pacing was used in vivo to induce AF.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/38645493' target='_blank' class='pmid-link'>38645493</a>:</span> <span class='sentence-part'>Therefore, we investigated the protective effect of Cor in angiotensin II (Ang II)-induced atrial fibrosis and atrial fibrillation (AF). In vivo    , transesophageal burst pacing was used to generate AF.</span></div></div>
<div class='streamlined-assertion'><div class='streamlined-header sticky-relation-header'><span class='label-text'>Subject:</span> <strong>Traumatic_Brain_Injury</strong> <span class='label-text'>Subject CUI:</span> <strong>C0876926</strong> â†’ <span class='label-text predicate-text'>CAUSES</span> â†’ <span class='label-text'>Object:</span> <strong>Alzheimers</strong> <span class='label-text'>Object CUI:</span> <strong>C0002395</strong></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/10499440' target='_blank' class='pmid-link'>10499440</a>:</span> <span class='sentence-part'>Brain trauma in humans increases the risk for developing Alzheimer disease (AD) and may induce the acute formation of AD-like plaques containing amyloid beta (A beta).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/10937919' target='_blank' class='pmid-link'>10937919</a>:</span> <span class='sentence-part'>Considering the increase in the prevalence of both traumatic brain injury and AD in recent times, the possibility that brain trauma may provoke the early development of AD has important implications for health service planning, preventative efforts, and medico-legal compensation settlements.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/11504565' target='_blank' class='pmid-link'>11504565</a>:</span> <span class='sentence-part'>BACKGROUND AND PURPOSE: The impact of traumatic brain injury (TBI) on the pathogenesis of Alzheimer disease (AD) is still controversial.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/18492093' target='_blank' class='pmid-link'>18492093</a>:</span> <span class='sentence-part'>Additionally, TBI induces AD-like amyloid beta (Abeta) plaque pathology within days of injury potentially resulting from massive accumulation of amyloid precursor protein (APP) in damaged axons. These findings fail to support the premise that progressive plaque pathology after TBI ultimately results in AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/19326964' target='_blank' class='pmid-link'>19326964</a>:</span> <span class='sentence-part'>Traumatic brain injury (TBI) induces the rapid formation of Alzheimer's disease (AD)-like amyloid-beta (AB) plaques in about 30% of patients.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25380674' target='_blank' class='pmid-link'>25380674</a>:</span> <span class='sentence-part'>Cognitive impairment represents a major debilitating feature of many neurodegenerative and psychiatric disorders, including Alzheimer's disease, mood disorders, schizophrenia and fragile X syndrome, as well as being a result of traumatic brain injury or cranial irradiation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26176913' target='_blank' class='pmid-link'>26176913</a>:</span> <span class='sentence-part'>Thus, cis P-tau is a major early driver of disease after TBI and leads to tauopathy in chronic traumatic encephalopathy and Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26899581' target='_blank' class='pmid-link'>26899581</a>:</span> <span class='sentence-part'>In addition, we discuss the evidence that supports the hypothesis that TBI may lead to AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27395469' target='_blank' class='pmid-link'>27395469</a>:</span> <span class='sentence-part'>[Late-onset Neurodegenerative Diseases Following Traumatic Brain Injury: Chronic Traumatic Encephalopathy (CTE) and Alzheimer's Disease Secondary to TBI (AD-TBI)].</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27654282' target='_blank' class='pmid-link'>27654282</a>:</span> <span class='sentence-part'>Although whether traumatic brain injury (TBI) could cause AD has not been established, CTE is shown to be associated with TBI.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27915236' target='_blank' class='pmid-link'>27915236</a>:</span> <span class='sentence-part'>We describe the common underlying neurobiology in alcohol and AD, and examine ways alcohol likely contributes to neuroinflammation directly via stimulation of Toll-like receptors and indirectly from small bowel changes, hepatic changes, withdrawal and traumatic brain injury to the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28776265' target='_blank' class='pmid-link'>28776265</a>:</span> <span class='sentence-part'>The present study intended to explore the effect of TBI on metabolism and its role in AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29318971' target='_blank' class='pmid-link'>29318971</a>:</span> <span class='sentence-part'>To address these issues, we have proposed the use of an animal model of concussion/TBI as a supplement to AD transgenic mice to provide an indication of an AD drug candidate's potential for preventing PPCD and resulting progression towards dementia in AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29933008' target='_blank' class='pmid-link'>29933008</a>:</span> <span class='sentence-part'>This review summarizes the current knowledge and concepts regarding the connection between long-term consequences of TBI and aging-associated neurodegenerative disorders including Alzheimer's disease (AD), chronic traumatic encephalopathy (CTE), and Parkinsonism, with implications for novel therapy targets.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30395237' target='_blank' class='pmid-link'>30395237</a>:</span> <span class='sentence-part'>The precise nature of how r-mTBI leads to, or precipitates, AD pathogenesis remains unclear.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30618712' target='_blank' class='pmid-link'>30618712</a>:</span> <span class='sentence-part'>However, the precise nature of how r-mTBI leads to or precipitates AD pathogenesis is currently not understood.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30837829' target='_blank' class='pmid-link'>30837829</a>:</span> <span class='sentence-part'>Investigation of secondary mechanisms triggered by aberrant downstream alterations in bioactive metabolites of these phospholipids, and their modulation at the appropriate time-windows of opportunity could help facilitate development of novel therapeutic strategies to ameliorate the neurodegenerative consequences of rmTBI or the potential triggering of AD pathogenesis by rmTBI.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30906371' target='_blank' class='pmid-link'>30906371</a>:</span> <span class='sentence-part'>Unusual FDG-PET Findings in Traumatic Brain Injury; Did Traumatic Brain Injury Provoke Rapid Progression of Alzheimer's Disease?</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31778772' target='_blank' class='pmid-link'>31778772</a>:</span> <span class='sentence-part'>Knockout of AEP or C/EBPbeta diminishes TBI-induced AD-like pathology and cognitive impairment in the 3xTg AD mouse model.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31975836' target='_blank' class='pmid-link'>31975836</a>:</span> <span class='sentence-part'>DSM-5     recognizes the following etiologies for NCDs: NCD due to Alzheimer's disease, vascular NCD, NCD with Lewy bodies, frontotemporal NCD, substance-/medication-induced NCD, NCD due to traumatic brain injury, NCD due to Huntington's disease, NCD due to HIV infection, NCD due to prion disease, and NCD due to other medical conditions.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33171143' target='_blank' class='pmid-link'>33171143</a>:</span> <span class='sentence-part'>In the first part of this review, we analyze the experimental literatures on tau pathology in various TBI models and review the distribution, biological features and mechanisms of tau pathology following TBI with implications in AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34140411' target='_blank' class='pmid-link'>34140411</a>:</span> <span class='sentence-part'>Depletion of C/EBPbeta inhibits TBI-induced AD-like pathologies in these mice.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34539542' target='_blank' class='pmid-link'>34539542</a>:</span> <span class='sentence-part'>Various aspects of the mechanism of TBI-induced AD have been elucidated. However, there are also studies opposing the view that TBI is one of the causes of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34831202' target='_blank' class='pmid-link'>34831202</a>:</span> <span class='sentence-part'>However, no effective therapies are currently available for TBI-induced AD-like disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35136958' target='_blank' class='pmid-link'>35136958</a>:</span> <span class='sentence-part'>Unfortunately, no effective therapies are currently available for prevention and treatment of the traumatic brain injury-induced Alzheimer's disease-like neurodegenerative disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36966972' target='_blank' class='pmid-link'>36966972</a>:</span> <span class='sentence-part'>Several lines of evidence indicate that pharmacological or genetic inactivation of MAGL, which boosts 2-AG levels and reduces its hydrolytic metabolites, resolves neuroinflammation, mitigates neuropathology, and improves synaptic and cognitive functions in animal models of neurodegenerative diseases, including Alzheimer's disease (AD), multiple sclerosis (MS), Parkinson's disease (PD), and traumatic brain injury (TBI)-induced neurodegenerative disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37205508' target='_blank' class='pmid-link'>37205508</a>:</span> <span class='sentence-part'>Traumatic brain injury in mice generates early-stage Alzheimer's disease related protein pathology that correlates with neurobehavioral deficits.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37284155' target='_blank' class='pmid-link'>37284155</a>:</span> <span class='sentence-part'>Next, a critical new study has identified that acetylated tau protein, which has been found to be increased in the brains of Alzheimer's disease and CTE patients, can be induced by TBI, is neurotoxic, and that its reduction via already-existent therapeutics is neuroprotective.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/38261283' target='_blank' class='pmid-link'>38261283</a>:</span> <span class='sentence-part'>A comprehensive analysis of research results shows that the cascade of reactions triggered by TBI includes all the main elements of the pathogenesis of AD: disorders of energy metabolism, microcirculation and clearance of cerebral metabolic products.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/38411868' target='_blank' class='pmid-link'>38411868</a>:</span> <span class='sentence-part'>Traumatic Brain Injury in Mice Generates Early-Stage Alzheimer's Disease Related Protein Pathology that Correlates with Neurobehavioral Deficits.</span></div></div>
<div class='streamlined-assertion'><div class='streamlined-header sticky-relation-header'><span class='label-text'>Subject:</span> <strong>Vascular_Diseases</strong> <span class='label-text'>Subject CUI:</span> <strong>C0042373</strong> â†’ <span class='label-text predicate-text'>CAUSES</span> â†’ <span class='label-text'>Object:</span> <strong>Alzheimers</strong> <span class='label-text'>Object CUI:</span> <strong>C0002395</strong></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/11772511' target='_blank' class='pmid-link'>11772511</a>:</span> <span class='sentence-part'>The results show that serum TNF-alpha was lower in mild-moderate AD compared to severe AD and dementias due to vascular disease, as well as the TNF-alpha/IL-1beta ratio.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/15087585' target='_blank' class='pmid-link'>15087585</a>:</span> <span class='sentence-part'>In Alzheimer's disease (AD), white matter structural pathology is due to Wallerian degeneration and central angiopathy.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/1781965' target='_blank' class='pmid-link'>1781965</a>:</span> <span class='sentence-part'>Results confirm the frequent association of white matter abnormalities in patients with DAT that are possibly caused by amyloid angiopathy and may contribute to cognitive impairments.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20608291' target='_blank' class='pmid-link'>20608291</a>:</span> <span class='sentence-part'>Based on this viewpoint, this review article emphasizes that the morphological changes to small blood vessels in the brain with Alzheimer's disease convey crucial information and clues for solving the underlying mechanism that causes the disease. The atrophy of the brain with Alzheimer's disease is considered to be caused by the amyloid angiopathy of small blood vessels and the degeneration of capillaries and vascular feet.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21575878' target='_blank' class='pmid-link'>21575878</a>:</span> <span class='sentence-part'>Risk of Alzheimer's disease incidence attributable to vascular disease in the population.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/2377677' target='_blank' class='pmid-link'>2377677</a>:</span> <span class='sentence-part'>Despite the obviously more important degeneratively conditioned dementias, particularly of the Alzheimer-type, dementias due to vascular disorders are still of considerable relevance.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24084803' target='_blank' class='pmid-link'>24084803</a>:</span> <span class='sentence-part'>In the current review, the most common types of dementia, including Alzheimer disease, frontotemporal dementia, dementia due to vascular disease, and several others, are described.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28017827' target='_blank' class='pmid-link'>28017827</a>:</span> <span class='sentence-part'>Risk of incident clinical diagnosis of Alzheimer's disease-type dementia attributable to pathology-confirmed vascular disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34690734' target='_blank' class='pmid-link'>34690734</a>:</span> <span class='sentence-part'>Synaptic loss, senile plaques, and neurofibrillary tangles are the functional and diagnostic hallmarks of AD, but it is the structural changes as a consequence of vascular disease that reduce brain reserve and compensation, resulting in an earlier expression of the clinical dementia syndrome.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35578799' target='_blank' class='pmid-link'>35578799</a>:</span> <span class='sentence-part'>They had diagnoses of mild or major neurocognitive disorder due to suspected AD (N=20), mild or major neurocognitive disorder due to suspected VaD (N=44), or no neurocognitive diagnosis (i.e., healthy adult comparisons; HC, N=34).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37334605' target='_blank' class='pmid-link'>37334605</a>:</span> <span class='sentence-part'>Stroke prognosis impacts AD development due to vascular disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/9823829' target='_blank' class='pmid-link'>9823829</a>:</span> <span class='sentence-part'>BACKGROUND: Recent studies suggest that vascular disease may contribute to the cause of Alzheimer disease (AD).</span></div></div>
<div class='streamlined-assertion'><div class='streamlined-header sticky-relation-header'><span class='label-text'>Subject:</span> <strong>Virus</strong> <span class='label-text'>Subject CUI:</span> <strong>C0042776</strong> â†’ <span class='label-text predicate-text'>CAUSES</span> â†’ <span class='label-text'>Object:</span> <strong>Alzheimers</strong> <span class='label-text'>Object CUI:</span> <strong>C0002395</strong></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/11258753' target='_blank' class='pmid-link'>11258753</a>:</span> <span class='sentence-part'>The peripheral and central nervous system are harbouring herpes simplex virus type 1 (HSV-1) and this virus has been proposed to be implicated in the aetiology of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/12226537' target='_blank' class='pmid-link'>12226537</a>:</span> <span class='sentence-part'>The proposition that environmental agents, such as diet, aluminum, and viruses, are as important as genetic factors in the etiology of Alzheimer's disease (AD) was advanced by the authors at the Challenging Views of Alzheimer's Disease meeting held in Cincinnati on July 28 and 29, 2001.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/15319093' target='_blank' class='pmid-link'>15319093</a>:</span> <span class='sentence-part'>Various infectious agents, and viruses in particular, have been proposed as potential causes of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/19221424' target='_blank' class='pmid-link'>19221424</a>:</span> <span class='sentence-part'>Our previous studies have implicated herpes simplex virus type 1 (HSV1) as an etiological agent in AD, and so we investigated whether infection with this virus induces AD-like tau phosphorylation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/2443213' target='_blank' class='pmid-link'>2443213</a>:</span> <span class='sentence-part'>These results, although negative, do not totally exclude the possibility that conventional viruses may play a role in the aetiology and pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25747044' target='_blank' class='pmid-link'>25747044</a>:</span> <span class='sentence-part'>AREAS COVERED: The various roles that LRP/LR plays in cancer, AD and infectious diseases caused by viruses and bacteria have been examined in detail and an overview of the current patented therapeutic strategies targeting this receptor is given.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25932012' target='_blank' class='pmid-link'>25932012</a>:</span> <span class='sentence-part'>Chronic infection by spirochetes, and co-infection with other bacteria and viruses should be included in our current view on the etiology of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26444787' target='_blank' class='pmid-link'>26444787</a>:</span> <span class='sentence-part'>CONCLUSIONS: The lack of any relation between humoral immune response against HHV-6 and AD and aMCI seems to rule out a role for this virus in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/2840102' target='_blank' class='pmid-link'>2840102</a>:</span> <span class='sentence-part'>However, unconventional slow viral infections share some of these traits with AD and yet they are caused by retroviruses or suspected viruses.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30087609' target='_blank' class='pmid-link'>30087609</a>:</span> <span class='sentence-part'>However, the recent discovery that Abeta is an antimicrobial peptide (AMP) acting against bacteria, fungi, and viruses gives increased credence to an infection hypothesis in the etiology of AD. These findings led to the \beta-amyloid hypothesis\ that proposes that Abeta is the major cause of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/3024793' target='_blank' class='pmid-link'>3024793</a>:</span> <span class='sentence-part'>The concluding section, on parallels between AD and diseases of the brain caused by unconventional viruses, defines strategies for isolating genes related to pathology.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31093882' target='_blank' class='pmid-link'>31093882</a>:</span> <span class='sentence-part'>Binding between Prion Protein and Abeta Oligomers Contributes to the Pathogenesis of Alzheimer's Disease. In addition, we proposed a potential mechanism to explain why infectious agents, such as viruses, conduce AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31456237' target='_blank' class='pmid-link'>31456237</a>:</span> <span class='sentence-part'>Important new information was presented regarding: the mechanisms of chromosomal integration for HHV-6A and -6B; the biology of inherited chromosomally integrated HHV-6A and -6B; animal models for, and animal viruses with similarities to, HHV-6A, -6B, and -7; established and possible disease associations, including provocative new information suggesting these viruses may be one trigger of Alzheimer's disease, and new treatment strategies.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31526227' target='_blank' class='pmid-link'>31526227</a>:</span> <span class='sentence-part'>Furthermore, evidence suggests that traditional infectious agents, including certain viruses and bacteria, may trigger AD. However, amyloid beta (Abeta) or tau, which can act like infectious proteins, or prions, might induce Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34971176' target='_blank' class='pmid-link'>34971176</a>:</span> <span class='sentence-part'>Yet, it is possible that the viruses play a role in the pathogenesis of AD, perhaps in the early stages of this dementia.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37170683' target='_blank' class='pmid-link'>37170683</a>:</span> <span class='sentence-part'>Furthermore, we infected these microtissues with HSV-1 virus and determined the HSV-induced pathogenesis associated with Alzheimer's disease, including neuron loss and the expression of Abeta.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/38249527' target='_blank' class='pmid-link'>38249527</a>:</span> <span class='sentence-part'>This paradigm shift is substantiated by an extensive body of scientific literature, which underscores the significant contributions of microorganisms, encompassing viruses and gut-derived bacteria, to the pathogenesis of AD.</span></div></div>
<div class='streamlined-assertion'><div class='streamlined-header sticky-relation-header'><span class='label-text'>Subject:</span> <strong>Zinc</strong> <span class='label-text'>Subject CUI:</span> <strong>C0043481</strong> â†’ <span class='label-text predicate-text'>CAUSES</span> â†’ <span class='label-text'>Object:</span> <strong>Alzheimers</strong> <span class='label-text'>Object CUI:</span> <strong>C0002395</strong></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/12505647' target='_blank' class='pmid-link'>12505647</a>:</span> <span class='sentence-part'>Further research on the zinc paradox in AD is needed in order to elucidate the exact role zinc plays in AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/18376063' target='_blank' class='pmid-link'>18376063</a>:</span> <span class='sentence-part'>Recent studies also point to redox active metals such as iron, copper and zinc in mediating oxidative stress in AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/18603329' target='_blank' class='pmid-link'>18603329</a>:</span> <span class='sentence-part'>Zinc is also involved, in a sex-dependent manner, in the pathogenesis of Alzheimer's disease (AD), where substantial declines in plasticity may occur.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/19276540' target='_blank' class='pmid-link'>19276540</a>:</span> <span class='sentence-part'>Although multiple studies have suggested a role for alterations of zinc (Zn) and zinc transport (ZnT) proteins in the pathogenesis of Alzheimer's disease, the exact role of this essential trace element in the progression of the disease remains unclear.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/2025422' target='_blank' class='pmid-link'>2025422</a>:</span> <span class='sentence-part'>Hypothesis regarding amyloid and zinc in the pathogenesis of Alzheimer disease: potential for preventive intervention.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20730621' target='_blank' class='pmid-link'>20730621</a>:</span> <span class='sentence-part'>The aim of this review is to discuss the role of redox metals Fe and Cu and non-redox metal zinc (Zn) in oxidative stress-related etiology of AD and PD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30598025' target='_blank' class='pmid-link'>30598025</a>:</span> <span class='sentence-part'>Moreover, it is already established that metals (particularly copper, zinc and iron) have a key role in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/8073293' target='_blank' class='pmid-link'>8073293</a>:</span> <span class='sentence-part'>Rapid induction of Alzheimer A beta amyloid formation by zinc.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/9164672' target='_blank' class='pmid-link'>9164672</a>:</span> <span class='sentence-part'>This paper reviews current investigations that suggest a role of zinc in the etiology of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/9334223' target='_blank' class='pmid-link'>9334223</a>:</span> <span class='sentence-part'>Zinc-induced Alzheimer's Abeta1-40 aggregation is mediated by conformational factors.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/9358828' target='_blank' class='pmid-link'>9358828</a>:</span> <span class='sentence-part'>CONCLUSIONS: While earlier literature promoted the use of zinc in AD patients, a recent study has contradicted this and implicated zinc in the aetiology of Alzheimer's disease.</span></div></div>
<div class='streamlined-assertion'><div class='streamlined-header sticky-relation-header'><span class='label-text'>Subject:</span> <strong>aluminum</strong> <span class='label-text'>Subject CUI:</span> <strong>C0002367</strong> â†’ <span class='label-text predicate-text'>CAUSES</span> â†’ <span class='label-text'>Object:</span> <strong>Alzheimers</strong> <span class='label-text'>Object CUI:</span> <strong>C0002395</strong></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31894463' target='_blank' class='pmid-link'>31894463</a>:</span> <span class='sentence-part'>Here, we have evaluated the possible effects of Ginkgo biloba (GBE) against aggregation of the Abeta through activation of heat shock proteins (HSPs) in the Aluminium (Al) induced AD based model. In conclusion, our results indicate that GBE prevents the symptoms of Al induced AD like pathophysiology by upregulating the HSPs levels and decreasing the aggregation load.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31923036' target='_blank' class='pmid-link'>31923036</a>:</span> <span class='sentence-part'>Moreover, immunochemical and histopathological examination revealed marked protection with virgin coconut oil against aluminum-induced Alzheimer's disease-like pathology and cognitive deficit.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31958088' target='_blank' class='pmid-link'>31958088</a>:</span> <span class='sentence-part'>Human exposure to aluminum is linked to the etiology of Alzheimer's disease and recent research measured a high content of aluminum in brain tissue in familial Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32201908' target='_blank' class='pmid-link'>32201908</a>:</span> <span class='sentence-part'>Among well-known environmental risk factors, prolonged exposure to several heavy metals, for example, aluminum, arsenic, cadmium, lead, and mercury; particulate air, and some pesticides as well as metal-containing nanoparticles have been participated to cause AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32473558' target='_blank' class='pmid-link'>32473558</a>:</span> <span class='sentence-part'>Synchrotron Fourier transform infrared microspectroscopy (sFTIRM) analysis of Al-induced Alzheimer's disease in rat brain cortical tissue.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32619464' target='_blank' class='pmid-link'>32619464</a>:</span> <span class='sentence-part'>ATR-IR and EPR spectroscopy for following the membrane restoration of isolated cortical synaptosomes in aluminium-induced Alzheimer's disease - Like rat model. Here we investigated the therapeutic potential of Lepedium sativum (LS) as a natural anti-inflammatory, antioxidant and as acetyl cholinesterase inhibitor in treating Al induced AD-like in rat model.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32900247' target='_blank' class='pmid-link'>32900247</a>:</span> <span class='sentence-part'>Aluminum (Al), a neurotoxic element, can induce Alzheimer's disease (AD) via triggering neuronal death.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32990282' target='_blank' class='pmid-link'>32990282</a>:</span> <span class='sentence-part'>RhoA/Rock2/Limk1/cofilin1 pathway is involved in attenuation of neuronal dendritic spine loss by paeonol in the frontal cortex of D-galactose and aluminum-induced Alzheimer's disease-like rat model.Alzheimer's disease (AD) has become the most prevalent neurodegenerative disorder. RhoA/Rock2/Limk1/cofilin1 pathway is involved in attenuation of neuronal dendritic spine loss by paeonol in the frontal cortex of D-galactose and aluminum-induced Alzheimer's disease-like rat model.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33022965' target='_blank' class='pmid-link'>33022965</a>:</span> <span class='sentence-part'>Aluminium (Al) is clearly neurotoxic and considerable evidence exists that Al may play a role in the aetiology or pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33174148' target='_blank' class='pmid-link'>33174148</a>:</span> <span class='sentence-part'>Alteration in DNA methylation after aluminum exposure has been shown to contribute in pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33464538' target='_blank' class='pmid-link'>33464538</a>:</span> <span class='sentence-part'>Aluminum demonstrates clear neurotoxicity and can cause Alzheimer's disease (AD)-like symptoms, including cognitive impairment.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34111442' target='_blank' class='pmid-link'>34111442</a>:</span> <span class='sentence-part'>Following CHIT1 treatment, we found that the protein and mRNA levels of HDAC3 and NF-kappaB were reduced, the expression level of IkappaBalpha increased, anti-inflammatory factors (Arg-1, IL-10, and CD206) were elevated while pro-inflammatory factors (TNF-a, iNOS, and IL-1beta) were decreased in D-gal/aluminum-induced AD rats.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34396567' target='_blank' class='pmid-link'>34396567</a>:</span> <span class='sentence-part'>It is not yet known whether aluminium can travel from the skin to brain to cause Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34499332' target='_blank' class='pmid-link'>34499332</a>:</span> <span class='sentence-part'>Aluminum is a widespread environmental neurotoxicant that can induce Alzheimer's disease (AD)-like damage, such as neuronal injury and impairment of learning and memory.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34606775' target='_blank' class='pmid-link'>34606775</a>:</span> <span class='sentence-part'>Considering the suggested connection between aluminum exposure and Alzheimer's disease (AD) pathogenesis, there is a concern about the effect of nano-Al on cognitive function and brain health.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34706318' target='_blank' class='pmid-link'>34706318</a>:</span> <span class='sentence-part'>The influence of vinpocetine alone or in combination with Epigallocatechin-3-gallate, Coenzyme COQ10, Vitamin E and Selenium as a potential neuroprotective combination against aluminium-induced Alzheimer's disease in Wistar Albino Rats. To explore the possible neuroprotective effect as well as mechanism of action of Vinpocetine either alone or in combination with EGCG, CoQ10, or VE &amp; Se in ameliorating aluminum chloride-induced AD in rats.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34771159' target='_blank' class='pmid-link'>34771159</a>:</span> <span class='sentence-part'>Attenuative Effects of Fluoxetine and    Triticum aestivum     against Aluminum-Induced Alzheimer's Disease in Rats: The Possible Consequences on Hepatotoxicity and Nephrotoxicity.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34982355' target='_blank' class='pmid-link'>34982355</a>:</span> <span class='sentence-part'>Necrostatin-1 Relieves Learning and Memory Deficits in a Zebrafish Model of Alzheimer's Disease Induced by Aluminum.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35313783' target='_blank' class='pmid-link'>35313783</a>:</span> <span class='sentence-part'>Aluminum (Al), a neurotoxic element, can induce Alzheimer's disease-like (AD-like) changes by triggering neuronal death.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35668264' target='_blank' class='pmid-link'>35668264</a>:</span> <span class='sentence-part'>This study aimed to elucidate the role of the Wnt/beta-catenin pathway in BA protective activity against aluminum-induced Alzheimer's disease. The results conclude that BA administration modulated the expression of Wnt/beta-catenin pathway-related parameters, contributing to BA's role against Al-induced Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36306920' target='_blank' class='pmid-link'>36306920</a>:</span> <span class='sentence-part'>These results suggest that AS ameliorated Al-induced AD by affecting the expression of BACE1 and reducing the level of Abeta     1-42      , thereby exerting a neuroprotective effect. Combination of Alpinia Oxyphylla Fructus and Schisandra Chinensis Fructus ameliorates aluminum-induced Alzheimer's disease via reducing BACE1 expression.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36430429' target='_blank' class='pmid-link'>36430429</a>:</span> <span class='sentence-part'>The proposed in vivo Al-induced AD-resembling animal system seems to be adequate for the understanding of AD neuropathology and future drug testing and radiopharmaceutical development. In Vivo Preclinical Assessment of beta-Amyloid-Affine [     11      C]C-PIB Accumulation in Aluminium-Induced Alzheimer's Disease-Resembling Hypercholesterinaemic Rat Model.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36462588' target='_blank' class='pmid-link'>36462588</a>:</span> <span class='sentence-part'>The potential ameliorative effect of bromelain compared to donepezil was evaluated in an aluminum chloride (AlCl3)-induced AD in rats. Ameliorative effects of bromelain on aluminum-induced Alzheimer's disease in rats through modulation of TXNIP pathway.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36516571' target='_blank' class='pmid-link'>36516571</a>:</span> <span class='sentence-part'>CONCLUSION: The combination of taurine and DFP is a potential candidate for the treatment of AD induced by Al exposure.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37077707' target='_blank' class='pmid-link'>37077707</a>:</span> <span class='sentence-part'>Garden Cress (   Lepidium sativum    ) Seeds Ameliorated Aluminum-Induced Alzheimer Disease in Rats Through Antioxidant, Anti-Inflammatory, and Antiapoptotic Effects.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37631278' target='_blank' class='pmid-link'>37631278</a>:</span> <span class='sentence-part'>The aim of this study is to investigate the pathophysiological mechanisms underlying AD and explore the potential neuroprotective effects of cocoa, either alone or in combination with other nutraceuticals, in an animal model of aluminum-induced AD. These alterations contributed to the observed behavioral and histological changes in the AlCl     3      -induced AD model.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37801786' target='_blank' class='pmid-link'>37801786</a>:</span> <span class='sentence-part'>BACKGROUND: Studies have shown that aluminum (Al) is one of the environmental risk factors leading to Alzheimer's disease (AD), and Al exposure can cause elevated levels of BACE1mRNA, beta-secretase (BACE1), and amyloid beta (Abeta) in vivo and in vitro.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/38057817' target='_blank' class='pmid-link'>38057817</a>:</span> <span class='sentence-part'>A body of evidence suggest that oxidative stress and autophagy are involved in the pathogenesis of AD. However, its effects on aluminum-induced AD model have not been studied much.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/38070385' target='_blank' class='pmid-link'>38070385</a>:</span> <span class='sentence-part'>New bithiophene derivative attenuated Alzheimer's disease induced by aluminum in a rat model via antioxidant activity and restoration of neuronal and synaptic transmission.</span></div></div>
<div class='streamlined-assertion'><div class='streamlined-header sticky-relation-header'><span class='label-text'>Subject:</span> <strong>aluminum_chloride</strong> <span class='label-text'>Subject CUI:</span> <strong>C0102840</strong> â†’ <span class='label-text predicate-text'>CAUSES</span> â†’ <span class='label-text'>Object:</span> <strong>Alzheimers</strong> <span class='label-text'>Object CUI:</span> <strong>C0002395</strong></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22464639' target='_blank' class='pmid-link'>22464639</a>:</span> <span class='sentence-part'>DESIGN: Sixty female Sprague Dawley rats were divided into four groups n=15, (1) normal control group (con), (2) group underwent surgery to remove ovaries (ovx control group), (3) ovx group received aluminum chloride in a dose of 17 mg/kg daily for 2 months to induce AD (AD group), (4) AD group treated with alpha-chymotrypcin (alpha-ch) at dose (8.1 unit/rat/day) which is equivalent to the recommended human dose (alpha-ch-treated group) for three months. CONCLUSION: This study revealed that alpha-chymotrypcin significantly ameliorates the neuroinflammation characterizing Alzheimer's disease in ovariectomized rats due to it's proteolytic activity as well as it's anti-inflammatory effect.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23821590' target='_blank' class='pmid-link'>23821590</a>:</span> <span class='sentence-part'>Oral administration of aluminium chloride (AlCl3) in a dose of 17 mg/kg body weight (bw) daily for 45 days induced AD-like pathology in male rats with a significant increase in brain acetylcholinesterase (AchE) activity, transforming growth factor beta (TGF-beta), Fas and interleukin-6 (IL-6) levels.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25613582' target='_blank' class='pmid-link'>25613582</a>:</span> <span class='sentence-part'>Protective effect of selenium against aluminum chloride-induced Alzheimer's disease: behavioral and biochemical alterations in rats.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25630717' target='_blank' class='pmid-link'>25630717</a>:</span> <span class='sentence-part'>Neuroprotective effect of hesperidin on aluminium chloride induced Alzheimer's disease in Wistar rats.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25842984' target='_blank' class='pmid-link'>25842984</a>:</span> <span class='sentence-part'>The present study has been designed to explore the memory-enhancing effect of the tannoid principles of E. officinalis (EoT) at the biochemical, anatomical, behavioral, and molecular levels against aluminum chloride (AlCl3) induced Alzheimer's disease (AD) in rats.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26306462' target='_blank' class='pmid-link'>26306462</a>:</span> <span class='sentence-part'>Erratum to: Neuroprotective Effect of Hesperidin on Aluminium Chloride Induced Alzheimer's Disease in Wistar Rats.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26622218' target='_blank' class='pmid-link'>26622218</a>:</span> <span class='sentence-part'>70 female albino rats were divided equally into 7 groups as follows: group 1: healthy control; group 2: Aluminium chloride induced Alzheimer disease; group 3: induced Alzheimer rats that received intravenous injection of MSCs; group 4: induced Alzheimer rats that received MSCs and HO inducer cobalt protoporphyrin; group 5: induced Alzheimer rats that received MSCs and HO inhibitor zinc protoporphyrin; group 6: induced Alzheimer rats that received HO inducer; group7: induced Alzheimer rats that received HO inhibitor.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26897372' target='_blank' class='pmid-link'>26897372</a>:</span> <span class='sentence-part'>AD was induced by aluminum chloride (17 mg/kg, p.o. for 6 weeks) and confirmed by Morris water maze and Y-maze behavioral tests.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28003750' target='_blank' class='pmid-link'>28003750</a>:</span> <span class='sentence-part'>Group I: normal control group treated with water; Group II: disease control treated with AlCl3 to induce the mimicking AD for 4 successive weeks (SW); Group III: normal control group treated with baicalein (5 mg/kg) for 2 SW followed by combination of baicalein and AlCl3 for 4 SW; Group IV: normal control group treated with baicalein (10 mg/kg) for 2 SW followed by combination of baicalein and AlCl3 for 4 SW; Group V: normal control group treated with rivastigmine (0.3 mg/kg) for 2 SW followed by combination of rivastigmine and AlCl3 for 4 SW. Baicalein improves behavioral dysfunction induced by Alzheimer's disease in rats.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28499970' target='_blank' class='pmid-link'>28499970</a>:</span> <span class='sentence-part'>We also detected that chitnase1 could weaken the deposition of Abeta oligomers in the brain of D-galactose/ AlCl3-induced AD rats. Furthermore, anti-inflammation factors (Arginase 1, Arg-1, mannose receptor type C 1, MRC1/CD206) were increased and pro-inflammation factors (tumor necrosis factor alpha, TNFalpha, interleukin 1 beta, IL-1beta) were decreased in D-galactose/AlCl3-induced AD rats with chitinase1 treatment.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28514831' target='_blank' class='pmid-link'>28514831</a>:</span> <span class='sentence-part'>The present study aimed to identify the potential neuroprotective of HPE on AlCl3-induced AD rats. Our results showed HPE improved cognitive function in AlCl3-induced AD rats, and attenuated AlCl3-induced increase in acetylcholinesterase activity and glutamic acid level as well as decreased in noradrenaline and dopamine level. Hypericum perforatum extract attenuates behavioral, biochemical, and neurochemical abnormalities in Aluminum chloride-induced Alzheimer's disease rats. Thus, HPE is conferred neuroprotection against AlCl3-induced AD like pathology.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28650335' target='_blank' class='pmid-link'>28650335</a>:</span> <span class='sentence-part'>These findings suggest that co-administration of AlCl3 and D-gal for one week could induce AD like symptoms and may be used to develop AD animal model.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28697918' target='_blank' class='pmid-link'>28697918</a>:</span> <span class='sentence-part'>Sausage tree (Kigelia africana) flavonoid extract is neuroprotective in AlCl3-induced experimental Alzheimer's disease. In this study, the neuroprotective properties of a methanol extract of the leaves of Kigelia africana (KAE) and its flavonoid-rich fraction (FKAE) in aluminum chloride (AlCl3)-induced experimental AD was evaluated.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28715867' target='_blank' class='pmid-link'>28715867</a>:</span> <span class='sentence-part'>Therapeutic impact of grape leaves polyphenols on certain biochemical and neurological markers in AlCl3-induced Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29448848' target='_blank' class='pmid-link'>29448848</a>:</span> <span class='sentence-part'>Chronic treatment with morin-loaded micelles significantly increased the memory in AlCl3 induced Alzheimer's disease in Wistar rats.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29770796' target='_blank' class='pmid-link'>29770796</a>:</span> <span class='sentence-part'>In a D-galactose- and AlCl3-induced AD mouse model, administration of the FFDS composite solution significantly improved the learning and memory, as well as neuronal morphology, and decreased the serum levels of INF-gamma.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30010139' target='_blank' class='pmid-link'>30010139</a>:</span> <span class='sentence-part'>Moreover, VCO significantly increased the glutathione (GSH) level in both the hippocampus and cortex and significantly decreased the malondialdehyde (MDA) level in only the cortex of the AlCl3-induced AD rat model compared to an AlCl3-induced AD rat model with no VCO. Our findings therefore show that VCO preserved the ultrastructural morphology of the hippocampus and cortex of the AlCl3-induced AD rat model, potentially providing protection against the neurodegeneration in AD of both cortical and hippocampal neurons.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30537804' target='_blank' class='pmid-link'>30537804</a>:</span> <span class='sentence-part'>Furthermore, TM-10 exhibited a favorable dyskinesia recovery rate and response efficiency on an AlCl3-induced zebrafish AD model and a potent neuroprotective effect on Abeta1-40-induced zebrafish vascular injury.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30624431' target='_blank' class='pmid-link'>30624431</a>:</span> <span class='sentence-part'>Seeds of chia (Salvia hispanica L.) are highly rich in these nutrients, and thus, the present study investigated the effects of chia seeds on behavior and cognition in an aluminum-induced Alzheimer's disease model in rats. Detrimental effects of chia (Salvia hispanica L.) seeds on learning and memory in aluminum chloride-induced experimental Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30802512' target='_blank' class='pmid-link'>30802512</a>:</span> <span class='sentence-part'>After molecular docking simulation, AlCl3-induced Alzheimer's disease zebrafish model was established.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31014012' target='_blank' class='pmid-link'>31014012</a>:</span> <span class='sentence-part'>Results showed that co-administration of CA to d-gal/AlCl3 induced AD-like rat models significantly increased the levels of protein phosphatase 2 (PP2A) and decreased the levels of glycogen synthase kinase-3 beta (GSK-3beta). The results clearly demonstrated for the first time that CA could alleviate d-gal/AlCl3 induced AD-like pathologies in rats via inhibition of hyperphosphorylated tau (P-tau) bio-synthetic proteins, anti-apoptosis and maintenance of cytoarchitecture. This study aimed to evaluate the effectiveness of CA in preventing d-galactose/aluminium chloride (d-gal/AlCl3) induced AD-like pathologies and the underlying mechanisms of action were further investigated for the first time.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31103976' target='_blank' class='pmid-link'>31103976</a>:</span> <span class='sentence-part'>Neuroprotective evaluation of Tribulus terrestris L. in aluminum chloride induced Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31137621' target='_blank' class='pmid-link'>31137621</a>:</span> <span class='sentence-part'>Chenodeoxycholic Acid Ameliorates AlCl3-Induced Alzheimer's Disease Neurotoxicity and Cognitive Deterioration via Enhanced Insulin Signaling in Rats.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31148478' target='_blank' class='pmid-link'>31148478</a>:</span> <span class='sentence-part'>Both extracts significantly decreased the acetylcholinesterase activity and improved the histopathological changes in the cerebral cortex and cerebellum of rat model of aluminium chloride-induced Alzheimer disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31460853' target='_blank' class='pmid-link'>31460853</a>:</span> <span class='sentence-part'>This study was carried out to evaluate the neuroprotective effect of aqueous cinnamon extract against aluminum chloride (AlCl3)-induced Alzheimer's disease. Neuro-amelioration of cinnamaldehyde in aluminum-induced Alzheimer's disease rat model.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31553175' target='_blank' class='pmid-link'>31553175</a>:</span> <span class='sentence-part'>The in vivo study in an AlCl3-induced Alzheimer's (AD) mice model showed a significant improvement in behavioral responses. The study reported improved brain bioavailability of MEM in AlCl3-induced Alzheimer's mice leading to improved memory, with the resultant mechanism behind in a descriptive manner. Lactoferrin Coupled Lower Generation PAMAM Dendrimers for Brain Targeted Delivery of Memantine in Aluminum-Chloride-Induced Alzheimer's Disease in Mice.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31734542' target='_blank' class='pmid-link'>31734542</a>:</span> <span class='sentence-part'>Group II: received aluminum chloride to induce Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31860774' target='_blank' class='pmid-link'>31860774</a>:</span> <span class='sentence-part'>Nootropic effect of neferine on aluminium chloride-induced Alzheimer's disease in experimental models.Alzheimer's disease (AD) is an age-associated neurodegenerative disease, which is developed by oxidative stress and acetylcholine contraction in the synaptic cleft of the neurons. Nootropic effect of neferine on aluminium chloride-induced Alzheimer's disease in experimental models.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32030557' target='_blank' class='pmid-link'>32030557</a>:</span> <span class='sentence-part'>The present study aimed to investigate the neuroprotective role of ethyl pyruvate against in vitro and in vivo model of aluminum chloride (AlCl     3      )-induced AD. Neuroprotective Effects of Ethyl Pyruvate against Aluminum Chloride-Induced Alzheimer's Disease in Rats via Inhibiting Toll-Like Receptor 4.Alzheimer's disease (AD) is a progressive neurodegenerative disease characterized by the formation of insoluble deposits of beta-amyloid (Abeta) plaques within the parenchyma of the brain. Thus, ethyl pyruvate is effective against in vitro and in vivo models of AlCl     3      -induced AD. Neuroprotective Effects of Ethyl Pyruvate against Aluminum Chloride-Induced Alzheimer's Disease in Rats via Inhibiting Toll-Like Receptor 4.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32329360' target='_blank' class='pmid-link'>32329360</a>:</span> <span class='sentence-part'>Nutritional supplementation of GA preserve the morphological and physiological integrity of the hippocampus against environmental neurotoxins (AlCl     3      ) by mopping up free radicals associated with oxidative stress induced AD. This study aimed at investigating the neuroprotective effects of Gallic Acid (GA) against aluminum-chloride induced AD in adult Wistar rats.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32383521' target='_blank' class='pmid-link'>32383521</a>:</span> <span class='sentence-part'>Biotin, coenzyme Q10, and their combination ameliorate aluminium chloride-induced Alzheimer's disease via attenuating neuroinflammation and improving brain insulin signaling.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32932753' target='_blank' class='pmid-link'>32932753</a>:</span> <span class='sentence-part'>Here, we elucidated the neuroprotective effects of silymarin (SM) on the hippocampal tissues of aluminum chloride (AlCl     3      )-induced Alzheimer-like disease in rats using biochemical, histological, and ultrastructural approaches.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33327909' target='_blank' class='pmid-link'>33327909</a>:</span> <span class='sentence-part'>OBJECTIVE: Here the aim was to evaluate the antioxidant therapeutic effects of ellagic acid (EA) and EA-loaded nanoparticles (EA-NP) in an aluminum chloride-induced AD rat model.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33582452' target='_blank' class='pmid-link'>33582452</a>:</span> <span class='sentence-part'>The present investigation established that the betalain treatment ameliorated the AlCl     3       induced AD by modulating NF-kappaB pathway activation. Hence, this study was intended to investigate the possible protective effect of betalain against aluminum chloride (AlCl     3      ) induced AD on Sprague Dawley (SD) rats. AlCl     3       (100 mg/kg) was administrated orally to induce the AD in SD rats. Neuroprotective effect of Betalain against AlCl     3      -induced Alzheimer's disease in Sprague Dawley Rats via putative modulation of oxidative stress and nuclear factor kappa B (NF-kappaB) signaling pathway.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33587299' target='_blank' class='pmid-link'>33587299</a>:</span> <span class='sentence-part'>The objective of this study was to investigate the neuroprotective activity in an aluminum chloride (AlCl     3       )-induced AD in vivo model and phytochemical profile of the traditional Egyptian herb Mentha longifolia (Ml).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33971493' target='_blank' class='pmid-link'>33971493</a>:</span> <span class='sentence-part'>Natural antioxidants enhance the power of physical and mental activities versus risk factors inducing progression of Alzheimer's disease in rats. METHODS: Aluminum chloride (70 mg/kg, I.P for 5 weeks) was used to induce AD in rats that either normally fed or socially isolated and protein malnourished (SI&amp;PM).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34070220' target='_blank' class='pmid-link'>34070220</a>:</span> <span class='sentence-part'>Additionally, histopathological analysis of hippocampus revealed the potential of CUR in decreasing the hallmarks in the AlCl     3      -induced AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34103557' target='_blank' class='pmid-link'>34103557</a>:</span> <span class='sentence-part'>An AD-like rat model was induced by aluminum chloride (AlCl     3      ; 50 mg/kg/day for six consecutive weeks; i.p), whereas a methanolic standardized P. harmala seed extract (187.5 mg/kg; p.o) was given to AD rats starting 2 weeks post AlCl     3       exposure.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34208063' target='_blank' class='pmid-link'>34208063</a>:</span> <span class='sentence-part'>A Leaf Extract of    Harrisonia abyssinica     Ameliorates Neurobehavioral, Histological and Biochemical Changes in the Hippocampus of Rats with Aluminum Chloride-Induced Alzheimer's Disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34354404' target='_blank' class='pmid-link'>34354404</a>:</span> <span class='sentence-part'>Neuroprotective effects of ononin against the aluminium chloride-induced Alzheimer's disease in rats.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34537230' target='_blank' class='pmid-link'>34537230</a>:</span> <span class='sentence-part'>The present study aimed to evaluate the alpha-secretase stimulatory function of Q through activation of ADAM10 and ADAM17 gene expression in the aluminum chloride (AlCl3)-induced AD rat model. Quercetin stimulates the non-amyloidogenic pathway via activation of ADAM10 and ADAM17 gene expression in aluminum chloride-induced Alzheimer's disease rat model.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34542066' target='_blank' class='pmid-link'>34542066</a>:</span> <span class='sentence-part'>Taurine and Camel Milk Modulate Neurobehavioral and Biochemical Changes in Aluminum Chloride-Induced Alzheimer's Disease in Rats.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34706318' target='_blank' class='pmid-link'>34706318</a>:</span> <span class='sentence-part'>The influence of vinpocetine alone or in combination with Epigallocatechin-3-gallate, Coenzyme COQ10, Vitamin E and Selenium as a potential neuroprotective combination against aluminium-induced Alzheimer's disease in Wistar Albino Rats. To explore the possible neuroprotective effect as well as mechanism of action of Vinpocetine either alone or in combination with EGCG, CoQ10, or VE &amp; Se in ameliorating aluminum chloride-induced AD in rats.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34727278' target='_blank' class='pmid-link'>34727278</a>:</span> <span class='sentence-part'>The present research work is designed to investigate the neuroprotective effect of spermine in aluminium chloride (AlCl     3      ), and iron (Fe) induced AD-like symptoms in rats.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34954699' target='_blank' class='pmid-link'>34954699</a>:</span> <span class='sentence-part'>We also found that supplementation of B. coagulans JA845 alleviated amyloid-beta deposits and hyperphosphorylated tau in hippocampus of D-gal/AlCl3-induced AD model mice.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34971104' target='_blank' class='pmid-link'>34971104</a>:</span> <span class='sentence-part'>Effect of taurine and camel milk on amyloid beta peptide concentration and oxidative stress changes in aluminium chloride-induced Alzheimer's disease rats.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35236271' target='_blank' class='pmid-link'>35236271</a>:</span> <span class='sentence-part'>OBJECTIVES: The present study aimed to: (1) study the effect of MSCs with/without acitretin on the regulation of Adam10 gene expression in AlCl3-induced AD rat model, (2) validate the hypothesis that AD is a time-dependent progressive disease that spreads spontaneously even after the stopping of exposure to AlCl3.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35243060' target='_blank' class='pmid-link'>35243060</a>:</span> <span class='sentence-part'>Aluminium chloride induces AD like pathology in rats. Both Captopril and Perindopril protects against aluminium chloride induced amyloidogenesis and AD like pathology. Captopril is more effective than Perindopril against aluminium chloride induced amyloidogenesis and AD like pathology.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35453412' target='_blank' class='pmid-link'>35453412</a>:</span> <span class='sentence-part'>We evaluated the drug release profile and cytotoxicity of PGC and its effects on AD pathology through in vitro and in vivo studies and on cognitive function through an aluminum-chloride-induced AD rat model.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35507244' target='_blank' class='pmid-link'>35507244</a>:</span> <span class='sentence-part'>Correction to: Neuroprotective Effect of Hesperidin on Aluminium Chloride Induced Alzheimer's Disease in Wistar Rats.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35525893' target='_blank' class='pmid-link'>35525893</a>:</span> <span class='sentence-part'>Differential neuroprotective effect of curcuminoid formulations in aluminum chloride-induced Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35596040' target='_blank' class='pmid-link'>35596040</a>:</span> <span class='sentence-part'>Hence, the present study aims to investigate the potential of chronic intranasal oxytocin in halting memory impairment &amp; AD pathology in aluminum chloride-induced AD in female rats.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36015156' target='_blank' class='pmid-link'>36015156</a>:</span> <span class='sentence-part'>Neuroprotective Effects of Phytochemicals against Aluminum Chloride-Induced Alzheimer's Disease through ApoE4/LRP1, Wnt3/beta-Catenin/GSK3beta, and TLR4/NLRP3 Pathways with Physical and Mental Activities in a Rat Model.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36194986' target='_blank' class='pmid-link'>36194986</a>:</span> <span class='sentence-part'>Interestingly, treatment with p-CA alleviated all the above-mentioned neuropathological changes in the AlCl     3      -induced AD rat model.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36246933' target='_blank' class='pmid-link'>36246933</a>:</span> <span class='sentence-part'>Herein, we evaluated the protective effects of    Lactobacillus casei     ATCC 393 (   L. casei     ATCC 393) and selenium nanoparticles-enriched    L. casei     ATCC 393 (   L. casei     ATCC 393-SeNPs) against D-galactose/aluminum chloride-induced AD model mice.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36290710' target='_blank' class='pmid-link'>36290710</a>:</span> <span class='sentence-part'>The present study aims to evaluate the role of quercetin nanoemulsion (QCNE) in attenuating neuronal dysfunction in aluminum chloride (AlCl     3      )-induced experimental AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36312298' target='_blank' class='pmid-link'>36312298</a>:</span> <span class='sentence-part'>This work aimed to comprehend the role of naringin in the defense of the cerebellum against aluminum chloride (AlCl     3      )-induced AD in rats by investigating the behavioral, neurochemical, immunohistochemical, and molecular mechanisms that underpin its possible neuroprotective effects. Collectively, these findings suggested that naringin could contribute to the combat of oxidative and autophagic stress in the cerebellum of AlCl     3      -induced AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36385687' target='_blank' class='pmid-link'>36385687</a>:</span> <span class='sentence-part'>In this study, for the first time, the potential prophylactic and therapeutic effects of leflunomide were investigated either alone or in combination with rivastigmine in aluminum chloride (AlCl     3      )-induced AD-like rats using behavioral, biochemical, and histological approaches. Our findings suggest that leflunomide can potentially restore most of the neuronal damage in the hippocampal tissues of AlCl     3      -induced AD rats. However, administration of leflunomide alone or with rivastigmine in AlCl     3      -induced AD rats restored most of the behavioral, biochemical, and histological parameters triggered by AlCl     3       in rats.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36462588' target='_blank' class='pmid-link'>36462588</a>:</span> <span class='sentence-part'>The potential ameliorative effect of bromelain compared to donepezil was evaluated in an aluminum chloride (AlCl3)-induced AD in rats. Ameliorative effects of bromelain on aluminum-induced Alzheimer's disease in rats through modulation of TXNIP pathway.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36554305' target='_blank' class='pmid-link'>36554305</a>:</span> <span class='sentence-part'>Wistar rats were given an i.p. injection of 60 mg/kg D-gal and 10 mg/kg AlCl     3       to induce AD and three doses of 1 mg/kg, 5 mg/kg or 10 mg/kg 5-MTHF by oral gavage.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36678510' target='_blank' class='pmid-link'>36678510</a>:</span> <span class='sentence-part'>Characterization of Orange Peel Extract and Its Potential Protective Effect against Aluminum Chloride-Induced Alzheimer's Disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36761834' target='_blank' class='pmid-link'>36761834</a>:</span> <span class='sentence-part'>In the Alcl3-induced AD model in rats, disease progression was confirmed by Y-maze, the preliminary histopathology evaluation showed significantly higher efficacy of the prepared liposomes (CLCAE and CLAA) compared to the    Centella asiatica     extract (CAE) and they were found to have equivalent efficacy to the standard drug (rivastigmine tartrate).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37035098' target='_blank' class='pmid-link'>37035098</a>:</span> <span class='sentence-part'>Insights into the function of the retina by electroretinogram (ERG) and the changes thought to have occurred in the molecular structure of the retina and brain using Fourier transform infrared spectroscopy (FTIR) as a result of AD progression induced by AlCl     3       in rats were done.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37242536' target='_blank' class='pmid-link'>37242536</a>:</span> <span class='sentence-part'>This study aims to examine the possible mechanisms of the neuroprotective effects of dapagliflozin against aluminum chloride (AlCl     3      )-induced AD. The current data demonstrate that dapagliflozin represents a possible approach to combat AlCl     3      -induced AD in rats through inhibiting oxidative stress, enhancing glucose metabolism and activating AMPK signaling. Dapagliflozin Ameliorates Cognitive Impairment in Aluminum-Chloride-Induced Alzheimer's Disease via Modulation of AMPK/mTOR, Oxidative Stress and Glucose Metabolism.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37323056' target='_blank' class='pmid-link'>37323056</a>:</span> <span class='sentence-part'>Aluminum chloride was used to induce AD in rats, and afterward, a group of AD-induced rats received a single dose of Ad-MSCs (2 * 10     6       cell, I.V per rat).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37368609' target='_blank' class='pmid-link'>37368609</a>:</span> <span class='sentence-part'>Jambolan fruit extract and choline were investigated for Aluminum tri chloride (AlCl     3      )-induced Alzheimer's disease in rats.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37380861' target='_blank' class='pmid-link'>37380861</a>:</span> <span class='sentence-part'>The rats were administered 300 mg/kg of oral AlCl     3       to induce AD and were then treated with oral PB at a dosage of 50 mg/kg, BEE at a dosage of 50 mg/kg, and rivastigmine at a dosage of 1 mg/kg as a standard drug for 21 days. Therefore, its activity was evaluated against an aluminum chloride (AlCl     3      )-induced AD rat model, and a berberine-enriched extract (BEE) was used to determine if its activity is equivalent to pure berberine (PB).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37454825' target='_blank' class='pmid-link'>37454825</a>:</span> <span class='sentence-part'>AD was induced by AlCl     3       (50mg/kg) for 6 weeks.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37505462' target='_blank' class='pmid-link'>37505462</a>:</span> <span class='sentence-part'>The mice model of Alzheimer's disease (AD) induced by aluminum chloride (AlCl3) combined with D-galactose (D-gal) was established to comprehend the mechanism behind PAF's anti-AD activity from both behavioural and pathological perspectives.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37631278' target='_blank' class='pmid-link'>37631278</a>:</span> <span class='sentence-part'>The aim of this study is to investigate the pathophysiological mechanisms underlying AD and explore the potential neuroprotective effects of cocoa, either alone or in combination with other nutraceuticals, in an animal model of aluminum-induced AD. These alterations contributed to the observed behavioral and histological changes in the AlCl     3      -induced AD model.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37851769' target='_blank' class='pmid-link'>37851769</a>:</span> <span class='sentence-part'>Therefore, the current study explored the possible mitigating effects of a combination of Boswellia papyrifera and Syzygium aromaticum against aluminum chloride (AlCl3) induced AD. In conclusion, the present study provided primary evidence for using a combination of B. papyrifera and S. aromaticum to treat cognitive dysfunction associated with AlCl3 Induced AD by improving the AChE levels and modulating oxidative stress in the brain. Neuroprotective effects of a combination of Boswellia papyrifera and Syzygium aromaticum on AlCl3 induced Alzheimer's disease in male albino rat.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/38052316' target='_blank' class='pmid-link'>38052316</a>:</span> <span class='sentence-part'>These findings suggest that coconut oil shows protective effects against cognitive and non-cognitive impairment, AD pathology markers, oxidative stress, synaptic transmission, and cholinergic function in a D-GAL/AlCl     3      -induced AD rat model. Thus, we investigated the effects of coconut oil on spatial cognitive ability and non-cognitive functions in a rat model of AD induced by G-galactose (D-GAL) and aluminum chloride (AlCl     3      ), and examined the changes in synaptic transmission, cholinergic activity, neurotrophic factors and oxidative stress in this process.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/38074017' target='_blank' class='pmid-link'>38074017</a>:</span> <span class='sentence-part'>Enhanced Neuroprotective Synergy of Atorvastatin and Magnesium L-Threonate in a Rat Model of Alzheimer's Disease Induced by Aluminum Chloride.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/38090736' target='_blank' class='pmid-link'>38090736</a>:</span> <span class='sentence-part'>The    in-vivo     studies were performed using aluminum chloride-induced experimental AD in rats.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/38141332' target='_blank' class='pmid-link'>38141332</a>:</span> <span class='sentence-part'>Summarily, the results demonstrated intranasal delivery of CurCOO to show better efficacy than Cur and COO in preventing neurodegeneration associated with AlCl     3       induced Alzheimer's disease. A supercritical fluid co-extract of turmeric powder and dried coconut shreds shows neuroprotection against AlCl     3      -induced Alzheimer's disease in rats through nose to brain delivery. This study was aimed at investigating the neuroprotective potential of a co-extract obtained by supercritical fluid extraction (SFE) of turmeric powder and dried coconut shreds against aluminium chloride (AlCl     3      )-induced Alzheimer's disease (AD) in male Wistar rats.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/38181932' target='_blank' class='pmid-link'>38181932</a>:</span> <span class='sentence-part'>Protective effect of a hydromethanolic extract from Fraxinus excelsior L. bark against a rat model of aluminum chloride-induced Alzheimer's disease: Relevance to its anti-inflammatory and antioxidant effects.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/38448794' target='_blank' class='pmid-link'>38448794</a>:</span> <span class='sentence-part'>3-Acetyl coumarin alleviate neuroinflammatory responses and oxidative stress in aluminum chloride-induced Alzheimer's disease rat model.</span></div></div>
<div class='streamlined-assertion'><div class='streamlined-header sticky-relation-header'><span class='label-text'>Subject:</span> <strong>angiotensin_II</strong> <span class='label-text'>Subject CUI:</span> <strong>C0003009</strong> â†’ <span class='label-text predicate-text'>CAUSES</span> â†’ <span class='label-text'>Object:</span> <strong>Atrial_Fibrillation</strong> <span class='label-text'>Object CUI:</span> <strong>C0004238</strong></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32682626' target='_blank' class='pmid-link'>32682626</a>:</span> <span class='sentence-part'>AF was induced either by transesophageal burst pacing in vivo or by burst/extrastimuli in isolated perfused hearts using a Langendorff apparatus. CONCLUSION: Our results demonstrated that RKT prevented atrial fibrosis and attenuated enhanced vulnerability to AF induced by AngII.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33251220' target='_blank' class='pmid-link'>33251220</a>:</span> <span class='sentence-part'>Importantly, blocking PTEN activity by VO-Ohpic markedly reversed the GA-mediated protective effects on Ang II-induced AF and atrial remodeling. Gallic Acid Ameliorates Angiotensin II-Induced Atrial Fibrillation by Inhibiting Immunoproteasome- Mediated PTEN Degradation in Mice. However, the effect of GA on angiotensin II (Ang II)-induced AF and atrial remodeling as well as the underlying mechanisms remain unknown.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33329030' target='_blank' class='pmid-link'>33329030</a>:</span> <span class='sentence-part'>However, the effect of apelin on Ang II-induced atrial fibrosis and subsequent AF still remains unknown. Apelin Inhibits Angiotensin II-Induced Atrial Fibrosis and Atrial Fibrillation via TGF-beta1/Smad2/alpha-SMA Pathway.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34132026' target='_blank' class='pmid-link'>34132026</a>:</span> <span class='sentence-part'>PU.1 inhibition attenuates atrial fibrosis and atrial fibrillation vulnerability induced by angiotensin-II by reducing TGF-beta1/Smads pathway activation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34379753' target='_blank' class='pmid-link'>34379753</a>:</span> <span class='sentence-part'>MFAP4 deletion attenuates the progression of angiotensin II-induced atrial fibrosis and atrial fibrillation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35013064' target='_blank' class='pmid-link'>35013064</a>:</span> <span class='sentence-part'>Time series proteome profile analysis reveals a protective role of citrate synthase in angiotensin II-induced atrial fibrillation. CONCLUSION: The current study defines the dynamic changes of the DEPs involved in Ang II-induced atrial fibrillation, and identifies that citrate synthase plays a protective role in regulating atrial fibrillation development, and increased citrate synthase expression may represent a potential therapeutic option for atrial fibrillation treatment. However, the proteome profiles and key mediators/signaling pathways involved in the development of Ang II-induced atrial fibrillation remain unclear.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35710020' target='_blank' class='pmid-link'>35710020</a>:</span> <span class='sentence-part'>Overall, our study demonstrates that melatonin protects against Ang II-induced AF by inhibiting proteasome activity and stabilizing ATRAP expression, and these effects are partially dependent on melatonin receptor activation. Melatonin inhibits angiotensin II-induced atrial fibrillation through preventing degradation of Ang II Type I Receptor-Associated Protein (ATRAP). Angiotensin II (Ang II) induced Atrial fibrillation (AF) often accompanied with reduced ATRAP which is a negative modulator of Ang II type 1 receptor (AT1R). In this study, Ang II was used to induce AF, and AF inducibility and duration were documented telemetrically.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36304536' target='_blank' class='pmid-link'>36304536</a>:</span> <span class='sentence-part'>In this study, a mouse model of AF was induced by Ang II infusion. Cardiac-specific knockdown of Bhlhe40 attenuates angiotensin II (Ang II)-Induced atrial fibrillation in mice.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36540030' target='_blank' class='pmid-link'>36540030</a>:</span> <span class='sentence-part'>The present study investigated the effect of isorhamnetin on angiotensin II (AngII)-induced AF in mice.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36748188' target='_blank' class='pmid-link'>36748188</a>:</span> <span class='sentence-part'>Adipose Triglyceride Lipase Deficiency Aggravates Angiotensin II-Induced Atrial Fibrillation by Reducing Peroxisome Proliferator-Activated Receptor alpha Activation in Mice.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37051105' target='_blank' class='pmid-link'>37051105</a>:</span> <span class='sentence-part'>Objectives: The present study's objective was to investigate the association between angiopoietin-like 4 (ANGPTL4) levels and the prognosis of Atrial fibrillation (AF), the causative effect in angiotensin II- (Ang II) induced AF, and its underlying mechanisms.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37275755' target='_blank' class='pmid-link'>37275755</a>:</span> <span class='sentence-part'>Irisin attenuates angiotensin II-induced atrial fibrillation and atrial fibrosis via LOXL2 and TGFbeta1/Smad2/3 signaling pathways.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37584842' target='_blank' class='pmid-link'>37584842</a>:</span> <span class='sentence-part'>Furthermore, it was verified by the downregulation of COMP in angiotensin-II (Ang-II)-induced AF in mice. COMP acts as a major factor and can improve Ang-II-induced AF via TGF-beta signaling pathway. COMP Improves Ang-II-Induced Atrial Fibrillation via TGF-beta Signaling Pathway.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/38645493' target='_blank' class='pmid-link'>38645493</a>:</span> <span class='sentence-part'>Therefore, we investigated the protective effect of Cor in angiotensin II (Ang II)-induced atrial fibrosis and atrial fibrillation (AF). In vivo    , transesophageal burst pacing was used to generate AF.</span></div></div>
<div class='streamlined-assertion'><div class='streamlined-header sticky-relation-header'><span class='label-text'>Subject:</span> <strong>apolipoprotein_E_4_APOE</strong> <span class='label-text'>Subject CUI:</span> <strong>C0052201|348</strong> â†’ <span class='label-text predicate-text'>CAUSES</span> â†’ <span class='label-text'>Object:</span> <strong>Alzheimers</strong> <span class='label-text'>Object CUI:</span> <strong>C0002395</strong></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/11464462' target='_blank' class='pmid-link'>11464462</a>:</span> <span class='sentence-part'>Many hypotheses have been proposed to explain the mechanism whereby one of the isoforms of apoE, apoE4, could cause AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/16270302' target='_blank' class='pmid-link'>16270302</a>:</span> <span class='sentence-part'>We propose that the overproduction of apoE4 in neurons may suppress normal IK channel activities and thus be responsible for the late-developed neuronal damages related to the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20531185' target='_blank' class='pmid-link'>20531185</a>:</span> <span class='sentence-part'>ApoE4 carriers account for 65-80% of all Alzheimer's disease cases, highlighting the importance of apoE4 in Alzheimer's disease pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21266538' target='_blank' class='pmid-link'>21266538</a>:</span> <span class='sentence-part'>Our observations suggest that apoE4 strongly stabilizes Abeta oligomers, the pathological species responsible for Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24386905' target='_blank' class='pmid-link'>24386905</a>:</span> <span class='sentence-part'>Emerging data indicate that levels of soluble oAbeta are increased with APOE4, providing a potential mechanism of APOE4-induced AD risk. Soluble apoE/Abeta complex: mechanism and therapeutic target for APOE4-induced AD risk.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25871773' target='_blank' class='pmid-link'>25871773</a>:</span> <span class='sentence-part'>ApoE4 confers a gain of toxic function, a loss of neuroprotective function or a combination of both in AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27788676' target='_blank' class='pmid-link'>27788676</a>:</span> <span class='sentence-part'>Developing therapeutic strategies based on AGFs may be particularly efficacious for APOE4-induced AD risk.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28550258' target='_blank' class='pmid-link'>28550258</a>:</span> <span class='sentence-part'>APOE?4 is central to the events that lead to AD in cognitively normal older adults, likely through a quantitative role in the disruption of A? clearance.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29133888' target='_blank' class='pmid-link'>29133888</a>:</span> <span class='sentence-part'>Given the observations of neuronal hyperactivity in prodromal AD, we propose that this APOE4-driven hyperactivity may be a causative factor driving increased risk of AD among APOE4 carriers.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29311783' target='_blank' class='pmid-link'>29311783</a>:</span> <span class='sentence-part'>These findings directly link the APOE4 genotype to endosomal-lysosomal dysregulation in an in vivo, AD pathology-free setting, which may play a causative role in the increased incidence of AD among APOE4 carriers.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31331998' target='_blank' class='pmid-link'>31331998</a>:</span> <span class='sentence-part'>In activating neuronal signaling, the three ApoE variants exhibit a differential potency of ApoE4&gt;ApoE3&gt;ApoE2, which mirrors their relative effects on AD risk, suggesting that differential signaling by ApoE variants may contribute to AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/9894876' target='_blank' class='pmid-link'>9894876</a>:</span> <span class='sentence-part'>These findings suggest a relationship between APOE4 and a DLST locus in the pathogenesis of AD in very elderly subjects.</span></div></div>
<div class='streamlined-assertion'><div class='streamlined-header sticky-relation-header'><span class='label-text'>Subject:</span> <strong>beta_site_APP_cleaving_enzyme_1_BACE1</strong> <span class='label-text'>Subject CUI:</span> <strong>C0965087|23621</strong> â†’ <span class='label-text predicate-text'>CAUSES</span> â†’ <span class='label-text'>Object:</span> <strong>Alzheimers</strong> <span class='label-text'>Object CUI:</span> <strong>C0002395</strong></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/15614428' target='_blank' class='pmid-link'>15614428</a>:</span> <span class='sentence-part'>Oxidative stress has been shown to affect A(beta) generation in the AD pathogenesis and the mechanism of such effect is unknown. Thus, upregulation of BACE1 transcription by oxidative stress may contribute to the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/18695942' target='_blank' class='pmid-link'>18695942</a>:</span> <span class='sentence-part'>The identification of the aspartic protease BACE1 (beta-secretase) was a defining event in research aimed at understanding the molecular mechanisms that underlie Alzheimer's disease (AD) pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/19486882' target='_blank' class='pmid-link'>19486882</a>:</span> <span class='sentence-part'>BACE1 is a novel type I transmembrane aspartyl protease that has been implicated in the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20731874' target='_blank' class='pmid-link'>20731874</a>:</span> <span class='sentence-part'>BACKGROUND: BACE1 is a key enzyme in the generation of the Abeta peptide that plays a central role in the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23770985' target='_blank' class='pmid-link'>23770985</a>:</span> <span class='sentence-part'>It was particularly interesting to discover a dual inhibitor that targets both Abeta42 aggregation and BACE1, the two crucial players in the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23816176' target='_blank' class='pmid-link'>23816176</a>:</span> <span class='sentence-part'>BACE1, a beta secretase candidate enzyme, initiates the Alzheimer's disease (AD) pathogenesis via amyloid beta (Abeta) peptide production serving as a potential therapeutic target.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25609634' target='_blank' class='pmid-link'>25609634</a>:</span> <span class='sentence-part'>BACE1 is a key protease controlling the formation of amyloid beta, a peptide hypothesized to play a significant role in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25716831' target='_blank' class='pmid-link'>25716831</a>:</span> <span class='sentence-part'>The beta-secretase BACE1 is widely known for its pivotal role in the amyloidogenic pathway leading to Alzheimer's disease, but how its action on transmembrane proteins other than the amyloid precursor protein affects the nervous system is only beginning to be understood.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28946017' target='_blank' class='pmid-link'>28946017</a>:</span> <span class='sentence-part'>In human AD brains, there is a significant decrease in Ser498 phosphorylation of BACE1 suggesting that defective phosphorylation-dependent retrograde transport of BACE1 is important in AD pathogenesis. Together, our studies provide mechanistic insight into a novel role for Par3 and aPKC in regulating the retrograde endosome-to-TGN trafficking of BACE1 and shed light on the mechanisms of AD pathogenesis. The cleavage of amyloid precursor protein (APP) by beta-site APP cleaving enzyme 1 (BACE1) is the rate-limiting step in beta amyloid generation during Alzheimer's disease (AD) pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29371969' target='_blank' class='pmid-link'>29371969</a>:</span> <span class='sentence-part'>Our results demonstrated that miR-124 is a potent negative regulator of BACE1 in the cellular AD phenotype and might be involved in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30496823' target='_blank' class='pmid-link'>30496823</a>:</span> <span class='sentence-part'>Beta secretase 1 (BACE1) is an enzyme involved in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30530107' target='_blank' class='pmid-link'>30530107</a>:</span> <span class='sentence-part'>Several lines of evidence suggest that BACE1 is a key enzyme in the pathogenesis of AD and its inhibition is of particular importance in AD treatment.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30930125' target='_blank' class='pmid-link'>30930125</a>:</span> <span class='sentence-part'>Analysis of microRNAs (miRNAs) revealed that miR-9 and miR-181a negatively coregulated BACE1 and TGFBIp, which was directly associated with the pathogenesis of AD and GCD2, respectively.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31223308' target='_blank' class='pmid-link'>31223308</a>:</span> <span class='sentence-part'>Therefore, revealing the underlying mechanism of BACE1 in the pathogenesis of AD might have a significant impact on the future development of therapeutic agents targeting dementia. Increased amyloid-beta (Abeta) plaque deposition is thought to be the main cause of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31608840' target='_blank' class='pmid-link'>31608840</a>:</span> <span class='sentence-part'>BACE1 is a beta-secretase involved in the cleavage of amyloid precursor protein and the pathogenesis of Alzheimer's disease.</span></div></div>
<div class='streamlined-assertion'><div class='streamlined-header sticky-relation-header'><span class='label-text'>Subject:</span> <strong>cytokine</strong> <span class='label-text'>Subject CUI:</span> <strong>C0079189</strong> â†’ <span class='label-text predicate-text'>CAUSES</span> â†’ <span class='label-text'>Object:</span> <strong>Alzheimers</strong> <span class='label-text'>Object CUI:</span> <strong>C0002395</strong></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/10564528' target='_blank' class='pmid-link'>10564528</a>:</span> <span class='sentence-part'>S100beta is an astrocyte-derived uritotrophic' cytokine which has been implicated in the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/10782042' target='_blank' class='pmid-link'>10782042</a>:</span> <span class='sentence-part'>Prostaglandins and proinflammatory cytokines are implicated in the etiology of neurodegenerative diseases, such as Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/11578774' target='_blank' class='pmid-link'>11578774</a>:</span> <span class='sentence-part'>This multifunctional cytokine might be centrally involved in several aspects of AD pathogenesis by regulating beta-amyloid precursor protein synthesis and processing, plaque formation, astroglial and microglial response and neuronal cell death. Recent studies have implicated pro- and anti-inflammatory cytokines as integral to Alzheimer's disease (AD) pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/1491745' target='_blank' class='pmid-link'>1491745</a>:</span> <span class='sentence-part'>These findings span many of the major immune system phenomena, from major histocompatibility complex (MHC) antigens through cytokines and the complement cascade and suggest that some facets of AD pathogenesis may be immune related.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17420099' target='_blank' class='pmid-link'>17420099</a>:</span> <span class='sentence-part'>To further investigate the proposed association and to clarify the role of cytokines as a potential cause for AD susceptibility, we analyzed genotypes, allele distributions and haplotypes of IL10 promoter polymorphisms -1082 (rs1800896) and -819 (rs1800871) in an Italian sample of 222 sporadic AD patients and 179 normal controls.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21143158' target='_blank' class='pmid-link'>21143158</a>:</span> <span class='sentence-part'>Under stress and injury, astrocytes become astrogliotic leading to an upregulation of the expression of proinflammatory cytokines and chemokines, which are associated with the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21482536' target='_blank' class='pmid-link'>21482536</a>:</span> <span class='sentence-part'>OBJECTIVE: Serum amyloid A (A-SAA) is an acute-phase protein with cytokine-like properties implicated in the pathogenesis of rheumatoid arthritis (RA), atherosclerosis, diabetes and Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22408651' target='_blank' class='pmid-link'>22408651</a>:</span> <span class='sentence-part'>Neuroinflammatory Cytokines-The Common Thread in Alzheimer's Pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22437436' target='_blank' class='pmid-link'>22437436</a>:</span> <span class='sentence-part'>Amyloid beta42 (Abeta42) and proinflammatory cytokines such as interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha) have been suggested to contribute to the pathogenesis of Alzheimer's disease (AD) and vascular dementia (VaD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22970774' target='_blank' class='pmid-link'>22970774</a>:</span> <span class='sentence-part'>The potential role of proinflammatory and antiinflammatory cytokines in Alzheimer disease pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24054992' target='_blank' class='pmid-link'>24054992</a>:</span> <span class='sentence-part'>Previously we identified that palmitate can induce primary astrocytes to produce cytokines, causing AD-like changes in primary neurons.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24141019' target='_blank' class='pmid-link'>24141019</a>:</span> <span class='sentence-part'>Together our data suggest a cell-autonomous role of microglia, and identify TNFalpha as the responsible cytokine, in promoting neuronal CCEs in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24478534' target='_blank' class='pmid-link'>24478534</a>:</span> <span class='sentence-part'>Furthermore, findings in brains of patients dying with conditions known to predispose to Alzheimer's disease suggest that activation of glia and overexpression of glial cytokines are early events in Alzheimer pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25078115' target='_blank' class='pmid-link'>25078115</a>:</span> <span class='sentence-part'>However, accumulating evidence indicates that Abeta may activate astrocytes, which leads to an increase in cytokines that has been suggested to be a causative factor in the cognitive dysfunction of AD; thus, a vicious circle may be created.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25620241' target='_blank' class='pmid-link'>25620241</a>:</span> <span class='sentence-part'>Oxidative stress and inflammatory response are important elements of Alzheimer's disease (AD) pathogenesis, but the role of redox signaling cascade and its cross-talk with inflammatory mediators have not been elucidated in details in this disorder. The biology of NF-kappaB and its activation by reactive oxygen species (ROS) and proinflammatory cytokines in the pathogenesis of AD have been specially highlighted citing evidence both from post-mortem studies in AD brain and experimental research in animal or cell-based models of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27054030' target='_blank' class='pmid-link'>27054030</a>:</span> <span class='sentence-part'>Here, we review the progress in understanding the important role that these cytokines or neuroinflammation has played in AD etiology and pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27474414' target='_blank' class='pmid-link'>27474414</a>:</span> <span class='sentence-part'>To further investigate the proposed association and to clarify the role of cytokines as a potential cause for AD susceptibility, we analyzed genotypes, allele distributions and haplotypes of IL-10 promoter polymorphisms -1082 (rs1800896) and -819 (rs1800871) in a Mexican population: 986 normal controls and 221 cases divided as follows: 122 with Alzheimer disease (AD), 67 with (VaD) and 32 with mixed dementia (AD/VaD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31044031' target='_blank' class='pmid-link'>31044031</a>:</span> <span class='sentence-part'>Conclusion: Altogether, our results show that treatment with serotype b-LPS triggers the secretion of proinflammatory cytokines by microglia, induces neurite shrinking, and increases the extracellular Abeta1-42 levels, all features strongly associated with the etiology of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31217937' target='_blank' class='pmid-link'>31217937</a>:</span> <span class='sentence-part'>S100B is an astrocytic cytokine with a possible role in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34685770' target='_blank' class='pmid-link'>34685770</a>:</span> <span class='sentence-part'>The Potential Role of Cytokines and Growth Factors in the Pathogenesis of Alzheimer's Disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/8164471' target='_blank' class='pmid-link'>8164471</a>:</span> <span class='sentence-part'>Since IL-1 and tumor necrosis factor (TNF) tend to act synergistically in physiological conditions and in some pathological processes, we have studied the concentration of TNF-alpha in patients with Alzheimer's disease (AD) or multi-infarct dementia (MID) and in age-matched control subjects (CS) in order to evaluate possible changes in the levels of this cytokine with potential influence on the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/8793035' target='_blank' class='pmid-link'>8793035</a>:</span> <span class='sentence-part'>The participation of interleukin-6, a stress-inducible cytokine, in the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/8892353' target='_blank' class='pmid-link'>8892353</a>:</span> <span class='sentence-part'>These findings are supported by numerous circumstantial findings suggesting a role for cytokines and acute phase reactants in the pathogenesis of AD.</span></div></div>
<div class='streamlined-assertion'><div class='streamlined-header sticky-relation-header'><span class='label-text'>Subject:</span> <strong>galactose</strong> <span class='label-text'>Subject CUI:</span> <strong>C0016945</strong> â†’ <span class='label-text predicate-text'>CAUSES</span> â†’ <span class='label-text'>Object:</span> <strong>Alzheimers</strong> <span class='label-text'>Object CUI:</span> <strong>C0002395</strong></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32382276' target='_blank' class='pmid-link'>32382276</a>:</span> <span class='sentence-part'>Preventive Electroacupuncture Ameliorates D-Galactose-Induced Alzheimer's Disease-Like Pathology and Memory Deficits Probably via Inhibition of GSK3beta/mTOR Signaling Pathway.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32959549' target='_blank' class='pmid-link'>32959549</a>:</span> <span class='sentence-part'>[Effects of electroacupuncture on cognitive function and neuronal autophagy in rats with D-galactose induced Alzheimer's disease].</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32990282' target='_blank' class='pmid-link'>32990282</a>:</span> <span class='sentence-part'>RhoA/Rock2/Limk1/cofilin1 pathway is involved in attenuation of neuronal dendritic spine loss by paeonol in the frontal cortex of D-galactose and aluminum-induced Alzheimer's disease-like rat model.Alzheimer's disease (AD) has become the most prevalent neurodegenerative disorder. RhoA/Rock2/Limk1/cofilin1 pathway is involved in attenuation of neuronal dendritic spine loss by paeonol in the frontal cortex of D-galactose and aluminum-induced Alzheimer's disease-like rat model.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33727095' target='_blank' class='pmid-link'>33727095</a>:</span> <span class='sentence-part'>Taken together, these findings suggest the role of LAP in ameliorating D-gal-induced AD in OVX rats via activating the pro-survival pathway; PI3K-Akt-GSK-3beta, while inhibiting p-mTOR, NOX-1, and p38 MAPK pathways.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33995945' target='_blank' class='pmid-link'>33995945</a>:</span> <span class='sentence-part'>Preventive electroacupuncture ameliorates D-galactose-induced Alzheimer's disease-like inflammation and memory deficits, probably via modulating the microbiota-gut-brain axis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34481907' target='_blank' class='pmid-link'>34481907</a>:</span> <span class='sentence-part'>As an epilogue, targeting MPC-1 in the D-gal-induced AD in OVX rats resulted in the enhancement of autophagy, and suppression of neuroinflammation and excitotoxicity.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35721206' target='_blank' class='pmid-link'>35721206</a>:</span> <span class='sentence-part'>In the present study, we focused on the microbiome-gut-brain axis to investigate the mechanism of action of Gas using a D-galactose (Dgal)-induced AD model.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36554305' target='_blank' class='pmid-link'>36554305</a>:</span> <span class='sentence-part'>Wistar rats were given an i.p. injection of 60 mg/kg D-gal and 10 mg/kg AlCl     3       to induce AD and three doses of 1 mg/kg, 5 mg/kg or 10 mg/kg 5-MTHF by oral gavage.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37329974' target='_blank' class='pmid-link'>37329974</a>:</span> <span class='sentence-part'>The multifactorial role of vanillin in amelioration of aluminium chloride and D-galactose induced Alzheimer's disease in mice.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37414289' target='_blank' class='pmid-link'>37414289</a>:</span> <span class='sentence-part'>Here, we investigated the effect and mechanism of DAU on D-galactose and AlCl     3       combined-induced AD mice based on the Ca     2+      /CaM pathway.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37460908' target='_blank' class='pmid-link'>37460908</a>:</span> <span class='sentence-part'>Neuromodulatory effect of vardenafil on aluminium chloride/D-galactose induced Alzheimer's disease in rats: emphasis on amyloid-beta, p-tau, PI3K/Akt/p53 pathway, endoplasmic reticulum stress, and cellular senescence. The current study explored the potential therapeutic effect of vardenafil (VAR), a phosphodiesterase-5 inhibitor, in AlCl     3      /D-galactose (D-gal)-induced AD in rats and its possible underlying mechanisms.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/38052316' target='_blank' class='pmid-link'>38052316</a>:</span> <span class='sentence-part'>These findings suggest that coconut oil shows protective effects against cognitive and non-cognitive impairment, AD pathology markers, oxidative stress, synaptic transmission, and cholinergic function in a D-GAL/AlCl     3      -induced AD rat model. Thus, we investigated the effects of coconut oil on spatial cognitive ability and non-cognitive functions in a rat model of AD induced by G-galactose (D-GAL) and aluminum chloride (AlCl     3      ), and examined the changes in synaptic transmission, cholinergic activity, neurotrophic factors and oxidative stress in this process.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/38617712' target='_blank' class='pmid-link'>38617712</a>:</span> <span class='sentence-part'>The objective of the current investigation was to examine the neuroprotective and anti-ferroptotic role of nanocurcumin and Donepezil against model of aluminum chloride AlCl     3       and D-galactose induced ad.</span></div></div>
<div class='streamlined-assertion'><div class='streamlined-header sticky-relation-header'><span class='label-text'>Subject:</span> <strong>gamma_secretase</strong> <span class='label-text'>Subject CUI:</span> <strong>C0379528</strong> â†’ <span class='label-text predicate-text'>CAUSES</span> â†’ <span class='label-text'>Object:</span> <strong>Alzheimers</strong> <span class='label-text'>Object CUI:</span> <strong>C0002395</strong></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/11152688' target='_blank' class='pmid-link'>11152688</a>:</span> <span class='sentence-part'>Processing of the beta-amyloid precursor protein (betaAPP) by beta- and gamma-secretases generates the amyloidogenic peptide Abeta, a major factor in the etiology of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/11316808' target='_blank' class='pmid-link'>11316808</a>:</span> <span class='sentence-part'>Generation of the amyloid peptide through proteolytic processing of the amyloid precursor protein by beta- and gamma-secretases is central to the etiology of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/11744687' target='_blank' class='pmid-link'>11744687</a>:</span> <span class='sentence-part'>The presenilin (PS) proteins are components of the gamma-secretase activity, which is central in the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/12697771' target='_blank' class='pmid-link'>12697771</a>:</span> <span class='sentence-part'>The ability to isolate gamma-secretase from post-mortem human brain may facilitate the identification of brain-specific modulators of beta-APP processing and provide new insights into the biology of this important factor in the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/12944419' target='_blank' class='pmid-link'>12944419</a>:</span> <span class='sentence-part'>Thus, identifying components and pathways by which the gamma-secretase activity is regulated is crucial to understanding the mechanisms underlying AD pathogenesis, and may provide new diagnostic tools and therapeutic targets.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/14505382' target='_blank' class='pmid-link'>14505382</a>:</span> <span class='sentence-part'>gamma-Secretase cleaves the transmembrane domain of the amyloid precursor protein, a process implicated in the pathogenesis of Alzheimer's disease, and this enzyme is a founding member of an emerging class of intramembrane proteases.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/16046406' target='_blank' class='pmid-link'>16046406</a>:</span> <span class='sentence-part'>Gamma-secretase activity leads to generation of the amyloid beta-peptide, a key event implicated in the pathogenesis of Alzheimer disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/16181553' target='_blank' class='pmid-link'>16181553</a>:</span> <span class='sentence-part'>OBJECTIVE: To study the role of presenilin1 (PS1) in the processing of beta-amyloid precursor protein (APP) to amyloid beta-peptide (Abeta) and its relation to gamma-secretase in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/16562666' target='_blank' class='pmid-link'>16562666</a>:</span> <span class='sentence-part'>OBJECTIVE: To identify the promoter of human nicastrin (NCT) gene, a major component of gamma-secretase which is closely related with pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/16597739' target='_blank' class='pmid-link'>16597739</a>:</span> <span class='sentence-part'>Our finding supports a protective role of Abeta40 against amyloid pathology and raises the possibility that impaired gamma-secretase activity could be the basis for AD pathogenesis in general.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/16978875' target='_blank' class='pmid-link'>16978875</a>:</span> <span class='sentence-part'>Proteolysis of beta-amyloid precursor protein (APP) into amyloid beta peptide (Abeta) by beta- and gamma-secretases is a critical step in the pathogenesis of Alzheimer's Disease (AD), but the pathways regulating secretases are not fully characterized.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17115048' target='_blank' class='pmid-link'>17115048</a>:</span> <span class='sentence-part'>Thus, beta(2)-AR activation can stimulate gamma-secretase activity and amyloid plaque formation, which suggests that abnormal activation of beta(2)-AR might contribute to Abeta accumulation in Alzheimer disease pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17156133' target='_blank' class='pmid-link'>17156133</a>:</span> <span class='sentence-part'>Generation and deposition of the amyloid beta (Abeta) peptide following proteolytic processing of the amyloid precursor protein (APP) by BACE-1 and gamma-secretase is central to the aetiology of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/18061918' target='_blank' class='pmid-link'>18061918</a>:</span> <span class='sentence-part'>Improper functioning of gamma-secretase was found to be critical in the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/18276590' target='_blank' class='pmid-link'>18276590</a>:</span> <span class='sentence-part'>Accumulation of extracellular amyloid beta peptide (Abeta), generated from amyloid precursor protein (APP) processing by beta- and gamma-secretases, is toxic to neurons and is central to the pathogenesis of Alzheimer disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/18575606' target='_blank' class='pmid-link'>18575606</a>:</span> <span class='sentence-part'>Thus, identification of factors that regulate APP steady state levels and/or APP cleavage by gamma-secretase is likely to provide insight into AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/19114088' target='_blank' class='pmid-link'>19114088</a>:</span> <span class='sentence-part'>Presenilin-1 is required for gamma-secretase activity, which participates in Notch receptor processing, the pathogenesis of Alzheimer's disease and the modulation of Ca(2+) signaling.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/19299585' target='_blank' class='pmid-link'>19299585</a>:</span> <span class='sentence-part'>The Aph1B complex contributes to total gamma-secretase activity in the human brain, and thus specific targeting of Aph1B-containing gamma-secretase complexes may help generate less toxic therapies for Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20062056' target='_blank' class='pmid-link'>20062056</a>:</span> <span class='sentence-part'>Therefore, this mode of regulation represents an unprecedented mechanism for modulating gamma-secretase, providing insight into the molecular basis of Alzheimer's disease pathogenesis and a potential strategy for the development of therapeutics.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20237298' target='_blank' class='pmid-link'>20237298</a>:</span> <span class='sentence-part'>Inhibition of gamma-secretase activity is thus an attractive therapeutic strategy to slow down the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20297736' target='_blank' class='pmid-link'>20297736</a>:</span> <span class='sentence-part'>Amyloid beta protein (Abeta), the major component of senile plaques, is a 40 to 43 amino acid peptide cleaved from amyloid precursor protein (APP) by beta-secretase and gamma-secretase and has been implicated as the primary cause of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21106832' target='_blank' class='pmid-link'>21106832</a>:</span> <span class='sentence-part'>gamma-Secretase is an intramembrane-cleaving protease that is responsible for the generation of amyloid-beta peptides linked to the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21119643' target='_blank' class='pmid-link'>21119643</a>:</span> <span class='sentence-part'>gamma-Secretase generates the peptides of Alzheimer's disease, Abeta(40) and Abeta(42), by cleaving the amyloid precursor protein within its transmembrane domain. gamma-Secretase also cleaves numerous other substrates, raising concerns about gamma-secretase inhibitor off-target effects.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21248114' target='_blank' class='pmid-link'>21248114</a>:</span> <span class='sentence-part'>Presenilin 1 (PS1) is an integral component of gamma-secretase and is also a protein closely linked to the etiology of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22170863' target='_blank' class='pmid-link'>22170863</a>:</span> <span class='sentence-part'>Processing of beta-CTF by gamma-secretase releases amyloid-beta (Abeta), which is assumed to cause AD. APP processing is linked to Alzheimer disease (AD) pathogenesis, which is consistent with a common mechanism involving toxic APP metabolites in both dementias.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22479317' target='_blank' class='pmid-link'>22479317</a>:</span> <span class='sentence-part'>Membrane-imbedded Abeta-bundles generated by gamma-secretase could be neurotoxic and thus crucial for our understanding of the amyloid hypothesis and AD pathogenesis. CONCLUSIONS: Gradual saturation of gamma-secretase with its substrate can be the pathogenic process in different alleged causes of AD. Modulation of gamma-secretase activity by multiple enzyme-substrate interactions: implications in pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22792182' target='_blank' class='pmid-link'>22792182</a>:</span> <span class='sentence-part'>Our findings allude to an integration of signaling pathways that utilize gamma-secretase activity, which may have significant implications for our understanding of Alzheimer's pathogenesis vis-a-vis vascular changes that set the stage for ensuing neurodegeneration.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23359429' target='_blank' class='pmid-link'>23359429</a>:</span> <span class='sentence-part'>Not exempt from this rule is gamma-secretase, an intramembrane-cleaving protease complex regulating a multitude of signaling pathways and biological processes by influencing gene transcription. gamma-Secretase is also implicated in the pathogenesis of Alzheimer's disease and several types of cancer.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23396974' target='_blank' class='pmid-link'>23396974</a>:</span> <span class='sentence-part'>gamma-Secretase is an intramembrane aspartyl protease that cleaves the amyloid precursor protein to produce neurotoxic beta-amyloid peptides (i.e. Abeta42) that have been implicated in the pathogenesis of Alzheimer disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23517619' target='_blank' class='pmid-link'>23517619</a>:</span> <span class='sentence-part'>Processing of beta-amyloid precursor protein (APP) by beta- and gamma-secretases in neurons produces amyloid-beta (Abeta), whose excess accumulation leads to Alzheimer's disease (AD). Knowledge on subcellular trafficking pathways of APP and its fragments is important for the understanding of AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25037285' target='_blank' class='pmid-link'>25037285</a>:</span> <span class='sentence-part'>Toxic amyloid-beta40-42 (Abeta40-42) peptide cleaved from Abeta protein precursor by beta- and gamma secretases plays a crucial role in the etiology of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25108625' target='_blank' class='pmid-link'>25108625</a>:</span> <span class='sentence-part'>It is the catalytic subunit of gamma-secretase, which plays critical roles in developmental biology and the molecular etiology of Alzheimer disease, together with three membrane protein cofactors, nicastrin, Aph-1 and Pen-2.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25545059' target='_blank' class='pmid-link'>25545059</a>:</span> <span class='sentence-part'>gamma-Secretase cleaves amyloid beta-precursor protein (APP) to generate amyloid-beta peptide (Abeta), which is a causative molecule of Alzheimer disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25893612' target='_blank' class='pmid-link'>25893612</a>:</span> <span class='sentence-part'>The transmembrane protease complex gamma-secretase is a key enzyme in Alzheimer disease pathogenesis as it liberates the neurotoxic amyloid beta-peptide (Abeta); however, the mechanism of regulation of its activity in various cell types and subcellular compartments is largely unknown.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26280335' target='_blank' class='pmid-link'>26280335</a>:</span> <span class='sentence-part'>Dysfunction of the intramembrane protease gamma-secretase is thought to cause Alzheimer's disease, with most mutations derived from Alzheimer's disease mapping to the catalytic subunit presenilin 1 (PS1).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27038342' target='_blank' class='pmid-link'>27038342</a>:</span> <span class='sentence-part'>Among them are the archaeal enzyme FlaK, processing its substrate FlaB2 during the formation of flagella and gamma-secretase, which is centrally involved in the etiology of the neurodegenerative Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28065262' target='_blank' class='pmid-link'>28065262</a>:</span> <span class='sentence-part'>gamma-Secretase is a key player in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28332150' target='_blank' class='pmid-link'>28332150</a>:</span> <span class='sentence-part'>Dynamic Nature of presenilin1/gamma-Secretase: Implication for Alzheimer's Disease Pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29103038' target='_blank' class='pmid-link'>29103038</a>:</span> <span class='sentence-part'>Besides familial mutations on the AbetaPP gene, or upon its overexpression, familial forms of AD are often caused by mutations or deletions in presenilin 1 (PSEN1) and 2 (PSEN2) genes: the catalytic components of the proteolytic enzyme gamma-secretase (GS). The processing of the amyloid-beta protein precursor (AbetaPP) by beta- and gamma-secretases is a pivotal event in the genesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30926830' target='_blank' class='pmid-link'>30926830</a>:</span> <span class='sentence-part'>Cleavage of the amyloid precursor protein's (APP) transmembrane domain (TMD) by gamma-secretase is a crucial step in the aetiology of Alzheimer's Disease (AD).</span></div></div>
<div class='streamlined-assertion'><div class='streamlined-header sticky-relation-header'><span class='label-text'>Subject:</span> <strong>gene_therapy</strong> <span class='label-text'>Subject CUI:</span> <strong>C0017296</strong> â†’ <span class='label-text predicate-text'>CAUSES</span> â†’ <span class='label-text'>Object:</span> <strong>Alzheimers</strong> <span class='label-text'>Object CUI:</span> <strong>C0002395</strong></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32091332' target='_blank' class='pmid-link'>32091332</a>:</span> <span class='sentence-part'>Moreover, in AD, oxidative stress is generated by both genetic and biochemical factors as well as the functioning of the systems responsible for their formation and removal.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32111138' target='_blank' class='pmid-link'>32111138</a>:</span> <span class='sentence-part'>Here, I champion a hypothesis whereby AD is initiated on a disruption of the blood-brain barrier (BBB) caused by either genetic or non-genetic risk factors.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32192521' target='_blank' class='pmid-link'>32192521</a>:</span> <span class='sentence-part'>Dynamics of plasma biomarkers in Down syndrome: the relative levels of Abeta42 decrease with age, whereas NT1 tau and NfL increase.BACKGROUND: Down syndrome (DS) is the most common genetic cause of Alzheimer's disease (AD), but diagnosis of AD in DS is challenging due to the intellectual disability which accompanies DS.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32429084' target='_blank' class='pmid-link'>32429084</a>:</span> <span class='sentence-part'>Exploring the genetic and non-genetic contributors to AD pathogenesis is essential to better understand its underlying biological mechanisms, and to develop novel preventive and therapeutic strategies. Our analyses provided stronger evidence for possible roles of four genes (i.e.,    AIM2    ,    C16orf80    ,    DGUOK    , and    ST14    ) in AD pathogenesis as they were also transcriptionally associated with AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32568209' target='_blank' class='pmid-link'>32568209</a>:</span> <span class='sentence-part'>Identification of environmental risk factor(s) and elucidation of the complex interactions between genetic and environmental risk factors plus aging and female sex in the onset of AD will be a key to our understanding of the etiology and pathogenesis of AD and the development of the strategies for its prevention and treatment.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33027797' target='_blank' class='pmid-link'>33027797</a>:</span> <span class='sentence-part'>OBJECTIVE: Bioinformatic analysis at the genetic level has become the best way for the pathogenesis research of AD, which can analyze the abovementioned relationship.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33231156' target='_blank' class='pmid-link'>33231156</a>:</span> <span class='sentence-part'>Next, we represent the probable molecular mechanism which might elucidate the genetic etiology of AD and highlight the role of massively parallel sequencing technologies for novel gene discoveries.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33269107' target='_blank' class='pmid-link'>33269107</a>:</span> <span class='sentence-part'>Studies have found many significant genetic and environmental factors, but the pathogenesis of AD is still unclear.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33596794' target='_blank' class='pmid-link'>33596794</a>:</span> <span class='sentence-part'>BACKGROUND: Alzheimer's disease is a nervous system destructive disease which causes structural, biochemical and electrical abnormalities inside the human brain and results due to genetic and various environmental factors.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33665345' target='_blank' class='pmid-link'>33665345</a>:</span> <span class='sentence-part'>Insight into the genetic etiology of Alzheimer's disease: A comprehensive review of the role of rare variants.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33892965' target='_blank' class='pmid-link'>33892965</a>:</span> <span class='sentence-part'>Consequently, we investigated the role of MMP1, 3, 13, MT1-MMP, and MT5-MMP in the genetic etiology of AD. Investigation of the role of matrix metalloproteinases in the genetic etiology of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34034776' target='_blank' class='pmid-link'>34034776</a>:</span> <span class='sentence-part'>Mutations in the Presenilin genes are the major genetic cause of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34276349' target='_blank' class='pmid-link'>34276349</a>:</span> <span class='sentence-part'>Down syndrome (DS) is the most common genetic cause of Alzheimer's disease (AD) due to trisomy for all or part of human chromosome 21 (Hsa21).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34961556' target='_blank' class='pmid-link'>34961556</a>:</span> <span class='sentence-part'>Down syndrome (DS), as the most common genetic cause of AD, presents promising opportunities to compare such features between early and advanced AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34971181' target='_blank' class='pmid-link'>34971181</a>:</span> <span class='sentence-part'>BACKGROUND: Down syndrome (DS) is caused by trisomy of chromosome 21 (Hsa21) and is a leading genetic cause of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34978149' target='_blank' class='pmid-link'>34978149</a>:</span> <span class='sentence-part'>DISCUSSION: The NIA-LOAD FBS is the largest collection of familial AD worldwide, and data or samples have been included in 123 publications addressing the genetic etiology of AD. INTRODUCTION: The National Institute on Aging Late-Onset Alzheimer's Disease Family Based Study (NIA-LOAD FBS) was established to study the genetic etiology of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35379992' target='_blank' class='pmid-link'>35379992</a>:</span> <span class='sentence-part'>New insights into the genetic etiology of Alzheimer's disease and related dementias.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35383839' target='_blank' class='pmid-link'>35383839</a>:</span> <span class='sentence-part'>Altered RNA editing may be one possible mechanism for the functional effect of ad associated variants and may contribute to observed differences in the genetic etiology of ad between ancestries.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35946953' target='_blank' class='pmid-link'>35946953</a>:</span> <span class='sentence-part'>BACKGROUND: The interaction of aging-related, genetic, and environmental factors is thought to contribute to the etiology of late-onset, sporadic Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35966919' target='_blank' class='pmid-link'>35966919</a>:</span> <span class='sentence-part'>In the United States, the Alzheimer Disease Sequencing Project (ADSP) has taken a leading role in sequencing AD-related samples at scale, with the resultant data being made publicly available to researchers to generate new insights into the genetic etiology of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36056839' target='_blank' class='pmid-link'>36056839</a>:</span> <span class='sentence-part'>Genetic Causes of Alzheimer's Disease and the Neuroprotective Role of Melatonin in its Management.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36809524' target='_blank' class='pmid-link'>36809524</a>:</span> <span class='sentence-part'>Therefore, understanding the genetic etiology of AD is essential to identifying targeted therapeutics.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37024647' target='_blank' class='pmid-link'>37024647</a>:</span> <span class='sentence-part'>As in other complex diseases, uncovering genetic causes of AD could identify underlying pathological mechanisms and lead to potential treatments. Rare, autosomal dominant forms of AD occur in middle age as a result of highly penetrant genetic mutations, but the most common form of AD occurs later in life.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37170141' target='_blank' class='pmid-link'>37170141</a>:</span> <span class='sentence-part'>BACKGROUND: APP duplication is a rare genetic cause of Alzheimer disease and cerebral amyloid angiopathy (CAA).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37577182' target='_blank' class='pmid-link'>37577182</a>:</span> <span class='sentence-part'>This article aims to briefly summarize the utilization of next-generation sequencing in deciphering the genetic causes of Alzheimer's disease and address the limitations of whole genome and exome sequencing.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37867597' target='_blank' class='pmid-link'>37867597</a>:</span> <span class='sentence-part'>A list of 15 candidate genes for AD risk was also generated to provide data support for further studies on the genetic etiology of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/38270275' target='_blank' class='pmid-link'>38270275</a>:</span> <span class='sentence-part'>Of the genetic causes of AD, people with DS represent the largest cohort.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/38559257' target='_blank' class='pmid-link'>38559257</a>:</span> <span class='sentence-part'>Down syndrome (DS), or trisomy 21, is the most common genetic cause of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/38565895' target='_blank' class='pmid-link'>38565895</a>:</span> <span class='sentence-part'>Evidence from genetic and epidemiological studies point to lipid metabolism defects in both the brain and periphery being at the core of Alzheimer's disease (AD) pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/38646507' target='_blank' class='pmid-link'>38646507</a>:</span> <span class='sentence-part'>Shared genetic aetiology of Alzheimer's disease and age-related macular degeneration by APOC1 and APOE genes.</span></div></div>
<div class='streamlined-assertion'><div class='streamlined-header sticky-relation-header'><span class='label-text'>Subject:</span> <strong>homocysteine</strong> <span class='label-text'>Subject CUI:</span> <strong>C0019878</strong> â†’ <span class='label-text predicate-text'>CAUSES</span> â†’ <span class='label-text'>Object:</span> <strong>Alzheimers</strong> <span class='label-text'>Object CUI:</span> <strong>C0002395</strong></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17522446' target='_blank' class='pmid-link'>17522446</a>:</span> <span class='sentence-part'>Homocysteine (HC) and its derivatives may be involved in the etiology of Alzheimer's Disease (AD), although the precise mechanisms by which these compounds could cause cellular pathology are still unclear.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17537547' target='_blank' class='pmid-link'>17537547</a>:</span> <span class='sentence-part'>These results suggest that homocysteine may be an upstream effector to induce AD-like tau hyperphosphorylation through inactivating PP2A.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/19087670' target='_blank' class='pmid-link'>19087670</a>:</span> <span class='sentence-part'>OBJECTIVE: To investigate the plasma levels of endogenous hydrogen sulfide (H2S), a gasotransmitter, and homocysteine (Hcy) in patients with Alzheimer's disease (AD), vascular dementia (VD), and cerebrovascular disease (CVD) and their role in the pathogenesis of AD and VD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21978079' target='_blank' class='pmid-link'>21978079</a>:</span> <span class='sentence-part'>Our data suggest that ALC could be a promising candidate for arresting Hcy-induced AD-like pathological and behavioral impairments.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23837610' target='_blank' class='pmid-link'>23837610</a>:</span> <span class='sentence-part'>Hydroxysafflor yellow A ameliorates homocysteine-induced Alzheimer-like pathologic dysfunction and memory/synaptic disorder. Our data suggest that HSYA might be a promising therapeutic candidate for attenuating Hcy-induced AD-like pathological and behavioral deficits.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24549986' target='_blank' class='pmid-link'>24549986</a>:</span> <span class='sentence-part'>Recent findings shown that Betaine rescued neuronal damage due to homocysteine induced Alzheimer's disease (AD) like pathological cascade, including tau hyperphosphorylation and amyloid-beta (Abeta) deposition.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26019015' target='_blank' class='pmid-link'>26019015</a>:</span> <span class='sentence-part'>Hydrogen Sulfide Ameliorates Homocysteine-Induced Alzheimer's Disease-Like Pathology, Blood-Brain Barrier Disruption, and Synaptic Disorder.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29254095' target='_blank' class='pmid-link'>29254095</a>:</span> <span class='sentence-part'>Dissecting the Role of 5-Lipoxygenase in the Homocysteine-Induced Alzheimer's Disease Pathology.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29710724' target='_blank' class='pmid-link'>29710724</a>:</span> <span class='sentence-part'>Homocysteine (Hcy) injection for 14 days was used to induce AD-like pathology. Moringa Oleifera Alleviates Homocysteine-Induced Alzheimer's Disease-Like Pathology and Cognitive Impairments.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30065790' target='_blank' class='pmid-link'>30065790</a>:</span> <span class='sentence-part'>On the other hand, betaine has been demonstrated to attenuate Alzheimer-like pathological changes induced by homocysteine.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30425189' target='_blank' class='pmid-link'>30425189</a>:</span> <span class='sentence-part'>In the present study, Tamarix gallica (TG), a naturally occurring plant known for its strong antioxidative, anti-inflammatory and anti-amyloidogenic properties, was evaluated on homocysteine (Hcy) induced AD-like pathology and cognitive impairments in rats. Our data for the first time provide evidence that TG attenuates Hcy-induced AD-like pathological changes and cognitive impairments, making TG a promising candidate for the treatment of AD-associated pathological changes.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34122042' target='_blank' class='pmid-link'>34122042</a>:</span> <span class='sentence-part'>Background:     Recent studies have reported that homocysteine (Hcy) may play a vital role in the pathogenesis of vascular dementia (VaD) and Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34169425' target='_blank' class='pmid-link'>34169425</a>:</span> <span class='sentence-part'>Our data demonstrate that ligustrazine may be used as a promising neuroprotective agent to treat the Hcy-induced AD-like pathologies. Here, we investigated whether homocysteine (Hcy) can induce AD-like pathologies and the effects of ligustrazine on these pathologies.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/9359935' target='_blank' class='pmid-link'>9359935</a>:</span> <span class='sentence-part'>Homocysteine (Hcy) may represent a metabolic link in the pathogenesis of atherosclerotic vascular diseases and old-age dementias.</span></div></div>
<div class='streamlined-assertion'><div class='streamlined-header sticky-relation-header'><span class='label-text'>Subject:</span> <strong>imbalance</strong> <span class='label-text'>Subject CUI:</span> <strong>C1397014</strong> â†’ <span class='label-text predicate-text'>CAUSES</span> â†’ <span class='label-text'>Object:</span> <strong>Alzheimers</strong> <span class='label-text'>Object CUI:</span> <strong>C0002395</strong></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/10404393' target='_blank' class='pmid-link'>10404393</a>:</span> <span class='sentence-part'>Imbalances of cytoskeletal organization can lead to disease such as Alzheimer's, muscular disorders, and cancer.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/12862394' target='_blank' class='pmid-link'>12862394</a>:</span> <span class='sentence-part'>Amyloid precursor protein gene mutations responsible for early-onset autosomal dominant Alzheimer's disease. The imbalance between A beta production and A beta clearance releases a cascade of subsequent cellular processes leading to AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/16360221' target='_blank' class='pmid-link'>16360221</a>:</span> <span class='sentence-part'>An accumulation of amyloid beta peptide (Abeta) due to an imbalance between anabolism and catabolism triggers Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/16781020' target='_blank' class='pmid-link'>16781020</a>:</span> <span class='sentence-part'>Much experimental evidence suggests that an imbalance in cellular redox status is a major factor in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/1717039' target='_blank' class='pmid-link'>1717039</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) and its hallmark, plaques, may be due to an imbalance of trophic support.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/18085519' target='_blank' class='pmid-link'>18085519</a>:</span> <span class='sentence-part'>Chronic imbalance between production and degradation of the human amyloid-beta peptide (Abeta) is assumed to play an important role in pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/18393845' target='_blank' class='pmid-link'>18393845</a>:</span> <span class='sentence-part'>An imbalance between the production and clearance of Abeta is thought by many to represent the earliest event in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/19413589' target='_blank' class='pmid-link'>19413589</a>:</span> <span class='sentence-part'>Imbalanced generation of the Abeta42 peptide from the amyloid beta protein precursor (APP) is implicated in the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20463236' target='_blank' class='pmid-link'>20463236</a>:</span> <span class='sentence-part'>The accumulation of amyloid beta (Abeta) in Alzheimer's disease is caused by an imbalance of production and clearance, which leads to increased soluble Abeta species and extracellular plaque formation in the brain.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21148344' target='_blank' class='pmid-link'>21148344</a>:</span> <span class='sentence-part'>Alzheimer's disease is hypothesized to be caused by an imbalance between beta-amyloid (Abeta) production and clearance that leads to Abeta accumulation in the central nervous system (CNS).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21551909' target='_blank' class='pmid-link'>21551909</a>:</span> <span class='sentence-part'>Moreover, since alpha1-antitrypsin, the principal inhibitor of elastase, is highly susceptible to oxidative stress, our findings suggest a link between proteolytic imbalance and oxidative stress in the pathogenesis of Alzheimer disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22055653' target='_blank' class='pmid-link'>22055653</a>:</span> <span class='sentence-part'>DISCUSSION: The positive correlation between sAPPalpha and sAPPbeta challenges the hypothesis that AD is caused by an imbalance of the alpha- and beta-secretase APP proteolysis through competing mechanisms.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22241730' target='_blank' class='pmid-link'>22241730</a>:</span> <span class='sentence-part'>These observations are consistent with the hypothesis that AD proceeds as a result of an imbalance between Abeta production and Abeta clearance, suggesting a role for myosin Vb in this process.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22415062' target='_blank' class='pmid-link'>22415062</a>:</span> <span class='sentence-part'>The possible imbalance between the Abeta production/degradation process was suggested to contribute to the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22491325' target='_blank' class='pmid-link'>22491325</a>:</span> <span class='sentence-part'>Therefore, restoration of sAPP-alpha or enhancement of its association with BACE may be viable strategies to ameliorate imbalances in APP processing that can lead to AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23378928' target='_blank' class='pmid-link'>23378928</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) is characterized by the accumulation of beta-amyloid peptide (Abeta) in the brain because of an imbalance between Abeta production and clearance.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24115839' target='_blank' class='pmid-link'>24115839</a>:</span> <span class='sentence-part'>Metal imbalance is the leading cause for many neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, and multiple sclerosis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24310478' target='_blank' class='pmid-link'>24310478</a>:</span> <span class='sentence-part'>Imbalance of zinc ion (Zn(2+)) in human body causes diseases like Alzheimer's and Parkinson's and therefore Zn(2+) estimation in biological fluids has diagnostic values.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24983737' target='_blank' class='pmid-link'>24983737</a>:</span> <span class='sentence-part'>Alzheimer's disease is a consequence of an imbalance between the generation and clearance of amyloid-beta peptide in the brain.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25649650' target='_blank' class='pmid-link'>25649650</a>:</span> <span class='sentence-part'>In particular, our previous studies on GSH redox imbalance have implicated oxidative stress induced by excessive reactive oxygen species as a major mediator of AD-like events, with the presence of S- glutathionylated proteins (Pr-SSG) appearing prior to overt AD neuropathology.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25866779' target='_blank' class='pmid-link'>25866779</a>:</span> <span class='sentence-part'>The identified common subnetworks showed that inflammation of the brain nerves is one of the critical factors of AD and calcium imbalance may be a link among several causative factors in AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26254061' target='_blank' class='pmid-link'>26254061</a>:</span> <span class='sentence-part'>The imbalance between beta-amyloid (Abeta) generation and clearance plays a fundamental role in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26390937' target='_blank' class='pmid-link'>26390937</a>:</span> <span class='sentence-part'>An imbalance of intracellular calcium homeostasis induced by amyloid beta-protein (Abeta) contributes to the pathogenesis of Alzheimer's disease (AD), such as deficits in learning and memory.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26639718' target='_blank' class='pmid-link'>26639718</a>:</span> <span class='sentence-part'>AD is caused by an imbalance between Abeta production and clearance, resulting in increased amount of Abeta in various forms [2].</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27031475' target='_blank' class='pmid-link'>27031475</a>:</span> <span class='sentence-part'>Although the pathogenesis of AD remains unclear, AD is thought to result from an imbalance in the production and clearance of amyloid-beta protein (Abeta).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27234294' target='_blank' class='pmid-link'>27234294</a>:</span> <span class='sentence-part'>AD is associated with increased oxidative stress, resulting from imbalance in production and clearance of reactive oxygen species (ROS).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27412291' target='_blank' class='pmid-link'>27412291</a>:</span> <span class='sentence-part'>Strong evidence indicates that an imbalance between production and degradation of key proteins contributes to the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28281098' target='_blank' class='pmid-link'>28281098</a>:</span> <span class='sentence-part'>The metal imbalance is also among leading causes of AD, owing to the fact that Abeta aggregation takes place in the synaptic cleft where Abeta, Cu(II) and Fe(III) are found in abnormally high concentrations.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28666362' target='_blank' class='pmid-link'>28666362</a>:</span> <span class='sentence-part'>Inference of Causative Genes for Alzheimer's Disease Due to Dosage Imbalance. Although it has been reported that AD is strongly affected by CNVs, most of AD-causing genes with pathogenic CNVs have not been identified yet.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29609077' target='_blank' class='pmid-link'>29609077</a>:</span> <span class='sentence-part'>In the present study, we investigated whether this neurotrophic imbalance can produce an AD-like retrograde degeneration of BFCNs.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30098078' target='_blank' class='pmid-link'>30098078</a>:</span> <span class='sentence-part'>Oxidative stress and oxidative DNA damage are early features of mild cognitive impairment and Alzheimer's disease (AD), occurring before the formation of classical AD neuropathology, and resulting from an imbalance between pro- and anti-oxidants.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30595042' target='_blank' class='pmid-link'>30595042</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) is considered as a potential risk factor for the development of seizure due to neurodegeneration and imbalance between stimulatory and inhibitory circuits in the brain.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30822648' target='_blank' class='pmid-link'>30822648</a>:</span> <span class='sentence-part'>An imbalance in Ca2+ homeostasis represents an early event in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30866445' target='_blank' class='pmid-link'>30866445</a>:</span> <span class='sentence-part'>Imbalances of excitatory/inhibitory synaptic transmission occur early in the pathogenesis of Alzheimer's disease (AD), leading to hippocampal hyperexcitability and causing synaptic, network, and cognitive dysfunctions.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31379578' target='_blank' class='pmid-link'>31379578</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) is characterized by two landmark pathologies, the overproduction of amyloid-beta peptides (Abeta), predominated by the beta-amyloid protein precursor cleaving enzyme 1 (BACE1), and hyperphosphorylation of the microtubule protein, tau, because of an imbalance in a kinase/phosphatase system that involves the activation of the protein kinase A (PKA).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31795606' target='_blank' class='pmid-link'>31795606</a>:</span> <span class='sentence-part'>We surmise that any imbalance in MeCP2 function would accelerate or cause Alzheimer disease pathogenesis, implying that MeCP2 may be a potential drug target for the treatment and prevention of Alzheimer disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/835158' target='_blank' class='pmid-link'>835158</a>:</span> <span class='sentence-part'>Apparently, this vasocontrictive reflex becomes excessive in Alzheimer's disease, possibly due to cerebral neurogenic imbalance.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/9603784' target='_blank' class='pmid-link'>9603784</a>:</span> <span class='sentence-part'>These findings demonstrate that oxidative imbalance and stress are key elements in the pathogenesis of Alzheimer disease.</span></div></div>
<div class='streamlined-assertion'><div class='streamlined-header sticky-relation-header'><span class='label-text'>Subject:</span> <strong>neuron_loss</strong> <span class='label-text'>Subject CUI:</span> <strong>C0598940</strong> â†’ <span class='label-text predicate-text'>CAUSES</span> â†’ <span class='label-text'>Object:</span> <strong>Alzheimers</strong> <span class='label-text'>Object CUI:</span> <strong>C0002395</strong></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/12651959' target='_blank' class='pmid-link'>12651959</a>:</span> <span class='sentence-part'>This is especially important in the study of Alzheimer's disease (AD), in which spatial neuronal organization and relationships are highly disrupted because of neuronal loss.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/15574357' target='_blank' class='pmid-link'>15574357</a>:</span> <span class='sentence-part'>Accumulating evidence indicates that two distinct Cdk pathways may have a role in the neuronal loss that is responsible for Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/15630088' target='_blank' class='pmid-link'>15630088</a>:</span> <span class='sentence-part'>Amyloid deposition, neuronal loss, and disturbed synaptic transmission are considered to be the main causes of Alzheimer's disease dementia.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17112517' target='_blank' class='pmid-link'>17112517</a>:</span> <span class='sentence-part'>The neurological deficits that are characteristic of Alzheimer's Disease (AD) are ultimately a result of neuronal loss in distinct anatomical regions of the brain.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20689579' target='_blank' class='pmid-link'>20689579</a>:</span> <span class='sentence-part'>BACKGROUND: A devastating aspect of Alzheimer's disease (AD) is the progressive deterioration of memory due to neuronal loss.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21447108' target='_blank' class='pmid-link'>21447108</a>:</span> <span class='sentence-part'>CONCLUSIONS: The CBF reduction in the PCC in AD was partly caused by neuronal loss in the PCC and partly supported the hypothesis that CBF reduction in the PCC was a result of functional deafferentation by neural degeneration in areas other than the PCC.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22175653' target='_blank' class='pmid-link'>22175653</a>:</span> <span class='sentence-part'>It was developed as a symptomatic treatment to compensate for the progressive loss of cholinergic signal between neurons, a consequence of neuronal cell loss in the brains of patients with Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23305945' target='_blank' class='pmid-link'>23305945</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) is a neurodegenerative disorder that causes progressive memory and cognitive decline due to the selective neuronal loss in the cortex and hippocampus of the brains.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23921129' target='_blank' class='pmid-link'>23921129</a>:</span> <span class='sentence-part'>Amyloid-beta (Abeta) induces neuronal loss and cognitive deficits and is believed to be a prominent cause of Alzheimer's disease (AD); however, the cellular pathology of the disease is not fully understood.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26440450' target='_blank' class='pmid-link'>26440450</a>:</span> <span class='sentence-part'>In Alzheimer's disease (AD), the deposition of beta-amyloid (Abeta) is hypothesized to result in a series of secondary neurodegenerative processes, leading ultimately to synaptic dysfunction and neuronal loss.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27357648' target='_blank' class='pmid-link'>27357648</a>:</span> <span class='sentence-part'>Overall, our results strongly suggest that Ras activity is required for soluble Abeta oligomer-induced aberrant neuronal cell cycle reentry and subsequent neuronal loss, which are considered important mechanisms in AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28253985' target='_blank' class='pmid-link'>28253985</a>:</span> <span class='sentence-part'>Extensive research has revealed that multiple cellular pathways involved, including amyloid beta production, mitochondrial structural and functional changes, hyperphosphorylation of Tau and NFT formation, inflammatory responses, and neuronal loss in AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28849458' target='_blank' class='pmid-link'>28849458</a>:</span> <span class='sentence-part'>Through the misfolding process of Abeta in the brain, oligomeric forms of Abeta accumulate and significantly damage the brain cells inducing neuronal loss and cognitive dysfunctions that lead to AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30741673' target='_blank' class='pmid-link'>30741673</a>:</span> <span class='sentence-part'>Conversely, the increased evolvability conditions including gene mutations of APs are supposed to be beneficial for offspring, but might lead to AD in parents. Alzheimer's disease (AD), the most common neurodegenerative dementia, leads to memory dysfunction due to widespread neuronal loss associated with aggregation of amyloidogenic proteins (APs), while schizophrenia (SCZ) represents a major psychiatric disorder characterized by delusions, hallucinations, and other cognitive abnormalities, the underlying mechanisms of which remain obscure.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/7780790' target='_blank' class='pmid-link'>7780790</a>:</span> <span class='sentence-part'>In Alzheimer's disease, the loss of memory is likely to be due to neuronal loss in cerebral cortex and hippocampal formation, along with alterations in neurotransmitter systems (specially cholinergic, monoaminergic and aminoacidergic systems).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/9202333' target='_blank' class='pmid-link'>9202333</a>:</span> <span class='sentence-part'>Activation of the classical complement pathway has been widely investigated in recent years as a potential mechanism for the neuronal loss and neuritic dystrophy characteristic of Alzheimer's disease (AD) pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/9589388' target='_blank' class='pmid-link'>9589388</a>:</span> <span class='sentence-part'>Alzheimer's disease (AD) is associated with a reduction in cholinergic activity as a result of specific neuronal loss.</span></div></div>
<div class='streamlined-assertion'><div class='streamlined-header sticky-relation-header'><span class='label-text'>Subject:</span> <strong>neuronal</strong> <span class='label-text'>Subject CUI:</span> <strong>C0521390</strong> â†’ <span class='label-text predicate-text'>CAUSES</span> â†’ <span class='label-text'>Object:</span> <strong>Alzheimers</strong> <span class='label-text'>Object CUI:</span> <strong>C0002395</strong></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31920472' target='_blank' class='pmid-link'>31920472</a>:</span> <span class='sentence-part'>Dysfunction in neurovascular coupling that results in a mismatch between cerebral blood flow and neuronal activity has been suggested to play a key role in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32892233' target='_blank' class='pmid-link'>32892233</a>:</span> <span class='sentence-part'>Neuronal dysfunction and loss are thought to be one of the causes of cognitive impairment in Alzheimer's disease (AD), but the specific mechanism of neuronal loss in the pathogenesis of AD remains controversial.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34080759' target='_blank' class='pmid-link'>34080759</a>:</span> <span class='sentence-part'>The relationship between neuronal loss and Abeta deposits is one of the fundamental questions in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34211387' target='_blank' class='pmid-link'>34211387</a>:</span> <span class='sentence-part'>Amyloidogenicity and vascular dysfunction are the key players in the pathogenesis of Alzheimer's disease (AD), involving dysregulated cellular interactions. Overall, the current review informs about the interaction of neuronal and glial cell types in AD pathogenesis and its critical association with cerebrovascular dysfunction.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35154497' target='_blank' class='pmid-link'>35154497</a>:</span> <span class='sentence-part'>Conclusion:     We found that the MeCP2-mediated dysregulation of the epigenome in the striatum is linked to the defects in cognitive behavior and neuronal activity in the AD animal model, and that this alteration is initiated even in the very early stages of AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35768560' target='_blank' class='pmid-link'>35768560</a>:</span> <span class='sentence-part'>In silico studies suggested that the SNP's alter the expression of CD36 thus potentially affecting CD36-related neuroinflammation and other molecular and cellular mechanisms known to be involved in the neuronal loss leading to AD. CD36 was selected as a gene previously shown to be implicated in the etiology of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37147110' target='_blank' class='pmid-link'>37147110</a>:</span> <span class='sentence-part'>Together, our results indicate that PREPL affects neuronal function by modulating protein trafficking and synaptic function, an important mechanism of AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37207075' target='_blank' class='pmid-link'>37207075</a>:</span> <span class='sentence-part'>Neurodegenerative diseases, such as Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS), are caused by neuronal loss and dysfunction.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37574734' target='_blank' class='pmid-link'>37574734</a>:</span> <span class='sentence-part'>BACKGROUND: Amyloid-beta (Abeta) is a normal product of neuronal activity, including that of the aggregation-prone Abeta42 variant that is thought to cause Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/38226680' target='_blank' class='pmid-link'>38226680</a>:</span> <span class='sentence-part'>Therefore, our results clarified the important role and mechanism of the Maf1-NMDAR1 signaling pathway in the stability of the synaptic structure, neuronal function, and behavior during the pathogenesis of AD, serving as a potential diagnostic and therapeutic target for the early onset of AD.</span></div></div>
<div class='streamlined-assertion'><div class='streamlined-header sticky-relation-header'><span class='label-text'>Subject:</span> <strong>presenilin</strong> <span class='label-text'>Subject CUI:</span> <strong>C0872078</strong> â†’ <span class='label-text predicate-text'>CAUSES</span> â†’ <span class='label-text'>Object:</span> <strong>Alzheimers</strong> <span class='label-text'>Object CUI:</span> <strong>C0750901</strong></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/10493744' target='_blank' class='pmid-link'>10493744</a>:</span> <span class='sentence-part'>Presenilins are a highly conserved family of proteins first identified as causative genes in early onset familial Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/10984440' target='_blank' class='pmid-link'>10984440</a>:</span> <span class='sentence-part'>Presenilins were first identified as causative factors in early onset, familial Alzheimer's Disease (FAD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/11684347' target='_blank' class='pmid-link'>11684347</a>:</span> <span class='sentence-part'>Presenilin 1 mutations are the major cause of autosomal dominant Alzheimer's disease: here we identify a new missense mutation causing a methionine to valine change at codon 233. A novel presenilin mutation (M233V) causing very early onset Alzheimer's disease with Lewy bodies.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/12476348' target='_blank' class='pmid-link'>12476348</a>:</span> <span class='sentence-part'>Studies of the pathogenic actions of mutations in presenilins and amyloid precursor protein that cause early-onset familial AD have established central roles for perturbed cellular calcium homeostasis and oxidative stress in the neurodegenerative process. The clinical presentation of patients with AD is dominated by cognitive deficits and emotional disturbances that result from dysfunction and degeneration of neurons in the limbic system and cerebral cortex.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/12849363' target='_blank' class='pmid-link'>12849363</a>:</span> <span class='sentence-part'>Mutant genes for amyloid precursor protein (APP) or presenilin cause early-onset familial Alzheimer's disease (&lt;1% of all cases) and have helped to elucidate APP processing and amyloid-peptide formation by alpha, beta, and gamma secretases.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/12902342' target='_blank' class='pmid-link'>12902342</a>:</span> <span class='sentence-part'>Presenilins, whose mutant forms are the most common cause of early onset familial Alzheimer's disease, are involved in two very distinct processes: (i) proteolytic activity as gamma-secretase acting on amyloid precursor protein to produce amyloid peptides and (ii) storage of Ca2+ in the endoplasmic reticulum (ER).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/15565529' target='_blank' class='pmid-link'>15565529</a>:</span> <span class='sentence-part'>According to the beta-amyloid cascade hypothesis, the accumulation of beta-amyloid (Abeta) deposits as amyloid plaques in the patient's brain is the primary event in the pathogenesis of Alzheimer's disease (AD). The majority of known APP and presenilin mutations responsible for familial early onset AD affect APP processing causing overproduction of Abeta, especially Abeta42.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/16148264' target='_blank' class='pmid-link'>16148264</a>:</span> <span class='sentence-part'>Numerous mutations in the presenilins are known to cause early-onset familial Alzheimer's disease (FAD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17568632' target='_blank' class='pmid-link'>17568632</a>:</span> <span class='sentence-part'>Presenilin proteins, mutated forms of which cause early onset familial Alzheimer's disease, are capable of modulating various cell signal transduction pathways, the most extensively studied of which has been intracellular calcium signalling.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17582777' target='_blank' class='pmid-link'>17582777</a>:</span> <span class='sentence-part'>The presenilins (PSs) were identified as causative genes in cases of early-onset familial Alzheimer's disease (AD) and current evidence indicates that PSs are part of the gamma-secretase complex responsible for proteolytic processing of type I membrane proteins.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20798900' target='_blank' class='pmid-link'>20798900</a>:</span> <span class='sentence-part'>Mutations in PSEN genes, which encode presenilin proteins, cause familial early-onset Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21725719' target='_blank' class='pmid-link'>21725719</a>:</span> <span class='sentence-part'>beta-amyloid precursor protein (APP) and presenilins mutations cause early-onset familial Alzheimer's disease (FAD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22489754' target='_blank' class='pmid-link'>22489754</a>:</span> <span class='sentence-part'>This is true for HTT, the beta-amyloid precursor protein (APP) and presenilins, responsible for early onset Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24977484' target='_blank' class='pmid-link'>24977484</a>:</span> <span class='sentence-part'>By the use of mutated PS causing early onset AD in cell culture and transgenic mice we found that GCS is increased in AD, further substantiated by the use of AD post mortem brains, suffering from sporadic AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25814654' target='_blank' class='pmid-link'>25814654</a>:</span> <span class='sentence-part'>Of nearly 200 PRESENILIN mutations causing early onset, familial Alzheimer's disease (FAD) only the K115Efx10 mutation of PSEN2 causes truncation of the open reading frame.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30763650' target='_blank' class='pmid-link'>30763650</a>:</span> <span class='sentence-part'>Mutations in the genes encoding amyloid precursor protein (APP) or presenilin (PS) cause early onset familial Alzheimer's disease (AD), and sequential cleavages of the APP by beta-secretase and gamma-secretase/presenilin generate amyloid beta protein (Abeta), the major component of pathological hallmark, neuritic plaques, in brains of AD patients.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31625391' target='_blank' class='pmid-link'>31625391</a>:</span> <span class='sentence-part'>Dominant mutations in APP and presenilin cause early onset familial Alzheimer's disease (FAD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/8651641' target='_blank' class='pmid-link'>8651641</a>:</span> <span class='sentence-part'>Mutations in three of these, the amyloid precursor protein, presenilin I, and presenilin II, cause early-onset AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/9106355' target='_blank' class='pmid-link'>9106355</a>:</span> <span class='sentence-part'>Various mutations in the amyloid protein precursor and presenilin genes can lead to early onset, autosomal Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/9189043' target='_blank' class='pmid-link'>9189043</a>:</span> <span class='sentence-part'>The prevalence of known mutations in presenilin genes (PS1 and PS2) causing early-onset familial Alzheimer's disease (FAD) was assessed in a population of 98 singleton early-onset AD cases, 29 early-onset FAD cases, and 15 late-onset FAD cases.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/9831466' target='_blank' class='pmid-link'>9831466</a>:</span> <span class='sentence-part'>Numerous mutations in the presenilin (PS) genes cause early onset familial Alzheimer's disease (FAD).</span></div></div>
<div class='streamlined-assertion'><div class='streamlined-header sticky-relation-header'><span class='label-text'>Subject:</span> <strong>presenilin_1</strong> <span class='label-text'>Subject CUI:</span> <strong>C0299212</strong> â†’ <span class='label-text predicate-text'>CAUSES</span> â†’ <span class='label-text'>Object:</span> <strong>Alzheimers</strong> <span class='label-text'>Object CUI:</span> <strong>C0750901</strong></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/10230703' target='_blank' class='pmid-link'>10230703</a>:</span> <span class='sentence-part'>Genetic studies on some families have shown that mutations in the genes encoding beta-amyloid precursor protein and presenilins 1 and 2 are responsible for early-onset AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/10329743' target='_blank' class='pmid-link'>10329743</a>:</span> <span class='sentence-part'>OBJECTIVE: Presenilin-1 is a major causative gene for early onset familial Alzheimer's disease, and the apolipoprotein E epsilon4 allele is a major genetic risk factor known to influence late onset and sporadic early onset Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/10775535' target='_blank' class='pmid-link'>10775535</a>:</span> <span class='sentence-part'>We describe 21 affected individuals from a kindred with early-onset autosomal dominant familial Alzheimer's disease caused by an intronic presenilin-1 mutation (in intron 4). Alzheimer's disease due to an intronic presenilin-1 (PSEN1 intron 4) mutation: A clinicopathological study.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/11906199' target='_blank' class='pmid-link'>11906199</a>:</span> <span class='sentence-part'>Presenilin-1 (PS1) is a causative gene in early onset familial Alzheimer's disease (FAD). This findings suggest that the direct generation of Abeta from the complex may play an important role in the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/15330337' target='_blank' class='pmid-link'>15330337</a>:</span> <span class='sentence-part'>Here, we show that mutations of presenilin (PS) 1 and 2, which cause familial early-onset AD (FAD), induce more severe lysosomal system neuropathology in humans than does sporadic AD (SAD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/20854432' target='_blank' class='pmid-link'>20854432</a>:</span> <span class='sentence-part'>Presenilins 1 and 2 are the major causative genes of early-onset familial AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21159009' target='_blank' class='pmid-link'>21159009</a>:</span> <span class='sentence-part'>Early-onset familial Alzheimer's disease (AD) caused by presenilin-1 mutation E280A (PS1-E280A) presents wide clinical and neuropathological variabilities.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22133015' target='_blank' class='pmid-link'>22133015</a>:</span> <span class='sentence-part'>The findings support the notion that a deficit in the coordination mechanism of the central executive may be a pre-clinical marker for the early detection of AD due to the E280A presenilin-1 gene mutation. This study examined dual task abilities in individuals who are at risk of early-onset familial AD due to an E280A presenilin-1 mutation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22267728' target='_blank' class='pmid-link'>22267728</a>:</span> <span class='sentence-part'>Accumulation of Abeta could be caused by increased production, as indicated by several mutations in the amyloid precursor protein or the gamma-secretase components presenilin-1 and presenilin-2 that cause familial early-onset AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23123781' target='_blank' class='pmid-link'>23123781</a>:</span> <span class='sentence-part'>BACKGROUND: Mutations in the gene for presenilin-1 cause familial, early-onset Alzheimer's disease. CONCLUSIONS: This novel presenilin-1 sequence variant cosegregated with early onset dementia in the proband and at least one other affected family member, and likely represents a mutation causing familial, early-onset Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31391004' target='_blank' class='pmid-link'>31391004</a>:</span> <span class='sentence-part'>BACKGROUND: Presenilin-1 (PSEN1) is one of the causative genes for early onset Alzheimer's disease (EOAD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/8741394' target='_blank' class='pmid-link'>8741394</a>:</span> <span class='sentence-part'>[Presenilin-1 (S182) causative gene of early-onset familial Alzheimer's disease].</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/9160754' target='_blank' class='pmid-link'>9160754</a>:</span> <span class='sentence-part'>Presenilin-1 (PS1) is the major gene responsible for early-onset familial Alzheimer's disease (FAD).</span></div></div>
<div class='streamlined-assertion'><div class='streamlined-header sticky-relation-header'><span class='label-text'>Subject:</span> <strong>presenilin_1_PSEN1</strong> <span class='label-text'>Subject CUI:</span> <strong>C0299212|5663</strong> â†’ <span class='label-text predicate-text'>CAUSES</span> â†’ <span class='label-text'>Object:</span> <strong>Alzheimers</strong> <span class='label-text'>Object CUI:</span> <strong>C0750901</strong></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/10078973' target='_blank' class='pmid-link'>10078973</a>:</span> <span class='sentence-part'>Mutations in two related genes, presenilin 1 and presenilin 2 (PS1 and PS2), cause a subset of early-onset familial Alzheimer's disease (FAD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/10340748' target='_blank' class='pmid-link'>10340748</a>:</span> <span class='sentence-part'>Because distinct mutations in presenilin 1 and presenilin 2 are a major cause of early-onset familial Alzheimer's disease, we generated four monoclonal antibodies for the identification, localization, and investigation of presenilins in various cell lines and tissues from patients and controls.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/11071766' target='_blank' class='pmid-link'>11071766</a>:</span> <span class='sentence-part'>In humans, many naturally occurring mutations in Presenilin 1 or 2 cause early onset Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/11405810' target='_blank' class='pmid-link'>11405810</a>:</span> <span class='sentence-part'>Autopsy-confirmed familial early-onset Alzheimer disease caused by the l153V presenilin 1 mutation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/11701593' target='_blank' class='pmid-link'>11701593</a>:</span> <span class='sentence-part'>Cerebral amyloid angiopathy is a pathogenic lesion in Alzheimer's disease due to a novel presenilin 1 mutation. This was unusually severe CAA reminiscent of the Flemish amyloid precursor protein (A692G) mutation we reported previously, which causes Alzheimer's disease and/or cerebral haemorrhages. Here, we report a family (family GB) in which early-onset Alzheimer's disease was caused by a novel presenilin 1 mutation (L282V). Nevertheless, in &gt; 90% of cases of Alzheimer's disease amyloid is also deposited in cerebral blood vessel walls (congophilic amyloid angiopathy; CAA) but its role in Alzheimer's disease pathogenesis remains enigmatic.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/11710891' target='_blank' class='pmid-link'>11710891</a>:</span> <span class='sentence-part'>This genetic change may be a prevalent cause of early-onset familial AD in the Caribbean Hispanic population. A founder mutation in presenilin 1 causing early-onset Alzheimer disease in unrelated Caribbean Hispanic families.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/18479822' target='_blank' class='pmid-link'>18479822</a>:</span> <span class='sentence-part'>Over 160 rare genetic variants in presenilin 1 (PSEN1) are known to cause Alzheimer's disease (AD). The P117A variant is a novel mutation in PSEN1, which causes early-onset AD in an autosomal dominant manner.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/18580586' target='_blank' class='pmid-link'>18580586</a>:</span> <span class='sentence-part'>OBJECTIVE: Early onset familial Alzheimer disease (EOFAD) can be caused by mutations in genes for amyloid precursor protein, presenilin 1 (PSEN1), or presenilin 2 (PSEN2). CONCLUSIONS: This is the first description of neuropathologic findings in EOFAD owing to N135S PSEN1 mutation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22044463' target='_blank' class='pmid-link'>22044463</a>:</span> <span class='sentence-part'>BACKGROUND: Missense mutations in three different genes encoding amyloid-beta precursor protein, presenilin 1 and presenilin 2 are recognized to cause familial early-onset Alzheimer disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22702962' target='_blank' class='pmid-link'>22702962</a>:</span> <span class='sentence-part'>Mutations in genes such as those encoding amyloid precursor protein (APP), presenilin 1 and presenilin 2, are responsible for early-onset familial AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23142261' target='_blank' class='pmid-link'>23142261</a>:</span> <span class='sentence-part'>Mutations in the genes encoding amyloid precursor protein (APP), presenilin 1 (PSEN1) and presenilin 2 (PSEN2) are responsible for early-onset autosomal dominant AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24838203' target='_blank' class='pmid-link'>24838203</a>:</span> <span class='sentence-part'>Mutations in the genes encoding amyloid precursor protein (APP), presenilin 1 (PSEN1) and presenilin 2 (PSEN2) are responsible for early-onset autosomal dominant AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24906965' target='_blank' class='pmid-link'>24906965</a>:</span> <span class='sentence-part'>Clinical presentation of early-onset Alzheimer's disease as a result of mutation in exon 12 of the PSEN-1 gene. INTRODUCTION: Mutations in the gene for presenilin 1 (PSEN-1) cause familial, early-onset Alzheimer's disease (EOAD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26141474' target='_blank' class='pmid-link'>26141474</a>:</span> <span class='sentence-part'>To date, mutations in three different genes, the Amyloid precursor protein (APP), Presenilin 1 (PS1), and Presenilin 2 (PS2), have been identified as causative in early-onset AD, making predictive testing possible.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30041064' target='_blank' class='pmid-link'>30041064</a>:</span> <span class='sentence-part'>Seizures have traditionally been related to neuronal loss in the late stages of AD as a consequence of neurodegeneration, however, recent studies indicated that seizures may contribute to the emergence of AD symptoms in early stages of the disease, mainly in familial AD. Mutations in genes encoding presenilin 1 (PSEN1), presenilin 2 (PSEN2) and amyloid precursor protein (APP) are responsible for early-onset familial AD (EOFAD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30681848' target='_blank' class='pmid-link'>30681848</a>:</span> <span class='sentence-part'>More than 200 distinct mutations in presenilin 1 (PSEN1) cause severe early-onset familial AD (FAD) and are thus of central interest to the etiology of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31440394' target='_blank' class='pmid-link'>31440394</a>:</span> <span class='sentence-part'>Presenilin 1 (PSEN1), presenilin 2 (PSEN2), and amyloid precursor protein (APP) mutations are responsible for autosomal dominant early-onset Alzheimer's disease (AD-EOAD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/8645246' target='_blank' class='pmid-link'>8645246</a>:</span> <span class='sentence-part'>Presenilin 1 (PSNL1) is a novel causative gene for early-onset familial Alzheimer's disease (EOFAD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/8878479' target='_blank' class='pmid-link'>8878479</a>:</span> <span class='sentence-part'>Mutations in the genes encoding amyloid-beta precursor protein (APP), presenilin 1 (PS1) and presenilin 2 (PS2) are known to cause early-onset, autosomal dominant Alzheimer's disease. These results indicate that the presenilin mutations probably cause Alzheimer's disease through a gain of deleterious function that increases the amount of A beta42(43) in the brain.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/9740395' target='_blank' class='pmid-link'>9740395</a>:</span> <span class='sentence-part'>Yet, the physiological function of presenilin 1 and the pathological mechanisms of the mutations leading to Alzheimer's disease are still unknown. Mutations in the gene for presenilin 1 are causative for the majority of cases of early onset familial Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/9834545' target='_blank' class='pmid-link'>9834545</a>:</span> <span class='sentence-part'>The second part describes the three genes, amyloid precusor protein (APP), presenilin 1 (PS1) and presenilin 2 (PS2) genes, which when mutated cause early-onset autosomal dominant AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/9886077' target='_blank' class='pmid-link'>9886077</a>:</span> <span class='sentence-part'>Presenilin 1 (PS1) has been identified as a causative gene for most early-onset familial Alzheimer's disease.</span></div></div>
<div class='streamlined-assertion'><div class='streamlined-header sticky-relation-header'><span class='label-text'>Subject:</span> <strong>receptor</strong> <span class='label-text'>Subject CUI:</span> <strong>C0597357</strong> â†’ <span class='label-text predicate-text'>CAUSES</span> â†’ <span class='label-text'>Object:</span> <strong>Alzheimers</strong> <span class='label-text'>Object CUI:</span> <strong>C0002395</strong></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/11263271' target='_blank' class='pmid-link'>11263271</a>:</span> <span class='sentence-part'>These receptors play important roles in memory and cognition and participate in the pathogenesis of several brain disorders (Parkinson's and Alzheimer's diseases, Tourette's syndrome, schizophrenia, depression, attention deficit disorder).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/15013213' target='_blank' class='pmid-link'>15013213</a>:</span> <span class='sentence-part'>In this context, it is interesting that LDL receptor-related protein is a receptor for MK and PTN, and this receptor has been implicated in the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17493709' target='_blank' class='pmid-link'>17493709</a>:</span> <span class='sentence-part'>In order to examine the neuroprotective effects of the alpha7 nicotinic receptor (nAChR) in relationship to the pathogenesis of Alzheimer's disease (AD), neuroblastoma (SH-SY5Y) cells were transfected with small interference RNAs (siRNAs) that targets specifically towards alpha7 nAChR or exposed to 20microM 3-[2,4-dimethoxybenzylidene] anabaseine (DMXB), a selective agonist of this same receptor. These findings indicate that alpha7 nAChR may play a significant neuroprotective role by enhancing cleavage of APP by alpha-secretase, regulating signal transduction, improving antioxidant defenses and inhibiting the toxicity of Abeta, which is connected with the pathogenesis of AD. The consequences of reducing expression of the alpha7 nicotinic receptor by RNA interference and of stimulating its activity with an alpha7 agonist in SH-SY5Y cells indicate that this receptor plays a neuroprotective role in connection with the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/18800618' target='_blank' class='pmid-link'>18800618</a>:</span> <span class='sentence-part'>These receptors play important roles in attention, memory, and cognition and participate in the pathogenesis of several neuropsychiatric disorders (schizophrenia, depression, anxiety disorders, Parkinson's and Alzheimer's diseases, attention-deficit hyperactivity disorders, Tourette's syndrome, and autosomal dominant nocturnal frontal lobe epilepsy).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/19374848' target='_blank' class='pmid-link'>19374848</a>:</span> <span class='sentence-part'>The significant decrease of IP accumulation by cholesterol depletion was also observed in cells expressing M(3) receptors and by both cholesterol depletion and enrichment in cells expressing M(1) receptors indicating relevance of reduced G(q/11) signaling for the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/19584434' target='_blank' class='pmid-link'>19584434</a>:</span> <span class='sentence-part'>Amyloid-beta protein precursor (AbetaPP) is a receptor-like, type-I membrane protein that plays a central role in the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23098038' target='_blank' class='pmid-link'>23098038</a>:</span> <span class='sentence-part'>Targeting the imidazoline I(2) receptor emerges as a new mechanism of action to inhibit tPA-induced signaling in neurons for the treatment of AD and other neurodegenerative diseases.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23928573' target='_blank' class='pmid-link'>23928573</a>:</span> <span class='sentence-part'>This Review highlights recent insights into the structural features that determine the function of scavenger receptors and the emerging role that these receptors have in immune responses, notably in macrophage polarization and in the pathogenesis of diseases such as atherosclerosis and Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24162852' target='_blank' class='pmid-link'>24162852</a>:</span> <span class='sentence-part'>Notably, CD36 is also a receptor for modified lipoproteins and beta-amyloid, and has been implicated in the pathogenesis of atherosclerosis and of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25362032' target='_blank' class='pmid-link'>25362032</a>:</span> <span class='sentence-part'>Computationally-derived clusters and modules within the networks indicated strong ties between RORA and genes involved in the AD etiology.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26738988' target='_blank' class='pmid-link'>26738988</a>:</span> <span class='sentence-part'>AGEs and receptor for AGEs (RAGE) play important roles in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26837733' target='_blank' class='pmid-link'>26837733</a>:</span> <span class='sentence-part'>We also address the importance of APP function as a receptor in Alzheimer's disease etiology and discuss how this function might be potentially important for the development of novel therapeutic approaches.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28373833' target='_blank' class='pmid-link'>28373833</a>:</span> <span class='sentence-part'>Misfolding of PrPC is associated with the transmissible spongiform encephalopathies (TSEs), whereas its normal conformer serves as a receptor for oligomers of the beta-amyloid peptide, which play a major role in the pathogenesis of Alzheimer's Disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28826177' target='_blank' class='pmid-link'>28826177</a>:</span> <span class='sentence-part'>Although a number of studies focusing on pharmacological or genetic manipulation of TNF-alpha and its receptors in AD mice have provided significant knowledge regarding the role of TNF-alpha signaling pathway in the pathogenesis of AD, the consequences of TNF-alpha genetic deletion have not been thoroughly examined.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30459541' target='_blank' class='pmid-link'>30459541</a>:</span> <span class='sentence-part'>This mini-review reinforces the rationale to consider major depressive disorder (MDD) as an important risk factor to develop AD and points the central role played by the hypothalamic-pituitary-adrenal (HPA) axis, glucocorticoids (GC) and their receptors (GR) in the etiology of MDD and AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30916478' target='_blank' class='pmid-link'>30916478</a>:</span> <span class='sentence-part'>Surprisingly, these Abeta oligomers reportedly bind to prion protein (PrP), which acts as a receptor on the cell membrane, possibly resulting in AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31655116' target='_blank' class='pmid-link'>31655116</a>:</span> <span class='sentence-part'>In this review, we have summarized the different calcium channels and receptors involved in calcium dysregulation which in turn play a critical role in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31702505' target='_blank' class='pmid-link'>31702505</a>:</span> <span class='sentence-part'>Dysfunction of these receptors can cause neurodegenerative diseases such as Alzheimer's disease, Parkinson Disease, X-fragile syndrome, anxiety, depression etc., hence these receptors are high profile targets for pharmaceutical industries.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34731369' target='_blank' class='pmid-link'>34731369</a>:</span> <span class='sentence-part'>In this review, we will provide a summary of recent findings regarding the role of FGFs and their receptors in the pathogenesis of AD, and discuss the possible opportunities for targeting these molecules as novel treatment strategies in AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36091826' target='_blank' class='pmid-link'>36091826</a>:</span> <span class='sentence-part'>Disturbed retinoic acid signaling causes inflammatory responses, mitochondrial impairment, oxidative stress, and neurodegeneration, leading to Alzheimer's disease (AD) progression. We outlined the physiology of retinoids in this review, focusing on their possible neuroprotective actions, which will aid in elucidating the critical function of such receptors in AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37843792' target='_blank' class='pmid-link'>37843792</a>:</span> <span class='sentence-part'>Orexin and its receptors are closely related to the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/38007666' target='_blank' class='pmid-link'>38007666</a>:</span> <span class='sentence-part'>BACKGROUND: Emerging evidence has revealed that dysregulation of the hormone ghrelin and its receptor, growth hormone secretagogue receptor (GHSR), contributes to the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/38014048' target='_blank' class='pmid-link'>38014048</a>:</span> <span class='sentence-part'>Triggering receptor expressed on myeloid cells 2 (TREM2) plays a central role in microglial biology and the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/38033552' target='_blank' class='pmid-link'>38033552</a>:</span> <span class='sentence-part'>Several lipid species and their receptors have essential functions in AD pathogenesis and may be potential biomarkers.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/38172904' target='_blank' class='pmid-link'>38172904</a>:</span> <span class='sentence-part'>Triggering receptor expressed on myeloid cells 2 (TREM2) plays a critical role in microglial activation, survival, and apoptosis, as well as in Alzheimer's disease (AD) pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/38548872' target='_blank' class='pmid-link'>38548872</a>:</span> <span class='sentence-part'>Triggering receptors expressed on myeloid cells-2 (TREM2) are known to protect against AD pathogenesis.</span></div></div>
<div class='streamlined-assertion'><div class='streamlined-header sticky-relation-header'><span class='label-text'>Subject:</span> <strong>scopolamine</strong> <span class='label-text'>Subject CUI:</span> <strong>C0036442</strong> â†’ <span class='label-text predicate-text'>CAUSES</span> â†’ <span class='label-text'>Object:</span> <strong>Alzheimers</strong> <span class='label-text'>Object CUI:</span> <strong>C0002395</strong></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32573587' target='_blank' class='pmid-link'>32573587</a>:</span> <span class='sentence-part'>The Morris water maze experiment showed that scopolamine-induced AD-like dementia in rats treated with PC/SHP-2-Bn/SHP-2-16 nanoparticles was significantly reduced.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33324798' target='_blank' class='pmid-link'>33324798</a>:</span> <span class='sentence-part'>Neuroprotective Effect of Spice Oleoresins on Memory and Cognitive Impairment Associated with Scopolamine-Induced Alzheimer's Disease in Rats.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34013783' target='_blank' class='pmid-link'>34013783</a>:</span> <span class='sentence-part'>We investigated the pharmacodynamics and pharmacokinetics of 2-week intranasal galantamine-bound chitosan nanoparticles (G-NP) treatment in scopolamine-induced Alzheimer's disease rat model.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34147486' target='_blank' class='pmid-link'>34147486</a>:</span> <span class='sentence-part'>Passive avoidance test showed that 1 or 5 mg/kg TFK restored memory impairment in scopolamine-induced Alzheimer's disease-like dementia in rats.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34170456' target='_blank' class='pmid-link'>34170456</a>:</span> <span class='sentence-part'>To investigate the possible neuroprotective role of Hespin an AD-like rat model induced experimentally by Scopolamine (Scop).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34173038' target='_blank' class='pmid-link'>34173038</a>:</span> <span class='sentence-part'>The method was used to study in vivo brain uptake and pharmacokinetics of galantamine from brain homogenate and plasma samples following the administration of nasal galantamine-bound chitosan nanoparticles compared to oral and nasal galantamine solutions, in scopolamine-induced Alzheimer's disease rat model.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34204787' target='_blank' class='pmid-link'>34204787</a>:</span> <span class='sentence-part'>The administration of    H. erinaceus     extract to zebrafish, with a pattern of AD induced by scopolamine, showed an improvement in memory evaluated by behavioral and biochemical tests on brain tissue.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34347557' target='_blank' class='pmid-link'>34347557</a>:</span> <span class='sentence-part'>This study aimed to investigate the effect of vitamin B     12       on restoration of Synaptic Plasticity on scopolamine-induced AD in rats.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35137748' target='_blank' class='pmid-link'>35137748</a>:</span> <span class='sentence-part'>Accordingly, the present study demonstrates the beneficial effects of    Salvia     species from Egypt and Jordan against scopolamine-induced AD-like disorder. Alzheimer's disease (AD) is the most prevalent form of dementia affecting people worldwide Therefore, the current research aimed to investigate potential therapeutic benefits of    Salvia officinalis     (SOL) cultivated in Jordan and    Salvia microphylla     (SML) cultivated in Egypt with regard to acetylcholinesterase activity, beta-amyloid deposition and oxidative stress associated with scopolamine-induced AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35178203' target='_blank' class='pmid-link'>35178203</a>:</span> <span class='sentence-part'>Improvement of cognitive deficit of curcumin on scopolamine-induced Alzheimer's disease models. Conclusion: We revealed that curcumin provides a protective effect on scopolamine-induced cognitive impairment mimicking Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35411685' target='_blank' class='pmid-link'>35411685</a>:</span> <span class='sentence-part'>Hence, this study was designed to investigate the possible therapeutic effect of betanin against SCO-induced AD on Wistar rats. SCO (1 mg/kg) was administrated intraperitoneally to induce the AD in Wistar rats. Mitochondrial dysfunction and oxidative stress are identified to contribute to the mechanisms responsible for the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35559146' target='_blank' class='pmid-link'>35559146</a>:</span> <span class='sentence-part'>Clavulanic Acid: A Novel Potential Agent in Prevention and Treatment of Scopolamine-Induced Alzheimer's Disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35599481' target='_blank' class='pmid-link'>35599481</a>:</span> <span class='sentence-part'>OBJECTIVE: The effects of SE from Helix aspersa on learning and memory deficits in Alzheimer's type dementia (ATD) induced by scopolamine (Sco) in male Wistar rats were examined and some mechanisms of action underlying these effects were evaluated.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35718231' target='_blank' class='pmid-link'>35718231</a>:</span> <span class='sentence-part'>TMQ diminished the lipid peroxidation and cholinergic dysfunction in the scopolamine-induced AD rat model which all reflected in improving the MMN/theta response and spatial memory.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36305148' target='_blank' class='pmid-link'>36305148</a>:</span> <span class='sentence-part'>Ellagic acid prevents oxidative stress and memory deficits in a rat model of scopolamine-induced Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36467923' target='_blank' class='pmid-link'>36467923</a>:</span> <span class='sentence-part'>The level of malondialdehyde decreased in AD animals treated with BBR-TRANS, CUR-TRANS, and BBR-CUR-TRANS, respectively, as compared to the scopolamine-induced AD animals.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36687096' target='_blank' class='pmid-link'>36687096</a>:</span> <span class='sentence-part'>Magnoflorine-Loaded Chitosan Collagen Nanocapsules Ameliorate Cognitive Deficit in Scopolamine-Induced Alzheimer's Disease-like Conditions in a Rat Model by Downregulating IL-1beta, IL-6, TNF-alpha, and Oxidative Stress and Upregulating Brain-Derived Neurotrophic Factor and DCX Expressions.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36817151' target='_blank' class='pmid-link'>36817151</a>:</span> <span class='sentence-part'>Anticholinergic effect of resveratrol with vitamin E on scopolamine-induced Alzheimer's disease in rats: Mechanistic approach to prevent inflammation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36969860' target='_blank' class='pmid-link'>36969860</a>:</span> <span class='sentence-part'>Both Augmentin and memantine improved spatial memory in AD rats, particularly in the group that received memantine; however, the outcomes were more substantial when Augmentin was administered before scopolamine was given to induce AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36986277' target='_blank' class='pmid-link'>36986277</a>:</span> <span class='sentence-part'>Rosmarinus officinalis     and    Mentha piperita     Oils Supplementation Enhances Memory in a Rat Model of Scopolamine-Induced Alzheimer's Disease-like Condition.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37261605' target='_blank' class='pmid-link'>37261605</a>:</span> <span class='sentence-part'>We, therefore, hypothesized to study the neuroprotective potential of Zinc Ortho Methyl Carbonodithioate (thereafter called ZOMEC) against Scopolamine (SCOP) induced Alzheimer's disease (AD) model using adult albino mice.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37269967' target='_blank' class='pmid-link'>37269967</a>:</span> <span class='sentence-part'>Investigation of the protective effect of long-term exercise on molecular pathways and behaviours in scopolamine induced alzheimer's disease-like condition.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37416682' target='_blank' class='pmid-link'>37416682</a>:</span> <span class='sentence-part'>Natural products have pronounced capability in treating Alzheimer disease therefore current study aimed to evaluate the neuro-protective capability of folicitin against scopolamine-induced Alzheimer disease neuropathology in mice.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37652196' target='_blank' class='pmid-link'>37652196</a>:</span> <span class='sentence-part'>CONCLUSION: This study identified numerous metabolic networks modulated by DWP that can mitigate scopolamine-induced AD neuropathology and cognitive dysfunction. Neuroprotective mechanisms of defatted walnut powder against scopolamine-induced Alzheimer's disease in mice revealed through metabolomics and proteomics analyses.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37662728' target='_blank' class='pmid-link'>37662728</a>:</span> <span class='sentence-part'>Objectives: The main objectives of proposed work are to increase the bioavailability of naringin in brain by developing Nano-suspension and preclinical evaluation of neuroprotective effect of Naringin Nano-suspension (NNS) against Scopolamine induced Alzheimer's disease in rats.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37764343' target='_blank' class='pmid-link'>37764343</a>:</span> <span class='sentence-part'>RESULTS: TQ has the potential to ameliorate cognitive deficits observed in SCOP-induced AD-like model, as evidenced by the improvement in behavioral outcomes, histopathological changes, modulation of the expression pattern of PPAR-gamma downstream targets with a significant decrease in the deposition of amyloid beta (Abeta). The Potential Neuroprotective Effect of Thymoquinone on Scopolamine-Induced In Vivo Alzheimer's Disease-like Condition: Mechanistic Insights.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37779395' target='_blank' class='pmid-link'>37779395</a>:</span> <span class='sentence-part'>Montelukast Ameliorates Scopolamine-induced Alzheimer's Disease: Role on Cholinergic Neurotransmission, Antioxidant Defence System, Neuroinflammation and Expression of BDNF.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37793605' target='_blank' class='pmid-link'>37793605</a>:</span> <span class='sentence-part'>Forst. overcome scopolamine-induced Alzheimer's type dementia in mice by activating the cholinergic system, anti-oxidant and protection of neuronal death in the brain (hippocampus region).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37832760' target='_blank' class='pmid-link'>37832760</a>:</span> <span class='sentence-part'>Preparation and characterization of brain-targeted polymeric nanocarriers (Frankincense-PMBN-lactoferrin) and in-vivo evaluation on an Alzheimer's disease-like rat model induced by scopolamine. Experiments have demonstrated that frankincense may offer protection against scopolamine-induced Alzheimer's disease by mitigating cholinergic dysfunction and inhibiting inflammatory mediators.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37924999' target='_blank' class='pmid-link'>37924999</a>:</span> <span class='sentence-part'>AIM OF THE STUDY: The study aims to assess the effects of co-treatment with WCW and donepezil on cognitive functions and serum metabolic profiles in a scopolamine-induced AD model.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/38018298' target='_blank' class='pmid-link'>38018298</a>:</span> <span class='sentence-part'>Screening of the Active Substances for the Assessment of Walnut Kernel in the Treatment of Scopolamine-Induced AD Animals.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/38278026' target='_blank' class='pmid-link'>38278026</a>:</span> <span class='sentence-part'>Sinomenine regulates the cholinergic anti-inflammatory pathway to inhibit TLR4/NF-kappaB pathway and protect the homeostasis in brain and gut in scopolamine-induced Alzheimer's disease mice.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/38360390' target='_blank' class='pmid-link'>38360390</a>:</span> <span class='sentence-part'>Scopolamine is commonly used as a model to induce Alzheimer's disease (AD-like) symptoms.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/38397604' target='_blank' class='pmid-link'>38397604</a>:</span> <span class='sentence-part'>This study used scopolamine to induce AD in rats.</span></div></div>
<div class='streamlined-assertion'><div class='streamlined-header sticky-relation-header'><span class='label-text'>Subject:</span> <strong>streptozocin</strong> <span class='label-text'>Subject CUI:</span> <strong>C0038432</strong> â†’ <span class='label-text predicate-text'>CAUSES</span> â†’ <span class='label-text'>Object:</span> <strong>Alzheimers</strong> <span class='label-text'>Object CUI:</span> <strong>C0002395</strong></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31855046' target='_blank' class='pmid-link'>31855046</a>:</span> <span class='sentence-part'>Effects of recurrent sevoflurane anesthesia on cognitive functions with streptozotocin induced Alzheimer disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31997154' target='_blank' class='pmid-link'>31997154</a>:</span> <span class='sentence-part'>Our study highlights that treatment with TA prevents memory deficits and reestablishes Akt and pAkt expression, protecting against neuronal death and neuroinflammation in STZ-induced SDAT in rats. Tannic Acid Ameliorates STZ-Induced Alzheimer's Disease-Like Impairment of Memory, Neuroinflammation, Neuronal Death and Modulates Akt Expression. Tannic Acid Ameliorates STZ-Induced Alzheimer's Disease-Like Impairment of Memory, Neuroinflammation, Neuronal Death and Modulates Akt Expression.Tannic acid (TA) is a hydrolysable glycosidic polyphenol polymer of gallic acid, which possesses neuroprotective properties. TA treatment protected against the impairment of memory in STZ-induced SDAT.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32038117' target='_blank' class='pmid-link'>32038117</a>:</span> <span class='sentence-part'>In conclusion, our study demonstrated that AS605240 exhibited immense potential in attenuating STZ-induced sporadic AD features in rats and may be developed as a therapeutic agent in the treatment and management of sporadic AD. Phosphoinositide 3-kinase inhibitor AS605240 ameliorates streptozotocin-induced Alzheimer's disease like sporadic dementia in experimental rats. Phosphoinositide 3-kinase inhibitor AS605240 ameliorates streptozotocin-induced Alzheimer's disease like sporadic dementia in experimental rats.The quest for chemical entities able to curb the action of the phosphoinositide 3-kinase, (PI3K)/protein kinase B (AKT) signaling pathways is evolving as a potential therapeutic strategy for the treatment and/or prevention of neurodegenerative disorders including Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32202739' target='_blank' class='pmid-link'>32202739</a>:</span> <span class='sentence-part'>METHODS: Male Wistar rats were injected with streptozocin (STZ) in the lateral ventricles of the brain to induce AD or saline (sham operated animals - SO) during stereotactic operations. [Streptozocin-induced Alzheimer's disease as an independent risk factor for the development of hyperglycemia in Wistar rats].BACKGROUND: In recent years the theme of the relationship of Alzheimers disease (AD) and metabolic disorders has been widely discussed. [Streptozocin-induced Alzheimer's disease as an independent risk factor for the development of hyperglycemia in Wistar rats].</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32336744' target='_blank' class='pmid-link'>32336744</a>:</span> <span class='sentence-part'>Schisandrin ameliorates cognitive deficits, endoplasmic reticulum stress and neuroinflammation in STZ-induced Alzheimer's disease rats.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32365983' target='_blank' class='pmid-link'>32365983</a>:</span> <span class='sentence-part'>Orthosiphon stamineus     Standardized Extract Reverses Streptozotocin-induced Alzheimer's Disease-Like Condition in a Rat Model. Orthosiphon stamineus     Standardized Extract Reverses Streptozotocin-induced Alzheimer's Disease-Like Condition in a Rat Model.Alzheimer's disease (AD) is a chronic neurodegenerative brain disease that is characterized by impairment in cognitive functioning as well as the presence of intraneuronal neurofibrillary tangles (NFTs) and extracellular senile plaques.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32473247' target='_blank' class='pmid-link'>32473247</a>:</span> <span class='sentence-part'>Metformin loaded phosphatidylserine nanoliposomes improve memory deficit and reduce neuroinflammation in streptozotocin-induced Alzheimer's disease model. Metformin loaded phosphatidylserine nanoliposomes improve memory deficit and reduce neuroinflammation in streptozotocin-induced Alzheimer's disease model.Alzheimer's disease (AD) is closely associated with neuroinflammation development in the brain.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32480228' target='_blank' class='pmid-link'>32480228</a>:</span> <span class='sentence-part'>A potent natural neuroprotective agent for the prevention of streptozotocin-induced Alzheimer's disease in mice. In vivo, streptozotocin induced AD in mice model was established and Hibiscus extracts were tested at a dose of 200 mg kg     -1       compared to celecoxib (30 mg/kg).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32504391' target='_blank' class='pmid-link'>32504391</a>:</span> <span class='sentence-part'>Protective Effects of Co-administration of Zinc and Selenium Against Streptozotocin-Induced Alzheimer's Disease: Behavioral, Mitochondrial Oxidative Stress, and GPR39 Expression Alterations in Rats. Findings of the current study showed that ZnR/GPR39 receptor, mitochondrial dysfunction, and oxidative stress play important roles in the pathogenesis of AD. Co-treatment of Zn and Se improved the cognitive performance, mitochondrial dysfunction, and oxidative stress caused by STZ-induced AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32522682' target='_blank' class='pmid-link'>32522682</a>:</span> <span class='sentence-part'>Eight days after AD induction by streptozotocin (STZ), mice were subjected to the swimming exercise for four weeks.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32566864' target='_blank' class='pmid-link'>32566864</a>:</span> <span class='sentence-part'>In Silico Study and Pharmacological Evaluation of Eplerinone as an Anti-Alzheimer's Drug in STZ-Induced Alzheimer's Disease Model.Alzheimer's disease (AD) is the neurodegenerative disorder characterized by impairment of higher intellectual dysfunctions associated with changes in the cognitive, behavioral, and social activities. In Silico Study and Pharmacological Evaluation of Eplerinone as an Anti-Alzheimer's Drug in STZ-Induced Alzheimer's Disease Model.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32599128' target='_blank' class='pmid-link'>32599128</a>:</span> <span class='sentence-part'>Taken together, these data demonstrated that rapamycin improved STZ-induced AD-like tauopathies and memory deficit in mice via improving p70S6K and AKT/AMPK/GSK-3beta signaling and decreasing AGEs. Inhibition of mTORC1 improves STZ-induced AD-like impairments in mice.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32728854' target='_blank' class='pmid-link'>32728854</a>:</span> <span class='sentence-part'>Thus, NR1-dependent mitochondrial calcium accumulation could be considered as a major attribute to the animal model of ICV-STZ-induced AD-like manifestations.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32738031' target='_blank' class='pmid-link'>32738031</a>:</span> <span class='sentence-part'>Protective effects of isoquercitrin on streptozotocin-induced neurotoxicity.Alzheimer's disease (AD) is characterized by irreversible and progressive memory loss and has no effective treatment. Moreover, oral administration of ISO protects hippocampal neurons from STZ-induced neurotoxicity and significantly improves the cognitive and behavioural impairment in STZ-induced AD rats.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32876502' target='_blank' class='pmid-link'>32876502</a>:</span> <span class='sentence-part'>Also these NPs acquired a high concentration in mice brain and better pharmacokinetic profile than ALN solution (intranasal) CS-ALN-NPs were then evaluated against intracerebroventricular-streptozotocin (ICV-STZ) induced Alzheimer's disease (AD)-like pathologies in mice.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32903692' target='_blank' class='pmid-link'>32903692</a>:</span> <span class='sentence-part'>Streptozotocin Induces Alzheimer's Disease-Like Pathology in Hippocampal Neuronal Cells    via     CDK5/Drp1-Mediated Mitochondrial Fragmentation. We also determined that inhibition of mitochondrial fragmentation suppresses STZ-induced AD-like pathology. Furthermore, we found that phosphorylation of Drp1 was induced by CDK5, and inhibition of CDK5 suppresses STZ-induced mitochondrial fragmentation and AD-like pathology.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33352241' target='_blank' class='pmid-link'>33352241</a>:</span> <span class='sentence-part'>CONCLUSION: These findings indicate that RGLS prevented learning and memory impairments in the present rat model of streptozotocin-induced sporadic Alzheimer's disease, and these effects depended on a decrease in Abeta expression and Tau hyperphosphorylation and the modulation of BDNF-TrkB signaling in the hippocampus. Prophylactic effects of sporoderm-removed Ganoderma lucidum spores in a rat model of streptozotocin-induced sporadic Alzheimer's disease. RESULTS: Treatment with RGLS (360 and 720 mg/kg) significantly enhanced memory in the rat model of STZ-induced sporadic Alzheimer's disease and reversed the streptozotocin-induced increases in Abeta expression and Tau protein expression and phosphorylation at Ser199, Ser202, and Ser396.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33479638' target='_blank' class='pmid-link'>33479638</a>:</span> <span class='sentence-part'>Five synthetic sulfonamides derived from carvacrol, a natural product and a small molecule with druglike properties, were evaluated with respect to their effects on the cognitive deficits of animals with streptozotocin (STZ)-induced Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33732137' target='_blank' class='pmid-link'>33732137</a>:</span> <span class='sentence-part'>Conclusion:     A bilateral hippocampal microinjection of STZ could induce not only AD-like behavioral performance in mice, but also adaptive changes of synaptic plasticity against neuroinflammatory and endocrinal injuries.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33814439' target='_blank' class='pmid-link'>33814439</a>:</span> <span class='sentence-part'>Enhancement of O-GlcNAcylation to moderate levels by using low-dose OGA inhibitor in ICV-STZ mice prevented STZ-induced body weight loss, rescued cognitive impairments, and restored AD-like pathologies, including hyperphosphorylation of tau and abnormalities in synaptic proteins and neuroinflammation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33877499' target='_blank' class='pmid-link'>33877499</a>:</span> <span class='sentence-part'>Drotaverine Inhibitor of PDE4: Reverses the Streptozotocin Induced Alzheimer's Disease in Mice. Groups II-VII were given STZ (3 mg/kg, ICV) on 1st and 3rd day of treatment to induce AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34116571' target='_blank' class='pmid-link'>34116571</a>:</span> <span class='sentence-part'>In the current study, the protective effect of beta boswellic acid on streptozotocin-induced sporadic Alzheimer's disease was surveyed.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34170261' target='_blank' class='pmid-link'>34170261</a>:</span> <span class='sentence-part'>Hippocampal and intraperitoneal injections of streptozocin were used to induce AD and diabetes in male Wistar rats, followed by intranasal administration of a single dose of TSP-1-hEDSCs and intraperitoneal administration of artemisinin for 4 weeks.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34235591' target='_blank' class='pmid-link'>34235591</a>:</span> <span class='sentence-part'>Protective effect of andrographolide against STZ induced Alzheimer's disease in experimental rats: possible neuromodulation and Abeta     (1-42)       analysis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34306309' target='_blank' class='pmid-link'>34306309</a>:</span> <span class='sentence-part'>Probiotics Fermentation Technology, a Novel Kefir Product, Ameliorates Cognitive Impairment in Streptozotocin-Induced Sporadic Alzheimer's Disease in Mice.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34319254' target='_blank' class='pmid-link'>34319254</a>:</span> <span class='sentence-part'>BACKGROUND: To explore the effect of albiflorin (AL) on streptozotocin (STZ)-induced Alzheimer's disease (AD) in rats.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34320500' target='_blank' class='pmid-link'>34320500</a>:</span> <span class='sentence-part'>Zuoguiwan Ameliorates Cognitive Deficits and Neuro-Inflammation in Streptozotocin-Induced Alzheimer's Disease Rats.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34428446' target='_blank' class='pmid-link'>34428446</a>:</span> <span class='sentence-part'>Tadalafil and bergapten mitigate streptozotocin-induced sporadic Alzheimer's disease in mice via modulating neuroinflammation, PI3K/Akt, Wnt/beta-catenin, AMPK/mTOR signaling pathways.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34706756' target='_blank' class='pmid-link'>34706756</a>:</span> <span class='sentence-part'>Furthermore, both UTE and URE significantly enhanced Akt activation, down regulated the activation of glycogen synthase kinase 3beta (GSK-3beta), and induced the nuclear translocation of Nrf2 in the STZ-induced AD rats. Morris water maze (MWM) test was conducted to assess the neurological functions in the STZ-induced AD rats. We found for the first time that both of them could ameliorate cognitive deficits in the STZ-induced AD rats.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34715140' target='_blank' class='pmid-link'>34715140</a>:</span> <span class='sentence-part'>Deferoxamine preconditioning enhances the protective effects of stem cells in streptozotocin-induced Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34792730' target='_blank' class='pmid-link'>34792730</a>:</span> <span class='sentence-part'>The aim of this study was to evaluate the effects of inosine on memory, neuroinflammatory cytokines, neurotrophic factors, expression of purinergic receptors, and morphological changes in the hippocampus and cerebral cortex of the rats with AD induced by streptozotocin (STZ).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34802394' target='_blank' class='pmid-link'>34802394</a>:</span> <span class='sentence-part'>AD was induced by the injection of STZ (3 mg/kg, bilaterally, ICV). This study investigated the neuroprotective effect of green tea (GT) on cognitive disorder, inflammation, and oxidative stress in the streptozotocin (STZ)- induced AD model.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34967205' target='_blank' class='pmid-link'>34967205</a>:</span> <span class='sentence-part'>Our results showed that siRNA mediated knockdown of the GSK3beta gene reduced expression of amyloid pathway genes (APP and BACE1), which was further confirmed by reduced amyloid beta (Abeta) levels in the    in vitro     STZ-induced sAD model. Behavioral data from Morris water maze (MWM), open field (OF), novel object recognition (NOR), Y maze, and radial arm maze (RAM) tests showed that 0.5 MUg nanoformulation (GOc-PP-siRNA     GSK3beta      ) intranasally for 7 days improved spatial memory, rescued anxiety like behavior, improved visual and working memory, and rescued exploratory behavior in STZ-induced sAD rats.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34968163' target='_blank' class='pmid-link'>34968163</a>:</span> <span class='sentence-part'>After the model of streptozotocin-induced AD mice with brain insulin resistance was established, the mice were treated with Magnolol or miR-200c antagomiR.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35027835' target='_blank' class='pmid-link'>35027835</a>:</span> <span class='sentence-part'>To evaluate whether DMF reduces neuroinflammation based on the peripheral inflammatory response inhibition, we determined peripheral inflammatory mediators in young and aged rats with the ICV-STZ-induced AD pathology following DMF therapy.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35048324' target='_blank' class='pmid-link'>35048324</a>:</span> <span class='sentence-part'>In addition, a significant increase in amino acid neurotransmitters occurred in the hippocampus, whereas a significant decrease was obtained in the cortex of STZ-induced AD rats.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35106732' target='_blank' class='pmid-link'>35106732</a>:</span> <span class='sentence-part'>The Methylglyoxal/RAGE/NOX-2 Pathway is Persistently Activated in the Hippocampus of Rats with STZ-Induced Sporadic Alzheimer's Disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35108957' target='_blank' class='pmid-link'>35108957</a>:</span> <span class='sentence-part'>Streptozotocin-induced sporadic Alzheimer's disease: Behavioral effects in female rats.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35150419' target='_blank' class='pmid-link'>35150419</a>:</span> <span class='sentence-part'>Several studies have shown the neuroprotective role of capsaicin against oxidative damage, behavioral impairment, with 6-hydroxydopamine (6-OHDA) induced Parkinson's disease, pentylenetetrazol-induced seizures, global cerebral ischemia, and streptozotocin-induced Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35163003' target='_blank' class='pmid-link'>35163003</a>:</span> <span class='sentence-part'>Cannabidiol Treatment Improves Glucose Metabolism and Memory in Streptozotocin-Induced Alzheimer's Disease Rat Model: A Proof-of-Concept Study.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35192144' target='_blank' class='pmid-link'>35192144</a>:</span> <span class='sentence-part'>Thus, the current investigation was undertaken to investigate the therapeutic potential of the PDE-4 inhibitor roflumilast (RFM) against intracerebroventricular (ICV) streptozotocin (STZ)-induced sporadic AD in rats.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35316021' target='_blank' class='pmid-link'>35316021</a>:</span> <span class='sentence-part'>We investigated the possible neuroprotective potential of the dual MAGL/FAAH inhibitor JZL-195 (20 mg/kg) against ICV-STZ-induced sporadic Alzheimer's disease (SAD) in Swiss albino mice using donepezil (5 mg/kg) as the standard.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35395244' target='_blank' class='pmid-link'>35395244</a>:</span> <span class='sentence-part'>In hippocampal and cortical tissues of ICV-STZ-induced AD mice, insulin receptor (IR) and Akt expressions were unchanged, while phosphorylated insulin receptor (pIR) and pAkt expressions decreased compared to control. KEY FINDINGS: ICV-STZ-induced AD mice displayed impaired learning and memory functions which were improved by metformin treatment.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35510084' target='_blank' class='pmid-link'>35510084</a>:</span> <span class='sentence-part'>Galantamine tethered hydrogel as a novel therapeutic target for streptozotocin-induced Alzheimer's disease in Wistar rats. Investigations were conducted to evaluate the behavioral activities of STZ-induced AD experimental rats under STZ + GelMA + Gal treatment.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35527550' target='_blank' class='pmid-link'>35527550</a>:</span> <span class='sentence-part'>Experimental Periodontitis Deteriorates Cognitive Function and Impairs Insulin Signaling in a Streptozotocin-Induced Alzheimer's Disease Rat Model. OBJECTIVE: To assess the impact of experimental periodontitis on cognitive function deficits in a rat model of streptozotocin-induced AD and determine the mechanisms underlying these effects. METHODS: Rats were randomly assigned to the control (C), experimental periodontitis (P), Alzheimer's disease (AD), and experimental periodontitis with streptozotocin-induced AD (AD-P) groups. In the AD-P group, AD was induced by intracerebroventricular injection of streptozotocin after 6 weeks of experimental periodontitis induction.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35556434' target='_blank' class='pmid-link'>35556434</a>:</span> <span class='sentence-part'>The streptozotocin (STZ) -induced AD model mimics respiratory problems seen in humans and exhibits neuronal hyperactivity in the nucleus tractus solitarii (nTS), the central integration site for respiratory afferents in the brainstem. AD was induced by intracerebroventricular injection of 2 mg/kg STZ in 6-week old male Sprague Dawley rats.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35679720' target='_blank' class='pmid-link'>35679720</a>:</span> <span class='sentence-part'>This study investigated the effects of drug delivery of COQ10 by exosomes derived from adipose-derived stem cells (ADSCs-Exo) on cognition, memory, and neuronal proliferation in a rat model of Streptozotocin (STZ)-induced AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35834993' target='_blank' class='pmid-link'>35834993</a>:</span> <span class='sentence-part'>Bilateral intracerebroventricular injection of streptozotocin induces AD-like behavioral impairments and neuropathological features in mice: Involved with the fundamental role of neuroinflammation. OBJECTIVE: To establish an Alzheimer's disease (AD) mouse model, investigate the behavioral performance changes and intracerebral molecular changes induced by bilateral intracerebroventricular injection of streptozotocin (STZ/I.C.V), and explore the potential pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35843421' target='_blank' class='pmid-link'>35843421</a>:</span> <span class='sentence-part'>The purpose of this study was to investigate the therapeutic effect of RES in Alzheimer's disease (AD)-like behavioral dysfunction induced by streptozotocin (STZ) and explore it's potential mechanism of action. These findings indicate that RES could ameliorate STZ-induced AD-like neuropathological injuries, the mechanism of which could be partly related to its regulation of BDNF expression and synaptic plasticity-associated proteins in the hippocampus.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35936440' target='_blank' class='pmid-link'>35936440</a>:</span> <span class='sentence-part'>All groups except group I were injected with Streptozotocin on the first day and third day of treatment at the dose of 3 mg/kg through an intracerebroventricular route to induce Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36108371' target='_blank' class='pmid-link'>36108371</a>:</span> <span class='sentence-part'>The current experimental findings also amply demonstrated that PA could improve the cognitive and memory impairments in the STZ-induced AD rat model. Morris water maze (MWM) test was performed to determine the learning and memory functions of the STZ-induced AD rats.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36145723' target='_blank' class='pmid-link'>36145723</a>:</span> <span class='sentence-part'>In vivo studies performed in a streptozotocin-induced AD model confirmed that HG@MSN-CCM reverted the cognitive deficit in mice, acting as a potential formulation in the treatment of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36288088' target='_blank' class='pmid-link'>36288088</a>:</span> <span class='sentence-part'>In a streptozocin-induced AD-like mouse model, behavioral tests showed that    SZM679     apparently ameliorated learning and memory dysfunction.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36301335' target='_blank' class='pmid-link'>36301335</a>:</span> <span class='sentence-part'>The role of sleep deprivation in streptozotocin-induced Alzheimer's disease-like sporadic dementia in rats with respect to the serum level of oxidative and inflammatory markers.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36436686' target='_blank' class='pmid-link'>36436686</a>:</span> <span class='sentence-part'>Animal model of Alzheimer's disease induced by streptozotocin: new insights about cholinergic pathway. Disorders of the cholinergic system are well known to be involved in the pathogenesis of AD, characterized by increased acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) and decreased acetyltransferase (ChAT) enzymatic activities.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36518345' target='_blank' class='pmid-link'>36518345</a>:</span> <span class='sentence-part'>Embelin prevents amyloid-beta accumulation via modulation of SOD1 in a Streptozotocin-induced AD-like condition: An evidence from    in vitro     investigation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36521513' target='_blank' class='pmid-link'>36521513</a>:</span> <span class='sentence-part'>Synaptic Loss and Gliosis in the Nucleus Tractus Solitarii with Streptozotocin-Induced Alzheimer's Disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36536049' target='_blank' class='pmid-link'>36536049</a>:</span> <span class='sentence-part'>Streptozotocin-induced Alzheimer's disease investigation by one-dimensional plasmonic grating chip. The next step was to measure the activity of neuron cells injected with different concentrations of STZ (0.5, 1, 2 mM) to induce the formation of Alzheimer's disease in the cultured neuron cells. Streptozotocin (STZ) is used to induce Alzheimer's disease experimentally.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36610115' target='_blank' class='pmid-link'>36610115</a>:</span> <span class='sentence-part'>Inhibition of GluN2B pathway is involved in the neuroprotective effect of silibinin on streptozotocin-induced Alzheimer's disease models.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36631849' target='_blank' class='pmid-link'>36631849</a>:</span> <span class='sentence-part'>The molecular mechanisms underlying the progression of STZ-induced AD pathology were analyzed two weeks after the final injection.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36725243' target='_blank' class='pmid-link'>36725243</a>:</span> <span class='sentence-part'>This study investigated the mechanism of Danggui Shaoyao Powder(DSP) against mitophagy in rat model of Alzheimer's disease(AD) induced by streptozotocin(STZ) based on PTEN induced putative kinase 1(PINK1)-Parkin signaling pathway.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36926592' target='_blank' class='pmid-link'>36926592</a>:</span> <span class='sentence-part'>Melatonin reduces beta-amyloid accumulation and improves short-term memory in streptozotocin-induced sporadic Alzheimer's disease model.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37043150' target='_blank' class='pmid-link'>37043150</a>:</span> <span class='sentence-part'>AD and diabetes were induced using streptozotocin.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37072341' target='_blank' class='pmid-link'>37072341</a>:</span> <span class='sentence-part'>These findings demonstrate for the first time that the anti-AD effect of PHS is associated with the regulation of primary bile acid biosynthesis and taurine and hypotaurine metabolism in STZ-induced AD rats. The results revealed that ptimary bile acid biosynthesis and taurine and hypotaurine metabolism were significantly correlated with STZ-induced AD rats.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37114959' target='_blank' class='pmid-link'>37114959</a>:</span> <span class='sentence-part'>In this study, we investigate the neuroprotective effects of this plant on Streptozotocin (STZ)-induced AD in rats.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37267300' target='_blank' class='pmid-link'>37267300</a>:</span> <span class='sentence-part'>Clostridium butyricum improves cognitive dysfunction in ICV-STZ-induced Alzheimer's disease mice via suppressing TLR4 signaling pathway through the gut-brain axis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37273654' target='_blank' class='pmid-link'>37273654</a>:</span> <span class='sentence-part'>The present study aims to investigate the effect of the iTBS protocol on the animal model of STZ-induced sAD-like pathology in the context of antioxidant, anti-inflammatory, and anti-amyloidogenic effects in the cortex, striatum, hippocampus, and cerebellum.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37275760' target='_blank' class='pmid-link'>37275760</a>:</span> <span class='sentence-part'>The effect of intracerebroventricular injection of insulin (Ins) and oral cinnamon extract (Cinn) on glucose transporter (GLUT) 1, 3, and 4 gene expressions in the hippocampus and spatial memory in a streptozotocin (STZ)-induced AD rat model was investigated in the present study.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37296210' target='_blank' class='pmid-link'>37296210</a>:</span> <span class='sentence-part'>Retraction Note: Protective effects of gingerol on streptozotocin-induced sporadic Alzheimer's disease: emphasis on inhibition of beta-amyloid, COX-2, alpha-, beta - secretases and APH1a.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37309299' target='_blank' class='pmid-link'>37309299</a>:</span> <span class='sentence-part'>IN administration of the NPs to streptozotocin (STZ) induced AD-like models lead to a significant number of entrances of the treated rats to the target arm in the radial arm water maze (RAWM) test.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37351177' target='_blank' class='pmid-link'>37351177</a>:</span> <span class='sentence-part'>Methods:     Using a streptozotocin (STZ)-induced sporadic AD rat model, we investigated the effects of high-intensity interval training on AD pathologies. Results:     High-intensity interval training (HIIT) alleviates cognitive dysfunction in STZ-induced AD-like rat models and provides neuroprotection against neurodegeneration, neuronal damage, and neuronal loss.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37473980' target='_blank' class='pmid-link'>37473980</a>:</span> <span class='sentence-part'>These results imply that silibinin exerts neuroprotective effect on an STZ-induced sporadic AD model by downregulating ferroptotic damage and thus the downstream STING-mediated neuroinflammation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37598127' target='_blank' class='pmid-link'>37598127</a>:</span> <span class='sentence-part'>Interestingly, Nobiletin ameliorated STZ-induced AD through enhancing the motor performance and repressing memory defects. The citrus flavonoid \Nobiletin\ impedes STZ-induced Alzheimer's disease in a mouse model through regulating autophagy mastered by SIRT1/FoxO3a mechanism.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37629545' target='_blank' class='pmid-link'>37629545</a>:</span> <span class='sentence-part'>Considering the results obtained, DTZ might have a potential therapeutic role in treating and managing AD and related dementia pathologies due to its anti-dementia activity in SAD-type conditions in rats induced by ICV-STZ. Repurposing Diltiazem for Its Neuroprotective Anti-Dementia Role against Intra-Cerebroventricular Streptozotocin-Induced Sporadic Alzheimer's Disease-Type Rat Model. In the present study, the neuroprotective anti-dementia effects of DTZ against intra-cerebroventricular-streptozotocin (ICV-STZ)-induced sporadic AD (SAD)-type rat model was investigated.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37665449' target='_blank' class='pmid-link'>37665449</a>:</span> <span class='sentence-part'>In conclusion, our results suggest that Voglibose has potent neuroprotective effects against the ICV-STZ-induced AD model. Voglibose attenuates cognitive impairment, Abeta aggregation, oxidative stress, and neuroinflammation in streptozotocin-induced Alzheimer's disease rat model.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37755583' target='_blank' class='pmid-link'>37755583</a>:</span> <span class='sentence-part'>Protective Effects of Repetitive Transcranial Magnetic Stimulation Against Streptozotocin-Induced Alzheimer's Disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37780033' target='_blank' class='pmid-link'>37780033</a>:</span> <span class='sentence-part'>AD was induced by streptozotocin(STZ; 3 mg/kg, intracerebroventricular (ICV)) and the treatment groups received injections of CM [(200 ul, intraperitoneally (i.p.), and/or PRP (100 ul, intravenously(i.v)] for 8 days.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37834398' target='_blank' class='pmid-link'>37834398</a>:</span> <span class='sentence-part'>This study used inductively coupled plasma mass spectrometry (ICP-MS) to examine the levels of metals in the blood plasma, frontal cortex, and hippocampus of Wistar rats with AD induced by streptozotocin (STZ).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37882235' target='_blank' class='pmid-link'>37882235</a>:</span> <span class='sentence-part'>Taken together, our data indicated that Pirh2 is critically involved in STZ induced AD pathogenesis through its interaction with ER-chaperone GRP78, improves the neuronal connectivity, affects the altered level of chaperones, co-chaperones, &amp; autophagic markers, and collectively inhibits the Abeta aggregation.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/38006400' target='_blank' class='pmid-link'>38006400</a>:</span> <span class='sentence-part'>Streptozotocin-induced AD rat model was used to verify important targets and predicted pathways.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/38031940' target='_blank' class='pmid-link'>38031940</a>:</span> <span class='sentence-part'>Effects of thymoquinone and memantine alone and in combination on memory and hippocampal morphology in rats with streptozotocin-induced Alzheimer's disease. We aimed to evaluate the effect of TQ alone or in combination with MEM on memory and hippocampal morphology in an STZ-induced rat AD model.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/38333746' target='_blank' class='pmid-link'>38333746</a>:</span> <span class='sentence-part'>The present study evaluated whether inhibiting AMPK and activating mTOR could stop metformin from improving memory in rats with streptozotocin (STZ) -induced Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/38430352' target='_blank' class='pmid-link'>38430352</a>:</span> <span class='sentence-part'>Thus, the aim of this study was to evaluate the effect of treatment with blackberry extract in a model of AD induced by streptozotocin (STZ) and compare it with metformin treatment.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/38486405' target='_blank' class='pmid-link'>38486405</a>:</span> <span class='sentence-part'>OBJECTIVES: The present study was conducted to investigate the efficacy of GW9508 administered peripherally on cognitive dysfunction in streptozotocin (STZ)-induced AD mice.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/38570152' target='_blank' class='pmid-link'>38570152</a>:</span> <span class='sentence-part'>Aurothioglucose encapsulated nanoparticles fostered neuroprotection in streptozotocin-induced Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/38688962' target='_blank' class='pmid-link'>38688962</a>:</span> <span class='sentence-part'>The STZ-induced AD caused cognitive and behavioural deficits demonstrated by considerable increases in acetylcholinesterase activity and escape latency compared to sham control. Intracerebroventricular injection of STZ (3 mg/kg) induced experimental AD and the rats were treated with low dose (200 mg/kg), high dose (400 mg/kg) of ORV and donepezil (10 mg/kg) for 21 days.</span></div></div>
<div class='streamlined-assertion'><div class='streamlined-header sticky-relation-header'><span class='label-text'>Subject:</span> <strong>tau_Proteins</strong> <span class='label-text'>Subject CUI:</span> <strong>C0085401</strong> â†’ <span class='label-text predicate-text'>CAUSES</span> â†’ <span class='label-text'>Object:</span> <strong>Alzheimers</strong> <span class='label-text'>Object CUI:</span> <strong>C0002395</strong></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23789343' target='_blank' class='pmid-link'>23789343</a>:</span> <span class='sentence-part'>[Intensive protein synthesis in neurons and phosphorylation of beta-amyloid precursor protein and tau-protein are triggering factors of neuronal amyloidosis and Alzheimer's disease].</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24577753' target='_blank' class='pmid-link'>24577753</a>:</span> <span class='sentence-part'>Aggregation of the microtubule associated protein tau (MAPT) within neurons of the brain is the leading cause of tauopathies such as Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32403399' target='_blank' class='pmid-link'>32403399</a>:</span> <span class='sentence-part'>Amyloid-beta and tau proteins are triggers for AD pathogenesis, and usually used as AD candidate biomarkers in the clinical research.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/32867562' target='_blank' class='pmid-link'>32867562</a>:</span> <span class='sentence-part'>miR-132 plays a critical role in regulating TAU protein levels and is important for preventing tau protein aggregation that causes Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33065402' target='_blank' class='pmid-link'>33065402</a>:</span> <span class='sentence-part'>Tau protein is an important biomarker in the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33093174' target='_blank' class='pmid-link'>33093174</a>:</span> <span class='sentence-part'>Clearance of intracellular tau protein from neuronal cells via VAMP8-induced secretion.In Alzheimer's disease (AD), tau - a microtubule-associated protein - becomes hyperphosphorylated, aggregates and accumulates in the somato-dendritic compartment of neurons.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33662757' target='_blank' class='pmid-link'>33662757</a>:</span> <span class='sentence-part'>Although the etiology of AD is not well understood, however, several factors such as oxidative stress, deposition of amyloid-beta (Abeta) peptides to form Abeta plaques, intraneuronal accumulation of hyperphosphorylated tau protein, and low level of acetylcholine are thought to play a major role in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33843226' target='_blank' class='pmid-link'>33843226</a>:</span> <span class='sentence-part'>Abnormal expression of Tau protein can cause the development of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34123738' target='_blank' class='pmid-link'>34123738</a>:</span> <span class='sentence-part'>Amyloid and tau protein abnormalities have been identified as the main causes of Alzheimer's disease but exact mechanisms remain to be revealed.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34308969' target='_blank' class='pmid-link'>34308969</a>:</span> <span class='sentence-part'>Misfolded, pathological tau protein propagates from cell to cell causing neuronal degeneration in Alzheimer's disease and other tauopathies.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34671002' target='_blank' class='pmid-link'>34671002</a>:</span> <span class='sentence-part'>[Beta Amyloid, Tau Protein, and Neuroinflammation: An Attempt to Integrate Different Hypotheses of Alzheimer's Disease Pathogenesis].</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34671708' target='_blank' class='pmid-link'>34671708</a>:</span> <span class='sentence-part'>According to the glymphatic hypothesis, in physiological conditions, cerebrospinal fluid flows primarily during sleep and serves to remove metabolic wastes like the amyloid-beta and tau proteins whose accumulation is believed to cause Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/34900398' target='_blank' class='pmid-link'>34900398</a>:</span> <span class='sentence-part'>Aluminum is a known neurotoxin that can induce Abeta deposition and abnormal phosphorylation of tau protein, leading to Alzheimer disease (AD)-like damages such as neuronal damage and decreased learning and memory functions.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35367762' target='_blank' class='pmid-link'>35367762</a>:</span> <span class='sentence-part'>Amyloid deposits and hyperphosphorylation of the tau protein are still believed to be the two main causes of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/35771127' target='_blank' class='pmid-link'>35771127</a>:</span> <span class='sentence-part'>The cyclin-dependent kinase (CDK5) forms a stable complex with its activator p25, leading to the hyperphosphorylation of tau proteins and to the formation of plaques and tangles that are considered to be one of the typical causes of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36120782' target='_blank' class='pmid-link'>36120782</a>:</span> <span class='sentence-part'>BACKGROUND: Amyloid-beta (Abeta) and tau protein accumulation in the brain is thought to be one of the causes of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/36389082' target='_blank' class='pmid-link'>36389082</a>:</span> <span class='sentence-part'>The complicated pathophysiology of AD is not well understood, although beta-amyloid (Abeta) cascade and hyperphosphorylated tau protein were regarded as the two main causes of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37315665' target='_blank' class='pmid-link'>37315665</a>:</span> <span class='sentence-part'>Microtubule affinity regulating kinase 4 (MARK4) is known to hyperphosphorylate tau protein, which subsequently causes Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37386272' target='_blank' class='pmid-link'>37386272</a>:</span> <span class='sentence-part'>This flawed miRNA expression is responsible for the unusual buildup of amyloid proteins, fibrillation of tau proteins in the brain, neuronal death and other hallmarks leading to AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/37905874' target='_blank' class='pmid-link'>37905874</a>:</span> <span class='sentence-part'>ABSTRACT: The aggregation of amyloid-beta peptide and tau protein dysregulation are implicated to play key roles in Alzheimer's disease pathogenesis and are considered the main pathological hallmarks of this devastating disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/38559176' target='_blank' class='pmid-link'>38559176</a>:</span> <span class='sentence-part'>It is well known that Abeta and tau proteins are deposited stereotypically in brain regions to cause Alzheimer's disease.</span></div></div>
<div class='streamlined-assertion'><div class='streamlined-header sticky-relation-header'><span class='label-text'>Subject:</span> <strong>tau_Proteins_MAPT</strong> <span class='label-text'>Subject CUI:</span> <strong>C0085401|4137</strong> â†’ <span class='label-text predicate-text'>CAUSES</span> â†’ <span class='label-text'>Object:</span> <strong>Alzheimers</strong> <span class='label-text'>Object CUI:</span> <strong>C0002395</strong></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/12716059' target='_blank' class='pmid-link'>12716059</a>:</span> <span class='sentence-part'>Here we hypothesize that while short-term induction of calcipressin1 can provide stress protection, its long-term or chronic induction may cause gradual accumulation of hyperphosphorylated tau protein, eventually leading to Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/14706948' target='_blank' class='pmid-link'>14706948</a>:</span> <span class='sentence-part'>BACKGROUND: Abnormal hyperphosphorylation of the microtubule-associated protein tau and its incorporation into neurofibrillary tangles are major hallmarks of the pathogenesis of Alzheimer disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/1527090' target='_blank' class='pmid-link'>1527090</a>:</span> <span class='sentence-part'>It has been suggested that hyperphosphorylation of the tau protein in neurofibrillary tangles may be relevant to the etiology of Alzheimer's disease and that at least one of the hyperphosphorylated sites lies within a consensus sequence for the p34cdc2/cdc28 family of kinases.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/16855914' target='_blank' class='pmid-link'>16855914</a>:</span> <span class='sentence-part'>It has been pointed out that hyperphosphorylation of microtubule-associated protein tau caused by stress might participate in the early stages of Alzheimer's disease pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/17266954' target='_blank' class='pmid-link'>17266954</a>:</span> <span class='sentence-part'>Abnormal phosphorylation of tau protein represents one of the major candidate pathological mechanisms leading to Alzheimer's disease (AD) and related tauopathies.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/18396294' target='_blank' class='pmid-link'>18396294</a>:</span> <span class='sentence-part'>Neuroinflammation and abnormal phosphorylation of TAU proteins have been implicated in the etiology of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/19246243' target='_blank' class='pmid-link'>19246243</a>:</span> <span class='sentence-part'>The microtubule-associated protein tau is integral to the pathogenesis of Alzheimer's disease (AD), as well as several related disorders, termed tauopathies, in which tau is deposited in affected brain regions.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21841250' target='_blank' class='pmid-link'>21841250</a>:</span> <span class='sentence-part'>Phosphorylation of tau protein is a critical event in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/21985244' target='_blank' class='pmid-link'>21985244</a>:</span> <span class='sentence-part'>Hyperphosphorylation of tau protein (tau) causes neurodegenerative diseases such as Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22222439' target='_blank' class='pmid-link'>22222439</a>:</span> <span class='sentence-part'>Specifically, we have analyzed levels of hyperphosphorylated tau proteins, bearing the AD-specific phospho-epitopes (AT-8, pT181, and PHF-1), which are implicated in the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22288403' target='_blank' class='pmid-link'>22288403</a>:</span> <span class='sentence-part'>The Abeta and tau proteins, two key players in the pathogenesis of Alzheimer's disease (AD), are highly homologous among primates.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24254705' target='_blank' class='pmid-link'>24254705</a>:</span> <span class='sentence-part'>Tau protein has been proposed as a trigger of Alzheimer's disease once it is hyperphosphorylated.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24497730' target='_blank' class='pmid-link'>24497730</a>:</span> <span class='sentence-part'>CDK5 and GSK3B are the two main protein kinases that have an important role in the abnormal hyperphosphorylation of MAPT which leads to Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24618580' target='_blank' class='pmid-link'>24618580</a>:</span> <span class='sentence-part'>Hyperphosphorylation of tau protein is an important mechanism for aggregation, so many studies on the pathogenesis of AD and other tauopathies have focused on regulation of tau phosphorylation by kinases and phosphatases.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/24936619' target='_blank' class='pmid-link'>24936619</a>:</span> <span class='sentence-part'>Changes in spatial learning ability and memory and induction of AD-like pathogenesis were not detected by in vivo brain imaging for amyloid-beta peptide accumulation and by immunohistochemical staining of amyloid precursor protein, amyloid-beta protein, tau, and phosphorylated tau protein.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25524708' target='_blank' class='pmid-link'>25524708</a>:</span> <span class='sentence-part'>Abnormally phosphorylated Tau protein, the major component of neurofibrillary tangles, is critical in the pathogenesis of Alzheimer's disease and related Tauopathies.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25903151' target='_blank' class='pmid-link'>25903151</a>:</span> <span class='sentence-part'>Overexpression of the amyloid precursor protein (APP) and the hyperphosphorylation of the tau protein are vital in the understanding of the cause of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/26453208' target='_blank' class='pmid-link'>26453208</a>:</span> <span class='sentence-part'>Conversion of monomeric tau protein into filamentous aggregates is a defining event in the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/27660034' target='_blank' class='pmid-link'>27660034</a>:</span> <span class='sentence-part'>Accumulation of amyloid beta (Abeta) peptide and hyperphosphorylated tau protein has been proposed to play roles in neural destruction which induce Alzheimer's disease (AD) progresses, glutamate transporter type 1 (GLT-1) and Glycogen synthase kinase3beta (GSK3beta) may be the pathological links between Abeta and tau pathology.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28179579' target='_blank' class='pmid-link'>28179579</a>:</span> <span class='sentence-part'>Glycogen synthase kinase-3 beta and cyclin-dependent kinase 5 have been identified as being involved in the pathological hyperphosphorylation of tau proteins, which leads to the formation of neurofibrillary tangles and causes Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/28184302' target='_blank' class='pmid-link'>28184302</a>:</span> <span class='sentence-part'>In this review, we will discuss the role of exosomes in the metabolism and secretion of APP and Tau proteins and their subsequent impact on AD pathogenesis.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/29065845' target='_blank' class='pmid-link'>29065845</a>:</span> <span class='sentence-part'>BACKGROUND &amp; OBJECTIVE: Involvement of amyloid beta and tau proteins in pathogenesis of Alzheimer's disease (AD) has been studied extensively.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30062675' target='_blank' class='pmid-link'>30062675</a>:</span> <span class='sentence-part'>Clinical drug research targeting at classic pathology hallmarks, such as amyloid-beta (Abeta) and tau protein, failed to achieve effective cognitive improvement, suggesting that the pathogenesis of AD is much complicated, and there are still other unknown and undetermined important factors.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/30251388' target='_blank' class='pmid-link'>30251388</a>:</span> <span class='sentence-part'>The two hexapeptide amino acid sequences 306 VQIVYK311 and 275 VQIINK280 of the tau protein are responsible for aggregation, and subsequent functional loss leading to Alzheimer's progression.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/31470053' target='_blank' class='pmid-link'>31470053</a>:</span> <span class='sentence-part'>The intrinsically disordered tau protein plays a pivotal role in the pathogenesis of Alzheimer's disease (AD) and other human tauopathies.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/9794144' target='_blank' class='pmid-link'>9794144</a>:</span> <span class='sentence-part'>The particular contribution of muscarinic receptors, beta-amyloid and tau proteins in the pathogenesis of Alzheimer's disease remains still unclear. Probably Alzheimer's disease could be due to a progressive degeneration in the relationship between the three components covered in this review.</span></div></div>
<div class='streamlined-assertion'><div class='streamlined-header sticky-relation-header'><span class='label-text'>Subject:</span> <strong>vascular_factor</strong> <span class='label-text'>Subject CUI:</span> <strong>C0078057</strong> â†’ <span class='label-text predicate-text'>CAUSES</span> â†’ <span class='label-text'>Object:</span> <strong>Alzheimers</strong> <span class='label-text'>Object CUI:</span> <strong>C0002395</strong></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/10423114' target='_blank' class='pmid-link'>10423114</a>:</span> <span class='sentence-part'>Although the role of vascular factors for the pathogenesis of AD is becoming recognized, the effectiveness of antihypertensive treatment on the prevention of AD should be further clarified in the future studies.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/10818514' target='_blank' class='pmid-link'>10818514</a>:</span> <span class='sentence-part'>The increased OEF with preserved vascular reserve seen in AD may implicate participation of a vascular factor in the pathogenesis of AD, possibly at the capillary level.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/10867215' target='_blank' class='pmid-link'>10867215</a>:</span> <span class='sentence-part'>The increase of OEF and preserved VTT and VR seen in AD patients indicate the possible participation of vascular factors in the pathogenesis of AD perhaps at the capillary level.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/12657895' target='_blank' class='pmid-link'>12657895</a>:</span> <span class='sentence-part'>Vascular factors may play a role in the etiology of Alzheimer's disease (AD) and increased serum apolipoprotein E (APOE) levels in AD could be of interest, as APOE concentration is associated with vascular disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/15883314' target='_blank' class='pmid-link'>15883314</a>:</span> <span class='sentence-part'>The dementia was attributable to only vascular factors in 56 cases (probable VaD); VaD coexisted with AD in 61 cases, although the VaD component was the leading cause of dementia (probable VaD with AD); AD was the leading cause of dementia in 61 cases (possible VaD and probable AD); and in 29 cases, it was not clear that either AD or VaD was the primary diagnosis (possible AD and possible VaD). The diagnosis of vascular dementia is difficult in epidemiologic studies because poststroke dementia can be due to Alzheimer disease (AD) and evidence of vascular disease can be found in the MRI of dementia cases without clinical strokes.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/16179827' target='_blank' class='pmid-link'>16179827</a>:</span> <span class='sentence-part'>Our finding may be another step in providing a rationale on how vascular factors could ultimately result in Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/16288900' target='_blank' class='pmid-link'>16288900</a>:</span> <span class='sentence-part'>There is already considerable evidence from epidemiological, pathological and clinical reports that vascular factors are crucial in the pathogenesis of Alzheimer's disease (AD).</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/18305170' target='_blank' class='pmid-link'>18305170</a>:</span> <span class='sentence-part'>Substantial evidence from epidemiological, pathological, and clinical reports suggests that vascular factors are critical in the pathogenesis of Alzheimer's disease (AD), and changes in blood flow are currently the most reliable indicators of the disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22377662' target='_blank' class='pmid-link'>22377662</a>:</span> <span class='sentence-part'>Some of them are related to the severity of the degenerative process itself, implying additional vascular factors in the pathogenesis of Alzheimer's dementia.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/22869466' target='_blank' class='pmid-link'>22869466</a>:</span> <span class='sentence-part'>Vascular factors play a role in the etiology of Alzheimer's disease (AD), presumably due to emergence of white matter lesions.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/23026534' target='_blank' class='pmid-link'>23026534</a>:</span> <span class='sentence-part'>Vascular factors and epigenetic modifications in the pathogenesis of Alzheimer's disease.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/25554493' target='_blank' class='pmid-link'>25554493</a>:</span> <span class='sentence-part'>In Alzheimer's disease (AD), large populations of endothelial cells undergo angiogenesis due to brain hypoxia and inflammation. Substantial evidence from epidemiologic, pathologic, and clinical reports suggests that vascular factors are critical for the pathogenesis of AD.</span></div><div class='pmid-sentence-line'><span class='pmid-part'><a href='https://pubmed.ncbi.nlm.nih.gov/33579850' target='_blank' class='pmid-link'>33579850</a>:</span> <span class='sentence-part'>BACKGROUND: Vascular factors and mitochondria dysfunction contribute to the pathogenesis of Alzheimer's disease (AD).</span></div></div>
</div>
<div class='footer'><p><strong>CausalKnowledgeTrace</strong> - Evidence Report</p></div></div></body></html>
